PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Goossens, H; Ferech, M; Stichele, RV; Elseviers, M				Goossens, H; Ferech, M; Stichele, RV; Elseviers, M		ESAC Project Grp	Outpatient antibiotic use in Europe and association with resistance: a cross-national database study.	LANCET			English	Article							STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL CONSUMPTION; ESCHERICHIA-COLI; TRENDS	Background Resistance to antibiotics is a major public-health problem and antibiotic use is being increasingly recognised as the main selective pressure driving this resistance. Our aim was to assess outpatient use of antibiotics and the association with resistance. Methods We, investigated outpatient antibiotic use in 26 countries in Europe that provided. internationally M comparable distribution or reimbursement data, between Jan 1, 1997, and Dec 31, 2002; by calculating the number R of defined daily doses (DDD) per 1000 inhabitants per day, according to WHO anatomic therapeutic chemical M classification and DDD measurement methodology. We assessed the ecological association between antibiotic use and antibiotic resistance rates using Spearman's correlation coefficients. Findings Prescription of antibiotics in primary care in Europe varied greatly; the highest rate was in France (32.2 DDD per 1000 inhabitants daily) and the lowest was in the Netherlands (10.0 DDD per 1000 inhabitants daily). We noted a shift from the old narrow-spectrum antibiotics to the new broad-spectrum antibiotics. We also recorded striking seasonal fluctuations with heightened winter peaks in countries with high yearly use of antibiotics. We showed higher rates of antibiotic resistance in high consuming countries, probably related, to the higher consumption in southern and eastern Europe than in northern Europe. Interpretation These data might provide a useful method for assessing public-health strategies that aim to reduce antibiotic use and resistance levels.	Univ Antwerp, Dept Microbiol, ESAC Management Team, B-2610 Antwerp, Belgium; Leiden Univ, Med Ctr, Dept Med Microbiol, NL-2300 RA Leiden, Netherlands	University of Antwerp; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Goossens, H (corresponding author), Univ Antwerp, Dept Microbiol, ESAC Management Team, B-2610 Antwerp, Belgium.	Herman.Goossens@uza.be	Stichele, Robert Vander/K-7203-2015	Stichele, Robert Vander/0000-0001-9118-9651; Elseviers, Monique/0000-0001-9415-6900				Albrich WC, 2004, EMERG INFECT DIS, V10, P514, DOI 10.3201/eid1003.030252; Austin DJ, 1999, P NATL ACAD SCI USA, V96, P1152, DOI 10.1073/pnas.96.3.1152; Bergman M, 2004, CLIN INFECT DIS, V38, P1251, DOI 10.1086/383309; BRONZWAER S, 2003, THESIS RIJKSUNIVERSI; Bronzwaer SL, 2000, EMERG INFECT DIS, V3, P278; Cars O, 2001, LANCET, V357, P1851, DOI 10.1016/S0140-6736(00)04972-2; Chow KM, 2003, ARCH INTERN MED, V163, P1617, DOI 10.1001/archinte.163.13.1617-a; *DAN VET LAB, 2001, DANMAP 2000 CONS ANT; De Laat E., 2002, DOES PHARM MARKETING; DESCHEPPER R, 2002, PATIENT EDUC COUNS, V1590, P1; Enne VI, 2001, LANCET, V357, P1325, DOI 10.1016/S0140-6736(00)04519-0; Garcia-Rey C, 2004, J ANTIMICROB CHEMOTH, V54, P465, DOI 10.1093/jac/dkh375; GARCIAREY C, IMPORTANCE LOCAL VAR; Goossens H, 1998, BRIT MED J, V317, P654, DOI 10.1136/bmj.317.7159.654; GOOSSENS H, 2003, CORRELATION MACROLID, P111; Guillemot D, 1998, J INFECT DIS, V177, P492, DOI 10.1086/517384; Ho PL, 2001, J ANTIMICROB CHEMOTH, V48, P659, DOI 10.1093/jac/48.5.659; Hooper DC, 2002, LANCET INFECT DIS, V2, P530, DOI 10.1016/S1473-3099(02)00369-9; Hutchinson JM, 2001, CAN FAM PHYSICIAN, V47, P1217; Kahlmeter G, 2003, J ANTIMICROB CHEMOTH, V52, P1005, DOI 10.1093/jac/dkg488; Kahlmeter G, 2003, J ANTIMICROB CHEMOTH, V51, P69, DOI 10.1093/jac/dkg028; McCormick AW, 2003, NAT MED, V9, P424, DOI 10.1038/nm839; Monnet DL, 2004, J ANTIMICROB CHEMOTH, V53, P1109, DOI 10.1093/jac/dkh230; Nasrin D, 2002, BRIT MED J, V324, P28, DOI 10.1136/bmj.324.7328.28; Orero A, 1997, MED CLIN-BARCELONA, V109, P782; Price DB, 2004, RESP MED, V98, P17, DOI 10.1016/j.rmed.2003.08.011; Rovers MM, 2004, LANCET, V363, P465, DOI 10.1016/S0140-6736(04)15495-0; Van Zuijlen DA, 2001, PEDIATR INFECT DIS J, V20, P140, DOI 10.1097/00006454-200102000-00004; Vander Stichele RH, 2004, BRIT J CLIN PHARMACO, V58, P419, DOI 10.1111/j.1365-2125.2004.02164.x; World Health Organization (WHO), 2004, AN THER CHEM CLASS S; WORLD HEALTH ORGANIZATION (WHO) REGIONAL OFFICE FOR EUROPE, 2003, EUR HLTH ALL DAT	31	2091	2159	12	284	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					579	587		10.1016/S0140-6736(05)17907-0	http://dx.doi.org/10.1016/S0140-6736(05)17907-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708101				2023-01-03	WOS:000226984300030
J	Maddison, P; Jones, J; Breslin, A; Bargon, C; Fleur, J; Lewis, R; McSweeney, L; Norgain, C; Smith, S; Thomas, C; Tillson, C				Maddison, P; Jones, J; Breslin, A; Bargon, C; Fleur, J; Lewis, R; McSweeney, L; Norgain, C; Smith, S; Thomas, C; Tillson, C			Improved access and targeting of musculoskeletal services in northwest Wales: targeted early access to musculoskeletal services (TEAMS) programme	BRITISH MEDICAL JOURNAL			English	Article								Problem The hospital based musculoskeletal service in northwest Wales was unable to cope with the demand for referrals from general practitioners. Waiting times were long, duplicate referrals to other departments were common, and general practitioners were reluctant to refer patients with common problems because of the perceived lack of service. Many referrals were made to the inappropriate specialty, especially orthopaedics. At least part of this problem was due to a lack of coordination between the four hospital departments providing musculoskeletal services and the emphasis on district general hospital based rather than community provision. Design Review over 18 months of impact of the targeted early access to musculoskeletal services (TEAMS) programme on accessibility to musculoskeletal services. Setting Northwest Wales. Key measures for improvement Number of patients referred and seen with musculoskeletal problems, waiting times, number of duplicate referrals, and surgery conversion rates in orthopaedic clinics. Strategies for change Establishing with central clinical triage a common pathway for all musculoskeletal referrals so that patients attend the appropriate department. A back pain pathway led by extended scope physiotherapists was developed, and general practitioners with special interests and extended. scope physiotherapists were trained to provide services for patients with uncomplicated musculoskeletal problems in the Community. Effects of change Over 18 months the number of referrals more than doubled. Despite this, waiting times for musculoskeletal services fell; this was noticeable for rheumatology and pain management. Duplicate referrals were abolished. Surgery conversion rates did not, however, change. Questionnaires from the clinics showed a high level of patient satisfaction. Lessons learnt Integration of hospital services that traditionally have worked in isolation can result in greatly improved access to musculoskeletal services. Community based multidisciplinary clinics run by specially trained general practitioners with special interests and extended scope physiotherapists are an effective way of managing patients with uncomplicated musculoskeletal problems and have been well received by patients and general practitioners. The huge unmet burden of need was reflected by the great increase in musculoskeletal referrals. Other approaches are needed to meet this, including better education of general practitioners and methods for identifying and modifying psychosocial risk factors for chronic pain at an early stage.	NW Wales NHS Trust, Bangor LL57 2PW, Gwynedd, Wales; Gwynedd Local Hlth Board, Eryldon, Caernarfon, Wales	Bangor University	Maddison, P (corresponding author), NW Wales NHS Trust, Bangor LL57 2PW, Gwynedd, Wales.	peter.maddison@nww-tr.wales.nhs.uk						BURTON AK, 1995, SPINE, V20, P722, DOI 10.1097/00007632-199503150-00014; Department of Health/Royal College of General Practitioners, 2002, IMPL SCHEM GEN PRACT; *JOINT HLTH SURV U, 1997, HLTH SURV ENGL 1995, V1; MCCORMICK A, 1995, MORBIDITY STAT GEN P; *WELSH OFF, 1998, BETT HLTH BETT WAL C	5	76	76	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 4	2004	329	7478					1325	1327		10.1136/bmj.329.7478.1325	http://dx.doi.org/10.1136/bmj.329.7478.1325			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	878PC	15576743	Green Published			2023-01-03	WOS:000225657800021
J	Amedi, A; Floel, A; Knecht, S; Zohary, E; Cohen, LG				Amedi, A; Floel, A; Knecht, S; Zohary, E; Cohen, LG			Transcranial magnetic stimulation of the occipital pole interferes with verbal processing in blind subjects	NATURE NEUROSCIENCE			English	Article							INFERIOR PREFRONTAL CORTEX; VISUAL-CORTEX; ACTIVATION; MEMORY; BRAIN; ORGANIZATION; CONNECTIONS; DEPRIVATION; CORTICES; PEOPLE	Recent neuroimaging studies in blind persons show that the occipital cortex, including the primary visual cortex (V1), is active during language-related and verbal-memory tasks. No studies, however, have identified a causal link between early visual cortex activity and successful performance on such tasks. We show here that repetitive transcranial magnetic stimulation (rTMS) of the occipital pole reduces accuracy on a verb-generation task in blind subjects, but not in sighted controls. An analysis of error types revealed that the most common error produced by rTMS was semantic; phonological errors and interference with motor execution or articulation were rare. Thus, in blind persons, a transient 'virtual lesion' of the left occipital cortex interferes with high-level verbal processing.	NINDS, Human Cort Physiol Sect, NIH, Bethesda, MD 20892 USA; Hebrew Univ Jerusalem, Dept Neurobiol, Inst Life Sci, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Interdisciplinary Ctr Neural Computat, IL-91904 Jerusalem, Israel; Univ Munster, D-48148 Munster, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Munster	Cohen, LG (corresponding author), NINDS, Human Cort Physiol Sect, NIH, Bethesda, MD 20892 USA.	udiz@lobster.ls.huji.ac.il; cohenl@ninds.nih.gov	Floel, Agnes/A-9426-2017	Amedi, Amir/0000-0001-5042-2533; Knecht, Stefan/0000-0003-1056-9228				Amedi A, 2003, NAT NEUROSCI, V6, P758, DOI 10.1038/nn1072; Amedi A, 2001, NAT NEUROSCI, V4, P324, DOI 10.1038/85201; Boroojerdi B, 2000, CEREB CORTEX, V10, P529, DOI 10.1093/cercor/10.5.529; Buchel C, 2003, NAT NEUROSCI, V6, P657, DOI 10.1038/nn0703-657; Buchel C, 1998, BRAIN, V121, P409, DOI 10.1093/brain/121.3.409; Buckner RL, 1999, NAT NEUROSCI, V2, P311, DOI 10.1038/7221; Burton H, 2003, J NEUROSCI, V23, P4005; Burton H, 2003, J NEUROPHYSIOL, V90, P1965, DOI 10.1152/jn.00279.2003; Burton H, 2002, J NEUROPHYSIOL, V88, P3359, DOI 10.1152/jn.00129.2002; Chouinard PA, 2003, J NEUROPHYSIOL, V90, P1071, DOI 10.1152/jn.01105.2002; Cohen LG, 1997, NATURE, V389, P180, DOI 10.1038/38278; DEHAY C, 1984, EXP BRAIN RES, V57, P208; Devlin JT, 2003, J COGNITIVE NEUROSCI, V15, P71, DOI 10.1162/089892903321107837; DISTLER C, 1993, J COMP NEUROL, V334, P125, DOI 10.1002/cne.903340111; Floel A, 2004, CEREB CORTEX, V14, P404, DOI 10.1093/cercor/bhh002; Gabrieli JDE, 1998, P NATL ACAD SCI USA, V95, P906, DOI 10.1073/pnas.95.3.906; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; Korpilahti P, 2001, BRAIN LANG, V76, P332, DOI 10.1006/brln.2000.2426; KUCERA WN, 1967, COMPUTATIONAL ANAL P; Levelt WJM, 2001, P NATL ACAD SCI USA, V98, P13464, DOI 10.1073/pnas.231459498; Lisanby SH, 2001, BIOL PSYCHIAT, V49, P460, DOI 10.1016/S0006-3223(00)01110-0; MALACH R, 1995, P NATL ACAD SCI USA, V92, P8135, DOI 10.1073/pnas.92.18.8135; Noppeney U, 2003, BRAIN, V126, P1620, DOI 10.1093/brain/awg152; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pascual-Leone A, 2001, PROG BRAIN RES, V134, P427; Pascual-Leone A, 2000, CURR OPIN NEUROBIOL, V10, P232, DOI 10.1016/S0959-4388(00)00081-7; PascualLeone A, 1995, ANN NEUROL, V38, P910, DOI 10.1002/ana.410380611; Paus T, 1999, NEUROPSYCHOLOGIA, V37, P219; Poldrack RA, 1999, NEUROIMAGE, V10, P15, DOI 10.1006/nimg.1999.0441; Rempel-Clower NL, 2000, CEREB CORTEX, V10, P851, DOI 10.1093/cercor/10.9.851; Roder B, 2002, EUR J NEUROSCI, V16, P930, DOI 10.1046/j.1460-9568.2002.02147.x; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; Shapiro KA, 2001, J COGNITIVE NEUROSCI, V13, P713, DOI 10.1162/08989290152541386; Stewart L, 2001, NEUROIMAGE, V13, P472, DOI 10.1006/nimg.2000.0701	35	196	199	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	NOV	2004	7	11					1266	1270		10.1038/nn1328	http://dx.doi.org/10.1038/nn1328			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	866CB	15467719				2023-01-03	WOS:000224749400020
J	Lindsberg, PJ; Soinne, L; Tatlisumak, T; Roine, RO; Kallela, M; Happola, O; Kaste, M				Lindsberg, PJ; Soinne, L; Tatlisumak, T; Roine, RO; Kallela, M; Happola, O; Kaste, M			Long-term outcome after intravenous thrombolysis of basilar artery occlusion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE ISCHEMIC-STROKE; THERAPY; ASSOCIATION; QUALITY; LIFE; CARE	Context Basilar artery occlusion (BAO) is an infrequent disease with high morbidity and mortality. Intra-arterial thrombolysis is advocated for treatment but is limited to use at specialized centers. Objective To evaluate outcomes for patients with BAO treated with intravenous thrombolytic therapy. Design, Setting, and Participants During 1995 to 2003, 50 consecutive patients with angiographically proven BAO were treated according to an institutional therapy protocol based on intravenous thrombolysis with recombinant tissue plasminogen activator (alteplase). Patients were treated at an urban university teaching hospital receiving all patients with ischemic stroke who were considered for thrombolysis in a catchment area of 1.5 million inhabitants in Helsinki, Finland. Intervention Intravenous administration of alteplase (0.9 mg/kg) during a 1-hour infusion. Main Outcome Measures Basilar artery recanalization determined by magnetic resonance angiography and clinical outcomes at 3 months and at 1 year or longer determined by modified Rankin Scale and Barthel index scores. Results Recanalization was studied in 43 patients and verified in 26 (52%) of all patients. By 3 months, 20 patients (40%) had died while 11 had good outcomes (modified Rankin Scale score, 0-2); 12 (24%) reached independence in activities of daily living (Barthel Index score, 95-100), and 6 (16%) were severely disabled (Barthel Index score, 0-50). in the long term (median follow-up 2.8 years), 15 patients (30%) reached good outcomes (modified Rankin Scale score, 0-2) while 23 (46%) died. Conclusions Intravenous administration of alteplase for patients with BAO appears to be associated with rates of survival, recanalization, and independent functional outcome comparable with those reported with endovascular approaches. These data suggest that a randomized trial is needed to compare these approaches for treatment of BAO.	Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki 00029, Finland; Biomedicum Helsinki, Program Neurosci, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Lindsberg, PJ (corresponding author), Univ Helsinki, Cent Hosp, Dept Neurol, POB 340, Helsinki 00029, Finland.	perttu.lindsberg@hus.fi	Soinne, Lauri/E-3703-2019; Lindsberg, Perttu J/F-1271-2010	Lindsberg, Perttu/0000-0001-7690-811X				Adams HP, 1996, STROKE, V27, P1711; Brandt T, 1996, STROKE, V27, P875, DOI 10.1161/01.STR.27.5.875; Cross DT, 1997, AM J NEURORADIOL, V18, P1221; Devuyst G, 2002, ARCH NEUROL-CHICAGO, V59, P567, DOI 10.1001/archneur.59.4.567; Eckert B, 2002, CEREBROVASC DIS, V14, P42, DOI 10.1159/000063722; HACKE W, 1988, STROKE, V19, P1216, DOI 10.1161/01.STR.19.10.1216; Hacke W, 2004, LANCET, V363, P768; Levy EI, 1999, NEUROSURGERY, V45, P539, DOI 10.1097/00006123-199909000-00025; Lindsberg P J, 1998, Duodecim, V114, P889; Lindsberg PJ, 2003, STROKE, V34, P1443, DOI 10.1161/01.STR.0000071111.98505.C7; Lindsberg PJ, 2003, CURR OPIN NEUROL, V16, P73, DOI 10.1097/00019052-200302000-00010; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Patrick DL, 2000, J CLIN EPIDEMIOL, V53, P779, DOI 10.1016/S0895-4356(00)00205-5; Richardson P G, 2001, Emerg Med (Fremantle), V13, P367, DOI 10.1046/j.1035-6851.2001.00242.x; Wijdicks EFM, 1997, MAYO CLIN PROC, V72, P1005, DOI 10.4065/72.11.1005	15	141	153	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2004	292	15					1862	1866		10.1001/jama.292.15.1862	http://dx.doi.org/10.1001/jama.292.15.1862			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IV	15494584	Bronze			2023-01-03	WOS:000224485100025
J	Petrylak, DP; Tangen, CM; Hussain, MHA; Lara, PN,J; Jones, JA; Taplin, ME; Burch, PA; Berry, D; Moinpour, C; Kohli, M; Benson, MC; Small, EJ; Raghavan, D; Crawford, ED				Petrylak, DP; Tangen, CM; Hussain, MHA; Lara, PN,J; Jones, JA; Taplin, ME; Burch, PA; Berry, D; Moinpour, C; Kohli, M; Benson, MC; Small, EJ; Raghavan, D; Crawford, ED			Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL ESTRAMUSTINE; PHASE-II; CONTROLLED-TRIAL; MEN; HYDROCORTISONE; CHEMOTHERAPY; PHOSPHATE; CARCINOMA; FLUTAMIDE; TAXOTERE	BACKGROUND: Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer. We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate cancer. METHODS: We randomly assigned 770 men to one of two treatments, each given in 21-day cycles: 280 mg of estramustine three times daily on days 1 through 5, 60 mg of docetaxel per square meter of body-surface area on day 2, and 60 mg of dexamethasone in three divided doses before docetaxel, or 12 mg of mitoxantrone per square meter on day 1 plus 5 mg of prednisone twice daily. The primary end point was overall survival; secondary end points were progression-free survival, objective response rates, and post-treatment declines of at least 50 percent in serum prostate-specific antigen (PSA) levels. RESULTS: Of 674 eligible patients, 338 were assigned to receive docetaxel and estramustine and 336 to receive mitoxantrone and prednisone. In an intention-to-treat analysis, the median overall survival was longer in the group given docetaxel and estramustine than in the group given mitoxantrone and prednisone (17.5 months vs. 15.6 months, P=0.02 by the log-rank test), and the corresponding hazard ratio for death was 0.80 (95 percent confidence interval, 0.67 to 0.97). The median time to progression was 6.3 months in the group given docetaxel and estramustine and 3.2 months in the group given mitoxantrone and prednisone (P<0.001 by the log-rank test). PSA declines of at least 50 percent occurred in 50 percent and 27 percent of patients, respectively (P<0.001), and objective tumor responses were observed in 17 percent and 11 percent of patients with bidimensionally measurable disease, respectively (P=0.30). Grade 3 or 4 neutropenic fevers (P=0.01), nausea and vomiting (P<0.001), and cardiovascular events (P=0.001) were more common among patients receiving docetaxel and estramustine than among those receiving mitoxantrone and prednisone. Pain relief was similar in both groups. CONCLUSIONS: The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.	Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA; SW Oncol Grp, Ctr Stat, Seattle, WA USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Calif Davis, Sacramento, CA 95817 USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Massachusetts, Med Ctr, Worcester, MA USA; Mayo Clin, Rochester, MN USA; Univ Washington, Seattle, WA 98195 USA; Univ Arkansas Med Sci, Little Rock, AR 72205 USA; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	Columbia University; Southwest Oncology Group; University of Michigan System; University of Michigan; University of California System; University of California Davis; Baylor College of Medicine; University of Massachusetts System; University of Massachusetts Worcester; Mayo Clinic; University of Washington; University of Washington Seattle; University of Arkansas System; University of Arkansas Medical Sciences; University of California System; University of California San Francisco; Cleveland Clinic Foundation; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Petrylak, DP (corresponding author), SW Oncol Grp S9916 Operat Off, 14980 Omicron Dr, San Antonio, TX 78245 USA.		Kohli, Manish/AAN-8862-2021		NATIONAL CANCER INSTITUTE [U10CA042777, U10CA058658, U10CA012644, U10CA045377, U10CA046282, U10CA058416, U10CA068183, U10CA035119, U10CA014028, U10CA045461, U10CA037981, U10CA058861, U10CA038926, U10CA022433, U10CA063850, U10CA063844, U10CA067575, U10CA035090, U10CA067663, U10CA035281, U10CA020319, U10CA011083, U10CA086780, U10CA037135, U10CA045450, U10CA046368, U10CA058686, U10CA004919, U10CA035178, U10CA045808, U10CA035431, U10CA016385, U10CA074647, U10CA046113, R01CA046462, U10CA013612, U10CA074811, U10CA063845, U10CA012213, U10CA032102, U10CA046136, U10CA027057, U10CA076447, U10CA058723, U10CA035128, U10CA035192, U10CA046441, U10CA035261, U10CA025224, U10CA035176, U10CA003096, U10CA058882, U10CA063848] Funding Source: NIH RePORTER; NCI NIH HHS [CA58416, CA58658, CA46462, CA58686, CA58723, CA58861, CA58882, CA63844, CA63845, CA46441, CA46368, CA46282, CA63848, CA63850, CA67575, CA67663, CA68183, CA74647, CA74811, CA76129, CA76132, CA46136, CA46113, CA76447, CA86780, CA45808, CA45807, CA45461, CA45450, CA45377, CA42777, CA38926, CA37981, CA37135, CA35996, CA35431, CA35281, CA35261, CA35192, CA35178, CA35176, CA35128, CA35119, CA35090, CA32102, CA27057, CA25224, CA22433, CA20319, CA16385, CA14028, CA13612, CA12644, CA12213, CA11083, CA04919, CA03096] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENSON R, 1990, CANCER INVEST, V8, P375, DOI 10.3109/07357909009012056; Berry W, 2002, J UROLOGY, V168, P2439, DOI 10.1016/S0022-5347(05)64163-8; Bubley GJ, 1999, J CLIN ONCOL, V17, P3461, DOI 10.1200/JCO.1999.17.11.3461; BUBLEY GJ, 2000, J CLIN ONCOL, V18, P2644; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P1420; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Ernst DS, 2003, J CLIN ONCOL, V21, P3335, DOI 10.1200/JCO.2003.03.042; Fakih M, 2002, UROLOGY, V60, P553, DOI 10.1016/S0090-4295(02)01741-7; Haldar S, 1996, CANCER RES, V56, P1253; Hudes G, 1999, J CLIN ONCOL, V17, P3160, DOI 10.1200/JCO.1999.17.10.3160; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kantoff PW, 1999, J CLIN ONCOL, V17, P2506, DOI 10.1200/JCO.1999.17.8.2506; Kreis W, 1999, SEMIN ONCOL, V26, P34; Kreis W, 1997, BRIT J UROL, V79, P196, DOI 10.1046/j.1464-410X.1997.06310.x; McDonnell TJ, 1997, J UROLOGY, V157, P569, DOI 10.1016/S0022-5347(01)65204-2; Petrylak DP, 1999, J CLIN ONCOL, V17, P958, DOI 10.1200/JCO.1999.17.3.958; Petrylak DP, 1999, SEMIN ONCOL, V26, P28; Savarese DM, 2001, J CLIN ONCOL, V19, P2509, DOI 10.1200/JCO.2001.19.9.2509; Sinibaldi VJ, 2002, CANCER-AM CANCER SOC, V94, P1457, DOI 10.1002/cncr.10350; Tannock IF, 1996, J CLIN ONCOL, V14, P1756, DOI 10.1200/JCO.1996.14.6.1756; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Weitzman AL, 2000, J UROLOGY, V163, P834, DOI 10.1016/S0022-5347(05)67815-9; YAGODA A, 1993, CANCER-AM CANCER SOC, V71, P1098, DOI 10.1002/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G	24	2904	3025	10	127	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 7	2004	351	15					1513	1520		10.1056/NEJMoa041318	http://dx.doi.org/10.1056/NEJMoa041318			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	859UP	15470214				2023-01-03	WOS:000224293700009
J	Go, AS; Chertow, GM; Fan, DJ; McCulloch, CE; Hsu, CY				Go, AS; Chertow, GM; Fan, DJ; McCulloch, CE; Hsu, CY			Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	36th Annual Meeting of the American-Society-of-Nephrology	NOV 12-17, 2003	SAN DIEGO, CA	Amer Soc Nephrol			CHRONIC RENAL-INSUFFICIENCY; 3RD NATIONAL-HEALTH; SERUM CREATININE; ALL-CAUSE; MORTALITY; OUTCOMES; CARE; HYPERTENSION; IMPACT; COHORT	Background: End-stage renal disease substantially increases the risks of death, cardiovascular disease, and use of specialized health care, but the effects of less severe kidney dysfunction on these outcomes are less well defined. Methods: We estimated the longitudinal glomerular filtration rate (GFR) among 1,120,295 adults within a large, integrated system of health care delivery in whom serum creatinine had been measured between 1996 and 2000 and who had not undergone dialysis or kidney transplantation. We examined the multivariable association between the estimated GFR and the risks of death, cardiovascular events, and hospitalization. Results: The median follow-up was 2.84 years, the mean age was 52 years, and 55 percent of the group were women. After adjustment, the risk of death increased as the GFR decreased below 60 ml per minute per 1.73 m(2) of body-surface area: the adjusted hazard ratio for death was 1.2 with an estimated GFR of 45 to 59 ml per minute per 1.73 m(2) (95 percent confidence interval, 1.1 to 1.2), 1.8 with an estimated GFR of 30 to 44 ml per minute per 1.73 m(2) (95 percent confidence interval, 1.7 to 1.9), 3.2 with an estimated GFR of 15 to 29 ml per minute per 1.73 m(2) (95 percent confidence interval, 3.1 to 3.4), and 5.9 with an estimated GFR of less than 15 ml per minute per 1.73 m(2) (95 percent confidence interval, 5.4 to 6.5). The adjusted hazard ratio for cardiovascular events also increased inversely with the estimated GFR: 1.4 (95 percent confidence interval, 1.4 to 1.5), 2.0 (95 percent confidence interval, 1.9 to 2.1), 2.8 (95 percent confidence interval, 2.6 to 2.9), and 3.4 (95 percent confidence interval, 3.1 to 3.8), respectively. The adjusted risk of hospitalization with a reduced estimated GFR followed a similar pattern. Conclusions: An independent, graded association was observed between a reduced estimated GFR and the risk of death, cardiovascular events, and hospitalization in a large, community-based population. These findings highlight the clinical and public health importance of chronic renal insufficiency.	Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	Kaiser Permanente; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Go, AS (corresponding author), Kaiser Permanente No Calif, Div Res, 2000 Broadway,3rd Fl, Oakland, CA 94612 USA.	alan.s.go@kp.org	Go, Alan S./AAE-7745-2019	Hsu, Chi-yuan/0000-0001-8182-1238; Chertow, Glenn/0000-0002-7599-0534	NIDDK NIH HHS [R01 DK58411] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058411] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander M, 1999, ARCH INTERN MED, V159, P2673, DOI 10.1001/archinte.159.22.2673; [Anonymous], 2003, USRDS 2003 ANN DAT R; ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; Blacher J, 2003, KIDNEY INT, V63, P1852, DOI 10.1046/j.1523-1755.2003.00932.x; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007; Culleton BF, 1999, KIDNEY INT, V56, P2214, DOI 10.1046/j.1523-1755.1999.00773.x; DAMSGAARD EM, 1990, BRIT MED J, V300, P297, DOI 10.1136/bmj.300.6720.297; Drey N, 2003, AM J KIDNEY DIS, V42, P677, DOI 10.1016/S0272-6386(03)00916-8; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Feldman HI, 2003, J AM SOC NEPHROL, V14, pS148, DOI 10.1097/01.ASN.0000070149.78399.CE; Fireman BH, 2000, J NATL CANCER I, V92, P136, DOI 10.1093/jnci/92.2.136; Garg AX, 2002, KIDNEY INT, V61, P1486, DOI 10.1046/j.1523-1755.2002.00270.x; Go AS, 1999, ANN INTERN MED, V131, P927, DOI 10.7326/0003-4819-131-12-199912210-00004; Hsu CY, 2002, J AM SOC NEPHROL, V13, P504, DOI 10.1681/ASN.V132504; Karter AJ, 2002, JAMA-J AM MED ASSOC, V287, P2519, DOI 10.1001/jama.287.19.2519; Karter AJ, 2002, JAMA-J AM MED ASSOC, V288, P46; Khan SS, 2002, KIDNEY INT, V62, P229, DOI 10.1046/j.1523-1755.2002.00432.x; Landis JR, 2003, J AM SOC NEPHROL, V14, p294A; LANGFORD HG, 1986, PROG CARDIOVASC DIS, V29, P29, DOI 10.1016/0033-0620(86)90033-2; Levey Andrew S., 2000, Journal of the American Society of Nephrology, V11, p155A; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Levin A, 1999, AM J KIDNEY DIS, V34, P125, DOI 10.1016/S0272-6386(99)70118-6; London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414; Manjunath G, 2003, KIDNEY INT, V63, P1121, DOI 10.1046/j.1523-1755.2003.00838.x; Manjunath G, 2003, J AM COLL CARDIOL, V41, P47, DOI 10.1016/S0735-1097(02)02663-3; Mann JFE, 2001, ANN INTERN MED, V134, P629, DOI 10.7326/0003-4819-134-8-200104170-00007; Muntner P, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133745; Muntner P, 2004, ANN INTERN MED, V140, P9, DOI 10.7326/0003-4819-140-1-200401060-00006; Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735-1097(01)01781-8; Ruilope LM, 2001, J AM SOC NEPHROL, V12, P218, DOI 10.1681/ASN.V122218; Selby JV, 1997, DIABETES CARE, V20, P1396, DOI 10.2337/diacare.20.9.1396; SHEMESH O, 1985, KIDNEY INT, V28, P830, DOI 10.1038/ki.1985.205; Shlipak MG, 2002, ANN INTERN MED, V137, P555, DOI 10.7326/0003-4819-137-7-200210010-00006; Shlipak MG, 2001, J AM COLL CARDIOL, V38, P705, DOI 10.1016/S0735-1097(01)01450-4; Shlipak MG, 2003, CIRCULATION, V107, P87, DOI 10.1161/01.CIR.0000042700.48769.59; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; Therneau T.M., 2000, STAT BIOL HEALTH, DOI 10.1007/978-1-4757-3294-8; *US BUR CENS, 2001, 2000 CENS POP HOUS S; Wang JG, 2001, HYPERTENSION, V37, P1069, DOI 10.1161/01.HYP.37.4.1069; Wannamethee SG, 1997, STROKE, V28, P557, DOI 10.1161/01.STR.28.3.557	42	8360	8675	12	602	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	2004	351	13					1296	1305		10.1056/NEJMoa041031	http://dx.doi.org/10.1056/NEJMoa041031			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	855TP	15385656	Bronze			2023-01-03	WOS:000223997700007
J	Lappe, JM; Muhlestein, JB; Lappe, DL; Badger, RS; Bair, TL; Brockman, R; French, TK; Hofmann, LC; Horne, BD; Kralick-Goldberg, S; Nicponski, N; Orton, JA; Pearson, RR; Renlund, DG; Rimmasch, H; Roberts, C; Anderson, JL				Lappe, JM; Muhlestein, JB; Lappe, DL; Badger, RS; Bair, TL; Brockman, R; French, TK; Hofmann, LC; Horne, BD; Kralick-Goldberg, S; Nicponski, N; Orton, JA; Pearson, RR; Renlund, DG; Rimmasch, H; Roberts, C; Anderson, JL			Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE; STATIN THERAPY; UNITED-STATES; ASPIRIN; MORTALITY; PREVENTION; ANGINA; TRIAL	Background: Despite recent advances in the treatment and prevention of cardiovascular disease, a treatment gap for secondary prevention medications still exists. Objective: To develop and implement a program ensuring appropriate prescription of aspirin, statins, beta-blockers, angiotensin-converting enzyme inhibitors, and warfarin at hospital discharge. Design: A nonrandomized before-after study comparing patients hospitalized before (1996-1998) and after (1999-2002) implementation of a discharge medication program (DMP). Patients were followed for up to 1 year. Setting: The 10 largest hospitals in the Utah-based Intermountain Health Care system. Patients: In the pre-DMP and DMP time periods, 26 000 and 31465 patients, respectively, were admitted to cardiovascular services (n = 57 465). Measurements: Prescription of indicated medications at hospital discharge; postdischarge death or readmission. Results: By 1 year, the rate of prescription of each medication increased significantly to more than 90% (P < 0.001); this rate was sustained. At 1 year, unadjusted absolute event rates for readmission and death, respectively, were 210 per 1000 years and 96 per 1000 person-years before DMP implementation and 191 per 1000 person-years and 70 per 1000 person-years afterward. Relative risk for death and readmission at 30 days decreased after DMP implementation; hazard ratios (HRs) for death and readmission were 0.81 (95% Cl, 0.73 to 0.89) and 0.92 (Cl, 0.87 to 0.99) (P < 0.001 and P = 0.017, respectively). At 1 year, risk for death continued to decrease (hazard ratio, 0.79 [Cl, 0.75 to 0.84]; P < 0.001) while risk for readmission stabilized (hazard ratio, 0.94 [Cl, 0.90 to 0.98]; P = 0.002), probably because survivors had more opportunities to be readmitted. Limitations: The study design was observational and nonrandomized, and the authors could not control for potential confounders or determine the extent to which secular trends accounted for the observed improvements. Conclusions: A relatively simple quality improvement program aimed at enhancing the prescription of appropriate discharge medications among cardiovascular patients is feasible and can be sustained within an integrated multihospital system. Such a program may be associated with improvements in cardiovascular readmission rates and mortality.	LDS Hosp, Intermt Hlth Care, Salt Lake City, UT USA	Intermountain Healthcare	Muhlestein, JB (corresponding author), Hosp Cardiovasc Dept, 8th Ave & C St, Salt Lake City, UT 84143 USA.		Horne, Benjamin/GQP-7851-2022					*AM HEART ASS, 2001, HEART DIS STROK STAT; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Fonarow GC, 2001, AM J CARDIOL, V87, P819, DOI 10.1016/S0002-9149(00)01519-8; Frolkis JP, 1998, CIRCULATION, V98, P851, DOI 10.1161/01.CIR.98.9.851; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; Horne BD, 2000, J AM COLL CARDIOL, V36, P1774, DOI 10.1016/S0735-1097(00)00950-5; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; Maycock CAA, 2002, J AM COLL CARDIOL, V40, P1777, DOI 10.1016/S0735-1097(02)02477-4; Miller M, 2000, ARCH INTERN MED, V160, P343, DOI 10.1001/archinte.160.3.343; Muhlestein JB, 2001, AM J CARDIOL, V87, P257, DOI 10.1016/S0002-9149(00)01354-0; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PEDERSEN TR, 1994, LANCET, V344, P1383; PETERSEN P, 1989, LANCET, V1, P175; Stafford RS, 2000, CIRCULATION, V101, P1097, DOI 10.1161/01.CIR.101.10.1097; Sueta CA, 1999, AM J CARDIOL, V83, P1303, DOI 10.1016/S0002-9149(99)00117-4; *UT DEP HLTH CTR H, 2001, UT VIT STAT 2001; *UT DEP HTLH CTR H, 1998, VIT STAT 1998; 1929, N ENGL J MED, V328, P293	20	104	103	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	2004	141	6					446	453		10.7326/0003-4819-141-6-200409210-00010	http://dx.doi.org/10.7326/0003-4819-141-6-200409210-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	856TM	15381518				2023-01-03	WOS:000224067900005
J	Rietjens, JAC; van der Heide, A; Vrakking, AM; Onwuteaka-Philipsen, BD; van der Maas, PJ; van der Wal, G				Rietjens, JAC; van der Heide, A; Vrakking, AM; Onwuteaka-Philipsen, BD; van der Maas, PJ; van der Wal, G			Physician reports of terminal sedation without hydration or nutrition for patients nearing death in the Netherlands	ANNALS OF INTERNAL MEDICINE			English	Article							LAST RESORT; UNCONTROLLED SYMPTOMS; CAREFUL CONVERSATION; PALLIATIVE OPTIONS; ASSISTED SUICIDE; END; CANCER; LIFE	Background: Terminal sedation in patients nearing death is an important issue related to end-of-life care. Objective: To describe the practice of terminal sedation in the Netherlands. Design: Face-to-face interviews. Setting: The Netherlands. Participants: Nationwide stratified sample of 482 physicians; 410 responded and 211 of these reported characteristics of their most recent terminal sedation case. Measurements: Physician reports of frequency of terminal sedation (defined as the administration of drugs to keep the patient in deep sedation or coma until death, without giving artificial nutrition or hydration), characteristics of the decision-making process, drugs used, the estimated life-shortening effect, and frequency of euthanasia discussions. Results: Of respondents, 52% (95% CI, 48% to 57%) had ever used terminal sedation. Of the 211 most recent cases, physicians used terminal sedation to alleviate severe pain in 51% of patients (CI, 44% to 58%), agitation in 38% (CI, 32% to 45%), and dyspnea in 38% (CI, 32% to 45%). Physicians reported discussing with patients the decision to use deep sedation in 59% of the 211 most recent cases (CI, 52% to 66%) and the decision to forgo artificial nutrition or hydration in 34% (CI, 28% to 41%). Hastening death was partly the intention of the physician in 47% (CI, 41% to 54%) of cases and the explicit intention in 17% (CI, 13% to 22%) of cases. Limitations: The generalizability of physician reports about their most recent cases to all terminal sedation cases is uncertain. In addition, the findings are subject to recall bias and may not apply to other geographic settings. Conclusions: Terminal sedation precedes a substantial number of deaths in the Netherlands. In about two thirds of most recently reported cases, physicians indicated that in addition to alleviating symptoms, they intended to hasten death.	Erasmus MC, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Vrije Universiteit Amsterdam	Rietjens, JAC (corresponding author), Erasmus MC, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.	j.rietjens@erasmusmc.nl						Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; Chater S, 1998, PALLIATIVE MED, V12, P255, DOI 10.1191/026921698671831786; Cherny N I, 1994, J Palliat Care, V10, P31; Chiu TY, 2001, J PAIN SYMPTOM MANAG, V21, P467, DOI 10.1016/S0885-3924(01)00286-X; Coyle N, 1990, J Pain Symptom Manage, V5, P83; Emanuel LL, 1998, JAMA-J AM MED ASSOC, V280, P643, DOI 10.1001/jama.280.7.643; Fainsinger RL, 2000, PALLIATIVE MED, V14, P257, DOI 10.1191/026921600666097479; Fainsinger RL, 1998, J PAIN SYMPTOM MANAG, V16, P145, DOI 10.1016/S0885-3924(98)00066-9; Jansen LA, 2002, ANN INTERN MED, V136, P845, DOI 10.7326/0003-4819-136-11-200206040-00014; Kvasnicka John H, 2002, Ann Intern Med, V137, pW2; Letvak R, 1998, JAMA-J AM MED ASSOC, V279, P1065, DOI 10.1001/jama.279.14.1065; LETVAK R, 1998, JAMA-J AM MED ASSOC, V279, P1066; Loewy EH, 2001, ARCH INTERN MED, V161, P329, DOI 10.1001/archinte.161.3.329; Morita T, 2003, J PAIN SYMPTOM MANAG, V25, P357, DOI 10.1016/S0885-3924(02)00684-X; Morita T, 2002, J CLIN ONCOL, V20, P758, DOI 10.1200/JCO.2002.20.3.758; Morita T, 2001, LANCET, V358, P335, DOI 10.1016/S0140-6736(01)05515-5; Morita Tatsuya, 2002, Ann Intern Med, V137, pW1; Muller-Busch H Christof, 2003, BMC Palliat Care, V2, P2, DOI 10.1186/1472-684X-2-2; Quill TE, 2000, ANN INTERN MED, V132, P488, DOI 10.7326/0003-4819-132-6-200003210-00011; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Quill TE, 2002, ANN INTERN MED, V137, P1009, DOI 10.7326/0003-4819-137-12-200212170-00026; Rousseau P, 2002, ANN INTERN MED, V137, P1009, DOI 10.7326/0003-4819-137-12-200212170-00027; Sasser CG, 2002, ANN INTERN MED, V137, P1008, DOI 10.7326/0003-4819-137-12-200212170-00025; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; Stone P, 1997, PALLIATIVE MED, V11, P140, DOI 10.1177/026921639701100208; Sulmasy DP, 2000, ANN INTERN MED, V133, P562, DOI 10.7326/0003-4819-133-7-200010030-00023; Sulmasy DP, 2000, ANN INTERN MED, V133, P560, DOI 10.7326/0003-4819-133-7-200010030-00021; Sykes N, 2003, LANCET ONCOL, V4, P312, DOI 10.1016/S1470-2045(03)01079-9; Sykes N, 2003, ARCH INTERN MED, V163, P341, DOI 10.1001/archinte.163.3.341; Vainio A, 1996, J PAIN SYMPTOM MANAG, V12, P3, DOI 10.1016/0885-3924(96)00042-5; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; VANDERWAL G, 2003, MED BESLUITVORMING L; Ventafridda V, 1990, J Palliat Care, V6, P7; 2004, STAT NETHERLANDS CEN	35	133	134	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	2004	141	3					178	185		10.7326/0003-4819-141-3-200408030-00006	http://dx.doi.org/10.7326/0003-4819-141-3-200408030-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	843HG	15289214	Green Published			2023-01-03	WOS:000223068600002
J	Andre, T; Boni, C; Mounedji-Boudiaf, L; Navarro, M; Tabernero, J; Hickish, T; Topham, C; Zaninelli, M; Clingan, P; Bridgewater, J; Tabah-Fisch, I; de Gramont, A				Andre, T; Boni, C; Mounedji-Boudiaf, L; Navarro, M; Tabernero, J; Hickish, T; Topham, C; Zaninelli, M; Clingan, P; Bridgewater, J; Tabah-Fisch, I; de Gramont, A		MOSAIC Investigators	Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METASTATIC COLORECTAL-CANCER; HIGH-DOSE LEUCOVORIN; RANDOMIZED-TRIAL; FOLINIC ACID; DUKES B; 1ST-LINE TREATMENT; THERAPY; BREAST; CHEMOTHERAPY; CARCINOMA	Background: The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL). Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting. Methods: We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to receive FL alone or with oxaliplatin for six months. The primary end point was disease-free survival. Results: A total of 1123 patients were randomly assigned to each group. After a median follow-up of 37.9 months, 237 patients in the group given FL plus oxaliplatin had had a cancer-related event, as compared with 293 patients in the FL group (21.1 percent vs. 26.1 percent; hazard ratio for recurrence, 0.77; P=0.002). The rate of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in the group given FL plus oxaliplatin and 72.9 percent (95 percent confidence interval, 70.2 to 75.7) in the FL group (P=0.002 by the stratified log-rank test). In the group given FL plus oxaliplatin, the incidence of febrile neutropenia was 1.8 percent, the incidence of gastrointestinal adverse effects was low, and the incidence of grade 3 sensory neuropathy was 12.4 percent during treatment, decreasing to 1.1 percent at one year of follow-up. Six patients in each group died during treatment (death rate, 0.5 percent). Conclusions: Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.	Hop St Antoine, F-75012 Paris, France; Hop Tenon, F-75970 Paris, France; GERCOR Oncol Multidisciplinary Grp, Paris, France; Arcisped Santa Maria Nuova, Reggio Emilia, Italy; Sanofi Synthelabo, Paris, France; Hosp Llobregat, Hosp Duran & Reynals, Lhospitalet De Llobregat, Spain; Valle Hebron Univ Hosp, Barcelona, Spain; Royal Bournemouth Hosp, Dorset Canc Ctr, Bournemouth, Dorset, England; Poole Hosp, Dorset Canc Ctr, Bournemouth, Dorset, England; Royal Surrey Cty Hosp, Surrey, England; Osped Borgotrento, Verona, Italy; So Med Day Care Ctr, Wollongong, NSW, Australia; N Middlesex Hosp, London, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; IRCCS Arcispedale S. Maria Nuova; Sanofi-Aventis; Sanofi France; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Hospital Universitari Vall d'Hebron; Poole Hospital; Royal Surrey County Hospital; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	de Gramont, A (corresponding author), Hop St Antoine, 184 Rue Faubourg St Antoine, F-75012 Paris, France.	aimery.de-gramont@sat.ap-hop-paris.fr	Bridgewater, John/J-5957-2018; Tabernero, Josep/AAG-5026-2019; André, Thierry P/N-8830-2017	Tabernero, Josep/0000-0002-2495-8139; André, Thierry P/0000-0002-5103-7095; Hickish, Tamas/0000-0001-6770-7279				*AM JOINT COMM CAN, 1997, AJCC CANC STAG MAN, P83; Andre T, 1999, J CLIN ONCOL, V17, P3560, DOI 10.1200/JCO.1999.17.11.3560; Andre T, 2003, J CLIN ONCOL, V21, P2896, DOI 10.1200/JCO.2003.10.065; Buyse M, 2001, SEMIN ONCOL, V28, P20, DOI 10.1053/sonc.2001.19727; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; deGramont A, 1997, J CLIN ONCOL, V15, P808, DOI 10.1200/JCO.1997.15.2.808; Elfenbein GJ, 2003, NEW ENGL J MED, V349, P80, DOI 10.1056/NEJMe030087; Erlichman C, 1999, J CLIN ONCOL, V17, P1356, DOI 10.1200/JCO.1999.17.5.1356; EXTRA JM, 1990, CANCER CHEMOTH PHARM, V25, P299, DOI 10.1007/BF00684890; FRANCINI G, 1994, GASTROENTEROLOGY, V106, P899, DOI 10.1016/0016-5085(94)90748-X; Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136; Gill S., 2003, PROGRAM P AM SOC CLI, V22; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Haller DG, 1998, P AN M AM SOC CLIN, V17, p256a; LABIANCA R, 1995, LANCET, V345, P939; Mamounas E, 1999, J CLIN ONCOL, V17, P1349, DOI 10.1200/JCO.1999.17.5.1349; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; O'Connell MJ, 1998, J CLIN ONCOL, V16, P295, DOI 10.1200/JCO.1998.16.1.295; Obrand DI, 1997, DIS COLON RECTUM, V40, P15, DOI 10.1007/BF02055676; OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246; Rothenberg ML, 2001, J CLIN ONCOL, V19, P3801, DOI 10.1200/JCO.2001.19.18.3801; SARGENT D, 2003, 3 YEAR DFS VS 5 YEAR; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; Wolmark N, 1999, J CLIN ONCOL, V17, P3553, DOI 10.1200/JCO.1999.17.11.3553; Wolmark N, 1998, J NATL CANCER I, V90, P1810, DOI 10.1093/jnci/90.23.1810; Zaniboni A, 1997, J CLIN ONCOL, V15, P2432, DOI 10.1200/JCO.1997.15.6.2432; 2001, IARC CANCERBASE	28	2693	2779	4	154	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2004	350	23					2343	2351		10.1056/NEJMoa032709	http://dx.doi.org/10.1056/NEJMoa032709			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825JY	15175436	Green Published, Bronze			2023-01-03	WOS:000221754200005
J	Nalin, DR; Hirschhorn, N; Greenough, W; Fuchs, GJ; Cash, RA				Nalin, DR; Hirschhorn, N; Greenough, W; Fuchs, GJ; Cash, RA			Clinical concerns about reduced-osmolarity oral rehydration solution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MAINTENANCE THERAPY; STOOL OUTPUT; CHOLERA; DIARRHEA; CHILDREN; ELECTROLYTE; DEHYDRATION; EFFICACY; SAFETY; TRIAL		Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Johns Hopkins Sch Med, Baltimore, MD USA; Univ Arkansas, Sch Med, Little Rock, AR 72204 USA; Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA	Yale University; Johns Hopkins University; Johns Hopkins Medicine; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Harvard University; Harvard T.H. Chan School of Public Health	Nalin, DR (corresponding author), 100 Lucky Hill Rd, W Chester, PA 19382 USA.	davidnalin@aol.com	Fuchs, George/GLV-1285-2022	Fuchs, George/0000-0002-8679-8265				Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; Alam NH, 2003, J PEDIATR-US, V143, P614, DOI 10.1067/S0022-3476(03)00500-6; Alam NH, 1999, LANCET, V354, P296, DOI 10.1016/S0140-6736(98)09332-5; Alam NH, 2001, PEDIATRICS, V107, P613, DOI 10.1542/peds.107.4.613; Alam S, 2000, Indian Pediatr, V37, P952; BLACK RE, 1982, ACUTE DIARRHEA ITS N, P79; CASH RA, 1970, LANCET, V2, P549; CASH RA, 1970, AM J TROP MED HYG, V19, P653, DOI 10.4269/ajtmh.1970.19.653; Dutta D, 2000, ACTA PAEDIATR, V89, P787, DOI 10.1080/080352500750043657; Faruque ASG, 1996, SCAND J INFECT DIS, V28, P87, DOI 10.3109/00365549609027156; FAYAD IM, 1992, LANCET, V339, P389, DOI 10.1016/0140-6736(92)90079-I; Fuchs GJ, 2001, BRIT MED J, V323, P59, DOI 10.1136/bmj.323.7304.59; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; GREENOUGH WB, 1964, LANCET, V1, P355; GUZMAN C, 1988, J PEDIATR GASTR NUTR, V7, P694, DOI 10.1097/00005176-198809000-00013; Hahn S, 2001, BMJ-BRIT MED J, V323, P81, DOI 10.1136/bmj.323.7304.81; HIRSCHHORN N, 1968, NEW ENGL J MED, V279, P176, DOI 10.1056/NEJM196807252790402; HIRSCHHORN N, 1980, AM J CLIN NUTR, V33, P637, DOI 10.1093/ajcn/33.3.637; MATA L, 1982, ACUTE DIARRHEA ITS N, P10; NALIN D R, 1970, Bulletin of the World Health Organization, V43, P361; Nalin D.R., 1970, ANN, V72, P288, DOI [10.7326/0003-4819-72-2-288_3, DOI 10.7326/0003-4819-72-2-288_3]; NALIN DR, 1972, J INFECT DIS, V125, P528, DOI 10.1093/infdis/125.5.528; NALIN DR, 1979, B WORLD HEALTH ORGAN, V57, P453; NALIN DR, 1980, J PEDIATR-US, V97, P848, DOI 10.1016/S0022-3476(80)80287-3; NALIN DR, 1970, T ROY SOC TROP MED H, V64, P769, DOI 10.1016/0035-9203(70)90020-9; NALIN DR, 1968, LANCET, V2, P370; NALIN DR, 1973, USES EPIDEMIOLOGY PL, P1048; PARKER RL, 1980, POPULATION REPORTS, V8, pL41; PATRA FC, 1984, ACTA PAEDIATR SCAND, V73, P18, DOI 10.1111/j.1651-2227.1984.tb09891.x; PIERCE NF, 1969, ANN INTERN MED, V70, P1173, DOI 10.7326/0003-4819-70-6-1173; RABBANI H, 1992, CHOLERA, P213; Wright EM, 1997, J EXP BIOL, V200, P287	32	10	13	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2632	2635		10.1001/jama.291.21.2632	http://dx.doi.org/10.1001/jama.291.21.2632			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825EM	15173156				2023-01-03	WOS:000221738800028
J	van Steijn, JHM; van der Voort, PHJ				van Steijn, JHM; van der Voort, PHJ			Pneumoperitoneum	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Med Ctr Leeuwarden, NL-8901 BR Leeuwarden, Netherlands	Medical Center Leeuwarden	van Steijn, JHM (corresponding author), Med Ctr Leeuwarden, NL-8901 BR Leeuwarden, Netherlands.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	2004	350	18					E16	E16		10.1056/ENEJMicm020442	http://dx.doi.org/10.1056/ENEJMicm020442			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	815ZN	15115846				2023-01-03	WOS:000221080300012
J	Sargent, RP; Shepard, RM; Glantz, SA				Sargent, RP; Shepard, RM; Glantz, SA			Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; ACUTE CORONARY SYNDROMES; CARDIO2000 CASE-CONTROL; HEALTHY-YOUNG ADULTS; PASSIVE SMOKING; HEART-DISEASE; SECONDHAND SMOKE; ENDOTHELIUM; EXPOSURE; RISK	Objective To determine whether there was a change in hospital admissions for acute myocardial infarction while a local law banning smoking in public and in workplaces was in effect. Design Analysis of admissions front December 1997 through November 2003 using Poisson analysis. Setting Helena, Montana, a geographical]), isolated community with one hospital serving a population of 68140. Participants All patients admitted for acute myocardial infarction. Main outcome measures Number of monthly admissions for acute myocardial infarction for people living in mid outside Helena. Results During the six months the law was enforced the number of admissions fell significantly (-16 admissions, 95% confidence interval -31.7 to -0.3), from an average of 40 admissions during the same 0 months in die years before and after the law to a total of 24 admissions during die six months the law was in effect. There was a non-significant increase of 5.6 (-5.2 to 16.4) in the number of admissions from outside Helena during the same period, from 12.4 in the years before and after the law to 18 while the law was in effect. Conclusions Laws to enforce smoke-free workplaces and public places may be associated with art effect on morbidity from heart disease.	Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA; St Peters Community Hosp, HealthCare Qual Performance Council, Helena, MT 59601 USA	University of California System; University of California San Francisco	Glantz, SA (corresponding author), Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA.	glantz@medicine.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Celermajer DS, 1996, NEW ENGL J MED, V334, P150, DOI 10.1056/NEJM199601183340303; DAVIS JW, 1989, ARCH INTERN MED, V149, P386, DOI 10.1001/archinte.149.2.386; Fichtenberg CM, 2000, NEW ENGL J MED, V343, P1772, DOI 10.1056/NEJM200012143432406; Fichtenberg CM, 2002, BMJ-BRIT MED J, V325, P188, DOI 10.1136/bmj.325.7357.188; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; Glantz SA, 2001, JAMA-J AM MED ASSOC, V286, P462, DOI 10.1001/jama.286.4.462; He J, 1999, NEW ENGL J MED, V340, P920, DOI 10.1056/NEJM199903253401204; Law MR, 1997, BMJ-BRIT MED J, V315, P973, DOI 10.1136/bmj.315.7114.973; Lightwood JM, 1997, CIRCULATION, V96, P1089, DOI 10.1161/01.CIR.96.4.1089; ONG M, IN PRESS AM J MED; Otsuka R, 2001, JAMA-J AM MED ASSOC, V286, P436, DOI 10.1001/jama.286.4.436; Panagiotakos DB, 2002, BMC PUBLIC HEALTH, V2, DOI 10.1186/1471-2458-2-9; Pierce JP, 1994, TOBACCO USE CALIFORN; Pierce JP, 1994, TOB CONTROL, V3, P15, DOI DOI 10.1136/TC.3.1.15; Pitsavos C, 2002, TOB CONTROL, V11, P220, DOI 10.1136/tc.11.3.220; Pope CA, 2001, ENVIRON HEALTH PERSP, V109, P711, DOI 10.2307/3454788; Rosenlund M, 2001, EPIDEMIOLOGY, V12, P558, DOI 10.1097/00001648-200109000-00016; SCHACHINGER V, 2000, CIRCULATION, V100, P2153; Stefanadis C, 1998, ANN INTERN MED, V128, P426, DOI 10.7326/0003-4819-128-6-199803150-00002; Sumida H, 1998, J AM COLL CARDIOL, V31, P811, DOI 10.1016/S0735-1097(98)00010-2; *TOB CONTR SECT, MOD CHANG CAL EXP TO; Valkonen M, 1998, CIRCULATION, V97, P2012, DOI 10.1161/01.CIR.97.20.2012	23	343	349	1	29	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 24	2004	328	7446					977	980		10.1136/bmj.38055.715683.55	http://dx.doi.org/10.1136/bmj.38055.715683.55			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816SR	15066887	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000221130100011
J	Lister, G; Fontan, JJP				Lister, G; Fontan, JJP			Can resuscitation jeopardize survival?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EPINEPHRINE		Univ Texas, SW Med Sch, Dept Pediat, Dallas, TX 75230 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Washington University (WUSTL)	Lister, G (corresponding author), Univ Texas, SW Med Sch, Dept Pediat, Dallas, TX 75230 USA.							Behringer W, 1998, ANN INTERN MED, V129, P450, DOI 10.7326/0003-4819-129-6-199809150-00004; CAIN SM, 1973, AM J PHYSIOL, V225, P1405, DOI 10.1152/ajplegacy.1973.225.6.1405; Gueugniaud PY, 1998, NEW ENGL J MED, V339, P1595, DOI 10.1056/NEJM199811263392204; 1986, JAMA, V255, P2961	4	3	3	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	2004	350	17					1708	1709		10.1056/NEJMp048055	http://dx.doi.org/10.1056/NEJMp048055			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	814AJ	15102995				2023-01-03	WOS:000220947300003
J	Cooper, DJ; Myles, PS; McDermott, FT; Murray, LJ; Laidlaw, J; Cooper, G; Tremayne, AB; Bernard, SS; Ponsford, J				Cooper, DJ; Myles, PS; McDermott, FT; Murray, LJ; Laidlaw, J; Cooper, G; Tremayne, AB; Bernard, SS; Ponsford, J		HTS Study Investigators	Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Scientific Meeting of the Australian-and-New Zealand-Intensive-Care-Society	SEP   13, 2003	Cairns, AUSTRALIA	Australia & New Zealand Intens Care Soc			SEVERE HEAD-INJURY; CRITICALLY ILL PATIENTS; GLASGOW OUTCOME SCALE; STRUCTURED INTERVIEWS; FLUID RESUSCITATION; MULTICENTER TRIAL; REHABILITATION; RELIABILITY; DEXTRAN-70; DISABILITY	Context Prehospital hypertonic saline (HTS) resuscitation of patients with traumatic brain injury (TBI) may increase survival but whether HTS improves neurological outcomes is unknown. Objective To determine whether prehospital resuscitation with intravenous HTS improves long-term neurological outcome in patients with severe TBI compared with resuscitation with conventional fluids. Design, Setting, and Patients Double-blind, randomized controlled trial of 229 patients with TBI who were comatose (Glasgow Coma Scale score, <9) and hypotensive (systolic blood pressure, <100 mm Hg). The patients were enrolled between December 14, 1998, and April 9, 2002, in Melbourne, Australia. Interventions Patients were randomly assigned to receive a rapid intravenous infusion of either 250 mL of 7.5% saline (n = 114) or 250 mL of Ringer's lactate solution (n = 115; controls) in addition to conventional intravenous fluid and resuscitation protocols administered by paramedics. Treatment allocation was concealed. Main Outcome Measure Neurological function at 6 months, measured by the extended Glasgow Outcome Score (GOSE). Results Primary outcomes were obtained in 226 (99%) of 229 patients enrolled. Baseline characteristics of the groups were equivalent. At hospital admission, the mean serum sodium level was 149 mEq/L for HTS patients vs 141 mEq/L for controls (P<.001). The proportion of patients surviving to hospital discharge was similar in both groups (n =63 [55%] for HTS group and n =57 [50%] for controls; P=32); at 6 months, survival rates were n =62 (55%) in the HTS group and n =53 (47%) in the control group (P=.23). At 6 months, the median (interquartile range) GOSE was 5 (3-6) in the HTS group vs 5 (5-6) in the control group (P=.45). There was no significant difference between the groups in favorable outcomes (moderate disability and good outcome survivors [GOSE of 5-8]) (risk ratio, 0.99; 95% confidence interval, 0.76-1.30; P=.96) or in any other measure of postinjury neurological function. Conclusion In this study, patients with hypotension and severe TBI who received prehospital resuscitation with HTS had almost identical neurological function 6 months after injury as patients who received conventional fluid.	Monash Univ, Alfred Hosp, Dept Intens Care, Melbourne, Vic 3004, Australia; Monash Univ, Alfred Hosp, Dept Anaesthesia, Melbourne, Vic 3004, Australia; Monash Univ, Dept Psychol, Melbourne, Vic 3004, Australia; Metropolitan Ambulance Serv, Melbourne, Vic, Australia; Consulat Comm Rd Traff Fatil Victoria, Melbourne, Vic, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; Florey Institute of Neuroscience & Mental Health; Monash University; Monash University	Cooper, DJ (corresponding author), Monash Univ, Alfred Hosp, Dept Intens Care, Commercial Rd, Melbourne, Vic 3004, Australia.	j.cooper@alfred.org.au	Morley, Peter/G-5280-2017; Myles, Paul/AAU-9524-2020; Cooper, D. James/G-7961-2013	Morley, Peter/0000-0003-2653-090X; Myles, Paul/0000-0002-3324-5456; Cooper, D. James/0000-0002-5872-9051				*AM COLL SURG COMM, 2003, ADV TRAUM LIF SUPP P; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Choi PTL, 1999, CRIT CARE MED, V27, P200, DOI 10.1097/00003246-199901000-00053; *COMM AUSTR, 1999, NAT STAT ETH COND RE; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; DUBICK MA, 1994, J TRAUMA, V36, P323, DOI 10.1097/00005373-199403000-00007; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GABRIEL EJ, 2000, GUIDELINES PREHOSPIT, P7; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HAGEN C, 1982, COGNITIVE REHABILITA, P131; HUNT J, 1995, AUST NZ J SURG, V65, P83, DOI 10.1111/j.1445-2197.1995.tb07266.x; JENNETT B, 1975, LANCET, V1, P480; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kramer GC, 2003, J TRAUMA, V54, pS89, DOI 10.1097/01.TA.0000065609.82142.F1; Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; Schierhout G, 1998, BMJ-BRIT MED J, V316, P961, DOI 10.1136/bmj.316.7136.961; SVENSEN CH, 2002, TRAUMA CARE J INT TR, P6; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; *US NIH, 1998, REH PERS TRAUM BRAIN; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; WADE CE, 1997, J TRAUMA, V42, P561; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478	32	283	302	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	2004	291	11					1350	1357		10.1001/jama.291.11.1350	http://dx.doi.org/10.1001/jama.291.11.1350			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	802PF	15026402	Bronze			2023-01-03	WOS:000220174700029
J	Kariminia, A; Chamberlain, ME; Keogh, J; Shea, A				Kariminia, A; Chamberlain, ME; Keogh, J; Shea, A			Randomised controlled trial of effect of hands and knees posturing on incidence of occiput posterior position at birth	BRITISH MEDICAL JOURNAL			English	Article							DELIVERY	Objective To evaluate the efficacy of hands and knees position and pelvic rocking exercises on the incidence of fetal occiput posterior position at birth. Design Multicentre randomised controlled trial. Setting Seven maternity units in New South Wales, Australia, encompassing teaching hospitals and district general hospitals. Participants 2547 pregnant women at 37 weeks' gestation; 1292 randomised to the intervention group and 1255 to the control group. Intervention Hands and knees position and pelvic rocking exercises from 37 weeks' gestation until the onset of labour. Main outcome measure Incidence of fetal occiput posterior position at birth. Results 1046 women in the intervention group and 1209 women in the control group remained in the study until they went into labour. No significant difference existed between the groups for the incidence of occiput posterior position at birth: 105 (8.1%) women in the intervention group and 98 (7.8%) in the control group had a baby in a posterior position at delivery (difference in risk 0.3%, 95% confidence interval -1.8 to 2.4). The incidence of fetal transverse arrest was 3.4% (44 women) in the intervention group and 3.0% (38 women) in the control group (difference in risk 0.4, - 1 to 1.7). No differences occurred between intervention and control groups for induction of labour, use of epidural, duration of labour, mode of delivery, use of episiotomy, or Apgar score. Conclusion Hands and knees exercise with pelvic rocking from 37 weeks' gestation to the onset of labour did not reduce the incidence of persistent occiput posterior position at birth.	Hornsby Hosp, Dept Obstet & Gynaecol, Hornsby, NSW 2077, Australia; Univ Sydney, Sydney, NSW 2006, Australia	University of Sydney	Kariminia, A (corresponding author), Pub Hlth Unit, Long Bay Complex,Anzac Parade,POB 150, Matraville, NSW 2036, Australia.	karimia@chs.health.nsw.gov.au						ANDREWS CM, 1983, NURS RES, V32, P336; ANDREWS CM, 1981, J ADV NURS, V3, P53; Badawi N, 1998, BMJ-BRIT MED J, V317, P1554, DOI 10.1136/bmj.317.7172.1554; BIANCUZZO M, 1991, BIRTH-ISS PERINAT C, V18, P40, DOI 10.1111/j.1523-536X.1991.tb00053.x; Cunningham FG, 1997, WILLIAMS OBSTET; Fitzpatrick M, 2001, OBSTET GYNECOL, V98, P1027, DOI 10.1016/S0029-7844(01)01600-3; Gardberg M, 1998, OBSTET GYNECOL, V91, P746, DOI 10.1016/S0029-7844(98)00074-X; HOFMEYR GJ, 2002, COCHRANE DATABASE SY, DOI UNSP CD0010163; Neri A., 1995, Clinical and Experimental Obstetrics and Gynecology, V22, P126; PEARL ML, 1993, J REPROD MED, V38, P955; Public Health Division, 2001, NEW S WAL MOTH BAB 2; PUDDICOMBE JF, 1958, INT COLL SURG, V23, P73; RICHTMULLER D, 1999, J GYNECOL OBST BIO R, V28, P41; *ROYAL N SHOR HOSP, 1997, ROYAL N SHOR HOSP 19	14	23	27	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 28	2004	328	7438					490	493		10.1136/bmj.37942.594456.44	http://dx.doi.org/10.1136/bmj.37942.594456.44			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800BC	14744821	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000220002900019
J	McKiernan, S; Bua, E; McGorray, J; Aiken, J				McKiernan, S; Bua, E; McGorray, J; Aiken, J			Early-onset calorie restriction conserves fiber number in aging rat skeletal muscle	FASEB JOURNAL			English	Article						sarcopenia; muscle fibers	VASTUS LATERALIS MUSCLE; DNA DELETION MUTATIONS; MITOCHONDRIAL ABNORMALITIES; OXIDATIVE DAMAGE; FOOD RESTRICTION; AGE; ATROPHY; PROPORTION; SARCOPENIA; APOPTOSIS	The purpose of this work was to determine the effect of early-onset calorie restriction on sarcopenia in the aging rat. Ad libitum (AL) fed animals were examined at 5, 18, 21, and 36 months of age. Calorie-restricted (CR) rats, 40% restricted since 4 months of age, were examined at 21 and 36 months of age. By 36 months, vastus lateralis, rectus femoris and soleus muscles, from AL-fed rats, had significant muscle mass and fiber loss, and reduced muscle cross-sectional area. Mean fiber diameter decreased with age in the vastus lateralis and rectus femoris but not the soleus of AL-fed rats. The number of Type I fibers significantly increased in the vastus lateralis with age. Calorie restriction did not prevent muscle mass loss with age; however, it significantly reduced muscle mass loss between 21 and 36 months of age compared with age-matched AL cohorts. Calorie restriction prevented fiber loss with age, and this conservation of fiber number reduced muscle mass loss with age.	Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Aiken, J (corresponding author), Univ Wisconsin, Dept Anim Hlth & Biomed Sci, 1656 Linden Dr, Madison, WI 53706 USA.	aiken@svm.vetmed.wisc.edu	Smolarz, Andrzej/A-5491-2013; Kozbakova, Ainur/K-5077-2018; Ballester, Javier/E-7310-2012	Smolarz, Andrzej/0000-0002-6473-9627; Kozbakova, Ainur/0000-0002-5213-4882; Aiken, Judd/0000-0001-6119-4521				Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Balagopal P, 1997, AM J PHYSIOL-ENDOC M, V272, pE45, DOI 10.1152/ajpendo.1997.272.1.E45; Borisov AB, 2001, ANAT REC, V264, P203, DOI 10.1002/ar.1155; Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001; Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502; CARMELI E, 1994, P SOC EXP BIOL MED, V206, P103; Cartee G D, 1994, Exerc Sport Sci Rev, V22, P91; CARTEE GD, 1995, J GERONTOL A-BIOL, V50, P137; Carter CS, 2001, EXP AGING RES, V27, P271, DOI 10.1080/036107301300208709; Dirks A, 2002, AM J PHYSIOL-REG I, V282, pR519, DOI 10.1152/ajpregu.00458.2001; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Dubowitz V., 1973, MUSCLE BIOPSY MODERN; Dutta C, 1997, J NUTR, V127, pS992, DOI 10.1093/jn/127.5.992S; HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S; HAVENITH MG, 1990, HISTOCHEMISTRY, V93, P497, DOI 10.1007/BF00266407; Higami Y, 2000, CELL TISSUE RES, V301, P125, DOI 10.1007/s004419900156; HOLLOSZY JO, 1991, MECH AGEING DEV, V60, P199, DOI 10.1016/0047-6374(91)90131-I; ISHIHARA A, 1988, MECH AGEING DEV, V45, P213, DOI 10.1016/0047-6374(88)90003-6; Kanda K, 2002, MICROSC RES TECHNIQ, V59, P301, DOI 10.1002/jemt.10208; Kirkendall DT, 1998, AM J SPORT MED, V26, P598, DOI 10.1177/03635465980260042401; Lee CM, 1998, FREE RADICAL BIO MED, V25, P964, DOI 10.1016/S0891-5849(98)00185-3; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; Lopez ME, 2000, MUTAT RES-FUND MOL M, V452, P123, DOI 10.1016/S0027-5107(00)00059-2; Lu DX, 1997, ANAT REC, V248, P355; MCCARTER R, 1978, NUTR REP INT, V17, P339; McCarter RJM, 1997, AGING-CLIN EXP RES, V9, P73, DOI 10.1007/BF03340130; MCCARTER RJM, 1982, AM J PHYSIOL, V242, pR89, DOI 10.1152/ajpregu.1982.242.1.R89; NAVARRO A, 2001, FRONT BIOSCI, V6, P26; PARK JHY, 1982, FED PROC, V41, P464; Proctor DN, 1998, J NUTR, V128, p351S, DOI 10.1093/jn/128.2.351S; Rosenberg IH, 1997, J NUTR, V127, pS990, DOI 10.1093/jn/127.5.990S; SAS, 1989, SAS US GUID; Sheehan D.C., 1980, THEORY PRACTICE HIST; SIECK GC, 1989, J APPL PHYSIOL, V66, P2196, DOI 10.1152/jappl.1989.66.5.2196; SJOSTROM M, 1992, ANAT REC, V234, P183, DOI 10.1002/ar.1092340205; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, pE38, DOI 10.1152/ajpendo.00387.2001; Thompson LV, 2002, J ORTHOP SPORT PHYS, V32, P44, DOI 10.2519/jospt.2002.32.2.44; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492; Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com; Weindruch R, 2001, J NUTR, V131, p918S, DOI 10.1093/jn/131.3.918S; Weindruch R., 1988, RETARDATION AGING DI; WINEINGER MA, 1995, GROWTH DEVELOP AGING, V59, P107; YU BP, 1982, J GERONTOL, V37, P130, DOI 10.1093/geronj/37.2.130; YU BP, 1985, J GERONTOL, V40, P657, DOI 10.1093/geronj/40.6.657	46	62	64	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					580	+		10.1096/fj.03-0667fje	http://dx.doi.org/10.1096/fj.03-0667fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734642				2023-01-03	WOS:000188829300002
J	Ellner, A				Ellner, A			Rethinking prescribing in the United States	BMJ-BRITISH MEDICAL JOURNAL			English	Article									BMJ Knowledge, London WC1H 9JR, England		Ellner, A (corresponding author), BMJ Knowledge, London WC1H 9JR, England.	aellner@bmjgroup.com						*AM COLL PHYS, 2001, AMB CAR FORM PHARM B; [Anonymous], 2002, WORLD HLTH REP 2002; Blumenthal D, 2000, DESCRIPTION ANAL VA; Goff V V, 2001, Issue Brief Natl Health Policy Forum, P1; Holmer AF, 2002, NEW ENGL J MED, V346, P526, DOI 10.1056/NEJM200202143460714; Horn SD, 1996, LANCET, V348, P619, DOI 10.1016/S0140-6736(05)64839-8; Ioannides-Demos LL, 2002, PHARMACOECONOMICS, V20, P577, DOI 10.2165/00019053-200220090-00002; KITCHMAN M, 2002, SENIORS PRESCRIPTION; *NIH CAR MAN FDN, 2000, PRESCR DRUGS MASS ME; *PROD COMM, 2001, INT PHARM PRIC DIFF; *REF DRUG PROGR CO, 2002, REP MIN HLTH PLANN; Rennie D, 2000, JAMA-J AM MED ASSOC, V283, P2158, DOI 10.1001/jama.283.16.2158; Rosenthal MB, 2002, NEW ENGL J MED, V346, P498, DOI 10.1056/NEJMsa012075; RossDegnan D, 1996, LANCET, V347, P1264, DOI 10.1016/S0140-6736(96)90782-5; Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087; Schneeweiss S, 2002, CAN MED ASSOC J, V166, P737; Steinbrook R, 2002, NEW ENGL J MED, V346, P790, DOI 10.1056/NEJM200203143461102; STUART B, 2000, REPORT PRESIDENT PRE; WHO, WHO MOD LIST ESS MED	19	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 13	2003	327	7428					1397	1400		10.1136/bmj.327.7428.1397	http://dx.doi.org/10.1136/bmj.327.7428.1397			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755PL	14670892	Green Published			2023-01-03	WOS:000187417900030
J	Wainberg, MA				Wainberg, MA			Generic HIV drugs - Enlightened policy for global health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RESISTANCE		McGill Univ, Jewish Gen Hosp, AIDS Ctr, Montreal, PQ H3T 1E2, Canada	McGill University	Wainberg, MA (corresponding author), McGill Univ, Jewish Gen Hosp, AIDS Ctr, Montreal, PQ H3T 1E2, Canada.							*GLOB HIV AIDS PRO, 2004, AIDS S, V18, pS1; Kuritzkes DR, 1996, AIDS, V10, P975, DOI 10.1097/00002030-199610090-00007; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; *WHO, 2004, 3 AIDS MED REM PREQ	5	17	18	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2005	352	8					747	750		10.1056/NEJMp048356	http://dx.doi.org/10.1056/NEJMp048356			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899MC	15728804				2023-01-03	WOS:000227147500001
J	Hendrix, SL; Cochrane, BB; Nygaard, IE; Handa, VL; Barnabei, VM; Iglesia, C; Aragaki, A; Naughton, MJ; Wallace, RB; McNeeley, SG				Hendrix, SL; Cochrane, BB; Nygaard, IE; Handa, VL; Barnabei, VM; Iglesia, C; Aragaki, A; Naughton, MJ; Wallace, RB; McNeeley, SG			Effects of estrogen with and without progestin on urinary incontinence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; STRESS-INCONTINENCE; RISK-FACTORS; RECEPTORS; SYMPTOMS; PREVALENCE; MANAGEMENT; SUPPLEMENTATION; ESTRADIOL; HORMONES	Context Menopausal hormone therapy has long been credited with many benefits beyond the indications of relieving hot flashes, night sweats, and vaginal dryness, and it is often prescribed to treat urinary incontinence (UI). Objective To assess the effects of menopausal hormone therapy on the incidence and severity of symptoms of stress, urge, and mixed UI in healthy postmenopausal women. Design, Setting, and Participants Women's Health Initiative multicenter double-blind, placebo-controlled, randomized clinical trials of menopausal hormone therapy in 27347 postmenopausal women aged 50 to 79 years enrolled between 1993 and 1998, for whom UI symptoms were known in 23 296 participants at baseline and 1 year. Interventions Women were randomized based on hysterectomy status to active treatment or placebo in either the estrogen plus progestin (E + P) or estrogen alone trials. The E + P hormones were 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate (CEE + MPA); estrogen alone consisted of 0.625 mg/d of conjugated equine estrogen (CEE). There were 8506 participants who received CEE + MPA (8102 who received placebo) and 5310 who received CEE alone (5429 who received placebo). Main Outcome Measures Incident UI at 1 year among women without UI at baseline and severity of UI at 1 year among women who had UI at baseline. Results Menopausal hormone therapy increased the incidence of all types of UI at 1 year among women who were continent at baseline. The risk was highest for stress UI (CEE + MPA: relative risk [RR], 1.87 [95% confidence interval {CI}, 1.61-2.18]; CEE alone: RR, 2.15 [95% CI, 1.77-2.62]), followed by mixed UI (CEE + MPA: RR, 1.49 [95% Cl, 1.10-2.01]; CEE alone: RR, 1.79 [95% Cl, 1.26-2.53]). The combination of CEE + MPA had no significant effect on developing urge UI (RR, 1.15; 95% Cl, 0.99-1.34), but CEE alone increased the risk (RR, 1.32; 95% Cl, 1.10-1.58). Among women experiencing UI at baseline, frequency worsened in both trials (CEE + MPA: RR, 1.38 [95% Cl, 1.28-1.49]; CEE alone: RR, 1.47 [95% Cl, 1.35-1.61]). Amount of UI worsened at 1 year in both trials (CEE + MPA: RR, 1.20 [95% Cl, 1.06-1.36]; CEE alone: RR, 1.59 [95% Cl, 1.39-1.82]). Women receiving menopausal hormone therapy were more likely to report that UI limited their daily activities (CEE + MPA: RR, 1.18 [95% Cl, 1.06-1.32]; CEE alone: RR, 1.29 [95% Cl, 1.15-1.45]) and bothered or disturbed them (CEE + MPA: RR, 1.22 [95% Cl, 1.13-1.32]; CEE alone: RR, 1.50 [95% Cl, 1.37-1.65]) at 1 year. Conclusions Conjugated equine estrogen alone and CEE + MPA increased the risk of UI among continent women and worsened the characteristics of UI among symptomatic women after 1 year. Conjugated equine estrogen with or without progestin should not be prescribed for the prevention or relief of UI.	Wayne State Univ, Sch Med, Hutzel Womens Hosp, Dept Obstet & Gynecol, Detroit, MI 48201 USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA; Univ Iowa, Carver Coll Med, Dept Obstet & Gynecol, Iowa City, IA USA; Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA; Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Baltimore, MD 21205 USA; Med Coll Wisconsin, Dept Obstet & Gynecol, Milwaukee, WI 53226 USA; Washington Hosp Ctr, Dept Obstet & Gynecol, Washington, DC 20010 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA	Wayne State University; Fred Hutchinson Cancer Center; University of Iowa; University of Iowa; Johns Hopkins University; Medical College of Wisconsin; MedStar Washington Hospital Center; Wake Forest University; Wake Forest Baptist Medical Center	Hendrix, SL (corresponding author), Wayne State Univ, Sch Med, Hutzel Womens Hosp, Dept Obstet & Gynecol, Detroit, MI 48201 USA.	shendrix@med.wayne.edu						*1 DATABANK INC, 2000, MDDB PROD LIN DOC MA; AHLSTROM K, 1990, GYNECOL OBSTET INVES, V30, P37, DOI 10.1159/000293211; *AM COLL OBST GYN, 2003, RESP WOM HLTH IN RES; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Andersson KE, 1999, BJU INT, V84, P923; BATRA SC, 1987, J UROLOGY, V138, P1301, DOI 10.1016/S0022-5347(17)43588-9; Brown JS, 1996, OBSTET GYNECOL, V87, P715, DOI 10.1016/0029-7844(96)00013-0; Brown JS, 1999, OBSTET GYNECOL, V94, P66, DOI 10.1016/S0029-7844(99)00263-X; Butler RN, 1999, GERIATRICS, V54, P31; Fantl JA, 1996, OBSTET GYNECOL, V88, P745; FANTL JA, 1994, OBSTET GYNECOL, V83, P12; Fornell EU, 2004, ACTA OBSTET GYN SCAN, V83, P383, DOI 10.1111/j.0001-6349.2004.00367.x; Grady D, 2001, OBSTET GYNECOL, V97, P116, DOI 10.1016/S0029-7844(00)01115-7; Griebling TL, 1997, ENDOCRIN METAB CLIN, V26, P347, DOI 10.1016/S0889-8529(05)70251-6; Grodstein F, 2003, AM J OBSTET GYNECOL, V189, P428, DOI 10.1067/S0002-9378(03)00361-2; Hays J, 2003, ANN EPIDEMIOL, V13, pS18, DOI 10.1016/S1047-2797(03)00042-5; Hunskaar S, 2003, UROLOGY, V62, P16, DOI 10.1016/S0090-4295(03)00755-6; IOSIF CS, 1981, AM J OBSTET GYNECOL, V141, P817, DOI 10.1016/0002-9378(81)90710-9; IOSIF CS, 1984, ACTA OBSTET GYN SCAN, V63, P257, DOI 10.3109/00016348409155509; Jackson S, 2002, BJOG-INT J OBSTET GY, V109, P339; Jackson S, 1999, BRIT J OBSTET GYNAEC, V106, P711, DOI 10.1111/j.1471-0528.1999.tb08372.x; JUDGE TG, 1969, GERONTOL CLIN, V11, P159, DOI 10.1159/000245230; Moehrer B, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001405; Muscatello DJ, 2001, INTERN MED J, V31, P151, DOI 10.1046/j.1445-5994.2001.00035.x; Novielli Karen D., 2003, International Urology and Nephrology, V35, P423, DOI 10.1023/B:UROL.0000022868.73066.9a; Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6; RESNICK NM, 1994, J AM GERIATR SOC, V42, P202, DOI 10.1111/j.1532-5415.1994.tb04953.x; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rufford J, 2003, INT UROGYNECOL J, V14, P78, DOI 10.1007/s00192-003-1054-3; SAEZ S, 1981, J STEROID BIOCHEM, V15, P317, DOI 10.1016/0022-4731(81)90291-0; Sampselle CM, 2002, OBSTET GYNECOL, V100, P1230, DOI 10.1016/S0029-7844(02)02241-X; Sarkar PK, 2000, J CLIN PHARM THER, V25, P251; SCHREITER F, 1976, UROL INT, V31, P13, DOI 10.1159/000280026; Swithinbank LV, 1999, BRIT J GEN PRACT, V49, P897; Thom DH, 1998, J AM GERIATR SOC, V46, P1411; WILSON PD, 1987, BRIT J OBSTET GYNAEC, V94, P568, DOI 10.1111/j.1471-0528.1987.tb03152.x	37	330	336	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2005	293	8					935	948		10.1001/jama.293.8.935	http://dx.doi.org/10.1001/jama.293.8.935			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899LR	15728164	Bronze			2023-01-03	WOS:000227146400015
J	Fost, N				Fost, N			Institutionalization of children: America's Gulag archipelago	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Med Hist & Bioeth, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Fost, N (corresponding author), Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA.							Advisory Committee on Human Radiation Experiments, 1995, FIN REP; Kevles Daniel J., 1985, NAME EUGENICS GENETI	2	0	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2004	351	23					2369	2370		10.1056/NEJMp048207	http://dx.doi.org/10.1056/NEJMp048207			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875OC	15575051				2023-01-03	WOS:000225429000004
J	McGuire, W; Henderson, G; Fowlie, PW				McGuire, W; Henderson, G; Fowlie, PW			ABC of preterm birth - Feeding the preterm infant	BMJ-BRITISH MEDICAL JOURNAL			English	Review							DIET		Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 4HN, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Neonatal Intens Care Unit, Dundee DD1 9SY, Scotland; Perth Royal Infirm, Perth, Scotland	University of Dundee; University of Dundee	Henderson, G (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 4HN, Scotland.			McGuire, William/0000-0001-8572-3467				Ainsworth SB, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004219.pub3; Cooke RJ, 2000, ARCH DIS CHILD-FETAL, V83, pF215, DOI 10.1136/fn.83.3.F215; KENNEDY KA, 2003, COCHRANE DB SYST REV; KENNEDY KA, 2003, COCHRANE DB SYST REV; Lucas A, 1998, BRIT MED J, V317, P1481, DOI 10.1136/bmj.317.7171.1481; MCGUIRE W, 2003, COCHRANE DATABASE SY; Moore ER, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003519.pub2; Morley R, 2000, AM J CLIN NUTR, V71, P822, DOI 10.1093/ajcn/71.3.822; TYSON JE, 2004, COCHRANE DATABASE SY	9	36	38	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	2004	329	7476					1227	1230		10.1136/bmj.329.7476.1227	http://dx.doi.org/10.1136/bmj.329.7476.1227			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874FG	15550428	Green Published			2023-01-03	WOS:000225335700021
J	Polak, JF				Polak, JF			Ultrasound energy and the dissolution of thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Tufts Univ New England Med Ctr, Dept Radiol, Boston, MA 02111 USA; Tufts Sch Med, Boston, MA USA	Tufts Medical Center	Polak, JF (corresponding author), Tufts Univ New England Med Ctr, Dept Radiol, 750 Washington St, Boston, MA 02111 USA.							Hacke W, 2004, LANCET, V363, P768; Sakharov DV, 1999, THROMB HAEMOSTASIS, V81, P605	2	45	47	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2154	2155		10.1056/NEJMp048249	http://dx.doi.org/10.1056/NEJMp048249			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548774				2023-01-03	WOS:000225160600004
J	Vamvakas, EC				Vamvakas, EC			Platelet transfusion and adverse outcomes	LANCET			English	Editorial Material							ALLOGENEIC BLOOD-TRANSFUSION; RANDOMIZED CONTROLLED-TRIAL; POSTOPERATIVE INFECTION; CARDIAC-SURGERY		Univ Ottawa, Dept Pathol & Lab Med, Canadian Blood Serv, Ottawa, ON K1G 4J5, Canada	Canadian Blood Services; University of Ottawa	Vamvakas, EC (corresponding author), Univ Ottawa, Dept Pathol & Lab Med, Canadian Blood Serv, Ottawa, ON K1G 4J5, Canada.	stephen.vamvakas@bloodservices.ca						Akbiyik F, 2004, BLOOD, V104, P1361, DOI 10.1182/blood-2004-03-0926; Bilgin YM, 2004, CIRCULATION, V109, P2755, DOI 10.1161/01.CIR.0000130162.11925.21; BORDIN JO, 1994, BLOOD, V84, P344; Bracey AW, 2002, TRANSFUSION, V42, p5S; Magee CC, 1997, CURR OPIN IMMUNOL, V9, P669, DOI 10.1016/S0952-7915(97)80047-7; MVAKAS EC, 2003, TRANSFUSION, V43, P963; Rao SV, 2004, JAMA-J AM MED ASSOC, V292, P1555, DOI 10.1001/jama.292.13.1555; Spiess BD, 2004, TRANSFUSION, V44, P1143, DOI 10.1111/j.1537-2995.2004.03322.x; Vamvakas EC, 2002, TRANSFUS MED REV, V16, P304, DOI 10.1053/tmrv.2002.35209; Vamvakas EC, 2001, BLOOD, V97, P1180, DOI 10.1182/blood.V97.5.1180; van de Watering LMG, 1998, CIRCULATION, V97, P562; van Hilten JA, 2004, BMJ-BRIT MED J, V328, P1281, DOI 10.1136/bmj.38103.735266.55; Wallis JP, 2002, TRANSFUSION, V42, P1127, DOI 10.1046/j.1537-2995.2002.00181.x	13	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	2004	364	9447					1736	1738		10.1016/S0140-6736(04)17414-X	http://dx.doi.org/10.1016/S0140-6736(04)17414-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541433				2023-01-03	WOS:000225070600007
J	Horbar, JD; Carpenter, JH; Buzas, J; Soll, RF; Suresh, G; Bracken, MB; Leviton, LC; Plsek, PE; Sinclair, JC				Horbar, JD; Carpenter, JH; Buzas, J; Soll, RF; Suresh, G; Bracken, MB; Leviton, LC; Plsek, PE; Sinclair, JC			Collaborative quality improvement to promote evidence based surfactant for preterm infants: a cluster randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To test a multifaceted collaborative quality improvement intervention designed to promote evidence based surfactant treatment for preterm infants of 23-29 weeks' gestation. Design Cluster randomised controlled trial. Setting and participants 114 neonatal intensive care units (which treated 6039 infants of 23-29 weeks gestation born in 2001). Main outcome measures Process of care measures: proportion of infants receiving first surfactant in the delivery room, proportion receiving first surfactant more than two hours after birth, and median time from birth to first dose of surfactant. Clinical outcomes: death before discharge home, and pneumothorax. Intervention Multifaceted collaborative quality improvement advice including audit and feedback, evidence reviews, an interactive training workshop, and ongoing faculty support via conference calls and email. Results Compared with those in control hospitals, infants in intervention hospitals were more likely to receive surfactant in the delivery room (adjusted odds ratio 5.38 (95% confidence interval 2.84 to 10.20)), were less likely to receive the first dose more than two hours after birth (adjusted odds ratio 0.35 (0.24 to 0.53)), and received the first dose of surfactant sooner after birth (median of 21 minutes v 78 minutes, P<0.001). The intervention effect on timing of surfactant was larger for infants born in the participating hospitals than for infants transferred to a participating hospital after birth. There were no significant differences in mortality or pneumothorax. Conclusion A multifaceted intervention including audit and feedback, evidence reviews, quality improvement training, and follow up support changed the behaviour of health professionals and promoted evidence based practice.	Vermont Oxford Network, Burlington, VT 05401 USA; Univ Vermont, Burlington, VT USA; Med Univ S Carolina, Charleston, SC 29425 USA; Yale Univ, Ctr Perinatal Pediat & Environm Epidemiol, New Haven, CT USA; Robert Wood Johnson Fdn, Princeton, NJ 08540 USA; Paul E Plsek & Associates, Atlanta, GA USA; McMaster Univ, Dept Pediat, Hamilton, ON, Canada	University of Vermont; Medical University of South Carolina; Yale University; Robert Wood Johnson Foundation (RWJF); McMaster University	Horbar, JD (corresponding author), Vermont Oxford Network, 33 Kilburn St, Burlington, VT 05401 USA.	horbar@vtoxford.org			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010528] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS10528] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Berwick DM, 2003, JAMA-J AM MED ASSOC, V289, P1969, DOI 10.1001/jama.289.15.1969; Campbell Marion K, 2004, BMC Med Res Methodol, V4, P9, DOI 10.1186/1471-2288-4-9; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; Collett D, 2015, MODELLING SURVIVAL D; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; Horbar JD, 2004, PEDIATRICS, V113, P1593, DOI 10.1542/peds.113.6.1593; Horbar JD, 2003, PEDIATRICS, V111; Horbar JD, 2002, PEDIATRICS, V110, P143, DOI 10.1542/peds.110.1.143; Horbar JD, 2001, PEDIATRICS, V107, P14, DOI 10.1542/peds.107.1.14; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; Ivers N, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000259.PUB3; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Langley Gj., 1996, IMPROVEMENT GUIDE PR; LEE EW, 1994, STAT MED, V13, P1241, DOI 10.1002/sim.4780131206; OBRIEN MAT, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003030; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Plsek P E, 1999, Pediatrics, V103, P203; Puffer S, 2003, BMJ-BRIT MED J, V327, P785, DOI 10.1136/bmj.327.7418.785; PUFLIER S, 2003, BMJ-BRIT MED J, V327, P785; Sackett DL, 2000, EVIDENCE BASED MED P; Soll RF, 2000, COCHRANE DB SYST REV, V2; SOLL RF, 2001, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD000510, 10.1002/14651858.CD000510]; *VT OXF NETW, 1999, DAT MAN OP REL 4 0; Wilson Tim, 2003, Jt Comm J Qual Saf, V29, P85; Yost CC, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001456; Zwarentein M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000072.pub2	26	120	124	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 30	2004	329	7473					1004	1007		10.1136/bmj.329.7473.1004	http://dx.doi.org/10.1136/bmj.329.7473.1004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OR	15514344	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000224852400017
J	Cushman, M; Kuller, LH; Prentice, R; Rodabough, RJ; Psaty, BM; Stafford, RS; Sidney, S; Rosendaal, FR				Cushman, M; Kuller, LH; Prentice, R; Rodabough, RJ; Psaty, BM; Stafford, RS; Sidney, S; Rosendaal, FR		Women's Hlth Initiative Investigat	Estrogen plus progestin and risk of venous thrombosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; HEALTHY POSTMENOPAUSAL WOMEN; FACTOR-V-LEIDEN; THROMBOEMBOLISM; HEART; OUTCOMES; DISEASE; CANCER; BREAST; USERS	Context Postmenopausal hormone therapy increases the risk of venous thrombosis. It is not known whether other factors influencing thrombosis add to this risk. Objective To report final data on incidence of venous thrombosis in the Women's Health Initiative Estrogen Plus Progestin clinical trial and the association of hormone therapy with venous thrombosis in the setting of other thrombosis risk factors. Design, Setting, and Participants Double-blind randomized controlled trial of 16608 postmenopausal women between the ages of 50 and 79 years, who were enrolled in 1993 through 1998 at 40 US clinical centers with 5.6 years of follow up; and a nested case-control study. Baseline gene variants related to thrombosis risk were measured in the first 147 women who developed thrombosis and in 513 controls. Intervention Random assignment to 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate, or placebo. Main Outcome Measures Centrally validated deep vein thrombosis and pulmonary embolus. Results Venous thrombosis occurred in 167 women taking estrogen plus progestin (3.5 per 1000 person-years) and in 76 taking placebo (1.7 per 1000 person-years); hazard ratio (HR), 2.06 (95% confidence interval [CI], 1.57-2.70). Compared with women between the ages of 50 and 59 years who were taking placebo, the risk associated with hormone therapy was higher with age: HR of 4.28 (95% CI, 2.38-7.72) for women aged 60 to 69 years and 7.46 (95% CI, 4.32-14.38) for women aged 70 to 79 years. Compared with women who were of normal weight and taking placebo, the risk associated with taking estrogen plus progestin was increased among overweight and obese women: HR of 3.80 (95% CI, 2.08-6.94) and 5.61 (95% CI, 3.12-10.11), respectively. Factor V Leiden enhanced the hormone-associated risk of thrombosis with a 6.69-fold increased risk compared with women in the placebo group without the mutation (95% CI, 3.09-14.49). Other genetic variants (prothrombin 20210A, methylenetetrahydrofolate reductase C677T, factor XIII Val34Leu, PAI-14G/5G, and factor V HR2) did not modify the association of hormone therapy with venous thrombosis. Conclusions Estrogen plus progestin was associated with doubling the risk of venous thrombosis. Estrogen plus progestin therapy increased the risks associated with age, overweight or obesity, and factor V Leiden.	Univ Vermont, Dept Med, Burlington, VT USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA; Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Stanford Univ, Stanford Prevent Res Ctr, Program Prevent Outcomes & Practices, Stanford, CA 94305 USA; Kaiser Permanente, Div Res, Oakland, CA USA; Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands	University of Vermont; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Stanford University; Kaiser Permanente; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Cushman, M (corresponding author), Univ Vermont, 208 S Pk Dr,Suite 2, Colchester, VT 05446 USA.	mary.cushman@uvm.edu	Rosendaal, Frits/Q-3842-2017; Stafford, Randall/F-3974-2017	Rosendaal, Frits/0000-0003-2558-7496; Stafford, Randall/0000-0003-1805-1271; Cushman, Mary/0000-0002-7871-6143				Abdollahi M, 2003, THROMB HAEMOSTASIS, V89, P493, DOI 10.1055/s-0037-1613379; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Berkowitz DE, 2003, CIRCULATION, V108, P2000, DOI 10.1161/01.CIR.0000092948.04444.C7; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P235; Curb JD, 2003, ANN EPIDEMIOL, V13, pS122, DOI 10.1016/S1047-2797(03)00048-6; Cuzick J, 2002, LANCET, V360, P817; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Doggen CJM, 2004, J THROMB HAEMOST, V2, P700, DOI 10.1111/j.1538-7836.2004.00696.x; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; Herrington DM, 2002, ARTERIOSCL THROM VAS, V22, P1012, DOI 10.1161/01.ATV.0000018301.91721.94; Hoibraaten E, 2000, THROMB HAEMOSTASIS, V84, P961; Holbraaten E, 1999, THROMB HAEMOSTASIS, V82, P1218; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Middeldorp S, 2001, ANN INTERN MED, V135, P322, DOI 10.7326/0003-4819-135-5-200109040-00008; O'Brien J, 2000, LANCET, V355, P1295; Ray JG, 2001, ARCH INTERN MED, V161, P1405, DOI 10.1001/archinte.161.11.1405; Rosendaal FR, 2002, ARTERIOSCL THROM VAS, V22, P201, DOI 10.1161/hq0202.102318; Rosendaal FR, 2002, BRIT J HAEMATOL, V116, P851, DOI 10.1046/j.0007-1048.2002.03356.x; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Samama MM, 2000, ARCH INTERN MED, V160, P3415, DOI 10.1001/archinte.160.22.3415; Scarabin PY, 2003, LANCET, V362, P428, DOI 10.1016/S0140-6736(03)14066-4; Skrondal A, 2003, AM J EPIDEMIOL, V158, P251, DOI 10.1093/aje/kwg113; Tsai AW, 2002, ARCH INTERN MED, V162, P1182, DOI 10.1001/archinte.162.10.1182; Varas-Lorenzo C, 1998, AM J EPIDEMIOL, V147, P387; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673	33	438	449	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	2004	292	13					1573	1580		10.1001/jama.292.13.1573	http://dx.doi.org/10.1001/jama.292.13.1573			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	859HS	15467059	Green Published, Bronze			2023-01-03	WOS:000224254600024
J	Li, ZB; Kesselman, E; Talmon, Y; Hillmyer, MA; Lodge, TP				Li, ZB; Kesselman, E; Talmon, Y; Hillmyer, MA; Lodge, TP			Multicompartment micelles from ABC miktoarm stars in water	SCIENCE			English	Article							FLUOROCARBON; HYDROCARBON; NANOTECHNOLOGY; POLYMERS; STRATEGY	By combining three mutually immiscible polymeric components in a mixed-arm star block terpolymer architecture, we have observed the formation of a previously unknown class of multicompartment micelles in dilute aqueous solution. Connection of water-soluble poly(ethylene oxide) and two hydrophobic but immiscible components (a polymeric hydrocarbon and a perfluorinated polyether) at a common junction leads to molecular frustration when dispersed in aqueous solution. The incompatible hydrophobic blocks form cores that are protected from the water by the poly(ethylene oxide) blocks, but both are forced to make contact with the poly(ethylene oxide) by virtue of the chain architecture. The structures that emerge depend on the relative lengths of the blocks and can be tuned from discrete multicompartment micelles to extended wormlike structures with segmented cores.	Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA; Technion Israel Inst Technol, Dept Chem Engn, IL-32000 Haifa, Israel	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Technion Israel Institute of Technology	Hillmyer, MA (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.	hillmyer@chem.umn.edu; lodge@chem.umn.edu	Li, Zhibo/K-1614-2013; Talmon, Yeshayahu/N-1076-2019	Li, Zhibo/0000-0001-9512-1507; Talmon, Yeshayahu/0000-0002-9854-3972; Hillmyer, Marc/0000-0001-8255-3853; Lodge, Timothy/0000-0001-5916-8834				Bailey TS, 2002, MACROMOLECULES, V35, P7007, DOI 10.1021/ma011716x; Balsamo V, 2003, MACROMOLECULES, V36, P4515, DOI 10.1021/ma020129o; BATES FS, 1991, SCIENCE, V251, P898, DOI 10.1126/science.251.4996.898; Collier JH, 2001, ANNU REV MATER RES, V31, P237, DOI 10.1146/annurev.matsci.31.1.237; Danino D, 2001, COLLOID SURFACE A, V183, P113, DOI 10.1016/S0927-7757(01)00543-X; Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972; Dormidontova EE, 1997, MACROMOLECULES, V30, P1980, DOI 10.1021/ma961076b; Gohy JF, 2001, ANGEW CHEM INT EDIT, V40, P3214, DOI 10.1002/1521-3773(20010903)40:17<3214::AID-ANIE3214>3.0.CO;2-F; Goldacker T, 1999, NATURE, V398, P137, DOI 10.1038/18191; Hadjichristidis N, 1999, J POLYM SCI POL CHEM, V37, P857, DOI 10.1002/(SICI)1099-0518(19990401)37:7<857::AID-POLA1>3.0.CO;2-P; HALPERIN A, 1992, ADV POLYM SCI, V100, P31; Hamley I.W., 1998, PHYS BOCK COPOLYMERS; Jain S, 2003, SCIENCE, V300, P460, DOI 10.1126/science.1082193; Kisak ET, 2004, CURR MED CHEM, V11, P199, DOI 10.2174/0929867043456197; Kotzev A, 2002, MACROMOLECULES, V35, P1091, DOI 10.1021/ma011047n; Laschewsky A, 2003, CURR OPIN COLLOID IN, V8, P274, DOI 10.1016/S1359-0294(03)00049-9; LI Z, UNPUB; Lodge TP, 2004, MACROMOLECULES, V37, P6680, DOI 10.1021/ma048708b; Lodge TP, 2003, MACROMOL CHEM PHYSIC, V204, P265, DOI 10.1002/macp.200290073; Park C, 2003, POLYMER, V44, P6725, DOI 10.1016/j.polymer.2003.08.011; Park M, 1997, SCIENCE, V276, P1401, DOI 10.1126/science.276.5317.1401; Riess G, 2003, PROG POLYM SCI, V28, P1107, DOI 10.1016/S0079-6700(03)00015-7; Savic R, 2003, SCIENCE, V300, P615, DOI 10.1126/science.1078192; SEMENOV AN, 1995, MACROMOLECULES, V28, P7491, DOI 10.1021/ma00126a029; Shimomura M, 2001, CURR OPIN COLLOID IN, V6, P11, DOI 10.1016/S1359-0294(00)00081-9; Sioula S, 1998, MACROMOLECULES, V31, P8429, DOI 10.1021/ma980622t; Stahler K, 1999, LANGMUIR, V15, P7565, DOI 10.1021/la990431z; Weberskirch R, 2000, MACROMOL CHEM PHYSIC, V201, P995, DOI 10.1002/1521-3935(20000601)201:10<995::AID-MACP995>3.0.CO;2-T; Zhou ZL, 2003, J AM CHEM SOC, V125, P10182, DOI 10.1021/ja036551h	29	892	911	7	431	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	2004	306	5693					98	101		10.1126/science.1103350	http://dx.doi.org/10.1126/science.1103350			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	859YJ	15459387				2023-01-03	WOS:000224304000044
J	Boutla, M; Supalla, T; Newport, EL; Bavelier, D				Boutla, M; Supalla, T; Newport, EL; Bavelier, D			Short-term memory span: insights from sign language	NATURE NEUROSCIENCE			English	Article							WORKING-MEMORY; WORD-LENGTH; PHONOLOGICAL COMPLEXITY; DEAF SIGNERS; INFORMATION; RECALL; SIMILARITY; CHILDHOOD; DURATION; CAPACITY	Short-term memory (STM), or the ability to hold information in mind for a few seconds, is thought to be limited in its capacity to about 7 +/- 2 items. Notably, the average STM capacity when using American Sign Language (ASL) rather than English is only 5 +/- 1 items. Here we show that, contrary to previous interpretations, this difference cannot be attributed to phonological factors, item duration or reduced memory abilities in deaf people. We also show that, despite this difference in STM span, hearing speakers and deaf ASL users have comparable working memory resources during language use, indicating similar abilities to maintain and manipulate linguistic information. The shorter STM span in ASL users therefore confirms the view that the spoken span of 7 +/- 2 is an exception, probably owing to the reliance of speakers on auditory-based rather than visually based representations in linguistic STM, and calls for adjustments in the norms used with deaf individuals.	Univ Rochester, Dept Brain & Cognit Sci, Rochester, NY 14627 USA	University of Rochester	Bavelier, D (corresponding author), Univ Rochester, Dept Brain & Cognit Sci, 601 Elmwood Ave, Rochester, NY 14627 USA.	daphne@bcs.rochester.edu		Bavelier, Daphne/0000-0002-5904-1240	NIDCD NIH HHS [R01 DC000167-26, R01 DC000167, DC04418, R01 DC004418, R01 DC004418-08, DC00167] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000167, R01DC004418] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Alvarez GA, 2004, PSYCHOL SCI, V15, P106, DOI 10.1111/j.0963-7214.2004.01502006.x; Baddeley A, 2003, J COMMUN DISORD, V36, P189, DOI 10.1016/S0021-9924(03)00019-4; Baddeley A., 1986, WORKING MEMORY; BELLUGI U, 1972, COGNITION, V1, P173, DOI 10.1016/0010-0277(72)90018-2; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; CAPLAN D, 1992, Q J EXP PSYCHOL-A, V45, P177, DOI 10.1080/14640749208401323; CAPLAN D, 1994, Q J EXP PSYCHOL-A, V47, P1055, DOI 10.1080/14640749408401108; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; CONRAD R, 1972, BRIT J PSYCHOL, V63, P173, DOI 10.1111/j.2044-8295.1972.tb02097.x; CONRAD R, 1970, BRIT J PSYCHOL, V61, P179, DOI 10.1111/j.2044-8295.1970.tb01236.x; Cowan N, 2001, BEHAV BRAIN SCI, V24, P87, DOI 10.1017/S0140525X01003922; DANEMAN M, 1986, J MEM LANG, V25, P1, DOI 10.1016/0749-596X(86)90018-5; Daneman M, 1996, PSYCHON B REV, V3, P422, DOI 10.3758/BF03214546; DARWIN CJ, 1972, COGNITIVE PSYCHOL, V3, P255, DOI 10.1016/0010-0285(72)90007-2; ELLIOTT JM, 1992, PERCEPT MOTOR SKILL, V74, P291, DOI 10.2466/PMS.74.1.291-295; ELLIS NC, 1980, BRIT J PSYCHOL, V71, P43, DOI 10.1111/j.2044-8295.1980.tb02728.x; Engle RW, 1999, MODELS WORKING MEMOR, V4, P102; Fortkamp M. B. M., 1999, COMMUN COGNITION, V32, P259; HANSON VL, 1990, MEM COGNITION, V18, P604, DOI 10.3758/BF03197103; HANSON VL, 1982, J EXP PSYCHOL LEARN, V8, P572, DOI 10.1037/0278-7393.8.6.572; Kanabus M, 2002, ACTA NEUROBIOL EXP, V62, P263; Keppel G., 1991, DESIGN ANAL RES HDB; Klima E.S., 1979, SIGNS LANGUAGE; Lau CW, 1999, PSYCHOLOGIA, V42, P139; LOSIEWICZ BL, 2000, SW J LINGUIST, V19, P63; Macsweeney M, 1996, J Deaf Stud Deaf Educ, V1, P249; Marschark M, 1998, SCAND J PSYCHOL, V39, P145, DOI 10.1111/1467-9450.393069; Martin RC, 2001, SCI CON SER, P331; MAYBERRY RI, 1993, J SPEECH HEAR RES, V36, P1258, DOI 10.1044/jshr.3606.1258; MAYBERRY RI, 1991, J MEM LANG, V30, P486, DOI 10.1016/0749-596X(91)90018-F; METCALFE J, 1981, MEM COGNITION, V9, P351, DOI 10.3758/BF03197559; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/0033-295X.101.2.343; Mueller ST, 2003, J EXP PSYCHOL LEARN, V29, P1353, DOI 10.1037/0278-7393.29.6.1353; NEATH I, 1990, J EXP PSYCHOL LEARN, V16, P316, DOI 10.1037/0278-7393.16.2.316; Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366; Perfetti C. A., 1977, COGNITIVE PROCESS, P141; Service E, 1998, Q J EXP PSYCHOL-A, V51, P283, DOI 10.1080/027249898391639; SPERLING G, 1960, PSYCHOL MONOGR, V74, P1, DOI 10.1037/h0093759; Wechsler D., 2008, WECHSLER ADULT INTEL; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson M, 2000, SIGNS OF LANGUAGE REVISITED, P135; Wilson M, 1997, J Deaf Stud Deaf Educ, V2, P150; Wilson M, 1998, MEM COGNITION, V26, P584, DOI 10.3758/BF03201164; Wilson M, 2001, PSYCHON B REV, V8, P44, DOI 10.3758/BF03196138; Wilson M, 1997, MEM COGNITION, V25, P313, DOI 10.3758/BF03211287	45	87	88	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	SEP	2004	7	9					997	1002		10.1038/nn1298	http://dx.doi.org/10.1038/nn1298			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	849NX	15311279	Green Accepted			2023-01-03	WOS:000223546700020
J	Dolgachev, V; Farooqui, MS; Kulaeva, OI; Tainsky, MA; Nagy, B; Hanada, K; Separovic, D				Dolgachev, V; Farooqui, MS; Kulaeva, OI; Tainsky, MA; Nagy, B; Hanada, K; Separovic, D			De novo ceramide accumulation due to inhibition of its conversion to complex sphingolipids in apoptotic photosensitized cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERAPY-INDUCED APOPTOSIS; CULTURED HUMAN KERATINOCYTES; MOUSE EMBRYONIC FIBROBLASTS; EPIDERMOID CARCINOMA-CELLS; PHOTODYNAMIC THERAPY; SERINE PALMITOYLTRANSFERASE; SPHINGOMYELIN SYNTHASE; LYMPHOMA-CELLS; GLUCOSYLCERAMIDE SYNTHASE; SILICON PHTHALOCYANINE	The oxidative stress induced by photodynamic therapy (PDT) with the photosensitizer phthalocyanine 4 is accompanied by increases in ceramide mass. To assess the regulation of de novo sphingolipid metabolism during PDT-induced apoptosis, Jurkat human T lymphoma and Chinese hamster ovary cells were labeled with [C-14] serine, a substrate of serine palmitoyltransferase (SPT), the enzyme catalyzing the initial step in the sphingolipid biosynthesis. A substantial elevation in [C-14] ceramide with a concomitant decrease in [C-14] sphingomyelin was detected. The labeling of [C-14] ceramide was completely abrogated by the SPT inhibitor ISP-1. In addition, ISP-1 partly suppressed PDT-induced apoptosis. Pulse-chase experiments showed that the contribution of sphingomyelin degradation to PDT-initiated increase in de novo ceramide was absent or minor. PDT had no effect on either mRNA amounts of the SPT subunits LCB1 and LCB2, LCB1 protein expression, or SPT activity in Jurkat cells. Moreover in Chinese hamster ovary cells LCB1 protein underwent substantial photodestruction, and SPT activity was profoundly inhibited after treatment. We next examined whether PDT affects conversion of ceramide to complex sphingolipids. Sphingomyelin synthase, as well as glucosylceramide synthase, was inactivated by PDT in both cell lines in a dose-dependent manner. These results are the first to show that in the absence of SPT up-regulation PDT induces accumulation of de novo ceramide by inhibiting its conversion to complex sphingolipids.	Eugene Applebaum Coll Pharm & Hlth Sci, Dept Fundamental & Appl Sci, Detroit, MI 48201 USA; Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA; Univ Zagreb, Fac Sci, Zagreb 10000, Croatia; Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan	Barbara Ann Karmanos Cancer Institute; Wayne State University; University of Zagreb; National Institute of Infectious Diseases (NIID)	Separovic, D (corresponding author), Eugene Applebaum Coll Pharm & Hlth Sci, Dept Fundamental & Appl Sci, Rm 5142,259 Mack Ave, Detroit, MI 48201 USA.	dseparovic@wayne.edu	Studitskaia, Olga/D-8551-2014	Studitskaia, Olga/0000-0001-5417-9964; Tainsky, Michael/0000-0002-0261-831X; Hanada, Kentaro/0000-0003-1383-2781	NCI NIH HHS [R29 CA77475] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA077475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1991, CANCER RES, V51, P5993; Bleicher RJ, 2002, BBA-MOL CELL BIOL L, V1585, P172, DOI 10.1016/S1388-1981(02)00338-4; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chiu SM, 2000, INT J ONCOL, V16, P423; del Pulgar TG, 2002, BIOCHEM J, V363, P183, DOI 10.1042/0264-6021:3630183; Dolgachev V, 2003, EXP CELL RES, V288, P425, DOI 10.1016/S0014-4827(03)00235-0; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Elabbadi N, 1997, BIOCHEM J, V324, P435, DOI 10.1042/bj3240435; Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200; Farrell AM, 1998, J LIPID RES, V39, P2031; Garzotto M, 1998, CANCER RES, V58, P2260; Gomer CJ, 1996, CANCER RES, V56, P2355; Hanada K, 2000, J BIOL CHEM, V275, P8409, DOI 10.1074/jbc.275.12.8409; Hanada K, 2000, METHOD ENZYMOL, V312, P304; HANADA K, 1991, BIOCHIM BIOPHYS ACTA, V1086, P151, DOI 10.1016/0005-2760(91)90002-Y; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Hanada K, 2003, BBA-MOL CELL BIOL L, V1632, P16, DOI 10.1016/S1388-1981(03)00059-3; Hanlon JG, 2001, J PHOTOCH PHOTOBIO B, V64, P55, DOI 10.1016/S1011-1344(01)00189-0; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Herget T, 2000, J BIOL CHEM, V275, P30344, DOI 10.1074/jbc.M000714200; HOLLERAN WM, 1990, J LIPID RES, V31, P1655; Kalka K, 2000, CANCER RES, V60, P5984; Kick G, 1996, BRIT J CANCER, V74, P30, DOI 10.1038/bjc.1996.311; Kuge O, 2003, J BIOCHEM, V133, P397, DOI 10.1093/jb/mvg052; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200; Luberto C, 2003, J BIOL CHEM, V278, P32733, DOI 10.1074/jbc.M300932200; Memon RA, 2001, J LIPID RES, V42, P452; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; Nagy B, 2001, ARCH BIOCHEM BIOPHYS, V385, P194, DOI 10.1006/abbi.2000.2143; Nagy B, 2000, J PHOTOCH PHOTOBIO B, V57, P132, DOI 10.1016/S1011-1344(00)00088-9; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Scarlatti F, 2003, FASEB J, V17, P2339, DOI 10.1096/fj.03-0292fje; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Separovic D, 1999, BIOCHEM BIOPH RES CO, V258, P506, DOI 10.1006/bbrc.1999.0670; Separovic D, 1998, PHOTOCHEM PHOTOBIOL, V68, P101, DOI 10.1111/j.1751-1097.1998.tb03259.x; Separovic D, 1997, CANCER RES, V57, P1717; SEPAROVIC D, 2001, RRD PHOTOCHEM PHOTOB, V5, P155; Shayman JA, 2000, KIDNEY INT, V58, P11, DOI 10.1046/j.1523-1755.2000.00136.x; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; Tepper AD, 2000, J BIOL CHEM, V275, P34810, DOI 10.1074/jbc.M005142200; Uchida Y, 2002, J LIPID RES, V43, P1293, DOI 10.1194/jlr.M100442-JLR200; Usuda J, 2003, J BIOL CHEM, V278, P2021, DOI 10.1074/jbc.M205219200; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; Vivekananda J, 2001, AM J PHYSIOL-LUNG C, V281, pL98, DOI 10.1152/ajplung.2001.281.1.L98; Wang HP, 2002, PHOTOCHEM PHOTOBIOL, V76, P98, DOI 10.1562/0031-8655(2002)076<0098:UROHPA>2.0.CO;2; Wang HT, 2003, UROLOGY, V61, P1047, DOI 10.1016/S0090-4295(02)02511-6; Whitacre CM, 2000, CLIN CANCER RES, V6, P2021; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; Wispriyono B, 2002, EXP CELL RES, V279, P153, DOI 10.1006/excr.2002.5599; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; Yasuda S, 2003, J BIOL CHEM, V278, P4176, DOI 10.1074/jbc.M209602200; Zhao H, 2003, FASEB J, V17, P723, DOI 10.1096/fj.02-0806fje	58	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23238	23249		10.1074/jbc.M311974200	http://dx.doi.org/10.1074/jbc.M311974200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15020599	hybrid			2023-01-03	WOS:000221570900056
J	Himelstein, BP; Hilden, JM; Boldt, AM; Weissman, D				Himelstein, BP; Hilden, JM; Boldt, AM; Weissman, D			Medical progress - Pediatric palliative care	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							QUALITY-OF-LIFE; GENERIC CORE SCALES; POSTTRAUMATIC STRESS; AFFECTIONAL BONDS; INTENSIVE-CARE; YOUNG-CHILDREN; CANCER; DEATH; RELIABILITY; SYMPTOMS		Med Coll Wisconsin, Dept Pediat, Div Hematol Oncol, Milwaukee, WI 53201 USA; Childrens Hosp Wisconsin, Pediat Palliat Care Program, Milwaukee, WI 53201 USA; Med Coll Wisconsin, Dept Internal Med, Div Neoplast Dis & Related Disorders, Milwaukee, WI 53201 USA; Cleveland Clin, Childrens Hosp, Dept Pediat Hematol Oncol, Cleveland, OH 44106 USA; Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Palliat Care Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Children's Hospital of Wisconsin; Medical College of Wisconsin; Cleveland Clinic Foundation; Medical College of Wisconsin	Himelstein, BP (corresponding author), Med Coll Wisconsin, Dept Pediat, Div Hematol Oncol, 9000 W Wisconsin Ave,MS 792, Milwaukee, WI 53201 USA.	bhimelstein@chw.org						Arias E, 2003, PEDIATRICS, V112, P1215, DOI 10.1542/peds.112.6.1215; ARMSTRONGDAILEY A, 1993, HOSPICE CARE CHILDRE; Balk, 1996, HDB ADOLESCENT DEATH; BERTMAN SL, 1999, GRIEF HEALING ARTS C; BOWLBY J, 1977, BRIT J PSYCHIAT, V130, P201, DOI 10.1192/bjp.130.3.201; BOWLBY J, 1977, BRIT J PSYCHIAT, V130, P421, DOI 10.1192/bjp.130.5.421; Bradley EH, 2001, AM J MED, V111, P218, DOI 10.1016/S0002-9343(01)00798-7; Byock IR, 1998, PALLIATIVE MED, V12, P231, DOI 10.1191/026921698670234618; Carson MG, 2000, PALLIATIVE MED, V14, P25, DOI 10.1191/026921600677786382; *CHILDR HOSP INT, 1998, 1998 SURV HOSP CAR C; *CHILDR HOSP INT, 2004, STAND CAR CHI PACC P; *CHIPPS ADM POL WO, 2001, CALL CHANG REC IMPR; Christ G. H., 2003, CHILDREN DIE IMPROVI, P553; Christ GH, 2002, JAMA-J AM MED ASSOC, V288, P1269, DOI 10.1001/jama.288.10.1269; Collins JJ, 2002, J PAIN SYMPTOM MANAG, V23, P10, DOI 10.1016/S0885-3924(01)00375-X; Collins JJ, 2000, J PAIN SYMPTOM MANAG, V19, P363, DOI 10.1016/S0885-3924(00)00127-5; Contro N, 2002, ARCH PEDIAT ADOL MED, V156, P14, DOI 10.1001/archpedi.156.1.14; CORR C, 1995, CHILDREN MOURNING MO, P8; *CTR ADV PALL CAR, 2004, PALL CAR LEAD CTR OV; *CTR MED MED SERV, 2003, MED HOSP BEN; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; Davies B, 2002, J PALLIATIVE CARE, V18, P59, DOI 10.1177/082585970201800109; Davies B., 1999, SHADOWS SUN EXPERIEN; Doka KJ, 1993, LIVING LIFE THREATEN; DOKA KJ, 1995, CHILDREN MOURNING MO; Faulkner K. W., 2001, HOSPICE CARE CHILDRE, P9; Feudtner C, 2000, PEDIATRICS, V106, P205; Feudtner C, 2002, PEDIATRICS, V109, P887, DOI 10.1542/peds.109.5.887; Field M.J., 2003, CHILDREN DIE IMPROVI; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Furth G. M., 1988, SECRET WORLD DRAWING; Ginzburg K, 2002, OMEGA-J DEATH DYING, V45, P119, DOI 10.2190/XUW5-QGQ9-KCB8-K6WW; Grimaldo DA, 2001, ANESTHESIOLOGY, V95, P43, DOI 10.1097/00000542-200107000-00012; Hilden JM, 2001, IMPROVING PALLIATIVE, P161; Hughes P, 2002, LANCET, V360, P114, DOI 10.1016/S0140-6736(02)09410-2; KANE JR, 2002, PRINCIPLES PRACTICE, P1044; Kenyon BL, 2001, OMEGA-J DEATH DYING, V43, P63, DOI 10.2190/0X2B-B1N9-A579-DVK1; KOPELMAN LM, 1988, NEW ENGL J MED, V318, P677, DOI 10.1056/NEJM198803173181105; Kornblith AB, 2001, J CLIN ONCOL, V19, P2111, DOI 10.1200/JCO.2001.19.8.2111; Kunin H, 1997, ETHICS BEHAV, V7, P43, DOI 10.1207/s15327019eb0701_4; *LAST ACTS PALL CA, PREC PALL CAR CHILDR; LEVETOWN M, 2000, COMPENDIUM PEDIAT PA; Li J, 2003, LANCET, V361, P363, DOI 10.1016/S0140-6736(03)12387-2; Middleton Warwick, 1993, P44, DOI 10.1017/CBO9780511664076.004; *NAT VIT STAT SYST, 2004, MORT DAT NAT VIT STA; National Hospice and Palliative Care Organization, 2003, NHPCO FACTS FIG; Nelson JE, 2001, CRIT CARE MED, V29, P277, DOI 10.1097/00003246-200102000-00010; Nelson RM, 2000, PEDIATRICS, V106, P351; Pfefferbaum B, 2000, PSYCHIATR SERV, V51, P386, DOI 10.1176/appi.ps.51.3.386; Pfefferbaum B, 2000, PSYCHIATRY, V63, P358, DOI 10.1080/00332747.2000.11024929; *ROYAL COLL PAED C, 1997, GUID DEV CHILDR PALL; Sabatino CP, 1999, J LAW MED ETHICS, V27, P297, DOI 10.1111/j.1748-720X.1999.tb01465.x; SCHNEIDERMAN G, 1994, CAN J PSYCHIAT, V39, P215, DOI 10.1177/070674379403900404; Schulz R, 2003, NEW ENGL J MED, V349, P1936, DOI 10.1056/NEJMsa035373; SHAPIRO DL, 1984, JAMA-J AM MED ASSOC, V252, P2031, DOI 10.1001/jama.252.15.2031; Silveira MJ, 2000, JAMA-J AM MED ASSOC, V284, P2483, DOI 10.1001/jama.284.19.2483; Smith TJ, 1998, CANC TREAT, P81; Sourkes BM, 1995, ARMFULS TIME PSYCHOL; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Sterkenburg CA, 1996, J PALLIATIVE CARE, V12, P18, DOI 10.1177/082585979601200104; Stevens M.M., 1998, OXFORD TXB PALLIATIV, P1045; Stoppelbein L, 2000, J AM ACAD CHILD PSY, V39, P1112, DOI 10.1097/00004583-200009000-00010; TAKETOMO CG, 2001, PEDIAT DOSAGE HDB; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Weir RF, 1997, HASTINGS CENT REP, V27, P29, DOI 10.2307/3527716; Wheeler I, 2001, DEATH STUD, V25, P51, DOI 10.1080/07481180126147; WHITE ML, 1991, JAMA-J AM MED ASSOC, V266, P410, DOI 10.1001/jama.1991.03470030110035; *WHO, 1998, RED MORT MAJ KILL CH; Wolfe J, 2000, NEW ENGL J MED, V342, P326, DOI 10.1056/NEJM200002033420506; Wolfe J, 2000, JAMA-J AM MED ASSOC, V284, P2469, DOI 10.1001/jama.284.19.2469; ZISOOK S, 1988, International Journal of Family Psychiatry, V9, P135; [No title captured]	74	327	339	1	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 22	2004	350	17					1752	1762		10.1056/NEJMra030334	http://dx.doi.org/10.1056/NEJMra030334			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	814AJ	15103002				2023-01-03	WOS:000220947300010
J	Legg, L; Langhorne, P; Andersen, HE; Corr, S; Drummond, A; Duncan, P; Gershkoff, A; Gilbertson, L; Gladman, J; Hui, E; Jongbloed, L; Leonardi-Bee, J; Logan, P; Meade, T; de Vet, R; Stoker-Yates, J; Tilling, K; Walker, M; Wolfe, C				Legg, L; Langhorne, P; Andersen, HE; Corr, S; Drummond, A; Duncan, P; Gershkoff, A; Gilbertson, L; Gladman, J; Hui, E; Jongbloed, L; Leonardi-Bee, J; Logan, P; Meade, T; de Vet, R; Stoker-Yates, J; Tilling, K; Walker, M; Wolfe, C		Outpatient Serv Trialists	Rehabilitation therapy services for stroke patients living at home: systematic review of randomised trials	LANCET			English	Review							OCCUPATIONAL-THERAPY	Background Stroke-unit care can be valuable for stroke patients in hospital, but effectiveness of outpatient care is less certain. We aimed to assess the effects of therapy-based rehabilitation services targeted at stroke patients resident in the community within 1 year of stroke onset or discharge from hospital. Methods We did a systematic review of randomised trials of outpatient services, including physiotherapy, occupational therapy, and multidisciplinary teams. We used Cochrane collaboration methodology. Findings We identified a heterogeneous group of 14 trials (1617 patients). Therapy-based rehabilitation services for stroke patients living at home reduced the odds of deteriorating in personal activities of daily living (odds ratio 0.72 [95% CI 0.57-0.92], p=0.009) and increased ability of patients to do personal activities of daily living (standardised mean difference 0.14 [95% CI 0.02-0.25], p=0.02). For every 100 stroke patients resident in the community receiving therapy-based rehabilitation services, seven (95% CI 2-11) would not deteriorate. Interpretation Therapy-based rehabilitation services targeted at selected patients resident in the community after stroke improve ability to undertake personal activities of daily living and reduce risk of deterioration in ability. These findings should be considered in future service planning.	Glasgow Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland	University of Glasgow	Legg, L (corresponding author), Glasgow Royal Infirm, Acad Sect Geriatr Med, Level 3,Ctr Block, Glasgow G4 0SF, Lanark, Scotland.	Lynn@Legg80.freeserve.co.uk	Tilling, Kate/AAY-1578-2021	Tilling, Kate/0000-0002-1010-8926				Andersen HE, 2000, STROKE, V31, P1038, DOI 10.1161/01.STR.31.5.1038; [Anonymous], 2001, IMPR STROK SERV PAT; Corr S, 1995, CLIN REHABIL, V9, P291; Department of Health, 2001, NAT SERV FRAM OLD PE; Drummond A, 1995, CLIN REHABIL, V9, P283, DOI DOI 10.1177/026921559500900402; Duncan P, 1998, STROKE, V29, P2055, DOI 10.1161/01.STR.29.10.2055; EBRAHIM S, 1999, STROKE CARE MATTER C; Gilbertson L, 2000, BRIT MED J, V320, P603, DOI 10.1136/bmj.320.7235.603; GILBERTSON L, 1998, THESIS U GLASGOW; Goldberg G, 1997, Top Stroke Rehabil, V4, P64, DOI 10.1310/L9B9-6TB8-N4NQ-YRVH; HUI E, 1995, STROKE, V26, P1616, DOI 10.1161/01.STR.26.9.1616; JONGBLOED L, 1991, AM J OCCUP THER, V45, P420, DOI 10.5014/ajot.45.5.420; Logan PA, 1997, CLIN REHABIL, V11, P107, DOI 10.1177/026921559701100203; Mulrow CD, 1994, COCHRANE LIB; *OUTP SERV TRIAL, 1999, P 7 COCHR C OCT 5 8; *OUTP SERV TRIAL, 2003, COCHR LIB; Parker CJ, 2001, CLIN REHABIL, V15, P42, DOI 10.1191/026921501666968247; SANDERCOCK P, 2003, COCHRANE LIB; SMITH DS, 1981, BMJ-BRIT MED J, V282, P517, DOI 10.1136/bmj.282.6263.517; *STROK UN TRIAL CO, 2004, COCHR LIB; Wade DT, 2001, CLIN REHABIL, V15, P1, DOI 10.1191/026921501675961253; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5; WALKER MF, 1996, CLIN REHABIL, V10, P23, DOI DOI 10.1177/026921559601000105; Warlow CP., 2001, STROKE PRACTICAL GUI; Wolfe CDA, 2000, CLIN REHABIL, V14, P563, DOI 10.1191/0269215500cr362oa	25	158	170	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	2004	363	9406					352	356						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070563				2023-01-03	WOS:000188590900008
J	Thielman, NM; Guerrant, RL				Thielman, NM; Guerrant, RL			Acute infectious diarrhea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMOLYTIC-UREMIC SYNDROME; DOUBLE-BLIND; TRAVELERS DIARRHEA; ANTIBIOTIC-TREATMENT; TRIMETHOPRIM-SULFAMETHOXAZOLE; CLOSTRIDIUM-DIFFICILE; BISMUTH SUBSALICYLATE; CIPROFLOXACIN; THERAPY; PLACEBO		Univ Virginia, Sch Med, Ctr Global Hlth, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Med, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA; Duke Univ, Med Ctr, Dept Med, Div Infect Dis & Int Hlth, Durham, NC USA	University of Virginia; University of Virginia; Duke University	Guerrant, RL (corresponding author), Univ Virginia, Sch Med, Ctr Global Hlth, HSC 801379, Charlottesville, VA 22908 USA.	rlg9a@virginia.edu						ANDERS BJ, 1982, LANCET, V1, P131; Armon K, 2001, ARCH DIS CHILD, V85, P132, DOI 10.1136/adc.85.2.132; Bartlett JG, 2002, NEW ENGL J MED, V346, P334, DOI 10.1056/NEJMcp011603; Bauer TH, 2001, JAMA-J AM MED ASSOC, V285, P313, DOI 10.1001/jama.285.3.313; BENNISH ML, 1990, J INFECT DIS, V162, P711, DOI 10.1093/infdis/162.3.711; Carr A, 1998, LANCET, V351, P256, DOI 10.1016/S0140-6736(97)07529-6; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P41; Cheng Allen C., 2002, Curr Infect Dis Rep, V4, P70, DOI 10.1007/s11908-002-0070-7; Choi SW, 1996, J CLIN MICROBIOL, V34, P928, DOI 10.1128/JCM.34.4.928-932.1996; CIMOLAI N, 1994, CLIN NEPHROL, V42, P85; Dryden MS, 1996, CLIN INFECT DIS, V22, P1019, DOI 10.1093/clinids/22.6.1019; DUPONT HL, 1990, AM J MED, V88, pS15, DOI 10.1016/0002-9343(90)90270-N; DuPont HL, 1997, AM J GASTROENTEROL, V92, P1962; DUPONT HL, 1973, JAMA-J AM MED ASSOC, V226, P1525, DOI 10.1001/jama.226.13.1525; DUPONT HL, 1977, GASTROENTEROLOGY, V73, P715; DUPONT HL, 1987, JAMA-J AM MED ASSOC, V257, P1347, DOI 10.1001/jama.257.10.1347; FDA, 2003, FED REGISTER, V68, P18869; FIGUEROAQUINTANILLA D, 1993, NEW ENGL J MED, V328, P1653, DOI 10.1056/NEJM199306103282301; Fine KD, 1998, AM J GASTROENTEROL, V93, P1300; Gill CJ, 2003, CLIN INFECT DIS, V37, P365, DOI 10.1086/375896; GOODMAN LJ, 1990, ARCH INTERN MED, V150, P541, DOI 10.1001/archinte.150.3.541; Guerrant RL, 2001, CLIN INFECT DIS, V32, P331, DOI 10.1086/318514; Guerrant RL, 2002, TRENDS PARASITOL, V18, P281; Guerrant RL, 2002, TRENDS PARASITOL, V18, P191, DOI 10.1016/S1471-4922(02)02253-5; Haque R, 2003, NEW ENGL J MED, V348, P1565, DOI 10.1056/NEJMra022710; Herikstad H, 2002, EPIDEMIOL INFECT, V129, P9, DOI 10.1017/S0950268801006628; JOHNSON PC, 1986, JAMA-J AM MED ASSOC, V255, P757, DOI 10.1001/jama.255.6.757; JOHNSON S, 1992, ANN INTERN MED, V117, P297, DOI 10.7326/0003-4819-117-4-297; Khan WA, 1997, ANN INTERN MED, V126, P697, DOI 10.7326/0003-4819-126-9-199705010-00004; King Caleb K, 2003, MMWR Recomm Rep, V52, P1; Kosek M, 2003, B WORLD HEALTH ORGAN, V81, P197; Manatsathit S, 2002, J GASTROEN HEPATOL, V17, pS54, DOI 10.1046/j.1440-1746.17.s1.11.x; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; MURPHY GS, 1993, ANN INTERN MED, V118, P582, DOI 10.7326/0003-4819-118-8-199304150-00002; Murphy MS, 1998, ARCH DIS CHILD, V79, P279, DOI 10.1136/adc.79.3.279; Nachamkin I, 2002, EMERG INFECT DIS, V8, P1501, DOI 10.3201/eid0812.020115; Nazarian LF, 1996, PEDIATRICS, V97, P424; NEILL MA, 1991, ANN INTERN MED, V114, P195, DOI 10.7326/0003-4819-114-3-195; PAPE JW, 1994, ANN INTERN MED, V121, P654, DOI 10.7326/0003-4819-121-9-199411010-00004; PETRUCCELLI BP, 1992, J INFECT DIS, V165, P557, DOI 10.1093/infdis/165.3.557; Rossignol JFA, 2001, J INFECT DIS, V184, P103, DOI 10.1086/321008; Safdar N, 2002, JAMA-J AM MED ASSOC, V288, P996, DOI 10.1001/jama.288.8.996; SALAZARLINDO E, 1986, J PEDIATR-US, V109, P355, DOI 10.1016/S0022-3476(86)80404-8; SANCHEZ C, 1993, J INFECT DIS, V168, P1304, DOI 10.1093/infdis/168.5.1304; Smith KE, 1999, NEW ENGL J MED, V340, P1525, DOI 10.1056/NEJM199905203402001; Steffen R, 2003, AM J GASTROENTEROL, V98, P1073, DOI [10.1016/S0002-9270(02)06005-7, 10.1111/j.1572-0241.2003.07283.x]; STEFFEN R, 1986, ANTIMICROB AGENTS CH, V29, P625, DOI 10.1128/AAC.29.4.625; STEINHOFF MC, 1980, GASTROENTEROLOGY, V78, P1495; THIELMAN NM, 1997, J CLIN OUTCOMES MANA, V4, P36; TONG MJ, 1970, J AMER MED ASSOC, V214, P1841, DOI 10.1001/jama.214.10.1841; Verdier RI, 2000, ANN INTERN MED, V132, P885, DOI 10.7326/0003-4819-132-11-200006060-00006; WISTROM J, 1992, ANN INTERN MED, V117, P202, DOI 10.7326/0003-4819-117-3-202; Wong CS, 2000, NEW ENGL J MED, V342, P1930, DOI 10.1056/NEJM200006293422601; Zhang XP, 2000, J INFECT DIS, V181, P664, DOI 10.1086/315239; ZIMBASA Dysentery Study Grp, 2002, PEDIATR INFECT DIS J, V21, P1136, DOI [10.1097/00006454-200212000-00010, 10.1097/01.inf.0000040824.83814.a9]; 2003, MMWR MORB MORTAL WKL, V52, P340; 2003, MMWR MORB MORTAL WKL, V52, P113	57	221	242	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 1	2004	350	1					38	47		10.1056/NEJMcp031534	http://dx.doi.org/10.1056/NEJMcp031534			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758PT	14702426				2023-01-03	WOS:000187659900008
J	Volanti, C; Hendrickx, N; Van Lint, J; Matroule, JY; Agostinis, P; Piette, J				Volanti, C; Hendrickx, N; Van Lint, J; Matroule, JY; Agostinis, P; Piette, J			Distinct transduction mechanisms of cyclooxygenase 2 gene activation in tumour cells after photodynamic therapy	ONCOGENE			English	Article						photodynamic therapy; COX-2; NF-kappa B; PI3K; PKC; T24 cells; HeLa cells; pyropheophorbide	NF-KAPPA-B; KINASE-C-ALPHA; RELA/P65 SUBUNIT; NITRIC-OXIDE; APOPTOSIS; AKT; PHOSPHORYLATION; EXPRESSION; PHOTOSENSITIZATION; PHARMACOKINETICS	Photodynamic therapy (PDT) is a minimally invasive treatment for cancer and several noncancerous proliferating cell diseases. PDT relies on the uptake of a photosensitizing compound by the pathologic tissue followed by a selective irradiation with visible light, which leads to oxidative stress-mediated cell death. However, some studies showed that PDT induces the release of proangiogenic factors, such as vascular endothelial growth factor, and/or cyclooxygenase-2 (COX-2), thereby promoting cancer cell regrowth following PDT. In this work, we focused on the molecular mechanisms regulating COX-2 expression after low-dose PDT in two cancer cell lines, namely HeLa and T24. We report that PDT induces COX-2 expression in these cells and this expression is mainly due to nuclear factor kappa B (NF-kappa B)-dependent transcription of cox-2 gene without any post-transcriptional regulation. However, the transduction mechanism leading to NF-kappa B activation and subsequent cox-2 gene transcription differs in both cell types. In T24, NF-kappa B activation occurs through a protein kinase C (PKC)alpha- and phosphoinositide-3-kinase (PI3K)-dependent I kappa B kinase (IKK) complex activation, whereas in HeLa cells, NF-kappa B activation is mediated by PKC- and PI3K-independent IKK complex activation.	Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Catholic Univ Louvain, Div Biochem, B-3000 Louvain, Belgium	University of Liege; Universite Catholique Louvain	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium.	jpiette@ulg.ac.be	Van Lint, Johan/P-9073-2019; Agostinis, Patrizia/AAO-2468-2020; Agostinis, Patrizia/ABI-1177-2020	Agostinis, Patrizia/0000-0003-1314-2115; Van Lint, Johan/0000-0002-0275-571X				BELLNIER DA, 1993, J PHOTOCH PHOTOBIO B, V20, P55, DOI 10.1016/1011-1344(93)80131-R; Bork PM, 1999, PLANTA MED, V65, P297, DOI 10.1055/s-1999-13989; Deane JA, 2004, ANNU REV IMMUNOL, V22, P563, DOI 10.1146/annurev.immunol.22.012703.104721; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dougherty TJ, 2002, J CLIN LASER MED SUR, V20, P3, DOI 10.1089/104454702753474931; Ferrario A, 2000, CANCER RES, V60, P4066; Ferrario A, 2002, CANCER RES, V62, P3956; FLATOW U, 1987, INT J CANCER, V40, P240, DOI 10.1002/ijc.2910400220; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Henderson BW, 1997, CANCER RES, V57, P4000; Hendrickx N, 2003, J BIOL CHEM, V278, P52231, DOI 10.1074/jbc.M307591200; Huang WC, 2003, J BIOL CHEM, V278, P9944, DOI 10.1074/jbc.M208521200; Jang BC, 2004, BIOCHEM BIOPH RES CO, V316, P398, DOI 10.1016/j.bbrc.2004.02.060; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Khan KMF, 2004, J BIOL CHEM, V279, P22039, DOI 10.1074/jbc.M312735200; Kim SJ, 2003, BIOCHEM BIOPH RES CO, V303, P206, DOI 10.1016/S0006-291X(03)00305-X; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Makowski M, 2003, CLIN CANCER RES, V9, P5417; Matroule JY, 2000, ANTIOXID REDOX SIGN, V2, P301, DOI 10.1089/ars.2000.2.2-301; Matroule JY, 1999, J BIOL CHEM, V274, P2988, DOI 10.1074/jbc.274.5.2988; Matroule JY, 2000, METHOD ENZYMOL, V319, P119; Morita I, 2002, PROSTAG OTH LIPID M, V68-9, P165, DOI 10.1016/S0090-6980(02)00029-1; Nemeth JF, 2001, BIOCHEMISTRY-US, V40, P3109, DOI 10.1021/bi002313c; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; Ozes ON, 1999, NATURE, V401, P82; Payne JT, 1996, LASER SURG MED, V18, P406, DOI 10.1002/(SICI)1096-9101(1996)18:4<406::AID-LSM10>3.3.CO;2-7; Piette J, 2003, BIOCHEM PHARMACOL, V66, P1651, DOI 10.1016/S0006-2952(03)00539-2; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Taher MM, 2002, IUBMB LIFE, V54, P357, DOI 10.1080/15216540216039; Tang QB, 2001, CANCER RES, V61, P4329; Trushin SA, 2003, MOL CELL BIOL, V23, P7068, DOI 10.1128/MCB.23.19.7068-7081.2003; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027	45	32	33	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2981	2991		10.1038/sj.onc.1208481	http://dx.doi.org/10.1038/sj.onc.1208481			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735712	Green Published			2023-01-03	WOS:000228649500007
J	Kaminski, MS; Tuck, M; Estes, J; Kolstad, A; Ross, CW; Zasadny, K; Regan, D; Kison, P; Fisher, S; Kroll, S; Wahl, RL				Kaminski, MS; Tuck, M; Estes, J; Kolstad, A; Ross, CW; Zasadny, K; Regan, D; Kison, P; Fisher, S; Kroll, S; Wahl, RL			I-131-tositumomab therapy as initial treatment for follicular lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IODINE I-131 TOSITUMOMAB; NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; TERM-FOLLOW-UP; ANTI-CD20 MONOCLONAL-ANTIBODY; LOW-GRADE; STAGE-I; CHEMOTHERAPY; RITUXIMAB; RADIOIMMUNOTHERAPY	BACKGROUND: Advanced-stage follicular B-cell lymphoma is considered incurable. Anti-CD20 radioimmunotherapy is effective in patients who have had a relapse after chemotherapy or who have refractory follicular lymphoma, but it has not been tested in previously untreated patients. METHODS: Seventy-six patients with stage III or IV follicular lymphoma received as initial therapy a single course of treatment with I-131-tositumomab therapy (registered as Tositumomab and Iodine I 131 Tositumomab [the Bexxar therapeutic regimen]). This consisted of a dosimetric dose of tositumomab and I-131-labeled tositumomab followed one week later by a therapeutic dose, delivering 75 cGy of radiation to the total body. RESULTS: Ninety-five percent of the patients had any response, and 75 percent had a complete response. The use of polymerase chain reaction (PCR) to detect rearrangement of the BCL2 gene showed molecular responses in 80 percent of assessable patients who had a clinical complete response. After a median follow-up of 5.1 years, the actuarial 5-year progression-free survival for all patients was 59 percent, with a median progression-free survival of 6.1 years. The annualized rate of relapse progressively decreased over time: 25 percent, 13 percent, and 12 percent during the first, second, and third years, respectively, and 4.4 percent per year after three years. Of 57 patients who had a complete response, 40 remained in remission for 4.3 to 7.7 years. Hematologic toxicity was moderate, with no patient requiring transfusions or hematopoietic growth factors. No cases of myelodysplastic syndrome have been observed. CONCLUSIONS: A single one-week course of I-131-tositumomab therapy as initial treatment can induce prolonged clinical and molecular remissions in patients with advanced follicular lymphoma.	Univ Michigan, Med Ctr, Ctr Canc, Dept Internal Med,Div Hematol & Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA; Norwegian Radium Hosp, Dept Oncol, Oslo, Norway; Corixa, Seattle, WA USA; Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, Div Nucl Sci, Baltimore, MD USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Oslo; Corixa; Johns Hopkins University	Kaminski, MS (corresponding author), Univ Michigan, Med Ctr, Ctr Canc, Dept Internal Med,Div Hematol & Oncol, Rm 4316,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mkaminsk@umich.edu		WAHL, RICHARD L./0000-0002-7306-2590	NATIONAL CANCER INSTITUTE [R01CA056794] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA56794] Funding Source: Medline; NCRR NIH HHS [M01 RR00042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BUCHSBAUM DJ, 1992, CANCER RES, V52, P6476; Cardarelli PM, 2002, CANCER IMMUNOL IMMUN, V51, P15, DOI 10.1007/s00262-001-0247; Coleman M, 2003, BLOOD, V102, p29A; Colombat P, 2001, BLOOD, V97, P101, DOI 10.1182/blood.V97.1.101; COX DR, 1972, J R STAT SOC B, V34, P187; Czuczman M, 2003, BLOOD, V102, p411A; Czuczman MS, 1999, J CLIN ONCOL, V17, P268, DOI 10.1200/JCO.1999.17.1.268; DANA BW, 1993, J CLIN ONCOL, V11, P644, DOI 10.1200/JCO.1993.11.4.644; Fisher RI, 2000, J CLIN ONCOL, V18, P2010, DOI 10.1200/JCO.2000.18.10.2010; GOLDSMITH SJ, 2001, PROG P AM SOC CLIN S, V20, pA295; Hainsworth JD, 2002, J CLIN ONCOL, V20, P4261, DOI 10.1200/JCO.2002.08.674; Harris NL, 1999, J CLIN ONCOL, V17, P3835, DOI 10.1200/JCO.1999.17.12.3835; Horning SJ, 2002, BLOOD, V100, p357A; Johnson PWM, 1999, ANN ONCOL, V10, P1349, DOI 10.1023/A:1008385924543; Kaminski MS, 2000, BLOOD, V96, P1259, DOI 10.1182/blood.V96.4.1259.h8001259_1259_1266; Kaminski MS, 2001, J CLIN ONCOL, V19, P3918, DOI 10.1200/JCO.2001.19.19.3918; Kaminski MS, 1996, J CLIN ONCOL, V14, P1974, DOI 10.1200/JCO.1996.14.7.1974; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; KAMINSKI MS, 1998, P AN M AM SOC CLIN, V17, pA2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lopez-Guillermo A, 1999, BLOOD, V93, P3081, DOI 10.1182/blood.V93.9.3081; MacManus MP, 1996, J CLIN ONCOL, V14, P1282, DOI 10.1200/JCO.1996.14.4.1282; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; REDDY S, 1989, INT J RADIAT ONCOL, V16, P687, DOI 10.1016/0360-3016(89)90486-0; Shan D, 1998, BLOOD, V91, P1644, DOI 10.1182/blood.V91.5.1644.1644_1644_1652; SOLALCELIGNY P, 1993, NEW ENGL J MED, V329, P1608, DOI 10.1056/NEJM199311253292203; TEDDER TF, 1986, EUR J IMMUNOL, V16, P881, DOI 10.1002/eji.1830160802; Tsimberidou AM, 2002, BLOOD, V100, P4351, DOI 10.1182/blood-2001-12-0269; Vose JM, 2000, J CLIN ONCOL, V18, P1316, DOI 10.1200/JCO.2000.18.6.1316; Wahl RL, 2003, SEMIN ONCOL, V30, P31, DOI 10.1053/sonc.2003.23799; ZELENETZ A, 2001, PROG P AM SOC CLIN S, V20, pA287	31	513	542	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2005	352	5					441	449		10.1056/NEJMoa041511	http://dx.doi.org/10.1056/NEJMoa041511			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893NE	15689582				2023-01-03	WOS:000226725400004
J	Grinspoon, S; Carr, A				Grinspoon, S; Carr, A			Medical progress - Cardiovascular risk and body-fat abnormalities in HIV-infected adults.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; ACTIVE ANTIRETROVIRAL THERAPY; PROTEASE INHIBITOR THERAPY; CORONARY-HEART-DISEASE; RANDOMIZED CONTROLLED-TRIAL; ATHEROGENIC LIPID PROFILE; INSULIN-RESISTANCE; HIV-1-INFECTED PATIENTS; LIPODYSTROPHY SYNDROME; COMBINATION THERAPY		Massachusetts Gen Hosp, Program Nutr Metab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; St Vincents Hosp, HIV Immunol & Infect Dis Clin Serv Unit, Sydney, NSW 2010, Australia	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; St Vincents Hospital Sydney	Grinspoon, S (corresponding author), Massachusetts Gen Hosp, Program Nutr Metab, 55 Fruit St,LON207, Boston, MA 02114 USA.	sgrinspoon@partners.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059535] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL65953] Funding Source: Medline; NIDDK NIH HHS [R01DK59535] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arioglu E, 2000, ANN INTERN MED, V133, P263, DOI 10.7326/0003-4819-133-4-200008150-00009; Badiou S, 2004, ATHEROSCLEROSIS, V172, P273, DOI 10.1016/j.atherosclerosis.2003.10.006; Barreiro P, 2000, AIDS, V14, P807, DOI 10.1097/00002030-200005050-00006; Barrios A, 2002, AIDS, V16, P2079, DOI 10.1097/00002030-200210180-00014; Bastard JP, 2002, LANCET, V359, P1026, DOI 10.1016/S0140-6736(02)08094-7; Behrens GMN, 2002, J CLIN INVEST, V110, P1319, DOI 10.1172/JCI200215626; Ben-Romano R, 2003, AIDS, V17, P23, DOI 10.1097/00002030-200301030-00005; Bernasconi E, 2002, JAIDS-J ACQ IMM DEF, V31, P50, DOI 10.1097/00126334-200209010-00007; Bonnet E, 2001, J CLIN ENDOCR METAB, V86, P296, DOI 10.1210/jc.86.1.296; Bozzette SA, 2003, NEW ENGL J MED, V348, P702, DOI 10.1056/NEJMoa022048; BROWN TT, 2004, P 11 C RETR OPP INF, P73; Calmy A, 2003, AIDS, V17, P770, DOI 10.1097/00002030-200303280-00022; Calza L, 2003, AIDS, V17, P851, DOI 10.1097/00002030-200304110-00010; Caron M, 2003, AIDS, V17, P2437, DOI 10.1097/00002030-200311210-00005; Caron M, 2001, DIABETES, V50, P1378, DOI 10.2337/diabetes.50.6.1378; Carr A, 2003, LANCET, V361, P726, DOI 10.1016/S0140-6736(03)12656-6; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 2004, LANCET, V363, P429, DOI 10.1016/S0140-6736(04)15489-5; Carr A, 1998, NEW ENGL J MED, V339, P1296, DOI 10.1056/NEJM199810293391806; Christeff N, 2002, EUR J CLIN INVEST, V32, P43, DOI 10.1046/j.0014-2972.2001.00940.x; Currier JS, 2003, JAIDS-J ACQ IMM DEF, V33, P506, DOI 10.1097/00126334-200308010-00012; Dowell P, 2000, J BIOL CHEM, V275, P41325, DOI 10.1074/jbc.M006474200; Dressman J, 2003, J CLIN INVEST, V111, P389, DOI 10.1172/JCI200316261; Driscoll SD, 2004, AIDS, V18, P465, DOI 10.1097/00002030-200402200-00013; Driscoll SD, 2004, J CLIN ENDOCR METAB, V89, P2171, DOI 10.1210/jc.2003-031858; Dube MP, 2002, ANTIVIR THER, V7, pL18; Engelson ES, 2002, J ACQ IMMUN DEF SYND, V30, P379, DOI 10.1097/01.QAI.0000020501.93209.1C; Fichtenbaum CJ, 2002, AIDS, V16, P569, DOI 10.1097/00002030-200203080-00008; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Friis-Moller N, 2003, AIDS, V17, P1179, DOI 10.1097/00002030-200305230-00010; FriisMoller N, 2004, NEW ENGL J MED, V350, P955; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Galli M, 2003, JAIDS-J ACQ IMM DEF, V34, P58, DOI 10.1097/00126334-200309010-00008; Gan SK, 2002, DIABETES, V51, P3163, DOI 10.2337/diabetes.51.11.3163; Gelato MC, 2002, JAIDS-J ACQ IMM DEF, V31, P163, DOI 10.1097/00126334-200210010-00006; Gervasoni C, 1999, AIDS, V13, P465, DOI 10.1097/00002030-199903110-00004; Grunfeld C, 1997, J CLIN ENDOCR METAB, V82, P3734, DOI 10.1210/jc.82.11.3734; GRUNFELD C, 1992, J CLIN ENDOCR METAB, V74, P1045, DOI 10.1210/jc.74.5.1045; GRUNFELD C, 2002, 14 INT AIDS C BARC S, V81; Hadigan C, 2004, ANN INTERN MED, V140, P786, DOI 10.7326/0003-4819-140-10-200405180-00008; Hadigan C, 2001, CLIN INFECT DIS, V32, P130, DOI 10.1086/317541; Hadigan C, 2000, JAMA-J AM MED ASSOC, V284, P472, DOI 10.1001/jama.284.4.472; Hadigan C, 2002, J CLIN ENDOCR METAB, V87, P4611, DOI 10.1210/jc.2002-020709; Hadigan C, 2002, METABOLISM, V51, P1143, DOI 10.1053/meta.2002.34704; Hadigan C, 2001, J CLIN ENDOCR METAB, V86, P939, DOI 10.1210/jc.86.2.939; Heath KV, 2002, J ACQ IMMUN DEF SYND, V30, P440, DOI [10.1097/00042560-200208010-00010, 10.1097/01.QAI.0000021701.48448.20]; HELLERSTEIN MK, 1993, J CLIN ENDOCR METAB, V76, P559, DOI 10.1210/jc.76.3.559; Henry K, 1998, LANCET, V352, P1031, DOI 10.1016/S0140-6736(98)00022-1; Hsue PY, 2004, CIRCULATION, V109, P1603, DOI 10.1161/01.CIR.0000124480.32233.8A; John M, 2003, JAIDS-J ACQ IMM DEF, V33, P29, DOI 10.1097/00126334-200305010-00005; Jones SP, 2001, AIDS, V15, P2049, DOI 10.1097/00002030-200110190-00021; Klein D, 2002, J ACQ IMMUN DEF SYND, V30, P471, DOI 10.1097/00126334-200208150-00002; Koppel K, 2002, J ACQ IMMUN DEF SYND, V29, P441, DOI 10.1097/00042560-200204150-00003; Kotler DP, 2004, JAIDS-J ACQ IMM DEF, V35, P239, DOI 10.1097/00126334-200403010-00004; Koutkia P, 2004, JAMA-J AM MED ASSOC, V292, P210, DOI 10.1001/jama.292.2.210; Kurowski M, 2003, HIV Med, V4, P94, DOI 10.1046/j.1468-1293.2003.00143.x; LAW MG, 2004, P 11 C RETR OPP INF, P737; Lee GA, 2004, AIDS, V18, P641, DOI 10.1097/00002030-200403050-00008; Lenhard JM, 2000, ANTIVIR RES, V47, P121, DOI 10.1016/S0166-3542(00)00102-9; Lenhard JM, 2000, ARTERIOSCL THROM VAS, V20, P2625, DOI 10.1161/01.ATV.20.12.2625; Liang JS, 2001, NAT MED, V7, P1327, DOI 10.1038/nm1201-1327; Lichtenstein KA, 2001, AIDS, V15, P1389, DOI 10.1097/00002030-200107270-00008; Mallon PWG, 2003, AIDS, V17, P971, DOI 10.1097/00002030-200305020-00005; Martin A, 2004, AIDS, V18, P1029, DOI 10.1097/00002030-200404300-00011; Martinez E, 2003, ANTIVIR THER, V8, P403; Martinez E, 2003, NEW ENGL J MED, V349, P1036, DOI 10.1056/NEJMoa021589; Martinez E, 1999, AIDS, V13, P805, DOI 10.1097/00002030-199905070-00009; Martinez E, 2001, LANCET, V357, P592, DOI 10.1016/S0140-6736(00)04056-3; Mary-Krause M, 2003, AIDS, V17, P2479, DOI 10.1097/00002030-200311210-00010; Matthews GV, 2000, J ACQ IMMUN DEF SYND, V24, P310; Miller J, 2002, AIDS, V16, P2195, DOI 10.1097/00002030-200211080-00012; Miller J, 2003, HIV Med, V4, P293; Monforte AD, 2004, AIDS, V18, P1811, DOI 10.1097/00002030-200409030-00010; Moyle GJ, 2004, HIV MED, V5, P82, DOI 10.1111/j.1468-1293.2004.00190.x; Moyle GJ, 2003, JAIDS-J ACQ IMM DEF, V33, P22, DOI 10.1097/00126334-200305010-00004; Moyle GJ, 2001, AIDS, V15, P1503, DOI 10.1097/00002030-200108170-00007; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Murphy RL, 2003, AIDS, V17, P2603, DOI 10.1097/00002030-200312050-00007; Negredo E, 2002, AIDS, V16, P1383, DOI 10.1097/00002030-200207050-00010; Nolan D, 2003, AIDS, V17, P1329, DOI 10.1097/00002030-200306130-00007; Noor MA, 2002, AIDS, V16, pF1, DOI 10.1097/00002030-200203290-00002; NOOR MA, 2004, P 11 C RETR OPP INF, P702; Pace CS, 2003, ANTIVIR THER, V8, P323; Periard D, 1999, CIRCULATION, V100, P700, DOI 10.1161/01.CIR.100.7.700; Reiss P, 2004, HIV MED, V5, P11, DOI 10.1111/j.1468-1293.2004.00178.x; Riddler SA, 2003, JAMA-J AM MED ASSOC, V289, P2978, DOI 10.1001/jama.289.22.2978; Roche R, 2002, AIDS, V16, P13, DOI 10.1097/00002030-200201040-00003; Roubenoff R, 2002, CLIN INFECT DIS, V34, P390, DOI 10.1086/338402; Rudich A, 2001, DIABETES, V50, P1425, DOI 10.2337/diabetes.50.6.1425; Saint-Marc T, 1999, AIDS, V13, P1000, DOI 10.1097/00002030-199905280-00023; Schmitz M, 2001, J ACQ IMMUN DEF SYND, V26, P225, DOI 10.1097/00126334-200103010-00004; Shlay JC, 2003, ANTIVIR THER, V8, pL12; Stein JH, 2001, CIRCULATION, V104, P257, DOI 10.1161/01.CIR.104.3.257; Sutinen J, 2003, ANTIVIR THER, V8, P199; Sutinen J, 2002, AIDS, V16, P2183, DOI 10.1097/00002030-200211080-00011; Thoni GJ, 2002, DIABETES METAB, V28, P397; Tong Q, 2003, J CLIN ENDOCR METAB, V88, P1559, DOI 10.1210/jc.2002-021600; van der Valk M, 2001, AIDS, V15, P2407, DOI 10.1097/00002030-200112070-00008; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Woerle IJ, 2003, DIABETES, V52, P918, DOI 10.2337/diabetes.52.4.918	100	790	817	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2005	352	1					48	62		10.1056/NEJMra041811	http://dx.doi.org/10.1056/NEJMra041811			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884UP	15635112				2023-01-03	WOS:000226112500007
J	Childs, JD; Fritz, JM; Flynn, TW; Irrgang, JJ; Johnson, KK; Majkowski, GR; Delitto, A				Childs, JD; Fritz, JM; Flynn, TW; Irrgang, JJ; Johnson, KK; Majkowski, GR; Delitto, A			A clinical prediction rule to identify patients with low back pain most likely to benefit from spinal manipulation: A validation study	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY-CARE; INTERRATER RELIABILITY; MEDICAL LITERATURE; USERS GUIDES; THERAPY; EXERCISES; COST; FEAR; IMPLEMENTATION; QUESTIONNAIRE	Background: Conflicting evidence exists about the effectiveness of spinal manipulation. Objective: To validate a manipulation clinical prediction rule. Design: Multicenter randomized, controlled trial. Setting: Physical therapy clinics. Patients: 131 consecutive patients with low back pain, 18 to 60 years of age, who were referred to physical therapy. Intervention: Patients were randomly assigned to receive manipulation plus exercise or exercise alone by a physical therapist for 4 weeks. Measurements: Patients were examined according to the clinical prediction rule criteria (symptom duration, symptom location, fear-avoidance beliefs, lumbar mobility, and hip rotation range of motion). Disability and pain at 1 and 4 weeks and 6 months were assessed. Results: Outcome from spinal manipulation depends on a patient's status on the prediction rule. Treatment effects are greatest for the subgroup of patients who were positive on the rule (at least 4 of 5 criteria met); health care utilization among this subgroup was decreased at 6 months. Compared with patients who were negative on the rule and received exercise, the odds of a successful outcome among patients who were positive on the rule and received manipulation were 60.8 (95% CI, 5.2 to 704.7). The odds were 2.4 (CI, 0.83 to 6.9) among patients who were negative on the rule and received manipulation and 1.0 (CI, 0.28 to 3.6) among patients who were positive on the rule and received exercise. A patient who was positive on the rule and received manipulation has a 92% chance of a successful outcome, with an associated number needed to treat for benefit at 4 weeks of 1.9 (CI, 1.4 to 3.5). Limitations: The response rate for the 6-month follow-up resulted in inadequate power to detect statistically significant differences for some comparisons. Conclusions: The spinal manipulation clinical prediction rule can be used to improve decision making for patients with low back pain.	Lackland AFB, Wilford Hall Med Ctr, San Antonio, TX USA; Univ Pittsburgh, Pittsburgh, PA USA; Baylor Univ, USA, Grad Program Phys Therapy, Houston, TX 77030 USA; Hill AFB, Med Clin, Ogden, UT USA; Luke AFB, Med Clin, Phoenix, AZ USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor University; United States Department of Defense; United States Air Force	Childs, JD (corresponding author), Lackland AFB, Wilford Hall Med Ctr, San Antonio, TX USA.	childsjd@sbcglobal.net		Flynn, Timothy/0000-0003-3122-2901				Albright J, 2001, PHYS THER, V81, P1641; Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; BIGOS S, 1991, AHCPR PUBLICATION; BINKLEY J, 1995, PHYS THER, V75, P786, DOI 10.1093/ptj/75.9.786; BINKLEY J, 1995, PHYS THER, V75, P794, DOI 10.1093/ptj/75.9.794; Borkan JM, 1998, SPINE, V23, P1992, DOI 10.1097/00007632-199809150-00016; Bouter LM, 1998, SPINE, V23, P2014, DOI 10.1097/00007632-199809150-00019; CHAN CW, 1993, SPINE, V18, P1717, DOI 10.1097/00007632-199310000-00001; Cherkin DC, 2003, ANN INTERN MED, V138, P898, DOI 10.7326/0003-4819-138-11-200306030-00011; Childs JD, 2003, J ORTHOP SPORT PHYS, V33, P259, DOI 10.2519/jospt.2003.33.5.259; Crombez G, 1999, PAIN, V80, P329, DOI 10.1016/S0304-3959(98)00229-2; Deyo RA, 1996, SPINE, V21, P2826, DOI 10.1097/00007632-199612150-00003; Ehrmann-Feldman D, 1996, PHYS THER, V76, P156; EhrmannFeldman D, 1996, PHYS THER, V76, P150, DOI 10.1093/ptj/76.2.150; ELLISON JB, 1990, PHYS THER, V70, P537, DOI 10.1093/ptj/70.9.537; ERHARD RE, 1994, PHYS THER, V74, P1093, DOI 10.1093/ptj/74.12.1093; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; FIARBANK JC, 2000, SPINE, V25, P2952; Flynn T, 2002, SPINE, V27, P2835, DOI 10.1097/00007632-200212150-00021; Frank JW, 1996, SPINE, V21, P2918, DOI 10.1097/00007632-199612150-00025; Freburger JK, 2001, PHYS THER, V81, P1135, DOI 10.1093/ptj/81.5.1135; Fritz JM, 2000, SPINE, V25, P106, DOI 10.1097/00007632-200001010-00018; Fritz JM, 2002, PHYS THER, V82, P973, DOI 10.1093/ptj/82.10.973; Fritz JM, 2001, PHYS THER, V81, P776, DOI 10.1093/ptj/81.2.776; Fritz JM, 2001, PHYS THER, V81, P1546, DOI 10.1093/ptj/81.9.1546; FRITZ JM, 2001, EXERCISE PRESCRIPTIO, P167; Glass G, 1996, STAT METHODS ED PSYC, V3rd; GONNELLA C, 1982, PHYS THER, V62, P436, DOI 10.1093/ptj/62.4.436; Guyatt G., 2015, USERS GUIDES MED LIT, V3rd Ed; Hagen KB, 2002, SPINE, V27, P1736, DOI 10.1097/00007632-200208150-00010; Hashemi L, 1998, J OCCUP ENVIRON MED, V40, P1110; Hiebert R, 2003, SPINE, V28, P722, DOI 10.1097/00007632-200304010-00019; Jacob T, 2001, ARCH PHYS MED REHAB, V82, P735, DOI 10.1053/apmr.2001.22623; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; JENSEN MP, 1994, PAIN, V58, P387, DOI 10.1016/0304-3959(94)90133-3; Koes BW, 2001, SPINE, V26, P2504, DOI 10.1097/00007632-200111150-00022; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; Lundberg G, 1999, SCAND J REHABIL MED, V31, P197; Luo XM, 2004, SPINE, V29, P79, DOI 10.1097/01.BRS.0000105527.13866.0F; MAHER C, 1994, PHYS THER, V74, P801, DOI 10.1093/ptj/74.9.801; Maher CG, 1998, PHYS THER, V78, P829, DOI 10.1093/ptj/78.8.829; Maitland GD., 1986, VERTEBRAL MANIPULATI; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; MANN NH, 1993, SPINE, V18, P41, DOI 10.1097/00007632-199301000-00008; McGill SM, 1998, PHYS THER, V78, P754, DOI 10.1093/ptj/78.7.754; McGinn T, 2002, USERS GUIDES MED LIT, P471; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Sackett DL, 2000, EVIDENCE BASED MED P; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; Stewart WF, 2003, JAMA-J AM MED ASSOC, V290, P2443, DOI 10.1001/jama.290.18.2443; Stiell IG, 1997, JAMA-J AM MED ASSOC, V278, P2075, DOI 10.1001/jama.278.23.2075; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; Stiell IG, 2001, JAMA-J AM MED ASSOC, V286, P1841, DOI 10.1001/jama.286.15.1841; Strender LE, 1997, SPINE, V22, P814, DOI 10.1097/00007632-199704010-00021; UDEN A, 1988, SPINE, V13, P389, DOI 10.1097/00007632-198804000-00002; van Tulder M, 2000, SPINE, V25, P2784, DOI 10.1097/00007632-200011010-00011; van Tulder MW, 2000, SPINE, V25, P2501, DOI 10.1097/00007632-200010010-00013; van Tulder MW, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000335; vanTulder MW, 1997, SPINE, V22, P2128, DOI 10.1097/00007632-199709150-00012; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; WADDELL G, 1992, SPINE, V17, P617, DOI 10.1097/00007632-199206000-00001; WERNEKE MW, 1993, SPINE, V18, P2412, DOI 10.1097/00007632-199312000-00008	63	578	581	3	43	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	2004	141	12					920	928		10.7326/0003-4819-141-12-200412210-00008	http://dx.doi.org/10.7326/0003-4819-141-12-200412210-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	882EY	15611489				2023-01-03	WOS:000225923000003
J	Willcox, ML; Bodeker, G				Willcox, ML; Bodeker, G			Traditional herbal medicines for malaria	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CHLOROQUINE; EFFICACY; TRIAL		Res Initiat Tradit Antimalarial Methods, Buckingham MK18 7EW, England; Univ Oxford, John Radcliffe Hosp, Div Med Sci, Med Sci Off, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Willcox, ML (corresponding author), Res Initiat Tradit Antimalarial Methods, Buckingham MK18 7EW, England.	merlinwillcox@doctors.org.uk	Willcox, Merlin/I-6255-2019	Willcox, Merlin/0000-0002-5227-3444				Benoit-Vical F, 2003, J ETHNOPHARMACOL, V89, P111, DOI 10.1016/S0378-8741(03)00277-0; Bodeker G, 2000, J ALTERN COMPLEM MED, V6, P127, DOI [10.1089/acm.2000.6.127, 10.1089/acm.2000.6.195]; Bruhn JG, 1981, P INT S E W MED SEOU, P405; *CENTR COUNC RES A, 1987, AYUSH 64 NEW ANT HER; Guindo M, 1988, THESIS NATL SCH MED; Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0; KOITA N, 1991, P INT C EXP DEV COUN; Leaman DJ, 1995, J ETHNOPHARMACOL, V49, P1, DOI 10.1016/0378-8741(95)01289-3; Mueller MS, 2004, T ROY SOC TROP MED H, V98, P318, DOI 10.1016/j.trstmh.2003.09.001; THIOMBIANO A, 1991, SEM CREDES PAR 4 9 N; TSU CF, 1947, TROP MED HYG, V50, P75; Valecha N, 2000, CURR SCI INDIA, V78, P1120; Wan Y D, 1992, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V10, P290; WHO, 2003, ASS MON ANT DRUG EFF; Willcox M, 2004, TRADITIONAL MED PLAN; Williams MS, 2001, GENET MED, V3, P318, DOI 10.1097/00125817-200107000-00010	16	202	206	1	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2004	329	7475					1156	1159		10.1136/bmj.329.7475.1156	http://dx.doi.org/10.1136/bmj.329.7475.1156			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539672	Green Published			2023-01-03	WOS:000225169600023
J	Naegele, S; Morley, SJ				Naegele, S; Morley, SJ			Molecular cross-talk between MEK1/2 and mTOR signaling during recovery of 293 cells from hypertonic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; ACTIVATED PROTEIN-KINASE; CAP-DEPENDENT TRANSLATION; GENE-PRODUCTS; FACTOR 4G; PHOSPHORYLATION; BINDING; TUBERIN; MNK1; TSC2	To investigate the role for initiation factor phosphorylation in de novo translation, we have studied the recovery of human kidney cells from hypertonic stress. Previously, we have demonstrated that hypertonic shock causes a rapid inhibition of protein synthesis, the disaggregation of polysomes, the dephosphorylation of eukaryotic translation initiation factor (eIF)4E, 4E-BP1, and ribosomal protein S6, and increased association of 4E-BP1 with eIF4E. The return of cells to isotonic medium promotes a transient activation of Erk1/2 and the phosphorylation of initiation factors, promoting an increase in protein synthesis that is independent of a requirement for eIF4E phosphorylation. As de novo translation is associated with the phosphorylation of 4E-BP1, we have investigated the role of the signaling pathways required for this event by the use of cell-permeable inhibitors. Surprisingly, although rapamycin, RAD001, wortmannin, and LY294002 inhibited the phosphorylation of 4E-BP1 and its release from eIF4E, they did not prevent the recovery of translation rates. These data suggest that only a small proportion of the available eIF4F complex is required for maximal translation rates under these conditions. Similarly, prevention of Erk1/2 activity alone with low concentrations of PD184352 did not impinge upon de novo translation until later times of recovery from salt shock. However, U0126, which prevented the phosphorylation of Erk1/2, ribosomal protein S6, TSC2, and 4E-BP1, attenuated de novo protein synthesis in recovering cells. These results indicate that the phosphorylation of 4E-BP1 is mediated by both phosphatidylinositol 3-kinase-dependent rapamycin-sensitive and Erk1/2-dependent signaling pathways and that activation of either pathway in isolation is sufficient to promote de novo translation.	Univ Sussex, Sch Life Sci, Biochem Lab, Brighton BN1 9QG, E Sussex, England	University of Sussex	Morley, SJ (corresponding author), Univ Sussex, Sch Life Sci, Biochem Lab, Brighton BN1 9QG, E Sussex, England.	s.j.morley@sussex.ac.uk						Allen LF, 2003, SEMIN ONCOL, V30, P105, DOI 10.1053/j.seminoncol.2003.08.012; Blenis J, 2003, FASEB J, V17, pA149; Brown VI, 2003, PEDIATR RES, V53, p287A; Bushell M, 2000, EUR J BIOCHEM, V267, P1083, DOI 10.1046/j.1432-1327.2000.01101.x; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Fraser CS, 1999, BIOCHEM J, V342, P519, DOI 10.1042/0264-6021:3420519; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 2001, PROG MOLEC, V27, P143; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Iijima Y, 2002, J BIOL CHEM, V277, P23065, DOI 10.1074/jbc.M200328200; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Krymskaya VP, 2003, CELL SIGNAL, V15, P729, DOI 10.1016/S0898-6568(03)00040-8; Kwiatkowski DJ, 2003, CANCER BIOL THER, V2, P471, DOI 10.4161/cbt.2.5.446; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; Lehman JA, 2002, BIOCHEM BIOPH RES CO, V293, P463, DOI 10.1016/S0006-291X(02)00238-3; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; MADER S, 1995, MOL CELL BIOL, V15, P4990; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; MORLEY SJ, 1995, J CELL SCI, V108, P1751; Morley SJ, 2003, CELL SIGNAL, V15, P741, DOI 10.1016/S0898-6568(03)00008-1; Morley SJ, 2001, PROG MOLEC, V27, P1; Morley SJ, 2002, J BIOL CHEM, V277, P32855, DOI 10.1074/jbc.C200376200; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; Novoa I, 1999, MOL CELL BIOL, V19, P2445; Parra-Palau JL, 2003, J BIOL CHEM, V278, P44197, DOI 10.1074/jbc.M302398200; Preiss T, 2003, BIOESSAYS, V25, P1201, DOI 10.1002/bies.10362; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Proud CG, 2002, EUR J BIOCHEM, V269, P5337, DOI 10.1046/j.1432-1033.2002.03289.x; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Pyronnet S, 2000, BIOCHEM PHARMACOL, V60, P1237, DOI 10.1016/S0006-2952(00)00429-9; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Shi YY, 2002, J BIOL CHEM, V277, P15712, DOI 10.1074/jbc.M200043200; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Wang LJ, 2002, FEBS LETT, V531, P285, DOI 10.1016/S0014-5793(02)03536-6; Wang LJ, 2001, J BIOL CHEM, V276, P32670, DOI 10.1074/jbc.M102776200; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909	54	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46023	46034		10.1074/jbc.M404945200	http://dx.doi.org/10.1074/jbc.M404945200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15292274	hybrid			2023-01-03	WOS:000224694900088
J	den Herder, C; Schmeck, J; Appelboom, DJK; de Vries, N				den Herder, C; Schmeck, J; Appelboom, DJK; de Vries, N			Risks of general anaesthesia in people with obstructive sleep apnoea	BRITISH MEDICAL JOURNAL			English	Review							PERIOPERATIVE COMPLICATIONS; UPPER AIRWAY; SURGERY; MANAGEMENT; INTUBATION; DISORDERS; MORPHINE; CHILDREN; SNORERS; MEN		St Lucas Andreas Hosp, Dept Otolaryngol Head & Neck Surg, NL-1006 AE Amsterdam, Netherlands; St Lucas Andreas Hosp, Dept Anaesthesiol, NL-1006 AE Amsterdam, Netherlands; Univ Heidelberg, Univ Hosp Mannheim, Dept Anaesthesiol & Operat Intens Care Med, D-68167 Mannheim, Germany	Sint Lucas Andreas Hospital; Sint Lucas Andreas Hospital; Ruprecht Karls University Heidelberg	den Herder, C (corresponding author), St Lucas Andreas Hosp, Dept Otolaryngol Head & Neck Surg, Tooropstr 164, NL-1006 AE Amsterdam, Netherlands.	c.denherder@slaz.nl						Baik UB, 2002, ANGLE ORTHOD, V72, P124; Barthel SW, 1999, MED CLIN N AM, V83, P85, DOI 10.1016/S0025-7125(05)70089-4; Boushra NN, 1996, CAN J ANAESTH, V43, P599, DOI 10.1007/BF03011774; BURGESS LPA, 1992, OTOLARYNG HEAD NECK, V106, P81, DOI 10.1177/019459989210600132; Caplan RA, 2003, ANESTHESIOLOGY, V98, P1269; CHAUVIN M, 1982, BRIT J ANAESTH, V54, P843, DOI 10.1093/bja/54.8.843; CHUNG F, 1982, CAN ANAESTH SOC J, V29, P439, DOI 10.1007/BF03009406; CHUNG F, 2002, CAN J ANESTH, V49, pR1; Connolly L A, 1991, J Clin Anesth, V3, P461, DOI 10.1016/0952-8180(91)90094-4; CRADDOCK M, 1989, GEN ANESTHESIA, P346; Do KL, 2000, LARYNGOSCOPE, V110, P1552, DOI 10.1097/00005537-200009000-00027; ESCLAMADO RM, 1989, LARYNGOSCOPE, V99, P1125; Friedman M, 1999, LARYNGOSCOPE, V109, P1901, DOI 10.1097/00005537-199912000-00002; GLEADHILL IC, 1991, AM REV RESPIR DIS, V143, P1300, DOI 10.1164/ajrccm/143.6.1300; Gupta RM, 2001, MAYO CLIN PROC, V76, P897, DOI 10.4065/76.9.897; Hoekema A, 2003, J ORAL REHABIL, V30, P690, DOI 10.1046/j.1365-2842.2003.01130.x; KAFER ER, 1983, ANESTHESIOLOGY, V58, P418, DOI 10.1097/00000542-198305000-00005; KNILL RL, 1990, ANESTHESIOLOGY, V73, P52, DOI 10.1097/00000542-199007000-00009; KRAVATH RE, 1980, J PEDIATR-US, V96, P645, DOI 10.1016/S0022-3476(80)80730-X; Liistro G, 2003, EUR RESPIR J, V21, P248, DOI 10.1183/09031936.03.00292403; Loadsman JA, 2001, BRIT J ANAESTH, V86, P254, DOI 10.1093/bja/86.2.254; MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357; MCCOLLEY SA, 1992, ARCH OTOLARYNGOL, V118, P940; Mortimore IL, 1998, AM J RESP CRIT CARE, V157, P280, DOI 10.1164/ajrccm.157.1.9703018; NUNN JF, 1993, NUNNS APPL RESP PHYS, P333; Ostermeier AM, 1997, ANESTH ANALG, V85, P452, DOI 10.1097/00000539-199708000-00037; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; RAFFERTY TD, 1980, BRIT J ANAESTH, V52, P619, DOI 10.1093/bja/52.6.619; Reimer MA, 2003, SLEEP MED REV, V7, P335, DOI 10.1053/smrv.2001.0220; Shahar E, 2001, AM J RESP CRIT CARE, V163, P19, DOI 10.1164/ajrccm.163.1.2001008; SHAPIRO CM, ABC SLEEP DISORDERS, P5; SHEPPARD L, 1992, LASER SURG MED, V12, P137, DOI 10.1002/lsm.1900120205; Siyam MA, 2002, ANESTH ANALG, V95, P1098, DOI 10.1097/00000539-200210000-00058; STROHL KP, 1986, AM REV RESPIR DIS, V134, P791; TAASAN VC, 1981, AM J MED, V71, P240; VALNICEK SM, 1994, PLAST RECONSTR SURG, V93, P954, DOI 10.1097/00006534-199404001-00009; Verin E, 2002, RESP PHYSIOL, V129, P335, DOI 10.1016/S0034-5687(01)00324-3; Verse T, 2002, LARYNGOSCOPE, V112, P64, DOI 10.1097/00005537-200201000-00012; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 1997, SLEEP, V20, P705, DOI 10.1093/sleep/20.9.705; 2003, PHARM THERAPEUTIC CO, P51	41	56	81	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 23	2004	329	7472					955	959		10.1136/bmj.329.7472.955	http://dx.doi.org/10.1136/bmj.329.7472.955			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866KU	15499112	Green Published			2023-01-03	WOS:000224773200019
J	Schubert, C				Schubert, C			Mitochondria's secret weapon	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1051	1051						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459706				2023-01-03	WOS:000224245800028
J	Shah, J				Shah, J			Recent developments - Criteria influencing the clinical uptake of pharmacogenomic strategies	BMJ-BRITISH MEDICAL JOURNAL			English	Review									London Sch Econ & Polit Sci, Dept Social Policy, London WC2A 2AE, England	University of London; London School Economics & Political Science	Shah, J (corresponding author), London Sch Econ & Polit Sci, Dept Social Policy, London WC2A 2AE, England.	jai.shah-alumni@lse.ac.uk		Shah, Jai/0000-0002-7549-6990				Birmingham K, 2001, NAT MED, V7, P262, DOI 10.1038/85364; BRANCA M, BIO IT WORLD 2002; Bristol L. A., 2002, Pharmacogenomics Journal, V2, P83, DOI 10.1038/sj.tpj.6500079; Burke W, 2002, AM J EPIDEMIOL, V156, P311, DOI 10.1093/aje/kwf055; Evans JP, 2001, BMJ-BRIT MED J, V322, P1052, DOI 10.1136/bmj.322.7293.1052; Hughes AR, 2004, PHARMACOGENOMICS, V5, P203, DOI 10.1517/phgs.5.2.203.27481; Issa AM, 2002, NAT REV DRUG DISCOV, V1, P300, DOI 10.1038/nrd771; Krynetski E, 2003, ONCOGENE, V22, P7403, DOI 10.1038/sj.onc.1206944; Lindpaintner K, 2002, PHARMACOGENOMICS, V3, P835, DOI 10.1517/14622416.3.6.835; Marshall E, 2003, SCIENCE, V302, P588, DOI 10.1126/science.302.5645.588; Melzer David, 2003, MY VERY OWN MED WHAT; Moriguchi H, 2002, HEPATOLOGY, V36, P177, DOI 10.1053/jhep.2002.33895; *NAT I CLIN EXC, 2002, 34 NAT I CLIN EXC; Norton RM, 2001, DRUG DISCOV TODAY, V6, P180, DOI 10.1016/S1359-6446(00)01648-2; OWENS J, 2001, DRUG DISCOV TODAY, V6, P450; Phillips KA, 2003, PHARMACOGENOMICS, V4, P231, DOI 10.1517/phgs.4.3.231.22691; Phillips KA, 2001, JAMA-J AM MED ASSOC, V286, P2270, DOI 10.1001/jama.286.18.2270; Robertson JA, 2002, HEALTH AFFAIR, V21, P155, DOI 10.1377/hlthaff.21.4.155; *ROCH DIAGN, 2003, ROCH DIAGN LAUNCH AM; Rothstein MA, 2001, NAT REV GENET, V2, P228, DOI 10.1038/35056075; Shah J, 2003, NAT BIOTECHNOL, V21, P747, DOI 10.1038/nbt0703-747; Tollman PA, 2001, REVOLUTION R D GENOM; van Aken Jan, 2003, Am J Pharmacogenomics, V3, P149, DOI 10.2165/00129785-200303030-00001; Veenstra DL, 2000, AAPS PHARMSCI, V2, part. no.; WARD SJ, 2001, BIOTECHNIQUES, P64; Wolf CR, 1999, BRIT MED BULL, V55, P366, DOI 10.1258/0007142991902439	26	30	34	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	2004	328	7454					1482	1486		10.1136/bmj.328.7454.1482	http://dx.doi.org/10.1136/bmj.328.7454.1482			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832CK	15205293	Green Submitted, Green Published			2023-01-03	WOS:000222244600019
J	Worrall, A; O'Herlihy, A; Banerjee, S; Jaffa, T; Lelliott, P; Hill, P; Scott, A; Brook, H				Worrall, A; O'Herlihy, A; Banerjee, S; Jaffa, T; Lelliott, P; Hill, P; Scott, A; Brook, H			Inappropriate admission of young people with mental disorder to adult psychiatric wards and paediatric wards: cross sectional study of six months' activity	BRITISH MEDICAL JOURNAL			English	Article									Royal Coll Psychiatrists, Res Unit, London SW1H 0HW, England; Univ London Kings Coll, Inst Psychiat, Hlth Serv Res Dept, London, England; Fulbourne Hosp, Phoenix Ctr, Cambridge, England; Great Ormond St Hosp Children, Dept Psychol Med, London, England	University of London; King's College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Worrall, A (corresponding author), Royal Coll Psychiatrists, Res Unit, 6th Floor,83 Victoria St, London SW1H 0HW, England.	aworrall@cru.rcpsych.ac.uk	Banerjee, Sube/E-3757-2010	Banerjee, Sube/0000-0002-8083-7649				Barker S, 2000, ENV UNFRIENDLY PATIE; *MILMIS PROJ GROUP, 1995, PSYCHIAT B, V19, P276; OHERLIHY A, 2001, UNPUB NATL IN PATIEN; Scott D., 2001, MENTAL HLTH LEARNING, V4, P305; Worrall A., 2001, PSYCHIAT B, V25, P219, DOI [10.1192/pb.25.6.219, DOI 10.1192/PB.25.6.219]	5	19	19	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 10	2004	328	7444					867	868		10.1136/bmj.38058.605787.AE	http://dx.doi.org/10.1136/bmj.38058.605787.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	812XE	15066888	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000220871400016
J	Friedrich, MJ				Friedrich, MJ			Institute probes music's therapeutic potential	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Coleman J., 1997, INT J ARTS MED, V5, P4; 2003, PAIN MANAG NURS, V4, P54	2	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1554	1555		10.1001/jama.291.13.1554	http://dx.doi.org/10.1001/jama.291.13.1554			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809PQ	15069033				2023-01-03	WOS:000220649000005
J	Stubblefield, PG				Stubblefield, PG			Antenatal day care or admission to hospital: a mother's choice?	LANCET			English	Editorial Material							BED REST; WOMEN		Boston Univ, Med Ctr, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA	Boston University	Stubblefield, PG (corresponding author), Boston Univ, Med Ctr, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA.	Phillip.stubblefield@bmc.org						Adelson PL, 1999, MED J AUSTRALIA, V170, P211, DOI 10.5694/j.1326-5377.1999.tb140319.x; FRANKS AL, 1992, AM J OBSTET GYNECOL, V166, P1339, DOI 10.1016/0002-9378(92)91601-6; Heaman M, 1998, BIRTH-ISS PERINAT C, V25, P252, DOI 10.1046/j.1523-536X.1998.00252.x; Maloni JA, 2002, NURS RES, V51, P92, DOI 10.1097/00006199-200203000-00005; MALONI JA, 2000, MCN AM J MATERN CHIL, V256, P204	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	2004	363	9415					1089	1089		10.1016/S0140-6736(04)15930-8	http://dx.doi.org/10.1016/S0140-6736(04)15930-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808VB	15064022				2023-01-03	WOS:000220595500003
J	Young, J; De Geest, S; Spirig, R; Flepp, M; Rickenbach, M; Furrer, H; Bernasconi, E; Hirschel, B; Telenti, A; Vernazza, P; Battegay, M; Bucher, HC				Young, J; De Geest, S; Spirig, R; Flepp, M; Rickenbach, M; Furrer, H; Bernasconi, E; Hirschel, B; Telenti, A; Vernazza, P; Battegay, M; Bucher, HC		Swiss HIV Cohort Study Grp	Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study	BRITISH MEDICAL JOURNAL			English	Article							SOCIAL SUPPORT; MYOCARDIAL-INFARCTION; ALAMEDA COUNTY; MORTALITY; MEN; HEALTH; ASSOCIATION; DEPRESSION; POPULATION; ADHERENCE	Objectives To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART). Design Prospective cohort study of adults with HIV (Swiss HIV cohort study). Setting Seven outpatient clinics throughout Switzerland. Participants The 3736. patients in the cohort who started HAART before 2002 (median age 36 years, 29% female, median follow up 3.6 years). Main outcome measures Time to AIDS or death (primary endpoint), death alone, increases in CD4 cell count of at least 50 and 100 above baseline, optimal viral suppression (a viral load below 400 copies/ml), and viral rebound. Results During follow up 2985 (80%) participants reported a stable partnership on at least one occasion. When starting HAART, 52% (545/1042) of participants reported a stable partnership; after five years of follow up 46% (190/412) of participants reported a stable partnership. In an analysis stratified by previous antiretroviral therapy and clinical stage when starting HAART (US Centers for Disease Control and Prevention group A, B, or C), the adjusted hazard ratio for progression to AIDS or death was 0.79 (95% confidence interval 0.63 to 0.98) for participants with a stable partnership compared with those without. Adjusted hazards ratios for other endpoints were 0.59 (0.44 to 0.79) for progression to death, 1.15 (1.06 to 1.24) for an increase in CD4 cells of 100 counts/mul or more, and 1.06 (0.98 to 1.14) for optimal viral suppression. Conclusions A stable partnership is associated with a slower rate of progression to AIDS or death in HIV infected patients receiving HAART.	Univ Basel Hosp, Basel Inst Clin Epidemiol, CH-4031 Basel, Switzerland; Univ Basel Hosp, Div Infect Dis & Hosp Hyg, CH-4031 Basel, Switzerland; Univ Basel, Inst Nursing Sci, Basel, Switzerland; Univ Zurich, Div Infect Dis, Zurich, Switzerland; Univ Lausanne, Swiss HIV Cohort Study, Ctr Data, Lausanne, Switzerland; Univ Hosp Bern, Div Infect Dis, CH-3010 Bern, Switzerland; Osped Civ, Ambulattorio Malattie Infett, Lugano, Switzerland; Hop Univ Geneve, Div Malad Infect, Geneva, Switzerland; CHU Vaudois, Div Malad Infect, Lausanne, Switzerland; Cantonal Hosp St Gall, Div Internal Med, St Gallen, Switzerland	University of Basel; University of Basel; University of Basel; University of Zurich; University of Lausanne; University of Bern; University Hospital of Bern; University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Kantonsspital St. Gallen	Bucher, HC (corresponding author), Univ Basel Hosp, Basel Inst Clin Epidemiol, Hebelstr 10, CH-4031 Basel, Switzerland.		De Geest, Sabina M/F-7724-2010; Furrer, Hansjakob/G-6768-2013; VALLET, Yannick/F-9979-2011	Furrer, Hansjakob/0000-0002-1375-3146; Young, Jim/0000-0002-4314-3007; De Geest, Sabina/0000-0001-6596-7237				ANCELLEPARK R, 1993, LANCET, V341, P441, DOI 10.1016/0140-6736(93)93040-8; BERKMAN LF, 1992, ANN INTERN MED, V117, P1003, DOI 10.7326/0003-4819-117-12-1003; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; Berkman LF, 2000, SOC SCI MED, V51, P843, DOI 10.1016/S0277-9536(00)00065-4; BERKMAN LF, 1995, PSYCHOSOM MED, V57, P245, DOI 10.1097/00006842-199505000-00006; CASE RB, 1992, JAMA-J AM MED ASSOC, V267, P515, DOI 10.1001/jama.267.4.515; Eng PM, 2002, AM J EPIDEMIOL, V155, P700, DOI 10.1093/aje/155.8.700; FrasureSmith N, 1997, LANCET, V350, P473, DOI 10.1016/S0140-6736(97)02142-9; Glesby MJ, 1996, ANN INTERN MED, V124, P999, DOI 10.7326/0003-4819-124-11-199606010-00008; Gordillo V, 1999, AIDS, V13, P1763, DOI 10.1097/00002030-199909100-00021; HANSON BS, 1989, AM J EPIDEMIOL, V130, P100, DOI 10.1093/oxfordjournals.aje.a115301; Ingram KM, 1999, AIDS CARE, V11, P313, DOI 10.1080/09540129947947; Johnson JG, 2001, J CONSULT CLIN PSYCH, V69, P1056, DOI 10.1037//0022-006X.69.6.1056; Kimberly JA, 1999, AIDS EDUC PREV, V11, P465; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Leserman J, 2000, AM J PSYCHIAT, V157, P1221, DOI 10.1176/appi.ajp.157.8.1221; LEVINE C, 1990, MILBANK Q, V68, P33, DOI 10.2307/3350175; PageShafer K, 1996, ANN EPIDEMIOL, V6, P420, DOI 10.1016/S1047-2797(96)00064-6; Penninx BWJH, 1997, AM J EPIDEMIOL, V146, P510, DOI 10.1093/oxfordjournals.aje.a009305; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; SEEMAN TE, 1987, AM J EPIDEMIOL, V126, P714, DOI 10.1093/oxfordjournals.aje.a114711; Spire B, 2002, SOC SCI MED, V54, P1481, DOI 10.1016/S0277-9536(01)00125-3; THEORELL T, 1995, PSYCHOSOM MED, V57, P32, DOI 10.1097/00006842-199501000-00005; Uchino BN, 1996, PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488; WILLIAMS RB, 1992, JAMA-J AM MED ASSOC, V267, P520, DOI 10.1001/jama.267.4.520	25	34	39	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 3	2004	328	7430					15	18B		10.1136/bmj.328.7430.15	http://dx.doi.org/10.1136/bmj.328.7430.15			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	761QG	14703538	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000187919000014
J	Bua, EA; McKiernan, SH; Aiken, JM				Bua, EA; McKiernan, SH; Aiken, JM			Calorie restriction limits the generation but not the progression of mitochondrial abnormalities in aging skeletal muscle	FASEB JOURNAL			English	Article						age; skeletal muscle; atrophy	DNA DELETION MUTATIONS; DIETARY RESTRICTION; RAT MUSCLE; SARCOPENIA; ATROPHY; STRESS; DAMAGE; LIVER	The effect of early-onset calorie restriction and aging on the accumulation of electron transport system (ETS) abnormalities was studied in rat skeletal muscle. Rectus femoris and vastus lateralis muscle fibers were analyzed for cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) enzyme activities. Fibers displaying COX negative and SDH hyper reactive (COX-/SDH++) phenotype were followed through 1000-2000 micrometers to determine the frequency and length of these abnormalities as well as the physiological impact on fiber structure. Calorie restricted rats had fewer ETS abnormal muscle fibers. The mean length of ETS abnormal regions in ad libitum rat muscle fibers was similar to calorie restricted rat muscles. ETS abnormal fibers from both diet groups exhibited intra-fiber atrophy. A negative correlation between ETS abnormality length and fiber cross-sectional area (CSA) ratio was observed in both ad libitum and calorie-restricted rats. Although calorie restriction reduced the number of ETS abnormalities, it did not affect the length or associated fiber atrophy of ETS abnormal regions once the abnormality was established. Thus, calorie restriction affects the onset but not the progression of electron transport system abnormalities, thereby, limiting a process that ultimately results in fiber breakage and fiber loss.	Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Aiken, JM (corresponding author), Univ Wisconsin, Dept Anim Hlth & Biomed Sci, 1656 Linden Dr, Madison, WI 53706 USA.	jma@svm.vetmed.wisc.edu		Aiken, Judd/0000-0001-6119-4521				Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; BENJAMIN IJ, 1989, CIRC RES, V65, P657, DOI 10.1161/01.RES.65.3.657; Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001; Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502; Carmeli E, 2002, EXP GERONTOL, V37, P477, DOI 10.1016/S0531-5565(01)00220-0; Cortopassi GA, 2002, MECH AGEING DEV, V123, P851, DOI 10.1016/S0047-6374(02)00022-2; Coskun PE, 2003, P NATL ACAD SCI USA, V100, P2174, DOI 10.1073/pnas.0630589100; Cottrell DA, 2001, NEUROPATH APPL NEURO, V27, P206, DOI 10.1046/j.1365-2990.2001.00315.x; Dubowitz V, 1985, MUSCLE BIOPSY PRACTI, P19; Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7; HART RW, 1990, EFFECTS CALORIC REST, P351; Kapahi P, 1999, FREE RADICAL BIO MED, V26, P495, DOI 10.1016/S0891-5849(98)00323-2; LARSSON L, 1995, PROG NEUROBIOL, V45, P397, DOI 10.1016/0301-0082(95)98601-Z; Lee CM, 1998, ANN NY ACAD SCI, V854, P182, DOI 10.1111/j.1749-6632.1998.tb09901.x; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; Lopez ME, 2000, MUTAT RES-FUND MOL M, V452, P123, DOI 10.1016/S0027-5107(00)00059-2; Lopez-Torres M, 2002, FREE RADICAL BIO MED, V32, P882, DOI 10.1016/S0891-5849(02)00773-6; MCKIERNAN SH, IN PRESS EARLY ONSET; Merry BJ, 2002, INT J BIOCHEM CELL B, V34, P1340, DOI 10.1016/S1357-2725(02)00038-9; Morley JE, 2001, J LAB CLIN MED, V137, P231, DOI 10.1067/mlc.2001.113504; Nair K S, 2000, Mayo Clin Proc, V75 Suppl, pS14; Nikolic M, 2001, COLLEGIUM ANTROPOL, V25, P545; RAO G, 1990, J NUTR, V120, P602, DOI 10.1093/jn/120.6.602; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, pE38, DOI 10.1152/ajpendo.00387.2001; VANZEELAND N, 1999, J ANTI-AGING MED, V2, P231; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com; Welle S, 2002, CAN J APPL PHYSIOL, V27, P19, DOI 10.1139/h02-002; WERAARCHAKUL N, 1989, EXP CELL RES, V181, P197, DOI 10.1016/0014-4827(89)90193-6	31	36	38	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					582	+		10.1096/fj.03-0668fje	http://dx.doi.org/10.1096/fj.03-0668fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734641				2023-01-03	WOS:000188829300003
J	Clyde, PW; Harari, AE; Getka, EJ; Shakir, KMM				Clyde, PW; Harari, AE; Getka, EJ; Shakir, KMM			Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUBCLINICAL HYPOTHYROIDISM; REPLACEMENT THERAPY; L-THYROXINE; THYROTROPIN ASSAY; TRIIODOTHYRONINE; EUTHYROIDISM; POPULATION; COMMUNITY; TISSUES; HEALTH	Context Standard therapy for patients with primary hypothyroidism is replacement with synthetic thyroxine, which undergoes peripheral conversion to triiodothyronine, the active form of thyroid hormone. Within the lay population and in some medical communities, there is a perception that adding synthetic triiodothyronine, or liothyronine, to levothyroxine improves the symptoms of hypothyroidism despite insufficient evidence to support this practice. Objective To evaluate the benefits of treating primary hypothyroidism with levothyroxine plus liothyronine combination therapy vs levothyroxine monotherapy. Design, Setting, and Patients Randomized, double-blind, placebo-controlled trial conducted from May 2000 to February 2002 at a military treatment facility that serves active duty and retired military personnel and their family members. The trial included a total of 46 patients aged 24 to 65 years with at least a 6-month history of treatment with levothyroxine for primary hypothyroidism. Intervention Patients received either their usual dose of levothyroxine (n = 23) or combination therapy (n = 23), in which their usual levothyroxine dose was reduced by 50 mug/d and substituted with liothyronine, 7.5 mug, taken twice daily for 4 months. Main Outcome Measures Scores on a hypothyroid-specif ic health -related quality-of-life (HRQL) questionnaire, body weight, serum lipid levels, and 13 neuropsychological tests measured before and after treatment. Results Serum thyrotropin levels remained similar and within the normal range in both treatment groups from baseline to 4 months. Body weight and serum lipid levels did not change. The HRQL questionnaire scores improved significantly in both the control group (23%; P<.001) and the combination therapy group (12%; P=.02), but these changes were statistically similar (P=.54). In 12 of 13 neuropsychological tests, outcomes between groups were not significantly different; the 1 remaining test (Grooved Peg Board) showed better performance in the control group. Conclusion Compared with levothyroxine alone, treatment of primary hypothyroidism with combination levothyroxine plus liothyronine demonstrated no beneficial changes in body weight, serum lipid levels, hypothyroid symptoms as measured by a HRQL questionnaire, and standard measures of cognitive performance.	Natl Naval Med Res Inst, Dept Endocrinol & Metab, Bethesda, MD 20889 USA; Naval Med Ctr San Diego, Dept Psychol, San Diego, CA USA; Naval Med Ctr San Diego, Dept Endocrinol & Metab, San Diego, CA USA	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; Naval Medical Center San Diego; United States Department of Defense; United States Navy; Naval Medical Center San Diego	Clyde, PW (corresponding author), Natl Naval Med Res Inst, Dept Endocrinol & Metab, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.	pwclyde@mar.med.navy.mil						*AACE THYR TASK FO, 2002, ENDOCR PRACT, V8, P457; Baldini IM, 1997, PROG NEURO-PSYCHOPH, V21, P925, DOI 10.1016/S0278-5846(97)00089-4; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Brent G. A, 2000, WERNER INGBARS THYRO, P853; Bunevicius R, 2000, INT J NEUROPSYCHOPH, V3, P167, DOI 10.1017/S1461145700001826; Bunevicius R, 1999, NEW ENGL J MED, V340, P424, DOI 10.1056/NEJM199902113400603; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CARR D, 1988, CLIN ENDOCRINOL, V28, P325, DOI 10.1111/j.1365-2265.1988.tb01219.x; COOPER DS, 1984, ANN INTERN MED, V101, P18, DOI 10.7326/0003-4819-101-1-18; EscobarMorreale HF, 1996, ENDOCRINOLOGY, V137, P2490, DOI 10.1210/en.137.6.2490; EscobarMorreale HF, 1995, J CLIN INVEST, V96, P2828, DOI 10.1172/JCI118353; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; Jaeschke R, 1996, J GEN INTERN MED, V11, P744, DOI 10.1007/BF02598988; JAESCHKE R, 1994, QUAL LIFE RES, V3, P323, DOI 10.1007/BF00451724; Klove H., 1963, MED CLIN N AM; Larsen PR, 1998, WILLIAMS TXB ENDOCRI, P389; MACGREGOR A, 1961, LANCET, V1, P329; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Saravanan P, 2002, CLIN ENDOCRINOL, V57, P577, DOI 10.1046/j.1365-2265.2002.01654.x; SCHLOTE B, 1992, BIOL PSYCHIAT, V32, P48, DOI 10.1016/0006-3223(92)90141-L; SMITH RN, 1970, BRIT MED J, V4, P145, DOI 10.1136/bmj.4.5728.145; SPENCER CA, 1990, J CLIN ENDOCR METAB, V70, P453, DOI 10.1210/jcem-70-2-453; SPENCER CA, 2002, LAB MED PRACTICE GUI; Stuss D, 1987, CLIN NEUROPSYCHOL, V1, P139, DOI [10.1080/13854048708520046, DOI 10.1080/13854048708520046]; TAYLOR S, 1970, BRIT MED J, V2, P270, DOI 10.1136/bmj.2.5704.270; Thurstone, 1962, PRIMARY MENTAL ABILI; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; Wechsler D., 1997, WECHSLER MEMORY SCAL	30	128	135	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	2003	290	22					2952	2958		10.1001/jama.290.22.2952	http://dx.doi.org/10.1001/jama.290.22.2952			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	751WH	14665656	Bronze			2023-01-03	WOS:000187112700026
J	Harries, M				Harries, M			ABC of resuscitation - Near drowning	BRITISH MEDICAL JOURNAL			English	Review									Northwick Pk & St Marks NHS Trust, Harrow, Middx, England	Imperial College London	Harries, M (corresponding author), Northwick Pk & St Marks NHS Trust, Harrow, Middx, England.							Gilbert M, 2000, LANCET, V355, P375, DOI 10.1016/S0140-6736(00)01021-7; Golden F S, 1991, J R Nav Med Serv, V77, P139; GOLDEN FS, 1998, OXFORD TXB SPORTS ME, P241; ORLOWSKI JP, 1987, CRIT CARE MED, V15, P126, DOI 10.1097/00003246-198702000-00009; WALPOTH BH, 1997, NEW ENGL J MED, V337, P500	5	20	23	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 6	2003	327	7427					1336	1338		10.1136/bmj.327.7427.1336	http://dx.doi.org/10.1136/bmj.327.7427.1336			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	752DE	14656846	Green Published			2023-01-03	WOS:000187131100024
J	Walker, A; Sirel, JM; Marsden, AK; Cobbe, SM; Pell, JP				Walker, A; Sirel, JM; Marsden, AK; Cobbe, SM; Pell, JP			Cost effectiveness and cost utility model of public place defibrillators in improving survival after prehospital cardiopulmonary arrest	BRITISH MEDICAL JOURNAL			English	Article							AMERICAN-HEART-ASSOCIATION; HOSPITAL CARDIAC-ARREST; ACCESS DEFIBRILLATION; PERINATAL-MORTALITY; TASK-FORCE; RISK; PROFESSIONALS; RESUSCITATION; STATEMENT; COHORT	Objective To determine the cost effectiveness and cost utility of locating defibrillators in all major airports, railway stations, and bus stations throughout Scotland. Design Economic modelling exercise with data from Heartstart (Scotland). Parameters used in economic model included direct costs derived for increased accident and emergency attendances, increased hospital bed days, purchase and maintenance of defibrillators, and training in their use; life years gained calculated from increased discharges from hospital and mean survival after discharge; utility (quality of life) obtained from published data. Sensitivity analyses tested the robustness of model. Future gains discounted at 1.5% a year and future costs at 6%. Setting Whole of Scotland. Subjects Records,of all prehospital cardiac arrests due to presumed heart disease that occurred in a major airport, railway, or bus station between May 1991 and March 1998 and were not witnessed by ambulance or medical staff. Main outcome measures Observed survival to hospital admission and observed survival to discharge. Predicted survival calculated by applying observed survival in patients attended by ambulance staff within three minutes to those who waited longer. Results The total discounted direct costs were pound18 325 a year. The cost per life year gained was pound29 625 ($49 625, (sic)43 151) and the cost per quality adjusted life year (QALY) gained was pound41 146 ($68 924, (sic)59 932). More widespread provision of public place defibrillators would increase these figures. Conclusions The cost per QALY calculated for public place defibrillators represents poorer value for money than some alternative strategies for improving survival after prehospital cardiopulmonary arrest, such as the use of other trained first responders. The figure exceeds the commonly discussed cut off levels for funding in the United Kingdom and United States of pound30 000 and $50 000 per QALY, respectively.	Greater Glasgow NHS Board, Glasgow G3 8YZ, Lanark, Scotland; Scottish Ambulance Serv Headquarters, Edinburgh EH10 5UU, Midlothian, Scotland; Univ Glasgow, Dept Med Cardiol, Glasgow G32 2ER, Lanark, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Glasgow	Pell, JP (corresponding author), Greater Glasgow NHS Board, Glasgow G3 8YZ, Lanark, Scotland.			Pell, Jill/0000-0002-8898-7035				Banister J., 1987, CHINAS CHANGING POPU; Chu JH, 2001, POPUL DEV REV, V27, P259; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Gratton M, 1999, Prehosp Emerg Care, V3, P303, DOI 10.1080/10903129908958958; GROENEVELD P, 2001, JAMA-J AM MED ASSOC, V28, P1482; Hummel S, 1997, PHARMACOECONOMICS, V12, P182, DOI 10.2165/00019053-199712020-00008; *I POP STUD, 2000, ZHONG GUO REN KOU NI; *INF STAT DIV, 2001, SCOTT HLTH SERV COST; Kane R, 1999, BRIT MED J, V319, P992, DOI 10.1136/bmj.319.7215.992; Kulmala T, 2000, PAEDIATR PERINAT EP, V14, P219, DOI 10.1046/j.1365-3016.2000.00270.x; Kuntz KM, 1996, CIRCULATION, V94, P957, DOI 10.1161/01.CIR.94.5.957; Lee KH, 1996, CRIT CARE MED, V24, P2046, DOI 10.1097/00003246-199612000-00019; LI XT, 1995, ZHONG GUO FU YOU BAO, V10, P246; Liu Y, 2001, WORLD J MICROB BIOT, V17, P111, DOI 10.1023/A:1016625209839; MU L, 1995, ZHONG GUO CHU JI WEI, V9, P34; *NAT I CLIN EXC, 2000, GUID IMPL CARD DEF A; NETTEN A, 2002, UNIT COSTS HLTH SOCI; Nichol G, 1998, CIRCULATION, V97, P1309, DOI 10.1161/01.CIR.97.13.1309; Nichol G, 1998, CIRCULATION, V97, P1315, DOI 10.1161/01.CIR.97.13.1315; Nichol G, 1996, ANN EMERG MED, V27, P711, DOI 10.1016/S0196-0644(96)70188-9; Pell JP, 2002, BRIT MED J, V325, P515, DOI 10.1136/bmj.325.7363.515; Pell JP, 2001, BRIT MED J, V322, P1385, DOI 10.1136/bmj.322.7299.1385; Pickin DM, 1999, HEART, V82, P325, DOI 10.1136/hrt.82.3.325; RAYMOND EG, 1994, BRIT J OBSTET GYNAEC, V101, P301, DOI 10.1111/j.1471-0528.1994.tb13614.x; *SECR STAT HLTH, 1999, SAV LIV OUR HLTH NAT; Shah D, 2000, INT J GYNECOL OBSTET, V71, P209, DOI 10.1016/S0020-7292(00)00215-0; Shah NM, 2000, SOC SCI MED, V51, P539, DOI 10.1016/S0277-9536(99)00485-2; WEI YZ, 1992, GUI YANG YI XUE YUAN, V17, P42; WEISFELDT ML, 1995, CIRCULATION, V92, P2763, DOI 10.1161/01.CIR.92.9.2763; Woollard M, 2001, J PUBLIC HEALTH MED, V23, P98, DOI 10.1093/pubmed/23.2.98; XU BZ, 1995, PERINATAL MORTALITY; Yao J S, 1991, Zhonghua Fu Chan Ke Za Zhi, V26, P224; ZHANG J, 1991, INT J EPIDEMIOL, V20, P958, DOI 10.1093/ije/20.4.958; ZHU XL, 1996, XIN JIANG YI XUE YUA, V19, P83	34	27	28	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 6	2003	327	7427					1316	1319		10.1136/bmj.327.7427.1316	http://dx.doi.org/10.1136/bmj.327.7427.1316			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	752DE	14656838	Green Published, Bronze			2023-01-03	WOS:000187131100016
J	Nieschlag, E; Henke, A				Nieschlag, E; Henke, A			Hopes for male contraception	LANCET			English	Editorial Material							HORMONAL MALE CONTRACEPTION; MONKEYS; IMPACT; EPPIN		Univ Munster, Inst Reprod Med, D-48129 Munster, Germany	University of Munster	Nieschlag, E (corresponding author), Univ Munster, Inst Reprod Med, Steinfurter Str 107, D-48129 Munster, Germany.	eberhard.nieschlag@ukmuenster.de						[Anonymous], 1990, Lancet, V336, P955; DARCANGUES C, 2000, DEP REPROD HLTH RES, P109; Diczfalusy E, 2004, MOL CELL ENDOCRINOL, V216, P1, DOI 10.1016/j.mce.2003.10.067; Kamischke A, 2004, TRENDS PHARMACOL SCI, V25, P49, DOI 10.1016/j.tips.2003.11.009; Martin CW, 2000, HUM REPROD, V15, P637, DOI 10.1093/humrep/15.3.637; Moudgal NR, 1997, HUM REPROD UPDATE, V3, P335, DOI 10.1093/humupd/3.4.335; Nieschlag E, 2001, ANDROLOGY, 2ND EDITION, P399; Nieschlag E, 2004, TESTOSTERONE ACTION, P685; Nieschlag E, 1986, MALE CONTRACEPTION A, p[1986, 395]; O'Rand MG, 2004, SCIENCE, V306, P1189, DOI 10.1126/science.1099743; Richardson RT, 2001, GENE, V270, P93, DOI 10.1016/S0378-1119(01)00462-0; THAU RB, 1987, AM J REPROD IMMUNOL, V15, P92; Waites GMH, 2003, FERTIL STERIL, V80, P1, DOI 10.1016/S0015-0282(03)00577-6; 2002, INT J ANDROL, V25, P375	14	28	29	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					554	556						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708085				2023-01-03	WOS:000226984300008
J	Todd, MM; Hindman, BJ; Clarke, WR; Torner, JC; Todd, M; Hindman, B; Clarke, W; Chaloner, K; Torner, J; Davis, P; Howard, M; Tranel, D; Anderson, S; Todd, M; Hindman, B; Weeks, J; Moss, L; Winn, J; Clarke, W; Chaloner, K; Wichman, M; Peters, R; Hansen, M; Anderson, D; Lang, J; Yoo, B; Adams, H; Clifton, G; Gelb, A; Loftus, C; Schubert, A; Warner, D; Young, W; Frankowski, R; Kieburtz, K; Prough, D; Sternau, L; Marler, J; Moy, C; Matta, B; Kirkpatrick, P; Chatfield, D; Skilbeck, C; Kirollos, R; Rasulo, F; English, K; Duffy, C; Pedersen, K; Scurrah, N; Burnstein, R; Prabhu, A; Salmond, C; Blackwell, A; Birrell, J; Jackson, S; Kassell, N; Pajewski, T; Fraley, H; Morris, A; Alden, T; Shaffrey, M; Bogdonoff, D; Durieux, M; Zuo, Z; Littlewood, K; Nemergut, E; Bedford, R; Stone, D; Balestrieri, P; Mason, J; Henry, G; Ting, P; Shafer, J; Blount, T; Kim, L; James, A; Farace, E; Clark, L; Irons, M; Sasaki, T; Webb, K; Short, T; Mee, E; Ormrod, J; Jane, J; Alden, T; Heppner, P; Olson, S; Ellegala, D; Lind, C; Sheehan, J; Woodfield, M; Law, A; Harrison, M; Davies, P; Campbell, D; Robertson, N; Fry, R; Sage, D; Laurent, S; Bradfield, C; Pedersen, K; Smith, K; Young, Y; Chambers, C; Hodkinson, B; Biddulph, J; Jensen, L; Ogden, J; Thayer, Z; Lee, F; Crump, S; Quaedackers, J; Wray, A; Roelfsema, V; Greif, R; Kleinpeter, G; Lothaller, C; Knosp, E; Pfisterer, W; Schatzer, R; Salem, C; Kutalek, W; Tuerkkan, E; Koller, L; Weber, T; Buchmann, A; Merhaut, C; Graf, M; Rapf, B; Lam, A; Newell, D; Tanzi, P; Lee, L; Domino, K; Vavilala, M; Bramhall, J; Souter, M; Britz, G; Winn, H; Bybee, H; Costello, T; Murphy, M; Harris, K; Thien, C; Nye, D; Han, T; McNeill, P; O'Brien, B; Cormack, J; Wyss, A; Grauer, R; Popovic, R; Jones, S; Deam, R; Heard, G; Watson, R; Evered, L; Bardenhagen, F; Meade, C; Haartsen, J; Kruger, J; Wilson, M; Maktabi, M; Traynelis, V; McAllister, A; Leonard, P; Hindman, B; Brian, J; Mensink, F; From, R; Papworth, D; Schmid, P; Dehring, D; Howard, M; Hitchon, P; VanGilder, J; Weeks, J; Moss, L; Manzel, K; Anderson, S; Tack, R; Taggard, D; Lennarson, P; Menhusen, M; Gelb, A; Lownie, S; Craen, R; Novick, T; Ferguson, G; Duggal, N; Findlay, J; Ng, W; Cowie, D; Badner, N; Herrick, I; Smith, H; Heard, G; Peterson, R; Howell, J; Lindsey, L; Carriere, L; von Lewinski, M; Schaefer, B; Bisnaire, D; Doyle-Pettypiece, P; McTaggart, M; Giannotta, S; Zelman, V; Thomson, E; Babayan, E; McCleary, C; Fishback, D; Samra, S; Thompson, B; Chandler, W; Mcgillicuddy, J; Tremper, K; Turner, C; Smythe, P; Dy, E; Pai, S; Portman, V; Palmisano, J; Auer, D; Quigley, M; Giordani, B; Freymuth, A; Scott, P; Silbergleit, R; Hickenbottom, S; Litt, L; Lawton, M; Hannegan, L; Gupta, D; Bickler, P; Dodson, B; Talke, P; Rampil, I; Chen, B; Wright, P; Mitchell, J; Ryan, S; Walker, J; Quinnine, N; Applebury, C; Myles, P; Rosenfeld, J; Hunt, J; Wallace, S; D'Urso, P; Thien, C; McMahon, J; Wadanamby, S; Siu, K; Malham, G; Laidlaw, J; Salerno, S; Alatakis, S; Madder, H; Cairo, S; Konstantatos, A; Smart, J; Lindholm, D; Bain, D; Machlin, H; Moloney, J; Buckland, M; Silvers, A; Downey, G; Molnar, A; Langley, M; McIlroy, D; Daly, D; Bennett, P; Forlano, L; Testa, R; Burnett, W; Johnson, F; Angliss, M; Fletcher, H; Manninen, P; Wallace, M; Lukitto, K; Tymianski, M; Porter, P; Gentili, F; El-Beheiry, H; Mosa, M; Mak, P; Balki, M; Shaikh, S; Sawyer, R; Quader, K; Chelliah, R; Berklayd, P; Merah, N; Ghazali, G; McAndrews, M; Ridgley, J; Odukoya, O; Yantha, S; Wilson, J; Petrozza, P; Miller, C; O'Brien, K; Tong, C; Olympio, M; Reynolds, J; Colonna, D; Glazier, S; Nobles, S; Hill, D; Hulbert, H; Jenkins, W; Lanier, W; Piepgras, D; Wilson, R; Meyer, F; Atkinson, J; Link, M; Weglinski, M; Berge, K; McGregor, D; Trenerry, M; Smith, G; Walkes, J; Felmlee-Devine, M; Van Aken, H; Greiner, C; Freise, H; Brors, H; Hahnenkamp, K; de Oliveira, NM; Schul, C; Moskopp, D; Greiner, C; Woelfer, J; Hoenemann, C; Gramke, H; Bone, H; Gibmeier, I; Wirtz, S; Lohmann, H; Freyhoff, J; Bauer, B; Hogan, K; Dempsey, R; Rusy, D; Badie, B; Iskandar, B; Resnick, D; Deshmukh, P; Fitzpatrick, J; Sasse, F; Broderick, T; Willmann, K; Connery, L; Kish, J; Weasler, C; Page, N; Hermann, B; Jones, J; Dulli, D; Stanko, H; Geraghty, M; Elbe, R; Salevsky, F; Leblanc, R; Lapointe, N; Macgregor, H; Sinclair, D; Sirhan, D; Maleki, M; Abou-Madi, M; Chartrand, D; Angle, M; Milovan, D; Painchaud, Y; Mirski, M; Tamargo, R; Rice, S; Olivi, A; Kim, D; Rigamonti, D; Naff, N; Hemstreet, M; Berkow, L; Chery, P; Ulatowski, J; Moore, L; Cunningham, T; McBee, N; Hartman, T; Heidler, J; Hillis, A; Tuffiash, E; Chase, C; Kane, A; Greene-Chandos, D; Torbey, M; Ziai, W; Lane, K; Bhardwaj, A; Subhas, N; Schubert, A; Mayberg, M; Beven, M; Rasmussen, P; Bhatia, S; Ebrahim, Z; Lotto, M; Vasarhelyi, F; Munis, J; Graves, K; Woletz, J; Chelune, G; Samples, S; Evans, J; Blair, D; Abou-Chebl, A; Shutway, F; Manke, D; Beven, C; Fogarty-Mack, P; Stieg, P; Eliazo, R; Li, P; Riina, H; Lien, C; Ravdin, L; Wang, J; Kuo, Y; Jaffe, R; Steinberg, G; Luu, D; Chang, S; Giffard, R; Lemmens, H; Morgan, R; Mathur, A; Angst, M; Meyer, A; Yi, H; Karzmark, P; Bell-Stephens, T; Marcellus, M; Sneyd, J; Pobereskin, L; Salsbury, S; Whitfield, P; Sawyer, R; Dashfield, A; Struthers, R; Davies, P; Rushton, A; Petty, V; Harding, S; Richardson, E; Yonas, H; Gyulai, F; Kirby, L; Kassam, A; Bircher, N; Meng, L; Krugh, J; Seever, G; Hendrickson, R; Gebel, J; Cowie, D; Fabinyi, G; Poustie, S; Davis, G; Drnda, A; Chandrasekara, D; Sturm, J; Phan, T; Shelton, A; Clausen, M; Micallef, S; Sills, A; Steinman, F; Sutton, P; Sanders, J; Van Alstine, D; Leggett, D; Cunningham, E; Hamm, W; Frankel, B; Sorenson, J; Atkins, L; Redmond, A; Dalrymple, S; Black, S; Fisher, W; Hall, C; Wilhite, D; Moore, T; Blanton, IP; Sha, Z; Szmuk, P; Kim, D; Ashtari, A; Hagberg, C; Matuszczak, M; Shahen, A; Moise, O; Novy, D; Govindaraj, R; Jameson, L; Breeze, R; Awad, I; Mattison, R; Anderson, T; Salvia, L; Mosier, M; Loftus, C; Smith, J; Lilley, W; White, B; Lenaerts, M				Todd, MM; Hindman, BJ; Clarke, WR; Torner, JC; Todd, M; Hindman, B; Clarke, W; Chaloner, K; Torner, J; Davis, P; Howard, M; Tranel, D; Anderson, S; Todd, M; Hindman, B; Weeks, J; Moss, L; Winn, J; Clarke, W; Chaloner, K; Wichman, M; Peters, R; Hansen, M; Anderson, D; Lang, J; Yoo, B; Adams, H; Clifton, G; Gelb, A; Loftus, C; Schubert, A; Warner, D; Young, W; Frankowski, R; Kieburtz, K; Prough, D; Sternau, L; Marler, J; Moy, C; Matta, B; Kirkpatrick, P; Chatfield, D; Skilbeck, C; Kirollos, R; Rasulo, F; English, K; Duffy, C; Pedersen, K; Scurrah, N; Burnstein, R; Prabhu, A; Salmond, C; Blackwell, A; Birrell, J; Jackson, S; Kassell, N; Pajewski, T; Fraley, H; Morris, A; Alden, T; Shaffrey, M; Bogdonoff, D; Durieux, M; Zuo, Z; Littlewood, K; Nemergut, E; Bedford, R; Stone, D; Balestrieri, P; Mason, J; Henry, G; Ting, P; Shafer, J; Blount, T; Kim, L; James, A; Farace, E; Clark, L; Irons, M; Sasaki, T; Webb, K; Short, T; Mee, E; Ormrod, J; Jane, J; Alden, T; Heppner, P; Olson, S; Ellegala, D; Lind, C; Sheehan, J; Woodfield, M; Law, A; Harrison, M; Davies, P; Campbell, D; Robertson, N; Fry, R; Sage, D; Laurent, S; Bradfield, C; Pedersen, K; Smith, K; Young, Y; Chambers, C; Hodkinson, B; Biddulph, J; Jensen, L; Ogden, J; Thayer, Z; Lee, F; Crump, S; Quaedackers, J; Wray, A; Roelfsema, V; Greif, R; Kleinpeter, G; Lothaller, C; Knosp, E; Pfisterer, W; Schatzer, R; Salem, C; Kutalek, W; Tuerkkan, E; Koller, L; Weber, T; Buchmann, A; Merhaut, C; Graf, M; Rapf, B; Lam, A; Newell, D; Tanzi, P; Lee, L; Domino, K; Vavilala, M; Bramhall, J; Souter, M; Britz, G; Winn, H; Bybee, H; Costello, T; Murphy, M; Harris, K; Thien, C; Nye, D; Han, T; McNeill, P; O'Brien, B; Cormack, J; Wyss, A; Grauer, R; Popovic, R; Jones, S; Deam, R; Heard, G; Watson, R; Evered, L; Bardenhagen, F; Meade, C; Haartsen, J; Kruger, J; Wilson, M; Maktabi, M; Traynelis, V; McAllister, A; Leonard, P; Hindman, B; Brian, J; Mensink, F; From, R; Papworth, D; Schmid, P; Dehring, D; Howard, M; Hitchon, P; VanGilder, J; Weeks, J; Moss, L; Manzel, K; Anderson, S; Tack, R; Taggard, D; Lennarson, P; Menhusen, M; Gelb, A; Lownie, S; Craen, R; Novick, T; Ferguson, G; Duggal, N; Findlay, J; Ng, W; Cowie, D; Badner, N; Herrick, I; Smith, H; Heard, G; Peterson, R; Howell, J; Lindsey, L; Carriere, L; von Lewinski, M; Schaefer, B; Bisnaire, D; Doyle-Pettypiece, P; McTaggart, M; Giannotta, S; Zelman, V; Thomson, E; Babayan, E; McCleary, C; Fishback, D; Samra, S; Thompson, B; Chandler, W; Mcgillicuddy, J; Tremper, K; Turner, C; Smythe, P; Dy, E; Pai, S; Portman, V; Palmisano, J; Auer, D; Quigley, M; Giordani, B; Freymuth, A; Scott, P; Silbergleit, R; Hickenbottom, S; Litt, L; Lawton, M; Hannegan, L; Gupta, D; Bickler, P; Dodson, B; Talke, P; Rampil, I; Chen, B; Wright, P; Mitchell, J; Ryan, S; Walker, J; Quinnine, N; Applebury, C; Myles, P; Rosenfeld, J; Hunt, J; Wallace, S; D'Urso, P; Thien, C; McMahon, J; Wadanamby, S; Siu, K; Malham, G; Laidlaw, J; Salerno, S; Alatakis, S; Madder, H; Cairo, S; Konstantatos, A; Smart, J; Lindholm, D; Bain, D; Machlin, H; Moloney, J; Buckland, M; Silvers, A; Downey, G; Molnar, A; Langley, M; McIlroy, D; Daly, D; Bennett, P; Forlano, L; Testa, R; Burnett, W; Johnson, F; Angliss, M; Fletcher, H; Manninen, P; Wallace, M; Lukitto, K; Tymianski, M; Porter, P; Gentili, F; El-Beheiry, H; Mosa, M; Mak, P; Balki, M; Shaikh, S; Sawyer, R; Quader, K; Chelliah, R; Berklayd, P; Merah, N; Ghazali, G; McAndrews, M; Ridgley, J; Odukoya, O; Yantha, S; Wilson, J; Petrozza, P; Miller, C; O'Brien, K; Tong, C; Olympio, M; Reynolds, J; Colonna, D; Glazier, S; Nobles, S; Hill, D; Hulbert, H; Jenkins, W; Lanier, W; Piepgras, D; Wilson, R; Meyer, F; Atkinson, J; Link, M; Weglinski, M; Berge, K; McGregor, D; Trenerry, M; Smith, G; Walkes, J; Felmlee-Devine, M; Van Aken, H; Greiner, C; Freise, H; Brors, H; Hahnenkamp, K; de Oliveira, NM; Schul, C; Moskopp, D; Greiner, C; Woelfer, J; Hoenemann, C; Gramke, H; Bone, H; Gibmeier, I; Wirtz, S; Lohmann, H; Freyhoff, J; Bauer, B; Hogan, K; Dempsey, R; Rusy, D; Badie, B; Iskandar, B; Resnick, D; Deshmukh, P; Fitzpatrick, J; Sasse, F; Broderick, T; Willmann, K; Connery, L; Kish, J; Weasler, C; Page, N; Hermann, B; Jones, J; Dulli, D; Stanko, H; Geraghty, M; Elbe, R; Salevsky, F; Leblanc, R; Lapointe, N; Macgregor, H; Sinclair, D; Sirhan, D; Maleki, M; Abou-Madi, M; Chartrand, D; Angle, M; Milovan, D; Painchaud, Y; Mirski, M; Tamargo, R; Rice, S; Olivi, A; Kim, D; Rigamonti, D; Naff, N; Hemstreet, M; Berkow, L; Chery, P; Ulatowski, J; Moore, L; Cunningham, T; McBee, N; Hartman, T; Heidler, J; Hillis, A; Tuffiash, E; Chase, C; Kane, A; Greene-Chandos, D; Torbey, M; Ziai, W; Lane, K; Bhardwaj, A; Subhas, N; Schubert, A; Mayberg, M; Beven, M; Rasmussen, P; Bhatia, S; Ebrahim, Z; Lotto, M; Vasarhelyi, F; Munis, J; Graves, K; Woletz, J; Chelune, G; Samples, S; Evans, J; Blair, D; Abou-Chebl, A; Shutway, F; Manke, D; Beven, C; Fogarty-Mack, P; Stieg, P; Eliazo, R; Li, P; Riina, H; Lien, C; Ravdin, L; Wang, J; Kuo, Y; Jaffe, R; Steinberg, G; Luu, D; Chang, S; Giffard, R; Lemmens, H; Morgan, R; Mathur, A; Angst, M; Meyer, A; Yi, H; Karzmark, P; Bell-Stephens, T; Marcellus, M; Sneyd, J; Pobereskin, L; Salsbury, S; Whitfield, P; Sawyer, R; Dashfield, A; Struthers, R; Davies, P; Rushton, A; Petty, V; Harding, S; Richardson, E; Yonas, H; Gyulai, F; Kirby, L; Kassam, A; Bircher, N; Meng, L; Krugh, J; Seever, G; Hendrickson, R; Gebel, J; Cowie, D; Fabinyi, G; Poustie, S; Davis, G; Drnda, A; Chandrasekara, D; Sturm, J; Phan, T; Shelton, A; Clausen, M; Micallef, S; Sills, A; Steinman, F; Sutton, P; Sanders, J; Van Alstine, D; Leggett, D; Cunningham, E; Hamm, W; Frankel, B; Sorenson, J; Atkins, L; Redmond, A; Dalrymple, S; Black, S; Fisher, W; Hall, C; Wilhite, D; Moore, T; Blanton, IP; Sha, Z; Szmuk, P; Kim, D; Ashtari, A; Hagberg, C; Matuszczak, M; Shahen, A; Moise, O; Novy, D; Govindaraj, R; Jameson, L; Breeze, R; Awad, I; Mattison, R; Anderson, T; Salvia, L; Mosier, M; Loftus, C; Smith, J; Lilley, W; White, B; Lenaerts, M		IHAST Investigators	Mild intraoperative hypothermia during surgery for intracranial aneurysm	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TEMPORARY ARTERIAL-OCCLUSION; MODERATE HYPOTHERMIA; BRAIN-DAMAGE; SUBARACHNOID HEMORRHAGE; SURGICAL-TREATMENT; ISCHEMIA; NORMOTHERMIA; PROTECTION; PROPOFOL	Background: Surgery for intracranial aneurysm often results in postoperative neurologic deficits. We conducted a randomized trial at 30 centers to determine whether intraoperative cooling during open craniotomy would improve the outcome among patients with acute aneurysmal subarachnoid hemorrhage. Methods: A total of 1001 patients with a preoperative World Federation of Neurological Surgeons score of I, II, or III ("good-grade patients''), who had had a subarachnoid hemorrhage no more than 14 days before planned surgical aneurysm clipping, were randomly assigned to intraoperative hypothermia (target temperature, 33 degreesC, with the use of surface cooling techniques) or normothermia (target temperature, 36.5 degreesC). Patients were followed closely postoperatively and examined approximately 90 days after surgery, at which time a Glasgow Outcome Score was assigned. Results: There were no significant differences between the group assigned to intraoperative hypothermia and the group assigned to normothermia in the duration of stay in the intensive care unit, the total length of hospitalization, the rates of death at follow-up (6 percent in both groups), or the destination at discharge (home or another hospital, among surviving patients). At the final follow-up, 329 of 499 patients in the hypothermia group had a Glasgow Outcome Score of 1 (good outcome), as compared with 314 of 501 patients in the normothermia group (66 percent vs. 63 percent; odds ratio, 1.14; 95 percent confidence interval, 0.88 to 1.48; P=0.32). Postoperative bacteremia was more common in the hypothermia group than in the normothermia group (5 percent vs. 3 percent, P=0.05). Conclusions: Intraoperative hypothermia did not improve the neurologic outcome after craniotomy among good-grade patients with aneurysmal subarachnoid hemorrhage.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Anesthesia, Iowa City, IA 52242 USA; Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA; Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA; Univ Iowa, Coll Publ Hlth, Data Management Ctr, Iowa City, IA USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa	Todd, MM (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Anesthesia, 200 Hawkins Dr,6546 JCP, Iowa City, IA 52242 USA.	michael-todd@uiowa.edu	Balki, Mrinalini/A-2669-2015; Lind, Christopher/K-3629-2012; Littlewood, Keith/ABC-8858-2020; Sneyd, John/AFV-7887-2022; McAndrews, MP/GWV-3841-2022; Robert, Greif/O-6392-2016; Burnstein, Rowan/AAF-3611-2021; Zuo, Zhiyi/F-3950-2010; Schubert, Armin/D-3589-2011; D'Urso, Pietro/AAL-8919-2020; Sneyd, John/AFV-7886-2022; Giordani, Bruno/AAR-1910-2021; Black, Sandra E./C-7294-2011; Littlewood, Keith E/H-4785-2013; Prough, Donald S/G-5793-2013; Sneyd, John Robert/B-2957-2012	Lind, Christopher/0000-0001-9991-1725; Littlewood, Keith/0000-0003-1049-3227; Sneyd, John/0000-0003-3546-9856; Robert, Greif/0000-0003-0160-2073; Zuo, Zhiyi/0000-0002-3542-5047; Sneyd, John/0000-0003-3546-9856; Prough, Donald S/0000-0001-7994-532X; Sneyd, John Robert/0000-0003-3546-9856; Steinberg, Gary/0000-0001-6374-1058; Hindman, Bradley/0000-0003-2242-7980; Angst, Martin/0000-0002-1550-8136; Tymianski, Mike/0000-0002-6311-9565; Burnstein, Rowan/0000-0003-2107-1433; Jaffe, Richard/0000-0003-0443-495X; RASULO, Francesco Antonio/0000-0002-7187-5168; Honemann, Christian/0000-0002-9658-253X; Quaedackers, Josine/0000-0002-7873-6216	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038554] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS38554] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREWS RJ, 1993, NEUROSURGERY, V33, P1052; BAKER CJ, 1992, J NEUROSURG, V77, P438, DOI 10.3171/jns.1992.77.3.0438; BAKER KZ, 1994, ANESTHESIOLOGY, V81, P361, DOI 10.1097/00000542-199408000-00014; BATJER HH, 1988, J NEUROSURG, V68, P234, DOI 10.3171/jns.1988.68.2.0234; Baumgardner JE, 1999, ANESTH ANALG, V89, P163, DOI 10.1097/00000539-199907000-00029; BENDTSEN AO, 1984, ACTA ANAESTH SCAND, V28, P473, DOI 10.1111/j.1399-6576.1984.tb02101.x; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Cheng MA, 1997, CRIT CARE CLIN, V13, P185, DOI 10.1016/S0749-0704(05)70301-8; Clifton G L, 1992, Tex Med, V88, P66; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DRAKE CG, 1988, J NEUROSURG, V68, P985; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.2307/2332323; Fridriksson S, 2002, J NEUROSURG, V96, P515, DOI 10.3171/jns.2002.96.3.0515; GRIZZLE JE, 1969, BIOMETRICS, V25, P489, DOI 10.2307/2528901; Hindman BJ, 1999, NEUROSURGERY, V44, P23, DOI 10.1097/00006123-199901000-00009; Holzer M, 2002, NEW ENGL J MED, V346, P549; Iwata T, 2003, BRIT J ANAESTH, V90, P32, DOI 10.1093/bja/aeg016; JENNETT B, 1975, LANCET, V1, P480; Kawai N, 2000, STROKE, V31, P1982, DOI 10.1161/01.STR.31.8.1982; Kettner SC, 2003, ANESTH ANALG, V96, P1772, DOI 10.1213/01.ANE.0000062520.65192.C9; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; LOUGHEED WM, 1955, J NEUROSURG, V12, P240, DOI 10.3171/jns.1955.12.3.0240; MAHONEY F I, 1965, Md State Med J, V14, P61; MANTEL N, 1959, J NATL CANCER I, V22, P719; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCDERMOTT MW, 1989, NEUROSURGERY, V25, P54, DOI 10.1227/00006123-198907000-00010; MELLERGARD P, 1991, NEUROSURGERY, V28, P709, DOI 10.1227/00006123-199105000-00012; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; OLGILVY CS, 1996, J NEUROSURG, V84, P785; Pemberton PL, 2003, ANAESTHESIA, V58, P370; Piepgras A, 2001, NEUROSURGERY, V48, P1128, DOI 10.1097/00006123-200105000-00033; RANKIN J, 1957, Scott Med J, V2, P200; RAVUSSIN P, 1993, NEUROSURGERY, V32, P236, DOI 10.1227/00006123-199302000-00013; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; SAMSON D, 1994, NEUROSURGERY, V34, P22; Sato K, 2000, ACTA NEUROCHIR, V142, P1013, DOI 10.1007/s007010070056; Schmied H, 1996, LANCET, V347, P289, DOI 10.1016/S0140-6736(96)90466-3; Wiebers D, 1999, NEW ENGL J MED, V340, P744; Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401; WITYK RJ, 1994, STROKE, V25, P362, DOI 10.1161/01.STR.25.2.362; WITYK RJ, 1994, STROKE, V25, P1300; ZHANG RL, 1993, STROKE, V24, P1235, DOI 10.1161/01.STR.24.8.1235; 1998, JAMA, V279, P1256	49	317	337	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2005	352	2					135	145		10.1056/NEJMoa040975	http://dx.doi.org/10.1056/NEJMoa040975			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886TG	15647576				2023-01-03	WOS:000226251700006
J	Fletcher, KE; Davis, SQ; Underwood, W; Mangrulkar, RS; McMahon, LF; Saint, S				Fletcher, KE; Davis, SQ; Underwood, W; Mangrulkar, RS; McMahon, LF; Saint, S			Systematic review: Effects of resident work hours on patient safety	ANNALS OF INTERNAL MEDICINE			English	Article							NIGHT-FLOAT SYSTEM; SLEEP-DEPRIVATION; DUTY HOURS; CARE; FATIGUE; CALL; SATISFACTION; PERFORMANCE; INTERN	Background: The Accreditation Council for Graduate Medical Education (ACGME) mandated new work hours rules for all residency programs in July 2003. Purpose: To critically evaluate the evidence that adhering to the ACGME standards will improve patient safety. Data Sources: Searches of electronic databases (MEDLINE, EMBASE, PREMEDLINE, and Current Contents) and other methods to identify the English-language literature for studies on resident work hours for the years 1966 to 2004. Study Selection: Studies that assessed a system change designed to counteract the effects of work hours, fatigue, or sleep deprivation and that included an outcome related to patient safety were included. Seven studies met these criteria. Data Extraction: Two investigators abstracted data from all included studies by using a standard data abstraction form; each study was rated according to established criteria to assess study design quality. Data Synthesis: Interventions used were float systems, other cross-coverage systems, or unspecified schedule changes. Outcomes included mortality, adverse events, and medication errors. The results suggest that introducing such interventions has an unclear effect on selected patient safety indicators. Specifically, some indicators (such as mortality) may not change after interventions, while other indicators may improve or worsen. Limitations: This analysis is limited by the study designs of the included studies, the diversity of interventions in the studies, and the possibility of publication bias favoring studies that demonstrated statistically significant differences. Conclusion: Evidence on patient safety is insufficient to inform the process of reducing resident work hours.	Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA; Ann Arbor Vet Affairs Med Ctr, Ann Arbor, MI USA; Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Chicago	Fletcher, KE (corresponding author), Zablocki Vet Adm Med Ctr, Primary Care Div, 5000 W Natl Ave, Milwaukee, WI 53295 USA.	kathlyn.fletcher@med.va.gov	Saint, Sanjay/AAF-5126-2019		AHRQ HHS [P20-HS11540] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM MED STUD ASS, 2003, RES WORK HOUR ISS; Bero LA, 1997, ANN INTERN MED, V127, P37, DOI 10.7326/0003-4819-127-1-199707010-00007; BUFF DD, 1995, J GEN INTERN MED, V10, P400, DOI 10.1007/BF02599842; Charap M, 2004, ANN INTERN MED, V140, P814, DOI 10.7326/0003-4819-140-10-200405180-00011; Cook RI, 2000, BRIT MED J, V320, P791, DOI 10.1136/bmj.320.7237.791; DAIGLER GE, 1990, AM J DIS CHILD, V144, P799, DOI 10.1001/archpedi.1990.02150310067030; Denisco R A, 1987, J Clin Monit, V3, P22, DOI 10.1007/BF00770879; Drazen JM, 2002, NEW ENGL J MED, V347, P1271, DOI 10.1056/NEJMe020110; FLETCHER KE, IN PRESS ACAD MED; FRIEDMAN RC, 1971, NEW ENGL J MED, V285, P201, DOI 10.1056/NEJM197107222850405; Gaba DM, 2002, NEW ENGL J MED, V347, P1249, DOI 10.1056/NEJMsa020846; GOTTLIEB DJ, 1991, ARCH INTERN MED, V151, P2065, DOI 10.1001/archinte.151.10.2065; Griffith CH, 1997, J GEN INTERN MED, V12, P308, DOI 10.1046/j.1525-1497.1997.012005308.x; Howard DL, 2004, J GEN INTERN MED, V19, P1, DOI 10.1111/j.1525-1497.2004.30336.x; HULLEY SB, 2001, DESIGNING CLIN RES E, P125; LAINE C, 1993, JAMA-J AM MED ASSOC, V269, P374, DOI 10.1001/jama.269.3.374; Leape LL, 2002, JAMA-J AM MED ASSOC, V288, P501, DOI 10.1001/jama.288.4.501; LIEU TA, 1992, AM J DIS CHILD, V146, P307, DOI 10.1001/archpedi.1992.02160150047018; LINGENFELSER T, 1994, MED EDUC, V28, P566, DOI 10.1111/j.1365-2923.1994.tb02737.x; LOFGREN RP, 1990, J GEN INTERN MED, V5, P501, DOI 10.1007/BF02600880; Mann F A, 1993, Invest Radiol, V28, P92, DOI 10.1097/00004424-199301000-00032; NAGOURNEY E, 2003, NY TIMES        0513, pF6; Ozuah PO, 2001, ARCH PEDIAT ADOL MED, V155, P1073; PACIO N, 2002, ANN ARBOR NEWS  0613, pA1; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Philibert I, 2002, JAMA-J AM MED ASSOC, V288, P1112, DOI 10.1001/jama.288.9.1112; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; *PUBL CIT HLTH RES, MED RES WORK HOURS; SAMKOFF JS, 1991, ACAD MED, V66, P687, DOI 10.1097/00001888-199111000-00013; SHOJANIA K, 2001, AHRQ PUBLICATION; Skeff KM, 2004, ANN INTERN MED, V140, P816, DOI 10.7326/0003-4819-140-10-200405180-00012; Steinbrook R, 2002, NEW ENGL J MED, V347, P1296, DOI 10.1056/NEJMhpr022383; STORER JS, 1989, ACAD MED, V64, P29, DOI 10.1097/00001888-198901000-00013; Taffinder NJ, 1998, LANCET, V352, P1191, DOI 10.1016/S0140-6736(98)00034-8; Veasey S, 2002, JAMA-J AM MED ASSOC, V288, P1116, DOI 10.1001/jama.288.9.1116; Weinstein DF, 2002, NEW ENGL J MED, V347, P1275, DOI 10.1056/NEJMsb022065	36	156	158	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	2004	141	11					851	857		10.7326/0003-4819-141-11-200412070-00009	http://dx.doi.org/10.7326/0003-4819-141-11-200412070-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	876WZ	15583227				2023-01-03	WOS:000225530700005
J	Vas, J; Mendez, C; Perea-Milla, E; Vega, E; Panadero, MD; Leon, JM; Borge, MA; Gaspar, O; Sanchez-Rodriguez, F; Aguilar, I; Jurado, R				Vas, J; Mendez, C; Perea-Milla, E; Vega, E; Panadero, MD; Leon, JM; Borge, MA; Gaspar, O; Sanchez-Rodriguez, F; Aguilar, I; Jurado, R			Acupuncture as a complementary therapy to the pharmacological treatment of osteoarthritis of the knee: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To analyse the efficacy of acupuncture as a complementary therapy to the pharmacological treatment of osteoarthritis of the knee, with respect to pain relief, reduction of stiffness, and increased physical function during treatment; modifications in the consumption of diclofenac during treatment; and changes in the patient's quality of life. Design Randomised, controlled, single blind trial, with blinded evaluation and statistical analysis of results. Setting Pain management unit in a public primary care centre in southern Spain, over a period of two years. Participants 97 outpatients presenting with osteoarthritis of the knee. Interventions Patients were randomly separated into two groups, one receiving acupuncture plus diclofenac (n=48) and the other placebo acupuncture plus diclofenac (n=49). Main outcome measures The clinical variables examined included intensity of pain as measured by a visual analogue scale; pain, stiffness, and physical function subscales of the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index; dosage of diclofenac taken during treatment; and the profile of quality of life in the chronically ill (PQLC) instrument, evaluated before and after the treatment programme. Results 88 patients completed the trial. In the intention to treat analysis, the WOMAC; index presented a greater reduction in the intervention group than in the control group (mean difference 23.9, 95% confidence interval 15.0 to 32.8) The reduction was greater in the subscale of functional activity. The same result was observed in the pain visual analogue scale, with a reduction of 26.6 (18.5 to 34.8). The PQLC results indicate that acupuncture treatment produces significant changes in physical capability (P=0.021) and psychological functioning (P=0.046). Three patients reported bruising after the acupuncture sessions. Conclusions Acupuncture plus diclofenac is more effective than placebo acupuncture plus diclofenac for the symptomatic treatment of osteoarthritis of the knee.	Ctr Salud Dos Hermanas A, Dist Sanitario Sevilla Sur, Pain Treatment Unit, Dos Hermanas 41700, Spain; Dist Sanitario Sevilla Sur, Alcala De Guadaira 41500, Spain; Hosp Costa Sol, Res Support Unit, Marbella 29600, Spain; Univ Seville, Dept Social Psychol, Seville 41018, Spain; Serv Ordenac Sanitaria, Serv Andaluz Salud, Seville 41001, Spain; Municipal Med Serv, Mairena Del Aljarafe 41927, Spain; Ctr Salud Castilleja De La Cuesta, Pain Treatment Unit, Castilleja de la Cuesta 41950, Spain	University of Sevilla	Vas, J (corresponding author), Ctr Salud Dos Hermanas A, Dist Sanitario Sevilla Sur, Pain Treatment Unit, Dos Hermanas 41700, Spain.	jvas@acmas.com	León-Rubio, José María/E-7734-2010; Vas, Jorge/P-7946-2016; Vas, Jorge/B-1138-2012	León-Rubio, José María/0000-0003-0197-5291; Vas, Jorge/0000-0003-1326-856X; Vas, Jorge/0000-0003-1326-856X				AHLBACK S, 1968, ACTA RADIOL DIAGN S, V72; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; AYZAGNER LCS, 1993, MUESTREO INVESTIGACI; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Berman BM, 1999, RHEUMATOLOGY, V38, P346, DOI 10.1093/rheumatology/38.4.346; BROWN BW, 2000, DSTPLAN CALCULATIONS; Cheng X, 1987, CHINESE ACUPUNCTURE; CHRISTENSEN BV, 1992, ACTA ANAESTH SCAND, V36, P519, DOI 10.1111/j.1399-6576.1992.tb03511.x; COBOS R, 2000, MANUAL ACUPUNCTURA M; Cobos R, 2000, MANUAL ACUPUNTURA MO; Creamer P, 1997, LANCET, V350, P503, DOI 10.1016/S0140-6736(97)07226-7; FELSON DT, 1990, SEMIN ARTHRITIS RHEU, V20, P42, DOI 10.1016/0049-0172(90)90046-I; FERRANDEZ IA, 2002, ATEN PRIMARIA, V30, P602; Perrot S, 1996, DRUGS, V52, P21, DOI 10.2165/00003495-199600523-00005; Siegrist J., 1996, PROFIL LEBENSQUALIT; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; Takeda W, 1994, Arthritis Care Res, V7, P118, DOI 10.1002/art.1790070304; Vas Jorge, 2004, Acupunct Med, V22, P23; Yurtkuran M, 1999, Am J Acupunct, V27, P133	19	126	140	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	2004	329	7476					1216	1219		10.1136/bmj.38238.601447.3A	http://dx.doi.org/10.1136/bmj.38238.601447.3A			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874FG	15494348	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000225335700018
J	Escher, M; Perneger, TV; Chevrolet, JC				Escher, M; Perneger, TV; Chevrolet, JC			National questionnaire survey on what influences doctors' decisions about admission to intensive care	BRITISH MEDICAL JOURNAL			English	Article							ILL PATIENTS; UNIT; TRIAGE; PHYSICIANS; RESUSCITATION; CANCER; ALLOCATION; RESOURCES; JUDGMENT; SUPPORT	Objectives To determine what influences doctors' decisions about admission of patients to intensive care. Design National questionnaire survey using eight clinical vignettes involving hypothetical patients. Setting Switzerland. Participants 402 Swiss doctors specialising in intensive care. Main outcome measures Rating of factors influencing decisions on admission and response to eight hypothetical clinical scenarios. Results Of 381 doctors agreeing to participate, 232 (61%) returned questionnaires. Most rated as important or very important the prognosis of the underlying disease (82%) and of the acute illness (81%) and the patients' wishes (71%). Few considered the important socioeconomic circumstances of the patient (20%), religious beliefs (3%) and emotional state (6%). In the vignettes, underlying disease (cancer versus non-cancerous disease) was not associated with admission to intensive care, but four other factors were: patients' wishes (odds ratio 3.0, 95% confidence interval 2.0 to 4.6), upbeat personality (2.9, 1.9 to 4.4), younger age (1.5, 1.1 to 2.2), and a greater number of beds available in intensive care (1.8, 1.2 to 2.5). Conclusions Doctors' decisions to admit patients to intensive care are influenced by patients' wishes and ethically problematic non-medical factors such as a patient's personality or availability of beds. Patients with cancer are not discriminated against.	Univ Hosp Geneva, Div Clin Pharmacol & Toxicol, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Qual Care Unit, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Med Intens Care Div, CH-1211 Geneva 14, Switzerland	University of Geneva; University of Geneva; University of Geneva	Escher, M (corresponding author), Univ Hosp Geneva, Div Clin Pharmacol & Toxicol, CH-1211 Geneva 14, Switzerland.	monica.escher@hcuge.ch						Azoulay E, 2000, CRIT CARE MED, V28, P3044, DOI 10.1097/00003246-200008000-00061; Azoulay E, 2001, CRIT CARE MED, V29, P2132, DOI 10.1097/00003246-200111000-00014; Claessens MT, 2000, J AM GERIATR SOC, V48, pS146, DOI 10.1111/j.1532-5415.2000.tb03124.x; Coppola KM, 2001, ARCH INTERN MED, V161, P431, DOI 10.1001/archinte.161.3.431; Egol A, 1999, CRIT CARE MED, V27, P633; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; ELY JW, 1992, J AM GERIATR SOC, V40, P471, DOI 10.1111/j.1532-5415.1992.tb02013.x; Furnham A, 2000, J SOC BEHAV PERS, V15, P185; Ghusn HF, 1997, J AM GERIATR SOC, V45, P1118, DOI 10.1111/j.1532-5415.1997.tb05977.x; Hanson LC, 1996, ARCH INTERN MED, V156, P785, DOI 10.1001/archinte.156.7.785; JACOBS P, 1990, CRIT CARE MED, V18, P1282, DOI 10.1097/00003246-199011000-00020; Joynt GM, 2001, INTENS CARE MED, V27, P1459, DOI 10.1007/s001340101041; KOHLENBERGER C, 1994, JAMA-J AM MED ASSOC, V271, P1200; Lanken PN, 1997, AM J RESP CRIT CARE, V156, P1282; LAWRENCE VA, 1987, ARCH INTERN MED, V147, P1637, DOI 10.1001/archinte.147.9.1637; NUCKTON TJ, 1995, ARCH INTERN MED, V155, P1087, DOI 10.1001/archinte.155.10.1087; Redelmeier DA, 2001, CAN MED ASSOC J, V164, P358; Sprung CL, 1997, INTENS CARE MED, V23, P1011, DOI 10.1007/s001340050449; SUHL J, 1994, ARCH INTERN MED, V154, P90, DOI 10.1001/archinte.154.1.90; Tanvetyanon T, 2003, CRIT CARE MED, V31, P60, DOI 10.1097/00003246-200301000-00009; Tarnow-Mordi WO, 2000, LANCET, V356, P185, DOI 10.1016/S0140-6736(00)02478-8; Vincent JL, 1998, INTENS CARE MED, V24, P1251, DOI 10.1007/s001340050758; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525	23	80	84	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 21	2004	329	7463					425	428		10.1136/bmj.329.7463.425	http://dx.doi.org/10.1136/bmj.329.7463.425			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EA	15321898	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000223520300015
J	Wingerchuk, D				Wingerchuk, D			Cannabis for medical purposes: cultivating science, weeding out the fiction	LANCET			English	Editorial Material							MULTIPLE-SCLEROSIS; MARIJUANA USE; PREVALENCE; EPILEPSY		Mayo Clin, Dept Neurol, Multiple Sclerosis Ctr, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix	Wingerchuk, D (corresponding author), Mayo Clin, Dept Neurol, Multiple Sclerosis Ctr, Scottsdale, AZ 85259 USA.	wingerchuk.dean@mayo.edu						Baker D, 2003, LANCET NEUROL, V2, P291, DOI 10.1016/S1474-4422(03)00381-8; Clark AJ, 2004, NEUROLOGY, V62, P2098, DOI 10.1212/01.WNL.0000127707.07621.72; Compton WM, 2004, JAMA-J AM MED ASSOC, V291, P2114, DOI 10.1001/jama.291.17.2114; Fox P, 2004, NEUROLOGY, V62, P1105, DOI 10.1212/01.WNL.0000118203.67138.3E; GREENBERG HS, 1994, CLIN PHARMACOL THER, V55, P324, DOI 10.1038/clpt.1994.33; Gross DW, 2004, NEUROLOGY, V62, P2095, DOI 10.1212/01.WNL.0000127623.03766.75; Iversen L, 2003, BRAIN, V126, P1252, DOI 10.1093/brain/awg143; Killestein J, 2002, NEUROLOGY, V58, P1404, DOI 10.1212/WNL.58.9.1404; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Ogborne AC, 2000, SUBST USE MISUSE, V35, P301, DOI 10.3109/10826080009147698; Page SA, 2003, CAN J NEUROL SCI, V30, P201, DOI 10.1017/S0317167100002584; Sirven JI, 2004, NEUROLOGY, V62, P1924, DOI 10.1212/01.WNL.0000129703.59857.D6; Webb E, 1996, LANCET, V348, P922, DOI 10.1016/S0140-6736(96)03410-1; Zajicek J, 2003, LANCET, V362, P1517, DOI 10.1016/S0140-6736(03)14738-1	14	15	32	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 24	2004	364	9431					315	316		10.1016/S0140-6736(04)16741-X	http://dx.doi.org/10.1016/S0140-6736(04)16741-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840IZ	15276375				2023-01-03	WOS:000222853300010
J	Yeni, PG; Hammer, SM; Hirsch, MS; Saag, MS; Schechter, M; Carpenter, CCJ; Fischl, MA; Gatell, JM; Gazzard, BG; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Schooley, RT; Thompson, MA; Vella, S; Volberding, PA				Yeni, PG; Hammer, SM; Hirsch, MS; Saag, MS; Schechter, M; Carpenter, CCJ; Fischl, MA; Gatell, JM; Gazzard, BG; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Schooley, RT; Thompson, MA; Vella, S; Volberding, PA			Treatment for adult HIV infection - 2004 recommendations of the International AIDS Society-USA panel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS TYPE-1; STRUCTURED TREATMENT INTERRUPTION; SEQUENTIAL 3-DRUG REGIMENS; CD4(+) CELL COUNT; PROGNOSTIC IMPORTANCE; COMBINATION THERAPY; LOPINAVIR-RITONAVIR; PROTEASE-INHIBITOR; INITIAL TREATMENT	Context Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection. Objective To update recommendations for physicians who provide HIV care regarding when to start antiretroviral therapy, what drugs to start with, when to change drug regimens, and what drug regimens to switch to after therapy fails. DataSources Evidence was identified and reviewed by a 16-member noncompensated panel of physicians with expertise in HIV-related basic science and clinical research, antiretroviral therapy, and HIV patient care. The panel was designed to have broad US and international representation for areas with adequate access to antiretroviral management. Study Selection Evidence considered included published basic science, clinical research, and epidemiological data (identified by experts in the field or extracted through MEDLINE searches using terms relevant to antiretroviral therapy) and abstracts from HIV-oriented scientific conferences between July 2002 and May 2004. DataExtraction Data were reviewed to identify any information that might change previous guidelines. Based on panel; discussion, guidelines were drafted by a writing committee and discussed by the panel until consensus was reached. Data Synthesis Four antiretroviral drugs recently have been made available and have broadened the options for initial and subsequent regimens. New data allow more definitive recommendations for specific drugs or regimens to include or avoid, particularly with regard to initial therapy. Recommendations are rated according to 7 evidence categories, ranging from I (data from prospective randomized clinical trials) to VII (expert opinion of the panel). Conclusion Further insights into the roles of drug toxic effects, drug resistance, and pharmacological interactions have resulted in additional guidance for strategic approaches to antiretroviral management.	Hop Bichat Claude Bernard, X Bichat Med Sch, Dept Infect Dis, F-75877 Paris 18, France; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA; Harvard Univ, Sch Med, Dept Immunol & Infect Dis, Boston, MA USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Fed Rio de Janeiro, Dept Prevent Med, Rio De Janeiro, Brazil; Brown Univ, Sch Med, Dept Biomed, Providence, RI 02912 USA; Univ Miami, Sch Med, Dept Med, Miami, FL USA; Univ Barcelona, Dept Med, Barcelona, Spain; Chelsea & Westminster Hosp, Dept HIV Med, London, England; Int AIDS Soc USA, San Francisco, CA USA; Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA; Univ British Columbia, Dept Med, Vancouver, BC, Canada; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; San Diego VA Healthcare Syst, San Diego, CA USA; Univ Colorado, Sch Med, Dept Med, Denver, CO USA; AIDS Res Consortium Atlanta, Atlanta, GA USA; Ist Super Sanita, I-00161 Rome, Italy; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; San Francisco VA Med Ctr, San Francisco, CA USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Columbia University; Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham; Universidade Federal do Rio de Janeiro; Brown University; University of Miami; University of Barcelona; Imperial College London; Stanford University; University of British Columbia; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Istituto Superiore di Sanita (ISS); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Yeni, PG (corresponding author), Hop Bichat Claude Bernard, X Bichat Med Sch, Dept Infect Dis, 46 Rue Henri Huchard, F-75877 Paris 18, France.	Patrick.Yeni@Bch.Ap-Hop-Paris.Fr	VELLA, STEFANO/V-8440-2019; Montaner, Julio/K-7621-2012; Schechter, Mauro/AAG-7445-2020; Vella, Stefano/GZM-0519-2022; VELLA, STEFANO/ABI-3368-2020	VELLA, STEFANO/0000-0003-2347-5984; katzenstein, david/0000-0002-8593-4560				Anastos K, 2004, ANN INTERN MED, V140, P256, DOI 10.7326/0003-4819-140-4-200402170-00007; Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3; BARTLETT JA, 2002, 14 INT AIDS C JUL 7; BENSON C, 2004, 11 C RETR OPP INF FE; Bertz R, 2000, AIDS, V14, pS100; CAHN P, 2004, 10 C RETR OPP INF; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; Chen RY, 2003, CLIN INFECT DIS, V37, P714, DOI 10.1086/377271; Chene G, 2003, LANCET, V362, P679, DOI 10.1016/S0140-6736(03)14229-8; Cossarizza A, 2004, AIDS, V18, P137, DOI 10.1097/00002030-200401230-00002; de Pinho AMF, 2001, AIDS, V15, P2129, DOI 10.1097/00002030-200111090-00008; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; DEGEN O, 2002, 14 INT AIDS C JUL 7; DEJESUS E, 2003, 10 C RETR OPP INF FE; DEJESUS E, 2004, 11 C RETR OPP INF FE; DEJESUS E, 2003, 43 INT C ANT AG CHEM; *DEP HLTH HUM SERV, 1998, ANN INTERN MED, V128, P1079; *DUP PHARM INC, 2002, SUST PACK INS; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Falloon J, 2000, CLIN INFECT DIS, V30, P313, DOI 10.1086/313667; Ferry JJ, 1998, J ACQ IMMUN DEF SYND, V18, P252, DOI 10.1097/00042560-199807010-00009; Fiske W, 1998, 12 WORLD AIDS C JUN; FISKE WD, 1997, 4 C RETR OPP INF JAN; GALLANT JE, 2003, 43 INT C ANT AG CHEM; GAZZARD BG, 2003, 43 INT C ANT AG CHEM; Gerstoft J, 2003, AIDS, V17, P2045, DOI 10.1097/00002030-200309260-00005; GERSTOFT J, 2002, 42 INT C ANT AG CHEM; *GIL SCI INC, 2003, VIR PACK INS; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; Harris M, 1998, J INFECT DIS, V177, P1514, DOI 10.1086/515317; Havlir DV, 2001, JAMA-J AM MED ASSOC, V286, P171, DOI 10.1001/jama.286.2.171; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; Hsu A, 2003, ANTIMICROB AGENTS CH, V47, P350, DOI 10.1128/AAC.47.1.350-359.2003; JEMSEK J, 2004, 11 C RETR OPP INF FE; JOURDAIN G, 2004, 11 C RETR OPP INF FE; Katlama C, 2004, AIDS, V18, P217, DOI 10.1097/00002030-200401230-00011; KEARNEY B, 2001, 1 INT AIDS SOC C HIV; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; LANDMAN R, 2004, 11 C RETR OPP INF FE; Lawrence J, 2003, NEW ENGL J MED, V349, P837, DOI 10.1056/NEJMoa035103; Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211; Lichtenstein KA, 2003, JAIDS-J ACQ IMM DEF, V32, P48, DOI 10.1097/00126334-200301010-00007; Lopez-Cortes LF, 2003, JAIDS-J ACQ IMM DEF, V32, P240, DOI 10.1097/00126334-200302010-00019; LYONS F, 2004, 11 C RETR OPP INF FE; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; Martin A, 2004, AIDS, V18, P1029, DOI 10.1097/00002030-200404300-00011; Martinez E, 2003, NEW ENGL J MED, V349, P1036, DOI 10.1056/NEJMoa021589; MARTINEZ E, IN PRESS LANCET; MELLORS J, 2004, 11 C RETR OPP INF FE; MONTANER J, 2003, 2 INT AIDS SOC C HIV; MONTANER JSG, 42 INT C ANT AG CHEM; Moyle G, 2000, J ACQ IMMUN DEF SYND, V23, P128; MURO E, 2004, 11 C RETR OPP INF FE; Murphy RL, 2003, AIDS, V17, P2603, DOI 10.1097/00002030-200312050-00007; NADLER J, 2003, 10 C RETR OPP INF FE; NEGREDO E, 2004, 11 C RETR OPP INF FE; NEGREDO E, 2002, 14 INT AIDS C JUL 7; NIETOCISNEROS L, 2003, 2 INT AIDS SOC C HIV; Palella FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007; PALMER S, 2004, 11 C RETR OPP INF FE; PALMISANO L, 2004, 11 C RETR OPP INF FE; Podzamczer D, 2002, ANTIVIR THER, V7, P81; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; *ROX LAB INC, 2000, VIR PACK INS; Ruiz L, 2003, J INFECT DIS, V188, P977, DOI 10.1086/378411; SAAG M, 2002, 42 INT C ANT AG CHEM; Saag MS, 2002, TOPICS HIV MED, V10, P47; Schambelan M, 2002, JAIDS-J ACQ IMM DEF, V31, P257, DOI 10.1097/00126334-200211010-00001; SCHURMANN D, 2002, 6 INT C DRUG THER HI; Shafer RW, 2003, NEW ENGL J MED, V349, P2304, DOI 10.1056/NEJMoa030265; SQUIRES KE, 2002, 42 INT C ANT AG CHEM; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Staszewski S, 2001, JAMA-J AM MED ASSOC, V285, P1155, DOI 10.1001/jama.285.9.1155; STASZEWSKI S, 2002, 14 INT AIDS C JUL 7; Sterling TR, 2003, J INFECT DIS, V188, P1659, DOI 10.1086/379741; TABURET AM, 2003, 10 C RETR OPP INF FE; TAYLOR S, 2004, 11 C RETR OPP INF FE; Tran JQ, 2002, CLIN PHARMACOL THER, V72, P615, DOI 10.1067/mcp.2002.128868; van Leeuwen R, 2003, AIDS, V17, P987, DOI 10.1097/00002030-200305020-00007; van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7; VELDKAMP AI, 2000, 7 C RETR OPP INF JAN; Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354; *WHO GUID, 2002, SCAL ANT THER RES LI; Wood E, 2003, ANN INTERN MED, V139, P810, DOI 10.7326/0003-4819-139-10-200311180-00008; Wood E, 2003, J INFECT DIS, V188, P1421, DOI 10.1086/379201; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222	88	439	471	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2004	292	2					251	265		10.1001/jama.292.2.251	http://dx.doi.org/10.1001/jama.292.2.251			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836TS	15249575				2023-01-03	WOS:000222579300031
J	Goldacre, MJ; Roberts, SE				Goldacre, MJ; Roberts, SE			Hospital admission for acute pancreatitis in an English population, 1963-98: database study of incidence and mortality	BRITISH MEDICAL JOURNAL			English	Article							ETIOLOGY; ENGLAND; COUNTY; EPIDEMIOLOGY; PATTERNS; DISEASES; SCOTLAND; AUDIT	Objectives To investigate trends in the incidence of acute pancreatitis resulting in admission to hospital, and mortality after admission, from 1963 to 1998. Design Analysis of hospital inpatient statistics for acute pancreatitis, linked to data from death certificates. Setting Southern England. Subjects 5312 people admitted to hospital with acute pancreatitis. Main outcome measures Incidence rates for admission to hospital, case fatality rates at 0-29 and 30-364 days after admission, and standardised mortality ratios at monthly intervals up to one year after admission. Results The incidence of acute pancreatitis with admission to hospital increased from 1963-98: age standardised incidence rates were 4.9 per 100 000 population in 1963-74,7.7 in 1975-86, and 9.8 in 1987-98. Age standardised case fatality rates within 30 days of admission were 14.2% in 1963-74,7.6% in 1975-86, and 6.7% in 1987-98. From 1975-98, standardised mortality ratios at 30 days were 30 in men and 31 in women (compared with the general population of equivalent age in the same period = 1), and they remained significantly increased until month 5 for men and month 6 for women. Conclusions Incidence rates for acute pancreatitis with admission to hospital rose in both men and women from 1963 to 1998, particularly among younger age groups. This probably reflects, at least in part, an increase in alcoholic pancreatitis. Mortality after admission has not declined since the 1970s. This presumably reflects the fact that no major innovations in the treatment of acute pancreatitis have been introduced. Pancreatitis remains a disease with a poor prognosis during the acute phase.	Univ Oxford, Unit Hlth Care Epidemiol, Dept Publ Hlth, Oxford OX3 7LF, England	University of Oxford	Goldacre, MJ (corresponding author), Univ Oxford, Unit Hlth Care Epidemiol, Dept Publ Hlth, Old Rd, Oxford OX3 7LF, England.	michael.goldacre@dphpc.ox.ac.uk						Appelros S, 1999, BRIT J SURG, V86, P465, DOI 10.1046/j.1365-2168.1999.01049.x; BOURKE JB, 1975, LANCET, V2, P967; CORFIELD AP, 1985, GUT, V26, P724, DOI 10.1136/gut.26.7.724; Eland IA, 2000, SCAND J GASTROENTERO, V35, P1110; Floyd A, 2002, SCAND J GASTROENTERO, V37, P1461, DOI 10.1080/003655202762671369; Go Vay Liang W., 1994, P235; Gronroos JM, 1999, HEPATO-GASTROENTEROL, V46, P2572; Halvorsen FA, 1996, SCAND J GASTROENTERO, V31, P411, DOI 10.3109/00365529609006419; JOHNSON CD, 1991, GUT, V32, P1401, DOI 10.1136/gut.32.11.1401; LANKISCH PG, 1989, DIGESTION, V44, P20, DOI 10.1159/000199888; Lankisch PG, 2002, PANCREATOLOGY, V2, P469, DOI 10.1159/000064713; MANN DV, 1994, BRIT J SURG, V81, P890, DOI 10.1002/bjs.1800810632; McKay CJ, 1999, BRIT J SURG, V86, P1302, DOI 10.1046/j.1365-2168.1999.01246.x; MERO M, 1982, ANN CHIR GYNAECOL FE, V71, P126; *NAT STAT, 2001, LIV BRIT RES 2000 GE, P159; OSULLIVAN JN, 1972, GASTROENTEROLOGY, V62, P373; Secknus R, 2000, CHIRURG, V71, P249; THOMSON SR, 1987, BRIT J SURG, V74, P398, DOI 10.1002/bjs.1800740526; Tinto A, 2002, ALIMENT PHARM THER, V16, P2097, DOI 10.1046/j.1365-2036.2002.01367.x; Toh SKC, 2000, GUT, V46, P239, DOI 10.1136/gut.46.2.239; Tran D. D., 1994, Digestion, V55, P342; TRAPNELL JE, 1975, BRIT MED J, V2, P179, DOI 10.1136/bmj.2.5964.179; WILSON C, 1990, BRIT J SURG, V77, P731, DOI 10.1002/bjs.1800770705; [No title captured]	24	157	162	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 19	2004	328	7454					1466	1469		10.1136/bmj.328.7454.1466	http://dx.doi.org/10.1136/bmj.328.7454.1466			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832CK	15205290	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000222244600015
J	Turgeon, JL; McDonnell, DP; Martin, KA; Wise, PM				Turgeon, JL; McDonnell, DP; Martin, KA; Wise, PM			Hormone therapy: Physiological complexity belies therapeutic simplicity	SCIENCE			English	Review							ESTROGEN-RECEPTOR-ALPHA; RANDOMIZED CONTROLLED-TRIAL; C-REACTIVE PROTEIN; PROGESTERONE-RECEPTOR; REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; BREAST-CANCER; MEDROXYPROGESTERONE ACETATE; CARDIOVASCULAR-DISEASE; TISSUE-SPECIFICITY	The results of the Women's Health Initiative, a study anticipated to provide definitive answers about health benefits and risks of postmenopausal hormone therapy, have generated debate and confusion among clinicians, researchers, and the lay public. The ovarian hormones estrogen and progesterone, which decline at menopause, normally elicit complex tissue-specific responses throughout the body. Major advances are providing a detailed molecular definition of how that differential action is achieved. Here we review estrogen and progestin actions, discuss how effectively knowledge of steroid hormone endocrinology has been incorporated into clinical studies, and consider the impact on modern hormone therapy protocols and pharmaceutical development.	Univ Calif Davis, Dept Internal Med, Div Endocrinol Clin Nutr & Vasc Med, Davis, CA 95616 USA; Univ Calif Davis, Dept Neurobiol Physiol & Behav, Div Biol Sci, Davis, CA 95616 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Reprod Endocrine Unit, Boston, MA 02114 USA	University of California System; University of California Davis; University of California System; University of California Davis; Duke University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Turgeon, JL (corresponding author), Univ Calif Davis, Dept Internal Med, Div Endocrinol Clin Nutr & Vasc Med, Davis, CA 95616 USA.	jlturgeon@ucdavis.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050495, R01DK048807, R21DK066606, R37DK048807] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002224, P01AG017164, R37AG002224] Funding Source: NIH RePORTER; NIA NIH HHS [AG17164, AG02224] Funding Source: Medline; NICHD NIH HHS [HD12137] Funding Source: Medline; NIDDK NIH HHS [DK50495, DK66606, DK48807] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Bamberger CM, 1999, J CLIN ENDOCR METAB, V84, P4055, DOI 10.1210/jc.84.11.4055; Bhavnani BR, 2003, J STEROID BIOCHEM, V85, P473, DOI 10.1016/S0960-0760(03)00220-6; CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505; Dhandapani KM, 2002, BIOL REPROD, V67, P1379, DOI 10.1095/biolreprod.102.003848; Gao JG, 2000, MOL ENDOCRINOL, V14, P1954, DOI 10.1210/me.14.12.1954; Giangrande PH, 1999, RECENT PROG HORM RES, V54, P291; Godsland IF, 2001, FERTIL STERIL, V75, P898, DOI 10.1016/S0015-0282(01)01699-5; Gregory CW, 2002, J CLIN ENDOCR METAB, V87, P2960, DOI 10.1210/jc.87.6.2960; Gustaftson JA, 2003, TRENDS PHARMACOL SCI, V24, P479, DOI 10.1016/S0165-6147(03)00229-3; Hall JM, 2002, MOL ENDOCRINOL, V16, P469, DOI 10.1210/me.16.3.469; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Harris HA, 2003, ENDOCRINOLOGY, V144, P4241, DOI 10.1210/en.2003-0550; Herrington DM, 2002, CIRCULATION, V105, P1879, DOI 10.1161/01.CIR.0000016173.98826.88; Ke HZ, 2004, ENDOCRINOLOGY, V145, P1996, DOI 10.1210/en.2003-1481; Key TJ, 2003, J NATL CANCER I, V95, P1218, DOI 10.1093/jnci/djg022; Labrie F, 2003, ENDOCRINOLOGY, V144, P4700, DOI 10.1210/en.2003-0269; Leonhardt SA, 2003, STEROIDS, V68, P761, DOI 10.1016/S0039-128X(03)00129-6; Li XT, 2003, J BIOL CHEM, V278, P39261, DOI 10.1074/jbc.R300024200; Liu XM, 2002, CHEM RES TOXICOL, V15, P512, DOI 10.1021/tx0101649; Losel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; Manson JE, 2001, NEW ENGL J MED, V345, P34, DOI 10.1056/NEJM200107053450106; McCullough LD, 2003, TRENDS ENDOCRIN MET, V14, P228, DOI 10.1016/S1043-2760(03)00076-6; McDonnell DP, 2002, RECENT PROG HORM RES, V57, P295, DOI 10.1210/rp.57.1.295; Mendelsohn ME, 2002, AM J CARDIOL, V90, p3F, DOI 10.1016/S0002-9149(02)02418-9; Mikkola TS, 2002, CARDIOVASC RES, V53, P605, DOI 10.1016/S0008-6363(01)00466-7; Miller AP, 2003, HYPERTENSION, V42, P657, DOI 10.1161/01.HYP.0000085560.02979.0C; Miyagawa K, 1997, NAT MED, V3, P324, DOI 10.1038/nm0397-324; Mote PA, 2002, BREAST CANCER RES TR, V72, P163, DOI 10.1023/A:1014820500738; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Oger E, 2003, ARTERIOSCL THROM VAS, V23, P1671, DOI 10.1161/01.ATV.0000087141.05044.1F; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Otsuki M, 2001, ARTERIOSCL THROM VAS, V21, P243, DOI 10.1161/01.ATV.21.2.243; Rajala MW, 2003, ENDOCRINOLOGY, V144, P3765, DOI 10.1210/en.2003-0580; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shearman AM, 2003, JAMA-J AM MED ASSOC, V290, P2263, DOI 10.1001/jama.290.17.2263; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Sun J, 2002, ENDOCRINOLOGY, V143, P941, DOI 10.1210/en.143.3.941; Vegeto E, 2003, P NATL ACAD SCI USA, V100, P9614, DOI 10.1073/pnas.1531957100; Vongpatanasin W, 2003, J AM COLL CARDIOL, V41, P1358, DOI 10.1016/S0735-1097(03)00156-6; Webb P, 2003, J BIOL CHEM, V278, P6912, DOI 10.1074/jbc.M208501200; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207; Wong CW, 2002, P NATL ACAD SCI USA, V99, P14783, DOI 10.1073/pnas.192569699; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Zhi L, 2003, J MED CHEM, V46, P4104, DOI 10.1021/jm020477g	49	223	234	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	2004	304	5675					1269	1273		10.1126/science.1096725	http://dx.doi.org/10.1126/science.1096725			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15166356				2023-01-03	WOS:000221669600030
J	Watts, G				Watts, G			Commentary: the defence of dirt	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DISEASE				Watts, G (corresponding author), 28 New End Sq, London NW3 1LS, England.	geoff@scileg.freeserve.co.uk						Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V107, P531, DOI 10.1067/mai.2001.113081; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Benn CS, 2004, BRIT MED J, V328, P1223, DOI 10.1136/bmj.38069.512245.FE; Rook GAW, 2004, SPRINGER SEMIN IMMUN, V25, P237, DOI 10.1007/s00281-003-0148-9; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2	5	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	2004	328	7450					1226	1226		10.1136/bmj.38075.565822.55	http://dx.doi.org/10.1136/bmj.38075.565822.55			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824HL	15121715	Green Published			2023-01-03	WOS:000221677200016
J	Wonderling, D; Vickers, AJ; Grieve, R; McCarney, R				Wonderling, D; Vickers, AJ; Grieve, R; McCarney, R			Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TENSION-TYPE HEADACHE; PROPHYLACTIC TREATMENT; NEEDLE ACUPUNCTURE; MIGRAINE; HEALTH; PLACEBO; SUMATRIPTAN; ACCESS	Objective To evaluate the cost effectiveness of acupuncture in the management of chronic headache. Design Cost effectiveness analysis of a randomised controlled trial. Setting General practices in England and Wales. Participants 401 patients with chronic headache, predominantly migraine. Interventions Patients were randomly allocated to receive up to 12 acupuncture treatments over three months from appropriately trained physiotherapists, or to usual care alone. Main outcome measure Incremental cost per quality adjusted life year (QALY) gained. Results Total costs during the one year period of the study were on average higher for the acupuncture group (1,103; $768; E598) than for controls (A:217) because of the acupuncture practitioners' costs. The mean health gain from acupuncture during the one year of the trial was 0.021 quality adjusted life years (QALYs), leading to a base case estimate of 9180 per QALY gained. This result was robust to sensitivity analysis. Cost per QALY dropped substantially when the analysis incorporated likely QALY differences for the years after the trial. Conclusions Acupuncture for chronic headache improves health related quality of life at a small additional cost; it is relatively cost effective compared with a number of other interventions provided by the NHS.	Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England; Mem Sloan Kettering Canc Ctr, Biostat Serv, Integrat Med Serv, New York, NY 10021 USA; Univ London Imperial Coll Sci Technol & Med, Dept Psychol Med, London W2 1PD, England	University of London; London School of Hygiene & Tropical Medicine; Memorial Sloan Kettering Cancer Center; Imperial College London	Wonderling, D (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, Keppel St, London WC1E 7HT, England.	David.Wonderling@lshtm.ac.uk		Wonderling, David/0000-0003-0315-6273; Grieve, Richard/0000-0001-8899-1301; Vickers, Andrew/0000-0003-1525-6503				Allais G, 2002, HEADACHE, V42, P855, DOI 10.1046/j.1526-4610.2002.02203.x; BLAU JN, 1991, MIGRAINE; BOSANQUET N, 1992, BR J MED EC, V2, P81; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; CULL RE, 1992, BR J MED EC, V2, P81; Evans KW, 1997, PHARMACOECONOMICS, V12, P565, DOI 10.2165/00019053-199712050-00007; Goadsby PJ, 2002, NEW ENGL J MED, V346, P257, DOI 10.1056/NEJMra010917; Karakurum B, 2001, CEPHALALGIA, V21, P813, DOI 10.1046/j.1468-2982.2001.218238.x; Karst M, 2000, PAIN, V88, P199, DOI 10.1016/S0304-3959(00)00315-8; Karst M, 2001, CEPHALALGIA, V21, P637, DOI 10.1046/j.1468-2982.2001.00198.x; Kee W. G., 1998, AM J PAIN MANAGEMENT, V8, P83; LENHARD L, 1983, NEW ZEAL MED J, V96, P663; Lipton RB, 2003, NEUROLOGY, V60, P441, DOI 10.1212/WNL.60.3.441; McCarney R, 2002, COMPLEMENT THER MED, V10, P63, DOI 10.1054/ctim.2002.0516; Melchart D, 2003, J INTERN MED, V253, P181, DOI 10.1046/j.1365-2796.2003.01081.x; MELCHART D, 2001, COCHRANE DATABASE SY; Melchart D., 2001, COCHRANE DATABASE SY; NETTEN A, 2002, UNIT COSTS HLTH SOCI; *OFF NAT STAT, 2003, 1 REL CONS PRIC IND; Raftery J, 2001, BRIT MED J, V323, P1300, DOI 10.1136/bmj.323.7324.1300; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Solomon GD, 1997, PHARMACOECONOMICS, V11, P1, DOI 10.2165/00019053-199700111-00003; Solomon GD, 1997, NEUROLOGY, V48, pS10, DOI 10.1212/WNL.48.3_Suppl_3.10S; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; STEEDMAN SM, 1992, CLIN J PAIN, V8, P204, DOI 10.1097/00002508-199209000-00004; STEWART WF, 1994, EUR NEUROL, V34, P12, DOI 10.1159/000119527; Stinnett AA, 1998, MED DECIS MAKING, V18, pS68, DOI 10.1177/0272989X98018002S09; Tfelt-Hansen P, 2000, CEPHALALGIA, V20, P765; Thomas KJ, 2001, BRIT J GEN PRACT, V51, P25; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; VICKERS A, 1999, COMPLEMENT THER MED, V7, P8; Vickers A. J., 2004, BMJ, V328; VINCENT CA, 1989, CLIN J PAIN, V5, P305, DOI 10.1097/00002508-198912000-00006; Wadlow G., 1996, COMPLEMENT THER MED, V4, P1, DOI [10.1016/S0965-2299(96)80048-3, DOI 10.1016/S0965-2299(96)80048-3]; WHITE A, 2001, BRIT MED J, V323, P4485; Whittaker SJ, 1996, BT TECHNOL J, V14, P11	37	83	88	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 27	2004	328	7442					747	749		10.1136/bmj.38033.896505.EB	http://dx.doi.org/10.1136/bmj.38033.896505.EB			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809WH	15023830	Green Accepted, Green Published, Bronze, Green Submitted			2023-01-03	WOS:000220666300018
J	Viscusi, ER; Reynolds, L; Chung, F; Atkinson, LE; Khanna, S				Viscusi, ER; Reynolds, L; Chung, F; Atkinson, LE; Khanna, S			Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED ANALGESIA; EFFICACY; MANAGEMENT; SAFETY	Context Patient-controlled analgesia (PCA) with morphine is commonly used to provide acute postoperative pain control after major surgery. The fentanyl hydrochloride patient-controlled transdermal system eliminates the need for venous access and complicated programming of pumps. Objective To assess the efficacy and safety of an investigational patient-controlled iontophoretic transdermal system using fentanyl hydrochloride compared with a standard intravenous morphine patient-controlled pump. Design, Setting, and Patients Prospective randomized controlled parallel-group trial conducted between September 2000 and March 2001 at 33 North American hospitals, enrolling 636 adult patients who had just undergone major surgery. Interventions In surgical recovery rooms, patients were randomly assigned to intravenous morphine (1-mg bolus every 5 minutes; maximum of 10 mg/h) by a patient-controlled analgesia pump (n=320) or iontophoretic fentanyl hydrochloride (40-mug infusion over 10 minutes) by a patient-controlled transdermal system (n =316). Supplemental analgesia (morphine or fentanyl intravenous boluses) was administered as needed before and for the first 3 hours after activation of the PCA treatments. Patients then used the PCA treatments without additional analgesics for up to 72 hours. Main Outcome Measures The primary efficacy variable was patient global assessment of the method of pain control during the first 24 hours. Additional efficacy measures were the proportion of patients discontinuing the study because of inadequate analgesia for any reason, patient-reported pain intensity scores on a 100-mm visual analog scale WAS), and patient global assessments at 48 and 72 hours. Adverse effects were also recorded. Results Ratings of good or excellent after 24 hours of treatment for the method of pain control were given by 73.7% of patients (233/316) who used transdermal fentanyl PCA and 76.9% of patients (246/320) who used intravenous morphine PCA-1 treatment difference was -3.2% (95% confidence interval, -9.9% to 3.5%; P=36). Early patient discontinuations (25.9% fentanyl vs 25.0% morphine; P=.78) and last pain intensity scores (32.7 fentanyl vs 31.1 morphine on the VAS; P=.45) were not different between the 2 treatments. With continued treatment for up to 48 or 72 hours, more than 80% of patient assessments in each treatment group were good or excellent. The incidence of opioid-related adverse events was similar between the Conclusion An investigational PCA transclermal system using iontophoresis to deliver fentanyl provided postsurgical pain control equivalent to that of a standard intravenous morphine regimen delivered by a PCA pump.	Thomas Jefferson Univ, Dept Anesthesiol, Philadelphia, PA 19107 USA; Loma Linda Univ, Ctr Pain Management, Loma Linda, CA 92350 USA; Univ Toronto, Toronto Western Hosp, Dept Anesthesiol, Toronto, ON, Canada; ALZA Corp, Stat & Data Management, Mountain View, CA USA; ALZA Corp, Clin Dev, Mountain View, CA USA	Jefferson University; Loma Linda University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Johnson & Johnson; Johnson & Johnson USA; Johnson & Johnson; Johnson & Johnson USA	Viscusi, ER (corresponding author), Thomas Jefferson Univ, Dept Anesthesiol, 111 S 11th St,Suite G 8490, Philadelphia, PA 19107 USA.	eugene.viscusi@jefferson.edu	Chung, Frances/F-5618-2015	Chung, Frances/0000-0001-9576-3606				*AC PAIN MAN PAN, 1992, AC PAIN MAN OP MED P; *AM PAIN SOC, 1999, PRINC AN US TREATM A; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Byrom B., 2002, APPL CLIN TRIALS, V2002, P36; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; GINSBERG B, 1995, PAIN, V62, P95, DOI 10.1016/0304-3959(94)00255-D; GLASS PSA, 1992, ANESTH ANALG, V74, P345; HOWELL PR, 1995, CAN J ANAESTH, V42, P41, DOI 10.1007/BF03010570; Lehmann KA, 1999, EUR SURG RES, V31, P112, DOI 10.1159/000008629; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; OWEN H, 1989, ANAESTHESIA, V44, P7, DOI 10.1111/j.1365-2044.1989.tb11087.x; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; ROWBOTHAM DJ, 1989, ANAESTHESIA, V44, P922, DOI 10.1111/j.1365-2044.1989.tb09151.x; Schumann R, 2003, ANESTH ANALG, V96, P469, DOI 10.1097/00000539-200302000-00032; SINATRA RS, 1989, ANESTHESIOLOGY, V70, P585, DOI 10.1097/00000542-198904000-00005; WELCHEW EA, 1983, ANAESTHESIA, V38, P19, DOI 10.1111/j.1365-2044.1983.tb10367.x; Woodhouse A, 1996, PAIN, V64, P115, DOI 10.1016/0304-3959(95)00082-8	19	143	166	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	2004	291	11					1333	1341		10.1001/jama.291.11.1333	http://dx.doi.org/10.1001/jama.291.11.1333			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	802PF	15026400	Bronze			2023-01-03	WOS:000220174700027
J	Wertheim, HFL; Vos, MC; Ott, A; Voss, A; Kluytmans, JAJW; Vandenbroucke-Grauls, CMJE; Meester, MHM; van Keulen, PHJ; Verbrugh, HA				Wertheim, HFL; Vos, MC; Ott, A; Voss, A; Kluytmans, JAJW; Vandenbroucke-Grauls, CMJE; Meester, MHM; van Keulen, PHJ; Verbrugh, HA			Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients	ANNALS OF INTERNAL MEDICINE			English	Article							SURGICAL-SITE INFECTIONS; NASAL CARRIAGE; HEMODIALYSIS-PATIENTS; CLINICAL-TRIAL; DOUBLE-BLIND; OINTMENT; SURVEILLANCE; DEFINITIONS; ELIMINATION; CRITERIA	Background: Staphylococcus aureus nasal carriage is a major risk factor for nosocomial S. aureus infection. Studies show that intranasal mupirocin can prevent nosocomial surgical site infections. No data are available on the efficacy of mupirocin in nonsurgical patients. Objective: To assess the efficacy of mupirocin prophylaxis in preventing nosocomial S. aureus infections in nonsurgical patients. Design: Randomized, double-blind, placebo-controlled trial. Setting: 3 tertiary care academic hospitals and 1 nonacademic hospital. Patients: 1602 culture-proven S. aureus carriers hospitalized in nonsurgical departments. Intervention: Therapy with mupirocin 2% nasal ointment (n = 793) or placebo ointment (n = 809), twice daily for 5 days, started 1 to 3 days after admission. Measurements: Nosocomial S. aureus infections according to defined criteria, in-hospital mortality, duration of hospitalization, and time to nosocomial S. aureus infection. Staphylococcus aureus isolates were genotyped to assess whether infection was caused by endogenous strains. Results: The mupirocin and placebo groups did not statistically differ in the rates of nosocomial S. aureus infections (mupirocin, 2.6%; placebo, 2.8%; risk difference, 0.2 percentage point [95% CI, -1.5 to 1.9 percentage points]), mortality (mupirocin, 3.0%; placebo, 2.8%; risk difference, -0.2 percentage point [CI, -1.9 to 1.5 percentage points]), or duration of hospitalization (median for both, 8 days). However, time to nosocomial S. aureus infection was decreased in the mupirocin group from 12 to 25 days (P > 0.2). A total of 77% of S. aureus nosocomial infections were endogenous. Limitations: A few infections in both groups may have been missed because investigators assessed a patient for infection only if microbiology culture results were positive for S. aureus. Conclusion: Routine culture for S. aureus nasal carriage at admission and subsequent mupirocin application does not provide effective prophylaxis against nosocomial S. aureus infections in nonsurgical patients.	Erasmus MC, Dept Med Microbiol & Infect Dis, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Wertheim, HFL (corresponding author), Erasmus MC, Dept Med Microbiol & Infect Dis, POB 2040, NL-3000 CA Rotterdam, Netherlands.	h.wertheim@erasmusmc.nl	Vandenbroucke-Grauls, Christina/AAO-7953-2020; Wertheim, Heiman FL/F-3338-2016; Voss, A./H-8111-2014	Vandenbroucke-Grauls, Christina/0000-0003-2074-1597; Wertheim, Heiman FL/0000-0002-5003-5565; 				Bending M, 1996, J AM SOC NEPHROL, V7, P2403; BOELAERT JR, 1989, NEPHROL DIAL TRANSPL, V4, P278, DOI 10.1093/oxfordjournals.ndt.a091872; Boelaert JR, 1996, INFECT CONT HOSP EP, V17, P809; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Cookson BD, 1998, J ANTIMICROB CHEMOTH, V41, P11, DOI 10.1093/jac/41.1.11; Corbella X, 1997, EUR J CLIN MICROBIOL, V16, P351, DOI 10.1007/BF01726362; FERNANDEZ C, 1995, J ANTIMICROB CHEMOTH, V35, P399, DOI 10.1093/jac/35.3.399; Finlay JE, 1997, ANTIMICROB AGENTS CH, V41, P1137, DOI 10.1128/AAC.41.5.1137; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GROSS PA, 1980, INFECT CONT HOSP EP, V1, P233, DOI 10.1017/S0195941700053078; Johnson DW, 2002, NEPHROL DIAL TRANSPL, V17, P1802, DOI 10.1093/ndt/17.10.1802; Kalmeijer MD, 2002, CLIN INFECT DIS, V35, P353, DOI 10.1086/341025; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505; Kluytmans JAJW, 1996, INFECT CONT HOSP EP, V17, P780; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Martin JN, 1999, J INFECT DIS, V180, P896, DOI 10.1086/314949; Mintjes-de Groot AJ, 2000, J HOSP INFECT, V46, P36, DOI 10.1053/jhin.2000.0755; Perl TM, 2002, NEW ENGL J MED, V346, P1871, DOI 10.1056/NEJMoa003069; PITTET D, 1995, ARCH INTERN MED, V155, P1177, DOI 10.1001/archinte.155.11.1177; Pujol M, 1996, AM J MED, V100, P509, DOI 10.1016/S0002-9343(96)00014-9; Raz R, 1996, ARCH INTERN MED, V156, P1109, DOI 10.1001/archinte.156.10.1109; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; Richards MJ, 2000, INFECT CONT HOSP EP, V21, P510, DOI 10.1086/501795; Sesso R, 1998, J AM SOC NEPHROL, V9, P1085; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; VandenBergh MFQ, 1996, INFECT CONT HOSP EP, V17, P786; von Eiff C, 2001, NEW ENGL J MED, V344, P11, DOI 10.1056/NEJM200101043440102	27	91	92	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 16	2004	140	6					419	425		10.7326/0003-4819-140-6-200403160-00007	http://dx.doi.org/10.7326/0003-4819-140-6-200403160-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803AU	15023707				2023-01-03	WOS:000220204800002
J	Guppy, MPB; Mickan, SM; Del Mar, CB				Guppy, MPB; Mickan, SM; Del Mar, CB			"Drink plenty of fluids": a systematic review of evidence for this recommendation in acute respiratory infections	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PNEUMONIA; HYPONATREMIA; INFANTS; WATER		Univ Queensland, Sch Med, Ctr Gen Practice, Herston, Qld 4006, Australia	University of Queensland	Del Mar, CB (corresponding author), Univ Queensland, Sch Med, Ctr Gen Practice, Herston, Qld 4006, Australia.	c.delmar@cgp.uq.edu.au	Mickan, Sharon/AAZ-6262-2021; Del Mar, Chris B/B-1136-2008; Mickan, Sharon m/C-8840-2012	Mickan, Sharon/0000-0002-5690-1997; Del Mar, Chris B/0000-0003-3821-8163; Mickan, Sharon m/0000-0002-5690-1997; Guppy, Michelle/0000-0001-7256-4938				DHAWAN A, 1992, ANN TROP PAEDIATR, V12, P455, DOI 10.1080/02724936.1992.11747614; DREYFUSS D, 1988, AM REV RESPIR DIS, V138, P583, DOI 10.1164/ajrccm/138.3.583; GOZAL D, 1990, PEDIATR RES, V27, P204, DOI 10.1203/00006450-199002000-00023; RIVERS RPA, 1981, ARCH DIS CHILD, V56, P358, DOI 10.1136/adc.56.5.358; SHANN F, 1985, ARCH DIS CHILD, V60, P963, DOI 10.1136/adc.60.10.963	5	25	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	2004	328	7438					499	500		10.1136/bmj.38028.627593.BE	http://dx.doi.org/10.1136/bmj.38028.627593.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800BC	14988184	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000220002900025
J	Kerr, D				Kerr, D			Of Struldbruggs, sugar, and gatekeepers: a tale of our times	BRITISH MEDICAL JOURNAL			English	Article							PEOPLE; CARE; RISK		Royal Bournemouth Hosp, Bournemouth Diabet & Endocrine Ctr, Bournemouth BH7 7DW, Dorset, England		Kerr, D (corresponding author), Royal Bournemouth Hosp, Bournemouth Diabet & Endocrine Ctr, Bournemouth BH7 7DW, Dorset, England.							Armitage M, 2002, CLIN MED, V2, P331, DOI 10.7861/clinmedicine.2-4-331; Basile JN, 2002, BMJ-BRIT MED J, V325, P917, DOI 10.1136/bmj.325.7370.917; Evans JMM, 2002, DIABETIC MED, V19, P685, DOI 10.1046/j.1464-5491.2002.00749.x; GRANKS P, 1992, NEW ENGL J MED, V327, P424; Gregg EW, 2002, BRIT MED J, V325, P916, DOI 10.1136/bmj.325.7370.916; GROVES JE, 1978, NEW ENGL J MED, V298, P883, DOI 10.1056/NEJM197804202981605; Hampton JR, 2002, AGE AGEING, V31, P3, DOI 10.1093/ageing/31.1.3; McGouran RCM, 2002, CLIN MED, V2, P43, DOI 10.7861/clinmedicine.2-1-43; Schwartz AV, 2002, DIABETES CARE, V25, P1749, DOI 10.2337/diacare.25.10.1749; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SWIFT J, GULLIVERS TRAVELS 3, pCH10; Trewby PN, 2002, CLIN MED, V2, P527, DOI 10.7861/clinmedicine.2-6-527; WILSON AN, 2002, DAILY TELEGRAPH 0127; Winocour PH, 2002, BMJ-BRIT MED J, V324, P1577, DOI 10.1136/bmj.324.7353.1577	14	1	1	1	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 20	2003	327	7429					1451	1453		10.1136/bmj.327.7429.1451	http://dx.doi.org/10.1136/bmj.327.7429.1451			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757LA	14684643	Green Published, Green Submitted			2023-01-03	WOS:000187562700014
J	Grace, MJ; Lee, S; Bradshaw, S; Chapman, J; Spond, J; Cox, S; DeLorenzo, M; Brassard, D; Wylie, D; Cannon-Carlson, S; Cullen, C; Indelicato, S; Voloch, M; Bordens, R				Grace, MJ; Lee, S; Bradshaw, S; Chapman, J; Spond, J; Cox, S; DeLorenzo, M; Brassard, D; Wylie, D; Cannon-Carlson, S; Cullen, C; Indelicato, S; Voloch, M; Bordens, R			Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE INTERFERON; CHRONIC HEPATITIS-C; CYTO-TOXIC ACTIVITY; PEGINTERFERON ALPHA-2A; POSITIONAL ISOMERS; RECOMBINANT; RECEPTOR; PHARMACOKINETICS; PHARMACODYNAMICS; RESPONSIVENESS	Therapeutic pegylated interferon-alphas (IFN-alpha) are mixtures of positional isomers that have been monopegylated at specific sites on the core IFN-alpha molecule. The pegylation results in lower in vitro specific activity associated with the core IFN-a molecule that is related to the site of pegylation and size of polyethylene glycol (PEG) attached. We prepared purified, homogeneous, positional pegylation isomers of IFN-alpha2b that were monopegylated using 5-30-kDa linear PEG molecules attached at 7 primary reactive amino acid residues: Cys(1), His(34), Lys(31), Lys(83), Lys(121), Lys(131), and Lys(134). The isomers were evaluated for STAT translocation and antiviral and antiproliferative activity. The site of pegylation strongly influenced activity relative to an IFN-a2b control. The highest residual activity was observed with the His(34) positional isomers, and the lowest was observed with the Cys(1) positional isomers. The Lys positional isomers demonstrated intermediate activity, with a general order of Lys(134) > Lys(83) similar to Lys(131) similar to Lys(121) > Lys(31). The progressive relationship between decreased activity and increased PEG size suggests that pegylation may interfere with interaction and binding of IFN-alpha to the IFNAR1-IFNAR2 heterodimeric receptor. The higher specific activity associated with the His(34) positional isomer suggests that this site may be favorable for pegylating IFN-alpha2b molecules.	Schering Plough Res Inst, Union, NJ 07083 USA; Aventis Pharmaceut, Bridgewater, NJ 08807 USA	Merck & Company; Schering-Plough Research Institute; Sanofi-Aventis	Grace, MJ (corresponding author), 1011 Morris Ave, Union, NJ 07083 USA.	michael.grace@spcorp.com						Bailon P, 2001, BIOCONJUGATE CHEM, V12, P195, DOI 10.1021/bc000082g; Cook JR, 1996, J BIOL CHEM, V271, P13448, DOI 10.1074/jbc.271.23.13448; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Ding GJF, 1998, J BIOL CHEM, V273, P28897, DOI 10.1074/jbc.273.44.28897; FELIX AM, 1995, INT J PEPT PROT RES, V46, P253; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; FORTI RL, 1986, METHOD ENZYMOL, V119, P533; Foser S, 2003, PROTEIN EXPRES PURIF, V30, P78, DOI 10.1016/S1046-5928(03)00055-X; Glue P, 2000, CLIN PHARMACOL THER, V68, P556, DOI 10.1067/mcp.2000.110973; Grace M, 2001, J INTERF CYTOK RES, V21, P1103, DOI 10.1089/107999001317205240; Heathcote EJ, 2000, NEW ENGL J MED, V343, P1673, DOI 10.1056/NEJM200012073432302; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Hu RQ, 2001, J IMMUNOL, V167, P1482, DOI 10.4049/jimmunol.167.3.1482; HU RQ, 1993, J BIOL CHEM, V268, P12591; Klaus W, 1997, J MOL BIOL, V274, P661, DOI 10.1006/jmbi.1997.1396; KNAUF MJ, 1988, J BIOL CHEM, V263, P15064; Kozlowski A, 2001, BIODRUGS, V15, P419, DOI 10.2165/00063030-200115070-00001; Lee CK, 1997, J BIOL CHEM, V272, P21872, DOI 10.1074/jbc.272.35.21872; Leonard WJ, 1996, NAT MED, V2, P968, DOI 10.1038/nm0996-968; Lindsay KL, 2001, HEPATOLOGY, V34, P395, DOI 10.1053/jhep.2001.26371; Luxon BA, 2002, CLIN THER, V24, P1363, DOI 10.1016/S0149-2918(02)80042-X; Meager A, 2001, J IMMUNOL METHODS, V257, P17, DOI 10.1016/S0022-1759(01)00460-4; Monkarsh SP, 1997, ANAL BIOCHEM, V247, P434, DOI 10.1006/abio.1997.2128; Nagabhushan TL, 2002, CAN J CHEM, V80, P1166, DOI 10.1139/V02-158; ORTALDO JR, 1983, INT J CANCER, V31, P285, DOI 10.1002/ijc.2910310306; ORTALDO JR, 1983, J BIOL CHEM, V258, P5011; ORTALDO JR, 1984, P NATL ACAD SCI-BIOL, V81, P4926, DOI 10.1073/pnas.81.15.4926; PESTKA S, 1997, SEMIN ONCOL, V24; Piehler J, 1999, J MOL BIOL, V289, P57, DOI 10.1006/jmbi.1999.2726; Piehler J, 2000, J BIOL CHEM, V275, P40425, DOI 10.1074/jbc.M006854200; Radhakrishnan R, 1996, STRUCTURE, V4, P1453, DOI 10.1016/S0969-2126(96)00152-9; REHBERG E, 1982, J BIOL CHEM, V257, P1497; Roisman LC, 2001, P NATL ACAD SCI USA, V98, P13231, DOI 10.1073/pnas.221290398; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; *SCH CORP, 2004, PEG INTR PRESCR INF; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; Seeff Leonard B, 2003, Clin Liver Dis, V7, P261, DOI 10.1016/S1089-3261(02)00078-8; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; van der Auwera P, 2001, AM J HEMATOL, V66, P245, DOI 10.1002/ajh.1052; Walter MR, 1997, SEMIN ONCOL, V24, P952; Wang YS, 2000, BIOCHEMISTRY-US, V39, P10634, DOI 10.1021/bi000617t; Wylie DC, 2001, PHARM RES-DORDR, V18, P1354, DOI 10.1023/A:1013006515587; Youngster S, 2002, CURR PHARM DESIGN, V8, P2139, DOI 10.2174/1381612023393242; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301	44	75	130	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6327	6336		10.1074/jbc.M412134200	http://dx.doi.org/10.1074/jbc.M412134200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15596441	hybrid			2023-01-03	WOS:000227332700013
J	Martis, L; Patel, M; Giertych, J; Mongoven, J; Taminne, M; Perrier, MA; Mendoza, O; Goud, N; Costigan, A; Denjoy, N; Verger, C; Owen, WF				Martis, L; Patel, M; Giertych, J; Mongoven, J; Taminne, M; Perrier, MA; Mendoza, O; Goud, N; Costigan, A; Denjoy, N; Verger, C; Owen, WF			Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution	LANCET			English	Article							CHEMICAL PERITONITIS; STERILE PERITONITIS; CYTOKINE RELEASE; ICODEXTRIN; ENDOTOXIN; PYROGENS; ASSAY; CAPD	Background Manufacturers of parenteral solutions adhere to European and US Pharmacopoeia standards to define safety and sterility. In response to excess cases of aseptic peritonitis in peritonea,l dialysis patients using icodextrin-containing dialysate that met all Pharmacopoeia standards, a global recall was issued in May, 2002. We aimed to establish the cause of aseptic peritonitis. Methods We analysed 186 reports of aseptic peritonitis between September, 2001, and January, 2003. Extensive physical, chemical, and microbiological investigations of recalled dialysate were done. We calculated dose-response curves for peptidoglycan-induced interleukin 6 elaboration in peripheral blood mononuclear cells (PBMCs) from healthy donors and for sterile peritonitis in rats. Findings Although its chemical constituents and concentrations of endotoxin were within pharmacopoeia specifications, the dialysis solution elicited an interlukin 6 response in vivo and in vitro. We identified peptidoglycan from thermophilic acidophilic bacteria (Aticyclobacillus acidocaidarius) as the contaminating proinflammatory substance. In the PBMC assay, strong dose-response relations were noted between peptidoglycan concentrations and interleukin 6. in rats injected with peptidoglycan, dose-dependent increases of intraperitoneal neutrophils and pyrogenic cytokines were recorded. We measured a positive relation between peptidoglycan concentrations in recalled dialysate and reports of aseptic peritonitis. After implementation of corrective actions, the rate of peritonitis returned to baseline. Interpretation Excess cases of aseptic peritonitis in peritoneal dialysis patients were due to peptidoglycan contamination of dialysate by Alicyclobacillus. This outbreak serves as an example of how contemporary parenteral products with microbial contaminants can be considered safe under current Pharmacopoeia tests, but provoke adverse clinical effects.	Baxter Healthcare Corp, Mcgaw Pk, IL USA; Hosp Pontoise, Serv Nephrol, Pontoise, France; Duke Univ, Med Ctr, Sch Med, Dept Med, Durham, NC 27710 USA	Baxter International Inc; Duke University	Owen, WF (corresponding author), 1620 Waukegan Rd, Mcgaw Pk, IL 60085 USA.	william_owen@baxter.com	Verger, Christian/T-5139-2019; Verger, Christian/GQA-4459-2022	Verger, Christian/0000-0002-8009-5366; 				BENEVENT D, 1984, PRESSE MED, V13, P1844; Burke RA, 1997, J CHROMATOGR B, V693, P353, DOI 10.1016/S0378-4347(97)00073-X; Fennrich S, 1999, Dev Biol Stand, V101, P131; Garner RE, 1996, INFECT IMMUN, V64, P4561, DOI 10.1128/IAI.64.11.4561-4566.1996; GOKAL R, 1981, CLIN NEPHROL, V15, P328; Gokal R, 2002, PERITON DIALYSIS INT, V22, P445; Henderson B, 1996, MICROBIOL REV, V60, P316, DOI 10.1128/MMBR.60.2.316-341.1996; KARANICOLAS S, 1977, NEW ENGL J MED, V296, P1336, DOI 10.1056/NEJM197706092962309; Mangram AJ, 1998, KIDNEY INT, V54, P1367, DOI 10.1046/j.1523-1755.1998.00110.x; Mascoli C C, 1979, J Parenter Drug Assoc, V33, P81; Matsubara H, 2002, INT J SYST EVOL MICR, V52, P1681, DOI [10.1099/ijs.0.02169-0, 10.1099/00207713-52-5-1681]; MISTRY CD, 1987, LANCET, V2, P178; Nakagawa Y, 2002, CLIN DIAGN LAB IMMUN, V9, P588, DOI 10.1128/CDLI.9.3.588-597.2002; *NAT RES COUNC, 1996, GUID CAR US LAB AN; Pool EJ, 1999, J IMMUNOASSAY, V20, P79, DOI 10.1080/01971529909349315; POOLE S, 1988, LANCET, V1, P130; RAY A, 1991, FEMS MICROBIOL LETT, V79, P211, DOI 10.1016/0378-1097(91)90088-R; Royce CL, 1996, J ENDOTOXIN RES, V3, P437, DOI 10.1177/096805199600300601; SCHWAB JH, 1993, INFECT IMMUN, V61, P4535, DOI 10.1128/IAI.61.11.4535-4539.1993; SMITH TA, 1991, DICP ANN PHARMAC, V25, P602, DOI 10.1177/106002809102500607; SRISKANDAN S, 1999, BACTERIAL SEPSIS SEP, P397; TAKTAK YS, 1991, J PHARM PHARMACOL, V43, P578, DOI 10.1111/j.2042-7158.1991.tb03540.x; Tintillier M, 2002, PERITON DIALYSIS INT, V22, P534; Tsuchiya M, 1996, FEMS IMMUNOL MED MIC, V15, P129, DOI 10.1016/0928-8244(96)00053-3; Tuncer H, 2000, NEPHROL DIAL TRANSPL, V15, P2037, DOI 10.1093/ndt/15.12.2037; Vas SI, 1989, PERITONEAL DIALYSIS, V3rd, P261; WEARY M, 1987, DETECTION BACTERIAL, P307; Williams PF, 2002, PERITON DIALYSIS INT, V22, P89; Wolfson M, 2002, AM J KIDNEY DIS, V40, P1055, DOI 10.1053/ajkd.2002.36344; 2002, EUROPEAN PHARMACOPOE, P131	30	66	71	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					588	594						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708102				2023-01-03	WOS:000226984300031
J	Peake, JB				Peake, JB			Beyond the purple heart - Continuity of care for the wounded in Iraq.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Peake, JB (corresponding author), Project HOPE, Millwood, VA USA.								0	35	36	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2005	352	3					219	222		10.1056/NEJMp048312	http://dx.doi.org/10.1056/NEJMp048312			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888JP	15659720				2023-01-03	WOS:000226370500001
J	Choudhry, NK; Detsky, AS				Choudhry, NK; Detsky, AS			A perspective on US drug reimportation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DEVELOPMENT COSTS; PRICES; MEDICARE; BENEFITS; MARKET; PAY		Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Hlth Network, Toronto, ON, Canada	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Choudhry, NK (corresponding author), Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	choudhry@fas.harvard.edu						ALEXANDER D, 2004, VANCOUVER SUN   0825, pA1; BAKER C, 2004, WORLD PRESCRIPTION D; Bartlett Donald L., 2004, TIME            0920, P51; COHEN JC, 2003, GLOBE MAIL      0826, pA17; CONNOLLY C, 2004, WASHINGTON POST 0219, pA10; CONNOLLY C, 2004, WASHINGTON POST 0423; Danzon PM, 1998, PHARMACOECONOMICS, V13, P293, DOI 10.2165/00019053-199813030-00004; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; Frank RG, 2004, NEW ENGL J MED, V351, P1375, DOI 10.1056/NEJMp048158; Frank RG, 2003, HEALTH AFFAIR, V22, P46, DOI 10.1377/hlthaff.22.3.46; Frank RG, 2003, J HEALTH ECON, V22, P325, DOI 10.1016/S0167-6296(03)00002-X; Frank RG, 2001, HEALTH AFFAIR, V20, P115, DOI 10.1377/hlthaff.20.2.115; FRIESEN J, 2004, GLOBE MAIL      1111; Gibbons Moira, 2004, Manag Care, V13, P21; *HLTH CAN HLTH PRO, SUMM REP COMPL INSP; HUBBARD WK, 2003, CANADIAN PRESCRIPTIO; Huskamp HA, 2003, HEALTH AFFAIR, V22, P149, DOI 10.1377/hlthaff.22.3.149; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; KAMATH R, 2003, REPORT FEASIBILITY E; Kanavos P, 2003, HEALTH AFFAIR, V22, P16, DOI 10.1377/hlthaff.22.3.16; LESTER W, 3 AM SAY PAYING DRUG; LUECK S, 2004, WALL ST J       0108, pA4; MAJESKI T, 2004, ST PAUL PIONEER 0520, pB8; MARIMOW AE, 2004, CONTRA COSIA TI 0826; Maynard A, 2003, HEALTH AFFAIR, V22, P31, DOI 10.1377/hlthaff.22.3.31; Menon D, 2001, HEALTH AFFAIR, V20, P92, DOI 10.1377/hlthaff.20.3.92; Newhouse JP, 2004, HEALTH AFFAIR, V23, P89, DOI 10.1377/hlthaff.23.1.89; *NIH, 2000, NIH CONTR PHARM DEV; NITKIN D, 2004, BALTIMORE SUN   0331, pB1; PEAR R, 2004, NY TIMES        0422, pA23; *PUBL CIT C WATCH, AM OTH DRUG PROBL BN; Rector TS, 2004, HEALTH AFFAIR, V23, P213, DOI 10.1377/hlthaff.23.4.213; RICHER S, 2004, GLOBE MAIL      0517, pA1; Saatsoglou Paul, 2004, Manag Care, V13, P7; SAGER A, 2000, PRESCRIPTION DRUG PE; SAGER A, 2004, DO DRUG MAKERS LOSE; SANDERS B, 2003, INT PRESCRIPTION DRU; Scherer FM, 2004, NEW ENGL J MED, V351, P927, DOI 10.1056/NEJMhpr040117; Scherer FM, 2001, HEALTH AFFAIR, V20, P216, DOI 10.1377/hlthaff.20.5.216; Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087; Soumerai SB, 2004, HEALTH AFFAIR, V23, P135, DOI 10.1377/hlthaff.23.1.135; STRAHINICH J, 2004, BOSTON HERALD   1118, P46; *US C OFF TECHN AS, 1993, OTAH522; *US DEP HHS, PRESCR DRUG COV SPEN; *US FDA, FDA US CUST IMP BLIT; *US GEN ACC OFF, 2003, NIH PRIV SECT PARTN; *US GEN ACC OFF, 2004, INT PHARM SOM POS SA; Wagner JL, 2004, ANNU REV PUBL HEALTH, V25, P475, DOI 10.1146/annurev.publhealth.25.101802.123042; Ward Christopher, 2004, Manag Care, V13, P17; Wilson JF, 2004, ANN INTERN MED, V140, P677, DOI 10.7326/0003-4819-140-8-200404200-00044; Wolfe W., 2004, MINNEAPOLIS STA 0514, p1B; WALL STREET U; 2004, AARP             JUL	53	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2005	293	3					358	362		10.1001/jama.293.3.358	http://dx.doi.org/10.1001/jama.293.3.358			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888FA	15657329				2023-01-03	WOS:000226358400030
J	Young, B; Krahn, A				Young, B; Krahn, A			Implications of defibrillation	LANCET			English	Editorial Material							HOSPITAL CARDIAC-ARREST; THERAPEUTIC HYPOTHERMIA; COMATOSE SURVIVORS		Univ Western Ontario, London, ON N6A 5A5, Canada	Western University (University of Western Ontario)	Young, B (corresponding author), Univ Western Ontario, London, ON N6A 5A5, Canada.	bryan.young@lhsc.on.ca						Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Grubb NR, 1996, BMJ-BRIT MED J, V313, P143, DOI 10.1136/bmj.313.7050.143; Guglin ME, 2004, PACE, V27, P1072, DOI 10.1111/j.1540-8159.2004.00586.x; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; Holzer M, 2002, NEW ENGL J MED, V346, P549; Kapp M B, 1989, Issues Law Med, V5, P337; Stiell IG, 2004, NEW ENGL J MED, V351, P647, DOI 10.1056/NEJMoa040325; Virkkunen I, 2004, RESUSCITATION, V62, P299, DOI 10.1016/j.resuscitation.2004.04.003	9	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	2004	364	9448					1836	1837		10.1016/S0140-6736(04)17454-0	http://dx.doi.org/10.1016/S0140-6736(04)17454-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555650				2023-01-03	WOS:000225269300006
J	Hamel, MB; Epstein, AM				Hamel, MB; Epstein, AM			Prior-authorization programs for controlling drug spending	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*HJ KAIS FAM FDN K, MED DRUG BEN HIGHL K; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; Levit K, 2003, HEALTH AFFAIR, V22, P154, DOI 10.1377/hlthaff.22.1.154; Mello MM, 2004, NEW ENGL J MED, V350, P608, DOI 10.1056/NEJMlim035683	4	23	23	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2156	2158		10.1056/NEJMp048294	http://dx.doi.org/10.1056/NEJMp048294			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548775				2023-01-03	WOS:000225160600005
J	Clement, K; Viguerie, N; Poitou, C; Carette, C; Pelloux, V; Curat, CA; Sicard, A; Rome, S; Benis, A; Zucker, JD; Vidal, H; Laville, M; Barsh, GS; Basdevant, A; Stich, V; Cancello, R; Langin, D				Clement, K; Viguerie, N; Poitou, C; Carette, C; Pelloux, V; Curat, CA; Sicard, A; Rome, S; Benis, A; Zucker, JD; Vidal, H; Laville, M; Barsh, GS; Basdevant, A; Stich, V; Cancello, R; Langin, D			Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects	FASEB JOURNAL			English	Article						obesity; gene profiling; calorie restriction; microarray	INTERLEUKIN-1 RECEPTOR ANTAGONIST; INSULIN-RESISTANCE SYNDROME; IN-VIVO; EXPRESSION; MICROARRAY; WOMEN; FAT; MACROPHAGE; MARKERS; ATHEROSCLEROSIS	Adipose tissue produces inflammation and immunity molecules suspected to be involved in obesity-related complications. The pattern of expression and the nutritional regulation of these molecules in humans are poorly understood. We analyzed the gene expression profiles of subcutaneous white adipose tissue from 29 obese subjects during very low calorie diet (VLCD) using cDNA microarray and reverse transcription quantitative PCR. The patterns of expression were compared with that of 17 non-obese subjects. We determined whether the regulated genes were expressed in adipocytes or stromavascular fraction cells. Gene expression profiling identified 100 inflammation-related transcripts that are regulated in obese individuals when eating a 28 day VLCD but not a 2 day VLCD. Cluster analysis showed that the pattern of gene expression in obese subjects after 28 day VLCD was closer to the profile of lean subjects than to the pattern of obese subjects before VLCD. Weight loss improves the inflammatory profile of obese subjects through a decrease of proinflammatory factors and an increase of anti-inflammatory molecules. The genes are expressed mostly in the stromavascular fraction of adipose tissue, which is shown to contain numerous macrophages. The beneficial effect of weight loss on obesity-related complications may be associated with the modification of the inflammatory profile in adipose tissue.	Hop Hotel Dieu, Dept Nutr, INSERM, Dept Nutr,AP HP, F-75181 Paris 04, France; Univ Toulouse 3, Unite Rech Obesites Inserm UPS U586, Inst Louis Bugnard, Ctr Hosp Univ Toulouse, F-31062 Toulouse, France; Charles Univ Prague, Franco Czech Lab Clin Res Obes, French Inst Hlth & Med Res, Inserm U586, Prague, Czech Republic; Charles Univ Prague, Fac Med 3, Prague, Czech Republic; Goethe Univ Frankfurt, Inst Kardiovasc Physiol, D-6000 Frankfurt, Germany; Fac Med R Laennec, INSERM, U449, Lyon, France; Fac Med R Laennec, Human Nutr Res Ctr Lyon, Lyon, France; Univ Paris 13, LIM & BIO, F-93430 Villetaneuse, France; Stanford Univ, Sch Med, Dept Pediat & Genet, Howard Hughes Med Inst,Beckman Ctr, Stanford, CA 94305 USA; Charles Univ Prague, Fac Med 3, Dept Sports Med, Prague, Czech Republic; Charles Univ Prague, Fac Med 3, Obesity Unit, Prague, Czech Republic	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Charles University Prague; Charles University Prague; Goethe University Frankfurt; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris 13; Howard Hughes Medical Institute; Stanford University; Charles University Prague; Charles University Prague	Clement, K (corresponding author), Hop Hotel Dieu, Dept Nutr, INSERM, Dept Nutr,AP HP, Ave Paris 6 Univ,EA 3502, F-75181 Paris 04, France.	karine.clement@htd.ap-hop-paris.fr; langin@inserm.toulouse.fr	Benis, Arriel/M-6262-2016; Vidal, Hubert/M-6674-2017; ZUCKER, Jean-Daniel/K-3008-2016; Clément, karine/R-1120-2017; Viguerie, Nathalie/M-2422-2017	Benis, Arriel/0000-0002-9125-8300; Vidal, Hubert/0000-0002-9467-0317; ZUCKER, Jean-Daniel/0000-0002-5597-7922; Viguerie, Nathalie/0000-0002-1730-9915; Langin, Dominique/0000-0002-2669-7825; ROME, SOPHIE/0000-0003-3986-5936				Albu JB, 2000, ANN NY ACAD SCI, V904, P491; Argiles J M, 1998, Curr Opin Clin Nutr Metab Care, V1, P245, DOI 10.1097/00075197-199805000-00002; Asadullah K, 2003, PHARMACOL REV, V55, P241, DOI 10.1124/pr.55.2.4; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bastard JP, 1999, CIRCULATION, V99, P2221; Bastard JP, 2000, J CLIN ENDOCR METAB, V85, P3338, DOI 10.1210/jc.85.9.3338; Braat H, 2003, EXPERT OPIN BIOL TH, V3, P725, DOI 10.1517/eobt.3.5.725.21237; Bruunsgaard H, 2003, IMMUNOL ALLERGY CLIN, V23, P15, DOI 10.1016/S0889-8561(02)00056-5; Charriere G, 2003, J BIOL CHEM, V278, P9850, DOI 10.1074/jbc.M210811200; Chiellini C, 2002, J CELL PHYSIOL, V190, P251, DOI 10.1002/JCP.10061; Clement K, 2002, GENOME RES, V12, P281, DOI 10.1101/gr.207702; Colgan SP, 1999, P NATL ACAD SCI USA, V96, P13938, DOI 10.1073/pnas.96.24.13938; Curat CA, 2004, DIABETES, V53, P1285, DOI 10.2337/diabetes.53.5.1285; Dusserre E, 2000, BBA-MOL BASIS DIS, V1500, P88, DOI 10.1016/S0925-4439(99)00091-5; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eriksson P, 2000, THROMB HAEMOSTASIS, V83, P545; Esposito K, 2003, JAMA-J AM MED ASSOC, V289, P1799, DOI 10.1001/jama.289.14.1799; Feldman AL, 2002, BIOTECHNIQUES, V33, P906, DOI 10.2144/02334mt04; Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42; Friedland RP, 2002, ANN NY ACAD SCI, V977, P387, DOI 10.1111/j.1749-6632.2002.tb04842.x; FRIEDRICHS WE, 1995, BIOCHEM BIOPH RES CO, V209, P250, DOI 10.1006/bbrc.1995.1496; Gabrielsson BG, 2003, OBES RES, V11, P699, DOI 10.1038/oby.2003.100; Gerhardt CC, 2001, MOL CELL ENDOCRINOL, V175, P81, DOI 10.1016/S0303-7207(01)00394-X; Gomez-Ambrosi J, 2004, FASEB J, V18, P215, DOI 10.1096/fj.03-0591fje; Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015; Hanusch-Enserer U, 2003, INT J OBESITY, V27, P355, DOI 10.1038/sj.ijo.0802240; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hotamisligil GS, 1997, DIABETES, V46, P451, DOI 10.2337/diabetes.46.3.451; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; Juge-Aubry CE, 2003, DIABETES, V52, P1104, DOI 10.2337/diabetes.52.5.1104; Kopp HP, 2003, ARTERIOSCL THROM VAS, V23, P1042, DOI 10.1161/01.ATV.0000073313.16135.21; Laimer M, 2002, INT J OBESITY, V26, P659, DOI 10.1038/sj.ijo.0801970; Linder K, 2004, J LIPID RES, V45, P148, DOI 10.1194/jlr.M300256-JLR200; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Marculescu R, 2002, DIABETES, V51, P3582, DOI 10.2337/diabetes.51.12.3582; Marette A, 2002, CURR OPIN CLIN NUTR, V5, P377, DOI 10.1097/00075197-200207000-00005; Merlini G, 2003, NEW ENGL J MED, V349, P583, DOI 10.1056/NEJMra023144; Mohamed-Ali V, 2001, J CLIN ENDOCR METAB, V86, P5864, DOI 10.1210/jc.86.12.5864; Mora S, 2002, DIABETES-METAB RES, V18, P345, DOI 10.1002/dmrr.321; Moraes RC, 2003, ENDOCRINOLOGY, V144, P4773, DOI 10.1210/en.2003-0456; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Rome S, 2003, J BIOL CHEM, V278, P18063, DOI 10.1074/jbc.M300293200; Rose D.W., 1992, COMPILER, V10, P18; Saillan-Barreau C, 2003, BIOCHEM BIOPH RES CO, V309, P502, DOI 10.1016/j.bbrc.2003.08.034; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; Shin WS, 2002, ATHEROSCLEROSIS, V160, P91, DOI 10.1016/S0021-9150(01)00571-8; Smith SR, 2001, METABOLISM, V50, P425, DOI 10.1053/meta.2001.21693; Soukas A, 2000, GENE DEV, V14, P963; Takahashi K, 2003, J BIOL CHEM, V278, P46654, DOI 10.1074/jbc.M309895200; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Viguerie N, 2004, J CLIN ENDOCR METAB, V89, P2000, DOI 10.1210/jc.2003-031733; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Ziccardi P, 2002, CIRCULATION, V105, P804, DOI 10.1161/hc0702.104279	54	461	495	1	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					1657	1669		10.1096/fj.04-2204com	http://dx.doi.org/10.1096/fj.04-2204com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522911				2023-01-03	WOS:000225482100034
J	Molassiotis, A				Molassiotis, A			The prince and the professor - With respect, Professor Baum, you've got it wrong	BRITISH MEDICAL JOURNAL			English	Letter									Univ Manchester, Sch Nursing Midwifery & Hlth Visiting, Manchester M13 9PL, Lancs, England	University of Manchester	Molassiotis, A (corresponding author), Univ Manchester, Sch Nursing Midwifery & Hlth Visiting, Manchester M13 9PL, Lancs, England.	alex.molassiotis@man.ac.uk		Molassiotis, Alex/0000-0001-6351-9991				Baum M, 2004, BRIT MED J, V329, P118, DOI 10.1136/bmj.329.7457.118; BRIGHTHOPE I, DO YOU TRUST ORTHODO	2	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 9	2004	329	7470					858	858		10.1136/bmj.329.7470.858-a	http://dx.doi.org/10.1136/bmj.329.7470.858-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862EK	15472282	Green Published			2023-01-03	WOS:000224472800040
J	Burk, O; Koch, I; Raucy, J; Hustert, E; Eichelbaum, M; Brockmoller, J; Zanger, UM; Wojnowski, L				Burk, O; Koch, I; Raucy, J; Hustert, E; Eichelbaum, M; Brockmoller, J; Zanger, UM; Wojnowski, L			The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; HUMAN HEPATOCYTES; INTERINDIVIDUAL VARIABILITY; RESPONSIVE ENHANCER; DRUG-INTERACTIONS; EXPRESSION; MIDAZOLAM; GENE; IDENTIFICATION; METABOLISM	Induction of cytochrome P450 3A (CYP3A) by xenobiotics may lead to clinically relevant drug interactions. In contrast with other CYP3A family members, studies on the inducibility of CYP3A5 indicate conflicting results. We report the induction of CYP3A5 mRNA in 13 of 16 hepatocyte preparations exposed to rifampin. Furthermore, induction of CYP3A5 mRNA was observed in intestinal biopsies in three of eight probands following exposure to the antibiotic. The highest absolute levels of CYP3A5 transcripts were found following rifampin treatment in hepatocytes and intestines from carriers of CYP3A5*1 alleles. Elucidation of the mechanism involved in CYP3A5 induction revealed that constitutively activated receptor (CAR) and pregnane X receptor (PXR) transactivated the CYP3A5 promoter (-688 to +49) and that the transactivation was dependent on an everted repeat separated by 6 bp (ER6-dependent). Treatment with the prototypical PXR ligand rifampin led to a 2-fold induction of the CYP3A5 promoter activity. In agreement with these observations, PXR and CAR bound specifically to the ER6 motif. Hepatic expression of PXR correlated with that of CYP3A5 mRNA levels in a bank of liver samples. Taken together, studies here revealed the presence of a functional ER6 motif in the CYP3A5 promoter located -100 bp upstream from the transcription start site, suggesting that CYP3A5 is inducible by mechanisms similar to those involved in CYP3A4 induction. Enhanced expression of CYP3A5 caused by exposure to inducers may phenocopy the effects of the high expression allele CYP3A5*1. In this manner, induction of CYP3A5 may contribute to the overall importance of this P450 in drug metabolism and drug interactions.	Univ Gottingen, Dept Clin Pharmacol, D-37085 Gottingen, Germany; Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany; Epidauros Biotechnol AG, D-82347 Bernried, Germany; Calif Toxicol Res Inst, Carlsbad, CA 92009 USA; Johannes Gutenberg Univ Mainz, Dept Pharmacol, D-55101 Mainz, Germany	University of Gottingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Johannes Gutenberg University of Mainz	Wojnowski, L (corresponding author), Univ Gottingen, Dept Clin Pharmacol, Robert Koch Str 40, D-37085 Gottingen, Germany.	wojnowski@uni-mainz.de	Zanger, Ulrich M./A-9364-2012	Zanger, Ulrich M./0000-0002-5276-2002				Backman JT, 1998, EUR J CLIN PHARMACOL, V54, P53, DOI 10.1007/s002280050420; Barwick JL, 1996, MOL PHARMACOL, V50, P10; Bertilsson G, 2001, BIOCHEM BIOPH RES CO, V280, P139, DOI 10.1006/bbrc.2000.4066; Burk O, 2004, N-S ARCH PHARMACOL, V369, P105, DOI 10.1007/s00210-003-0815-3; Burk O, 2002, J BIOL CHEM, V277, P24280, DOI 10.1074/jbc.M202345200; Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Finta C, 2000, GENE, V260, P13, DOI 10.1016/S0378-1119(00)00470-4; Geick A, 2001, J BIOL CHEM, V276, P14581, DOI 10.1074/jbc.M010173200; Gellner K, 2001, PHARMACOGENETICS, V11, P111, DOI 10.1097/00008571-200103000-00002; Gibson GG, 2002, XENOBIOTICA, V32, P165, DOI 10.1080/00498250110102674; GILLUM JG, 1993, CLIN PHARMACOKINET, V25, P450, DOI 10.2165/00003088-199325060-00005; Goh BC, 2002, J CLIN ONCOL, V20, P3683, DOI 10.1200/JCO.2002.01.025; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; GORSKI JC, 1994, BIOCHEM PHARMACOL, V47, P1643; GRANGE JM, 1994, DRUG SAFETY, V11, P242, DOI 10.2165/00002018-199411040-00003; Greiner B, 1999, J CLIN INVEST, V104, P147, DOI 10.1172/JCI6663; Hukkanen J, 2003, J PHARMACOL EXP THER, V304, P745, DOI 10.1124/jpet.102.038208; Hustert E, 2001, PHARMACOGENETICS, V11, P773, DOI 10.1097/00008571-200112000-00005; Hustert E, 2001, DRUG METAB DISPOS, V29, P1454; JOUNAIDI Y, 1994, BIOCHEM BIOPH RES CO, V205, P1741, DOI 10.1006/bbrc.1994.2870; Koch I, 2002, DRUG METAB DISPOS, V30, P1108, DOI 10.1124/dmd.30.10.1108; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Li AP, 1995, TOXICOLOGY, V104, P1, DOI 10.1016/0300-483X(95)03155-9; Lin YS, 2002, MOL PHARMACOL, V62, P162, DOI 10.1124/mol.62.1.162; LUCEY MR, 1990, LANCET, V335, P11, DOI 10.1016/0140-6736(90)90137-T; Rae JM, 2001, J PHARMACOL EXP THER, V299, P849; Raucy JL, 2003, DRUG METAB DISPOS, V31, P533, DOI 10.1124/dmd.31.5.533; Rodriguez-Antona C, 2000, ARCH BIOCHEM BIOPHYS, V376, P109, DOI 10.1006/abbi.2000.1697; SCHUETZ EG, 1993, HEPATOLOGY, V18, P1254; Schuetz JD, 1996, MOL PHARMACOL, V49, P63; Shih PS, 2002, DRUG METAB DISPOS, V30, P1491, DOI 10.1124/dmd.30.12.1491; Tirona RG, 2003, NAT MED, V9, P220, DOI 10.1038/nm815; WESTLINDJOHNSSO.A, 2003, DRUG METAB DISPOS, V31, P1; Wilkinson GR, 1996, J PHARMACOKINET BIOP, V24, P475, DOI 10.1007/BF02353475; Wolbold R, 2003, HEPATOLOGY, V38, P978, DOI 10.1053/jhep.2003.50393; WRIGHTON SA, 1989, MOL PHARMACOL, V36, P97; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116	38	146	153	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38379	38385		10.1074/jbc.M404949200	http://dx.doi.org/10.1074/jbc.M404949200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252010	hybrid			2023-01-03	WOS:000223684100039
J	Callans, DJ				Callans, DJ			Out-of-hospital cardiac arrest - The solution is shocking	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Penn, Sch Med, Dept Med, Div Cardiovasc Dis, Philadelphia, PA 19104 USA	University of Pennsylvania	Callans, DJ (corresponding author), Univ Penn, Sch Med, Dept Med, Div Cardiovasc Dis, Philadelphia, PA 19104 USA.		Callans, David/ABH-2176-2021						0	68	70	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2004	351	7					632	634		10.1056/NEJMp048174	http://dx.doi.org/10.1056/NEJMp048174			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	845FZ	15306663				2023-01-03	WOS:000223225500004
J	Dennis, C				Dennis, C			Cooling off	NATURE			English	News Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 5	2004	430	7000					605	605						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	843LM	15309806				2023-01-03	WOS:000223085400015
J	Wood, JG; Rogina, B; Lavu, S; Howitz, K; Helfand, SL; Tatar, M; Sinclair, D				Wood, JG; Rogina, B; Lavu, S; Howitz, K; Helfand, SL; Tatar, M; Sinclair, D			Sirtuin activators mimic caloric restriction and delay ageing in metazoans	NATURE			English	Article							LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; SIR2 PROTEIN; LONGEVITY; DEACETYLASE; YEAST; NAD; SELECTION; NUTRITION	Caloric restriction extends lifespan in numerous species. In the budding yeast Saccharomyces cerevisiae this effect requires Sir2 (ref. 1), a member of the sirtuin family of NAD(+)-dependent deacetylases(2,3). Sirtuin activating compounds (STACs) can promote the survival of human cells and extend the replicative lifespan of yeast(4). Here we show that resveratrol and other STACs activate sirtuins from Caenorhabditis elegans and Drosophila melanogaster, and extend the lifespan of these animals without reducing fecundity. Lifespan extension is dependent on functional Sir2, and is not observed when nutrients are restricted. Together these data indicate that STACs slow metazoan ageing by mechanisms that may be related to caloric restriction.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; BIOMOL Res Labs Inc, Plymouth Meeting, PA 19462 USA; Brown Univ, Dept Ecol & Evolutionary Biol, Providence, RI 02912 USA	Harvard University; Harvard Medical School; University of Connecticut; Brown University	Sinclair, D (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	shelfand@neuron.uchc.edu; marc_tatar@brown.edu; david_sinclair@hms.harvard.edu		Sinclair, David/0000-0002-9936-436X; Tatar, Marc/0000-0003-3232-6884	NATIONAL INSTITUTE ON AGING [R01AG024353, R37AG016667] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG028730, RF1 AG024353, R37 AG016667] Funding Source: Medline; NIDDK NIH HHS [R01 DK100263] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chapman T, 1996, P ROY SOC B-BIOL SCI, V263, P755, DOI 10.1098/rspb.1996.0113; CHIPPINDALE AK, 1993, J EVOLUTION BIOL, V6, P171, DOI 10.1046/j.1420-9101.1993.6020171.x; EDGECOMB RS, 1994, J EXP BIOL, V197, P215; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Guarente L, 2000, GENE DEV, V14, P1021; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jiang JC, 2000, FASEB J, V14, P2135; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Marden JH, 2003, P NATL ACAD SCI USA, V100, P3369, DOI 10.1073/pnas.0634985100; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Rogina B, 2002, SCIENCE, V298, P1745, DOI 10.1126/science.1078986; Sinclair DA, 2002, MECH AGEING DEV, V123, P857, DOI 10.1016/S0047-6374(02)00023-4; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Walker DW, 2000, NATURE, V405, P296, DOI 10.1038/35012693	24	1447	1515	6	191	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	2004	430	7000					686	689		10.1038/nature02789	http://dx.doi.org/10.1038/nature02789			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	843LM	15254550				2023-01-03	WOS:000223085400048
J	Cohen, HY; Miller, C; Bitterman, KJ; Wall, NR; Hekking, B; Kessler, B; Howitz, KT; Gorospe, M; de Cabo, R; Sinclair, DA				Cohen, HY; Miller, C; Bitterman, KJ; Wall, NR; Hekking, B; Kessler, B; Howitz, KT; Gorospe, M; de Cabo, R; Sinclair, DA			Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase	SCIENCE			English	Article							LIFE-SPAN EXTENSION; SACCHAROMYCES-CEREVISIAE; AGING PROCESS; APOPTOSIS; P53; SENESCENCE; LONGEVITY; KU70; NAD; BAX	A major cause of aging is thought to result from the cumulative effects of cell loss over time. In yeast, caloric restriction (CR) delays aging by activating the Sir2 deacetylase. Here we show that expression of mammalian Sir2 (SIRT1) is induced in CR rats as well as in human cells that are treated with serum from these animals. Insulin and insulin-like growth factor 1 (IGF-1) attenuated this response. SIRT1 deacetylates the DNA repair factor Ku70, causing it to sequester the proapoptotic factor Bax away from mitochondria, thereby inhibiting stress-induced apoptotic cell death. Thus, CR could extend life-span by inducing SIRT1 expression and promoting the long-term survival of irreplaceable cells.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; BIOMOL Res Labs, Plymouth Meeting, PA 19462 USA; NIA, Cellular & Mol Biol Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA; NIA, Lab Expt Gerontol, Gerontol Res Ctr, Baltimore, MD 21224 USA	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Sinclair, DA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	david_sinclair@hms.harvard.edu	Kessler, Benedikt/AAY-8614-2021; Wall, Nathan R./H-7368-2015; de Cabo, Rafael/E-7996-2010; de Cabo, Rafael Carlos/J-5230-2016; de Cabo, Rafael/J-5230-2016	Kessler, Benedikt/0000-0002-8160-2446; Wall, Nathan R./0000-0002-3235-4386; de Cabo, Rafael/0000-0003-2830-5693; de Cabo, Rafael Carlos/0000-0003-2830-5693; de Cabo, Rafael/0000-0002-3354-2442; Cohen, Haim Y./0000-0002-6613-8710; Sinclair, David/0000-0002-9936-436X	NATIONAL CANCER INSTITUTE [F32CA097802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019719, R37AG028730, P01AG027916, R01AG028730, R01AG019972, Z01AG000368, Z01AG000511] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA097802] Funding Source: Medline; NIA NIH HHS [R01 AG019972, P01 AG027916, AG19719-03, AG19972-02, R01 AG019719, R37 AG028730, R01 AG028730] Funding Source: Medline; NIGMS NIH HHS [R01 GM068072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Ando K, 2002, MICROSC RES TECHNIQ, V59, P293, DOI 10.1002/jemt.10207; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; BRUNET A, 2004, SCIENCE, V203, P530; Campisi J, 2003, EXP GERONTOL, V38, P5, DOI 10.1016/S0531-5565(02)00152-3; COHEN HT, UNPUB; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; ECABO R, 2003, EXP GERONTOL, V38, P631; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Higami Y, 2000, CELL TISSUE RES, V301, P125, DOI 10.1007/s004419900156; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2002, MOL CELL BIOL, V22, P8056, DOI 10.1128/MCB.22.22.8056-8066.2002; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Zhang YP, 2002, MECH AGEING DEV, V123, P245, DOI 10.1016/S0047-6374(01)00349-9	24	1516	1615	3	181	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					390	392		10.1126/science.1099196	http://dx.doi.org/10.1126/science.1099196			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15205477				2023-01-03	WOS:000222662400036
J	Yuan, CS; Wei, G; Dey, L; Karrison, T; Nahlik, L; Maleckar, S; Kasza, K; Ang-Lee, M; Moss, J				Yuan, CS; Wei, G; Dey, L; Karrison, T; Nahlik, L; Maleckar, S; Kasza, K; Ang-Lee, M; Moss, J			Brief communication: American ginseng reduces warfarin's effect in healthy patients - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							ST-JOHNS WORT; DRUG-INTERACTIONS; METABOLISM; PLATELETS; UPDATE; GINKGO	Background: People using prescription medication often concurrently take herbal supplements. in a case report, the anticoagulant effect of warfarin decreased after patients consumed ginseng. Objective: To evaluate the interactions between American ginseng and warfarin. Design: Randomized, double-blind, placebo-controlled trial. Setting: General Clinical Research Center, University of Chicago, Chicago, Illinois. Participants: 20 healthy patients. Intervention: in this 4-week study, 20 patients received warfarin for 3 days during weeks 1 and 4. Beginning in week 2, patients were assigned to receive either American ginseng or placebo. Measurements: International normalized ratio (INR) and plasma warfarin level. Results: The peak INR statistically significantly decreased after 2 weeks of ginseng administration compared with placebo (difference between ginseng and placebo, -0.19 [95% Cl, -0.36 to -0.07]; P = 0.0012). The INR area under the curve (AUC), peak plasma warfarin level, and warfarin AUC were also statistically significantly reduced in the ginseng group as compared with the placebo group. Peak INR and peak plasma warfarin level were positively correlated. Limitations: The study sample consisted of young, healthy volunteers in a research setting rather than patients taking therapeutic doses of warfarin. Conclusions: American ginseng reduces warfarin's anticoagulant effect. When prescribing warfarin, physicians should ask patients about ginseng use.	Univ Chicago, Pritzker Sch Med, Tang Ctr Herbal Med Res, Comm Clin Pharmacol & Pharmacogen,Anticoagulat Con, Chicago, IL 60637 USA	University of Chicago	Yuan, CS (corresponding author), Univ Chicago, Pritzker Sch Med, Tang Ctr Herbal Med Res, Comm Clin Pharmacol & Pharmacogen,Anticoagulat Con, 5841 S Maryland Ave,MC 4028, Chicago, IL 60637 USA.	cyuan@uchicago.edu			NCCIH NIH HHS [AT00563] Funding Source: Medline; NCI NIH HHS [CA79042, CA14599] Funding Source: Medline; NCRR NIH HHS [M01 RR00055] Funding Source: Medline; NIGMS NIH HHS [T32-GM07019] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014599, R01CA079042] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT000563] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007019] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ang-Lee MK, 2001, JAMA-J AM MED ASSOC, V286, P208, DOI 10.1001/jama.286.2.208; Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9; BEERS MH, 1999, MERCK MANUAL DIAGNOS, P902; Ernst E, 2002, ANN INTERN MED, V136, P42, DOI 10.7326/0003-4819-136-1-200201010-00010; Gruenwald J., 2000, PDR HERBAL MED, P346; Harder S, 1996, CLIN PHARMACOKINET, V30, P416, DOI 10.2165/00003088-199630060-00002; HOLANDER M, 1973, NONPARAMETRIC STAT M, P78; Janetzky K, 1997, AM J HEALTH-SYST PH, V54, P692, DOI 10.1093/ajhp/54.6.692; Kaminsky LS, 1997, PHARMACOL THERAPEUT, V73, P67, DOI 10.1016/S0163-7258(96)00140-4; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; KIMURA Y, 1988, J PHARM PHARMACOL, V40, P838, DOI 10.1111/j.2042-7158.1988.tb06285.x; Meyer UA, 1996, J PHARMACOKINET BIOP, V24, P449, DOI 10.1007/BF02353473; Park HJ, 1996, BIOL PHARM BULL, V19, P1434, DOI 10.1248/bpb.19.1434; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; Roby CA, 2000, CLIN PHARMACOL THER, V67, P451, DOI 10.1067/mcp.2000.106793; Vaes LPJ, 2000, ANN PHARMACOTHER, V34, P1478, DOI 10.1345/aph.10031; Wittkowsky AK, 2001, J THROMB THROMBOLYS, V12, P67, DOI 10.1023/A:1012742628628; Zhang G D, 1980, Yao Xue Xue Bao, V15, P375; Zhu M, 1999, J PHARM PHARMACOL, V51, P175, DOI 10.1211/0022357991772105; 2000, NUTR BUSINESS J	20	159	173	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	2004	141	1					23	27		10.7326/0003-4819-141-1-200407060-00011	http://dx.doi.org/10.7326/0003-4819-141-1-200407060-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834RF	15238367				2023-01-03	WOS:000222427600004
J	Apfel, CC; Korttila, K; Abdalla, M; Kerger, H; Turan, A; Vedder, I; Zernak, C; Danner, K; Jokela, R; Pocock, SJ; Trenkler, S; Kredel, M; Biedler, A; Sessler, DI; Roewer, N				Apfel, CC; Korttila, K; Abdalla, M; Kerger, H; Turan, A; Vedder, I; Zernak, C; Danner, K; Jokela, R; Pocock, SJ; Trenkler, S; Kredel, M; Biedler, A; Sessler, DI; Roewer, N		IMPACT Investigators	A factorial trial of six interventions for the prevention of postoperative nausea and vomiting	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 11-15, 2003	SAN FRANCISCO, CA	Amer Soc Anesthesiologists			SUPPLEMENTAL OXYGEN; COST-EFFECTIVENESS; ONDANSETRON; DROPERIDOL; EFFICACY; DEXAMETHASONE; ANESTHESIA; MANAGEMENT; EMPHYSEMA; REDUCE	BACKGROUND Untreated, one third of patients who undergo surgery will have postoperative nausea and vomiting. Although many trials have been conducted, the relative benefits of prophylactic antiemetic interventions given alone or in combination remain unknown. METHODS We enrolled 5199 patients at high risk for postoperative nausea and vomiting in a randomized, controlled trial of factorial design that was powered to evaluate interactions among as many as three antiemetic interventions. Of these patients, 4123 were randomly assigned to 1 of 64 possible combinations of six prophylactic interventions: 4 mg of ondansetron or no ondansetron; 4 mg of dexamethasone or no dexamethasone; 1.25 mg of droperidol or no droperidol; propofol or a volatile anesthetic; nitrogen or nitrous oxide; and remifentanil or fentanyl. The remaining patients were randomly assigned with respect to the first four interventions. The primary outcome was nausea and vomiting within 24 hours after surgery, which was evaluated blindly. Results Ondansetron, dexamethasone, and droperidol each reduced the risk of postoperative nausea and vomiting by about 26 percent. Propofol reduced the risk by 19 percent, and nitrogen by 12 percent; the risk reduction with both of these agents ( i.e., total intravenous anesthesia) was thus similar to that observed with each of the antiemetics. All the interventions acted independently of one another and independently of the patients' baseline risk. Consequently, the relative risks associated with the combined interventions could be estimated by multiplying the relative risks associated with each intervention. Absolute risk reduction, though, was a critical function of patients' baseline risk. CONCLUSIONS Because antiemetic interventions are similarly effective and act independently, the safest or least expensive should be used first. Prophylaxis is rarely warranted in low-risk patients, moderate-risk patients may benefit from a single intervention, and multiple interventions should be reserved for high-risk patients.	Univ Wurzburg, Wurzburg, Germany; Univ Louisville, Louisville, KY 40292 USA; Univ Helsinki, Cent Hosp, Helsinki, Finland; London Sch Hyg & Trop Med, London WC1, England; Univ Klin Mannheim, Mannheim, Germany; Trakya Univ Hosp, Edirne, Turkey; Bodelschwingsche Anstalten Bethel, Bielefeld, Germany; Kreiskrankenhaus Garmisch Partenkirchen, Garmisch Partenkirchen, Germany; Westpfalz Klinikum, Kaiserslautern, Germany; Reiman Univ Hosp, Presov, Slovakia; Univ Saarlandes Kliniken, Homburg, Germany	University of Wurzburg; University of Louisville; University of Helsinki; Helsinki University Central Hospital; University of London; London School of Hygiene & Tropical Medicine; Trakya University; Westpfalz-Klinikum GmbH; Universitatsklinikum des Saarlandes	Apfel, CC (corresponding author), Outcomes Res Inst, 501 E Broadway,Suite 210, Louisville, KY 40202 USA.	apfel@ponv.org	Sneyd, John/AFV-7887-2022; Sneyd, John/AFV-7886-2022; Sneyd, John Robert/B-2957-2012; Jokela, Ritva/E-1286-2013; Sessler, Daniel/D-3504-2011	Sneyd, John/0000-0003-3546-9856; Sneyd, John/0000-0003-3546-9856; Sneyd, John Robert/0000-0003-3546-9856; Sessler, Daniel/0000-0001-9932-3077; Kredel, Markus/0000-0003-2183-033X	NIGMS NIH HHS [R01 GM061655, GM 061655, R01 GM061655-03] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061655] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apfel CC, 2002, BRIT J ANAESTH, V88, P234, DOI 10.1093/bja/88.2.234; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2003, CONTROL CLIN TRIALS, V24, P736, DOI 10.1016/S0197-2456(03)00107-7; Apfel CC, 2002, ACTA ANAESTH SCAND, V46, P921, DOI 10.1034/j.1399-6576.2002.460801.x; Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; BREMNER WGM, 1993, BRIT J ANAESTH, V71, P296, DOI 10.1093/bja/71.2.296; Darkow T, 2001, PHARMACOTHERAPY, V21, P540, DOI 10.1592/phco.21.6.540.34543; Divatia JV, 1996, ANESTHESIOLOGY, V85, P1055, DOI 10.1097/00000542-199611000-00014; Gan TJ, 2002, JAMA-J AM MED ASSOC, V287, P1233, DOI 10.1001/jama.287.10.1233; Gan TJ, 2002, ANESTHESIOLOGY, V97, P287, DOI 10.1097/00000542-200207000-00059; Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95; GOLD BS, 1989, JAMA-J AM MED ASSOC, V262, P3008, DOI 10.1001/jama.262.21.3008; Goll V, 2001, ANESTH ANALG, V92, P112, DOI 10.1097/00000539-200101000-00022; Greif R, 1999, ANESTHESIOLOGY, V91, P1246, DOI 10.1097/00000542-199911000-00014; Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038; Hill RP, 2000, ANESTHESIOLOGY, V92, P958, DOI 10.1097/00000542-200004000-00012; Joris JL, 2003, BRIT J ANAESTH, V91, P857, DOI 10.1093/bja/aeg267; Koivuranta M, 1997, ANAESTHESIA, V52, P443, DOI 10.1111/j.1365-2044.1997.117-az0113.x; Kovac AL, 1999, J CLIN ANESTH, V11, P453, DOI 10.1016/S0952-8180(99)00067-7; Kovac AL, 2000, DRUGS, V59, P213, DOI 10.2165/00003495-200059020-00005; Lim BSL, 1999, ANAESTH INTENS CARE, V27, P371, DOI 10.1177/0310057X9902700407; Liu K, 1999, ANESTH ANALG, V89, P1316, DOI 10.1213/00000539-199911000-00046; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; MELNICK B, 1989, ANESTH ANALG, V69, P748; Pierre S, 2002, CAN J ANAESTH, V49, P237, DOI 10.1007/BF03020521; Purhonen S, 2003, ANESTH ANALG, V96, P91, DOI 10.1097/00000539-200301000-00020; Schumann R, 1999, ANESTH ANALG, V89, P796; Scuderi PE, 2000, ANESTH ANALG, V91, P1408, DOI 10.1097/00000539-200012000-00020; Sinclair DR, 1999, ANESTHESIOLOGY, V91, P109, DOI 10.1097/00000542-199907000-00018; Sneyd JR, 1998, EUR J ANAESTH, V15, P433, DOI 10.1097/00003643-199807000-00009; Tang J, 1998, ANESTH ANALG, V86, P274, DOI 10.1097/00000539-199802000-00010; Tramer MR, 2001, ACTA ANAESTH SCAND, V45, P4, DOI 10.1034/j.1399-6576.2001.450102.x; Wang JJ, 2000, ANESTH ANALG, V91, P136, DOI 10.1097/00000539-200007000-00025; Watcha M.F., 2002, ANESTHESIOL CLIN N A, V20, P709; Watcha MF, 2000, ANESTHESIOLOGY, V92, P931, DOI 10.1097/00000542-200004000-00007	35	870	946	4	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	2004	350	24					2441	2451		10.1056/NEJMoa032196	http://dx.doi.org/10.1056/NEJMoa032196			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	827GH	15190136	Green Accepted			2023-01-03	WOS:000221887200003
J	Chlebowski, RT; Wactawski-Wende, J; Ritenbaugh, C; Hubbell, FA; Ascensao, J; Rodabough, RJ; Rosenberg, CA; Taylor, VM; Harris, R; Chen, C; Adams-Campbell, LL; White, E; Alving, B; Rossouw, J; Pottern, L; Ludlam, S; McGowan, J; Prentice, R; Anderson, G; LaCroix, A; Patterson, R; McTiernan, A; Cochrane, B; Hunt, J; Tinker, L; Kooperberg, C; McIntosh, M; Wang, CY; Chen, C; Bowen, D; Kristal, A; Stanford, J; Urban, N; Weiss, N; White, E; Shumaker, S; Rautaharju, P; Prineas, R; Naughton, M; Stein, E; Laskarzewski, P; Cummings, S; Nevitt, M; Dockrell, M; Harnack, L; Cammarata, F; Lindenfelser, S; Psaty, B; Heckbert, S; Wassertheil-Smoller, S; Frishman, W; Wylie-Rosett, J; Barad, D; Freeman, R; Hays, J; Young, R; Anderson, J; Lithgow, S; Bray, P; Manson, J; Buring, J; Gaziano, JM; Rexrode, K; Chae, C; Assaf, AR; Wheeler, C; Eaton, C; Cyr, M; Phillips, L; Pedersen, M; Strickland, O; Huber, M; Porter, V; Beresford, SAA; Taylor, VM; Woods, NF; Henderson, M; Kestin, M; Hsia, J; Gaba, N; Ascensao, J; Chlebowski, R; Detrano, R; Nelson, A; Heiner, J; Marshall, J; Ritenbaugh, C; Valanis, B; Elmer, P; Stevens, V; Karanja, N; Caan, B; Sidney, S; Bailey, G; Hirata, J; Kotchen, JM; Barnabei, V; Kotchen, TA; Gilligan, MAC; Neuner, J; Howard, BV; Adams-Campbell, L; Passaro, M; Rainford, M; Agurs-Collins, T; Van Horn, L; Greenland, P; Khandekar, J; Liu, K; Rosenberg, C; Black, H; Powell, L; Mason, E; Stefanick, ML; Hlatky, MA; Chen, B; Stafford, RS; Giudice, LC; Lane, D; Granek, I; Lawson, W; San Roman, G; Messina, C; Jackson, R; Harris, R; Paskett, E; Mysiw, WJ; Blumenfeld, M; Lewis, CE; Oberman, A; Shikany, JM; Safford, M; Britt, BK; Bassford, T; Mattox, J; Ko, M; Lohman, T; Wactawski-Wende, J; Trevisan, M; Smit, E; Graham, S; Chang, J; Robbins, J; Yasmeen, S; Lindfors, K; Stern, J; Hubbell, A; Frank, G; Wong, N; Greep, N; Monk, B; Judd, H; Heber, D; Elashoff, R; Langer, RD; Criqui, MH; Talavera, GT; Garland, CF; Hanson, RE; Gass, M; Wernke, S; Watts, N; Limacher, M; Perri, M; Kaunitz, A; Williams, RS; Brinson, Y; Curb, D; Petrovitch, H; Rodriguez, B; Masaki, K; Sharma, S; Wallace, R; Torner, J; Johnson, S; Snetselaar, L; VanVoorhis, B; Ockene, J; Rosal, M; Ockene, I; Yood, R; Aronson, P; Lasser, N; Singh, B; Lasser, V; Kostis, J; O'Sullivan, MJ; Parker, L; Estape, R; Fernandez, D; Margolis, KL; Grimm, RH; Hunninghake, DB; LaValleur, J; Kempainen, S; Brunner, R; Graettinger, W; Oujevolk, V; Heiss, G; Haines, P; Ontjes, D; Sueta, C; Wells, E; Kuller, L; Cauley, J; Milas, NC; Johnson, KC; Satterfield, S; Ke, RW; Vile, J; Tylavsky, F; Brzyski, R; Schenken, R; Trabal, J; Rodriguez-Sifuentes, M; Mouton, C; Sarto, G; Laube, D; McBride, P; Mares-Perlman, J; Loevinger, B; Bonds, D; Burke, G; Crouse, R; Parsons, L; Vitolins, M; Hendrix, S; Simon, M; McNeely, G; Gordon, P; Makela, P; Allen, C; Dougherty, S; Carleton, R				Chlebowski, RT; Wactawski-Wende, J; Ritenbaugh, C; Hubbell, FA; Ascensao, J; Rodabough, RJ; Rosenberg, CA; Taylor, VM; Harris, R; Chen, C; Adams-Campbell, LL; White, E; Alving, B; Rossouw, J; Pottern, L; Ludlam, S; McGowan, J; Prentice, R; Anderson, G; LaCroix, A; Patterson, R; McTiernan, A; Cochrane, B; Hunt, J; Tinker, L; Kooperberg, C; McIntosh, M; Wang, CY; Chen, C; Bowen, D; Kristal, A; Stanford, J; Urban, N; Weiss, N; White, E; Shumaker, S; Rautaharju, P; Prineas, R; Naughton, M; Stein, E; Laskarzewski, P; Cummings, S; Nevitt, M; Dockrell, M; Harnack, L; Cammarata, F; Lindenfelser, S; Psaty, B; Heckbert, S; Wassertheil-Smoller, S; Frishman, W; Wylie-Rosett, J; Barad, D; Freeman, R; Hays, J; Young, R; Anderson, J; Lithgow, S; Bray, P; Manson, J; Buring, J; Gaziano, JM; Rexrode, K; Chae, C; Assaf, AR; Wheeler, C; Eaton, C; Cyr, M; Phillips, L; Pedersen, M; Strickland, O; Huber, M; Porter, V; Beresford, SAA; Taylor, VM; Woods, NF; Henderson, M; Kestin, M; Hsia, J; Gaba, N; Ascensao, J; Chlebowski, R; Detrano, R; Nelson, A; Heiner, J; Marshall, J; Ritenbaugh, C; Valanis, B; Elmer, P; Stevens, V; Karanja, N; Caan, B; Sidney, S; Bailey, G; Hirata, J; Kotchen, JM; Barnabei, V; Kotchen, TA; Gilligan, MAC; Neuner, J; Howard, BV; Adams-Campbell, L; Passaro, M; Rainford, M; Agurs-Collins, T; Van Horn, L; Greenland, P; Khandekar, J; Liu, K; Rosenberg, C; Black, H; Powell, L; Mason, E; Stefanick, ML; Hlatky, MA; Chen, B; Stafford, RS; Giudice, LC; Lane, D; Granek, I; Lawson, W; San Roman, G; Messina, C; Jackson, R; Harris, R; Paskett, E; Mysiw, WJ; Blumenfeld, M; Lewis, CE; Oberman, A; Shikany, JM; Safford, M; Britt, BK; Bassford, T; Mattox, J; Ko, M; Lohman, T; Wactawski-Wende, J; Trevisan, M; Smit, E; Graham, S; Chang, J; Robbins, J; Yasmeen, S; Lindfors, K; Stern, J; Hubbell, A; Frank, G; Wong, N; Greep, N; Monk, B; Judd, H; Heber, D; Elashoff, R; Langer, RD; Criqui, MH; Talavera, GT; Garland, CF; Hanson, RE; Gass, M; Wernke, S; Watts, N; Limacher, M; Perri, M; Kaunitz, A; Williams, RS; Brinson, Y; Curb, D; Petrovitch, H; Rodriguez, B; Masaki, K; Sharma, S; Wallace, R; Torner, J; Johnson, S; Snetselaar, L; VanVoorhis, B; Ockene, J; Rosal, M; Ockene, I; Yood, R; Aronson, P; Lasser, N; Singh, B; Lasser, V; Kostis, J; O'Sullivan, MJ; Parker, L; Estape, R; Fernandez, D; Margolis, KL; Grimm, RH; Hunninghake, DB; LaValleur, J; Kempainen, S; Brunner, R; Graettinger, W; Oujevolk, V; Heiss, G; Haines, P; Ontjes, D; Sueta, C; Wells, E; Kuller, L; Cauley, J; Milas, NC; Johnson, KC; Satterfield, S; Ke, RW; Vile, J; Tylavsky, F; Brzyski, R; Schenken, R; Trabal, J; Rodriguez-Sifuentes, M; Mouton, C; Sarto, G; Laube, D; McBride, P; Mares-Perlman, J; Loevinger, B; Bonds, D; Burke, G; Crouse, R; Parsons, L; Vitolins, M; Hendrix, S; Simon, M; McNeely, G; Gordon, P; Makela, P; Allen, C; Dougherty, S; Carleton, R		Women's Hlth Initiative Investigat	Estrogen plus progestin and colorectal cancer in postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; RANDOMIZED CONTROLLED-TRIAL; REPLACEMENT THERAPY; COLON-CANCER; HORMONE-THERAPY; ESTROGEN/PROGESTIN REPLACEMENT; RISK; GUIDELINES; SULINDAC; INSULIN	BACKGROUND: Although the Women's Health Initiative (WHI) trial of estrogen plus progestin in postmenopausal women identified more overall health risks than benefits among women in the hormone group, the use of estrogen plus progestin was associated with a significant decrease in the risk of colorectal cancer. We analyzed features of the colorectal cancers that developed and their relation to the characteristics of the participants. METHODS: In the WHI trial, 16,608 postmenopausal women who were 50 to 79 years of age and had an intact uterus were randomly assigned to a combination of conjugated equine estrogens (0.625 mg per day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo. The main outcome measures were the incidence, stages, and types of colorectal cancer, as determined by blinded central adjudication. RESULTS: There were 43 invasive colorectal cancers in the hormone group and 72 in the placebo group (hazard ratio, 0.56; 95 percent confidence interval, 0.38 to 0.81; P=0.003). The invasive colorectal cancers in the hormone group were similar in histologic features and grade to those in the placebo group but with a greater number of positive lymph nodes (mean +/-SD, 3.2+/-4.1 vs. 0.8+/-1.7; P=0.002) and were more advanced (regional or metastatic disease, 76.2 percent vs. 48.5 percent; P=0.004). In exploratory analyses, women in the hormone group with antecedent vaginal bleeding had colorectal cancers with a greater number of positive nodes than women in the hormone group who did not have vaginal bleeding (3.8+/-4.3 vs. 0.7+/-1.5 nodes, P=0.006). CONCLUSIONS: Relatively short-term use of estrogen plus progestin was associated with a decreased risk of colorectal cancer. However, colorectal cancers in women who took estrogen plus progestin were diagnosed at a more advanced stage than those in women who took placebo.	Harbor UCLA Res & Educ Inst, Dept Med, Torrance, CA 90502 USA; SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA; SUNY Buffalo, Dept Gynecol & Obstet, Buffalo, NY 14260 USA; Kaiser Permanente Ctr Hlth Res, Portland, OR USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; George Washington Univ, Dept Med, Div Hematol Oncol, Washington, DC USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA; Evanston NW Healthcare, Dept Internal Med, Evanston, IL USA; Ohio State Univ, Coll Med & Publ Hlth, Columbus, OH 43210 USA; Howard Univ, Ctr Canc, Dept Med, Washington, DC 20059 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Kaiser Permanente; University of California System; University of California Irvine; George Washington University; Fred Hutchinson Cancer Center; NorthShore University Health System; University System of Ohio; Ohio State University; Howard University	Chlebowski, RT (corresponding author), Harbor UCLA Res & Educ Inst, Dept Med, 1124 W Carson St, Torrance, CA 90502 USA.	rchlebowski@rei.edu	Greenland, Philip/ABD-5528-2021; Rexrode, Kathryn M/I-1177-2018; Cauley, Jane A/N-4836-2015; Wactawski-Wende, Jean/AGH-5457-2022; Kaunitz, Andrew/AAL-8448-2020; Rosenberg, Carol/AAZ-5018-2020; Mysiw, Walter/E-3724-2011; Sueta, Carla/AAH-8100-2021; Kristal, Alan/A-8779-2008; Stafford, Randall/F-3974-2017	Cauley, Jane A/0000-0003-0752-4408; Wactawski-Wende, Jean/0000-0003-3096-9595; Stafford, Randall/0000-0003-1805-1271; Ritenbaugh, Cheryl/0000-0002-3307-2727				ALBERTS DS, 2003, P AN M AM SOC CLIN, V22, P91; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; [Anonymous], 2001, MMWR MORB MORTAL WKL, V50, P162; Baron JA, 1999, NEW ENGL J MED, V340, P101, DOI 10.1056/NEJM199901143400204; CALLE EE, 1995, J NATL CANCER I, V87, P517, DOI 10.1093/jnci/87.7.517; Chang CK, 2003, DIABETOLOGIA, V46, P595, DOI 10.1007/s00125-003-1109-5; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Fernandez E, 1998, CANCER EPIDEM BIOMAR, V7, P329; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; Hays J, 2003, ANN EPIDEMIOL, V13, pS18, DOI 10.1016/S1047-2797(03)00042-5; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; JACOBS EJ, 1994, CANCER CAUSE CONTROL, V5, P359, DOI 10.1007/BF01804987; Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kanaya AM, 2003, ANN INTERN MED, V138, P1, DOI 10.7326/0003-4819-138-1-200301070-00005; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Langenbach MR, 2003, WORLD J SURG, V27, P304, DOI 10.1007/s00268-002-6678-9; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; Majumdar SR, 1999, AM J GASTROENTEROL, V94, P3039, DOI 10.1111/j.1572-0241.1999.01454.x; MARSHALL JR, 1986, WOMEN HEALTH, V11, P67; MCMICHAEL AJ, 1980, J NATL CANCER I, V65, P1201; Mor V, 1990, J Community Health, V15, P253, DOI 10.1007/BF01350291; NEWCOMB PA, 1995, J NATL CANCER I, V87, P1416; Paganini-Hill A, 1999, DIS COLON RECTUM, V42, P1300, DOI 10.1007/BF02234219; Pardi DS, 2003, GASTROENTEROLOGY, V124, P889, DOI 10.1053/gast.2003.50156; Pilon D, 2001, OBSTET GYNECOL, V97, P97, DOI 10.1016/S0029-7844(00)01104-2; Ries LAG, 2003, SEER CANC STAT REV 1; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Sandler RS, 2003, NEW ENGL J MED, V348, P1939; Saydah SH, 2003, CANCER EPIDEM BIOMAR, V12, P412; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Smith RA, 2003, CA-CANCER J CLIN, V53, P27, DOI 10.3322/canjclin.53.1.27; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; THOMAS ML, 1993, ENDOCRINOLOGY, V132, P426, DOI 10.1210/en.132.1.426; TIETZ NW, 1987, FUNDAMENTALS CLIN CH, P544; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044; Witte D, 2001, HUM PATHOL, V32, P940, DOI 10.1053/hupa.2001.27117; Zhang YQ, 2001, AM J EPIDEMIOL, V153, P31, DOI 10.1093/aje/153.1.31	40	463	479	0	11	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2004	350	10					991	1004		10.1056/NEJMoa032071	http://dx.doi.org/10.1056/NEJMoa032071			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	780GH	14999111	Bronze			2023-01-03	WOS:000189363600007
J	Crawford, F; Langhorne, P				Crawford, F; Langhorne, P			Commentary: Time to review all the evidence for hormone replacement therapy	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Tayside Ctr Gen Practice, Dundee DD2 4BF, Scotland; Univ Glasgow, Glasgow Royal Infirm, Acad Dept Geriatr Med, Glasgow G31 2ER, Lanark, Scotland	University of Dundee; University of Glasgow	Crawford, F (corresponding author), Tayside Ctr Gen Practice, MacKenzie Bldg, Dundee DD2 4BF, Scotland.	f.crawford@chs.dundee.ac.uk		Crawford, Fay/0000-0002-0473-9959				Bath PMW, 2005, BRIT MED J, V330, P342, DOI 10.1136/bmj.38331.655347.8F; Grady D, 2003, NEW ENGL J MED, V348, P1835, DOI 10.1056/NEJMp030038; HAYS J, 2004, NEW ENGL J MED, V384, P1839; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673	5	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2005	330	7487					345	345		10.1136/bmj.330.7487.345	http://dx.doi.org/10.1136/bmj.330.7487.345			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897OZ	15705691	Green Published			2023-01-03	WOS:000227015800021
J	Squadrone, V; Coha, M; Cerutti, E; Schellino, MM; Biolino, P; Occella, P; Belloni, G; Vilianis, G; Fiore, G; Cavallo, F; Ranieri, VM				Squadrone, V; Coha, M; Cerutti, E; Schellino, MM; Biolino, P; Occella, P; Belloni, G; Vilianis, G; Fiore, G; Cavallo, F; Ranieri, VM		Piedmont Intensive Care Units Netw	Continuous positive airway pressure for treatment of postoperative hypoxemia - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; FACE MASK; RESPIRATORY-FAILURE; NONINVASIVE VENTILATION; CONSENSUS CONFERENCE; GENERAL-ANESTHESIA; ABDOMINAL-SURGERY; CLINICAL-TRIALS; ATELECTASIS; HELMET	Context Hypoxemia complicates the recovery of 30% to 50% of patients after abdominal surgery; endotracheal intubation and mechanical ventilation may be required in 8% to 10% of cases, increasing morbidity and mortality and prolonging intensive care unit and hospital stay. Objective To determine the effectiveness of continuous positive airway pressure compared with standard treatment in preventing the need for intubation and mechanical ventilation in patients who develop acute hypoxemia after elective major abdominal surgery. Design and Setting Randomized, controlled, unblinded study with concealed allocation conducted between June 2002 and November 2003 at 15 intensive care units of the Piedmont Intensive Care Units Network in Italy. Patients Consecutive patients who developed severe hypoxemia after major elective abdominal surgery. The trial was stopped for efficacy after 209 patients had been enrolled. Interventions Patients were randomly assigned to receive oxygen (n=104) or oxygen plus continuous positive airway pressure (n = 105). Main Outcome Measures The primary end point was incidence of endotracheal intubation; secondary end points were intensive care unit and hospital lengths of stay, incidence of pneumonia, infection and sepsis, and hospital mortality. Results Patients who received oxygen plus continuous positive airway pressure had a lower intubation rate (1% vs 10%; P=.005; relative risk [RR], 0.099; 95% confidence interval [CI], 0.01-0.76) and had a lower occurrence rate of pneumonia (2% vs 10%, RR, 0.19; 95% Cl, 0.04-0.88; P=.02), infection (3% vs 10%, RR, 0.27; 95% Cl, 0.07-0.94; P=.03), and sepsis (2% vs 9%; RR, 0.22; 95% Cl, 0.04-0.99; P=.03) than did patients treated with oxygen alone. Patients who received oxygen plus continuous positive airway pressure also spent fewer mean (SD) days in the intensive care unit (1.4 [1.6] vs 2.6 [4.2], P=.09) than patients treated with oxygen alone. The treatments did riot affect the mean (SD) days that patients spent in the hospital (115 [131 vs 17 [151, respectively; P=.10). None of those treated with oxygen plus continuous positive airway pressure died in the hospital while 3 deaths occurred among those treated with oxygen alone (P=.12). Conclusion Continuous positive airway pressure may decrease the incidence of endotracheal intubation and other severe complications in patients who develop hypoxemia after elective major abdominal surgery.	Univ Turin, Azienda Osped S Giovanni Battista Molinette, Dipartimento Anestesia, I-10126 Turin, Italy; Osped Civile Chivasso, Serv Anestesia & Rianimaz, Chivasso, Italy; Osped Civile Ivrea, Serv Anestesia & Rianimaz, Ivrea, Italy; Osped Civile Pinerolo, Serv Anestesia & Rianimaz, Pinerolo, Italy; Osped S Croce di Monacalieri, Serv Anestesia & Rianimaz, Monacalieri, Italy; Univ Turin, Dipartimento Sanita Pubbl & Microbiol, I-10124 Turin, Italy	A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin; University of Turin	Ranieri, VM (corresponding author), Univ Turin, Azienda Osped S Giovanni Battista Molinette, Dipartimento Anestesia, Corso Dogliotti 14, I-10126 Turin, Italy.	marco.ranieri@unito.it	Ranieri, Marco/AFX-8152-2022					Antonelli M, 2001, INTENS CARE MED, V27, P1718, DOI 10.1007/s00134-001-1114-4; Antonelli M, 2004, ANESTHESIOLOGY, V100, P16, DOI 10.1097/00000542-200401000-00007; Arozullah AM, 2000, ANN SURG, V232, P242, DOI 10.1097/00000658-200008000-00015; BENDIXEN HH, 1963, NEW ENGL J MED, V269, P991, DOI 10.1056/NEJM196311072691901; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; CARLSSON C, 1981, INTENS CARE MED, V7, P225, DOI 10.1007/BF01702624; Chiumello D, 2003, INTENS CARE MED, V29, P1671, DOI 10.1007/s00134-003-1825-9; Collins TC, 1999, ANN SURG, V230, P251, DOI 10.1097/00000658-199908000-00016; DEHAVEN CB, 1985, CRIT CARE MED, V13, P46, DOI 10.1097/00003246-198501000-00012; Delclaux C, 2000, JAMA-J AM MED ASSOC, V284, P2352, DOI 10.1001/jama.284.18.2352; Drummond GB, 2002, ANESTHESIOLOGY, V96, P817, DOI 10.1097/00000542-200204000-00007; Duggan M, 2003, AM J RESP CRIT CARE, V167, P1633, DOI 10.1164/rccm.200210-1215OC; Evans T W, 2001, Intensive Care Med, V27, P166, DOI 10.1007/s001340000721; Glanemann M, 2001, ACTA ANAESTH SCAND, V45, P333, DOI 10.1034/j.1399-6576.2001.045003333.x; Hedenstierna G, 1990, Acta Anaesthesiol Scand Suppl, V94, P27; Kaneko Y, 2003, NEW ENGL J MED, V348, P1233, DOI 10.1056/NEJMoa022479; Keenan SP, 2000, JAMA-J AM MED ASSOC, V284, P2376, DOI 10.1001/jama.284.18.2376; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lang M, 2001, BRIT J SURG, V88, P1006, DOI 10.1046/j.0007-1323.2001.01812.x; LINDBERG P, 1992, ACTA ANAESTH SCAND, V36, P546, DOI 10.1111/j.1399-6576.1992.tb03516.x; LINDNER KH, 1987, CHEST, V92, P66, DOI 10.1378/chest.92.1.66; Mehta S, 2001, AM J RESP CRIT CARE, V163, P540, DOI 10.1164/ajrccm.163.2.9906116; MOLLER JT, 1990, ANESTHESIOLOGY, V73, P890, DOI 10.1097/00000542-199011000-00016; Morse MA, 2001, JAMA-J AM MED ASSOC, V285, P1201, DOI 10.1001/jama.285.9.1201; ODONOHUE WJ, 1985, CHEST, V87, P76, DOI 10.1378/chest.87.1.76; Pang D, 1998, CHEST, V114, P1185, DOI 10.1378/chest.114.4.1185; Patroniti N, 2003, INTENS CARE MED, V29, P1680, DOI 10.1007/s00134-003-1931-8; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; Rothaar Robert C, 2003, Curr Opin Crit Care, V9, P59, DOI 10.1097/00075198-200302000-00011; Rusca M, 2003, ANESTH ANALG, V97, P1835, DOI 10.1213/01.ANE.0000087042.02266.F6; Slutsky AS, 2004, NEW ENGL J MED, V350, P1143, DOI 10.1056/NEJMsb033476; STOCK MC, 1985, CHEST, V87, P151, DOI 10.1378/chest.87.2.151; Thompson JS, 2003, ARCH SURG-CHICAGO, V138, P596, DOI 10.1001/archsurg.138.6.596; Tonnelier JM, 2003, INTENS CARE MED, V29, P2077, DOI 10.1007/s00134-003-1925-6; van Kaam AH, 2004, AM J RESP CRIT CARE, V169, P1046, DOI 10.1164/rccm.200312-1779OC	38	404	434	2	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2005	293	5					589	595		10.1001/jama.293.5.589	http://dx.doi.org/10.1001/jama.293.5.589			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893BL	15687314	Bronze			2023-01-03	WOS:000226694200022
J	Riley, J; Ross, JR				Riley, J; Ross, JR			Research into care at the end of life	LANCET			English	Editorial Material							PALLIATIVE CARE		Royal Marsden Hosp Fdn Trust, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust	Riley, J (corresponding author), Royal Marsden Hosp Fdn Trust, London SW3 6JJ, England.	Julia.riley@rmh.nhs.uk						Acquaviva K, 2004, J PAIN SYMPTOM MANAG, V28, P488, DOI 10.1016/j.jpainsymman.2004.08.003; Casarett D, 2001, J Palliat Med, V4, P441, DOI 10.1089/109662101753381566; Casarett DJ, 2000, J PAIN SYMPTOM MANAG, V20, P130, DOI 10.1016/S0885-3924(00)00164-0; Grande GE, 2000, PALLIATIVE MED, V14, P69, DOI 10.1191/026921600677940614; *NIH, 2004, IN PRESS NIH STAT OF; Patrick D, 2004, J NATL CANC I MONOGR, V32, P9; Rees E, 2003, BRIT MED J, V327, P198, DOI 10.1136/bmj.327.7408.198	7	20	21	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB-MAR	2005	365	9461					735	737						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	901LZ	15733702				2023-01-03	WOS:000227285300007
J	Pignotti, MS; Indolfi, G; Ciuti, R; Donzelli, G				Pignotti, MS; Indolfi, G; Ciuti, R; Donzelli, G			Lesson of the week - Perinatal asphyxia and inadvertent neonatal intoxication from local anaesthetics given to the mother during labour	BRITISH MEDICAL JOURNAL			English	Review							LIDOCAINE		Anna Meyer Childrens Hosp, Dept Paediat, I-50132 Florence, Italy; Careggi Hosp, Toxicol Lab, Florence, Italy	University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; Azienda Ospedaliero Universitaria Careggi	Pignotti, MS (corresponding author), Anna Meyer Childrens Hosp, Dept Paediat, Via L Giordano 13, I-50132 Florence, Italy.	m.pignotti@mcyer.it	Pignotti, Maria Serenella/H-8387-2013; Indolfi, Giuseppe/AAK-5548-2020	Indolfi, Giuseppe/0000-0003-3830-9823				DEPRAETER C, 1991, EUR J PEDIATR, V150, P685, DOI 10.1007/BF02072637; Edwards AD, 1998, BMJ-BRIT MED J, V317, P1537, DOI 10.1136/bmj.317.7172.1537; PHILIPSON EH, 1984, AM J OBSTET GYNECOL, V149, P403, DOI 10.1016/0002-9378(84)90154-6; SINCLAIR JC, 1965, NEW ENGL J MED, V273, P1173, DOI 10.1056/NEJM196511252732201; Volpe JJ, 2001, NEUROLOGY NEWBORN, P178; WALSON PD, 1982, PEDIATR PHARMACOL, V2, P341	6	5	5	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 1	2005	330	7481					34	35		10.1136/bmj.330.7481.34	http://dx.doi.org/10.1136/bmj.330.7481.34			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885SH	15626804	Green Published			2023-01-03	WOS:000226176700019
J	Scott, T; Stanford, N; Thompson, DR				Scott, T; Stanford, N; Thompson, DR			Killing me softly: myth in pharmaceutical advertising	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADVERTISEMENTS		Univ St Andrews, Sch Management, St Andrews KY16 9AJ, Fife, Scotland; Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; Chinese Univ Hong Kong, Sch Nursing, Hong Kong, Hong Kong, Peoples R China	University of St Andrews; University of York - UK; Chinese University of Hong Kong	Scott, T (corresponding author), Univ St Andrews, Sch Management, St Andrews KY16 9AJ, Fife, Scotland.	jts1@st-andrews.ac.uk	Thompson, David R/E-2431-2018; Thompson, David R/C-6320-2009	Thompson, David R/0000-0001-8518-6307; 				Barthes Roland., 1972, MYTHOLOGIES; Baudrillard Jean., 1970, SOC CONSOMMATION; De Saussure F., 1966, COURSE GEN LINGUISTI; Derrida Jacques., 1981, DISSEMINATION; FARRELL L, 2000, BRIT MED J, V321, P578; GOLDMAN R, 1986, SOC SCI MED, V22, P1047, DOI 10.1016/0277-9536(86)90205-4; HUTCHEON L, 1987, QUEENS QUART, V94, P904; LANDGREN FT, 1988, MED J AUSTRALIA, V149, P595, DOI 10.5694/j.1326-5377.1988.tb120797.x; LEXCHIN J, DRUG PROMOTION DATAB; Mansfield P R, 1991, Int J Risk Saf Med, V2, P171, DOI 10.3233/JRS-1991-2401; Mansfield PR, 2003, MED J AUSTRALIA, V179, P644, DOI 10.5694/j.1326-5377.2003.tb05730.x; MANSFIELD PR, 2003, HLTH SKEPTICISM INT, V1, P10; Morgan S, 2000, HEALTH ECON, V9, P659, DOI 10.1002/1099-1050(200012)9:8<659::AID-HEC578>3.0.CO;2-0; SCOTT DK, 1994, BRIT J CLIN PHARMACO, V37, P217, DOI 10.1111/j.1365-2125.1994.tb04265.x; Sontag S, 2002, ILLNESS METAPHOR AID; STIMSON GV, 1975, J COMMUN, V25, P153, DOI 10.1111/j.1460-2466.1975.tb00618.x; Sutherland Max, 1993, ADVERTISING MIND CON; WADE VA, 1989, LANCET, V2, P1261; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912	19	15	17	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 18	2004	329	7480					1484	1487		10.1136/bmj.329.7480.1484	http://dx.doi.org/10.1136/bmj.329.7480.1484			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	882VB	15604192	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000225965800035
J	Hudspith, J; Rayatt, S				Hudspith, J; Rayatt, S			ABC of burns - First aid and treatment of minor burns	BRITISH MEDICAL JOURNAL			English	Review									Chelsea & Westminster Hosp, Burns Ctr, London, England; W Midlands Training Scheme, Birmingham, W Midlands, England	Imperial College London	Hudspith, J (corresponding author), Chelsea & Westminster Hosp, Burns Ctr, London, England.							DAVIES JWL, 1982, BURNS, V9, P1, DOI 10.1016/0305-4179(82)90127-9; Herndon DN, 2018, TOTAL BURN CARE; *NAT BURN CAR REV, 2001, STAND STRAT BURN CAR, P68; Settle J. A., 1996, PRINCIPLES PRACTICE; Slater R M, 1971, Br J Plast Surg, V24, P296, DOI 10.1016/S0007-1226(71)80074-7; WILSON G, 1987, BRIT MED J, V294, P556, DOI 10.1136/bmj.294.6571.556	6	64	68	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 19	2004	328	7454					1487	1489		10.1136/bmj.328.7454.1487	http://dx.doi.org/10.1136/bmj.328.7454.1487			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832CK	15205294	Green Published			2023-01-03	WOS:000222244600023
J	Kato, H; Ichinose, Y; Ohta, M; Hata, E; Tsubota, N; Tada, H; Watanabe, Y; Wada, H; Tsuboi, M; Hamajima, N; Ohta, M				Kato, H; Ichinose, Y; Ohta, M; Hata, E; Tsubota, N; Tada, H; Watanabe, Y; Wada, H; Tsuboi, M; Hamajima, N; Ohta, M		Japan Lung Canc Res Grp Postsurgic	A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-II-TRIAL; UFT PLUS CISPLATIN; RESECTED STAGE-I; CANCER; 5-FLUOROURACIL; CARCINOMA; SURVIVAL	Background: In a previous phase 3 trial of adjuvant chemotherapy after resection of non-small-cell lung cancer, a combination of uracil and tegafur (often referred to as UFT) taken orally was shown to prolong survival. A subgroup analysis disclosed that most patients who benefited had pathological stage I adenocarcinoma. Methods: We randomly assigned patients with completely resected pathological stage I adenocarcinoma of the lung to receive either oral uracil-tegafur (250 mg of tegafur per square meter of body-surface area per day) for two years or no treatment. Randomization was performed with stratification according to the pathological tumor category (T1 vs. T2), sex, and age. The primary end point was overall survival. Results: From January 1994 through March 1997, 999 patients were enrolled. Twenty patients were found to be ineligible and were excluded from the analysis after randomization; 491 patients were assigned to receive uracil-tegafur and 488 were assigned to observation. The median duration of follow-up for surviving patients was 73 months. The difference in overall survival between the two groups was statistically significant in favor of the uracil-tegafur group (P=0.04 by a stratified log-rank test). Grade 3 toxic effects occurred in 10 of the 482 patients (2 percent) who actually received uracil-tegafur. Conclusions: Adjuvant chemotherapy with uracil-tegafur improves survival among patients with completely resected pathological stage I adenocarcinoma of the lung.	Kyushu Natl Canc Ctr, Dept Thorac Oncol, Minami Ku, Fukuoka 8111395, Japan; Tokyo Med Univ, Dept Surg, Tokyo, Japan; Natl Okinawa Hosp, Dept Surg, Okinawa, Japan; Mitsui Mem Hosp, Dept Surg, Resp Dis Ctr, Tokyo 101, Japan; Hyogo Med Ctr Adults, Dept Thorac Surg, Akashi, Hyogo, Japan; Osaka City Gen Hosp, Dept Pulm Surg, Osaka, Japan; Kanazawa Univ, Dept Surg 1, Kanazawa, Ishikawa 920, Japan; Kyoto Univ, Dept Thorac Surg, Kyoto, Japan; Nagoya Univ, Dept Prevent Med Biostat & Med Decis Making, Nagoya, Aichi, Japan	Tokyo Medical University; Mitsui Memorial Hospital; Osaka City General Hospital; Kanazawa University; Kyoto University; Nagoya University	Ichinose, Y (corresponding author), Kyushu Natl Canc Ctr, Dept Thorac Oncol, Minami Ku, 3-1-1 Notame, Fukuoka 8111395, Japan.	yichinos@nk-cc.go.jp	Hamajima, Nobuyuki/I-7237-2014					Breathnach OS, 2001, J THORAC CARDIOV SUR, V121, P42, DOI 10.1067/mtc.2001.110190; COX DR, 1972, J R STAT SOC B, V34, P187; Endo C, 2003, LUNG CANCER-J IASLC, V40, P181, DOI 10.1016/S0169-5002(03)00032-1; FELD R, 1993, JNCI-J NATL CANCER I, V85, P299, DOI 10.1093/jnci/85.4.299; FUJII S, 1979, GANN, V70, P209; HAMADA C, 2003, PROG P EUR CANC C, V39, pS231; Hamajima Nobuyuki, 1999, International Journal of Clinical Oncology, V4, P133, DOI 10.1007/s101470050042; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; Ho DH, 1998, CLIN CANCER RES, V4, P2085; ICHINOSE Y, 1995, CANCER, V75, P2677, DOI 10.1002/1097-0142(19950601)75:11<2677::AID-CNCR2820751106>3.0.CO;2-D; Ichinose Y, 1999, ONCOLOGY-NY, V13, P98; Ichinose Y, 2000, CANCER, V88, P318, DOI 10.1002/(SICI)1097-0142(20000115)88:2<318::AID-CNCR11>3.0.CO;2-6; ICHINOSE Y, 2002, PROG P AM SOC CLIN O, V21, pA321; ICHINOSE Y, 2001, P AN M AM SOC CLIN, V20, pA311; IKENAKA K, 1979, GANN, V70, P353; IMAIZUMI M, 2003, PROG P WORLD C LUNG, V41, pS54; KEICHO N, 1986, JPN J CLIN ONCOL, V16, P143, DOI 10.1093/oxfordjournals.jjco.a039130; Kodama K, 2001, LUNG CANCER-J IASLC, V33, P17, DOI 10.1016/S0169-5002(01)00185-4; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; Myrdal G, 2003, ANN THORAC SURG, V75, P356, DOI 10.1016/S0003-4975(02)04321-7; NOGUCHI M, 1995, CANCER-AM CANCER SOC, V75, P2844, DOI 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#; OHTA M, 1993, J THORAC CARDIOV SUR, V106, P703, DOI 10.1016/S0022-5223(19)33714-6; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; OKIMOTO N, 1996, JPN J LUNG CANC, V36, P863; Saito J, 2001, LUNG CANCER-J IASLC, V31, P285, DOI 10.1016/S0169-5002(00)00183-5; Scagliotti GV, 2003, JNCI-J NATL CANCER I, V95, P1453, DOI 10.1093/jnci/djg059; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; SCHOENFELD DA, 1982, BIOMETRICS, V38, P163, DOI 10.2307/2530299; Shimizu E, 1986, Gan To Kagaku Ryoho, V13, P2970; Shirakusa T, 2002, JPN J LUNG CANC, V42, P555, DOI DOI 10.2482/HAIGAN.42.555; TADA H, 2002, P AN M AM SOC CLIN, V21, pA313; Tanaka F, 2001, BRIT J CANCER, V84, P263, DOI 10.1054/bjoc.2000.1579; TANAKA F, 2001, PROG P EUR CANC C, V37, pS29; The Japan Lung Cancer Society, 1987, GEN RUL CLIN PATH RE; Vokes EE, 2002, J CLIN ONCOL, V20, P4191, DOI 10.1200/JCO.2002.03.054; Wada H, 1996, J CLIN ONCOL, V14, P1048, DOI 10.1200/JCO.1996.14.4.1048; *WHO, 1979, OFFS PUBL WHO, V48, P14; Yonekura K, 1999, CLIN CANCER RES, V5, P2185	38	616	637	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 22	2004	350	17					1713	1721		10.1056/NEJMoa032792	http://dx.doi.org/10.1056/NEJMoa032792			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	814AJ	15102997				2023-01-03	WOS:000220947300005
J	Lilford, R; Mohammed, MA; Spiegelhalter, D; Thomson, R				Lilford, R; Mohammed, MA; Spiegelhalter, D; Thomson, R			Use and misuse of process and outcome data in managing performance of acute medical care: avoiding institutional stigma	LANCET			English	Article							ADJUSTED SURGICAL OUTCOMES; PROSPECTIVE PAYMENT SYSTEM; NEW-YORK-STATE; INTENSIVE-CARE; MORTALITY-RATES; MYOCARDIAL-INFARCTION; CLINICAL GOVERNANCE; QUALITY IMPROVEMENT; RISK ADJUSTMENT; CARDIAC-SURGERY	The history of monitoring the outcomes of health care by external agencies can be traced to ancient times. However, the danger, now as then, is that in the search for improvement, comparative measures of mortality and morbidity are often overinterpreted, resulting in judgments about the underlying quality of care. Such judgments can translate into performance management strategies in the form of capricious sanctions (such as star ratings) and unjustified rewards (such as special freedoms or financial allocations). The resulting risk of stigmatising an entire institution injects huge tensions into health-care organisations and can divert attention from genuine improvement towards superficial improvement or even gaming behaviour (ie, manipulating the system). These dangers apply particularly to measures of outcome and throughput. We argue that comparative outcome data (league tables) should not be used by external agents to make judgments about quality of hospital care. Although they might provide a reasonable measure of quality in some high-risk surgical situations, they have little validity in acute medical settings. Their use to support a system of reward and punishment is unfair and, unsurprisingly, often resisted by clinicians and managers. We argue further that although outcome data are useful for research and monitoring trends within an organisation, those who wish to improve care for patients and not penalise doctors and managers, should concentrate on direct measurement of adherence to clinical and managerial standards.	Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Publ Hlth & Epidemiol, Birmingham B15 2TT, W Midlands, England; Univ Newcastle, Sch Populat & Hlth Sci Epidemiol & Publ Hlth, Newcastle Upon Tyne, Tyne & Wear, England; Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England	University of Birmingham; University of Birmingham; Newcastle University - UK; MRC Biostatistics Unit; University of Cambridge	Lilford, R (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England.	R.J.Lilford@Bham.ac.uk						Aiken LH, 2002, JAMA-J AM MED ASSOC, V288, P1987, DOI 10.1001/jama.288.16.1987; [Anonymous], 2001, SUNDAY TIMES; ASH AS, 1997, RISK ADJUSTMENT MEAS, P427; Aylin P, 2001, LANCET, V358, P181, DOI 10.1016/S0140-6736(01)05404-6; Baker R, 2003, BRIT MED J, V326, P274, DOI 10.1136/bmj.326.7383.274; BATES DW, 1995, MED CARE, V33, P452, DOI 10.1097/00005650-199505000-00002; BEST WR, 1994, MED CARE, V32, P390, DOI 10.1097/00005650-199404000-00007; Blumberg M S, 1986, Med Care Rev, V43, P351, DOI 10.1177/107755878604300205; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Burack JH, 1999, ANN THORAC SURG, V68, P1195, DOI 10.1016/S0003-4975(99)00907-8; Carey J S, 1998, Bull Am Coll Surg, V83, P24; Carmel S, 2001, Curr Opin Crit Care, V7, P284, DOI 10.1097/00075198-200108000-00013; Carthey J, 2003, SAFETY SCI, V41, P409, DOI 10.1016/S0925-7535(01)00076-5; Chambler AFW, 1997, ANN ROY COLL SURG, V79, P174; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; Daley J, 2001, ANNU REV MED, V52, P275, DOI 10.1146/annurev.med.52.1.275; Daley J, 1997, J AM COLL SURGEONS, V185, P341, DOI 10.1016/S1072-7515(97)00091-4; DALEY J, 1997, RISK ADJUSTMENT MEAS, P331; DAVIES HTO, 1995, BRIT MED J, V311, P766, DOI 10.1136/bmj.311.7008.766; Deming WE., 2018, OUT CRISIS; *DEP HLTH, 2002, NAT SURV NHS PAT CAN; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; Dunn PM, 1998, BRIT MED J, V317, P1144; Ebrahim S, 2000, BRIT MED J, V320, P1155, DOI 10.1136/bmj.320.7243.1155; Edhouse JA, 1996, J ACCID EMERG MED, V13, P123; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; EPSTEIN AM, 1990, NEW ENGL J MED, V323, P266, DOI 10.1056/NEJM199007263230410; FEY CF, 2000, SERIES BUSINESS ADM, V2000; Freeman C, 2002, QUAL SAF HEALTH CARE, V11, P239, DOI 10.1136/qhc.11.3.239; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; Gibbs J, 2001, INT J QUAL HEALTH C, V13, P187, DOI 10.1093/intqhc/13.3.187; Glance LG, 2002, CRIT CARE MED, V30, P1976, DOI 10.1097/00003246-200209000-00005; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; Gunning K, 1999, BRIT MED J, V319, P241, DOI 10.1136/bmj.319.7204.241; Gupta N, 2002, J INTENSIVE CARE MED, V17, P211, DOI 10.1177/088506602237105; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HARTZ AJ, 1994, AM J PUBLIC HEALTH, V84, P1609, DOI 10.2105/AJPH.84.10.1609; HAYWARD RA, 1993, MED CARE, V31, P394, DOI 10.1097/00005650-199305000-00002; HENDERSON J, 1992, J EPIDEMIOL COMMUN H, V46, P297, DOI 10.1136/jech.46.3.297; HUSELID MA, 1995, ACAD MANAGE J, V38, P635, DOI 10.2307/256741; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; Iezzoni LI, 2012, RISK ADJUSTMENT MEAS, V4th; Inquiry. BRI Inquiry Panel, 2001, LEARN BRIST REP PUBL; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; Julious SA, 2000, BRIT J SURG, V87, P8, DOI 10.1046/j.1365-2168.2000.01328.x; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; Kaska SC, 1998, SPINE, V23, P629, DOI 10.1097/00007632-199803010-00019; Khuri SF, 2002, ARCH SURG-CHICAGO, V137, P20, DOI 10.1001/archsurg.137.1.20; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; Koch MJ, 1996, STRATEGIC MANAGE J, V17, P335; Krumholz HM, 2002, JAMA-J AM MED ASSOC, V287, P1277, DOI 10.1001/jama.287.10.1277; KUHN EM, 1994, MED CARE, V32, P1098, DOI 10.1097/00005650-199411000-00003; Landrum MB, 2000, HLTH SERVICES OUTCOM, V1, P23, DOI [10.1023/A:1010093701870, DOI 10.1023/A:1010093701870]; LEHRER S, 1979, EXPLORERS BODY; Lilford R J, 2003, Health Serv Manage Res, V16, P147, DOI 10.1258/095148403322167906; Lilford RJ, 2003, QUAL SAF HEALTH CARE, V12, pII8, DOI 10.1136/qhc.12.suppl_2.ii8; Mant J, 2001, INT J QUAL HEALTH C, V13, P475, DOI 10.1093/intqhc/13.6.475; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; Mason S, 2002, BRIT MED J, V324, P419, DOI 10.1136/bmj.324.7334.419; McKee M, 1995, Qual Health Care, V4, P5, DOI 10.1136/qshc.4.1.5; McNaughton H, 2003, STROKE, V34, P713, DOI 10.1161/01.STR.0000057580.23952.0D; McQuillan P, 1998, BMJ-BRIT MED J, V316, P1853; Meehan TP, 1997, JAMA-J AM MED ASSOC, V278, P2080, DOI 10.1001/jama.278.23.2080; Mohammed MA, 2001, LANCET, V357, P463, DOI 10.1016/S0140-6736(00)04019-8; MULLEY A, 1994, OUTCOMES CLIN PRACTI, P13; Neale G, 2001, J ROY SOC MED, V94, P322, DOI 10.1177/014107680109400702; Nelson EC, 1998, ANN INTERN MED, V128, P460, DOI 10.7326/0003-4819-128-6-199803150-00007; NORMAND SL, 1997, JAMA-J AM MED ASSOC, V92, P802; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; Pfeffer J., 1995, ACAD MANAGEMENT EXEC, V9, P55; Pronovost P J, 2001, Curr Opin Crit Care, V7, P297, DOI 10.1097/00075198-200108000-00014; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Scally G, 1998, BRIT MED J, V317, P61, DOI 10.1136/bmj.317.7150.61; Shahian DM, 2001, ANN THORAC SURG, V72, P2155, DOI 10.1016/S0003-4975(01)03222-2; Sirio CA, 1999, CHEST, V115, P793, DOI 10.1378/chest.115.3.793; Spiegelhalter D, 2003, INT J QUAL HEALTH C, V15, P7, DOI 10.1093/intqhc/15.1.7; Spiegelhalter DJ, 1999, J ROY STAT SOC A STA, V162, P45, DOI 10.1111/1467-985X.00120; *STAT OFF, 2002, 1 STAT OFF; THOMAS JW, 1993, INQUIRY-J HEALTH CAR, V30, P6; Thomas JW, 1998, MED CARE RES REV, V55, P371, DOI 10.1177/107755879805500401; Thomson RG, 2000, QUAL HEALTH CARE, V9, P201, DOI 10.1136/qhc.9.4.201; Treasure Tom, 2002, Health Care Manag Sci, V5, P243, DOI 10.1023/A:1020373921395; Vaughan-Sarrazin MS, 2002, JAMA-J AM MED ASSOC, V288, P1859, DOI 10.1001/jama.288.15.1859; WEST MA, 2002, INT J HUMAN RES MANA, V13, P1310; Wilson B, 2002, INT J QUAL HEALTH C, V14, P175, DOI 10.1093/oxfordjournals.intqhc.a002609; Young M P, 2000, Eff Clin Pract, V3, P284	90	336	342	1	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	2004	363	9415					1147	1154		10.1016/S0140-6736(04)15901-1	http://dx.doi.org/10.1016/S0140-6736(04)15901-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	808VB	15064036				2023-01-03	WOS:000220595500025
J	Cirillo, DJ; Wallace, RB; Rodabough, RJ; Greenland, P; LaCroix, AZ; Limacher, MC; Larson, JC				Cirillo, DJ; Wallace, RB; Rodabough, RJ; Greenland, P; LaCroix, AZ; Limacher, MC; Larson, JC			Effect of estrogen therapy on gallbladder disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPLACEMENT THERAPY; GALLSTONE DISEASE; POSTMENOPAUSAL; CHOLECYSTECTOMY; RISK; MANAGEMENT	Context Estrogen therapy is thought to promote gallstone formation and cholecystitis but most data derive from observational studies rather than randomized trials. Objective To determine the effect of estrogen therapy in healthy postmenopausal women on gallbladder disease outcomes. Design, Setting, and Participants Two randomized, double-blind, placebo-controlled trials conducted at 40 US clinical centers. The volunteer sample was 22 579 community-dwelling women aged 50 to 79 years without prior cholecystectomy. Intervention Women with hysterectomy were randomized to 0.625 mg/d of conjugated equine estrogens (CEE) or placebo (n=8376). Women without hysterectomy were randomized to estrogen plus progestin (E+P), given as CEE plus 2.5 mg/d of medroxyprogesterone acetate (n=14203). Main Outcome Measures Participants reported hospitalizations for gallbladder diseases and gallbladder-related procedures, with events ascertained through medical record review. Cox proportional hazards regression was used to assess hazard ratios (HRs) and 95% confidence intervals (Cls) using intention-to-treat and time-to-event methods. Results The CEE and the E+P groups were similar to their respective placebo groups at baseline. The mean follow-up times were 7.1 years and 5.6 years for the CEE and the E+P trials, respectively. The annual incidence rate for any gallbladder event was 78 events per 10000 person-years for the CEE group (vs 47/10000 person-years for placebo) and 55 per 10000 person-years for E+P (vs 35/10000 person-years for placebo). Both trials showed greater risk of any gallbladder disease or surgery with estrogen (CEE: HR, 1.67; 95% CI, 1.35-2.06; E+P: HR, 1.59; 95% CI, 1.28-1.97). Both trials indicated a higher risk for cholecystitis (CEE: HR, 1.80; 95% CI, 1.42-2.28; E+P: HR, 1.54; 95% CI 1.22-1.94); and for cholelithiasis (CEE: HR, 1.86; 95% CI, 1.48-2.35; E+P: HR, 1.68; 95% CI, 1.34-2.11) for estrogen users. Also, women undergoing estrogen therapy were more likely to receive cholecystectomy (CEE: HR, 1;93; 95% CI, 1.52-2.44; E+P: HR, 1.67; 95% Cl, 1.32-2.11), but not other biliary tract surgery (CEE: HR, 1.18; 95% CI, 0.68-2.04; E+P: HR, 1.49; 95% CI, 0.78-2.84). Conclusions These data suggest an increase in risk of biliary tract disease among postmenopausal women using estrogen therapy. The morbidity and cost associated with these outcomes may need to be considered in decisions regarding the use of estrogen therapy.	Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA; Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA; Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; Univ Florida, Coll Med, Div Cardiovasc Med, Gainesville, FL USA	University of Iowa; University of Iowa; Fred Hutchinson Cancer Center; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; State University System of Florida; University of Florida	Wallace, RB (corresponding author), Dept Epidemiol C21NGH, 200 Hawkins Dr, Iowa City, IA 52242 USA.	robert-wallace@uiowa.edu	Greenland, Philip/ABD-5528-2021; Cirillo, Dominic J/B-4739-2008	Cirillo, Dominic J/0000-0001-7017-221X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal S, 2000, POSTGRAD MED, V108, P143, DOI 10.3810/pgm.2000.09.1.1212; Ahmed A, 2000, AM FAM PHYSICIAN, V61, P1673; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2003, ANN EPIDEMIOL, V13, pS5, DOI 10.1016/S1047-2797(03)00043-7; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Boland LL, 2002, ANN EPIDEMIOL, V12, P131, DOI 10.1016/S1047-2797(01)00260-5; DEFRANCES CJ, 2004, ADV DATA VITAL HLTH, V342; Donovan JM, 1999, GASTROENTEROL CLIN N, V28, P75, DOI 10.1016/S0889-8553(05)70044-3; EVERSON RB, 1982, GASTROENTEROLOGY, V82, P4; GEORGE ED, 2000, CLIN FAM PRACT, V2, P155; GRODSTEIN F, 1994, OBSTET GYNECOL, V83, P5; JORGENSEN T, 1988, GUT, V29, P433, DOI 10.1136/gut.29.4.433; KAKAR F, 1988, AM J PUBLIC HEALTH, V78, P564, DOI 10.2105/AJPH.78.5.564; Mamdani MM, 2000, CAN MED ASSOC J, V162, P1421; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; OWINGS MF, 1996, AMBULATORY INPATIENT; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SANTEN S, 2001, CHOLECYSTITIS BILIAR; Simon JA, 2001, ANN INTERN MED, V135, P493, DOI 10.7326/0003-4819-135-7-200110020-00008; Stefanick ML, 2003, ANN EPIDEMIOL, V13, pS78, DOI 10.1016/S1047-2797(03)00045-0; Sterling RK, 1998, AM J GASTROENTEROL, V93, P1405, DOI 10.1111/j.1572-0241.1998.01405.x; *SURG CONF GALLBL, 1974, NEW ENGL J MED, V290, P15; Uhler ML, 1998, J CLIN ENDOCR METAB, V83, P410, DOI 10.1210/jc.83.2.410	23	173	185	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2005	293	3					330	339		10.1001/jama.293.3.330	http://dx.doi.org/10.1001/jama.293.3.330			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888FA	15657326	Green Published, Bronze			2023-01-03	WOS:000226358400027
J	Kirkevold, O; Engedal, K				Kirkevold, O; Engedal, K			Concealment of drugs in food and beverages in nursing homes: cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COVERT MEDICATION; RESTRAINTS; SCALE; CARE	Objective To examine the practice of concealing drugs in patients' foodstuff in nursing homes. Design Structured interview study with data collected by structured interview. Setting All five health regions in Norway. Participants Professional carers of 1362 patients in 160 regular nursing home units and 564 patients in 90 special care units for people with dementia. Main outcome measures Frequency of concealment of drugs; who decided to conceal the drugs; how this practice was documented in the patients' records; and what types of drugs were given this way. Results 11% of the patients in regular nursing home units and 17% of the patients in special care units for people with dementia received drugs mixed in their food or beverages at least once during seven days. In 95% of cases, drugs were routinely mixed in the food or beverages. The practice was documented in patients' records in 40% (96/241) of cases. The covert administration of drugs was more often documented when the physician took the decision to hide the drugs in the patient's foodstuff (57%; 27/47) than when the person who made the decision was unknown or not recorded (23%; 7/30). Patients who got drugs covertly more often received antiepileptics, antipsychotics, and anxiolytics compared with patients who were given their drugs openly. Conclusions The covert administration of drugs is common in Norwegian nursing homes. Routines for such practice are arbitrary, and the practice is poorly documented in the patients' records.	Vestfold Mental Hlth Care Trust, Norwegian Ctr Dementia Res, N-3107 Sem, Norway; Ullevaal Univ Hosp, Dept Geriatr Med, Norwegian Ctr Dementia Res, Oslo, Norway	University of Oslo	Kirkevold, O (corresponding author), Vestfold Mental Hlth Care Trust, Norwegian Ctr Dementia Res, Postbox 64, N-3107 Sem, Norway.	oyvind.kirkevold@nordemens.no		Kirkevold, Oyvind/0000-0001-5698-5636				Blythe J, 2000, BRIT MED J, V321, P402, DOI 10.1136/bmj.321.7258.402; FINKEL SI, 1993, J AM GERIATR SOC, V41, P50, DOI 10.1111/j.1532-5415.1993.tb05948.x; Honkanen L, 2001, WESTERN J MED, V174, P229, DOI 10.1136/ewjm.174.4.229; Hox J.J., 2018, MULTILEVEL ANAL; Hughes CM, 2000, MED CARE, V38, P1164, DOI 10.1097/00005650-200012000-00003; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Kirkevold O, 2003, INT J GERIATR PSYCH, V18, P491, DOI 10.1002/gps.883; Kow JV, 2000, CAN MED ASSOC J, V162, P339; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lindesay J, 2003, INT J GERIATR PSYCH, V18, P511, DOI 10.1002/gps.871; MCCULLA MM, 1989, ARCH NEUROL-CHICAGO, V46, P1210, DOI 10.1001/archneur.1989.00520470070029; Middleton H, 1999, J Gerontol Nurs, V25, P26; NYGAARD HA, 1994, INT J GERIATR PSYCH, V9, P387, DOI 10.1002/gps.930090507; Phillips CD, 2000, AM J PUBLIC HEALTH, V90, P92, DOI 10.2105/AJPH.90.1.92; Ramsay S, 2001, LANCET, V358, P900, DOI 10.1016/S0140-6736(01)06092-5; Ruths S, 2001, EUR J CLIN PHARMACOL, V57, P523; Schmidt IK, 2002, SOC SCI MED, V54, P1767, DOI 10.1016/S0277-9536(01)00146-0; Sorensen L, 2001, INT J GERIATR PSYCH, V16, P615, DOI 10.1002/gps.390; Thurmond JA, 1999, APPL NURS RES, V12, P159, DOI 10.1016/S0897-1897(99)80078-0; Treloar A, 2000, J ROY SOC MED, V93, P408, DOI 10.1177/014107680009300805	20	36	36	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 1	2005	330	7481					20	22A		10.1136/bmj.38268.579097.55	http://dx.doi.org/10.1136/bmj.38268.579097.55			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885SH	15561732	Bronze, Green Published			2023-01-03	WOS:000226176700013
J	Corton, JC; Apte, U; Anderson, SP; Limaye, P; Yoon, L; Latendresse, J; Dunn, C; Everitt, JI; Voss, KA; Swanson, C; Kimbrough, C; Wong, JS; Gill, SS; Chandraratna, RAS; Kwak, MK; Kensler, TW; Stulnig, TM; Steffensen, KR; Gustafsson, JA; Mehendale, HM				Corton, JC; Apte, U; Anderson, SP; Limaye, P; Yoon, L; Latendresse, J; Dunn, C; Everitt, JI; Voss, KA; Swanson, C; Kimbrough, C; Wong, JS; Gill, SS; Chandraratna, RAS; Kwak, MK; Kensler, TW; Stulnig, TM; Steffensen, KR; Gustafsson, JA; Mehendale, HM			Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-NULL MICE; PEROXISOME-PROLIFERATOR; GENE-EXPRESSION; ACETAMINOPHEN HEPATOTOXICITY; TISSUE-REPAIR; DIABETIC MICE; MOUSE-LIVER; PPAR-ALPHA; FATTY-ACID; DISEASE	The obesity epidemic in industrialized countries is associated with increases in cardiovascular disease (CVD) and certain types of cancer. In animal models, caloric restriction (CR) suppresses these diseases as well as chemical-induced tissue damage. These beneficial effects of CR overlap with those altered by agonists of nuclear receptors (NR) under control of the fasting-responsive transcriptional co-activator, peroxisome proliferator-activated co-activator 1alpha (PGC-1alpha). In a screen for compounds that mimic CR effects in the liver, we found statistically significant overlaps between the CR transcript profile in wild-type mice and the profiles altered by agonists of lipid-activated NR, including peroxisome proliferator-activated receptor alpha (PPARalpha), liver X receptor, and their obligate heterodimer partner, retinoid X receptor. The overlapping genes included those involved in CVD (lipid metabolism and inflammation) and cancer (cell fate). Based on this overlap, we hypothesized that some effects of CR are mediated by PPARalpha. As determined by transcript profiling, 19% of all gene expression changes in wild-type mice were dependent on PPARalpha, including Cyp4a10 and Cyp4a14, involved in fatty acid omega-oxidation, acute phase response genes, and epidermal growth factor receptor but not increases in PGC-1alpha. CR protected the livers of wild-type mice from damage induced by thioacetamide, a liver toxicant and hepatocarcinogen. CR protection was lost in PPARalpha-null mice due to inadequate tissue repair. These results demonstrate that PPARalpha mediates some of the effects of CR and indicate that a pharmacological approach to mimicking many of the beneficial effects of CR may be possible.	ToxicoGenomics, Chapel Hill, NC 27514 USA; NE Louisiana Univ, Coll Pharm, Dept Toxicol, Monroe, LA 71209 USA; GlaxoSmithKline, Res & Dev, Dept Safety Assessment, Res Triangle Pk, NC 27709 USA; Natl Ctr Toxicol Res, Pathol Associates Int, Jefferson, AR 72079 USA; CIIT Ctr Hlth Res, Res Triangle Pk, NC 27709 USA; ARS, Toxicol & Mycotoxin Res Unit, USDA, Athens, GA 30604 USA; Univ Calif Riverside, Dept Cell Biol & Neurosci, Environm Toxicol Grad Program, Riverside, CA 92521 USA; Allergan Pharmaceut Inc, Dept Biol & Chem, Irvine, CA 92612 USA; Allergan Pharmaceut Inc, Dept Reginoid Res, Irvine, CA 92612 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Karolinska Inst, Novum, Dept Biosci, S-14186 Huddinge, Sweden; Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden	University of Louisiana System; University of Louisiana Monroe; GlaxoSmithKline; US Food & Drug Administration (FDA); United States Department of Agriculture (USDA); University of California System; University of California Riverside; AbbVie; Allergan; AbbVie; Allergan; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Karolinska Institutet; Karolinska Institutet	Corton, JC (corresponding author), ToxicoGenomics, 209 Silver Creek Tr, Chapel Hill, NC 27514 USA.	ccorton@msn.com; mehendale@ulm.edu	Kensler, Thomas W/D-8686-2014	Kensler, Thomas W/0000-0002-6676-261X; Everitt, Jeffrey/0000-0003-0273-6284; Steffensen, Knut/0000-0001-6093-2801; Stulnig, Thomas/0000-0003-3300-6161	NIEHS NIH HHS [ES-09870] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009870] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967; Aghi M, 1999, J NATL CANCER I, V91, P1233, DOI 10.1093/jnci/91.14.1233; Anderson SP, 2002, HEPATOLOGY, V36, P544, DOI 10.1053/jhep.2002.35276; Apte UM, 2003, TOXICOL SCI, V72, P272, DOI 10.1093/toxsci/kfg021; Baldi A, 2003, EXP DERMATOL, V12, P213, DOI 10.1034/j.1600-0625.2003.00026.x; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; BARTLES JR, 1990, CANCER RES, V50, P669; Bauer M, 2004, PHYSIOL GENOMICS, V17, P230, DOI 10.1152/physiolgenomics.00203.2003; Bernard DJ, 2001, RECENT PROG HORM RES, V56, P417, DOI 10.1210/rp.56.1.417; Bugni JM, 2001, CARCINOGENESIS, V22, P1853, DOI 10.1093/carcin/22.11.1853; Chen C, 2000, TOXICOL SCI, V57, P338, DOI 10.1093/toxsci/57.2.338; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; Dhahbi JM, 2004, P NATL ACAD SCI USA, V101, P5524, DOI 10.1073/pnas.0305300101; Dhawan P, 2002, J LEUKOCYTE BIOL, V72, P9; Edwards PA, 2002, VASC PHARMACOL, V38, P249, DOI 10.1016/S1537-1891(02)00175-1; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El-Rifai W, 2002, CANCER RES, V62, P6823; FAN LQ, 1908, BIOCHEM PHARMACOL, V65, P949; Forster MJ, 2003, FASEB J, V17, P690, DOI 10.1096/fj.02-0533fje; Frame LT, 1998, ENVIRON HEALTH PERSP, V106, P313; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREENWELL A, 1991, CANCER LETT, V59, P251, DOI 10.1016/0304-3835(91)90149-C; Guan JZ, 2003, TOHOKU J EXP MED, V201, P251, DOI 10.1620/tjem.201.251; Hart RW, 1997, ENVIRON HEALTH PERSP, V105, P989, DOI 10.2307/3433316; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Higashitsuji H, 2002, CANCER CELL, V2, P335, DOI 10.1016/S1535-6108(02)00152-6; James WPT, 1998, EXP CLIN ENDOCR DIAB, V106, P1; Kari C, 2003, CANCER RES, V63, P1; Keenan KP, 1998, J TOXICOL ENV HEAL B, V1, P135, DOI 10.1080/10937409809524548; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kirkland JL, 2002, CLIN GERIATR MED, V18, P383, DOI 10.1016/S0749-0690(02)00023-X; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Maglich JM, 2004, J BIOL CHEM, V279, P19832, DOI 10.1074/jbc.M313601200; McCarroll SA, 2004, NAT GENET, V36, P197, DOI 10.1038/ng1291; Mehendale HM, 2000, TOXICOL SCI, V57, P187, DOI 10.1093/toxsci/57.2.187; Miller RA, 2002, MOL ENDOCRINOL, V16, P2657, DOI 10.1210/me.2002-0142; Miller RT, 2001, TOXICOL PATHOL, V29, P149, DOI 10.1080/019262301301418964; Murakami S, 2003, FASEB J, V17, P1565, DOI 10.1096/fj.02-1092fje; Nakamura Y, 2000, LEUKEMIA LYMPHOMA, V38, P505, DOI 10.3109/10428190009059269; Oberkofler H, 2003, BIOCHEM J, V371, P89, DOI 10.1042/BJ20021665; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Ramaiah SK, 1998, TOXICOL SCI, V45, P233, DOI 10.1006/toxs.1998.2511; Shankar K, 2003, FASEB J, V17, P1748, DOI 10.1096/fj.02-1186fje; Shankar K, 2003, TOXICOL SCI, V73, P220, DOI 10.1093/toxsci/kfg059; Shankar K, 2003, TOXICOL APPL PHARM, V188, P122, DOI 10.1016/S0041-008X(02)00037-6; Shin DJ, 2003, J BIOL CHEM, V278, P50047, DOI 10.1074/jbc.M309736200; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Standeven AM, 1997, BIOCHEM PHARMACOL, V54, P517, DOI 10.1016/S0006-2952(97)00209-8; Stulnig TM, 2002, MOL PHARMACOL, V62, P1299, DOI 10.1124/mol.62.6.1299; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Tobin KAR, 2000, MOL ENDOCRINOL, V14, P741, DOI 10.1210/me.14.5.741; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Torra IP, 2001, CURR OPIN LIPIDOL, V12, P245, DOI 10.1097/00041433-200106000-00002; Tsuchiya T, 2004, PHYSIOL GENOMICS, V17, P307, DOI 10.1152/physiolgenomics.00039.2004; Weindruch R, 2001, J GERONTOL A-BIOL, V56, P20, DOI 10.1093/gerona/56.suppl_1.20; Weindruch R, 2002, MECH AGEING DEV, V123, P177, DOI 10.1016/S0047-6374(01)00344-X; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; WEINDRUCH R, 1988, RETARDATION AGING DI, P73; Wong JS, 2002, TOXICOL APPL PHARM, V185, P180, DOI 10.1006/taap.2002.9540; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3; Zhang LB, 2004, J BIOL CHEM, V279, P2053, DOI 10.1074/jbc.M310357200	65	91	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46204	46212		10.1074/jbc.M406739200	http://dx.doi.org/10.1074/jbc.M406739200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15302862	hybrid			2023-01-03	WOS:000224694900107
J	Luft, AR; McCombe-Waller, S; Whitall, J; Forrester, LW; Macko, R; Sorkin, JD; Schulz, JB; Goldberg, AP; Hanley, DF				Luft, AR; McCombe-Waller, S; Whitall, J; Forrester, LW; Macko, R; Sorkin, JD; Schulz, JB; Goldberg, AP; Hanley, DF			Repetitive bilateral arm training and motor cortex activation in chronic stroke - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED MOVEMENT THERAPY; CORTICAL REORGANIZATION; FUNCTIONAL MRI; HEMIPLEGIC STROKE; BRAIN ACTIVATION; LIMB MOVEMENT; RECOVERY; PLASTICITY; EVOLUTION; FMRI	Context Reorganization in central motor networks occurs during early recovery from hemiparetic stroke. In chronic stroke survivors, specific rehabilitation therapy can improve upper extremity function. Objective To test the hypothesis that in patients who have chronic motor impairment following stroke, specific rehabilitation therapy that improves arm function is associated with reorganization of cortical networks. Design, Setting, and Patients A randomized controlled clinical trial conducted in a US ambulatory rehabilitation program with 21 patients (median [IQR], 50.3 [34.8-77.3] months after unilateral stroke). Data were collected between 2001 and 2004. Interventions Patients were randomly assigned to bilateral arm training with rhythmic auditory cueing (BATRAC) (n=9) or standardized dose-matched therapeutic exercises (DMTE) (n=12). Both were conducted for 1 hour, 3 times a week, for 6 weeks. Main Outcome Measures Within 2 weeks before and after the intervention, brain activation during elbow movement assessed by functional magnetic resonance imaging (fMRI) and functional outcome assessed using arm function scores. Results Patients in the BATRAC group but not in the DMTE group increased hemispheric activation during paretic arm movement (P=.03). Changes in activation were observed in the contralesional cerebrum and ipsilesional cerebellum (P=.009). BATRAC was associated with significant increases in activation in precentral (P<.001) and postcentral gyri (P=.03) and the cerebellum (P<.001), although 3 BATRAC patients showed no fMRI changes. Considering all patients, there were no differences in functional outcome between groups. When only BATRAC patients with fMRI response were included (n=6), BATRAC improved arm function more than DMTE did (P=.02). Conclusions These preliminary findings suggest that BATRAC induces reorganization in contralesional motor networks and provide biological plausibility for repetitive bilateral training as a potential therapy for upper extremity rehabilitation in hemiparetic stroke.	Univ Maryland, Sch Med, Dept Phys Therapy & Rehabil Sci, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Div Gerontol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; Johns Hopkins Univ, Dept Neurol, Div Brain Injury Outcome, Baltimore, MD 21218 USA; Univ Tubingen, Hertie Inst Clin Brain Res, Dept Gen Neurol, Tubingen, Germany; Baltimore Vet Affairs Maryland Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Geriatric Research Education & Clinical Center	Whitall, J (corresponding author), Univ Maryland, Sch Med, Dept Phys Therapy & Rehabil Sci, 100 Penn St, Baltimore, MD 21201 USA.	Jwhitall@som.umaryland.edu	Schulz, Jörg B/D-9786-2012	Schulz, Jörg B/0000-0002-8903-0593; Hanley, Daniel/0000-0002-9536-4258	NIA NIH HHS [P60 AG012583, P60AG 12583, P60 AG012583-08] Funding Source: Medline; NINDS NIH HHS [R01 NS024282, 1R01 NS 24282-08] Funding Source: Medline; PHS HHS [M01-00052] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG012583] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Calautti C, 2003, STROKE, V34, P1553, DOI 10.1161/01.STR.0000071761.36075.A6; Cao Y, 1998, STROKE, V29, P112, DOI 10.1161/01.STR.29.1.112; Carey JR, 2002, BRAIN, V125, P773, DOI 10.1093/brain/awf091; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Classen J, 1997, BRAIN, V120, P605, DOI 10.1093/brain/120.4.605; Cramer SC, 1997, STROKE, V28, P2518, DOI 10.1161/01.STR.28.12.2518; Cramer SC, 2000, NEUROPHARMACOLOGY, V39, P842, DOI 10.1016/S0028-3908(99)00258-0; Cuadrado ML, 1999, CEREBROVASC DIS, V9, P337, DOI 10.1159/000016009; DAVIES PM, 2000, STEPS FOLLOW COMPREH, V7, P2; Feydy A, 2002, STROKE, V33, P1610, DOI 10.1161/01.STR.0000017100.68294.52; Friston K.J., 1994, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Friston Karl J., 1996, P363; Geyer S, 2000, ANAT EMBRYOL, V202, P443, DOI 10.1007/s004290000127; GOWLAND C, 1992, PHYS THER, V72, P624, DOI 10.1093/ptj/72.9.624; Green JB, 1999, STROKE, V30, P2659, DOI 10.1161/01.STR.30.12.2659; GRESHAM GE, 1979, ARCH PHYS MED REHAB, V60, P487; Hallett M, 2001, BRAIN RES REV, V36, P169, DOI 10.1016/S0165-0173(01)00092-3; Herholz K, 2000, J CEREBR BLOOD F MET, V20, P1619, DOI 10.1097/00004647-200012000-00001; Honda M, 1997, J NEUROL SCI, V146, P117, DOI 10.1016/S0022-510X(96)00291-2; Jang SH, 2003, NEUROREPORT, V14, P1305, DOI 10.1097/01.wnr.0000078700.79393.09; Jang SH, 2003, NEUROREPORT, V14, P137, DOI 10.1097/00001756-200301200-00025; Johansen-Berg H, 2002, BRAIN, V125, P2731, DOI 10.1093/brain/awf282; Johansen-Berg H, 2002, P NATL ACAD SCI USA, V99, P14518, DOI 10.1073/pnas.222536799; Jorgensen H S, 1999, Phys Med Rehabil Clin N Am, V10, P887; Levy CE, 2001, AM J PHYS MED REHAB, V80, P4, DOI 10.1097/00002060-200101000-00003; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; Luft AR, 2002, HUM BRAIN MAPP, V17, P131, DOI 10.1002/hbm.10058; Luft AR, 1998, HUM BRAIN MAPP, V6, P105, DOI 10.1002/(SICI)1097-0193(1998)6:2<105::AID-HBM3>3.0.CO;2-7; Luft AR, 2004, NEUROIMAGE, V21, P924, DOI 10.1016/j.neuroimage.2003.10.026; Marshall RS, 2000, STROKE, V31, P656, DOI 10.1161/01.STR.31.3.656; Mayo NE, 1999, DISABIL REHABIL, V21, P258; Murase N, 2004, ANN NEUROL, V55, P400, DOI 10.1002/ana.10848; Nelles G, 1999, ANN NEUROL, V46, P901, DOI 10.1002/1531-8249(199912)46:6<901::AID-ANA13>3.0.CO;2-7; PARLOW SE, 1991, BEHAV BRAIN RES, V46, P1, DOI 10.1016/S0166-4328(05)80091-9; SANFORD J, 1993, PHYS THER, V73, P447, DOI 10.1093/ptj/73.7.447; Schaechter JD, 2002, NEUROREHAB NEURAL RE, V16, P326, DOI 10.1177/154596830201600403; Small SL, 2002, BRAIN, V125, P1544, DOI 10.1093/brain/awf148; Taub E, 1999, J REHABIL RES DEV, V36, P237; Thaut MH, 2002, NEUROPSYCHOLOGIA, V40, P1073, DOI 10.1016/S0028-3932(01)00141-5; Turton A, 1996, ELECTROMYOGR MOTOR C, V101, P316, DOI 10.1016/0924-980X(96)95560-5; UGAWA Y, 1993, NEUROSCI LETT, V160, P153, DOI 10.1016/0304-3940(93)90401-6; Ward NS, 2003, BRAIN, V126, P1430, DOI 10.1093/brain/awg145; Ward NS, 2003, BRAIN, V126, P2476, DOI 10.1093/brain/awg245; Werhahn KJ, 2003, ANN NEUROL, V54, P464, DOI 10.1002/ana.10686; Whitall J, 2000, STROKE, V31, P2390, DOI 10.1161/01.STR.31.10.2390; Wolf SL, 2001, STROKE, V32, P1635, DOI 10.1161/01.STR.32.7.1635	46	399	418	0	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2004	292	15					1853	1861		10.1001/jama.292.15.1853	http://dx.doi.org/10.1001/jama.292.15.1853			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IV	15494583	Bronze, Green Accepted			2023-01-03	WOS:000224485100024
J	Ansermino, M; Hemsley, C				Ansermino, M; Hemsley, C			ABC of burns - Intensive care management and control of infection	BRITISH MEDICAL JOURNAL			English	Review							THERAPY		British Columbia Childrens Hosp, Vancouver, BC V6H 3V4, Canada; John Radcliffe Hosp, Oxford OX3 9DU, England	BC Childrens Hospital; University of British Columbia; University of Oxford	Ansermino, M (corresponding author), British Columbia Childrens Hosp, Vancouver, BC V6H 3V4, Canada.			Ansermino, J Mark/0000-0001-8427-2035				Desai MH, 1998, J BURN CARE REHABIL, V19, P210, DOI 10.1097/00004630-199805000-00004; MONAFO WW, 1990, DRUGS, V40, P364, DOI 10.2165/00003495-199040030-00004; Pruitt BA, 1998, WORLD J SURG, V22, P135; Still JM, 2000, CLIN PLAST SURG, V27, P23; Warren S, 1991, Curr Clin Top Infect Dis, V11, P206	5	42	47	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 24	2004	329	7459					220	223		10.1136/bmj.329.7459.220	http://dx.doi.org/10.1136/bmj.329.7459.220			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840NW	15271835	Green Published			2023-01-03	WOS:000222866900023
J	Pitts, S; Kellermann, AL				Pitts, S; Kellermann, AL			Hyperventilation during cardiac arrest	LANCET			English	Editorial Material							CARDIOPULMONARY-RESUSCITATION		Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA	Emory University	Kellermann, AL (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA.	akell01@emory.edu						ANDERSEN MN, 1966, ANN SURG, V163, P161, DOI 10.1097/00000658-196602000-00001; [Anonymous], 2000, CIRCULATION S, V102, P186; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; Lurie KG, 2002, CIRCULATION, V105, P124, DOI 10.1161/hc0102.101391; Maheshwari A, 2002, EMERG MED CLIN N AM, V20, P759, DOI 10.1016/S0733-8627(02)00026-3; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; Sigurdsson Gardar, 2003, Curr Opin Crit Care, V9, P183, DOI 10.1097/00075198-200306000-00002	8	32	37	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 24	2004	364	9431					313	315		10.1016/S0140-6736(04)16740-8	http://dx.doi.org/10.1016/S0140-6736(04)16740-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840IZ	15276374				2023-01-03	WOS:000222853300009
J	Berwick, DM				Berwick, DM			My right knee	ANNALS OF INTERNAL MEDICINE			English	Article							REGIONAL-VARIATIONS; CARE	Despite some impressive recent gains, improving the glaring deficiencies in health care quality is proving to be very hard. Improvement is local, rather than system-wide, and is sustained with difficulty, rather than becoming an intrinsic feature of care. My right knee will probably need to be replaced soon. This has given me the opportunity to define, in very personal terms, 5 specific dimensions of "total quality" that I will require from the medical institution that does my surgery and that every patient has the right to require of their encounters with the health care system. Don't kill me (no needless deaths). Do help me, and don't hurt me (no needless pain). Don't make me feel helpless. Don't keep me waiting. And don't waste resources, mine or anyone else's. Given my requirements, it is not clear that any health care institution in the United States will want to take me on as a patient. Although at this point individual institutions can meet some of these requirements, no single institution can deliver on all of them. Generating the energy, insight, and courage we need to get to "total quality" may require those of us who work in health care to get much better at seeing images of ourselves in the people we help. As Gandhi said, "You must be the change you wish to see in the world."	Inst Healthcare Improvement, Cambridge, MA 02138 USA	Institute for Healthcare Improvement	Berwick, DM (corresponding author), Inst Healthcare Improvement, 20 Univ Rd,7th Floor, Cambridge, MA 02138 USA.	dberwick@ihi.org						Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; *I HLTH CAR IMPR, PRIM CAR ACC; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; JULIUSSON R, 1984, ARCH ORTHOP TRAUM SU, V103, P42, DOI 10.1007/BF00451317; McManus ML, 2003, ANESTHESIOLOGY, V98, P1491, DOI 10.1097/00000542-200306000-00029; *PA HLTH CAR COST, 1999, TOT HIP KNEE REPL SU; Reinhardt UE, 2004, HEALTH AFFAIR, V23, P10, DOI 10.1377/hlthaff.23.3.10; SCHWARTZ DE, 1995, ANESTHESIOLOGY, V82, P367, DOI 10.1097/00000542-199502000-00007; *SWED BOARD HLTH, NAT REG KNEE INJ; Wennberg JE, 1998, DARTMOUTH ATLAS HLTH; *WI COLL HEALTHC Q, 2003, PERF PROGR REP	12	19	20	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 18	2005	142	2					121	125		10.7326/0003-4819-142-2-200501180-00011	http://dx.doi.org/10.7326/0003-4819-142-2-200501180-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915LQ	15657160				2023-01-03	WOS:000228306100006
J	Moffett, JAK; Jackson, DA; Richmond, S; Hahn, S; Coulton, S; Farrin, A; Manca, A; Torgerson, DJ				Moffett, JAK; Jackson, DA; Richmond, S; Hahn, S; Coulton, S; Farrin, A; Manca, A; Torgerson, DJ			Randomised trial of a brief physiotherapy intervention compared with usual physiotherapy for neck pain patients: outcomes and patients' preference	BRITISH MEDICAL JOURNAL			English	Article							LOW-BACK-PAIN; CLINICAL-TRIALS; QUESTIONNAIRE; MANAGEMENT; DISABILITY; CARE	Objectives Firstly, to compare the effectiveness of a brief physiotherapy intervention with "usual" physiotherapy for patients with neck pain. Secondly, to evaluate the effect of patients' preferences on outcome. Design Non-inferiority randomised controlled trial eliciting preferences independently of randomisation. Setting Physiotherapy departments in a community setting in Yorkshire and north Lincolnshire. Participants 268 patients (mean age 48 years) with subacute and chronic neck pain, who were referred by their general practitioner quid randomly assigned to a brief physiotherapy intervention (one to three sessions) using cognitive behaviour principles to encourage self management and return to normal function or usual physiotherapy, at the discretion of the physiotherapist concerned. Main outcome measures The Northwick Park neck pain questionnaire (NPQ), a specific measure of functional disability resulting from neck pain. Also, the short form 36 (SF-36) questionnaire, a generic, health related. quality of life measure; and the Tampa scale for kinesophobia, a treasure of fear and avoidance of movement. Results At 12 months, patients allocated to usual physiotherapy had a small but significant improvement in NPQ scores compared with patients in the brief intervention group (mean difference 1.99, 95% confidence interval 0.45 to 3.52; P = 0.01). Although the result shows a significant inferiority of the intervention, the confidence interval shows that the effect could be in the lion-inferiority range for the brief intervention (below 1.2 points of NPQ score). Patients who preferred the brief intervention and received this treatment had similar outcomes to patients receiving usual physiotherapy. Conclusions Usual physiotherapy array be only marginally better than a brief physiotherapy intervention for neck pain. Patients with a preference for die brief intervention may do at least as well with this approach. Additional training for the physiotherapists in cognitive behaviour techniques might improve this approach further.	Univ Hull, Inst Rehabil, Kingston Upon Hull HU3 2PG, N Humberside, England; Univ Hull, Hull & E Riding Community NHS Hlth Trust, Kingston Upon Hull HU3 2PG, N Humberside, England; Univ Hull, Dept Publ Hlth & Primary Care, Kingston Upon Hull HU6 7RX, N Humberside, England; Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; Univ York, York Trials Unit, York YO10 5DD, N Yorkshire, England; Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England	University of Hull; University of Hull; University of Hull; University of York - UK; University of York - UK; University of York - UK	Moffett, JAK (corresponding author), Univ Hull, Inst Rehabil, Kingston Upon Hull HU3 2PG, N Humberside, England.	j.k.moffett@hull.ac.uk	Hahn, Seokyung/J-5705-2012; Torgerson, David/L-4566-2019; Kovacs, Francisco/L-9083-2014	Torgerson, David/0000-0002-1667-4275; Kovacs, Francisco/0000-0002-2984-4800; Coulton, Simon/0000-0002-7704-3274; Hahn, Seokyung/0000-0002-4684-4917; Farrin, Amanda/0000-0002-2876-0584				BATTIE MC, 1994, PHYS THER, V74, P219, DOI 10.1093/ptj/74.3.219; BOVIM G, 1994, SPINE, V19, P1307, DOI 10.1097/00007632-199406000-00001; BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; Cote P, 1998, SPINE, V23, P1689, DOI 10.1097/00007632-199808010-00015; Croft PR, 2001, PAIN, V93, P317, DOI 10.1016/S0304-3959(01)00334-7; Foster NE, 2003, RHEUMATOLOGY, V42, P401, DOI 10.1093/rheumatology/keg165; Foster NE, 1999, SPINE, V24, P1332, DOI 10.1097/00007632-199907010-00011; GROSS AR, 2000, COCHRANE DB SYST REV; HACKETT GI, 1993, BRIT J GEN PRACT, V43, P61; KLABERMOFFETT J, 1999, BRIT MED J, V319, P279; Kori S, 1990, PAIN MANAG, V3, P35; LEAK AM, 1994, BRIT J RHEUMATOL, V33, P469; McPherson K, 1998, BRIT MED J, V317, P78, DOI 10.1136/bmj.317.7150.78; METCALFE C, 2003, THESIS U HULL HULL; MYNORSWALLIS LM, 1995, BMJ-BRIT MED J, V310, P441, DOI 10.1136/bmj.310.6977.441; RUTA A, 1994, QUAL HEALTH CARE, V3, P186; Torgerson D J, 1996, J Health Serv Res Policy, V1, P194; Torgerson DJ, 1998, BRIT MED J, V316, P360, DOI 10.1136/bmj.316.7128.360; Walker LG, 1996, EUR J CANCER, V32A, P1457, DOI 10.1016/0959-8049(96)00151-7	19	83	84	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 8	2005	330	7482					75	78A		10.1136/bmj.38286.493206.82	http://dx.doi.org/10.1136/bmj.38286.493206.82			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887GR	15585539	Green Published, Bronze			2023-01-03	WOS:000226294300016
J	Pimpalnerkar, A; Datta, A; Longhino, D; Mohtadi, N				Pimpalnerkar, A; Datta, A; Longhino, D; Mohtadi, N			An unusual complication of Kocher's manoeuvre	BRITISH MEDICAL JOURNAL			English	Article							ANTERIOR DISLOCATION; SHOULDER; REDUCTION		Royal Ctr Def Med, Birmingham B29 6JD, W Midlands, England; Ctr Sports Med, Calgary, AB T2N 1N4, Canada	Royal Centre for Defence Medicine	Pimpalnerkar, A (corresponding author), Royal Ctr Def Med, Birmingham B29 6JD, W Midlands, England.							Bak K, 2000, KNEE SURG SPORT TR A, V8, P113, DOI 10.1007/s001670050197; BEATTIE TF, 1986, INJURY, V17, P349, DOI 10.1016/0020-1383(86)90161-0; Kocher T, 1870, BERLINER KLIN WEHNSC, V7, P101; Mattick A, 2000, J ROY COLL SURG EDIN, V45, P312; MCNAMARA RM, 1993, ANN EMERG MED, V22, P1140, DOI 10.1016/S0196-0644(05)80979-5; Milch H, 1938, SURGERY, V3, P732; Patissier P., 1882, TRAITE MALADIES ARTI, P162; RIEBEL GD, 1991, AM J EMERG MED, V9, P180, DOI 10.1016/0735-6757(91)90187-O; STIMSON LA, 1900, MED REC, P356	9	7	7	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 18	2004	329	7480					1472	1473		10.1136/bmj.329.7480.1472	http://dx.doi.org/10.1136/bmj.329.7480.1472			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	882VB	15604188	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000225965800031
J	Alexandrov, AV; Molina, CA; Grotta, JC; Garami, Z; Ford, SR; Alvarez-Sabin, J; Montaner, J; Saqqur, M; Demchuk, AM; Moye, LA; Hill, MD; Wojner, AW; Al-Senani, F; Burgin, S; Calleja, S; Campbell, M; Chen, CI; Chernyshev, O; Choi, J; El-Mitwalli, A; Felberg, R; Ford, S; Garami, Z; Irr, W; Grotta, J; Hall, C; Iguchi, Y; Ireland, J; Labiche, L; Malkoff, M; Morgenstern, L; Noser, E; Okon, N; Piriyawat, P; Robinson, D; Shaltoni, H; Shaw, S; Uchino, K; Yatsu, F; Alvarez-Sabin, J; Arenillas, JF; Huertas, R; Molina, C; Montaner, J; Ribo, M; Rubiera, M; Santamarina, E; Saqqur, M; Alchtar, N; O'Rourke, F; Hussain, S; Shuaib, A; Abdalla, E; Demchuk, A; Fischer, K; Hill, MD; Kennedy, J; Roy, J; Ryckborst, KJ; Schebel, M				Alexandrov, AV; Molina, CA; Grotta, JC; Garami, Z; Ford, SR; Alvarez-Sabin, J; Montaner, J; Saqqur, M; Demchuk, AM; Moye, LA; Hill, MD; Wojner, AW; Al-Senani, F; Burgin, S; Calleja, S; Campbell, M; Chen, CI; Chernyshev, O; Choi, J; El-Mitwalli, A; Felberg, R; Ford, S; Garami, Z; Irr, W; Grotta, J; Hall, C; Iguchi, Y; Ireland, J; Labiche, L; Malkoff, M; Morgenstern, L; Noser, E; Okon, N; Piriyawat, P; Robinson, D; Shaltoni, H; Shaw, S; Uchino, K; Yatsu, F; Alvarez-Sabin, J; Arenillas, JF; Huertas, R; Molina, C; Montaner, J; Ribo, M; Rubiera, M; Santamarina, E; Saqqur, M; Alchtar, N; O'Rourke, F; Hussain, S; Shuaib, A; Abdalla, E; Demchuk, A; Fischer, K; Hill, MD; Kennedy, J; Roy, J; Ryckborst, KJ; Schebel, M		CLOTBUST Investigators	Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; FLOW; RECANALIZATION; CRITERIA; FIBRINOLYSIS; OCCLUSION; RECOVERY; THERAPY	Background: Transcranial Doppler ultrasonography that is aimed at residual obstructive intracranial blood flow may help expose thrombi to tissue plasminogen activator (t-PA). Our objective was to determine whether ultrasonography can safely enhance the thrombolytic activity of t-PA. Methods: We treated all patients who had acute ischemic stroke due to occlusion of the middle cerebral artery with intravenous t-PA within three hours after the onset of symptoms. The patients were randomly assigned to receive continuous 2-MHz transcranial Doppler ultrasonography (the target group) or placebo (the control group). The primary combined end point was complete recanalization as assessed by transcranial Doppler ultrasonography or dramatic clinical recovery. Secondary end points included recovery at 24 hours, a favorable outcome at three months, and death at three months. Results: A total of 126 patients were randomly assigned to receive continuous ultrasonography (63 patients) or placebo (63 patients). Symptomatic intracerebral hemorrhage occurred in three patients in the target group and in three in the control group. Complete recanalization or dramatic clinical recovery within two hours after the administration of a t-PA bolus occurred in 31 patients in the target group (49 percent), as compared with 19 patients in the control group (30 percent; P=0.03). Twenty-four hours after treatment of the patients eligible for follow-up, 24 in the target group (44 percent) and 21 in the control group (40 percent) had dramatic clinical recovery (P=0.7). At three months, 22 of 53 patients in the target group who were eligible for follow-up analysis (42 percent) and 14 of 49 in the control group (29 percent) had favorable outcomes (as indicated by a score of 0 to 1 on the modified Rankin scale) (P=0.20). Conclusions: In patients with acute ischemic stroke, continuous transcranial Doppler augments t-PA-induced arterial recanalization, with a nonsignificant trend toward an increased rate of recovery from stroke, as compared with placebo.	Univ Texas, Sch Med, Stroke Treatment Team, Houston, TX 77030 USA; Vall Hebron Hosp, Neurovasc Unit, Barcelona, Spain; Univ Alberta, Dept Med, Div Neurol, Edmonton, AB, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; Univ Calgary, Dept Med, Calgary, AB, Canada; Univ Texas, Sch Publ Hlth, Dept Biostat, Houston, TX USA	University of Texas System; Hospital Universitari Vall d'Hebron; University of Alberta; University of Calgary; University of Calgary; University of Calgary; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	Alexandrov, AV (corresponding author), Univ Texas, Sch Med, Stroke Treatment Team, MSB 7-044,6431 Fannin St, Houston, TX 77030 USA.	avalexandrov@att.net	Malkoff, Marc/ABA-2754-2021; Demchuk, Andrew M/E-1103-2012; El-Mitwalli, Ashraf/ABB-2877-2022; Uchino, Ken/ABC-1611-2021; Arenillas, Juan F./AAE-1142-2020; Grotta, James/AAH-7423-2021; Montaner, Joan/D-3063-2015; Hill, Michael D/C-9073-2012	Demchuk, Andrew M/0000-0002-4930-7789; Uchino, Ken/0000-0001-9468-4172; Montaner, Joan/0000-0003-4845-2279; Hill, Michael D/0000-0002-6269-1543; Alvarez-Sabin, Jose/0000-0002-8054-9209; Alexandrov, Andrei V/0000-0001-8871-1023	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS044227, K23NS002229] Funding Source: NIH RePORTER; NINDS NIH HHS [1K23NS02229-01, 1P50NS044227] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Akiyama M, 1998, NEUROSURGERY, V43, P828, DOI 10.1097/00006123-199810000-00062; Albers GW, 2000, JAMA-J AM MED ASSOC, V283, P1145, DOI 10.1001/jama.283.9.1145; Alexandrov AV, 2000, STROKE, V31, P610, DOI 10.1161/01.STR.31.3.610; Alexandrov AV, 2004, J NEUROIMAGING, V14, P108, DOI 10.1177/1051228403261459; Alexandrov AV, 2002, NEUROLOGY, V59, P862, DOI 10.1212/WNL.59.6.862; Alexandrov AV, 2001, CIRCULATION, V103, P2897, DOI 10.1161/01.CIR.103.24.2897; Behrens S, 2001, ULTRASOUND MED BIOL, V27, P1683, DOI 10.1016/S0301-5629(01)00481-1; BLINC A, 1993, BLOOD, V81, P2636; BLINC A, 1994, THROMB HAEMOSTASIS, V71, P230; Burgin WS, 2000, STROKE, V31, P1128, DOI 10.1161/01.STR.31.5.1128; Caplan LR, 1997, NEW ENGL J MED, V337, P1309; Cintas P, 2002, STROKE, V33, P626, DOI 10.1161/hs0202.103073; Daffertshofer M, 2003, LANCET NEUROL, V2, P283, DOI 10.1016/S1474-4422(03)00380-6; DAFFERTSHOFER M, IN PRESS CEREBROVASC; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; Demchuk AM, 2001, STROKE, V32, P89, DOI 10.1161/01.STR.32.1.89; Demchuk AM, 2000, J NEUROIMAGING, V10, P1; Eggers J, 2003, ANN NEUROL, V53, P797, DOI 10.1002/ana.10590; FRANCIS CW, 1995, ULTRASOUND MED BIOL, V21, P419, DOI 10.1016/0301-5629(94)00119-X; Francis CW, 2001, ECHOCARDIOGR-J CARD, V18, P239, DOI 10.1046/j.1540-8175.2001.00239.x; Grolimund P., 1986, TRANSCRANIAL DOPPLER, P10; KIMURA M, 1994, BIOL PHARM BULL, V17, P126; LAUER CG, 1992, CIRCULATION, V86, P1257, DOI 10.1161/01.CIR.86.4.1257; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Moehring MA, 2002, ULTRASOUND MED BIOL, V28, P49, DOI 10.1016/S0301-5629(01)00486-0; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; Saqqur M, 2003, STROKE, V34, P267; Sloan MA, 2004, NEUROLOGY, V62, P1468, DOI 10.1212/WNL.62.9.1468; Suchkova V, 1998, CIRCULATION, V98, P1030, DOI 10.1161/01.CIR.98.10.1030; Suchkova VN, 2002, THROMB HAEMOSTASIS, V88, P865, DOI 10.1055/s-0037-1613315; TACHIBANA S, 1981, THROMB HAEMOSTASIS, V46, P211; TRUBESTEIN G, 1976, CLIN SCI MOL MED, V51, pS697	33	760	792	3	77	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2170	2178		10.1056/NEJMoa041175	http://dx.doi.org/10.1056/NEJMoa041175			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548777				2023-01-03	WOS:000225160600007
J	Annas, GJ				Annas, GJ			Extremely preterm birth and parental authority to refuse treatment - The case of Sidney Miller	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				Annas GJ, 2004, RIGHT PATIENTS, P273; ATKINSON J, 2002, TEXAS MONTHLY    DEC, P88; Cole FS, 2000, NEW ENGL J MED, V343, P429, DOI 10.1056/NEJM200008103430609; Hansmann G, 2004, LANCET, V364, P1293, DOI 10.1016/S0140-6736(04)17203-6; Linden Dana Wechsler, 2002, N Y Times Web, pF8; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DEC FOR LIF SUST TRE, P218; Robertson JA, 2004, HASTINGS CENT REP, V34, P32, DOI 10.2307/3528691; Weir Robert F., 1984, SELECTIVE NONTREATME; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601	9	31	32	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					2118	2123		10.1056/NEJMlim041201	http://dx.doi.org/10.1056/NEJMlim041201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15537910	Green Published			2023-01-03	WOS:000225007200016
J	Schubert, C				Schubert, C			Fish fix	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1051	1051						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459706				2023-01-03	WOS:000224245800025
J	Salvesen, KA; Morkved, S				Salvesen, KA; Morkved, S			Randomised controlled trial of pelvic floor muscle training during pregnancy	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To examine a possible effect on labour of training the muscles of the pelvic floor during pregnancy. Design Randomised controlled trial. Setting Trondheim University Hospital and three outpatient physiotherapy clinics in a primary care setting. Participants 301 healthy nulliparous women randomly allocated to a training group (148) or a control group (153). Intervention A structured training programme with exercises for the pelvic floor muscles between the 20th and 36th week of pregnancy. Main outcome measures Duration of the second stage of labour and number of deliveries lasting longer than 60 minutes of active pushing among women with spontaneous start of labour after 37 weeks of pregnancy with a singleton fetus in cephalic position. Results Women randomised to pelvic floor muscle training had a lower rate of prolonged second stage labour (24%,95% confidence interval 16% to 33%; 22 out of 105 women were at risk (undelivered) at 60 minutes in the survival analysis) than women allocated to no training (38% (37/109),28% to 47%). The duration of the second stage was not significantly shorter (40 minutes v 45 minutes, P = 0.06). Conclusions A structured training programme for the pelvic floor muscles is associated with fewer cases of active pushing in the second stage of labour as g longer than 60 minutes.	Univ Trondheim Hosp, Dept Obstet & Gynaecol, N-7006 Trondheim, Norway; Norwegian Univ Sci & Technol, Dept Community Med & Gen Practice, N-7489 Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Salvesen, KA (corresponding author), Univ Trondheim Hosp, Dept Obstet & Gynaecol, N-7006 Trondheim, Norway.	pepes@medisin.ntnu.no						*BAB CTR, DO PELV FLOOR EX HEL; BERGSJO P, 1987, OBSTETRIKK; Cunningham FG, 1997, WILLIAMS OBSTET; HOFMEYR GJ, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651958.CD000051; Morkved S, 2003, OBSTET GYNECOL, V101, P313, DOI 10.1016/S0029-7844(02)02711-4; NIELSEN CA, 1988, ACTA OBSTET GYN SCAN, V67, P437; Reilly ETC, 2002, BJOG-INT J OBSTET GY, V109, P68, DOI 10.1016/S1470-0328(02)01116-3	7	77	87	1	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 14	2004	329	7462					378	380		10.1136/bmj.38163.724306.3A	http://dx.doi.org/10.1136/bmj.38163.724306.3A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YI	15253920	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000223433600017
J	Laurent, C; Kouanfack, C; Koulla-Shiro, S; Nkoue, N; Bourgeois, A; Calmy, A; Lactuock, B; Nzeusseu, V; Mougnutou, R; Peytavin, G; Liegeois, F; Nerrienet, E; Tardy, M; Peeters, M; Andrieux-Meyer, I; Zekeng, L; Kazatchkine, M; Mpoudi-Ngole, E; Delaporte, E				Laurent, C; Kouanfack, C; Koulla-Shiro, S; Nkoue, N; Bourgeois, A; Calmy, A; Lactuock, B; Nzeusseu, V; Mougnutou, R; Peytavin, G; Liegeois, F; Nerrienet, E; Tardy, M; Peeters, M; Andrieux-Meyer, I; Zekeng, L; Kazatchkine, M; Mpoudi-Ngole, E; Delaporte, E		ANRS 1274 Study Grp	Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial	LANCET			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; PERFORMANCE LIQUID-CHROMATOGRAPHY; ULTRAVIOLET DETECTION; HUMAN PLASMA; REGIMENS; OUTCOMES	Background Generic fixed-dose combinations have been prequalified by WHO to treat HIV-infected patients in resource-limited countries. Despite their widespread use they are, however, not yet recommended by some of the major donor agencies owing to scarcity of clinical data on effectiveness, safety, and quality. We aimed to assess these issues for one of the most frequently prescribed treatments in Africa, a generic fixed-dose combination of nevirapine, stavudine, and lamivudine. Methods 60 patients were followed in an open-label, 24-week multicentre trial in Cameroon. All patients received one tablet of the fixed-dose combination drug twice daily. The primary outcome measure was the proportion of patients with viral load less than 400 copies per mL at the end of the study period, in an intention-to-treat analysis. Findings At baseline, 92% of patients (n=55) had AIDS; median CD4 count was 118 cells per muL (IQR 78-167) and median plasma HIV-1 RNA was 104 736 copies per mL (40 804-243 787). The proportion of patients with undetectable viral load (<400 copies per mL) after 24 weeks of treatment was 80% (95% Cl 68-89). Median (IQR) change in viral load was -3.1 log(10) copies per mL (-2.5 to -3.6) and in CD4 count 83 cells per mu L (40-178). The probability of remaining alive or free of new AIDS-defining events was 0.85 (95% Cl 0.73-0.92). Frequency of disease progression was 32.0 (95% CI 16.6-61.5), severe adverse effects 17.8 (7.4-42.7), and genotypic resistance mutations 7.1 (1.8-28.4) per 100 person-years. Mean reported adherence rate was 99%. Median drug concentrations in tablets were 96% of expected values for nevirapine, 89% for stavudine, and 99% for lamivudine. Interpretation Our findings lend support to use and funding of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine as first-line antiretroviral treatment in developing countries.	Univ Montpellier, Inst Rech Dev, UMR 145, F-34394 Montpellier 5, France; Univ Montpellier, Dept Int Hlth, UMR 145, F-34394 Montpellier 5, France; Cent Hosp, Yaounde, Cameroon; Mil Hosp, Projet PRESICA PARVY, Yaounde, Cameroon; Med Sans Frontieres, Geneva, Switzerland; Ctr Hosp Univ Bichat Claude Bernard, Lab Toxicol & Dosage Med, Paris, France; Ctr Pasteur, Yaounde, Cameroon; Lab Sante & Hyg Mobile, Yaounde, Cameroon; Natl AIDS Program, Yaounde, Cameroon; French Natl Agcy Res AIDS, Paris, France	Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Universite de Montpellier; Doctors Without Borders; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP	Delaporte, E (corresponding author), Univ Montpellier, Inst Rech Dev, UMR 145, 911 Ave Agropolis,BP 64501, F-34394 Montpellier 5, France.	Eric.Delaporte@mpl.ird.fr	Florian, Liegeois/D-3798-2013; Delaporte, Eric/J-5397-2018	Florian, Liegeois/0000-0003-1048-0661; Delaporte, Eric/0000-0002-1822-9853; Laurent, Christian/0000-0003-2658-7113				BURGER DM, 1992, J CHROMATOGR-BIOMED, V584, P239, DOI 10.1016/0378-4347(92)80581-A; Centers for Disease Control and Prevention, 1992, MMWR RECOMM REP, V41, P1; Chesney M, 2003, AIDS PATIENT CARE ST, V17, P169, DOI 10.1089/108729103321619773; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Djomand G, 2003, AIDS, V17, pS5, DOI 10.1097/00002030-200317003-00002; FLEMING TR, 1982, BIOMETRICS, V38, P143, DOI 10.2307/2530297; Frater AJ, 2002, AIDS, V16, P1139, DOI 10.1097/00002030-200205240-00007; HALVIR D, 1995, J INFECT DIS, V171, P537; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HARKER AJ, 1994, J CHROMATOGR B, V657, P227, DOI 10.1016/0378-4347(94)80092-8; Henry K, 2004, JAIDS-J ACQ IMM DEF, V35, P537, DOI 10.1097/00126334-200404150-00012; HOSSEINIPOUR M, 2003, 10 C RETR OPP INF FE; JOURDAIN G, 2004, 11 C RETR OPP INF FE; Kumarasamy N, 2003, AIDS, V17, P2267, DOI 10.1097/00002030-200310170-00019; Landman R, 2003, AIDS, V17, P1017, DOI 10.1097/00002030-200305020-00010; Laurent C, 2002, AIDS, V16, P1363, DOI 10.1097/00002030-200207050-00008; Martinez E, 2001, AIDS, V15, P1261, DOI 10.1097/00002030-200107060-00007; Tassie JM, 2003, AIDS, V17, P1995, DOI 10.1097/00002030-200309050-00023; *UNAIDS, 2002, REP GLOB HIV AIDS EP; *USAID, HIV AIDS PRES EM PLA; van Heeswijk RPG, 1998, J CHROMATOGR B, V713, P395, DOI 10.1016/S0378-4347(98)00217-5; van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7; Vergne L, 2003, AIDS, V17, pS31, DOI 10.1097/00002030-200317003-00005; Vergne L, 2003, VIROLOGY, V310, P254, DOI 10.1016/S0042-6822(03)00167-3; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; *WHO, PREQ PROJ PROC QUAL; *WHO, 2003, UNAIDS TRAT 3 MILL 2; World Health Organization, 2003, SCAL ANT THER RES LT	28	188	194	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					29	34		10.1016/S0140-6736(04)16586-0	http://dx.doi.org/10.1016/S0140-6736(04)16586-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234853				2023-01-03	WOS:000222392900028
J	Shumaker, SA; Legault, C; Kuller, L; Rapp, SR; Thal, L; Lane, DS; Fillit, H; Stefanick, ML; Hendrix, SL; Lewis, CE; Masaki, K; Coker, LH				Shumaker, SA; Legault, C; Kuller, L; Rapp, SR; Thal, L; Lane, DS; Fillit, H; Stefanick, ML; Hendrix, SL; Lewis, CE; Masaki, K; Coker, LH		Women's Hlth Initiative Memory Stu	Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women - Women's Health Initiative Memory Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; RANDOMIZED CONTROLLED-TRIAL; MIDLIFE BLOOD-PRESSURE; SILENT BRAIN INFARCTS; ALZHEIMERS-DISEASE; OLDER WOMEN; CARDIOVASCULAR HEALTH; PLUS PROGESTIN; DOUBLE-BLIND; RISK-FACTORS	Context The Women's Health Initiative Memory Study (WHIMS) previously found increased risk for dementia and no effect on mild cognitive impairment (MCI) in women treated with conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA). Objective To determine the effects of CEE alone and CEE plus MPA on incidence of probable dementia and MCI in older women. Design, Setting, and Participants Randomized, double-blind, placebo-controlled clinical trials of CEE (estrogen-alone trial) or CEE plus MPA (estrogen plus progestin trial) in community-dwelling women aged 65 to 79 years, conducted from June 1995 to July 8, 2002 (estrogen plus progestin; n=4532), or to February 29, 2004 (estrogen-alone; n=2947), in 39 of the 40 WHI clinical centers. Interventions In the estrogen-alone trial, 1 daily tablet containing either 0.625 mg/d of CEE vs matching placebo; in the estrogen plus progestin trial, 1 daily tablet containing CEE (0.625 mg/d) plus MPA (2.5 mg/d) vs matching placebos. Main Outcome Measures Probable dementia and MCI. Results In the estrogen-alone trial, 47 participants were diagnosed with probable dementia, of whom 28 were assigned to CEE and 19 to placebo (hazard ratio [HR], 1.49; 95% confidence interval [CI], 0.83-2.66). Incidence rates for probable dementia in the estrogen-alone trial were statistically similar to those in the estrogen plus progestin trial (45 vs 22 per 10000 person-years for CEE plus MPA vs placebo, respectively; P=.11). When data were pooled per the original WHIMS protocol, the overall HR for probable dementia was 1.76 (95% Cl, 1.19-2.60; P=.005). After excluding participants with baseline Modified Mini-Mental State Examination scores at or below the screening cut point, the HR was 1.77 (95% Cl, 0.74-4.23; P=.20) in the estrogen-alone trial and 2.19 (95% Cl, 1.25-3.84; P=.006) in the pooled trials. In the estrogen-alone trial, 76 participants were diagnosed with MCI in the CEE group vs 58 in the placebo group (HR, 1.34; 95% Cl 0.95-1.89). In the combined trial data, the HR was similar (1.25; 95% Cl, 0.97-1.60). In the estrogen-alone trial, 93 participants receiving CEE were diagnosed with either probable dementia or MCI vs 69 receiving placebo (HR, 1.38; 95% Cl, 1.01-1.89; P=.04). Conclusions Estrogen therapy alone did not reduce dementia or MCI incidence and increased the risk for both end points combined. Pooling data for estrogen alone and estrogen plus progestin resulted in increased risks for both end points. Use of hormone therapy to prevent dementia or cognitive decline in women 65 years of age or older is not recommended.	Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC 27157 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA; Inst Study Aging, New York, NY USA; Stanford Univ, Stanford Prevent Res Ctr, Stanford, CA 94305 USA; Wayne State Univ, Sch Med, Hutzel Hosp, Dept Obstet & Gynecol, Detroit, MI USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Hawaii, Dept Geriatr Med, Honolulu, HI 96822 USA	Wake Forest University; Wake Forest University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Diego; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stanford University; Wayne State University; University of Alabama System; University of Alabama Birmingham; University of Hawaii System	Shumaker, SA (corresponding author), Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA.	sshumake@wfubmc.edu						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; Beck TJ, 2001, J BONE MINER RES, V16, P2103, DOI 10.1359/jbmr.2001.16.11.2103; Bethea CL, 2002, FRONT NEUROENDOCRIN, V23, P41, DOI 10.1006/frne.2001.0225; Bryan RN, 1997, RADIOLOGY, V202, P47, DOI 10.1148/radiology.202.1.8988191; Burke W J, 1991, J Geriatr Psychiatry Neurol, V4, P173, DOI 10.1177/089198879100400310; COX DR, 1972, J R STAT SOC B, V34, P187; Esiri MM, 2001, LANCET, V357, P169; Fisk JD, 2003, NEUROLOGY, V61, P1179, DOI 10.1212/01.WNL.0000089238.07771.C7; GANGULI M, 1993, J GERONTOL, V48, pM152, DOI 10.1093/geronj/48.4.M152; Gibbs RB, 1999, HORM BEHAV, V36, P222, DOI 10.1006/hbeh.1999.1541; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Henderson VW, 2000, NEUROLOGY, V54, P295, DOI 10.1212/WNL.54.2.295; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; Hogervorst E, 2000, NEUROSCIENCE, V101, P485, DOI 10.1016/S0306-4522(00)00410-3; Iadecola C, 2003, STROKE, V34, P335, DOI 10.1161/01.STR.0000054050.51530.76; Jacobs DM, 1998, NEUROLOGY, V50, P368, DOI 10.1212/WNL.50.2.368; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Kuller LH, 2003, NEUROEPIDEMIOLOGY, V22, P13, DOI 10.1159/000067109; LAUNER LJ, 1995, JAMA-J AM MED ASSOC, V274, P1846, DOI 10.1001/jama.274.23.1846; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; Linzmayer L, 2001, ARZNEIMITTEL-FORSCH, V51, P238; Longstreth WT, 2002, STROKE, V33, P2376, DOI 10.1161/01.STR.0000032241.58727.49; Lopez OL, 2003, ARCH NEUROL-CHICAGO, V60, P1385, DOI 10.1001/archneur.60.10.1385; Matthews K, 1999, J AM GERIATR SOC, V47, P518, DOI 10.1111/j.1532-5415.1999.tb02563.x; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Petersen RC, 2000, NEUROLOGY, V54, P581, DOI 10.1212/WNL.54.3.581; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Rapp PR, 2003, J NEUROSCI, V23, P5708; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sherwin BB, 2003, ENDOCR REV, V24, P133, DOI 10.1210/er.2001-0016; Shumaker SA, 1998, CONTROL CLIN TRIALS, V19, P604, DOI 10.1016/S0197-2456(98)00038-5; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Steffens DC, 1999, J AM GERIATR SOC, V47, P1171, DOI 10.1111/j.1532-5415.1999.tb05195.x; Swan GE, 1998, NEUROLOGY, V51, P986, DOI 10.1212/WNL.51.4.986; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; *US FDA, FDA UPD HORM THER IN; Vermeer SE, 2002, STROKE, V33, P21, DOI 10.1161/hs0102.101629; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Wang PN, 2000, NEUROLOGY, V54, P2061, DOI 10.1212/WNL.54.11.2061; Waring SC, 1999, NEUROLOGY, V52, P965, DOI 10.1212/WNL.52.5.965; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688; Zandi PP, 2002, JAMA-J AM MED ASSOC, V288, P2123, DOI 10.1001/jama.288.17.2123	50	907	940	2	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2004	291	24					2947	2958		10.1001/jama.291.24.2947	http://dx.doi.org/10.1001/jama.291.24.2947			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831HD	15213206				2023-01-03	WOS:000222184600024
J	Moon, SY; Chang, GY				Moon, SY; Chang, GY			A complication of cosmetic surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									US Army Gen Hosp 121st, Seoul, South Korea	United States Department of Defense; United States Army	Moon, SY (corresponding author), US Army Gen Hosp 121st, Seoul, South Korea.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 8	2004	350	15					1549	1549		10.1056/NEJMicm010941	http://dx.doi.org/10.1056/NEJMicm010941			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	810CI	15071129				2023-01-03	WOS:000220682000010
J	Hardy, SE; Gill, TM				Hardy, SE; Gill, TM			Recovery from disability among community-dwelling older persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the American-Geriatrics-Society	MAY 14-18, 2003	BALTIMORE, MD	Amer Geriatr Soc			PHYSICAL PERFORMANCE; FUNCTIONAL DEPENDENCE; RESTRICTED ACTIVITY; RISK-FACTORS; PEOPLE; POPULATION; DECLINE; UNDERESTIMATION; IMPAIRMENTS; IMPACT	Context Previous studies have found that a sizeable minority of newly disabled older persons recover independent function; however, long intervals between assessments have led to difficulty in determining the true incidence and duration of disability, and therefore in accurately characterizing the probability and course of recovery. Objectives To determine the rate of and time to recovery of independent function in community-dwelling older persons who become newly disabled in their activities of daily living (ADLs), to determine the duration of recovery, and to compare the likelihood of recovery among pertinent subgroups of older persons. Design, Setting, and Participants Prospective cohort study, with monthly assessments of ADL function, for 754 initially nondisabled, community-dwelling persons aged 70 years or older, performed in a small urban area from March 1998 to May 2003. Main Outcome Measures Demographic features, chronic conditions, cognitive function, and physical frailty were determined during comprehensive assessments at 18-month intervals. Disability, defined as needing personal assistance with 1 or more key ADLs (bathing, dressing, walking, and transferring), was assessed during monthly telephone interviews. Results A total of 420 participants (56%) experienced disability during a median follow-up of 51 months. Of these participants, 399 (81%) recovered (ie, regained independence in all 4 ADLs) within 12 months of their initial disability episode, and a majority (57%) of these maintained independence for at least 6 months. Among participants who experienced 3 or more consecutive months of disability, a majority (60%) recovered, but only a third of these maintained independence for at least 6 months. Persons who were cognitively impaired, physically frail, or severely disabled (ie, in 3-4 ADLs) at onset were less likely to recover than those who were cognitively intact, non-frail, or mildly disabled, respectively. Nonetheless, a majority of participants within each subgroup recovered. Conclusions Newly disabled older persons recover independent ADL function at rates far exceeding those that have been previously reported. Recovery from disability, however, is often short-lasting, suggesting that additional efforts are warranted to maintain independence in this high-risk group.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA	Yale University	Hardy, SE (corresponding author), 20 York St,Tompkins Bsmt 15, New Haven, CT 06504 USA.	susan.hardy@yale.edu	Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368	NIA NIH HHS [T32AG1934, K24AG021507, K23AG00759, R01AG17560] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K23AG000759, K24AG021507, R01AG017560, R01AG001934] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 2000, SAS STAT US GUID VER; Beckett LA, 1996, AM J EPIDEMIOL, V143, P766; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; Buchner D M, 1992, Clin Geriatr Med, V8, P1; de Leon CFM, 1999, J GERONTOL B-PSYCHOL, V54, pS162, DOI 10.1093/geronb/54B.3.S162; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR; Ferroni MA, 1996, EUR J CLIN PHARMACOL, V51, P23, DOI 10.1007/s002280050155; Ferrucci L, 1997, JAMA-J AM MED ASSOC, V277, P728; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GILL TM, 1995, J GERONTOL A-BIOL, V50, pM235, DOI 10.1093/gerona/50A.5.M235; Gill TM, 2002, NEW ENGL J MED, V347, P1068, DOI 10.1056/NEJMoa020423; Gill TM, 2003, AM J EPIDEMIOL, V158, P1090, DOI 10.1093/aje/kwg237; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; Gill TM, 2003, ARCH INTERN MED, V163, P1317, DOI 10.1001/archinte.163.11.1317; Gill TM, 2003, J GERONTOL A-BIOL, V58, P70; Gill TM, 1996, J GERONTOL A-BIOL, V51, pM283, DOI 10.1093/gerona/51A.6.M283; Gill TM, 1997, J GEN INTERN MED, V12, P757, DOI 10.1046/j.1525-1497.1997.07161.x; Gill TM, 2002, J AM GERIATR SOC, V50, P1492, DOI 10.1046/j.1532-5415.2002.50403.x; Gill TM, 2001, ANN INTERN MED, V135, P313, DOI 10.7326/0003-4819-135-5-200109040-00007; Gill TM, 1999, J GERONTOL A-BIOL, V54, pM377, DOI 10.1093/gerona/54.7.M377; GILL TM, IN PRESS ARCH PHYS M; Guralnik JM, 2000, J GERONTOL A-BIOL, V55, pM221, DOI 10.1093/gerona/55.4.M221; Guralnik JM, 2002, J AM GERIATR SOC, V50, P1599, DOI 10.1046/j.1532-5415.2002.50421.x; Hansen K, 1999, J AM GERIATR SOC, V47, P360, DOI 10.1111/j.1532-5415.1999.tb03002.x; Hardy SE, 2002, J GEN INTERN MED, V17, P841, DOI 10.1046/j.1525-1497.2002.20105.x; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; Kempen GIJM, 1998, AGE AGEING, V27, P595, DOI 10.1093/ageing/27.5.595; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MAGAZINER J, 1990, J GERONTOL, V45, pM101, DOI 10.1093/geronj/45.3.M101; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; Rodgers W, 1997, J GERONTOL B-PSYCHOL, V52, P21, DOI 10.1093/geronb/52B.Special_Issue.21; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; Studenski S, 2003, J AM GERIATR SOC, V51, P314, DOI 10.1046/j.1532-5415.2003.51104.x; Szklo M, 1998, EPIDEMIOL REV, V20, P81, DOI 10.1093/oxfordjournals.epirev.a017974; *US BUR CENS, AM FACTF; VERBRUGGE LM, 1994, J HEALTH SOC BEHAV, V35, P97, DOI 10.2307/2137359; VERBRUGGE LM, 1989, MILBANK Q, V67, P450, DOI 10.2307/3350223	39	256	256	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1596	1602		10.1001/jama.291.13.1596	http://dx.doi.org/10.1001/jama.291.13.1596			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	809PQ	15069047	Bronze			2023-01-03	WOS:000220649000024
J	Nakamura, T; Peng, KW; Vongpunsawad, S; Harvey, M; Mizuguchi, H; Hayakawa, T; Cattaneo, R; Russell, SJ				Nakamura, T; Peng, KW; Vongpunsawad, S; Harvey, M; Mizuguchi, H; Hayakawa, T; Cattaneo, R; Russell, SJ			Antibody-targeted cell fusion	NATURE BIOTECHNOLOGY			English	Article							FUSOGENIC MEMBRANE-GLYCOPROTEINS; SINGLE-CHAIN ANTIBODY; CD46 DOWN-REGULATION; MEASLES-VIRUS; CARCINOEMBRYONIC ANTIGEN; RECEPTOR; HEMAGGLUTININ; GENE; IDENTIFICATION; TRANSDUCTION	Membrane fusion has many potential applications in biotechnology. Here we show that antibody-targeted cell fusion can be achieved by engineering a fusogenic viral membrane glycoprotein complex. Three different single-chain antibodies were displayed at the extracellular C terminus of the measles hemagglutinin (H) protein, and combinations of point mutations were introduced to ablate its ability to trigger fusion through the native viral receptors CD46 and SLAM. When coexpressed with the measles fusion (F) protein, using plasmid cotransfection or bicistronic adenoviral vectors, the retargeted H proteins could mediate antibody-targeted cell fusion of receptor-negative or receptor-positive index cells with receptor-positive target cells. Adenoviral expression vectors mediating human epidermal growth factor receptor (EGFR)-targeted cell fusion were potently cytotoxic against EGFR-positive tumor cell lines and showed superior antitumor potency against EGFR-positive tumor xenografts as compared with control adenoviruses expressing native (untargeted) or CD38-targeted H proteins.	Mayo Clin & Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA; Div Cellular & Gene Therapy Prod, Tokyo 1588501, Japan; Natl Inst Hlth Sci, Tokyo 1588501, Japan	Mayo Clinic; National Institute of Health Sciences - Japan	Russell, SJ (corresponding author), Mayo Clin & Mayo Fdn, Program Mol Med, 200 1st St SW, Rochester, MN 55905 USA.	sjr@mayo.edu	Nakamura, Takafumi/AAO-8199-2020	Nakamura, Takafumi/0000-0002-0196-0754; Mizuguchi, Hiroyuki/0000-0003-0594-8178; vongpunsawad, sompong/0000-0001-7520-8728	NCI NIH HHS [CA100634-01, CA90636-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090636, R01CA100634] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bateman A, 2000, CANCER RES, V60, P1492; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; Cathomen T, 1995, VIROLOGY, V214, P628, DOI 10.1006/viro.1995.0075; CATTANEO R, 1993, J VIROL, V67, P1493, DOI 10.1128/JVI.67.3.1493-1502.1993; CHESTER KA, 1994, LANCET, V343, P455, DOI 10.1016/S0140-6736(94)92695-6; Cohen JI, 2001, FIELDS VIROLOGY, P2707; Dieken ES, 1996, NAT GENET, V12, P174, DOI 10.1038/ng0296-174; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Dorssers LCJ, 1997, INT J CANCER, V72, P700, DOI 10.1002/(SICI)1097-0215(19970807)72:4<700::AID-IJC24>3.0.CO;2-D; Firsching R, 1999, J VIROL, V73, P5265, DOI 10.1128/JVI.73.7.5265-5273.1999; Freed E. O., 2001, FIELDS VIROLOGY, P1971; Galanis E, 2001, HUM GENE THER, V12, P811, DOI 10.1089/104303401750148766; GRIFFIN DE, 2001, FIELDS VIROLOGY, P1402; GUO YJ, 1994, SCIENCE, V263, P518, DOI 10.1126/science.7507262; Hammond AL, 2001, J VIROL, V75, P2087, DOI 10.1128/JVI.75.5.2087-2096.2001; Holden C, 2002, SCIENCE, V296, P2126, DOI 10.1126/science.296.5576.2126; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kemper C, 2003, NATURE, V421, P388, DOI 10.1038/nature01315; KETTLEBOROUGH CA, 1991, PROTEIN ENG, V4, P773, DOI 10.1093/protein/4.7.773; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Langedijk JPM, 1997, J VIROL, V71, P6155, DOI 10.1128/JVI.71.8.6155-6167.1997; Lecouturier V, 1996, J VIROL, V70, P4200, DOI 10.1128/JVI.70.7.4200-4204.1996; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Mizuguchi H, 2003, HUM GENE THER, V14, P1265, DOI 10.1089/104303403767740803; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; Peng KW, 2003, BLOOD, V101, P2557, DOI 10.1182/blood-2002-07-2195; Peng KW, 2002, CANCER RES, V62, P4656; ROBBINS PF, 1991, CANCER RES, V51, P3657; Schneider U, 2000, J VIROL, V74, P9928, DOI 10.1128/JVI.74.21.9928-9936.2000; Shemer G, 2000, DEV DYNAM, V218, P30, DOI 10.1002/(SICI)1097-0177(200005)218:1<30::AID-DVDY4>3.0.CO;2-W; Tatsuo H, 2000, NATURE, V406, P893, DOI 10.1038/35022579; von Messling V, 2001, J VIROL, V75, P6418, DOI 10.1128/JVI.75.14.6418-6427.2001; Vongpunsawad S, 2004, J VIROL, V78, P302, DOI 10.1128/JVI.78.1.302-313.2004; Wang G, 1998, NAT MED, V4, P168, DOI 10.1038/nm0298-168; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Xie MF, 1999, ARCH VIROL, V144, P1689, DOI 10.1007/s007050050697	37	100	108	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2004	22	3					331	336		10.1038/nbt942	http://dx.doi.org/10.1038/nbt942			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	779LE	14990955				2023-01-03	WOS:000189297200027
J	Piepoli, MF; Davos, C; Francis, DP; Coats, AJS; Belardinelli, R; Purcaro, A; Dubach, P; Myers, J; Giannuzzi, P; Temporelli, PL; Hambrecht, R; Linke, A; Kiilavuori, K; Leinonen, H; McKelvie, RS; Teo, KK; Volterrani, M; Giordano, A; Wielenga, RP; Baselier, MRP; Willenheimer, R; Rydberg, E; Adamopoulos, S; Dickestein, K; Gordon, A; Kostis, JB; Sellier, P; Toman, J				Piepoli, MF; Davos, C; Francis, DP; Coats, AJS; Belardinelli, R; Purcaro, A; Dubach, P; Myers, J; Giannuzzi, P; Temporelli, PL; Hambrecht, R; Linke, A; Kiilavuori, K; Leinonen, H; McKelvie, RS; Teo, KK; Volterrani, M; Giordano, A; Wielenga, RP; Baselier, MRP; Willenheimer, R; Rydberg, E; Adamopoulos, S; Dickestein, K; Gordon, A; Kostis, JB; Sellier, P; Toman, J		ExTraMATCH Collaborative	Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; CAPACITY; MEN	Objective To determine the effect of exercise training on survival in patients with heart failure due to left ventricular systolic dysfunction. Design Collaborative meta-analysis. Inclusion criteria Randomised parallel group controlled trials of exercise training, for at least eight weeks with individual patient data on survival for at least three months. Studies reviewed Nine datasets, totalling 801 patients: 395 received exercise training and 406 were controls. Main outcome measure Death from all causes. Results During a mean (SD) follow up of 705 (729) days there were 88 (22%) deaths in the exercise arm and 105 (26%) in the control arm. Exercise training significantly reduced mortality (hazard ratio 0.65, 95% confidence interval, 0.46 to 0.92; log rank chi(2) = 5.9; P = 0.015). The secondary end point of death or admission to hospital was also reduced (0.72, 0.56 to 0.93; log rank chi(2) = 6.4; P = 0.011). No statistically significant subgroup specific treatment effect was observed. Conclusion Meta-analysis of randomised trials to date gives no evidence that properly supervised medical training programmes for patients with heart failure might be dangerous, and indeed there is clear evidence of an overall reduction in mortality. Further research should focus on optimising exercise programmes and identifying appropriate patient groups to target.	Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Dept Clin Cardiol, London SW3 6NP, England; Lancisi Inst, Div Cardiol, Ancona, Italy; Kantonsspital, Dept Cardiol, Chur, Switzerland; IRCCS, Ist Sci Veruno, Fdn Salvatore Maugeri, Novara, Italy; Univ Leipzig, Herzzentrum, Leipzig, Germany; Univ Helsinki, Cent Hosp, Div Cardiol, FIN-00014 Helsinki, Finland; McMaster Univ, Hamilton, ON, Canada; IRCCS, Ctr Med Gussago, Fdn Salvatore Maugeri, Brescia, Italy; Amphia Hosp, Breda, Netherlands; Univ Hosp, Dept Cardiol, Malmo, Sweden; Onassis Cardiac Surg Ctr, Dept Cardiol, Athens, Greece; Cent Hosp Rogaland, Div Cardiol, Stavanger, Norway; Huddinge Univ Hosp, Karolinska Inst, Dept Cardiol, Stockholm, Sweden; UMDNJ Robert Wood Inst, Johnson Med Sch, Dept Med, New Brunswick, NJ USA; Hop Broussais, Serv Readaptat Cardiaque, F-75674 Paris, France; Masaryk Univ, Dept Med 1, Brno, Czech Republic	Imperial College London; Royal Brompton Hospital; Kantonsspital Aarau AG (KSA); Istituti Clinici Scientifici Maugeri IRCCS; Heart Center Leipzig GMBH; Leipzig University; University of Helsinki; Helsinki University Central Hospital; McMaster University; IRCCS Fatebenefratelli; Istituti Clinici Scientifici Maugeri IRCCS; Amphia Hospital; Lund University; Skane University Hospital; Onassis Cardiac Surgery Center; Karolinska Institutet; Rutgers State University New Brunswick; Rutgers State University Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Masaryk University Brno	Piepoli, MF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Dept Clin Cardiol, London SW3 6NP, England.	m.piepoli@imperial.ac.uk	Coats, Andrew J Stewart/E-4451-2012; Temporelli, Pier Luigi/AAB-9754-2020; Davos, Constantinos H./AAR-9392-2020; Piepoli, Massimo F/J-9437-2016; volterrani, maurizio/K-5919-2016; Giannuzzi, Pantaleo/K-2797-2016; Davos, Constantinos/AAR-3259-2021; Piepoli, Massimo/HHC-3488-2022	Coats, Andrew J Stewart/0000-0002-2771-4260; Temporelli, Pier Luigi/0000-0002-6220-2471; Piepoli, Massimo F/0000-0003-1124-234X; volterrani, maurizio/0000-0002-2624-9213; Giannuzzi, Pantaleo/0000-0002-2313-9115; Davos, Constantinos/0000-0002-0321-7569; Piepoli, Massimo/0000-0003-1124-234X				BEGG C. B., 1994, HDB RES SYNTHESIS, P400; Belardinelli R, 1999, CIRCULATION, V99, P1173, DOI 10.1161/01.CIR.99.9.1173; Dubach P, 1997, J AM COLL CARDIOL, V29, P1591, DOI 10.1016/S0735-1097(97)82540-5; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Giannuzzi P, 1997, CIRCULATION, V96, P1790, DOI 10.1161/01.CIR.96.6.1790; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hambrecht R, 2000, JAMA-J AM MED ASSOC, V283, P3095, DOI 10.1001/jama.283.23.3095; HAMBRECHT R, 1995, J AM COLL CARDIOL, V25, P1239, DOI 10.1016/0735-1097(94)00568-B; Kiilavuori K, 2000, EUR J HEART FAIL, V2, P53, DOI 10.1016/S1388-9842(00)00058-1; LAUGHLIN MH, 1992, J APPL PHYSIOL, V73, P2209, DOI 10.1152/jappl.1992.73.6.2209; MANCINI DM, 1991, CIRCULATION, V83, P778, DOI 10.1161/01.CIR.83.3.778; Maugeri FS, 1998, EUR HEART J, V19, P466; McKelvie RS, 2002, AM HEART J, V144, P23, DOI 10.1067/mhj.2002.123310; Myers J, 2002, NEW ENGL J MED, V346, P793, DOI 10.1056/NEJMoa011858; Myers J, 2002, AM HEART J, V144, P719, DOI 10.1067/mhj.2002.124401; Quittan M, 1999, SCAND J REHABIL MED, V31, P223; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; VANOLI E, 1991, CIRC RES, V68, P1471, DOI 10.1161/01.RES.68.5.1471; WHITE FC, 1993, COLLATERAL CIRCULATI, P261; Wielenga RP, 1999, EUR HEART J, V20, P872, DOI 10.1053/euhj.1999.1485; Willenheimer R, 1998, EUR HEART J, V19, P774, DOI 10.1053/euhj.1997.0853; Zanelli E., 1997, European Heart Journal, V18, P647; ZANELLI F, 1997, EUR HEART J SUPPL, V18, P647	23	665	700	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 24	2004	328	7433					189	192		10.1136/bmj.37938.645220.EE	http://dx.doi.org/10.1136/bmj.37938.645220.EE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LU	14729656	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000188652200011
J	Vokes, EE; Stenson, KM				Vokes, EE; Stenson, KM			Therapeutic options for laryngeal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; Univ Chicago, Dept Surg, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA; Univ Chicago, Ctr Canc Res, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Vokes, EE (corresponding author), Univ Chicago, Dept Med, Hematol Oncol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA.		Vokes, Everett/Q-2146-2019						0	21	22	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 27	2003	349	22					2087	2089		10.1056/NEJMp038171	http://dx.doi.org/10.1056/NEJMp038171			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746ZV	14645634				2023-01-03	WOS:000186779700001
J	Alatrakchi, N; Koziel, MJ				Alatrakchi, N; Koziel, MJ			A tale of two viruses: hepatitis C in the age of HAART	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; COINFECTED PATIENTS; INFECTED PATIENTS; LIVER FIBROSIS; PROGRESSION; MORTALITY; HEPATOTOXICITY; DISEASE; IMPACT		Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Koziel, MJ (corresponding author), Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.							Aceti A, 2002, J ACQ IMMUN DEF SYND, V29, P41, DOI 10.1097/00042560-200201010-00005; Armstrong GL, 2000, HEPATOLOGY, V31, P777, DOI 10.1002/hep.510310332; Babik JM, 2003, J VIROL, V77, P1940, DOI 10.1128/JVI.77.3.1940-1950.2003; Benhamou Y, 1999, HEPATOLOGY, V30, P1054, DOI 10.1002/hep.510300409; Bica I, 2001, CLIN INFECT DIS, V32, P492, DOI 10.1086/318501; den Brinker M, 2000, AIDS, V14, P2895, DOI 10.1097/00002030-200012220-00011; Einav S, 2002, Transpl Infect Dis, V4, P85, DOI 10.1034/j.1399-3062.2002.t01-2-02001.x; Ghany MG, 2003, GASTROENTEROLOGY, V124, P97, DOI 10.1053/gast.2003.50018; Graham CS, 2001, CLIN INFECT DIS, V33, P562, DOI 10.1086/321909; Macias J, 2002, EUR J CLIN MICROBIOL, V21, P775, DOI 10.1007/s10096-002-0823-0; Martin-Carbonero L, 2002, AIDS, V16, P1423, DOI 10.1097/00002030-200207050-00016; Martinez-Sierra C, 2003, CLIN INFECT DIS, V36, P491, DOI 10.1086/367643; Nunez M, 2001, J ACQ IMMUN DEF SYND, V27, P426, DOI 10.1097/00126334-200108150-00002; Sulkowski MS, 2000, JAMA-J AM MED ASSOC, V283, P74, DOI 10.1001/jama.283.1.74; Tedaldi EM, 2003, CLIN INFECT DIS, V36, P363, DOI 10.1086/345953	15	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 22	2003	362	9397					1687	1688		10.1016/S0140-6736(03)14881-7	http://dx.doi.org/10.1016/S0140-6736(03)14881-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643113				2023-01-03	WOS:000186767700003
J	O'Brien, CL; Gage, BF				O'Brien, CL; Gage, BF			Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIRECT THROMBIN INHIBITOR; ANTICOAGULANT-THERAPY; RISK-FACTORS; BLEEDING COMPLICATIONS; ANTITHROMBOTIC THERAPY; ORAL ANTICOAGULATION; INTRACEREBRAL HEMORRHAGE; DECISION-ANALYSIS; PREVENT STROKE; WARFARIN	Context Recent trials have found that ximelagatran and warfarin are equally effective in stroke prevention for patients with atrial fibrillation. Because ximelagatran can be taken in a fixed, oral dose without international normalized ratio monitoring and may have a lower risk of hemorrhage, it might improve quality-adjusted survival compared with dose-adjusted warfarin. Objective To compare quality-adjusted survival and cost among 3 alternative therapies for patients with chronic atrial fibrillation: ximelagatran, warfarin, and aspirin. Design Semi-Markov decision model. Patients Hypothetical cohort of 70-year-old patients with chronic atrial fibrillation, varying risk of stroke, and no contraindications to anticoagulation therapy. Main Outcome Measures Quality-adjusted life-years (QALYs) and costs in US dollars. Results For patients with atrial fibrillation but no additional risk factors for stroke, both ximelagatran and warfarin cost more than $50000 per QALY compared with aspirin. For patients with additional stroke risk factors and low hemorrhage risk, ximelagatran modestly increased quality-adjusted survival (0.12 QALY) at a substantial cost ($116000 per QALY) compared with warfarin. For ximelagatran to cost less than $50000 per QALY it would have to cost less than $1100 per year or be prescribed to patients who have an elevated risk of intracranial hemorrhage (>1.0% per year of warfarin) or a low quality of life with warfarin therapy. Conclusion Assuming equal effectiveness in stroke prevention and decreased hemorrhage risk, ximelagatran is not likely to be cost-effective in patients with atrial fibrillation unless they have a high risk of intracranial hemorrhage or a low quality of life with warfarin.	Washington Univ, Sch Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Gage, BF (corresponding author), Washington Univ, Sch Med, Campus Box 8005,660 S Euclid Ave, St Louis, MO 63110 USA.	bgage@im.wustl.edu		Gage, Brian/0000-0002-4727-8742	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010133] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS10133] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Agency for Healthcare Research and Quality, HCUPNET HEALTHC COST; Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690; Albers GW, 2003, LANCET, V362, P1691; Ariesen MJ, 2003, STROKE, V34, P2060, DOI 10.1161/01.STR.0000080678.09344.8D; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Beyth Rebecca J, 2002, Curr Hematol Rep, V1, P41; Blackshear JL, 1996, LANCET, V348, P633; Buckingham TA, 2002, CLIN CARDIOL, V25, P447, DOI 10.1002/clc.4960251003; Bungard TJ, 2000, ARCH INTERN MED, V160, P41, DOI 10.1001/archinte.160.1.41; Casais P, 2000, AM J HEMATOL, V63, P192, DOI 10.1002/(SICI)1096-8652(200004)63:4<192::AID-AJH5>3.0.CO;2-K; Chesebro JH, 1996, ARCH INTERN MED, V156, P409; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; Copland M, 2001, ARCH INTERN MED, V161, P2125, DOI 10.1001/archinte.161.17.2125; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; Dries DL, 1998, J AM COLL CARDIOL, V32, P695, DOI 10.1016/S0735-1097(98)00297-6; Eckman MH, 2003, STROKE, V34, P1710, DOI 10.1161/01.STR.0000078311.18928.16; Elg M, 1999, THROMB RES, V94, P187, DOI 10.1016/S0049-3848(98)00213-8; Eriksson UG, 2003, DRUG METAB DISPOS, V31, P294, DOI 10.1124/dmd.31.3.294; Eriksson UG, 2003, EUR J CLIN PHARMACOL, V59, P35, DOI 10.1007/s00228-003-0565-7; Evans A, 2001, ARCH INTERN MED, V161, P1443, DOI 10.1001/archinte.161.11.1443; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gage BF, 2000, AM J MED, V109, P481, DOI 10.1016/S0002-9343(00)00545-3; Gage BF, 2000, STROKE, V31, P822, DOI 10.1161/01.STR.31.4.822; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Gage BF, 2004, THROMB HAEMOSTASIS, V91, P87, DOI 10.1160/TH03-06-0379; Gage BF, 2004, CIRCULATION, V110, P2287, DOI 10.1161/01.CIR.0000145172.55640.93; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; GAGE BF, IN PRESS AM HEART J; GAGE BF, IN PRESS AM J MED; GITTER MJ, 1995, MAYO CLIN PROC, V70, P725, DOI 10.4065/70.8.725; Go AS, 2003, JAMA-J AM MED ASSOC, V290, P2685, DOI 10.1001/jama.290.20.2685; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Gorter JW, 1999, NEUROLOGY, V53, P1319, DOI 10.1212/WNL.53.6.1319; Gullov AL, 1998, ARCH INTERN MED, V158, P1513, DOI 10.1001/archinte.158.14.1513; Gullov AL, 1999, ARCH INTERN MED, V159, P1322, DOI 10.1001/archinte.159.12.1322; Gyrd-Hansen D, 2003, HEALTH ECON, V12, P1049, DOI 10.1002/hec.799; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hellemons BSP, 1999, BMJ-BRIT MED J, V319, P958, DOI 10.1136/bmj.319.7215.958; Holloway RG, 1996, NEUROLOGY, V46, P854; Hylek EM, 2003, NEW ENGL J MED, V349, P1019, DOI 10.1056/NEJMoa022913; Johnston JA, 2003, MED DECIS MAKING, V23, P361, DOI 10.1177/0272989X03256881; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LAUNBJERG J, 1991, J INTERN MED, V229, P351, DOI 10.1111/j.1365-2796.1991.tb00358.x; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lee SH, 2004, NEUROLOGY, V62, P72, DOI 10.1212/01.WNL.0000101463.50798.0D; Leibson CL, 1996, NEUROLOGY, V46, P861; Man-Son-Hing M, 1999, JAMA-J AM MED ASSOC, V282, P737, DOI 10.1001/jama.282.8.737; Matchar DB, 2000, AHRQ PUBLICATION, V00-N001; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; Minino Arialdi M, 2002, Natl Vital Stat Rep, V50, P1; *NDA, 2004, 21686 NDA; Owens DK, 1998, J GEN INTERN MED, V13, P716, DOI 10.1046/j.1525-1497.1998.00211.x; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; PETERSEN P, 1989, LANCET, V1, P175; Petersen P, 2003, J AM COLL CARDIOL, V41, P1445, DOI 10.1016/S0735-1097(03)00255-9; *PRATT MED GROUP, 1995, SMLTREE COMP PROGR V; *ROCH DIAGN, 2003, COAG SYST 2003 MED R; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; *THOMS PDR, 2003, 2003 DRUG TOP RED BO; Thomson R, 2000, LANCET, V355, P956, DOI 10.1016/S0140-6736(00)90012-6; *US BUR CENS, 1992, STAT ABSTR US; *US DEP LAB BUR LA, CONS PRIC IND TABL C; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441; Waterman AD, 2004, AM J HEALTH-SYST PH, V61, P1258, DOI 10.1093/ajhp/61.12.1258; Wehinger C, 2001, STROKE, V32, P2246, DOI 10.1161/hs1001.097090; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Wyse DG, 2001, J INTERV CARD ELECTR, V5, P267, DOI 10.1023/A:1011460631369; Yuan Z, 1998, AM J PUBLIC HEALTH, V88, P395, DOI 10.2105/AJPH.88.3.395	74	124	124	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2005	293	6					699	706		10.1001/jama.293.6.699	http://dx.doi.org/10.1001/jama.293.6.699			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895DX	15701911	Bronze			2023-01-03	WOS:000226842200023
J	Logan, PA; Gladman, JRF; Avery, A; Walker, MF; Dyas, J; Groom, L				Logan, PA; Gladman, JRF; Avery, A; Walker, MF; Dyas, J; Groom, L			Randomised controlled trial of an occupational therapy intervention to increase outdoor mobility after stroke	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE	Objective To evaluate an occupational therapy intervention to improve outdoor mobility after stroke. Design Randomised controlled trial. Setting General practice registers, social services departments, a primary care rehabilitation service, and a geriatric day hospital. Participants 168 community dwelling people with a clinical diagnosis of stroke in previous 36 months: 86 were allocated to the intervention group and 82 to the control group. Interventions Leaflets describing local transport services for disabled people (control group) and leaflets with assessment and up to seven intervention sessions by an occupational therapist (intervention group). Main outcome measures Responses to postal questionnaires at four and 10 months: primary outcome measure was response to whether participant got out of the house as much as he or she would like, and secondary outcome measures were response to how many journeys outdoors had been made in the past month and scores on the Nottingham extended activities of daily living scale, Nottingham leisure questionnaire, and general health questionnaire. Results Participants in the treatment group were more likely to get out of the house as often as they wanted at both four months (relative risk 1.72, 95% confidence interval 1.25 to 2.37) and 10 months (1.74, 1.24 to 2.44). The treatment group reported more journeys outdoors in the month before assessment at both four months (median 37 in intervention group, 14 in control group: P < 0.0 1) and 10 months (median 42 in intervention group, 14 in control group: P < 0.01). At four months the mobility scores on the Nottingham extended activities of daily living scale were significantly higher in the intervention group, but there Were no significant differences in the other secondary outcomes. No significant differences were observed in these measures at 10 months. Conclusion A targeted occupational therapy intervention at home increases outdoor mobility in people after stroke.	Univ Nottingham, Sch Community Hlth Sci, Nottingham NG7 2RD, England; Hucknall Hlth Ctr, Broxtowe & Hucknall Primary Care Trust, Off Res & Dev, Nottingham NG15 7JE, England	University of Nottingham	Gladman, JRF (corresponding author), Univ Nottingham, Sch Community Hlth Sci, Nottingham NG7 2RD, England.	john.gladman@nottingham.ac.uk	; Gladman, John/M-7429-2015	Walker, Marion/0000-0002-3534-591X; Avery, Anthony/0000-0001-7591-4438; Gladman, John/0000-0002-8506-7786; Logan, Philippa/0000-0002-6657-2381				Collin C, 1988, Int Disabil Stud, V10, P61; Drummond A, 2001, CLIN REHABIL, V15, P647, DOI 10.1191/0269215501cr438oa; Goldberg D., 1992, GEN HLTH QUESTIONNAI; Legg L, 2004, LANCET, V363, P352; Logan PA, 2004, CLIN REHABIL, V18, P703, DOI 10.1191/0269215504cr742oa; Logan PA., 2001, BRIT J OCCUP THER, V64, P261; Nouri FMLN., 1987, CLIN REHABIL, V1, P301, DOI DOI 10.1177/026921558700100409; Parker CJ, 2001, CLIN REHABIL, V15, P42, DOI 10.1191/026921501666968247; Parker CJ, 2000, INT J EPIDEMIOL, V29, P1065, DOI 10.1093/ije/29.6.1065; Pound P, 1998, CLIN REHABIL, V12, P338, DOI 10.1191/026921598677661555; Steultjens EMJ, 2003, STROKE, V34, P676, DOI 10.1161/01.STR.0000057576.77308.30; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5	12	77	80	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	2004	329	7479					1372	1374A		10.1136/bmj.38264.679560.8F	http://dx.doi.org/10.1136/bmj.38264.679560.8F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	880JB	15564229	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000225785000017
J	Siegal, M				Siegal, M			Signposts to the essence of language	SCIENCE			English	Editorial Material									Univ Sheffield, Dept Psychol, Sheffield S10 2TP, S Yorkshire, England	University of Sheffield	Siegal, M (corresponding author), Univ Sheffield, Dept Psychol, Sheffield S10 2TP, S Yorkshire, England.	m.siegal@sheffield.ac.uk						Chomsky N, 1980, RULES REPRESENTATION; EPSTEIN R, 1980, SCIENCE, V207, P543, DOI 10.1126/science.207.4430.543; GELMAN R, IN PRESS TRENDS COGN; Goldin-Meadow S., 2003, RESILIENCE LANGUAGE; LANE H, 1977, WILD BOY AVEYRON, P83; Mayberry RI, 2002, NATURE, V417, P38, DOI 10.1038/417038a; PETITTO LA, 1991, SCIENCE, V251, P1493, DOI 10.1126/science.2006424; Sacks O., 1989, SEEING VOICES; Senghas A, 2004, SCIENCE, V305, P1779, DOI 10.1126/science.1100199; STROMSWOLD K, 2000, NEW COGNITIVE NEUROS, P909; Vouloumanos A, 2004, DEVELOPMENTAL SCI, V7, P270, DOI 10.1111/j.1467-7687.2004.00345.x; Woolfe T, 2002, CHILD DEV, V73, P768, DOI 10.1111/1467-8624.00437	12	2	2	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	2004	305	5691					1720	1721		10.1126/science.1102894	http://dx.doi.org/10.1126/science.1102894			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	856IS	15375252				2023-01-03	WOS:000224039500023
J	Chen, IA; Roberts, RW; Szostak, JW				Chen, IA; Roberts, RW; Szostak, JW			The emergence of competition between model protocells	SCIENCE			English	Article							VESICLES; GROWTH	The transition from independent molecular entities to cellular structures with integrated behaviors was a crucial aspect of the origin of life. We show that simple physical principles can mediate a coordinated interaction between genome and compartment boundary, independent of any genomic functions beyond self-replication. RNA, encapsulated in fatty acid vesicles, exerts an osmotic pressure on the vesicle membrane that drives the uptake of additional membrane components, leading to membrane growth at the expense of relaxed vesicles, which shrink. Thus, more efficient RNA replication could cause faster cell growth, leading to the emergence of Darwinian evolution at the cellular level.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Massachusetts Gen Hosp, Howard Hughes Med Inst, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Program Biophys, Cambridge, MA 02138 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; California Institute of Technology	Szostak, JW (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.	szostak@molbio.mgh.harvard.edu		Chen, Irene/0000-0001-6040-7927	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008313, T32GM007753] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartel David P., 1999, Trends in Cell Biology, V9, pM9, DOI 10.1016/S0962-8924(99)01669-4; Chen IA, 2004, BIOPHYS J, V87, P988, DOI 10.1529/biophysj.104.039875; Chen IA, 2004, P NATL ACAD SCI USA, V101, P7965, DOI 10.1073/pnas.0308045101; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2857, DOI 10.1021/bi00333a007; GEBICKI JM, 1973, NATURE, V243, P232, DOI 10.1038/243232a0; Hanczyc MM, 2003, SCIENCE, V302, P618, DOI 10.1126/science.1089904; Jin AJ, 1999, EUR BIOPHYS J BIOPHY, V28, P187, DOI 10.1007/s002490050199; JONES JD, 1989, BIOCHEMISTRY-US, V28, P129, DOI 10.1021/bi00427a019; Landweber LF, 1998, BIOSCIENCE, V48, P94, DOI 10.2307/1313134; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; Monnard PA, 2002, ASTROBIOLOGY, V2, P139, DOI 10.1089/15311070260192237; Morowitz H.J, 1992, BEGINNINGS CELLULAR; MUI BLS, 1993, BIOPHYS J, V64, P443, DOI 10.1016/S0006-3495(93)81385-7; NEEDHAM D, 1990, BIOPHYS J, V58, P997, DOI 10.1016/S0006-3495(90)82444-9; Olbrich K, 2000, BIOPHYS J, V79, P321, DOI 10.1016/S0006-3495(00)76294-1; Shoemaker SD, 2002, IND ENG CHEM RES, V41, P324, DOI 10.1021/ie010049t; Szostak JW, 2001, NATURE, V409, P387, DOI 10.1038/35053176; WALDE P, 1994, J AM CHEM SOC, V116, P11649, DOI 10.1021/ja00105a004; Watson J.D., 1965, MOL BIOL GENE; Zhang FL, 1996, BIOCHEMISTRY-US, V35, P16055, DOI 10.1021/bi961685b	20	297	311	1	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1474	1476		10.1126/science.1100757	http://dx.doi.org/10.1126/science.1100757			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353806	Green Accepted			2023-01-03	WOS:000223761900052
J	D'Amico, AV; Manola, J; Loffredo, M; Renshaw, AA; DellaCroce, A; Kantoff, PW				D'Amico, AV; Manola, J; Loffredo, M; Renshaw, AA; DellaCroce, A; Kantoff, PW			6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHASE-III TRIAL; DEPRIVATION THERAPY; RADIOTHERAPY; NEOADJUVANT; CARCINOMA; MORTALITY; MEN	Context Survival benefit in the management of high-grade clinically localized prostate cancer has been shown for 70 Gy radiation therapy combined with 3 years of androgen suppression therapy (AST), but long-term AST is associated with many adverse events. Objective To assess the survival benefit of 3-dimensional conformal radiation therapy (3D-CRT) alone or in combination with 6 months of AST in patients with clinically localized prostate cancer. Design, Setting, and Patients A prospective randomized controlled trial of 206 patients with clinically localized prostate cancer who were randomized to receive 70 Gy 3D-CRT alone (n=104) or in combination with 6 months of AST (n=102) from December 1, 1995, to April 15, 2001. Eligible patients included those with a prostate-specific antigen (PSA) of at least 10 ng/mL, a Gleason score of at least 7, or radiographic evidence of extraprostatic disease. Main Outcome Measures Time to PSA failure (PSA >11.0 ng/mL and increasing >0.2 ng/mL on 2 consecutive visits) and overall survival. Results After a median follow-up of 4.52 years, patients randomized to receive 3D-CRT plus AST had a significantly higher survival (P=.04), lower prostate cancer-specific mortality (P=.02), and higher survival free of salvage AST (P=.002). Kaplan-Meier estimates of 5-year survival rates were 88% (95% confidence interval [Cl], 80%-95%) in the 3D-CRT plus AST group vs 78% (95% Cl, 68%-88%) in the 3D-CRT group. Rates of survival free of salvage AST at 5 years were 82% (95% Cl, 73%-90%) in the 3D-CRT plus AST group vs 57% (95% Cl, 46%-69%) in the 3D-CRT group. Conclusion The addition of 6 months of AST to 70 Gy 3D-CRT confers an overall survival benefit for patients with clinically localized prostate cancer.	Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Biostat, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med Oncol, Boston, MA 02215 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute	D'Amico, AV (corresponding author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St,L-2 Level, Boston, MA 02215 USA.	adamico@lroc.harvard.edu		Kantoff, Philip/0000-0001-7275-0597				*AG HLTH CAR POL R, 1999, REL EFF COST EFF MET; Beahrs O. H., 1992, AM JOINT COMMITTEE C; Bolla M, 1997, NEW ENGL J MED, V337, P295, DOI 10.1056/NEJM199707313370502; Bolla M, 2002, LANCET, V360, P103, DOI 10.1016/S0140-6736(02)09408-4; Chen Z, 2002, CANCER-AM CANCER SOC, V95, P2136, DOI 10.1002/cncr.10967; D'Amico AV, 2003, J CLIN ONCOL, V21, P2163, DOI 10.1200/JCO.2003.01.075; D'Amico AV, 2003, J NATL CANCER I, V95, P1376, DOI 10.1093/jnci/djg043; GAYNOR JJ, 1993, J AM STAT ASSOC, V88, P400, DOI 10.2307/2290318; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; Green HJ, 2002, BJU INT, V90, P427, DOI 10.1046/j.1464-410X.2002.02917.x; Hanks GE, 2003, J CLIN ONCOL, V21, P3972, DOI 10.1200/JCO.2003.11.023; Holzbeierlein JM, 2004, ONCOLOGY-NY, V18, P303; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klein JP, 1997, SURVIVAL ANAL TECHNI, P96; MEHTA CR, 1984, BIOMETRICS, V40, P819, DOI 10.2307/2530927; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Pollack A, 2002, INT J RADIAT ONCOL, V53, P1097, DOI 10.1016/S0360-3016(02)02829-8; Roach M, 2003, J CLIN ONCOL, V21, P1904, DOI 10.1200/JCO.2003.05.004; Roden DM, 2004, NEW ENGL J MED, V350, P1013, DOI 10.1056/NEJMra032426; Smith MR, 2002, CANCER METAST REV, V21, P159, DOI 10.1023/A:1020840311573; Trotti A, 2000, INT J RADIAT ONCOL, V47, P13, DOI 10.1016/S0360-3016(99)00559-3	21	630	642	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2004	292	7					821	827		10.1001/jama.292.7.821	http://dx.doi.org/10.1001/jama.292.7.821			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847FO	15315996				2023-01-03	WOS:000223378300022
J	Cooper, TM; Mockett, RJ; Sohal, BH; Sohal, RS; Orr, WC				Cooper, TM; Mockett, RJ; Sohal, BH; Sohal, RS; Orr, WC			Effect of caloric restriction on life span of the housefly, Musca domestica	FASEB JOURNAL			English	Article						aging; metabolic rate; insect nutrition; oxygen; fertility	DIETARY RESTRICTION; EXTENSION; LONGEVITY; GROWTH	Caloric restriction (CR) has been found to extend the life spans of a wide variety of species, transcending phylogenetic boundaries. The objective of this study was to test the generality of this phenomenon, using the male housefly as an insect model in which food intake can be quantified precisely. Sucrose was found to promote a longer life span than diets additionally containing proteins and lipids. Flies were fed sucrose or a more complex diet ad libitum (AL), or in amounts ranging from 50% to 100% of the average amount consumed by young flies. CR shortened rather than prolonged the life span of houseflies, particularly flies fed sucrose only. The rate of oxygen consumption was not affected by caloric restriction or by the exclusion of proteins and lipids from the diet, and the reproductive activity of male flies remained unchanged by sucrose feeding. Thus, it is unlikely that the life-shortening effects of CR can be explained either in terms of an adaptive response in metabolic rate or use of a suboptimal food source. Results of this study contradict the widely held view that CR has a life-extending effect in all species.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA	Southern Methodist University; University of Southern California	Orr, WC (corresponding author), So Methodist Univ, Dept Biol Sci, Dedman Life Sci Bldg,6501 Airline Rd, Dallas, TX 75275 USA.	borr@mail.smu.edu			NIA NIH HHS [R01 AG7657] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007657] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AUSTAD SN, 1989, EXP GERONTOL, V24, P83, DOI 10.1016/0531-5565(89)90037-5; BOURG L, 1991, AGE NUTR, V2, P90; CHIPPINDALE AK, 1993, J EVOLUTION BIOL, V6, P171, DOI 10.1046/j.1420-9101.1993.6020171.x; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; COMFORT A, 1963, GERONTOLOGY, V8, P150, DOI 10.1159/000211216; FANESTIL DD, 1965, J GERONTOL, V20, P462; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Forster MJ, 2003, FASEB J, V17, P690, DOI 10.1096/fj.02-0533fje; Good TP, 2001, J INSECT PHYSIOL, V47, P1467, DOI 10.1016/S0022-1910(01)00138-X; Jiang JC, 2000, FASEB J, V14, P2135; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; MASORO E, 2002, CALORIE RESTRICTION; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Pletcher SD, 2002, CURR BIOL, V12, P712, DOI 10.1016/S0960-9822(02)00808-4; RAGLAND SS, 1973, EXP GERONTOL, V8, P135, DOI 10.1016/0531-5565(73)90003-X; RAGLAND SS, 1984, THESIS SO METHODIST; RUDZINSKA MA, 1952, J GERONTOL, V7, P544; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; WEST L, 1951, HOUSEFLY ITS NATURAL	22	80	83	1	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1591	+		10.1096/fj.03-1464fje	http://dx.doi.org/10.1096/fj.03-1464fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319362				2023-01-03	WOS:000223554900003
J	Schrag, D				Schrag, D			The price tag on progress - Chemotherapy for colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Schrag, D (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.			Schrag, Deborah/0000-0002-4334-5717					0	349	354	0	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	2004	351	4					317	319		10.1056/NEJMp048143	http://dx.doi.org/10.1056/NEJMp048143			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839RC	15269308				2023-01-03	WOS:000222801200002
J	Finfer, S; Bellomo, R; Boyce, N; French, J; Myburgh, J; Norton, R; Norton, R; French, J; Bellomo, R; Finfer, S; Myburgh, J; Doig, M; Hayek, M; O'Donnell, S; Finfer, S; Bell, A; Bellomo, R; Boyce, N; Blythe, D; Cade, J; Chapman, M; Cole, L; Cooper, J; Davies, A; French, C; French, J; Joyce, C; McArthur, C; MacMahon, S; Myburgh, J; Neal, B; Norton, R; Presneill, J; Saul, P; Seppelt, I; Stephens, D; Turner, A; Williams, A; Woolfe, C; Peto, R; Sandercock, P; Sprung, C; Young, D; Lo, SK; Sivarajasingham, S; Francis, L; Woodward, M; Charlton, J; Cooper, J; Davies, A; Harry, C; Higgins, L; Moulden, K; Vallance, S; Chadderton, J; Newby, L; McArthur, C; Bates, S; Bellomo, R; Goldsmith, D; Voss, A; Boyce, N; Blythe, D; Palermo, A; Francis, L; French, J; Hayek, M; Jayne, K; MacMahon, S; Merai, M; Neal, B; Norton, B; Pandey, S; O'Donnell, S; Schmidt, M; Sivarajasingham, S; Woodward, M; Carroll, R; McFadyen, B; Saul, P; Clarke, J; Powell, J; Williams, A; Tai, J; Cole, L; Hynesova, I; Seppelt, I; Weisbrodt, L; Bradley, L; Joyce, C; Kelly, T; Limpus, A; Moore, R; Chapman, M; Creed, S; Kaplan, S; Rivett, J; Stephens, D; Thomas, J; Bell, A; Marsden, K; Turner, A; Boyce, C; Cade, J; Howe, B; Presneill, J; Robertson, M; Doig, G; Finfer, S; O'Connor, A; Potter, J; Ramakrishnan, N; Powell, C; Rajbhandari, D; Woolfe, C; Girling, K; Hodgetts, M; Jovanovska, A; Myburgh, J; French, C; Little, L				Finfer, S; Bellomo, R; Boyce, N; French, J; Myburgh, J; Norton, R; Norton, R; French, J; Bellomo, R; Finfer, S; Myburgh, J; Doig, M; Hayek, M; O'Donnell, S; Finfer, S; Bell, A; Bellomo, R; Boyce, N; Blythe, D; Cade, J; Chapman, M; Cole, L; Cooper, J; Davies, A; French, C; French, J; Joyce, C; McArthur, C; MacMahon, S; Myburgh, J; Neal, B; Norton, R; Presneill, J; Saul, P; Seppelt, I; Stephens, D; Turner, A; Williams, A; Woolfe, C; Peto, R; Sandercock, P; Sprung, C; Young, D; Lo, SK; Sivarajasingham, S; Francis, L; Woodward, M; Charlton, J; Cooper, J; Davies, A; Harry, C; Higgins, L; Moulden, K; Vallance, S; Chadderton, J; Newby, L; McArthur, C; Bates, S; Bellomo, R; Goldsmith, D; Voss, A; Boyce, N; Blythe, D; Palermo, A; Francis, L; French, J; Hayek, M; Jayne, K; MacMahon, S; Merai, M; Neal, B; Norton, B; Pandey, S; O'Donnell, S; Schmidt, M; Sivarajasingham, S; Woodward, M; Carroll, R; McFadyen, B; Saul, P; Clarke, J; Powell, J; Williams, A; Tai, J; Cole, L; Hynesova, I; Seppelt, I; Weisbrodt, L; Bradley, L; Joyce, C; Kelly, T; Limpus, A; Moore, R; Chapman, M; Creed, S; Kaplan, S; Rivett, J; Stephens, D; Thomas, J; Bell, A; Marsden, K; Turner, A; Boyce, C; Cade, J; Howe, B; Presneill, J; Robertson, M; Doig, G; Finfer, S; O'Connor, A; Potter, J; Ramakrishnan, N; Powell, C; Rajbhandari, D; Woolfe, C; Girling, K; Hodgetts, M; Jovanovska, A; Myburgh, J; French, C; Little, L		SAFE Study Investigators	A comparison of albumin and saline for fluid resuscitation in the intensive care unit	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED-TRIALS; CLINICAL-TRIALS; MULTICENTER; DEFINITIONS	BACKGROUND: It remains uncertain whether the choice of resuscitation fluid for patients in intensive care units (ICUs) affects survival. We conducted a multicenter, randomized, double-blind trial to compare the effect of fluid resuscitation with albumin or saline on mortality in a heterogeneous population of patients in the ICU. METHODS: We randomly assigned patients who had been admitted to the ICU to receive either 4 percent albumin or normal saline for intravascular-fluid resuscitation during the next 28 days. The primary outcome measure was death from any cause during the 28-day period after randomization. RESULTS: Of the 6997 patients who underwent randomization, 3497 were assigned to receive albumin and 3500 to receive saline; the two groups had similar baseline characteristics. There were 726 deaths in the albumin group, as compared with 729 deaths in the saline group (relative risk of death, 0.99; 95 percent confidence interval, 0.91 to 1.09; P=0.87). The proportion of patients with new single-organ and multiple-organ failure was similar in the two groups (P=0.85). There were no significant differences between the groups in the mean (+/-SD) numbers of days spent in the ICU (6.5+/-6.6 in the albumin group and 6.2+/-6.2 in the saline group, P=0.44), days spent in the hospital (15.3+/-9.6 and 15.6+/-9.6, respectively; P=0.30), days of mechanical ventilation (4.5+/-6.1 and 4.3+/-5.7, respectively; P=0.74), or days of renal-replacement therapy (0.5+/-2.3 and 0.4+/-2.0, respectively; P=0.41). CONCLUSIONS: In patients in the ICU, use of either 4 percent albumin or normal saline for fluid resuscitation results in similar outcomes at 28 days.	ANZICS CTG, Melbourne, Vic 3053, Australia		Finfer, S (corresponding author), ANZICS CTG, Level 3,10 Levers St, Melbourne, Vic 3053, Australia.	ctg@anzics.com.au	Woodward, Mark/D-8492-2015; French, Craig/ABF-5087-2020; Presneill, Jeffrey J/B-4894-2012; FRENCH, CRAIG/HGA-5299-2022; Woodward, Mark/L-6817-2017; Cooper, D. James/G-7961-2013; ODonnell, Jane/GEX-9181-2022; Goldsmith, David J A/H-6965-2018; Norton, Brian/O-9170-2017; Carroll, Rosemary/W-5427-2018; Joyce, Christopher/B-7437-2013	French, Craig/0000-0003-1363-9711; Presneill, Jeffrey J/0000-0001-7177-7667; Cooper, D. James/0000-0002-5872-9051; ODonnell, Jane/0000-0002-9554-5497; Goldsmith, David J A/0000-0002-4349-9193; Norton, Brian/0000-0001-9123-0845; Carroll, Rosemary/0000-0002-2162-2744; Young, John Duncan/0000-0002-6838-4835; Finfer, Simon/0000-0002-2785-5864; NOIRI, Eisei/0000-0002-9515-7582; MacMahon, Stephen/0000-0003-2064-7699; Stephens, Dianne/0000-0002-3785-6828; Myburgh, John/0000-0003-4088-7016; Bellomo, Rinaldo/0000-0002-1650-8939; Bates, Samantha Jean/0000-0002-8613-1946; Neal, Bruce/0000-0002-0490-7465				*ANZICS CLIN TRIAL, 2004, SAL VS ALB FLUID EV; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Boldt J, 2003, ANESTH ANALG, V97, P1595, DOI 10.1213/01.ANE.0000089961.15975.78; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BUNN F, 2003, COCHRANE DB SYST REV, V1, P1319; Choi PTL, 1999, CRIT CARE MED, V27, P200, DOI 10.1097/00003246-199901000-00053; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; Cook D, 2001, ANN INTERN MED, V135, P205, DOI 10.7326/0003-4819-135-3-200108070-00013; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1999, NEW ENGL J MED, V340, P1056; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; TEASDALE G, 1974, LANCET, V2, P81; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Wilkes MM, 2001, ANN INTERN MED, V135, P149, DOI 10.7326/0003-4819-135-3-200108070-00007; Woodward M, 2014, EPIDEMIOLOGY STUDY D	17	1614	1743	1	66	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	2004	350	22					2247	2256						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823VP	15163774				2023-01-03	WOS:000221641900005
J	Ferner, RE				Ferner, RE			Commentary: Computer aided prescribing leaves holes in the safety net	BRITISH MEDICAL JOURNAL			English	Editorial Material									City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England	University of Birmingham	Ferner, RE (corresponding author), City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England.	r.e.ferner@bham.ac.uk		Ferner, Robin/0000-0003-3769-1346				Anderson JG, 2002, J AM MED INFORM ASSN, V9, P479, DOI 10.1197/jamia.M1099; *AUSTR DEP HLTH AG, 2002, BETT MED MAN SYST DR; Fernando B, 2004, BMJ-BRIT MED J, V328, P1171, DOI 10.1136/bmj.328.7449.1171; Nightingale PG, 2000, BMJ-BRIT MED J, V320, P750, DOI 10.1136/bmj.320.7237.750; Smith J., 2004, BUILDING SAFER NHS P; Weingart SN, 2003, ARCH INTERN MED, V163, P2625, DOI 10.1001/archinte.163.21.2625	6	18	19	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 15	2004	328	7449					1172	1173		10.1136/bmj.328.7449.1172	http://dx.doi.org/10.1136/bmj.328.7449.1172			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142923	Bronze, Green Submitted, Green Published			2023-01-03	WOS:000221497500024
J	Haines, TP; Bennell, KL; Osborne, RH; Hill, KD				Haines, TP; Bennell, KL; Osborne, RH; Hill, KD			Effectiveness of targeted falls prevention programme in subacute hospital setting: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							REHABILITATION; FRAILTY	Objective To assess the effectiveness of a targeted, multiple intervention falls prevention programme in reducing falls and injuries related to falls in a subacute hospital. Design Randomised controlled trial of a targeted multiple intervention programme implemented in addition to usual care compared with usual care alone. Setting Three subacute wards in a metropolitan hospital specialising in rehabilitation and care of elderly patients. Participants 626 men and women aged 38 to 99 years (average 80 years) were recruited from consecutive admissions to subacute hospital wards. Intervention Falls risk alert card with information brochure, exercise programme, education programme, and hip protectors. Main outcome measures Incidence rate of falls, injuries related to falls, and proportion of participants who experienced one or more falls during their stay in hospital. Results Participants in the intervention group (n = 310) experienced 30% fewer falls than participants in the control group (n = 316). This difference was significant (Peto log rank test P = 0.045) and was most obvious after 45 days of observation. In the intervention group there was a trend for a reduction in the proportion of participants who experienced falls (relative risk 0.78, 95% confidence interval 0.56 to 1.06) and 28% fewer falls resulted in injury (log rank test P = 0.20). Conclusions A targeted multiple intervention falls prevention programme reduces the incidence of falls in the subacute hospital setting.	Natl Ageing Res Inst, Parkville, Vic, Australia; Univ Melbourne, Sch Physiotherapy, Parkville, Vic 3052, Australia; Royal Melbourne Hosp, Ctr Rheumat Dis, Parkville, Vic 3050, Australia; Melbourne Extended Care & Rehabil Serv, Parkville, Vic, Australia	National Ageing Research Institute; University of Melbourne; Royal Melbourne Hospital	Hill, KD (corresponding author), Natl Ageing Res Inst, Parkville, Vic, Australia.	k.hill@nari.unimelb.edu.au	Haines, Terrence/E-9372-2015; Hill, Keith D/L-6398-2017; Osborne, Richard H/A-9447-2010; Bennell, Kim/C-7022-2014	Haines, Terrence/0000-0003-3150-6154; Hill, Keith D/0000-0002-2191-0308; Osborne, Richard H/0000-0002-9081-2699; Bennell, Kim/0000-0003-4982-5639				Altman D, 1993, PRACTICAL STAT MED R; Brandis S, 1999, J Qual Clin Pract, V19, P215, DOI 10.1046/j.1440-1762.1999.00337.x; Donald IP, 2000, CLIN REHABIL, V14, P178, DOI 10.1191/026921500677888641; Fleiss J. L., 1981, STAT METHODS RATES P, V2; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Grenier-Sennelier C, 2002, INT J QUAL HEALTH C, V14, P419, DOI 10.1093/intqhc/14.5.419; Liddle J., 1995, CLIN REHABIL, V9, P110, DOI DOI 10.1177/026921559500900204; MAYO NE, 1994, ARCH PHYS MED REHAB, V75, P1302; Mion L C, 1989, Rehabil Nurs, V14, P17; NELSON W, 1972, TECHNOMETRICS, V14, P945, DOI 10.2307/1267144; Oliver D, 2000, J AM GERIATR SOC, V48, P1679, DOI 10.1111/j.1532-5415.2000.tb03883.x; PEPE MS, 1993, J AM STAT ASSOC, V88, P811, DOI 10.2307/2290770; Perell KL, 2001, J GERONTOL A-BIOL, V56, pM761, DOI 10.1093/gerona/56.12.M761; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; RAPPORT LJ, 1993, ARCH PHYS MED REHAB, V74, P621, DOI 10.1016/0003-9993(93)90160-C; TIDEIKSAAR R, 1993, MT SINAI J MED, V60, P522; *VICT DEP HUM SERV, 2002, VICT ADM EP DAT; VLAHOV D, 1990, ARCH PHYS MED REHAB, V71, P8; WOLF SL, 1993, J AM GERIATR SOC, V41, P329, DOI 10.1111/j.1532-5415.1993.tb06713.x; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x	22	196	198	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 20	2004	328	7441					676	+		10.1136/bmj.328.7441.676	http://dx.doi.org/10.1136/bmj.328.7441.676			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VB	15031238	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000220392700018
J	Bassotti, G; Chistolini, F; Sietchiping-Nzepa, F; de Roberto, G; Morelli, A; Chiarioni, G				Bassotti, G; Chistolini, F; Sietchiping-Nzepa, F; de Roberto, G; Morelli, A; Chiarioni, G			Biofeedback for pelvic floor dysfunction in constipation	BMJ-BRITISH MEDICAL JOURNAL			English	Review							VISUAL BIOFEEDBACK; RANDOMIZED-TRIAL; THERAPY; ENCOPRESIS		Univ Perugia, Dept Clin & Expt Med, Gastroenterol & Hepatol Sect, I-06100 Perugia, Italy; Azienda Osped, Valeggio sul Mincio Hosp, Gastrointestinal Rehabil Div, Valeggio Sul Mincio, VR, Italy; Univ Verona, Valeggio Sul Mincio, VR, Italy	University of Perugia; University of Verona	Bassotti, G (corresponding author), Str Cimitero 2-A, I-06131 Perugia, Italy.	gabassot@tin.it	Chiarioni, Giuseppe/C-1876-2016; de Roberto, giuseppe/AAQ-4818-2020	Chiarioni, Giuseppe/0000-0002-9183-4750; 				[Anonymous], 1999, GASTROENTEROLOGY, V116, P732, DOI 10.1016/S0016-5085(99)70195-2; Azpiroz F, 2002, AM J GASTROENTEROL, V97, P232; Bassotti G, 1997, QJM-INT J MED, V90, P545, DOI 10.1093/qjmed/90.8.545; Battaglia E, 2004, DIS COLON RECTUM, V47, P90, DOI 10.1007/s10350-003-0010-0; BLEIJENBERG G, 1994, AM J GASTROENTEROL, V89, P1021; BLEIJENBERG G, 1987, DIS COLON RECTUM, V30, P108, DOI 10.1007/BF02554946; Brazzelli M, 2001, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002240; Chiarioni G, 2002, AM J GASTROENTEROL, V97, P109; CHIARIONI G, IN PRESS DIS COLON R; COX DJ, 1994, BIOFEEDBACK SELF-REG, V19, P41, DOI 10.1007/BF01720669; D'Hoore A, 2003, Colorectal Dis, V5, P280, DOI 10.1046/j.1463-1318.2003.00497.x; DROSSMAN DA, 2000, ROME II FUNCTIONAL G; Gilliland R, 1997, BRIT J SURG, V84, P1123, DOI 10.1046/j.1365-2168.1997.02746.x; Glia A, 1997, DIS COLON RECTUM, V40, P889, DOI 10.1007/BF02051194; Heymen S, 2003, DIS COLON RECTUM, V46, P1208, DOI 10.1007/s10350-004-6717-8; Heymen S, 1999, DIS COLON RECTUM, V42, P1388, DOI 10.1007/BF02235034; KAWIMBE BM, 1991, GUT, V32, P1175, DOI 10.1136/gut.32.10.1175; KOUTSOMANIS D, 1995, GUT, V37, P95, DOI 10.1136/gut.37.1.95; LOENINGBAUCKE V, 1990, J PEDIATR-US, V116, P214, DOI 10.1016/S0022-3476(05)82877-X; Mason HJ, 2002, AM J GASTROENTEROL, V97, P3154; Nolan T, 1998, ARCH DIS CHILD, V79, P131, DOI 10.1136/adc.79.2.131; Rao SSC, 1997, DIGEST DIS SCI, V42, P2197, DOI 10.1023/A:1018846113210; Sunic-Omejc M, 2002, COLLEGIUM ANTROPOL, V26, P93; Thompson WG, 1999, GUT, V45, P43; vanderPlas RN, 1996, LANCET, V348, P776, DOI 10.1016/S0140-6736(96)03206-0; WALD A, 1987, J PEDIATR GASTR NUTR, V6, P554, DOI 10.1097/00005176-198707000-00011; Wang J, 2003, WORLD J GASTROENTERO, V9, P2109, DOI 10.3748/wjg.v9.i9.2109; Whitehead WE, 2000, ROME 2 FUNCTIONAL GA, V2nd, P483; Whitehead WEHS, 2002, SCHUSTER ATLAS GASTR, V2nd, P381	29	49	54	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	2004	328	7436					393	396		10.1136/bmj.328.7436.393	http://dx.doi.org/10.1136/bmj.328.7436.393			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	775GA	14962877	Green Published			2023-01-03	WOS:000189031300027
J	Smith, EJ; Rothman, MT; Timmis, AD				Smith, EJ; Rothman, MT; Timmis, AD			Prolonged hospital stay after acute myocardial infarction: assessing the evidence	LANCET			English	Editorial Material							EARLY DISCHARGE; PRIMARY ANGIOPLASTY; COST-EFFECTIVENESS; MANAGEMENT; REGISTRY; THERAPY		London Chest Hosp, Dept Cardiol, London E2 9JX, England	University of London; Queen Mary University London	Timmis, AD (corresponding author), London Chest Hosp, Dept Cardiol, London E2 9JX, England.	timmis@lch.demon.co.uk						ENWBY LK, 2003, EUR HEART J, V24, P182; Every NR, 1996, J AM COLL CARDIOL, V28, P287, DOI 10.1016/0735-1097(96)00168-4; Grines CL, 1998, J AM COLL CARDIOL, V31, P967, DOI 10.1016/S0735-1097(98)00031-X; Ham C, 2003, BRIT MED J, V327, P1257, DOI 10.1136/bmj.327.7426.1257; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; MARK DB, 1991, CIRCULATION, V83, P1186, DOI 10.1161/01.CIR.83.4.1186; Newby LK, 1996, J AM COLL CARDIOL, V27, P625; Newby LK, 2000, NEW ENGL J MED, V342, P749, DOI 10.1056/NEJM200003163421101; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; Sayer JW, 2000, HEART, V84, P258, DOI 10.1136/heart.84.3.258; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8; Varnava AM, 2002, HEART, V87, P216, DOI 10.1136/heart.87.3.216; Wallentin L, 1999, LANCET, V354, P708	13	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	2004	363	9408					502	503		10.1016/S0140-6736(04)15574-8	http://dx.doi.org/10.1016/S0140-6736(04)15574-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975607				2023-01-03	WOS:000188999900002
J	Holmberg, L; Anderson, H				Holmberg, L; Anderson, H		HABITS Steering Data Monitoring Co	HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped	LANCET			English	Article							WOMEN	In the 1990s, two randomised clinical trials started in Scandinavia addressing whether hormone replacement therapy (HRT) is safe for women with previous breast cancer. We report the findings of the safety analysis in HABITS (hormonal replacement therapy after breast cancer-is it safe?), an open randomised clinical trial with allocation to either HRT or best treatment without hormones. The main endpoint was any new breast cancer event. All analyses were done according to intention-to-treat. Until September, 2003, 434 women were randomised; 345 had at least one follow-up report. After a median follow-up of 2.1 years, 26 women in the HRT group and seven in the non-HRT group had a new breast-cancer event. All women with an event in the HRT group and two of those in the non-HRT group were exposed to HRT and most women had their event when on treatment. We decided that these findings indicated an unacceptable risk for women exposed to HRT in the HABITS trial, and the trial was terminated on Dec 17, 2003.	Univ Hosp, Reg Oncol Ctr, SE-75185 Uppsala, Sweden; Lund Univ, Dept Canc Epidemiol, Lund, Sweden	Uppsala University; Uppsala University Hospital; Lund University	Holmberg, L (corresponding author), Univ Hosp, Reg Oncol Ctr, SE-75185 Uppsala, Sweden.	lars.holmberg@lul.se						Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Col NF, 2001, J CLIN ONCOL, V19, P2357, DOI 10.1200/JCO.2001.19.8.2357; O'Meara ES, 2001, JNCI-J NATL CANCER I, V93, P754, DOI 10.1093/jnci/93.10.754	5	344	356	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	2004	363	9407					453	455		10.1016/S0140-6736(04)15493-7	http://dx.doi.org/10.1016/S0140-6736(04)15493-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962527				2023-01-03	WOS:000188999500013
J	Karande, P; Jain, A; Mitragotri, S				Karande, P; Jain, A; Mitragotri, S			Discovery of transdermal penetration enhancers by high-throughput screening	NATURE BIOTECHNOLOGY			English	Article							PERCUTANEOUS-ABSORPTION; SKIN; PHARMACOKINETICS; SOLUTES; TESTS	Although transdermal drug delivery is more attractive than injection, it has not been applied to macromolecules because of low skin permeability. Here we describe particular mixtures of penetration enhancers that increase skin permeability to macromolecules (-1-10 kDa) by up to similar to100-fold without inducing skin irritation. The discovery of these mixtures was enabled by an experimental tool, in vitro skin impedance guided high-throughput (INSIGHT) screening, which is >100-fold more efficient than current tools. In vitro experiments demonstrated that the mixtures delivered macromolecular drugs, including heparin, leutinizing hormone releasing hormone (LHRH) and oligonulceotides, across the skin. In vivo experiments on hairless rats with leuprolide acetate confirmed the potency and safety of one such mixture, sodium laureth sulfate (SLA) and phenyl piperazine (PP). These studies show the feasibility of using penetration enhancers for systemic delivery of macromolecules from a transdermal patch.	Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Mitragotri, S (corresponding author), Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA.	samir@engineering.ucsb.edu	张, 张鑫月/AAP-1001-2020; Karande, Pankaj/B-5641-2008					Akimoto T, 2003, J CONTROL RELEASE, V88, P243, DOI 10.1016/S0168-3659(03)00006-3; [Anonymous], 2001, INT J TOXICOL, V20, P1; BERARDESCA E, 1990, CONTACT DERMATITIS, V23, P1, DOI 10.1111/j.1600-0536.1990.tb00075.x; BLACK G, 1993, PHARM SKIN PENETRATI, P145; Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x; Fentem JH, 2002, ATLA-ALTERN LAB ANIM, V30, P61, DOI 10.1177/026119290203002S09; Fentem JH, 2001, TOXICOL IN VITRO, V15, P57, DOI 10.1016/S0887-2333(01)00002-9; Finnin BC, 1999, J PHARM SCI-US, V88, P955, DOI 10.1021/js990154g; FRENCH EJ, 1993, PHARM SKIN PENETRATI, P113; Frydman A, 1996, HAEMOSTASIS, V26, P24; Funke AP, 2002, PHARMACEUT RES, V19, P661, DOI 10.1023/A:1015314314796; Guy RH, 2000, J CONTROL RELEASE, V64, P129, DOI 10.1016/S0168-3659(99)00132-7; HALLMANNING J, 1995, ALLERGOLOGIE, V18, P465; Kanikkannan N, 2000, CURR MED CHEM, V7, P593, DOI 10.2174/0929867003374840; Karande P, 2002, PHARMACEUT RES, V19, P655, DOI 10.1023/A:1015362230726; LASHMAR UT, 1989, J PHARM PHARMACOL, V41, P118, DOI 10.1111/j.2042-7158.1989.tb06405.x; Loffler H, 2003, CONTACT DERMATITIS, V48, P26, DOI 10.1034/j.1600-0536.2003.480105.x; Mitragotri S, 2000, PHARMACEUT RES, V17, P1354, DOI 10.1023/A:1007522114438; MITRAGOTRI S, 1995, SCIENCE, V269, P850, DOI 10.1126/science.7638603; Mitragotri S, 2003, J CONTROL RELEASE, V86, P69, DOI 10.1016/S0168-3659(02)00321-8; Mitragotri S, 2000, J CONTROL RELEASE, V63, P41, DOI 10.1016/S0168-3659(99)00178-9; MITRAGOTRI S, 2001, PHARM RES, V18, P1022; PECK KD, 1994, PHARMACEUT RES, V11, P1306, DOI 10.1023/A:1018998529283; Periti P, 2002, CLIN PHARMACOKINET, V41, P485, DOI 10.2165/00003088-200241070-00003; Robinson Michael K, 2002, Am J Contact Dermat, V13, P21, DOI 10.1053/ajcd.2002.30471; RONAUGH RL, 1989, PERCUTANEOUS ABSORPT; Suhonen TM, 1999, J CONTROL RELEASE, V59, P149, DOI 10.1016/S0168-3659(98)00187-4; Takanashi Y, 1999, DRUG DEV IND PHARM, V25, P89, DOI 10.1081/DDC-100102146; Tang H, 2001, J PHARM SCI, V90, P545, DOI 10.1002/1520-6017(200105)90:5<545::AID-JPS1012>3.0.CO;2-H; Tezel A, 2003, J PHARM SCI-US, V92, P381, DOI 10.1002/jps.10299; Wertz PW, 1989, TRANSDERMAL DRUG DEL, V35th, P1; WILLIAMS AC, 1992, CRIT REV THER DRUG, V9, P305; ZAFFARONI A, 1991, ANN NY ACAD SCI, V618, P405, DOI 10.1111/j.1749-6632.1991.tb27260.x	33	206	229	2	71	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2004	22	2					192	197		10.1038/nbt928	http://dx.doi.org/10.1038/nbt928			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	770KT	14704682				2023-01-03	WOS:000188730500018
J	Hersh, AL; Stefanick, ML; Stafford, RS				Hersh, AL; Stefanick, ML; Stafford, RS			National use of postmenopausal hormone therapy - Annual trends and response to recent evidence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN PLUS PROGESTIN; RANDOMIZED CONTROLLED-TRIAL; CALCIUM-CHANNEL BLOCKERS; HEALTH INITIATIVE MEMORY; CORONARY-HEART-DISEASE; REPLACEMENT THERAPY; CARDIOVASCULAR-DISEASE; UNITED-STATES; NONCONTRACEPTIVE ESTROGENS; PRIMARY PREVENTION	Context Postmenopausal hormone therapy use increased dramatically during the past 2 decades because of a prevailing belief in its health benefits. Recent evidence from randomized trials published in July 2002 demonstrated adverse cardiovascular disease events and other risks with hormone therapy in the form of oral estrogen combined with progestin. Objective To describe patterns of hormone therapy use from 1995 until July 2003, including the impact of recent evidence. Design, Setting, and Population Two databases were used to describe national trends in hormone therapy use from January 1995 to July 2003. The National Prescription Audit database provided data on the number of hormone therapy prescriptions filled by retail pharmacies and the National Disease and Therapeutic Index database provided data on patient visits to office-based physicians during which hormone therapy was prescribed. Main Outcome Measures Annual number of hormone therapy prescriptions and characteristics of visits to physicians during which hormone therapy was prescribed. Results Annual hormone therapy prescriptions increased from 58 million in 1995 to 90 million in 1999, representing approximately 15 million women per year, then remained stable through June 2002. Adoption of new oral estrogen/progestin combinations, primarily Prempro, accounted for most of this growth. Obstetrician/gynecologists provided more than 70% of hormone therapy prescriptions, and more than one third of patients were older than 60 years. Following the publication of trial results in July 2002, hormone therapy prescriptions declined in successive months. Relative to January-June 2002, prescriptions from January-June 2003 declined by 66% for Prempro and 33% for Premarin. Small increases were observed in vaginal formulations and in new prescriptions for low-dose Premarin. If prescription rates observed through July 2003 remain stable, a decline to 57 million prescriptions for 2003, similar to the rate in 1995, is projected. Conclusions Clinical practice responded rapidly to recent evidence of harms associated with hormone therapy. Since July 2002, many patients have discontinued hormone therapy or are tapering to lower doses.	Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Program Prevent Outcomes & Practices, Stanford, CA 94305 USA	Stanford University	Stafford, RS (corresponding author), Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Program Prevent Outcomes & Practices, Stanford, CA 94305 USA.		Stafford, Randall/F-3974-2017	Stafford, Randall/0000-0003-1805-1271	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS013405] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007034] Funding Source: NIH RePORTER; AHRQ HHS [R01-HS013405] Funding Source: Medline; NHLBI NIH HHS [5T32-HL07034] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ascott-Evans BH, 2003, ARCH INTERN MED, V163, P789, DOI 10.1001/archinte.163.7.789; Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; Berg AO, 2002, ANN INTERN MED, V137, P834, DOI 10.7326/0003-4819-137-10-200211190-00013; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Erblich J, 2000, PREV MED, V31, P714, DOI 10.1006/pmed.2000.0765; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; HEMMINKI E, 1988, AM J PUBLIC HEALTH, V78, P1478, DOI 10.2105/AJPH.78.11.1479; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; KENNEDY DL, 1985, OBSTET GYNECOL, V65, P441; Maclure M, 1998, LANCET, V352, P943, DOI 10.1016/S0140-6736(97)11390-3; Majumdar SR, 2001, J GEN INTERN MED, V16, P351, DOI 10.1046/j.1525-1497.2001.016006351.x; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Mosca L, 2001, CIRCULATION, V104, P499, DOI 10.1161/hc2901.092200; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P882, DOI 10.1001/jama.288.7.882; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Solomon CG, 2003, NEW ENGL J MED, V348, P579, DOI 10.1056/NEJMp030006; STAFFORD RS, IN PRESS ARCH INTERN; *US CENS BUR, RES POP EST US AG SE; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; *WHI, HRT UPD 2001; Whitlock EP, 1998, J WOMENS HEALTH, V7, P1017, DOI 10.1089/jwh.1998.7.1017; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F	31	728	738	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2004	291	1					47	53		10.1001/jama.291.1.47	http://dx.doi.org/10.1001/jama.291.1.47			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760LX	14709575				2023-01-03	WOS:000187836000018
J	Weeks, AD; Alia, G; Ononge, S; Mutungi, A; Otolorin, EO; Mirembe, FM				Weeks, AD; Alia, G; Ononge, S; Mutungi, A; Otolorin, EO; Mirembe, FM			Introducing criteria based audit into Ugandan maternity units	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Problem Maternal mortality in Uganda has remained unchanged at 500/100 000 over the past 10 years despite concerted efforts to improve the standard of maternity care. It is especially difficult to improve standards in rural areas, where there is little money for improvements. Furthermore, staff may be isolated, poorly paid, disempowered, lacking in morale, and have few skills to bring about change. Design Training programme to introduce criteria based audit into rural Uganda. Setting Makerere University Medical School, Mulago Hospital (large government teaching hospital in Kampala), and Mpigi District (rural area with 10 small health centres around a district hospital). Strategies for change Didactic teaching about criteria based audit followed by practical work in own units, with ongoing support and follow up workshops. Effects of change Improvements were seen in many standards of care. Staff showed universal enthusiasm for the training; many staff produced simple, cost-free improvements in their standard of care. Lessons learnt Teaching of criteria based audit to those providing health care in developing countries can produce low cost improvements in the standards of care. Because the method is simple and can be used to provide improvements even without new funding, it has the potential to produce sustainable and cost effective changes in the standard of health care. Follow up is needed to prevent a waning of enthusiasm with time.	Makerere Univ, Dept Obstet & Gynaecol, Kampala, Uganda; Makerere Univ, Reg Ctr Qual Hlth Care, Kampala, Uganda	Makerere University; Makerere University	Weeks, AD (corresponding author), Liverpool Womens Hosp, Dept Obstet & Gynaecol, Liverpool L8 7SS, Merseyside, England.	aweeks@liverpool.ac.uk	Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Weeks, Andrew/0000-0002-1909-337X; OTOLORIN, EMMANUEL/0000-0001-7474-0683				Graham W, 2000, B WORLD HEALTH ORGAN, V78, P614; Jahn A, 2001, STUD HLTH SERV ORGAN, V17, P229; LANDE RE, 2002, POPULATION REPORTS J, V52; *MAK I SOC RES, 2001, HUM RES DEM ASS PERS; Mathai M, 2000, MANAGING COMPLICATIO; Miller E, 1998, BRIT MED J, V316, P875, DOI 10.1136/bmj.316.7135.875; *MIN HLTH, 2001, ESS MAT NEON CAR CLI; MORREL C, 1999, CLIN AUDIT HDB; National Institute for Clinical Excellence, 2002, PRINC BEST PRACT CLI; *PRIME 2 PROJ, PERF IMPR STAG STEPS; Uganda Bureau of Statistics and ORC Macro, 2001, UG DEM HLTH SURV 200	11	16	16	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 6	2003	327	7427					1329	1331		10.1136/bmj.327.7427.1329	http://dx.doi.org/10.1136/bmj.327.7427.1329			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	752DE	14656844	Green Submitted, Green Published			2023-01-03	WOS:000187131100022
J	Olsen, OE; Myklebust, G; Engebretsen, L; Holme, I; Bahr, R				Olsen, OE; Myklebust, G; Engebretsen, L; Holme, I; Bahr, R			Exercises to prevent lower limb injuries in youth sports: cluster randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							CRUCIATE LIGAMENT INJURIES; TEAM HANDBALL; PROSPECTIVE INTERVENTION; PHYSICAL-ACTIVITY; SOCCER INJURIES; KNEE INJURY; PLAYERS; PATTERNS; SEASONS; HEALTH	Objective To investigate the effect of a structured warm-up programme designed to reduce the incidence of knee and ankle injuries in young people participating in sports. Design Cluster randomised controlled trial with clubs as the unit of randomisation. Setting 120 team handball clubs from central and eastern Norway (61 clubs in the intervention group, 59 in the control group) followed for one league season (eight months). Participants 1837 players aged 15-17 years; 958 players (808 female and 150 male) in the intervention group; 879 players (778 female and 101 male) in the control group. Intervention A structured warm-up programme to improve running, cutting, and landing technique as well as neuromuscular control, balance, and strength. Main outcome measure The rate of acute injuries to the knee or ankle. Results During the season, 129 acute knee or ankle injuries occurred, 81 injuries in the control group (0.9 (SE 0.09) injuries per 1000 player hours; 0.3 (SE 0.17) in training v 5.3 (SE 0.06) during matches) and 48 injuries in the intervention group (0.5 (SE 0.11) injuries per 1000 player hours; 0.2 (SE 0.18) in training v 2.5 (SE 0.06) during matches). Fewer injured players were in the intervention group than in the control group (46 (4.8%) v (76 (8.6%); relative risk intervention group v control group 0.53, 95% confidence interval 0.35 to 0.81). Conclusion A structured programme of warm-up exercises can prevent knee and ankle injuries in young people playing sports. Preventive training should therefore be introduced as an integral part of youth sports programmes.	Norwegian Univ Sport & Phys Educ, Oslo Sports Trauma Res Ctr, N-0806 Oslo, Norway	Norwegian School of Sport Sciences	Olsen, OE (corresponding author), Norwegian Univ Sport & Phys Educ, Oslo Sports Trauma Res Ctr, N-0806 Oslo, Norway.	odd-egil.olsen@nih.no	Bahr, Roald/B-6964-2014	Bahr, Roald/0000-0001-5725-4237				ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; Bahr R, 1997, SCAND J MED SCI SPOR, V7, P172, DOI 10.1111/j.1600-0838.1997.tb00135.x; Bahr R, 2003, TXB SPORTS MED BASIC, P299, DOI 10.1002/9780470757277.ch1; Caraffa A, 1996, Knee Surg Sports Traumatol Arthrosc, V4, P19, DOI 10.1007/BF01565992; Chappell JD, 2002, AM J SPORT MED, V30, P261, DOI 10.1177/03635465020300021901; Ebstrup JF, 2000, SCAND J MED SCI SPOR, V10, P114, DOI 10.1034/j.1600-0838.2000.010002114.x; Fagenbaum R, 2003, AM J SPORT MED, V31, P233, DOI 10.1177/03635465030310021301; Fletcher GF, 1996, CIRCULATION, V94, P857, DOI 10.1161/01.CIR.94.4.857; Heidt RS, 2000, AM J SPORT MED, V28, P659, DOI 10.1177/03635465000280050601; Hewett TE, 1999, AM J SPORT MED, V27, P699, DOI 10.1177/03635465990270060301; Hewett TE, 1996, AM J SPORT MED, V24, P765, DOI 10.1177/036354659602400611; Holm I, 2004, CLIN J SPORT MED, V14, P88, DOI 10.1097/00042752-200403000-00006; Junge A, 2002, AM J SPORT MED, V30, P652, DOI 10.1177/03635465020300050401; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Mjolsnes R, 2004, SCAND J MED SCI SPOR, V14, P311, DOI 10.1046/j.1600-0838.2003.367.x; Myklebust G, 2003, CLIN J SPORT MED, V13, P71, DOI 10.1097/00042752-200303000-00002; Myklebust G, 1997, SCAND J MED SCI SPOR, V7, P289, DOI 10.1111/j.1600-0838.1997.tb00155.x; MYKLEBUST G, IN PRESS BR J SPORTS; NIELSEN AB, 1988, INT J SPORTS MED, V9, P341, DOI 10.1055/s-2007-1025037; Olsen OE, 2004, AM J SPORT MED, V32, P1002, DOI 10.1177/0363546503261724; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; Wedderkopp N, 1999, SCAND J MED SCI SPOR, V9, P41	23	426	434	1	108	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 26	2005	330	7489					449	452		10.1136/bmj.38330.632801.8F	http://dx.doi.org/10.1136/bmj.38330.632801.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	901XK	15699058	Green Published, Bronze			2023-01-03	WOS:000227315400017
J	Guarente, L; Picard, F				Guarente, L; Picard, F			Calorie restriction - the SIR2 connection	CELL			English	Review							SILENCING PROTEIN SIR2; CEREVISIAE LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; DIETARY-RESTRICTION; METABOLIC-RATE; CELL-SURVIVAL; NEURODEGENERATIVE DISORDERS; CAENORHABDITIS-ELEGANS; TRANSCRIPTION FACTORS; MOLECULAR MECHANISMS	A nutritious diet low in calories improves the health and extends the life span of rodents. Recent studies identified a gene, SIR2, which encodes an NAD-dependent deacetylase and may mediate the effects of calorie restriction. In this review, we discuss SIR2 genes and calorie restriction in the lower organisms yeast and Drosophila. We then describe the physiological changes in mammals during calorie restriction and how they may lead to the observed health benefits. We summarize the roles of mammalian Sirt1 in mediating these changes in tissues and endocrine systems and propose that Sirt1 regulates calorie restriction by sensing low calories and triggering physiological changes linked to health and longevity.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	leng@mit.edu						Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; Barzilai N, 2001, J NUTR, V131, p903S, DOI 10.1093/jn/131.3.903S; Berrigan D, 2002, CARCINOGENESIS, V23, P817, DOI 10.1093/carcin/23.5.817; BERTRAND HA, 1980, J GERONTOL, V35, P827, DOI 10.1093/geronj/35.6.827; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Chin CH, 2004, GENE DEV, V18, P1970, DOI 10.1101/gad.1213104; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Combs TP, 2003, DIABETES, V52, P268, DOI 10.2337/diabetes.52.2.268; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Guarente L, 2000, GENE DEV, V14, P1021; HARMAN D, 1956, J NUTR, V114, P411; HARRISON DE, 1989, GROWTH DEVELOP AGING, V53, P3; HOLLIDAY R, 1989, BIOESSAYS, V10, P125, DOI 10.1002/bies.950100408; Houthoofd K, 2002, EXP GERONTOL, V37, P1359, DOI 10.1016/S0531-5565(02)00172-9; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Hulbert AJ, 2004, EXP GERONTOL, V39, P1137, DOI 10.1016/j.exger.2004.04.006; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kaeberlein M, 2002, GENETICS, V160, P83; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lane MA, 1999, TOXICOL SCI, V52, P41, DOI 10.1093/toxsci/52.suppl_1.41; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lee CH, 2002, TRENDS ENDOCRIN MET, V13, P331, DOI 10.1016/S1043-2760(02)00668-9; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; MARGOLSKEE JP, 1988, MOL GEN GENET, V211, P430, DOI 10.1007/BF00425696; MASARO EJ, 1984, PHYSIOLOGIST, V27, P98; MASORO EJ, 1982, P NATL ACAD SCI-BIOL, V79, P4239, DOI 10.1073/pnas.79.13.4239; Mattson MP, 2003, ANN INTERN MED, V139, P441, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00012; Mattson MP, 2001, MECH AGEING DEV, V122, P757, DOI 10.1016/S0047-6374(01)00226-3; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; MCCARTER R, 1985, AM J PHYSIOL, V248, pE488; MCCARTER RJ, 1992, AM J PHYSIOL, V263, pE448, DOI 10.1152/ajpendo.1992.263.3.E448; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Merry BJ, 2002, INT J BIOCHEM CELL B, V34, P1340, DOI 10.1016/S1357-2725(02)00038-9; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Pajvani Utpal B, 2003, Curr Diab Rep, V3, P207, DOI 10.1007/s11892-003-0065-2; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; RICHARDSON A, 1985, HDB NUTRITION AGED, P31; RINE J, 1987, GENETICS, V116, P9; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Rogina B, 2002, SCIENCE, V298, P1745, DOI 10.1126/science.1078986; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Speakman JR, 2004, AGING CELL, V3, P87, DOI 10.1111/j.1474-9728.2004.00097.x; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, pE38, DOI 10.1152/ajpendo.00387.2001; Stern JS, 2001, J NUTR, V131, p913S, DOI 10.1093/jn/131.3.913S; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Weindruch R., 1988, RETARDATION AGING DI; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Xiao H, 2004, EXP BIOL MED, V229, P479, DOI 10.1177/153537020422900605; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	76	639	670	1	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	2005	120	4					473	482		10.1016/j.cell.2005.01.029	http://dx.doi.org/10.1016/j.cell.2005.01.029			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	901GR	15734680	Bronze			2023-01-03	WOS:000227271500005
J	Jensen, LS; Puho, E; Pedersen, L; Mortensen, FV; Sorensen, HT				Jensen, LS; Puho, E; Pedersen, L; Mortensen, FV; Sorensen, HT			Long-term survival after colorectal surgery associated with buffy-coat-poor and leucocyte-depleted blood transfusion: a follow-up study	LANCET			English	Article							CANCER	A Danish clinical trial showed that transfusion with leucocyte-depleted red blood cells reduces postoperative infectious complications compared with cells without buffy-coat. However, the effect on long-term outcome is unknown. We followed up the 142 cancer patients transfused with buffy-coat-poor red cells, the 118 transfused with leucocyte-depleted blood, and the 329 who were not transfused, until 2003. After 7 years' follow-up, survival for those with leucocyte-depleted blood transfusion (46 [41%]) was not significantly different from transfusion of blood without buffy-coat (59 [45%], p=0.51). Although survival is reduced by blood transfusion, it does not differ between the two transfusion regimens.	Aarhus Univ Hosp, Dept Gastrointestinal Surg L, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Jensen, LS (corresponding author), Aarhus Univ Hosp, Dept Gastrointestinal Surg L, Noerrebrogade 44, DK-8000 Aarhus C, Denmark.	lonej@dadlnet.dk	Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Mortensen, Frank Viborg/0000-0001-7580-8037				GANTT CL, 1981, LANCET, V2, P363; HOUBIERS JGA, 1994, LANCET, V344, P573, DOI 10.1016/S0140-6736(94)91965-8; Jensen LS, 1996, LANCET, V348, P841, DOI 10.1016/S0140-6736(96)06168-5; van de Watering LMG, 2001, BRIT J SURG, V88, P267, DOI 10.1046/j.1365-2168.2001.01674.x	4	37	37	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					681	682						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721474				2023-01-03	WOS:000227096800026
J	Bath, PMW; Gray, LJ				Bath, PMW; Gray, LJ			Association between hormone replacement therapy and subsequent stroke: a meta-analysis	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED-TRIALS; WOMEN; RISK; ESTROGEN; DISEASE	Objectives To review completed trials assessing effect of hormone replacement therapy on subsequent risk of stroke, assessing stroke by pathological type, severity, and outcome. Design Systematic review of randomised controlled trials identified from the Cochrane Library, Embase, and Medline; reviews; and reference lists of relevant papers. Studies reviewed 28 trials, with 39 769 subjects, were identified. Review measures Rates for cerebrovascular events analysed with a random effects model. Sensitivity analyses for heterogeneity included phase of prevention (primary or secondary), type of hormone replacement therapy (oestrogen alone or combined with progesterone), type of oestrogen (estradiol or conjugated equine oestrogen), size of trial (< 5000 or > 5000 patients), length of follow up (less than or equal to3 years or > 3 years), sex (women only or men only), and trial quality (high or low). Results Hormone replacement therapy was associated with significant increases in total stroke (odds ratio 1.29 (95% confidence interval 1.13 to 1.47), n = 28), non-fatal stroke (1.23 (1.06 to 1.44), n = 21), stroke leading to death or disability (1.56 (1.11 to 2.20), n = 14), ischaemic stroke (1.29 (1.06 to 1.56), n = 16), and a trend to more fatal stroke (1.28 (0.87 to 1.88), n =, 22). It was not associated with haemorrhagic stroke (1.07 (0.65 to 1.75), n = 17) or transient ischaemic attack (1.02 (0.78 to 1.34), n = 22). Statistical heterogeneity was not present in any analysis. Conclusions Hormone replacement therapy was associated with an increased risk of stroke, particularly of ischaemic type. Among subjects who had a stroke, those taking hormone replacement therapy seemed to have a worse outcome. Hormone replacement therapy can-not be recommended for the primary or secondary prevention of stroke.	Univ Nottingham, Queens Med Ctr, Inst Neurosci, Div Stroke Med, Nottingham NG7 2UH, England	University of Nottingham	Bath, PMW (corresponding author), Univ Nottingham, Queens Med Ctr, Inst Neurosci, Div Stroke Med, Nottingham NG7 2UH, England.	philip.bath@nottingham.ac.uk	; Bath, Philip/F-9020-2011	Gray, Laura/0000-0002-9284-9321; Bath, Philip/0000-0003-2734-5132				Badimon L, 1999, HUM REPROD UPDATE, V5, P191, DOI 10.1093/humupd/5.3.191; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Collins P, 2002, AM J CARDIOL, V90, p30F, DOI 10.1016/S0002-9149(01)02220-2; Collins R, 2002, LANCET, V360, P1618, DOI 10.1016/S0140-6736(02)11650-3; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Glazier MG, 2001, ARCH INTERN MED, V161, P1161, DOI 10.1001/archinte.161.9.1161; Kannel WB, 1994, HEART, P185; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Paganini-Hill A, 2001, MATURITAS, V38, P243, DOI 10.1016/S0378-5122(01)00167-0; Salpeter SR, 2004, J GEN INTERN MED, V19, P791, DOI 10.1111/j.1525-1497.2004.30281.x; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; Wren BG, 1998, DRUG AGING, V12, P343, DOI 10.2165/00002512-199812050-00001; Zec RF, 2002, CLIMACTERIC, V5, P122, DOI 10.1080/713605231	15	129	131	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 12	2005	330	7487					342	344A		10.1136/bmj.38331.655347.8F	http://dx.doi.org/10.1136/bmj.38331.655347.8F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897OZ	15640250	Green Published, Bronze, Green Accepted, Green Submitted			2023-01-03	WOS:000227015800020
J	Wik, L; Kramer-Johansen, J; Myklebust, H; Sorebo, H; Svensson, L; Fellows, B; Steen, PA				Wik, L; Kramer-Johansen, J; Myklebust, H; Sorebo, H; Svensson, L; Fellows, B; Steen, PA			Quality of cardiopulmonary resuscitation during out-of-hospital cardiac arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AUTOMATED EXTERNAL DEFIBRILLATOR; CORONARY BLOOD-FLOW; BASIC LIFE-SUPPORT; VENTRICULAR-FIBRILLATION; CPR PERFORMANCE; COMPRESSION; RETENTION; SKILLS; GUIDELINES; SURVIVAL	Context Cardiopulmonary resuscitation (CPR) guidelines recommend target values for compressions, ventilations, and CPR-free intervals allowed for rhythm analysis and defibrillation. There is little information on adherence to these guidelines during advanced cardiac life support in the field. Objective To measure the quality of out-of-hospital CPR performed by ambulance personnel, as measured by adherence to CPR guidelines. Design and Setting Case series of 176 adult patients with out-of-hospital cardiac arrest treated by paramedics and nurse anesthetists in Stockholm Sweden, London, England, and Akershus, Norway, between March 2002 and October 2003. The defibrillators recorded chest compressions via a sternal pad fitted with an accelerometer and ventilations by changes in thoracic impedance between the defibrillator pads, in addition to standard event and electrocardiographic recordings. Main Outcome Measure Adherence to international guidelines for CPR. Results Chest compressions were not given 48% (95% CI, 45%-51%) of the time without spontaneous circulation; this percentage was 38% (95% CI, 36%-41%) when subtracting the time necessary for electrocardiographic analysis and defibrillation. Combining these data with a mean compression rate of 121/min (95% CI, 118-124/min) when compressions were given resulted in a mean compression rate of 64/min (95% CI, 61-67/min). Mean compression depth was 34 mm (95% CI, 33-35 mm), 28% (95% CI, 24%-32%) of the compressions had a depth of 38 mm to 51 mm (guidelines recommendation), and the compression part of the duty cycle was 42% (95% CI, 41%-42%). A mean of 11 (95% Cl, 11-12) ventilations were given per minute. Sixty-one patients (35%) had return of spontaneous circulation, and 5 of 6 patients discharged alive from the hospital had normal neurological outcomes. Conclusions In this study of CPR during out-of-hospital cardiac arrest, chest compressions were not delivered half of the time, and most compressions were too shallow. Electrocardiographic analysis and defibrillation accounted for only small parts of intervals without chest compressions.	Ullevaal Univ Hosp, Expt Med Res Inst, N-0407 Oslo, Norway; Ullevaal Univ Hosp, Natl Competence Ctr Emergency Med, N-0407 Oslo, Norway; Ullevaal Univ Hosp, Div Prehosp Emergency Med, N-0407 Oslo, Norway; Ullevaal Univ Hosp, Div Surg, N-0407 Oslo, Norway; Norwegian Air Ambulance, Dept Res & Educ Acute Med, Drobak, Norway; Laerdal Med Corp, Stavanger, Norway; Soder Sjukhuset, S-10064 Stockholm, Sweden; London Ambulance Serv NHS Trust, London, England	University of Oslo; University of Oslo; University of Oslo; University of Oslo; Sodersjukhuset Hospital	Wik, L (corresponding author), Ullevaal Univ Hosp, Expt Med Res Inst, N-0407 Oslo, Norway.		Kramer-Johansen, Jo/P-5132-2018	Kramer-Johansen, Jo/0000-0002-7881-1757				Aase SO, 2002, IEEE T BIO-MED ENG, V49, P263, DOI 10.1109/10.983461; ANDERSEN HS, 2003, THESIS STAVANGER U S; [Anonymous], 2000, GUID 2000 CARD RES E; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; BELLAMY RF, 1984, CIRCULATION, V69, P174, DOI 10.1161/01.CIR.69.1.174; Berg RA, 2001, CIRCULATION, V104, P2465, DOI 10.1161/hc4501.098926; Broomfield R, 1996, J ADV NURS, V23, P1016; Chamberlain DA, 2003, RESUSCITATION, V59, P11, DOI 10.1016/j.resuscitation.2003.08.011; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Donnelly P, 2000, RESUSCITATION, V45, P195, DOI 10.1016/S0300-9572(00)00186-6; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; GEDDES LA, 1989, PRINCIPLES APPL BIO; Handley AJ, 2003, RESUSCITATION, V57, P57, DOI 10.1016/S0300-9572(02)00400-8; KAYE W, 1986, CRIT CARE MED, V14, P620, DOI 10.1097/00003246-198607000-00007; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; Liberman M, 1999, RESUSCITATION, V42, P47, DOI 10.1016/S0300-9572(99)00082-9; MAIER GW, 1986, CIRCULATION, V74, P51; Marn-Pernat A, 2001, CRIT CARE MED, V29, P2360, DOI 10.1097/00003246-200112000-00019; MOSER DK, 1992, HEART LUNG, V21, P372; ORNATO JP, 1989, ANN EMERG MED, V18, P732, DOI 10.1016/S0196-0644(89)80005-8; Pellis T, 2002, CRIT CARE MED, V30, pS176, DOI 10.1097/00003246-200204001-00012; Standards for cardiopulmonary resuscitation (CPR) and emergency cardiac care (ECC), 1974, JAMA-J AM MED ASSOC, V227, P864; Sunde K, 1998, RESUSCITATION, V39, P197, DOI 10.1016/S0300-9572(98)00139-7; Sunde K, 1997, RESUSCITATION, V34, P235, DOI 10.1016/S0300-9572(96)01087-8; van Alem AP, 2003, ANN EMERG MED, V42, P449, DOI 10.1067/S0196-0644(03)00383-4; VANHOEYWEGHEN RJ, 1993, RESUSCITATION, V26, P47, DOI 10.1016/0300-9572(93)90162-J; WIK L, 1994, RESUSCITATION, V28, P195, DOI 10.1016/0300-9572(94)90064-7; Wik L, 2003, JAMA-J AM MED ASSOC, V289, P1389, DOI 10.1001/jama.289.11.1389; Wik L, 2001, RESUSCITATION, V50, P167, DOI 10.1016/S0300-9572(01)00331-8; WOLFE JA, 1988, J THORAC CARDIOV SUR, V95, P523; World Medical Association, 1964, DECL HELS; Yu T, 2002, CIRCULATION, V106, P368, DOI 10.1161/01.CIR.0000021429.22005.2E; 2000, RESUSCITATION, V46, P1	33	957	1020	1	41	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2005	293	3					299	304		10.1001/jama.293.3.299	http://dx.doi.org/10.1001/jama.293.3.299			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888FA	15657322	Bronze, Green Published			2023-01-03	WOS:000226358400023
J	Hartmann, LC				Hartmann, LC			The octogenarian's plan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2005	293	1					15	16		10.1001/jama.293.1.15	http://dx.doi.org/10.1001/jama.293.1.15			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QY	15632320				2023-01-03	WOS:000226102100001
J	Martin, MD				Martin, MD			Shower time	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Martin, MD (corresponding author), 2901 Montopolis Dr, Austin, TX 78741 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	2004	141	8					647	647		10.7326/0003-4819-141-8-200410190-00017	http://dx.doi.org/10.7326/0003-4819-141-8-200410190-00017			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864SD	15492347				2023-01-03	WOS:000224652300011
J	Fowlie, PW; Booth, P; Skeoch, CH				Fowlie, PW; Booth, P; Skeoch, CH			ABC of preterm birth - Moving the preterm infant	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LONG-TERM METHYLPHENIDATE; CHILDREN; ADHD		Perth Royal Infirm, Perth, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Aberdeen Matern Hosp, Aberdeen, Scotland; Princess Royal Matern Hosp, Glasgow, Lanark, Scotland	University of Dundee; University of Aberdeen	Fowlie, PW (corresponding author), Perth Royal Infirm, Perth, Scotland.							Abikoff H, 2004, J AM ACAD CHILD PSY, V43, P802, DOI 10.1097/01.chi.0000128791.10014.ac; BARRY P, 2003, PAEDIAT NEONATAL CRI; *BRIT ASS PER MED, 1996, STAND HOSP PROV NEON; Davis PJ, 2001, ACTA PAEDIATR, V90, P1068; Hechtman L, 2004, J AM ACAD CHILD PSY, V43, P812, DOI 10.1097/01.chi.0000128796.84202.eb; Jensen PS, 1999, J AM ACAD CHILD PSY, V38, P797, DOI 10.1097/00004583-199907000-00008; Leslie AJ, 1997, ACTA PAEDIATR, V86, P1253, DOI 10.1111/j.1651-2227.1997.tb14856.x; *MED DEV AG, 1995, REP TLNA COMM; PHILP AV, 2002, MENTAL HLTH SCOTLAND, P55; RHODES SM, 2004, PSYCHOPHARMACOL 0508; Shlossman PA, 1997, AM J PERINAT, V14, P449, DOI 10.1055/s-2007-994178; TANNOCK R, 1995, J ABNORM CHILD PSYCH, V23, P235, DOI 10.1007/BF01447091; Wolraich ML, 2003, J CHILD PSYCHOL PSYC, V44, P159, DOI 10.1111/1469-7610.00110	13	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	2004	329	7471					904	906A		10.1136/bmj.329.7471.904	http://dx.doi.org/10.1136/bmj.329.7471.904			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863MU	15485974	Green Published			2023-01-03	WOS:000224566800026
J	Esposito, K; Marfella, R; Ciotola, M; Di Palo, C; Giugliano, F; Giugliano, G; D'Armiento, M; D'Andrea, F; Giugliano, D				Esposito, K; Marfella, R; Ciotola, M; Di Palo, C; Giugliano, F; Giugliano, G; D'Armiento, M; D'Andrea, F; Giugliano, D			Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; INSULIN-RESISTANCE; HEALTHY-SUBJECTS; OBESE WOMEN; RISK; NUTRITION; FAT; INTERLEUKIN-18; ASSOCIATIONS; PREVALENCE	Context The metabolic syndrome has been identified as a target for dietary therapies to reduce risk of cardiovascular disease; however, the role of diet in the etiology of the metabolic syndrome is poorly understood. Objective To assess the effect of a Mediterranean-style diet on endothelial function and vascular inflammatory markers in patients with the metabolic syndrome. Design, Setting, and Patients Randomized, single-blind trial conducted from June 2001 to January 2004 at a university hospital in Italy among 180 patients (99 men and 81 women) with the metabolic syndrome, as defined by the Adult Treatment Panel III. Interventions Patients in the intervention group (n=90) were instructed to follow a Mediterranean-style diet and received detailed advice about how to increase daily consumption of whole grains, fruits, vegetables, nuts, and olive oil; patients in the control group (n=90) followed a prudent diet (carbohydrates, 50%-60%; proteins, 15%-20%; total fat, <30%). Main Outcome Measures Nutrient intake; endothelial function score as a measure of blood pressure and platelet aggregation response to L-arginine; lipid and glucose parameters; insulin sensitivity; and circulating levels of high-sensitivity C-reactive protein (hs-CRP) and interleukinsr 6 (IL-6), 7 (IL-7), and 18 (IL-18). Results After 2 years, patients following the Mediterranean-style diet consumed more foods rich in monounsaturated fat, polyunsaturated fat, and fiber and had a lower ratio of omega-6 to omega-3 fatty acids. Total fruit, vegetable, and nuts intake (274 g/d), whole grain intake (103 g/d), and olive oil consumption (8 g/d) were also significantly higher in the intervention group (P<.001). The level of physical activity increased in both groups by approximately 60%, without difference between groups (P=.22). Mean (SD) body weight decreased more in patients in the intervention group (-4.0 [1.1] kg) than in those in the control group (-1.2 [0.6) kg) (P<.001). Compared with patients consuming the control diet, patients consuming the intervention diet had significantly reduced serum concentrations of hs-CRP (P=.01), IL-6 (P=.04), IL-7 (P=0.4), and IL-18 (P=0.3), as well as decreased insulin resistance (P<.001). Endothelial function score improved in the intervention group (mean [SD] change, +1.9 [0.6]; P<.001) but remained stable in the control group (+0.2 [0.2]; P=33). At 2 years of follow-up, 40 patients in the intervention group still had features of the metabolic syndrome, compared with 78 patients in the control group (P<.001). Conclusion A Mediterranean-style diet might be effective in reducing the prevalence of the metabolic syndrome and its associated cardiovascular risk.	Univ Naples 2, Chair & Div Metab Dis, Naples, Italy; Univ Naples 2, Chair Urol, Naples, Italy; Univ Naples 2, Chair Plast & Reconstruct Surg, Naples, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Giugliano, D (corresponding author), Policlin Seconda Univ Napoli, Dept Geriatr & Metab Dis, Div Metab Dis, Piazza L Miraglia, I-80031 Naples, Italy.	dario.giugliano@unina2.it	Esposito, Katherine/AHE-2564-2022; Maiorino, Maria Ida/AHE-9986-2022; Marfella, Raffaele/C-6899-2012	Esposito, Katherine/0000-0002-3652-5154; Maiorino, Maria Ida/0000-0003-4659-7546; Marfella, Raffaele/0000-0003-3960-9270; D'andrea, Francesco/0000-0002-3518-0406; Giugliano, Dario/0000-0002-9377-873X				Andoh A, 1999, JPEN-PARENTER ENTER, V23, pS70, DOI 10.1177/014860719902300518; Bastard JP, 2000, J CLIN ENDOCR METAB, V85, P3338, DOI 10.1210/jc.85.9.3338; Blankenberg S, 2002, CIRCULATION, V106, P24, DOI 10.1161/01.CIR.0000020546.30940.92; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Damas JK, 2003, CIRCULATION, V107, P2670, DOI 10.1161/01.CIR.0000070542.18001.87; Dandona P, 2002, DIABETOLOGIA, V45, P924, DOI 10.1007/s00125-001-0766-5; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; Esposito K, 2003, AM J CLIN NUTR, V78, P1135, DOI 10.1093/ajcn/78.6.1135; Esposito K, 2003, AM J CLIN NUTR, V77, P139, DOI 10.1093/ajcn/77.1.139; Esposito K, 2003, J CLIN ENDOCR METAB, V88, P1055, DOI 10.1210/jc.2002-021437; Fernandez-Real JM, 2003, ENDOCR REV, V24, P278, DOI 10.1210/er.2002-0010; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Giugliano D, 1997, AM J PHYSIOL-ENDOC M, V273, pE606, DOI 10.1152/ajpendo.1997.273.3.E606; Groop L, 2000, BRIT J NUTR, V83, pS39; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; Han TS, 2002, DIABETES CARE, V25, P2016, DOI 10.2337/diacare.25.11.2016; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Hu FB, 2002, JAMA-J AM MED ASSOC, V288, P2569, DOI 10.1001/jama.288.20.2569; Krauss RM, 2000, CIRCULATION, V102, P2284; Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94; Lidfeldt J, 2003, DIABETES OBES METAB, V5, P106, DOI 10.1046/j.1463-1326.2003.00250.x; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; McKeown NM, 2004, DIABETES CARE, V27, P538, DOI 10.2337/diacare.27.2.538; Mennen LI, 2000, NUTR RES, V20, P335, DOI 10.1016/S0271-5317(00)00127-5; Nappo F, 2002, J AM COLL CARDIOL, V39, P1145, DOI 10.1016/S0735-1097(02)01741-2; Pasceri V, 2000, CIRCULATION, V102, P2165; Plotnick GD, 1997, JAMA-J AM MED ASSOC, V278, P1682, DOI 10.1001/jama.278.20.1682; Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05; Robertson RM, 2001, CIRCULATION, V103, P1821, DOI 10.1161/01.CIR.103.13.1821; Singh RB, 2002, LANCET, V360, P1455, DOI 10.1016/S0140-6736(02)11472-3; Tamakoshi K, 2003, INT J OBESITY, V27, P443, DOI 10.1038/sj.ijo.0802260; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Wirfalt E, 2001, AM J EPIDEMIOL, V154, P1150, DOI 10.1093/aje/154.12.1150; Yeh ETH, 2001, CIRCULATION, V104, P974, DOI 10.1161/01.CIR.104.9.974; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972; Ziccardi P, 2002, CIRCULATION, V105, P804, DOI 10.1161/hc0702.104279	36	1464	1550	4	278	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2004	292	12					1440	1446		10.1001/jama.292.12.1440	http://dx.doi.org/10.1001/jama.292.12.1440			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	856FT	15383514				2023-01-03	WOS:000224031800025
J	Steinman, L				Steinman, L			Immune therapy for autoimmune diseases	SCIENCE			English	Review							CHIMERIC MONOCLONAL-ANTIBODY; ALTERED PEPTIDE LIGAND; NECROSIS-FACTOR-ALPHA; MYELIN BASIC-PROTEIN; T-CELL-ACTIVATION; PHASE-II TRIAL; MULTIPLE-SCLEROSIS; RHEUMATOID-ARTHRITIS; IMMUNODOMINANT EPITOPE; NERVOUS-SYSTEM	Our increasing understanding of the pathophysiology of autoimmune disease has revealed a number of checkpoints that can be targeted with immune therapy, including key mediators of lymphocyte adhesion and migration, destructive cytokines involved in tissue damage, and the complex of molecules critical in the presentation of self-antigen and the activation of autoaggressive T lymphocytes. In many organ-specific autoimmune diseases, the identity of the molecules attacked by T cells and autoantibodies is known and attempts are under way to tolerize the immune system with a high level of specificity to these targets.	Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Interdepartmental Program Immunol, Stanford, CA 94305 USA	Stanford University; Stanford University	Steinman, L (corresponding author), Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.	steinman@stanford.edu		Steinman, Lawrence/0000-0002-2437-2250				Aharoni R, 1999, P NATL ACAD SCI USA, V96, P634, DOI 10.1073/pnas.96.2.634; Alleva DG, 2001, J CLIN INVEST, V107, P173, DOI 10.1172/JCI8525; AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Asseman C., 2002, Autoimmunity Reviews, V1, P190, DOI 10.1016/S1568-9972(02)00054-X; Bach JF, 2001, ANNU REV IMMUNOL, V19, P131, DOI 10.1146/annurev.immunol.19.1.131; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Blom T, 2003, SCIENCE, V299; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Coles AJ, 1999, LANCET, V354, P1691, DOI 10.1016/S0140-6736(99)02429-0; Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; CONSTANTINESCU CS, 1995, IMMUNOPHARM IMMUNOT, V17, P471, DOI 10.3109/08923979509016382; Darnell RB, 2003, NEW ENGL J MED, V349, P1543, DOI 10.1056/NEJMra023009; De Vita S, 2002, ARTHRITIS RHEUM, V46, P2029, DOI 10.1002/art.10467; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; DEVAJYOTHI C, 1993, J BIOL CHEM, V268, P18794; Duda PW, 2000, J CLIN INVEST, V105, P967, DOI 10.1172/JCI8970; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Ghoreschi K, 2003, NAT MED, V9, P40, DOI 10.1038/nm804; Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Lin MS, 1997, J CLIN INVEST, V99, P31, DOI 10.1172/JCI119130; Lovett-Racke AE, 2004, J IMMUNOL, V172, P5790, DOI 10.4049/jimmunol.172.9.5790; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nishimoto N, 2003, J RHEUMATOL, V30, P1426; Ostensen M, 2002, TRANSPL IMMUNOL, V9, P155, DOI 10.1016/S0966-3274(02)00017-5; PATY DW, 1994, ANN NEUROL, V36, pS113, DOI 10.1002/ana.410360726; Pedotti R, 2003, TRENDS IMMUNOL, V24, P479, DOI 10.1016/S1471-4906(03)00233-3; Pozzilli P, 2002, DIABETES-METAB RES, V18, P257, DOI 10.1002/dmrr.316; Raz I, 2001, LANCET, V358, P1749, DOI 10.1016/S0140-6736(01)06801-5; Robinson WH, 2003, NAT BIOTECHNOL, V21, P1033, DOI 10.1038/nbt859; Ruiz PJ, 2001, J IMMUNOL, V167, P2688, DOI 10.4049/jimmunol.167.5.2688; Ruiz-Ortega M, 2001, HYPERTENSION, V38, P1382, DOI 10.1161/hy1201.100589; Sela M, 1999, Int Rev Immunol, V18, P201, DOI 10.3109/08830189909043025; Slavin Anthony J., 2002, Autoimmunity Reviews, V1, P213, DOI 10.1016/S1568-9972(02)00051-4; STEINMAN L, 1993, SCI AM, V269, P106, DOI 10.1038/scientificamerican0993-106; Steinman L, 2004, NAT IMMUNOL, V5, P575, DOI 10.1038/ni1078; Steinman L, 2003, SCIENCE, V299; STEINMAN L, 1990, FASEB J, V4, P2726, DOI 10.1096/fasebj.4.10.2197152; Steinman L, 1999, J EXP MED, V189, P1021, DOI 10.1084/jem.189.7.1021; Stuve O, 1996, ANN NEUROL, V40, P853, DOI 10.1002/ana.410400607; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5; Verge CF, 1996, DIABETES, V45, P926, DOI 10.2337/diabetes.45.7.926; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; von Andrian UH, 2003, NEW ENGL J MED, V348, P68, DOI 10.1056/NEJMe020157; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zamvil SS, 2003, NEURON, V38, P685, DOI 10.1016/S0896-6273(03)00326-X	59	103	119	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					212	216		10.1126/science.1099896	http://dx.doi.org/10.1126/science.1099896			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247472				2023-01-03	WOS:000222501000043
J	Marik, PE; Zaloga, GP				Marik, PE; Zaloga, GP			Meta-analysis of parenteral nutrition versus enteral nutrition in patients with acute pancreatitis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL-MALFORMATIONS; CHILDHOOD-CANCER; RECORD-LINKAGE; BIRTH-DEFECTS; RISK; ROUTE; COMPLICATIONS; POPULATION; CHILDREN; INFANTS	Objective To compare the safety and clinical outcomes of enteral and parenteral nutrition in patients with acute pancreatitis. Data sources Medline, Embase, Cochrane controlled trials register, and citation review of relevant primary and review articles. Study selection Randomised controlled studies that compared enteral nutrition with parenteral nutrition in patients with acute pancreatitis. From 117 articles screened, six were identified as randomised controlled trials and were included for data extraction. Data extraction Six studies with 263 participants were analysed. Descriptive and outcome data were extracted. Main outcome measures were infections, complications other than infections, operative interventions, length of hospital stay, and mortality. The meta-analysis was performed with the random effects model. Data synthesis Enteral nutrition was associated with a significantly lower incidence of infections (relative risk 0.45; 95% confidence interval 0.26 to 0.78, P = 0.004), reduced surgical interventions to control pancreatitis (0.48, 0.22 to 1.0, P = 0.05), and a reduced length of hospital stay (mean reduction 2.9 days, 1.6 days to 4.3 days, P < 0.001). There were no significant differences in mortality (relative risk 0.66, 0.32 to 1.37, P = 0.3) or non-infectious complications (0.61, 0.31 to 1.22, P = 0.16) between the two groups of patients. Conclusions Enteral nutrition should be the preferred route of nutritional support in patients with acute pancreatitis.	Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA 15261 USA; Methodist Res Inst, Indianapolis, IN 46202 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Indiana University System	Marik, PE (corresponding author), Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA 15261 USA.	maripe@ccm.upmc.edu	Marik, Paul E/U-9733-2019					Abou-Assi S, 2002, AM J GASTROENTEROL, V97, P2255, DOI 10.1111/j.1572-0241.2002.05979.x; [Anonymous], 1989, Ann Intern Med, V110, P734; Bistrian BR, 2001, AM J CLIN NUTR, V74, P153; Braga M, 1998, CRIT CARE MED, V26, P24, DOI 10.1097/00003246-199801000-00012; Christensen K, 1999, CLEFT PALATE-CRAN J, V36, P96, DOI 10.1597/1545-1569(1999)036<0096:TCDFCP>2.3.CO;2; CHRISTENSEN K, 1995, NEW ENGL J MED, V333, P161, DOI 10.1056/NEJM199507203330305; Christensen K, 2002, CLEFT PALATE-CRAN J, V39, P392, DOI 10.1597/1545-1569(2002)039<0392:FCAPDA>2.0.CO;2; CHRISTENSEN K, 1994, CLIN GENET, V46, P329; Dominguez-Cherit Guillermo, 2002, Curr Opin Crit Care, V8, P285; Fogh-Andersen, 1942, INHERITANCE HARELIP; Gianotti L, 1997, ARCH SURG-CHICAGO, V132, P1222, DOI 10.1001/archsurg.1997.01430350072012; GOODGAME JT, 1977, ANN SURG, V186, P651, DOI 10.1097/00000658-197711000-00018; GRANT JP, 1984, ANN SURG, V200, P627, DOI 10.1097/00000658-198411000-00012; Gupta R, 2003, PANCREATOLOGY, V3, P406, DOI 10.1159/000073657; HUJOEL PP, 1992, CLEFT PALATE-CRAN J, V29, P451, DOI 10.1597/1545-1569(1992)029<0451:FYMAIW>2.3.CO;2; Hunt GM, 2003, BRIT MED J, V326, P1365, DOI 10.1136/bmj.326.7403.1365; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jeejeebhoy KN, 2001, AM J CLIN NUTR, V74, P160; Juel K, 1999, DAN MED BULL, V46, P354; Kalfarentzos F, 1997, BRIT J SURG, V84, P1665, DOI 10.1002/bjs.1800841207; KALFARENTZOS FE, 1991, J AM COLL NUTR, V10, P156; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; Lin MT, 1996, ANN SURG, V223, P84, DOI 10.1097/00000658-199601000-00012; Lipman TO, 1998, JPEN-PARENTER ENTER, V22, P167, DOI 10.1177/0148607198022003167; Mackeprang M, 1972, Cleft Palate J, V9, P51; Marik PE, 2003, INTENS CARE MED, V29, P867, DOI 10.1007/s00134-003-1744-9; McClave SA, 1997, JPEN-PARENTER ENTER, V21, P14, DOI 10.1177/014860719702100114; MILI F, 1993, AM J EPIDEMIOL, V137, P629, DOI 10.1093/oxfordjournals.aje.a116720; MILI F, 1993, AM J EPIDEMIOL, V137, P639, DOI 10.1093/oxfordjournals.aje.a116721; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; Nopoulos P, 2002, GENET MED, V4, P1, DOI 10.1097/00125817-200201000-00001; Olah A, 2002, NUTRITION, V18, P259, DOI 10.1016/S0899-9007(01)00755-9; Ramstad T, 1995, SCAND J PLAST RECONS, V29, P329, DOI 10.3109/02844319509008968; STRINGER MD, 1998, PEDIAT SURG UROLOGY; Varga P, 2003, INTENS CARE MED, V29, P1861, DOI 10.1007/s00134-003-2006-6; Vu MK, 1999, EUR J CLIN INVEST, V29, P1053; WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525; WINDHAM GC, 1985, AM J EPIDEMIOL, V121, P49, DOI 10.1093/oxfordjournals.aje.a113982; Windsor ACJ, 1998, GUT, V42, P431, DOI 10.1136/gut.42.3.431; YEO CJ, 1997, TXB SURG BIOL BASIS, P1151; ZACK M, 1991, CANCER RES, V51, P3696; Zhu JL, 2002, BRIT J CANCER, V87, P524, DOI 10.1038/sj.bjc.6600488	42	285	319	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	2004	328	7453					1407	1410		10.1136/bmj.38118.593900.55	http://dx.doi.org/10.1136/bmj.38118.593900.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830IB	15175229	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000222114400017
J	Merten, GJ; Burgess, WP; Gray, LV; Holleman, JH; Roush, TS; Kowalchuk, GJ; Bersin, RM; Van Moore, A; Simonton, CA; Rittase, RA; Norton, HJ; Kennedy, TP				Merten, GJ; Burgess, WP; Gray, LV; Holleman, JH; Roush, TS; Kowalchuk, GJ; Bersin, RM; Van Moore, A; Simonton, CA; Rittase, RA; Norton, HJ; Kennedy, TP			Prevention of contrast-induced nephropathy with sodium bicarbonate - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE-RENAL-FAILURE; NITRIC-OXIDE; N-ACETYLCYSTEINE; FREE-RADICALS; RADIOCONTRAST; EXCRETION; HYPOXIA; NEPHROTOXICITY; INTERVENTION; INVOLVEMENT	Context Contrast-induced nephropathy remains a common complication of radiographic procedures. Pretreatment with sodium bicarbonate is more protective than sodium chloride in animal models of acute ischemic renal failure. Acute renal failure from both ischemia and contrast are postulated to occur from free-radical injury. However, no studies in humans or animals have evaluated the efficacy of sodium bicarbonate for prophylaxis against contrast-induced nephropathy. Objective To examine the efficacy of sodium bicarbonate compared with sodium chloride for preventive hydration before and after radiographic contrast. Design, Setting, and Patients A prospective, single-center, randomized trial conducted from September 16, 2002, to June 17, 2003, of 119 patients with stable serum creatinine levels of at least 1.1 mg/dL (greater than or equal to97.2 mumol/L) who were randomized to receive a 154-mEq/L infusion of either sodium chloride (n = 59) or sodium bicarbonate (n = 60) before and after iopamidol administration (370 mg iodine/mL). Serum creatinine levels were measured at baseline and 1 and 2 days after contrast. Interventions Patients received 154 mEq/L of either sodium chloride or sodium bicarbonate, as a bolus of 3 mL/kg per hour for 1 hour before iopamidol contrast, followed by an infusion of 1 mL/kg per hour for 6 hours after the procedure. Main Outcome Measure Contrast-induced nephropathy, defined as an increase of 25% or more in serum creatinine within 2 days of contrast. Results There were no significant group differences in age, sex, incidence of diabetes mellitus, ethnicity, or contrast volume. Baseline serum creatinine was slightly higher but not statistically different in patients receiving sodium bicarbonate treatment (mean [SD], 1.71 [0.42] mg/dL [151.2 {37.1} mumol/L] for sodium chloride and 1.89 [0.69] mg/dL [167.1 {61.0} mumol/L] for sodium bicarbonate; P = .09). The primary end point of contrast-induced nephropathy occurred in 8 patients (13.6%) infused with sodium chloride but in only 1 (1.7%) of those receiving sodium bicarbonate (mean difference, 11.9%; 95% confidence interval [Cl], 2.6%-21.2%; P = .02). A follow-up registry of 191 consecutive patients receiving prophylactic sodium bicarbonate and meeting the same inclusion criteria as the study resulted in 3 cases of contrast-induced nephropathy (1.6%; 95% Cl, 0%-3.4%). Conclusion Hydration with sodium bicarbonate before contrast exposure is more effective than hydration with sodium chloride for prophylaxis of contrast-induced renal failure.	Carolinas Med Ctr, Dept Internal Med, Charlotte, NC 28232 USA; Carolinas Med Ctr, Dept Radiol, Charlotte, NC 28232 USA; Carolinas Med Ctr, Dept Clin Pharm, Charlotte, NC 28232 USA; Carolinas Med Ctr, Dept Biostat, Charlotte, NC 28232 USA; Carolinas Med Ctr, Dept Sanger Cardiol, Charlotte, NC 28232 USA; Carolinas Med Ctr, Dept Sanger Cardiovasc Surg, Charlotte, NC 28232 USA; Carolinas Med Ctr, Dept Metrolina Nephrol, Charlotte, NC 28232 USA	Carolinas Medical Center; Carolinas Medical Center; Carolinas Medical Center; Carolinas Medical Center; Carolinas Medical Center; Carolinas Medical Center; Carolinas Medical Center	Kennedy, TP (corresponding author), Carolinas Med Ctr, Dept Internal Med, MEB 507,POB 38162, Charlotte, NC 28232 USA.	tkennedy@carolinas.org						AGMON Y, 1994, J CLIN INVEST, V94, P1069, DOI 10.1172/JCI117421; Allaqaband S, 2002, CATHETER CARDIO INTE, V57, P279, DOI 10.1002/ccd.10323; Alpern RJ, 2000, KIDNEY, P455; Aspelin P, 2003, NEW ENGL J MED, V348, P491, DOI 10.1056/NEJMoa021833; ATKINS JL, 1986, NEPHRON, V44, P70, DOI 10.1159/000183915; Baker CSR, 2003, J AM COLL CARDIOL, V41, P2114, DOI 10.1016/S0735-1097(03)00487-X; Baker CSR, 2001, HEART, V85, P361, DOI 10.1136/heart.85.4.361; BAKRIS GL, 1990, AM J PHYSIOL, V258, pF115, DOI 10.1152/ajprenal.1990.258.1.F115; BAKRIS GL, 1990, RADIOLOGY, V175, P57, DOI 10.1148/radiology.175.1.2315505; Baroni EA, 1999, AM J KIDNEY DIS, V34, P328, DOI 10.1016/S0272-6386(99)70363-X; Birck R, 2003, LANCET, V362, P598, DOI 10.1016/S0140-6736(03)14189-X; Boccalandro F, 2003, CATHETER CARDIO INTE, V58, P336, DOI 10.1002/ccd.10389; BREZIS M, 1995, NEW ENGL J MED, V332, P647, DOI 10.1056/NEJM199503093321006; Briguori C, 2003, PROG CARDIOVASC DIS, V45, P493, DOI 10.1053/pcad.2003.YPCAD16; Caulfield JL, 1996, J BIOL CHEM, V271, P25859, DOI 10.1074/jbc.271.42.25859; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Cohen G., 1985, CRC HDB METHODS OXYG, P55; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Durham JD, 2002, KIDNEY INT, V62, P2202, DOI 10.1046/j.1523-1755.2002.00673.x; Gonzalez NC, 2001, ADV EXP MED BIOL, V502, P39; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HEYMAN SN, 1991, KIDNEY INT, V40, P632, DOI 10.1038/ki.1991.255; JULIAN BA, 1982, J LAB CLIN MED, V100, P261; Katholi RE, 1998, AM J KIDNEY DIS, V32, P64, DOI 10.1053/ajkd.1998.v32.pm9669426; Kay J, 2003, JAMA-J AM MED ASSOC, V289, P553, DOI 10.1001/jama.289.5.553; KOTCHEN TA, 1983, ANN INTERN MED, V98, P817, DOI 10.7326/0003-4819-98-5-817; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lindinger MI, 2000, J APPL PHYSIOL, V88, P540, DOI 10.1152/jappl.2000.88.2.540; Loitsch SM, 2000, BIOCHEM BIOPH RES CO, V276, P571, DOI 10.1006/bbrc.2000.3504; Marenzi G, 2003, NEW ENGL J MED, V349, P1333, DOI 10.1056/NEJMoa023204; McCullough PA, 1997, AM J MED, V103, P368, DOI 10.1016/S0002-9343(97)00150-2; Murphy ME, 1998, INVEST RADIOL, V33, P356, DOI 10.1097/00004424-199806000-00007; Novikov M, 2003, J AM SOC NEPHROL, V14, p354A; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Qin SF, 1999, BIOCHEM BIOPH RES CO, V262, P231, DOI 10.1006/bbrc.1999.1079; RUDNICK MR, 1995, KIDNEY INT, V47, P254, DOI 10.1038/ki.1995.32; Safirstein R, 2000, NEW ENGL J MED, V343, P210, DOI 10.1056/NEJM200007203430311; Shyu KG, 2002, J AM COLL CARDIOL, V40, P1383, DOI 10.1016/S0735-1097(02)02308-2; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; SPORER H, 1981, EUR J CLIN INVEST, V11, P311, DOI 10.1111/j.1365-2362.1981.tb02122.x; Stone GW, 2003, JAMA-J AM MED ASSOC, V290, P2284, DOI 10.1001/jama.290.17.2284; Tepel M, 2000, NEW ENGL J MED, V343, P180, DOI 10.1056/NEJM200007203430304; TERUEL JL, 1989, NEPHRON, V51, P282, DOI 10.1159/000185304; Vallero A, 2002, G Ital Nefrol, V19, P529	44	719	769	0	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	2004	291	19					2328	2334		10.1001/jama.291.19.2328	http://dx.doi.org/10.1001/jama.291.19.2328			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821JD	15150204	Bronze			2023-01-03	WOS:000221455400020
J	McNutt, R; Abrams, R; Hasler, S				McNutt, R; Abrams, R; Hasler, S			Why blame systems for unsafe care?	LANCET			English	Editorial Material							ERRORS		Rush Univ, Med Ctr, Dept Med, Chicago, IL 60621 USA	Rush University	McNutt, R (corresponding author), Rush Univ, Med Ctr, Dept Med, Chicago, IL 60621 USA.	Robert_McNutt@rush.edu						Berwick DM, 2003, NEW ENGL J MED, V348, P2570, DOI 10.1056/NEJMe030044; Berwick DM, 2001, BMJ-BRIT MED J, V322, P247, DOI 10.1136/bmj.322.7281.247; Cleghorn GD, 1996, JOINT COMM J QUAL IM, V22, P206, DOI 10.1016/S1070-3241(16)30223-1; McNutt RA, 2002, JAMA-J AM MED ASSOC, V287, P1997, DOI 10.1001/jama.287.15.1997; Pande P.S., 2000, 6 SIGMA WAY GE MOTOR; SCHRIEBER J, 2003, MANAGEMENT DIABETIC	6	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	2004	363	9413					913	914		10.1016/S0140-6736(04)15821-2	http://dx.doi.org/10.1016/S0140-6736(04)15821-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043956				2023-01-03	WOS:000220308600005
J	Phillips, CO; Wright, SM; Kern, DE; Singa, RM; Shepperd, S; Rubin, HR				Phillips, CO; Wright, SM; Kern, DE; Singa, RM; Shepperd, S; Rubin, HR			Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MANAGEMENT TELEPHONE INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; HOME-BASED INTERVENTION; HOSPITAL READMISSIONS; MEDICARE BENEFICIARIES; ELDERLY PATIENTS; CLINICAL-TRIALS; CARE; MULTIDISCIPLINARY; QUALITY	Context Comprehensive discharge planning plus postdischarge support may reduce readmission rates for older patients with congestive heart failure(CHF). Objective To evaluate the effect of comprehensive discharge planning plus postdischarge support on the rate of readmission in patients with CHF, all-cause mortality, length of stay (LOS), quality of life (QOL), and medical costs. DataSources We searched MEDLINE (1966 to October 2003), the Cochrane Clinical Trials Register (all years), Social Science Citation Index (1992 to October 2003), and other databases for studies that described such an intervention and evaluated its effect in patients with CHF. Where possible we also contacted lead investigators and experts in the field. Study Selection We selected English-language publications of randomized clinical trials that described interventions to modify hospital discharge for older patients with CHF (mean age 55 years), delineated clearly defined inpatient and outpatient components, compared efficacy with usual care, and reported readmission as the primary outcome. Data Extraction Two authors independently reviewed each report, assigned quality scores, and extracted data for primary and secondary outcomes in an unblinded standardized manner. Data Synthesis Eighteen studies representing data from 8 countries randomized 3304 older inpatients with CHF to comprehensive discharge planning plus postdischarge support or usual care. During a pooled mean observation period of 8 months (range, 3-12 months), fewer intervention patients were readmitted compared with controls (555/ 1590 vs 741/1714, number needed to treat = 12; relative risk [RR], 0.75; 95% confidence interval [CI], 0.64-0.88). Analysis of studies reporting secondary outcomes found a trend toward lower all-cause mortality for patients assigned to an intervention compared with usual care (RR, 0.87 95 % Cl, 0.73-1.03; n = 14 studies), similar initial LOS (mean [SE]: 8.4 [2.5] vs 8.5 [2.2] days, P=.60; n=10), greater percentage improvement in QOL scores compared with baseline scores (25.7% [95% Cl, 11.0%-40.4%] vs 13.5% [95% Cl, 5.1%-22.0%]; n=6, P=.01), and similaror lower charges for medical care per patient per month for the initial hospital stay, administering the intervention, outpatient care, and readmission (-$359 [95 % Cl, -$763 to $45]; n =4, P=. 10 for non-US trials and -$536 [95% Cl, -$956 to -$115]; n=4, P=.03, for US trials). Conclusion Comprehensive discharge planning plus postdischarge support for older patients with CHF significantly reduced readmission rates and may improve health outcomes such as survival and QOL without increasing costs.	Univ Oxford, Inst Hlth Sci, Oxford, England; Johns Hopkins Univ, Dept Med, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Johns Hopkins Bayview Med Ctr, Div Gen Internal Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA	University of Oxford; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Phillips, CO (corresponding author), Brigham & Womens Hosp, 75 Francis St,Tower 5-509A, Boston, MA 02115 USA.	chr_phi@yahoo.com		Shepperd, Sasha/0000-0001-6384-8322	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [T32PE010025] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL073347] Funding Source: NIH RePORTER; NHLBI NIH HHS [K24 HL073347] Funding Source: Medline; BHP HRSA HHS [2-T32-PE10025] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BHP HRSA HHS		*AM MED ASS, 1996, PHYS CURR PROC TERM; ANDERSON GF, 1984, NEW ENGL J MED, V311, P1349, DOI 10.1056/NEJM198411223112105; ASHTON CM, 1995, ANN INTERN MED, V122, P415, DOI 10.7326/0003-4819-122-6-199503150-00003; Berlin JA, 1997, LANCET, V350, P185, DOI 10.1016/S0140-6736(05)62352-5; Blue L, 2001, BRIT MED J, V323, P715, DOI 10.1136/bmj.323.7315.715; Capomolla S, 2002, J AM COLL CARDIOL, V40, P1259, DOI 10.1016/S0735-1097(02)02140-X; Cline CMJ, 1998, HEART, V80, P442, DOI 10.1136/hrt.80.5.442; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DESHARNAIS S, 1991, EVAL HEALTH PROF, V14, P228, DOI 10.1177/016327879101400206; FISHER ES, 1994, NEW ENGL J MED, V331, P989, DOI 10.1056/NEJM199410133311506; Funk M, 1996, J Cardiovasc Nurs, V10, P1; GHALI JK, 1990, ARCH INTERN MED, V150, P769, DOI 10.1001/archinte.150.4.769; Grancelli H, 2003, J CARD FAIL, V9, P172, DOI 10.1054/jcaf.2003.33; Harrison MB, 2002, MED CARE, V40, P271, DOI 10.1097/00005650-200204000-00003; *HLTH CAR FIN REV, 1997, MED MED STAT SUPPL 1; Hunt SA, 2002, J HEART LUNG TRANSPL, V21, P189, DOI 10.1016/S1053-2498(01)00776-8; Jaarsma T, 1999, EUR HEART J, V20, P673, DOI 10.1053/euhj.1998.1341; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; KONSTAM M, 1994, AHCPR PUBLICATION; Krumholz HM, 1997, ARCH INTERN MED, V157, P99, DOI 10.1001/archinte.157.1.99; Krumholz HM, 2002, J AM COLL CARDIOL, V39, P83, DOI 10.1016/S0735-1097(01)01699-0; Laramee AS, 2003, ARCH INTERN MED, V163, P809, DOI 10.1001/archinte.163.7.809; LOEB JM, 1993, JAMA-J AM MED ASSOC, V269, P1282; Macaskill P, 2001, STAT MED, V20, P641, DOI 10.1002/sim.698; MAMON J, 1992, HEALTH SERV RES, V27, P155; Marcantonio ER, 1999, AM J MED, V107, P13, DOI 10.1016/S0002-9343(99)00159-X; McAlister FA, 2001, AM J MED, V110, P378, DOI 10.1016/S0002-9343(00)00743-9; McDonald K, 2002, J CARD FAIL, V8, P142, DOI 10.1054/jcaf.2002.124340; Moher D, 2000, J CLIN EPIDEMIOL, V53, P964, DOI 10.1016/S0895-4356(00)00188-8; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; NOETHER M, 1988, PUBLICATION HCFA; Oddone E Z, 1999, Eff Clin Pract, V2, P201; Parker S G, 2002, Health Technol Assess, V6, P1; Parkes J, 2000, COCHRANE DB SYST REV, V4; Payne SMC, 2002, HEALTH SERV RES, V37, P683, DOI 10.1111/1475-6773.00044; Peterson GM, 2002, ARCH INTERN MED, V162, P2142, DOI 10.1001/archinte.162.18.2142-a; Philbin EF, 1999, J GEN INTERN MED, V14, P130, DOI 10.1046/j.1525-1497.1999.00291.x; Rainville EC, 1999, AM J HEALTH-SYST PH, V56, P1339, DOI 10.1093/ajhp/56.13.1339; RICH MW, 1993, J GEN INTERN MED, V8, P585, DOI 10.1007/BF02599709; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Riegel B, 2002, ARCH INTERN MED, V162, P705, DOI 10.1001/archinte.162.6.705; Serxner S, 1998, CONGESTIVE HEART FAI, V4, P23; Stewart S, 1999, LANCET, V354, P1077, DOI 10.1016/S0140-6736(99)03428-5; Stewart S, 1998, ARCH INTERN MED, V158, P1067, DOI 10.1001/archinte.158.10.1067; THOMAS JW, 1991, MED CARE, V29, P377, DOI 10.1097/00005650-199104000-00006; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; Wolinsky FD, 1997, J AM GERIATR SOC, V45, P558, DOI 10.1111/j.1532-5415.1997.tb03087.x	48	591	604	2	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	2004	291	11					1358	1367		10.1001/jama.291.11.1358	http://dx.doi.org/10.1001/jama.291.11.1358			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	802PF	15026403				2023-01-03	WOS:000220174700030
J	Holroyd-Leduc, JM; Straus, SE				Holroyd-Leduc, JM; Straus, SE			Management of urinary incontinence in women - Scientific review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RANDOMIZED CONTROLLED TRIAL; RISK-FACTORS; DOUBLE-BLIND; ELECTRICAL-STIMULATION; DETRUSOR INSTABILITY; STRESS-INCONTINENCE; OVERACTIVE BLADDER; URGE INCONTINENCE; OLDER PERSONS; PREVALENCE	Context Urinary incontinence is a common health problem among women that negatively impacts quality of life. Therefore, it is important that primary care physicians have an understanding of how to manage urinary incontinence effectively. Objective To review the most recent, high-quality evidence regarding the etiology and management of urinary incontinence in women. Data Sources and Study Selection Searches of MEDLINE, EMBASE, The Cochrane Library, and the ACP Journal Club were performed to identify English-language articles published between 1998-2003 that focused on the etiology or treatment of urinary incontinence in adult women. The references of each retrieved article were reviewed and an expert in the field was contacted to identify additional relevant articles. Data Extraction Using a combination of more than 80 search terms, we included articles of etiology that were cohort studies, case-control studies, cross-sectional studies, or systematic reviews of cohort, case-control, and/or cross-sectional studies. Studies of treatment had to be randomized controlled trials or systematic reviews of randomized controlled trials. The quality of each article was assessed independently by each author and inclusion (n = 66) was determined by consensus. Data Synthesis Multiple factors have been found to be associated with urinary incontinence, some of which are amenable to modification. Factors associated with incontinence include age, white race, higher educational attainment, pregnancy-related factors, gynecological factors, urological and gastrointestinal tract factors, comorbid diseases, higher body mass index, medications, smoking, caffeine, and functional impairment. There are several effective non pharmacological treatments including pelvic floor muscle training, electrical stimulation, bladder training, and prompted voiding. Anticholinergic drugs are effective in the treatment of urge urinary incontinence. Several surgical interventions are effective in the management of stress incontinence, including open retropubic colposuspension and suburethral sling procedure. Conclusion Urinary incontinence in women is an important public health concern, and effective treatment options exist.	San Francisco VA Med Ctr, San Francisco, CA USA; Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA; Univ Toronto, Univ Hlth Network, Div Gen Internal Med, Toronto, ON, Canada	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Holroyd-Leduc, JM (corresponding author), SFVAMC 181G, 4150 Clement St,Bldg 1, San Francisco, CA 94121 USA.	Jayna.Holroyd-Leduc@med.va.gov; sstraus@mtsinai.on.ca						Abrams P, 2003, UROLOGY, V61, P37, DOI 10.1016/S0090-4295(02)02243-4; Aggazzotti G, 2000, UROLOGY, V56, P245, DOI 10.1016/S0090-4295(00)00643-9; ALHASSO A, 2003, COCHRANE LIB; Appell RA, 2001, MAYO CLIN PROC, V76, P358; Arya LA, 2000, OBSTET GYNECOL, V96, P85, DOI 10.1016/S0029-7844(00)00808-5; Arya LA, 2001, AM J OBSTET GYNECOL, V185, P1318, DOI 10.1067/mob.2001.120365; Aukee P, 2002, UROLOGY, V60, P1020, DOI 10.1016/S0090-4295(02)02125-8; BEZERRA CA, 2003, COCHRANE LIB; Bo K, 2001, MED SCI SPORT EXER, V33, P1797; Bortolotti A, 2000, EUR UROL, V37, P30, DOI 10.1159/000020096; Brown JS, 2000, LANCET, V356, P535, DOI 10.1016/S0140-6736(00)02577-0; Brown JS, 1999, OBSTET GYNECOL, V94, P66, DOI 10.1016/S0029-7844(99)00263-X; Burgio KL, 2002, JAMA-J AM MED ASSOC, V288, P2293, DOI 10.1001/jama.288.18.2293; Burgio KL, 1998, JAMA-J AM MED ASSOC, V280, P1995, DOI 10.1001/jama.280.23.1995; Chaliha C, 1999, OBSTET GYNECOL, V94, P689, DOI 10.1016/S0029-7844(99)00364-6; Chiarelli P, 1999, NEUROUROL URODYNAM, V18, P567, DOI 10.1002/(SICI)1520-6777(1999)18:6<567::AID-NAU7>3.0.CO;2-F; Davila GW, 2001, J UROLOGY, V166, P140, DOI 10.1016/S0022-5347(05)66095-8; DeLancey J, 2001, AM J OBSTET GYNECOL, V185, P1323; Dugan E, 2000, J AM GERIATR SOC, V48, P413, DOI 10.1111/j.1532-5415.2000.tb04699.x; EUSTICE S, 2003, COCHRANE LIB; Finkelstein MM, 2002, CAN FAM PHYSICIAN, V48, P96; Foldspang A, 1999, AM J PUBLIC HEALTH, V89, P209, DOI 10.2105/AJPH.89.2.209; Fultz NH, 1999, J GERONTOL A-BIOL, V54, pM299, DOI 10.1093/gerona/54.6.M299; Garcia A, 2000, Can J Urol, V7, P1077; GLAZENER CM, 2003, COCHRANE LIB; Goode PS, 2003, JAMA-J AM MED ASSOC, V290, P345, DOI 10.1001/jama.290.3.345; Gordon D, 1998, BRIT J OBSTET GYNAEC, V105, P667, DOI 10.1111/j.1471-0528.1998.tb10183.x; Haeusler G, 2002, OBSTET GYNECOL, V100, P1003, DOI 10.1016/S0029-7844(02)02238-X; HAYSMITH EJ, 2003, COCHRANE LIB; HAYSMITH J, 2003, COCHRANE LIB; HERBISON P, 2003, COCHRANE LIB; HERZOG AR, 1990, J AM GERIATR SOC, V38, P273, DOI 10.1111/j.1532-5415.1990.tb03504.x; Holtedahl K, 1998, MATURITAS, V28, P205, DOI 10.1016/S0378-5122(97)00085-6; HROBJARTSSON A, 2003, COCHRANE LIB; Janssen CCM, 2001, BJU INT, V87, P201, DOI 10.1046/j.1464-410x.2001.02040.x; Jeyaseelan SM, 2000, CLIN REHABIL, V14, P631, DOI 10.1191/0269215500cr372oa; Johnson TM, 1998, J AM GERIATR SOC, V46, P693, DOI 10.1111/j.1532-5415.1998.tb03802.x; Kjerulff KH, 2002, J UROLOGY, V167, P2088, DOI 10.1016/S0022-5347(05)65091-4; Kuh D, 1999, J EPIDEMIOL COMMUN H, V53, P453, DOI 10.1136/jech.53.8.453; Landi F, 2002, CLIN PHARMACOL THER, V72, P729, DOI 10.1067/mcp.2002.129318; LAPITAN MC, 2003, COCHRANE LIB; Lee JG, 2002, INT J UROL, V9, P247, DOI 10.1046/j.1442-2042.2002.00460.x; Lee PE, 2001, J UROLOGY, V165, P153, DOI 10.1097/00005392-200101000-00037; Leung HY, 2002, BJU INT, V90, P375, DOI 10.1046/j.1464-410X.2002.02905.x; Maggi S, 2001, J GERONTOL A-BIOL, V56, pM14, DOI 10.1093/gerona/56.1.M14; Malone-Lee J, 2001, J UROLOGY, V165, P1452, DOI 10.1016/S0022-5347(05)66326-4; McDowell BJ, 1999, J AM GERIATR SOC, V47, P309, DOI 10.1111/j.1532-5415.1999.tb02994.x; MOEHRER B, 2003, COCHRANE LIB; Moller LA, 2000, OBSTET GYNECOL, V96, P446, DOI 10.1097/00006250-200009000-00022; Morkved S, 2002, OBSTET GYNECOL, V100, P730, DOI 10.1016/S0029-7844(02)02160-9; Naglie G, 2002, J UROLOGY, V167, P586, DOI 10.1016/S0022-5347(01)69090-6; Nelson R, 2001, J AGING HEALTH, V13, P539, DOI 10.1177/089826430101300406; Norton PA, 2002, AM J OBSTET GYNECOL, V187, P40, DOI 10.1067/mob.2002.124840; Persson J, 2000, OBSTET GYNECOL, V96, P440, DOI 10.1016/S0029-7844(00)00950-9; PICKARD R, 2003, COCHRANE LIB; ROE B, 2003, COCHRANE LIB; Roovers JPWR, 2001, ACTA OBSTET GYN SCAN, V80, P945, DOI 10.1080/791200711; Rortveit G, 2001, OBSTET GYNECOL, V98, P1004, DOI 10.1016/S0029-7844(01)01566-6; Rortveit G, 2003, NEW ENGL J MED, V348, P900, DOI 10.1056/NEJMoa021788; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sampselle CM, 2002, OBSTET GYNECOL, V100, P1230, DOI 10.1016/S0029-7844(02)02241-X; Samuelsson E, 2000, ACTA OBSTET GYN SCAN, V79, P208, DOI 10.1034/j.1600-0412.2000.079003208.x; Samuelsson EC, 2000, AM J OBSTET GYNECOL, V183, P568, DOI 10.1067/mob.2000.106763; Schmidbauer J, 2001, EUR UROL, V39, P565, DOI 10.1159/000052504; Sherburn M, 2001, OBSTET GYNECOL, V98, P628, DOI 10.1016/S0029-7844(01)01508-3; Temml C, 2000, NEUROUROL URODYNAM, V19, P259, DOI 10.1002/(SICI)1520-6777(2000)19:3<259::AID-NAU7>3.0.CO;2-U; Thom D, 1998, J AM GERIATR SOC, V46, P473, DOI 10.1111/j.1532-5415.1998.tb02469.x; van der Vaart CH, 2002, BJOG-INT J OBSTET GY, V109, P149, DOI 10.1016/S1470-0328(02)01332-0; Van Kessel K, 2001, AM J OBSTET GYNECOL, V184, P1571, DOI 10.1067/mob.2001.114856; Van Oyen H, 2002, ACTA CLIN BELG, V57, P207, DOI 10.1179/acb.2002.043; Viktrup L, 2001, AM J OBSTET GYNECOL, V185, P82, DOI 10.1067/mob.2001.114501; Wyman JF, 1998, AM J OBSTET GYNECOL, V179, P999, DOI 10.1016/S0002-9378(98)70206-6; WYMAN JF, 1990, J AM GERIATR SOC, V38, P282, DOI 10.1111/j.1532-5415.1990.tb03505.x; Yamanishi T, 2000, UROLOGY, V55, P353, DOI 10.1016/S0090-4295(99)00476-8; Zinner NR, 2002, J AM GERIATR SOC, V50, P799, DOI 10.1046/j.1532-5415.2002.50203.x	75	135	138	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2004	291	8					986	995		10.1001/jama.291.8.986	http://dx.doi.org/10.1001/jama.291.8.986			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	777MK	14982915	Bronze			2023-01-03	WOS:000189182000027
J	Woolf, SH				Woolf, SH			Patient safety is not enough: Targeting quality improvements to optimize the health of the population	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICAL ERRORS; CHRONIC DISEASES; UNITED-STATES; DEATHS; CARE; RISK; NEED; PREVENTABILITY; MANAGEMENT	Ensuring patient safety is essential for better health care, but preoccupation with niches of medicine, such as patient safety, can inadvertently compromise outcomes if it distracts from other problems that pose a greater threat to health. The greatest benefit for the population comes from a comprehensive view of population needs and making improvements in proportion with their potential effect on public health; anything less subjects an excess of people to morbidity and death. Patient safety, in context, is a subset of health problems affecting Americans. Safety is a subcategory of medical errors, which also includes mistakes in health promotion and chronic disease management that cost lives but do not affect "safety." These errors are a subset of lapses in quality, which result not only from errors but also from systemic problems, such as lack of access, inequity, and flawed system designs. Lapses in quality are a subset of deficient caring, which encompasses gaps in therapeutics, respect, and compassion that are undetected by normative quality indicators. These larger problems arguably cost hundreds of thousands more lives than do lapses in safety, and the system redesigns to correct them should receive proportionately greater emphasis. Ensuring such rational prioritization requires policy and medical leaders to eschew parochialism and take a global perspective in gauging health problems. The public's well-being requires policymakers to view the system as a whole and consider the potential effect on overall population health when prioritizing care improvements and system redesigns.	Virginia Commonwealth Univ, Med Ctr, Dept Family Practice, Fairfax, VA 22033 USA	Virginia Commonwealth University	Woolf, SH (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Family Practice, 3712 Charles Stewart Dr, Fairfax, VA 22033 USA.	swoolf@vcu.edu						Adams K., 2003, PRIORITY AREAS NATL; *AG HEALTHC RES QU, 2004, JUST BUDG EST APPR C; Brennan TA, 2000, NEW ENGL J MED, V342, P1123, DOI 10.1056/NEJM200004133421510; CALLAHAN D, 1991, HEALTH AFFAIR, V10, P78, DOI 10.1377/hlthaff.10.2.78; *CDC, 2002, MMWR-MORBID MORTAL W, V51, P300; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Chyka PA, 2000, AM J MED, V109, P122, DOI 10.1016/S0002-9343(00)00460-5; Coffield AB, 2001, AM J PREV MED, V21, P1, DOI 10.1016/S0749-3797(01)00308-7; Cooper J, 2001, CURRENT RES PATIENT; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Feinstein Alvan R., 2001, LOST ART CARING CHAL, P201; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; HAHN RA, 1990, JAMA-J AM MED ASSOC, V264, P2654, DOI 10.1001/jama.264.20.2654; Hayward RA, 2001, JAMA-J AM MED ASSOC, V286, P415, DOI 10.1001/jama.286.4.415; *I MED, 2002, CAR WITH COV TOO LIT; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Kelley MA, 2001, BMJ-BRIT MED J, V323, P61, DOI 10.1136/bmj.323.7304.61; Kirsner JB, 2002, JAMA-J AM MED ASSOC, V287, P1909, DOI 10.1001/jama.287.15.1909; Kohn LT, 1999, ERR IS HUMAN BUILDIN, DOI DOI 10.17226/9728; LAMBREW JM, 2003, SMALL SIGNIFICANT ST; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Leape LL, 2002, JAMA-J AM MED ASSOC, V288, P501, DOI 10.1001/jama.288.4.501; Lee TH, 2002, NEW ENGL J MED, V347, P1965, DOI 10.1056/NEJMe020149; Manuel DG, 2002, AM J PUBLIC HEALTH, V92, P1481, DOI 10.2105/AJPH.92.9.1481; MCCRERY J, 2002, C MUST FINALLY SOLVE; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; McNutt RA, 2002, JAMA-J AM MED ASSOC, V287, P1997, DOI 10.1001/jama.287.15.1997; *NAT COMM QUAL ASS, 2003, STAT HLTH CAR QUAL; Phillips KA, 2000, JAMA-J AM MED ASSOC, V284, P2748, DOI 10.1001/jama.284.21.2748; Rundall TG, 2002, BMJ-BRIT MED J, V325, P958, DOI 10.1136/bmj.325.7370.958; Shojania KG, 2002, JAMA-J AM MED ASSOC, V288, P508, DOI 10.1001/jama.288.4.508; Smedley BD, 2003, UNEQUAL TREATMENT CO; Stafford RS, 1998, CIRCULATION, V97, P1231, DOI 10.1161/01.CIR.97.13.1231; Teich JM, 2000, ARCH INTERN MED, V160, P2741, DOI 10.1001/archinte.160.18.2741; Vincent C, 2000, BRIT MED J, V320, P777, DOI 10.1136/bmj.320.7237.777; Wagner E H, 2001, Jt Comm J Qual Improv, V27, P63; Wagner EH, 2002, BMJ-BRIT MED J, V325, P913, DOI 10.1136/bmj.325.7370.913; WHO, 2002, REDUCING RISKS PROMO; Woolf SH, 1999, JAMA-J AM MED ASSOC, V282, P2358, DOI 10.1001/jama.282.24.2358; 2001, EVIT REP TECHNOL ASS, V43, P1	41	48	50	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 6	2004	140	1					33	36		10.7326/0003-4819-140-1-200401060-00009	http://dx.doi.org/10.7326/0003-4819-140-1-200401060-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760VH	14706970				2023-01-03	WOS:000187855600005
J	Moller, M; Botti, H; Batthyany, C; Rubbo, H; Radi, R; Denicola, A				Moller, M; Botti, H; Batthyany, C; Rubbo, H; Radi, R; Denicola, A			Direct measurement of nitric oxide and oxygen partitioning into liposomes and low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZED LIPID DERIVATIVES; ORGANIC PEROXYL RADICALS; BILAYER-MEMBRANES; ALPHA-TOCOPHEROL; NITROGEN-DIOXIDE; AQUEOUS-SOLUTION; N-ALKANES; DIFFUSION; OXIDATION; PEROXIDATION	Nitric oxide ((NO)-N-.) has been proposed to play a relevant role in modulating oxidative reactions in lipophilic media like biomembranes and lipoproteins. Two factors that will regulate (NO)-N-. reactivity in the lipid milieu are its diffusion and solubility, but there is no data concerning the actual diffusion (D) and partition coefficients (K-P) of (NO)-N-. in biologically relevant hydrophobic phases. Herein, a "equilibrium-shift" method was designed to directly determine the (NO)-N-. and O-2 partition coefficients in liposomes and low density lipoprotein (LDL) relative to water. It was found that (NO)-N-. partitions 4.4- and 3.4-fold in liposomes and LDL, respectively, whereas O-2 behaves similarly with values of 3.9 and 2.9, respectively. In addition, actual diffusion coefficients in these hydrophobic phases were determined using fluorescence quenching and found that (NO)-N-. diffuses similar to2 times slower than O-2 in the core of LDL and 12 times slower than in buffer (D-NO(LDL) = 3.9 x 10(-6) cm(2) s(-1), D-O2(LDL) = 7.0 x 10(-6) cm(2) s(-1), D-NO(buffer) = D-O2(buffer) = 4.5 x 10(-5) cm(2) s(-1)). The influence of (NO)-N-. and O-2 partitioning and diffusion in membranes and lipoproteins on (NO)-N-. reaction with lipid radicals and auto-oxidation is discussed. Particularly, the 3-4- fold increase in O-2 and (NO)-N-. concentration within biological hydrophobic phases provides quantitative support for the idea of an accelerated auto-oxidation of (NO)-N-. in lipid-containing structures, turning them into sites of enhanced local production of oxidant and nitrosating species.	Univ Republica, Lab Fisicoquim Biol, Fac Ciencias, Montevideo 11400, Uruguay; Univ Republica, Dept Bioquim, Fac Med, Montevideo 11400, Uruguay; Univ Republica, Ctr Free Rad & Biomed Res, Montevideo 11400, Uruguay	Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay	Denicola, A (corresponding author), Univ Republica, Lab Fisicoquim Biol, Fac Ciencias, Igua 4225, Montevideo 11400, Uruguay.	denicola@fcien.edu.uy	Batthyany, Carlos I./A-6478-2009	Moller, Matias N./0000-0002-3486-8217; Batthyany, Carlos/0000-0002-0627-1982; Denicola, Ana/0000-0002-5181-9708; Rubbo, Homero/0000-0002-7897-6551	FOGARTY INTERNATIONAL CENTER [R03TW001493] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW001493] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Balazy M, 2001, J PHARMACOL EXP THER, V299, P611; Batthyany C, 2000, ARCH BIOCHEM BIOPHYS, V384, P335, DOI 10.1006/abbi.2000.2102; BECKMAN JS, 1996, NITRIC OXIDE PRINCIP, P1, DOI DOI 10.1016/B978-012435555-2/50002-4; Botti H, 2004, FREE RADICAL BIO MED, V36, P152, DOI 10.1016/j.freeradbiomed.2003.10.006; Brookes PS, 2003, J BIOL CHEM, V278, P31603, DOI 10.1074/jbc.M211784200; Byun J, 1999, FEBS LETT, V455, P243, DOI 10.1016/S0014-5793(99)00893-5; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0; COGAN U, 1973, BIOCHEMISTRY-US, V12, P521, DOI 10.1021/bi00727a026; Coles B, 2002, CIRC RES, V91, P375, DOI 10.1161/01.RES.0000032114.68919.EF; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V328, P208, DOI 10.1006/abbi.1996.0162; Denicola A, 2002, J BIOL CHEM, V277, P932, DOI 10.1074/jbc.M106589200; DEYOUNG LR, 1990, J PHYS CHEM-US, V94, P801, DOI 10.1021/j100365a054; Dzikovski BG, 2003, BIOPHYS J, V85, P1005, DOI 10.1016/S0006-3495(03)74539-1; EVANS DF, 1981, J CHEM PHYS, V74, P1298, DOI 10.1063/1.441190; GOLDSTEIN S, 1995, J AM CHEM SOC, V117, P12078, DOI 10.1021/ja00154a007; Goldstein S, 2004, J PHYS CHEM A, V108, P1719, DOI 10.1021/jp037431z; Goss SPA, 1997, J BIOL CHEM, V272, P21647, DOI 10.1074/jbc.272.34.21647; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Han P, 1996, J PHYS CHEM-US, V100, P5597, DOI 10.1021/jp952903y; HARE F, 1979, BIOCHIM BIOPHYS ACTA, V555, P388, DOI 10.1016/0005-2736(79)90393-6; Hevonoja T, 2000, BBA-MOL CELL BIOL L, V1488, P189, DOI 10.1016/S1388-1981(00)00123-2; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; Kelley EE, 1999, ARCH BIOCHEM BIOPHYS, V370, P97, DOI 10.1006/abbi.1999.1386; Kowert BA, 1999, J PHYS CHEM A, V103, P779, DOI 10.1021/jp984025k; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; LAKOWICZ JR, 1977, BIOCHIM BIOPHYS ACTA, V471, P401, DOI 10.1016/0005-2736(77)90045-1; Lide D.R., 2003, CRC HDB CHEM PHYS, V84; LIEB WR, 1986, J MEMBRANE BIOL, V92, P111, DOI 10.1007/BF01870701; LISSI EA, 1989, J BIOENERG BIOMEMBR, V21, P375, DOI 10.1007/BF00762728; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; MARQUSEE JA, 1986, J CHEM PHYS, V85, P434, DOI 10.1063/1.451621; O'Donnell VB, 2001, CIRC RES, V88, P12, DOI 10.1161/01.RES.88.1.12; ODonnell VB, 1997, BIOCHEMISTRY-US, V36, P15216, DOI 10.1021/bi971891z; Orlova EV, 1999, P NATL ACAD SCI USA, V96, P8420, DOI 10.1073/pnas.96.15.8420; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; POWER GG, 1970, J APPL PHYSIOL, V29, P145, DOI 10.1152/jappl.1970.29.2.145; Radi R, 1996, CHEM RES TOXICOL, V9, P828, DOI 10.1021/tx950176s; Radi R., 2000, BIOL CHEM PEROXYNITR, Vfirst, P57; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Rubbo H, 1995, ARCH BIOCHEM BIOPHYS, V324, P15, DOI 10.1006/abbi.1995.9935; Rubbo H, 2002, METHOD ENZYMOL, V359, P200; Rubbo H, 1996, METHOD ENZYMOL, V269, P385; SALERNO JC, 1996, NITRIC OXIDE PRINCIP, P83; SHAW AW, 1977, J CHEM SOC FARADAY T, V8, P1239; SHINITZKY M, 1974, J BIOL CHEM, V249, P2652; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; SMOTKIN ES, 1991, BIOCHIM BIOPHYS ACTA, V1061, P33, DOI 10.1016/0005-2736(91)90265-A; Subczynski WK, 1996, FREE RADICAL RES, V24, P343, DOI 10.3109/10715769609088032; Subczynski WK, 1998, BIOCHEMISTRY-US, V37, P3156, DOI 10.1021/bi972148+; Teerlink T, 2004, J LIPID RES, V45, P954, DOI 10.1194/jlr.M300521-JLR200; WINDREM DA, 1980, BIOCHIM BIOPHYS ACTA, V600, P655, DOI 10.1016/0005-2736(80)90469-1; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; Xiang TX, 1998, BIOPHYS J, V75, P2658, DOI 10.1016/S0006-3495(98)77711-2; Zhang H, 2003, J BIOL CHEM, V278, P8969, DOI 10.1074/jbc.M211561200	55	113	151	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8850	8854		10.1074/jbc.M413699200	http://dx.doi.org/10.1074/jbc.M413699200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15632138	hybrid			2023-01-03	WOS:000227453100029
J	Tsai, AG; Wadden, TA				Tsai, AG; Wadden, TA			Systematic review: An evaluation of major commercial weight loss programs in the United States	ANNALS OF INTERNAL MEDICINE			English	Review							LOW-CALORIE DIET; LONG-TERM MAINTENANCE; BEHAVIOR-THERAPY; BODY-COMPOSITION; CONTROLLED-TRIAL; OBESE-PATIENTS; FOLLOW-UP; INTERVENTION; REDUCTION; VLCD	Background: Each year millions of Americans enroll in commercial and self-help weight loss programs. Health care providers and their obese patients know little about these programs because of the absence of systematic reviews. Purpose: To describe the components, costs, and efficacy of the major commercial and organized self-help weight loss programs in the United States that provide structured in-person or online counseling. Data Sources: Review of company Web sites, telephone discussion with company representatives, and search of the MEDLINE database. Study Selection: Randomized trials at least 12 weeks in duration that enrolled only Adults and assessed interventions as they are usually provided to the public, or case series that met these criteria, stated the number of enrollees, and included a follow-up evaluation that lasted 1 year or longer. Data Extraction: Data were extracted on study design, attrition, weight loss, duration of follow-up, and maintenance of weight loss. Data Synthesis: we found studies of eDiets.com, Health Management Resources, Take Off Pounds Sensibly, OPTIFAST, and Weight Watchers. Of 3 randomized, controlled trials of Weight Watchers, the largest reported a loss of 3.2% of initial weight at 2 years. One randomized trial and several case series of medically supervised very-low-calorie diet programs found that patients who completed treatment lost approximately 15% to 25% of initial weight. These programs were associated with high costs, high attrition rates, and a high probability of regaining 50% or more of lost weight in 1 to 2 years. Commercial interventions available over the Internet and organized self-help programs produced minimal weight loss. Limitations: Because many studies did not control for high attrition rates, the reported results are probably a best-case scenario. Conclusions: With the exception of 1 trial of Weight Watchers, the evidence to support the use of the major commercial and self-help weight loss programs is suboptimal. Controlled trials are needed to assess the efficacy and cost-effectiveness of these interventions.	Univ Penn, Weight & Eating Disorders Program, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Wadden, TA (corresponding author), Univ Penn, Weight & Eating Disorders Program, Sch Med, 3535 Market St,Suite 3029, Philadelphia, PA 19104 USA.	wadden@mail.med.upenn.edu	Biguzzi, Felipe A/E-4724-2015		NIDDK NIH HHS [K24-DK-065018] Funding Source: Medline; PHS HHS [2-T32-HP-010026] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK065018] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agras WS, 1996, J CONSULT CLIN PSYCH, V64, P610, DOI 10.1037/0022-006X.64.3.610; ANDERSON JW, 1994, J AM COLL NUTR, V13, P256, DOI 10.1080/07315724.1994.10718406; ANDERSON JW, 1994, DIABETES CARE, V17, P602, DOI 10.2337/diacare.17.6.602; ANDERSON JW, 1991, J AM DIET ASSOC, V91, P1582; Anderson JW, 2001, AM J CLIN NUTR, V74, P579; Anderson JW, 1999, J AM COLL NUTR, V18, P620, DOI 10.1080/07315724.1999.10718897; [Anonymous], 1993, JAMA, V270, P967; Apfelbaum M, 1999, AM J MED, V106, P179, DOI 10.1016/S0002-9343(98)00411-2; Astrup A, 2000, Obes Rev, V1, P17, DOI 10.1046/j.1467-789x.2000.00004.x; BELIARD D, 1992, INT J OBESITY, V16, P505; Brownell K. D., 2000, LEARN PROGRAM WEIGHT; Bryner RW, 1999, J AM COLL NUTR, V18, P115, DOI 10.1080/07315724.1999.10718838; Christakis G, 1996, NUTR TODAY, V31, P29; Clelland R, 2001, CRIT REV FOOD SCI, V41, P45; Daly A, 2000, J AM DIET ASSOC, V100, P1456, DOI 10.1016/S0002-8223(00)00034-1; Ditschuneit HH, 1999, AM J CLIN NUTR, V69, P198; Djuric Z, 2002, OBES RES, V10, P657, DOI 10.1038/oby.2002.89; DONNELLY JE, 1994, INT J OBESITY, V18, P469; DONNELLY JE, 1991, AM J CLIN NUTR, V54, P56, DOI 10.1093/ajcn/54.1.56; Flechtner-Mors M, 2000, OBES RES, V8, P399, DOI 10.1038/oby.2000.48; Flynn T J, 1993, Arch Fam Med, V2, P1042, DOI 10.1001/archfami.2.10.1042; FOSTER GD, 1992, AM J CLIN NUTR, V55, P811, DOI 10.1093/ajcn/55.4.811; FRANK A, 1993, JAMA-J AM MED ASSOC, V269, P2132, DOI 10.1001/jama.269.16.2132; Grodstein F, 1996, ARCH INTERN MED, V156, P1302, DOI 10.1001/archinte.156.12.1302; HARTMAN WM, 1993, INT J EAT DISORDER, V14, P87, DOI 10.1002/1098-108X(199307)14:1&lt;87::AID-EAT2260140112&gt;3.0.CO;2-2; Heshka S, 2003, JAMA-J AM MED ASSOC, V289, P1792, DOI 10.1001/jama.289.14.1792; HYMAN FN, 1993, ANN INTERN MED, V119, P681, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00011; Institute of Medicine, 1995, WEIGH OPT CRIT EV WE; KANDERS BS, 1989, INT J OBESITY, V13, P131; KIRSCHNER MA, 1988, INT J OBESITY, V12, P69; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Latner JD, 2000, INT J OBESITY, V24, P893, DOI 10.1038/sj.ijo.0801249; LEVITZ LS, 1974, AM J PSYCHIAT, V131, P423; Lowe MR, 2001, INT J OBESITY, V25, P325, DOI 10.1038/sj.ijo.0801521; MIURA J, 1989, INT J OBESITY, V13, P73; 2000, PRACT GUID ID EV TRE; PAVLOU KN, 1989, AM J CLIN NUTR, V49, P1110, DOI 10.1093/ajcn/49.5.1110; Pekkarinen T, 1997, ARCH INTERN MED, V157, P1581, DOI 10.1001/archinte.157.14.1581; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Rippe JM, 1998, OBES RES, V6, P208, DOI 10.1002/j.1550-8528.1998.tb00339.x; Rossner S, 1997, INT J OBESITY, V21, P22, DOI 10.1038/sj.ijo.0800355; Ryttig KR, 1997, INT J OBESITY, V21, P574, DOI 10.1038/sj.ijo.0800444; Saris WHM, 2001, OBES RES, V9, p295S, DOI 10.1038/oby.2001.134; Serdula MK, 2003, JAMA-J AM MED ASSOC, V289, P1747, DOI 10.1001/jama.289.14.1747; SIKAND G, 1988, J AM DIET ASSOC, V88, P487; Stern J S, 1995, Obes Res, V3, P591; Tate DF, 2001, JAMA-J AM MED ASSOC, V285, P1172, DOI 10.1001/jama.285.9.1172; Tate DF, 2003, JAMA-J AM MED ASSOC, V289, P1833, DOI 10.1001/jama.289.14.1833; Torgerson JS, 1997, INT J OBESITY, V21, P987, DOI 10.1038/sj.ijo.0800507; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; VOLKMAR FR, 1981, ARCH INTERN MED, V141, P426, DOI 10.1001/archinte.141.4.426; Wadden T A, 1995, Obes Res, V3, P549; WADDEN TA, 1990, JAMA-J AM MED ASSOC, V263, P83, DOI 10.1001/jama.263.1.83; WADDEN TA, 1994, J CONSULT CLIN PSYCH, V62, P165, DOI 10.1037/0022-006X.62.1.165; WADDEN TA, 1992, ARCH INTERN MED, V152, P961, DOI 10.1001/archinte.152.5.961; WADDEN TA, 1986, J CONSULT CLIN PSYCH, V54, P482, DOI 10.1037/0022-006X.54.4.482; WADDEN TA, 1989, INT J OBESITY, V13, P39; WALSH MF, 1995, J FAM PRACTICE, V41, P231; WING RR, 1994, AM J MED, V97, P354, DOI 10.1016/0002-9343(94)90302-6; WING RR, 1991, ARCH INTERN MED, V151, P1334, DOI 10.1001/archinte.151.7.1334; Witherspoon Barbara, 2004, J Am Acad Nurse Pract, V16, P198, DOI 10.1111/j.1745-7599.2004.tb00442.x; WOLFE BL, 1992, ADDICT BEHAV, V17, P469, DOI 10.1016/0306-4603(92)90007-I; Womble L. G., 2002, Handbook of obesity treatment, P395; Womble LG, 2004, OBES RES, V12, P1011, DOI 10.1038/oby.2004.124; World Health Organization,, 1998, WHO TECHN REP SER; WYDEN R, 1990, MEMORANDUM SUBCOMMIT, P185; 1989, TAKE IT OFF KEEP IT; 2003, PARTNERSHIP HLTH WEI	68	469	473	0	72	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2005	142	1					56	66		10.7326/0003-4819-142-1-200501040-00012	http://dx.doi.org/10.7326/0003-4819-142-1-200501040-00012			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916DS	15630109				2023-01-03	WOS:000228366200006
J	McGuire, W; McEwan, P; Fowlie, PW				McGuire, W; McEwan, P; Fowlie, PW			ABC of preterm birth - Care in the early newborn period	BRITISH MEDICAL JOURNAL			English	Review									Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland	University of Dundee	McGuire, W (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland.			McGuire, William/0000-0001-8572-3467				Cornblath M, 2000, PEDIATRICS, V105, P1141, DOI 10.1542/peds.105.5.1141; EVANS NJ, PRACTICAL ECHOCARDIO; Flenady VJ, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000435, DOI 10.1002/14651858.CD000435]; FOWLIE PW, 2003, COCHRANE DB SYST REV; Malviya M., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003951.PUB2; Rabe H., 2012, COCHRANE DATABASE SY	6	3	3	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 6	2004	329	7474					1087	1089		10.1136/bmj.329.7474.1087	http://dx.doi.org/10.1136/bmj.329.7474.1087			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PN	15528621	Green Published			2023-01-03	WOS:000225070300024
J	Newman, S; Steed, L; Mulligan, K				Newman, S; Steed, L; Mulligan, K			Self-management interventions for chronic illness	LANCET			English	Review							RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; INTENSIVE PATIENT EDUCATION; COGNITIVE-BEHAVIOR THERAPY; TYPE-2 DIABETES-MELLITUS; JOINT PROTECTION PROGRAM; RHEUMATOID-ARTHRITIS; ECONOMIC-EVALUATION; STRESS MANAGEMENT; CHRONIC DISEASE	An increasing number of interventions have been developed for patients to better manage their chronic illnesses. They are characterised by substantial responsibility taken by patients, and are commonly referred to as self. management interventions. We examine the background, content, and efficacy of such interventions for type 2 diabetes, arthritis, and asthma. Although the content and intensity of the programmes were affected by the objectives of management of the illness, the interventions differed substantially even within the three illnesses. When comparing across conditions, it is important to recognise the different objectives of the interventions and the complexity of the issues that they are attempting to tackle. For both diabetes and asthma, the objectives are concerned with the underlying control of the condition with clear strategies to achieve the desired outcome. By contrast, strategies to deal with symptoms of pain and the consequences of disability in arthritis can be more complex. The interventions that were efficacious provide some guidance as to the components needed in future programmes to achieve the best results. But to ensure that these results endure over time remains an important issue for self-management interventions.	UCL, Ctr Behav & Social Sci Med, Unit Hlth Psychol, London W1W 7EY, England	University of London; University College London	Newman, S (corresponding author), UCL, Ctr Behav & Social Sci Med, Unit Hlth Psychol, 2nd Floor,Wolfson Bldg,48 Riding House St, London W1W 7EY, England.	s.newman@uci.ac.uk	Mulligan, Kathleen/M-6670-2019; Newman, Stanton P/D-3972-2011	Mulligan, Kathleen/0000-0002-6003-3029; Newman, Stanton/0000-0001-6712-6079				AgursCollins TD, 1997, DIABETES CARE, V20, P1503, DOI 10.2337/diacare.20.10.1503; Aikens JE, 1997, PSYCHOTHER PSYCHOSOM, V66, P302, DOI 10.1159/000289152; Astin JA, 2002, ARTHRIT RHEUM-ARTHR, V47, P291, DOI 10.1002/art.10416; Bailey WC, 1999, ARCH INTERN MED, V159, P2422, DOI 10.1001/archinte.159.20.2422; Bandura A, 1986, SOCIAL FDN THOUGHT A; Barlow J, 2002, PATIENT EDUC COUNS, V48, P177, DOI 10.1016/S0738-3991(02)00032-0; Barlow JH, 2000, HEALTH EDUC RES, V15, P665, DOI 10.1093/her/15.6.665; Bell MJ, 1998, J RHEUMATOL, V25, P231; Berg J, 1997, Clin Nurs Res, V6, P225, DOI 10.1177/105477389700600304; Blixen CE, 2001, J ASTHMA, V38, P23, DOI 10.1081/JAS-10000000264; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; BROWN SA, 1992, RES NURS HEALTH, V15, P409, DOI 10.1002/nur.4770150603; Brown SA, 2002, DIABETES CARE, V25, P259, DOI 10.2337/diacare.25.2.259; Brown SA, 1999, DIABETES EDUCATOR, V25, P52, DOI 10.1177/014572179902500623; Brus HLM, 1998, ANN RHEUM DIS, V57, P146, DOI 10.1136/ard.57.3.146; Cline CMJ, 1999, EUR J HEART FAIL, V1, P145, DOI 10.1016/S1388-9842(99)00014-8; Coates VE, 1996, PATIENT EDUC COUNS, V29, P99, DOI 10.1016/0738-3991(96)00938-X; Cochrane GM, 1999, RESP MED, V93, P763, DOI 10.1016/S0954-6111(99)90260-3; COHEN JL, 1986, ARTHRITIS RHEUM, V29, P388, DOI 10.1002/art.1780290312; Cote J, 2000, Can Respir J, V7, P395; Cote J, 2001, AM J RESP CRIT CARE, V163, P1415, DOI 10.1164/ajrccm.163.6.2006069; Couturaud F, 2002, J ASTHMA, V39, P493, DOI 10.1081/JAS-120004913; Cronan TA, 1997, ARTHRIT CARE RES, V10, P99, DOI 10.1002/art.1790100205; de Oliveira MA, 1999, EUR RESPIR J, V14, P908, DOI 10.1034/j.1399-3003.1999.14d30.x; Denollet J, 2001, CIRCULATION, V104, P2018, DOI 10.1161/hc4201.097940; DeRubeis RJ, 1998, J CONSULT CLIN PSYCH, V66, P37, DOI 10.1037/0022-006X.66.1.37; Epping-Jordan J, 2001, BMJ-BRIT MED J, V323, P947, DOI 10.1136/bmj.323.7319.947; Evers AWM, 2002, PAIN, V100, P141, DOI 10.1016/S0304-3959(02)00274-9; FOLKMAN S, 1984, J PERS SOC PSYCHOL, V46, P839, DOI 10.1037/0022-3514.46.4.839; Freeman K, 2002, CLIN REHABIL, V16, P828, DOI 10.1191/0269215502cr565oa; Fries JF, 1997, J RHEUMATOL, V24, P1378; Gallefoss F, 1999, AM J RESP CRIT CARE, V159, P812, DOI 10.1164/ajrccm.159.3.9804047; Gallefoss F, 2001, EUR RESPIR J, V17, P206, DOI 10.1183/09031936.01.17202060; George MR, 1999, ARCH INTERN MED, V159, P1710, DOI 10.1001/archinte.159.15.1710; Gibson PG, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001005, DOI 10.1002/14651858.CD001005]; Gibson PG, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001117], 10.1002/14651858.CD001117]; GLASGOW RE, 1992, DIABETES CARE, V15, P1423, DOI 10.2337/diacare.15.10.1423; Glasgow RE, 2000, MED CARE, V38, P1062, DOI 10.1097/00005650-200011000-00002; Glasgow RE, 1999, ANN BEHAV MED, V21, P159, DOI 10.1007/BF02908297; Glasgow RE, 2002, PATIENT EDUC COUNS, V48, P115, DOI 10.1016/S0738-3991(02)00025-3; GLASGOW RE, 1991, PATIENT COMPLIANCE M, P209; GRIFFIN S, 1989, ED PSYCHOSOCIAL INTE; Hammond A, 2001, RHEUMATOLOGY, V40, P1044, DOI 10.1093/rheumatology/40.9.1044; Hammond A, 1999, PATIENT EDUC COUNS, V37, P19, DOI 10.1016/S0738-3991(98)00093-7; Harish Z, 2001, ANN ALLERG ASTHMA IM, V86, P185, DOI 10.1016/S1081-1206(10)62689-0; HAWLEY DJ, 1993, J RHEUMATOL, V20, P2025; HAWLEY DJ, 1995, BAILLIERE CLIN RHEUM, V9, P803, DOI 10.1016/S0950-3579(05)80315-2; Helliwell PS, 1999, RHEUMATOLOGY, V38, P303, DOI 10.1093/rheumatology/38.4.303; Henry JL, 1997, PSYCHOL HEALTH MED, V2, P109; Hill J, 2001, ANN RHEUM DIS, V60, P869; Hockemeyer J, 2002, BEHAV MED, V27, P161, DOI 10.1080/08964280209596041; Holman H, 2000, BRIT MED J, V320, P526, DOI 10.1136/bmj.320.7234.526; Hopman-Rock M, 2000, J RHEUMATOL, V27, P1947; Jablon SL, 1997, APPL PSYCHOPHYS BIOF, V22, P155, DOI 10.1023/A:1026259725197; Juenger J, 2002, HEART, V87, P235, DOI 10.1136/heart.87.3.235; Kauppinen R, 1998, RESP MED, V92, P300, DOI 10.1016/S0954-6111(98)90113-5; Kauppinen R, 1999, RESP MED, V93, P283, DOI 10.1016/S0954-6111(99)90026-4; Kauppinen R, 2001, RESP MED, V95, P56, DOI 10.1053/rmed.2000.0971; Keefe FJ, 1999, ARTHRIT CARE RES, V12, P101, DOI 10.1002/1529-0131(199904)12:2<101::AID-ART5>3.0.CO;2-9; KEEFE FJ, 1996, CLIN CARE RHEUMATIC; Kenardy J, 2002, DIABETIC MED, V19, P234, DOI 10.1046/j.1464-5491.2002.00679.x; Keyserling TC, 2000, DIABETES EDUCATOR, V26, P796, DOI 10.1177/014572170002600508; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Kirk AF, 2001, DIABETIC MED, V18, P877, DOI 10.1046/j.0742-3071.2001.00570.x; Klein JJ, 2001, EUR RESPIR J, V17, P386, DOI 10.1183/09031936.01.17303860; KRAVITZ RL, 1993, ARCH INTERN MED, V153, P1869, DOI 10.1001/archinte.153.16.1869; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Lazarus R S, 1992, WHO Reg Publ Eur Ser, V44, P11; Lehrer P, 2002, J CONSULT CLIN PSYCH, V70, P691, DOI 10.1037//0022-006X.70.3.691; Leibing E, 1999, CLIN J PAIN, V15, P58, DOI 10.1097/00002508-199903000-00009; Levetan CS, 2002, DIABETES CARE, V25, P2, DOI 10.2337/diacare.25.1.2; Levy ML, 2000, RESP MED, V94, P900, DOI 10.1053/rmed.2000.0861; Lindroth Y, 1997, ARTHRIT CARE RES, V10, P325, DOI 10.1002/art.1790100507; Lord J, 1999, Health Technol Assess, V3, P1; Lorig K, 1995, HMO Pract, V9, P60; LORIG K, 1989, ARTHRITIS RHEUM, V32, P91, DOI 10.1002/anr.1780320116; LORIG K, 1986, J RHEUMATOL, V13, P763; LORIG K, 1987, PATIENT EDUC COUNS, V10, P207, DOI 10.1016/0738-3991(87)90126-1; Lorig K R, 2001, Eff Clin Pract, V4, P256; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Lundgren S, 1999, SCAND J RHEUMATOL, V28, P47; Lustman PJ, 1998, ANN INTERN MED, V129, P613, DOI 10.7326/0003-4819-129-8-199810150-00005; Marabini A, 2002, RESP MED, V96, P993, DOI 10.1053/rmed.2002.1394; Maurer BT, 1999, ARCH PHYS MED REHAB, V80, P1293, DOI 10.1016/S0003-9993(99)90032-1; McKay HG, 2002, REHABIL PSYCHOL, V47, P31, DOI 10.1037/0090-5550.47.1.31; McKay HG, 2001, DIABETES CARE, V24, P1328, DOI 10.2337/diacare.24.8.1328; Mensing C, 2003, DIABETES CARE, V26, P149; Miller CK, 2002, PREV MED, V34, P252, DOI 10.1006/pmed.2001.0985; Morley S, 1999, PAIN, V80, P1, DOI 10.1016/S0304-3959(98)00255-3; Multon KD, 2001, ARTHRIT RHEUM-ARTHR, V45, P122, DOI 10.1002/1529-0131(200104)45:2<122::AID-ANR163>3.3.CO;2-Z; Murray CJL, 1996, GLOBAL BURDEN DIS CO; Neinstein LS, 2001, WESTERN J MED, V175, P293, DOI 10.1136/ewjm.175.5.293; Norris SL, 2002, DIABETES CARE, V25, P1159, DOI 10.2337/diacare.25.7.1159; Norris SL, 2001, DIABETES CARE, V24, P561, DOI 10.2337/diacare.24.3.561; PADGETT D, 1988, J CLIN EPIDEMIOL, V41, P1007, DOI 10.1016/0895-4356(88)90040-6; PARCEL GS, 1986, SELF MANAGEMENT CHRO, P3; Perneger TV, 2002, AM J MED, V113, P7, DOI 10.1016/S0002-9343(02)01136-1; Peterman AH, 1998, HDB HLTH BEHAV CHANG, P462; Pincus T, 1996, BRIT J RHEUMATOL, V35, P879; PROCHASKA JO, 1992, BRIT J ADDICT, V87, P825; Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38; Ray NF, 1998, DIABETES CARE, V21, P296; Rickheim PL, 2002, DIABETES CARE, V25, P269, DOI 10.2337/diacare.25.2.269; Ridgeway NA, 1999, SOUTHERN MED J, V92, P667, DOI 10.1097/00007611-199907000-00004; RIEMSMA RP, 2002, PATIENT ED ADULTS RH; Rubin RR, 1999, DIABETES-METAB RES, V15, P205, DOI 10.1002/(SICI)1520-7560(199905/06)15:3<205::AID-DMRR29>3.0.CO;2-O; Samaras K, 1997, DIABETES RES CLIN PR, V37, P121, DOI 10.1016/S0168-8227(97)00061-2; Schmaling KB, 2001, J CLIN PSYCHOL MED S, V8, P167, DOI 10.1023/A:1011365519345; Scholten C, 1999, ARCH PHYS MED REHAB, V80, P1282, DOI 10.1016/S0003-9993(99)90030-8; Sharpe L, 2001, PAIN, V89, P275, DOI 10.1016/S0304-3959(00)00379-1; Smith DE, 1997, DIABETES CARE, V20, P52, DOI 10.2337/diacare.20.1.52; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; Smyth JM, 1999, JAMA-J AM MED ASSOC, V281, P1304, DOI 10.1001/jama.281.14.1304; Snoek FJ, 2002, DIABETIC MED, V19, P265, DOI 10.1046/j.1464-5491.2002.00678.x; Solomon DH, 2002, J RHEUMATOL, V29, P362; STEED L, 2002, DIABETIC MED, V19, P22; Sudre P, 1999, THORAX, V54, P681, DOI 10.1136/thx.54.8.681; Surwit RS, 2002, DIABETES CARE, V25, P30, DOI 10.2337/diacare.25.1.30; Taal E, 1997, SEMIN ARTHRITIS RHEU, V26, P805, DOI 10.1016/S0049-0172(97)80024-8; Thomas KS, 2002, BMJ-BRIT MED J, V325, P752, DOI 10.1136/bmj.325.7367.752; Trento M, 2002, DIABETOLOGIA, V45, P1231, DOI 10.1007/s00125-002-0904-8; Turner MO, 1998, AM J RESP CRIT CARE, V157, P540, DOI 10.1164/ajrccm.157.2.9703060; United Nations department of economic and social affairs, 2001, WORLD POP PROSP 2000; van der Palen J, 2001, PATIENT EDUC COUNS, V43, P161, DOI 10.1016/S0738-3991(00)00155-5; vantSpijker A, 1997, PSYCHOSOM MED, V59, P280, DOI 10.1097/00006842-199705000-00011; Vazquez IM, 1998, AM J HEALTH PROMOT, V13, P116, DOI 10.4278/0890-1171-13.2.116; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; *WHO, 2000, 206 WHO; 1991, J ALLERGY CLIN IMMUN, V88, P425	130	582	596	2	113	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2004	364	9444					1523	1537		10.1016/S0140-6736(04)17277-2	http://dx.doi.org/10.1016/S0140-6736(04)17277-2			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	864PN	15500899				2023-01-03	WOS:000224645500032
J	Hansmann, G				Hansmann, G			Neonatal resuscitation on air: it is time to turn down the oxygen tanks?	LANCET			English	Editorial Material							ROOM AIR; 100-PERCENT OXYGEN; NEWBORN-INFANTS; OXIDATIVE STRESS; TERM INFANTS; VENTILATION		Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA	Stanford University	Hansmann, G (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA.	georg.hansmann@stanford.edu	Hansmann, Georg/AAW-5843-2020	Hansmann, Georg/0000-0003-0709-3935				Askie LM, 2003, NEW ENGL J MED, V349, P959, DOI 10.1056/NEJMoa023080; CARTER BS, 1993, CLIN PERINATOL, V20, P287, DOI 10.1016/S0095-5108(18)30394-4; Casey BM, 2001, NEW ENGL J MED, V344, P467, DOI 10.1056/NEJM200102153440701; Collins MP, 2001, PEDIATR RES, V50, P712, DOI 10.1203/00006450-200112000-00014; Finer NN, 2004, CURR OPIN PEDIATR, V16, P157, DOI 10.1097/00008480-200404000-00007; Kattwinkel J, 2003, J PEDIATR-US, V142, P221, DOI 10.1067/mpd.2003.147; LUNDSTROM KE, 1995, ARCH DIS CHILD-FETAL, V73, pF81, DOI 10.1136/fn.73.2.F81; Niermeyer S, 2004, J Matern Fetal Neonatal Med, V15, P75, DOI 10.1080/14767050310001650761; Niermeyer S, 2000, PEDIATRICS, V106; O'Donnell CPF, 2004, ACTA PAEDIATR, V93, P583, DOI 10.1111/j.1651-2227.2004.tb02981.x; Ramji S, 2003, Indian Pediatr, V40, P510; RAMJI S, 1993, PEDIATR RES, V34, P809, DOI 10.1203/00006450-199312000-00023; Saugstad AD, 2004, CLIN PERINATOL, V31, P431, DOI 10.1016/j.clp.2004.04.021; Saugstad OD, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e1; Saugstad OD, 2005, BIOL NEONATE, V87, P27, DOI 10.1159/000080950; Tin W, 2001, ARCH DIS CHILD-FETAL, V84, pF106, DOI 10.1136/fn.84.2.F106; Tin Win, 2003, Paediatr Respir Rev, V4, P9, DOI 10.1016/S1526-0542(02)00307-X; Vento M, 2003, J PEDIATR-US, V142, P240, DOI 10.1067/mpd.2003.91; Vento M, 2001, PEDIATRICS, V107, P642, DOI 10.1542/peds.107.4.642; Vento M, 2001, BIOL NEONATE, V79, P261	20	19	21	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	2004	364	9442					1293	1294		10.1016/S0140-6736(04)17203-6	http://dx.doi.org/10.1016/S0140-6736(04)17203-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860NG	15474119				2023-01-03	WOS:000224349700006
J	Schubert, C				Schubert, C			HIV's lair	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1051	1051		10.1038/nm1004-1051	http://dx.doi.org/10.1038/nm1004-1051			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459706				2023-01-03	WOS:000224245800024
J	Hallstrom, AP; Ornato, JP; Weisfeldt, M; Travers, A; Christenson, J; McBurnie, MA; Zalenski, R; Becker, LB; Schron, EB; Proschan, M; Vijayaraghavan, K; Mattioni, T; Williams, C; Anton, AR; Jones, CD; Yahn, S; Rabel, D; O'Connor, RE; McGraw, P; Bollinger, M; Megargel, RE; Craven, RA; Bosken, LA; Burke, MP; Paulsen, J; Newton, G; Mahoney, BD; Knudson-Ballard, R; Vasquez, G; Groh, WJ; Cordes, D; Bondurant, SJ; Mann, NC; Shaum, B; Brown, K; Jacobsen, K; Aufderheide, TP; Pirrallo, RG; Conrad, CJ; Kitscha, DJ; Sparks, CW; von Briesen, C; Deja, KA; LeStarge, MM; Janisch, RW; Schmidt, SS; Parmenter, L; Grabowski, L; Ehrlich, S; Haynes, B; Asbury, L; Amaya, M; Richardson, LD; Ehlert, F; Freyberg, C; Richmond, N; Shields, C; Wilets, I; Holohan, J; Daya, M; Gunnels, MD; Hedges, JR; Jui, J; Schmidt, T; Wittwer, L; Brooks, H; Burke, C; Griffiths, D; Osur, M; MacGavin, B; Myrin, B; Weil, MH; Sehra, R; Cummins, RO; Doherty, A; Thompson, S; Wood, S; Christenson, J; Pennington, S; Holmes, A; Payne, H; Webb, R; Douglas, N; Lawson, P; Henry, MC; Johnson, S; Thode, H; Stapleton, ER; Reed, DB; Brown, LH; Evans, LM; Varghese, PJ; Lucas, R; Terndrup, TE; Stephens, S; Nafziger, S; Sanford, J; Travers, A; Panylyk, A; Irwin, K; Heisz, B; Becker, LB; Barry, A; Demertsidis, E; Van Zile, J; Grimmelsman, C; Nolting, L; Mosesso, VN; Slater, BK; Campbell, VJ; Hostler, D; Ornato, JP; Peberdy, MA; Overton, J; Schaffer, K; Zalenski, R; Compton, S; Dunne, R; Swor, R; Welch, R; Mango, LM; Bilicki, K; Weisfeldt, M; Sayre, MR; Schron, EB; Fleg, J; Domanski, MJ; Proschan, M; Rosenberg, Y; O'Neill, L; Simmons-Morton, D; Salive, ME; Nichol, G; Wells, G; Huszti, E; Rokosh, J; Morris, D; Kuntz, K; Feeny, D; Hallstrom, AP; Greene, HL; McBurnie, MA; Powell, J; Van Ottingham, L; Birnbaum, A; Ledingham, RB; Moore, R; Morris, M; Scholz, M; Kerr, A				Hallstrom, AP; Ornato, JP; Weisfeldt, M; Travers, A; Christenson, J; McBurnie, MA; Zalenski, R; Becker, LB; Schron, EB; Proschan, M; Vijayaraghavan, K; Mattioni, T; Williams, C; Anton, AR; Jones, CD; Yahn, S; Rabel, D; O'Connor, RE; McGraw, P; Bollinger, M; Megargel, RE; Craven, RA; Bosken, LA; Burke, MP; Paulsen, J; Newton, G; Mahoney, BD; Knudson-Ballard, R; Vasquez, G; Groh, WJ; Cordes, D; Bondurant, SJ; Mann, NC; Shaum, B; Brown, K; Jacobsen, K; Aufderheide, TP; Pirrallo, RG; Conrad, CJ; Kitscha, DJ; Sparks, CW; von Briesen, C; Deja, KA; LeStarge, MM; Janisch, RW; Schmidt, SS; Parmenter, L; Grabowski, L; Ehrlich, S; Haynes, B; Asbury, L; Amaya, M; Richardson, LD; Ehlert, F; Freyberg, C; Richmond, N; Shields, C; Wilets, I; Holohan, J; Daya, M; Gunnels, MD; Hedges, JR; Jui, J; Schmidt, T; Wittwer, L; Brooks, H; Burke, C; Griffiths, D; Osur, M; MacGavin, B; Myrin, B; Weil, MH; Sehra, R; Cummins, RO; Doherty, A; Thompson, S; Wood, S; Christenson, J; Pennington, S; Holmes, A; Payne, H; Webb, R; Douglas, N; Lawson, P; Henry, MC; Johnson, S; Thode, H; Stapleton, ER; Reed, DB; Brown, LH; Evans, LM; Varghese, PJ; Lucas, R; Terndrup, TE; Stephens, S; Nafziger, S; Sanford, J; Travers, A; Panylyk, A; Irwin, K; Heisz, B; Becker, LB; Barry, A; Demertsidis, E; Van Zile, J; Grimmelsman, C; Nolting, L; Mosesso, VN; Slater, BK; Campbell, VJ; Hostler, D; Ornato, JP; Peberdy, MA; Overton, J; Schaffer, K; Zalenski, R; Compton, S; Dunne, R; Swor, R; Welch, R; Mango, LM; Bilicki, K; Weisfeldt, M; Sayre, MR; Schron, EB; Fleg, J; Domanski, MJ; Proschan, M; Rosenberg, Y; O'Neill, L; Simmons-Morton, D; Salive, ME; Nichol, G; Wells, G; Huszti, E; Rokosh, J; Morris, D; Kuntz, K; Feeny, D; Hallstrom, AP; Greene, HL; McBurnie, MA; Powell, J; Van Ottingham, L; Birnbaum, A; Ledingham, RB; Moore, R; Morris, M; Scholz, M; Kerr, A		PAD Trial	Public-access defibrillation and survival after out-of-hospital cardiac arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AUTOMATED EXTERNAL DEFIBRILLATORS; PAD TRIAL; POLICE; EXPERIENCE; RATIONALE; OFFICERS; IMPACT; DESIGN	Background: The rate of survival after out-of-hospital cardiac arrest is low. It is not known whether this rate will increase if laypersons are trained to attempt defibrillation with the use of automated external defibrillators (AEDs). Methods: We conducted a prospective, community-based, multicenter clinical trial in which we randomly assigned community units (e.g., shopping malls and apartment complexes) to a structured and monitored emergency-response system involving lay volunteers trained in cardiopulmonary resuscitation (CPR) alone or in CPR and the use of AEDs. The primary outcome was survival to hospital discharge. Results: More than 19,000 volunteer responders from 993 community units in 24 North American regions participated. The two study groups had similar unit and volunteer characteristics. Patients with treated out-of-hospital cardiac arrest in the two groups were similar in age (mean, 69.8 years), proportion of men (67 percent), rate of cardiac arrest in a public location (70 percent), and rate of witnessed cardiac arrest (72 percent). No inappropriate shocks were delivered. There were more survivors to hospital discharge in the units assigned to have volunteers trained in CPR plus the use of AEDs (30 survivors among 128 arrests) than there were in the units assigned to have volunteers trained only in CPR (15 among 107; P=0.03; relative risk, 2.0; 95 percent confidence interval, 1.07 to 3.77); there were only 2 survivors in residential complexes. Functional status at hospital discharge did not differ between the two groups. Conclusions: Training and equipping volunteers to attempt early defibrillation within a structured response system can increase the number of survivors to hospital discharge after out-of-hospital cardiac arrest in public locations. Trained laypersons can use AEDs safely and effectively.	Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Publ Access Defibrillat Clin Trial Ctr, Seattle, WA 98105 USA; Virginia Commonwealth Univ, Richmond, VA 23284 USA	University of Washington; University of Washington Seattle; Virginia Commonwealth University	Hallstrom, AP (corresponding author), Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Publ Access Defibrillat Clin Trial Ctr, 1107 NE 45th St,Room 505, Seattle, WA 98105 USA.	padctc@u.washington.edu	Hedges, Jerris/AAC-1847-2021; Daya, Mohamud R/A-9322-2012; Nichol, Graham/Z-4996-2019; Compton, Scott/AAF-5657-2020	Brown, Lawrence/0000-0002-5940-1840	NHLBI NIH HHS [N01-HC-95177] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC095177] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Becker L, 1998, CIRCULATION, V97, P2106, DOI 10.1161/01.CIR.97.21.2106; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; Caffrey SL, 2002, NEW ENGL J MED, V347, P1242, DOI 10.1056/NEJMoa020932; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P123; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; EPSTEIN AE, 1995, AM J CARDIOL, V75, P470; Mosesso VN, 2004, RESUSCITATION, V61, P29, DOI 10.1016/j.resuscitation.2003.11.016; Mosesso VN, 1998, ANN EMERG MED, V32, P200, DOI 10.1016/S0196-0644(98)70137-4; Myerburg RJ, 2002, CIRCULATION, V106, P1058, DOI 10.1161/01.CIR.0000028147.92190.A7; Ornato JP, 2003, RESUSCITATION, V56, P135, DOI 10.1016/S0300-9572(02)00442-2; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Pell JP, 2002, BRIT MED J, V325, P515, DOI 10.1136/bmj.325.7363.515; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; Sayre MR, 2004, RESUSCITATION, V62, P25, DOI 10.1016/j.resuscitation.2004.02.007; Stiell IG, 1999, JAMA-J AM MED ASSOC, V281, P1175, DOI 10.1001/jama.281.13.1175; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; Valenzuela TD, 1997, CIRCULATION, V96, P3308; White RD, 1998, RESUSCITATION, V39, P145, DOI 10.1016/S0300-9572(98)00135-X; 2000, CIRCULATION S1, V102, P60	19	785	806	3	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2004	351	7					637	646						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	845FZ	15306665				2023-01-03	WOS:000223225500006
J	Veronin, MA; Youan, BBC				Veronin, MA; Youan, BBC			Medicine - Magic bullet gone astray: Medications and the Internet	SCIENCE			English	Editorial Material									Texas Tech Univ, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX 79106 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Veronin, MA (corresponding author), Texas Tech Univ, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX 79106 USA.	michael.veronin@ttuhsc.edu						ABDOU H. M., 2000, REMINGTON SCI PRACTI, P654; Gee Michael, 2002, J Manag Care Pharm, V8, P453; Gibson Liza, 2004, BMJ, V328, P486, DOI 10.1136/bmj.328.7438.486-c; Mudur Ganapati, 2003, BMJ, V327, P414, DOI 10.1136/bmj.327.7412.414-b; WALKER J, 2002, E PHARM GUIDE INTERN, P192; Young D, 2003, AM J HEALTH-SYST PH, V60, P729, DOI 10.1093/ajhp/60.8.729	6	36	36	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	2004	305	5683					481	481		10.1126/science.1097355	http://dx.doi.org/10.1126/science.1097355			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	840AH	15273381				2023-01-03	WOS:000222828900025
J	McDonald, SP; Craig, JC				McDonald, SP; Craig, JC		Australian New Zealand Paediat Nep	Long-term survival of children with end-stage renal disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; DIALYSIS; MORTALITY; INFANTS; TRANSPLANTATION; RECIPIENTS; FAILURE; COHORT	Background Although renal-replacement therapy for children with end-stage renal disease has been used for several decades, data on patients' long-term survival are sparse. Methods We examined the long-term survival of all children and adolescents who were under 20 years of age when renal-replacement therapy commenced (study period, April 1963 through March 2002), using data from the Australia and New Zealand Dialysis and Transplant Registry. Survival was analyzed with the use of Kaplan-Meier methods and age-standardized mortality rates. Risk factors for death were analyzed with the use of Cox regression analysis with time-dependent covariates. Results A total of 1634 children and adolescents were followed for a median of 9.7 years. The long-term survival rate among children requiring renal-replacement therapy was 79 percent at 10 years and 66 percent at 20 years. Mortality rates were 30 times as high as for children without end-stage renal disease. Risk factors for death were a young age at the time renal-replacement therapy was initiated (especially for children under 1 year of age, among whom the risk was four times as high as for children 15 to 19 years of age) and treatment with dialysis (which was associated with a risk more than four times as high as for renal transplantation). Overall, a trend toward improved survival was observed over the four decades of the study. Conclusions Despite improvement in long-term survival, mortality rates among children requiring renal-replacement therapy remain substantially higher than those among children without end-stage renal disease. Increasing the proportion of children treated with renal transplantation rather than with dialysis can improve survival further.	Queen Elizabeth Hosp, ANZDATA Registry, Adelaide, SA, Australia; Childrens Hosp Westmead, Ctr Kidney Res, Sydney, NSW, Australia; Childrens Hosp Westmead, Natl Hlth & Med Res Council Ctr Clin Res Excellen, Sydney, NSW, Australia; Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney; University of Sydney	McDonald, SP (corresponding author), Queen Elizabeth Hosp, ANZDATA Registry, 28 Woodville Rd, Woodville S, SA 5011, Australia.	stephenm@anzdata.org.au	Craig, Jonathan/E-2813-2013	Craig, Jonathan/0000-0002-2548-4035				[Anonymous], 2003, USRDS 2003 ANN DAT R; *AUSTR BUR STAT, 2001, 33020 ABS; Bakkaloglu SA, 2000, PERITON DIALYSIS INT, V20, P568; Coulthard MG, 2002, ARCH DIS CHILD, V87, P511, DOI 10.1136/adc.87.6.511; EHRICH JHH, 1992, NEPHROL DIAL TRANSPL, V7, P1171, DOI 10.1093/ndt/7.12.1171; Geary DF, 1998, J PEDIATR-US, V133, P154, DOI 10.1016/S0022-3476(98)70199-4; Groothoff JW, 2002, KIDNEY INT, V61, P621, DOI 10.1046/j.1523-1755.2002.00156.x; HELD PJ, 1992, CLIN TRANSPLANTS 199, P71; HENNING P, 1988, ARCH DIS CHILD, V63, P35, DOI 10.1136/adc.63.1.35; Ledermann SE, 2000, J PEDIATR-US, V136, P24, DOI 10.1016/S0022-3476(00)90044-1; Leonard MB, 2003, KIDNEY INT, V63, P744, DOI 10.1046/j.1523-1755.2003.00788.x; Li SQ, 2003, AUST NZ J PUBL HEAL, V27, P419, DOI 10.1111/j.1467-842X.2003.tb00420.x; McDonald SP, 2002, NEPHROL DIAL TRANSPL, V17, P2212, DOI 10.1093/ndt/17.12.2212; Mitsnefes MM, 2000, PEDIATR NEPHROL, V14, P898, DOI 10.1007/s004670000303; *NAPRTCS, 2003, 2003 ANN REP REN TRA; Parekh RS, 2002, J PEDIATR-US, V141, P191, DOI 10.1067/mpd.2002.125910; RUSS GR, 2002, AUSTR NZ DIALYSIS TR; Silverstein DM, 2000, PEDIATR NEPHROL, V14, P105, DOI 10.1007/s004670050022; Vats AN, 2000, TRANSPLANTATION, V69, P1414, DOI 10.1097/00007890-200004150-00035; WLAKER RG, 1999, 22 REPORT AUSTR NZ D, P90; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; Wood EG, 2001, AM J KIDNEY DIS, V37, P573, DOI 10.1053/ajkd.2001.22083	22	535	556	2	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2004	350	26					2654	2662		10.1056/NEJMoa031643	http://dx.doi.org/10.1056/NEJMoa031643			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831MR	15215481				2023-01-03	WOS:000222199000006
J	Groce, NE; Trasi, R				Groce, NE; Trasi, R			Rape of individuals with disability: AIDS and the folk belief of virgin cleansing	LANCET			English	Editorial Material							SOUTH-AFRICA; ABUSE; WOMEN		Yale Univ, Sch Publ Hlth, Global Hlth Div, New Haven, CT 06520 USA	Yale University	Groce, NE (corresponding author), Yale Univ, Sch Publ Hlth, Global Hlth Div, New Haven, CT 06520 USA.	nora.groce@yale.edu		Groce, Nora/0000-0002-7885-7042				Cambridge P, 1997, DISABIL SOC, V12, P427, DOI 10.1080/09687599727272; DOSSANTOS V, 2004, STATEMENT SEXUAL ABU; Earl-Taylor M, 2002, HIV AIDS STATS VIRGI; Groce NE, 2003, LANCET, V361, P1401, DOI 10.1016/S0140-6736(03)13146-7; Jewkes R, 2002, LANCET, V359, P711, DOI 10.1016/S0140-6736(02)07794-2; Jewkes R, 2002, LANCET, V359, P319, DOI 10.1016/S0140-6736(02)07530-X; *MENT DIS RIGHTS I, 2002, NOT AG HUM RIGHTS PE; Nosek MA, 2001, VIOLENCE AGAINST WOM, V7, P477, DOI 10.1177/10778010122182569; Pitcher GJ, 2002, LANCET, V359, P274, DOI 10.1016/S0140-6736(02)07532-3; Saxton M, 2001, VIOLENCE AGAINST WOM, V7, P393, DOI 10.1177/10778010122182523; SMITH C, 2003, IASSCS C SEX SECR JO; SOBSEY D, 1991, VIOLENCE ABUSE LIVES; *UN INT REG INF NE, 2002, FOC VIRG MYTH HIV AI; Womendez C., 1991, SEX DISABIL, V9, P273, DOI DOI 10.1007/BF01102397; *YAL U WORLD BANK, 2004, HIV AIDS DIS GLOB SU	15	84	84	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	2004	363	9422					1663	1664		10.1016/S0140-6736(04)16288-0	http://dx.doi.org/10.1016/S0140-6736(04)16288-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	822NG	15158626				2023-01-03	WOS:000221546300005
J	Saito, H; Dhanasekaran, P; Nguyen, D; Deridder, E; Holvoet, P; Lund-Katz, S; Phillips, MC				Saito, H; Dhanasekaran, P; Nguyen, D; Deridder, E; Holvoet, P; Lund-Katz, S; Phillips, MC			alpha-Helix formation is required for high affinity binding of human apolipoprotein A-I to lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN PARTICLES; C-TERMINAL DOMAIN; CELLULAR CHOLESTEROL EFFLUX; UNILAMELLAR VESICLES; APOA-I; EXCHANGEABLE APOLIPOPROTEINS; TITRATION CALORIMETRY; AMPHIPATHIC PEPTIDES; ALANINE PEPTIDE; COIL TRANSITION	Apolipoprotein (apo) A-I is thought to undergo a conformational change during lipid association that results in the transition of random coil to alpha-helix. Using a series of deletion mutants lacking different regions along the molecule, we examined the contribution of alpha-helix formation in apoA-I to the binding to egg phosphatidylcholine (PC) small unilamellar vesicles (SUV). Binding isotherms determined by gel filtration showed that apoA-I binds to SUV with high affinity and deletions in the C-terminal region markedly decrease the affinity. Circular dichroism measurements demonstrated that binding to SUV led to an increase in alpha-helix content, but the helix content was somewhat less than in reconstituted discoidal PC . apoA-I complexes for all apoA-I variants, suggesting that the helical structure of apoA-I on SUV is different from that in discs. Isothermal titration calorimetry showed that the binding of apoA-I to SUV is accompanied by a large exothermic heat and deletions in the C-terminal regions greatly decrease the heat. Analysis of the rate of release of heat on binding, as well as the kinetics of quenching of tryptophan fluorescence by brominated PC, indicated that the opening of the N-terminal helix bundle is a rate-limiting step in apoA-I binding to the SUV surface. Significantly, the correlation of thermodynamic parameters of binding with the increase in the number of helical residues revealed that the contribution of alpha-helix formation upon lipid binding to the enthalpy and the free energy of the binding of apoA-I is - 1.1 and - 0.04 kcal/mol per residue, respectively. These results indicate that alpha-helix formation, especially in the C-terminal regions, provides the energetic source for high affinity binding of apoA-I to lipids.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Abramson Res Ctr,Div Gastroenterol & Nutr, Philadelphia, PA 19104 USA; Univ Louvain, Ctr Expt Surg & Anesthesiol, B-3000 Louvain, Belgium	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Phillips, MC (corresponding author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Abramson Res Ctr,Div Gastroenterol & Nutr, Ste 1102,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	phillipsmi@email.chop.edu	HOLVOET, PAUL/T-8434-2017	HOLVOET, PAUL/0000-0001-9201-0772; Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL 22633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P14524, DOI 10.1021/bi990930z; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Corsico B, 2001, J BIOL CHEM, V276, P16978, DOI 10.1074/jbc.M011533200; Davidson WS, 1999, BIOCHEMISTRY-US, V38, P14387, DOI 10.1021/bi991428h; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; Fang YL, 2003, BIOCHEMISTRY-US, V42, P13260, DOI 10.1021/bi0354031; Fang YL, 2003, BIOCHEMISTRY-US, V42, P6881, DOI 10.1021/bi034152t; Favari E, 2002, BIOCHEM BIOPH RES CO, V299, P801, DOI 10.1016/S0006-291X(02)02745-6; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Frank PG, 2000, J LIPID RES, V41, P853; Gazzara JA, 1997, J LIPID RES, V38, P2134; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; GONZALEZMANAS JM, 1992, BIOCHEMISTRY-US, V31, P7294, DOI 10.1021/bi00147a013; Gorshkova IN, 2002, BIOCHEMISTRY-US, V41, P10529, DOI 10.1021/bi025807d; Gorshkova IN, 2000, BIOCHEMISTRY-US, V39, P15910, DOI 10.1021/bi0014406; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; Kiss RS, 1999, BIOCHEMISTRY-US, V38, P4327, DOI 10.1021/bi982597p; Klon AE, 2002, BIOCHEMISTRY-US, V41, P10895, DOI 10.1021/bi020315m; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773; Li HH, 2000, J BIOL CHEM, V275, P37048, DOI 10.1074/jbc.M005336200; Li HH, 2002, J BIOL CHEM, V277, P39093, DOI 10.1074/jbc.M206770200; Liu LJ, 2003, J BIOL CHEM, V278, P42976, DOI 10.1074/jbc.M308420200; Lopez MM, 2002, P NATL ACAD SCI USA, V99, P1298, DOI 10.1073/pnas.032665199; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lund-Katz S, 2003, FRONT BIOSCI-LANDMRK, V8, pD1044, DOI 10.2741/1077; LUNDKATZ S, 1993, J BIOL CHEM, V268, P23008; MAO D, 1984, BIOCHEMISTRY-US, V23, P2667, DOI 10.1021/bi00307a020; MASSEY JB, 1979, J BIOL CHEM, V254, P9359; MCLEAN LR, 1984, BIOCHIM BIOPHYS ACTA, V776, P21, DOI 10.1016/0005-2736(84)90246-3; Mishra VK, 1998, BIOCHEMISTRY-US, V37, P10313, DOI 10.1021/bi980042o; Mishra VK, 1996, BIOCHEMISTRY-US, V35, P11210, DOI 10.1021/bi960760f; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; Oda MN, 2003, NAT STRUCT BIOL, V10, P455, DOI 10.1038/nsb931; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Panagotopulos SE, 2001, J BIOL CHEM, V276, P42965, DOI 10.1074/jbc.M106462200; Phillips JC, 1997, BIOPHYS J, V73, P2337, DOI 10.1016/S0006-3495(97)78264-X; Roberts LM, 1997, BIOCHEMISTRY-US, V36, P7615, DOI 10.1021/bi962952g; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; Rothblat GH, 1999, J LIPID RES, V40, P781; Saito H, 1997, J LIPID RES, V38, P287; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; SCHOLTZ JM, 1991, P NATL ACAD SCI USA, V88, P2854, DOI 10.1073/pnas.88.7.2854; Schulthess G, 2000, BIOCHEMISTRY-US, V39, P12623, DOI 10.1021/bi0011633; Seelig J, 1997, BBA-REV BIOMEMBRANES, V1331, P103, DOI 10.1016/S0304-4157(97)00002-6; SEGREST JP, 1992, J LIPID RES, V33, P141; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; Tricerri MA, 2000, BIOCHEMISTRY-US, V39, P14682, DOI 10.1021/bi0014251; Tricerri MA, 2002, J LIPID RES, V43, P187; Wang LB, 2003, J BIOL CHEM, V278, P37480, DOI 10.1074/jbc.M303133200; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wieprecht T, 1999, J MOL BIOL, V294, P785, DOI 10.1006/jmbi.1999.3268; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD; YOKOYAMA S, 1980, J BIOL CHEM, V255, P7333; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	66	112	116	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20974	20981		10.1074/jbc.M402043200	http://dx.doi.org/10.1074/jbc.M402043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	15020600	hybrid			2023-01-03	WOS:000221273800052
J	Rudolf, PM; Bernstein, IBG				Rudolf, PM; Bernstein, IBG			Counterfeit drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Rudolf, PM (corresponding author), US FDA, Rockville, MD 20857 USA.							*FOOD DRUG ADM, 2004, COMB COUNT DRUGS REP	1	47	47	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 1	2004	350	14					1384	1386		10.1056/NEJMp038231	http://dx.doi.org/10.1056/NEJMp038231			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808IJ	15070787				2023-01-03	WOS:000220562500004
J	Snyder, PJ				Snyder, PJ			Hypogonandism in elderly men - What to do until the evidence comes	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA	University of Pennsylvania	Snyder, PJ (corresponding author), Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.							LIVERMAN CT, IN PRESS TESTOSTERON	1	81	89	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					440	442		10.1056/NEJMp038207	http://dx.doi.org/10.1056/NEJMp038207			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749451				2023-01-03	WOS:000188463900005
J	Markowitz, AJ; Rabow, MW				Markowitz, AJ; Rabow, MW			Overcoming the false dichotomy of "curative" vs "palliative" care for late-stage HIV/AIDS - "Let me live the way I want to live, until I can't"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article														Markowitz, Amy/0000-0001-9314-2814				Selwyn PA, 2003, JAMA-J AM MED ASSOC, V290, P806, DOI 10.1001/jama.290.6.806	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	2004	291	4					492	492		10.1001/jama.291.4.492	http://dx.doi.org/10.1001/jama.291.4.492			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767EF	14747507				2023-01-03	WOS:000188426700035
J	Young, T; Brailsford, S; Connell, C; Davies, R; Harper, P; Klein, JH				Young, T; Brailsford, S; Connell, C; Davies, R; Harper, P; Klein, JH			Using industrial processes to improve patient care	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; SIMULATION		Brunel Univ, Dept Informat Syst & Comp, Uxbridge UB8 3PH, Middx, England; Univ Southampton, Sch Management, Southampton SO17 1BJ, Hants, England; Univ Warwick, Warwick Business Sch, Coventry CV4 7AL, W Midlands, England; Univ Southampton, Sch Math, Southampton SO9 5NH, Hants, England	Brunel University; University of Southampton; University of Warwick; University of Southampton	Young, T (corresponding author), Brunel Univ, Dept Informat Syst & Comp, Uxbridge UB8 3PH, Middx, England.	terry.young@brunel.ac.uk		Harper, Paul/0000-0001-7894-4907; Klein, Jonathan/0000-0002-5495-8738; Young, Terry/0000-0001-9545-2269; Brailsford, Sally/0000-0002-6665-8230				BECKETT P, 2000, AEROSPACE INT    NOV, P12; CRAIGHEAD IB, 2001, BMJ; Davies R, 2002, DIABETIC MED, V19, P762, DOI 10.1046/j.1464-5491.2002.00773.x; Feachem RGA, 2002, BMJ-BRIT MED J, V324, P135, DOI 10.1136/bmj.324.7330.135; Fontan JE, 2003, PHARM WORLD SCI, V25, P112, DOI 10.1023/A:1024053514359; *GEN EL, WHAT 6 SIGMA; Goldratt E, 2000, GOAL; Harry M., 1999, 6 SIGMA BREAKTHROUGH; Jun JB, 1999, J OPER RES SOC, V50, P109, DOI 10.1057/palgrave.jors.2600669; *NHS, 2000, INP ADM BED MAN NHS, P9; PENDLETON D, 2002, BRIT MED J, V325, P1354; Smith J, 2001, BRIT MED J, V322, P1257, DOI 10.1136/bmj.322.7297.1257; WILCON T, 2001, BMJ; Wolstenholme E, 1999, SYST DYNAM REV, V15, P253, DOI 10.1002/(SICI)1099-1727(199923)15:3<253::AID-SDR172>3.3.CO;2-G; Womack J.P., 1996, LEAN THINKING	15	149	150	0	18	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 17	2004	328	7432					162	164		10.1136/bmj.328.7432.162	http://dx.doi.org/10.1136/bmj.328.7432.162			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	14726351	Green Published			2023-01-03	WOS:000188249900030
J	Doran, T; Drever, F; Whitehead, M				Doran, T; Drever, F; Whitehead, M			Health of young and elderly informal carers: analysis of UK census data	BRITISH MEDICAL JOURNAL			English	Article									Univ Liverpool, Dept Publ Hlth, Liverpool L69 3GB, Merseyside, England	University of Liverpool	Doran, T (corresponding author), Univ Liverpool, Dept Publ Hlth, Liverpool L69 3GB, Merseyside, England.							Banks P, 2001, DISABIL SOC, V16, P797, DOI 10.1080/09687590120083967; *GEN REG OFF SCOTL, SCOTL CENS; MAHER J, 2002, CAREERS 2000; *NO IR STAT RES AG, 2001, NO IR CENS 2001 OUTP; *ONS, 2003, CENS 2001 S	5	44	44	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 13	2003	327	7428					1388	1388		10.1136/bmj.327.7428.1388	http://dx.doi.org/10.1136/bmj.327.7428.1388			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	755PL	14670886	Green Published, Bronze			2023-01-03	WOS:000187417900025
J	Brady, M				Brady, M			Health care in remote Australian Indigenous communities	LANCET			English	Article									Australian Natl Univ, Ctr Aboriginal Econ Policy Res, Canberra, ACT 0200, Australia	Australian National University	Brady, M (corresponding author), Australian Natl Univ, Ctr Aboriginal Econ Policy Res, Canberra, ACT 0200, Australia.								0	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S36	S37		10.1016/S0140-6736(03)15069-6	http://dx.doi.org/10.1016/S0140-6736(03)15069-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698123				2023-01-03	WOS:000187790200019
J	Qurishi, N; Kreuzberg, C; Luchters, G; Effenberger, W; Kupfer, B; Sauerbruch, T; Rockstroh, JK; Spengler, U				Qurishi, N; Kreuzberg, C; Luchters, G; Effenberger, W; Kupfer, B; Sauerbruch, T; Rockstroh, JK; Spengler, U			Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEASE INHIBITOR; INFECTED PATIENTS; DRUG-USERS; NATURAL-HISTORY; DISEASE; PROGRESSION; VIREMIA; IMPACT; HCV	Background Highly active antiretroviral therapy (HAART) has improved the prognosis of HIV infection. However, replication of hepatitis C virus (HCV) is not inhibited by HAART, and treatment-related hepatotoxicity is common. To clarify the effect of HAART in HIV/HCV-coinfected patients, we studied liver-related mortality and overall mortality in 285 patients who were regularly treated during the period 1990-2002 at our department. Methods Survival was analysed retrospectively by Kaplan-Meier and Cox's regression analyses after patients (81% haemophiliacs) had been stratified into three groups according to their antiretroviral therapy (HAART n=93, available after 1995; treatment exclusively with nucleoside analogues n=55, available after 1992; or no treatment, n=137). Findings Liver-related mortality rates were 0.45, 0.69, and 1.70 per 100 person-years in the HAART, antiretroviral-treatment, and untreated groups. Kaplan-Meier analysis of liver related mortality confirmed the significant survival benefit in patients with antiretroviral therapy (p=0.018), and regression analysis identified HAART (odds ratio 0.106 [95% CI 0.020-0.564]), antiretroviral treatment (0.283 [0.103-0.780]), CD4-positive T-cell count (0.746 [0.641-0.868] per 0.05X10(9) cells/L), serum cholinesterase (0.962 [0.938-0.986] per 100 U/L), and age (1.065 [1.027-1.105] per year) as independent predictors of liver-related survival. Severe drug-related hepatotoxicity was seen in five patients treated with nucleoside analogues alone and 13 treated with HAART. No patient died from drug-related hepatotoxicity. Interpretation In addition to improved overall survival, antiretroviral therapy significantly reduced long-term liver related mortality in our patients. This survival benefit seems to outweigh by far the associated risks of severe hepatotoxicity.	Univ Bonn, Med Klin & Poliklin 1, Dept Internal Med, D-53105 Bonn, Germany; Univ Bonn, Inst Expt Hematol & Transfus Med, D-53105 Bonn, Germany; Univ Bonn, Inst Microbiol & Immunol, D-53105 Bonn, Germany	University of Bonn; University of Bonn; University of Bonn	Spengler, U (corresponding author), Univ Bonn, Med Klin & Poliklin 1, Dept Internal Med, Sigmund Freud Str 25, D-53105 Bonn, Germany.	spengler@uni-bonn.de						Benhamou Y, 2001, HEPATOLOGY, V34, P283, DOI 10.1053/jhep.2001.26517; Benhamou Y, 1999, HEPATOLOGY, V30, P1054, DOI 10.1002/hep.510300409; Bica I, 2001, CLIN INFECT DIS, V32, P492, DOI 10.1086/318501; Cacoub P, 2001, CLIN INFECT DIS, V32, P1207, DOI 10.1086/319747; Carr A, 1997, LANCET, V349, P995, DOI 10.1016/S0140-6736(05)62892-9; *CDC, 1986, MMWR-MORBID MORTAL W, V35, P334; Daar ES, 2001, J INFECT DIS, V183, P589, DOI 10.1086/318539; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; Delladetsima J, 2002, HAEMOPHILIA, V8, P668, DOI 10.1046/j.1365-2516.2002.00670.x; Di Martino V, 2001, HEPATOLOGY, V34, P1193, DOI 10.1053/jhep.2001.29201; EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602; Fialaire P, 1999, J INFECT DIS, V180, P574, DOI 10.1086/314910; Garcia-Samaniego J, 1998, J HEPATOL, V28, P526, DOI 10.1016/S0168-8278(98)80334-6; HAYASHI PH, 1991, J MED VIROL, V33, P177, DOI 10.1002/jmv.1890330307; Hernandez-Aguado I, 2001, EUR J EPIDEMIOL, V17, P539, DOI 10.1023/A:1014560431726; IMBERTI L, 1991, J VIROL METHODS, V34, P233, DOI 10.1016/0166-0934(91)90103-7; MARTIN P, 1989, GASTROENTEROLOGY, V97, P1559, DOI 10.1016/0016-5085(89)90405-8; Martin-Carbonero L, 2001, AIDS RES HUM RETROV, V17, P1467, DOI 10.1089/08892220152644160; Martinez-Sierra C, 2003, CLIN INFECT DIS, V36, P491, DOI 10.1086/367643; MEDINA DJ, 1994, ANTIMICROB AGENTS CH, V38, P1824, DOI 10.1128/AAC.38.8.1824; MILITO AD, 1999, J MED VIROL, V57, P140; Mokrzycki MH, 2000, CLIN INFECT DIS, V30, P198, DOI 10.1086/313594; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perez-Olmeda M, 2000, AIDS, V14, P212, DOI 10.1097/00002030-200001280-00023; Pol S, 2002, J VIRAL HEPATITIS, V9, P1, DOI 10.1046/j.1365-2893.2002.00326.x; Puoti M, 2000, J ACQ IMMUN DEF SYND, V24, P211; Ragni MV, 1999, J INFECT DIS, V180, P2027, DOI 10.1086/315143; Ragni MV, 2001, J INFECT DIS, V183, P1112, DOI 10.1086/319273; Rizzieri DA, 1997, LANCET, V349, P775, DOI 10.1016/S0140-6736(05)60200-0; Rockstroh JK, 1996, AM J GASTROENTEROL, V91, P2563; Rockstroh JK, 1998, AIDS, V12, pS42; RUMI MG, 1990, ANN INTERN MED, V112, P379, DOI 10.7326/0003-4819-112-5-379; Rutschmann OT, 1998, J INFECT DIS, V177, P783, DOI 10.1086/517808; Saves M, 1999, AIDS, V13, pF115, DOI 10.1097/00002030-199912030-00002; SHERMAN KE, 1991, J INFECT DIS, V163, P414, DOI 10.1093/infdis/163.2.414; Soriano V, 1999, EUR J EPIDEMIOL, V15, P1, DOI 10.1023/A:1007506617734; Soto B, 1997, J HEPATOL, V26, P1, DOI 10.1016/S0168-8278(97)80001-3; Sterling RK, 2003, JAIDS-J ACQ IMM DEF, V32, P30, DOI 10.1097/00126334-200301010-00005; Sulkowski MS, 2002, JAMA-J AM MED ASSOC, V288, P199, DOI 10.1001/jama.288.2.199; Sulkowski MS, 2000, JAMA-J AM MED ASSOC, V283, P74, DOI 10.1001/jama.283.1.74; Takamatsu J, 2001, HAEMOPHILIA, V7, P575, DOI 10.1046/j.1365-2516.2001.00567.x; TELFER PT, 1994, BRIT J HAEMATOL, V88, P397, DOI 10.1111/j.1365-2141.1994.tb05038.x; Toyoda H, 1999, CLIN INFECT DIS, V29, P1332, DOI 10.1086/313480; VANGEMEN B, 1993, J VIROL METHODS, V43, P177, DOI 10.1016/0166-0934(93)90075-3; Vento S, 1998, AIDS, V12, P116; Woitas RP, 1997, J IMMUNOL, V159, P1012; Yokozaki S, 2000, BLOOD, V96, P4293; Zylberberg H, 1998, CLIN INFECT DIS, V26, P1104, DOI 10.1086/520281	48	398	407	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	2003	362	9397					1708	1713		10.1016/S0140-6736(03)14844-1	http://dx.doi.org/10.1016/S0140-6736(03)14844-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643119				2023-01-03	WOS:000186767700009
J	Gluckman, PD; Wyatt, JS; Azzopardi, D; Ballard, R; Edwards, AD; Ferriero, DM; Polin, RA; Robertson, CM; Thoresen, M; Whitelaw, A; Gunn, AJ				Gluckman, PD; Wyatt, JS; Azzopardi, D; Ballard, R; Edwards, AD; Ferriero, DM; Polin, RA; Robertson, CM; Thoresen, M; Whitelaw, A; Gunn, AJ		CoolCap Study Grp	Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial	LANCET			English	Article							AMPLITUDE-INTEGRATED ELECTROENCEPHALOGRAPHY; CEREBRAL HYPOXIA-ISCHEMIA; WHOLE-BODY HYPOTHERMIA; PERINATAL ASPHYXIA; NEWBORN-INFANTS; TERM INFANTS; BRAIN-INJURY; THERAPEUTIC HYPOTHERMIA; BIRTH ASPHYXIA; CARDIAC-ARREST	Background Cerebral hypothermia can improve outcome of experimental perinatal hypoxia-ischaemia. We did a multicentre randomised controlled trial to find out if delayed head cooling can improve neurodevelopmental outcome in babies with neonatal encephalopathy. Methods 234 term infants with moderate to severe neonatal encephalopathy and abnormal amplitude integrated electroencephalography (aEEG) were randomly assigned to either head cooling for 72 h, within 6 h of birth, with rectal temperature maintained at 34-35degreesC (n=116), or conventional care (n=118). Primary outcome was death or severe disability at 18 months. Analysis was by intention to treat. We examined in two predefined subgroup analyses the effect of hypothermia in babies with the most severe aEEG changes before randomisation-ie, severe loss of background amplitude, and seizures-and those with less severe changes. Findings In 16 babies, follow-up data were not available. Thus in 218 infants (93%), 73/110 (66%) allocated conventional care and 59/108 (55%) assigned head cooling died or had severe disability at 18 months (odds ratio 0.61; 95% CI 0.34-1-09, p=0.1). After adjustment for the severity of aEEG changes with a logistic regression model, the odds ratio for hypothermia treatment was 0.57 (0.32-1.01, p=0.05). No difference was noted in the frequency of clinically important complications. Predefined subgroup analysis suggested that head cooling had no effect in infants with the most severe aEEG changes (n=46, 1.8; 0.49-6.4, p=0.51), but was beneficial in infants with less severe aEEG changes (n=172, 0.42; 0.22-0.80, p=0.009). Interpretation These data suggest that although induced head cooling is not protective in a mixed population of infants with neonatal encephalopathy, it could safely improve survival without severe neurodevelopmental. disability in infants with less severe aEEG changes.	Univ Auckland, Fac Med & Hlth Sci, Dept Physiol, Auckland, New Zealand; Univ Auckland, Liggins Inst, Auckland 1, New Zealand; UCL, London, England; Univ London Imperial Coll Sci Technol & Med, London, England; Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Univ Alberta, Dept Paediat, Edmonton, AB, Canada; Univ Bristol, St Michaels Hosp, Bristol, Avon, England; Univ Bristol, Southmead Hosp, Bristol, Avon, England	University of Auckland; University of Auckland; University of London; University College London; Imperial College London; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of California System; University of California San Francisco; Columbia University; University of Alberta; University of Bristol; Southmead Hospital; University of Bristol	Gunn, AJ (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Dept Physiol, Private Bag 92019, Auckland, New Zealand.	aj.gunn@auckland.ac.nz	Edwards, Anthony/HCI-9626-2022	Edwards, Anthony David/0000-0003-4801-7066; Gunn, Alistair/0000-0003-0656-7035	MRC [MC_U120081323] Funding Source: UKRI; Medical Research Council [MC_U120081323] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		al Naqeeb N, 1999, PEDIATRICS, V103, P1263, DOI 10.1542/peds.103.6.1263; AZZOPARDI D, 1989, PEDIATR RES, V25, P445, DOI 10.1203/00006450-198905000-00004; Azzopardi D, 2000, PEDIATRICS, V106, P684, DOI 10.1542/peds.106.4.684; Battin MR, 2003, PEDIATRICS, V111, P244, DOI 10.1542/peds.111.2.244; Battin MR, 2001, PEDIATRICS, V107, P480, DOI 10.1542/peds.107.3.480; Bayley N., 2006, BAYLEY SCALES INFANT, V3rd; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bona E, 1998, PEDIATR RES, V43, P738, DOI 10.1203/00006450-199806000-00005; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; Compagnoni G, 2002, BIOL NEONATE, V82, P222, DOI 10.1159/000065890; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; Gunn AJ, 2000, CURR OPIN PEDIATR, V12, P111, DOI 10.1097/00008480-200004000-00004; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Haaland K, 1997, PEDIATR RES, V41, P505, DOI 10.1203/00006450-199704000-00009; Holzer M, 2002, NEW ENGL J MED, V346, P549; HONZIK MP, 1976, ORIGINS INTELLIGENCE, P46; Nedelcu J, 2000, BRAIN PATHOL, V10, P61; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; ROBERTSON CMT, 1989, J PEDIATR-US, V114, P753, DOI 10.1016/S0022-3476(89)80132-5; ROTH SC, 1992, DEV MED CHILD NEUROL, V34, P285; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; SCHUBERT A, 1995, J NEUROSURG ANESTH, V7, P139, DOI 10.1097/00008506-199504000-00021; Shalak LF, 2003, PEDIATRICS, V111, P351, DOI 10.1542/peds.111.2.351; Shankaran S, 2002, PEDIATRICS, V110, P377, DOI 10.1542/peds.110.2.377; Sirimanne ES, 1996, PEDIATR RES, V39, P591, DOI 10.1203/00006450-199604000-00005; Thoresen M, 2000, PEDIATRICS, V106, P92, DOI 10.1542/peds.106.1.92; THORESEN M, 1995, PEDIATR RES, V37, P667, DOI 10.1203/00006450-199505000-00019; Tooley JR, 2003, ANN NEUROL, V53, P65, DOI 10.1002/ana.10402; Wagner BP, 2002, PEDIATR RES, V51, P354, DOI 10.1203/00006450-200203000-00015	30	1560	1637	2	66	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 19	2005	365	9460					663	670		10.1016/S0140-6736(05)17946-X	http://dx.doi.org/10.1016/S0140-6736(05)17946-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721471				2023-01-03	WOS:000227096800023
J	Holland, R; Lenaghan, E; Harvey, I; Smith, R; Shepstone, L; Lipp, A; Christou, M; Evans, D; Hand, C				Holland, R; Lenaghan, E; Harvey, I; Smith, R; Shepstone, L; Lipp, A; Christou, M; Evans, D; Hand, C			Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ELDERLY-PATIENTS; PHARMACIST; EQ-5D	Objective To determine whether home based medication review by pharmacists affects hospital readmission rates among older people. Design Randomised controlled trial. Setting Home based medication review after discharge from acute or community hospitals in Norfolk and Suffolk. Participants 872 patients aged over 80 recruited during an emergency admission (any cause) if returning to own home or warden controlled accommodation and taking two or more drugs daily on discharge. Intervention Two home visits by a pharmacist within two weeks and eight weeks of discharge to educate patients and carers about their drugs, remove out of date drugs, inform general practitioners of drug reactions or interactions, and inform the local pharmacist if a compliance aid is needed. Control arm received usual care. Main outcome measure Total emergency readmissions to hospital at six months. Secondary outcomes included death and quality of life measured with the EQ-5D. Results By six months 178 readmissions had occurred in the control group and 234 in the intervention group (rate ratio = 1.30, 95% confidence interval 1.07 to 1.58; P = 0.009, Poisson model). 49 deaths Occurred in the intervention group compared with 63 in the control group (hazard ratio = 0.75, 0.52 to 1.10; P = 0.14). EQ-5D scores decreased (worsened) by a mean of 0.14 in the control group and 0.13 in the intervention group (difference = 0.01, -0.05 to 0.06; P = 0.84 t test). Conclusions The intervention was associated with a significantly higher rate of hospital admissions and did not significantly improve quality of life or reduce deaths. Further research is needed to explain this counterintuitive finding and to identify more effective methods of medication review.	Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Acad Pharm Practice Unit, Norwich NR4 7TJ, Norfolk, England; Great Yarmouth Teaching Primary Care Trust, Great Yarmouth NR14 8AB, Norfolk, England; Suffolk Publ Hlth Network, Pharmaceut Serv, Ipswich IP3 8LS, Suffolk, England	University of East Anglia; University of East Anglia	Holland, R (corresponding author), Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England.	r.holland@uea.ac.uk		Holland, Richard/0000-0002-4663-6923; Smith, Richard/0000-0003-3837-6559				Al-Eidan FA, 2002, BRIT J CLIN PHARMACO, V53, P163, DOI 10.1046/j.0306-5251.2001.01531.x; Al-Rashed SA, 2002, BRIT J CLIN PHARMACO, V54, P657, DOI 10.1046/j.1365-2125.2002.01707.x; Begley S., 1997, INT J PHARM PRACT, V5, P111, DOI [10.1111/j.2042-7174.1997.tb00895.x, DOI 10.1111/J.2042-7174.1997.TB00895.X, DOI 10.1111/j.2042-7174.1997.tb00895.x]; Department of Health, 2001, NAT SERV FRAM OLD PE; GOODYER II, 1995, BR J CLIN PRACT, V19, P173; Holland R, 2004, HEALTH ECON, V13, P793, DOI 10.1002/hec.858; JITAPUNKUL S, 1991, AGE AGEING, V20, P332, DOI 10.1093/ageing/20.5.332; Krska J, 2001, AGE AGEING, V30, P205, DOI 10.1093/ageing/30.3.205; LAW R, 1976, BMJ-BRIT MED J, V1, P565, DOI 10.1136/bmj.1.6009.565; Lowe CJ, 2000, BRIT J CLIN PHARMACO, V50, P172, DOI 10.1046/j.1365-2125.2000.00247.x; National Health Service (NHS), GUIDANCE ROLE USE; Nazareth I, 2001, AGE AGEING, V30, P33, DOI 10.1093/ageing/30.1.33; Office for National Statistics, UK CENS 2001; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; *PRESCR SUPP UN, 2001, ASTRO PUS CHAPT STAR; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; RAYNOR DK, 1993, BRIT MED J, V306, P1158, DOI 10.1136/bmj.306.6886.1158; Stewart S, 1998, J AM GERIATR SOC, V46, P174, DOI 10.1111/j.1532-5415.1998.tb02535.x; Tidermark J, 2003, QUAL LIFE RES, V12, P1069, DOI 10.1023/A:1026193812514; Varma S, 1999, PHARMACOTHERAPY, V19, P860, DOI 10.1592/phco.19.10.860.31565; WRIGHT EC, 1993, LANCET, V342, P909, DOI 10.1016/0140-6736(93)91951-H; Zermansky AG, 2001, BRIT MED J, V323, P1340, DOI 10.1136/bmj.323.7325.1340	22	210	215	1	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2005	330	7486					293	295		10.1136/bmj.38338.674583.AE	http://dx.doi.org/10.1136/bmj.38338.674583.AE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895EM	15665005	Green Published, Bronze, Green Accepted			2023-01-03	WOS:000226843700018
J	Berman, BM; Lao, LX; Langenberg, P; Lee, WL; Gilpin, AMK; Hochberg, MC				Berman, BM; Lao, LX; Langenberg, P; Lee, WL; Gilpin, AMK; Hochberg, MC			Effectiveness of acupuncture as adjunctive therapy in osteoarthritis of the knee - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							CHINESE ACUPUNCTURE; RESEARCH-SOCIETY; CLINICAL-TRIALS; ORAL-SURGERY; TASK-FORCE; ARTHRITIS; COMPLEMENTARY; PAIN; EFFICACY; RECOMMENDATIONS	Background: Evidence on the efficacy of acupuncture for reducing the pain and dysfunction of osteoarthritis is equivocal. Objective: To determine whether acupuncture provides greater pain relief and improved function compared with sham acupuncture or education in patients with osteoarthritis of the knee. Design: Randomized, controlled trial. Setting: Two outpatient clinics (an integrative medicine facility and a rheumatology facility) located in academic teaching hospitals and 1 clinical trials facility. Patients: 570 patients with osteoarthritis of the knee (mean age [+/-SD], 65.5 +/- 8.4 years). Intervention: 23 true acupuncture sessions over 26 weeks. Controls received 6 two-hour sessions over 12 weeks or 23 sham acupuncture sessions over 26 weeks. Measurements: Primary outcomes were changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and function scores at 8 and 26 weeks. Secondary outcomes were patient global assessment, 6-minute walk distance, and physical health scores of the 36-Item Short-Form Health Survey (SF-36). Results: Participants in the true acupuncture group experienced greater improvement in WOMAC function scores than the sham acupuncture group at 8 weeks (mean difference, -2.9 [95% CI, -5.0 to -0.8]; P = 0.01) but not in WOMAC pain score (mean difference, -0.5 [CI, -1.2 to 0.2]; P = 0.18) or the patient global assessment (mean difference, 0.16 [CI, -0.02 to 0.34]; P > 0.2). At 26 weeks, the true acupuncture group experienced significantly greater improvement than the sham group in the WOMAC function score (mean difference, -2.5 [CI, -4.7 to -0.4]; P = 0.01), WOMAC pain score (mean difference, -0.87 [CI, -1.58 to -0.16]; P = 0.003), and patient global assessment (mean difference, 0.26 [CI, 0.07 to 0.45]; P = 0.02). Limitations: At 26 weeks, 43% of the participants in the education group and 25% in each of the true and sham acupuncture groups were not available for analysis. Conclusions: Acupuncture seems to provide improvement in function and pain relief as an adjunctive therapy for osteoarthritis of the knee when compared with credible sham acupuncture and education control groups.	Univ Maryland, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Berman, BM (corresponding author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA.		Lao, Lixing/I-7979-2013	Lao, Lixing/0000-0003-0198-9714	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [U01AT000171] Funding Source: NIH RePORTER; NCCIH NIH HHS [U01 AT-00171] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Altman R, 1996, OSTEOARTHR CARTILAGE, V4, P217, DOI 10.1016/S1063-4584(05)80101-3; Altman RD, 2004, J RHEUMATOL, V31, P5; Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; Astin JA, 2000, J GERONTOL A-BIOL, V55, pM4; Bausell R.Barker., 2002, POWER ANAL EXPT RES; Bausell RB, 2001, MED CARE, V39, P190, DOI 10.1097/00005650-200102000-00009; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; BERMAN BM, 1995, OSTEOARTHR CARTILAGE, V3, P139, DOI 10.1016/S1063-4584(05)80046-9; Berman BM, 2002, ARCH INTERN MED, V162, P766, DOI 10.1001/archinte.162.7.766; Berman BM, 1999, RHEUMATOLOGY, V38, P346, DOI 10.1093/rheumatology/38.4.346; Cheng X., 1999, CHINESE ACUPUNCTURE; Ezzo J, 2001, ARTHRITIS RHEUM, V44, P819, DOI 10.1002/1529-0131(200104)44:4<819::AID-ANR138>3.0.CO;2-P; Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003-4819-133-8-200010170-00016; Felson DT, 2000, ANN INTERN MED, V133, P726, DOI 10.7326/0003-4819-133-9-200011070-00015; GAW AC, 1975, NEW ENGL J MED, V293, P375, DOI 10.1056/NEJM197508212930803; Hernandez-Diaz Sonia, 2001, American Journal of Medicine, V110, p20S; Hochberg MC, 2003, ANN INTERN MED, V139, P781, DOI 10.7326/0003-4819-139-9-200311040-00013; Hochberg MC, 2001, BEST PRACT RES CL RH, V15, P583, DOI 10.1053/berh.2001.0175; LAO LX, 1995, ORAL SURG ORAL MED O, V79, P423, DOI 10.1016/S1079-2104(05)80121-0; Lao LX, 1999, ARCH OTOLARYNGOL, V125, P567, DOI 10.1001/archotol.125.5.567; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Lorig K, 1998, ARTHRIT CARE RES, V11, P448, DOI 10.1002/art.1790110604; MEENAN RF, 1992, ARTHRITIS RHEUM, V35, P1, DOI 10.1002/art.1780350102; OConnor J, 1981, ACUPUNCTURE COMPREHE; Pendleton A, 2000, ANN RHEUM DIS, V59, P936, DOI 10.1136/ard.59.12.936; Pham T, 2004, OSTEOARTHR CARTILAGE, V12, P389, DOI 10.1016/j.joca.2004.02.001; Rao JK, 1999, ANN INTERN MED, V131, P409, DOI 10.7326/0003-4819-131-6-199909210-00003; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Strand V, 2002, ARTHRIT RHEUM-ARTHR, V47, P349, DOI 10.1002/art.10560; Takeda W, 1994, Arthritis Care Res, V7, P118, DOI 10.1002/art.1790070304; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WONG TW, 1991, FAM PRACT, V8, P168, DOI 10.1093/fampra/8.2.168	32	378	404	1	83	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	2004	141	12					901	910		10.7326/0003-4819-141-12-200412210-00006	http://dx.doi.org/10.7326/0003-4819-141-12-200412210-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	882EY	15611487				2023-01-03	WOS:000225923000001
J	Watts, G				Watts, G			Commentary: Golden rules	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							STAPHYLOCOCCUS-AUREUS				Watts, G (corresponding author), 28 New End Sq, London NW3 1LS, England.	geoff@scileg.freeserve.co.uk						Biant LC, 2004, BRIT MED J, V329, P149; Cooper BS, 2004, BMJ-BRIT MED J, V329, P533, DOI 10.1136/bmj.329.7465.533; Muto CA, 2003, INFECT CONT HOSP EP, V24, P362, DOI 10.1086/502213	3	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	2004	329	7465					538	539		10.1136/bmj.329.7465.538	http://dx.doi.org/10.1136/bmj.329.7465.538			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853DE	15345627	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000223805800017
J	Lee, YC; Lee, KS; Park, SJ; Park, HS; Lim, JS; Park, KH; Im, MJ; Choi, IW; Lee, HK; Kim, UH				Lee, YC; Lee, KS; Park, SJ; Park, HS; Lim, JS; Park, KH; Im, MJ; Choi, IW; Lee, HK; Kim, UH			Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by a prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid	FASEB JOURNAL			English	Article						eosinophilia; NF-kappa B; oxidative stress; signal transduction	NF-KAPPA-B; OXIDATIVE STRESS; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; LUNG-DISEASES; GROWTH-FACTOR; T-CELLS; GLUTATHIONE; ACTIVATION; RESPONSES	Oxidative stress plays an important role in the pathogenesis of bronchial asthma. An excess production of reactive oxygen species (ROS) and defective endogenous antioxidant defense mechanisms may be present in asthma. Reduced glutathione (GSH) is one of the most important reducing agents against oxidant free radicals. A reducing agent, L-2-oxothiazolidine-4-carboxylic acid (OTC), a prodrug of cysteine, increases intracellular GSH. We have used a mouse model for asthma to determine effects of OTC on allergen-induced bronchial inflammation and airway hyper-responsiveness. The administration of OTC reduced bronchial inflammation and airway hyper-responsiveness. ROS generation in bronchoalveolar lavage fluids was increased by ovalbumin ( OVA) inhalation, but this increase was diminished by administration of OTC. The increased IL-4, IL-5, IL-13, and eosinophil cationic protein levels in lungs after OVA inhalation were significantly reduced by the administration of OTC. In addition, the increased expression of ICAM-1, VCAM-1, RANTES, and eotaxin in lungs after OVA inhalation was significantly reduced by the administration of OTC. We also showed that the increased NF-kappaB levels in nuclear protein extracts of lung tissues at 72 h after OVA inhalation were decreased by the administration of OTC. These findings suggest that OTC may reduce airway inflammation and hyper-responsiveness through regulation of NF-kappaB activity.	Chonbuk Natl Univ Med Sch, Dept Internal Med, Jeonju 561712, South Korea; Chonbuk Natl Univ Med Sch, Res Ctr Allerg Immune Dis, Jeonju 561712, South Korea; Chonbuk Natl Univ Med Sch, Dept Biochem, Jeonju 561712, South Korea; Chonbuk Natl Univ Med Sch, Dept Immunol, Jeonju 561712, South Korea; Chonbuk Natl Univ Med Sch, Inst Cardiovasc Res, Jeonju 561712, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University	Lee, YC (corresponding author), Chonbuk Natl Univ Med Sch, Dept Internal Med, 634-18 Keumamdong, Jeonju 561712, South Korea.	leeyc@chonbuk.ac.kr						Adam L, 1999, J BIOL CHEM, V274, P26337, DOI 10.1074/jbc.274.37.26337; ASTI C, 1995, PHARMACOL RES, V31, P387, DOI 10.1016/1043-6618(95)80094-8; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Barnes PJ, 1997, TRENDS PHARMACOL SCI, V18, P46, DOI 10.1016/S0165-6147(97)89796-9; Blesa S, 2002, PHARMACOL RES, V45, P135, DOI 10.1006/phrs.2001.0917; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Cheng JJ, 1996, BIOCHEM BIOPH RES CO, V225, P100, DOI 10.1006/bbrc.1996.1136; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cortijo J, 1999, FREE RADICAL BIO MED, V27, P392, DOI 10.1016/S0891-5849(99)00070-2; Dworski R, 2000, THORAX, V55, pS51, DOI 10.1136/thorax.55.suppl_2.S51; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; GinnPease ME, 1996, BIOCHEM BIOPH RES CO, V226, P695, DOI 10.1006/bbrc.1996.1416; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Han MK, 2002, J BIOL CHEM, V277, P5315, DOI 10.1074/jbc.M106439200; Han SJ, 2002, J BIOL CHEM, V277, P44715, DOI 10.1074/jbc.M202524200; Harper R, 2001, AM J RESP CELL MOL, V25, P178, DOI 10.1165/ajrcmb.25.2.4471; HAZELTON GA, 1986, J PHARMACOL EXP THER, V237, P341; Henderson WR, 2002, J IMMUNOL, V169, P5294, DOI 10.4049/jimmunol.169.9.5294; HULSMANN AR, 1994, AM J RESP CRIT CARE, V149, P519, DOI 10.1164/ajrccm.149.2.8306055; JUN DY, 1997, J BIOL CHEM, V272, P30952; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Lee M, 2002, BIOCHEM J, V366, P937, DOI 10.1042/BJ20020453; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; Lin YL, 1997, MOL PHARMACOL, V52, P465, DOI 10.1124/mol.52.3.465; MacNee W, 2001, EUR J PHARMACOL, V429, P195, DOI 10.1016/S0014-2999(01)01320-6; MESINA JE, 1989, BRAIN RES, V478, P181, DOI 10.1016/0006-8993(89)91494-7; Mori A, 1999, J ALLERGY CLIN IMMUN, V103, pS429, DOI 10.1016/S0091-6749(99)70158-2; MOSLEN MT, 1989, J PHARMACOL EXP THER, V248, P157; Nishida S, 2002, FREE RADICAL RES, V36, P601, DOI 10.1080/10715760210872; Oiry J, 1999, J MED CHEM, V42, P4733, DOI 10.1021/jm980289j; OWEN S, 1991, NEW ENGL J MED, V325, P586; PORTA P, 1991, J PHARMACOL EXP THER, V257, P331; Rahman I, 1996, FREE RADICAL BIO MED, V21, P669, DOI 10.1016/0891-5849(96)00155-4; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055, DOI 10.1164/ajrccm.154.4.8887607; Rahman I, 1997, THORAX, V52, P565, DOI 10.1136/thx.52.6.565; Rahman I, 1998, THORAX, V53, P601, DOI 10.1136/thx.53.7.601; SANG F, 1997, J BIOL CHEM, V272, P23086; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stutz AM, 1999, J IMMUNOL, V163, P4383; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; Verhasselt V, 1999, J IMMUNOL, V162, P2569; Vita JA, 1998, J CLIN INVEST, V101, P1408, DOI 10.1172/JCI1155; WILLIAMSON JM, 1981, P NATL ACAD SCI-BIOL, V78, P936, DOI 10.1073/pnas.78.2.936; WILLIAMSON JM, 1982, P NATL ACAD SCI-BIOL, V79, P6246, DOI 10.1073/pnas.79.20.6246; Zhang MJ, 2002, FREE RADICAL BIO MED, V32, P454, DOI 10.1016/S0891-5849(01)00825-5	49	62	63	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1917	+		10.1096/fj.04-2212fje	http://dx.doi.org/10.1096/fj.04-2212fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15385436				2023-01-03	WOS:000224243200018
J	Jack, L; Liburd, L; Spencer, T; Airhihenbuwa, CO				Jack, L; Liburd, L; Spencer, T; Airhihenbuwa, CO			Understanding the environmental issues in diabetes self-management education research: A reexamination of 8 studies in community-based settings	ANNALS OF INTERNAL MEDICINE			English	Article							MEXICAN-AMERICANS; HEALTH-PROMOTION; INTERVENTIONS; OUTCOMES; NIDDM; INITIATIVES; FRAMEWORK; FAMILIES; EXERCISE; PROGRAM	Eight studies included in a recent systematic review of the efficacy of diabetes self-management education were qualitatively reexamined to determine the presence of theoretical frameworks, methods used to ensure cultural appropriateness, and the quality of the instrument. Theoretical frameworks that help to explain complex pathways that produce health outcomes were lacking; culture indices were not incorporated into diabetes self-management education; and the instruments used to measure outcomes were inadequate. We provide recommendations to improve research on diabetes self-management education in community settings through use of a contextual framework that encourages targeting multiple levels of influence-individual, family, organizational, community, and policy.	CDCP, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30341 USA; Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA; Penn State Univ, University Pk, PA 16802 USA	Centers for Disease Control & Prevention - USA; Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Jack, L (corresponding author), CDCP, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Mailstop K-10,4770 Buford Highway NE, Atlanta, GA 30341 USA.	ljack@cdc.gov						Airhihenbuwa C. O., 1995, HLTH CULTURE W PARAD; [Anonymous], 1991, NURSING CONCEPTS PRA; BARNARD RJ, 1994, DIABETES CARE, V17, P1469, DOI 10.2337/diacare.17.12.1469; BARRERA M, 1981, SOCIAL NETWORKS SOCI; Brody GH, 1998, CHILD DEV, V69, P803, DOI 10.1111/j.1467-8624.1998.tb06244.x; Brody GH, 2001, DIABETES EDUCATOR, V27, P685, DOI 10.1177/014572170102700509; BROWN SA, 1995, DIABETES EDUCATOR, V21, P203, DOI 10.1177/014572179502100307; Brown SA, 1998, DIABETES EDUCATOR, V24, P331, DOI 10.1177/014572179802400308; Brown SA, 1999, DIABETES EDUCATOR, V25, P52, DOI 10.1177/014572179902500623; CAMPBELL T, 1994, FAMILIES CHANGE COPI; DeBourdeaudhuij I, 1997, HEALTH EDUC RES, V12, P77, DOI 10.1093/her/12.1.77; ELSHAWS EB, 1994, DIABETES EDUCATOR, V20, P228, DOI 10.1177/014572179402000309; Fisher L, 2000, J FAM PRACTICE, V49, P561; Flores E T, 1995, J Natl Cancer Inst Monogr, P101; GLASGOW RE, 1988, DIABETES CARE, V11, P377, DOI 10.2337/diacare.11.5.377; GLASGOW RE, 1992, DIABETES CARE, V15, P1423, DOI 10.2337/diacare.15.10.1423; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Goodman R M, 1998, J Public Health Manag Pract, V4, P37; GOODMAN RM, 1994, J COMMUNITY PSYCHOL, P6; Hahn JM, 1998, DIABETES EDUCATOR, V24, P153, DOI 10.1177/014572179802400204; HEATH GW, 1987, DIABETES CARE, V10, P579, DOI 10.2337/diacare.10.5.579; Hepworth J, 1997, HEALTH PROMOT INT, V12, P233, DOI 10.1093/heapro/12.3.233; Jack L, 1999, DIABETES EDUCATOR, V25, P775, DOI 10.1177/014572179902500510; JACK L, 2002, DIABETES EDUCATOR, V28, P922; Kumanyika S. K., 1997, Overweight and weight management: the health professional's guide to understanding and practice., P69; Nader P.R., 1988, HLTH BEHAV, P107; Narayan KMV, 2000, DIABETES RES CLIN PR, V50, pS77; NOBLES WW, 1978, J MARRIAGE FAM, V40, P679, DOI 10.2307/351188; Norris SL, 2002, AM J PREV MED, V22, P39, DOI 10.1016/S0749-3797(02)00424-5; Petersen DM, 2002, AM J EVAL, V23, P55, DOI 10.1177/109821400202300106; Resnicow Ken, 1999, Ethnicity and Disease, V9, P10; Rychetnik L, 2002, J EPIDEMIOL COMMUN H, V56, P119, DOI 10.1136/jech.56.2.119; Shiell A, 1996, HEALTH ECON, V5, P241, DOI 10.1002/(SICI)1099-1050(199605)5:3<241::AID-HEC197>3.3.CO;2-7; Sorensen G, 1998, ANNU REV PUBL HEALTH, V19, P379, DOI 10.1146/annurev.publhealth.19.1.379; Wang CY, 1998, PUBLIC HEALTH NURS, V15, P406, DOI 10.1111/j.1525-1446.1998.tb00367.x; WILSON W, 1987, AM J PUBLIC HEALTH, V77, P634, DOI 10.2105/AJPH.77.5.634	36	27	27	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2004	140	11					964	971		10.7326/0003-4819-140-11-200406010-00038	http://dx.doi.org/10.7326/0003-4819-140-11-200406010-00038			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	824IS	15172922				2023-01-03	WOS:000221680600028
J	Block, GA; Martin, KJ; de Francisco, ALM; Turner, SA; Avram, MM; Suranyi, MG; Hercz, G; Cunningham, J; Abu-Alfa, AK; Messa, P; Coyne, DW; Locatelli, F; Cohen, RM; Evenepoel, P; Moe, SM; Fournier, A; Braun, J; McCary, LC; Zani, VJ; Olson, KA; Drueke, TB; Goodman, WG				Block, GA; Martin, KJ; de Francisco, ALM; Turner, SA; Avram, MM; Suranyi, MG; Hercz, G; Cunningham, J; Abu-Alfa, AK; Messa, P; Coyne, DW; Locatelli, F; Cohen, RM; Evenepoel, P; Moe, SM; Fournier, A; Braun, J; McCary, LC; Zani, VJ; Olson, KA; Drueke, TB; Goodman, WG			Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARATHYROID-HORMONE LEVELS; STAGE RENAL-DISEASE; DIALYSIS PATIENTS; CALCIMIMETIC AMG-073; PHOSPHATE-METABOLISM; MORTALITY RISK; CALCIUM; CALCIFICATION; RECEPTOR; ASSOCIATION	BACKGROUND: Treatment of secondary hyperparathyroidism with vitamin D and calcium in patients receiving dialysis is often complicated by hypercalcemia and hyperphosphatemia, which may contribute to cardiovascular disease and adverse clinical outcomes. Calcimimetics target the calcium-sensing receptor and lower parathyroid hormone levels without increasing calcium and phosphorus levels. We report the results of two identical randomized, double-blind, placebo-controlled trials evaluating the safety and effectiveness of the calcimimetic agent cinacalcet hydrochloride. METHODS: Patients who were receiving hemodialysis and who had inadequately controlled secondary hyperparathyroidism despite standard treatment were randomly assigned to receive cinacalcet (371 patients) or placebo (370 patients) for 26 weeks. Once-daily doses were increased from 30 mg to 180 mg to achieve intact parathyroid hormone levels of 250 pg per milliliter or less. The primary end point was the percentage of patients with values in this range during a 14-week efficacy-assessment phase. RESULTS: Forty-three percent of the cinacalcet group reached the primary end point, as compared with 5 percent of the placebo group (P<0.001). Overall, mean parathyroid hormone values decreased 43 percent in those receiving cinacalcet but increased 9 percent in the placebo group (P<0.001). The serum calcium-phosphorus product declined by 15 percent in the cinacalcet group and remained unchanged in the placebo group (P<0.001). Cinacalcet effectively reduced parathyroid hormone levels independently of disease severity or changes in vitamin D sterol dose. CONCLUSIONS: Cinacalcet lowers parathyroid hormone levels and improves calcium-phosphorus homeostasis in patients receiving hemodialysis who have uncontrolled secondary hyperparathyroidism.	Denver Nephrologists, Denver, CO 80218 USA; St Louis Univ, St Louis, MO 63103 USA; Hosp Marques Valdecilla, Santander, Spain; Amgen Inc, Thousand Oaks, CA USA; Long Isl Coll Hosp, Brooklyn, NY 11201 USA; Liverpool Hosp, Liverpool, NSW, Australia; Humber River Reg Hosp, Toronto, ON, Canada; UCL Hosp, London, England; Yale Univ, Sch Med, New Haven, CT USA; Osped Civile S Andrea, La Spezia, Italy; Washington Univ, Sch Med, St Louis, MO 63130 USA; Osped Manzoni, Lecce, Italy; Presbyterian Med Ctr, Philadelphia, PA USA; Univ Ziekenhuis Gasthuisberg, Louvain, Belgium; Indiana Univ, Sch Med, Indianapolis, IN USA; Ctr Hosp Univ Amiens, Amiens, France; Kuratorium Dialyse, Nurnberg, Germany; Hop Necker Enfants Malad, Paris, France; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA	Saint Louis University; Hospital Universitario Marques de Valdecilla (HUMV); Amgen; Long Island College Hospital; Liverpool Hospital; University College London Hospitals NHS Foundation Trust; University of London; University College London; Yale University; Washington University (WUSTL); University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Presbyterian Medical Center; KU Leuven; University Hospital Leuven; Indiana University System; Indiana University-Purdue University Indianapolis; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Block, GA (corresponding author), Denver Nephrologists, 1601 E 19th Ave 4300, Denver, CO 80218 USA.	gablock@denverneph.net	Centeno, Patricia Pacios/O-8368-2016; Block, Geoffrey/AAV-8070-2021; P, Evenepoel/D-9597-2018	Block, Geoffrey/0000-0002-4646-7074; P, Evenepoel/0000-0002-2846-2026				Block GA, 2000, AM J KIDNEY DIS, V35, P1226, DOI 10.1016/S0272-6386(00)70064-3; Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176; Brown E M, 1993, Curr Opin Nephrol Hypertens, V2, P541, DOI 10.1097/00041552-199307000-00004; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272-6386(03)00111-2; Fox J, 1999, ENDOCRINE, V10, P97, DOI 10.1385/ENDO:10:2:97; Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131; Goodman WG, 2000, KIDNEY INT, V58, P436, DOI 10.1046/j.1523-1755.2000.00183.x; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; Goodman WG, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341017; Goodman WG, 2001, KIDNEY INT, V59, P1187, DOI 10.1046/j.1523-1755.2001.00605.x; Hammerland LG, 1998, MOL PHARMACOL, V53, P1083; HRUSKA KA, 1995, NEW ENGL J MED, V333, P166, DOI 10.1056/NEJM199507203330307; Hsu CH, 1997, AM J KIDNEY DIS, V29, P641, DOI 10.1016/S0272-6386(97)90352-8; Indridason OS, 2000, KIDNEY INT, V57, P282, DOI 10.1046/j.1523-1755.2000.00819.x; Johnson CA, 2002, AM J KIDNEY DIS, V39, P1270, DOI 10.1053/ajkd.2002.33401; KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011; LARSSON L, 1978, CLIN CHEM, V24, P1962; Lindberg JS, 2003, KIDNEY INT, V63, P248, DOI 10.1046/j.1523-1755.2003.00720.x; Locatelli F, 2002, NEPHROL DIAL TRANSPL, V17, P723, DOI 10.1093/ndt/17.5.723; Maung HM, 2001, AM J KIDNEY DIS, V37, P532; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364; Owda A, 2003, RENAL FAILURE, V25, P595, DOI 10.1081/JDI-120022551; Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD; Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735-1097(01)01781-8; Ribeiro S, 1998, NEPHROL DIAL TRANSPL, V13, P2037, DOI 10.1093/ndt/13.8.2037; Salem MM, 1997, AM J KIDNEY DIS, V29, P862, DOI 10.1016/S0272-6386(97)90459-5; Silverberg SJ, 1997, NEW ENGL J MED, V337, P1506, DOI 10.1056/NEJM199711203372104; Slatopolsky E, 1999, KIDNEY INT, V56, pS14, DOI 10.1046/j.1523-1755.1999.07304.x; WANG M, 1995, AM J KIDNEY DIS, V26, P836, DOI 10.1016/0272-6386(95)90453-0	31	804	840	1	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 8	2004	350	15					1516	1525		10.1056/NEJMoa031633	http://dx.doi.org/10.1056/NEJMoa031633			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	810CI	15071126				2023-01-03	WOS:000220682000007
J	Zou, Y; Jung, KJ; Kim, JW; Yu, BP; Chung, HY				Zou, Y; Jung, KJ; Kim, JW; Yu, BP; Chung, HY			Alteration of soluble adhesion molecules during aging and their modulation by calorie restriction	FASEB JOURNAL			English	Article						vascular aging; inflammation; oxidative stress; endothelial cells; reactive oxygen/nitrogen species	OXIDATIVE STRESS; DIETARY RESTRICTION; INFLAMMATION HYPOTHESIS; XANTHINE-OXIDASE; HEART-DISEASE; LUNG-CELLS; AGE; PLASMA; INHALATION; ENDOTOXIN	To investigate the status of soluble adhesion molecules (sAMs) during aging, the present study determined protein levels of several major sAMs in serum samples obtained from rats at different ages. These sAMs include E-selection, P-selection, vascular cell adhesion molecule 1 (VCAM-1), and intercellular adhesion molecule 1 (ICAM-1) Fischer 344 rats, ages 6, 12, 18, and 24 months, fed ad libitum (AL) and calorie restricted (CR) diets were used in this study. Analysis by Western blotting showed that the levels of all sAMs studied increased during aging in AL rats, but were effectively blunted in the CR rats. Total reactive oxygen species/reactive nitrogen species (ROS/RNS) levels were measured by fluorescent probe 2',7'-dichlorofluorescin diacetate. Increased ROS/RNS levels were found to coincide with increase levels of superoxide-generating xanthine oxidase in serum during aging, but were found suppressed by CR. Increases in sAMs levels were duplicated in another experiment in which young (13-month-old) and old (31-month-old) rats were injected with proinflammatory lipopolysaccharide. These findings suggest that the altered expressions of sAMs may be due to increased oxidative stress with advanced age and that these increases were prevented by CR through its antioxidative action.	Pusan Natl Univ, Coll Pharm, Dept Pharm, Pusan 609735, South Korea; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	Pusan National University; University of Texas System; University of Texas Health San Antonio	Chung, HY (corresponding author), Pusan Natl Univ, Coll Pharm, Dept Pharm, 30 Jangjeon Dong, Pusan 609735, South Korea.	hyjung@pusan.ac.kr	zou, yani/F-6361-2011					BERTRAND HA, 1999, METHODS AGING RES, P271; Brown AA, 2001, AM J CLIN NUTR, V73, P673; Calingasan NY, 2000, BRAIN RES, V885, P62, DOI 10.1016/S0006-8993(00)02933-4; CATHCART R, 1984, METHOD ENZYMOL, V105, P352; Chung H Y, 1999, J Nutr Health Aging, V3, P19; Chung HY, 1997, AGE, V20, P127, DOI 10.1007/s11357-997-0012-2; Chung HY, 2002, MICROSC RES TECHNIQ, V59, P264, DOI 10.1002/jemt.10203; Chung HY, 2001, ANN NY ACAD SCI, V928, P327; DEROCHEMONTEIXGALVE B, 1991, INFECT IMMUN, V59, P3646, DOI 10.1128/IAI.59.10.3646-3650.1991; Droge W, 2002, EXP GERONTOL, V37, P1333, DOI 10.1016/S0531-5565(02)00175-4; Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Guo ZM, 2002, MECH AGEING DEV, V123, P1121, DOI 10.1016/S0047-6374(02)00008-8; HABIB A, 1993, J BIOL CHEM, V268, P32448; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Hawes E M, 1993, Am J Cardiovasc Pathol, V4, P326; Heinz A, 2003, PSYCHOPHARMACOLOGY, V165, P111, DOI 10.1007/s00213-002-1244-6; HSIEH V, 1994, INT ARCH ALLERGY IMM, V104, P42, DOI 10.1159/000236707; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARTIGUEMATTEI C, 1990, J CHROMATOGR-BIOMED, V529, P93, DOI 10.1016/S0378-4347(00)83810-4; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lowe JB, 1997, J CLIN INVEST, V100, pS47; Lyons PD, 1998, GLIA, V22, P103, DOI 10.1002/(SICI)1098-1136(199802)22:2<103::AID-GLIA1>3.0.CO;2-8; Marin J, 1999, EXP GERONTOL, V34, P503, DOI 10.1016/S0531-5565(99)00029-7; Miles EA, 2001, CLIN SCI, V100, P91, DOI 10.1042/CS20000198; Morisaki N, 1997, ATHEROSCLEROSIS, V131, P43, DOI 10.1016/S0021-9150(97)06083-8; Mukherjee P, 2002, BRIT J CANCER, V86, P1615, DOI 10.1038/sj.bjc.6600298; Nash MC, 1996, CLIN EXP IMMUNOL, V103, P167, DOI 10.1046/j.1365-2249.1996.925616.x; Nielsen VG, 1996, AM J RESP CRIT CARE, V154, P1364, DOI 10.1164/ajrccm.154.5.8912749; Pu FR, 2002, BIOMATERIALS, V23, P4705, DOI 10.1016/S0142-9612(02)00219-3; Purschwitz K, 2001, Z GERONTOL GERIATR, V34, P476, DOI 10.1007/s003910170022; Radi ZA, 2001, J VET INTERN MED, V15, P516, DOI 10.1892/0891-6640(2001)015&lt;0516:CAMLTA&gt;2.3.CO;2; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; Yu BP, 2001, DIABETES RES CLIN PR, V54, pS73, DOI 10.1016/S0168-8227(01)00338-2; Yu BP, 1996, FREE RADICAL BIO MED, V21, P651, DOI 10.1016/0891-5849(96)00162-1; YU BP, 1985, J GERONTOL, V40, P657, DOI 10.1093/geronj/40.6.657; Zaremba Jaroslaw, 2002, Folia Morphol (Warsz), V61, P1	38	88	90	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					320	+		10.1096/fj.03-0849fje	http://dx.doi.org/10.1096/fj.03-0849fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688195				2023-01-03	WOS:000188067500001
J	Ballen, KK; Hasserjian, RP				Ballen, KK; Hasserjian, RP			A 39-year-old woman with headache, stiff neck, and photophobia - AML, not otherwise categorized, with normal karyotype, mutation of the FLT3 tyrosine kinase domain, and cytoplasmic localization of NPM.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACUTE MYELOID-LEUKEMIA; MENINGITIS; THERAPY; CLASSIFICATION; REARRANGEMENT; CYTOGENETICS; LIGAND; CELLS		Massachusetts Gen Hosp, Dept Med, Div Hematol & Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Ballen, KK (corresponding author), Massachusetts Gen Hosp, Dept Med, Div Hematol & Oncol, Boston, MA 02114 USA.							Abdou SMH, 2002, LEUKEMIA LYMPHOMA, V43, P89, DOI 10.1080/10428190290000437; Arber DA, 2003, AM J CLIN PATHOL, V119, P672, DOI 10.1309/EM7KCOR4GLMHRCX4; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BERGER R, 1987, CANCER GENET CYTOGEN, V29, P9, DOI 10.1016/0165-4608(87)90026-4; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Burnett AK, 1998, LANCET, V351, P700, DOI 10.1016/S0140-6736(97)09214-3; Castagnola C, 1997, HAEMATOLOGICA, V82, P577; Ellerin TB, 2004, LANCET, V363, P1772, DOI 10.1016/S0140-6736(04)16303-4; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Frohling S, 2002, BLOOD, V100, P4372, DOI 10.1182/blood-2002-05-1440; Gamerdinger U, 2003, GENE CHROMOSOME CANC, V36, P261, DOI 10.1002/gcc.10168; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; JOFFE AM, 1989, AM J MED, V87, P332, DOI 10.1016/S0002-9343(89)80160-3; Kochar DK, 2000, NEUROL INDIA, V48, P170; Kong XT, 1997, BLOOD, V90, P1192; Lisovsky M, 1996, BLOOD, V88, P3987, DOI 10.1182/blood.V88.10.3987.bloodjournal88103987; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; MALDONADO JE, 1965, MAYO CLIN PROC, V40, P248; National Comprehensive Cancer Network, 2003, J Natl Compr Canc Netw, V1, P520; Shi GP, 1997, CANCER GENET CYTOGEN, V96, P58, DOI 10.1016/S0165-4608(96)00293-2; Shurin MR, 1998, CYTOKINE GROWTH F R, V9, P37, DOI 10.1016/S1359-6101(97)00035-X; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075; SPANOS A, 1989, JAMA-J AM MED ASSOC, V262, P2700, DOI 10.1001/jama.262.19.2700; Tchinda J, 2003, LEUKEMIA LYMPHOMA, V44, P1843, DOI 10.1080/10428190310001603605; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Vardiman J., 2001, WHO CLASSIFICATION T, V3; WIERNIK PH, 1992, BLOOD, V79, P313	28	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2005	352	3					274	283		10.1056/NEJMcpc049034	http://dx.doi.org/10.1056/NEJMcpc049034			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888JP	15659728				2023-01-03	WOS:000226370500009
J	Mansfield, P				Mansfield, P			Commentary: Accepting what we can learn from advertising's mirror of desire	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Healthy Skepticism, Willunga, SA 5172, Australia		Mansfield, P (corresponding author), Healthy Skepticism, 34 Methodist St, Willunga, SA 5172, Australia.	peter@healthyskepticism.org	Mansfield, Peter/Q-8707-2019					Black H, 2004, LANCET, V364, P1655, DOI 10.1016/S0140-6736(04)17375-3; Mansfield PR, 2003, MED J AUSTRALIA, V179, P644, DOI 10.5694/j.1326-5377.2003.tb05730.x; OGILVY D, 1995, OGILVY ADVERTISING; Sagarin BJ, 2002, J PERS SOC PSYCHOL, V83, P526, DOI 10.1037//0022-3514.83.3.526; SCOTT DK, 1994, BRIT J CLIN PHARMACO, V37, P217, DOI 10.1111/j.1365-2125.1994.tb04265.x; Scott T, 2004, BMJ-BRIT MED J, V329, P1484, DOI 10.1136/bmj.329.7480.1484; Sweet M, 2004, BRIT MED J, V329, P998, DOI 10.1136/bmj.329.7473.998	7	9	9	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 18	2004	329	7480					1487	1488		10.1136/bmj.329.7480.1487	http://dx.doi.org/10.1136/bmj.329.7480.1487			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	882VB	15604193	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000225965800036
J	Volanti, C; Gloire, G; Vanderplasschen, A; Jacobs, N; Habraken, Y; Piette, J				Volanti, C; Gloire, G; Vanderplasschen, A; Jacobs, N; Habraken, Y; Piette, J			Downregulation of ICAM-1 and VCAM-1 expression in endothelial cells treated by photodynamic therapy	ONCOGENE			English	Article						NF-kappa B; pyropheophorbide; photodynamic therapy; endothelial cells; oxidative stress; adhesion molecules	NF-KAPPA-B; PYROPHEOPHORBIDE-A; OXIDATIVE STRESS; IN-VIVO; CHOROIDAL NEOVASCULARIZATION; TUMOR; MATRIX-METALLOPROTEINASE-9; ACTIVATION; PHOTOSENSITIZATION; PHARMACOKINETICS	Photodynamic therapy (PDT) is a treatment for cancer and several noncancerous proliferating cell diseases that depends on the uptake of a photosensitizing compound followed by selective irradiation with visible light. In the presence of oxygen, irradiation leads to the production of reactive oxygen species (ROS). A large production of ROS induces the death of cancer cells by apoptosis or necrosis. A small ROS production can activate various cellular pathways. Here, we show that PDT by pyropheophorbide-a methyl ester (PPME) induces the activation of nuclear factor kappa B (NF-kappaB) in HMEC-1 cells. NF-kappaB is active since it binds to the NF-kappaB sites of both ICAM-1 and vascular cell adhesion molecule-1 (VCAM-1) promoters and induces the transcription of several NF-kappaB target genes such as those of IL-6, ICAM-1, VCAM-I. In contrast, expression of ICAM-1 and VCAM-I at the protein level was not observed, although we measured an IL-6 secretion. Using specific chemical inhibitors, we showed that the lack of ICAM-1 and VCAM-I expression is the consequence of their degradation by lysosomal proteases. The proteasome and calpain pathways were not involved. All these observations were consistent with the fact that no adhesion of granulocytes was observed in these conditions.	Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Univ Liege, Dept Immunol & Vaccinol, B-4000 Liege, Belgium; Univ Liege, Inst Pathol B23, Dept Pathol, B-4000 Liege, Belgium	University of Liege; University of Liege; University of Liege	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium.	jpiette@ulg.ac.be		Jacobs, Nathalie/0000-0002-9895-8465				Aiello L P, 1997, Curr Opin Ophthalmol, V8, P19; Arkell J, 2003, CELL BIOCHEM FUNCT, V21, P381, DOI 10.1002/cbf.1037; BELLNIER DA, 1993, J PHOTOCH PHOTOBIO B, V20, P55, DOI 10.1016/1011-1344(93)80131-R; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cecic I, 2001, PHOTOCHEM PHOTOBIOL, V74, P712, DOI 10.1562/0031-8655(2001)074<0712:IOSNRI>2.0.CO;2; Chen B, 2002, INT J CANCER, V98, P284, DOI 10.1002/ijc.10175; deVree WJA, 1996, CANCER RES, V56, P2908; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dougherty TJ, 2002, J CLIN LASER MED SUR, V20, P3, DOI 10.1089/104454702753474931; Fiore E, 2002, ONCOGENE, V21, P5213, DOI 10.1038/sj.onc.1205684; Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864; Gollnick SO, 1997, CANCER RES, V57, P3904; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; HENDERSON BW, 1995, PHOTOCHEM PHOTOBIOL, V62, P780, DOI 10.1111/j.1751-1097.1995.tb08730.x; Henderson BW, 1997, CANCER RES, V57, P4000; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kolev K, 2003, THROMB HAEMOSTASIS, V90, P528, DOI 10.1160/TH03-02-0070; Korbelik M, 1996, J Clin Laser Med Surg, V14, P329; Krammer B, 2001, ANTICANCER RES, V21, P4271; KROSL G, 1995, BRIT J CANCER, V71, P549, DOI 10.1038/bjc.1995.108; Lee JM, 2003, ANN NEUROL, V54, P379, DOI 10.1002/ana.10671; Levesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289; Marcinkowska A, 2001, FOLIA HISTOCHEM CYTO, V39, P177; Matroule JY, 1999, J BIOL CHEM, V274, P2988, DOI 10.1074/jbc.274.5.2988; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Niziolek M, 2003, PHOTOCHEM PHOTOBIOL, V78, P262, DOI 10.1562/0031-8655(2003)078<0262:CAACAO>2.0.CO;2; Ochsner M, 1997, J PHOTOCH PHOTOBIO B, V39, P1, DOI 10.1016/S1011-1344(96)07428-3; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; Payne JT, 1996, LASER SURG MED, V18, P406, DOI 10.1002/(SICI)1096-9101(1996)18:4<406::AID-LSM10>3.3.CO;2-7; Rousset N, 1999, J PHOTOCH PHOTOBIO B, V52, P65, DOI 10.1016/S1011-1344(99)00104-9; Santos CF, 2003, AM J PHYSIOL-HEART C, V285, pH775, DOI 10.1152/ajpheart.00818.2002; Schmidt-Erfurth U, 1998, OPHTHALMOLOGE, V95, P725, DOI 10.1007/s003470050343; Schreiber S, 2002, INT J CANCER, V99, P279, DOI 10.1002/ijc.10299; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9; Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2; Wagner JG, 2000, PHARMACOL REV, V52, P349; Wang LX, 2003, J IMMUNOL, V171, P3194, DOI 10.4049/jimmunol.171.6.3194; Woodburn KW, 2002, RETINA-J RET VIT DIS, V22, P391, DOI 10.1097/00006982-200208000-00001; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	42	40	42	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8649	8658		10.1038/sj.onc.1207871	http://dx.doi.org/10.1038/sj.onc.1207871			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467759				2023-01-03	WOS:000224988800011
J	Seo, SK; Choi, JH; Kim, YH; Kang, WJ; Park, HY; Suh, JH; Choi, BK; Vinay, DS; Kwon, BS				Seo, SK; Choi, JH; Kim, YH; Kang, WJ; Park, HY; Suh, JH; Choi, BK; Vinay, DS; Kwon, BS			4-1BB-mediated immunotherapy of rheumatoid arthritis	NATURE MEDICINE			English	Article							T-CELL PROLIFERATION; MONOCLONAL-ANTIBODIES; TRYPTOPHAN CATABOLISM; IN-VIVO; 4-1BB LIGAND; EXPRESSION; PATHOGENESIS; DISEASE	Collagen type II-induced arthritis is a CD4(+) T-cell-dependent chronic inflammation in susceptible DBA/1 mice and represents an animal model of human rheumatoid arthritis. We found that development of this condition, and even established disease, are inhibited by an agonistic anti-4-1BB monoclonal antibody. Anti-4-1BB suppressed serum antibodies to collagen type II and CD4(+) T-cell recall responses to collagen type II. Crosslinking of 4-1BB evoked an antigen-specific, active suppression mechanism that differed from the results of blocking the interaction between 4-1BB and its ligand, 4-1BBL. Anti-4-1BB monoclonal antibodies induced massive, antigen-dependent clonal expansion of CD11c(+)CD8(+) T cells and accumulation of indoleamine 2,3-dioxygenase in CD11b(+) monocytes and CD11c(+) dendritic cells. Both anti-interferon-gamma and 1-methyltryptophan, a pharmacological inhibitor of indoleamine 2,3-dioxygenase, reversed the anti-4-1BB effect. We conclude that the suppression of collagen-induced arthritis was caused by an expansion of new CD11c(+)CD8(+) T cells, and that interferon-gamma produced by these cells suppresses antigen-specific CD4(+) T cells through an indoleamine 2,3-dioxygenase-dependent mechanism.	Univ Ulsan, Immunomodulat Res Ctr, Ulsan 680749, South Korea; Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Pathol, Ulsan 682060, South Korea; Louisiana State Univ, Ctr Eye, Hlth Sci Ctr, New Orleans, LA 70112 USA	University of Ulsan; University of Ulsan; Ulsan University Hospital; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Kwon, BS (corresponding author), Univ Ulsan, Immunomodulat Res Ctr, 29 Mukeo Dong, Ulsan 680749, South Korea.	bskwon@mail.ulsan.ac.kr	康, 宇鎭/GRO-6256-2022	Kang, Woojin/0000-0002-4880-3406	NATIONAL EYE INSTITUTE [P30EY002377, R01EY013325] Funding Source: NIH RePORTER; NEI NIH HHS [P30EY002377, R01EY013325] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arend WP, 1997, ARTHRITIS RHEUM, V40, P595, DOI 10.1002/art.1780400402; Bertram EM, 2002, J IMMUNOL, V168, P3777, DOI 10.4049/jimmunol.168.8.3777; Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; EDWARDS D, 1987, BIOMETRICS, V43, P913, DOI 10.2307/2531545; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Foell J, 2003, J CLIN INVEST, V111, P1505, DOI 10.1172/JCI200317662; Futagawa T, 2002, INT IMMUNOL, V14, P275, DOI 10.1093/intimm/14.3.275; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; Halstead ES, 2002, NAT IMMUNOL, V3, P536, DOI 10.1038/ni798; Holmdahl R, 2002, AGEING RES REV, V1, P135, DOI 10.1016/S0047-6374(01)00371-2; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; Mauri C, 2000, NAT MED, V6, P673, DOI 10.1038/76251; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Mellor AL, 2003, J IMMUNOL, V171, P1652, DOI 10.4049/jimmunol.171.4.1652; Mellor AL, 2003, J IMMUNOL, V170, P5809, DOI 10.4049/jimmunol.170.12.5809; Milliken G. A., 1984, ANAL MESSY DATA; Mittler RS, 1999, J EXP MED, V190, P1535, DOI 10.1084/jem.190.10.1535; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Myers L, 2003, P NATL ACAD SCI USA, V100, P5348, DOI 10.1073/pnas.0837611100; NAKAJIMA H, 1990, CLIN EXP IMMUNOL, V81, P441; POLLOK KE, 1993, J IMMUNOL, V150, P771; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; Sun YL, 2002, NAT MED, V8, P1405, DOI 10.1038/nm796; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; WILLIAMS RO, 1994, P NATL ACAD SCI USA, V91, P2762, DOI 10.1073/pnas.91.7.2762; Ye ZM, 2002, NAT MED, V8, P343, DOI 10.1038/nm0402-343; ZVAIFLER NJ, 1983, AM J MED, V75, P3, DOI 10.1016/0002-9343(83)90469-2	28	263	286	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2004	10	10					1088	1094		10.1038/nm1107	http://dx.doi.org/10.1038/nm1107			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15448685				2023-01-03	WOS:000224245800039
J	Morrow, AL; Dawodu, A				Morrow, AL; Dawodu, A			Influencing birth outcomes in Nepal	LANCET			English	Editorial Material							HEALTH; MORTALITY		Childrens Hosp, Med Ctr, Ctr Biostat & Epidemiol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Morrow, AL (corresponding author), Childrens Hosp, Med Ctr, Ctr Biostat & Epidemiol, Cincinnati, OH 45229 USA.	ardythe.morrow@chmcc.org	Morrow, Ardythe/GQO-8482-2022; dawodu, adekunle/M-9985-2014	dawodu, adekunle/0000-0002-2050-800X				Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; Bhandari N, 2003, LANCET, V361, P1418, DOI 10.1016/S0140-6736(03)13134-0; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Claeson M, 2003, LANCET, V362, P323, DOI 10.1016/S0140-6736(03)13977-3; Ensor T, 2004, HEALTH POLICY PLANN, V19, P69, DOI 10.1093/heapol/czh009; HOWARDGRABMAN L, 2002, MOTHERCARE SAVE CHIL; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Morgan LM, 2001, HEALTH POLICY PLANN, V16, P221, DOI 10.1093/heapol/16.3.221; Morrow AL, 1999, LANCET, V353, P1226, DOI 10.1016/S0140-6736(98)08037-4; Pradhan Elizabeth Kimbrough, 1994, Controlled Clinical Trials, V15, P220; United Nations General Assembly, 2001, A56326 UN GEN ASS; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7	12	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	2004	364	9438					914	915		10.1016/S0140-6736(04)17036-0	http://dx.doi.org/10.1016/S0140-6736(04)17036-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364172				2023-01-03	WOS:000223831000005
J	Dodek, P; Keenan, S; Cook, D; Heyland, D; Jacka, M; Hand, L; Muscedere, J; Foster, D; Mehta, N; Hall, R; Brun-Buisson, C				Dodek, P; Keenan, S; Cook, D; Heyland, D; Jacka, M; Hand, L; Muscedere, J; Foster, D; Mehta, N; Hall, R; Brun-Buisson, C		Canadian Critical Care Trials Grp	Evidence-based clinical practice guideline for the prevention of ventilator-associated pneumonia	ANNALS OF INTERNAL MEDICINE			English	Review							INTENSIVE-CARE-UNIT; NOSOCOMIAL MAXILLARY SINUSITIS; RESPIRATORY-TRACT INFECTIONS; ILL ADULT PATIENTS; MOISTURE EXCHANGERS; RISK-FACTORS; SELECTIVE DECONTAMINATION; MECHANICAL VENTILATION; DIGESTIVE-TRACT; SUBGLOTTIC SECRETIONS	Background: Ventilator-associated pneumonia (VAP) is an important patient safety issue in critically ill patients. Purpose: To develop an evidence-based guideline for the prevention of VAP. Data Sources: MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews. Study Selection: The authors systematically searched for relevant randomized, controlled trials and systematic reviews that involved mechanically ventilated adults and were published before 1 April 2003. Data Extraction: Physical, positional, and pharmacologic interventions that may influence the development of VAP were considered. Independently and in duplicate, the authors scored the validity of trials; the effect size and confidence intervals; the homogeneity of results; and safety, feasibility, and economic issues. Data Synthesis: Recommended. The orotracheal route of intubation, changes of ventilator circuits only for each new patient and if the circuits are soiled, use of closed endotracheal suction systems that are changed for each new patient and as clinically indicated, heat and moisture exchangers in the absence of contraindications, weekly changes of heat and moisture exchangers, and semi-recumbent positioning in the absence of contraindications. Consider subglottic secretion drainage and kinetic beds. Not recommended: Sucralfate to prevent VAP in patients at high risk for gastrointestinal bleeding and topical antibiotics to prevent VAP. Because of insufficient or conflicting evidence, no recommendations were made about systematically searching for maxillary sinusitis, chest physiotherapy, the timing of tracheostomy, prone positioning, prophylactic intravenous antibiotics, or intravenous plus topical antibiotics. Limitations: No formal economic analysis was performed, and patient perspectives were not considered. Conclusion: if effectively implemented, this guideline may decrease the morbidity, mortality, and costs of VAP in mechanically ventilated patients.	Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Queens Univ, Kingston, ON K7L 3N6, Canada; McMaster Univ, Hamilton, ON L8S 4L8, Canada; Hotel Dieu Grace Hosp, Windsor, CT USA; Univ Toronto, Toronto, ON, Canada; Sudbury Reg Hosp, Sudbury, ON, Canada; Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada; Dalhousie Univ, Halifax, NS, Canada; Univ Paris 12, Hop Henri Mondor, F-94010 Creteil, France	University of British Columbia; Queens University - Canada; McMaster University; University of Toronto; Health Sciences North; University of Alberta; Dalhousie University; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Dodek, P (corresponding author), St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	pedodek@interchange.ubc.ca	Mehta, Neil/AAL-9824-2020; Muscedere, John/AAH-9291-2021					AERDTS SJA, 1993, BRIT MED J, V307, P525; BACH A, 1992, ANAESTHESIA, V47, P335, DOI 10.1111/j.1365-2044.1992.tb02177.x; Baker AM, 1996, AM J RESP CRIT CARE, V153, P343, DOI 10.1164/ajrccm.153.1.8542141; BENMENACHEM T, 1994, ANN INTERN MED, V121, P568, DOI 10.7326/0003-4819-121-8-199410150-00003; Beuret P, 2002, INTENS CARE MED, V28, P564, DOI 10.1007/s00134-002-1266-x; Black N, 1999, J Health Serv Res Policy, V4, P236; Boots RJ, 1997, CRIT CARE MED, V25, P1707, DOI 10.1097/00003246-199710000-00021; BUENOCAVANILLAS A, 1994, CRIT CARE MED, V22, P55, DOI 10.1097/00003246-199401000-00013; Campbell GD, 1996, AM J RESP CRIT CARE, V153, P1711; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; Choudhry NK, 2002, JAMA-J AM MED ASSOC, V287, P612, DOI 10.1001/jama.287.5.612; Cluzeau FA, 1999, INT J QUAL HEALTH C, V11, P21, DOI 10.1093/intqhc/11.1.21; Combes P, 2000, INTENS CARE MED, V26, P878, DOI 10.1007/s001340051276; Cook D, 2000, CRIT CARE MED, V28, P3547, DOI 10.1097/00003246-200010000-00034; Cook DJ, 1997, ANN INTERN MED, V127, P210, DOI 10.7326/0003-4819-127-3-199708010-00006; Cook DJ, 1998, JAMA-J AM MED ASSOC, V279, P1605, DOI 10.1001/jama.279.20.1605; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Cook DJ, 2002, CRIT CARE MED, V30, P1472, DOI 10.1097/00003246-200207000-00012; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; CRAIG CP, 1984, AM J INFECT CONTROL, V12, P233, DOI 10.1016/0196-6553(84)90114-7; CRAVEN DE, 1988, ARCH INTERN MED, V148, P1161, DOI 10.1001/archinte.148.5.1161; Cunnion KM, 1996, AM J RESP CRIT CARE, V153, P158, DOI 10.1164/ajrccm.153.1.8542110; D'Amico R, 1998, BMJ-BRIT MED J, V316, P1275, DOI 10.1136/bmj.316.7140.1275; Davis K, 2000, CRIT CARE MED, V28, P1412, DOI 10.1097/00003246-200005000-00026; DEBOISBLANC BP, 1993, CHEST, V103, P1543, DOI 10.1378/chest.103.5.1543; DECLERCQ J, 1983, ACTA ANAESTH BELG, V34, P179; DEMAREST GB, 1989, WESTERN J MED, V150, P35; DEPPE SA, 1990, CRIT CARE MED, V18, P1389, DOI 10.1097/00003246-199012000-00016; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; DREYFUSS D, 1995, AM J RESP CRIT CARE, V151, P986; DREYFUSS D, 1991, AM REV RESPIR DIS, V143, P738, DOI 10.1164/ajrccm/143.4_Pt_1.738; DUNHAM CM, 1984, J TRAUMA, V24, P120, DOI 10.1097/00005373-198402000-00005; EDDLESTON JM, 1994, CRIT CARE MED, V22, P1949; Fagon JY, 1996, JAMA-J AM MED ASSOC, V275, P866, DOI 10.1001/jama.275.11.866; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; Feder G, 1999, BRIT MED J, V318, P728; FINK MP, 1990, CHEST, V97, P132, DOI 10.1378/chest.97.1.132; GENTILELLO L, 1988, CRIT CARE MED, V16, P783, DOI 10.1097/00003246-198808000-00010; George JN, 1997, ANN INTERN MED, V126, P319; Girou E, 1998, AM J RESP CRIT CARE, V157, P1151, DOI 10.1164/ajrccm.157.4.9701129; Graham ID, 2001, CAN MED ASSOC J, V165, P157; Grilli R, 2000, LANCET, V355, P103, DOI 10.1016/S0140-6736(99)02171-6; GRIMSHAW JM, 2001, MED CARE S, V39, P112; Grol R, 1999, Jt Comm J Qual Improv, V25, P503; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; Hayward R S, 1993, Ann Intern Med, V118, P731; Hayward RSA, 1997, CAN MED ASSOC J, V156, P1715; HEYLAND DK, 1994, CHEST, V105, P1221, DOI 10.1378/chest.105.4.1221; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; Heyland DK, 1999, AM J RESP CRIT CARE, V159, P1249, DOI 10.1164/ajrccm.159.4.9807050; Heyland DK, 1999, CRIT CARE MED, V27, P1195, DOI 10.1097/00003246-199906000-00052; HOLZAPFEL L, 1993, CRIT CARE MED, V21, P1132, DOI 10.1097/00003246-199308000-00010; Holzapfel L, 1999, AM J RESP CRIT CARE, V159, P695, DOI 10.1164/ajrccm.159.3.9712076; HURLEY JC, 1995, ANTIMICROB AGENTS CH, V39, P941, DOI 10.1128/AAC.39.4.941; JIMENEZ P, 1989, CRIT CARE MED, V17, P882, DOI 10.1097/00003246-198909000-00007; JOHNSON KL, 1994, CRIT CARE MED, V22, P658, DOI 10.1097/00003246-199404000-00023; KAPPSTEIN I, 1992, EUR J CLIN MICROBIOL, V11, P504, DOI 10.1007/BF01960804; KERVER AJH, 1987, INTENS CARE MED, V13, P347; Kirschenbaum L, 2002, CRIT CARE MED, V30, P1983, DOI 10.1097/00003246-200209000-00006; Kirton OC, 1997, CHEST, V112, P1055, DOI 10.1378/chest.112.4.1055; KOLLEF MH, 1994, CHEST, V105, P1101, DOI 10.1378/chest.105.4.1101; Kollef MH, 1999, CHEST, V116, P1339, DOI 10.1378/chest.116.5.1339; Kollef MH, 1998, CHEST, V113, P759, DOI 10.1378/chest.113.3.759; KOLLEF MH, 1995, ANN INTERN MED, V123, P168, DOI 10.7326/0003-4819-123-3-199508010-00002; LIBERATI A, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000022.PUB2; Long MN, 1996, INFECT CONT HOSP EP, V17, P14; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; MAHUL P, 1992, INTENS CARE MED, V18, P20, DOI 10.1007/BF01706421; MARTIN C, 1990, CHEST, V97, P144, DOI 10.1378/chest.97.1.144; McMullin JP, 2002, INTENS CARE MED, V28, P304, DOI 10.1007/s00134-002-1225-6; Memish ZA, 2001, AM J INFECT CONTROL, V29, P301, DOI 10.1067/mic.2001.115404; Metz C., 1998, CLIN INTENSIVE CARE, V9, P20, DOI [10.3109/tcic.9.1.20.24, DOI 10.3109/TCIC.9.1.20.24]; MICHELSON A, 1991, ANAESTHESIST, V40, P100; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; Nathens AB, 1999, ARCH SURG-CHICAGO, V134, P170, DOI 10.1001/archsurg.134.2.170; Ntoumenopoulos G, 2002, INTENS CARE MED, V28, P850, DOI 10.1007/s00134-002-1342-2; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; POTGIETER PD, 1987, CRIT CARE MED, V15, P495, DOI 10.1097/00003246-198705000-00008; RELLO J, 1991, CHEST, V100, P439, DOI 10.1378/chest.100.2.439; RODRIGUEZ JL, 1990, SURGERY, V108, P655; ROUBY JJ, 1994, AM J RESP CRIT CARE, V150, P776, DOI 10.1164/ajrccm.150.3.8087352; ROUSTAN JP, 1992, INTENS CARE MED, V18, P97, DOI 10.1007/BF01705040; SALORD F, 1990, INTENS CARE MED, V16, P390, DOI 10.1007/BF01735177; Shaneyfelt TM, 1999, JAMA-J AM MED ASSOC, V281, P1900, DOI 10.1001/jama.281.20.1900; Shekelle P, 2001, BMJ-BRIT MED J, V323, P155, DOI 10.1136/bmj.323.7305.155; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; Shiffman RN, 2003, ANN INTERN MED, V139, P493, DOI 10.7326/0003-4819-139-6-200309160-00013; Shorr AF, 2001, CHEST, V119, P228, DOI 10.1378/chest.119.1.228; Smulders K, 2002, CHEST, V121, P858, DOI 10.1378/chest.121.3.858; Sugerman HJ, 1997, J TRAUMA, V43, P741, DOI 10.1097/00005373-199711000-00002; SUMMER WR, 1989, J CRIT CARE, V4, P45, DOI 10.1016/0883-9441(89)90091-9; TABLAN OC, 1994, AM J INFECT CONTROL, V22, P247; Thomachot L, 2002, CRIT CARE MED, V30, P232, DOI 10.1097/00003246-200201000-00033; Tonnesen E K, 1999, Ugeskr Laeger, V161, P15; TRAVER GA, 1995, J CRIT CARE, V10, P97, DOI 10.1016/0883-9441(95)90000-4; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; VALLES J, 1995, ANN INTERN MED, V122, P179, DOI 10.7326/0003-4819-122-3-199502010-00004; van Nieuwenhoven CA, 2001, JAMA-J AM MED ASSOC, V286, P335, DOI 10.1001/jama.286.3.335; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; Whiteman K, 1995, Am J Crit Care, V4, P133; WOOLF SH, 1990, J CLIN EPIDEMIOL, V43, P891, DOI 10.1016/0895-4356(90)90073-X; Zeitoun S S, 2001, Rev Lat Am Enfermagem, V9, P46	105	306	343	0	42	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2004	141	4					305	313		10.7326/0003-4819-141-4-200408170-00011	http://dx.doi.org/10.7326/0003-4819-141-4-200408170-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	846BX	15313747				2023-01-03	WOS:000223290900008
J	Kumarasamy, M; Desai, SP				Kumarasamy, M; Desai, SP			Drug points - Anterior uveitis is associated with travoprost	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LATANOPROST; EDEMA		Doncaster Royal Infirm, Dept Ophthalmol, Doncaster DN2 5LT, England		Desai, SP (corresponding author), Doncaster Royal Infirm, Dept Ophthalmol, Doncaster DN2 5LT, England.	desaisp@hotmail.com						*BRIT MED ASS ROYA, 2003, BRIT NAT FORM, V515; Faulkner WJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P1054, DOI 10.1001/archopht.121.7.1054; Fechtner RD, 1998, AM J OPHTHALMOL, V126, P37, DOI 10.1016/S0002-9394(98)00071-3; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Warwar RE, 1998, OPHTHALMOLOGY, V105, P263, DOI 10.1016/S0161-6420(98)92977-3	5	11	11	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	2004	329	7459					205	205		10.1136/bmj.329.7459.205	http://dx.doi.org/10.1136/bmj.329.7459.205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840NW	15271831	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000222866900018
J	Patel, A; Knapp, M; Evans, A; Perez, I; Kalra, L				Patel, A; Knapp, M; Evans, A; Perez, I; Kalra, L			Training care givers of stroke patients: economic evaluation	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFORMAL CARE; PEOPLE; BURDEN; COSTS	Background. Training care givers reduces their burden and improves psychosocial outcomes in care givers and patients at one year. However, the cost effectiveness of this approach has not been investigated. Objective To evaluate the cost effectiveness of caregiver training by examining health and social care costs, informal care costs, and quality adjusted life years in care givers. Design A single, blind, randomised controlled trial. Setting Stroke rehabilitation unit. Subjects 300 stroke patients and their care givers. Interventions Caregiver training in basic nursing and facilitation of personal care techniques compared with no caregiver training. Main outcome measures Health and social care costs, informal care costs, and quality adjusted life years in care givers over one year after stroke. Results Total health and social care costs over one year for patients whose care givers received training were significantly lower (mean difference pound4043 ($7249; C6072), 95% confidence interval -pound6544 to -pound1595). Inclusion of informal care costs, which were similar between the two groups, did not alter this conclusion. The cost difference was largely due to differences in length of hospital stay. The EQ-5D did not detect changes in quality adjusted life years in care givers. Conclusion Compared with no training, caregiver training during rehabilitation of patients reduced costs of care while improving overall quality of life in care givers at one year.	Guys Kings & St Thomass Sch Med, Dept Med, London SE5 9PJ, England; Kings Coll London, Inst Psychiat, Ctr Econ Mental Hlth, London WC2R 2LS, England	University of London; King's College London; University of London; King's College London	Kalra, L (corresponding author), Guys Kings & St Thomass Sch Med, Dept Med, London SE5 9PJ, England.	lalit.kalra@kcl.ac.uk	Knapp, Martin RJ/G-3011-2011; Patel, Anita/F-9832-2010	Patel, Anita/0000-0003-0769-1732; Knapp, Martin/0000-0003-1427-0215				ANDERSON CS, 1995, STROKE, V26, P843, DOI 10.1161/01.STR.26.5.843; Bauld L., 2000, CARING OLDER PEOPLE; Beecham J., 2001, MEASURING MENTAL HLT; Bugge C, 1999, STROKE, V30, P1517, DOI 10.1161/01.STR.30.8.1517; Claesson L, 2000, STROKE, V31, P2569, DOI 10.1161/01.STR.31.11.2569; *DEP TRAD IND, 2001, DET GUID NAT MIN WAG; Department of Health (UK), 1999, CAR CAR NAT STRAT CA; Dewey HM, 2002, STROKE, V33, P1028, DOI 10.1161/01.STR.0000013067.24300.B0; DOLAN P, 1995, 138 U YORK; DONALDSON C, 1988, J HEALTH ECON, V7, P239, DOI 10.1016/0167-6296(88)90027-6; FORSTER A, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001919; Godber E, 1997, HEALTH ECON, V6, P275, DOI 10.1002/(SICI)1099-1050(199705)6:3<275::AID-HEC255>3.0.CO;2-2; Gunnell D, 2000, AGE AGEING, V29, P137, DOI 10.1093/ageing/29.2.137; Kalra L, 2004, BMJ-BRIT MED J, V328, P1099, DOI 10.1136/bmj.328.7448.1099; LONGWORTH L, IN PRESS HLTH EC; McDaid D, 2001, INT J GERIATR PSYCH, V16, P400, DOI 10.1002/gps.353; NETTEN A, 2002, UNIT COSTS HLTH SOCI; Parker G, 2002, POLICY POLIT, V30, P347, DOI 10.1332/030557302760094711; Twigg J., 1998, SOCIAL POLICY OLD AG, P128; Wilkinson PR, 1997, STROKE, V28, P507, DOI 10.1161/01.STR.28.3.507; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	21	92	94	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	2004	328	7448					1102	1104A		10.1136/bmj.328.7448.1102	http://dx.doi.org/10.1136/bmj.328.7448.1102			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818YS	15130978	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000221281000016
J	Nelson, HD				Nelson, HD			Postmenopausal estrogen for treatment of hot flashes - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HORMONE REPLACEMENT THERAPY; PLUS PROGESTIN; BREAST-CANCER; ESTROGEN/PROGESTIN REPLACEMENT; DOUBLE-BLIND; MEDROXYPROGESTERONE ACETATE; CLIMACTERIC SYMPTOMS; MENOPAUSAL SYMPTOMS; DISEASE OUTCOMES; WOMEN	Use of postmenopausal estrogen has changed since the release of the first results from the Women's Health Initiative in 2002. Professional organizations, the US Food and Drug Administration, and the US Preventive Services Task Force have issued new recommendations against use of estrogen and progestin or progesterone for prevention of chronic conditions. This article applies the current state of evidence for postmenopausal estrogen use to management decisions in 2 clinical scenarios: initiating therapy in a peri-menopausal woman with hot flashes and discontinuing estrogen use in a long-term user.	Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Oregon Evidence Based Practice Ctr, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Nelson, HD (corresponding author), Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Oregon Evidence Based Practice Ctr, Mail Code BICC 504,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	nelsonh@ohsu.edu						Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; BacchiModena A, 1997, MATURITAS, V27, P285, DOI 10.1016/S0378-5122(97)00039-X; Barry MJ, 2002, ANN INTERN MED, V136, P127, DOI 10.7326/0003-4819-136-2-200201150-00010; Bech P, 1998, PSYCHOTHER PSYCHOSOM, V67, P259, DOI 10.1159/000012289; Berg AO, 2002, ANN INTERN MED, V137, P526, DOI 10.7326/0003-4819-137-6-200209170-00014; Blumel J E, 1994, Rev Chil Obstet Ginecol, V59, P354; CAMPBELL S, 1976, MANAGEMENT MENOPAUSE; Cauley JA, 2003, JAMA-J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Connelly MT, 1999, ANN INTERN MED, V131, P265, DOI 10.7326/0003-4819-131-4-199908170-00005; Coope J, 1981, J R Coll Gen Pract, V31, P134; de Vrijer B, 2000, MATURITAS, V34, P47, DOI 10.1016/S0378-5122(99)00085-7; DITKOFF EC, 1991, OBSTET GYNECOL, V78, P991; Good W R, 1999, Climacteric, V2, P29, DOI 10.3109/13697139909025560; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Grady D, 2002, JAMA-J AM MED ASSOC, V287, P2130, DOI 10.1001/jama.287.16.2130; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; GRODSTEIN F, 1994, OBSTET GYNECOL, V83, P5; Harris PF, 2002, J PAIN SYMPTOM MANAG, V23, P501, DOI 10.1016/S0885-3924(02)00395-0; HATCHER RA, 1998, CONTRACEPTIVE TECHNO; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Humphrey LL, 2002, ANN INTERN MED, V137, P273, DOI 10.7326/0003-4819-137-4-200208200-00012; JENSEN PB, 1987, MATURITAS, V9, P207, DOI 10.1016/0378-5122(87)90003-X; Kam IW, 2002, MENOPAUSE, V9, P72, DOI 10.1097/00042192-200201000-00011; Khoo S K, 1998, Climacteric, V1, P55, DOI 10.3109/13697139809080682; Kronenberg F, 2002, ANN INTERN MED, V137, P805, DOI 10.7326/0003-4819-137-10-200211190-00009; KRONENBERG F, 1990, ANN NY ACAD SCI, V592, P52; Lindsay R, 2002, JAMA-J AM MED ASSOC, V287, P2668, DOI 10.1001/jama.287.20.2668; LIVINGSTON WW, 1994, J GEN INTERN MED, V9, P385, DOI 10.1007/BF02629518; Loprinzi CL, 2000, LANCET, V356, P2059, DOI 10.1016/S0140-6736(00)03403-6; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; MacLennan A, 2001, Climacteric, V4, P58, DOI 10.1080/713605036; Maclennan A H, 2004, Cochrane Database Syst Rev, pCD002978, DOI 10.1002/14651858.CD002978.pub2; Mansfield P K, 1997, Health Care Women Int, V18, P55; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; MARSLEW U, 1992, OBSTET GYNECOL, V79, P202; Miller J, 2002, ANN INTERN MED, V136, P680, DOI 10.7326/0003-4819-136-9-200205070-00011; Nelson HD, 2004, JAMA-J AM MED ASSOC, V291, P1610, DOI 10.1001/jama.291.13.1610; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Nelson HD, 2002, ANN INTERN MED, V137, P529, DOI 10.7326/0003-4819-137-6-200209170-00015; Pandya KJ, 2000, ANN INTERN MED, V132, P788, DOI 10.7326/0003-4819-132-10-200005160-00004; Polo-Kantola P, 1998, AM J OBSTET GYNECOL, V178, P1002, DOI 10.1016/S0002-9378(98)70539-3; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; ROTHERT M, 1994, EXP GERONTOL, V29, P463, DOI 10.1016/0531-5565(94)90026-4; Rymer J, 2003, BRIT MED J, V326, P322, DOI 10.1136/bmj.326.7384.322; Saure A, 2000, MATURITAS, V34, P133, DOI 10.1016/S0378-5122(99)00103-6; Simon JA, 2001, ANN INTERN MED, V135, P493, DOI 10.7326/0003-4819-135-7-200110020-00008; Soares CD, 2001, ARCH GEN PSYCHIAT, V58, P529; Speroff L, 2001, CLIN GUIDE CONTRACEP; Stearns V, 2000, ANN ONCOL, V11, P17, DOI 10.1023/A:1008382706068; Stephenson J, 2003, JAMA-J AM MED ASSOC, V289, P537, DOI 10.1001/jama.289.5.537; Tice JA, 2003, JAMA-J AM MED ASSOC, V290, P207, DOI 10.1001/jama.290.2.207; UTIAN WH, 1994, MENOPAUSE, V1, P39; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Wells G, 2002, ENDOCR REV, V23, P529, DOI 10.1210/er.2001-5002; Whitney SN, 2004, ANN INTERN MED, V140, P54, DOI 10.7326/0003-4819-140-1-200401060-00012; *WYETH PHARM, 2004, WEB SIT; 2000, CONSUM REP, V65, P17; 2004, WOMENS HLTH INITATIV	63	25	27	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1621	1625		10.1001/jama.291.13.1621	http://dx.doi.org/10.1001/jama.291.13.1621			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809PQ	15069050				2023-01-03	WOS:000220649000027
J	Campbell, DE; Lynn, J; Louis, TA; Shugarman, LR				Campbell, DE; Lynn, J; Louis, TA; Shugarman, LR			Medicare program expenditures associated with hospice use	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL COMORBIDITY INDEX; COST SAVINGS; LAST YEAR; PROPENSITY SCORES; CARE; LIFE; END; PATTERNS; SERVICES; FAILURE	Background: Hospice providers contend that enrollment reduces the cost of the Medicare programs, but estimates of effects are dated, methodologically limited, and focused on persons with cancer. Objective: To estimate the effects of hospice care on Medicare program payments during the last year of life from 1996 to 1999 within cohorts defined by age and diagnosis. Design: Retrospective cohort. Setting: Deceased Medicare enrollees. Participants: Elderly Medicare fee-for-service beneficiaries who received 36 months of continuous Part A and B coverage before death during 1996 to 1999 (n = 245 326). Age- and condition-specific (cancer or noncancer and principal condition) cohorts were defined. Measurements: Medicare expenditures in the last year of life, as a total figure and by service type. The cost effects of hospice were estimated by using linear regression within the cohorts for hospice enrollees compared with nonenrollees after adjustment for propensity to use hospice, gender, race, enrollment in Medicaid, urban setting, duration of illness, comorbid conditions, low use of Medicare, nursing home residence, and year of death. Results: Adjusted mean expenditures were 4.0% higher overall among hospice enrollees than among nonenrollees. Adjusted mean expenditures were 1% lower for hospice enrollees with cancer than for patients with cancer who did not use hospice. Savings were highest (7% to 17%) among enrollees with lung cancer and other very aggressive types of cancer diagnosed in the last year of life. Expenditures for hospice enrollees without cancer were 11% higher than for nonenrollees, ranging from 20% to 44% for patients with dementia and 0% to 16% for those with chronic heart failure or failure of most other organ systems. Hospice-related savings decreased and relative costs increased with age. Conclusion: Hospice enrollment correlates with reduced Medicare expenditures among younger decedents with cancer but increased expenditures among decedents without cancer and those older than 84 years of age. Future studies should assess the effects of hospice on quality and on expenditures from all payment sources.	Washington Home Ctr Palliat Care Studies, Washington, DC 20016 USA; Med Outcomes Res & Evaluat Serv, Thetford, VT USA; RAND Corp, Santa Monica, CA 90407 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	RAND Corporation; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Lynn, J (corresponding author), Washington Home Ctr Palliat Care Studies, 4200 Wisconsin Ave,4th Floor, Washington, DC 20016 USA.	jlynn@rand.org						[Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Banaszak-Holl J, 1996, Hosp J, V11, P1, DOI 10.1300/J011v11n03_01; BRANCH LG, 1995, GERONTOLOGIST, V35, P349, DOI 10.1093/geront/35.3.349; BROOKS CH, 1984, MED CARE, V22, P691, DOI 10.1097/00005650-198408000-00002; Byock I, 2000, CA-CANCER J CLIN, V50, P123, DOI 10.3322/canjclin.50.2.123; Christakis N A, 1998, Hosp J, V13, P71; Christakis NA, 1999, DEATH FORETOLD PROPH; *COMM STAT PARTN I, 2001, HOSP CAR 1, P11; Connor S R, 1996, HMO Pract, V10, P20; Covinsky KE, 2003, J AM GERIATR SOC, V51, P492, DOI 10.1046/j.1532-5415.2003.51157.x; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; Emanuel EJ, 2002, ARCH INTERN MED, V162, P1722, DOI 10.1001/archinte.162.15.1722; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; Field MJ, 1997, APPROACHING DEATH IM; FOLEY DM, 2001, IMPROVING PALLIATIVE; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; GAGE B, 2000, SYNTHESIS ANAL MEDIC; GAGE B, 2003, MEDICARES HOSPICE BE; *GEN ACC OFF, 2000, GAOHEHS00182; Ghelfi Linda M., 1997, RURAL DEV PERSPECTIV, V12, P32; HARRINGTON C, 1993, GERONTOLOGIST, V33, P790, DOI 10.1093/geront/33.6.790; HOGAN C, 2000, MEDPAC PUBLICATION; HOYERT DL, 1999, DEATHS FINAL DATA 19, V47; Joffe MM, 1999, AM J EPIDEMIOL, V150, P327; Kane RL, 1996, J AM GERIATR SOC, V44, P545, DOI 10.1111/j.1532-5415.1996.tb01440.x; KANE RL, 1984, LANCET, V1, P890; KANE RL, 2001, HDB AGING SOCIAL SCI; KIDDER D, 1992, HEALTH SERV RES, V27, P195; Levenson JW, 2000, J AM GERIATR SOC, V48, pS101, DOI 10.1111/j.1532-5415.2000.tb03119.x; Levinsky NG, 1999, J AM GERIATR SOC, V47, P553, DOI 10.1111/j.1532-5415.1999.tb02569.x; Levinsky NG, 2001, JAMA-J AM MED ASSOC, V286, P1349, DOI 10.1001/jama.286.11.1349; Lubitz J, 1984, Health Care Financ Rev, V5, P117; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Lunney JR, 2002, J AM GERIATR SOC, V50, P1108, DOI 10.1046/j.1532-5415.2002.50268.x; Lynn J, 1997, New Horiz, V5, P56; Lynn J, 1996, Duquesne Law Rev, V35, P311; Lynn J, 2000, J AM GERIATR SOC, V48, pS91, DOI 10.1111/j.1532-5415.2000.tb03147.x; Lynn J, 1998, Hosp J, V13, P151; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; McCarthy EP, 2000, J AM GERIATR SOC, V48, pS110, DOI 10.1111/j.1532-5415.2000.tb03120.x; *MED PAYM ADV COMM, 2002, REP C ASS MED BEN; Medicare Payment Advisory Commission, 2002, REP C MED BEN ACC HO; MILLER GW, 2002, DELIVERING QUALITY C; MILLER SC, 2000, SYNTHESIS ANAL MEDIC; MOON M, 2003, MEDICARE END LIFE CA; MOR V, 1985, HEALTH SERV RES, V20, P407; *NAT HOSP ORG, 1995, AN COST SAV MED HOS; *NAT HOSP PALL CAR, 2001, HOSP HOSP PARTN PALL; *NAT PACE ASS, 2000, PACE PROF PROGR ALL; REIS LA, 2000, SEER STAT REV 1973 1; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Somogyi-Zalud E, 2000, J AM GERIATR SOC, V48, pS140, DOI 10.1111/j.1532-5415.2000.tb03123.x; SPECTOR WD, 1984, INQUIRY-J HEALTH CAR, V21, P328; WHITE AJ, 2000, EVALUATION PROGRAM A	60	102	104	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 17	2004	140	4					269	277		10.7326/0003-4819-140-4-200402170-00009	http://dx.doi.org/10.7326/0003-4819-140-4-200402170-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774GA	14970150				2023-01-03	WOS:000188970400005
J	Gilliland, FD; Li, YF; Saxon, A; Diaz-Sanchez, D				Gilliland, FD; Li, YF; Saxon, A; Diaz-Sanchez, D			Effect of glutathione-S-transferase M1 and P1 genotypes on xenobiotic enhancement of allergic responses: randomised, placebo-controlled crossover study	LANCET			English	Article							DIESEL EXHAUST PARTICLES; AIR-POLLUTION; IN-VIVO; NASAL CHALLENGE; CYTOKINE PRODUCTION; TOBACCO-SMOKE; LUNG-CANCER; ASTHMA; EXPOSURE; IGE	Background Particulate pollution is associated with the occurrence of asthma and allergy. The model pollutant, diesel exhaust particles, can participate with allergens in starting and exacerbating allergic airway diseases in part by production of reactive oxygen species. Glutathione-S-transferases (GSTs) can metabolise reactive oxygen species and detoxify xenobiotics present in diesel exhaust particles. We tested the hypothesis that null genotypes for GSTM1 and GSTT1, and GSTP1 codon 105 variants (I105 and V105) are key regulators of the adjuvant effects of diesel exhaust particles on allergic responses. Methods Patients sensitive to the ragweed allergen were challenged intranasally with allergen alone and with allergen plus diesel exhaust particles in a randomised order at separate visits. Nasal allergen-specific IgE, histamine, interleukin 4, and interferon gamma concentrations were measured before and 24 h after challenge. Findings Individuals with GSTM1 null or the GSTP1 I105 wildtype genotypes showed enhanced nasal allergic responses in the presence of diesel exhaust particles. Compared with patients with a functional GSTM1 genotype, GSTM1 null patients had a significantly larger increase in IgE (median 102.5 U/mL [range 1.0-510.5] vs 45.5 U/mL [1.5-60.6], p=0.03) and histamine (14.0 nmol/L [-0.2-24.7] vs 7.4 nmol/L [1.2-12.3], p=0.02) after diesel exhaust particles plus allergen challenge. The I105 GSTP1 genotype was associated with an increase in IgE (120.3 U/mL [6.7-510.5] vs 27.7 U/mL [-1.5-60.6], p=0.03) and histamine (13.8 nmol/L [3.1-24.7] vs 5.2 nmol/L [-0.2-19.6], p=0.01) after challenge with diesel exhaust particles and allergens. The diesel exhaust particles enhancement was largest in patients with both the GSTM1 null and GSTP1 I/I genotypes. Interpretation GSTM1 and GSTP1 modify the adjuvant effect of diesel exhaust particles on allergic inflammation.	Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Clin Immunol,Hart & Louis Lab, Los Angeles, CA USA	University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gilliland, FD (corresponding author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.	gillilan@usc.edu	LI, YU-FEN/F-4770-2010	LI, YU-FEN/0000-0002-3960-6101	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040945, R21AI040945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009581, P30ES007048] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-61768] Funding Source: Medline; NIAID NIH HHS [AI-40945] Funding Source: Medline; NIEHS NIH HHS [ES-07048, ES-09581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Al-Humadi NH, 2002, ENVIRON HEALTH PERSP, V110, P349, DOI 10.1289/ehp.02110349; Barfknecht T R, 1982, Dev Toxicol Environ Sci, V10, P277; BASCOM R, 1991, PHARMACOGENETICS, V1, P102, DOI 10.1097/00008571-199111000-00008; BASCOM R, 1990, AM REV RESPIR DIS, V142, P594, DOI 10.1164/ajrccm/142.3.594; D'Amato G, 2002, Monaldi Arch Chest Dis, V57, P136; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573, DOI 10.1289/ehp.02110s4573; Diaz-Sanchez D, 2000, CLIN IMMUNOL, V97, P140, DOI 10.1006/clim.2000.4921; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; Diaz-Sanchez D, 2000, IMMUNOLOGY, V101, P11, DOI 10.1046/j.1365-2567.2000.00108.x; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437, DOI 10.1164/ajrccm.161.5.9903006; FRYER AA, 1986, BIOCHIM BIOPHYS ACTA, V883, P448, DOI 10.1016/0304-4165(86)90283-7; Gilliland FD, 1999, ENVIRON HEALTH PERSP, V107, P403, DOI 10.1289/ehp.99107s3403; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P346, DOI 10.1164/rccm.2111048; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hiura TS, 2000, J IMMUNOL, V165, P2703, DOI 10.4049/jimmunol.165.5.2703; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; MANCHESTER J, 2001, DETERMINATION ELEM B, P1; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P505, DOI 10.1016/S0091-6749(97)70143-X; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; Ng D, 1998, J IMMUNOL, V161, P942; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161, DOI 10.1164/ajrccm.162.1.9908092; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Pandya RJ, 2002, ENVIRON HEALTH PERSP, V110, P103, DOI 10.1289/ehp.02110s1103; Piirila P, 2001, PHARMACOGENETICS, V11, P437, DOI 10.1097/00008571-200107000-00007; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; SAGAI M, 1998, INVOLVEMENTS SUPEROX; Samet J M, 2000, Res Rep Health Eff Inst, V94, P5; Strand V, 1997, AM J RESP CRIT CARE, V155, P881, DOI 10.1164/ajrccm.155.3.9117021; ToFigueras J, 1997, CARCINOGENESIS, V18, P1529, DOI 10.1093/carcin/18.8.1529; Trenga CA, 1999, OCCUP ENVIRON MED, V56, P544, DOI 10.1136/oem.56.8.544; Wang M, 1999, CLIN IMMUNOL, V90, P47, DOI 10.1006/clim.1998.4628; Whitekus MJ, 2002, J IMMUNOL, V168, P2560, DOI 10.4049/jimmunol.168.5.2560; WILLIAMS PT, 1986, FUEL, V65, P1150, DOI 10.1016/0016-2361(86)90184-5; XU GB, 1987, AEROSOL SCI TECH, V7, P117, DOI 10.1080/02786828708959152	44	255	265	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 10	2004	363	9403					119	125		10.1016/S0140-6736(03)15262-2	http://dx.doi.org/10.1016/S0140-6736(03)15262-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761WV	14726165				2023-01-03	WOS:000187939200009
J	Ulmer, TS; Bax, A; Cole, NB; Nussbaum, RL				Ulmer, TS; Bax, A; Cole, NB; Nussbaum, RL			Structure and dynamics of micelle-bound human alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDIMENSIONAL NMR EXPERIMENTS; MODEL-FREE APPROACH; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; DIPOLAR COUPLINGS; CHEMICAL-SHIFTS; STRUCTURE REFINEMENT; SECONDARY STRUCTURE; GLOBULAR-PROTEINS; LEWY BODIES	Misfolding of the protein alpha-synuclein (aS), which associates with presynaptic vesicles, has been implicated in the molecular chain of events leading to Parkinson's disease. Here, the structure and dynamics of micelle- bound aS are reported. Val(3)-Val(37) and Lys(45)Thr(92) form curved alpha-helices, connected by a well ordered, extended linker in an unexpected anti-parallel arrangement, followed by another short extended region (Gly(93)-Lys(97)), overlapping the recently identified chaperone- mediated autophagy recognition motif and a highly mobile tail (Asp(98)-Ala(140)). Helix curvature is significantly less than predicted based on the native micelle shape, indicating a deformation of the micelle by aS. Structural and dynamic parameters show a reduced helical content for Ala(30)-Val37. A dynamic variation in interhelical distance on the microsecond timescale is complemented by enhanced sub-nanosecond timescale dynamics, particularly in the remarkably glycine-rich segments of the helices. These unusually rich dynamics may serve to mitigate the effect of aS binding on membrane fluidity. The well ordered conformation of the helix- helix connector indicates a defined interaction with lipidic surfaces, suggesting that, when bound to larger diameter synaptic vesicles, it can act as a switch between this structure and a previously proposed uninterrupted helix.	NHGRI, Lab Chem Phys, NIDDK, NIH, Bethesda, MD 20892 USA; NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Ulmer, TS (corresponding author), NHGRI, Lab Chem Phys, NIDDK, NIH, Bethesda, MD 20892 USA.	tobias.ulmer@nih.gov			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029020] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson CAF, 2002, STRUCTURE, V10, P175, DOI 10.1016/S0969-2126(02)00700-1; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Bansal M, 2000, J BIOMOL STRUCT DYN, V17, P811, DOI 10.1080/07391102.2000.10506570; Bertini I, 2001, METHOD ENZYMOL, V339, P314, DOI 10.1016/S0076-6879(01)39320-5; Bruce CD, 2002, J PHYS CHEM B, V106, P3788, DOI 10.1021/jp013616z; Bussell R, 2003, J MOL BIOL, V329, P763, DOI 10.1016/S0022-2836(03)00520-5; Case DA, 1998, CURR OPIN STRUC BIOL, V8, P624, DOI 10.1016/S0959-440X(98)80155-3; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Chou JJ, 2000, J BIOMOL NMR, V18, P101, DOI 10.1023/A:1008358318863; Chou JJ, 2001, J BIOMOL NMR, V21, P377, DOI 10.1023/A:1013336502594; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Curran AR, 2003, CURR OPIN STRUC BIOL, V13, P412, DOI 10.1016/S0959-440X(03)00102-7; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Delaglio F, 2000, J AM CHEM SOC, V122, P2142, DOI 10.1021/ja993603n; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; Dev KK, 2003, NEUROPHARMACOLOGY, V45, P14, DOI 10.1016/S0028-3908(03)00140-0; Donaldson LW, 2001, J AM CHEM SOC, V123, P9843, DOI 10.1021/ja011241p; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fernandez CO, 2004, EMBO J, V23, P2039, DOI 10.1038/sj.emboj.7600211; Garg G, 2004, PRAMANA-J PHYS, V63, P351, DOI 10.1007/BF02704997; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Goto NK, 1999, J BIOMOL NMR, V13, P369, DOI 10.1023/A:1008393201236; Grishaev A, 2004, J AM CHEM SOC, V126, P7281, DOI 10.1021/ja0319994; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z; Hu JS, 1997, J BIOMOL NMR, V9, P323, DOI 10.1023/A:1018691228238; Iwahara J, 2004, J AM CHEM SOC, V126, P5879, DOI 10.1021/ja031580d; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jao CC, 2004, P NATL ACAD SCI USA, V101, P8331, DOI 10.1073/pnas.0400553101; Jaroniec CP, 2004, J BIOMOL NMR, V30, P181, DOI 10.1023/B:JNMR.0000048946.71249.2f; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jo E, 2004, EUR J BIOCHEM, V271, P3180, DOI 10.1111/j.1432-1033.2004.04250.x; Kahle PJ, 2002, J NEUROCHEM, V82, P449, DOI 10.1046/j.1471-4159.2002.01020.x; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kumar S, 1998, BIOPHYS J, V75, P1935, DOI 10.1016/S0006-3495(98)77634-9; Kuszewski J, 2000, J MAGN RESON, V146, P249, DOI 10.1006/jmre.2000.2142; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Louhivuori M, 2004, J BIOMOL NMR, V29, P517, DOI 10.1023/B:JNMR.0000034347.01925.ad; Meiler J, 2001, J AM CHEM SOC, V123, P6098, DOI 10.1021/ja010002z; Mezey E, 1998, MOL PSYCHIATR, V3, P493, DOI 10.1038/sj.mp.4000446; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; Nuscher B, 2004, J BIOL CHEM, V279, P21966, DOI 10.1074/jbc.M401076200; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Oldfield E, 2002, ANNU REV PHYS CHEM, V53, P349, DOI 10.1146/annurev.physchem.53.082201.124235; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Phillips GR, 2001, NEURON, V32, P63, DOI 10.1016/S0896-6273(01)00450-0; Ramakrishnan M, 2003, BIOCHEMISTRY-US, V42, P12919, DOI 10.1021/bi035048e; REHAGE H, 1991, MOL PHYS, V74, P933, DOI 10.1080/00268979100102721; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; Sharon R, 2003, J BIOL CHEM, V278, P49874, DOI 10.1074/jbc.M309127200; Shortle D, 2001, SCIENCE, V293, P487, DOI 10.1126/science.1060438; SKLENAR V, 1995, J MAGN RESON SER A, V114, P132, DOI 10.1006/jmra.1995.1119; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tolman JR, 2001, J AM CHEM SOC, V123, P1416, DOI 10.1021/ja002500y; Tycko R, 2000, J AM CHEM SOC, V122, P9340, DOI 10.1021/ja002133q; Ulmer TS, 2003, J AM CHEM SOC, V125, P9179, DOI 10.1021/ja0350684; Vekrellis K, 2004, MOL NEUROBIOL, V30, P1, DOI 10.1385/MN:30:1:001; Weigelt J, 1998, J AM CHEM SOC, V120, P10778, DOI 10.1021/ja982649y; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9; Zhu G, 2000, J MAGN RESON, V143, P423, DOI 10.1006/jmre.2000.2022	70	654	661	4	186	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9595	9603		10.1074/jbc.M411805200	http://dx.doi.org/10.1074/jbc.M411805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15615727	hybrid			2023-01-03	WOS:000227453100114
J	Paul, C				Paul, C			The relentless therapeutic imperative	BRITISH MEDICAL JOURNAL			English	Article									Univ Otago, Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand	University of Otago	Paul, C (corresponding author), Univ Otago, Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand.	charlotte.paul@stonebow.otago.ac.nz							0	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 18	2004	329	7480					1457	1459		10.1136/bmj.329.7480.1457	http://dx.doi.org/10.1136/bmj.329.7480.1457			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	882VB	15604183	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000225965800026
J	Fowlie, PW; McHaffie, H				Fowlie, PW; McHaffie, H			ABC of preterm birth - Supporting parents in the neonatal unit	BRITISH MEDICAL JOURNAL			English	Review									Perth Royal Infirm, Dundee, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Inst Med Eth, Loanhead, Midlothian, Scotland	University of Dundee	Fowlie, PW (corresponding author), Perth Royal Infirm, Dundee, Scotland.							Affleck G, 1991, Child Health Care, V20, P6, DOI 10.1207/s15326888chc2001_2; HARRISON H, 1993, PEDIATRICS, V92, P643; McHaffie Hazel, 2001, CRUCIAL DECISIONS BE; MCHAFFIE HE, 1996, LIFE DEATH DECISIONS; Miles MS, 1997, SEMIN PERINATOL, V21, P254, DOI 10.1016/S0146-0005(97)80067-5; Singer LT, 1999, JAMA-J AM MED ASSOC, V281, P799, DOI 10.1001/jama.281.9.799	6	50	53	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 4	2004	329	7478					1336	1338		10.1136/bmj.329.7478.1336	http://dx.doi.org/10.1136/bmj.329.7478.1336			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	878PC	15576746	Green Published			2023-01-03	WOS:000225657800024
J	Pardoll, D; Allison, J				Pardoll, D; Allison, J			Cancer immunotherapy: breaking the barriers to harvest the crop	NATURE MEDICINE			English	Editorial Material							METASTATIC MELANOMA; ANTIGEN-4 BLOCKADE; T-CELLS; ANTIBODY; THERAPY; AUTOIMMUNITY; REGRESSION; RESPONSES; PLUS	Successful translation of modern molecular immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Canc Ctr, Baltimore, MD 21218 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Johns Hopkins University; Memorial Sloan Kettering Cancer Center	Pardoll, D (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Canc Ctr, Baltimore, MD 21218 USA.	dmpardol@jhmi.edu		Allison, James/0000-0001-8980-5697				Akhtar S, 2002, NEW ENGL J MED, V346, P1830; Blattman JN, 2004, SCIENCE, V305, P200, DOI 10.1126/science.1100369; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Ergenzinger E, 2003, SCIENTIST, V17, P43; Grilley BJ, 2003, CYTOTHERAPY, V5, P197, DOI 10.1080/14653240310001271; Hersey P, 2003, INTERN MED J, V33, P33, DOI 10.1046/j.1445-5994.2002.00289.x; Levitsky HI, 2000, CANCER J, V6, pS281; Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith MA, 2002, ACTA NEUROPATHOL, V104, P110, DOI 10.1007/s00401-002-0572-2; Stolberg Sheryl Gay, 1999, N Y Times Mag, P136; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Waldmann H, 2002, MED ONCOL, V19, pS3, DOI 10.1385/MO:19:2S:S03; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; WINTER G, 1993, TRENDS PHARMACOL SCI, V14, P139, DOI 10.1016/0165-6147(93)90197-R; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099	20	110	114	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2004	10	9					887	892		10.1038/nm0904-887	http://dx.doi.org/10.1038/nm0904-887			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	851AZ	15340404				2023-01-03	WOS:000223658400010
J	Jagsi, R; Lehmann, S				Jagsi, R; Lehmann, S			The ethics of medical education	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LEGAL IMPLICATIONS; INFORMED CONSENT; STUDENT DOCTOR; CARE; RESIDENTS; ATTITUDES; PATIENT		Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02120 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Lehmann, S (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA.	llehmann1@partners.org		Jagsi, Reshma/0000-0001-6562-1228				ANNAS GJ, 1980, B NEW YORK ACAD MED, V56, P403; BASSON MD, 1982, HASTINGS CENT REP, V12, P27; BEATTY ME, 1995, ACAD MED, V70, P175, DOI 10.1097/00001888-199503000-00002; Brody BA, 1998, ETHICS BIOMEDICAL RE; Butters JM, 1996, ACAD MED, V71, P583, DOI 10.1097/00001888-199606000-00008; COHEN DL, 1987, J MED EDUC, V62, P789; COHEN DL, 1988, J MED EDUC, V63, P821; Coldicott Y, 2003, BRIT MED J, V326, P97, DOI 10.1136/bmj.326.7380.97; Diekema DS, 1996, AM J EMERG MED, V14, P6, DOI 10.1016/S0735-6757(96)90002-9; Doyal L, 2001, BRIT MED J, V322, P685, DOI 10.1136/bmj.322.7288.685; Frank SH, 1997, JAMA-J AM MED ASSOC, V278, P712, DOI 10.1001/jama.278.9.712; Hicks LK, 2001, BRIT MED J, V322, P709, DOI 10.1136/bmj.322.7288.709; KAPP MB, 1983, J MED EDUC, V58, P293; KING D, 1992, MED EDUC, V26, P360, DOI 10.1111/j.1365-2923.1992.tb00186.x; Magrane D, 1996, OBSTET GYNECOL, V88, P298, DOI 10.1016/0029-7844(96)00191-3; Marracino RK, 1998, J GEN INTERN MED, V13, P266, DOI 10.1046/j.1525-1497.1998.00078.x; RICH EC, 1990, JAMA-J AM MED ASSOC, V263, P953; Vinicky J K, 1991, J Clin Ethics, V2, P35; WILLIG C, 1992, J COMMUNITY APPL SOC, V2, P217, DOI 10.1002/casp.2450020306	19	29	31	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 7	2004	329	7461					332	334		10.1136/bmj.329.7461.332	http://dx.doi.org/10.1136/bmj.329.7461.332			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	846FF	15297341	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000223300300024
J	Delbaldo, C; Michiels, S; Syz, N; Soria, JC; Le Chevalier, T; Pignon, JP				Delbaldo, C; Michiels, S; Syz, N; Soria, JC; Le Chevalier, T; Pignon, JP			Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PHASE-III TRIAL; HIGH-DOSE CISPLATIN; VINDESINE PLUS CISPLATIN; INDIVIDUAL PATIENT DATA; RANDOMIZED-TRIAL; COMBINATION CHEMOTHERAPY; VINORELBINE-CISPLATIN; COMPARING CISPLATIN; ELDERLY-PATIENTS; ONCOLOGY-GROUP	Context Randomized trials have demonstrated that adding a drug to a single-agent or to a 2-agent regimen increased the tumor response rate in patients with advanced non-small-cell lung cancer (NSCLC), although its impact on survival remains controversial. Objective To evaluate the clinical benefit of adding a drug to a single-agent or 2-agent chemotherapy regimen in terms of tumor response rate, survival, and toxicity in patients with advanced NSCLC. Data Sources and Study Selection Data from all randomized controlled trials performed between 1980 and 2001 (published between January 1980 and October 2003) comparing a doublet regimen with a single-agent regimen or comparing a triplet regimen with a doublet regimen in patients with advanced NSCLC. There were no language restrictions. Searches of MEDLINE and EMBASE were performed using the search terms non-small-cell lung carcinoma/drug therapy, adenocarcinoma, large-cell carcinoma, squamous-cell carcinoma, lung, neoplasms, clinical trial phase III, and randomized trial. Manual searches were also performed to find conference proceedings published between January 1982 and October 2003. Data Extraction Two independent investigators reviewed the publications and extracted the data. Pooled odds ratios (ORs) for the objective tumor response rate, 1-year survival rate, and toxicity rate were calculated using the fixed-effect model. Pooled median ratios (MRS) for median survival also were calculated using the fixed-effect model. ORs and MRS lower than unity (<1.0) indicate a benefit of a doublet regimen compared with a single-agent regimen (or a triplet regimen compared with a doublet regimen). Data Synthesis Sixty-five trials (13601 patients) were eligible. In the trials comparing a doublet regimen with a single-agent regimen, a significant increase was observed in tumor response (OR, 0.42; 95% confidence interval [CI], 0.37-0.47; P<.001) and 1-year survival (OR, 0.80; 95% Cl, 0.70-0.91; P<.001) in favor of the doublet regimen. The median survival ratio was 0.83 (95% Cl, 0.79-0.89; P<.001). An increase also was observed in the tumor response rate (OR, 0.66; 95% Cl, 0.58-0.75; P<.001) in favor of the triplet regimen, but not for 1-year survival (OR, 1.01; 95% Cl, 0.85-1.21; P=.88). The median survival ratio was 1.00 (95% Cl, 0.94-1.06; P=.97). Conclusion Adding a second drug improved tumor response and survival rate. Adding a third drug had a weaker effect on, tumor response and no effect on survival.	Inst Gustave Roussy, Dept Biostat & Epidemiol, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Pignon, JP (corresponding author), Inst Gustave Roussy, Dept Biostat & Epidemiol, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	jppignon@igr.fr	Michiels, Stefan/L-1516-2013; Soria, Jean-Charles/F-3619-2014	Michiels, Stefan/0000-0002-6963-2968; PIGNON, Jean-Pierre/0000-0003-2047-1582				AGGSTROM MQ, 2003, P AN M AM SOC CLIN, V22, P624; ALBAIN KS, 1991, J CLIN ONCOL, V9, P1618, DOI 10.1200/JCO.1991.9.9.1618; Alberola V, 2003, J CLIN ONCOL, V21, P3207, DOI 10.1200/JCO.2003.12.038; ALBERTI W, 1995, BRIT MED J, V311, P899; ARECO A, 1989, P AN M AM SOC CLIN, V8, P240; Baggstrom MQ, 2002, P AN M AM SOC CLIN, V21, p306a; Bando H, 1986, Gan To Kagaku Ryoho, V13, P2094; BERARDI R, 2001, P AN M AM SOC CLIN, V20, pA347; BISSETT D, 2002, P AN M AM SOC CLIN, V21, pA296; BONOMI PD, 1989, J CLIN ONCOL, V7, P1602, DOI 10.1200/JCO.1989.7.11.1602; Breathnach OS, 2001, J CLIN ONCOL, V19, P1734, DOI 10.1200/JCO.2001.19.6.1734; BREAU JL, 1988, P AN M AM SOC CLIN, V7, P212; Bunn PA, 1998, CLIN CANCER RES, V4, P1087; Bunn PA, 2002, J CLIN ONCOL, V20, P3565, DOI 10.1200/JCO.2002.20.17.3565; Bunn PA, 2000, CHEST, V117, p138S, DOI 10.1378/chest.117.4_suppl_1.138S; Comella P, 2000, J CLIN ONCOL, V18, P1451, DOI 10.1200/JCO.2000.18.7.1451; CRINO L, 1990, CANCER CHEMOTH PHARM, V26, P52, DOI 10.1007/BF02940294; Crino L, 2002, SEMIN ONCOL, V29, P9, DOI 10.1053/sonc.2002.34266; DENKMAYR M, 1991, LUNG CANCER S, V7, P130; DEPIERRE A, 1994, ANN ONCOL, V5, P37, DOI 10.1093/oxfordjournals.annonc.a058687; DEZA EG, 1996, P AN M AM SOC CLIN, V15, P394; DHINGRA HM, 1985, J CLIN ONCOL, V3, P176, DOI 10.1200/JCO.1985.3.2.176; Edelman MJ, 2001, CANCER CHEMOTH PHARM, V48, P141, DOI 10.1007/s002800000273; EINHORN LH, 1986, J CLIN ONCOL, V4, P1037, DOI 10.1200/JCO.1986.4.7.1037; ELLIOTT JA, 1984, EUR J CANCER CLIN ON, V20, P1025, DOI 10.1016/0277-5379(84)90104-4; ERKISI M, 1995, LUNG CANCER, V12, P237, DOI 10.1016/0169-5002(95)00447-9; Frasci G, 2000, J CLIN ONCOL, V18, P2529, DOI 10.1200/JCO.2000.18.13.2529; FUKUOKA M, 1991, J CLIN ONCOL, V9, P606, DOI 10.1200/JCO.1991.9.4.606; GANDARA DR, 1993, J CLIN ONCOL, V11, P873, DOI 10.1200/JCO.1993.11.5.873; Gatzemeier U, 2000, J CLIN ONCOL, V18, P3390, DOI 10.1200/JCO.2000.18.19.3390; GATZEMEIER U, 2002, P AN M AM SOC CLIN, V21, pA297; GEORGOULIAS G, 2003, CLIN LUNG CANCER, V4, P288; GIACCONE G, 2004, J CLIN ONCOL, V22, P759; GOROSPE A, 2000, LUNG CANCER, V29, P70; GRALLA RJ, 1994, P AN M AM SOC CLIN, V13, P347; Greco FA, 2002, CANCER, V95, P1279, DOI 10.1002/cncr.10810; Gridelli C, 2003, JNCI-J NATL CANCER I, V95, P362, DOI 10.1093/jnci/95.5.362; GRILLI R, 1993, J CLIN ONCOL, V11, P1866, DOI 10.1200/JCO.1993.11.10.1866; HAINSWORTH JD, 1989, AM J CLIN ONCOL-CANC, V12, P345, DOI 10.1097/00000421-198908000-00014; Herbst RS, 2004, J CLIN ONCOL, V22, P785, DOI 10.1200/JCO.2004.07.215; HIRAKI S, 1991, LUNG CANCER S, V7, P111; HOFFMAN PC, 1985, P AN M AM SOC CLIN, V4, P185; HUSSEIN A, 2000, P AN M AM SOC CLIN, V19, pA504; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; IHDE DC, 1991, CURR PROB CANCER, V15, P61; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; JENSEN NV, 2002, P AN M AM SOC CLIN, V21, pA322; Jeremic B, 1997, LUNG CANCER, V18, P179, DOI 10.1016/S0169-5002(97)00063-9; Juretic A, 1999, ANN ONCOL, V10, P93, DOI 10.1023/A:1008385731605; KAWAHARA M, 1991, CANCER, V68, P714, DOI 10.1002/1097-0142(19910815)68:4<714::AID-CNCR2820680408>3.0.CO;2-J; KLASTERSKY J, 1989, J CLIN ONCOL, V7, P1087, DOI 10.1200/JCO.1989.7.8.1087; Klastersky J, 2001, LUNG CANCER-J IASLC, V34, pS95; Kodani T, 2002, LUNG CANCER, V36, P313, DOI 10.1016/S0169-5002(02)00008-9; KOSMIDIS P, 1994, ANN ONCOL, V5, P159, DOI 10.1093/oxfordjournals.annonc.a058769; Laack E, 2002, ANN ONCOL, V13, P1550, DOI 10.1093/annonc/mdf270; Langer CJ, 2003, P AN M AM SOC CLIN, V22, P639; LECHEVALIER T, 1994, J CLIN ONCOL, V12, P360, DOI 10.1200/JCO.1994.12.2.360; Lilenbaum RC, 1998, CANCER, V82, P116, DOI 10.1002/(SICI)1097-0142(19980101)82:1<116::AID-CNCR14>3.0.CO;2-5; LILENBAUM RC, 2002, P AN M AM SOC CLIN, V21, P2; LORUSSO V, 1995, INT J ONCOL, V6, P65; LUEDKE DW, 1990, J CLIN ONCOL, V8, P886, DOI 10.1200/JCO.1990.8.5.886; MARINO P, 1994, CHEST, V106, P861, DOI 10.1378/chest.106.3.861; Masutani M, 1996, Respirology, V1, P49, DOI 10.1111/j.1440-1843.1996.tb00010.x; Mencoboni M, 1997, ANTICANCER RES, V17, P2795; MICHIELS S, IN PRESS INT J TECHN; NAKABAYASHI T, 1986, LUNG CANCER, V2, P124; Natale RB, 1997, SEMIN ONCOL, V24, pS29; Negoro S, 2003, BRIT J CANCER, V88, P335, DOI 10.1038/sj.bjc.6600725; NEGORO S, 1988, LUNG CANCER S, V4, pA126; PACCAGNELLA A, 1990, CANCER, V65, P2631, DOI 10.1002/1097-0142(19900615)65:12<2631::AID-CNCR2820651205>3.0.CO;2-Y; Perol M, 2002, ANN ONCOL, V13, P742, DOI 10.1093/annonc/mdf128; RICHARDS F, 1991, CANCER, V67, P2974; RIVERO S, 1999, P AN M AM SOC CLIN, V18, P2010; Rosell R, 2002, ANN ONCOL, V13, P1539, DOI 10.1093/annonc/mdf332; ROSSO R, 1990, CANCER-AM CANCER SOC, V66, P130, DOI 10.1002/1097-0142(19900701)66:1<130::AID-CNCR2820660123>3.0.CO;2-P; Sandler AB, 2000, J CLIN ONCOL, V18, P122, DOI 10.1200/JCO.2000.18.1.122; Sederholm C, 2002, SEMIN ONCOL, V29, P50, DOI 10.1053/sonc.2002.34276; SHAH S, 1988, P AN M AM SOC CLIN, V7, P211; SHINKAI T, 1991, EUR J CANCER, V27, P571, DOI 10.1016/0277-5379(91)90220-8; SIMES RJ, 1987, STAT MED, V6, P11, DOI 10.1002/sim.4780060104; Somerfield MR, 1997, J CLIN ONCOL, V15, P2996; Soria JC, 2002, ANN ONCOL, V13, P1515, DOI 10.1093/annonc/mdf331; Soria JC, 2001, ANN ONCOL, V12, P1667, DOI 10.1023/A:1013574413217; SORIA JC, 1999, P AN M AM SOC CLIN, V18, pA491; SOUQUET PJ, 1993, LANCET, V342, P19; Souquet PJ, 2002, ANN ONCOL, V13, P1853, DOI 10.1093/annonc/mdf316; Splinter TAW, 1996, J CLIN ONCOL, V14, P127, DOI 10.1200/JCO.1996.14.1.127; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; Sweeney CJ, 2001, CANCER, V92, P2639, DOI 10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8; TSURUTA M, 1986, LUNG CANCER, V2, P113; von Pawel J, 2000, J CLIN ONCOL, V18, P1351, DOI 10.1200/JCO.2000.18.6.1351; Waters JS, 2002, BRIT J CANCER, V87, P481, DOI 10.1038/sj.bjc.6600491; Williamson PR, 2000, J EVAL CLIN PRACT, V6, P205, DOI 10.1046/j.1365-2753.2000.00236.x; Wozniak AJ, 1998, J CLIN ONCOL, V16, P2459, DOI 10.1200/JCO.1998.16.7.2459; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Zoli W, 1999, BRIT J CANCER, V81, P609, DOI 10.1038/sj.bjc.6690737	96	254	269	1	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	2004	292	4					470	484		10.1001/jama.292.4.470	http://dx.doi.org/10.1001/jama.292.4.470			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	841AA	15280345				2023-01-03	WOS:000222900500024
J	Guillemard, V; Saragovi, HU				Guillemard, V; Saragovi, HU			Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity	ONCOGENE			English	Article						prodrug; chemotherapy; resistance; target; selectivity; efficacy	GROWTH-FACTOR RECEPTOR; MULTIDRUG-RESISTANCE; MONOCLONAL-ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CELLS; DOXORUBICIN; CANCER; TRANSPORTERS; PERIODATE; OXIDATION	Doxorubicin intercalates into DNA, causes double-strand breaks, and leads to apoptotic death. Limitations to the efficacy and therapeutic index of doxorubicin include poor tumor selectivity, high systemic toxicity, and the development of resistance, especially p-glycoprotein (p-gp)mediated. We chemically coupled doxorubicin to a monoclonal antibody directed to the insulin-like growth factor-1 receptor, a receptor highly overexpressed in most tumors and validated as a tumor target. The prodrug conjugate bounded to tumor cells selectively, and accumulated efficiently and only in receptor-expressing cells. The conjugate was processed to release free doxorubicin inside target cells leading to selective toxicity, had >200-fold improved therapeutic index, and in vivo reduced tumor load with no systemic toxicity. Importantly, the prodrug conjugate is not subject to p-gp efflux and can bypass resistance in vivo. Our studies de. ne a strategy to develop improved and more selective anticancer agents.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Ctr Canc, Montreal, PQ H3T 1E2, Canada	McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Saragovi, HU (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond Ave,1320, Montreal, PQ H3G 1Y6, Canada.	uri@pharma.mcgill.ca			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038569] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS38569] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Berezov A, 2002, J BIOL CHEM, V277, P28330, DOI 10.1074/jbc.M202880200; Berezov A, 2001, J MED CHEM, V44, P2565, DOI 10.1021/jm000527m; Casares S, 2001, NAT BIOTECHNOL, V19, P142, DOI 10.1038/84404; da Rocha Adriana B., 2001, Current Opinion in Pharmacology, V1, P364; Fakata KL, 1998, LIFE SCI, V62, P2441, DOI 10.1016/S0024-3205(98)00227-6; Fritzer M, 1996, BIOCHEM PHARMACOL, V51, P489, DOI 10.1016/0006-2952(95)02225-2; Garsky VM, 2001, J MED CHEM, V44, P4216, DOI 10.1021/jm0101996; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Guillemard V, 2001, CANCER RES, V61, P694; Hage DS, 1997, BIOCONJUGATE CHEM, V8, P914, DOI 10.1021/bc970112o; Hailey J, 2002, MOL CANCER THER, V1, P1349; KATO H, 1993, J BIOL CHEM, V268, P2655; King HD, 1999, BIOCONJUGATE CHEM, V10, P279, DOI 10.1021/bc980100i; Langer M, 2001, J MED CHEM, V44, P1341, DOI 10.1021/jm001065f; Maliartchouk S, 1997, J NEUROSCI, V17, P6031; Matsui H, 2002, LEUKEMIA, V16, P813, DOI 10.1038/sj.leu.2402459; Monneret C, 2001, EUR J MED CHEM, V36, P483, DOI 10.1016/S0223-5234(01)01244-2; MOSCOW JA, 1988, J NATL CANCER I, V80, P14, DOI 10.1093/jnci/80.1.14; Munns J, 1998, BRIT J UROL, V82, P284; Nagy A, 1998, P NATL ACAD SCI USA, V95, P1794, DOI 10.1073/pnas.95.4.1794; Omelyanenko V, 1996, J DRUG TARGET, V3, P357, DOI 10.3109/10611869608996827; Salerno M, 2002, BIOCHEM PHARMACOL, V63, P1471, DOI 10.1016/S0006-2952(02)00895-X; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Screaton RA, 1997, J CELL BIOL, V137, P939, DOI 10.1083/jcb.137.4.939; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Stan AC, 1999, CANCER RES, V59, P115; Tan B, 2000, CURR OPIN ONCOL, V12, P450, DOI 10.1097/00001622-200009000-00011; TANNOCK IF, 1992, BASIC SCI ONCOLOGY, P305; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; TRAIL PA, 1993, SCIENCE, V261, P212, DOI 10.1126/science.8327892; WOLFE CAC, 1995, ANAL BIOCHEM, V231, P123, DOI 10.1006/abio.1995.1511; Yang XD, 1999, CANCER RES, V59, P1236	36	47	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3613	3621		10.1038/sj.onc.1207463	http://dx.doi.org/10.1038/sj.onc.1207463			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15034547				2023-01-03	WOS:000221101700013
J	Shand, D				Shand, D			Pilates to pit	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Shand, D (corresponding author), The Lancet, London NW1 7BY, England.								0	8	8	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	2004	363	9418					1340	1340		10.1016/S0140-6736(04)16085-6	http://dx.doi.org/10.1016/S0140-6736(04)16085-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	814TF	15110489				2023-01-03	WOS:000220996300006
J	Chlebowski, RT; Col, N				Chlebowski, RT; Col, N			Menopausal hormone therapy after breast cancer	LANCET			English	Editorial Material							ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN		Harbor UCLA Res & Educ Inst, Torrance, CA 90502 USA; Brigham & Womens Hlth Hosp, Boston, MA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Harvard University; Brigham & Women's Hospital	Chlebowski, RT (corresponding author), Harbor UCLA Res & Educ Inst, Torrance, CA 90502 USA.	rchlebow@whi.org	Col, Nananda/AAE-3445-2019	Col, Nananda/0000-0001-7106-662X				ANDERSON GL, 2003, JAMA-J AM MED ASSOC, V230, P1739; Armstrong K, 2000, NEW ENGL J MED, V342, P564, DOI 10.1056/NEJM200002243420807; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Chlebowski RT, 2003, SEMIN ONCOL, V30, P776, DOI 10.1053/j.seminoncol.2003.08.021; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; HOLMBERG I, 1997, HABITS HORMONAL REPL; Kim HJ, 2002, AM J NEPHROL, V22, P532, DOI 10.1159/000065292; MacLennan A, 2002, CLIMACTERIC, V5, P313, DOI 10.1080/713605308; O'Meara ES, 2001, JNCI-J NATL CANCER I, V93, P754, DOI 10.1093/jnci/93.10.754; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; *WRIT GROUP WOM HL, 2002, JAMA-J AM MED ASSOC, V255, P3243	12	16	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	2004	363	9407					410	411		10.1016/S0140-6736(04)15519-0	http://dx.doi.org/10.1016/S0140-6736(04)15519-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774RX	14962515	Green Published			2023-01-03	WOS:000188999500002
J	Cepeda, JA; Whitehouse, T; Cooper, B; Hails, J; Jones, K; Kwaku, F; Taylor, L; Hayman, S; Cookson, B; Show, S; Kibbler, C; Singer, M; Bellingan, G; Wilson, APR				Cepeda, JA; Whitehouse, T; Cooper, B; Hails, J; Jones, K; Kwaku, F; Taylor, L; Hayman, S; Cookson, B; Show, S; Kibbler, C; Singer, M; Bellingan, G; Wilson, APR			Isolation of patients in single rooms or cohorts to reduce spread of MRSA in intensive-care units: prospective two-centre study	LANCET			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; FIELD GEL-ELECTROPHORESIS; NOSOCOMIAL INFECTION; CONTACT ISOLATION; RISK-FACTORS; ACQUISITION; OUTBREAK; HOSPITALS; PREVALENCE; BACTERIA	Background Hospital-acquired infection due to meticillin-resistant Staphylococcus aureus (MRSA) is common within intensive-care units. Single room or cohort isolation of infected or colonised patients is used to reduce spread, but its benefit over and above other contact precautions is not known. We aimed to assess the effectiveness of moving versus not moving infected or colonised patients in intensive-care units to prevent transmission of MRSA. Methods We undertook a prospective 1-year study in the intensive-care units of two teaching hospitals. Admission and weekly screens were used to ascertain the incidence of MRSA colonisation. In the middle 6 months, MRSA-positive patients were not moved to a single room or cohort nursed unless they were carrying other multiresistant or notifiable pathogens. Standard precautions were practised throughout. Hand hygiene was encouraged and compliance audited. Findings Patients' characteristics and MRSA acquisition rates were similar in the periods when patients were moved and not moved. The crude (unadjusted) Cox proportional-hazards model showed no evidence of increased transmission during the non-move phase (0.73 [95% CI 0.49-1.10], p = 0.94 one-sided). There were no changes in transmission of any particular strain of MRSA nor in handwashing frequency between management phases. Interpretation Moving MRSA-positive patients into single rooms or cohorted bays does not reduce crossinfection. Because transfer and isolation of critically ill patients in single rooms carries potential risks, our findings suggest that re-evaluation of isolation policies is required in intensive-care units where MRSA is endemic, and that more effective means of preventing spread of MRSA in such settings need to be found.	UCL Hosp, Windeyer Inst Med Sci, Dept Clin Microbiol, London W1T 4JF, England; UCL, Dept Med, Bloomsbury Inst Intens Care Med, London W1T 3AA, England; Royal Free Hosp, Dept Med Microbiol, London NW3 2QG, England; Royal Free Hosp, Intens Care Unit, London NW3 2QG, England; Hlth Protect Agcy, Specialist & Reference Microbiol Div, London NW9 5HT, England	University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Health Protection Agency	Wilson, APR (corresponding author), UCL Hosp, Windeyer Inst Med Sci, Dept Clin Microbiol, 46 Cleveland St, London W1T 4JF, England.	peter.wilson@uclh.nhs.uk	Singer, Mervyn/J-4425-2012; Cooper, Ben/HGC-7082-2022; Singer, Mervyn/Q-6142-2019; Whitehouse, Tony/AAC-1215-2020	Singer, Mervyn/0000-0002-1042-6350; Singer, Mervyn/0000-0002-1042-6350; Whitehouse, Tony/0000-0002-4387-3421; Cooper, Ben/0000-0002-9445-7217; Wilson, Andrew Peter Richard/0000-0003-1109-5650	NIAID NIH HHS [1R21AI55825] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI055825] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aucken HM, 2002, J CLIN MICROBIOL, V40, P292, DOI 10.1128/JCM.40.1.292-293.2002; Ayliffe GAJ, 1998, J HOSP INFECT, V39, P253, DOI 10.1016/S0195-6701(98)90293-6; Barrett SP, 1998, J HOSP INFECT, V39, P85, DOI 10.1016/S0195-6701(98)90322-X; Boyce JM, 2002, AM J INFECT CONTROL, V30, pS1, DOI 10.1067/mic.2002.130391; BOYCE JM, 1981, INFECT CONT HOSP EP, V2, P110, DOI 10.1017/S0195941700053881; Bronzwaer S L, 2001, Euro Surveill, V6, P2; Cepeda JA, 2004, J ANTIMICROB CHEMOTH, V53, P345, DOI 10.1093/jac/dkh048; Chaix C, 1999, JAMA-J AM MED ASSOC, V282, P1745, DOI 10.1001/jama.282.18.1745; Christensen A, 2001, SCAND J INFECT DIS, V33, P663, DOI 10.1080/00365540110026944; Cook PP, 2004, J ANTIMICROB CHEMOTH, V53, P853, DOI 10.1093/jac/dkh163; Cooper BS, 2004, BMJ-BRIT MED J, V329, P533, DOI 10.1136/bmj.329.7465.533; CULLEN DJ, 1994, CRIT CARE MED, V22, P1406, DOI 10.1097/00003246-199409000-00009; de Jonge E, 2003, LANCET, V362, P1011, DOI 10.1016/S0140-6736(03)14409-1; Duck WM, 2003, J CLIN MICROBIOL, V41, P3035, DOI 10.1128/JCM.41.7.3035-3042.2003; Esveld M I, 1999, Ned Tijdschr Geneeskd, V143, P205; Evans HL, 2003, SURGERY, V134, P180, DOI 10.1067/msy.2003.222; Farrington M, 1998, QJM-MON J ASSOC PHYS, V91, P539, DOI 10.1093/qjmed/91.8.539; Fluit AC, 2001, EUR J CLIN MICROBIOL, V20, P617; Garner JS, 1996, AM J INFECT CONTROL, V24, P24; Gastmeier P, 2004, INFECT CONT HOSP EP, V25, P109, DOI 10.1086/502359; Gastmeier P, 2002, INFECTION, V30, P198, DOI 10.1007/s15010-002-2043-z; GOODMAN SN, 1994, ANN INTERN MED, V121, P200, DOI 10.7326/0003-4819-121-3-199408010-00008; Hails J, 2003, INTENS CARE MED, V29, P481, DOI 10.1007/s00134-003-1645-y; *HOSP INF CONTR PR, 1996, AM J INFECT CONTROL, V24, P32; Jernigan JA, 1996, AM J EPIDEMIOL, V143, P496, DOI 10.1093/oxfordjournals.aje.a008770; Khatib M, 1999, CHEST, V116, P172, DOI 10.1378/chest.116.1.172; Kirkland KB, 1999, LANCET, V354, P1177, DOI 10.1016/S0140-6736(99)04196-3; KLEIN BS, 1989, NEW ENGL J MED, V320, P1714, DOI 10.1056/NEJM198906293202603; Korn G P, 2001, Braz J Infect Dis, V5, P1; Lucet JC, 2003, ARCH INTERN MED, V163, P181, DOI 10.1001/archinte.163.2.181; Marshall C, 2004, J HOSP INFECT, V57, P245, DOI 10.1016/j.jhin.2004.03.024; Marshall C, 2003, INFECT CONT HOSP EP, V24, P322, DOI 10.1086/502215; Moreno R, 1998, CHEST, V113, P752, DOI 10.1378/chest.113.3.752; Murchan S, 2003, J CLIN MICROBIOL, V41, P1574, DOI 10.1128/JCM.41.4.1574-1585.2003; *NAT AUD OFF, 2004, IMPR PAT CAR RED RIS; *NAT AUD OFF, 2000, MAN CONTR HOSP ACQ I; Nijssen S, 2003, ARCH INTERN MED, V163, P2785, DOI 10.1001/archinte.163.22.2785; O'Connell NH, 2000, J HOSP INFECT, V45, P255, DOI 10.1053/jhin.2000.0768; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; Pittet D, 1999, ANN INTERN MED, V130, P126, DOI 10.7326/0003-4819-130-2-199901190-00006; Stelfox HT, 2003, JAMA-J AM MED ASSOC, V290, P1899, DOI 10.1001/jama.290.14.1899; Takeda S, 2000, INT J ANTIMICROB AG, V14, P39, DOI 10.1016/S0924-8579(99)00148-X; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Theaker C, 2001, J HOSP INFECT, V48, P98, DOI 10.1053/jhin.2001.0960; Thompson BL, 1997, INFECT CONT HOSP EP, V18, P97; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; Waddell G, 1975, Nurs Times, V71, P1937; Warren DK, 2004, INFECT CONT HOSP EP, V25, P99, DOI 10.1086/502357; Yap FHY, 2004, CLIN INFECT DIS, V39, P511, DOI 10.1086/422641	49	231	237	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2005	365	9456					295	304		10.1016/S0140-6736(05)17783-6	http://dx.doi.org/10.1016/S0140-6736(05)17783-6			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664224				2023-01-03	WOS:000226449600032
J	Flores, G				Flores, G			Preventing hospitalisations for children	LANCET			English	Editorial Material							HOSPITALS; CARE		Med Coll Wisconsin, Ctr Advancement Undersaved Children, Dept Pediat, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Ctr Advancement Undersaved Children, Dept Epidemiol, Milwaukee, WI 53226 USA; Childrens Hosp Wisconsin, Childrens Res Inst, Milwaukee, WI 53201 USA	Medical College of Wisconsin; Medical College of Wisconsin; Children's Hospital of Wisconsin	Flores, G (corresponding author), Med Coll Wisconsin, Ctr Advancement Undersaved Children, Dept Pediat, Milwaukee, WI 53226 USA.	gflores@mail.mcw.edu						Billings J, 1989, USE SMALL AREA ANAL; CASANOVA C, 1995, INT J HEALTH SERV, V25, P283, DOI 10.2190/PCF7-ALX9-6CN3-7X9G; Flores G, 2003, PEDIATRICS, V112, P1021, DOI 10.1542/peds.112.5.1021; Johnston Grant, 2004, J Health Serv Res Policy, V9 Suppl 2, P23, DOI 10.1258/1355819042349907; Martinez-Mir I, 1999, BRIT J CLIN PHARMACO, V47, P681, DOI 10.1046/j.1365-2125.1999.00943.x; Miller MR, 2004, PEDIATRICS, V113, P1741, DOI 10.1542/peds.113.6.1741; OWENS P, 2003, AHRQ PUBLICATION; Raymond J, 2000, INFECT CONT HOSP EP, V21, P260, DOI 10.1086/501755; Rennick JE, 2002, J DEV BEHAV PEDIATR, V23, DOI 10.1097/00004703-200206000-00002	9	11	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2005	365	9455					201	202						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887MG	15652590				2023-01-03	WOS:000226309600008
J	Priebe, S; Badesconyi, A; Fioritti, A; Hansson, L; Kilian, RT; Torres-Gonzales, F; Turner, T; Wiersma, D				Priebe, S; Badesconyi, A; Fioritti, A; Hansson, L; Kilian, RT; Torres-Gonzales, F; Turner, T; Wiersma, D			Reinstitutionalisation in mental-health care: comparison of data on service provision from six European countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PEOPLE; HOMICIDES; ILLNESS	Objective To establish whether reinstitutionalisation is occurring in mental health care mid, if so, with What variations between Western European countries. Design Comparison of data on changes in service provision. Setting Six European countries with different traditions of mental health care that have all experienced deinstitutionalisation since the 1970s - England, Germany, Italy, the Netherlands, Spain, mid Sweden. Outcome measures Changes in die number of forensic hospital beds, involuntary hospital admissions, places in supported housing, general psychiatric hospital beds, and general prison population between 1990-1 mid 2002-3. Results Forensic beds and places in supported housing have increased in all countries, whereas changes in it involuntary hospital admissions have been inconsistent. The number of psychiatric hospital beds h is been reduced in five countries, but only in two countries does this reduction outweigh the number of additional places in forensic institutions and supported housing The general prison population has substantially increased in all countries. Conclusions Reinstitutionalisation is taking place in European countries with different, traditions of health care, although with significant variation between the six countries studied. The precise reasons for the phenomenon remain unclear. General attitudes to risk containment in a society, as indicated by the size of the prison population, may be more Important than changing morbidity and new methods of mental healthcare delivery.	Queen Mary Univ London, Newham Ctr Mental Hlth, Social & Community Psychiat Unit, London E13 SSP, England; AUSL Rimini, I-47900 Rimini, Italy; Lund Univ, Dept Nursing, S-22100 Lund, Sweden; Univ Ulm, Dept Psychiat 2, D-89312 Gunzburg, Germany; Univ Granada, Dept Psychiat, E-18071 Granada, Spain; Univ Groningen Hosp, Dept Psychiat, NL-9700 RB Groningen, Netherlands	University of London; Queen Mary University London; Lund University; Ulm University; University of Granada; University of Groningen	Priebe, S (corresponding author), Queen Mary Univ London, Newham Ctr Mental Hlth, Social & Community Psychiat Unit, London E13 SSP, England.	s.priebe@qmul.ac.uk		Priebe, Stefan/0000-0001-9864-3394				Becker T, 2001, ACTA PSYCHIAT SCAND, V104, P8, DOI 10.1034/j.1600-0447.2001.1040s2008.x; Department of Health, 2001, SAF 1 5 YEAR REP NAT; Fakhoury W, 2002, CURR OPIN PSYCHIATR, V15, P187, DOI 10.1097/00001504-200203000-00011; Fazel S, 2002, LANCET, V359, P545, DOI 10.1016/S0140-6736(02)07740-1; FREEMAN H, 1999, CENTURY PSYCHIAT, P213; JONES K, 1993, ASYLUMS AFTER; LEFF J, 2004, PSYCHIAT B, V24, P165; LEVY C, 2002, 3 POST WAR ERAS COMP; Munro E, 2000, BRIT J PSYCHIAT, V176, P116, DOI 10.1192/bjp.176.2.116; Priebe S, 2004, ACTA PSYCHIAT SCAND, V110, P81, DOI 10.1111/j.1600-0047.2004.00386.x; Priebe S, 2003, BRIT MED J, V326, P175, DOI 10.1136/bmj.326.7382.175; Shaw J, 2004, BRIT MED J, V328, P734, DOI 10.1136/bmj.328.7442.734; Taylor PJ, 1999, BRIT J PSYCHIAT, V174, P9, DOI 10.1192/bjp.174.1.9	13	337	343	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 15	2005	330	7483					123	126		10.1136/bmj.38296.611215.AE	http://dx.doi.org/10.1136/bmj.38296.611215.AE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889PM	15567803	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000226454900017
J	Bach, PB; Schrag, D; Begg, CB				Bach, PB; Schrag, D; Begg, CB			Resurrecting treatment histories of dead patients - A study design that should be laid to rest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TERMINAL CANCER-PATIENTS; LAST YEAR; MEDICAL EXPENDITURES; MANAGED CARE; UNITED-STATES; OLDER-ADULTS; HOSPICE USE; LIFE; END; COSTS	In this article we address whether studies of care rendered to patients prior to their death ("studies of decedents") produce an accurate portrait of care provided to patients who are dying. Studies of decedents typically analyze the care provided to patients over a defined interval antecedent to death. Studies of dying patients analyze care provided to patients subsequent to the time that their terminal status is perceived. We address whether 2 fundamental differences between studies of decedents and studies of the dying-the Ways that subjects are identified and the time periods that are examined-lead to differences in interpretation of study results. Using examples from population-based cohorts of individuals with cancer, we show that both the differences in subject selection and time period introduce very substantial biases into studies of decedents. We conclude that studying care received prior to death can lead to invalid conclusions about the quality or type of care provided to dying patients.	Mem Sloan Kettering Canc Ctr, Hlth Outcomes Res Grp, Dept Epidemiol & Biostat, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Bach, PB (corresponding author), Mem Sloan Kettering Canc Ctr, Hlth Outcomes Res Grp, Dept Epidemiol & Biostat, 1275 York Ave,Box 221, New York, NY 10021 USA.	bachp@mskcc.org		Schrag, Deborah/0000-0002-4334-5717	NATIONAL CANCER INSTITUTE [R01CA090226, K23CA086968] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA090226, K23CA86968] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bach PB, 1998, AM J RESP CRIT CARE, V158, P1410, DOI 10.1164/ajrccm.158.5.9804042; Bird Chloe E, 2002, J Palliat Med, V5, P705, DOI 10.1089/109662102320880525; Christakis N A, 1998, Hosp J, V13, P71; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; Collett D., 1994, MODELLING SURVIVAL D; Earle CC, 2003, J CLIN ONCOL, V21, P1133, DOI 10.1200/JCO.2003.03.059; Earle CC, 2002, J CLIN ONCOL, V20, P1786, DOI 10.1200/JCO.2002.07.142; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; Emanuel EJ, 2003, ANN INTERN MED, V138, P639, DOI 10.7326/0003-4819-138-8-200304150-00011; Emanuel EJ, 2002, ARCH INTERN MED, V162, P1722, DOI 10.1001/archinte.162.15.1722; Greiner KA, 2003, J AM GERIATR SOC, V51, P970, DOI 10.1046/j.1365-2389.2003.51310.x; Hefflin BJ, 1998, J AM GERIATR SOC, V46, P1396, DOI 10.1111/j.1532-5415.1998.tb06006.x; Hogan C, 2001, HEALTH AFFAIR, V20, P188, DOI 10.1377/hlthaff.20.4.188; Hoover DR, 2002, HEALTH SERV RES, V37, P1625, DOI 10.1111/1475-6773.01113; Levinsky NG, 1999, J AM GERIATR SOC, V47, P553, DOI 10.1111/j.1532-5415.1999.tb02569.x; Levinsky NG, 2001, JAMA-J AM MED ASSOC, V286, P1349, DOI 10.1001/jama.286.11.1349; Lin DY, 1997, BIOMETRICS, V53, P419, DOI 10.2307/2533947; Lipton H L, 1987, Compr Gerontol B, V1, P89; LONG SH, 1984, INQUIRY-J HEALTH CAR, V21, P315; Lubitz J, 1984, Health Care Financ Rev, V5, P117; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Lynn J, 1997, New Horiz, V5, P56; MCCALL N, 1984, MED CARE, V22, P329, DOI 10.1097/00005650-198404000-00004; McCarthy EP, 2003, JAMA-J AM MED ASSOC, V289, P2238, DOI 10.1001/jama.289.17.2238; Mukamel DB, 2002, MED CARE, V40, P1136, DOI 10.1097/00005650-200212000-00002; *NAT CANC POL BOAR, 2003, DESCR DEATH AM WHAT; Ngo-Metzger Q, 2003, AM J MED, V115, P47, DOI 10.1016/S0002-9343(03)00258-4; RILEY G, 1987, INQUIRY-J HEALTH CAR, V24, P233; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; SPECTOR WD, 1984, INQUIRY-J HEALTH CAR, V21, P328; Teno J M, 2001, J Palliat Med, V4, P457, DOI 10.1089/109662101753381593; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2987, DOI 10.1001/jama.285.23.2987; Warren JL, 2002, MED CARE, V40, P3; Wennberg JE, 2004, BMJ-BRIT MED J, V328, P607, DOI 10.1136/bmj.328.7440.607	35	199	199	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	2004	292	22					2765	2770		10.1001/jama.292.22.2765	http://dx.doi.org/10.1001/jama.292.22.2765			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877CY	15585737				2023-01-03	WOS:000225546600026
J	Stradner, A; Sedgwick, H; Cardinaux, F; Poon, WCK; Egelhaaf, SU; Schurtenberger, P				Stradner, A; Sedgwick, H; Cardinaux, F; Poon, WCK; Egelhaaf, SU; Schurtenberger, P			Equilibrium cluster formation in concentrated protein solutions and colloids	NATURE			English	Article							PHASE-TRANSITIONS; MODEL; SEPARATION; GELATION; LIQUID; STATES	Controlling interparticle interactions, aggregation and cluster formation is of central importance in a number of areas, ranging from cluster formation in various disease processes to protein crystallography and the production of photonic crystals. Recent developments in the description of the interaction of colloidal particles with short-range attractive potentials have led to interesting findings including metastable liquid-liquid phase separation and the formation of dynamically arrested states (such as the existence of attractive and repulsive glasses, and transient gels)(1-7). The emerging glass paradigm has been successfully applied to complex soft-matter systems, such as colloid polymer systems(8) and concentrated protein solutions(9). However, intriguing problems like the frequent occurrence of cluster phases remain(10-13). Here we report small-angle scattering and confocal microscopy investigations of two model systems: protein solutions and colloid-polymer mixtures. We demonstrate that in both systems, a combination of short-range attraction and long-range repulsion results in the formation of small equilibrium clusters. We discuss the relevance of this finding for nucleation processes during protein crystallization, protein or DNA self-assembly and the previously observed formation of cluster and gel phases in colloidal suspensions(12-17).	Univ Fribourg, Dept Phys, CH-1700 Fribourg, Switzerland; Univ Edinburgh, Sch Phys, Edinburgh EH9 3JZ, Midlothian, Scotland; Univ Edinburgh, COSMIC, Edinburgh EH9 3JZ, Midlothian, Scotland; Univ Edinburgh, Sch Chem, Edinburgh EH9 3JJ, Midlothian, Scotland	University of Fribourg; University of Edinburgh; University of Edinburgh; University of Edinburgh	Schurtenberger, P (corresponding author), Univ Fribourg, Dept Phys, Chemin Musee 3, CH-1700 Fribourg, Switzerland.	peter.schurtenberger@unifr.ch	Poon, Wilson/V-3495-2019; Poon, Wilson C K/B-5960-2013; Schurtenberger, Peter/K-1777-2013; Stradner, Anna/B-5195-2015	Poon, Wilson/0000-0003-0760-7940; Poon, Wilson C K/0000-0003-0760-7940; Schurtenberger, Peter/0000-0002-2790-8831; Stradner, Anna/0000-0003-3310-3412; Egelhaaf, Stefan U./0000-0002-2574-3498	Engineering and Physical Sciences Research Council [GR/S10377/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Bergenholtz J, 2003, LANGMUIR, V19, P4493, DOI 10.1021/la0340089; Broide ML, 1996, PHYS REV E, V53, P6325, DOI 10.1103/PhysRevE.53.6325; Dawson KA, 2002, CURR OPIN COLLOID IN, V7, P218, DOI 10.1016/S1359-0294(02)00052-3; Eckert T, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.125701; Foffi G, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.031407; Groenewold J, 2001, J PHYS CHEM B, V105, P11702, DOI 10.1021/jp011646w; Guillot S, 2003, LANGMUIR, V19, P230, DOI 10.1021/la0206561; Kulkarni AM, 2003, FARADAY DISCUSS, V123, P37, DOI 10.1039/b204453f; Malfois M, 1996, J CHEM PHYS, V105, P3290, DOI 10.1063/1.471843; Muschol M, 1997, J CHEM PHYS, V107, P1953, DOI 10.1063/1.474547; PEDERSEN JS, 1994, EUR BIOPHYS J BIOPHY, V22, P379, DOI 10.1007/BF00180159; Pham KN, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.011503; Pham KN, 2002, SCIENCE, V296, P104, DOI 10.1126/science.1068238; Piazza R, 2000, CURR OPIN COLLOID IN, V5, P38, DOI 10.1016/S1359-0294(00)00034-0; Poon WCK, 2002, J PHYS-CONDENS MAT, V14, pR859, DOI 10.1088/0953-8984/14/33/201; Puertas AM, 2004, J CHEM PHYS, V121, P2813, DOI 10.1063/1.1768936; Rojas LF, 2002, EUROPHYS LETT, V60, P802, DOI 10.1209/epl/i2002-00380-5; SCHURTENBERGER P, 1989, PHYS REV LETT, V63, P2064, DOI 10.1103/PhysRevLett.63.2064; Sciortino F, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.055701; Sciortino F, 2002, NAT MATER, V1, P145, DOI 10.1038/nmat752; Segre PN, 2001, PHYS REV LETT, V86, P6042, DOI 10.1103/PhysRevLett.86.6042; TANFORD C, 1972, BIOCHEMISTRY-US, V11, P2192, DOI 10.1021/bi00761a029; Trappe V, 2001, NATURE, V411, P772, DOI 10.1038/35081021; Weeks ER, 2000, SCIENCE, V287, P627, DOI 10.1126/science.287.5453.627; Yethiraj A, 2003, NATURE, V421, P513, DOI 10.1038/nature01328	25	881	884	7	409	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					492	495		10.1038/nature03109	http://dx.doi.org/10.1038/nature03109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565151	Green Submitted			2023-01-03	WOS:000225322100043
J	Hogerzeil, HV				Hogerzeil, HV			The concept of essential medicines: lessons for rich countries	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL GUIDELINES		WHO, Drugs & Med Policy, CH-1211 Geneva, Switzerland	World Health Organization	Hogerzeil, HV (corresponding author), WHO, Drugs & Med Policy, CH-1211 Geneva, Switzerland.	hogerzeilh@who.int						*COMM DEP HLTH AG, 2000, NAT MED POL; *DEP HLTH, 1999, PHIL NAT DRUG POL; *DEP HLTH, 2003, STAND TREATM GUID ES; DRUMMOND MF, 1992, HEALTH AFFAIR, V11, P191, DOI 10.1377/hlthaff.11.4.191; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Kafuko J, 1994, IMPACT NATL STANDARD; Laing RO, 2001, HEALTH POLICY PLANN, V16, P13, DOI 10.1093/heapol/16.1.13; Lipton HL, 2000, HEALTH AFFAIR, V19, P42, DOI 10.1377/hlthaff.19.2.42; *MIN HLTH CHILD WE, 2000, EDLIZ 4 ESS DRUGS LI; *MIN SAUD, 1981, GUIA TER; Minister of Health, 1996, NAT DRUG POL S AFR; Ministerio de Salud, 1972, VAD OFF MED BAS SECT; *PAP NEW GUIN, 1974, STAND TREATM COMM IL; SHARMA S, 2002, STANDARD TREATMENT G; *THER GUID, 2003, THER GUID ANT VERS 1; *UN C TRAD DEV, 1980, UNCTADTT33; Van Amelsvoort V, 1970, STANDARD NOTES TANZA; Walley T, 2000, BRIT MED J, V321, P1523, DOI 10.1136/bmj.321.7275.1523; WHO, 2004, WHO MED STRAT 2004 2; WHO, 2003, TECHN REP SER WHO, V914, P15; *WHO, 2003, TECHN REP SER WHO, V914; *WHO, 2001, EST IMPL NAT DRUG PO; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; 1978, LANCET, V1, P977	25	86	93	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 13	2004	329	7475					1169	1172		10.1136/bmj.329.7475.1169	http://dx.doi.org/10.1136/bmj.329.7475.1169			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539676	Green Published			2023-01-03	WOS:000225169600029
J	Villareal, DT; Holloszy, JO				Villareal, DT; Holloszy, JO			Effect of DHEA on abdominal fat and insulin action in elderly women and men - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVATED RECEPTOR-ALPHA; DEHYDROEPIANDROSTERONE-SULFATE CONCENTRATIONS; REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; BODY-COMPOSITION; GENE-EXPRESSION; VISCERAL FAT; OBESITY; RESISTANCE; RATS	Context Dehydroepiandrosterone (DHEA) administration has been shown to reduce accumulation of abdominal visceral fat and protect against insulin resistance in laboratory animals, but it is not known whether DHEA decreases abdominal obesity in humans. DHEA is widely available as a dietary supplement without a prescription. Objective To determine whether DHEA replacement therapy decreases abdominal fat and improves insulin action in elderly persons. Design and Setting Randomized, double-blind, placebo-controlled trial conducted in a US university-based research center from June 2001 to February 2004. Participants Fifty-six elderly persons (28 women and 28 men aged 71 [range, 65-78] years) with age-related decrease in DHEA level. Intervention Participants were randomly assigned to receive 50 mg/d of DHEA or matching placebo for 6 months. Main Outcome Measures The primary outcome measures were 6-month change in visceral and subcutaneous abdominal fat measured by magnetic resonance imaging and glucose and insulin responses to an oral glucose tolerance test (OGTT). Results Of the 56 men and women enrolled, 52 underwent follow-up evaluations. Compliance with the intervention was 97% in the DHEA group and 95% in the placebo group. Based on intention-to-treat analyses, DHEA therapy compared with placebo induced significant decreases in visceral fat area (-13 cm(2) vs +3 cm(2), respectively; P=.001) and subcutaneous fat (-13 cm(2) vs +2 cm(2), P=.003). The insulin area under the curve (AUC) during the OGTT was significantly reduced after 6 months of DHEA therapy compared with placebo (-1119 muU/mL per 2 hours vs +818 muU/mL per 2 hours, P=.007). Despite the lower insulin levels, the glucose AUC was unchanged, resulting in a significant increase in an insulin sensitivity index in response to DHEA compared with placebo (+1.4 vs -0.7, P=.005). Conclusion DHEA replacement could play a role in prevention and treatment of the metabolic syndrome associated with abdominal obesity.	Washington Univ, Sch Med, Dept Med, Div Geriatr & Nutr Sci, St Louis, MO 63110 USA	Washington University (WUSTL)	Holloszy, JO (corresponding author), Washington Univ, Sch Med, Dept Med, Div Geriatr & Nutr Sci, Campus Box 8113,4566 Scott Ave, St Louis, MO 63110 USA.	jho1losz@im.wustl.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020579, P30DK056341, P60DK020579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020076, P60AG013629] Funding Source: NIH RePORTER; NCRR NIH HHS [K23RR16191, RR00036] Funding Source: Medline; NIA NIH HHS [AG20076, AG13629] Funding Source: Medline; NIDDK NIH HHS [DK56341, DK20579] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AER CTR, 1997, MED SCI SPORT EXER S, V6, P10; ALLISON DB, 1995, DIABETES CARE, V18, P245, DOI 10.2337/diacare.18.2.245; Arlt W, 2001, J CLIN ENDOCR METAB, V86, P4686, DOI 10.1210/jc.86.10.4686; Arlt W, 1999, J CLIN ENDOCR METAB, V84, P2170, DOI 10.1210/jc.84.6.2170; BarrettConnor E, 1996, J CLIN ENDOCR METAB, V81, P59, DOI 10.1210/jc.81.1.59; Baulieu EE, 2000, P NATL ACAD SCI USA, V97, P4279, DOI 10.1073/pnas.97.8.4279; Burman P, 1997, J CLIN ENDOCR METAB, V82, P550, DOI 10.1210/jc.82.2.550; CEFALU WT, 1995, METABOLISM, V44, P954, DOI 10.1016/0026-0495(95)90251-1; Chou CJ, 2002, J BIOL CHEM, V277, P24484, DOI 10.1074/jbc.M202449200; CLEARY MP, 1986, INT J OBESITY, V10, P193; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; DAUGHADAY WH, 1980, J CLIN ENDOCR METAB, V51, P781, DOI 10.1210/jcem-51-4-781; Diamond P, 1996, J ENDOCRINOL, V150, pS43; Ferrannini E, 1997, HYPERTENSION, V30, P1144, DOI 10.1161/01.HYP.30.5.1144; Flynn MA, 1999, J CLIN ENDOCR METAB, V84, P1527, DOI 10.1210/jc.84.5.1527; Friedman L.M., 1980, FUNDAMENTALS CLIN TR; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HAARBO J, 1991, METABOLISM, V40, P1323, DOI 10.1016/0026-0495(91)90037-W; HAFFNER SM, 1994, METABOLISM, V43, P599, DOI 10.1016/0026-0495(94)90202-X; HAFFNER SM, 1993, INT J OBESITY, V17, P643; Han DH, 1998, J GERONTOL A-BIOL, V53, pB19, DOI 10.1093/gerona/53A.1.B19; Hansen PA, 1997, AM J PHYSIOL-REG I, V273, pR1704, DOI 10.1152/ajpregu.1997.273.5.R1704; Jedrzejuk D, 2003, Aging Male, V6, P151, DOI 10.1080/713604785; Kawano H, 2003, J CLIN ENDOCR METAB, V88, P3190, DOI 10.1210/jc.2002-021603; KHORRAM O, 1997, J GERONTOL A-BIOL, V52, P1; Kim H, 2003, DIABETES, V52, P1770, DOI 10.2337/diabetes.52.7.1770; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; MOHAN PF, 1990, J NUTR, V120, P1103, DOI 10.1093/jn/120.9.1103; Morales AJ, 1998, CLIN ENDOCRINOL, V49, P421, DOI 10.1046/j.1365-2265.1998.00507.x; MORALES AJ, 1995, J CLIN ENDOCR METAB, V80, P2799; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Munzer T, 2001, J CLIN ENDOCR METAB, V86, P3604, DOI 10.1210/jc.86.8.3604; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; Peters JM, 1996, MOL PHARMACOL, V50, P67; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Schoonjans K, 1996, J LIPID RES, V37, P907; SHIMOKATA H, 1989, J GERONTOL, V44, P66; Tenenbaum A, 2004, CIRCULATION, V109, P2197, DOI 10.1161/01.CIR.0000126824.12785.B6; Villareal D, 2000, J AM GERIATR SOC, V48, pS24; Villareal DT, 2000, CLIN ENDOCRINOL, V53, P561, DOI 10.1046/j.1365-2265.2000.01131.x; YEN TT, 1977, LIPIDS, V12, P409, DOI 10.1007/BF02533624	44	181	199	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2004	292	18					2243	2248		10.1001/jama.292.18.2243	http://dx.doi.org/10.1001/jama.292.18.2243			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PK	15536111	Bronze			2023-01-03	WOS:000225070000025
J	Rao, SV; Jollis, JG; Harrington, RA; Granger, CB; Newby, LK; Armstrong, PW; Moliterno, DJ; Lindblad, L; Pieper, K; Topol, EJ; Stamler, JS; Califf, RM				Rao, SV; Jollis, JG; Harrington, RA; Granger, CB; Newby, LK; Armstrong, PW; Moliterno, DJ; Lindblad, L; Pieper, K; Topol, EJ; Stamler, JS; Califf, RM			Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CELL TRANSFUSION; TRIAL; STRATEGIES; SURVIVAL; IMPACT	Context It is unclear if blood transfusion in anemic patients with acute coronary syndromes is associated with improved survival. Objective To determine the association between blood transfusion and mortality among patients with acute coronary syndromes who develop bleeding, anemia, or both during their hospital course. Design, Setting, and Patients We analyzed 24112 enrollees in 3 large international trials of patients with acute coronary syndromes (the GUSTO IIb, PURSUIT, and PARAGON B trials). Patients were grouped according to whether they received a blood transfusion during the hospitalization. The association between transfusion and outcome was assessed using Cox proportional hazards modeling that incorporated transfusion as a time-dependent covariate and the propensity to receive blood, and a landmark analysis. Main Outcome Measure Thirty-day mortality. Results Of the patients included, 2401 (10.0%) underwent at least 1 blood transfusion during their hospitalization. Patients who underwent transfusion were older and had more comorbid illness at presentation and also had a significantly higher unadjusted rate of 30-day death (8.00% vs 3.08%; P<.001), myocardial infarction (MI) (25.16% vs 8.16%; P<.001), and death/Ml (29.24% vs 10.02%; P<.001) compared with patients who did not undergo transfusion. Using Cox proportional hazards modeling that incorporated transfusion as a time-dependent covariate, transfusion was associated with an increased hazard for 30-day death (adjusted hazard ratio [HR], 3.94; 95% confidence interval [CI], 3.26-4.75) and 30-day death/Ml (HR, 2.92; 95% Cl, 2.55-3.35). In the landmark analysis that included procedures and bleeding events, transfusion was associated with a trend toward increased mortality. The predicted probability of 30-day death was higher with transfusion at nadir hematocrit values above 25%. Conclusions Blood transfusion in the setting of acute coronary syndromes is associated with higher mortality, and this relationship persists after adjustment for other predictive factors and timing of events. Given the limitations of post hoc analysis of clinical trials data, a randomized trial of transfusion strategies is warranted to resolve the disparity in results between our study and other observational studies. We suggest caution regarding the routine use of blood transfusion to maintain arbitrary hematocrit levels in stable patients with ischemic heart disease.	Duke Clin Res Inst, Durham, NC 27715 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Univ Alberta, Dept Cardiol, Edmonton, AB, Canada; Univ Kentucky, Div Cardiol, Lexington, KY USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Duke University; Duke University; Howard Hughes Medical Institute; Duke University; University of Alberta; University of Kentucky; Cleveland Clinic Foundation	Rao, SV (corresponding author), Duke Clin Res Inst, POB 17969,2400 Pratt St, Durham, NC 27715 USA.	sunil.rao@duke.edu	Granger, Christopher B/D-3458-2014	Granger, Christopher B/0000-0002-0045-3291; Stamler, Jonathan/0000-0002-6866-1572; Armstrong, Paul/0000-0002-0460-3445; Topol, Eric/0000-0002-1478-4729				ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710; ANDERSON JR, 1985, CANCER TREAT REP, V69, P1139; Boersma E, 2000, CIRCULATION, V101, P2557, DOI 10.1161/01.CIR.101.22.2557; Bush RL, 1997, AM J SURG, V174, P143, DOI 10.1016/S0002-9610(97)00073-1; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; Casutt M, 1999, CRIT CARE MED, V27, P2194, DOI 10.1097/00003246-199910000-00021; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; DIETRICH KA, 1990, CRIT CARE MED, V18, P940, DOI 10.1097/00003246-199009000-00007; FORTUNE JB, 1987, J TRAUMA, V27, P243, DOI 10.1097/00005373-198703000-00003; Fransen E, 1999, CHEST, V116, P1233, DOI 10.1378/chest.116.5.1233; GOODNOUGH LT, 1993, AM J MED, V94, P509, DOI 10.1016/0002-9343(93)90086-5; Greenburg AG, 1995, AM J SURG, V170, pS44, DOI 10.1016/S0002-9610(99)80058-0; Hebert PC, 2001, CRIT CARE MED, V29, P227, DOI 10.1097/00003246-200102000-00001; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HEBERT PC, 2001, CMAJ S11, V156, pS27; JOHNSON RG, 1992, J THORAC CARDIOV SUR, V104, P307; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; PARAGON B, 2002, CIRCULATION, V105, P316; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 1996, NEW ENGL J MED, V335, P775; WELCH HG, 1992, ANN INTERN MED, V116, P393, DOI 10.7326/0003-4819-116-5-393; Wu WC, 2001, NEW ENGL J MED, V345, P1230, DOI 10.1056/NEJMoa010615	23	788	818	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	2004	292	13					1555	1562		10.1001/jama.292.13.1555	http://dx.doi.org/10.1001/jama.292.13.1555			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	859HS	15467057				2023-01-03	WOS:000224254600022
J	Schubert, C				Schubert, C			Asthma edges ahead	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1051	1051						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459706				2023-01-03	WOS:000224245800026
J	Garcia-Blanco, MA; Baraniak, AP; Lasda, EL				Garcia-Blanco, MA; Baraniak, AP; Lasda, EL			Alternative splicing in disease and therapy	NATURE BIOTECHNOLOGY			English	Review							PRE-MESSENGER-RNA; SPINAL MUSCULAR-ATROPHY; DOMINANT RETINITIS-PIGMENTOSA; GROWTH-FACTOR RECEPTOR; TRACT BINDING-PROTEIN; TRANSMEMBRANE REGULATOR EXON-9; GLYCOGEN-SYNTHASE KINASE-3; INHERITED DEMENTIA FTDP-17; NONSENSE-MEDIATED DECAY; NUCLEAR FACTOR TDP-43	Alternative splicing is the major source of proteome diversity in humans and thus is highly relevant to disease and therapy. For example, recent work suggests that the long-sought-after target of the analgesic acetaminophen is a neural-specific, alternatively spliced isoform of cyclooxygenase 1 (COX-1). Several important diseases, such as cystic fibrosis, have been linked with mutations or variations in either cis-acting elements or trans-acting factors that lead to aberrant splicing and abnormal protein production. Correction of erroneous splicing is thus an important goal of molecular therapies. Recent experiments have used modified oligonucleotides to inhibit cryptic exons or to activate exons weakened by mutations, suggesting that these reagents could eventually lead to effective therapies.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr RNA Biol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Garcia-Blanco, MA (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Box 3053,Res Dr, Durham, NC 27710 USA.	garci001@mc.duke.edu			NATIONAL CANCER INSTITUTE [R33CA097502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063090] Funding Source: NIH RePORTER; NCI NIH HHS [R33 CA97502] Funding Source: Medline; NIGMS NIH HHS [R01 GM63090] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Andreassi C, 2001, HUM MOL GENET, V10, P2841, DOI 10.1093/hmg/10.24.2841; ARNAREZ I, 2003, HUM MOL GENET, V12, P2031; Atweh GF, 2001, CURR OPIN HEMATOL, V8, P123, DOI 10.1097/00062752-200103000-00010; Auboeuf D, 2004, P NATL ACAD SCI USA, V101, P2270, DOI 10.1073/pnas.0308133100; Baraniak AP, 2003, MOL CELL BIOL, V23, P9327, DOI 10.1128/MCB.23.24.9327-9337.2003; Baron-Delage S, 2000, MOL MED, V6, P957, DOI 10.1007/BF03401830; Belfort R, 2002, AM J OPHTHALMOL, V133, P467; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Bingham CO, 2002, CLEV CLIN J MED, V69, P5; BOUCHER RC, 2001, HARRISONS PRINCIPLES, P1487; Bracco L, 2003, TRENDS BIOTECHNOL, V21, P346, DOI 10.1016/S0167-7799(03)00146-X; Brichta L, 2003, HUM MOL GENET, V12, P2481, DOI 10.1093/hmg/ddg256; Buchner DA, 2003, SCIENCE, V301, P967, DOI 10.1126/science.1086187; BUCKANOVICH RJ, 1993, NEURON, V11, P657, DOI 10.1016/0896-6273(93)90077-5; Buratti E, 2001, J BIOL CHEM, V276, P36337, DOI 10.1074/jbc.M104236200; Buratti E, 2001, EMBO J, V20, P1774, DOI 10.1093/emboj/20.7.1774; Buratti E, 2003, TRENDS MOL MED, V9, P229, DOI 10.1016/S1471-4914(03)00072-8; Burge CB, 1998, MOL CELL, V2, P773, DOI 10.1016/S1097-2765(00)80292-0; BUSSLINGER M, 1981, CELL, V27, P289, DOI 10.1016/0092-8674(81)90412-8; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cartegni L, 2003, NAT STRUCT BIOL, V10, P120, DOI 10.1038/nsb887; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Celotto AM, 2002, RNA, V8, P718, DOI 10.1017/S1355838202021064; Chakarova CF, 2002, HUM MOL GENET, V11, P87, DOI 10.1093/hmg/11.1.87; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Chang JG, 2001, P NATL ACAD SCI USA, V98, P9808, DOI 10.1073/pnas.171105098; Chao HJ, 2003, NAT MED, V9, P1015, DOI 10.1038/nm900; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; Chiba-Falek O, 1998, GENOMICS, V53, P276, DOI 10.1006/geno.1998.5517; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; COSTES B, 1995, EUR J HUM GENET, V3, P285; Crooke ST, 2004, ANNU REV MED, V55, P61, DOI 10.1146/annurev.med.55.091902.104408; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Cuppens H, 1998, J CLIN INVEST, V101, P487, DOI 10.1172/JCI639; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Daoud R, 2002, J NEUROSCI, V22, P5889; De Angelis FG, 2002, P NATL ACAD SCI USA, V99, P9456, DOI 10.1073/pnas.142302299; Deidda G, 2003, NAT BIOTECHNOL, V21, P1499, DOI 10.1038/nbt908; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; Dunckley MG, 1998, HUM MOL GENET, V7, P1083, DOI 10.1093/hmg/7.7.1083; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Eperon IC, 2003, TRENDS MOL MED, V9, P233, DOI 10.1016/S1471-4914(03)00068-6; Fairbrother WG, 2000, MOL CELL BIOL, V20, P6816, DOI 10.1128/MCB.20.18.6816-6825.2000; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; FLOWER RJ, 1972, NATURE, V240, P410, DOI 10.1038/240410a0; Fomenkov A, 2003, J BIOL CHEM, V278, P23906, DOI 10.1074/jbc.M300746200; Friedman KJ, 1999, J BIOL CHEM, V274, P36193, DOI 10.1074/jbc.274.51.36193; Gao QS, 2000, J NEUROCHEM, V74, P490, DOI 10.1046/j.1471-4159.2000.740490.x; Garcia-Blanco MA, 2003, J CLIN INVEST, V112, P474, DOI 10.1172/JCI200319462; GARCIACLANCO MA, 2001, RNA, P109; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; Goedert M, 2000, ANN NY ACAD SCI, V920, P74; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; Gorman L, 1998, P NATL ACAD SCI USA, V95, P4929, DOI 10.1073/pnas.95.9.4929; Graveley BR, 1998, EMBO J, V17, P6747, DOI 10.1093/emboj/17.22.6747; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Grover A, 2002, NEUROSCI LETT, V323, P33, DOI 10.1016/S0304-3940(02)00124-6; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hefferon TW, 2002, AM J HUM GENET, V71, P294, DOI 10.1086/341664; HEIDER KH, 2004, CANC IMMUNOL IMMUNOT; Helmken C, 2003, HUM GENET, V114, P11, DOI 10.1007/s00439-003-1025-2; Hernandez F, 2004, J BIOL CHEM, V279, P3801, DOI 10.1074/jbc.M311512200; Hommel JD, 2003, NAT MED, V9, P1539, DOI 10.1038/nm964; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; HORABIN JI, 1993, MOL CELL BIOL, V13, P7734, DOI 10.1128/MCB.13.12.7734; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IGNATIUS SH, 1995, J VIROL, V69, P3584, DOI 10.1128/JVI.69.6.3584-3596.1995; IMAI H, 1993, J CLIN INVEST, V92, P2419, DOI 10.1172/JCI116848; Isoherranen N, 2003, CURR OPIN NEUROL, V16, P203, DOI 10.1097/00019052-200304000-00014; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; Jiang ZH, 2000, MOL CELL BIOL, V20, P4036, DOI 10.1128/MCB.20.11.4036-4048.2000; Jiang ZH, 2003, J BIOL CHEM, V278, P18997, DOI 10.1074/jbc.M301800200; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Jones RB, 2001, J BIOL CHEM, V276, P4158, DOI 10.1074/jbc.M006151200; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kalbfuss B, 2001, J BIOL CHEM, V276, P42986, DOI 10.1074/jbc.M105113200; Kanadia RN, 2003, SCIENCE, V302, P1978, DOI 10.1126/science.1088583; Karras JG, 2001, BIOCHEMISTRY-US, V40, P7853, DOI 10.1021/bi010263l; Kashima T, 2003, NAT GENET, V34, P460, DOI 10.1038/ng1207; Khoo B, 2003, TRENDS BIOTECHNOL, V21, P328, DOI 10.1016/S0167-7799(03)00168-9; Kowalska Anna, 2002, Journal of Applied Genetics, V43, P535; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; Labrador M, 2003, GENOME RES, V13, P2220, DOI 10.1101/gr.1440703; Lacerra G, 2000, P NATL ACAD SCI USA, V97, P9591, DOI 10.1073/pnas.97.17.9591; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Larriba S, 1998, HUM MOL GENET, V7, P1739, DOI 10.1093/hmg/7.11.1739; Larsen AK, 2003, PHARMACOL THERAPEUT, V99, P167, DOI 10.1016/S0163-7258(03)00058-5; Le Guienr C, 2001, J BIOL CHEM, V276, P40638, DOI 10.1074/jbc.M105642200; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; Lim LP, 2001, P NATL ACAD SCI USA, V98, P11193, DOI 10.1073/pnas.201407298; Liu DL, 2002, CHINESE SCI BULL, V47, P52, DOI 10.1360/02tb9010; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lu QL, 2003, NAT MED, V9, P1009, DOI 10.1038/nm897; Lu XH, 1999, HUM MOL GENET, V8, P53, DOI 10.1093/hmg/8.1.53; LYNCH T, 1994, NEUROLOGY, V44, P1878, DOI 10.1212/WNL.44.10.1878; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; Mak V, 1997, HUM MOL GENET, V6, P2099, DOI 10.1093/hmg/6.12.2099; Manabe T, 2003, CELL DEATH DIFFER, V10, P698, DOI 10.1038/sj.cdd.4401221; Mann CJ, 2001, P NATL ACAD SCI USA, V98, P42, DOI 10.1073/pnas.011408598; MAQUAT LE, 1980, P NATL ACAD SCI-BIOL, V77, P4287, DOI 10.1073/pnas.77.7.4287; Maquat LE, 2002, CURR BIOL, V12, pR196, DOI 10.1016/S0960-9822(02)00747-9; McKie AB, 2001, HUM MOL GENET, V10, P1555, DOI 10.1093/hmg/10.15.1555; Mercatante DR, 2001, CURR CANCER DRUG TAR, V1, P211, DOI 10.2174/1568009013334124; Millar DS, 2003, HUM MUTAT, V21, P424, DOI 10.1002/humu.10168; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; Mine M, 2003, J BIOL CHEM, V278, P11768, DOI 10.1074/jbc.M211106200; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; MURAKI M, 2004, J BIOL CHEM     0308; Musunuru K, 2003, TRENDS CARDIOVAS MED, V13, P188, DOI 10.1016/S1050-1738(03)00075-6; Niksic M, 1999, HUM MOL GENET, V8, P2339, DOI 10.1093/hmg/8.13.2339; Nilsen TW, 2003, BIOESSAYS, V25, P1147, DOI 10.1002/bies.10394; Nissim-Rafinia M, 2000, HUM MOL GENET, V9, P1771, DOI 10.1093/hmg/9.12.1771; Nissim-Rafinia M, 2002, TRENDS GENET, V18, P123, DOI 10.1016/S0168-9525(01)02619-1; Noone PG, 2001, RESP RES, V2, P328, DOI 10.1186/rr82; Pagani F, 2000, J BIOL CHEM, V275, P21041, DOI 10.1074/jbc.M910165199; Pagani F, 2003, J BIOL CHEM, V278, P26580, DOI 10.1074/jbc.M212813200; Patel AA, 2003, NAT REV MOL CELL BIO, V4, P960, DOI 10.1038/nrm1259; Puttaraju M, 1999, NAT BIOTECHNOL, V17, P246, DOI 10.1038/6986; REES DJG, 1985, NATURE, V316, P643, DOI 10.1038/316643a0; Resch A, 2004, J PROTEOME RES, V3, P76, DOI 10.1021/pr034064v; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; Roca X, 2003, NUCLEIC ACIDS RES, V31, P6321, DOI 10.1093/nar/gkg830; Rogers CS, 2002, J CLIN INVEST, V110, P1783, DOI 10.1172/JCI200216481; Rowntree RK, 2003, ANN HUM GENET, V67, P471, DOI 10.1046/j.1469-1809.2003.00028.x; Ryther RCC, 2003, HUM GENET, V113, P140, DOI 10.1007/s00439-003-0949-x; Sazani P, 2002, NAT BIOTECHNOL, V20, P1228, DOI 10.1038/nbt759; Sazani P, 2003, J CLIN INVEST, V112, P481, DOI 10.1172/JCI200319547; Shaftel SS, 2003, MOL BRAIN RES, V119, P213, DOI 10.1016/j.molbrainres.2003.09.006; Simmons DL, 2003, THROMB RES, V110, P265, DOI 10.1016/S0049-3848(03)00380-3; Singh NN, 2004, BIOCHEM BIOPH RES CO, V315, P381, DOI 10.1016/j.bbrc.2004.01.067; Skordis LA, 2003, P NATL ACAD SCI USA, V100, P4114, DOI 10.1073/pnas.0633863100; Sorek R, 2004, TRENDS GENET, V20, P68, DOI 10.1016/j.tig.2003.12.004; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; SPRITZ RA, 1981, P NATL ACAD SCI-BIOL, V78, P2455, DOI 10.1073/pnas.78.4.2455; Srivastava S, 2001, AM J MED GENET, V101, P198, DOI 10.1002/ajmg.1386; Stanford PM, 2003, BRAIN, V126, P814, DOI 10.1093/brain/awg090; Stenson PD, 2003, HUM MUTAT, V21, P577, DOI 10.1002/humu.10212; STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; Sullenger BA, 2002, NATURE, V418, P252, DOI 10.1038/418252a; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Teng H, 1997, HUM MOL GENET, V6, P85, DOI 10.1093/hmg/6.1.85; Tolnay M, 2000, NEUROPATH APPL NEURO, V26, P368, DOI 10.1046/j.1365-2990.2000.00109.x; Vacek MM, 2003, BLOOD, V101, P104, DOI 10.1182/blood-2002-06-1869; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; Van Deerlin VM, 2003, CLIN CHEM, V49, P1717, DOI 10.1373/49.10.1717; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; Venables JP, 2000, HUM MOL GENET, V9, P685, DOI 10.1093/hmg/9.5.685; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Villemaire J, 2003, J BIOL CHEM, V278, P50031, DOI 10.1074/jbc.M308897200; Vithana EN, 2001, MOL CELL, V8, P375, DOI 10.1016/S1097-2765(01)00305-7; Wagner EJ, 2003, RNA, V9, P1552, DOI 10.1261/rna.5840803; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wall NR, 2003, LANCET, V362, P1401, DOI 10.1016/S0140-6736(03)14637-5; Watanabe T, 2000, ADV DRUG DELIVER REV, V44, P109, DOI 10.1016/S0169-409X(00)00089-2; Wilton SD, 1999, NEUROMUSCULAR DISORD, V9, P330, DOI 10.1016/S0960-8966(99)00010-3; Wollerton MC, 2004, MOL CELL, V13, P91, DOI 10.1016/S1097-2765(03)00502-1; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; Zhang XHF, 2003, GENOME RES, V13, P2637, DOI 10.1101/gr.1679003; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9; ZUCCATO E, 2004, J BIOL CHEM     0213	186	400	441	0	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2004	22	5					535	546		10.1038/nbt964	http://dx.doi.org/10.1038/nbt964			12	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	817EB	15122293				2023-01-03	WOS:000221159700021
J	Bion, JF; Heffner, JE				Bion, JF; Heffner, JE			Challenges in the care of the acutely ill	LANCET			English	Review							PATIENT SAFETY EFFORTS; QUALITY-OF-CARE; ADVERSE EVENTS; INTENSIVE-CARE; MEDICAL ERRORS; HOSPITALIZED-PATIENTS; ATTITUDINAL SURVEY; EMERGENCY; ADMISSION; TEAMWORK	Health care providers, hospital administrators, and politicians face competing challenges to reduce clinical errors, control expenditure, increase access and throughput, and improve quality of care. The safe management of the acutely ill inpatient presents particular difficulties. In the first of five Lancet articles on this topic we discuss patients' safety in the acute hospital. We also present a framework in which responsibility for improvement and better integration of care can be considered at the level of patient, local environment, hospital, and health care system; and the other four papers in the series will examine in greater detail methods for measuring, monitoring, and improving inpatient safety.	Univ Birmingham, Queen Elizabeth Hosp, Dept Anaesthesia & Intens Care Med, Birmingham B15 2TH, W Midlands, England; Med Univ S Carolina, Ctr Clin Effectiveness & Patient Safety, Charleston, SC 29425 USA	University of Birmingham; Medical University of South Carolina	Bion, JF (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Dept Anaesthesia & Intens Care Med, Birmingham B15 2TH, W Midlands, England.	j.f.bion@bham.ac.uk		Bion, Julian/0000-0003-0344-5403				Adams J., 1995, RISK, V1st ed.; *AG HEALTHC RES QU, MED ERR SCOP PROBL; Andrews LB, 1997, LANCET, V349, P309, DOI 10.1016/S0140-6736(96)08268-2; [Anonymous], ORG EC COOPERATION D; BAKER GR, PATIENT SAF HEALTHCA; Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; Bellomo R, 2002, MED J AUSTRALIA, V176, P216, DOI 10.5694/j.1326-5377.2002.tb04376.x; BELLOMO R, 2003, MJA, V179, P1; BELTON KJ, 1995, BRIT J CLIN PHARMACO, V39, P223, DOI 10.1111/j.1365-2125.1995.tb04440.x; Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Brennan TA, 2000, NEW ENGL J MED, V342, P1123, DOI 10.1056/NEJM200004133421510; Buchan J, 2002, BMJ-BRIT MED J, V324, P751, DOI 10.1136/bmj.324.7340.751; Buist MD, 1999, MED J AUSTRALIA, V171, P22, DOI 10.5694/j.1326-5377.1999.tb123492.x; Buist MD, 2002, BRIT MED J, V324, P387, DOI 10.1136/bmj.324.7334.387; Busse D K, 2000, Top Health Inf Manage, V20, P1; Camacho LAB, 1998, MED CARE, V36, P748, DOI 10.1097/00005650-199805000-00014; Chassin MR, 1998, MILBANK Q, V76, P565, DOI 10.1111/1468-0009.00106; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Classen DC, 2002, ACAD MED, V77, P963, DOI 10.1097/00001888-200210000-00007; Cohn JN, 2000, ARCH INTERN MED, V160, P2429, DOI 10.1001/archinte.160.16.2429; Cook RI, 2000, BRIT MED J, V320, P791, DOI 10.1136/bmj.320.7237.791; Darchy B, 1999, ARCH INTERN MED, V159, P71, DOI 10.1001/archinte.159.1.71; *DEP HLTH, SHAP FUT LONG TERM P; Department of Health, ORG MEM; Dexter PR, 2001, NEW ENGL J MED, V345, P965, DOI 10.1056/NEJMsa010181; DONCHIN Y, 1995, CRIT CARE MED, V23, P294, DOI 10.1097/00003246-199502000-00015; Druss BG, 2003, NEW ENGL J MED, V348, P130, DOI 10.1056/NEJMsa020993; Eland IA, 1999, BRIT J CLIN PHARMACO, V48, P623; ELIXHAUSER A, 2000, HOSP US 1997; Ely EW, 2001, CHEST, V120, p454S, DOI 10.1378/chest.120.6_suppl.454S; *EM MED SERV, WHO REP; Estrada CA, 2000, BRIT MED J, V321, P507; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Gaba DM, 2002, NEW ENGL J MED, V347, P1249, DOI 10.1056/NEJMsa020846; GIRAUD T, 1993, CRIT CARE MED, V21, P40, DOI 10.1097/00003246-199301000-00011; Goldfrad C, 2000, LANCET, V355, P1138, DOI 10.1016/S0140-6736(00)02062-6; Goldhill DR, 1999, ANAESTHESIA, V54, P853; GRIMSHAW JM, 2001, MED CARE S, V39, P112; Handler JA, 2000, ACAD EMERG MED, V7, P1183, DOI 10.1111/j.1553-2712.2000.tb00462.x; Hayward RA, 2001, JAMA-J AM MED ASSOC, V286, P415, DOI 10.1001/jama.286.4.415; HEINRICH H. W., 1941, Industrial Accident Prevention. A Scientific Approach.; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hofer TP, 2000, MED CARE, V38, P152, DOI 10.1097/00005650-200002000-00005; HOFER TP, 2000, WHAT IS ERROR; *JCAHO, 1996, COND ROOT CAUS AN RE; Kilbridge P, 2003, NEW ENGL J MED, V348, P881, DOI 10.1056/NEJMp030010; Kohn LT, 2000, ERR IS HUMAN BUILDIN; Lagasse RS, 2002, ANESTHESIOLOGY, V97, P1609, DOI 10.1097/00000542-200212000-00038; Layde PM, 2002, JAMA-J AM MED ASSOC, V287, P1993, DOI 10.1001/jama.287.15.1993; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Leape LL, 2000, JAMA-J AM MED ASSOC, V284, P95, DOI 10.1001/jama.284.1.95; Leape LL, 2002, NEW ENGL J MED, V347, P1633, DOI 10.1056/NEJMNEJMhpr011493; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LEE A, 1995, ANAESTH INTENS CARE, V23, P183, DOI 10.1177/0310057X9502300210; Lee TH, 2002, NEW ENGL J MED, V347, P1965, DOI 10.1056/NEJMe020149; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; Luck J, 2000, AM J MED, V108, P642, DOI 10.1016/S0002-9343(00)00363-6; McCaig LF, 2002, NATL HOSP AMBULATORY; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; McNutt RA, 2002, JAMA-J AM MED ASSOC, V287, P1997, DOI 10.1001/jama.287.15.1997; McQuillan P, 1998, BMJ-BRIT MED J, V316, P1853; Morey JC, 2002, HEALTH SERV RES, V37, P1553, DOI 10.1111/1475-6773.01104; MUCKART DJJ, 1994, S AFR J SURG, V32, P69; *NAT COORD GROUP P, REP CHIEF EX NHS EX; Neale G, 2001, J ROY SOC MED, V94, P322, DOI 10.1177/014107680109400702; ODEA J, 2003, INTENS CARE MED, V29, P1594; Pearson G, 1997, LANCET, V349, P1213, DOI 10.1016/S0140-6736(96)12396-5; Perkins GD, 1999, RESUSCITATION, V41, P19, DOI 10.1016/S0300-9572(99)00037-4; Perrow C., 1984, NORMAL ACCIDENTS LIV; Philibert I, 2002, JAMA-J AM MED ASSOC, V288, P1112, DOI 10.1001/jama.288.9.1112; PIZZI L, MAKING HLTH CARE SAF; Pizzi L, CREW RESOURCE MANAGE; POOL R, 1997, ENG SOC SHAPES TECHN; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; Reason J, 2000, BMJ-BRIT MED J, V320, P768, DOI 10.1136/bmj.320.7237.768; Reason J., 1990, HUMAN ERROR; REASON JT, 1995, CLIN RISK MANAGEMENT, P31; Risser DT, 1999, ANN EMERG MED, V34, P373, DOI 10.1016/S0196-0644(99)70134-4; Rothschild JM, 2000, ARCH INTERN MED, V160, P2717, DOI 10.1001/archinte.160.18.2717; SCHEIN RMH, 1990, CHEST, V98, P1388, DOI 10.1378/chest.98.6.1388; Sexton JB, 2000, BMJ-BRIT MED J, V320, P745, DOI 10.1136/bmj.320.7237.745; Shaw C, 2001, REPORTING ADVERSE CL; Shojania K G, 2002, Evid Rep Technol Assess (Summ), P1; Shojania K G, 2001, Eff Clin Pract, V4, P82; SHOJANIA KG, 2001, MAKING CARE SAFER CR; Steinbrook R, 2002, NEW ENGL J MED, V347, P1296, DOI 10.1056/NEJMhpr022383; Stenhouse C, 2000, BRIT J ANAESTH, V84, p663P, DOI DOI 10.1093/BJA/84.5.663; Vincent C, 2000, BRIT MED J, V320, P777, DOI 10.1136/bmj.320.7237.777; Vincent C, 2003, NEW ENGL J MED, V348, P1051, DOI 10.1056/NEJMhpr020760; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; WEICK KE, 1987, CALIF MANAGE REV, V29, P112, DOI 10.2307/41165243; Wilson DG, 1998, EUR J PEDIATR, V157, P769, DOI 10.1007/s004310050932; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x; Wolff AM, 2001, MED J AUSTRALIA, V174, P621, DOI 10.5694/j.1326-5377.2001.tb143469.x; WRIGHT D, 1991, LANCET, V338, P676, DOI 10.1016/0140-6736(91)91243-N; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; GUIDANCE IMPLEMENTIN; LEAPFROG PATIENT SAF	100	82	85	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	2004	363	9413					970	977		10.1016/S0140-6736(04)15793-0	http://dx.doi.org/10.1016/S0140-6736(04)15793-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043966				2023-01-03	WOS:000220308600024
J	O'Brien, JM; Welsh, CH; Fish, RH; Ancukiewicz, M; Kramer, AM				O'Brien, JM; Welsh, CH; Fish, RH; Ancukiewicz, M; Kramer, AM		Natl Heart Lung & Blood Inst Acute	Excess body weight is not independently associated with outcome in mechanically ventilated patients with acute lung injury	ANNALS OF INTERNAL MEDICINE			English	Article							MORBID-OBESITY; UNITED-STATES; MASS INDEX; TRACHEAL INTUBATION; GENERAL-ANESTHESIA; TRENDS; COMPLICATIONS; PREVALENCE; OVERWEIGHT; MORTALITY	Background: Despite an epidemic of obesity among adults, the effect of excess body weight on outcome from critical illness is not well studied. Objective: To examine the association between excess body weight and outcome in mechanically ventilated patients with acute lung injury. Design: Secondary analysis of participants in trials of therapy for acute lung injury. Setting: 10 U.S. medical centers that participate in the National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network. Patients: 902 mechanically ventilated patients who were enrolled in randomized, controlled trials of therapy for acute lung injury. Intervention: Assignment to higher (12 mL/kg of predicted weight) or lower (6 mL/kg of predicted weight) tidal volume ventilation strategies with specified weaning protocols. Some patients also received ketoconazole, lisofylline, or placebo by factorial design. Measurements: Mortality rate, rate of unassisted ventilation by day 28, and number of ventilator-free days. Results: Indirect causes of lung injury, including trauma, were more common in obese patients. Overweight and obese patients had higher peak and plateau airway pressures before enrollment because of higher set tidal volumes. After risk adjustment, excess body weight was not associated with death, achievement of unassisted ventilation, or number of ventilator-free days. This lack of effect persisted with categorical or continuous measures of body mass index (BMI). We found no significant interaction between ventilator protocol assignment and BMI category. Conclusions: After risk adjustment, overweight and obese patients with acute lung injury have outcomes similar to those of patients with normal BMI. The lack of interaction between ventilator protocol assignment and BMI suggests that patients with normal, overweight, or obese BMI benefit from lower tidal volume ventilation for acute lung injury.	Univ Colorado, Hlth Sci Ctr, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	O'Brien, JM (corresponding author), Div Pulm Sci & Crit Care Med, 4200 E 9th Ave,Box C-272, Denver, CO 80262 USA.	James.OBrien@uchsc.edu	O'Brien, James M/A-2624-2009		NHLBI NIH HHS [T32-HL07085, N01-HR 46054-64] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR046054] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007085] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS CH, 1993, WOMEN HEALTH, V20, P45, DOI 10.1300/J013v20n02_04; ALPERT MA, 1993, AM J MED SCI, V306, P117, DOI 10.1097/00000441-199308000-00011; BLUMBERG P, 1985, INT J EAT DISORDER, V4, P169, DOI 10.1002/1098-108X(198505)4:2<169::AID-EAT2260040204>3.0.CO;2-F; Brodsky JB, 2002, ANESTH ANALG, V94, P732, DOI 10.1097/00000539-200203000-00047; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; CHOBAN PS, 1991, J TRAUMA, V31, P1253, DOI 10.1097/00005373-199109000-00009; DEURENBERG P, 1991, BRIT J NUTR, V65, P105, DOI 10.1079/BJN19910073; El-Solh A, 2001, CHEST, V120, P1989, DOI 10.1378/chest.120.6.1989; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; ERIKSEN J, 1978, ACTA ANAESTH SCAND, V22, P241, DOI 10.1111/j.1399-6576.1978.tb01298.x; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; FORREST JB, 1992, ANESTHESIOLOGY, V76, P3, DOI 10.1097/00000542-199201000-00002; Freedman DS, 2002, JAMA-J AM MED ASSOC, V288, P1758, DOI 10.1001/jama.288.14.1758; GOLD BS, 1989, JAMA-J AM MED ASSOC, V262, P3008, DOI 10.1001/jama.262.21.3008; GOULD AB, 1962, ANESTH ANALG, V41, P448, DOI 10.1213/00000539-196241040-00012; Hebl MR, 2001, INT J OBESITY, V25, P1246, DOI 10.1038/sj.ijo.0801681; Janssen I, 2002, ARCH INTERN MED, V162, P2074, DOI 10.1001/archinte.162.18.2074; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; Kollef MH, 1997, CRIT CARE MED, V25, P567, DOI 10.1097/00003246-199704000-00004; MADDOX GL, 1969, J MED EDUC, V44, P214; MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357; Matthay MA, 2002, AM J PHYSIOL-LUNG C, V283, pL678, DOI 10.1152/ajplung.00154.2002; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; *NIH, 1998, NIH PUBL; POE RH, 1988, AM J MED SCI, V295, P29, DOI 10.1097/00000441-198801000-00007; PURDUE G F, 1990, Journal of Burn Care and Rehabilitation, V11, P32, DOI 10.1097/00004630-199001000-00007; RAND CSW, 1990, SOUTHERN MED J, V83, P1390, DOI 10.1097/00007611-199012000-00006; Teachman BA, 2001, INT J OBESITY, V25, P1525, DOI 10.1038/sj.ijo.0801745; Tremblay A, 2003, CHEST, V123, P1202, DOI 10.1378/chest.123.4.1202; Troiano RP, 1996, INT J OBESITY, V20, P63; VAUGHAN RW, 1980, LIFE SCI, V26, P2119, DOI 10.1016/0024-3205(80)90598-6; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wiedemann HP, 2000, JAMA-J AM MED ASSOC, V283, P1995; Wiedemann HP, 2002, CRIT CARE MED, V30, P1	35	110	114	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	2004	140	5					338	345		10.7326/0003-4819-140-5-200403020-00009	http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778NC	14996675				2023-01-03	WOS:000189246800003
J	Kales, SN; Christiani, DC				Kales, SN; Christiani, DC			Current concepts - Acute chemical emergencies	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SUBWAY SARIN ATTACK; EAR VESICANT MODEL; HYDROGEN-SULFIDE; SULFUR MUSTARD; HYDROFLUORIC-ACID; HYPERBARIC-OXYGEN; TOKYO SUBWAY; SODIUM-NITRITE; WARFARE AGENTS; UNITED-STATES		Harvard Univ, Sch Med, Cambridge Hlth Alliance, Dept Med Occupat & Environm Hlth, Cambridge, MA 02139 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Occupat Hlth Program, Boston, MA 02115 USA; Massachusetts Gen Hosp, Pulm Crit Care Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; NE Specialty & Rehabil Hosp, Ctr Occupat & Environm Med, Braintree, MA USA	Harvard University; Cambridge Health Alliance; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Kales, SN (corresponding author), Harvard Univ, Sch Med, Cambridge Hlth Alliance, Dept Med Occupat & Environm Hlth, 1493 Cambridge St, Cambridge, MA 02139 USA.	skales@challiance.org			NIEHS NIH HHS [ES00002] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		*AG TOX SUBST DIS, 2001, MAN HAZ MAT INC, V3; Babin MC, 2000, J APPL TOXICOL, V21, pS141; BAUD FJ, 1991, NEW ENGL J MED, V325, P1761, DOI 10.1056/NEJM199112193252502; BLEICH A, 1992, JAMA-J AM MED ASSOC, V268, P613, DOI 10.1001/jama.268.5.613; Blodgett DW, 2001, AM J IND MED, V40, P215, DOI 10.1002/ajim.1090.abs; BORAK J, 1992, ANN EMERG MED, V21, P303, DOI 10.1016/S0196-0644(05)80892-3; Borak J, 2001, J OCCUP ENVIRON MED, V43, P110, DOI 10.1097/00043764-200102000-00008; Brennan RJ, 1999, ANN EMERG MED, V34, P191, DOI 10.1016/S0196-0644(99)70229-5; Burgess JL, 1997, J OCCUP ENVIRON MED, V39, P760, DOI 10.1097/00043764-199708000-00011; Burgess JL, 1999, ANN EMERG MED, V34, P205, DOI 10.1016/S0196-0644(99)70230-1; CARAVATI EM, 1988, AM J EMERG MED, V6, P143, DOI 10.1016/0735-6757(88)90053-8; Carlton F. B., 1998, CLIN MANAGEMENT POIS, P836; Curry S., 2001, CLIN ENV HLTH TOXIC, P705; Dachir S, 2002, HUM EXP TOXICOL, V21, P197, DOI 10.1191/0960327102ht229oa; Davis KG, 2001, ANN EMERG MED, V37, P653, DOI 10.1067/mem.2001.114322; DOYLE CJ, 1998, CLIN MANAGEMENT POIS, P319; Ellenhorn MJ, 1997, ELLENHORNS MED TOXIC, P1267; FAWCETT TA, 1992, J OCCUP ENVIRON MED, V34, P12; Fuller DC, 2000, J OCCUP ENVIRON MED, V42, P939, DOI 10.1097/00043764-200009000-00019; Gabbay DS, 2001, J EMERG MED, V20, P141, DOI 10.1016/S0736-4679(00)00301-2; GRAUDINS A, 1998, CLIN MANAGEMENT POIS, P987; Greenfield RA, 2002, AM J MED SCI, V323, P326, DOI 10.1097/00000441-200206000-00005; GREGORAKOS L, 1995, ANGIOLOGY, V46, P1123, DOI 10.1177/000331979504601208; GUNDERSON CH, 1992, NEUROLOGY, V42, P946, DOI 10.1212/WNL.42.5.946; Gunn B, 2001, Emerg Med (Fremantle), V13, P240, DOI 10.1046/j.1442-2026.2001.00220.x; Hall AH, 1997, VET HUM TOXICOL, V39, P152; Hall Alan H., 1998, CLIN MANAGEMENT POIS, P899; Hall H. Irene, 1994, Morbidity and Mortality Weekly Report, V43, P1; Henretig FM, 2002, J PEDIATR-US, V141, P311, DOI 10.1067/mpd.2002.127408; Houck Peter M., 1997, Journal of Emergency Medicine, V15, P469, DOI 10.1016/S0736-4679(97)00079-6; Hurst CG, 2001, CHEMICAL WARFARE AGENTS: TOXICITY AT LOW LEVELS, P245; Kales SN, 1996, J OCCUP ENVIRON MED, V38, P394, DOI 10.1097/00043764-199604000-00018; Kerns W, 2002, GOLDFRANKS TOXICOLOG, V7th, P1498; Knudson G B, 2001, Mil Med, V166, P63; KULIG K, 1991, NEW ENGL J MED, V325, P1801, DOI 10.1056/NEJM199112193252508; LINDEN CH, 1998, CLIN MANAGEMENT POIS, P876; Macintyre AG, 2000, JAMA-J AM MED ASSOC, V283, P242, DOI 10.1001/jama.283.2.242; MARSHALL MD, 1995, CLIN CHEM, V41, P1434; MCMULLEN MJ, 1998, CLIN MANAGEMENT POIS, P978; MELIUS JM, 1998, ENV OCCUPATIONAL MED, P1239; Milby TH, 1999, AM J IND MED, V35, P192, DOI 10.1002/(SICI)1097-0274(199902)35:2<192::AID-AJIM11>3.0.CO;2-C; Moore DH, 2001, CHEMICAL WARFARE AGENTS: TOXICITY AT LOW LEVELS, P409; MRVOS R, 1993, SOUTHERN MED J, V86, P654, DOI 10.1097/00007611-199306000-00013; Nelson LS, 2002, GOLDFRANKS TOXICOLOG, P1453; Okudera H, 2002, J CLIN NEUROSCI, V9, P17, DOI 10.1054/jocn.2001.1020; Okumura T, 1998, ACAD EMERG MED, V5, P618, DOI 10.1111/j.1553-2712.1998.tb02471.x; Okumura T, 1996, ANN EMERG MED, V28, P129, DOI 10.1016/S0196-0644(96)70052-5; Piantadosi CA, 2002, NEW ENGL J MED, V347, P1054, DOI 10.1056/NEJMp020104; Ruhl Charles M., 1994, Journal of Emergency Medicine, V12, P159, DOI 10.1016/0736-4679(94)90693-9; Safarinejad MR, 2001, MIL MED, V166, P67, DOI 10.1093/milmed/166.1.67; Salem H, 2001, CHEMICAL WARFARE AGENTS: TOXICITY AT LOW LEVELS, P321; SALKOWSKI AA, 1994, VET HUM TOXICOL, V36, P455; SCOLNICK B, 1993, J OCCUP ENVIRON MED, V35, P577, DOI 10.1097/00043764-199306000-00014; SEGER DL, 2001, CLIN ENV HLTH TOXIC, P722; Sexton JD, 1998, J TOXICOL-CLIN TOXIC, V36, P87, DOI 10.3109/15563659809162593; Sharp TW, 1998, ANN EMERG MED, V32, P214, DOI 10.1016/S0196-0644(98)70139-8; SIDELL FR, 1990, POSTGRAD MED, V88, P70, DOI 10.1080/00325481.1990.11716446; SIDELL FR, 1994, J APPL TOXICOL, V14, P111, DOI 10.1002/jat.2550140212; SIDELL FR, 1992, ANN EMERG MED, V21, P865, DOI 10.1016/S0196-0644(05)81036-4; SMITH KJ, 1995, J AM ACAD DERMATOL, V32, P765, DOI 10.1016/0190-9622(95)91457-9; SNYDER JW, 1995, AM J EMERG MED, V13, P199, DOI 10.1016/0735-6757(95)90094-2; SPANJAARD H, 2003, TERRORISM PUBLIC HLT, P199; SUZUKI T, 1995, LANCET, V345, P980, DOI 10.1016/S0140-6736(95)90726-2; Thom SR, 2002, NEW ENGL J MED, V347, P1105, DOI 10.1056/NEJMe020103; Tomaszewski Christian A., 1994, Emergency Medicine Clinics of North America, V12, P437; *US ARM FORC RAD R, 1999, MED MAN RAD CAS; *US ARM MED COMM, 2001, BIOL CHEM WARF TERR; *US ARM MED RES I, 1999, MED MAN CHEM CAS HDB; *US ARM MED RES I, 1999, MED MAN CHEM CAS VES; Valent F, 2002, CHEST, V121, P969, DOI 10.1378/chest.121.3.969; WALDRON HA, 1994, OCCUPATIONAL LUNG DI, P593; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; Wheeler R, 1999, JAMA-J AM MED ASSOC, V282, P1326; Winder C, 2001, ENVIRON RES, V85, P105, DOI 10.1006/enrs.2000.4110; WING JS, 1991, ARCH ENVIRON HEALTH, V46, P155, DOI 10.1080/00039896.1991.9937443; 1999, ANN EMERG MED, V33, P735; 2002, MED LETT DRUGS THER, V44, P1	77	103	106	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2004	350	8					800	808		10.1056/NEJMra030370	http://dx.doi.org/10.1056/NEJMra030370			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774VM	14973213				2023-01-03	WOS:000189006400008
J	Langhorne, P; Taylor, G; Murray, G; Dennis, M; Anderson, C; Bautz-Holter, E; Dey, P; Indredavik, B; Mayo, N; Power, M; Rodgers, H; Ronning, OM; Rudd, A; Suwanwela, N; Widen-Holmqvist, L; Wolfe, C				Langhorne, P; Taylor, G; Murray, G; Dennis, M; Anderson, C; Bautz-Holter, E; Dey, P; Indredavik, B; Mayo, N; Power, M; Rodgers, H; Ronning, OM; Rudd, A; Suwanwela, N; Widen-Holmqvist, L; Wolfe, C			Early supported discharge services for stroke patients: a meta-analysis of individual patients' data	LANCET			English	Article							RANDOMIZED CONTROLLED-TRIAL; HOSPITAL DISCHARGE; REHABILITATION; HOME; CONSEQUENCES; CARE	Background Stroke patients conventionally undergo a substantial part of their rehabilitation in hospital. Services have been developed that offer patients early discharge from hospital with rehabilitation at home (early supported discharge [ESD]). We have assessed the effects and costs of such services. Methods We did a meta-analysis of data from individual patients who took part in randomised trials that recruited patients with stroke in hospital to receive either conventional care or any ESD service intervention that provided rehabilitation and support in a community setting with the aim of shortening the duration of hospital care. The primary outcome was death or dependency at the end of scheduled follow-up. Findings Outcome data were available for 11 trials (1597 patients). ESD services were mostly provided by specialist multidisciplinary teams to a selected group (median 41%) of stroke patients admitted to hospital. There was a reduced risk of death or dependency equivalent to six (95% Cl one to ten) fewer adverse outcomes for every 100 patients receiving an ESD service (p=0.02). The hospital stay was 8 days shorter for patients assigned ESD services than for those assigned conventional care (p<0.0001). There were also significant improvements in scores on the extended activities of daily living scale and in the odds of living at home and reporting satisfaction with services. The greatest benefits were seen in the trials evaluating a coordinated multidisciplinary ESD team and in stroke patients with mild to moderate disability. Interpretation Appropriately resourced ESD services provided for a selected group of stroke patients can reduce long-term dependency and admission to institutional care as well as shortening hospital stays.	Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland; Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland; Western Gen Hosp, Div Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Auckland, Dept Med, Auckland, New Zealand; Ullevaal Univ Hosp, Dept Med Phys & Rehabil, Oslo, Norway; Ctr Canc Epidemiol, Manchester, Lancs, England; Univ Trondheim Hosp, Dept Med, Stroke Unit, N-7006 Trondheim, Norway; McGill Univ, Royal Victoria Hosp, Div Clin Epidemiol, Montreal, PQ H3A 1A1, Canada; Ulster Hosp, Dept Hlth Care Elderly People, Belfast, Antrim, North Ireland; Newcastle Univ, Sch Med, Sch Clin Med Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Newcastle Univ, Sch Med, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Akershus Univ Hosp, Dept Neurol, Nordbyhagen, Norway; St Thomas Hosp, Stroke Unit, London, England; Chulalongkorn Univ, Fac Med, Neurol Unit, Bangkok 10330, Thailand; Karolinska Univ Hosp, Karolinska Inst, Neurotec Dept, Div Neurol, Stockholm, Sweden; Karolinska Univ Hosp, Karolinska Inst, Neurotec Dept, Div Physiotherapy, Stockholm, Sweden; Kings Coll London, London WC2R 2LS, England	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh; University of Auckland; University of Oslo; University of Manchester; Norwegian University of Science & Technology (NTNU); McGill University; Royal Victoria Hospital; Newcastle University - UK; Newcastle University - UK; University of Oslo; Guy's & St Thomas' NHS Foundation Trust; Chulalongkorn University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; University of London; King's College London	Langhorne, P (corresponding author), Royal Infirm, Acad Sect Geriatr Med, Level 3,Ctr Block, Glasgow G4 0SF, Lanark, Scotland.	P.Langhorne@clinmed.gla.ac.uk	Rodgers, Helen/K-4358-2012	dennis, martin/0000-0003-1148-8972; Ronning, Ole Morten/0000-0001-5080-5788; Murray, Gordon/0000-0001-9866-4734; Anderson, Craig/0000-0002-7248-4863; Power, Michael/0000-0001-9481-9225				Anderson C, 2000, STROKE, V31, P1032, DOI 10.1161/01.STR.31.5.1032; Anderson C, 2000, STROKE, V31, P1024, DOI 10.1161/01.STR.31.5.1024; Bautz-Holter E, 2002, DISABIL REHABIL, V24, P348, DOI 10.1080/09638280110093677; Beech R, 1999, STROKE, V30, P729, DOI 10.1161/01.STR.30.4.729; CLARKE M, 2003, COCHRANE LIB; Donnelly M, 2004, STROKE, V35, P127, DOI 10.1161/01.STR.0000106911.96026.8F; *EARL SUPP DISCH T, 2001, COCHRANE LIB; Holmqvist LW, 1998, STROKE, V29, P591, DOI 10.1161/01.STR.29.3.591; Indredavik B, 2000, STROKE, V31, P2989, DOI 10.1161/01.STR.31.12.2989; Kalra L, 2000, LANCET, V356, P894, DOI 10.1016/S0140-6736(00)02679-9; LANGHORNE P, 2001, COCHRANE LIB; Mayo NE, 2000, STROKE, V31, P1016, DOI 10.1161/01.STR.31.5.1016; McNamee P, 1998, AGE AGEING, V27, P345, DOI 10.1093/ageing/27.3.345; Rodgers H, 1997, CLIN REHABIL, V11, P280, DOI 10.1177/026921559701100403; Ronning OM, 1998, STROKE, V29, P779, DOI 10.1161/01.STR.29.4.779; Rudd AG, 1997, BMJ-BRIT MED J, V315, P1039, DOI 10.1136/bmj.315.7115.1039; SANDERCOCK P, 2003, COCHRANE LIB; SCHEINBERG L, 1986, CEREBROVASC DIS, V1, P289; *STROK UN TRIAL CO, 2004, COCHR LIB; Suwanwela NC, 2002, CEREBROVASC DIS, V13, P267, DOI 10.1159/000057854; Teng J, 2003, STROKE, V34, P528, DOI 10.1161/01.STR.0000049767.14156.2C; von Koch L, 2001, CEREBROVASC DIS, V12, P131, DOI 10.1159/000047692; Warlow CP., 2001, STROKE PRACTICAL GUI	23	172	178	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	2005	365	9458					501	506						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705460				2023-01-03	WOS:000226812500028
J	Corwin, P; Toop, L; McGeoch, G; Than, M; Wynn-Thomas, S; Wells, JE; Dawson, R; Abernethy, P; Pithie, A; Chambers, S; Fletcher, L; Richards, D				Corwin, P; Toop, L; McGeoch, G; Than, M; Wynn-Thomas, S; Wells, JE; Dawson, R; Abernethy, P; Pithie, A; Chambers, S; Fletcher, L; Richards, D			Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital	BRITISH MEDICAL JOURNAL			English	Article							THERAPY; CARE; SATISFACTION; CEFAZOLIN	Objectives To compare the efficacy, safety, and acceptability of treatment with intravenous antibiotics for cellulitis at home and in hospital. Design Prospective randomised controlled trial. Setting Christchurch, New Zealand. Participants 200 patients presenting or referred to the only emergency department in Christchurch who were thought to require intravenous antibiotic treatment for cellulitis and who did not have any contraindications to home care were randomly assigned to receive treatment either at home or in hospital. Main outcome measures Days to no advancement of cellulitis was the, primary outcome measure. Days on intravenous and oral antibiotics, days in hospital or in the home care programme, complications, degree of functioning and pain, and satisfaction with site of care were also recorded. Results The two treatment groups did not differ significantly for the primary outcome of days to no advancement of cellulitis, with a mean of 1.5 days (SD 0.11) for die group receiving treatment at home and 1.49 days (SD 0.10) for. the group receiving treatment in hospital (mean difference 0.01 days, 95% confidence interval -0.3 to 0.28). None of the other outcome measures differed significantly except for patients' satisfaction, which was greater in patients treated at home. Conclusions Treatment of cellulitis requiring intravenous antibiotics can be safely delivered at home. Patients prefer home treatment, but in this study only about one third of patients presenting at hospital for intravenous treatment of cellulitis were considered suitable for home treatment.	Christchurch Sch Med & Hlth Sci, Dept Publ Hlth & Gen Practice, Christchurch, New Zealand; Pegasus Hlth, Christchurch, New Zealand; Christchurch Hosp, Christchurch, New Zealand	University of Otago; Christchurch Hospital New Zealand	Corwin, P (corresponding author), Christchurch Sch Med & Hlth Sci, Dept Publ Hlth & Gen Practice, POB 4345, Christchurch, New Zealand.	paul.corwin@chmeds.ac.nz		Mangin, Dee/0000-0003-2149-9376; Chambers, Stephen/0000-0002-0698-3285				Board N, 2000, AUST NZ J PUBL HEAL, V24, P305, DOI 10.1111/j.1467-842X.2000.tb01573.x; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Caplan GA, 1999, MED J AUSTRALIA, V170, P156, DOI 10.5694/j.1326-5377.1999.tb127711.x; Dall L, 2003, INFECT MED, V20, P379; Dubois A, 2001, EVAL HEALTH PROF, V24, P84, DOI 10.1177/01632780122034812; Eron LJ, 2001, ARCH INTERN MED, V161, P61, DOI 10.1001/archinte.161.1.61; GRAYSON ML, 1995, MED J AUSTRALIA, V162, P249, DOI 10.5694/j.1326-5377.1995.tb139878.x; Grayson ML, 2002, CLIN INFECT DIS, V34, P1440, DOI 10.1086/340056; Leder K, 1998, MED J AUSTRALIA, V169, P519, DOI 10.5694/j.1326-5377.1998.tb123398.x; *MED OUTC TRUST, 1994, AUSTR NZ STAND SF 36; Montalto M, 1996, INT J QUAL HEALTH C, V8, P243; Montalto M, 1997, AUST NZ J MED, V27, P19, DOI 10.1111/j.1445-5994.1997.tb00908.x; Nathwani D, 2002, J ANTIMICROB CHEMOTH, V49, P149, DOI 10.1093/jac/49.1.149; TICE AD, 1995, EUR J CLIN MICROBIOL, V14, P655, DOI 10.1007/BF01690748; OPAT OUTCOMES REGIST	15	114	115	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 15	2005	330	7483					129	132B		10.1136/bmj.38309.447975.EB	http://dx.doi.org/10.1136/bmj.38309.447975.EB			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889PM	15604157	Green Published, Bronze			2023-01-03	WOS:000226454900020
J	Reynolds, EE				Reynolds, EE			A 15-month-old child with recurrent otitis media, 2 years later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Paradise JL, 2002, JAMA-J AM MED ASSOC, V288, P2589, DOI 10.1001/jama.288.20.2589	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2004	292	20					2515	2515		10.1001/jama.292.20.2515	http://dx.doi.org/10.1001/jama.292.20.2515			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873TD	15562132				2023-01-03	WOS:000225303000028
J	Bhutta, ZA; Khan, I; Salat, S; Raza, F; Khan, I; Ara, H				Bhutta, ZA; Khan, I; Salat, S; Raza, F; Khan, I; Ara, H			Reducing length of stay in hospital for very low birthweight infants by involving mothers in a stepdown unit: an experience from Karachi (Pakistan)	BRITISH MEDICAL JOURNAL			English	Article							NEONATAL-MORTALITY; OUTCOMES; BABIES; CARE; NETWORK; RISK; AGE	Problem Clinical care of infants with a very low birth weight (less than 1500 g) in developing Countries can be labour intensive and is often associated with a prolonged stay in hospital. The Aga Khan University Medical Center in Karachi, Pakistan, established a neonatal intensive care unit in 1987. By 1993-4, very low birthweight infants remained in hospital for 18-21 days. Strategies for change A stepdown unit was established in September 1994, with mothers providing all basic nursing care for their infants before being discharged under supervision. Key measures for improvement We analysed neonatal outcomes for the time periods before and after the stepdown unit was created (1987-94 and 1995-2001). We compared these two time periods for survival after birth until discharge, morbidity patterns during hospitalisation, length of stay in hospital, and readmission rates to hospital in the four weeks after discharge. Effects of change of 509 consecutive, very low birthweight infants, 494 (97%) preterm and 140 (28%) weighing < 1000 g at birth), 391 (76%) survived to discharge from the hospital. The length of hospitalisation fell significantly from 1987-90, when it was 34 (SD 18) days, to 16 (SD 14) days in 1999-2001 (P < 0.001). Readmission rates to hospital did not rise, nor did adverse outcomes at 12 months of age. Lessons learnt Our results indicate that it is possible to involve mothers in the active care of their very low birthweight infants before discharge. This may translate into earlier discharge from hospital to home settings without any increase in short term complications and readmissions.	Aga Khan Univ, Neonatal Intens Care Unit, Karachi 74800, Pakistan	Aga Khan University	Bhutta, ZA (corresponding author), Aga Khan Univ, Neonatal Intens Care Unit, Karachi 74800, Pakistan.	zulfiqar.b.hutta@aku.edu						ALI MM, 1988, BANGLADESH J CHILD H, V12, P90; Arce Casas A, 2003, An Pediatr (Barc), V59, P454; Arif MA, 1999, J TROP PEDIATRICS, V45, P278, DOI 10.1093/tropej/45.5.278; Atasay B, 2003, TURKISH J PEDIATR, V45, P283; BALCOM RJ, 1993, PEDIATRICS, V91, P540; Bhutta ZA, 1999, PEDIATR PULM, V27, P305, DOI 10.1002/(SICI)1099-0496(199905)27:5<305::AID-PPUL2>3.0.CO;2-Q; BOO N Y, 1992, SMJ Singapore Medical Journal, V33, P33; Boo NY, 1996, J PAEDIATR CHILD H, V32, P439, DOI 10.1111/j.1440-1754.1996.tb00946.x; Callaghan LA, 2003, ARCH DIS CHILD-FETAL, V88, pF94, DOI 10.1136/fn.88.2.F94; COCKBURN F, 1993, LANCET, V342, P193; Cooper PA, 1997, PEDIATRICS, V99, P537, DOI 10.1542/peds.99.4.537; Darlow BA, 2003, ARCH DIS CHILD-FETAL, V88, pF23, DOI 10.1136/fn.88.1.F23; Fanaroff AA, 2003, SEMIN PERINATOL, V27, P281, DOI 10.1016/S0146-0005(03)00055-7; GRAY RH, 1991, INT J EPIDEMIOL, V20, P467, DOI 10.1093/ije/20.2.467; *GRUP COL NEOC, 2002, J PERINATOL, V22, P2; Ho JJ, 1999, J PAEDIATR CHILD H, V35, P175, DOI 10.1046/j.1440-1754.1999.t01-1-00340.x; Kaiser Jeffrey R, 2004, J Perinatol, V24, P343, DOI 10.1038/sj.jp.7211113; Kambarami R. A., 1999, Central African Journal of Medicine, V45, P56; Kulmala T, 2000, PAEDIATR PERINAT EP, V14, P219, DOI 10.1046/j.1365-3016.2000.00270.x; Lincetto O, 1998, ACTA PAEDIATR, V87, P433; Mbweza E, 1996, Int Nurs Rev, V43, P53; Merritt T Allen, 2003, Semin Neonatol, V8, P95, DOI 10.1016/S1084-2756(02)00219-1; Ravikumara M., 1996, Indian Journal of Pediatrics, V63, P785, DOI 10.1007/BF02730930; Rogowski J, 2003, PEDIATRICS, V111; Tafari N, 1974, J Trop Pediatr Environ Child Health, V20, P73; Yasmin S, 2001, B WORLD HEALTH ORGAN, V79, P608	26	59	60	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 13	2004	329	7475					1151	1155		10.1136/bmj.329.7475.1151	http://dx.doi.org/10.1136/bmj.329.7475.1151			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539671	Green Published			2023-01-03	WOS:000225169600022
J	Hurwitz, CA; Duncan, J; Wolfe, J				Hurwitz, CA; Duncan, J; Wolfe, J			Caring for the child with cancer at the close of life - "There are people who make it, and I'm hoping I'm one of them"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PEDIATRIC PALLIATIVE CARE; MALIGNANT-DISEASE; TERMINAL CANCER; ILL PATIENTS; SYMPTOMS; END; PAIN; METHYLPHENIDATE; HYDRATION; DYSPNEA	Approximately 25% of children with cancer die of their disease. Early in the course of a patient's illness, it is often impossible to determine whether the disease will be cured with cancer-directed treatment. When potentially curative therapy is no longer an option, the patient, family, and oncology team face enormous medical, psychological, and spiritual challenges. Optimal palliative care requires willingness on the part of the physician and caregiver team to engage the patient and family in discussions of their hopes and fears and to provide solace and support for emotional and physical pain. Using the comments of a child in the terminal phase of acute leukemia, his mother, and his physician, we describe opportunities and important lessons often revealed only when families and their caregivers face the end of a child's life. A broad-minded assessment of the patient's and family's physical, emotional, and spiritual needs and clarification of realistic goals and hopes not only improves the clinical care that the patient receives but also contributes to the sense of satisfaction and meaning that the physician can gain from the experience of caring for children at the end of life.	Dana Farber Canc Inst, Dept Pediat Oncol, Pediat Adv Care Team, Boston, MA 02115 USA; Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Maine Med Ctr, Maine Childrens Canc Program, Portland, ME USA; Maine Med Ctr, Barbara Bush Childrens Hosp, Portland, ME USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Maine Medical Center; Maine Medical Center	Wolfe, J (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, Pediat Adv Care Team, 44 Binney St, Boston, MA 02115 USA.	joanne_wolfe@dfci.harvard.edu						Abrahm J, 2000, PHYS GUIDE PAIN SYMP; ADAMS VD, 1986, J WATER POLLUT CON F, V58, P449; ADAMS-GREENLY M, 1991, Pediatrician, V18, P3; Allard P, 1999, J PAIN SYMPTOM MANAG, V17, P256, DOI 10.1016/S0885-3924(98)00157-2; ANGELL M, 1982, NEW ENGL J MED, V306, P98, DOI 10.1056/NEJM198201143060210; Back Anthony L, 2003, Ann Intern Med, V138, P439; Berger AM, 2002, PRINCIPLES PRACTICE; Block SD, 2001, JAMA-J AM MED ASSOC, V285, P2898, DOI 10.1001/jama.285.22.2898; BLUEBLONDLANGNE.M, 1978, PRIVATE WORLDS DYING; BRUERA E, 1992, J PAIN SYMPTOM MANAG, V7, P365, DOI 10.1016/0885-3924(92)90091-U; BRUERA E, 1987, CANCER TREAT REP, V71, P67; Bruera E, 1996, SUPPORT CARE CANCER, V4, P147, DOI 10.1007/BF01845764; BRUERA E, 1993, ANN INTERN MED, V119, P906, DOI 10.7326/0003-4819-119-9-199311010-00007; Bruera Eduardo, 2002, J Palliat Med, V5, P127, DOI 10.1089/10966210252785097; BUCHAN ML, 1995, J CLIN ETHIC, V6, P53; Burns J P, 1997, New Horiz, V5, P72; Carrese JA, 2000, J GEN INTERN MED, V15, P92, DOI 10.1046/j.1525-1497.2000.03399.x; CHRIST G, 1984, CHILDHOOD CANCER IMP, P109; Christ GH, 2002, JAMA-J AM MED ASSOC, V288, P1269, DOI 10.1001/jama.288.10.1269; Christ GH, 2000, CANCER PRACT, V8, P72, DOI 10.1046/j.1523-5394.2000.82005.x; Collins JJ, 2000, J PAIN SYMPTOM MANAG, V19, P363, DOI 10.1016/S0885-3924(00)00127-5; Contro N, 2002, ARCH PEDIAT ADOL MED, V156, P14, DOI 10.1001/archpedi.156.1.14; Davis B, 2001, TXB PALLIATIVE NURSI, P363; Davis CL, 1997, BRIT MED J, V315, P931; Drake R, 2003, J PAIN SYMPTOM MANAG, V26, P594, DOI 10.1016/S0885-3924(03)00202-1; Escalante CP, 1996, CANCER, V78, P1314, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1314::AID-CNCR21>3.0.CO;2-2; Feudtner C, 2002, PEDIATRICS, V109, P887, DOI 10.1542/peds.109.5.887; Field M.J., 2003, CHILDREN DIE IMPROVI; HAIN RDW, 1995, PALLIATIVE MED, V9, P201, DOI 10.1177/026921639500900305; Hilden JM, 2001, IMPROVING PALLIATIVE, P161; Himelstein BP, 2004, NEW ENGL J MED, V350, P1752, DOI 10.1056/NEJMra030334; Hinds PS, 2001, CANCER NURS, V24, P122, DOI 10.1097/00002820-200104000-00007; Hongo T, 2003, PEDIATR INT, V45, P60, DOI 10.1046/j.1442-200X.2003.01668.x; Ingham J M, 1998, Hosp J, V13, P89; Jecker Nancy S, 1995, Rep Inst Philos Public Policy, V15, P10; KANE JR, 2002, PRINCIPLES PRACTICE, P1044; KOREN G, 1989, PEDIATR CLIN N AM, V36, P1141; Kreicbergs U, 2004, NEW ENGL J MED, V351, P1175, DOI 10.1056/NEJMoa040366; Mack JW, 2004, J CLIN ONCOL, V22, P563, DOI 10.1200/JCO.2004.04.078; MACK JW, 2004, 40 ANN M AM SOC CLIN; Mancini I, 1998, SUPPORT CARE CANCER, V6, P356, DOI 10.1007/s005200050177; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Meares C J, 1994, Am J Hosp Palliat Care, V11, P10, DOI 10.1177/104990919401100304; Miaskowski C, 1998, PRINC PR SUPPORT ONC, V1, P1; Mock V, 1997, Oncol Nurs Forum, V24, P991; MOUNT BM, 1986, J CLIN ONCOL, V4, P1127, DOI 10.1200/JCO.1986.4.7.1127; Nelson RM, 2000, PEDIATRICS, V106, P351; Ng K, 1998, J PAIN SYMPTOM MANAG, V16, P307, DOI 10.1016/S0885-3924(98)00097-9; Nitschke R, 2001, J CLIN ONCOL, V19, P595, DOI 10.1200/JCO.2001.19.2.595; Portenoy R K, 1991, J Palliat Care, V7, P13; Rabow MW, 2004, JAMA-J AM MED ASSOC, V291, P483, DOI 10.1001/jama.291.4.483; Rozans M, 2002, J CLIN ONCOL, V20, P335, DOI 10.1200/JCO.20.1.335; Rusy LM, 2000, PEDIATR CLIN N AM, V47, P589, DOI 10.1016/S0031-3955(05)70227-3; SHAPIRO DL, 1984, JAMA-J AM MED ASSOC, V252, P2031, DOI 10.1001/jama.252.15.2031; Sirkia K, 1998, J PAIN SYMPTOM MANAG, V15, P220, DOI 10.1016/S0885-3924(98)00366-2; SOURKES B M, 1991, Journal of Psychosocial Oncology, V9, P81, DOI 10.1300/J077v09n02_06; Sourkes BM, 1996, J PALLIATIVE CARE, V12, P56, DOI 10.1177/082585979601200312; Steiner N, 1998, J PALLIAT CARE, V14, P6, DOI 10.1177/082585979801400202; Stevens M.M., 1998, OXFORD TXB PALLIATIV, P1045; TAKETOMO CK, 2003, PEDIAT DOSAGE HDB; Tobias JD, 2000, PEDIATR CLIN N AM, V47, P527, DOI 10.1016/S0031-3955(05)70224-8; Vullo-Navich K, 1998, Am J Hosp Palliat Care, V15, P77, DOI 10.1177/104990919801500205; Waller A, 1994, Am J Hosp Palliat Care, V11, P22; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WHIPPEN DA, 1991, J CLIN ONCOL, V9, P1916, DOI 10.1200/JCO.1991.9.10.1916; WILWERDING MB, 1995, SUPPORT CARE CANCER, V3, P135, DOI 10.1007/BF00365854; Wolfe J, 2002, PEDIATR CLIN N AM, V49, P1043, DOI 10.1016/S0031-3955(02)00034-2; Wolfe J, 2000, NEW ENGL J MED, V342, P326, DOI 10.1056/NEJM200002033420506; Wolfe J, 2000, JAMA-J AM MED ASSOC, V284, P2469, DOI 10.1001/jama.284.19.2469; Wolfe J, 2000, J CLIN ETHIC, V11, P157; Worden JW., 1996, CHILDREN GRIEF PAREN; 2000, EVIDENCE BASED SYMPT	72	70	70	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2004	292	17					2141	2149		10.1001/jama.292.17.2141	http://dx.doi.org/10.1001/jama.292.17.2141			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868OC	15523075				2023-01-03	WOS:000224921900027
J	McAlister, FA; Ezekowitz, JA; Wiebe, N; Rowe, B; Spooner, C; Crumley, E; Hartling, L; Klassen, T; Abraham, W				McAlister, FA; Ezekowitz, JA; Wiebe, N; Rowe, B; Spooner, C; Crumley, E; Hartling, L; Klassen, T; Abraham, W			Systematic review: Cardiac resynchronization in patients with symptomatic heart failure	ANNALS OF INTERNAL MEDICINE			English	Review							INTRAVENTRICULAR-CONDUCTION DELAY; CHRONIC ATRIAL-FIBRILLATION; LEFT-VENTRICULAR DYSFUNCTION; QUALITY-OF-LIFE; CONTROLLED-TRIALS; TOTAL MORTALITY; ATLAS TRIAL; THERAPY; EXPERIENCE; LONG	Background: Even with optimal pharmacotherapy, symptomatic heart failure is associated with substantial morbidity and mortality. Purpose: To determine the efficacy and safety of cardiac resynchronization therapy in adults with advanced systolic heart failure. Data Sources: The Cochrane Central Register of Controlled Trials (2002, volume 4), MEDLINE (1980-2003), EMBASE (19802003), other electronic databases, and U.S. Food and Drug Administration reports. We contacted primary study authors and device manufacturers, and we hand searched bibliographies of relevant papers and conference proceedings. Study Selection: Randomized, controlled clinical trials for efficacy and controlled trials plus prospective cohort studies for safety. Data Extraction: Two reviewers chose studies and extracted data independently; random-effects models were used for analyses. Data Synthesis: Nine trials were included in the efficacy review (3216 patients). All trial participants had reduced ejection fraction and prolonged QRS duration, and 85% had New York Heart Association (NYHA) class III or IV symptoms. Cardiac resynchronization therapy improved ejection fraction (weighted mean difference, 0.035 [95% CI, 0.015 to 0.055]), quality of life (weighted mean reduction in score on the Minnesota Living with Heart Failure Questionnaire, 7.6 points [CI, 3.8 to 11.5 points]), and function (58% vs. 37% of patients improved by at least 1 NYHA class). Heart failure hospitalizations were reduced by 32% (relative risk [RR], 0.68 [CI, 0.41 to 1.12]), with benefits most marked in patients with NYHA class III or IV symptoms at baseline (RR, 0.65 [CI, 0.48 to 0.88]; number needed to treat for benefit [NNTB], 12). All-cause mortality was reduced by 21% (RR, 0.79 [CI, 0.66 to 0.96]; NNTB, 24), driven largely by reductions in death from progressive heart failure (RR, 0.60 [CI, 0.36 to 1.01]). Eighteen studies (total of 3701 patients with cardiac resynchronization devices) were included in the safety review. Implant success rate was 90% (CI, 89% to 91%), and 0.4% of patients died during implantation (CI, 0.2% to 0.7%). Over a median 6-month follow-up, leads dislodged in 9% of patients (CI, 7% to 10%) and mechanical malfunctions occurred in 7% (CI, 5% to 8%). Limitations: These trials enrolled only patients with heart failure with NYHA class III or IV symptoms despite medical therapy, a prolonged QRS duration, and reduced ejection fraction; in addition, experienced providers implanted the devices. Because all but one of these trials randomly assigned patients after device implantation, their results may overestimate the potential benefits of cardiac resynchronization. Finally, since few patients in these trials had bradyarrhythmias or atrial fibrillation, the role of cardiac resynchronization in such patients is uncertain. Conclusions: in selected patients with heart failure, cardiac resynchronization therapy improves functional and hemodynamic status, reduces heart failure hospitalizations, and reduces all-cause mortality.	Univ Alberta, Edmonton, AB, Canada; Capital Hlth Evidence Based Practice Ctr, Edmonton, AB, Canada; Ohio State Univ, Columbus, OH 43210 USA	University of Alberta; University System of Ohio; Ohio State University	McAlister, FA (corresponding author), Univ Alberta Hosp, 2E3-24,8440 112 St, Edmonton, AB T6G 2R7, Canada.	Finlay.McAlister@ualberta.ca	McAlister, Finlay/C-4151-2013; Ezekowitz, Justin A/C-4579-2013; Wiebe, Natasha/V-7803-2019	McAlister, Finlay/0000-0001-7435-3341; Ezekowitz, Justin A/0000-0002-2724-4086; Wiebe, Natasha/0000-0002-5613-1582; Klassen, Terry/0000-0002-5309-7091; Crumley, Ellen T./0000-0002-5198-6346				Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; Abraham WT, 2002, CURR OPIN CARDIOL, V17, P346, DOI 10.1097/00001573-200207000-00004; Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; *AM HEART ASS, 2002, HEART DIS STOK STAT; Auricchio A, 2002, J AM COLL CARDIOL, V39, P2026, DOI 10.1016/S0735-1097(02)01895-8; Baldasseroni S, 2002, AM HEART J, V143, P398, DOI 10.1067/mhj.2002.121264; Bradley DJ, 2003, JAMA-J AM MED ASSOC, V289, P730, DOI 10.1001/jama.289.6.730; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Brophy JM, 2001, ANN INTERN MED, V134, P550, DOI 10.7326/0003-4819-134-7-200104030-00008; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Cazeau S, 1996, PACE, V19, P1748, DOI 10.1111/j.1540-8159.1996.tb03218.x; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Curtin F, 2002, STAT MED, V21, P2131, DOI 10.1002/sim.1205; Ellenbogen KA, 2003, AM J CARDIOL, V92, P740, DOI 10.1016/S0002-9149(03)00844-0; Ezekowitz JA, 2003, ANN INTERN MED, V138, P445, DOI 10.7326/0003-4819-138-6-200303180-00007; FILHO MM, 2002, ARQ BRAS CARDIOL, V78, P110; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Garrigue S, 2002, HEART, V87, P529, DOI 10.1136/heart.87.6.529; Gras D, 2002, EUR J HEART FAIL, V4, P311, DOI 10.1016/S1388-9842(02)00018-1; Gregoratos G, 2002, J CARDIOVASC ELECTR, V13, P1183; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins SL, 2003, J AM COLL CARDIOL, V42, P1454, DOI 10.1016/S0735-1097(03)01042-8; Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295; Jong P, 2002, ARCH INTERN MED, V162, P1689, DOI 10.1001/archinte.162.15.1689; Kass DA, 2003, J AM COLL CARDIOL, V42, P2125, DOI 10.1016/j.jacc.2003.09.021; Krahn AD, 2002, CAN J CARDIOL, V18, P380; Krum H, 2003, LANCET, V362, P147, DOI 10.1016/S0140-6736(03)13869-X; Kuhlkamp V, 2002, J AM COLL CARDIOL, V39, P790, DOI 10.1016/S0735-1097(01)01819-8; Leclercq C, 2000, AM HEART J, V140, P862, DOI 10.1067/mhj.2000.110570; Leclercq C, 2002, EUR HEART J, V23, P1780, DOI 10.1053/euhj.2002.3232; LECLERQ C, 2003, EUR SOC CARD C VIENN; Leon AR, 2002, J AM COLL CARDIOL, V39, P1258, DOI 10.1016/S0735-1097(02)01779-5; Lloyd-Jones DM, 2002, CIRCULATION, V106, P3068, DOI 10.1161/01.CIR.0000039105.49749.6F; MacIntyre K, 2000, CIRCULATION, V102, P1126, DOI 10.1161/01.CIR.102.10.1126; Massie BM, 1998, LANCET, V352, P29; MCALISTER FA, 2004, IN PRESS J AM COLL C; Medina-Ravell VA, 2003, CIRCULATION, V107, P740, DOI 10.1161/01.CIR.0000048126.07819.37; Mehra MR, 2004, J AM COLL CARDIOL, V43, P1145, DOI 10.1016/j.jacc.2003.10.050; Molhoek SG, 2002, AM J CARDIOL, V90, P379, DOI 10.1016/S0002-9149(02)02493-1; Mortensen PT, 2004, PACE, V27, P339, DOI 10.1111/j.1540-8159.2004.00438.x; Nichol G, 2004, ANN INTERN MED, V141, P343, DOI 10.7326/0003-4819-141-5-200409070-00102; Pablos-Mendez A, 1998, JAMA-J AM MED ASSOC, V279, P222, DOI 10.1001/jama.279.3.222; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Poole-Wilson PA, 2003, HEART, V89, P42, DOI 10.1136/heart.89.1.42; RECTOR TS, 1993, AM J CARDIOL, V71, P1106, DOI 10.1016/0002-9149(93)90582-W; RECTOR TS, 1992, AM HEART J, V124, P1017, DOI 10.1016/0002-8703(92)90986-6; RECTOR TS, 1993, CIRCULATION, V87, P71; Shamim W, 1999, INT J CARDIOL, V70, P171, DOI 10.1016/S0167-5273(99)00077-7; Uretsky BF, 2000, CIRCULATION, V102, P611, DOI 10.1161/01.CIR.102.6.611; Werling C, 2002, THORAC CARDIOV SURG, V50, P67, DOI 10.1055/s-2002-26702; Young JB, 2003, JAMA-J AM MED ASSOC, V289, P2685, DOI 10.1001/jama.289.20.2685	52	227	254	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2004	141	5					381	390		10.7326/0003-4819-141-5-200409070-00101	http://dx.doi.org/10.7326/0003-4819-141-5-200409070-00101			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CW	15353430				2023-01-03	WOS:000223733800007
J	Brower, RG; Lanken, PN; MacIntyre, N; Matthay, MA; Morris, A; Ancukiewicz, M; Schoenfeld, D; Thompson, BT				Brower, RG; Lanken, PN; MacIntyre, N; Matthay, MA; Morris, A; Ancukiewicz, M; Schoenfeld, D; Thompson, BT		Natl Heart Lung Blood Inst ARDS Cl	Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	98th International Conference of the American-Thoracic-Society	MAY 17-23, 2002	ATLANTA, GA	Amer Thorac Soc			ACUTE LUNG INJURY; MECHANICAL VENTILATION; TIDAL VOLUME; PULMONARY-EDEMA; SURFACTANT; MORTALITY; ADULTS; PEEP	Background: Most patients requiring mechanical ventilation for acute lung injury and the acute respiratory distress syndrome (ARDS) receive positive end-expiratory pressure (PEEP) of 5 to 12 cm of water. Higher PEEP levels may improve oxygenation and reduce ventilator-induced lung injury but may also cause circulatory depression and lung injury from overdistention. We conducted this trial to compare the effects of higher and lower PEEP levels on clinical outcomes in these patients. Methods: We randomly assigned 549 patients with acute lung injury and ARDS to receive mechanical ventilation with either lower or higher PEEP levels, which were set according to different tables of predetermined combinations of PEEP and fraction of inspired oxygen. Results: Mean (+/-SD) PEEP values on days 1 through 4 were 8.3+/-3.2 cm of water in the lower-PEEP group and 13.2+/-3.5 cm of water in the higher-PEEP group (P<0.001). The rates of death before hospital discharge were 24.9 percent and 27.5 percent, respectively (P=0.48; 95 percent confidence interval for the difference between groups, -10.0 to 4.7 percent). From day 1 to day 28, breathing was unassisted for a mean of 14.5+/-10.4 days in the lower-PEEP group and 13.8+/-10.6 days in the higher-PEEP group (P=0.50). Conclusions: These results suggest that in patients with acute lung injury and ARDS who receive mechanical ventilation with a tidal-volume goal of 6 ml per kilogram of predicted body weight and an end-inspiratory plateau-pressure-limit of 30 cm of water, clinical outcomes are similar whether lower or higher PEEP levels are used.	Johns Hopkins Univ, Baltimore, MD 21205 USA; Univ Penn, Philadelphia, PA 19104 USA; Duke Univ, Durham, NC USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Latter Day St Hosp, Salt Lake City, UT 84143 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; NHLBI, ARDS, Clin Trials Network, Bethesda, MD 20892 USA	Johns Hopkins University; University of Pennsylvania; Duke University; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Brower, RG (corresponding author), Johns Hopkins Univ, 1830 E Monument St,Rm 549, Baltimore, MD 21205 USA.				DIVISION OF LUNG DISEASES [N01HR046057, N01HR046061, N01HR046054, N01HR046056, N01HR046059, N01HR046060, N01HR046055, N01HR046058, N01HR046063, N01HR046064, N01HR046062] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HR 46055, N01-HR 46060, N01-HR 46059, N01-HR 46054, N01-HR 46058, N01-HR 46057, N01-HR 46056, N01-HR 46064, N01-HR 46063, N01-HR 46062, N01-HR 46061] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; ALBERT RK, 1985, J APPL PHYSIOL, V59, P1555, DOI 10.1152/jappl.1985.59.5.1555; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201; ARDS Clinical Trials Network, 2003, CRIT CARE MED, V31, P2592, DOI 10.1097/01.CCM.0000090001.91640.45; Arons MM, 1999, CRIT CARE MED, V27, P699, DOI 10.1097/00003246-199904000-00020; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Brower RG, 2002, AM J RESP CRIT CARE, V166, P1515, DOI 10.1164/ajrccm.166.11.340; BROWER RG, 2003, AM J RESP CRIT CARE, V167, pA616; Brower RG, 2004, CRIT CARE MED, V32, P907; Carmichael LC, 1996, J CRIT CARE, V11, P9, DOI 10.1016/S0883-9441(96)90015-5; Conner ER, 1999, CHEST, V116, p83S, DOI 10.1378/chest.116.suppl_1.83S; CORBRIDGE TC, 1990, AM REV RESPIR DIS, V142, P311, DOI 10.1164/ajrccm/142.2.311; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Greene KE, 1999, AM J RESP CRIT CARE, V160, P1843, DOI 10.1164/ajrccm.160.6.9901117; JARDIN F, 1994, INTENS CARE MED, V20, P169, DOI 10.1007/BF01704693; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P169; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LODATO RF, 1994, PRINCIPLES PRACTICE, P837; Martynowicz MA, 2001, J APPL PHYSIOL, V90, P1744, DOI 10.1152/jappl.2001.90.5.1744; MEAD J, 1970, J APPL PHYSIOL, V28, P596, DOI 10.1152/jappl.1970.28.5.596; Miro AM, 1994, PRINCIPLES PRACTICE, P647; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; PARKER JC, 1993, CRIT CARE MED, V21, P131, DOI 10.1097/00003246-199301000-00024; PARKER JC, 1984, J APPL PHYSIOL, V57, P1809, DOI 10.1152/jappl.1984.57.6.1809; Pinsky MR, 1997, INTENS CARE MED, V23, P493, DOI 10.1007/s001340050364; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; ROUPIE E, 1995, AM J RESP CRIT CARE, V152, P121, DOI 10.1164/ajrccm.152.1.7599810; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Schoenfeld DA, 2001, BIOMETRICS, V57, P972, DOI 10.1111/j.0006-341X.2001.00972.x; Thompson BT, 2001, CHEST, V120, P1622, DOI 10.1378/chest.120.5.1622; TOUNG TJK, 1978, SURG GYNECOL OBSTET, V147, P518; TSUNO K, 1991, AM REV RESPIR DIS, V143, P1115, DOI 10.1164/ajrccm/143.5_Pt_1.1115; Wiedemann HP, 2002, CRIT CARE MED, V30, P1	37	1540	1626	1	62	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 22	2004	351	4					327	336						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	839RC	15269312				2023-01-03	WOS:000222801200006
J	Esteban, A; Frutos-Vivar, F; Ferguson, ND; Arabi, Y; Apezteguia, C; Gonzalez, M; Epstein, SK; Hill, NS; Nava, S; Soares, MA; D'Empaire, G; Alia, I; Anzueto, A				Esteban, A; Frutos-Vivar, F; Ferguson, ND; Arabi, Y; Apezteguia, C; Gonzalez, M; Epstein, SK; Hill, NS; Nava, S; Soares, MA; D'Empaire, G; Alia, I; Anzueto, A			Noninvasive positive-pressure ventilation for respiratory failure after extubation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MECHANICAL VENTILATION; SUPPORT VENTILATION; COPD PATIENTS; CARE-UNIT; DURATION; TRIAL; MASK	BACKGROUND The need for reintubation after extubation and discontinuation of mechanical ventilation is not uncommon and is associated with increased mortality. Noninvasive positive-pressure ventilation has been suggested as a promising therapy for patients with respiratory failure after extubation, but a single-center, randomized trial recently found no benefit. We conducted a multicenter, randomized trial to evaluate the effect of noninvasive positive-pressure ventilation on mortality in this clinical setting. METHODS Patients in 37 centers in eight countries who were electively extubated after at least 48 hours of mechanical ventilation and who had respiratory failure within the subsequent 48 hours were randomly assigned to either noninvasive positive-pressure ventilation by face mask or standard medical therapy. RESULTS A total of 221 patients with similar baseline characteristics had been randomly assigned to either noninvasive ventilation ( 114 patients) or standard medical therapy ( 107 patients) when the trial was stopped early, after an interim analysis. There was no difference between the noninvasive-ventilation group and the standard-therapy group in the need for reintubation ( rate of reintubation, 48 percent in both groups; relative risk in the noninvasive-ventilation group, 0.99; 95 percent confidence interval, 0.76 to 1.30). The rate of death in the intensive care unit was higher in the noninvasive-ventilation group than in the standard-therapy group ( 25 percent vs. 14 percent; relative risk, 1.78; 95 percent confidence interval, 1.03 to 3.20; P= 0.048), and the median time from respiratory failure to reintubation was longer in the noninvasive-ventilation group ( 12 hours vs. 2 hours 30 minutes, P= 0.02). CONCLUSIONS Noninvasive positive-pressure ventilation does not prevent the need for reintubation or reduce mortality in unselected patients who have respiratory failure after extubation.	Hosp Univ Getafe, Unidad Cuidados Intens, Madrid 28905, Spain; Univ Toronto, Univ Hlth Network, Dept Med, Div Respirol, Toronto, ON, Canada; Univ Toronto, Univ Hlth Network, Interdepartmental Div Crit Care Med, Toronto, ON, Canada; King Fahad Natl Guard Hosp, Riyadh, Saudi Arabia; Hosp Prof Posadas, Buenos Aires, DF, Argentina; Hosp Gen Medellin, Medellin, Colombia; Tufts Univ, Sch Med, New England Med Ctr, Dept Med,Pulm & Crit Care Div, Boston, MA 02111 USA; Fdn S Maugeri, Ist Sci Pavia, Resp Intens Care Unit, Pavia, Italy; Hosp Univ Sao Jose, Belo Horizonte, MG, Brazil; Hosp Clin, Caracas, Venezuela; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA	Hospital Universitario de Getafe; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Riyadh; Tufts Medical Center; Tufts University; Istituti Clinici Scientifici Maugeri IRCCS; University of Texas System; University of Texas Health San Antonio	Esteban, A (corresponding author), Hosp Univ Getafe, Unidad Cuidados Intens, Carretera Toledo Km 12,500, Madrid 28905, Spain.	aesteban@ucigetafe.com	Ferguson, Niall/D-7619-2019; Arabi, Yaseen/ABF-3316-2020	Ferguson, Niall/0000-0002-6213-5264; Arabi, Yaseen/0000-0001-5735-6241; Frutos-Vivar, Fernando/0000-0002-4648-9636				Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Celikel T, 1998, CHEST, V114, P1636, DOI 10.1378/chest.114.6.1636; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; Epstein SK, 1998, AM J RESP CRIT CARE, V158, P489, DOI 10.1164/ajrccm.158.2.9711045; Epstein SK, 1997, CHEST, V112, P186, DOI 10.1378/chest.112.1.186; Esteban, 1997, AM J RESP CRIT CARE, V156, P2028; Esteban A, 1999, AM J RESP CRIT CARE, V159, P512, DOI 10.1164/ajrccm.159.2.9803106; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 1997, AM J RESP CRIT CARE, V156, P459, DOI 10.1164/ajrccm.156.2.9610109; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; Gil B, 2003, CLIN PULM MED, V10, P226; Girault C, 2002, JAMA-J AM MED ASSOC, V288, P2540, DOI 10.1001/jama.288.20.2540; Hilbert G, 1998, EUR RESPIR J, V11, P1349, DOI 10.1183/09031936.98.11061349; *INT CONS C INT CA, 2001, AM J RESP CRIT CARE, V163, P283; Jiang J S, 1999, Respirology, V4, P161, DOI 10.1046/j.1440-1843.1999.00168.x; Keenan SP, 2002, JAMA-J AM MED ASSOC, V287, P3238, DOI 10.1001/jama.287.24.3238; Kilger E, 1999, INTENS CARE MED, V25, P1374, DOI 10.1007/s001340051084; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; Manthous CA, 2002, CHEST, V121, P1738, DOI 10.1378/chest.121.6.1738; MEDURI GU, 1989, CHEST, V95, P865, DOI 10.1378/chest.95.4.865; Munshi IA, 1999, CHEST, V116, P1025, DOI 10.1378/chest.116.4.1025; Peter JV, 2002, CRIT CARE MED, V30, P555, DOI 10.1097/00003246-200203000-00010; Pocock SJ., 2013, CLIN TRIALS PRACTICA; PUTENSEN C, 1993, CRIT CARE MED, V21, P357, DOI 10.1097/00003246-199303000-00011; TORRES A, 1995, AM J RESP CRIT CARE, V152, P137, DOI 10.1164/ajrccm.152.1.7599812; WYSOCKI M, 1995, CHEST, V107, P761, DOI 10.1378/chest.107.3.761	29	529	591	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	2004	350	24					2452	2460		10.1056/NEJMoa032736	http://dx.doi.org/10.1056/NEJMoa032736			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	827GH	15190137				2023-01-03	WOS:000221887200004
J	Figdor, CG; de Vries, IJM; Lesterhuis, WJ; Melief, CJM				Figdor, CG; de Vries, IJM; Lesterhuis, WJ; Melief, CJM			Dendritic cell immunotherapy: mapping the way	NATURE MEDICINE			English	Article							T-CELLS; MELANOMA PATIENTS; METASTATIC MELANOMA; IN-VIVO; ANTIGEN; VACCINATION; IMMUNE; GENERATION; MATURATION; RESPONSES	Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system, with the potential to either stimulate or inhibit immune responses. Exploiting the immune-regulatory capacities of dendritic cells holds great promise for the treatment of cancer, autoimmune diseases and the prevention of transplant rejection. Although early clinical trials indicate that DC vaccines can induce immune responses in some cancer patients, careful study design and use of standardized clinical and immunological criteria are needed.	Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Tumor Immunol, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Leiden, Dept Immunohematol & Blood Transfus, NL-2300 RA Leiden, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC)	Figdor, CG (corresponding author), Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Tumor Immunol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	c.figdor@ncmls.kun.nl	de Vries, Jolanda I.J.M./F-5563-2010; Liu, Xia/L-9425-2013; Figdor, Carl G/A-4232-2010	de Vries, Jolanda I.J.M./0000-0002-8653-4040; Figdor, Carl G/0000-0002-2366-9212; Lesterhuis, Willem Joost/0000-0002-2718-276X				Adorini L, 2003, J CELL BIOCHEM, V88, P227, DOI 10.1002/jcb.10340; Banchereau J, 2001, CANCER RES, V61, P6451; Banchereau J, 2001, CELL, V106, P271, DOI 10.1016/S0092-8674(01)00448-2; BERNHARD H, 1995, CANCER RES, V55, P1099; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Boonstra A, 2003, J EXP MED, V197, P101, DOI 10.1084/jem.20021908; Bostanci A, 2002, SCIENCE, V298, P1531; Bousso P, 2003, NAT IMMUNOL, V4, P579, DOI 10.1038/ni928; Cerundolo V, 2004, NAT IMMUNOL, V5, P7, DOI 10.1038/ni0104-7; de Vries IJM, 2003, CANCER RES, V63, P12; de Vries IJM, 2003, CLIN CANCER RES, V9, P5091; Dhodapkar MV, 2000, J CLIN INVEST, V105, pR9, DOI 10.1172/JCI9051; Dhodapkar MV, 1999, J CLIN INVEST, V104, P173, DOI 10.1172/JCI6909; Engering A, 2002, TRENDS IMMUNOL, V23, P480, DOI 10.1016/S1471-4906(02)02296-2; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; Fujii S, 2003, J EXP MED, V198, P267, DOI 10.1084/jem.20030324; Garg S, 2003, NAT IMMUNOL, V4, P907, DOI 10.1038/ni962; Geiger JD, 2001, CANCER RES, V61, P8513; Gilboa E, 1998, CANCER IMMUNOL IMMUN, V46, P82, DOI 10.1007/s002620050465; Heiser A, 2002, J CLIN INVEST, V109, P409, DOI 10.1172/JCI200214364; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Jonuleit H, 2001, INT J CANCER, V93, P243, DOI 10.1002/ijc.1323; Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; MacDonald KPA, 2002, BLOOD, V100, P4512, DOI 10.1182/blood-2001-11-0097; Mackensen A, 2000, INT J CANCER, V86, P385, DOI 10.1002/(SICI)1097-0215(20000501)86:3<385::AID-IJC13>3.0.CO;2-T; Mackensen A, 2000, CANCER IMMUNOL IMMUN, V49, P152, DOI 10.1007/s002620050614; Maraskovsky E, 2000, BLOOD, V96, P878, DOI 10.1182/blood.V96.3.878.015k15_878_884; Martin E, 2003, IMMUNITY, V18, P155, DOI 10.1016/S1074-7613(02)00503-4; Martin-Fontecha A, 2003, J EXP MED, V198, P615, DOI 10.1084/jem.20030448; Melief CJM, 2002, IMMUNOL REV, V188, P177, DOI 10.1034/j.1600-065X.2002.18816.x; Miller MJ, 2004, P NATL ACAD SCI USA, V101, P998, DOI 10.1073/pnas.0306407101; Mullins DW, 2003, J EXP MED, V198, P1023, DOI 10.1084/jem.20021348; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Nestle FO, 2001, NAT MED, V7, P761, DOI 10.1038/89863; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Pulendran B, 2000, J IMMUNOL, V165, P566, DOI 10.4049/jimmunol.165.1.566; Ratzinger G, 2002, J IMMUNOL, V168, P4361, DOI 10.4049/jimmunol.168.9.4361; Rea D, 2000, BLOOD, V95, P3162, DOI 10.1182/blood.V95.10.3162.010k18_3162_3167; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Salio M, 2003, EUR J IMMUNOL, V33, P1052, DOI 10.1002/eji.200323676; Sallusto F, 2018, J IMMUNOL, V200, P887, DOI 10.1084/jem.179.4.1109; Schuler-Thurner B, 2002, J EXP MED, V195, P1279, DOI 10.1084/jem.20012100; Steinman RM, 2002, J CLIN INVEST, V109, P1519, DOI 10.1172/JCI200215962; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Toes REM, 1999, J EXP MED, V189, P753, DOI 10.1084/jem.189.5.753; Wakkach A, 2003, IMMUNITY, V18, P605, DOI 10.1016/S1074-7613(03)00113-4	48	788	865	1	91	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2004	10	5					475	480		10.1038/nm1039	http://dx.doi.org/10.1038/nm1039			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	818JW	15122249				2023-01-03	WOS:000221242400023
J	Tashima, Y; Oe, R; Lee, S; Sugihara, G; Chambers, EJ; Takahashi, M; Yamada, T				Tashima, Y; Oe, R; Lee, S; Sugihara, G; Chambers, EJ; Takahashi, M; Yamada, T			The effect of cholesterol and monosialoganglioside (GM1) on the release and aggregation of amyloid beta-peptide from liposomes prepared from brain membrane-like lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; A-BETA; ULTRASTRUCTURAL EVIDENCE; PLASMALOGEN DEFICIENCY; PROTEIN; FIBRILLOGENESIS; GANGLIOSIDE; ASSOCIATION; DOMAIN	In order to investigate the influence of cholesterol (Ch) and monosialoganglioside (GM1) on the release and subsequent deposition/aggregation of amyloid beta peptide (Abeta)-(1-40) and Abeta-(1-42), we have examined Abeta peptide model membrane interactions by circular dichroism, turbidity measurements, and transmission electron microscopy (TEM). Model liposomes containing Abeta peptide and a lipid mixture composition similar to that found in the cerebral cortex membranes (CCM-lipid) have been prepared. In all, four Abeta-containing liposomes were investigated: CCM-lipid; liposomes with no GM1 (GM1-free lipid); those with no cholesterol (Ch-free lipid); liposomes with neither cholesterol nor GM1 (Ch-GM1-free lipid). In CCM liposomes, Abeta was rapidly released from membranes to form a well defined fibril structure. However, for the GM1-free lipid, Abeta was first released to yield a fibril structure about the membrane surface, then the membrane became disrupted resulting in the formation of small vesicles. In Ch-free lipid, a fibril structure with a phospholipid membrane-like shadow formed, but this differed from the well defined fibril structure seen for CCM-lipid. In Ch-GM1-free lipid, no fibril structure formed, possibly because of membrane solubilization by Abeta. The absence of fibril structure was noted at physiological extracellular pH (7.4) and also at liposomal/endosomal pH (5.5). Our results suggest a possible role for both Ch and GM1 in the membrane release of Abeta from brain lipid bilayers.	Fukuoka Univ, Fac Sci, Dept Chem, Fukuoka 8140180, Japan; Fukuoka Univ, Fac Pharmaceut Sci, Fukuoka 8140180, Japan; Fukuoka Univ, Sch Med, Fukuoka 8140180, Japan; Univ So Calif, Dept Pharmaceut Sci, Los Angeles, CA 90089 USA	Fukuoka University; Fukuoka University; Fukuoka University; University of Southern California	Lee, S (corresponding author), Fukuoka Univ, Fac Sci, Dept Chem, Fukuoka 8140180, Japan.	leesan@cis.fukuoka-u.ac.jp	Chambers, Eric J/B-7537-2012; Taylor, Graham/A-4027-2012					BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Bunnell WL, 1998, J BIOL CHEM, V273, P31947, DOI 10.1074/jbc.273.48.31947; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; De Strooper B, 2000, J CELL SCI, V113, P1857; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; Ferraretto A, 1997, BIOCHEMISTRY-US, V36, P9232, DOI 10.1021/bi970428j; Furuya T, 2003, BIOPHYS J, V84, P1950, DOI 10.1016/S0006-3495(03)75003-6; GINSBERG L, 1995, BRAIN RES, V698, P223, DOI 10.1016/0006-8993(95)00931-F; Gorman PM, 2003, J MOL BIOL, V325, P743, DOI 10.1016/S0022-2836(02)01279-2; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Han XL, 2001, J NEUROCHEM, V77, P1168, DOI 10.1046/j.1471-4159.2001.00332.x; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Ji SR, 2002, J BIOL CHEM, V277, P6273, DOI 10.1074/jbc.M104146200; Kakio A, 2001, J BIOL CHEM, V276, P24985, DOI 10.1074/jbc.M100252200; Kitamura A, 1999, BIOPHYS J, V76, P1457, DOI 10.1016/S0006-3495(99)77306-6; Lee S, 2001, J BIOL CHEM, V276, P41224, DOI 10.1074/jbc.M104705200; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LeVine H, 2002, ARCH BIOCHEM BIOPHYS, V404, P106; Li YH, 1999, J NEUROCHEM, V73, P1477; Matsuzaki K, 1999, BIOCHEMISTRY-US, V38, P4137, DOI 10.1021/bi982345o; McLaurin J, 1998, J BIOL CHEM, V273, P4506, DOI 10.1074/jbc.273.8.4506; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; MORIYAMA Y, 1992, FEBS LETT, V302, P18, DOI 10.1016/0014-5793(92)80274-K; Natte R, 1999, ACTA NEUROPATHOL, V98, P577, DOI 10.1007/s004010051121; ROSSITER RJ, 1962, NEUROCHEMISTRY; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; Shigematsu D, 2002, BBA-BIOMEMBRANES, V1564, P271, DOI 10.1016/S0005-2736(02)00462-5; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Torp R, 2000, NEUROSCIENCE, V96, P495, DOI 10.1016/S0306-4522(99)00568-0; UEDA K, 1994, BRAIN RES, V639, P240, DOI 10.1016/0006-8993(94)91736-1; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Waschuk SA, 2001, J BIOL CHEM, V276, P33561, DOI 10.1074/jbc.M103598200; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yip CM, 2002, J MOL BIOL, V318, P97, DOI 10.1016/S0022-2836(02)00028-1; Yip CM, 2001, J MOL BIOL, V311, P723, DOI 10.1006/jmbi.2001.4881; Yip CM, 2001, BIOPHYS J, V80, P1359, DOI 10.1016/S0006-3495(01)76109-7	43	46	48	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17587	17595		10.1074/jbc.M308622200	http://dx.doi.org/10.1074/jbc.M308622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14709559	hybrid			2023-01-03	WOS:000220870400087
J	Paul, M; Benuri-Silbiger, I; Soares-Weiser, K; Leibovici, L				Paul, M; Benuri-Silbiger, I; Soares-Weiser, K; Leibovici, L			beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SERIOUS BACTERIAL-INFECTIONS; STAPHYLOCOCCUS-AUREUS ENDOCARDITIS; NEGATIVE BACILLARY INFECTIONS; RESPIRATORY-TRACT INFECTIONS; PLUS CLAVULANIC ACID; PSEUDOMONAS-AERUGINOSA; HOSPITALIZED-PATIENTS; ANTIMICROBIAL THERAPY; TOBRAMYCIN-TICARCILLIN; IMIPENEM-CILASTATIN	Objective To compare beta lactam monotherapy with lactam-aminoglycoside combination therapy for severe infections. Data sources Medline, Embase, Lilacs, Cochrane Library, and conference proceedings, to 2003; references of included studies; contact with all authors. No restrictions, such as language, year of publication, or publication status. Study selection All randomised trials of beta lactam monotherapy compared with beta lactam-aminoglycoside combination therapy for patients without neutropenia who fulfilled criteria for sepsis. Data selection Two reviewers independently applied selection criteria, performed quality assessment, and extracted the data. The primary outcome assessed was all cause fatality by intention to treat. Relative risks were pooled with the random effect model (relative risk <1 favours monotherapy). Results 64 trials with 7586 patients were included. There was no difference in all cause fatality (relative risk 0.90, 95% confidence interval 0.77 to 1.06). 12 studies compared the same beta lactam (1.02,0.76 to 1.38), and 31 studies compared different beta lactams (0.85,0.69 to 1.05). Clinical failure was more common with combination treatment overall (0.87,0.78 to 0.97) and among studies comparing different beta lactams (0.76,0.68 to 0.86). There was no advantage to combination therapy among patients with Gram negative infections (1835 patients) or Pseudomonas aeruginosa infections (426 patients). There was no difference in the rate of development of resistance. Nephrotoxicity was significantly more common with combination therapy (0.36,0.28 to 0.47). Heterogeneity was not significant for these comparisons. Conclusions In the treatment of sepsis the addition of an aminoglycoside to beta lactams should be discouraged. Fatality remains unchanged, while the risk for adverse events is increased.	Rabin Med Ctr, Dept Med E, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Infect Dis Unit, IL-49100 Petah Tiqwa, Israel	Rabin Medical Center; Rabin Medical Center	Paul, M (corresponding author), Rabin Med Ctr, Dept Med E, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.	mica@zahav.net.il						ABRAMS B, 1979, ANN INTERN MED, V90, P789, DOI 10.7326/0003-4819-90-5-789; ARICH C, 1987, PATHOL BIOL PARIS, V36, P613; Bailey Jeffrey A, 2002, Surg Infect (Larchmt), V3, P315, DOI 10.1089/109629602762539544; Bayer AS, 1998, CIRCULATION, V98, P2936, DOI 10.1161/01.CIR.98.25.2936; BERGER A, 1988, PROG MATER SCI, V32, P1, DOI 10.1016/0079-6425(88)90009-6; Biglino A, 1991, J Chemother, V3 Suppl 1, P208; BODEY GP, 1972, CANCER-AM CANCER SOC, V29, P1697, DOI 10.1002/1097-0142(197206)29:6<1697::AID-CNCR2820290638>3.0.CO;2-K; BONE RC, 1992, CHEST, V101, P1481, DOI 10.1378/chest.101.6.1481; BROWN RB, 1984, CURR THER RES CLIN E, V36, P557; Carbon C, 1987, Chemioterapia, V6, P367; CARDOZO M, 2001, PEDIAT ASUNCION, V28, P15; CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; Clarke Mike, 2003, COCHRANE REV HDB 4 1; COMETTA A, 1994, ANTIMICROB AGENTS CH, V38, P1309, DOI 10.1128/AAC.38.6.1309; CONE LA, 1985, ANTIMICROB AGENTS CH, V28, P33, DOI 10.1128/AAC.28.1.33; COPPENS L, 1983, ANTIMICROB AGENTS CH, V23, P36, DOI 10.1128/AAC.23.1.36; Crabtree TD, 1999, ARCH SURG-CHICAGO, V134, P1293, DOI 10.1001/archsurg.134.12.1293; DANTONIO D, 1992, CHEMOTHERAPY, V38, P420, DOI 10.1159/000239037; denHollander JG, 1997, ANTIMICROB AGENTS CH, V41, P95, DOI 10.1128/AAC.41.1.95; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUFF P, 1982, AM J OBSTET GYNECOL, V142, P996, DOI 10.1016/0002-9378(82)90782-7; Dupont H, 2000, ANTIMICROB AGENTS CH, V44, P2028, DOI 10.1128/AAC.44.8.2028-2033.2000; FELISART J, 1985, HEPATOLOGY, V5, P457, DOI 10.1002/hep.1840050319; FINER N, 1992, J ROY SOC MED, V85, P530; GERECHT WB, 1989, ARCH INTERN MED, V149, P1279, DOI 10.1001/archinte.149.6.1279; GIAMARELLOU H, 1986, AM J MED, V80, P126, DOI 10.1016/0002-9343(86)90490-0; GIAMARELLOU H, 1984, ANTIMICROB AGENTS CH, V25, P534, DOI 10.1128/AAC.25.4.534; GRASELA TH, 1990, DICP ANN PHARMAC, V24, P1220, DOI 10.1177/106002809002401215; HAVIG O, 1973, SCAND J GASTROENTERO, V8, P55; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HILF M, 1989, AM J MED, V87, P540, DOI 10.1016/S0002-9343(89)80611-4; HOEPELMAN IM, 1988, LANCET, V1, P1305, DOI 10.1016/S0140-6736(88)92121-6; HOLLOWAY WJ, 1985, AM J MED, V79, P168, DOI 10.1016/0002-9343(85)90153-6; Iakovlev S V, 1998, Antibiot Khimioter, V43, P15; Jaspers CAJJ, 1998, ANTIMICROB AGENTS CH, V42, P1233, DOI 10.1128/AAC.42.5.1233; KLASTERSKY J, 1977, AM J MED SCI, V273, P157, DOI 10.1097/00000441-197703000-00005; KLASTERSKY J, 1973, CANCER-AM CANCER SOC, V31, P331, DOI 10.1002/1097-0142(197302)31:2<331::AID-CNCR2820310210>3.0.CO;2-S; KLASTERSKY J, 1982, REV INFECT DIS, V4, P294; KLJUCAR S, 1990, 30 INT C ANT AG CHEM; KOEHLER C O, 1990, International Journal of Experimental and Clinical Chemotherapy, V3, P211; Kollef MH, 1999, CHEST, V115, P462, DOI 10.1378/chest.115.2.462; KORVICK JA, 1992, ANTIMICROB AGENTS CH, V36, P2639, DOI 10.1128/AAC.36.12.2639; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; LANDAU Z, 1990, Harefuah, V118, P152; Leibovici L, 1997, ANTIMICROB AGENTS CH, V41, P1127, DOI 10.1128/AAC.41.5.1127; Leibovici L, 1998, J INTERN MED, V244, P379; Leone M, 2003, CRIT CARE MED, V31, P462, DOI 10.1097/01.CCM.0000050298.59549.4A; Lerma FA, 2001, J CHEMOTHERAPY, V13, P70, DOI 10.1179/joc.2001.13.1.70; Levison ME, 2000, INFECT DIS CLIN N AM, V14, P281, DOI 10.1016/S0891-5520(05)70248-8; LIBIEN J E M, 1992, Compendium de Investigaciones Clinicas Latinoamericanas, V12, P42; LIMSON BM, 1988, CLIN THER, V10, P589; MANDELL LA, 1987, J ANTIMICROB CHEMOTH, V20, P95, DOI 10.1093/jac/20.1.95; Martin P Y, 1991, Rev Med Suisse Romande, V111, P609; McCormick PA, 1997, HEPATOLOGY, V25, P833, DOI 10.1002/hep.510250408; MERGONI M, 1987, CHEMIOTERAPIA, V6, P286; MOELLERING RS, 2000, MANDELL DOUGLAS BENN; Montravers P, 2002, CRIT CARE MED, V30, P368, DOI 10.1097/00003246-200202000-00017; Moreno A, 1997, REV ESP QUIM, V10, P138; Mouton JW, 1999, INFECTION, V27, pS24, DOI 10.1007/BF02561666; MOUTON Y, 1990, PRESSE MED, V19, P607; MOUTON YJ, 1995, J ANTIMICROB CHEMOTH, V36, P145, DOI 10.1093/jac/36.suppl_A.145; MULLER EL, 1987, SURG GYNECOL OBSTET, V165, P285; Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010; Paul M, 2003, BRIT MED J, V326, P1111, DOI 10.1136/bmj.326.7399.1111; PAUL M, 2003, COCHRANE LIB; PICCART M, 1984, ANTIMICROB AGENTS CH, V26, P870, DOI 10.1128/AAC.26.6.870; Ramirez de Aguilar R., 1992, COMPEND INVEST CLIN, V12, P75; RAPP RP, 1984, PHARMACOTHERAPY, V4, P211; RASMUSSEN D, 1986, DAN MED BULL, V33, P49; Ribera E, 1996, ANN INTERN MED, V125, P969, DOI 10.7326/0003-4819-125-12-199612150-00005; RUBINSTEIN E, 1995, CLIN INFECT DIS, V20, P1217, DOI 10.1093/clinids/20.5.1217; Ruiz G, 1990, REV ESP QUIM, V3, P35; SAGE R, 1987, SCAND J INFECT DIS, V19, P331, DOI 10.3109/00365548709018479; Sandberg T, 1997, SCAND J INFECT DIS, V29, P175, DOI 10.3109/00365549709035880; Sanfilippo JS, 1989, INT PEDIAT, V4, P53; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCULIER JP, 1982, J ANTIMICROB CHEMOTH, V9, P63, DOI 10.1093/jac/9.1.63; Sexton DJ, 1998, CLIN INFECT DIS, V27, P1470, DOI 10.1086/515038; Sieger B, 1997, CRIT CARE MED, V25, P1663, DOI 10.1097/00003246-199710000-00015; Siegman-Igra Y, 1998, Int J Infect Dis, V2, P211, DOI 10.1016/S1201-9712(98)90055-8; SMITH CR, 1984, ANN INTERN MED, V101, P469, DOI 10.7326/0003-4819-101-4-469; Speich R, 1998, EUR J CLIN MICROBIOL, V17, P313, DOI 10.1007/BF01709453; STILLE W, 1992, EUR J CLIN MICROBIOL, V11, P683; Sukoh Matsunobu, 1994, Japanese Journal of Antibiotics, V47, P170; Takamoto Masahiro, 1994, Japanese Journal of Antibiotics, V47, P1131; THOMPSON JE, 1990, SURG GYNECOL OBSTET, V171, P275; THOMPSON JE, 1993, SURG GYNECOL OBSTET, V177, P30; VERGNON J M, 1985, Revue de Pneumologie Clinique, V41, P205; VERZASCONI R, 1995, SCHWEIZ MED WSCHR, V125, P1533; WARREN JW, 1983, REV INFECT DIS, V5, pS173; WIECEK A, 1986, Polski Tygodnik Lekarski, V41, P1242; Wing DA, 1998, OBSTET GYNECOL, V92, P249, DOI 10.1016/S0029-7844(98)00156-2; Wu YL, 1999, J ANTIMICROB CHEMOTH, V44, P389, DOI 10.1093/jac/44.3.389; YELLIN AE, 1993, SURG GYNECOL OBSTET, V177, P23; Zavala Trujillo I, 1992, COMPUT INVEST CLIN L, V12, P31	95	294	320	1	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 20	2004	328	7441					668	672F		10.1136/bmj.38028.520995.63	http://dx.doi.org/10.1136/bmj.38028.520995.63			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VB	14996699	Green Published, Bronze			2023-01-03	WOS:000220392700016
J	Hunter, DJ				Hunter, DJ			Commentary: Getting a grip on clinical variations in hospital services	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Durham, Sch Hlth, Wolfson Res Inst, Thornaby TS17 6BH, Stockton On Tee, England	Durham University	Hunter, DJ (corresponding author), Univ Durham, Sch Hlth, Wolfson Res Inst, Queens Campus, Thornaby TS17 6BH, Stockton On Tee, England.	d.j.hunter@durham.ac.uk						Degeling P, 2003, BRIT MED J, V326, P649, DOI 10.1136/bmj.326.7390.649; Department of Health, 2000, NHS PLAN PLAN INV PL; Department of Health, 2000, SHAP FUT NHS LONG TE; Leatherman S.T., 2003, QUEST QUALITY NHS MI; ROLAND M, 2003, QUEST QUALITY NHS MI; Smith J, 2001, BRIT MED J, V323, P1262, DOI 10.1136/bmj.323.7324.1262; WENNBERG JE, 2004, FBMJ, V328, P607	7	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	2004	328	7440					610	610		10.1136/bmj.328.7440.610	http://dx.doi.org/10.1136/bmj.328.7440.610			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803CB	15016693	Green Published			2023-01-03	WOS:000220208100016
J	Schwartz, RS				Schwartz, RS			Paul Ehrlich's magic bullets.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	124	126	2	25	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	2004	350	11					1079	1080		10.1056/NEJMp048021	http://dx.doi.org/10.1056/NEJMp048021			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801QJ	15014180				2023-01-03	WOS:000220110100004
J	Couch, RB				Couch, RB			Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine	Couch, RB (corresponding author), Baylor Coll Med, Houston, TX 77030 USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257					0	102	111	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2004	350	9					860	861		10.1056/NEJMp048006	http://dx.doi.org/10.1056/NEJMp048006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777UM	14985482				2023-01-03	WOS:000189197300003
J	Goodacre, S; Nicholl, J; Dixon, S; Cross, E; Angelini, K; Arnold, J; Revill, S; Locker, T; Capewell, SJ; Quinney, D; Campbell, S; Morris, F				Goodacre, S; Nicholl, J; Dixon, S; Cross, E; Angelini, K; Arnold, J; Revill, S; Locker, T; Capewell, SJ; Quinney, D; Campbell, S; Morris, F			Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care	BRITISH MEDICAL JOURNAL			English	Article							CARDIAC TROPONIN-T; EMERGENCY-DEPARTMENT; MYOCARDIAL-INFARCTION; CLINICAL-TRIAL; ISCHEMIA; PROTOCOL	Objectives To measure the effectiveness and cost effectiveness of providing care in a chest pain observation unit compared with routine care for patients with acute, undifferentiated chest pain. Design Cluster randomised controlled trial, with 442 days randomised to the chest pain observation unit or routine care, and cost effectiveness analysis from a health service costing perspective. Setting The emergency department at the Northern General Hospital, Sheffield, United Kingdom. Participants 972 patients with acute, undifferentiated chest pain (479 attending on days when care was delivered in the chest pain observation unit, 493 on days of routine care) followed up until six months after initial attendance. Main outcome measures The proportion of participants admitted to hospital, the proportion with acute coronary syndrome sent home inappropriately, major adverse cardiac events over six months, health utility, hospital reattendance and readmission, and costs per patient to the health service. Results Use of a chest pain observation unit reduced the proportion of patients admitted from 54% to 37% (difference 17%, odds ratio 0.50, 95% confidence interval 0.39 to 0.65, P < 0.001) and the proportion discharged with acute coronary syndrome from 14% to 6% (8%, -7% to 23%, P = 0.264). Rates of cardiac event were unchanged. Care in the chest pain observation unit was associated with improved health utility during follow up (0.0137 quality adjusted life years gained, 95% confidence interval 0.0030 to 0.0254, P = 0.022) and a saving of 178 per patient (-&POUND;56 to &POUND;210, P = 0.252). Conclusions Care in a chest pain observation unit can improve outcomes and may reduce costs to the health service. It seems to be more effective and more cost effective than routine care.	Univ Sheffield, Sch Hlth Related Res, Med Care Res Unit, Sheffield S1 4DA, S Yorkshire, England; No Gen Hosp, Med Care Res Unit, Dept Emergency, Sheffield S5 7AU, S Yorkshire, England; No Gen Hosp, Dept Cardiol, Sheffield S5 7AU, S Yorkshire, England; Univ Liverpool, Dept Publ Hlth, Liverpool L69 3GB, Merseyside, England	University of Sheffield; Northern General Hospital; University of Sheffield; Northern General Hospital; University of Liverpool	Goodacre, S (corresponding author), Univ Sheffield, Sch Hlth Related Res, Med Care Res Unit, Sheffield S1 4DA, S Yorkshire, England.	s.goodacre@sheffield.ac.uk	Nicholl, Jon/B-8257-2008	Goodacre, Steve/0000-0003-0803-8444; Dixon, Simon/0000-0001-7394-7009; Locker, Thomas/0000-0002-7960-0572				Briggs A, 1998, HEALTH ECON, V7, P723, DOI 10.1002/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.3.CO;2-F; Capewell S, 2000, BRIT MED J, V320, P951, DOI 10.1136/bmj.320.7240.951; Clancy M, 2002, BRIT MED J, V325, P116, DOI 10.1136/bmj.325.7356.116; Collinson PO, 2000, BRIT MED J, V320, P1702, DOI 10.1136/bmj.320.7251.1702; *DEP HLTH, 2002, NAT SCHED REF COSTS; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Farkouh ME, 1998, NEW ENGL J MED, V339, P1882, DOI 10.1056/NEJM199812243392603; Fesmire FM, 1998, AM HEART J, V136, P237, DOI 10.1053/hj.1998.v136.89571; Fesmire FM, 1998, ANN EMERG MED, V31, P3, DOI 10.1016/S0196-0644(98)70274-4; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; Gomez MA, 1996, J AM COLL CARDIOL, V28, P25, DOI 10.1016/0735-1097(96)00093-9; GOODACRE S, 2003, BR J CARDIOL, V10, P50; Goodacre SW, 2000, J ACCID EMERG MED, V17, P1; Goodacre SW, 2002, EMERG MED J, V19, P117, DOI 10.1136/emj.19.2.117; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; HANIM CW, 1997, NEW ENGL J MED, V337, P1648; Kirk JD, 1998, ANN EMERG MED, V32, P1, DOI 10.1016/S0196-0644(98)70091-5; Lindahl B, 1998, EUR HEART J, V19, pN51; Netten A., 2001, UNIT COSTS HLTH SOCI; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Panju AA, 1998, JAMA-J AM MED ASSOC, V280, P1256, DOI 10.1001/jama.280.14.1256; Pope JH, 2000, NEW ENGL J MED, V342, P1163, DOI 10.1056/NEJM200004203421603; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; Raftery J, 2001, BRIT MED J, V323, P1300, DOI 10.1136/bmj.323.7324.1300; Roberts RR, 1997, JAMA-J AM MED ASSOC, V278, P1670, DOI 10.1001/jama.278.20.1670	25	183	188	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 31	2004	328	7434					254	257		10.1136/bmj.37956.664236.EE	http://dx.doi.org/10.1136/bmj.37956.664236.EE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771LC	14724129	Green Accepted, Green Published, Bronze, Green Submitted			2023-01-03	WOS:000188786000016
J	Wenzel, V; Krismer, AC; Arntz, HR; Sitter, H; Stadlbauer, KH; Lindner, KH; Chamberlain, DA; Dick, WF; Bossaert, LL; Bruyneel, P; Sitter, H; Prunte, H; Wenzel, V; Krismer, AC; Stadlbauer, KH; Mayr, VD; Lienhart, HG; Arntz, HR; Breckwoldt, J; Baubin, MA; Voelckel, W; Menges, MM; Jenner, A; Prause, G; Kainz, J; Messelken, M; Roper, A; Bertschat, FL; Burkle, G; Koberne, F; Bandemer, G; Callies, A; Schmitz, B; Schuttler, J; Wilde, T; Ellinger, K; Burfeind, S; Genzwurker, HV; Koppenberg, J; Ebmeyer, U; Dirks, B; Lehle, B; Ummenhofer, W; Albrecht, R; Trimmel, H; Gaberszig, N; Beneker, J; Schlechtriemen, T; Altemeyer, KH; Wauer, H; Geyer, T; Kleinschmidt, S; Wilhelm, W; Lauber, P; Cartarius, R; Bottiger, BW; Bujard, M; Switalski, J; Hemicker, G; Lenz, R; Koster, J; Hahne, FU; Edelhoff, G; Besmer, I; Tietze-Schnur, P; Fischer, L; Poppelbaum, D				Wenzel, V; Krismer, AC; Arntz, HR; Sitter, H; Stadlbauer, KH; Lindner, KH; Chamberlain, DA; Dick, WF; Bossaert, LL; Bruyneel, P; Sitter, H; Prunte, H; Wenzel, V; Krismer, AC; Stadlbauer, KH; Mayr, VD; Lienhart, HG; Arntz, HR; Breckwoldt, J; Baubin, MA; Voelckel, W; Menges, MM; Jenner, A; Prause, G; Kainz, J; Messelken, M; Roper, A; Bertschat, FL; Burkle, G; Koberne, F; Bandemer, G; Callies, A; Schmitz, B; Schuttler, J; Wilde, T; Ellinger, K; Burfeind, S; Genzwurker, HV; Koppenberg, J; Ebmeyer, U; Dirks, B; Lehle, B; Ummenhofer, W; Albrecht, R; Trimmel, H; Gaberszig, N; Beneker, J; Schlechtriemen, T; Altemeyer, KH; Wauer, H; Geyer, T; Kleinschmidt, S; Wilhelm, W; Lauber, P; Cartarius, R; Bottiger, BW; Bujard, M; Switalski, J; Hemicker, G; Lenz, R; Koster, J; Hahne, FU; Edelhoff, G; Besmer, I; Tietze-Schnur, P; Fischer, L; Poppelbaum, D		European Resuscitation Council Vas	A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	76th Annual Scientific Session of the American-Heart-Association	NOV 07-12, 2003	ORLANDO, FL	Amer Heart Assoc			CORONARY PERFUSION-PRESSURE; PROLONGED CARDIAC-ARREST; ORGAN BLOOD-FLOW	Background: Vasopressin is an alternative to epinephrine for vasopressor therapy during cardiopulmonary resuscitation, but clinical experience with this treatment has been limited. Methods: We randomly assigned adults who had had an out-of-hospital cardiac arrest to receive two injections of either 40 IU of vasopressin or 1 mg of epinephrine, followed by additional treatment with epinephrine if needed. The primary end point was survival to hospital admission, and the secondary end point was survival to hospital discharge. Results: A total of 1219 patients underwent randomization; 33 were excluded because of missing study-drug codes. Among the remaining 1186 patients, 589 were assigned to receive vasopressin and 597 to receive epinephrine. The two treatment groups had similar clinical profiles. There were no significant differences in the rates of hospital admission between the vasopressin group and the epinephrine group either among patients with ventricular fibrillation (46.2 percent vs. 43.0 percent, P=0.48) or among those with pulseless electrical activity (33.7 percent vs. 30.5 percent, P=0.65). Among patients with asystole, however, vasopressin use was associated with significantly higher rates of hospital admission (29.0 percent, vs. 20.3 percent in the epinephrine group; P=0.02) and hospital discharge (4.7 percent vs. 1.5 percent, P=0.04). Among 732 patients in whom spontaneous circulation was not restored with the two injections of the study drug, additional treatment with epinephrine resulted in significant improvement in the rates of survival to hospital admission and hospital discharge in the vasopressin group, but not in the epinephrine group (hospital admission rate, 25.7 percent vs. 16.4 percent; P=0.002; hospital discharge rate, 6.2 percent vs. 1.7 percent; P=0.002). Cerebral performance was similar in the two groups. Conclusions: The effects of vasopressin were similar to those of epinephrine in the management of ventricular fibrillation and pulseless electrical activity, but vasopressin was superior to epinephrine in patients with asystole. Vasopressin followed by epinephrine may be more effective than epinephrine alone in the treatment of refractory cardiac arrest.	Univ Innsbruck, Dept Anesthesiol & Crit Care Med, A-6020 Innsbruck, Austria; Free Univ Berlin, Benjamin Franklin Med Ctr, Dept Med, Div Cardiol Pulmonol, D-1000 Berlin, Germany; Univ Marburg, Inst Theoret Surg, Marburg, Germany	University of Innsbruck; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Philipps University Marburg	Lindner, KH (corresponding author), Univ Innsbruck, Dept Anesthesiol & Crit Care Med, Anichstr 35, A-6020 Innsbruck, Austria.	volker.wenzel@uibk.ac.at						Babar SI, 1999, RESUSCITATION, V41, P185, DOI 10.1016/S0300-9572(99)00071-4; BERG RA, 1994, CRIT CARE MED, V22, P282, DOI 10.1097/00003246-199402000-00020; Bottiger BW, 2001, LANCET, V357, P1583, DOI 10.1016/S0140-6736(00)04726-7; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; FOX AW, 1992, J CARDIOVASC PHARM, V20, P282, DOI 10.1097/00005344-199208000-00014; Gottlieb R., 1896, ARCH EXPT PATHOLOGIE, V38, P99; GRMEC S, 2002, CRIT CARE S1, V6, pP162; Hallstrom A, 2000, NEW ENGL J MED, V342, P1546, DOI 10.1056/NEJM200005253422101; Holzer M, 2002, NEW ENGL J MED, V346, P549; Human Milk Banking Association of North America, 1995, GUID GOOD CLIN PRACT, P1; *INT CONS SCI, 2000, CIRCULATION S1, V102, P1; KELSEY SF, 1991, CONTROL CLIN TRIALS, V12, P525; Kudenchuk PJ, 1999, NEW ENGL J MED, V341, P871, DOI 10.1056/NEJM199909163411203; LINDNER KH, 1992, ANESTHESIOLOGY, V77, P662, DOI 10.1097/00000542-199210000-00008; LINDNER KH, 1995, CIRCULATION, V91, P215, DOI 10.1161/01.CIR.91.1.215; Lindner KH, 1997, LANCET, V349, P535, DOI 10.1016/S0140-6736(97)80087-6; Lindner KH, 1996, ANN INTERN MED, V124, P1061, DOI 10.7326/0003-4819-124-12-199606150-00006; Mayr VD, 2001, CIRCULATION, V104, P1651, DOI 10.1161/hc3901.095896; Morris DC, 1997, ACAD EMERG MED, V4, P878, DOI 10.1111/j.1553-2712.1997.tb03813.x; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; Paradis Norman A., 2002, Cardiology Clinics, V20, P61; Prengel AW, 1996, STROKE, V27, P1241, DOI 10.1161/01.STR.27.7.1241; Schneider T, 2000, CIRCULATION, V102, P1780; Stiell IG, 2001, LANCET, V358, P105, DOI 10.1016/S0140-6736(01)05328-4; Wenzel V, 2000, J AM COLL CARDIOL, V35, P527, DOI 10.1016/S0735-1097(99)00562-8; Wenzel V, 1999, CRIT CARE MED, V27, P486, DOI 10.1097/00003246-199903000-00022; Wenzel V, 1999, CIRCULATION, V99, P1379, DOI 10.1161/01.CIR.99.10.1379; 2000, CIRCULATION S1, V102, P1	29	407	427	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2004	350	2					105	113		10.1056/NEJMoa025431	http://dx.doi.org/10.1056/NEJMoa025431			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	760WP	14711909				2023-01-03	WOS:000187858500004
J	Meyers, CD; Carr, MC; Park, S; Brunzell, JD				Meyers, CD; Carr, MC; Park, S; Brunzell, JD			Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia	ANNALS OF INTERNAL MEDICINE			English	Article							SUSTAINED-RELEASE NIACIN; FULMINANT HEPATIC-FAILURE; CORONARY-ARTERY-DISEASE; LIPOPROTEIN LP(A); SERUM-CHOLESTEROL; MESO-INOSITOL; EFFICACY; SAFETY; THERAPY; NIASPAN	Background: Nicotinic acid is an effective treatment for dyslipidemia, but the content of over-the-counter niacin is not federally regulated. As a result, patients may use preparations of over-the-counter niacin that do not contain free nicotinic acid. Objective: To characterize the types, costs, and free nicotinic acid content of over-the-counter niacin preparations and to review literature on the use of over-the-counter niacin for dyslipidemia. Data Sources: Commonly used over-the-counter niacin preparations (500-mg tablets or capsules) from the 3 categories of immediate-release, sustained-release, and no-flush were purchased at health food stores and pharmacies and from Internet-based vitamin companies. Pertinent literature on the use of over-the-counter niacin was obtained by. searching PubMed. Measurements: For each preparation studied, the monthly cost of therapy (at 2000 mg/d) and the free nicotinic acid content (quantified by high-performance liquid chromatography) were reported. Data Synthesis: On average, immediate-release niacin preparations cost $7.10 per month, sustained-release preparations cost $9.75 per month, and no-flush preparations cost $21.70 per month. The average content of free nicotinic acid was 520.4 mg for immediate-release niacin, 502.6 mg for sustained-release niacin, and 0 for no-flush niacin. Conclusions: No-flush preparations of over-the-counter niacin contain no free nicotinic acid and should not be used to treat dyslipidemia. Over-the-counter sustained-release niacin contains free nicotinic acid, but some brands are hepatotoxic. Immediate-release niacin contains free nicotinic acid and is the least expensive form of over-the-counter niacin.	Univ Washington, Sch Med, Seattle, WA USA	University of Washington; University of Washington Seattle	Meyers, CD (corresponding author), Vet Affairs Med Ctr, 5901 E 7th St 11-111I, Long Beach, CA 90822 USA.	daniel.meyers@med.va.gov			NCRR NIH HHS [K23 RR16067] Funding Source: Medline; NHLBI NIH HHS [HL30086] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR016067] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABOUELENEIN AM, 1983, NUTR REP INT, V28, P899; AGUSTI R, 1978, REV INVEST CLIN, V30, P327; ALDERMAN JD, 1989, AM J CARDIOL, V64, P725, DOI 10.1016/0002-9149(89)90754-6; ALTSCHUL R, 1955, ARCH BIOCHEM BIOPHYS, V54, P558, DOI 10.1016/0003-9861(55)90070-9; Altschul R, 1964, NIACIN VASCULAR DISO; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; Aronov DM, 1996, ARCH FAM MED, V5, P567, DOI 10.1001/archfami.5.10.567; Azen SP, 1996, CIRCULATION, V93, P34, DOI 10.1161/01.CIR.93.1.34; Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; Capuzzi D M, 2000, Curr Atheroscler Rep, V2, P64, DOI 10.1007/s11883-000-0096-y; Capuzzi DM, 1998, AM J CARDIOL, V82, p74U, DOI 10.1016/S0002-9149(98)00731-0; CARLSON LA, 1989, J INTERN MED, V226, P271, DOI 10.1111/j.1365-2796.1989.tb01393.x; CARLSON LA, 1968, ACTA MED SCAND, V183, P423; Chojnowska-Jezierska J, 1998, INT J CLIN PHARM TH, V36, P326; Cohn G, 2001, Curr Cardiol Rep, V3, P416; DALTON TA, 1992, AM J MED, V93, P102, DOI 10.1016/0002-9343(92)90689-9; Elam MB, 2000, JAMA-J AM MED ASSOC, V284, P1263, DOI 10.1001/jama.284.10.1263; ETCHASON JA, 1991, MAYO CLIN PROC, V66, P23, DOI 10.1016/S0025-6196(12)61171-9; FISCHER DJ, 1991, WESTERN J MED, V155, P410; GAUT ZN, 1971, METABOLISM, V20, P1031, DOI 10.1016/0026-0495(71)90026-6; GIBBONS LW, 1995, AM J MED, V99, P378, DOI 10.1016/S0002-9343(99)80185-5; GRAY DR, 1994, ANN INTERN MED, V121, P252, DOI 10.7326/0003-4819-121-4-199408150-00003; Grundy SM, 2002, ARCH INTERN MED, V162, P1568, DOI 10.1001/archinte.162.14.1568; GURAKAR A, 1985, ATHEROSCLEROSIS, V57, P293, DOI 10.1016/0021-9150(85)90041-3; HARTHON J G, 1964, Arzneimittelforschung, V14, P1170; HARTHON L, 1979, ARZNEIMITTEL-FORSCH, V29-2, P1859; HENKIN Y, 1991, AM J MED, V91, P239, DOI 10.1016/0002-9343(91)90122-E; *I MED US STAND CO, 2000, PAN FOL OTH B VIT CH; KAHN SE, 1989, DIABETES, V38, P562, DOI 10.2337/diabetes.38.5.562; KEENAN JM, 1991, ARCH INTERN MED, V151, P1424, DOI 10.1001/archinte.151.7.1424; Knopp RH, 1998, METABOLISM, V47, P1097, DOI 10.1016/S0026-0495(98)90284-0; KNOPP RH, 1985, METABOLISM, V34, P642, DOI 10.1016/0026-0495(85)90092-7; KRUSE W, 1979, EUR J CLIN PHARMACOL, V16, P11, DOI 10.1007/BF00644960; MCKENNEY JM, 1994, JAMA-J AM MED ASSOC, V271, P672, DOI 10.1001/jama.271.9.672; MIYAUCHI Y, 1993, INT J VITAM NUTR RES, V63, P145; MULLIN GE, 1989, ANN INTERN MED, V111, P253, DOI 10.7326/0003-4819-111-3-253; PARSONS WB, 1961, ARCH INTERN MED, V107, P653, DOI 10.1001/archinte.1961.03620050019003; RADER JI, 1992, AM J MED, V92, P77, DOI 10.1016/0002-9343(92)90018-7; SHEPHERD J, 1979, J CLIN INVEST, V63, P858, DOI 10.1172/JCI109385; SIFTON DW, 2002, DRUG TOPICS RED BOOK; SOMMER H, 1965, ARZNEI-FORSCHUNG, V15, P1337; Spies TD, 1938, J AMER MED ASSOC, V110, P622, DOI 10.1001/jama.1938.02790090004002; SVEDMYR N, 1969, CLIN PHARMACOL THER, V10, P559; WAHLBERG G, 1990, J INTERN MED, V228, P151, DOI 10.1111/j.1365-2796.1990.tb00209.x; Ziliotto G R, 1977, Arch Sci Med (Torino), V134, P359; 1998, ALTERN MED REV, V3, P222	48	46	54	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 16	2003	139	12					996	1002		10.7326/0003-4819-139-12-200312160-00009	http://dx.doi.org/10.7326/0003-4819-139-12-200312160-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	756AG	14678919				2023-01-03	WOS:000187443200005
J	Carrizo, ME; Capaldi, S; Perduca, M; Irazoqui, FJ; Nores, GA; Monaco, HL				Carrizo, ME; Capaldi, S; Perduca, M; Irazoqui, FJ; Nores, GA; Monaco, HL			The antineoplastic lectin of the common edible mushroom (Agaricus bisporus) has two binding sites, each specific for a different configuration at a single epimeric hydroxyl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THOMSEN-FRIEDENREICH-ANTIGEN; XEROCOMUS-CHRYSENTERON LECTIN; MACLURA-POMIFERA AGGLUTININ; NUCLEAR-PROTEIN IMPORT; SALINE-SOLUBLE LECTIN; CRYSTAL-STRUCTURE; CARBOHYDRATE-RECOGNITION; CELL-PROLIFERATION; PEANUT AGGLUTININ; PARASITIC FUNGUS	The lectin from the common mushroom Agaricus bisporus, the most popular edible species in Western countries, has potent antiproliferative effects on human epithelial cancer cells, without any apparent cytotoxicity. This property confers to it an important therapeutic potential as an antineoplastic agent. The three-dimensional structure of the lectin was determined by x-ray diffraction. The protein is a tetramer with 222 symmetry, and each monomer presents a novel fold with two beta sheets connected by a helix-loop-helix motif. Selectivity was studied by examining the binding of four monosaccharides and seven disaccharides in two different crystal forms. The T-antigen disaccharide, Gal beta 1-3GalNAc, mediator of the antiproliferative effects of the protein, binds at a shallow depression on the surface of the molecule. The binding of N-acetylgalactosamine overlaps with that moiety of the T antigen, but surprisingly, N-acetylglucosamine, which differs from N-acetylgalactosamine only in the configuration of epimeric hydroxyl 4, binds at a totally different site on the opposite side of the helix-loop-helix motif. The lectin thus has two distinct binding sites per monomer that recognize the different configuration of a single epimeric hydroxyl. The structure of the protein and its two carbohydrate-binding sites are described in detail in this study.	Univ Verona, Dept Sci & Technol, Biocrystallog Lab, I-37134 Verona, Italy; Univ Nacl Cordoba, Fac Chem Sci, Dept Biol Chem, RA-5000 Cordoba, Argentina	University of Verona; National University of Cordoba	Monaco, HL (corresponding author), Univ Verona, Dept Sci & Technol, Biocrystallog Lab, Strada Grazie 15, I-37134 Verona, Italy.	monaco@sci.univr.it	Perduca, Massimiliano/AAS-2666-2020	Perduca, Massimiliano/0000-0001-8291-0523; capaldi, stefano/0000-0003-4632-8100; Carrizo, Maria Elena/0000-0003-0501-8894; Monaco, Hugo L./0000-0002-2067-0365				Adhikari P, 2001, J BIOL CHEM, V276, P40734, DOI 10.1074/jbc.M103040200; Athanasiadis A, 2001, STRUCTURE, V9, P341, DOI 10.1016/S0969-2126(01)00592-5; Babino A, 2003, FEBS LETT, V536, P106, DOI 10.1016/S0014-5793(03)00037-1; BANERJEE R, 1994, P NATL ACAD SCI USA, V91, P227, DOI 10.1073/pnas.91.1.227; BETAIL G, 1975, CR SOC BIOL, V169, P561; Birck C, 2004, J MOL BIOL, V344, P1409, DOI 10.1016/j.jmb.2004.10.007; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carrizo ME, 2004, ACTA CRYSTALLOGR D, V60, P718, DOI 10.1107/S0907444904001969; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; CRENSHAW RW, 1995, PLANT PHYSIOL, V107, P1465, DOI 10.1104/pp.107.4.1465; Holm L, 1999, NUCLEIC ACIDS RES, V27, P244, DOI 10.1093/nar/27.1.244; Hynes MJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-6-217; Irazoqui FJ, 1999, GLYCOBIOLOGY, V9, P59, DOI 10.1093/glycob/9.1.59; IRAZOQUI FJ, 1992, J IMMUNOL METHODS, V156, P199, DOI 10.1016/0022-1759(92)90026-P; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; Jeyaprakash AA, 2002, J MOL BIOL, V321, P637, DOI 10.1016/S0022-2836(02)00674-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee X, 1998, J BIOL CHEM, V273, P6312, DOI 10.1074/jbc.273.11.6312; LESLIE AGW, 1992, INT CCP4 ESRF AECMB, V26, P27; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; Loris R, 2002, BBA-GEN SUBJECTS, V1572, P198, DOI 10.1016/S0304-4165(02)00309-4; Loris R, 2000, J MOL BIOL, V301, P987, DOI 10.1006/jmbi.2000.4016; MAHANTA SK, 1992, BIOCHEM J, V284, P95, DOI 10.1042/bj2840095; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NORDBRINGHERTZ B, 1979, NATURE, V281, P477, DOI 10.1038/281477a0; Pearson WR, 1997, GENOMICS, V46, P24, DOI 10.1006/geno.1997.4995; Ponstingl H, 2000, PROTEINS, V41, P47; Rosen S, 1996, EUR J BIOCHEM, V238, P830, DOI 10.1111/j.1432-1033.1996.0830w.x; Rosen S, 1996, EUR J BIOCHEM, V238, P822, DOI 10.1111/j.1432-1033.1996.0822w.x; RYDER SD, 1992, JNCI-J NATL CANCER I, V84, P1410, DOI 10.1093/jnci/84.18.1410; Sacchettini JC, 2001, BIOCHEMISTRY-US, V40, P3009, DOI 10.1021/bi002544j; SAGE HJ, 1969, J BIOL CHEM, V244, P4713; Sankaranarayanan R, 1996, NAT STRUCT BIOL, V3, P596, DOI 10.1038/nsb0796-596; Sanner M. F., 1995, Proceedings of the Eleventh Annual Symposium on Computational Geometry, pC6; Saul FA, 2000, STRUCTURE, V8, P593, DOI 10.1016/S0969-2126(00)00142-8; SHELDRICK GM, 1991, P CCP4 STUDY WEEKEND, P23; Springer GF, 1997, J MOL MED, V75, P594, DOI 10.1007/s001090050144; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; SUEYOSHI S, 1985, BIOL CHEM H-S, V366, P213, DOI 10.1515/bchm3.1985.366.1.213; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Transue TR, 1997, NAT STRUCT BIOL, V4, P779, DOI 10.1038/nsb1097-779; Trigueros V, 2003, BBA-GEN SUBJECTS, V1621, P292, DOI 10.1016/S0304-4165(03)00098-9; Ueda H, 1999, J BIOCHEM-TOKYO, V126, P530, DOI 10.1093/oxfordjournals.jbchem.a022482; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; VandenAkker F, 1996, PROTEIN SCI, V5, P1184; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Walser PJ, 2004, STRUCTURE, V12, P689, DOI 10.1016/j.str.2004.03.002; Wu AM, 2003, BIOCHEM J, V371, P311, DOI 10.1042/BJ20021361; YOUNG NM, 1991, FEBS LETT, V282, P382, DOI 10.1016/0014-5793(91)80518-8; YOUNG NM, 1991, EUR J BIOCHEM, V196, P631, DOI 10.1111/j.1432-1033.1991.tb15859.x; Yu LG, 2000, EUR J BIOCHEM, V267, P2122, DOI 10.1046/j.1432-1327.2000.01230.x; Yu LG, 2002, J BIOL CHEM, V277, P24538, DOI 10.1074/jbc.M203550200; Yu LG, 1999, J BIOL CHEM, V274, P4890, DOI 10.1074/jbc.274.8.4890; Yu LG, 2001, J CELL PHYSIOL, V186, P282, DOI 10.1002/1097-4652(200102)186:2&lt;282::AID-JCP1028&gt;3.0.CO;2-2	58	79	82	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10614	10623		10.1074/jbc.M411989200	http://dx.doi.org/10.1074/jbc.M411989200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15596442	hybrid			2023-01-03	WOS:000227559600107
J	Mehta, SR; Yusuf, S; Diaz, R; Zhu, J; Pais, P; Xavier, D; Paolasso, E; Ahmed, R; Xie, CC; Kazmi, K; Tai, J; Orlandini, A; Pogue, J; Liu, LS				Mehta, SR; Yusuf, S; Diaz, R; Zhu, J; Pais, P; Xavier, D; Paolasso, E; Ahmed, R; Xie, CC; Kazmi, K; Tai, J; Orlandini, A; Pogue, J; Liu, LS		CREATE-ECLA Trial Grp Investigators	Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction - The CREATE-ECLA randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FATTY-ACIDS; ARRHYTHMIAS; ISCHEMIA; DEATH; RISK	Context Glucose-insulin-potassium (GlK) infusion is a widely applicable, low-cost therapy that has been postulated to improve mortality in patients with acute ST-segment elevation myocardial infarction (STEMI). Given the potential global importance of GIK infusion, a large, adequately powered randomized trial is required to determine the effect of GIK on mortality in patients with STEMI. Objective To determine the effect of high-dose GlK infusion on mortality in patients with STEMI. Design, Setting, and Participants Randomized controlled trial conducted in 470 centers worldwide among 20201 patients with STEMI who presented within 0 hours of symptom onset. The mean age of patients was 58.6 years, and evidence-based therapies were commonly used. Intervention Patients were randomly assigned to receive GIK intravenous Infusion for 24 hours plus usual care (n=10091) or to receive usual care alone (controls; n=10110). Main Outcome Measures Mortality, cardiac arrest, cardiogenic shock. and reinfarction at 30 days after randomization. Results At 30 days, 976 control patients (9.7%) and 1004 GIK infusion patients(10.0%) died (hazard ratio [HR], 1.03; 95% confidence interval [0), 0.95-1.13; P=.45). There were no significant differences in the rates of cardiac arrest (1.5% [151/10107) in control and 1.4% [139/10088] in GIK infusion; HR, 0.93; 95% Cl, 0.74-1.17; P=.51), cardiogenic shock (6.3% [640/10107] vs 6.6% [667/10088]; HR. 1.05; 95% Cl, 0.94-1.17] P=.38), or reinfarction (2.4% [246/10107] vs 2.3% (236/10088]; HR, 0.98; 95% Cl, 0.82-1.17; P=.81). The rates of heart failure at 7 days after randomization were also similar between the. groups (16.9% (1711/10107) vs 17.1% (1721/ 10088]; HR, 1.01; 95 % Cl, 0.95-1.08; P=.72). The lack of benefit of GIK infusion on mortality was consistent in prespecified subgroups, including in those with and without diabetes, in those presenting with and without heart failure, in those presenting early and later after symptom onset, and in those receiving and not receiving reperfusion therapy (thrombolysis or primary percutaneous coronary intervention). Conclusion In this large, international randomized trial, high-dose GIK infusion had a neutral effect on mortality, cardiac arrest, and cardiogenic shock in patients with acute STEMI.	McMaster Univ, Dept Med, Hamilton, ON L8L 2X2, Canada; Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada; Estudios Cardiol Latin Amer, Rosario, Santa Fe, Argentina; Chinese Hypertens League Inst, Cardiovasc Inst, Beijing, Peoples R China; Chinese Hypertens League Inst, Fu Wai Hosp, Beijing, Peoples R China; St Johns Med Coll, Natl Acad Hlth Sci, Bangalore, Karnataka, India; Aga Khan Univ, Karachi, Pakistan	McMaster University; McMaster University; Population Health Research Institute; Chinese Hypertension League; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Hypertension League; St. John's National Academy of Health Sciences; St. John's Medical College; Aga Khan University	Mehta, SR (corresponding author), McMaster Univ, Dept Med, 237 Barton St SE, Hamilton, ON L8L 2X2, Canada.	smehta@mcmaster.ca	Kalantri, Shriprakash/ABG-9318-2021; Reis, Gilmar/I-4500-2013; Paul, Sanjoy/F-8199-2010	Kalantri, Shriprakash/0000-0002-1633-1029; Joshi, Rajnish/0000-0002-4702-0522; Prabhakaran, Dorairaj/0000-0002-3172-834X; Piegas, Leopoldo/0000-0003-1021-817X; Li, Qifu/0000-0003-3904-410X; Gupta, Ruchika/0000-0003-0235-063X; Yusuf, Salim/0000-0003-4776-5601; Reis, Gilmar/0000-0002-4847-1034; Paul, Sanjoy/0000-0003-0848-7194				Antman E, 2002, LANCET, V360, P1189, DOI 10.1016/S0140-6736(02)11278-5; Apstein CS, 1997, CIRCULATION, V96, P1074, DOI 10.1161/01.CIR.96.4.1074; BROWN MJ, 1983, NEW ENGL J MED, V309, P1414, DOI 10.1056/NEJM198312083092303; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Cave AC, 2000, CIRCULATION, V101, P2090, DOI 10.1161/01.CIR.101.17.2090; Ceremuzynski L, 1999, CARDIOVASC DRUG THER, V13, P191, DOI 10.1023/A:1007787924085; COLLINS R, 1995, LANCET, V345, P669; Diaz R, 1998, CIRCULATION, V98, P2227, DOI 10.1161/01.CIR.98.21.2227; Eikelboom JW, 2001, JAMA-J AM MED ASSOC, V285, P444, DOI 10.1001/jama.285.4.444; FathOrdoubadi F, 1997, CIRCULATION, V96, P1152, DOI 10.1161/01.CIR.96.4.1152; HULTING J, 1981, ACTA MED SCAND, P109; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; NORDREHAUG JE, 1985, CIRCULATION, V71, P645, DOI 10.1161/01.CIR.71.4.645; OBEID AI, 1978, CIRC RES, V43, P601, DOI 10.1161/01.RES.43.4.601; OLIVER MF, 1968, LANCET, V1, P710; OLIVER MF, 1994, LANCET, V343, P155, DOI 10.1016/S0140-6736(94)90939-3; OPIE LH, 1977, LANCET, V2, P890; Pogue J, 1998, LANCET, V351, P47, DOI 10.1016/S0140-6736(97)08461-4; SODIPALLARES D, 1962, AM J CARDIOL, V9, P166, DOI 10.1016/0002-9149(62)90035-8; SOLOMON RJ, 1981, ACTA MED SCAND, P87; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; van der Horst ICC, 2003, J AM COLL CARDIOL, V42, P784, DOI 10.1016/S0735-1097(03)00830-1; Wahab NN, 2002, J AM COLL CARDIOL, V40, P1748, DOI 10.1016/S0735-1097(02)02483-X; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; Yusuf S, 2005, JAMA-J AM MED ASSOC, V293, P427; Yusuf S, 2004, AM HEART J, V148, P1068, DOI 10.1016/j.ahj.2004.08.033; YUSUF S, 1988, LANCET, V1, P1088	27	497	531	1	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2005	293	4					437	446						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890DW	15671428				2023-01-03	WOS:000226492900022
J	Phillips, T; Leeuwenburgh, C				Phillips, T; Leeuwenburgh, C			Muscle fiber-specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction	FASEB JOURNAL			English	Article						aging; muscle fiber type; life-extension; exercise	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SKELETAL-MUSCLE; TRANSCRIPTION FACTOR; MITOCHONDRIAL ABNORMALITIES; IKK-GAMMA; AGE; COMPLEX; MEN; ACTIVATION	Increased tumor necrosis factor-alpha (TNF-alpha) levels have been found with age and are connected to muscle atrophy and cell loss, yet the signaling events that occur in vivo are unknown. Calorie restriction (CR), a robust intervention shown to repeatedly evade the physiological declines associated with aging, has been reported to reduce TNF-alpha and may assist in understanding the mechanisms of muscle sarcopenia. The effects of age and CR on muscle mass, myocyte area, fiber number, myocyte TNF-alpha expression, plasma TNF-alpha levels, and specific elements linked with the TNF-alpha signaling cascade (TNF-R1, IKKgamma, IkappaBalpha, p65, NF-kappaB binding activity, FADD, caspase-8, and DNA fragmentation) were investigated in soleus ( predominately Type I fiber), and superficial vastus lateralis (SVL, predominately Type II fiber), of 6-month-old ad libitum fed (6AL), 26-month-old ad libitum fed (26AL), and 26-month-old calorie-restricted (26CR) male Fischer 344 rats ( CR = 40% restriction compared with ad libitum). Plasma TNF-alpha was increased with age, and the age-associated rise was attenuated with life-long CR. In soleus muscle, we reported a greater capacity to cultivate inflammatory signaling through the transcription factor NF-kappaB compared with that detected in SVL with age. In contrast, in the SVL TNF-alpha stimulated apoptotic signaling with age to a much higher extent than was observed in the soleus. Moreover, a reduction in muscle mass, cross-sectional area, and fiber number in the SVL coincided with this age-linked elevation in apoptosis. In agreement with CR's ability, TNF-alpha stimulation of both inflammatory and apoptotic pathways were abrogated. Our results suggest that TNF-alpha signals transmitted to specific fiber types determine the decision of selecting life or death signaling pathways and are linked to the extent of fiber loss experienced in the aging muscle. Such a specific potential may constitute a major proponent in the pathogenesis of sarcopenia.	Univ Florida, Biochem Aging Lab, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Leeuwenburgh, C (corresponding author), Univ Florida, Biochem Aging Lab, 25 FLG,POB 118206, Gainesville, FL 32611 USA.	cleeuwen@ufl.edu		Leeuwenburgh, Christiaan/0000-0003-0826-4257	NIA NIH HHS [R01-AG17994, AG21042] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG017994, R01AG021042] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALNAQEEB MA, 1987, J ANAT, V153, P31; Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Bartke A, 2001, J GERONTOL A-BIOL, V56, pB340, DOI 10.1093/gerona/56.8.B340; Baumgartner RN, 1999, MECH AGEING DEV, V107, P123, DOI 10.1016/S0047-6374(98)00130-4; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; Blough E, 1999, BIOTECHNIQUES, V26, P202, DOI 10.2144/99262bm05; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001; BUA EA, 2004, FASEB J; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chung HY, 2002, MICROSC RES TECHNIQ, V59, P264, DOI 10.1002/jemt.10203; Dalla Libera L, 1999, AM J PHYSIOL-CELL PH, V277, pC982, DOI 10.1152/ajpcell.1999.277.5.C982; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Dirks A, 2002, AM J PHYSIOL-REG I, V282, pR519, DOI 10.1152/ajpregu.00458.2001; Dirks AJ, 2004, FREE RADICAL BIO MED, V36, P27, DOI 10.1016/j.freeradbiomed.2003.10.003; Doherty TJ, 2003, J APPL PHYSIOL, V95, P1717, DOI 10.1152/japplphysiol.00347.2003; DOHERTY TJ, 1993, J APPL PHYSIOL, V74, P868, DOI 10.1152/jappl.1993.74.2.868; Dutta C, 1997, J NUTR, V127, pS992, DOI 10.1093/jn/127.5.992S; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Greiwe JS, 2001, FASEB J, V15, P475, DOI 10.1096/fj.00-0274com; Gupta S, 2002, J CLIN IMMUNOL, V22, P185, DOI 10.1023/A:1016089607548; Helenius M, 1996, BIOCHEM J, V318, P603, DOI 10.1042/bj3180603; HOLLOSZY JO, 1991, MECH AGEING DEV, V60, P199, DOI 10.1016/0047-6374(91)90131-I; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Janssen I, 2004, J AM GERIATR SOC, V52, P80, DOI 10.1111/j.1532-5415.2004.52014.x; Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898; Kim HJ, 2002, FREE RADICAL BIO MED, V32, P991, DOI 10.1016/S0891-5849(02)00798-0; Korhonen P, 1997, NEUROSCI LETT, V225, P61, DOI 10.1016/S0304-3940(97)00190-0; LARSSON L, 1995, PROG NEUROBIOL, V45, P397, DOI 10.1016/0301-0082(95)98601-Z; LARSSON L, 1978, ACTA PHYSIOL SCAND, V103, P31, DOI 10.1111/j.1748-1716.1978.tb06187.x; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; LEXELL J, 1995, J GERONTOL A-BIOL, V50, P11; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luff AR, 1998, ANN NY ACAD SCI, V854, P92, DOI 10.1111/j.1749-6632.1998.tb09895.x; MCKIERNAN S, 2004, FASEB J; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Morin CL, 1997, J GERONTOL A-BIOL, V52, pB190, DOI 10.1093/gerona/52A.4.B190; Morley JE, 2001, J LAB CLIN MED, V137, P231, DOI 10.1067/mlc.2001.113504; Nair K S, 2000, Mayo Clin Proc, V75 Suppl, pS14; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Paolisso G, 1998, AM J PHYSIOL-ENDOC M, V275, pE294, DOI 10.1152/ajpendo.1998.275.2.E294; Payne AM, 2003, J APPL PHYSIOL, V95, P2554, DOI 10.1152/japplphysiol.00758.2003; Reid MB, 2001, RESP RES, V2, P269, DOI 10.1186/rr67; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Roubenoff R, 2003, AM J MED, V115, P429, DOI 10.1016/j.amjmed.2003.05.001; Roubenoff R, 1998, J GERONTOL A-BIOL, V53, pM20, DOI 10.1093/gerona/53A.1.M20; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Spaulding CC, 1997, MECH AGEING DEV, V93, P87, DOI 10.1016/S0047-6374(96)01824-6; SPOONER CE, 1992, CLIN IMMUNOL IMMUNOP, V62, pS11, DOI 10.1016/0090-1229(92)90036-N; Suh Y, 2002, MECH AGEING DEV, V123, P881, DOI 10.1016/S0047-6374(02)00025-8; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Vescovo G, 1998, J MOL CELL CARDIOL, V30, P2449, DOI 10.1006/jmcc.1998.0807; World Medical Association, 2002, AM J PHYSIOL-REG I, V283, pR281, DOI DOI 10.1152/AJPREGU.00279.2002; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	60	213	224	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					668	+		10.1096/fj.04-2870fje	http://dx.doi.org/10.1096/fj.04-2870fje			33	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15665035				2023-01-03	WOS:000226576600014
J	Abdelgafar, B; Thorsteinsdottir, H; Quach, U; Singer, PA; Daar, AS				Abdelgafar, B; Thorsteinsdottir, H; Quach, U; Singer, PA; Daar, AS			The emergence of Egyptian biotechnology from generics	NATURE BIOTECHNOLOGY			English	Editorial Material									Amer Univ Cairo, Dept Management, Cairo 11511, Egypt; Univ Toronto, Joint Ctr Bioeth, Canadian Program Gen & Global Hlth, Toronto, ON M5G 1L4, Canada; Dept Publ Hlth Sci, Toronto, ON M5G 1L4, Canada; Univ Toronto, McLaughlin Ctr Mol Med, Toronto, ON, Canada	Egyptian Knowledge Bank (EKB); American University Cairo; University of Toronto; University of Toronto	Abdelgafar, B (corresponding author), Amer Univ Cairo, Dept Management, 113 Kasr El Aini St,POB 2511, Cairo 11511, Egypt.	halla.thorsteinsdottir@utoronto.ca						ELAWADY MK, 2003, BIOEXCHANGE     0114; ELJESRI M, 2004, EGYPT TODAY, V25, P87; ELNAHHAS M, 2002, AL AHRAM ONLINE 0822; GALAL EE, 1983, WORLD DEV, V11, P237, DOI 10.1016/0305-750X(83)90031-1; *MOSR, 1997, 28836 WB MOSR; *SCI METR, 2004, BENCHM GEN HLTH BIOT; *UNCTAD, 1999, INV POL REV EG; *WHO, 2000, ROL PAR ANT THER SPR; Zahlan A. B., 1997, SCI COMMUNITIES DEV, P81	9	4	4	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2004	22			S			DC25	DC30		10.1038/nbt1204supp-DC25	http://dx.doi.org/10.1038/nbt1204supp-DC25			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	879QF	15583680	hybrid			2023-01-03	WOS:000225731600006
J	Hansen, H				Hansen, H			Faith-based treatment for addiction in Puerto Rico	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Yale Univ, Sch Med, New Haven, CT 06510 USA	Yale University	Hansen, H (corresponding author), Yale Univ, Sch Med, New Haven, CT 06510 USA.				NIGMS NIH HHS [GM07205] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alegria M, 2001, INQUIRY-J HEALTH CAR, V38, P381, DOI 10.5034/inquiryjrnl_38.4.381; ALEGRIA M, 1998, DRUG ADDICTION RES H, P123; Brusco Elizabeth., 1995, REFORMATION MACHISMO; *CENTR INT AG, WORLD FACTB 2003; Cleary Edward L., 1997, POWER POLITICS PENTE; *COL U CASA NAT CT, SHOV IMP SUBST AB ST; *COL U NAT CTR ADD, SO HELP ME GOD SUBST; COLON H, 1998, HOUSEHOLD STUDY NEED; De la Rosa MR, 2001, J PSYCHOACTIVE DRUGS, V33, P233, DOI 10.1080/02791072.2001.10400570; GOODNOUGH A, 2003, NY TIMES        1228, P20; HOFFMAN F, 1994, INT J ADDICT, V29, P445, DOI 10.3109/10826089409047392; Martin D., 2001, PENTECOSTALISM WORLD; Melendez I., 1998, PUERTO RICO SUBSTANC; *NAT DRUG INT CTR, 2003, PUERT RIC US VIRG IS	14	8	9	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2004	291	23					2882	2882		10.1001/jama.291.23.2882	http://dx.doi.org/10.1001/jama.291.23.2882			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GT	15199043				2023-01-03	WOS:000221962500038
J	Peterson, S; Nsungwa-Sabiiti, J; Were, W; Nsabagasani, X; Magumba, G; Nambooze, J; Mukasa, G				Peterson, S; Nsungwa-Sabiiti, J; Were, W; Nsabagasani, X; Magumba, G; Nambooze, J; Mukasa, G			Coping with paediatric referral - Ugandan parents' experience	LANCET			English	Article							SEVERELY ILL CHILDREN; MANAGEMENT	Referral of severely ill children to hospital is key in the Integrated Management of Childhood Illness (IMCI). In rural Uganda, we documented the caretakers' ability to complete referral to hospital from 12 health facilities. Of 227 children, only 63 (28%) had completed referral after 2 weeks, at a median cost of US$8-85 (range 0.40-89.00). Failure to attend hospital resulted from lack of money (139 children, 90%), transport problems (39, 26%), and responsibilities at home (26, 17%). Children with incomplete referral continued treatment at referring health centres (87, 54%) or in the private sector (45, 28%). Our results show that cost of referral must decrease to make paediatric referral realistic. When referral is difficult, more specific IMCI referral criteria should be used and first-level health workers should be empowered to manage severely ill children.	Minist Hlth, Child Hlth Div, Kampala, Uganda; Rubaga Hosp, Kampala, Uganda; Makerere Univ, Makerere Inst Social Res, Kampala, Uganda; USAID, UPHOLD Program, Kampala, Uganda; Makerere Univ, Sch Med, Dept Paediat & Child Hlth, Kampala, Uganda	Makerere University; United States Agency for International Development (USAID); Makerere University	Peterson, S (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, S-17176 Stockholm, Sweden.	stefan.peterson@phs.ki.se		Peterson, Stefan/0000-0001-7203-3096				Font Fidel, 2002, BMC Int Health Hum Rights, V2, P4, DOI 10.1186/1472-698X-2-4; Gove S, 1997, B WORLD HEALTH ORGAN, V75, P119; Kalter HD, 2003, ACTA PAEDIATR, V92, P103; Macintyre K, 1999, SOC SCI MED, V49, P1473, DOI 10.1016/S0277-9536(99)00201-4; Simoes EAF, 2003, B WORLD HEALTH ORGAN, V81, P522	5	85	85	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	2004	363	9425					1955	1956		10.1016/S0140-6736(04)16411-8	http://dx.doi.org/10.1016/S0140-6736(04)16411-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GW	15194257				2023-01-03	WOS:000221962800011
J	Buchner, T; Berdel, WE; Hiddemann, W				Buchner, T; Berdel, WE; Hiddemann, W			Priming with granulocyte colony-stimulating factor - Relation to high-dose cytarabine in acute myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							CHEMOTHERAPY; REMISSION; TRIAL		Univ Munster, D-48129 Munster, Germany; Univ Munich, D-81377 Munich, Germany	University of Munster; University of Munich	Buchner, T (corresponding author), Univ Munster, D-48129 Munster, Germany.							Bloomfield CD, 1998, CANCER RES, V58, P4173; Buchner T, 2003, J CLIN ONCOL, V21, P4496, DOI 10.1200/JCO.2003.02.133; Burnett AK, 1998, LANCET, V351, P700, DOI 10.1016/S0140-6736(97)09214-3; Lowenberg B, 2003, NEW ENGL J MED, V349, P743, DOI 10.1056/NEJMoa025406	4	26	27	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	2004	350	21					2215	2216		10.1056/NEJM200405203502124	http://dx.doi.org/10.1056/NEJM200405203502124			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XM	15152074	Bronze			2023-01-03	WOS:000221496700040
J	Wilson, JF				Wilson, JF			Cheaper drugs in foreign markets increase the focus on domestic drug prices	ANNALS OF INTERNAL MEDICINE			English	News Item												jenwilson@acponline.org	Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136				CALFEE JE, 2003, HLTH POLICY OUTL NOV; DANZON PM, HLTH AFFAIRS; WAGNER JL, ANN REV PUBLIC HLTH	3	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	2004	140	8					677	680		10.7326/0003-4819-140-8-200404200-00044	http://dx.doi.org/10.7326/0003-4819-140-8-200404200-00044			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	812PP	15096358				2023-01-03	WOS:000220851700034
J	Fishman, JA; Dey, BR; Hasserjian, RP; Amrein, P; Harris, NL; Weinstein, H				Fishman, JA; Dey, BR; Hasserjian, RP; Amrein, P; Harris, NL; Weinstein, H			A man with acute myeloid leukemia and fever after chemotherapy - Acute myeloid leukemia with multilineage dysplasia after a myelodysplastic syndrome.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GRANULOCYTOPENIC CANCER-PATIENTS; NEUTROPENIC PATIENTS; ANTIBIOTIC-THERAPY		Massachusetts Gen Hosp, Div Infect Dis, Transplant Infect Dis & Compromised Host Program, Boston, MA 02114 USA; Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Div Hematol Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Fishman, JA (corresponding author), Massachusetts Gen Hosp, Div Infect Dis, Transplant Infect Dis & Compromised Host Program, Boston, MA 02114 USA.							Barton TD, 1996, CLIN INFECT DIS, V22, P1064, DOI 10.1093/clinids/22.6.1064; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; BRUNNING R, 2001, WHO CLASSIFICATION T, V3, P88; CALANDRA T, 1991, J INFECT DIS, V163, P951; CALANDRA T, 1991, J INFECT DIS, V164, P832; DONOWITZ GR, 1991, ARCH INTERN MED, V151, P701, DOI 10.1001/archinte.151.4.701; Hughes WT, 2002, CLIN INFECT DIS, V34, P730, DOI 10.1086/339215; KLASTERSKY J, 1988, EUR J CANCER CLIN ON, V24, pS35; Kocak U, 2002, SUPPORT CARE CANCER, V10, P58, DOI 10.1007/s005200100277; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; SCHIMPFF SC, 1986, AM J MED, V80, P13; Viscoli C, 1998, J ANTIMICROB CHEMOTH, V41, P65, DOI 10.1093/jac/41.suppl_4.65	12	0	0	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					1339	1347		10.1056/NEJMcpc030039	http://dx.doi.org/10.1056/NEJMcpc030039			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VN	15044646				2023-01-03	WOS:000220393900014
J	Rubin, HR; Fink, NE; Plantinga, LC; Sadler, JH; Kliger, AS; Powe, NR				Rubin, HR; Fink, NE; Plantinga, LC; Sadler, JH; Kliger, AS; Powe, NR			Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	33rd Annual Meeting American-Society-of-Nephrology	OCT 13-16, 2000	PHILADELPHIA, PENNSYLVANIA	Amer Soc Nephrol			STAGE RENAL-DISEASE; HEALTH SURVEY SF-36; MODALITY SELECTION; MORTALITY; OUTCOMES; QUALITY; QUESTIONNAIRE; NEPHROLOGISTS	Context In light of conflicting evidence of differential effects of dialysis modality on survival, patient experience becomes a more important consideration in choosing between hemodialysis and peritoneal dialysis. Objective To compare patient satisfaction with hemodialysis and peritoneal dialysis in a cohort of patients who have recently begun dialysis. Design and Setting Cross-sectional survey at enrollment in a prospective inception cohort study of patients who recently started dialysis at 37 dialysis centers participating in the Choices for Healthy Outcomes in Caring for End-stage Renal Disease (CHOICE) study, a national multicenter study of dialysis outcomes, from October 1995 to June 1998. Patients Of 736 enrolled incident dialysis patients, 656 (89%) returned a satisfaction questionnaire after an average of 7 weeks of dialysis. Main Outcome Measure Data collected from a patient-ad ministered questionnaire including 3 overall ratings and 20 items rating specific aspects of dialysis care. Results Patients receiving peritoneal dialysis were much more likely than those receiving hemodialysis to give excellent ratings of dialysis care overall (85% vs 56%, respectively; relative probability, 1.46 [95% confidence interval, 1.31-1.57]) and significantly more likely to give excellent ratings for each specific aspect of care rated. The 3 items with the greatest differences were in the domain of information provided (average of information items: peritoneal dialysis [69% excellent] vs hemodialysis [30% excellent]). The smallest differences were in ratings of accuracy of information from the nephrologist, response to pain, amount of fluid removed, and staff availability in an emergency. Adjustment for patient age, race, education, health status, marital status, employment status, distance from the center, and time since starting dialysis did not reduce the differences between peritoneal dialysis and hemodialysis patients. Conclusions After several weeks of initiating dialysis, patients receiving peritoneal dialysis rated their care higher than those receiving hemodialysis. These findings indicate that clinicians should give patients more information about the option of peritoneal dialysis.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Independent Dialysis Fdn, Baltimore, MD USA; Hosp St Raphael, Dept Med, New Haven, CT USA; Yale Univ, Dept Med, New Haven, CT 06520 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Hospital Saint Raphael; Yale University	Rubin, HR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 1830 E Monument St,Room 8015, Baltimore, MD 21205 USA.	hrubin@jhmi.edu	Kliger, Alan/AAN-6653-2021		AHRQ HHS [HS08365] Funding Source: Medline; NIDDK NIH HHS [DK59616, DK07024] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007024, R01DK059616] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Athienites NV, 2000, SEMIN DIALYSIS, V13, P320, DOI 10.1046/j.1525-139x.2000.00095.x; Collins AJ, 1999, AM J KIDNEY DIS, V34, P1065, DOI 10.1016/S0272-6386(99)70012-0; Cooper B S, 1997, Adv Ren Replace Ther, V4, P332; Eggers PW, 2002, AM J KIDNEY DIS, V39, P796, DOI 10.1053/ajkd.2002.32000; Golper T, 2001, NEPHROL DIAL TRANSPL, V16, P20, DOI 10.1093/ndt/16.suppl_7.20; Heaf JG, 2002, NEPHROL DIAL TRANSPL, V17, P112, DOI 10.1093/ndt/17.1.112; Hirth R A, 1997, Adv Ren Replace Ther, V4, P314; King K, 2000, ADV RENAL REPLACE TH, V7, P261, DOI 10.1053/jarr.2000.8123; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; *MED PAYM ADV COMM, 2001, REP C MED PAYM POL, P128; Mendelssohn DC, 2001, AM J KIDNEY DIS, V37, P22, DOI 10.1053/ajkd.2001.20573; Murphy SW, 2000, KIDNEY INT, V57, P1720, DOI 10.1046/j.1523-1755.2000.00017.x; Murray B P, 2000, Manag Care Interface, V13, P55; NELSON EC, 1990, MED CARE, V28, pS18, DOI 10.1097/00005650-199009001-00006; Powe NR, 1996, SEMIN DIALYSIS, V9, P9, DOI 10.1111/j.1525-139X.1996.tb00890.x; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; Rubin HR, 1997, AM J KIDNEY DIS, V30, P793, DOI 10.1016/S0272-6386(97)90084-6; Steinman TI, 1997, J AM SOC NEPHROL, V8, P1618; *US REN DAT SYST, 2002, USRDS 2002 ANN DAT R; Valderrabano F, 2001, NEPHROL DIAL TRANSPL, V16, P61, DOI 10.1093/ndt/16.suppl_7.61; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wu AW, 2001, AM J KIDNEY DIS, V37, P11, DOI 10.1053/ajkd.2001.20571; Wuerth DB, 2000, AM J KIDNEY DIS, V35, P638, DOI 10.1016/S0272-6386(00)70010-2; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; Zimmerman DL, 2003, NEPHROL DIAL TRANSPL, V18, P305, DOI 10.1093/ndt/18.2.305	25	219	223	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	2004	291	6					697	703		10.1001/jama.291.6.697	http://dx.doi.org/10.1001/jama.291.6.697			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AY	14871912	Bronze			2023-01-03	WOS:000188819200022
J	Rhoden, EL; Morgentaler, A				Rhoden, EL; Morgentaler, A			Medical progress - Risks of testosterone-replacement therapy and recommendations for monitoring	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROSTATE-SPECIFIC ANTIGEN; RANDOMIZED CONTROLLED-TRIAL; HORMONE-BINDING GLOBULIN; ESTROGEN PLUS PROGESTIN; SERUM-FREE TESTOSTERONE; CORONARY-HEART-DISEASE; HEALTHY OLDER MEN; HYPOGONADAL MEN; TRANSDERMAL TESTOSTERONE; AGING MALE		Beth Israel Deaconess Med Ctr, Div Urol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Morgentaler, A (corresponding author), 1 Brookline Pl,Suite 624, Brookline, MA 02445 USA.	amorgent@caregroup.harvard.edu						ANDERSON RA, 1995, THROMB HAEMOSTASIS, V74, P693; Bagatell CJ, 1996, NEW ENGL J MED, V334, P707, DOI 10.1056/NEJM199603143341107; BARRETTCONNOR EL, 1995, DIABETES METAB, V21, P156; Basaria S, 1999, DRUG AGING, V15, P131, DOI 10.2165/00002512-199915020-00006; Bhasin S, 2003, J ANDROL, V24, P299; Bhasin S, 1997, J CLIN ENDOCR METAB, V82, P3, DOI 10.1210/jc.82.1.3; Bhasin S, 2001, J ANDROL, V22, P718; CARRASCO D, 1985, J HEPATOL, V1, P573, DOI 10.1016/S0168-8278(85)80001-5; CARTER HB, 1995, PROSTATE, V27, P25, DOI 10.1002/pros.2990270106; CARTER HB, 1995, UROLOGY, V45, P591, DOI 10.1016/S0090-4295(99)80049-1; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; Carvalhal GF, 1999, J UROLOGY, V161, P835, DOI 10.1016/S0022-5347(01)61785-3; Cherrier MM, 2001, NEUROLOGY, V57, P80, DOI 10.1212/WNL.57.1.80; Comhaire FH, 2000, EUR UROL, V38, P655, DOI 10.1159/000020358; Curran MJ, 1999, UROLOGY, V53, P423, DOI 10.1016/S0090-4295(98)00348-3; Dobs AS, 1999, J CLIN ENDOCR METAB, V84, P3469, DOI 10.1210/jc.84.10.3469; *END SOC, 2001, 2 ANN ANDR CONS M CH; *END SOC, 2002, ENDOCR REP, V2, P1; English KM, 2000, CIRCULATION, V102, P1906, DOI 10.1161/01.CIR.102.16.1906; English KM, 2000, EUR HEART J, V21, P890, DOI 10.1053/euhj.1999.1873; Gann PH, 1996, J NATL CANCER I, V88, P1118, DOI 10.1093/jnci/88.16.1118; Gooren LJG, 1996, BRIT J UROL, V78, P763, DOI 10.1046/j.1464-410X.1996.05918.x; Gustafsson O, 1996, BRIT J UROL, V77, P433, DOI 10.1046/j.1464-410X.1996.89120.x; Gyllenborg J, 2001, METABOLISM, V50, P882, DOI 10.1053/meta.2001.24916; Hajjar RR, 1997, J CLIN ENDOCR METAB, V82, P3793, DOI 10.1210/jc.82.11.3793; Hak AE, 2002, J CLIN ENDOCR METAB, V87, P3632, DOI 10.1210/jc.87.8.3632; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; Heikkila R, 1999, CANCER, V86, P312, DOI 10.1002/(SICI)1097-0142(19990715)86:2<312::AID-CNCR15>3.3.CO;2-Z; Hoffman MA, 2000, J UROLOGY, V163, P824, DOI 10.1016/S0022-5347(05)67812-3; Hsing AW, 2001, EPIDEMIOL REV, V23, P42, DOI 10.1093/oxfordjournals.epirev.a000795; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; Kabakci G, 1999, CARDIOLOGY, V92, P221, DOI 10.1159/000006977; Kenny AM, 2001, J GERONTOL A-BIOL, V56, pM266, DOI 10.1093/gerona/56.5.M266; Kim YC, 1999, INT J IMPOT RES, V11, P343, DOI 10.1038/sj.ijir.3900446; Kouri EM, 1996, CLIN J SPORT MED, V6, P152, DOI 10.1097/00042752-199607000-00003; KRIEG M, 1993, J CLIN ENDOCR METAB, V77, P375, DOI 10.1210/jc.77.2.375; Krumholtz JS, 2002, UROLOGY, V60, P469, DOI 10.1016/S0090-4295(02)01875-7; Kunelius P, 2002, J CLIN ENDOCR METAB, V87, P1467, DOI 10.1210/jc.87.4.1467; Loughlin KR, 1997, J UROLOGY, V157, P1845, DOI 10.1016/S0022-5347(01)64881-X; Madersbacher S, 2002, UROLOGY, V60, P869, DOI 10.1016/S0090-4295(02)01893-9; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Marcelli M, 1999, J CLIN ENDOCR METAB, V84, P3463, DOI 10.1210/jc.84.10.3463; MATSUMOTO AM, 1985, CLIN ENDOCRINOL, V22, P713, DOI 10.1111/j.1365-2265.1985.tb00161.x; McNicholas TA, 2003, BJU INT, V91, P69, DOI 10.1046/j.1464-410X.2003.04016.x; Miller LR, 1998, J UROLOGY, V160, P449, DOI 10.1016/S0022-5347(01)62922-7; Moffat SD, 2002, J CLIN ENDOCR METAB, V87, P5001, DOI 10.1210/jc.2002-020419; Morgentaler A, 1996, JAMA-J AM MED ASSOC, V276, P1904, DOI 10.1001/jama.276.23.1904; Morley JE, 1997, METABOLISM, V46, P410, DOI 10.1016/S0026-0495(97)90057-3; Nieschlag E, 1998, J CLIN ENDOCRINOLOGY, V83, P3443; Pechersky AV, 2002, INT J ANDROL, V25, P119, DOI 10.1046/j.1365-2605.2002.00335.x; Punglia RS, 2003, NEW ENGL J MED, V349, P335, DOI 10.1056/NEJMoa021659; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SAKR WA, 1993, J UROLOGY, V150, P379, DOI 10.1016/S0022-5347(17)35487-3; SCHNEIDER BK, 1986, J APPL PHYSIOL, V61, P618, DOI 10.1152/jappl.1986.61.2.618; Schroder FH, 2003, NEW ENGL J MED, V349, P393, DOI 10.1056/NEJMe030073; Sih R, 1997, J CLIN ENDOCR METAB, V82, P1661, DOI 10.1210/jc.82.6.1661; Singh AB, 2002, J CLIN ENDOCR METAB, V87, P136, DOI 10.1210/jc.87.1.136; Slater S, 2000, DRUG AGING, V17, P431, DOI 10.2165/00002512-200017060-00001; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P1966, DOI 10.1210/jc.84.6.1966; Snyder PJ, 2001, AM J MED, V111, P255, DOI 10.1016/S0002-9343(01)00813-0; Snyder PJ, 2000, J CLIN ENDOCR METAB, V85, P2670, DOI 10.1210/jc.85.8.2670; Tangredi JF, 2001, ANN PHARMACOTHER, V35, P1205, DOI 10.1345/aph.1A020; Tenover JL, 1998, ENDOCRIN METAB CLIN, V27, P969, DOI 10.1016/S0889-8529(05)70050-5; Vermeulen A, 2001, J CLIN ENDOCR METAB, V86, P2380, DOI 10.1210/jc.86.6.2380; Viallard JF, 2000, BRIT J HAEMATOL, V110, P237, DOI 10.1046/j.1365-2141.2000.02072-3.x; Von Eckardstein S, 2002, J ANDROL, V23, P419; Wang C, 2000, J CLIN ENDOCR METAB, V85, P2839, DOI 10.1210/jc.85.8.2839; Webb CM, 1999, CIRCULATION, V100, P1690, DOI 10.1161/01.CIR.100.16.1690; WESTABY D, 1977, LANCET, V2, P261; Whitsel EA, 2001, AM J MED, V111, P261, DOI 10.1016/S0002-9343(01)00833-6; Zmuda JM, 1997, AM J EPIDEMIOL, V146, P609, DOI 10.1093/oxfordjournals.aje.a009326	71	495	517	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					482	492		10.1056/NEJMra022251	http://dx.doi.org/10.1056/NEJMra022251			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749457				2023-01-03	WOS:000188463900011
J	Rabow, MW; Hauser, JM; Adams, J				Rabow, MW; Hauser, JM; Adams, J			Supporting family Caregivers at the end of life - "They don't know what they don't know"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TERMINALLY-ILL PATIENTS; NURSING-HOME PLACEMENT; INTENSIVE-CARE UNIT; OF-LIFE; PALLIATIVE CARE; INFORMAL CAREGIVERS; ADVANCE DIRECTIVES; FUNCTIONAL DECLINE; ALZHEIMER-DISEASE; ELDERLY-PEOPLE	Even for patients receiving complex, intensive medical care for serious and life-threatening illness, family caregiving is typically at the core of what sustains patients at the end of life. The amorphous relationship between physicians and the families of patients at the end of life presents both challenges and opportunities for which physicians may be unprepared. Families play important roles in the practical and emotional aspects of patient care and in decision making at the end of life. At the same time, family members may carry significant burdens as a result of their work. Through the perspectives of the wife, daughter, and home care nurse of a patient who died from pancreatic cancer, we illustrate the range of family caregiver experiences and suggest potentially helpful physician interventions. We describe 5 burdens of family caregiving (time and logistics, physical tasks, financial costs, emotional burdens and mental health risks, and physical health risks) and review the responsibilities of physicians to family caregivers. Based on available evidence, we identify 5 areas of opportunity for physicians to be of service to family members caring for patients at the end of life, including promoting excellent communication with family, encouraging appropriate advance care planning and decision making, supporting home care, demonstrating empathy for family emotions and relationships, and attending to family grief and bereavement. In caring well for family caregivers at the end of life, physicians may not only improve the experiences of patients and family but also find greater sustenance and meaning in their own work.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Ctr Caregiver Training, San Francisco, CA USA; Northwestern Univ, Feinberg Sch Med, Dept Med,Buehler Ctr Aging, Palliat Care & Home Hospice Program, Chicago, IL 60611 USA	University of California System; University of California San Francisco; Northwestern University; Feinberg School of Medicine	Rabow, MW (corresponding author), Univ Calif San Francisco, Dept Med, 1701 Divisadero St,No 554, San Francisco, CA 94143 USA.	mrabow@medicine.ucsf.edu						ANDOLSEK KM, 1988, ARCH INTERN MED, V148, P2177, DOI 10.1001/archinte.148.10.2177; BASCOM PB, 1995, WESTERN J MED, V163, P292; BASS DM, 1991, GERONTOLOGIST, V31, P32, DOI 10.1093/geront/31.1.32; Bedell SE, 2001, NEW ENGL J MED, V344, P1162, DOI 10.1056/NEJM200104123441510; Benson J, 1996, BRIT MED J, V313, P729, DOI 10.1136/bmj.313.7059.729; Billings J A, 2001, J Palliat Med, V4, P361, DOI 10.1089/109662101753123986; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; Cameron JI, 2002, CANCER-AM CANCER SOC, V94, P521, DOI 10.1002/cncr.10212; Cannuscio CC, 2002, AM J PUBLIC HEALTH, V92, P1305, DOI 10.2105/AJPH.92.8.1305; Chochinov HM, 2002, JAMA-J AM MED ASSOC, V287, P2253, DOI 10.1001/jama.287.17.2253; Christakis NA, 2003, SOC SCI MED, V57, P465, DOI 10.1016/S0277-9536(02)00370-2; Cochrane JJ, 1997, AM J PUBLIC HEALTH, V87, P2002, DOI 10.2105/AJPH.87.12.2002; COLLINS C, 1994, J AM GERIATR SOC, V42, P719, DOI 10.1111/j.1532-5415.1994.tb06530.x; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Covinsky KE, 1996, ARCH INTERN MED, V156, P1737, DOI 10.1001/archinte.156.15.1737; Covinsky KE, 2001, J GERONTOL A-BIOL, V56, pM707, DOI 10.1093/gerona/56.11.M707; Crawley LM, 2002, ANN INTERN MED, V136, P673, DOI 10.7326/0003-4819-136-9-200205070-00010; Curtis JR, 2001, CRIT CARE MED, V29, pN26, DOI 10.1097/00003246-200102001-00006; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; Desbiens NA, 2001, J GERONTOL A-BIOL, V56, pM231, DOI 10.1093/gerona/56.4.M231; Donelan K, 2002, HEALTH AFFAIR, V21, P222, DOI 10.1377/hlthaff.21.4.222; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V284, P2460, DOI 10.1001/jama.284.19.2460; EMANUEL LL, 1995, J AM COLL CARDIOL, V25, P35, DOI 10.1016/0735-1097(94)00339-R; Falk S, 1997, BRIT MED J, V315, P1525, DOI 10.1136/bmj.315.7121.1525; Ferrell B R, 1999, Oncol Nurs Forum, V26, P1655; Field MJ, 1997, APPROACHING DEATH IM; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; Fried TR, 2003, ARCH INTERN MED, V163, P2073, DOI 10.1001/archinte.163.17.2073; Ganzini L, 2002, NEW ENGL J MED, V347, P582, DOI 10.1056/NEJMsa020562; Goldman L, 2001, AM J MED, V111, P36, DOI 10.1016/S0002-9343(01)00968-8; Haley W E, 2001, Hosp J, V15, P1, DOI 10.1300/J011v15n04_01; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; HARE J, 1992, ARCH INTERN MED, V152, P1049, DOI 10.1001/archinte.152.5.1049; Hayman JA, 2001, J CLIN ONCOL, V19, P3219, DOI 10.1200/JCO.2001.19.13.3219; Hebert R, 2003, J GERONTOL B-PSYCHOL, V58, pS58, DOI 10.1093/geronb/58.1.S58; Hickenbottom SL, 2002, NEUROLOGY, V58, P1754, DOI 10.1212/WNL.58.12.1754; Horowitz MJ, 1997, AM J PSYCHIAT, V154, P904; Hurley AC, 2002, JAMA-J AM MED ASSOC, V288, P2324, DOI 10.1001/jama.288.18.2324; Kagawa-Singer M, 2001, JAMA-J AM MED ASSOC, V286, P2993, DOI 10.1001/jama.286.23.2993; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; Karlawish JHT, 2001, J AM GERIATR SOC, V49, P1066, DOI 10.1046/j.1532-5415.2001.49210.x; Langa KM, 2002, J GERONTOL B-PSYCHOL, V57, pS177, DOI 10.1093/geronb/57.3.S177; Langa KM, 2001, J GEN INTERN MED, V16, P770, DOI 10.1111/j.1525-1497.2001.10123.x; LAWTON MP, 1989, GERONTOLOGIST, V29, P8, DOI 10.1093/geront/29.1.8; Levine C, 1999, ANN INTERN MED, V130, P148, DOI 10.7326/0003-4819-130-2-199901190-00010; Lilly CM, 2000, AM J MED, V109, P469, DOI 10.1016/S0002-9343(00)00524-6; LOEB JM, 1993, JAMA-J AM MED ASSOC, V269, P1282; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Lynn J, 2003, ANN INTERN MED, V138, P812, DOI 10.7326/0003-4819-138-10-200305200-00009; Main J, 2000, BRIT J GEN PRACT, V50, P863; Mant J, 2000, LANCET, V356, P808, DOI 10.1016/S0140-6736(00)02655-6; MARMAR CR, 1988, AM J PSYCHIAT, V145, P203; Matter CA, 2003, ACAD MED, V78, P793, DOI 10.1097/00001888-200308000-00009; McCallion P, 1999, J AM GERIATR SOC, V47, P203, DOI 10.1111/j.1532-5415.1999.tb04579.x; McConnell S, 1999, GENERATIONS, V23, P69; MetLife Mature Market Institute National Alliance for Caregiving & The National Center on Women and Aging, 1999, METL JUGGL ACT STUD; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; MORGAN DL, 1989, GERONTOLOGIST, V29, P101, DOI 10.1093/geront/29.1.101; MORRIS BA, 1995, J FAM PRACTICE, V40, P41; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; Navaie-Waliser M, 2002, AM J PUBLIC HEALTH, V92, P409, DOI 10.2105/AJPH.92.3.409; *OFF CIV RIGHTS, SUMM HIPAA PRIV RUL; *OFF CIV RIGHTS WE, MED PRIV NAT STAND P; Oldenquist GW, 2001, CLEV CLIN J MED, V68, P433, DOI 10.3949/ccjm.68.5.433; Pochard F, 2001, CRIT CARE MED, V29, P1893, DOI 10.1097/00003246-200110000-00007; Prendergast TJ, 2002, JAMA-J AM MED ASSOC, V288, P2732, DOI 10.1001/jama.288.21.2732; Prigerson HG, 2001, JAMA-J AM MED ASSOC, V286, P1369, DOI 10.1001/jama.286.11.1369; PRIGERSON HG, 1994, PSYCHIAT RES, V51, P33, DOI 10.1016/0165-1781(94)90045-0; Quill TE, 2001, ANN INTERN MED, V135, P551, DOI 10.7326/0003-4819-135-7-200110020-00022; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Rabow MW, 2003, J PAIN SYMPTOM MANAG, V26, P1010, DOI 10.1016/j.jpainsymman.2003.03.002; Rabow MW, 1999, WESTERN J MED, V171, P260; REUBEN SH, 2001, VOICES BROKEN SYSTEM; Saunders C, 1989, TXB PAIN, P624; Schneider D S, 1996, Ann Clin Psychiatry, V8, P51, DOI 10.3109/10401239609148802; Schulz R, 2001, JAMA-J AM MED ASSOC, V285, P3123, DOI 10.1001/jama.285.24.3123; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Shugarman LR, 2002, J AM GERIATR SOC, V50, P1079, DOI 10.1046/j.1532-5415.2002.50264.x; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; SILLIMAN RA, 1993, J AM GERIATR SOC, V41, P1039, DOI 10.1111/j.1532-5415.1993.tb06450.x; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Slutsman J, 2002, J AM GERIATR SOC, V50, P2077, DOI 10.1046/j.1532-5415.2002.50622.x; Smith MC, 1997, J AM GERIATR SOC, V45, P194, DOI 10.1111/j.1532-5415.1997.tb04506.x; Stein MD, 2000, AM J PUBLIC HEALTH, V90, P1138, DOI 10.2105/AJPH.90.7.1138; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Steinhauser KE, 2001, J PAIN SYMPTOM MANAG, V22, P727, DOI 10.1016/S0885-3924(01)00334-7; Stuck AE, 2002, JAMA-J AM MED ASSOC, V287, P1022, DOI 10.1001/jama.287.8.1022; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; *US GEN ACC OFF, 1994, LONG TERM CAR DIV GR; van Haastregt JCM, 2000, BMJ-BRIT MED J, V320, P754, DOI 10.1136/bmj.320.7237.754; von Gunten CF, 2000, JAMA-J AM MED ASSOC, V284, P3051, DOI 10.1001/jama.284.23.3051; von Gunten Charles F, 2002, J Palliat Med, V5, P35, DOI 10.1089/10966210252784999; Yaffe K, 2002, JAMA-J AM MED ASSOC, V287, P2090, DOI 10.1001/jama.287.16.2090; Yin T, 2002, NURS RES, V51, P199, DOI 10.1097/00006199-200205000-00009; Zarit SH, 1998, J GERONTOL B-PSYCHOL, V53, pS267, DOI 10.1093/geronb/53B.5.S267	98	282	291	3	73	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	2004	291	4					483	491		10.1001/jama.291.4.483	http://dx.doi.org/10.1001/jama.291.4.483			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	767EF	14747506				2023-01-03	WOS:000188426700034
J	Matsuo, H; Chevallier, J; Mayran, N; Le Blanc, I; Ferguson, C; Faure, J; Blanc, NS; Matile, S; Dubochet, J; Sadoul, R; Parton, RG; Vilbois, F; Gruenberg, J				Matsuo, H; Chevallier, J; Mayran, N; Le Blanc, I; Ferguson, C; Faure, J; Blanc, NS; Matile, S; Dubochet, J; Sadoul, R; Parton, RG; Vilbois, F; Gruenberg, J			Role of LBPA and Alix in multivesicular liposome formation and endosome organization	SCIENCE			English	Article							PROTEIN; APOPTOSIS; VESICLES; EXOSOMES; PATHWAY; ACID; CELL	What are the components that control the assembly of subcellular organelles in eukaryotic cells? Although membranes can clearly be distorted by cytosolic factors, very little is known about the intrinsic mechanisms that control the biogenesis, shape, and organization of organellar membranes. Here, we found that the unconventional phospholipid lysobisphosphatidic acid (LBPA) could induce the formation of multivesicular liposomes that resembled the multivesicular endosomes that exist where this lipid is found in vivo. This process depended on the same pH gradient that exists across endosome membranes in vivo and was selectively controlled by Alix. In turn, Alix regulated the organization of LBPA-containing endosomes in vivo.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; Univ Geneva, Dept Organ Chem, CH-1211 Geneva 4, Switzerland; Univ Queensland, Ctr Microscopy & Microanal, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; Univ Grenoble 1, Hop A Michallon, Neurodegenerescence & Plast Inserm, F-38043 Grenoble 9, France; Univ Lausanne, Lab Anal Ultrastruct, CH-1015 Lausanne, Switzerland; Serono Pharmaceut Res Inst, CH-1228 Plan Les Ouates, Switzerland	University of Geneva; University of Geneva; University of Queensland; University of Queensland; CHU Grenoble Alpes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Lausanne	Gruenberg, J (corresponding author), Univ Geneva, Dept Biochem, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.	jean.gruenberg@biochem.unige.ch	Fauré, julien/AAJ-1845-2020; Matile, Stefan/AFL-7826-2022; Parton, Robert G/C-5673-2009	Fauré, julien/0000-0002-3660-9809; Matile, Stefan/0000-0002-8537-8349; Parton, Robert G/0000-0002-7494-5248; SADOUL, Remy/0000-0002-4763-0320				Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Chevallier J, 2000, ORG LETT, V2, P1859, DOI 10.1021/ol0059246; Cluett EB, 1997, MOL BIOL CELL, V8, P2233, DOI 10.1091/mbc.8.11.2233; Cluett EB, 1996, J CELL SCI, V109, P2121; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; Dubochet J, 2001, MICRON, V32, P91, DOI 10.1016/S0968-4328(00)00026-3; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Galve-de Rochemonteix B, 2000, ARTERIOSCL THROM VAS, V20, P563; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Incardona JP, 2002, CURR BIOL, V12, P983, DOI 10.1016/S0960-9822(02)00895-3; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kleijmeer M, 2001, J CELL BIOL, V155, P53, DOI 10.1083/jcb.200103071; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; Mayran N, 2003, EMBO J, V22, P3242, DOI 10.1093/emboj/cdg321; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Tedesco MM, 1999, BIOORGAN MED CHEM, V7, P1373, DOI 10.1016/S0968-0896(99)00076-0; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; WHITNEY JA, 1995, CELL, V83, P703	26	515	526	2	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	2004	303	5657					531	534		10.1126/science.1092425	http://dx.doi.org/10.1126/science.1092425			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14739459				2023-01-03	WOS:000188316400040
J	Schoenbaum, SC; Bovbjerg, RR				Schoenbaum, SC; Bovbjerg, RR			Malpractice reform must include steps to prevent medical injury	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							IMPROVE PATIENT SAFETY; ADVERSE EVENTS; ERRORS; RESPONSIBILITY; NEGLIGENCE; PHYSICIANS; QUALITY	In the current malpractice insurance crisis, physicians have focused their advocacy and energy primarily on rapidly increasing liability premiums; problems in access to care; and demands for legal reform, especially caps on damages. An even more important focus, however, is prevention of injury and improvement of patient safety. Physicians largely control patient care and can play a critical role in systematically reducing injury. Reforms should go beyond liability issues; they should also harness and enhance physicians' ability to act. More visible efforts by physicians to reduce harm, better communication with patients and others, and true evidence of improved patient safety should reduce patient anger and litigiousness. Individually and collectively, physicians can and should ensure that "doing no harm" comes first in the malpractice debate.	Commonwealth Fund, New York, NY 10021 USA; Urban Inst, Washington, DC 20037 USA	Commonwealth Fund; Urban Institute	Schoenbaum, SC (corresponding author), Commonwealth Fund, 1 E 75th St, New York, NY 10021 USA.	scs@cmwf.org						BERWICK DM, 2003, I HEALTHC IMPR 13 AN; BOVBJERG RR, 2003, PATIENT SAFETY JUST; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Brennan TA, 2003, ANN INTERN MED, V139, P267, DOI 10.7326/0003-4819-139-4-200308190-00009; Chassin MR, 1998, MILBANK Q, V76, P565, DOI 10.1111/1468-0009.00106; Classen DC, 2002, ACAD MED, V77, P963, DOI 10.1097/00001888-200210000-00007; CORRIGAN JM, FOSTERING RAPID ADV; Danzon PM, 1985, MED MALPRACTICE THEO; Davis K, 2002, ROOM IMPROVEMENT PAT; DOMINO KB, 2002, ASA NEWSLETTER, V66, P5; Gawande AA, 2003, NEW ENGL J MED, V348, P229, DOI 10.1056/NEJMsa021721; Goode LD, 2002, ACAD MED, V77, P947, DOI 10.1097/00001888-200210000-00004; HELLINGER FJ, 2003, IMPACT STATE LAWS LI; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; James B C, 1989, QA Rev, V1, P4; Kohn LT, 1999, ERR IS HUMAN BUILDIN, DOI DOI 10.17226/9728; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; LOWES R, 2002, MED ECON, V13, P86; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; Mello MM, 2003, NEW ENGL J MED, V348, P2281, DOI 10.1056/NEJMp030064; Mello MM, 2002, TEX LAW REV, V80, P1595; Miller RH, 2002, J HEALTH POLIT POLIC, V27, P401, DOI 10.1215/03616878-27-3-401; *NAT PAT SAF FDN, BIBLIOGRAPHY; *NEW JERS DEP BANK, 2003, MED MALPR PRE DAT SU; Pierce E C Jr, 1990, QRB Qual Rev Bull, V16, P61; PRAGER LO, 2000, AM MED NEWS     0612; Reason J, 2000, BMJ-BRIT MED J, V320, P768, DOI 10.1136/bmj.320.7237.768; Silversin JB, 2000, LEADING PHYS CHANGE; STOLBERG SG, 2003, NY TIMES        0710; TAYLOR H, 2002, MOST DOCT REP FEAR M; *US C BUDG OFF, 2002, COST ESTIMATE HR 460; *US GEN ACC OFF, 2003, GAO03702; Wachter RM, 2002, ANN INTERN MED, V136, P850, DOI 10.7326/0003-4819-136-11-200206040-00015; Werner MJ, 1995, ANN INTERN MED, V122, P466, DOI 10.7326/0003-4819-122-6-199503150-00012; ZUCKERMAN S, 1990, INQUIRY-J HEALTH CAR, V27, P167	35	22	25	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 6	2004	140	1					51	53		10.7326/0003-4819-140-1-200401060-00011	http://dx.doi.org/10.7326/0003-4819-140-1-200401060-00011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760VH	14706972				2023-01-03	WOS:000187855600007
J	van Alem, AP; Vrenken, RH; de Vos, R; Tijssen, JGP; Koster, RW				van Alem, AP; Vrenken, RH; de Vos, R; Tijssen, JGP; Koster, RW			Use of automated external defibrillator by first responders in out of hospital cardiac arrest: prospective controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOPULMONARY-RESUSCITATION; VENTRICULAR-FIBRILLATION; POLICE OFFICERS; SURVIVAL	Objective To test the hypothesis that the use of an automated external defibrillator by police and fire fighters results in higher discharge rates for out of hospital cardiac arrest. Design Controlled clinical trial with initial random allocation of automated external defibrillators to first responders in four of the eight participating regions; each region switched from control to experimental, and vice versa, every four months. Setting Amsterdam and surroundings, the Netherlands. Participants Patients with witnessed out of hospital cardiac arrests, identified by the emergency medical system between January 2000 and January 2002. Main outcomes measures Survival to hospital discharge; return of spontaneous circulation; admission to hospital. Results 243 patients (65% in ventricular fibrillation) were included in the experimental area and 226 patients (67% in ventricular fibrillation) in the control area. The median time interval between collapse and first shock was 668 seconds in the experimental area and 769 seconds in the control area (P < 0.001). 44 (18%) patients in the experimental area versus 33 (15%) patients in the control area were discharged (odds ratio 1.3 (95% confidence interval 0.8 to 2.2), P = 0.33), 139 (57%) experimental versus 108 (48%) control patients had return of spontaneous circulation (1.5 (1.0 to 2.2), P = 0.05), and 103 (42%) experimental versus 74 (33%) control patients were admitted (1.5 (1.1 to 1.6), P = 0.02). The median delay from receipt of call to dispatch of the ambulance was 120 seconds, and the delay to dispatch of the first responder was 180 seconds. Conclusions Use of automated external defibrillators by first responders did not significantly increase survival to discharge from hospital, although it did improve return of spontaneous circulation and admission to hospital. Improved dispatch procedures should increase the success of programmes of first responders using external defibrillators.	Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; Municipal Hlth Serv, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	van Alem, AP (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Cardiol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	a.p.vanalem@amc.uva.nl	de Vos, Rien/AAN-7053-2020					[Anonymous], 2000, Resuscitation, V46, P73; Capucci A, 2002, CIRCULATION, V106, P1065, DOI 10.1161/01.CIR.0000028148.62305.69; Cobb LA, 1999, JAMA-J AM MED ASSOC, V281, P1182, DOI 10.1001/jama.281.13.1182; CUMMINS RO, 1984, LANCET, V2, P318; CUMMINS RO, 1986, CIRCULATION, V73, P381, DOI 10.1161/01.CIR.73.3.381; Davies CS, 2002, RESUSCITATION, V52, P13; Diggle PJ, 1994, ANAL LONGITUDINAL DA, V1st; EISENBERG MS, 1986, AM J EMERG MED, V4, P299, DOI 10.1016/0735-6757(86)90297-4; Groh WJ, 2001, ACAD EMERG MED, V8, P324, DOI 10.1111/j.1553-2712.2001.tb02109.x; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Jaffe A, 2001, NEW ENGL J MED, V344, P771; Mosesso VN, 1998, ANN EMERG MED, V32, P200, DOI 10.1016/S0196-0644(98)70137-4; Myerburg RJ, 2002, CIRCULATION, V106, P1058, DOI 10.1161/01.CIR.0000028147.92190.A7; ORNATO JP, 1999, PREHOSP EMERG CARE, V3, P298; Ross P, 2001, RESUSCITATION, V50, P141, DOI 10.1016/S0300-9572(01)00343-4; Valenzuela TD, 1997, CIRCULATION, V96, P3308; Waalewijn RA, 1998, RESUSCITATION, V38, P157, DOI 10.1016/S0300-9572(98)00102-6; Waalewijn RA, 2002, RESUSCITATION, V54, P31, DOI 10.1016/S0300-9572(02)00047-3; Waalewijn RA, 2001, RESUSCITATION, V51, P113, DOI 10.1016/S0300-9572(01)00407-5; White RD, 1996, ANN EMERG MED, V28, P480, DOI 10.1016/S0196-0644(96)70109-9; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	21	139	142	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 6	2003	327	7427					1312	1315		10.1136/bmj.327.7427.1312	http://dx.doi.org/10.1136/bmj.327.7427.1312			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	752DE	14656837	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000187131100015
J	Kaba, RA; Cox, D; Lewis, A; Bloom, P; Dubrey, S				Kaba, RA; Cox, D; Lewis, A; Bloom, P; Dubrey, S			Intraocular haemorrhage after thrombolysis	LANCET			English	Editorial Material									Hillingdon Hosp, Uxbridge UB8 3NN, Middx, England		Kaba, RA (corresponding author), Hillingdon Hosp, Uxbridge UB8 3NN, Middx, England.	r.kaba@imperial.ac.uk							0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2005	365	9456					330	330						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664229				2023-01-03	WOS:000226449600037
J	Saposnik, G; Young, B; Silver, B; Di Legge, S; Webster, F; Beletsky, V; Jain, V; Nilanont, Y; Hachinski, V				Saposnik, G; Young, B; Silver, B; Di Legge, S; Webster, F; Beletsky, V; Jain, V; Nilanont, Y; Hachinski, V			Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy - Predictors and association with outcome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE; EARLY RECANALIZATION; RELIABILITY; PREVALENCE; RECOVERY; NEGLECT; BRAIN; UNIT	Context The focus of thrombolytic therapy in acute stroke has been on favorable outcome at 3 months. Few studies have analyzed outcome at 24 hours. An early and reliable prediction of poor outcome has implications for clinical management and discharge planning. Objective To evaluate predictors of lack of improvement at 24 hours after receiving alteplase and their relationship with poor outcome at 3 months. Design, Setting, and Participants Prospective cohort of consecutive patients with acute stroke who received alteplase and were admitted to a university hospital from January 1999 to March 2003. Participants were recruited from 2 academic centers in a major city in Ontario and 33 affiliated hospitals from 7 counties. Main Outcome Measures Lack of improvement defined as a difference between the National Institutes of Health Stroke Scale score at baseline and at 24 hours of 3 points or less. Poor outcome at 3 months defined by a modified Rankin Scale score of 3 to 5 or death. Results Among 216 patients with acute stroke who were treated with alteplase, 111 (51.4%) had a lack of improvement at 24 hours. After adjusting for age, sex, and stroke severity, baseline glucose level on admission (odds ratio [OR] 2.89; 95% confidence interval [CI], 1.40-5.99 for a glucose level >144 mg/dL [>8 mmol/L]), cortical involvement (OR, 2.66; 95% Cl, 1.36-5.20), and time to treatment (OR, 1.01; 95% Cl, 1.0-1.02 for each 1 minute increase in time to treatment) were independent predictors of lack of improvement. At 3 months, 43 patients (20.2%) had died; of the 170 survivors, 75 patients (44%) had poor outcomes. After adjusting for age, sex, and stroke severity, lack of improvement at 24 hours was an independent predictor of poor outcome (OR, 12.9; 95% Cl, 5.7-29.6) and death (OR, 7.5; 95% Cl, 2.9-19.6). Patients with a lack of improvement had longer lengths of hospitalization (14.5 vs 9.6 days; P=.02). Conclusions Among patients with acute stroke treated with thrombolytic therapy, lack of improvement at 24 hours is associated with poor outcome and death at 3 months. Elevated glucose level, time to thrombolytic therapy, and cortical involvement were predictors of lack of improvement.	Univ Western Ontario, London Hlth Sci Ctr, Stroke Serv, Dept Clin Neurol Sci,Stroke Program, London, ON N6A 5A5, Canada; Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA	London Health Sciences Centre; Western University (University of Western Ontario); Henry Ford Health System; Henry Ford Hospital	Saposnik, G (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Stroke Serv, Dept Clin Neurol Sci,Stroke Program, 339 Windermere Rd,Off 7-GE5, London, ON N6A 5A5, Canada.	gsaposni@uwo.ca	Saposnik, Gustavo/M-3937-2017; Webster, Fiona/AAK-3253-2020	Saposnik, Gustavo/0000-0002-5950-9886; Webster, Fiona/0000-0002-7318-7713				Adams HP, 1996, STROKE, V27, P1711; Alexandrov AV, 2004, STROKE, V35, P449, DOI 10.1161/01.STR.0000113737.58014.B4; Alvarez-Sabin J, 2003, STROKE, V34, P1235, DOI 10.1161/01.STR.0000068406.30514.31; Arenillas JF, 2002, STROKE, V33, P2197, DOI 10.1161/01.STR.0000027861.75884.DF; Baird AE, 2001, LANCET, V357, P2095, DOI 10.1016/S0140-6736(00)05183-7; BROTT T, 1989, STROKE, V20, P871, DOI 10.1161/01.STR.20.7.871; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; Brown DL, 2004, STROKE, V35, P147, DOI 10.1161/01.STR.000010539.93273.72; Buxbaum LJ, 2004, NEUROLOGY, V62, P749, DOI 10.1212/01.WNL.0000113730.73031.F4; Chang KC, 2002, STROKE, V33, P2670, DOI 10.1161/01.STR.0000034396.68980.39; del Zoppo GJ, 2004, CEREBROVASC DIS, V17, P144, DOI 10.1159/000074807; Delsing BJP, 2001, PEDIATR NEUROL, V24, P283, DOI 10.1016/S0887-8994(01)00245-4; Demchuk AM, 2001, NEUROLOGY, V57, P474, DOI 10.1212/WNL.57.3.474; Demchuk AM, 2001, STROKE, V32, P89, DOI 10.1161/01.STR.32.1.89; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; Felberg RA, 2002, STROKE, V33, P1301, DOI 10.1161/01.STR.0000015556.48283.74; Foell RBT, 2003, CAN MED ASSOC J, V169, P193; Ganesan V, 2000, DEV MED CHILD NEUROL, V42, P455, DOI 10.1017/S0012162200000852; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; Grotta JC, 2001, STROKE, V32, P661, DOI 10.1161/01.STR.32.3.661; Hillis AE, 2004, NEURORADIOLOGY, V46, P31, DOI 10.1007/s00234-002-0918-4; Kalra L, 1997, STROKE, V28, P1386, DOI 10.1161/01.STR.28.7.1386; Kucinski T, 2003, NEURORADIOLOGY, V45, P11, DOI 10.1007/s00234-002-0881-0; Labiche LA, 2003, STROKE, V34, P695, DOI 10.1161/01.STR.0000055940.00316.6B; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; Martinez-Vila E, 2004, CEREBROVASC DIS, V17, P124, DOI 10.1159/000074804; Mendizabal JE, 2001, J NEUROIMAGING, V11, P101, DOI 10.1111/j.1552-6569.2001.tb00018.x; Merino JG, 2002, STROKE, V33, P141, DOI 10.1161/hs0102.100481; Poungvarin N, 1998, LANCET, V352, pSIII19; Saposnik G, 2003, STROKE, V34, P2103, DOI 10.1161/01.STR.0000088063.74250.DB; Schellinger PD, 2004, CURR OPIN NEUROL, V17, P69, DOI 10.1097/00019052-200402000-00012; Shafqat S, 1999, STROKE, V30, P2141, DOI 10.1161/01.STR.30.10.2141; *STAT CAN, POP DEM DAT TABL; Steiner T, 2004, STROKE, V35, P1018, DOI 10.1161/01.STR.0000120953.78592.72; Sulter G, 2003, STROKE, V34, P101, DOI 10.1161/01.STR.0000048148.09143.6C; Trouillas P, 1998, STROKE, V29, P2529, DOI 10.1161/01.STR.29.12.2529; Wardlaw JM, 2003, STROKE, V34, P1437, DOI 10.1161/01.STR.0000072513.72262.7E; WITYK RJ, 1994, STROKE, V25, P362, DOI 10.1161/01.STR.25.2.362	39	63	64	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2004	292	15					1839	1844		10.1001/jama.292.15.1839	http://dx.doi.org/10.1001/jama.292.15.1839			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862IV	15494581	Bronze			2023-01-03	WOS:000224485100022
J	O'Dowd, CD; Facchini, MC; Cavalli, F; Ceburnis, D; Mircea, M; Decesari, S; Fuzzi, S; Yoon, YJ; Putaud, JP				O'Dowd, CD; Facchini, MC; Cavalli, F; Ceburnis, D; Mircea, M; Decesari, S; Fuzzi, S; Yoon, YJ; Putaud, JP			Biogenically driven organic contribution to marine aerosol	NATURE			English	Article							SUBMICRON AEROSOL; CLOUD ALBEDO; SULFUR; FRACTIONATION; TRANSPORT; MATTER; MASS	Marine aerosol contributes significantly to the global aerosol load and consequently has an important impact on both the Earth's albedo and climate. So far, much of the focus on marine aerosol has centred on the production of aerosol from sea-salt(1) and non-sea-salt sulphates(2,3). Recent field experiments, however, have shown that known aerosol production processes for inorganic species cannot account for the entire aerosol mass that occurs in submicrometre sizes(4-6). Several experimental studies have pointed to the presence of significant concentrations of organic matter in marine aerosol(7-11). There is some information available about the composition of organic matter(12-14), but the contribution of organic matter to marine aerosol, as a function of aerosol size, as well as its characterization as hydrophilic or hydrophobic, has been lacking. Here we measure the physical and chemical characteristics of submicrometre marine aerosol over the North Atlantic Ocean during plankton blooms progressing from spring through to autumn. We find that during bloom periods, the organic fraction dominates and contributes 63% to the submicrometre aerosol mass (about 45% is water-insoluble and about 18% water-soluble). In winter, when biological activity is at its lowest, the organic fraction decreases to 15%. Our model simulations indicate that organic matter can enhance the cloud droplet concentration by 15% to more than 100% and is therefore an important component of the aerosol-cloud-climate feedback system involving marine biota.	CNR, Ist Sci Atmosfera & Clima, I-40129 Bologna, Italy; Natl Univ Ireland, Dept Expt Phys, Galway, Ireland; Natl Univ Ireland, Environm Change Inst, Galway, Ireland; Inst Phys, Environm Phys & Chem Div, LT-2053 Vilnius, Lithuania; Commiss European Communities, Inst Environm & Sustainabil, Joint Res Ctr, I-21021 Ispra, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell'Atmosfera e del Clima (ISAC-CNR); Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; European Commission Joint Research Centre; EC JRC ISPRA Site	Facchini, MC (corresponding author), CNR, Ist Sci Atmosfera & Clima, I-40129 Bologna, Italy.	mc.facchini@isac.cnr.it	O'Dowd, Colin D/K-8904-2012; Facchini, Maria Cristina/B-3369-2014; FACCHINI, MARIA CRISTINA/O-1230-2015; Ceburnis, Darius/C-1293-2012; Decesari, Stefano/B-9588-2015; Facchini, Maria Cristina/AAA-1592-2019; Fuzzi, Sandro/F-2675-2010	O'Dowd, Colin D/0000-0002-3068-2212; Facchini, Maria Cristina/0000-0003-4833-9305; FACCHINI, MARIA CRISTINA/0000-0003-4833-9305; Ceburnis, Darius/0000-0003-0231-5324; Decesari, Stefano/0000-0001-6486-3786; Facchini, Maria Cristina/0000-0003-4833-9305; Fuzzi, Sandro/0000-0002-5275-2381				Beardall J, 2004, PHYCOLOGIA, V43, P26, DOI 10.2216/i0031-8884-43-1-26.1; BLANCHARD DC, 1976, ADV CHEM SER, V145, P360; Cavalli F, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD005137; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; Facchini MC, 1999, NATURE, V401, P257, DOI 10.1038/45758; GAGOSIAN RB, 1981, NATURE, V291, P312, DOI 10.1038/291312a0; GEEVER M, 2003, J AER SCI, V1, pS637; GERSHEY RM, 1983, LIMNOL OCEANOGR, V28, P309, DOI 10.4319/lo.1983.28.2.0309; Gogou AI, 1998, J CHROMATOGR A, V799, P215, DOI 10.1016/S0021-9673(97)01106-0; HOFFMAN EJ, 1974, J GEOPHYS RES, V79, P4474, DOI 10.1029/JC079i030p04474; Huebert BJ, 1998, J GEOPHYS RES-ATMOS, V103, P16493, DOI 10.1029/98JD00770; KAWAMURA K, 1990, J ATMOS CHEM, V11, P107, DOI 10.1007/BF00053670; Kleefeld S, 2002, ATMOS ENVIRON, V36, P4479, DOI 10.1016/S1352-2310(02)00346-1; Martensson EM, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002263; McInnes LM, 1996, ATMOS ENVIRON, V30, P869, DOI 10.1016/1352-2310(95)00354-1; Middlebrook AM, 1998, J GEOPHYS RES-ATMOS, V103, P16475, DOI 10.1029/97JD03719; Mochida M, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001278; Nenes A, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015295; Novakov T, 1997, J GEOPHYS RES-ATMOS, V102, P21307, DOI 10.1029/97JD01487; ODowd CD, 1997, ATMOS ENVIRON, V31, P73, DOI 10.1016/S1352-2310(96)00106-9; Oppo C, 1999, MAR CHEM, V63, P235, DOI 10.1016/S0304-4203(98)00065-6; Putaud JP, 2000, TELLUS B, V52, P141, DOI 10.1034/j.1600-0889.2000.00056.x; Quinn PK, 2000, J GEOPHYS RES-ATMOS, V105, P6785, DOI 10.1029/1999JD901034; SHAW GE, 1983, CLIMATIC CHANGE, V5, P297, DOI 10.1007/BF02423524	24	682	692	13	306	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	2004	431	7009					676	680		10.1038/nature02959	http://dx.doi.org/10.1038/nature02959			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	859WS	15470425				2023-01-03	WOS:000224299300037
J	Wang, YQ; Zhang, DX; Renner, SS; Chen, ZY				Wang, YQ; Zhang, DX; Renner, SS; Chen, ZY			A new self-pollination mechanism	NATURE			English	Editorial Material							ZINGIBERACEAE; POLLEN		Chinese Acad Sci, S China Bot Garden, Guangzhou 510650, Peoples R China; Zhongkai Agrotech Coll, Guangzhou 510225, Peoples R China; Univ Munich, Dept Biol, D-80638 Munich, Germany	Chinese Academy of Sciences; South China Botanical Garden, CAS; University of Munich	Wang, YQ (corresponding author), Chinese Acad Sci, S China Bot Garden, Guangzhou 510650, Peoples R China.	dx-zhang@scib.ac.cn		Zhang, Dianxiang/0000-0001-6549-8872				Barrett SCH, 2003, PHILOS T R SOC B, V358, P991, DOI 10.1098/rstb.2003.1301; DOBSON HEM, 1988, AM J BOT, V75, P170, DOI 10.2307/2443884; HESLOPHARRISON Y, 1977, ANN BOT-LONDON, V41, P1233, DOI 10.1093/oxfordjournals.aob.a085414; KRONESTEDT E, 1981, NORD J BOT, V1, P523; Larsen K, 2002, NORD J BOT, V22, P409, DOI 10.1111/j.1756-1051.2002.tb01392.x; LARSEN K, 1972, Notes from the Royal Botanic Garden Edinburgh, V31, P287; LARSEN KAI, 1964, BOT TIDSSKR, V60, P165; ROSE MJ, 1995, PLANT SYST EVOL, V195, P61, DOI 10.1007/BF00982315; Williams KJ, 2004, AM J BOT, V91, P100, DOI 10.3732/ajb.91.1.100	9	42	62	8	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2004	431	7004					39	40		10.1038/431039b	http://dx.doi.org/10.1038/431039b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343325				2023-01-03	WOS:000223641500032
J	Munro, AJ				Munro, AJ			Oesophageal cancer: a view over overviews	LANCET			English	Editorial Material									Univ Dundee, Dept Surg & Mol Oncol, Dundee, Scotland	University of Dundee	Munro, AJ (corresponding author), Univ Dundee, Dept Surg & Mol Oncol, Dundee, Scotland.	a.j.munro@dundee.ac.uk						ARNOTT SJ, 2004, COCHRANE LIB; BEDENNE L, 2002, AM SOC CLINL ONCOL P, V519; Fiorica F, 2004, GUT, V53, P925, DOI 10.1136/gut.2003.025080; *IARC, 2000, GLOBOCAN; MALTHANER R, 2004, COCHRANE LIB; *SCOTT AUD GASTR C, 2002, SCOTT AUD GASTR CANC; Sur RK, 2002, INT J RADIAT ONCOL, V53, P127, DOI 10.1016/S0360-3016(02)02702-5; Wong R, 2004, COCHRANE LIB	8	18	20	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	2004	364	9434					566	568		10.1016/S0140-6736(04)16868-2	http://dx.doi.org/10.1016/S0140-6736(04)16868-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	845WD	15313344				2023-01-03	WOS:000223275100010
J	Jourdain, G; Ngo-Giang-Huong, N; Le Coeur, S; Bowonwatanuwong, C; Kantipong, P; Leechanachai, P; Ariyadej, S; Leenasirimakul, P; Hammer, S; Lallemant, M				Jourdain, G; Ngo-Giang-Huong, N; Le Coeur, S; Bowonwatanuwong, C; Kantipong, P; Leechanachai, P; Ariyadej, S; Leenasirimakul, P; Hammer, S; Lallemant, M		Perinatal HIV Prevention Trial Grp	Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	11th Conference on Retroviruses and Opportunistic Infections	FEB 08-11, 2004	San Francisco, CA				INFECTED PREGNANT-WOMEN; IMMUNODEFICIENCY-VIRUS TYPE-1; MULTIPLE SEQUENCE ALIGNMENT; HIV-1 VERTICAL TRANSMISSION; ZIDOVUDINE RESISTANCE; RECEIVING NEVIRAPINE; MUTATIONS; PHARMACOKINETICS; CLUSTAL	BACKGROUND: A single intrapartum dose of nevirapine for the prevention of mother-to-child transmission of human immunodeficiency virus (HIV) leads to the selection of resistance mutations. Whether there are clinically significant consequences in mothers who are subsequently treated with a nevirapine-containing regimen is unknown. METHODS: We randomly assigned 1844 women in Thailand who received zidovudine during the third trimester of pregnancy to receive intrapartum nevirapine or placebo. In the postpartum period, 269 of the women with a CD4 count below 250 cells per cubic millimeter began a nevirapine-containing antiretroviral regimen. Plasma samples were obtained 10 days post partum and analyzed for resistance mutations. Plasma HIV type 1 (HIV-1) RNA was measured before the initiation of therapy and three and six months thereafter. RESULTS: After six months of therapy, the HIV-1 RNA level was less than 50 copies per milliliter in 49 percent of the women who had received intrapartum nevirapine, as compared with 68 percent of the women who had not received intrapartum nevirapine (P=0.03). Resistance mutations to nonnucleoside reverse-transcriptase inhibitors were detectable in blood samples obtained 10 days post partum from 32 percent of the women who had received intrapartum nevirapine; the most frequent mutations were K103N, G190A, and Y181C. Among the women who had received intrapartum nevirapine, viral suppression was achieved at six months in 38 percent of those with resistance mutations and 52 percent of those without resistance mutations (P=0.08). An HIV-1 RNA level at or above the median of 4.53 log(sub 10) copies per milliliter before therapy and intrapartum exposure to nevirapine were independently associated with virologic failure. After six months of therapy, there was no significant difference between groups in the CD4 count (P=0.65). CONCLUSIONS: Women who received intrapartum nevirapine were less likely to have virologic suppression after six months of postpartum treatment with a nevirapine-containing regimen. Our data suggest the need for strategies to maximize the benefits of both antiretroviral prophylaxis against mother-to-child transmission of HIV and antiretroviral therapy for mothers.	Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Inst Rech Dev, Perinatal HIV Prevent Trial Grp, Paris, France; Inst Rech Dev, Perinatal HIV Prevent Trial Grp, Chiang Mai, Thailand; Inst Natl Etud Demog, F-75675 Paris, France; Minist Publ Hlth, Bangkok, Thailand; Chiang Mai Univ, Fac Associated Med Sci, Chiang Mai 50000, Thailand; Columbia Univ, Coll Phys & Surg, New York, NY USA	Harvard University; Harvard T.H. Chan School of Public Health; Institut de Recherche pour le Developpement (IRD); Institut de Recherche pour le Developpement (IRD); Ministry of Public Health - Thailand; Chiang Mai University; Columbia University	Jourdain, G (corresponding author), PHPT IRD54, 29-7-8 Samlan Rd,Soi 1 Prasing Muang, Chiang Mai 50200, Thailand.	gonzague@phpt.org	Jourdain, Gonzague/F-9117-2017; Ngo-Giang-Huong, Nicole/G-2860-2017	Jourdain, Gonzague/0000-0002-3365-7020; Ngo-Giang-Huong, Nicole/0000-0001-8950-3234	NICHD NIH HHS [R01 HD039615, 5 R01 HD 39615] Funding Source: Medline; PHS HHS [42848] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039615] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Acosta EP, 2004, ANTIMICROB AGENTS CH, V48, P430, DOI 10.1128/AAC.48.2.430-436.2004; CHAIX ML, 2004, 11 C RETR OPP INF SA, P657; CHALERMCHOKCHAR.A, 2004, 11 C RETR OPP INF SA, P96; Cunningham CK, 2002, J INFECT DIS, V186, P181, DOI 10.1086/341300; Eastman PS, 1998, J INFECT DIS, V177, P557, DOI 10.1086/514228; Ekpini RA, 2002, AIDS, V16, P625, DOI 10.1097/00002030-200203080-00015; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; ESHLEMAN SH, 2003, ANTIVIR THER, V8, pS86; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Jackson JB, 2000, AIDS, V14, pF111, DOI 10.1097/00002030-200007280-00001; Johnson Victoria A, 2003, Top HIV Med, V11, P215; JOURDAIN G, 2004, 11 C RETR OPP INF SA, P4118; KANTOR R, 2003, ANTIVIR THER, V8, pS85; KEARNEY M, 2004, 11 C RETR OPP INF SA, P695; Kosel BW, 2003, AIDS, V17, P1195, DOI 10.1097/00002030-200305230-00011; Kully C, 1999, J INFECT DIS, V179, P705, DOI 10.1086/314615; Lallemant M, 2004, NEW ENGL J MED, V351, P217, DOI 10.1056/NEJMoa033500; LECOSSIER D, 2003, ANTIVIR THER, V8, pS159; MARTINSON N, 2004, 11 C RETR OPP INF SA, P38; MELLORS J, 2004, 11 C RETR OPP INF SA, P39; *MIN PUBL HLTH DEP, 2000, NAT GUID CLIN MAN HI, P119; Morris L, 2003, AIDS, V17, P1698, DOI 10.1097/00002030-200307250-00017; PALMER S, 2004, 11 C RETR OPP INF SA, P37; *PAN CLIN PRACT TR, 2004, GUID US ANT AG HIV 1; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; SHEPARD KV, 2004, IMPORTANT NEW SAFETY; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; *WHO, 2004, ANT DRUGS PREV MOTH; World Health Organization, 2002, SCAL ANT THER RES LT	29	317	330	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					229	240		10.1056/NEJMoa041305	http://dx.doi.org/10.1056/NEJMoa041305			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	837KA	15247339				2023-01-03	WOS:000222627200007
J	Blattman, JN; Greenberg, PD				Blattman, JN; Greenberg, PD			Cancer immunotherapy: A treatment for the masses	SCIENCE			English	Review							REGULATORY T-CELLS; METASTATIC MELANOMA; ANTIGEN-4 BLOCKADE; DENDRITIC CELLS; TUMOR-DEVELOPMENT; IMMUNE-RESPONSES; GROWTH-FACTOR; KILLER-CELLS; BONE-MARROW; AUTOIMMUNITY	Cancer immunotherapy attempts to harness the exquisite power and specificity of the immune system for the treatment of malignancy. Although cancer cells are less immunogenic than pathogens, the immune system is clearly capable of recognizing and eliminating tumor cells. However, tumors frequently interfere with the development and function of immune responses. Thus, the challenge for immunotherapy is to use advances in cellular and molecular immunology to develop strategies that effectively and safely augment antitumor responses.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Greenberg, PD (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.	pgreen@u.washington.edu						Brentjens RJ, 2003, NAT MED, V9, P279, DOI 10.1038/nm827; BURNET M, 1957, BRIT MED J, V5022, P779; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; Cheng LE, 2002, P NATL ACAD SCI USA, V99, P3001, DOI 10.1073/pnas.052676899; Childs R, 2000, NEW ENGL J MED, V343, P750, DOI 10.1056/NEJM200009143431101; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Ehrlich P., 1909, NED TIJDSCHR GENEES, V5, P273; Engelhard VH, 2002, IMMUNOL REV, V188, P136, DOI 10.1034/j.1600-065X.2002.18812.x; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Ho WY, 2003, CANCER CELL, V3, P431, DOI 10.1016/S1535-6108(03)00113-2; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Homey B, 2002, NAT REV IMMUNOL, V2, P175, DOI 10.1038/nri748; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; Karanikas V, 2003, J IMMUNOL, V171, P4898, DOI 10.4049/jimmunol.171.9.4898; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Lejeune F J, 2001, Surg Oncol Clin N Am, V10, P821; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Marroquin CE, 2002, J IMMUNOTHER, V25, P278, DOI 10.1097/00002371-200205000-00011; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Nieda M, 2004, BLOOD, V103, P383, DOI 10.1182/blood-2003-04-1155; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; ROSENBERG SA, 1993, JNCI-J NATL CANCER I, V85, P622, DOI 10.1093/jnci/85.8.622; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Shimizu J, 1999, J IMMUNOL, V163, P5211; Staveley-O'Carroll K, 1998, P NATL ACAD SCI USA, V95, P1178, DOI 10.1073/pnas.95.3.1178; Street SEA, 2004, J EXP MED, V199, P879, DOI 10.1084/jem.20031981; STUTMAN O, 1974, SCIENCE, V183, P534, DOI 10.1126/science.183.4124.534; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Timmerman JM, 2002, BLOOD, V99, P1517, DOI 10.1182/blood.V99.5.1517; van Elsas A, 2001, J EXP MED, V194, P481, DOI 10.1084/jem.194.4.481; von Mehren M, 2003, ANNU REV MED, V54, P343, DOI 10.1146/annurev.med.54.101601.152442; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood-2002-12-3665; Woo EY, 2002, J IMMUNOL, V168, P4272, DOI 10.4049/jimmunol.168.9.4272; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	45	446	508	2	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					200	205		10.1126/science.1100369	http://dx.doi.org/10.1126/science.1100369			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247469				2023-01-03	WOS:000222501000040
J	Steinbrook, R				Steinbrook, R			The cost of admission - Tiered copayments for hospital use	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Gabel J, 2003, HEALTH AFFAIR, V22, P117, DOI 10.1377/hlthaff.22.5.117; Kindig DA, 2004, HLTH LITERACY PRESCR; Lee TH, 2004, NEW ENGL J MED, V350, P2409, DOI 10.1056/NEJMsb041193; Levit K, 2004, HEALTH AFFAIR, V23, P147, DOI 10.1377/hlthaff.23.1.147; Newhouse JP, 1993, FREE ALL LESSONS RAN	5	11	11	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2004	350	25					2539	2542		10.1056/NEJMp048107	http://dx.doi.org/10.1056/NEJMp048107			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829NE	15201407				2023-01-03	WOS:000222054700001
J	Moore, FA; McKinley, BA; Moore, EE				Moore, FA; McKinley, BA; Moore, EE			The next generation in shock resuscitation	LANCET			English	Review							HUMAN POLYMERIZED HEMOGLOBIN; MULTIPLE ORGAN FAILURE; ABDOMINAL COMPARTMENT SYNDROME; INDEPENDENT RISK-FACTOR; ACTIVATED FACTOR-VII; FLUID RESUSCITATION; HYPERTONIC SALINE; HEMORRHAGIC-SHOCK; BLOOD-TRANSFUSION; LACTATED RINGERS	Resuscitation of the severely injured patient who presents in shock has improved greatly, following focused wartime experience and insight from laboratory and clinical studies. Further benefit is probable from technologies that are being brought into clinical use, especially hypertonic saline dextran, haemoglobin-based oxygen carriers, less invasive early monitors, and medical informatics. These technologies could improve the potential of prehospital and early hospital care to pre-empt or more rapidly reverse hypoxaemia, hypovolaemia, and onset of shock. Damage control surgery and definitive interventional radiology will probably combine with more real-time detection and intervention for hypothermia, coagulopathy, and acidosis, to avoid extreme pathophysiology and the "bloody vicious cycle". Although now widely practised as standard of care in the USA and Europe, shock resuscitation strategies involving haemoglobin replacement and fluid volume loading to regain tissue perfusion and oxygenation vary between trauma centres. One of the difficulties is the scarcity of published evidence for or against seemingly basic intervention strategies, such as early or large-volume fluid loading. Standardised protocols for resuscitation, representing the best and most current knowledge of the clinical process, could be devised and widely implemented as interactive computerised applications among trauma centres in the USA and Europe. Prevention of injury is preferable and feasible, but early care of the severely injured patient and modulation of exaggerated systemic inflammatory response due to transfusion and other complications of traditional strategies will probably provide the next generation of improvements in shock resuscitation.	Univ Texas, Houston Med Sch, Dept Surg, Houston, TX 77030 USA; Univ Colorado, Denver Hlth Med Ctr, Dept Surg, Denver, CO 80202 USA	University of Texas System; University of Texas Health Science Center Houston; Denver Health Medical Center; University of Colorado System; University of Colorado Denver	Moore, FA (corresponding author), Univ Texas, Houston Med Sch, Dept Surg, 6431 Fannin St,Suite 4-264, Houston, TX 77030 USA.	Frederick.A.Moore@uth.tmc.edu			NIGMS NIH HHS [P50-GM4922, P50 GM38529, U54 GM62119] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062119, P50GM038529] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Siaidy W, 1979, Birth Defects Orig Artic Ser, V15, P149; AMBERSON WR, 1949, J APPL PHYSIOL, V1, P469, DOI 10.1152/jappl.1949.1.7.469; Amberson WR, 1933, SCIENCE, V78, P106, DOI 10.1126/science.78.2014.106; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Arvieux C, 2003, ANN CHIR, V128, P150, DOI 10.1016/S0003-3944(02)00029-9; Balogh Z, 2003, J TRAUMA, V54, P848, DOI 10.1097/01.TA.0000070166.29649.F3; Balogh Z, 2003, ARCH SURG-CHICAGO, V138, P637, DOI 10.1001/archsurg.138.6.637; Berezina TL, 2002, J SURG RES, V102, P6, DOI 10.1006/jsre.2001.6306; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Biffl WL, 1999, SURGERY, V126, P198, DOI 10.1067/msy.1999.98738; Biffl WL, 2001, J TRAUMA, V50, P426, DOI 10.1097/00005373-200103000-00005; BOEKSTEGERS P, 1994, CRIT CARE MED, V22, P640, DOI 10.1097/00003246-199404000-00021; BOTHA AJ, 1995, SURGERY, V118, P358, DOI 10.1016/S0039-6060(05)80345-9; BOTHA AJ, 1995, SHOCK, V3, P157, DOI 10.1097/00024382-199503000-00001; Burris D, 1999, J TRAUMA, V46, P216, DOI 10.1097/00005373-199902000-00003; BURROWS L, 1982, LANCET, V2, P662; Cairns CB, 1997, J TRAUMA, V42, P532, DOI 10.1097/00005373-199703000-00023; Carmichael FJL, 2000, CRIT CARE MED, V28, P2283, DOI 10.1097/00003246-200007000-00017; CARRY LC, 1971, CURR PROB SURG, P3; CERVERA AL, 1975, AM J SURG, V129, P670, DOI 10.1016/0002-9610(75)90343-8; Choi PTL, 1999, CRIT CARE MED, V27, P200, DOI 10.1097/00003246-199901000-00053; Cittanova ML, 1996, LANCET, V348, P1620, DOI 10.1016/S0140-6736(96)07588-5; Clemmer TP, 1998, NEW HORIZ-SCI PRACT, V6, P12; Coimbra R, 1997, J TRAUMA, V42, P602, DOI 10.1097/00005373-199704000-00004; Conhaim RL, 1999, J TRAUMA, V46, P800, DOI 10.1097/00005373-199905000-00007; Cope JT, 1997, ANN THORAC SURG, V63, P78; CORAN AG, 1971, SURGERY, V69, P874; Cosgriff N, 1997, J TRAUMA, V42, P857, DOI 10.1097/00005373-199705000-00016; CROWELL JW, 1959, AM J PHYSIOL, V196, P1033, DOI 10.1152/ajplegacy.1959.196.5.1033; CZER LSC, 1978, SURG GYN OBS, V147, P262; DILLON J, 1966, ARCH SURG-CHICAGO, V93, P537; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Durham RM, 1996, J TRAUMA, V41, P32, DOI 10.1097/00005373-199607000-00007; Fowler R, 2002, EMERG MED CLIN N AM, V20, P953, DOI 10.1016/S0733-8627(02)00038-X; Gan TJ, 1999, ANESTH ANALG, V88, P992, DOI 10.1097/00000539-199905000-00005; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; Gore DC, 1996, ANN SURG, V224, P97, DOI 10.1097/00000658-199607000-00015; Gould SA, 1997, J TRAUMA, V43, P325, DOI 10.1097/00005373-199708000-00019; Gould SA, 1998, J AM COLL SURGEONS, V187, P113, DOI 10.1016/S1072-7515(98)00095-7; Gould SA, 2002, J AM COLL SURGEONS, V195, P445, DOI 10.1016/S1072-7515(02)01335-2; Harkins HN, 1941, ANN SURG, V114, P891, DOI 10.1097/00000658-194111000-00010; Healey MA, 1998, J TRAUMA, V45, P894, DOI 10.1097/00005373-199811000-00010; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HESS JR, 1993, J APPL PHYSIOL, V74, P1769, DOI 10.1152/jappl.1993.74.4.1769; HIRSHBERG A, 1995, J TRAUMA, V39, P225, DOI 10.1097/00005373-199508000-00007; HOLCOMB JB, IN PRESS MIL MED; HOLCROFT JW, 1974, ANN SURG, V180, P408; James JH, 1999, LANCET, V354, P505, DOI 10.1016/S0140-6736(98)91132-1; Kao KJ, 2000, TRANSFUS MED REV, V14, P12, DOI 10.1016/S0887-7963(00)80112-1; Kern JW, 2002, CRIT CARE MED, V30, P1686, DOI 10.1097/00003246-200208000-00002; Kirkley SA, 1999, CLIN DIAGN LAB IMMUN, V6, P652, DOI 10.1128/CDLI.6.5.652-657.1999; Koustova E, 2002, J TRAUMA, V52, P872, DOI 10.1097/00005373-200205000-00009; Krausz MM, 2003, J TRAUMA, V54, pS39, DOI 10.1097/01.TA.0000064506.47688.51; KRAUSZ MM, 1992, SURG GYNECOL OBSTET, V174, P363; KWAN I, 2003, COCHRANE DATABASE SY, V0003, DOI DOI 10.1002/14651858; LANDRO L, 2001, WALL STREET J    JUN; Ley K, 2001, NAT MED, V7, P1105, DOI 10.1038/nm1001-1105; Ligtenberg JJM, 2002, J TRAUMA, V53, P1196, DOI 10.1097/00005373-200212000-00036; LOFGREN O, 1979, ACTA ANAESTH SCAND, V23, P534; LUCAS CE, 1980, J TRAUMA, V20, P446, DOI 10.1097/00005373-198006000-00002; Lucas CE, 2001, J AM COLL SURGEONS, V192, P86, DOI 10.1016/S1072-7515(00)00761-4; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; Mann DV, 1997, ANN SURG, V226, P653, DOI 10.1097/00000658-199711000-00010; Martinowitz U, 2001, J TRAUMA, V50, P721, DOI 10.1097/00005373-200104000-00021; Martinowitz U, 2001, J TRAUMA, V51, P431, DOI 10.1097/00005373-200109000-00002; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MAZZONI MC, 1989, CIRC SHOCK, V29, P27; McKinley BA, 2002, J TRAUMA, V53, P825, DOI 10.1097/00005373-200211000-00004; McKinley BA, 1998, J TRAUMA, V45, P633, DOI 10.1097/00005373-199809000-00043; McKinley BA, 2000, J TRAUMA, V48, P637, DOI 10.1097/00005373-200004000-00009; MILLER JH, 1951, J CLIN INVEST, V30, P1033, DOI 10.1172/JCI102522; Moore EE, 2003, J AM COLL SURGEONS, V196, P1, DOI 10.1016/S1072-7515(02)01704-0; MOORE EE, 1991, AUST NZ J SURG, V61, P732, DOI 10.1111/j.1445-2197.1991.tb00141.x; Moore FA, 1996, J TRAUMA, V40, P501, DOI 10.1097/00005373-199604000-00001; MOORE FA, 1991, SURG CLIN N AM, V71, P699; Moore FA, 1997, ARCH SURG-CHICAGO, V132, P620; MOORE FA, 2002, AM COLL SURG ACS SUR, P31; MOORE FA, 1998, CONTEMP SURG, V53, P213; MOSS GS, 1984, SURGERY, V95, P249; Nielsen HJ, 1996, TRANSFUSION, V36, P960, DOI 10.1046/j.1537-2995.1996.36111297091738.x; O'Neill PA, 2002, J TRAUMA, V52, P400, DOI 10.1097/00005373-200202000-00034; Offner PJ, 2002, ARCH SURG-CHICAGO, V137, P711, DOI 10.1001/archsurg.137.6.711; OPELZ G, 1973, TRANSPLANT P, V5, P253; PARTHASARATHI K, 1999, AM J PHYSIOL, V277, pY2145; RABINER SF, 1967, J EXP MED, V126, P1127, DOI 10.1084/jem.126.6.1127; RABINOVICI R, 1989, SURG GYNECOL OBSTET, V169, P137; Revell M, 2003, J TRAUMA, V54, pS63, DOI 10.1097/01.TA.0000056157.94970.FA; Rezende-Neto JB, 2003, SHOCK, V20, P303, DOI 10.1097/01.shk.0000082487.34705.d3; Rhee P, 2003, J TRAUMA, V54, pS52, DOI 10.1097/01.TA.0000064507.80390.10; Rhee P, 2000, CRIT CARE MED, V28, P74, DOI 10.1097/00003246-200001000-00012; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; ROOTH G, 1976, CRIT CARE MED, V4, P162, DOI 10.1097/00003246-197605000-00009; Rotstein OD, 2000, J TRAUMA, V49, P580, DOI 10.1097/00005373-200010000-00002; Sailors RM, 2000, J AM MED INFORM ASSN, P1127; Sauaia A, 1998, J TRAUMA, V45, P291, DOI 10.1097/00005373-199808000-00014; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SAVITSKY JP, 1978, CLIN PHARMACOL THER, V23, P73; Schierhout G, 1998, BMJ-BRIT MED J, V316, P961, DOI 10.1136/bmj.316.7136.961; Schortgen F, 2001, LANCET, V357, P911, DOI 10.1016/S0140-6736(00)04211-2; Schreiber MA, 2002, J TRAUMA, V53, P252, DOI 10.1097/00005373-200208000-00011; Shackford SR, 1997, J TRAUMA, V42, pS48, DOI 10.1097/00005373-199705001-00009; SHAH DM, 1982, J TRAUMA, V22, P741, DOI 10.1097/00005373-198209000-00004; Shanwell A, 1997, TRANSFUSION, V37, P678, DOI 10.1046/j.1537-2995.1997.37797369441.x; SHIRES T, 1964, ARCH SURG-CHICAGO, V88, P688; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; Silliman CC, 1998, J CLIN INVEST, V101, P1458, DOI 10.1172/JCI1841; SILLIMAN CC, 1994, J LAB CLIN MED, V124, P684; SIMCHON S, 1987, AM J PHYSIOL, V253, pH898, DOI 10.1152/ajpheart.1987.253.4.H898; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Sims CA, 2001, CRIT CARE MED, V29, P1513, DOI 10.1097/00003246-200108000-00003; SKILLMAN JJ, 1975, SURGERY, V78, P291; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; SMITH GJ, 1985, J SURG RES, V39, P517, DOI 10.1016/0022-4804(85)90120-9; Soucy DM, 1999, J TRAUMA, V46, P209, DOI 10.1097/00005373-199902000-00001; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; TREMPER KK, 1981, CRIT CARE MED, V9, P706, DOI 10.1097/00003246-198110000-00007; TREMPER KK, 1980, CRIT CARE MED, V8, P608, DOI 10.1097/00003246-198011000-00002; Vamvakas EC, 2000, TRANSFUS MED REV, V14, P23, DOI 10.1016/S0887-7963(00)80113-3; VASSAR MJ, 1990, ARCH SURG-CHICAGO, V125, P1309; VELANOVICH V, 1989, SURGERY, V105, P65; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664, DOI 10.1152/ajpheart.1980.239.5.H664; Velmahos GC, 2000, ANN SURG, V232, P409, DOI 10.1097/00000658-200009000-00013; Vlahakes G J, 1989, Eur J Cardiothorac Surg, V3, P353, DOI 10.1016/1010-7940(89)90034-1; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; WAXMAN K, 1983, AM J SURG, V146, P35, DOI 10.1016/0002-9610(83)90255-6; Weil MH, 1999, CRIT CARE MED, V27, P1225, DOI 10.1097/00003246-199907000-00001; Weiskopf RB, 1998, JAMA-J AM MED ASSOC, V279, P217, DOI 10.1001/jama.279.3.217; Wiggers CJ, 1942, PHYSIOL REV, V22, P74, DOI 10.1152/physrev.1942.22.1.74; Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1; Zallen G, 2000, J TRAUMA, V48, P45, DOI 10.1097/00005373-200001000-00008; ZALLEN G, 1998, SURG FORUM, V49, P100; [No title captured]	135	206	227	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	2004	363	9425					1988	1996		10.1016/S0140-6736(04)16415-5	http://dx.doi.org/10.1016/S0140-6736(04)16415-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GW	15194260				2023-01-03	WOS:000221962800021
J	Murphy, NF; MacIntyre, K; Capewell, S; Stewart, S; Pell, J; Chalmers, P; Redpath, A; Frame, S; Boyd, J; McMurray, JJV				Murphy, NF; MacIntyre, K; Capewell, S; Stewart, S; Pell, J; Chalmers, P; Redpath, A; Frame, S; Boyd, J; McMurray, JJV			Hospital discharge rates for suspected acute coronary syndromes between 1990 and 2000: population based analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; CASE-FATALITY RATES; MORTALITY		Western Infirm & Associated Hosp, Dept Cardiol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; Univ Liverpool, Dept Publ Hlth, Liverpool L69 3GB, Merseyside, England; Univ S Australia, Div Hlth Sci, Adelaide, SA 5000, Australia; Greater Glasgow Hlth Board, Glasgow G3 8YU, Lanark, Scotland; Informat & Stat Div, Edinburgh EH5 3SQ, Midlothian, Scotland	University of Glasgow; University of Liverpool; University of South Australia	McMurray, JJV (corresponding author), Western Infirm & Associated Hosp, Dept Cardiol, Glasgow G12 8QQ, Lanark, Scotland.	j.mcmurrray@bio.gla.ac.uk	Macintyre, Kate/J-7174-2014; Stewart, Simon/M-3316-2016; mcmurray, John/B-2467-2013	Macintyre, Kate/0000-0003-2741-0467; Stewart, Simon/0000-0001-9032-8998; mcmurray, John/0000-0002-6317-3975; Pell, Jill/0000-0002-8898-7035; Boyd, James/0000-0002-8925-8811				Goldberg RJ, 1999, J AM COLL CARDIOL, V33, P1533, DOI 10.1016/S0735-1097(99)00040-6; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; Marques-Vidal P, 2000, HEART, V84, P171, DOI 10.1136/heart.84.2.171; McGovern PG, 2001, CIRCULATION, V104, P19, DOI 10.1161/01.CIR.104.1.19; Rosen M, 2000, J INTERN MED, V248, P159, DOI 10.1046/j.1365-2796.2000.00716.x	5	36	36	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	2004	328	7453					1413	1414		10.1136/bmj.38111.650741.F7	http://dx.doi.org/10.1136/bmj.38111.650741.F7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830IB	15155470	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000222114400021
J	Benn, CS; Melbye, M; Wohlfahrt, J; Bjorksten, B; Aaby, P				Benn, CS; Melbye, M; Wohlfahrt, J; Bjorksten, B; Aaby, P			Cohort study of sibling effect, infectious diseases, and risk of atopic dermatitis during first 18 months of life	BRITISH MEDICAL JOURNAL			English	Article							FAMILY-SIZE; HAY-FEVER; RESPIRATORY-INFECTIONS; BIRTH COHORT; CHILDREN; ASTHMA; PREVALENCE; ALLERGY; DETERMINANTS; ANTIBODIES	Objectives To determine whether early infectious diseases could explain the association between number of siblings and other markers of microbial exposure and the development of atopic dermatitis before the age of 18 months. Design Cohort study. Information on atopic dermatitis, infectious diseases occurring before 6 months of age, number of siblings, early day care, pet keeping, farm residence, and background factors was collected in telephone interviews. Setting Danish national birth cohort. Participants 24341 mother-child pairs. Main outcome measures Incidence rate ratios of atopic dermatitis. Results 13070 children (54%) had at least one clinically apparent infectious disease before 6 months of age. At age 18 months, 2638 (10.8%) of the children had had atopic dermatitis. The risk of atopic dermatitis increased with each infectious disease before 6 months of age (incidence rate ratio 1.08,95% confidence interval 1.04 to 1.13). The risk of atopic dermatitis decreased with each additional exposure to three or more siblings, day care, pet ownership, and farm residence (0.86, 0.81 to 0.93). Conclusions Early infections do not seem to protect against allergic diseases. The protective effect of number of siblings, day care, pet ownership, and farm residence remained after adjustment for clinically apparent infectious diseases, suggesting that the effect is established independently early in life.	Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, Copenhagen, Denmark; Projecto Saude Bandim, Bissau, Guinea Bissau; Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Stockholm, Sweden	Aarhus University; Statens Serum Institut; Karolinska Institutet; Karolinska Institutet	Benn, CS (corresponding author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, Copenhagen, Denmark.	C.Benn.cb@ssi.dk		Aaby, Peter/0000-0001-8331-1389; melbye, mads/0000-0001-8264-6785				Benn CS, 2003, ACTA DERM-VENEREOL, V83, P347; Bjorksten B, 1999, J ALLERGY CLIN IMMUN, V104, P1119; Bodner C, 1998, THORAX, V53, P28, DOI 10.1136/thx.53.1.28; Bohme M, 2002, ACTA DERM-VENEREOL, V82, P98, DOI 10.1080/00015550252948112; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; Forastiere F, 1997, EPIDEMIOLOGY, V8, P566, DOI 10.1097/00001648-199709000-00015; Harris JM, 2001, BRIT J DERMATOL, V144, P795, DOI 10.1046/j.1365-2133.2001.04135.x; Kalliomaki M, 2003, CURR OPIN ALLERGY CL, V3, P15, DOI [10.1097/00130832-200302000-00003, 10.1097/01.all.0000053262.39029.a1]; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Karmaus W, 2001, AM J EPIDEMIOL, V154, P909, DOI 10.1093/aje/154.10.909; Linneberg A, 2003, J ALLERGY CLIN IMMUN, V111, P847, DOI 10.1067/mai.2003.1335; Matricardi PM, 2001, CURR OPIN ALLERGY CL, V1, P413, DOI 10.1097/00130832-200110000-00006; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; Nafstad P, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e38; Olsen J, 2001, SCAND J PUBLIC HEALT, V29, P300, DOI 10.1177/14034948010290040201; Ponsonby AL, 1999, THORAX, V54, P664, DOI 10.1136/thx.54.8.664; RYSTEDT I, 1986, BRIT J DERMATOL, V114, P575, DOI 10.1111/j.1365-2133.1986.tb04064.x; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1996, ARCH DIS CHILD, V74, P422, DOI 10.1136/adc.74.5.422; Strannegard O, 2001, ALLERGY, V56, P91, DOI 10.1034/j.1398-9995.2001.056002091.x; Wickens KL, 1999, EPIDEMIOLOGY, V10, P699, DOI 10.1097/00001648-199911000-00009	23	134	135	2	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 22	2004	328	7450					1223	1226		10.1136/bmj.38069.512245.FE	http://dx.doi.org/10.1136/bmj.38069.512245.FE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824HL	15121716	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000221677200015
J	Gertsch, JH; Basnyat, B; Johnson, EW; Onopa, J; Holck, PS				Gertsch, JH; Basnyat, B; Johnson, EW; Onopa, J; Holck, PS		Prevention High Altitude Illness T	Randomised, controlled trial of ginkgo biloba and acetazolamide for prevention of acute mountain sickness: the prevention of high altitude illness trial (PHAIT)	BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND; PROPHYLAXIS; EFFICACY	Objective To evaluate the efficacy of ginkgo biloba, acetazolamide, and their combination as prophylaxis against acute mountain sickness. Design Prospective, double blind, randomised, placebo controlled trial. Setting Approach to Mount Everest base camp in the Nepal Himalayas. at 4280 m or 4358 m and study end point at 4928 m during October and November 2002.. Participants 614 healthy western trekkers (487 completed the trial) assigned to receive ginkgo, acetazolamide, combined acetazolamide and ginkgo, or placebo, initially taking at least three or four doses before continued ascent. Main outcome measures Incidence measured by Lake Louise acute mountain sickness score greater than or equal to 3 with. headache and one other symptom. Secondary outcome measures included blood oxygen content, severity of syndrome (Lake Louise scores greater than or equal to 5), incidence of headache, and severity of headache. Results Ginkgo was not significantly different from placebo for any outcome; however participants in the acetazolamide group showed significant levels of protection. The incidence of acute mountain sickness was 34% for placebo, 12% for acetazolamide (odds ratio 3.76,95% confidence interval 1.91 to 7.39, number needed to treat 4),35% for ginkgo (0.95, 0.56 to 1.62), and 14% for combined ginkgo and acetazolamide (3.04, 1.62 to 5.69). The proportion of patients with increased severity of acute mountain sickness was 18% for placebo, 3% for acetazolamide (6.46, 2.15 to 19.40, number needed to treat 7), 18% for ginkgo (1, 0.52 to 1.90), and 7% for combined ginkgo and acetazolamide (2.95, 1.30 to 6.70). Conclusions When compared with placebo, ginkgo is not effective at preventing acute mountain sickness. Acetazolamide 250 mg twice daily afforded robust protection against symptoms of acute mountain sickness.	Maricopa Cty Gen Hosp, Dept Internal Med, Phoenix, AZ 85008 USA; Himalayan Rescue Associat, Kathmandu, Nepal; Univ Washington, Sch Med, Seattle, WA 98195 USA; Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA	Maricopa County General Hospital; University of Washington; University of Washington Seattle; University of Hawaii System	Gertsch, JH (corresponding author), Maricopa Cty Gen Hosp, Dept Internal Med, 2601 E Roosevelt Ave Number O-D-10, Phoenix, AZ 85008 USA.	jeffgertsch@hotmail.com						Bailey DM, 2001, HIGH ALT MED BIOL, V2, P21, DOI 10.1089/152702901750067882; BARTSCH P, 1993, HYPOXIA AND MOLECULAR MEDICINE, P265; Basnyat B, 2003, HIGH ALT MED BIOL, V4, P45, DOI 10.1089/152702903321488979; BASNYAT B, 2001, CONNS CURRENT THERAP, P1166; Chen X, 1997, CLIN EXP PHARMACOL P, V24, P958, DOI 10.1111/j.1440-1681.1997.tb02727.x; Chow T. K., 2002, Medicine and Science in Sports and Exercise, V34, pS246, DOI 10.1097/00005768-200205001-01377; Dumont L, 2000, BRIT MED J, V321, P267, DOI 10.1136/bmj.321.7256.267; GERTSCH JH, 2002, HIGH ALT MED BIOL, V2, P110; HACKETT PH, 1976, LANCET, V2, P1149; Hackett PH, 2001, NEW ENGL J MED, V345, P107, DOI 10.1056/NEJM200107123450206; Leadbetter G, 2001, HIGH ALT MED BIOL, V2, P110; LEADBETTER GW, 2003, HIGH ALT MED BIOL, V3, P455; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Maggiorini M, 1998, AVIAT SPACE ENVIR MD, V69, P1186; MORAGA F, 2003, HIGH ALT MED BIOL, V3, P453; MURDOCH DR, 1995, AVIAT SPACE ENVIR MD, V66, P148; ROACH RC, 1993, HYPOXIA AND MOLECULAR MEDICINE, P272; Roncin JP, 1996, AVIAT SPACE ENVIR MD, V67, P445	18	88	91	1	18	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 3	2004	328	7443					797	799		10.1136/bmj.38043.501690.7C	http://dx.doi.org/10.1136/bmj.38043.501690.7C			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	811CG	15070635	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000220749400018
J	Turnbull, DA; Wilkinson, C; Gerard, K; Shanahan, M; Ryan, P; Griffith, EC; Kruzins, G; Stamp, GE				Turnbull, DA; Wilkinson, C; Gerard, K; Shanahan, M; Ryan, P; Griffith, EC; Kruzins, G; Stamp, GE			Clinical, psychosocial, and economic effects of antenatal day care for three medical complications of pregnancy: a randomised controlled trial of 395 women	LANCET			English	Article							HYPERTENSION; MANAGEMENT; HOSPITALIZATIONS; SAMPLE; SIZE	Background Day care is increasingly being used for complications of pregnancy, but there is little published evidence on its efficacy. We assessed the clinical, psychosocial, and economic effects of day care for three pregnancy complications in a randomised trial of day care versus standard care on an antenatal ward. Methods 395 women were randomly assigned day (263) or ward (132) care in a ratio of two to one, stratified for major diagnostic categories (non-proteinuric hypertension, proteinuric hypertension, and preterm premature rupture of membranes). The research hypothesis was that for these disorders, as an alternative to admission, antenatal day care will reduce specified interventions and investigations, result in no differences in clinical outcome, lead to greater satisfaction and psychological wellbeing, and be more cost-effective. Data were collected through case-note review, self-report questionnaires (response rates 81.0% or higher) and via the hospital's financial system. Analysis was by intention to treat. Findings All participants were included in the analyses. There were no differences between the groups in antenatal tests or investigations or intrapartum interventions. The total duration of antenatal care episodes was shorter in the day-care group than in the ward group (median 17 [IQR 5-9] vs 57 [35-123] h; p = 0.001). Overall stay was also significantly shorter in the day-care group (mean 7.22 [SE 0.31] vs 8.53 [0.44]; p = 0.014). The median number of care episodes was three (range one to 14) in the day-care group and two (one to nine) in the ward group (p = 0.01). There were no statistically or clinically significant differences in maternal or perinatal outcomes. The day-care group reported greater satisfaction, with no evidence of unintended psychosocial sequelae. There was no significant difference in either average cost per patient or average cost per day of care. Interpretation Since clinical outcomes and costs are similar, adoption by maternity services of a policy providing specified women with the choice between admission and day-unit care seems appropriate.	Womens & Childrens Hosp, Dept Gen Practice, Adelaide, SA, Australia; Womens & Childrens Hosp, Dept Psychol, Adelaide, SA, Australia; Womens & Childrens Hosp, Dept Publ Hlth, Adelaide, SA, Australia; Womens & Childrens Hosp, Dept Obstet, Adelaide, SA, Australia; Univ Southampton, Southampton Gen Hosp, Hlth Care Res Unit, Southampton, Hants, England; Univ Technol Sydney, Ctr Hlth Econ Res & Evaluat, Sydney, NSW 2007, Australia; Univ Technol Sydney, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2007, Australia; Univ S Australia, Ctr Res Nursing & Hlth Care, Adelaide, SA 5001, Australia	Womens & Childrens Hospital Australia; Womens & Childrens Hospital Australia; Womens & Childrens Hospital Australia; Womens & Childrens Hospital Australia; University of Southampton; University of Technology Sydney; University of Technology Sydney; University of South Australia	Turnbull, DA (corresponding author), Univ Adelaide, Dept Gen Practice, North Terrace, Adelaide, SA 5005, Australia.	deborah.turnbull@adelaide.edu.au	Wilkinson, Chris/I-7649-2015	Wilkinson, Chris/0000-0003-1438-0422; Shanahan, Marian/0000-0001-9873-3576				Adelson PL, 1999, MED J AUSTRALIA, V170, P211, DOI 10.5694/j.1326-5377.1999.tb140319.x; BOYCE P, 1993, AUST NZ J PSYCHIAT, V27, P472, DOI 10.3109/00048679309075805; Briggs A, 2000, BRIT MED J, V321, P1362, DOI 10.1136/bmj.321.7273.1362; BROWN MA, 1993, MED J AUSTRALIA, V158, P700; Brown MA, 2000, AUST NZ J OBSTET GYN, V40, P139, DOI 10.1111/j.1479-828X.2000.tb01137.x; *COMM DEP HLTH AG, 2001, ARDRG40 COMM DEP HLT; FRANKS AL, 1992, AM J OBSTET GYNECOL, V166, P1339, DOI 10.1016/0002-9378(92)91601-6; KRONER C, 2001, COCHRANE LIB; Murray D., 1990, J REPROD INFANT PSYC, V8, P99, DOI [DOI 10.1080/02646839008403615, 10.1080/02646839008403615]; *NSW HLTH FUND SYS, 200102 NSW HLTH FUND; *ROYAL COLL OBST G, 1996, R COLL OBSTET GYNAEC, V10, P1; RUSSELL IT, 1977, LANCET, V1, P844; *S AUSTR GOV, WORKPL SERV ERIC EMP; Scott CL, 1997, OBSTET GYNECOL, V90, P225, DOI 10.1016/S0029-7844(97)00230-5; Snowdon C, 1999, CONTROL CLIN TRIALS, V20, P149, DOI 10.1016/S0197-2456(98)00049-X; Torgerson DJ, 2000, BRIT MED J, V321, P697, DOI 10.1136/bmj.321.7262.697; Torrance GW, 1987, METHODS EC EVALUATIO; TUFFNELL DJ, 1992, LANCET, V339, P224, DOI 10.1016/0140-6736(92)90017-W; Turnbull D, 1996, LANCET, V348, P213; TWADDLE S, 1992, BRIT J OBSTET GYNAEC, V99, P459, DOI 10.1111/j.1471-0528.1992.tb13781.x; WALKER JJ, 1993, BRIT J HOSP MED, V50, P225; *WOM CHILDR HOSP, 1996, CLIN INF SERV OBST D; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203	23	30	31	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	2004	363	9415					1104	1109		10.1016/S0140-6736(04)15893-5	http://dx.doi.org/10.1016/S0140-6736(04)15893-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	808VB	15064028				2023-01-03	WOS:000220595500009
J	Michels, KB; Ekbom, A				Michels, KB; Ekbom, A			Caloric restriction and incidence of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECREATIONAL PHYSICAL-ACTIVITY; EPIDERMAL-GROWTH-FACTOR; ANOREXIA-NERVOSA; BODY-SIZE; ENERGY RESTRICTION; DIFFERENT PERIODS; MAMMARY-TUMORS; UNITED-STATES; YOUNG-WOMEN; LONG-TERM	Context Restricting caloric intake is one of the most effective ways to extend lifespan and to reduce spontaneous tumor occurrence in experimental animals, but whether similar associations hold in humans has not been appropriately studied. Objective To determine whether caloric restriction in early life reduces the risk of invasive breast cancer. Design, Setting, and Participants Retrospective cohort study using data from the Swedish Inpatient Registry, the Swedish Cancer Registry, the Swedish Death Registry, and the Swedish Fertility Registry. Participants were 7303 Swedish women hospitalized for anorexia nervosa prior to age 40 years between 1965 and 1998. Women were excluded (n=31)if they were diagnosed with cancer prior to their first discharge from hospitalization for anorexia nervosa. Main Outcome Measure Incidence of invasive breast cancer. Results Compared with the Swedish general population, women hospitalized for anorexia nervosa prior to age 40 years had a 53% (95% confidence interval [CI], 3%-81%) lower incidence of breast cancer; nulliparous women with anorexia nervosa had a 23% (95% CI, 79% higher to 75% lower) lower incidence, and parous women with anorexia nervosa had a 76% (95 % CI, 13%-97%) lower incidence. Conclusions Severe caloric restriction in humans may confer protection from invasive breast cancer. Low caloric intake prior to first birth followed by a subsequent pregnancy appears to be associated with an even more pronounced reduction in risk.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Karolinska Inst, Karolinska Hosp, Dept Med, Clin Epidemiol Unit, S-10401 Stockholm, Sweden	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Karolinska Institutet; Karolinska University Hospital	Michels, KB (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Obstet & Gynecol Epidemiol Ctr, 221 Longwood Ave, Boston, MA 02115 USA.	kmichels@rics.bwh.harvard.edu						Berkey CS, 1999, CANCER-AM CANCER SOC, V85, P2400, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2400::AID-CNCR15>3.0.CO;2-O; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BRUNING PF, 1995, INT J CANCER, V62, P266, DOI 10.1002/ijc.2910620306; Cleary MP, 2002, CANCER EPIDEM BIOMAR, V11, P836; Coates RJ, 1999, BRIT J CANCER, V81, P167, DOI 10.1038/sj.bjc.6690667; Dirx MJM, 2003, INT J CANCER, V106, P766, DOI 10.1002/ijc.11277; ENGELMAN RW, 1995, CANCER RES, V55, P1289; FERNANDES G, 1995, P NATL ACAD SCI USA, V92, P6494, DOI 10.1073/pnas.92.14.6494; Friedenreich CM, 2001, EUR J CANCER PREV, V10, P15, DOI 10.1097/00008469-200102000-00003; FRISCH RE, 1987, AM J CLIN NUTR, V45, P328, DOI 10.1093/ajcn/45.1.328; Gammon MD, 1998, AM J EPIDEMIOL, V147, P273; Gammon MD, 1998, JNCI-J NATL CANCER I, V90, P100, DOI 10.1093/jnci/90.2.100; Hall K., 1999, Journal of Endocrinological Investigation, V22, P48; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hilakivi-Clarke L, 2001, BRIT J CANCER, V85, P1680, DOI 10.1054/bjoc.2001.2109; KREIPE RE, 1989, AM J DIS CHILD, V143, P1322, DOI 10.1001/archpedi.1989.02150230080027; LEMARCHAND L, 1988, AM J EPIDEMIOL, V128, P137; Magnusson C, 1998, INT J CANCER, V76, P29, DOI 10.1002/(SICI)1097-0215(19980330)76:1<29::AID-IJC6>3.3.CO;2-1; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; Mellemkjaer L, 2001, CANCER CAUSE CONTROL, V12, P173, DOI 10.1023/A:1008974414116; Michels KB, 1996, LANCET, V348, P1542, DOI 10.1016/S0140-6736(96)03102-9; Michels KB, 2002, BREAST CANCER RES, V4, P58, DOI 10.1186/bcr423; MITTENDORF R, 1995, CANCER CAUSE CONTROL, V6, P347, DOI 10.1007/BF00051410; Munoz MT, 2002, EUR J ENDOCRINOL, V147, P275, DOI 10.1530/eje.0.1470275; Patel AV, 2003, CANCER CAUSE CONTROL, V14, P519, DOI 10.1023/A:1024895613663; Rockhill B, 1998, J NATL CANCER I, V90, P1155, DOI 10.1093/jnci/90.15.1155; ROSS MH, 1971, J NATL CANCER I, V47, P1095; Rous P, 1915, B JOHNS HOPKINS HOSP, V26, P146; RUGGERI BA, 1989, CANCER RES, V49, P4130; Spady TJ, 1999, J NUTR, V129, p587S, DOI 10.1093/jn/129.2.587S; *STAT SWED, 2002, 20025 SCB STAT SWED; SWANSON CA, 1988, CANCER RES, V48, P5363; *SWED CANC REG, 1993, CANC INC SWED 1990; TANNENBAUM A, 1953, CANCER RES, V13, P532; THEANDER S, 1985, J PSYCHIATR RES, V19, P493, DOI 10.1016/0022-3956(85)90059-7; THEANDER S, 1970, ACTA PSYCHIAT SCAND, P1; Thune I, 1997, NEW ENGL J MED, V336, P1269, DOI 10.1056/NEJM199705013361801; Trentham-Dietz A, 2000, CANCER CAUSE CONTROL, V11, P533, DOI 10.1023/A:1008961931534; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; Tretli S, 1996, CANCER CAUSE CONTROL, V7, P507, DOI 10.1007/BF00051882; van den Brandt PA, 2000, AM J EPIDEMIOL, V152, P514, DOI 10.1093/aje/152.6.514; Visscher MB, 1942, SURGERY, V11, P48; World Health Organization, 2003, WORLD HLTH REP 2003; Zhu ZJ, 1999, MOL CARCINOGEN, V24, P241, DOI 10.1002/(SICI)1098-2744(199904)24:4<241::AID-MC1>3.0.CO;2-P	44	129	134	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	2004	291	10					1226	1230		10.1001/jama.291.10.1226	http://dx.doi.org/10.1001/jama.291.10.1226			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800XV	15010444				2023-01-03	WOS:000220061900023
J	Schott, GD				Schott, GD			William Blake's Milton, John Birch's "Electrical Magic", and the "falling star"	LANCET			English	Article									UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Schott, GD (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.	geoffrey.schott@uclh.org						ACKROYD P, 1995, BLAKE, P83; Adlard John, 1969, NEOPHILOLOGUS, V53, P422; BIRCH J, 1802, ESSAY MED APPL ELECT, V4, P1; BLAKE W, 1804, POEM; ESSICK RN, 1993, BLAKES ILLUMINATED B, V5, P27; FARA P, 2002, INTERTAINMENT ANGELS, P81; HYMES A, 1984, CLIN TRANSCUTANEOUS, P1; KANE K, 1975, PAIN, V1, P125, DOI 10.1016/0304-3959(75)90097-4; KEYNES G, 1965, W BLAKE POET PRINTER, P25; KEYNES G, 1966, COMPLETE WRITINGS VA, P590; Nduati R, 2001, LANCET, V358, P1096, DOI 10.1016/S0140-6736(01)06205-5; SCHUCHARD MK, 1989, BLAKE-ILLUSTRATED Q, V23, P20	12	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 20	2003	362	9401					2114	2116		10.1016/S0140-6736(03)15115-X	http://dx.doi.org/10.1016/S0140-6736(03)15115-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697819				2023-01-03	WOS:000187429600033
J	Shann, F				Shann, F			Hypothermia for traumatic brain injury: how soon, how cold, and how long?	LANCET			English	Editorial Material							LOW INTRACRANIAL-PRESSURE; SEVERE HEAD-INJURY; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; CARDIAC-ARREST; HYPERTENSION		Royal Childrens Hosp, Intens Care Unit, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne	Shann, F (corresponding author), Royal Childrens Hosp, Intens Care Unit, Flemington Rd, Parkville, Vic 3052, Australia.		Shann, Frank/C-9510-2011					Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Colbourne F, 1998, STROKE, V29, P1967, DOI 10.1161/01.STR.29.9.1967; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; GADKARY CA, 2003, COCHRANE LIB; Gunn AJ, 2000, CURR OPIN PEDIATR, V12, P111, DOI 10.1097/00008480-200004000-00004; HIRAYAMA T, 1994, INTRACRANIAL PRESSUR, V9; Holzer M, 2002, NEW ENGL J MED, V346, P549; Iida K, 2003, J NEUROSURG, V98, P793, DOI 10.3171/jns.2003.98.4.0793; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; LEROUX PD, 1991, CHILD NERV SYST, V7, P34, DOI 10.1007/BF00263831; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; MEISSNER W, 1998, CRITICAL CARE MED S1, V26, pA82; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; SCHUBERT A, 1995, J NEUROSURG ANESTH, V7, P139, DOI 10.1097/00008506-199504000-00021; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Yan Y, 2001, Chin J Traumatol, V4, P8; Zhang K, 2000, INNER MONGOLIA MED J, V32, P4	27	33	36	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 13	2003	362	9400					1950	1951		10.1016/S0140-6736(03)15083-0	http://dx.doi.org/10.1016/S0140-6736(03)15083-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	753BC	14683651				2023-01-03	WOS:000187210700004
J	Carriere, V; Vidal, R; Lazou, K; Lacasa, M; Delers, F; Ribeiro, A; Rousset, M; Chambaz, J; Lacorte, JM				Carriere, V; Vidal, R; Lazou, K; Lacasa, M; Delers, F; Ribeiro, A; Rousset, M; Chambaz, J; Lacorte, JM			HNF-4-dependent induction of apolipoprotein A-IV gene transcription by an apical supply of lipid micelles in intestinal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; POLYUNSATURATED FATTY-ACIDS; NUCLEAR FACTOR 4-ALPHA; FARNESOID-X-RECEPTOR; PROTEIN-KINASE-A; DIFFERENTIAL EXPRESSION; SUCRASE-ISOMALTASE; DIETARY N-3; SECRETION; ENHANCER	Apolipoprotein (apo) A-IV, a component of triglyceride-rich lipoproteins secreted by the small intestine, has been shown to play an important role in the control of lipid homeostasis. Numerous studies have described the induction of apoA-IV gene expression by lipids, but the molecular mechanisms involved in this process remain unknown. In this study, we have demonstrated that a lipid bolus induced transcription of the apoA-IV gene in transgenic mice and that the regulatory region of the apoA-IV gene, composed of the apoC-III enhancer and the apoA-IV promoter (eC3-A4), was responsible for this induction. In enterocyte Caco-2/TC7 cells, a permanent supply of lipids at the basal pole induced expression of the apoA-IV gene both at the transcriptional level and through mRNA stabilization. ApoA-11V gene transcription and protein secretion were further induced by an apical supply of complex lipid micelles mimicking the composition of duodenal micelles, and this effect was not reproduced by apical delivery of different combinations of micelle components. Only induction of the apoA-IV gene by lipid micelles involved the participation of hepatic nuclear factor (HNF)-4, as demonstrated using a dominant negative form of this transcription factor. Accordingly, lipid micelles increased the DNA binding activity of HNF-4 on the eC3-A4 region. These results emphasize the importance of physiological delivery of dietary lipids on apoA-IV gene expression and the implication of HNF-4 in this regulation.	UPMC, INSERM, Ctr Rech Biomed Cordeliers, UMR505, F-75006 Paris, France; Univ Paris 06, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite	Carriere, V (corresponding author), UPMC, INSERM, Ctr Rech Biomed Cordeliers, UMR505, 15 Rue Ecole Med, F-75006 Paris, France.	Veronique.Cai-riere-u505@bhdc.jussieu.fr	Ribeiro, Agnès/Q-9702-2017; Carrière, Véronique/AAQ-5027-2021	Ribeiro, Agnès/0000-0003-2063-6084; Carrière, Véronique/0000-0002-6263-0847				BLACK DD, 1990, J LIPID RES, V31, P497; Botham KM, 2003, EXP BIOL MED, V228, P143, DOI 10.1177/153537020322800203; Carriere V, 2001, BIOCHEM J, V354, P301, DOI 10.1042/0264-6021:3540301; Carriere V, 1998, AM J PHYSIOL-GASTR L, V274, pG1101, DOI 10.1152/ajpgi.1998.274.6.G1101; CHANTRET I, 1994, J CELL SCI, V107, P213; Chateau D, 2005, J CELL PHYSIOL, V202, P767, DOI 10.1002/jcp.20173; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CLANDININ MT, 1994, J PEDIATR-US, V125, pS25, DOI 10.1016/S0022-3476(06)80733-X; Claudel T, 2003, GASTROENTEROLOGY, V125, P544, DOI 10.1016/S0016-5085(03)00896-5; Dyer J, 2003, BIOCHEM SOC T, V31, P1140, DOI 10.1042/BST0311140; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; HAYASHI H, 1990, J LIPID RES, V31, P1613; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; HERNELL O, 1990, BIOCHEMISTRY-US, V29, P2041, DOI 10.1021/bi00460a012; Hertz R, 2003, J BIOL CHEM, V278, P22578, DOI 10.1074/jbc.M212138200; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Heshka JT, 2001, LIFE SCI, V69, P987, DOI 10.1016/S0024-3205(01)01201-2; Hirokane H, 2004, J BIOL CHEM, V279, P45685, DOI 10.1074/jbc.M404255200; Hong YH, 2003, J BIOL CHEM, V278, P27495, DOI 10.1074/jbc.M304112200; JUMARIE C, 1991, J CELL PHYSIOL, V149, P24, DOI 10.1002/jcp.1041490105; KINSELLA JE, 1990, JPEN-PARENTER ENTER, V14, pS200, DOI 10.1177/014860719001400511; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; Lacorte JM, 1996, BIOCHEM J, V318, P681, DOI 10.1042/bj3180681; Lambert G, 2003, J BIOL CHEM, V278, P2563, DOI 10.1074/jbc.M209525200; Lavrentiadou SN, 1999, BIOCHEMISTRY-US, V38, P964, DOI 10.1021/bi981068i; Le Beyec J, 1999, J BIOL CHEM, V274, P4954, DOI 10.1074/jbc.274.8.4954; Liu M, 2003, EXP BIOL MED, V228, P1181, DOI 10.1177/153537020322801013; Lu S, 2002, J LIPID RES, V43, P1303, DOI 10.1194/jlr.M200035-JLR200; Lu S, 2003, AM J PHYSIOL-GASTR L, V284, pG248, DOI 10.1152/ajpgi.00391.2002; Morel E, 2004, MOL BIOL CELL, V15, P132, DOI 10.1091/mbc.E03-04-0215; Petrescu AD, 2003, J BIOL CHEM, V278, P51813, DOI 10.1074/jbc.M303858200; Rajas F, 1999, GASTROENTEROLOGY, V117, P132, DOI 10.1016/S0016-5085(99)70559-7; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Rodolosse A, 1998, BIOCHEM J, V336, P115, DOI 10.1042/bj3360115; Sauvaget D, 2002, J BIOL CHEM, V277, P34540, DOI 10.1074/jbc.M206074200; Shih DQ, 2000, DIABETES, V49, P832, DOI 10.2337/diabetes.49.5.832; Shimamoto Y, 2004, J BIOL CHEM, V279, P7770, DOI 10.1074/jbc.M310577200; Stan S, 2003, BBA-MOL CELL BIOL L, V1631, P177, DOI 10.1016/S1388-1981(03)00004-0; Tillman TS, 2003, CELL BIOCHEM BIOPHYS, V38, P161, DOI 10.1385/CBB:38:2:161; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Wang AB, 2003, EXP CELL RES, V290, P1, DOI 10.1016/S0014-4827(03)00313-6; Yamamoto T, 2004, J BIOL CHEM, V279, P12027, DOI 10.1074/jbc.M310333200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zannis VI, 2001, FRONT BIOSCI-LANDMRK, V6, pD456, DOI 10.2741/Zannis; Zheng XZ, 2001, BIOCHEM J, V357, P481, DOI 10.1042/0264-6021:3570481	47	32	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5406	5413		10.1074/jbc.M408002200	http://dx.doi.org/10.1074/jbc.M408002200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15583007	hybrid			2023-01-03	WOS:000227217100037
J	Meijer, R; van Limbeek, J				Meijer, R; van Limbeek, J			Early supported discharge: a valuable alternative for some stroke patients	LANCET			English	Editorial Material							OF-THE-LITERATURE; PROGNOSTIC-FACTORS; SUBACUTE PHASE		Rehabil Ctr, Dept Neurol Rehabil, NL-6800 GG Arnhem, Netherlands; Sint Maartensklin Nijmegen, Dept Rehabil Med, Nijmegen, Netherlands; Sint Maartensklin Nijmegen, SMK Res, Nijmegen, Netherlands	Sint Maartens Clinic; Sint Maartens Clinic	Meijer, R (corresponding author), Rehabil Ctr, Dept Neurol Rehabil, Groot Klimmendaal, NL-6800 GG Arnhem, Netherlands.	r.meijer@grootklimmendaal.nl						Asplund K, 1997, STROKE, V28, P2139, DOI 10.1161/01.STR.28.11.2139; *EARL SUPP DISCH T, 2000, COCHRANE DATABASE SY, V2, DOI UNSP CD0004433; *EARL SUPP DISCH T, IN PRESS COCHRANE DA; Meijer R, 2004, DISABIL REHABIL, V26, P191, DOI 10.1080/09638280310001636437; Meijer R, 2003, INT J REHABIL RES, V26, P265, DOI 10.1097/00004356-200312000-00003; Meijer R, 2003, CLIN REHABIL, V17, P512, DOI 10.1191/0269215503cr644oa; Meijer R, 2003, CLIN REHABIL, V17, P119, DOI 10.1191/0269215503cr585oa; MULDER T, 1991, PHYS THER, V71, P157, DOI 10.1093/ptj/71.2.157; Mulder Theo, 2001, Neural Plasticity, V8, P131, DOI 10.1155/NP.2001.131; *STROK UN TRIAL CO, 2002, COCHRANE DB SYST REV, V1	10	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 5	2005	365	9458					455	456						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705442				2023-01-03	WOS:000226812500006
J	Clarke, J; Cranswick, G; Dennis, MS; Flaig, R; Fraser, A; Grant, S; Gunkel, A; Hunter, J; Lewis, S; Perry, D; Soosay, V; Williams, C; Williamson, A; Young, A; Bulpitt, CJ; Grant, A; Murray, G; Sandercock, P; Anderson, N; Bahar, S; Hankey, G; Ricci, S; Bathgate, G; Chalmers, C; Cranswick, G; Dennis, MS; Farrell, B; Forbes, J; Ghosh, S; Langhorne, P; Levis, S; MacIntyre, J; McAteer, CA; O'Neill, P; Potter, J; Roberts, M; Warlow, C; Dennis, MS; Lewis, SC; Warlow, C				Clarke, J; Cranswick, G; Dennis, MS; Flaig, R; Fraser, A; Grant, S; Gunkel, A; Hunter, J; Lewis, S; Perry, D; Soosay, V; Williams, C; Williamson, A; Young, A; Bulpitt, CJ; Grant, A; Murray, G; Sandercock, P; Anderson, N; Bahar, S; Hankey, G; Ricci, S; Bathgate, G; Chalmers, C; Cranswick, G; Dennis, MS; Farrell, B; Forbes, J; Ghosh, S; Langhorne, P; Levis, S; MacIntyre, J; McAteer, CA; O'Neill, P; Potter, J; Roberts, M; Warlow, C; Dennis, MS; Lewis, SC; Warlow, C		FOOD Trial Collaboration	Effect of timing and method of enteral tube feeding for dysphagic stroke patients (FOOD): a multicentre randomised controlled trial	LANCET			English	Article							NUTRITIONAL-STATUS; MALNUTRITION	Background Undernutrition is common inpatients admitted with stroke. We aimed to establish whether the timing and route of enteral tube feeding after stroke affected patients' outcomes at 6 months. Methods The FOOD trials consist of three pragmatic multicentre randomised controlled trials, two of which included dysphagic stroke patients. In one trial, patients enrolled within 7 days of admission were randomly allocated to early enteral tube feeding or no tube feeding for more than 7 days (early versus avoid). In the other, patients were allocated percutaneous endoscopic gastrostomy (PEG) or nasogastric feeding. The primary outcome was death or poor outcome at 6 months. Analysis was by intention to treat. Findings Between Nov 1, 1996, and July 31, 2003, 859 patients were enrolled by 83 hospitals in 15 countries into the early versus avoid trial. Early tube feeding was associated with an absolute reduction in risk of death of 5 . 8% (95% CI -0 . 8 to 12 . 5, p=0.09) and a reduction in death or poor outcome of 1 . 2% (-4.2 to 6.6, p=0.7). In the PEG versus nasogastric tube trial, 321 patients were enrolled by 47 hospitals in 11 countries. PEG feeding was associated with an absolute increase in risk of death of 1 . 0% (-10 . 0 to 11 . 9, p=0 . 9) and an increased risk of death or poor outcome of 7.8% (0 . 0 to 15 . 5, p=0 . 05). Interpretation Early tube feeding might reduce case fatality, but at the expense of increasing the proportion surviving with poor outcome. Our data do not support a policy of early initiation of PEG feeding in dysphagic stroke patients.	Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Dennis, MS (corresponding author), Western Gen Hosp, Dept Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	martin.dennis@ed.ac.uk	Hankey, Graeme J/H-4968-2014; Lindley, Richard/B-8148-2013; Forbes, John F/L-2558-2013	Hankey, Graeme J/0000-0002-6044-7328; Lindley, Richard/0000-0002-0104-5679; Forbes, John F/0000-0002-8255-3762; Cohen, David/0000-0001-7318-8567; dennis, martin/0000-0003-1148-8972	National Institute for Health Research [96/29/01] Funding Source: researchfish; Department of Health [96/29/01] Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); Department of Health		AXELSSON K, 1988, ACTA MED SCAND, V224, P217; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; BARER DH, J NEUROL NEUROSURG P, V52, P236; BATH PMW, 2002, COCHRANE LIB; Choi-Kwon S, 1998, ACTA NEUROL SCAND, V98, P187, DOI 10.1111/j.1600-0404.1998.tb07292.x; Counsell C, 2002, STROKE, V33, P1041, DOI 10.1161/hs0402.105909; COUNSELL CE, 1998, THESIS U CAMBRIDGE C; Davalos A, 1996, STROKE, V27, P1028, DOI 10.1161/01.STR.27.6.1028; Dennis M, 2005, LANCET, V365, P755, DOI 10.1016/S0140-6736(05)17982-3; Dennis M, 2003, STROKE, V34, P127, DOI 10.1161/01.STR.0000044165.41303.50; Dolan P, 1995, SOCIAL TARIFF EUROQO; Dorman PJ, 1997, BRIT MED J, V315, P461, DOI 10.1136/bmj.315.7106.461; EBRAHIM S, 1999, STROKE CARE MATTER C; FINESTONE HM, 1995, ARCH PHYS MED REHAB, V76, P310, DOI 10.1016/S0003-9993(95)80655-5; *FOOD TRIAL COLL, 2003, STROKE, V34, P140; Gariballa SE, 1998, AM J CLIN NUTR, V68, P275, DOI 10.1093/ajcn/68.2.275; Mann G, 1999, STROKE, V30, P744, DOI 10.1161/01.STR.30.4.744; Mead GE, 1998, INT J CLIN PRACT, V52, P316; Norton B, 1996, BRIT MED J, V312, P13, DOI 10.1136/bmj.312.7022.13; Smithard DG, 1997, DYSPHAGIA, V12, P188, DOI 10.1007/PL00009535; UNOSSON M, 1994, STROKE, V25, P366, DOI 10.1161/01.STR.25.2.366; Weir NU, 2003, J NEUROL NEUROSUR PS, V74, P447, DOI 10.1136/jnnp.74.4.447	22	179	215	2	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB-MAR	2005	365	9461					764	772						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	901LZ	15733717	Green Published			2023-01-03	WOS:000227285300023
J	Berndt, ER				Berndt, ER			To inform or persuade? Direct-to-consumer advetising of prescription drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									MIT, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Berndt, ER (corresponding author), MIT, Cambridge, MA 02139 USA.							AIKIN KJ, 2003, DIR TO CONS PROM PUB; *FOOD DRUG ADM, GUID IND BRIEF SUMM; WEISSMAN JS, 2004, PHYSICIANS REPORT PA; 2004, PINK SHEET      122, P16	4	37	37	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2005	352	4					325	328		10.1056/NEJMp048357	http://dx.doi.org/10.1056/NEJMp048357			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890UH	15673797				2023-01-03	WOS:000226535900002
J	Hewlett, S; Kirwan, J; Pollock, J; Mitchell, K; Hehir, M; Blair, PS; Memel, D; Perry, MG				Hewlett, S; Kirwan, J; Pollock, J; Mitchell, K; Hehir, M; Blair, PS; Memel, D; Perry, MG			Patient initiated outpatient follow up in rheumatoid arthritis: six year randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To determine whether direct access to hospital review initiated by patients with rheumatoid arthritis would result in improved clinical mid psychological outcome, reduced overall use of healthcare resources, and greater satisfaction with care than seen in patients receiving regular review initiated by a rheumatologist. Design two year randomised controlled trial extended to six years. Setting Rheumatology outpatient department in teaching hospital. Participants 209 consecutive patients with rheumatoid arthritis for over two years; 68 (65%) in the direct access group and 52 (50%) in the control group completed the study (P = 0.04). Main outcome measures Clinical outcome: pain, disease activity, early morning stiffness, inflammatory indices, disability, grip strength, range of movement in joints, and bone erosion. Psychological status: anxiety, depression, helplessness, self efficacy, satisfaction, and confidence in die system. Number of visits to hospital physician mid general,practitioner for arthritis. Results Participants were well matched at baseline. After six years there was only one significant difference between the two groups for the 14 clinical outcomes measured (deterioration in range of movement in elbow was less in direct access patients). There were no significant differences between groups for median change in psychological status. Satisfaction and confidence in the system were significantly higher in the direct access group at two, four, and six years: confidence 9.8 v 8.4, 9.4 v 8, 8.7 v 6.9; satisfaction 9.3 v 8.3, 9.3 v 7.7, 8.9 v 7.1 (All P < 0.02). Patients in the direct access go-roup had 38% fewer hospital appointments (median 8 v 13, P < 0.0001). years rheumatoid Conclusions Over six years, patients with rheumatoid arthritis who initiated their reviews through direct access were clinically and psychologically at least as well as patients having traditional reviews initiated by a physician. The), requested fewer appointments, found direct access more acceptable, mid had more than a third fewer medical appointments. This radical responsive management could be tested in other chronic diseases.	Univ Bristol Acad, Rheumatol Unit, Bristol Royal Infirm, Bristol BS2 8HW, Avon, England; Univ W England, Fac Hlth & Social Care, Bristol BS16 1DD, Avon, England; Univ Bristol, Inst Child Hlth, UBHT Educ Ctr, Bristol Royal Infirm, Bristol, Avon, England; Air Balloon Surg, Bristol BS5 7PD, Avon, England	Bristol Royal Infirmary; University of Bristol; University of West England; Bristol Royal Infirmary; University of Bristol	Hewlett, S (corresponding author), Univ Bristol Acad, Rheumatol Unit, Bristol Royal Infirm, Bristol BS2 8HW, Avon, England.	Sarah.Hewlett@bristol.ac.uk	Blair, Peter S/C-1213-2009	Blair, Peter/0000-0002-7832-8087; Kirwan, John/0000-0002-6617-3217				Bellamy N., 1993, MUSCULOSKELETAL CLIN; Department of Health, 2001, EXP PAT NEW APPR CHR; Dickson DJ, 1996, BRIT J RHEUMATOL, V35, P920; Dolan SA, 1995, J EPIDEMIOL COMMUN H, V49, pS30, DOI 10.1136/jech.49.Suppl_2.S30; FAULKNER A, 1993, EVALUATION DELIVERY, V48, P54; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; Hehir M, 2001, RHEUMATOLOGY, V40, P146; Hewlett S, 2000, RHEUMATOLOGY, V39, P990, DOI 10.1093/rheumatology/39.9.990; Kirwan JR, 1997, BRIT J RHEUMATOL, V36, P481; Kirwan JR, 2003, RHEUMATOLOGY, V42, P422, DOI 10.1093/rheumatology/keg130; KIRWAN JR, 1991, BRIT J RHEUMATOL, V30, P285; Kirwan JR, 2000, J RHEUMATOL, V27, P264; LARSEN A, 1977, ACTA RADIOL DIAGN, V18, P481, DOI 10.1177/028418517701800415; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37, DOI 10.1002/anr.1780320107; Memel D., 2003, PRIM HEALTH CARE RES, V4, P29, DOI DOI 10.1191/1463423603pc120oa; MOWAT AG, 1980, ANN RHEUM DIS, V39, P12, DOI 10.1136/ard.39.1.12; PINCUS T, 1993, BRIT J RHEUMATOL, V32, P28; Reeve H, 1997, FAM PRACT, V14, P24, DOI 10.1093/fampra/14.1.24; Robinson A, 2001, LANCET, V358, P976, DOI 10.1016/S0140-6736(01)06105-0; Schulpen G J.C., 2003, Eur J Intern Med, V14, P158, DOI 10.1016/S0953-6205(03)00031-1; STEIN MJ, 1988, J RHEUMATOL, V15, P427; SYMMONS D, 2002, HLTH CARE NEEDS ASSE; VANDAMME R, 1994, BRIT J GEN PRACT, V44, P9; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Williams JG, 2000, BRIT MED J, V320, P544, DOI 10.1136/bmj.320.7234.544; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	26	87	87	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 22	2005	330	7484					171	175		10.1136/bmj.38265.493773.8F	http://dx.doi.org/10.1136/bmj.38265.493773.8F			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891OQ	15546895	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000226590800016
J	Schanda, H				Schanda, H			Psychiatry reforms and illegal behaviour of the severely mentally ill	LANCET			English	Editorial Material							DISORDERS; DEINSTITUTIONALIZATION; SCHIZOPHRENIA; HOMICIDES; ILLNESS; 25-YEAR; CARE		Justizanstalt Gollersdorf, A-2013 Gollersdorf 17, Austria; Psychiat Univ Clin, Vienna, Austria		Schanda, H (corresponding author), Justizanstalt Gollersdorf, A-2013 Gollersdorf 17, Austria.	hans.schanda@meduniwien.ac.at						Erb Martin, 2001, Crim Behav Ment Health, V11, P6, DOI 10.1002/cbm.366; Eronen M, 1996, ARCH GEN PSYCHIAT, V53, P497; Fazel S, 2002, LANCET, V359, P545, DOI 10.1016/S0140-6736(02)07740-1; GOTTLIEB P, 1987, ACTA PSYCHIAT SCAND, V76, P285, DOI 10.1111/j.1600-0447.1987.tb02897.x; HODGINS S, 1996, ARCH GEN PSYCHIAT, V53, P486; Mullen PE, 2000, LANCET, V355, P614, DOI 10.1016/S0140-6736(99)05082-5; Munk-Jorgensen P, 1999, EUR ARCH PSY CLIN N, V249, P136, DOI 10.1007/s004060050078; Schanda H, 2000, INT J LAW PSYCHIAT, V23, P481, DOI 10.1016/S0160-2527(00)00045-5; Schanda H, 2004, EUR PSYCHIAT, V19, p30S; Schanda H, 2004, ACTA PSYCHIAT SCAND, V110, P98, DOI 10.1111/j.1600-0047.2004.00305.x; Simpson AIF, 2004, BRIT J PSYCHIAT, V185, P394, DOI 10.1192/bjp.185.5.394; Taylor PJ, 1999, BRIT J PSYCHIAT, V174, P9, DOI 10.1192/bjp.174.1.9; TAYLOR PJ, 1997, CRIMINAL BEHAV MENT, V7, P19; Wallace C, 2004, AM J PSYCHIAT, V161, P716, DOI 10.1176/appi.ajp.161.4.716	14	14	14	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN-FEB	2005	365	9457					367	369						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	891WE	15680440				2023-01-03	WOS:000226610900007
J	White, P; Lewith, G; Prescott, P; Conway, J				White, P; Lewith, G; Prescott, P; Conway, J			Acupuncture versus placebo for the treatment of chronic mechanical neck pain - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							CERVICAL SPONDYLOSIS; LONGITUDINAL DATA; DISABILITY INDEX; CLINICAL-TRIALS; OSTEOARTHRITIS; INTERVENTIONS; STIMULATION; RELIABILITY; DISORDERS; MEDICINE	Background: Despite substantial increases in its popularity and use, the efficacy of acupuncture for chronic mechanical neck pain remains unproved. Objective: To compare acupuncture and placebo for neck pain. Design: A randomized, single-blind, placebo-controlled, parallel-arm trial with 1-year follow-up. Setting: The outpatient departments of 2 major hospitals in the United Kingdom, 1999 to 2001. Patients: 135 patients 18 to 80 years of age who had chronic mechanical neck pain. Eleven patients withdrew from treatment, and 124 completed the primary end point. Measurements: The primary outcome was pain 1 week after treatment, according to a visual analogue scale. Secondary outcomes were pain at other time points, score on the Neck Disability Index and the Short Form-36, and use of analgesic medications. Interventions: Patients were randomly assigned to receive, over 4 weeks, 8 treatments with acupuncture or with mock transcutaneous electrical stimulation of acupuncture points using a decommissioned electroacupuncture stimulation unit. Results: Both groups improved statistically from baseline, and acupuncture and placebo had similar credibility. For the primary outcome (weeks 1 to 5), a statistically significant difference in visual analogue scale score in favor of acupuncture (6.3 mm [95% CI, 1.4 to 11.3 mm]; P = 0.01) was observed between the 2 study groups, after adjustment for baseline pain and other covariates. However, this difference was not clinically significant because it demonstrated only a 12% (CI, 3% to 21%) difference between acupuncture and placebo. Secondary outcomes showed a similar pattern. Limitations: All treatments were provided by 1 practitioner. Although the control was credible, it did not mimic the process of needling. A nonintervention group was not present to control for regression to the mean. Conclusions: Acupuncture reduced neck pain and produced a statistically, but not clinically, significant effect compared with placebo. The beneficial effects of acupuncture for pain may be due to both nonspecific and specific effects.	Univ Southampton, Southampton, Hants, England	University of Southampton	White, P (corresponding author), Univ Southampton, Southampton, Hants, England.	pjw1@soton.ac.uk		Lewith, George/0000-0002-2364-3960; Conway, Joy/0000-0001-6464-1526				Aker PD, 1996, BMJ-BRIT MED J, V313, P1291; Andresen EM, 1998, EVAL HEALTH PROF, V21, P244, DOI 10.1177/016327879802100206; BARLAS P, 1997, PHYS THERAPY REV, V2, P239; Beaton DE, 1997, J CLIN EPIDEMIOL, V50, P79, DOI 10.1016/S0895-4356(96)00296-X; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; Berman BM, 1997, PRIMARY CARE, V24, P743, DOI 10.1016/S0095-4543(05)70308-0; BOGDUK N, 1982, SPINE, V7, P319, DOI 10.1097/00007632-198207000-00001; Bogduk Nikolai, 1998, Current Opinion in Rheumatology, V10, P110, DOI 10.1097/00002281-199803000-00004; DELATORRE CS, 1993, FRONTIER PERSPECTIVE, V3, P33; Dincer F, 2003, COMPLEMENT THER MED, V11, P235, DOI 10.1016/S0965-2299(03)00124-9; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; ELLIS N, 1999, ACUPUNCTURE CLIN PRA; Ernst E, 1997, SCAND J RHEUMATOL, V26, P444, DOI 10.3109/03009749709065717; Hains F, 1998, J MANIP PHYSIOL THER, V21, P75; Hemingway H, 1997, BMJ-BRIT MED J, V315, P1273, DOI 10.1136/bmj.315.7118.1273; Kaptchuk TJ, 2000, J CLIN EPIDEMIOL, V53, P786, DOI 10.1016/S0895-4356(00)00206-7; Kjellman GV, 1999, SCAND J REHABIL MED, V31, P139; LAITINEN J, 1975, SCAND J REHABIL MED, V7, P114; LEWITH GT, 1983, PAIN, V16, P111, DOI 10.1016/0304-3959(83)90202-6; LIANGYUE D, 1990, CHINESE ACUPUNCTURE; McCormack BM, 1996, WESTERN J MED, V165, P43; MELZACK R, 1975, PAIN, V1, P357, DOI 10.1016/0304-3959(75)90073-1; MILLARD RW, 1997, CRITICAL REV PHYS RE, V9, P35; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; PETRIE J, 1985, CLIN EXP RHEUMATOL, V3, P151; PETRIE JP, 1986, BRIT J RHEUMATOL, V25, P271; PETRIE JP, 1983, CLIN EXP RHEUMATOL, V1, P333; Riddle DL, 1998, PHYS THER, V78, P951, DOI 10.1093/ptj/78.9.951; Sari-Kouzel H, 1999, PRACTITIONER, V243, P334; Shapiro ET, 1996, AM J SPORT MED, V24, P196, DOI 10.1177/036354659602400214; Thomas KJ, 2001, COMPLEMENT THER MED, V9, P2, DOI 10.1054/ctim.2000.0407; THOMAS M, 1991, AM J CHINESE MED, V19, P95, DOI 10.1142/S0192415X91000156; Twisk JWR, 2003, APPL LONGITUDINAL DA; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; Vernon H., 1996, J MUSCULOSKELET PAIN, V4, P95, DOI [10.1300/J094v04n04_09, DOI 10.1300/J094V04N04_09, DOI 10.1300/J094V04N04_]; VINCENT C, 1995, J ROY SOC MED, V88, P199; Vincent C, 1990, COMPLEMENT MED RES, V4, P8; Westaway MD, 1998, J ORTHOP SPORT PHYS, V27, P331, DOI 10.2519/jospt.1998.27.5.331; White AR, 1999, RHEUMATOLOGY, V38, P143, DOI 10.1093/rheumatology/38.2.143; White P, 2002, RHEUMATOLOGY, V41, P1224, DOI 10.1093/rheumatology/41.11.1224; WOOD R, 1998, COMPLEMENT THER MED, V6, P79; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	43	114	121	1	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	2004	141	12					911	919		10.7326/0003-4819-141-12-200412210-00007	http://dx.doi.org/10.7326/0003-4819-141-12-200412210-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	882EY	15611488				2023-01-03	WOS:000225923000002
J	Bishop, JP; Stenger, VJ				Bishop, JP; Stenger, VJ			Retroactive prayer: lots of history, not much mystery, and no science	BRITISH MEDICAL JOURNAL			English	Article							RELIGIOUS INVOLVEMENT; INTERCESSORY PRAYER; CONTROLLED-TRIAL; OUTCOMES; MEDICINE; REMOTE		Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Colorado, Dept Phys, Boulder, CO 80309 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Colorado System; University of Colorado Boulder	Bishop, JP (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jeffrey.bishop@utsouthwestern.edu						Bishop JP, 2003, ARCH INTERN MED, V163, P1405, DOI 10.1001/archinte.163.12.1405; BRONSON P, 2002, WIRED, V10; DEBEAUREGARD OC, 1953, CR HEBD ACAD SCI, V236, P1632; Dossey L., 1999, REINVENTING MED MIND; DRUCKMAN D, 1987, ENHANCING HUMAN PERF; George LK, 2002, PSYCHOL INQ, V13, P190, DOI 10.1207/S15327965PLI1303_04; Harris WS, 2000, ARCH INTERN MED, V160, P1878; Harris WS, 1999, ARCH INTERN MED, V159, P2273, DOI 10.1001/archinte.159.19.2273; Koenig H. G., 2003, HDB RELIG HLTH; Krucoff MW, 2001, AM HEART J, V142, P760, DOI 10.1067/mhj.2001.119138; Leibovici L, 2001, BRIT MED J, V323, P1450, DOI 10.1136/bmj.323.7327.1450; LEIBOVICI L, 2001, BMJ; Mueller PS, 2001, MAYO CLIN PROC, V76, P1225, DOI 10.4065/76.12.1225; Olshansky B, 2003, BMJ-BRIT MED J, V327, P1465, DOI 10.1136/bmj.327.7429.1465; PETRE J, 2003, DAILY TELEGRAPH 1015; Price H., 1996, TIMES ARROW ARCHIMED, DOI [10.1093/acprof:oso/9780195117981.001.0001, DOI 10.1093/ACPROF:OSO/9780195117981.001.0001]; SCHMIDT H, 1982, FOUND PHYS, V12, P565, DOI 10.1007/BF00731929; Sicher F, 1998, WESTERN J MED, V169, P356; Stenger V. J., 2000, TIMELESS REALITY SYM; STENGER VJ, 1990, PHYS PSYCHICS SEARCH	20	8	8	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 18	2004	329	7480					1444	1446		10.1136/bmj.329.7480.1444	http://dx.doi.org/10.1136/bmj.329.7480.1444			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	882VB	15604179	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000225965800022
J	Manca, A				Manca, A		UK BEAM Trial Team	United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACCEPTABILITY; PHYSIOTHERAPY; PACKAGE	Objective To assess the cost effectiveness of adding spinal manipulation, exercise classes, or manipulation followed by exercise ("combined treatment") to "best care in general practice for patients consulting with low back pain. Design Stochastic cost utility analysis alongside pragmatic randomised trial with factorial design. Setting 181 general practices and 63 community settings for physical treatments around 14 centres across the United Kingdom. Participants 1287 (96%) of 1334 trial participants. Main outcome measures Healthcare costs, quality adjusted life years (QALYs), and cost per QALY over 12 months. Results Over one year, mean treatment costs relative to "best care" were 1195 ($360; (sic)279; 95% credibility interval pound85 to pound308) for manipulation, pound140 (pound3 to pound278) for exercise, and pound125 (pound21 to pound228) for combined treatment. All three active treatments increased participants' average QALYs compared with best care alone. Each extra QALY that combined treatment yielded relative to best care cost pound3800; in economic terms it had an "incremental cost effectiveness ratio" of pound3800. Manipulation alone had a ratio of 5:8700 relative to combined treatment If the NHS was prepared to pay at least pound10 000 for each extra QALY (lower than previous recommendations in the United Kingdom), manipulation alone would probably be the best strategy. If manipulation was not available, exercise would have an incremental cost effectiveness ratio of pound8300 relative to best care. Conclusions Spinal manipulation is a cost effective addition to "best care" for back pain in general practice. Manipulation alone probably gives better value for money than manipulation followed by exercise.	Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England	University of York - UK	Manca, A (corresponding author), Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England.	am126@york.ac.uk	Russell, Ian T/H-1181-2012; Underwood, Martin/D-6364-2015	Coulton, Simon/0000-0002-7704-3274; Torgerson, David/0000-0002-1667-4275; Farrin, Amanda/0000-0002-2876-0584; Underwood, Martin/0000-0002-0309-1708; Burton, Kim/0000-0002-9462-2227				Baldwin M L, 2001, Spine J, V1, P138, DOI 10.1016/S1529-9430(01)00016-X; *BUPA HOSP UK, MUCH WILL IT COST; *CHART I PUBL FIN, 2002, HLTH SERV DAT 2002; Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903; Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635; Harvey E, 2003, MANUAL THER, V8, P46, DOI 10.1054/math.2002.0472; KIND P, 1999, 172 U YORK CTR HLTH; Kind P, 1996, QUALITY LIFE PHARMAC; KLABERMOFFETT J, 1999, BRIT MED J, V319, P279; Maetzel A, 2002, BEST PRACT RES CL RH, V16, P23, DOI 10.1053/berh.2001.0204; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; MANCA A, 2004, HLTH EC         1020; MANCA A, 2004, HLTH EC         0614; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; McAlister FA, 2003, JAMA-J AM MED ASSOC, V289, P2545, DOI 10.1001/jama.289.19.2545; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; Moffett JK, 1999, BRIT MED J, V319, P279, DOI 10.1136/bmj.319.7205.279; MOFFETT JK, 2000, PHYSIOTHERAPY, V85, P295; NETTEN A, 2002, UNIT COSTS HLTH SOCI; Raftery J, 2001, BRIT MED J, V323, P1300, DOI 10.1136/bmj.323.7324.1300; RASBACH J, 2000, USERS GUIDE MLWIN VE; RASBASH J, 2000, USERS GUIDE MLWIN VE; Roland M, 2000, BACK BOOK; Skargren EI, 1998, SPINE, V23, P1875, DOI 10.1097/00007632-199809010-00016; Underwood M, 2004, BMJ-BRIT MED J, V329, P1377, DOI 10.1136/bmj.38282.669225AE; Underwood M, 2002, FAM PRACT, V19, P511, DOI 10.1093/fampra/19.5.511; Weinstein MC., 1996, COST EFFECTIVENESS H	27	134	137	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	2004	329	7479					1381	1385		10.1136/bmj.38282.607859.AE	http://dx.doi.org/10.1136/bmj.38282.607859.AE			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	880JB	15556954	Green Published, Green Accepted, Green Submitted, Bronze			2023-01-03	WOS:000225785000021
J	Fischer, MA; Schneeweiss, S; Avorn, J; Solomon, DH				Fischer, MA; Schneeweiss, S; Avorn, J; Solomon, DH			Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; REGIONAL-VARIATIONS; ROFECOXIB; TRIAL; EFFICACY; OUTCOMES	Background: Over the past five years, selective cyclooxygenase-2 inhibitors (coxibs) have accounted for a growing proportion of prescriptions for nonsteroidal antiinflammatory drugs (NSAIDs). To control these expenses, many state Medicaid programs have implemented prior-authorization requirements before coxibs can be prescribed. We evaluated the effect of such programs on the use of coxibs by Medicaid beneficiaries. Methods: We surveyed state Medicaid agencies to determine whether prescription of coxibs required prior authorization and, if so, the criteria for authorization. For each program, we compared these criteria with evidence-based recommendations for prescribing of coxibs. Using data for all filled prescriptions in 50 state Medicaid programs from 1999 through the end of 2003, we calculated the proportion of defined daily doses of NSAIDs accounted for by coxibs. Time-series analyses were used to measure the changes in prescription patterns after the implementation of each prior-authorization program. Results: By 2001, coxibs accounted for half of all NSAID doses covered by Medicaid. This proportion varied widely according to the state in 2003, from a low of 11 percent to a high of 70 percent of all NSAID doses. Twenty-two states implemented prior-authorization programs for coxibs during the study period. Overall, the implementation of such programs reduced the proportion of NSAID doses made up by coxibs by 15.0 percent (95 percent confidence interval, 10.9 to 19.2 percent), corresponding to a decrease of $10.28 (95 percent confidence interval, $7.56 to $13.00) in spending per NSAID prescription. The effect of such programs was not influenced by the degree to which a prior-authorization program incorporated evidence-based prescribing recommendations. Conclusions: The use of coxibs and spending on NSAIDs varies widely by state and declined substantially after the implementation of prior-authorization programs. Determining whether these reductions are clinically appropriate will have important implications for the development of rational drug-reimbursement policies.	Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA; Brigham & Womens Hosp, Dept Med, Div Rheumatol, Boston, MA 02120 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Fischer, MA (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	mfischer@partners.org	Schneeweiss, Sebastian/C-2125-2013	Schneeweiss, Sebastian/0000-0003-2575-467X	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR048616] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015507] Funding Source: NIH RePORTER; AHRQ HHS [HS-010881] Funding Source: Medline; NIAMS NIH HHS [AR-48616] Funding Source: Medline; NIDA NIH HHS [DA-15507] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; [Anonymous], 2004, PHARM BEN STAT MED A; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; Avorn J, 2004, POWERFUL MED BENEFIT; Bensen WG, 1999, MAYO CLIN PROC, V74, P1095, DOI 10.4065/74.11.1095; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; *CTR MED MED SERV, 2003, MED ENR BEN SEL FISC; *CTR MED MED SERV, 2004, MSIS STAT REP FED FI; Day R, 2000, ARCH INTERN MED, V160, P1781, DOI 10.1001/archinte.160.12.1781; Dubois RW, 2004, ALIMENT PHARM THER, V19, P197, DOI 10.1111/j.0269-2813.2004.01834.x; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; *HLTH CAR FIN ADM, 2000, STAT DRUG UT DAT; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; *IMS HLTH IMS NAT, 2004, LEAD 20 THER CLASS U; JENKINS CL, 2004, WASHINGTON POST 0303, pB1; KAYE N, 2002, AFFORDING PRESCRIPTI; Lanza FL, 1998, AM J GASTROENTEROL, V93, P2037; LaPensee Kenneth T, 2003, J Manag Care Pharm, V9, P36; Mello MM, 2004, NEW ENGL J MED, V350, P608, DOI 10.1056/NEJMlim035683; Momani AA, 2002, ANN PHARMACOTHER, V36, P1686; Motheral B, 2001, MED CARE, V39, P1293, DOI 10.1097/00005650-200112000-00005; *NAT I CLIN EXC, 2001, GUID US CYCL COX 2 S; PEAR R, 2004, NY TIMES        0130, pA1; Saag K, 2000, ARCH FAM MED, V9, P1124, DOI 10.1001/archfami.9.10.1124; Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087; Smalley W, 2002, ARTHRITIS RHEUM, V46, P2195, DOI 10.1002/art.10425; SMALLEY WE, 1995, NEW ENGL J MED, V332, P1612, DOI 10.1056/NEJM199506153322406; Solomon DH, 2003, AM J MED, V115, P715, DOI 10.1016/j.amjmed.2003.08.025; SOMERS S, 2003, MODEL PRESCRIPTION D; STACY J, 2004, J MANAGE CARE PHARM, V10, P87; Stacy Jane, 2003, J Manag Care Pharm, V9, P327; Statacorp, 2001, STAT STAT SOFTW REL; STEIN C, 2004, BOSTON GLOBE    0217, pC1; STEIN C, 2004, BOSTON GLOBE    0217, pC4; *THOMS PDR, 2004, DRUG TOP RED BOOK; TILLY J, 2003, PRIOR AUTHORIZATION; Veney JE, 1991, EVALUATION DECISION; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; *WHO COLL CTR DRUG, 2004, ATC DDD IND 2004	41	104	105	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2187	2194		10.1056/NEJMsa042770	http://dx.doi.org/10.1056/NEJMsa042770			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548779				2023-01-03	WOS:000225160600009
J	Aitken, RJ; Koopman, P; Lewis, SEM				Aitken, RJ; Koopman, P; Lewis, SEM			Seeds of concern	NATURE			English	Article							PARENTAL OCCUPATIONAL-EXPOSURE; TESTICULAR DYSGENESIS SYNDROME; SEMEN QUALITY; SPERM; RISK; ABNORMALITIES; FREQUENCY; ESTROGENS; CANCER; TIME		Univ Newcastle, Sch Environm & Life Sci, Discipline Biol Sci, Callaghan, NSW 2308, Australia; Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Queens Univ Belfast, Belfast BT12 6BJ, Antrim, North Ireland	University of Newcastle; University of Queensland; Queens University Belfast	Aitken, RJ (corresponding author), Univ Newcastle, Sch Environm & Life Sci, Discipline Biol Sci, Callaghan, NSW 2308, Australia.	jaitken@mail.newcastle.edu.au	Lewis, Sheena E M/ABI-8338-2020; Aitken, Robert John/AAY-8238-2020; Koopman, Peter A/C-9416-2009	Aitken, Robert John/0000-0002-9152-156X; Koopman, Peter A/0000-0001-6939-0914				AITKEN RJ, IN PRESS INT J ANDRO; AITKEN RJ, IN PESS REPROD FERTI; Andersen AG, 2000, HUM REPROD, V15, P366, DOI 10.1093/humrep/15.2.366; Anderson D, 2003, MUTAT RES-REV MUTAT, V544, P173, DOI 10.1016/j.mrrev.2003.06.016; Anderson D, 2002, ADV EXP MED BIOL, V518, P11; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; Chitra K. C., 2004, Indian Journal of Experimental Biology, V42, P220; Fisher JS, 2003, HUM REPROD, V18, P1383, DOI 10.1093/humrep/deg273; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; Handelsman DJ, 2001, REPROD FERT DEVELOP, V13, P317, DOI 10.1071/RD00103; Hill KA, 2004, ENVIRON MOL MUTAGEN, V43, P110, DOI 10.1002/em.20004; Irvine S, 1996, BMJ-BRIT MED J, V312, P467, DOI 10.1136/bmj.312.7029.467; Jobling S, 2004, AQUAT TOXICOL, V66, P205, DOI 10.1016/j.aquatox.2004.01.001; Klaassen C.D., 2008, CASARETT DOULLS TOXI, V7th; Knight JA, 1997, J OCCUP ENVIRON MED, V39, P333, DOI 10.1097/00043764-199704000-00011; Kodama H, 1997, FERTIL STERIL, V68, P519, DOI 10.1016/S0015-0282(97)00236-7; Kuhnert B, 2004, HUM REPROD UPDATE, V10, P327, DOI 10.1093/humupd/dmh030; Oliva A, 2001, HUM REPROD, V16, P1768, DOI 10.1093/humrep/16.8.1768; Pettersson A, 2004, INT J CANCER, V109, P941, DOI 10.1002/ijc.20088; ROBAIRE B, 2003, ADV MALE MED DEV TOX; SAFE SH, 1995, ENVIRON HEALTH PERSP, V103, P346, DOI 10.2307/3432287; Schuppe HC, 2000, ANDROLOGIA, V32, P255, DOI 10.1046/j.1439-0272.2000.00393.x; Semenza JC, 1997, ENVIRON HEALTH PERSP, V105, P1030, DOI 10.2307/3433835; Sharpe RM, 2003, INT J ANDROL, V26, P2, DOI 10.1046/j.1365-2605.2003.00367.x; Shu XO, 1999, CANCER EPIDEM BIOMAR, V8, P783; Singh NP, 2003, FERTIL STERIL, V80, P1420, DOI 10.1016/j.fertnstert.2003.04.002; Skakkebaek NE, 2004, INT J ANDROL, V27, P189, DOI 10.1111/j.1365-2605.2004.00488.x; Slama R, 2002, HUM REPROD, V17, P503, DOI 10.1093/humrep/17.2.503; Swan SH, 2000, ENVIRON HEALTH PERSP, V108, P961, DOI 10.2307/3435055; TRACEY E, 2004, CANC NEW S WALES INC; WHORTON D, 1979, J OCCUP ENVIRON MED, V21, P161	31	247	250	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	2004	432	7013					48	52		10.1038/432048a	http://dx.doi.org/10.1038/432048a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	867PQ	15525979	Bronze			2023-01-03	WOS:000224854900036
J	Tate, SK; Goldstein, DB				Tate, SK; Goldstein, DB			Will tomorrow's medicines work for everyone?	NATURE GENETICS			English	Review							BLOOD-PRESSURE RESPONSE; ACUTE LYMPHOBLASTIC-LEUKEMIA; CONVERTING-ENZYME-INHIBITOR; CELL LUNG-CANCER; HLA-B REGION; RACIAL-DIFFERENCES; ETHNIC-DIFFERENCES; ANTIHYPERTENSIVE RESPONSE; MULTIDRUG-RESISTANCE; ENDOTHELIAL FUNCTION	Throughout much of the world, 'race' and 'ethnicity' are key determinants of health. For example, African Americans have, by some estimates, a twofold higher incidence of fatal heart attacks and a 10% higher incidence of cancer(1,2) than European Americans, and South Asian- or Caribbean-born British are similar to3.5 times as likely to die as a direct result of diabetes than are British of European ancestry(3). The health care that people receive also depends on 'race' and 'ethnicity'. African Americans are less likely to receive cancer-screening services and more likely to have late-stage cancer when diagnosed(2) than European Americans. Health disparities such as these are one of the greatest social injustices in the developed world and one of the most important scientific and political challenges.	UCL, Dept Biol, London WC1E 6BT, England	University of London; University College London	Goldstein, DB (corresponding author), UCL, Dept Biol, Darwin Bldg,Gower St, London WC1E 6BT, England.	d.goldstein@ucl.ac.uk	Goldstein, David/AAY-8125-2020					*AG HEALTHC RES QU, NAT HEALTHC DISP REP; Aviv A, 1996, Ethn Health, V1, P275; Bhatia S, 2002, BLOOD, V100, P1957, DOI 10.1182/blood-2002-02-0395; Bjornsson TD, 2003, J CLIN PHARMACOL, V43, P943, DOI 10.1177/0091270003256065; Blann A, 1999, BRIT J HAEMATOL, V107, P207, DOI 10.1046/j.1365-2141.1999.01672.x; Blann A, 2004, J THROMB HAEMOST, V2, P525, DOI 10.1111/j.1538-7933.2003.00620.x; Bradford LD, 2002, PHARMACOGENOMICS, V3, P229, DOI 10.1517/14622416.3.2.229; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; Cardillo C, 1999, CIRCULATION, V99, P90, DOI 10.1161/01.CIR.99.1.90; Carson P, 1999, J Card Fail, V5, P178, DOI 10.1016/S1071-9164(99)90001-5; Cepeda MS, 2001, CLIN PHARMACOL THER, V70, P351, DOI 10.1016/S0009-9236(01)45600-1; Chapman AB, 2002, KIDNEY INT, V61, P1047, DOI 10.1046/j.1523-1755.2002.00200.x; CHUNG H, 1995, PSYCHIATR SERV, V46, P586; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Collazo Y, 1996, MT SINAI J MED, V63, P310; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; Collins FS, 2004, NATURE, V429, P475, DOI 10.1038/nature02628; Cooper RS, 2003, NEW ENGL J MED, V348, P1166, DOI 10.1056/NEJMsb022863; Cooper RS, 2001, INT J EPIDEMIOL, V30, pS48, DOI 10.1093/ije/30.suppl_1.S48; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CUBEDDU LX, 1986, JAMA-J AM MED ASSOC, V256, P2214, DOI 10.1001/jama.256.16.2214; Cushman WC, 2000, ARCH INTERN MED, V160, P825, DOI 10.1001/archinte.160.6.825; Danoff TM, 2004, PHARMACOGENOMICS J, V4, P49, DOI 10.1038/sj.tpj.6500221; De Maria N, 2002, HEPATO-GASTROENTEROL, V49, P788; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Eichhorn E, 2001, NEW ENGL J MED, V344, P1659; Evans DA, 2003, ARCH NEUROL-CHICAGO, V60, P185, DOI 10.1001/archneur.60.2.185; Evelyn B, 2001, J NATL MED ASSOC, V93, p18S; Exner DV, 2001, NEW ENGL J MED, V344, P1351, DOI 10.1056/NEJM200105033441802; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Fellay J, 2002, LANCET, V359, P30, DOI 10.1016/S0140-6736(02)07276-8; Ferdinand KC, 2003, AM J HYPERTENS, V16, p50S, DOI 10.1016/S0895-7061(03)01069-0; *FOOD DRUG ADM, 2004, GUID IND PHARM DAT S; Foster MW, 2004, NAT REV GENET, V5, P467, DOI 10.1038/nrg1351; FREIS ED, 1983, AM J CARDIOL, V52, P1230; FRIEDMAN B, 1983, AM J CARDIOL, V52, pD43, DOI 10.1016/0002-9149(83)90641-0; Goldstein DB, 2003, NAT REV GENET, V4, P937, DOI 10.1038/nrg1229; Goran MI, 2002, DIABETES CARE, V25, P2184, DOI 10.2337/diacare.25.12.2184; Hassaballa H, 2001, NEUROLOGY, V57, P691, DOI 10.1212/WNL.57.4.691; Hetherington S, 2002, LANCET, V359, P1121, DOI 10.1016/S0140-6736(02)08158-8; Higashi MK, 2002, JAMA-J AM MED ASSOC, V287, P1690, DOI 10.1001/jama.287.13.1690; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Holtzman NA, 2003, PHARMACOGENOMICS: SOCIAL, ETHICAL, AND CLINICAL DIMENSIONS, P163, DOI 10.1002/047142613X.ch9; Hughes AR, 2004, PHARMACOGENOMICS, V5, P203, DOI 10.1517/phgs.5.2.203.27481; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; JANN MW, 1989, PSYCHIAT RES, V30, P45, DOI 10.1016/0165-1781(89)90170-4; Johnson JA, 2003, CLIN PHARMACOL THER, V74, P44, DOI 10.1016/S0009-9236(03)00068-7; JOHNSON JA, 1995, J CARDIOVASC PHARM, V25, P90, DOI 10.1097/00005344-199501000-00015; Kadan-Lottick NS, 2003, JAMA-J AM MED ASSOC, V290, P2008, DOI 10.1001/jama.290.15.2008; Kahn Jonathan, 2004, Yale J Health Policy Law Ethics, V4, P1; Kalinowski L, 2004, CIRCULATION, V109, P2511, DOI 10.1161/01.CIR.0000129087.81352.7A; Kimball P, 2001, J MED VIROL, V65, P510, DOI 10.1002/jmv.2065; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; LANG CC, 1995, NEW ENGL J MED, V333, P155, DOI 10.1056/NEJM199507203330304; Lang CC, 1997, HYPERTENSION, V30, P157, DOI 10.1161/01.HYP.30.2.157; Li RL, 2004, AM J HYPERTENS, V17, P560, DOI 10.1016/j.amjhyper.2004.02.013; LIN KM, 1989, AM J PSYCHIAT, V146, P1307; Lindpaintner K, 2003, J MOL MED-JMM, V81, P141, DOI 10.1007/s00109-002-0416-5; Liu J, 2003, CLIN PHARMACOL THER, V74, P372, DOI 10.1016/S0009-9236(03)00224-8; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; *LOND HLTH OSB, 2004, ETHN DISP HLTH HLTH; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Matsuda KT, 1996, PSYCHOPHARMACOL BULL, V32, P253; McLellan RA, 1997, PHARMACOGENETICS, V7, P187, DOI 10.1097/00008571-199706000-00003; McLeod HL, 2002, PHARMACOGENOMICS, V3, P89, DOI 10.1517/14622416.3.1.89; Millward MJ, 2003, ANN ONCOL, V14, P449, DOI 10.1093/annonc/mdg118; Mokwe E, 2004, HYPERTENSION, V43, P1202, DOI 10.1161/01.HYP.0000127924.67353.86; Muir AJ, 2004, NEW ENGL J MED, V350, P2265, DOI 10.1056/NEJMoa032502; Netland PA, 2003, ADV THER, V20, P149, DOI 10.1007/BF02850202; Oselin K, 2003, FUND CLIN PHARMACOL, V17, P463, DOI 10.1046/j.1472-8206.2003.00163.x; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pollock BH, 2000, J CLIN ONCOL, V18, P813, DOI 10.1200/JCO.2000.18.4.813; Pui CH, 2003, JAMA-J AM MED ASSOC, V290, P2001, DOI 10.1001/jama.290.15.2001; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Risch N., 2002, GENOME BIOL, V3, pcomm, DOI DOI 10.1186/GB-2002-3-7-COMMENT2007; Robertson JA, 2003, PHARMACOGENOMICS: SOCIAL, ETHICAL, AND CLINICAL DIMENSIONS, P291, DOI 10.1002/047142613X.ch15; Rosenbaum DA, 2002, ARTERIOSCL THROM VAS, V22, P1023, DOI 10.1161/01.ATV.0000017704.45007.1D; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Roses AD, 2002, NAT REV DRUG DISCOV, V1, P541, DOI 10.1038/nrd840; Sakaeda T, 2003, PHARMACOGENOMICS, V4, P397, DOI 10.1517/phgs.4.4.397.22747; SAUNDERS E, 1991, PRIMARY CARE, V18, P607; Schmith VD, 2003, CELL MOL LIFE SCI, V60, P1636, DOI 10.1007/s00018-003-2369-4; Schwartz RS, 2001, NEW ENGL J MED, V344, P1392, DOI 10.1056/NEJM200105033441810; Segal SP, 1996, PSYCHIAT SERV, V47, P282; Siddiqui A, 2003, NEW ENGL J MED, V348, P1442, DOI 10.1056/NEJMoa021986; Smith MW, 2004, AM J HUM GENET, V74, P1001, DOI 10.1086/420856; Sofowora GG, 2003, CLIN PHARMACOL THER, V73, P366, DOI 10.1016/S0009-9236(02)17734-4; Stein CM, 1997, CLIN PHARMACOL THER, V62, P436, DOI 10.1016/S0009-9236(97)90122-3; Stephens JC, 1998, AM J HUM GENET, V62, P1507, DOI 10.1086/301867; STRAKOWSKI SM, 1993, J CLIN PSYCHIAT, V54, P96; Takahashi H, 2003, CLIN PHARMACOL THER, V73, P253, DOI 10.1067/mcp.2003.26a; Taube J, 2000, BLOOD, V96, P1816, DOI 10.1182/blood.V96.5.1816.h8001816_1816_1819; TORNATORE KM, 1995, TRANSPLANTATION, V59, P729, DOI 10.1097/00007890-199503150-00016; Walkup JT, 2000, J CLIN PSYCHIAT, V61, P344, DOI 10.4088/JCP.v61n0504; WATKINS LL, 1995, LIFE SCI, V57, P1411, DOI 10.1016/0024-3205(95)02103-P; WEIR MR, 1995, HYPERTENSION, V26, P124, DOI 10.1161/01.HYP.26.1.124; Weir MR, 1998, AM J HYPERTENS, V11, P914, DOI 10.1016/S0895-7061(98)00087-9; Wilson JF, 2001, NAT GENET, V29, P265, DOI 10.1038/ng761; Xie HG, 2001, PHARMACOGENETICS, V11, P191, DOI 10.1097/00008571-200104000-00002; Xie HG, 2001, ANNU REV PHARMACOL, V41, P815, DOI 10.1146/annurev.pharmtox.41.1.815; Yamazaki K, 2002, J HUM GENET, V47, P469, DOI 10.1007/s100380200067; Zanchi A, 2003, CURR HYPERTENS REP, V5, P346, DOI 10.1007/s11906-003-0045-6; ZHOU HH, 1993, CLIN PHARMACOL THER, V54, P507, DOI 10.1038/clpt.1993.182	105	130	137	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2004	36	11		S			S34	S42		10.1038/ng1437	http://dx.doi.org/10.1038/ng1437			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	867PH	15508001	Bronze			2023-01-03	WOS:000224854000009
J	Thiel, KA				Thiel, KA			Biomanufacturing, from bust to boom ... to bubble?	NATURE BIOTECHNOLOGY			English	Article																		*BIOT IND ORG, 2004, ADV PLANTS PROD THER; FOX S, 2004, CONTRACT PHARM   JUN, P72; MOLOWA D, 2001, IND ANAL STATE BIOL	3	45	49	2	14	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2004	22	11					1365	1372		10.1038/nbt1104-1365	http://dx.doi.org/10.1038/nbt1104-1365			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	869CL	15529157				2023-01-03	WOS:000224960600023
J	Gray, JAM				Gray, JAM			Self-management in chronic illness	LANCET			English	Editorial Material									Inst Hlth Sci, UK Natl Screening Comm, Oxford OX3 7LF, England	University of Oxford	Gray, JAM (corresponding author), Inst Hlth Sci, UK Natl Screening Comm, Oxford OX3 7LF, England.							Coulter A, 2002, AUTONOMOUS PATIENT; GRAY JAM, 2002, RESOURCEFUL PATIENT; Holman H, 2004, JAMA-J AM MED ASSOC, V292, P1057, DOI 10.1001/jama.292.9.1057; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731	4	8	8	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	2004	364	9444					1467	1468		10.1016/S0140-6736(04)17288-7	http://dx.doi.org/10.1016/S0140-6736(04)17288-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864PN	15500873				2023-01-03	WOS:000224645500006
J	Cunningham, D; Humblet, Y; Siena, S; Khayat, D; Bleiberg, H; Santoro, A; Bets, D; Mueser, M; Harstrick, A; Verslype, C; Chau, I; Van Cutsem, E				Cunningham, D; Humblet, Y; Siena, S; Khayat, D; Bleiberg, H; Santoro, A; Bets, D; Mueser, M; Harstrick, A; Verslype, C; Chau, I; Van Cutsem, E			Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; MULTICENTER RANDOMIZED-TRIAL; RESISTANT CHINESE-HAMSTER; PHASE-II TRIAL; 1ST-LINE TREATMENT; TYROSINE KINASE; FLUOROURACIL-LEUCOVORIN; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY	Background: The epidermal growth factor receptor (EGFR), which participates in signaling pathways that are deregulated in cancer cells, commonly appears on colorectal-cancer cells. Cetuximab is a monoclonal antibody that specifically blocks the EGFR. We compared the efficacy of cetuximab in combination with irinotecan with that of cetuximab alone in metastatic colorectal cancer that was refractory to treatment with irinotecan. Methods: We randomly assigned 329 patients whose disease had progressed during or within three months after treatment with an irinotecan-based regimen to receive either cetuximab and irinotecan (at the same dose and schedule as in a prestudy regimen [218 patients]) or cetuximab monotherapy (111 patients). In cases of disease progression, the addition of irinotecan to cetuximab monotherapy was permitted. The patients were evaluated radiologically for tumor response and were also evaluated for the time to tumor progression, survival, and side effects of treatment. Results: The rate of response in the combination-therapy group was significantly higher than that in the monotherapy group (22.9 percent [95 percent confidence interval, 17.5 to 29.1 percent] vs. 10.8 percent [95 percent confidence interval, 5.7 to 18.1 percent], P=0.007). The median time to progression was significantly greater in the combination-therapy group (4.1 vs. 1.5 months, P<0.001 by the log-rank test). The median survival time was 8.6 months in the combination-therapy group and 6.9 months in the monotherapy group (P=0.48). Toxic effects were more frequent in the combination-therapy group, but their severity and incidence were similar to those that would be expected with irinotecan alone. Conclusions: Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory colorectal cancer.	Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England; Royal Marsden Hosp, London SW3 6JJ, England; Catholic Univ Louvain, St Luc Univ Hosp, B-1200 Brussels, Belgium; Osped Niguarda Ca Granda, Milan, Italy; Hop La Pitie Salpetriere, Paris, France; Inst Jules Bordet, B-1000 Brussels, Belgium; Ist Clin Humanitas, Rozzano Milano, Italy; Merck, Amsterdam, Netherlands; E Merck AG, D-6100 Darmstadt, Germany; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut Jules Bordet; Merck & Company; Merck KGaA; KU Leuven; University Hospital Leuven	Cunningham, D (corresponding author), Royal Marsden Hosp, Dept Med, Downs Rd, Sutton SM2 5PT, Surrey, England.	david.cunningham@icr.ac.uk	Santoro, Armando/J-9594-2018; Chau, Ian/ABC-2023-2020; SIENA, SALVATORE/AAC-5806-2019; Van+Cutsem, Eric/ABE-1762-2021	Santoro, Armando/0000-0003-1709-9492; Chau, Ian/0000-0003-0286-8703; SIENA, SALVATORE/0000-0002-2681-2846; Cunningham, David/0000-0001-5158-1069; Verslype, Chris/0000-0003-3857-466X				Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Chen ZS, 1999, MOL PHARMACOL, V55, P921; Chu XY, 1999, J PHARMACOL EXP THER, V288, P735; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Ciardiello F, 2003, EUR J CANCER, V39, P1348, DOI 10.1016/S0959-8049(03)00235-1; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; Douillard JY, 2000, LANCET, V355, P1372; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Goldstein NS, 2001, CANCER, V92, P1331, DOI 10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M; Huang SM, 2000, CLIN CANCER RES, V6, P2166; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klapper LN, 2000, ADV CANCER RES, V77, P25; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MAYER A, 1993, CANCER, V71, P2454, DOI 10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2; Messa C, 1998, ACTA ONCOL, V37, P285, DOI 10.1080/028418698429595; MEYERS MB, 1986, P NATL ACAD SCI USA, V83, P5521, DOI 10.1073/pnas.83.15.5521; MEYERS MB, 1993, BIOCHEM PHARMACOL, V46, P1841, DOI 10.1016/0006-2952(93)90591-J; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Naruse I, 2002, INT J CANCER, V98, P310, DOI 10.1002/ijc.10173; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Porebska I, 2000, TUMOR BIOL, V21, P105, DOI 10.1159/000030116; Prewett MC, 2002, CLIN CANCER RES, V8, P994; Rothenberg ML, 2003, J CLIN ONCOL, V21, P2059, DOI 10.1200/JCO.2003.11.126; Rougier P, 1998, LANCET, V352, P1407, DOI 10.1016/S0140-6736(98)03085-2; Rougier P, 1998, LANCET, V352, P1634; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SALTZ L, 2003, P AN M AM SOC CLIN, V22, P204; SALTZ L, 2001, P AN M AM SOC CLIN, V20, pA3; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Sclabas GM, 2003, J GASTROINTEST SURG, V7, P37, DOI 10.1016/S1091-255X(02)00088-4; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Xu Y, 2002, ANN ONCOL, V13, P1841, DOI 10.1093/annonc/mdf337	40	3942	4171	2	251	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 22	2004	351	4					337	345		10.1056/NEJMoa033025	http://dx.doi.org/10.1056/NEJMoa033025			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839RC	15269313	Bronze			2023-01-03	WOS:000222801200007
J	Brennan, TA; Lee, TH				Brennan, TA; Lee, TH			Allergic to generics	ANNALS OF INTERNAL MEDICINE			English	Article							MANAGED-CARE; DIFFICULT PATIENTS; HEALTH-CARE; PATIENT; ETHICS; PHYSICIAN	A 69-year-old woman with several medical problems believes that she is allergic to generic medications. She frequently conflicts with her long-time primary care physician, who, as required by the patient's insurance coverage, refuses to prescribe brand-name drugs when generic alternatives are available. This conflict intensifies to a crisis when the patient develops life-threatening problems and still will not take prescribed generic medications. The presentation of this real case is accompanied by a discussion of the ethical dilemmas of the patient's physician, who must weigh the interests of a patient who clings to beliefs that the physician thinks are unfounded against the interests of a just rationing program and the broader population it serves.	Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Brennan, TA (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	tabrennan@partners.org						Burton SL, 2001, HEALTH AFFAIR, V20, P150, DOI 10.1377/hlthaff.20.5.150; Daniels N, 1998, HEALTH AFFAIR, V17, P50, DOI 10.1377/hlthaff.17.5.50; Emanuel EJ, 1998, J HEALTH POLIT POLIC, V23, P635; GROVES JE, 1978, NEW ENGL J MED, V298, P883, DOI 10.1056/NEJM197804202981605; Hahn SR, 1996, J GEN INTERN MED, V11, P1, DOI 10.1007/BF02603477; *HLTH CAR MED PRIO, 1993, NO EAS CHOIC DIFF PR; Illingworth P, 2000, J MED PHILOS, V25, P62, DOI 10.1076/0360-5310(200002)25:1;1-V;FT062; JOHN C, 1987, J FAM PRACTICE, V24, P607; LECHKY O, 1992, CAN MED ASSOC J, V146, P1793; LIN EHB, 1991, J GEN INTERN MED, V6, P241, DOI 10.1007/BF02598969; Pearson SD, 1998, NEW ENGL J MED, V339, P689, DOI 10.1056/NEJM199809033391009; Pearson SD, 2002, J GEN INTERN MED, V17, P75, DOI 10.1046/j.1525-1497.2002.10503.x; Pellegrino ED, 1999, J MED PHILOS, V24, P243, DOI 10.1076/jmep.24.3.243.2523; Povar GJ, 2004, ANN INTERN MED, V141, P131, DOI 10.7326/0003-4819-141-2-200407200-00012; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; Wikler D, 1997, BIOETHICS, V11, P185, DOI 10.1111/1467-8519.00057	16	27	27	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	2004	141	2					126	130		10.7326/0003-4819-141-2-200407200-00011	http://dx.doi.org/10.7326/0003-4819-141-2-200407200-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839BL	15262668				2023-01-03	WOS:000222758200006
J	DeWitt, AL; Gunn, SR; Hopkins, P; Streat, S				DeWitt, AL; Gunn, SR; Hopkins, P; Streat, S			Critical care medicine mailing list: growth of an online forum	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PATIENT		Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA 15261 USA; Bartimus Frickleton Robertson & Obetz, Jefferson City, MO 65101 USA; Univ London Imperial Coll Sci Technol & Med, Fac Med, London W12 0NN, England; Auckland City Hosp, Dept Crit Care Med, Auckland 1003, New Zealand	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Imperial College London; Auckland City Hospital	Gunn, SR (corresponding author), Univ Pittsburgh, Med Ctr, Dept Crit Care Med, 646B Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	gunnsr@ccm.upmc.edu						Caldicott Committee Department of Health, 1997, REP REV PAT ID INF; Campbell D, 2000, CAN J ANAESTH, V47, P53, DOI 10.1007/BF03020733; Cassell J, 2003, CRIT CARE MED, V31, P1551, DOI 10.1097/00003246-200305000-00039; Crippen D, 1999, CRIT CARE CLIN, V15, P605, DOI 10.1016/S0749-0704(05)70074-9; Crippen Kileullen JK, 2002, 3 PATIENTS INT PERSP; HOPKINS P, 2002, CLIN INTENSIVE CARE, V13, P147; Nagappan R, 2000, CRIT CARE MED, V28, P2116, DOI 10.1097/00003246-200006000-00076; Porayko LD, 1999, CAN J ANAESTH, V46, P529, DOI 10.1007/BF03013542; PORAYKO LD, 1998, EUR J ANAESTH S, V15, P48; 2003, DOCTOR HONG KONG DEA	10	4	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	2004	328	7449					1180	1180		10.1136/bmj.328.7449.1180	http://dx.doi.org/10.1136/bmj.328.7449.1180			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142927	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000221497500028
J	Quill, TE				Quill, TE			Retrospective - Dying and decision making - Evolution of end-of-life options	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; EUTHANASIA		Univ Rochester, Sch Med, Rochester, NY 14627 USA	University of Rochester	Quill, TE (corresponding author), Univ Rochester, Sch Med, Rochester, NY 14627 USA.							Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Sullivan AD, 2001, NEW ENGL J MED, V344, P605, DOI 10.1056/NEJM200102223440811	4	29	29	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2004	350	20					2029	2032		10.1056/NEJMp038216	http://dx.doi.org/10.1056/NEJMp038216			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819ZB	15141040				2023-01-03	WOS:000221354000003
J	Forastiere, AA; Goepfert, H; Maor, M; Pajak, TF; Weber, R; Morrison, W; Glisson, B; Trotti, A; Ridge, JA; Chao, C; Peters, G; Lee, DJ; Leaf, A; Ensley, J; Cooper, J				Forastiere, AA; Goepfert, H; Maor, M; Pajak, TF; Weber, R; Morrison, W; Glisson, B; Trotti, A; Ridge, JA; Chao, C; Peters, G; Lee, DJ; Leaf, A; Ensley, J; Cooper, J			Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NECK-CANCER; HEAD	Background: Induction chemotherapy with cisplatin plus fluorouracil followed by radiotherapy is the standard alternative to total laryngectomy for patients with locally advanced laryngeal cancer. The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown. Methods: We randomly assigned patients with locally advanced cancer of the larynx to one of three treatments: induction cisplatin plus fluorouracil followed by radiotherapy, radiotherapy with concurrent administration of cisplatin, or radiotherapy alone. The primary end point was preservation of the larynx. Results: A total of 547 patients were randomly assigned to one of the three study groups. The median follow-up period was 3.8 years. At two years, the proportion of patients who had an intact larynx after radiotherapy with concurrent cisplatin (88 percent) differed significantly from the proportions in the groups given induction chemotherapy followed by radiotherapy (75 percent, P=0.005) or radiotherapy alone (70 percent, P<0.001). The rate of locoregional control was also significantly better with radiotherapy and concurrent cisplatin (78 percent, vs. 61 percent with induction cisplatin plus fluorouracil followed by radiotherapy and 56 percent with radiotherapy alone). Both of the chemotherapy-based regimens suppressed distant metastases and resulted in better disease-free survival than radiotherapy alone. However, overall survival rates were similar in all three groups. The rate of high-grade toxic effects was greater with the chemotherapy-based regimens (81 percent with induction cisplatin plus fluorouracil followed by radiotherapy and 82 percent with radiotherapy with concurrent cisplatin, vs. 61 percent with radiotherapy alone). The mucosal toxicity of concurrent radiotherapy and cisplatin was nearly twice as frequent as the mucosal toxicity of the other two treatments during radiotherapy. Conclusions: In patients with laryngeal cancer, radiotherapy with concurrent administration of cisplatin is superior to induction chemotherapy followed by radiotherapy or radiotherapy alone for laryngeal preservation and locoregional control.	Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Radiat Therapy Oncol Grp Headquarters, Philadelphia, PA USA; Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL USA; New York Harbor Healthcare Syst, Dept Vet Affairs, Brooklyn, NY USA; Wayne State Univ, Sch Med, Karmanos Canc Inst, Detroit, MI USA; NYU, Med Ctr, Dept Radiat Oncol, New York, NY 10016 USA	Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; UTMD Anderson Cancer Center; Radiation Therapy Oncology Group (RTOG); State University System of Florida; University of South Florida; Fox Chase Cancer Center; University of Alabama System; University of Alabama Birmingham; Barbara Ann Karmanos Cancer Institute; Wayne State University; New York University	Forastiere, AA (corresponding author), Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,Suite G90, Baltimore, MD 21231 USA.	af@jhmi.edu			NATIONAL CANCER INSTITUTE [U10CA037422, U10CA046282, U10CA021661, P01CA006294, U10CA020319, U10CA049957, U10CA032102, U10CA032115] Funding Source: NIH RePORTER; NCI NIH HHS [CA-46282, CA-32102, CA32115, CA21661, CA37422, CA06294, CA-20319, CA49957] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRISTOL DR, 1989, CONTROL CLIN TRIALS, V10, P142, DOI 10.1016/0197-2456(89)90027-5; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; HONG WK, 1993, CANCER RES, V53, P5113; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; List MA, 1996, CANCER-AM CANCER SOC, V77, P2294, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2294::AID-CNCR17>3.0.CO;2-S; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Weymuller EA, 2001, ARCH OTOLARYNGOL, V127, P489; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	11	2124	2198	2	92	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 27	2003	349	22					2091	2098		10.1056/NEJMoa031317	http://dx.doi.org/10.1056/NEJMoa031317			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746ZV	14645636	Bronze			2023-01-03	WOS:000186779700003
J	Abella, BS; Alvarado, JP; Myklebust, H; Edelson, DP; Barry, A; O'Hearn, N; Vanden Hoek, TL; Becker, LB				Abella, BS; Alvarado, JP; Myklebust, H; Edelson, DP; Barry, A; O'Hearn, N; Vanden Hoek, TL; Becker, LB			Quality of cardiopulmonary resuscitation during in-hospital cardiac arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BASIC LIFE-SUPPORT; CHEST COMPRESSIONS; VENTRICULAR-FIBRILLATION; PRECORDIAL COMPRESSION; CPR PERFORMANCE; BYSTANDER CPR; DEFIBRILLATION; SURVIVAL; SYSTEM	Context The survival benefit of well-performed cardiopulmonary resuscitation (CPR) is well-documented, but little objective data exist regarding actual CPR quality during cardiac arrest. Recent studies have challenged the notion that CPR is uniformly performed according to established international guidelines. Objectives To measure multiple parameters of in-hospital CPR quality and to determine compliance with published American Heart Association and international guidelines. Design and Setting A prospective observational study of 67 patients who experienced in-hospital cardiac arrest at the University of Chicago Hospitals, Chicago, III, between December 11, 2002, and April 5, 2004. Using a monitor/defibrillator with novel additional sensing capabilities, the parameters of CPR quality including chest compression rate, compression depth, ventilation rate, and the fraction of arrest time without chest compressions (no-flow fraction) were recorded. Main Outcome Measure Adherence to American Heart Association and international CPR guidelines. Results Analysis of the first 5 minutes of each resuscitation by 30-second segments revealed that chest compression rates were less than 90/min in 28.1% of segments. Compression depth was too shallow (defined as <38 mm) for 37.4% of compressions. Ventilation rates were high, with 60.9% of segments containing a rate of more than 20/min. Additionally, the mean (SD) no-flow fraction was 0.24 (0.18). A 10-second pause each minute of arrest would yield a no-flow fraction of 0.17. A total of 27 patients (40.3%) achieved return of spontaneous circulation and 7 (10.4%) were discharged from the hospital. Conclusions In this study of in-hospital cardiac arrest, the quality of multiple parameters of CPR was inconsistent and often did not meet published guideline recommendations, even when performed by well-trained hospital staff. The importance of high-quality CPR suggests the need for rescuer feedback and monitoring of CPR quality during resuscitation efforts.	Univ Chicago Hosp, Sect Emergency Med, Chicago, IL 60637 USA; Univ Chicago Hosp, Sect Crit Care, Chicago, IL 60637 USA; Laerdal Med Corp, Stavanger, Norway	University of Chicago; University of Illinois System; University of Chicago; University of Illinois System	Becker, LB (corresponding author), Univ Chicago Hosp, Sect Emergency Med, 5841 S Maryland Ave,MC 5068, Chicago, IL 60637 USA.	lbecker@medicine.bsd.uchicago.edu	Abella, Benjamin/G-3579-2010	Abella, Benjamin/0000-0003-2521-0891				Aase SO, 2000, IEEE T BIO-MED ENG, V47, P1440, DOI 10.1109/10.880095; Aase SO, 2002, IEEE T BIO-MED ENG, V49, P263, DOI 10.1109/10.983461; ABELLA BS, IN PRESS CIRCULATION; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; Becker L, 1996, CARDIAC ARREST SCI P, P28; Berg RA, 2001, CIRCULATION, V104, P2465, DOI 10.1161/hc4501.098926; CAMPBELL JP, 1995, ANN EMERG MED, V26, P590, DOI 10.1016/S0196-0644(95)70009-9; Cobb LA, 1999, JAMA-J AM MED ASSOC, V281, P1182, DOI 10.1001/jama.281.13.1182; Donnelly P, 2000, RESUSCITATION, V45, P195, DOI 10.1016/S0300-9572(00)00186-6; Dowie R, 2003, RESUSCITATION, V56, P173, DOI 10.1016/S0300-9572(02)00343-X; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; FENELEY MP, 1988, CIRCULATION, V77, P240, DOI 10.1161/01.CIR.77.1.240; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; HALPERIN HR, 1993, NEW ENGL J MED, V329, P762, DOI 10.1056/NEJM199309093291104; Handley AJ, 2003, RESUSCITATION, V57, P57, DOI 10.1016/S0300-9572(02)00400-8; HIGHTOWER D, 1995, ANN EMERG MED, V26, P300, DOI 10.1016/S0196-0644(95)70076-5; *INT CONS SCI, 2000, CIRCULATION S1, V102, P1; KAYE W, 1986, CRIT CARE MED, V14, P620, DOI 10.1097/00003246-198607000-00007; Keim SM, 2001, RESUSCITATION, V51, P269, DOI 10.1016/S0300-9572(01)00418-X; Kern KB, 2003, RESUSCITATION, V58, P273, DOI 10.1016/S0300-9572(03)00269-7; Koster RW, 2003, RESUSCITATION, V58, P275, DOI 10.1016/S0300-9572(03)00270-3; Marsch SCU, 2004, RESUSCITATION, V60, P51, DOI 10.1016/j.resuscitation.2003.08.004; MILANDER MM, 1995, ACAD EMERG MED, V2, P708, DOI 10.1111/j.1553-2712.1995.tb03622.x; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Pellis T, 2002, CRIT CARE MED, V30, pS176, DOI 10.1097/00003246-200204001-00012; Rea TD, 2003, CIRCULATION, V108, P1196, DOI 10.1161/01.CIR.0000087403.24467.A4; Sato Y, 1997, CRIT CARE MED, V25, P733, DOI 10.1097/00003246-199705000-00005; Steen S, 2003, RESUSCITATION, V58, P249, DOI 10.1016/S0300-9572(03)00265-X; Sunde K, 1997, RESUSCITATION, V34, P235, DOI 10.1016/S0300-9572(96)01087-8; Timerman S, 2004, RESUSCITATION, V61, P273, DOI 10.1016/j.resuscitation.2004.01.025; VANHOEYWEGHEN RJ, 1993, RESUSCITATION, V26, P47, DOI 10.1016/0300-9572(93)90162-J; WHITE RD, 1994, ANN EMERG MED, V23, P25, DOI 10.1016/S0196-0644(94)70003-6; Wik L, 2003, JAMA-J AM MED ASSOC, V289, P1389, DOI 10.1001/jama.289.11.1389; Wik L, 2001, RESUSCITATION, V50, P167, DOI 10.1016/S0300-9572(01)00331-8; Wik L, 2000, RESUSCITATION, V47, P7, DOI 10.1016/S0300-9572(00)00190-8; Yu T, 2002, CIRCULATION, V106, P368, DOI 10.1161/01.CIR.0000021429.22005.2E	36	891	958	2	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2005	293	3					305	310		10.1001/jama.293.3.305	http://dx.doi.org/10.1001/jama.293.3.305			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888FA	15657323	Bronze			2023-01-03	WOS:000226358400024
J	Morag-Sela, T; Cohn, I; Kowalski, TJ; Jarecki-Black, J; Clyde-Watson, Z				Morag-Sela, T; Cohn, I; Kowalski, TJ; Jarecki-Black, J; Clyde-Watson, Z			Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity	NATURE BIOTECHNOLOGY			English	Editorial Material									Reinhold Cohn & Partners, IL-61040 Tel Aviv, Israel; Frommer Lawrence & Haug LLP, New York, NY 10151 USA; Merial Ltd, Duluth, GA 30096 USA; D Young & Co, London EC1N 2DY, England		Morag-Sela, T (corresponding author), Reinhold Cohn & Partners, POB 4060, IL-61040 Tel Aviv, Israel.	tkowalski@flhlaw.com						*US, 2004, IP LAW B; 2004, GLOBES ONLINE   0926; 1981, PHARM ORDINANCE NEW; 2004, JERUSALEM POST  0909	4	1	1	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2004	22	12					1591	1592		10.1038/nbt1204-1591	http://dx.doi.org/10.1038/nbt1204-1591			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	878HX	15583670				2023-01-03	WOS:000225638600039
J	Harries, AD; Libamba, E; Schouten, EJ; Mwansambo, A; Salaniponi, FM; Mpazanje, R				Harries, AD; Libamba, E; Schouten, EJ; Mwansambo, A; Salaniponi, FM; Mpazanje, R			Expanding antiretroviral therapy in Malawi: drawing on the country's experience with tuberculosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Minist Hlth, HIV AIDS Unit, Lilongwe, Malawi; Minist Hlth, Natl TB Control Programme, Lilongwe, Malawi; Minist Hlth, Dept Clin Serv, Lilongwe, Malawi; Natl AIDS Commiss, Lilongwe, Malawi		Harries, AD (corresponding author), Minist Hlth, HIV AIDS Unit, POB 30377, Lilongwe, Malawi.	adharries@malawi.net						Banerjee A, 2000, INT J TUBERC LUNG D, V4, P333; Chimzizi R, 2004, REPORT COUNTRY WIDE; Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9; Lee JW, 2003, LANCET, V362, P2083, DOI 10.1016/S0140-6736(03)15107-0; Liechty CA, 2003, AIDS, V17, P1383, DOI 10.1097/00002030-200306130-00013; Manders AJE, 2001, INT J TUBERC LUNG D, V5, P838; *MIN HLTH POP, 2002, MAN NAT TUB CONTR PR; *MIN HLTH POP, 2001, MAL NAT HLTH ACC BRO; Mitty JA, 2002, CLIN INFECT DIS, V34, P984, DOI 10.1086/339447; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; *NAT AIDS COMM, 2003, NAT EST HIV AIDS MAL; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Stevens W, 2004, BMJ-BRIT MED J, V328, P280, DOI 10.1136/bmj.328.7434.280; *UNAIDS WHO, 2003, AIDS EP UPD; Warndorff DK, 2000, INT J TUBERC LUNG D, V4, P752; *WHO, 2004, WHOHTMTB2004331; World Health Organization, 2003, TREATM TUB GUID NAT; World Health Organization, 2003, SCAL ANT THER RES LT	18	38	38	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2004	329	7475					1163	1166		10.1136/bmj.329.7475.1163	http://dx.doi.org/10.1136/bmj.329.7475.1163			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539674	Green Accepted, Green Published			2023-01-03	WOS:000225169600027
J	Aadil, N; Houti, IE; Moussamih, S				Aadil, N; Houti, IE; Moussamih, S			Drug intake during ramadan	BMJ-BRITISH MEDICAL JOURNAL			English	Review							GRAPEFRUIT JUICE; BLOOD-PRESSURE; PHARMACOKINETICS; BIOAVAILABILITY; PROPRANOLOL; FORMULATION; THEOPHYLLINE; DIGOXIN; FIBER; DIET		Fac Med & Pharm, Lab Pharmacol & Toxicol, Casablanca 20000, Morocco	Mohammed First University of Oujda	Aadil, N (corresponding author), Fac Med & Pharm, Lab Pharmacol & Toxicol, 19 Rue Tarik Bnou Ziad, Casablanca 20000, Morocco.	aadil-nadia@yahoo.fr						Aadil N, 2000, METHOD FIND EXP CLIN, V22, P109, DOI 10.1358/mf.2000.22.2.796073; [Anonymous], 1997, 9 FIQH MED SEM ISL V; ASLAM M, 1992, J ROY SOC HEALTH, V112, P135, DOI 10.1177/146642409211200308; ASLAM M, 1986, PUBLIC HEALTH, V100, P49, DOI 10.1016/S0033-3506(86)80086-5; ASLAM M, 1986, J CLIN HOSP PHARM, V11, P321, DOI 10.1111/j.1365-2710.1986.tb00859.x; Bailey DG, 1998, BRIT J CLIN PHARMACO, V46, P101, DOI 10.1046/j.1365-2125.1998.00764.x; BEAM WR, 1992, AM REV RESPIR DIS, V146, P1524, DOI 10.1164/ajrccm/146.6.1524; BENVENGA S, 1995, THYROID, V5, P249, DOI 10.1089/thy.1995.5.249; DAGHFOUS J, 1994, ANN SAUDI MED, V14, P523, DOI 10.5144/0256-4947.1994.523; Dresser GK, 2002, CLIN PHARMACOL THER, V71, P11, DOI 10.1067/mcp.2002.121152; Erol K, 2001, CHRONOBIOL INT, V18, P841, DOI 10.1081/CBI-100107519; ETERNADYFAR M, 2001, C HLTH RAM OCT 2001, P32; *FACTS COMP, 1991, FACTS COMP DRUG INF, pA178; *FACTS COMP, 1991, FACTS COMP DRUG INF, pS132; Garg SK, 1998, CLIN PHARMACOL THER, V64, P286, DOI 10.1016/S0009-9236(98)90177-1; GAY J P, 1990, Journal of Interdisciplinary Cycle Research, V21, P190; GERTZ BJ, 1995, CLIN PHARMACOL THER, V58, P288, DOI 10.1016/0009-9236(95)90245-7; Glasser SP, 2003, AM J HYPERTENS, V16, P51, DOI 10.1016/S0895-7061(02)03153-9; Habbal R, 1998, ARCH MAL COEUR VAISS, V91, P995; Halsas M, 1999, INT J PHARM, V189, P179, DOI 10.1016/S0378-5173(99)00250-1; HAMAGUCHI T, 1993, INT J CLIN PHARM TH, V31, P326; HOLT GA, 1998, FOOD DRUG INTERACTIO, P93; Horiguchi Takahiko, 2004, Nihon Kokyuki Gakkai Zasshi, V42, P132; Iraki L, 1997, J CLIN ENDOCR METAB, V82, P1261, DOI 10.1210/jc.82.4.1261; JOHNSON BF, 1987, J CLIN PHARMACOL, V27, P487, DOI 10.1002/j.1552-4604.1987.tb03054.x; KHASAWNEH SM, 1992, AM J GASTROENTEROL, V87, P1180; LANGNER B, 1988, EUR J CLIN PHARMACOL, V33, P619, DOI 10.1007/BF00542498; LEMMER B, 1991, CHRONOBIOL INT, V8, P485, DOI 10.3109/07420529109059184; Liel Y, 1996, J CLIN ENDOCR METAB, V81, P857, DOI 10.1210/jc.81.2.857; Perk G, 2001, J HUM HYPERTENS, V15, P723, DOI 10.1038/sj.jhh.1001262; Pincus DJ, 1997, J ALLERGY CLIN IMMUN, V100, P771, DOI 10.1016/S0091-6749(97)70272-0; Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088-199936050-00002; SAOUR JN, 1989, ANN SAUDI MED, V9, P538, DOI 10.5144/0256-4947.1989.538; SHIGA T, 1993, J CLIN PHARMACOL, V33, P756, DOI 10.1002/j.1552-4604.1993.tb05620.x; Sica Domenic, 2003, Heart Dis, V5, P176, DOI 10.1097/01.HDX.0000074436.09658.3b; Sista S, 2003, J CLIN PHARMACOL, V43, P1149, DOI 10.1177/0091270003257214; Smith David H. G., 2001, American Journal of Hypertension, V14, p296S, DOI 10.1016/S0895-7061(01)02176-8; SMOLENSKY MH, 1987, CHRONOBIOL INT, V4, P435, DOI 10.3109/07420528709083532; WALLE T, 1981, CLIN PHARMACOL THER, V30, P790, DOI 10.1038/clpt.1981.239; Wang P, 2003, BIOMED CHROMATOGR, V17, P58, DOI 10.1002/bmc.214; WHCATLY RS, 1993, BRIT MED J, V307, P801; Wilder BJ, 2001, NEUROLOGY, V57, P582, DOI 10.1212/WNL.57.4.582; WITTE K, 1993, CLIN PHARMACOL THER, V54, P177, DOI 10.1038/clpt.1993.129	44	62	64	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 2	2004	329	7469					778	782B		10.1136/bmj.329.7469.778	http://dx.doi.org/10.1136/bmj.329.7469.778			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	859TW	15459052	Green Published			2023-01-03	WOS:000224291800022
J	Beliveau, R; Gingras, D				Beliveau, R; Gingras, D			Green tea: prevention and treatment of cancer by nutraceuticals	LANCET			English	Editorial Material									Hop Ste Justine UQAM, Ctr Canc Charles Bruneau, Mol Med Lab, Montreal, PQ H3T 1C, Canada	University of Quebec; University of Quebec Montreal	Beliveau, R (corresponding author), Hop Ste Justine UQAM, Ctr Canc Charles Bruneau, Mol Med Lab, Montreal, PQ H3T 1C, Canada.	beliveau.richard@uqam.ca						Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; de Botton S, 2004, J CLIN ONCOL, V22, P1404, DOI 10.1200/JCO.2004.09.008; Demeule Michel, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P441, DOI 10.2174/1568011023353930; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; GAO YT, 1994, JNCI-J NATL CANCER I, V86, P855, DOI 10.1093/jnci/86.11.855; Gescher AJ, 2001, LANCET ONCOL, V2, P371, DOI 10.1016/S1470-2045(00)00392-2; Lamy S, 2002, CANCER RES, V62, P381; Lee YK, 2004, BLOOD, V104, P788, DOI 10.1182/blood-2003-08-2763; Pisters KMW, 2001, J CLIN ONCOL, V19, P1830, DOI 10.1200/JCO.2001.19.6.1830	10	33	35	3	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	2004	364	9439					1021	1022		10.1016/S0140-6736(04)17076-1	http://dx.doi.org/10.1016/S0140-6736(04)17076-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	855FT	15380952				2023-01-03	WOS:000223959300008
J	Stiell, IG; Wells, GA; Field, B; Spaite, DW; Nesbitt, LP; De Maio, VJ; Nichol, G; Cousineau, D; Blackburn, J; Munkley, D; Luinstra-Toohey, L; Campeau, T; Dagnone, E; Lyver, M				Stiell, IG; Wells, GA; Field, B; Spaite, DW; Nesbitt, LP; De Maio, VJ; Nichol, G; Cousineau, D; Blackburn, J; Munkley, D; Luinstra-Toohey, L; Campeau, T; Dagnone, E; Lyver, M		Ontario Prehospital Adv Life Suppo	Advanced cardiac life support in out-of-hospital cardiac arrest.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EMERGENCY MEDICAL-SERVICES; SURVIVAL; OPALS; CARE; RESUSCITATION; TECHNICIANS; PARAMEDICS; VICTIMS; PROGRAM; SYSTEM	Background: The Ontario Prehospital Advanced Life Support (OPALS) Study tested the incremental effect on the rate of survival after out-of-hospital cardiac arrest of adding a program of advanced life support to a program of rapid defibrillation. Methods: This multicenter, controlled clinical trial was conducted in 17 cities before and after advanced-life-support programs were instituted and enrolled 5638 patients who had had cardiac arrest outside the hospital. Of those patients, 1391 were enrolled during the rapid-defibrillation phase and 4247 during the subsequent advanced-life-support phase. Paramedics were trained in standard advanced life support, which includes endotracheal intubation and the administration of intravenous drugs. Results: From the rapid-defibrillation phase to the advanced-life-support phase, the rate of admission to a hospital increased significantly (10.9 percent vs. 14.6 percent, P<0.001), but the rate of survival to hospital discharge did not (5.0 percent vs. 5.1 percent, P=0.83). The multivariate odds ratio for survival after advanced life support was 1.1 (95 percent confidence interval, 0.8 to 1.5); after an arrest witnessed by a bystander, 4.4 (95 percent confidence interval, 3.1 to 6.4); after cardiopulmonary resuscitation administered by a bystander, 3.7 (95 percent confidence interval, 2.5 to 5.4); and after rapid defibrillation, 3.4 (95 percent confidence interval, 1.4 to 8.4). There was no improvement in the rate of survival with the use of advanced life support in any subgroup. Conclusions: The addition of advanced-life-support interventions did not improve the rate of survival after out-of-hospital cardiac arrest in a previously optimized emergency-medical-services system of rapid defibrillation. In order to save lives, health care planners should make cardiopulmonary resuscitation by citizens and rapid-defibrillation responses a priority for the resources of emergency-medical-services systems.	Univ Ottawa, Ottawa Hlth Res Inst, Dept Emergency Med, Ottawa, ON, Canada; Univ Ottawa, Ottawa Hlth Res Inst, Dept Epidemiol & Community Med, Ottawa, ON, Canada; Univ Ottawa, Ottawa Hlth Res Inst, Dept Med, Ottawa, ON, Canada; Univ Ottawa, Ottawa Hlth Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; Interdev Technol, Toronto, ON, Canada; Univ Arizona, Dept Emergency Med, Tucson, AZ USA; Univ N Carolina, Dept Emergency Med, Chapel Hill, NC USA; Greater Niagara Base Hosp, Niagara Falls, ON, Canada; Ontario Minist Hlth & Long Term Care, Emergency Hlth Serv, Toronto, ON, Canada; Queens Univ, Dept Emergency Med, Kingston, ON, Canada; McMaster Univ, Dept Family Med, Hamilton, ON L8S 4L8, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Arizona; University of North Carolina; University of North Carolina Chapel Hill; Queens University - Canada; McMaster University	Stiell, IG (corresponding author), Ottawa Hosp, Clin Epidemiol Unit, Ottawa Hlth Res Inst, Off F657, Civ Campus,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.	istiell@ohri.ca	Nichol, Graham/Z-4996-2019	Spaite, Daniel/0000-0003-2601-6476; Stiell, Ian/0000-0002-2583-6408				Becker L, 1998, CIRCULATION, V97, P2106, DOI 10.1161/01.CIR.97.21.2106; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; Boyle, 1998, 9811 MCMAST U CTR HL; CARVETH SW, 1974, ARCH SURG-CHICAGO, V108, P528; Cone DC, 2003, ANN EMERG MED, V42, P251, DOI 10.1067/mem.2003.267; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; De Maio VJ, 2003, ANN EMERG MED, V42, P242, DOI 10.1067/mem.2003.266; DEMAIO VJ, 2003, ACAD EMERG MED, V10, P504; DONOVAN PJ, 1989, ANN EMERG MED, V18, P495, DOI 10.1016/S0196-0644(89)80831-5; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EISENBERG MS, 1980, JAMA-J AM MED ASSOC, V243, P1049, DOI 10.1001/jama.243.10.1049; Gratton M, 1999, Prehosp Emerg Care, V3, P303, DOI 10.1080/10903129908958958; GULY UM, 1995, BRIT MED J, V310, P1091, DOI 10.1136/bmj.310.6987.1091; KELSEY SF, 1991, CONTROL CLIN TRIALS, V12, P525; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; Mitchell RG, 1997, J ACCID EMERG MED, V14, P274; Nichol G, 1999, ANN EMERG MED, V34, P517, DOI 10.1016/S0196-0644(99)80054-7; Nichol G, 1996, ANN EMERG MED, V27, P700, DOI 10.1016/S0196-0644(96)70187-7; PANTRIDG.JF, 1967, LANCET, V2, P271; PEPE PE, 1994, ANN EMERG MED, V23, P1037, DOI 10.1016/S0196-0644(94)70100-8; Rainer TH, 1997, J ACCID EMERG MED, V14, P278; ROWLEY JM, 1987, BRIT MED J, V295, P1387, DOI 10.1136/bmj.295.6610.1387; Stiell I, 2003, CIRCULATION, V108, P1939, DOI 10.1161/01.CIR.0000095028.95929.B0; Stiell IG, 1998, ANN EMERG MED, V32, P180, DOI 10.1016/S0196-0644(98)70135-0; Stiell IG, 1999, JAMA-J AM MED ASSOC, V281, P1175, DOI 10.1001/jama.281.13.1175; Stiell IG, 1999, ANN EMERG MED, V33, P44, DOI 10.1016/S0196-0644(99)70415-4; VAILLANCOURT C, 2003, ACAD EMERG MED, V10, P466; VERTESI L, 1983, CAN MED ASSOC J, V128, P809; Zheng ZJ, 2001, CIRCULATION, V104, P2158, DOI 10.1161/hc4301.098254	33	611	628	1	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2004	351	7					647	656		10.1056/NEJMoa040325	http://dx.doi.org/10.1056/NEJMoa040325			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	845FZ	15306666				2023-01-03	WOS:000223225500007
J	Crepaz, N; Hart, TA; Marks, G				Crepaz, N; Hart, TA; Marks, G			Highly active antiretroviral therapy and sexual risk behavior - A meta-analytic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HIV-POSITIVE GAY; VIRAL LOAD; HOMOSEXUAL-MEN; HETEROSEXUAL TRANSMISSION; COMBINATION THERAPIES; TRANSMITTED DISEASES; PROTEASE INHIBITORS; VIROLOGICAL FAILURE; SAN-FRANCISCO; CONDOM USE	Context Evidence suggests that since highly active antiretroviral therapy (HAART) became available, the prevalence of unprotected sex and the incidence of sexually transmitted infections (STIs) have increased. Objective To conduct 3 meta-analyses to determine whether (1) being treated with HAART, (2) having an undetectable viral load, or (3) holding specific beliefs about HAART and viral load are associated with increased likelihood of engaging in unprotected sex. Data Sources A comprehensive search included electronic bibliographic databases, including AIDSLINE, MEDLINE, PubMed, CINHAL, PsycInfo, ERIC, EMBASE, and Sociofile, from January 1996 to August 2003, conference proceedings, hand searches of journals, reference lists of articles, and contacts with researchers. Study Selection Twenty-five English-language studies (some contributing >1 finding) met the selection criteria and examined the association of unprotected sexual intercourse or STIs with receiving HAART (21 findings), having an undetectable viral load (13 findings), or beliefs about HAART and viral load (18 findings). Data Extraction Reports were screened and information from eligible studies was abstracted independently by pairs of reviewers using a standardized spreadsheet. Data Synthesis Random-effects models were used to aggregate data. The prevalence of unprotected sex was not higher among persons with the human immunodeficiency virus (HIV) receiving HAART (prevalence range, 9%-56%; median, 33%) vs those not receiving HAART (range, 11%-77%; median, 44%; odds ratio [OR], 0.92; 95% confidence interval [CI], 0.65-1.31) or among HIV-positive persons with an undetectable viral load (range, 10%-68%; median, 39%) vs those with a detectable viral load (range, 14%-70%; median, 42%; OR, 0.99; 95% Cl, 0.82-1.21). The prevalence of unprotected sex was elevated (OR, 1.82; 95% Cl, 1.52-2.17) in HIV-positive, HIV-negative, and unknown serostatus persons who believed that receiving HAART or having an undetectable viral load protects against transmitting HIV or who had reduced concerns about engaging in unsafe sex given the availability of HAART (range, 17%-81% [median, 49%] vs 9%-68% [median, 38%] for counterparts). Conclusions In the studies reviewed, HIV-positive patients receiving HAART did not exhibit increased sexual risk behavior, even when therapy achieved an undetectable viral load. However, people's beliefs about HAART and viral load may promote unprotected sex and may be amenable to change through prevention messages.	Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Prevent Res Branch, Atlanta, GA 30333 USA; Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Emory University	Crepaz, N (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Prevent Res Branch, 1600 Clifton Rd,Mailstop E-37, Atlanta, GA 30333 USA.	ncrepaz@cdc.gov		Hart, Trevor/0000-0001-5107-7452				[Anonymous], 1999, MMWR MORB MORTAL WKL, V48, P45; BERN DJ, 1967, PSYCHOL REV, V74, P183, DOI DOI 10.1037/H0024835; Bouhnik AD, 2002, J EPIDEMIOL COMMUN H, V56, P349, DOI 10.1136/jech.56.5.349; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Catz SL, 2001, AIDS EDUC PREV, V13, P239, DOI 10.1521/aeap.13.3.239.19746; Chen SY, 2002, AM J PUBLIC HEALTH, V92, P1387, DOI 10.2105/AJPH.92.9.1387-a; Comulada WS, 2003, AM J HEALTH BEHAV, V27, P389, DOI 10.5993/AJHB.27.4.11; Cooper H.M., 1998, SYNTHESIZING RES GUI, V2; Cooper HM, 1994, HDB RES SYNTHESIS; De Rosa CJ, 1998, HEALTH PSYCHOL, V17, P224, DOI 10.1037/0278-6133.17.3.224; de Ven PV, 1999, AIDS, V13, P2289, DOI 10.1097/00002030-199911120-00011; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; Demmer C, 2002, J COMMUN HEALTH, V27, P63, DOI 10.1023/A:1013884310983; Desquilbet L, 2002, AIDS, V16, P2329, DOI 10.1097/00002030-200211220-00014; DiClemente RJ, 2002, SOUTH MED J, V95, P421, DOI 10.1097/00007611-200204000-00009; Dilley JW, 2003, AIDS CARE, V15, P27, DOI 10.1080/0954012021000039734; Dilley JW, 1997, NEW ENGL J MED, V337, P501, DOI 10.1056/NEJM199708143370715; Dionisio D, 2001, CLIN INFECT DIS, V33, P706, DOI 10.1086/322660; Dodds JP, 2000, BRIT MED J, V320, P1510, DOI 10.1136/bmj.320.7248.1510; Dukers NHTM, 2002, AIDS, V16, pF19, DOI 10.1097/00002030-200207050-00001; Dukers NHTM, 2001, AIDS, V15, P369, DOI 10.1097/00002030-200102160-00010; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elford J, 2003, JAIDS-J ACQ IMM DEF, V32, P545, DOI 10.1097/00126334-200304150-00013; Elford J, 2002, AIDS, V16, P1537, DOI 10.1097/00002030-200207260-00011; Elford J, 2000, J ACQ IMMUN DEF SYND, V23, P266; Festinger L., 1957, COGNITIVE DISSONANCE; FIDELI U, 2000, 7 C RETR OPP INF JAN; Friedland GH, 1999, AIDS, V13, pS61; GWADZ M, 1999, J SEX EDUC THER, V24, P81; Hedges LV, 1998, PSYCHOL METHODS, V3, P486, DOI 10.1037/1082-989X.3.4.486; Herlitz CA, 2001, EUR J PUBLIC HEALTH, V11, P251, DOI 10.1093/eurpub/11.3.251; Hogg RS, 2001, AIDS, V15, P1321, DOI 10.1097/00002030-200107060-00020; Huebner DM, 2001, ANN BEHAV MED, V23, P304, DOI 10.1207/S15324796ABM2304_10; Johnson WD, 2002, J ACQ IMMUN DEF SYND, V30, pS62, DOI 10.1097/01.QAI.0000018888.47949.1B; JUNE P, 2001, SYSTEMATIC REV HLTH; Kalichman SC, 1998, HEALTH PSYCHOL, V17, P546, DOI 10.1037/0278-6133.17.6.546; Kalichman SC, 2001, J ACQ IMMUN DEF SYND, V28, P303; Kalichman SC, 1999, AIDS CARE, V11, P415, DOI 10.1080/09540129947794; Katz MH, 2002, AM J PUBLIC HEALTH, V92, P388, DOI 10.2105/AJPH.92.3.388; Kelly JA, 1998, HEALTH PSYCHOL, V17, P310, DOI 10.1037/0278-6133.17.4.310; Kravcik S, 1998, J ACQ IMMUN DEF SYND, V19, P124, DOI 10.1097/00042560-199810010-00004; Lipsey M.W., 2001, PRACTICAL META ANAL; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; MARTICKATYNDALE.E, 2002, CAN J HUM SEX, V11, P33; Martin DJ, 2001, AM J HEALTH BEHAV, V25, P513, DOI 10.5993/AJHB.25.6.1; Miller M, 2000, AIDS, V14, pF33, DOI 10.1097/00002030-200003100-00001; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Ostrow DE, 2002, AIDS, V16, P775, DOI 10.1097/00002030-200203290-00013; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pedraza MA, 1999, J ACQ IMMUN DEF SYND, V21, P120; Posner SF, 1996, AM J PREV MED, V12, P472, DOI 10.1016/S0749-3797(18)30270-8; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Remien RH, 1998, AIDS, V12, P1560, DOI 10.1097/00002030-199812000-00025; Scheer S, 2001, LANCET, V357, P432, DOI 10.1016/S0140-6736(00)04007-1; Semple SJ, 2003, AIDS EDUC PREV, V15, P133, DOI 10.1521/aeap.15.3.133.23835; Stephenson JM, 2003, SEX TRANSM INFECT, V79, P7, DOI 10.1136/sti.79.1.7; Stolte IG, 2001, SEX TRANSM INFECT, V77, P184, DOI 10.1136/sti.77.3.184; Suarez TP, 2001, J ACQ IMMUN DEF SYND, V28, P471, DOI 10.1097/00042560-200112150-00011; SUTTON AJ, 1980, METHODS META ANAL ME; Tachet A, 1999, AIDS, V13, P823, DOI 10.1097/00002030-199905070-00012; van der Straten A, 1998, Focus, V13, P5; van der Straten A, 2000, AIDS, V14, pF47, DOI 10.1097/00002030-200003100-00003; Vanable PA, 2003, J PSYCHOSOM RES, V54, P263, DOI 10.1016/S0022-3999(02)00483-X; Vanable PA, 2000, HEALTH PSYCHOL, V19, P134, DOI 10.1037//0278-6133.19.2.134; Vernazza PL, 2000, AIDS, V14, P117, DOI 10.1097/00002030-200001280-00006; Vlahov D, 2001, AIDS, V15, P2311, DOI 10.1097/00002030-200111230-00013; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977; Wilson TE, 2001, J ACQ IMMUN DEF SYND, V27, P289, DOI 10.1097/00126334-200107010-00012; Wolf K, 2003, JAIDS-J ACQ IMM DEF, V33, P494, DOI 10.1097/00126334-200308010-00010; Wolitski RJ, 2001, AM J PUBLIC HEALTH, V91, P883, DOI 10.2105/AJPH.91.6.883; Yamey G, 2001, BRIT MED J, V322, P260, DOI 10.1136/bmj.322.7281.260; Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502; 2003, MMWR MOB MORTAL WKLY, V52, P1145	74	438	444	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2004	292	2					224	236		10.1001/jama.292.2.224	http://dx.doi.org/10.1001/jama.292.2.224			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	836TS	15249572				2023-01-03	WOS:000222579300028
J	Pirmohamed, M; James, S; Meakin, S; Green, C; Scott, AK; Walley, TJ; Farrar, K; Park, BK; Breckenridge, AM				Pirmohamed, M; James, S; Meakin, S; Green, C; Scott, AK; Walley, TJ; Farrar, K; Park, BK; Breckenridge, AM			Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ELDERLY PATIENTS; COSTS; METAANALYSIS; DEFINITIONS; PREVENTION; ASPIRIN; DISEASE; EVENTS; UNIT	Objective To ascertain the current burden of adverse drug reactions (ADRs) through a prospective analysis of all admissions to hospital. Design Prospective observational study. Setting Two large general hospitals in Merseyside, England. Participants 18 820 patients aged > 16 years admitted over six months and assessed for cause of admission. Main outcome measures Prevalence of admissions due to an ADR, length of stay, avoidability, and outcome. Results There were 1225. admissions related to an ADR, giving a prevalence of 6.5%, with the ADR directly leading to the admission in 80% of cases. The median bed stay was eight days, accounting for 4% of the hospital bed capacity. The projected annual cost of such admissions to the NHS is pound466m ((sic)706m, $847m). The overall fatality was 0.15%. Most reactions were either definitely or possibly avoidable. Drugs most commonly implicated in causing these admissions included low dose aspirin, diuretics, warfarin, and non-steroidal anti-inflammatory drugs other than aspirin, the most common reaction being gastrointestinal bleeding. Conclusion The burden of ADRs on the NHS is high accounting for considerable morbidity, mortality, and extra costs. Although many of the implicated drugs have proved benefit, measures need to be put into place to reduce the burden of ADRs and thereby further improve the benefit:harm ratio of the drugs.	Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England; Royal Liverpool Univ Hosp, Liverpool L7 8XP, Merseyside, England; Wirral Hosp NHS Trust, Wirral CH49 5PE, Merseyside, England	University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Pirmohamed, M (corresponding author), Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England.	munirp@liv.ac.uk	Pirmohamed, Munir/H-6004-2011	Pirmohamed, Munir/0000-0002-7534-7266				Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; Beijer HJM, 2002, PHARM WORLD SCI, V24, P46, DOI 10.1023/A:1015570104121; BHALLA N, 2003, PHARM J, V270, P583; *BRIT MED ASS ROYA, 2002, BRIT NAT FORM; *CIPFA, 2002, HLTH SERV FIN DAT CO; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; *DEP HLTH, 2001, HOSP EP STAT; Department of Health, 2001, MED OLD PEOPL IMPL M; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; Gaspoz J, 2002, NEW ENGL J MED, V346, P1800, DOI 10.1056/NEJM200206063462309; GHOSE K, 1980, J ROY SOC MED, V73, P853, DOI 10.1177/014107688007301207; GOSNEY M, 1984, LANCET, V2, P564; HALLAS J, 1990, J INTERN MED, V228, P83, DOI 10.1111/j.1365-2796.1990.tb00199.x; Howard RL, 2003, QUAL SAF HEALTH CARE, V12, P280, DOI 10.1136/qhc.12.4.280; HURWITZ N, 1969, BRIT MED J, V1, P536, DOI 10.1136/bmj.1.5643.536; HURWITZ N, 1969, BMJ-BRIT MED J, V1, P531, DOI 10.1136/bmj.1.5643.531; HURWITZ N, 1969, BRIT MED J, V1, P539, DOI 10.1136/bmj.1.5643.539; Jones J K, 1982, Fam Community Health, V5, P58; Kvasz M, 2000, MedGenMed, V2, pE3; Lagnaoui R, 2000, EUR J CLIN PHARMACOL, V56, P181, DOI 10.1007/s002280050738; Langman MJS, 2001, PHARMACOEPIDEM DR S, V10, P13, DOI 10.1002/pds.561; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEACH S, 1986, AGE AGEING, V15, P241, DOI 10.1093/ageing/15.4.241; LINDLEY CM, 1992, AGE AGEING, V21, P294, DOI 10.1093/ageing/21.4.294; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Rawlins MD, 1991, TXB ADVERSE DRUG REA, P18; Rodriguez-Monguio R, 2003, PHARMACOECONOMICS, V21, P623, DOI 10.2165/00019053-200321090-00002; Smith CC, 1996, BRIT J CLIN PHARMACO, V42, P423, DOI 10.1111/j.1365-2125.1996.tb00004.x; WEIL J, 1995, BMJ-BRIT MED J, V310, P827, DOI 10.1136/bmj.310.6983.827; Wiffen P, 2002, BANDOLIER EXTRA, P1; WILLIAMSON J, 1980, AGE AGEING, V9, P73, DOI 10.1093/ageing/9.2.73; Winterstein AG, 2002, ANN PHARMACOTHER, V36, P1238, DOI 10.1345/aph.1A225	33	1952	2031	0	123	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	2004	329	7456					15	19		10.1136/bmj.329.7456.15	http://dx.doi.org/10.1136/bmj.329.7456.15			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836PP	15231615	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000222568300015
J	Banks, E; Reeves, G; Beral, V; Bull, D; Crossley, B; Simmonds, M; Hilton, E; Bailey, S; Barren, N; Briers, P; English, R; Jackson, A; Kutt, E; Lavelle, J; Rockall, L; Wallis, MG; Wilson, M; Patnick, J				Banks, E; Reeves, G; Beral, V; Bull, D; Crossley, B; Simmonds, M; Hilton, E; Bailey, S; Barren, N; Briers, P; English, R; Jackson, A; Kutt, E; Lavelle, J; Rockall, L; Wallis, MG; Wilson, M; Patnick, J			Impact of use of hormone replacement therapy on false positive recall in the NHS breast screening programme: results from the million women study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CANCER		Radcliffe Infirm, Canc Res UK Epidemiol Unit, Oxford OX2 6HE, England; Princess Wales Community Hosp, Breast Screening Serv, Bromsgrove B61 0BB, England; Charing Cross Hosp, W London Breast Screening Serv, London W6 8RF, England; Gloucestershire Breast Screening Serv, Cheltenham GL53 7AS, Glos, England; Churchill Hosp, Oxford Radcliffe Hosp NHS Trust, Breast Care Unit, Oxford OX3 7JH, England; Queen Alexandra Hosp, Patricia Massey Breast Screening Unit, Portsmouth PO6 3LY, Hants, England; Cent Hlth Clin, Avon Breast Screening, Bristol BS2 0JD, Avon, England; Royal Lancaster Infirm, N Lancashire Breast Screening Serv, Lancaster LA1 4GG, England; Worthing Dist Hosp, W Sussex Breast Screening Serv, Worthing BN11 2DH, England; Coventry & Warwick Hosp, Breast Screening Unit, Coventry CV1 4FH, W Midlands, England; Nightingale Ctr, Greater Manchester Breast Screening Serv, Manchester M20 0PT, Lancs, England; NHS Breast Screening Programme, Sheffield S11 9PS, S Yorkshire, England	Cancer Research UK; Radcliffe Infirmary; Imperial College London; Oxford University Hospitals NHS Foundation Trust; University of Oxford; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital	Banks, E (corresponding author), Radcliffe Infirm, Canc Res UK Epidemiol Unit, Gibson Bldg, Oxford OX2 6HE, England.	emily.banks@anu.edu.au		Banks, Emily/0000-0002-4617-1302				Abbott S, 2002, BJOG-INT J OBSTET GY, V109, P1319; Banks E, 2001, J MED SCREEN, V8, P29, DOI 10.1136/jms.8.1.29; McCann J, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr455; PATNICK J, 2002, 2002 NHS BREAST SCRE; The Million Women Study Collaborative Group, 1999, BREAST CANCER RES, V1, P73, DOI DOI 10.1186/BCR16	5	23	24	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	2004	328	7451					1291	1292		10.1136/bmj.328.7451.1291	http://dx.doi.org/10.1136/bmj.328.7451.1291			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826PN	15166064	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000221841100019
J	Skeff, KM; Ezeji-Okoye, S; Pompei, P; Rockson, S				Skeff, KM; Ezeji-Okoye, S; Pompei, P; Rockson, S			Benefits of resident work hours regulation	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PATIENT-CARE; MEDICINE; PROGRAM		Stanford Univ, Med Ctr, Stanford, CA 94305 USA	Stanford University	Skeff, KM (corresponding author), Stanford Univ, Med Ctr, 300 Pasteur Dr,Room S101, Stanford, CA 94305 USA.			rockson, stanley/0000-0003-1253-474X				Baldwin DC, 2003, ACAD MED, V78, P1154, DOI 10.1097/00001888-200311000-00018; Berwick DM, 2003, QUAL SAF HEALTH CARE, V12, P448, DOI 10.1136/qhc.12.6.448; Clever LH, 2002, ANN INTERN MED, V136, P391, DOI 10.7326/0003-4819-136-5-200203050-00012; Cruess RL, 1999, ACAD MED, V74, P878, DOI 10.1097/00001888-199908000-00010; DaRosa DA, 2003, SURGERY, V133, P13, DOI 10.1067/msy.2003.67; GURJALA A, 2001, HRG PUBLICATION, V1570; Johnson T, 2003, ACAD MED, V78, P3, DOI 10.1097/00001888-200301000-00002; LAINE C, 1993, JAMA-J AM MED ASSOC, V269, P374, DOI 10.1001/jama.269.3.374; Lawrence Hal C 3rd, 2003, Curr Womens Health Rep, V3, P487; Petersen L A, 1998, Jt Comm J Qual Improv, V24, P77; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Shanafelt TD, 2002, ANN INTERN MED, V136, P358, DOI 10.7326/0003-4819-136-5-200203050-00008; Souba WW, 2002, ACAD MED, V77, P139, DOI 10.1097/00001888-200202000-00008; Whang EE, 2003, J AM COLL SURGEONS, V197, P624, DOI 10.1016/S1072-7515(03)00602-1	14	29	29	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	2004	140	10					816	817		10.7326/0003-4819-140-10-200405180-00012	http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822EX	15148069				2023-01-03	WOS:000221520900007
J	Bennewith, O; Gunnell, D; Peters, TJ; Hawton, K; House, A				Bennewith, O; Gunnell, D; Peters, TJ; Hawton, K; House, A			Variations in the hospital management of self harm in adults in England: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England; Univ Oxford, Warneford Hosp, Dept Psychiat, Ctr Suicide Res, Oxford OX3 7JX, England; Univ Leeds, Acad Unit Psychiat & Behav Sci, Leeds LS2 9JT, W Yorkshire, England	University of Bristol; University of Bristol; University of Oxford; University of Leeds	Gunnell, D (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	D.J.Gunnell@Bristol.ac.uk	Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470; House, Allan/0000-0001-8721-8026; Peters, Tim/0000-0003-2881-4180				Department of Health, 2002, NAT SUIC PREV STRAT; Gunnell DJ, 1996, J EPIDEMIOL COMMUN H, V50, P24, DOI 10.1136/jech.50.1.24; Hawton K, 1997, BRIT J PSYCHIAT, V171, P556, DOI 10.1192/bjp.171.6.556; Kapur N, 1998, BRIT MED J, V316, P831, DOI 10.1136/bmj.316.7134.831; *ROYAL COLL PSYCH, 1994, GEN HOSP MAN AD SELF	5	70	72	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	2004	328	7448					1108	1109		10.1136/bmj.328.7448.1108	http://dx.doi.org/10.1136/bmj.328.7448.1108			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818YS	15130979	Green Accepted, Green Submitted, Green Published, Bronze			2023-01-03	WOS:000221281000020
J	Jarman, B; Aylin, P; Bottle, A				Jarman, B; Aylin, P; Bottle, A			Dr Foster's case notes - Trends in admissions and deaths in English NHS hospitals	BRITISH MEDICAL JOURNAL			English	Article									Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England	Imperial College London	Jarman, B (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England.		Aylin, Paul/A-1073-2014	Aylin, Paul/0000-0003-4589-1743; Bottle, Alex/0000-0001-9978-2011					0	8	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 10	2004	328	7444					855	855		10.1136/bmj.328.7444.855	http://dx.doi.org/10.1136/bmj.328.7444.855			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	812XE	15073069	Green Published			2023-01-03	WOS:000220871400012
J	Rosenberg, SA				Rosenberg, SA			Shedding light on immunotherapy for cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							T-CELLS; AUTOIMMUNITY; REGRESSION		NCI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rosenberg, SA (corresponding author), NCI, Bethesda, MD 20892 USA.				Intramural NIH HHS [Z01 SC003811-32] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC003811, Z01SC003800] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Yu P, 2004, NAT IMMUNOL, V5, P141, DOI 10.1038/ni1029	5	123	135	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 1	2004	350	14					1461	1463		10.1056/NEJMcibr045001	http://dx.doi.org/10.1056/NEJMcibr045001			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808IJ	15070799	Green Accepted			2023-01-03	WOS:000220562500016
J	Vickers, AJ; Rees, RW; Zollman, CE; McCarney, R; Smith, C; Ellis, N; Fisher, P; Van Haselen, R				Vickers, AJ; Rees, RW; Zollman, CE; McCarney, R; Smith, C; Ellis, N; Fisher, P; Van Haselen, R			Acupuncture for chronic headache in primary care: large, pragmatic, randomised trial	BRITISH MEDICAL JOURNAL			English	Article							TENSION-TYPE HEADACHE; PROPHYLACTIC TREATMENT; NEEDLE ACUPUNCTURE; DOUBLE-BLIND; MIGRAINE; PLACEBO; FLUNARIZINE	Objectives To determine the effects of a policy of "use acupuncture" on headache, health status, days off sick, and use of resources in patients with chronic headache compared with a policy of "avoid acupuncture." Design Randomised, controlled trial. Setting General practices in England and Wales. Participants 401 patients with chronic headache, predominantly migraine. Interventions Patients were randomly allocated to receive up to 12 acupuncture treatments over three months or to a control intervention offering usual care. Main outcome measures Headache score, SF-36 health status, and use of medication were assessed at baseline, three, and 12 months. Use of resources was assessed every three months. Results Headache score at 12 months, the primary end point, was lower in the acupuncture group (16.2, SD 13.7, n = 161, 34% reduction from baseline) than in controls (22.3, SD 17.0, n = 140, 161% reduction from baseline). The adjusted difference between means is 4.6 (95% confidence interval 2.2 to 7.0; P = 0.0002). This result is robust to sensitivity analysis incorporating imputation for missing data. Patients in the acupuncture group experienced the equivalent of 22 fewer days of headache per year (8 to 38). SF-36 data favoured acupuncture, although differences reached significance only for physical role functioning, energy, and change in health. Compared with controls, patients randomised to acupuncture used 15% less medication (P = 0.02), made 25% fewer visits to general practitioners (P = 0.10), and took 15% fewer days off sick (P = 0.2). Conclusions Acupuncture leads to persisting, clinically relevant benefits for primary care patients with chronic headache, particularly migraine. Expansion of NHS acupuncture services should be considered.	Mem Sloan Kettering Canc Ctr, Biostat Serv, Integrat Med Serv, New York, NY 10021 USA; Inst Educ, Evidence Policy & Practice Informat & Coordinatin, Social Sci Res Unit, London WC1H 0NS, England; Montpelier Hlth Ctr, Bristol BS6 5PT, Avon, England; Univ London Imperial Coll Sci Technol & Med, Dept Psychol Med, London W2 1PD, England; Univ London Kings Coll, Weston Educ Ctr, London SE5 9RJ, England; Coventry Univ, Dept Hlth & Social Sci, Coventry CV1 5FB, W Midlands, England; Royal London Homeopath Hosp, London W1W 5PB, England	Memorial Sloan Kettering Cancer Center; University of London; University College London; UCL Institute of Education; Imperial College London; University of London; King's College London; Coventry University; University College London Hospitals NHS Foundation Trust	Vickers, AJ (corresponding author), Mem Sloan Kettering Canc Ctr, Biostat Serv, Integrat Med Serv, 1275 York Ave, New York, NY 10021 USA.	vickersa@mskcc.org		Vickers, Andrew/0000-0003-1525-6503; Rees, Rebecca/0000-0003-1413-1952				Allais G, 2002, HEADACHE, V42, P855, DOI 10.1046/j.1526-4610.2002.02203.x; Karakurum B, 2001, CEPHALALGIA, V21, P813, DOI 10.1046/j.1468-2982.2001.218238.x; Karst M, 2000, PAIN, V88, P199, DOI 10.1016/S0304-3959(00)00315-8; Karst M, 2001, CEPHALALGIA, V21, P637, DOI 10.1046/j.1468-2982.2001.00198.x; Kee W. G., 1998, AM J PAIN MANAGEMENT, V8, P83; LENHARD L, 1983, NEW ZEAL MED J, V96, P663; Melchart D, 2003, J INTERN MED, V253, P181, DOI 10.1046/j.1365-2796.2003.01081.x; MELCHART D, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001218; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Tfelt-Hansen P, 2000, CEPHALALGIA, V20, P765; Thomas KJ, 2001, BRIT J GEN PRACT, V51, P25; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; VINCENT CA, 1989, CLIN J PAIN, V5, P305, DOI 10.1097/00002508-198912000-00006; Wadlow G., 1996, COMPLEMENT THER MED, V4, P1, DOI [10.1016/S0965-2299(96)80048-3, DOI 10.1016/S0965-2299(96)80048-3]; Whittaker SJ, 1996, BT TECHNOL J, V14, P11	16	170	187	0	20	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 27	2004	328	7442					744	747		10.1136/bmj.38029.421863.EB	http://dx.doi.org/10.1136/bmj.38029.421863.EB			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809WH	15023828	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000220666300017
J	Wager, TD; Rilling, JK; Smith, EE; Sokolik, A; Casey, KL; Davidson, RJ; Kosslyn, SM; Rose, RM; Cohen, JD				Wager, TD; Rilling, JK; Smith, EE; Sokolik, A; Casey, KL; Davidson, RJ; Kosslyn, SM; Rose, RM; Cohen, JD			Placebo-induced changes in fMRI in the anticipation and experience of pain	SCIENCE			English	Article							PREFRONTAL CORTEX; FUNCTIONAL MRI; ORBITOFRONTAL CORTEX; ANTERIOR CINGULATE; BRAIN RESPONSES; OPIOID SYSTEMS; ANALGESIA; MECHANISMS; ACTIVATION; ATTENTION	The experience of pain arises from both physiological and psychological factors, including one's beliefs and expectations. Thus, placebo treatments that have no intrinsic pharmacological effects may produce analgesia by altering expectations. However, controversy exists regarding whether placebos alter sensory pain transmission, pain affect, or simply produce compliance with the suggestions of investigators. In two functional magnetic resonance imaging (fMRI) experiments, we found that placebo analgesia was related to decreased brain activity in pain-sensitive brain regions, including the thalamus, insula, and anterior cingulate cortex, and was associated with increased activity during anticipation of pain in the prefrontal cortex, providing evidence that placebos alter the experience of pain.	Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA; Princeton Univ, Ctr Study Brain Mind & Behav, Princeton, NJ 08544 USA; Univ Michigan, Vet Affairs Med Ctr, Dept Neurol, Ann Arbor, MI 48109 USA; Univ Wisconsin, Dept Psychol, Madison, WI 53706 USA; Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA; Univ Texas, Med Branch, Mind Brain Body & Hlth Initiat, Galveston, TX 77555 USA; Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA	University of Michigan System; University of Michigan; Princeton University; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Wisconsin System; University of Wisconsin Madison; Harvard University; University of Texas System; University of Texas Medical Branch Galveston; Princeton University	Wager, TD (corresponding author), Columbia Univ, Dept Psychol, 1190 Amsterdam Ave, New York, NY 10027 USA.	torw@umich.edu	anand, amit/A-7222-2009; Li, Chong/F-4265-2015	Davidson, Richard/0000-0002-8506-4964				Amanzio M, 1999, J NEUROSCI, V19, P484, DOI 10.1523/JNEUROSCI.19-01-00484.1999; Bantick SJ, 2002, BRAIN, V125, P310, DOI 10.1093/brain/awf022; Benedetti F, 1999, J NEUROSCI, V19, P3639; Brooks JCW, 2002, NEUROIMAGE, V15, P293, DOI 10.1006/nimg.2001.0974; Casey KL, 1999, P NATL ACAD SCI USA, V96, P7668, DOI 10.1073/pnas.96.14.7668; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; Craig AD, 2000, NAT NEUROSCI, V3, P184, DOI 10.1038/72131; Davis KD, 1997, J NEUROPHYSIOL, V77, P3370, DOI 10.1152/jn.1997.77.6.3370; Davis KD, 2000, NEUROL RES, V22, P313; Dias R, 1997, J NEUROSCI, V17, P9285; Drevets WC, 2000, BIOL PSYCHIAT, V48, P813, DOI 10.1016/S0006-3223(00)01020-9; GRACELY RH, 1983, NATURE, V306, P264, DOI 10.1038/306264a0; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Ingvar M, 1999, PHILOS T R SOC B, V354, P1347, DOI 10.1098/rstb.1999.0483; LEVINE JD, 1978, LANCET, V2, P654, DOI 10.1016/S0140-6736(78)92762-9; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; MELZACK R, 1968, P423; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; O'Doherty J, 2001, NAT NEUROSCI, V4, P95, DOI 10.1038/82959; O'Reilly RC, 2002, CEREB CORTEX, V12, P246, DOI 10.1093/cercor/12.3.246; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176; Petrovic P, 2000, PAIN, V85, P19, DOI 10.1016/S0304-3959(99)00232-8; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; Peyron R, 1999, BRAIN, V122, P1765, DOI 10.1093/brain/122.9.1765; Ploghaus A, 2001, J NEUROSCI, V21, P9896, DOI 10.1523/JNEUROSCI.21-24-09896.2001; Ploghaus A, 1999, SCIENCE, V284, P1979, DOI 10.1126/science.284.5422.1979; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0; Price DD, 2000, PROG BRAIN RES, V122, P255; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Rolls Edmund T., 1995, P1091; Schneider F, 2001, NEUROPSYCHOBIOLOGY, V43, P175, DOI 10.1159/000054887; Schoenbaum G, 2001, LEARN MEMORY, V8, P134, DOI 10.1101/lm.39901; Tracey I, 2002, J NEUROSCI, V22, P2748, DOI 10.1523/JNEUROSCI.22-07-02748.2002; VOUDOURIS NJ, 1989, PAIN, V38, P109, DOI 10.1016/0304-3959(89)90080-8; WALL PD, 1999, TXB PAIN, P1419	37	1311	1351	5	229	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	2004	303	5661					1162	1167		10.1126/science.1093065	http://dx.doi.org/10.1126/science.1093065			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14976306	Green Submitted			2023-01-03	WOS:000189074700037
J	Peter, BJ; Kent, HM; Mills, IG; Vallis, Y; Butler, PJG; Evans, PR; McMahon, HT				Peter, BJ; Kent, HM; Mills, IG; Vallis, Y; Butler, PJG; Evans, PR; McMahon, HT			BAR domains as sensors of membrane curvature: The amphiphysin BAR structure	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; SYNAPTIC VESICLE ENDOCYTOSIS; CLATHRIN-MEDIATED ENDOCYTOSIS; ADP-RIBOSYLATION FACTORS; ACTIN CYTOSKELETON; DROSOPHILA AMPHIPHYSIN; LYSOPHOSPHATIDIC ACID; TERMINAL DOMAIN; SH3 DOMAIN; BINDING	The BAR (Bin/amphiphysin/Rvs) domain is the most conserved feature in amphiphysins from yeast to human and is also found in endophilins and nadrins. We solved the structure of the Drosophila amphiphysin BAR domain. It is a crescent-shaped dimer that binds preferentially to highly curved negatively charged membranes. With its N-terminal amphipathic helix and BAR domain (N-BAR), amphiphysin can drive membrane curvature in vitro and in vivo. The structure is similar to that of arfaptin2, which we find also binds and tubulates membranes. From this, we predict that BAR domains are in many protein families, including sorting nexins, centaurins, and oligophrenins. The universal and minimal BAR domain is a dimerization, membrane-binding, and curvature-sensing module.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Evans, PR (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	pre@mrc-lmb.cam.ac.uk; hmm@mrc-lmb.cam.ac.uk	Peter, Brian/AAZ-7323-2020; Mills, Ian/AAK-9292-2020	Mills, Ian/0000-0001-5347-5083				Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Billuart P, 1998, PATHOL BIOL, V46, P678; Boudin H, 2000, NEURON, V28, P485, DOI 10.1016/S0896-6273(00)00127-6; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; Di Paolo G, 2002, NEURON, V33, P789, DOI 10.1016/S0896-6273(02)00601-3; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Fauchereau F, 2003, MOL CELL NEUROSCI, V23, P574, DOI 10.1016/S1044-7431(03)00078-2; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Ge K, 2000, GENOMICS, V67, P210, DOI 10.1006/geno.2000.6216; Greiner J, 2003, INT J CANCER, V106, P224, DOI 10.1002/ijc.11200; Guichet A, 2002, EMBO J, V21, P1661, DOI 10.1093/emboj/21.7.1661; Harada A, 2000, J BIOL CHEM, V275, P36885, DOI 10.1074/jbc.M004069200; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Jackson TR, 2000, TRENDS BIOCHEM SCI, V25, P489, DOI 10.1016/S0968-0004(00)01644-3; Lee EY, 2002, SCIENCE, V297, P1193, DOI 10.1126/science.1071362; Leventis PA, 2001, TRAFFIC, V2, P839; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; Modregger J, 2003, J BIOL CHEM, V278, P4160, DOI 10.1074/jbc.M208568200; Nie ZZ, 2002, J BIOL CHEM, V277, P48965, DOI 10.1074/jbc.M202969200; PETER BJ, UNPUB; Pilon M, 2000, MOL BIOL CELL, V11, P3277, DOI 10.1091/mbc.11.10.3277; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; Razzaq A, 2001, GENE DEV, V15, P2967, DOI 10.1101/gad.207801; Reinhard C, 2003, P NATL ACAD SCI USA, V100, P8253, DOI 10.1073/pnas.1432391100; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; Richnau N, 2001, J BIOL CHEM, V276, P35060, DOI 10.1074/jbc.M103540200; Salazar MA, 2003, J BIOL CHEM, V278, P49031, DOI 10.1074/jbc.M308104200; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Shin OH, 2001, BIOCHEM BIOPH RES CO, V285, P1267, DOI 10.1006/bbrc.2001.5330; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Slepnev VI, 2000, J BIOL CHEM, V275, P17583, DOI 10.1074/jbc.M910430199; Spitzenberger F, 2003, J BIOL CHEM, V278, P26166, DOI 10.1074/jbc.M213222200; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Van Valkenburgh H, 2001, J BIOL CHEM, V276, P22826, DOI 10.1074/jbc.M102359200; Verstreken P, 2002, CELL, V109, P101, DOI 10.1016/S0092-8674(02)00688-8; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Zelhof AC, 2001, DEVELOPMENT, V128, P5005; Zhang B, 2002, TRAFFIC, V3, P452, DOI 10.1034/j.1600-0854.2002.30702.x	46	1273	1307	0	162	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	2004	303	5657					495	499		10.1126/science.1092586	http://dx.doi.org/10.1126/science.1092586			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14645856				2023-01-03	WOS:000188316400030
J	Benazzouz, A; Tai, CH; Meissner, W; Bioulac, B; Bezard, E; Gross, C				Benazzouz, A; Tai, CH; Meissner, W; Bioulac, B; Bezard, E; Gross, C			High-frequency stimulation of both zona incerta and subthalamic nucleus induces a normalization of basal ganglia metabolic activity in experimental parkinsonism	FASEB JOURNAL			English	Article						cytochrome oxidase; globus pallidus; deep brain stimulation; Parkinson's Disease; substantia nigra	NIGRA PARS RETICULATA; DECARBOXYLASE MESSENGER-RNA; CONVERGENT SYNAPTIC INPUTS; GLOBUS-PALLIDUS NEURONS; DEEP BRAIN-STIMULATION; MPTP-TREATED MONKEYS; NIGROSTRIATAL DENERVATION; FIRING PATTERN; ENTOPEDUNCULAR NUCLEUS; CYTOCHROME-OXIDASE	High-frequency stimulation (HFS) of the subthalamic nucleus (STN) alleviates dramatically motor symptoms in Parkinson's disease, and recently it has been suggested that zona incerta (ZI) stimulation might be as beneficial to patients. We used in situ cytochrome oxidase (Col) mRNA hybridization to investigate and compare the effects of HFS of the STN and the ZI on metabolic activity of the STN, globus pallidus (GP), and substantia nigra reticulata (SNr) in normal rats as well as in rats with 6-hydroxydopamine (6-OHDA) lesion, an animal model of Parkinson's disease. In normal rats, HFS of the STN, as well as of the ZI, induced a significant decrease in Col mRNA expression within the STN and SNr but an increase within the GP. In 6-OHDA rats, HFS of the STN reversed dopamine denervation-induced changes in the expression of Col mRNA in the STN, SNr, and GP. Similar results were obtained with HFS of the ZI except for the STN, which showed only a trend toward nomlization. These data suggest that the ZI, as well as the STN, are implicated in the functional mechanism of HFS supporting the involvement of GABA transmission for the reduction of neuronal activity in the basal ganglia output structures.	Univ Victor Segalen, CNRS, UMR 5543, Lab Physiol & Physiopathol Signalisat Cellulaire, F-33076 Bordeaux, France; Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Taipei, Taiwan; Humboldt Univ, Charite Campus Virchow, Dept Neurol, Berlin, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; National Taiwan University; National Taiwan University Hospital; National Taiwan University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Benazzouz, A (corresponding author), Univ Victor Segalen, CNRS, UMR 5543, Lab Physiol & Physiopathol Signalisat Cellulaire, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	Abdelhamid.Benazzouz@umr5543.u-bordeaux2.fr	Benazzouz, Abdelhamid/E-5050-2016; Bezard, Erwan/ABD-5153-2021; Meissner, Wassilios/C-7817-2015; Bezard, Erwan/A-8173-2008	Meissner, Wassilios/0000-0003-2172-7527; Tai, Chun-Hwei/0000-0002-3493-8879; Bezard, Erwan/0000-0002-0410-4638				AZIZ TZ, 1992, BRIT J NEUROSURG, V6, P575, DOI 10.3109/02688699209002375; BENABID AL, 1994, STEREOT FUNCT NEUROS, V62, P76, DOI 10.1159/000098600; BENAZZOUZ A, 1995, NEUROSCI LETT, V189, P77, DOI 10.1016/0304-3940(95)11455-6; Benazzouz A, 2002, MOVEMENT DISORD, V17, pS145, DOI 10.1002/mds.10156; Benazzouz A, 1996, MOVEMENT DISORD, V11, P627, DOI 10.1002/mds.870110606; BENAZZOUZ A, 1993, EUR J NEUROSCI, V5, P382, DOI 10.1111/j.1460-9568.1993.tb00505.x; Benazzouz A, 2000, NEUROSCIENCE, V99, P289, DOI 10.1016/S0306-4522(00)00199-8; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; Beurrier C, 2001, J NEUROPHYSIOL, V85, P1351, DOI 10.1152/jn.2001.85.4.1351; BEVAN MD, 1994, BRAIN RES, V659, P99, DOI 10.1016/0006-8993(94)90868-0; BEVAN MD, 1994, EUR J NEUROSCI, V6, P320, DOI 10.1111/j.1460-9568.1994.tb00275.x; Bezard E, 1999, EUR J NEUROSCI, V11, P2167, DOI 10.1046/j.1460-9568.1999.00627.x; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; BEZARD E, 2001, FASEB J, V10, P1096; BOLAM JP, 1992, J COMP NEUROL, V321, P456, DOI 10.1002/cne.903210312; Boraud T, 2001, BRAIN, V124, P546, DOI 10.1093/brain/124.3.546; Boraud T, 1998, BRAIN RES, V787, P157, DOI 10.1016/S0006-8993(97)01563-1; BURBAUD P, 1995, EXP BRAIN RES, V105, P48; DELFS JM, 1995, EXP NEUROL, V133, P175, DOI 10.1006/exnr.1995.1020; DELFS JM, 1995, J NEUROSCI, V15, P6562; Dostrovsky JO, 2002, MOVEMENT DISORD, V17, pS63, DOI 10.1002/mds.10143; Gross CE, 2003, J NEUROCHEM, V84, P1246, DOI 10.1046/j.1471-4159.2003.01600.x; Gross CE, 1999, PROG NEUROBIOL, V59, P509, DOI 10.1016/S0301-0082(99)00015-5; Guridi J, 1996, BRAIN, V119, P1717, DOI 10.1093/brain/119.5.1717; Hashimoto T, 2003, J NEUROSCI, V23, P1916; Hassani OK, 1996, NEUROSCIENCE, V72, P105, DOI 10.1016/0306-4522(95)00535-8; HASSLER R, 1965, CONFIN NEUROL, V26, P282; HEVNER RF, 1992, NEUROSCI LETT, V138, P188, DOI 10.1016/0304-3940(92)90502-X; Hirsch EC, 2000, TRENDS NEUROSCI, V23, pS78, DOI 10.1016/S1471-1931(00)00021-5; HOLLERMAN JR, 1992, BRAIN RES, V590, P291, DOI 10.1016/0006-8993(92)91108-Q; Hutchison WD, 1998, ANN NEUROL, V44, P622, DOI 10.1002/ana.410440407; KINCAID AE, 1992, NEUROSCIENCE, V51, P705, DOI 10.1016/0306-4522(92)90309-P; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; MARGINOSASCONE C, 2002, NEUROSCIENCE, V115, P1109; Miller R.G, 1981, SIMULTANEOUS STAT IN, DOI DOI 10.1007/978-1-4613-8122-8; Miller WC, 1987, BASAL GANGLIA 2, VII, P415, DOI 10.1007/978-1- 4684-5347-8_29; MILNER KL, 1988, BRAIN RES, V452, P273, DOI 10.1016/0006-8993(88)90031-5; Murer MG, 1997, SYNAPSE, V27, P278, DOI 10.1002/(SICI)1098-2396(199712)27:4<278::AID-SYN2>3.3.CO;2-S; Ni ZG, 2001, BRAIN RES, V899, P142, DOI 10.1016/S0006-8993(01)02219-3; Ni ZG, 2001, SYNAPSE, V40, P145, DOI 10.1002/syn.1036.abs; Ni ZG, 2000, EUR J NEUROSCI, V12, P4338, DOI 10.1111/j.1460-9568.2000.01346.x; NI ZG, 2000, IN PRESS NEUROSCIENC; PAN HS, 1988, SYNAPSE, V2, P650, DOI 10.1002/syn.890020612; Paxinos G., 1996, RAT BRAIN STEREOTAXI; Perier C, 2000, NEUROREPORT, V11, P3275, DOI 10.1097/00001756-200009280-00045; Perier C, 2000, EXP NEUROL, V162, P215, DOI 10.1006/exnr.1999.7331; Perier C, 2002, J NEUROSCI, V22, P8711; Raz A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-03-j0006.2001; Saint-Cyr JA, 2002, J NEUROSURG, V97, P1152, DOI 10.3171/jns.2002.97.5.1152; Salin P, 2002, J NEUROSCI, V22, P5137, DOI 10.1523/JNEUROSCI.22-12-05137.2002; SOGHOMONIAN JJ, 1992, SYNAPSE, V11, P124, DOI 10.1002/syn.890110205; SUPKO DE, 1991, BRAIN RES, V564, P159, DOI 10.1016/0006-8993(91)91367-A; Tai CH, 2003, FASEB J, V17, P1820, DOI 10.1096/fj.03-0163com; Vila M, 2000, EUR J NEUROSCI, V12, P337, DOI 10.1046/j.1460-9568.2000.00901.x; Vila M, 1997, J NEUROSCI, V17, P765; Vila M, 1996, NEUROLOGY, V46, P802, DOI 10.1212/WNL.46.3.802; Voges J, 2002, J NEUROSURG, V96, P269, DOI 10.3171/jns.2002.96.2.0269; Wichmann T, 1999, EXP BRAIN RES, V125, P397, DOI 10.1007/s002210050696; WINDELS F, 2002, INVOLVEMENT GABA MEC; WONGRILEY MTT, 1989, TRENDS NEUROSCI, V12, P94, DOI 10.1016/0166-2236(89)90165-3	63	45	47	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					528	+		10.1096/fj.03-0576fje	http://dx.doi.org/10.1096/fj.03-0576fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715698				2023-01-03	WOS:000188829300020
J	Morris, S; Stacey, M				Morris, S; Stacey, M			ABC of resuscitation - Resuscitation in pregnancy	BRITISH MEDICAL JOURNAL			English	Review							PERIMORTEM CESAREAN-SECTION		Cardiff & Vale NHS Trust, Cardiff, S Glam, Wales	Cardiff University	Morris, S (corresponding author), Cardiff & Vale NHS Trust, Cardiff, S Glam, Wales.							Department of Health, 2001, REP CONF ENQ MAT DEA; European Resuscitation Council, 2000, RESUSCITATION, V46, P293; GOODWIN APL, 1992, ANAESTHESIA, V47, P433, DOI 10.1111/j.1365-2044.1992.tb02228.x; Page-Rodriguez A, 1999, ACAD EMERG MED, V6, P1072, DOI 10.1111/j.1553-2712.1999.tb01199.x; Whitten M, 2000, J ROY SOC MED, V93, P6, DOI 10.1177/014107680009300103	5	66	75	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 29	2003	327	7426					1277	1279		10.1136/bmj.327.7426.1277	http://dx.doi.org/10.1136/bmj.327.7426.1277			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	749VD	14644974	Green Published			2023-01-03	WOS:000186948800023
J	Takada, Y; Kobayashi, Y; Aggarwal, BB				Takada, Y; Kobayashi, Y; Aggarwal, BB			Evodiamine abolishes constitutive and inducible NF-kappa B activation by inhibiting I kappa B alpha kinase activation, thereby suppressing NF-kappa B-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION; CYCLIN D1; TRANSCRIPTIONAL REGULATION; DEPENDENT INDUCTION; P65 PHOSPHORYLATION; MEDIATED INDUCTION; ENDOTHELIAL-CELLS; TNF-ALPHA; CYCLOOXYGENASE-2	Evodiamine, an alkaloidal component extracted from the fruit of Evodiae fructus (Evodia rutaecarpa Benth., Rutaceae), exhibits antiproliferative, antimetastatic, and apoptotic activities through a poorly defined mechanism. Because several genes that regulate cellular proliferation, carcinogenesis, metastasis, and survival are regulated by nuclear factor-kappa B (NF-kappa B), we postulated that evodiamine mediates its activity by modulating NF-kappa B activation. In the present study, we investigated the effect of evodiamine on NF-kappa B and NF-kappa B-regulated gene expression activated by various carcinogens. We demonstrate that evodiamine was a highly potent inhibitor of NF-kappa B activation, and it abrogated both inducible and constitutive NF-kappa B activation. The inhibition corresponded with the sequential suppression of I kappa B alpha kinase activity, I kappa B alpha phosphorylation, I kappa B alpha degradation, p65 phosphorylation, p65 nuclear translocation, and p65 acetylation. Evodiamine also inhibited tumor necrosis factor (TNF)-induced Akt activation and its association with IKK. Suppression of Akt activation was specific, because it had no effect on JNK or p38 MAPK activation. Evodiamine also inhibited the NF-kappa B-dependent reporter gene expression activated by TNF, TNFR1, TRADD, TRAF2, NIK, and IKK but not that activated by the p65 subunit of NF-kappa B. NF-kappa B-regulated gene products such as Cyclin D1, c-Myc, COX-2, MMP-9, ICAM-1, MDR1, Survivin, XIAP, IAP1, IAP2, FLIP, Bcl-2, Bcl-x(L), and Bfl-1/A1 were all down-regulated by evodiamine. This down-regulation potentiated the apoptosis induced by cytokines and chemotherapeutic agents and suppressed TNF-induced invasive activity. Overall, our results indicated that evodiamine inhibits both constitutive and induced NF-kappa B activation and NF-kappa B-regulated gene expression and that this inhibition may provide a molecular basis for the ability of evodiamine to suppress proliferation, induce apoptosis, and inhibit metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Immunol, Houston, TX 77030 USA; Niigata Univ Pharm & Appl Sci, Fac Appl Life Sci, Niigata 9568603, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Niigata University	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013	Kobayashi, Yoshinori/0000-0002-4289-7392	NCI NIH HHS [CA16672, P01 CA91844, P50 CA97007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA091844, P50CA097007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; ALBINI A, 1987, CANCER RES, V47, P3239; Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Bentires-Alj M, 2003, ONCOGENE, V22, P90, DOI 10.1038/sj.onc.1206056; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chiou WF, 1997, J NAT PROD, V60, P708, DOI 10.1021/np960495z; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Fei XF, 2003, CANCER SCI, V94, P92, DOI 10.1111/j.1349-7006.2003.tb01358.x; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hirschowitz E, 2002, GENE THER, V9, P81, DOI 10.1038/sj.gt.3301621; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang YC, 2004, LIFE SCI, V75, P35, DOI 10.1016/j.lfs.2003.11.025; Kan SF, 2004, INT J CANCER, V110, P641, DOI 10.1002/ijc.20138; KING CL, 1980, J NAT PROD, V43, P577, DOI 10.1021/np50011a008; Kobayashi Y, 2003, PLANTA MED, V69, P425, DOI 10.1055/s-2003-39701; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Morris KR, 2003, INFECT IMMUN, V71, P1442, DOI 10.1128/IAI.71.3.1442-1452.2003; Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Ogasawara M, 2004, BIOL PHARM BULL, V27, P578, DOI 10.1248/bpb.27.578; Ogasawara M, 2002, BIOL PHARM BULL, V25, P1491, DOI 10.1248/bpb.25.1491; Ogasawara M, 2001, BIOL PHARM BULL, V24, P917, DOI 10.1248/bpb.24.917; Ogasawara M, 2001, BIOL PHARM BULL, V24, P720, DOI 10.1248/bpb.24.720; Ozes ON, 1999, NATURE, V401, P82; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; Richardson MA, 2002, SEMIN ONCOL, V29, P531, DOI 10.1053/sonc.2002.50002; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shiraga M, 2002, CANCER RES, V62, P5967; SHOJI N, 1986, J PHARM SCI, V75, P612, DOI 10.1002/jps.2600750619; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; Takada Y, 2004, ONCOGENE, V23, P9247, DOI 10.1038/sj.onc.1208169; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857; YAMAHARA J, 1989, J ETHNOPHARMACOL, V27, P185, DOI 10.1016/0378-8741(89)90090-1; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zhang Y, 2003, BIOL PHARM BULL, V26, P1543, DOI 10.1248/bpb.26.1543; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; [No title captured]	66	156	173	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17203	17212		10.1074/jbc.M500077200	http://dx.doi.org/10.1074/jbc.M500077200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15710601	hybrid			2023-01-03	WOS:000228615500082
J	Bonadonna, G; Moliterni, A; Zambetti, M; Daidone, MG; Pilotti, S; Gianni, L; Valagussa, P				Bonadonna, G; Moliterni, A; Zambetti, M; Daidone, MG; Pilotti, S; Gianni, L; Valagussa, P			30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study	BRITISH MEDICAL JOURNAL			English	Article							COMBINATION CHEMOTHERAPY; PREMENOPAUSAL PATIENTS; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; THERAPY; MANAGEMENT; TAMOXIFEN; GOSERELIN; TRIALS	Objective To assess the long term effectiveness of adjuvant treatment with cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of relapse, on the basis of three successive randomised trials and one observational study conducted from June 1973 to December 1980. Design Cohort study. Setting Istituto Nazionale Tumori in Milan, Italy. Main outcome measures Relapse free and overall survival, measured by univariate and multivariate analyses. Results After a median follow up of 28.5 years for the initial study, adjuvant CMF was found to reduce the relative risk of relapse significantly (hazard ratio 0.71, 95% confidence interval 0.56 to 0.91, P = 0.005) and death (0.79, 0.63 to 0.98, P = 0.04). Administration of CMF for 12 cycles does not seem superior to a shorter administration of six cycles. Tit the node negative and oestrogen receptor negative trial, intravenous CMF significantly reduced the relative risk of relapse of disease (0.65, 0.47 to 0.90, P = 0.009) and death (0.65, 0.47 to 0.92, P = 0.01) at a median follow up of 20 years. Conclusions When delivered optimally, CMF benefits patients at risk of relapse of distant disease Without evidence of detrimental effects in any of the examined subgroups.	Ist Nazl Tumori, Dept Med Oncol, Operat Off, I-20133 Milan, Italy; Ist Nazl Tumori, Div Med Oncol A, I-20133 Milan, Italy; Ist Nazl Tumori, Determinant Prognosis & Treatment Response Unit, I-20133 Milan, Italy; Ist Nazl Tumori, Div Pathol C, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Bonadonna, G (corresponding author), Ist Nazl Tumori, Dept Med Oncol, Operat Off, Via Venezian 1, I-20133 Milan, Italy.	gianni.bonadonna@istitutotumori.mi.it	Daidone, Maria Grazia/E-9232-2017	Daidone, Maria Grazia/0000-0002-4786-1321; Valagussa, Pinuccia/0000-0003-3590-7916; GIANNI, LUCA/0000-0002-2372-9625	NCI NIH HHS [N01-CM-07338, N01-CM-33714] Funding Source: Medline; DIVISION OF CANCER TREATMENT [N01CM007338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER TREATMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Treatment & Diagnosis)		Abe O, 1998, LANCET, V352, P930; ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710; BONADON G, 1975, P AM ASSOC CANC RES, V16, P254; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; BONADONNA G, 1995, NEW ENGL J MED, V332, P901, DOI 10.1056/NEJM199504063321401; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; Clarke M, 1998, LANCET, V351, P1451; COX DR, 1972, J R STAT SOC B, V34, P187; Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979; FISHER B, 1975, NEW ENGL J MED, V292, P117, DOI 10.1056/NEJM197501162920301; FISHER B, 1992, CANCER RES, V52, P2371; GOLDHIRSCH A, 1990, ANN ONCOL, V1, P183, DOI 10.1093/oxfordjournals.annonc.a057718; Jakesz R, 2002, J CLIN ONCOL, V20, P4621, DOI 10.1200/JCO.2002.09.112; Jonat W, 2002, J CLIN ONCOL, V20, P4628, DOI 10.1200/JCO.2002.05.042; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Marubini E, 1995, ANAL SURVIVAL DATA C; Menard S, 2001, J CLIN ONCOL, V19, P329, DOI 10.1200/JCO.2001.19.2.329; Miller R. G., 1981, SURVIVAL ANAL; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Peto R, 2000, LANCET, V355, P1822, DOI 10.1016/S0140-6736(00)02277-7; Pritchard KI, 2002, J CLIN ONCOL, V20, P4611, DOI 10.1200/JCO.2002.20.24.4611; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; TANCINI G, 1983, J CLIN ONCOL, V1, P2, DOI 10.1200/JCO.1983.1.1.2; Zambetti M, 1996, ANN ONCOL, V7, P481; ZAMBETTI M, 1992, J NATL CANC I MONOGR, V11, P79	25	184	198	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 29	2005	330	7485					217	220		10.1136/bmj.38314.622095.8F	http://dx.doi.org/10.1136/bmj.38314.622095.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894GR	15649903	Green Published, Bronze			2023-01-03	WOS:000226779400015
J	Stevenson, J; Abernethy, AP; Miller, C; Currow, DC				Stevenson, J; Abernethy, AP; Miller, C; Currow, DC			Managing comorbidities in patients at the end of life	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADVERSE DRUG-REACTIONS; THERAPY	Chronic conditions require careful management in patients who develop a life limiting illness. Doctors need to consider both the physical and psychological effects of treatment.	Flinders Univ S Australia, Dept Palliat & Support Serv, Adelaide, SA 5001, Australia; Repatriat Gen Hosp, So Adelaide Palliat Serv, Daw Pk, SA 5041, Australia; Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA; Repatriat Gen Hosp, Div Gen Med, Daw Pk, SA, Australia	Flinders University South Australia; Duke University	Currow, DC (corresponding author), Flinders Univ S Australia, Dept Palliat & Support Serv, Adelaide, SA 5001, Australia.	david.currow@rgh.sa.gov.au		Currow, David/0000-0003-1988-1250				Chalmers J, 1999, J HYPERTENS, V17, P151; Coebergh JWW, 1999, J CLIN EPIDEMIOL, V52, P1131, DOI 10.1016/S0895-4356(99)00098-0; Colven R, 2000, ANN INTERN MED, V133, P430, DOI 10.7326/0003-4819-133-6-200009190-00010; Diabet Control Complications Trial Res Grp, 1995, DIABETES CARE, V18, P1415; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; Goldberg RM, 1996, AM J EMERG MED, V14, P447, DOI 10.1016/S0735-6757(96)90147-3; Hensrud DD, 2000, MAYO CLIN PROC, V75, P165; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Kotler DP, 2000, ANN INTERN MED, V133, P622, DOI 10.7326/0003-4819-133-8-200010170-00015; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Mannesse CK, 2000, AGE AGEING, V29, P35, DOI 10.1093/ageing/29.1.35; Mayfield E, 1999, SOC WORK HEALTH CARE, V29, P21, DOI 10.1300/J010v29n02_02; Neal B, 2000, LANCET, V356, P1955; Olsen H, 1999, BLOOD PRESSURE, V8, P94; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WARD SE, 1992, NURS RES, V41, P362; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; Yusuf S, 2000, NEW ENGL J MED, V342, P145	20	98	100	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	2004	329	7471					909	912		10.1136/bmj.329.7471.909	http://dx.doi.org/10.1136/bmj.329.7471.909			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863MU	15485977	Green Published			2023-01-03	WOS:000224566800028
J	Weissman, DE				Weissman, DE			Decision making at a time of crisis near the end of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TERMINALLY ILL PATIENTS; CANCER-PATIENTS; PATIENTS PREFERENCES; FAMILY CAREGIVERS; ADVANCED DEMENTIA; DYING PATIENTS; CARE; PHYSICIAN; PATIENT; COMMUNICATION	As patients approach the end of life, their disease process may create an immediate life-threatening emergency, yet invasive interventions may be less likely to provide benefit while carrying the same or greater risks. Knowing when it is time to shift from life-prolonging to more palliative approaches, focused on quality of life and comfort, is emotionally and clinically challenging for patients, families, and physicians. Key factors in the decision process include prognosis, risk-benefit analysis of the proposed intervention, current symptom burden, temporal pattern of the illness, patient's age and life stage, and the patient's goals of care. A structured approach to decision making includes assessing the patient's physical, psychological, and spiritual needs; assessing the patient's support system; discussing prognosis; and assessing patient-specific goals. Physicians can best help patients decide which treatments are appropriate by taking the necessary time to explore all curative and palliative care options, providing honest and timely prognostic information, making clear recommendations, facilitating patient-family discussions, and affirming patient choices.	Med Coll Wisconsin, Palliat Care Ctr, Div Neoplast & Related Disorders, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Weissman, DE (corresponding author), Froedtert Hosp, Div Neoplast Dis & Related Disorders, Room 3961,9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	dweissma@mail.mcw.edu						Ahronheim JC, 1996, ARCH INTERN MED, V156, P2094, DOI 10.1001/archinte.156.18.2094; Back Anthony L, 2003, Ann Intern Med, V138, P439; Baile WF, 1999, ONCOLOGY-NY, V13, P1021; Bascom P B, 1997, Am J Hosp Palliat Care, V14, P57, DOI 10.1177/104990919701400202; Billings J A, 1998, J Palliat Med, V1, P73, DOI 10.1089/jpm.1998.1.73; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Block SD, 2001, JAMA-J AM MED ASSOC, V285, P2898, DOI 10.1001/jama.285.22.2898; Breitbart W, 2000, JAMA-J AM MED ASSOC, V284, P2907, DOI 10.1001/jama.284.22.2907; CARLSON RW, 1988, JAMA-J AM MED ASSOC, V259, P378, DOI 10.1001/jama.259.3.378; Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; Coulehan JL, 2001, ANN INTERN MED, V135, P221, DOI 10.7326/0003-4819-135-3-200108070-00022; Curtis JR, 2001, CRIT CARE MED, V29, pN26, DOI 10.1097/00003246-200102001-00006; Curtis JR, 2001, J GEN INTERN MED, V16, P41; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Fallowfield LJ, 2002, PALLIATIVE MED, V16, P297, DOI 10.1191/0269216302pm575oa; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; Fried Terri R, 2003, J Palliat Med, V6, P237, DOI 10.1089/109662103764978489; GERLE B, 1960, CANCER, V13, P1206, DOI 10.1002/1097-0142(196011/12)13:6<1206::AID-CNCR2820130609>3.0.CO;2-F; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; Hotopf M, 2002, PALLIATIVE MED, V16, P81, DOI 10.1191/02169216302pm507oa; HUANG Z, 2002, PRINCIPLES PRACTICE, P956; Jenkins C, 1998, J PALLIATIVE CARE, V14, P18, DOI 10.1177/082585979801400104; Kagawa-Singer M, 2001, JAMA-J AM MED ASSOC, V286, P2993, DOI 10.1001/jama.286.23.2993; KUSHNER K, 1989, J FAM PRACTICE, V28, P73; Lamont E, 2002, PRINCIPLES PRACTICE, P607; Lamont EB, 2001, ANN INTERN MED, V134, P1096, DOI 10.7326/0003-4819-134-12-200106190-00009; Lamont EB, 2003, JAMA-J AM MED ASSOC, V290, P98, DOI 10.1001/jama.290.1.98; Larson DG, 2000, JAMA-J AM MED ASSOC, V284, P1573, DOI 10.1001/jama.284.12.1573; Loprinzi CL, 2000, J CLIN ONCOL, V18, P699, DOI 10.1200/JCO.2000.18.3.699; Luce JM, 2001, JAMA-J AM MED ASSOC, V285, P1331, DOI 10.1001/jama.285.10.1331; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; McCahill LE, 2002, J AM COLL SURGEONS, V195, P411, DOI 10.1016/S1072-7515(02)01306-6; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Miettinen TT, 1999, J PALLIATIVE CARE, V15, P26, DOI 10.1177/082585979901500205; MUIR JC, 2002, PRINCIPLES PRACTICE, P653; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; *NAT AC SCI I MED, 1997, APPR DEATH IMPR CAR; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Rabow MW, 2004, JAMA-J AM MED ASSOC, V291, P483, DOI 10.1001/jama.291.4.483; Roter DL, 2002, JAMA-J AM MED ASSOC, V288, P756, DOI 10.1001/jama.288.6.756; Rousseau Paul, 2002, J Palliat Med, V5, P657, DOI 10.1089/109662102320880444; SCHNEIDERMAN LJ, 1993, J CLIN ETHIC, V4, P28; Schulz R, 2003, NEW ENGL J MED, V349, P1936, DOI 10.1056/NEJMsa035373; Tang ST, 2001, CANCER INVEST, V19, P165, DOI 10.1081/CNV-100000151; Teno J M, 2001, J Palliat Med, V4, P457, DOI 10.1089/109662101753381593; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; von Gunten C F, 1998, J Palliat Med, V1, P45; von Gunten CF, 2000, JAMA-J AM MED ASSOC, V284, P3051, DOI 10.1001/jama.284.23.3051; Walsh T D, 1990, J Pain Symptom Manage, V5, P273, DOI 10.1016/0885-3924(90)90043-J; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Weissman David E, 2003, J Palliat Med, V6, P1, DOI 10.1089/10966210360510046; Weissman DE, 1997, ARCH INTERN MED, V157, P733, DOI 10.1001/archinte.157.7.733; Wenrich MD, 2001, ARCH INTERN MED, V161, P868, DOI 10.1001/archinte.161.6.868	58	83	85	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2004	292	14					1738	1743		10.1001/jama.292.14.1738	http://dx.doi.org/10.1001/jama.292.14.1738			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861JS	15479939				2023-01-03	WOS:000224413400033
J	Tannock, IF; de Wit, R; Berry, WR; Horti, J; Pluzanska, A; Chi, KN; Oudard, S; Theodore, C; James, ND; Turesson, I; Rosenthal, MA; Eisenberger, MA				Tannock, IF; de Wit, R; Berry, WR; Horti, J; Pluzanska, A; Chi, KN; Oudard, S; Theodore, C; James, ND; Turesson, I; Rosenthal, MA; Eisenberger, MA		TAX 327 Investigators	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; LOW-DOSE HYDROCORTISONE; PHASE-II TRIAL; RANDOMIZED-TRIAL; DOUBLE-BLIND; MEN; PLACEBO; ESTRAMUSTINE; THERAPY; PAIN	BACKGROUND: Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We compared such treatment with docetaxel plus prednisone in men with this disease. METHODS: From March 2000 through June 2002, 1006 men with metastatic hormone-refractory prostate cancer received 5 mg of prednisone twice daily and were randomly assigned to receive 12 mg of mitoxantrone per square meter of body-surface area every three weeks, 75 mg of docetaxel per square meter every three weeks, or 30 mg of docetaxel per square meter weekly for five of every six weeks. The primary end point was overall survival. Secondary end points were pain, prostate-specific antigen (PSA) levels, and the quality of life. All statistical comparisons were against mitoxantrone. RESULTS: As compared with the men in the mitoxantrone group, men in the group given docetaxel every three weeks had a hazard ratio for death of 0.76 (95 percent confidence interval, 0.62 to 0.94; P=0.009 by the stratified log-rank test) and those given weekly docetaxel had a hazard ratio for death of 0.91 (95 percent confidence interval, 0.75 to 1.11; P=0.36). The median survival was 16.5 months in the mitoxantrone group, 18.9 months in the group given docetaxel every 3 weeks, and 17.4 months in the group given weekly docetaxel. Among these three groups, 32 percent, 45 percent, and 48 percent of men, respectively, had at least a 50 percent decrease in the serum PSA level (P<0.001 for both comparisons with mitoxantrone); 22 percent, 35 percent (P=0.01), and 31 percent (P=0.08) had predefined reductions in pain; and 13 percent, 22 percent (P=0.009), and 23 percent (P=0.005) had improvements in the quality of life. Adverse events were also more common in the groups that received docetaxel. CONCLUSIONS: When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plus prednisone.	Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Toronto, ON, Canada; Erasmus Univ, Med Ctr, Dept Med Oncol, Rotterdam, Netherlands; Raleigh Hematol Oncol Associates, Cary, NC USA; Natl Inst Oncol, Dept Chemotherapy & Clin Pharmacol, Budapest, Hungary; Med Univ Lodz, Dept Chemotherapy, Lodz, Poland; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Hop Europeen Georges Pompidou, Paris, France; Inst Gustave Roussy, Villejuif, France; Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England; Univ Uppsala Hosp, Sect Oncol, Uppsala, Sweden; Johns Hopkins Univ, Sydney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; Erasmus University Rotterdam; Erasmus MC; National Institute of Oncology Hungary; Medical University Lodz; British Columbia Cancer Agency; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; Cancer Research UK; University of Birmingham; Uppsala University; Uppsala University Hospital; Johns Hopkins University; Johns Hopkins Medicine	Tannock, IF (corresponding author), Princess Margaret Hosp, Dept Med Oncol & Hematol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	ian.tannock@uhn.on.ca	James, Nick/AAL-6802-2020	OUDARD, Stephane/0000-0003-0893-285X				*ACS, 2003, CANC FACTS FIG; Beer TM, 2001, ANN ONCOL, V12, P1273, DOI 10.1023/A:1012258723075; Beer TM, 2003, J CLIN ONCOL, V21, P123, DOI 10.1200/jco.2003.05.117; Berry W, 2001, SEMIN ONCOL, V28, P8, DOI 10.1053/sonc.2001.26893; Berry W, 2002, J UROLOGY, V168, P2439, DOI 10.1016/S0022-5347(05)64163-8; Chen TT, 2000, JNCI-J NATL CANCER I, V92, P1601, DOI 10.1093/jnci/92.19.1601; Dearnaley DP, 2003, J NATL CANCER I, V95, P1300, DOI 10.1093/jnci/djg038; Ernst DS, 2003, J CLIN ONCOL, V21, P3335, DOI 10.1200/JCO.2003.03.042; Esper P, 1997, UROLOGY, V50, P920, DOI 10.1016/S0090-4295(97)00459-7; Fossa SD, 2001, J CLIN ONCOL, V19, P62, DOI 10.1200/JCO.2001.19.1.62; Friedland D, 1999, SEMIN ONCOL, V26, P19; Kantoff PW, 1999, J CLIN ONCOL, V17, P2506, DOI 10.1200/JCO.1999.17.8.2506; Kelly WK, 1997, UROL CLIN N AM, V24, P421, DOI 10.1016/S0094-0143(05)70389-X; Kornblith AB, 2001, ANN ONCOL, V12, P633, DOI 10.1023/A:1011102619058; Martel CL, 2003, CANCER TREAT REV, V29, P171, DOI 10.1016/S0305-7372(02)00090-7; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Oades GM, 2002, PROSTATE CANCER P D, V5, P264, DOI 10.1038/sj.pcan.4500607; Osoba D, 1999, J CLIN ONCOL, V17, P1654, DOI 10.1200/JCO.1999.17.6.1654; Petrylak Daniel P, 2002, Semin Urol Oncol, V20, P31, DOI 10.1053/suro.2002.35052; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Picus J, 1999, SEMIN ONCOL, V26, P14; Saad F, 2002, JNCI-J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458; Savarese DM, 2001, J CLIN ONCOL, V19, P2509, DOI 10.1200/JCO.2001.19.9.2509; Small EJ, 2000, J CLIN ONCOL, V18, P1440, DOI 10.1200/JCO.2000.18.7.1440; TANNOCK I, 1989, J CLIN ONCOL, V7, P590, DOI 10.1200/JCO.1989.7.5.590; Tannock IF, 1996, J CLIN ONCOL, V14, P1756, DOI 10.1200/JCO.1996.14.6.1756; Weitzman AL, 2000, J UROLOGY, V163, P834, DOI 10.1016/S0022-5347(05)67815-9; Wirth MP, 1997, UROL RES, V25, pS67, DOI 10.1007/BF00941991; World Health Organization, 1979, WHO HDB REP RES CANC, V48	29	4395	4601	9	184	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 7	2004	351	15					1502	1512		10.1056/NEJMoa040720	http://dx.doi.org/10.1056/NEJMoa040720			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	859UP	15470213				2023-01-03	WOS:000224293700008
J	Duggan, C; Fontaine, O; Pierce, NF; Glass, RI; Mahalanabis, D; Alam, NH; Bhan, MK; Santosham, M				Duggan, C; Fontaine, O; Pierce, NF; Glass, RI; Mahalanabis, D; Alam, NH; Bhan, MK; Santosham, M			Scientific rationale for a change in the composition of oral rehydration solution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACUTE DIARRHEA; REDUCED OSMOLARITY; DOUBLE-BLIND; CLINICAL-TRIAL; SALT-SOLUTION; THERAPY; CHILDREN; GLUCOSE; CHOLERA; DISEASE		Childrens Hosp Boston, Div Gastroenterol & Nutr, Boston, MA 02115 USA; WHO, Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Soc Appl Studies, Kolkata, India; ICDDR B, Div Clin Sci, Ctr Hlth & Populat Res B, Dhaka, Bangladesh; All India Inst Med Sci, Dept Pediat, New Delhi, India	Harvard University; Boston Children's Hospital; World Health Organization; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Centers for Disease Control & Prevention - USA; International Centre for Diarrhoeal Disease Research (ICDDR); All India Institute of Medical Sciences (AIIMS) New Delhi	Duggan, C (corresponding author), Childrens Hosp Boston, Div Gastroenterol & Nutr, 300 Longwood Ave, Boston, MA 02115 USA.	christopher.duggan@childrens.harvard.edu						Alam NH, 1999, LANCET, V354, P296, DOI 10.1016/S0140-6736(98)09332-5; Alam NH, 2001, PEDIATRICS, V107, P613, DOI 10.1542/peds.107.4.613; Alam S, 2000, Indian Pediatr, V37, P952; [Anonymous], 1978, LANCET, V2, P300; AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BHAN MK, 1994, B WORLD HEALTH ORGAN, V72, P945; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; BROWN KH, 1988, J PEDIATR-US, V112, P191, DOI 10.1016/S0022-3476(88)80055-6; Cash R, 1999, LANCET, V354, P1733, DOI 10.1016/S0140-6736(05)76725-8; Duggan C, 1997, J PEDIATR-US, V131, P801, DOI 10.1016/S0022-3476(97)70024-6; Dutta D, 2000, ACTA PAEDIATR, V89, P787, DOI 10.1080/080352500750043657; Dutta P, 2001, ARCH DIS CHILD, V84, P237, DOI 10.1136/adc.84.3.237; ELMOUGI M, 1994, J PEDIATR GASTR NUTR, V19, P83, DOI 10.1097/00005176-199407000-00013; Farthing M J, 1989, Acta Paediatr Scand Suppl, V364, P23; FAYAD IM, 1992, LANCET, V339, P389, DOI 10.1016/0140-6736(92)90079-I; Field M, 2003, J CLIN INVEST, V111, P931, DOI 10.1172/JCI200318326; Fontaine O, 2000, COCHRANE DB SYST REV; Hahn S, 2001, BMJ-BRIT MED J, V323, P81, DOI 10.1136/bmj.323.7304.81; HIRSCHHORN N, 1968, NEW ENGL J MED, V279, P176, DOI 10.1056/NEJM196807252790402; Hirschhorn N, 2002, PEDIATRICS, V109, P713, DOI 10.1542/peds.109.4.713-a; Hirschhorn N, 2002, LANCET, V360, P340, DOI 10.1016/S0140-6736(02)09528-4; HIRSCHHORN N, 1980, AM J CLIN NUTR, V33, P637, DOI 10.1093/ajcn/33.3.637; HIRSCHHORN N, 1972, Lancet, V2, P15; HIRSCHHORN N, 1991, SCI AM, V264, P50, DOI 10.1038/scientificamerican0591-50; HUNT JB, 1994, GUT, V35, P211, DOI 10.1136/gut.35.2.211; King Caleb K, 2003, MMWR Recomm Rep, V52, P1; Kosek M, 2003, B WORLD HEALTH ORGAN, V81, P197; MAHALANABIS D, 1973, JOHNS HOPKINS MED J, V132, P197; MOLLA AM, 1989, LANCET, V2, P429; MOLLA AM, 1981, J PEDIATR-US, V98, P835, DOI 10.1016/S0022-3476(81)80863-3; NALIN DR, 1970, GUT, V11, P768, DOI 10.1136/gut.11.9.768; Nazarian LF, 1996, PEDIATRICS, V97, P424; NICHOLS BL, 1977, AM J CLIN NUTR, V30, P1457, DOI 10.1093/ajcn/30.9.1457; Parashar UD, 2003, EMERG INFECT DIS, V9, P565, DOI 10.3201/eid0905.020562; Penny M. E., 2003, Nutrition in pediatrics: basic science and clinical applications, P174; PIERCE NF, 1968, GASTROENTEROLOGY, V55, P333; RIBEIRO H, 1994, J AM COLL NUTR, V13, P251, DOI 10.1080/07315724.1994.10718405; SANTOSHAM M, 1986, J PEDIATR-US, V109, P795, DOI 10.1016/S0022-3476(86)80696-5; SANTOSHAM M, 1982, NEW ENGL J MED, V306, P1070, DOI 10.1056/NEJM198205063061802; SANTOSHAM M, 1985, PEDIATRICS, V76, P292; Santosham M, 1996, J PEDIATR-US, V128, P45, DOI 10.1016/S0022-3476(96)70426-2; Sarker SA, 2001, J PEDIATR-US, V138, P532, DOI 10.1067/mpd.2001.112161; SNYDER JD, 1982, B WORLD HEALTH ORGAN, V60, P605; Thillainayagam AV, 1998, GASTROENTEROLOGY, V114, P197, DOI 10.1016/S0016-5085(98)70647-X; Victora CG, 2000, B WORLD HEALTH ORGAN, V78, P1246; *WHO, 2001, WHOFCHCAH0122 UNICEF	46	40	48	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2628	2631		10.1001/jama.291.21.2628	http://dx.doi.org/10.1001/jama.291.21.2628			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825EM	15173155				2023-01-03	WOS:000221738800027
J	Goldman, DP; Joyce, GF; Escarce, JJ; Pace, JE; Solomon, MD; Laouri, M; Landsman, PB; Teutsch, SM				Goldman, DP; Joyce, GF; Escarce, JJ; Pace, JE; Solomon, MD; Laouri, M; Landsman, PB; Teutsch, SM			Pharmacy benefits and the use of drugs by the chronically ill	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST; IMPACT	Context Many health plans have instituted more cost sharing to discourage use of more expensive pharmaceuticals and to reduce drug spending. Objective To determine how changes in cost sharing affect use of the most commonly used drug classes among the privately insured and the chronically ill. Design, Setting, and Participants Retrospective US study conducted from 1997 to 2000, examining linked pharmacy claims data with health plan benefit designs from 30 employers and 52 health plans. Participants were 528969 privately insured beneficiaries aged 18 to 64 years and enrolled from 1 to 4 years (960791 person-years). Main Outcome Measure Relative change in drug days supplied (per member, per year) when co-payments doubled in a prototypical drug benefit plan. Results Doubling co-payments was associated with reductions in use of 8 therapeutic classes. The largest decreases occurred for nonsteroidal anti-inflammatory drugs (NSAIDs) (45%) and antihistamines (44%). Reductions in overall days supplied of antihyperlipidemics (34%), antiulcerants (33%), antiasthmatics (32%), antihypertensives (26%), antidepressants (26%), and antidiabetics (25%) were also observed. Among patients diagnosed as having a chronic illness and receiving ongoing care, use was less responsive to co-payment changes. Use of antidepressants by depressed patients declined by 8%; use of anti hypertensives by hypertensive patients decreased by 10%. Larger reductions were observed for arthritis patients taking NSAIDs (27%) and allergy patients taking antihistamines (31%). Patients with diabetes reduced their use of antidiabetes drugs by 23%. Conclusions The use of medications such as antihistamines and NSAIDs, which are taken intermittently to treat symptoms, was sensitive to co-payment changes. Other medications-antihypertensive, antiasthmatic, antidepressant, antihyperlipidemic, antiulcerant, and antidiabetic agents-also demonstrated significant price responsiveness. The reduction in use of medications for individuals in ongoing care was more modest. Still, significant increases in co-payments raise concern about adverse health consequences because of the large price effects, especially among diabetic patients.	RAND Corp, Santa Monica, CA 90407 USA; Merck, W Point, PA USA; Calif Healthcare Fdn, Oakland, CA USA	RAND Corporation	Goldman, DP (corresponding author), RAND Corp, 1700 Main St, Santa Monica, CA 90407 USA.	dgoldman@rand.org; gjoyce@rand.org	Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396				Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; HARRIS BL, 1990, MED CARE, V28, P907, DOI 10.1097/00005650-199010000-00005; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; Johnson RE, 1997, HEALTH SERV RES, V32, P103; Joyce GF, 2002, JAMA-J AM MED ASSOC, V288, P1733, DOI 10.1001/jama.288.14.1733; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Law MR, 2002, BMJ-BRIT MED J, V324, P1570, DOI 10.1136/bmj.324.7353.1570; LOHR KN, 1986, MED CARE S, V24, pS39; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; *MED EC CO, 2000, 2000 DRUG TOP RED BO; Motheral B, 2001, MED CARE, V39, P1293, DOI 10.1097/00005650-200112000-00005; Rector TS, 2003, MED CARE, V41, P398, DOI 10.1097/00005650-200303000-00008; REEDER CE, 1985, INQUIRY-J HEALTH CAR, V22, P396; Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421	15	419	423	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	2004	291	19					2344	2350		10.1001/jama.291.19.2344	http://dx.doi.org/10.1001/jama.291.19.2344			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821JD	15150206	Bronze			2023-01-03	WOS:000221455400022
J	Charap, M				Charap, M			Reducing resident work hours: Unproven assumptions and unforeseen outcomes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									NYU, Sch Med, Dept Med, New York, NY 10016 USA	New York University	Charap, M (corresponding author), NYU, Sch Med, Dept Med, 550 1st Ave, New York, NY 10016 USA.							*ACCR COUNC GRAD M, 2002, REP ACGME WORK GROUP; Kohn LT, 2000, ERR IS HUMAN BUILDIN; LUDMERER K, 1999, TIME HEAL, P320; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Philibert I, 2002, JAMA-J AM MED ASSOC, V288, P1112, DOI 10.1001/jama.288.9.1112; Steinbrook R, 2002, NEW ENGL J MED, V347, P1296, DOI 10.1056/NEJMhpr022383; Veasey S, 2002, JAMA-J AM MED ASSOC, V288, P1116, DOI 10.1001/jama.288.9.1116; Weinger MB, 2002, JAMA-J AM MED ASSOC, V287, P955, DOI 10.1001/jama.287.8.955	8	91	91	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	2004	140	10					814	815		10.7326/0003-4819-140-10-200405180-00011	http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822EX	15148068				2023-01-03	WOS:000221520900006
J	Banks, E; Beral, V; Reeves, G; Balkwill, A; Barnes, I				Banks, E; Beral, V; Reeves, G; Balkwill, A; Barnes, I		Million Women Study Collaborators	Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN PLUS PROGESTIN; INITIATIVE RANDOMIZED-TRIAL; BONE-MINERAL DENSITY; REPLACEMENT THERAPY; HIP FRACTURE; RISK; METAANALYSIS; FOREARM; BREAST; CANCER	Context Evidence is limited on the effects of different patterns of use of postmenopausal hormone therapy on fracture incidence and particularly on the effects of ceasing use. Objective To investigate the effect of different patterns of hormone therapy use on fracture incidence. Design, Setting, and Participants Prospective study of 138737 postmenopausal women aged 50 to 69 years recruited from the UK general population in 19961998 (the Million Women Study) and followed up for 1.9 to 3.9 years (average, 2.8 years) for fracture incidence. Main Outcome Measure Adjusted relative risk (RR) for incident fracture (except fracture of the fingers, toes, and ribs) in hormone therapy users compared with never users at baseline. Results A total of 5197 women (3.7%) reported 1 or more fractures, 79% resulting from falls. Current users of hormone therapy at baseline had a significantly reduced incidence of fracture (RR, 0.62; 95% confidence interval [CI], 0.58-0.66; P<.001). This protection was evident soon after hormone therapy began, and the RR decreased with increasing duration of use (P=.001). Among current users at baseline the RR of fracture did not vary significantly according to whether estrogen-only, estrogen-progestin, or other types of hormones were used (RR [95% CI], 0.64 [0.58-0.71], 0.58 [0.53-0.64], and 0.67 [0.56-0.80], respectively; P=19), nor did it vary significantly according to estrogen dose or estrogen or progestin constituents. The RR associated with current use of hormone therapy did not vary significantly according to 11 personal characteristics of study participants, including their age at menopause, body mass index, and physical activity. Past users of hormone therapy at baseline experienced no significant protection against fractures (RR, 1.07; 95% CI, 0.99-1.15); incidence rates returned to those of never-users within about a year of ceasing use. Conclusions All types of hormone therapy studied confer substantial protection against fracture while they are used. This protection appears rapidly after use commences and wears off rapidly after use ceases. The older women are, the greater is their absolute reduction in fracture incidence while using hormone therapy.	Radcliffe Infirm, Epidemiol Unit, Canc Res UK, Oxford OX2 6HE, England; Univ Reading, Sch Appl Stat, Reading, Berks, England	Cancer Research UK; Radcliffe Infirmary; University of Reading	Banks, E (corresponding author), Radcliffe Infirm, Epidemiol Unit, Canc Res UK, Oxford OX2 6HE, England.	emily.banks@anu.edu.au		Banks, Emily/0000-0002-4617-1302; Balkwill, Angela/0000-0002-6327-6245				Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Banks E, 2001, J Epidemiol Biostat, V6, P357; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Cauley JA, 2003, JAMA-J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Honkanen K, 1999, AM J EPIDEMIOL, V150, P511; Keegan THM, 2003, OSTEOPOROSIS INT, V14, P469, DOI 10.1007/s00198-003-1379-2; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; MEHTA D, 1999, BRIT NATL FORMULARY; Michaelsson K, 1998, BMJ-BRIT MED J, V316, P1858; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; *STAT CORP, 2003, STAT STAT SOFTW REL; The Million Women Study Collaborative Group, 1999, BREAST CANCER RES, V1, P73, DOI DOI 10.1186/BCR16; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Townsend PP., 1988, HLTH DEPRIVATION INE; Tremollieres FA, 2001, OSTEOPOROSIS INT, V12, P385, DOI 10.1007/s001980170107; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; Wells G, 2002, ENDOCR REV, V23, P529, DOI 10.1210/er.2001-5002	22	91	95	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	2004	291	18					2212	2220		10.1001/jama.291.18.2212	http://dx.doi.org/10.1001/jama.291.18.2212			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819GR	15138243	Bronze			2023-01-03	WOS:000221303500023
J	Kalra, L; Evans, A; Perez, I; Melbourn, A; Patel, A; Knapp, M; Donaldson, N				Kalra, L; Evans, A; Perez, I; Melbourn, A; Patel, A; Knapp, M; Donaldson, N			Training care givers of stroke patients: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SUPPORT; SURVIVORS; IMPACT	Background Informal care givers support disabled stroke patients at home but receive little training for the caregiving role. Objective To evaluate the effectiveness of training care givers in reducing burden of stroke in patients and their care givers. Design A single, blind, randomised controlled trial. Setting Stroke rehabilitation unit. Subjects 300 stroke patients and their care givers. Interventions Training care givers in basic nursing and facilitation of personal care techniques. Main outcome measures Cost to health and social services, caregiving burden, patients' and care givers' functional status (Barthel index, Frenchay activities index), psychological state (hospital anxiety and depression score), quality of life (EuroQol visual analogue scale) and patients' institutionalisation or mortality at one year. Results Patients were comparable for age (median 76 years; interquartile range 70-82 years), sex (53% men), and severity of stroke (median Barthel index 8; interquartile range 4-12). The costs of care over one year for patients whose care givers had received training were significantly lower (pound10133 v pound13794 ($18087 v $24619; C15204 v C20697); P=0.001). Trained care givers experienced less caregiving burden (care giver burden score 32 v 41; P=0.0001), anxiety (anxiety score 3 v 4; P=0.0001) or depression (depression score 2 v 3; P=0.0001) and had a higher quality of life (EuroQol score 80 v 70; P=0.001). Patients' mortality, institutionalisation, and disability were not influenced by caregiver training. However, patients reported less anxiety (3 v 4.5; P<0.0001) and depression (3 v 4; P<0.0001) and better quality of life (65 v 60; P=0.009) in the caregiver training group. Conclusion Training care givers during patients' rehabilitation reduced costs and caregiver burden while improving psychosocial outcomes in care givers and patients at one year.	Guys Kings & St Thomass Sch Med, Dept Med, London SE5 9PJ, England; Kings Coll London, Inst Psychiat, Ctr Econ Mental Hlth, London WC2R 2LS, England; Kings Coll Hosp London, Biostat Unit, Dept Res & Dev, London SE5 9RS, England; Orpington Hosp, Bromley Hosp NHS Trust, Bromley BR6 9JU, England	University of London; King's College London; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital	Kalra, L (corresponding author), Guys Kings & St Thomass Sch Med, Dept Med, London SE5 9PJ, England.	lalit.kalra@kcl.ac.uk	Knapp, Martin RJ/G-3011-2011; Patel, Anita/F-9832-2010	Knapp, Martin/0000-0003-1427-0215; Patel, Anita/0000-0003-0769-1732				ANDERSON CS, 1995, STROKE, V26, P843, DOI 10.1161/01.STR.26.5.843; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BOSANQUET N, 1998, STROKE CARE REDUCING; Dennis M, 1997, BRIT MED J, V314, P1071, DOI 10.1136/bmj.314.7087.1071; Dewey HM, 2002, STROKE, V33, P1028, DOI 10.1161/01.STR.0000013067.24300.B0; Duncan PW, 2000, STROKE, V31, P1429, DOI 10.1161/01.STR.31.6.1429; Forster A, 1996, BRIT MED J, V312, P1642, DOI 10.1136/bmj.312.7047.1642; FORSTER A, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001919; FRIEDLAND JF, 1992, ARCH PHYS MED REHAB, V73, P573; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Higginson IJ, 2001, BRIT MED J, V322, P1297, DOI 10.1136/bmj.322.7297.1297; Kavanagh S, 1999, J PUBLIC HEALTH MED, V21, P385, DOI 10.1093/pubmed/21.4.385; Kerr SM, 2001, CLIN REHABIL, V15, P428, DOI 10.1191/026921501678310234; Low JTS, 1999, SOC SCI MED, V49, P711, DOI 10.1016/S0277-9536(99)00194-X; Mant J, 2000, LANCET, V356, P808, DOI 10.1016/S0140-6736(00)02655-6; Patel A, 2004, BMJ-BRIT MED J, V328, P1102, DOI 10.1136/bmj.328.7448.1102; Persson U, 1990, Int J Technol Assess Health Care, V6, P125; Reimer WJMSO, 1998, STROKE, V29, P1605, DOI 10.1161/01.STR.29.8.1605; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Simon Chantal, 2002, Br J Community Nurs, V7, P292; van den Heuvel ETP, 2001, CLIN REHABIL, V15, P669, DOI 10.1191/0269215501cr446oa; WADE DT, 1986, BRIT MED J, V293, P418, DOI 10.1136/bmj.293.6544.418; Wade DT., 1992, MEASUREMENT NEUROLOG; WELLWOOD I, 1995, AGE AGEING, V24, P519, DOI 10.1093/ageing/24.6.519; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	25	243	249	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	2004	328	7448					1099	1101		10.1136/bmj.328.7448.1099	http://dx.doi.org/10.1136/bmj.328.7448.1099			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	818YS	15130977	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000221281000015
J	Hillmen, P; Hall, C; Marsh, JCW; Elebute, M; Bombara, MP; Petro, BE; Cullen, MJ; Richards, SJ; Rollins, SA; Mojcik, CF; Rother, RP				Hillmen, P; Hall, C; Marsh, JCW; Elebute, M; Bombara, MP; Petro, BE; Cullen, MJ; Richards, SJ; Rollins, SA; Mojcik, CF; Rother, RP			Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DECAY-ACCELERATING FACTOR; PIG-A GENE; MEMBRANE-PROTEIN; INAB PHENOTYPE; COMPLEMENT; DEFICIENCY; ERYTHROCYTES; SAFETY; ACTIVATION; ANTIBODIES	Background: Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem cell and the subsequent production of blood cells with a deficiency of surface proteins that protect the cells against attack by the complement system. We tested the clinical efficacy of eculizumab, a humanized antibody that inhibits the activation of terminal complement components, in patients with PNH. Methods: Eleven transfusion-dependent patients with PNH received infusions of eculizumab (600 mg) every week for four weeks, followed one week later by a 900-mg dose and then by 900 mg every other week through week 12. Clinical and biochemical indicators of hemolysis were measured throughout the trial. Results: Mean lactate dehydrogenase levels decreased from 3111 IU per liter before treatment to 594 IU per liter during treatment (P=0.002). The mean percentage of PNH type III erythrocytes increased from 36.7 percent of the total erythrocyte population to 59.2 percent (P=0.005). The mean and median transfusion rates decreased from 2.1 and 1.8 units per patient per month to 0.6 and 0.0 units per patient per month, respectively (P=0.003 for the comparison of the median rates). Episodes of hemoglobinuria were reduced by 96 percent (P<0.001), and measurements of the quality of life improved significantly. Conclusions: Eculizumab is safe and well tolerated in patients with PNH. This antibody against terminal complement protein C5 reduces intravascular hemolysis, hemoglobinuria, and the need for transfusion, with an associated improvement in the quality of life in patients with PNH.	Leeds Teaching Hosp Natl Hlth Sci Trust, Dept Haematol, Leeds, W Yorkshire, England; St George Hosp, Sch Med, Dept Haematol, London, England; Alexion Pharmaceut, Cheshire, CT USA	St Georges University London	Hillmen, P (corresponding author), Leeds Gen Infirm, Dept Haematol, Great George St, Leeds LS1 3EX, W Yorkshire, England.	peter.hillmen@panp-tr.northy.nhs.uk	Bidyuk, Petro/S-1161-2016	Richards, Stephen/0000-0002-8421-5353				BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; Colnot DR, 2003, CANCER IMMUNOL IMMUN, V52, P576, DOI 10.1007/s00262-003-0396-5; Corbin JD, 2002, UROLOGY, V60, P4, DOI 10.1016/S0090-4295(02)01686-2; FUJITA T, 1987, J EXP MED, V166, P1221, DOI 10.1084/jem.166.5.1221; HILLMEN P, 1995, NEW ENGL J MED, V333, P1253, DOI 10.1056/NEJM199511093331904; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; HOLGUIN MH, 1992, J IMMUNOL, V148, P498; MATIS LA, 1995, NAT MED, V1, P839, DOI 10.1038/nm0895-839; MERRY AH, 1989, BRIT J HAEMATOL, V73, P248, DOI 10.1111/j.1365-2141.1989.tb00260.x; MORGAN BP, 1992, BIOCHEM J, V282, P409, DOI 10.1042/bj2820409; MOTOYAMA N, 1992, EUR J IMMUNOL, V22, P2669, DOI 10.1002/eji.1830221029; MURRAY JA, 1995, GASTROENTEROLOGY, V109, P1241, DOI 10.1016/0016-5085(95)90584-7; OKADA N, 1990, CLIN EXP IMMUNOL, V80, P109; Przybelski RJ, 1996, CRIT CARE MED, V24, P1993, DOI 10.1097/00003246-199612000-00011; RICHARDS SJ, 2001, CLIN APPL IMMUNOL RE, V1, P315; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; RINDER CS, 1995, J CLIN INVEST, V96, P1564, DOI 10.1172/JCI118195; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROSSE WF, 2000, HEMATOLOGY BASIC PRI, P331; SAVITSKY JP, 1978, CLIN PHARMACOL THER, V23, P73; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TELEN MJ, 1989, BLOOD, V74, P437; Thomas TC, 1996, MOL IMMUNOL, V33, P1389, DOI 10.1016/S0161-5890(96)00078-8; YAMASHINA M, 1990, NEW ENGL J MED, V323, P1184, DOI 10.1056/NEJM199010253231707; YONEMURA Y, 1990, BRIT J HAEMATOL, V74, P108, DOI 10.1111/j.1365-2141.1990.tb02546.x	25	423	528	0	24	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2004	350	6					552	559		10.1056/NEJMoa031688	http://dx.doi.org/10.1056/NEJMoa031688			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770FP	14762182				2023-01-03	WOS:000188712800006
J	Staal, JB; Hlobil, H; Twisk, JWR; Smid, T; Koke, AJA; van Mechelen, W				Staal, JB; Hlobil, H; Twisk, JWR; Smid, T; Koke, AJA; van Mechelen, W			Graded activity for low back pain in occupational health care - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICAL-ACTIVITY; DISABILITY; QUESTIONNAIRE; RELIABILITY; VALIDITY	Background: Low back pain is a common medical and social problem frequently associated with disability and absence from work. However, data on effective return to work after interventions for low back pain are scarce. Objective: To determine the effectiveness of a behavior-oriented graded activity program compared with usual care. Design: Randomized, controlled trial. Setting: Occupational health services department of an airline company in the Netherlands. Patients: 134 workers who were absent from work because of low back pain were randomly assigned to either graded activity (n = 67) or usual care (n = 67). Intervention: Graded activity, a physical exercise program based on operant-conditioning behavioral principles, to stimulate a rapid return to work. Measurements: Outcomes were the number of days of absence from work because of low back pain, functional status (Roland Disability Questionnaire), and severity of pain (11-point numerical scale). Results: The median number of days of absence from work over 6 months of follow-up was 58 days in the graded activity group and 87 days in the usual care group. From randomization onward, graded activity was effective after 50 days of absence from work (hazard ratio, 1.9 [95% Cl, 1.2 to 3.2]; P = 0.009). The graded activity group was more effective in improving functional status and pain than the usual care group. The effects, however, were small and not statistically significant. Conclusions: Graded activity was more effective than usual care in reducing the number of days of absence from work because of low back pain.	Free Univ Amsterdam, Med Ctr, Dept Social Med, NL-1081 BT Amsterdam, Netherlands; Free Univ Amsterdam, Med Ctr, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands; KLM Hlth Safety & Environm, Schiphol, Netherlands; Univ Hosp Maastricht, Maastricht, Netherlands; TNO VUmc, Body Work Res Ctr Phys Act Work & Hlth, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Maastricht University; Maastricht University Medical Centre (MUMC); Netherlands Organization Applied Science Research	van Mechelen, W (corresponding author), Free Univ Amsterdam, Med Ctr, Dept Social Med, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	W.vanMechelen@vumc.nl	van Mechelen, Willem/C-8463-2013; Staal, Bart/ABA-4313-2020; Staal, J. Bart/A-9632-2014	Staal, Bart/0000-0002-0083-6380; Staal, J. Bart/0000-0002-0083-6380; van Mechelen, Willem/0000-0001-7136-6382				BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; Beurskens AJHM, 1996, PAIN, V65, P71, DOI 10.1016/0304-3959(95)00149-2; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; CARTER JT, 2004, OCCUPATION HLTH GUID; Chisholm D. M., 1978, PAR Q VALIDATION REP; *COLL STAT, 2001, STAT REF MAN REL 7; Faas A., 1996, HUIS WETEN, V39, P18; FLOR H, 1985, J CONSULT CLIN PSYCH, V53, P354, DOI 10.1037/0022-006X.53.3.354; Frank JW, 1996, SPINE, V21, P2918, DOI 10.1097/00007632-199612150-00025; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; GOLDSTEIN H, 1998, USERS GUIDE LMLWIN; LINDSTROM I, 1995, SCAND J REHABIL MED, V27, P153; LINDSTROM I, 1992, PHYS THER, V72, P279, DOI 10.1093/ptj/72.4.279; LINDSTROM I, 1992, PHYS THER, V72, P292, DOI 10.1093/ptj/72.4.292; Ostelo RWJG, 2000, J MANIP PHYSIOL THER, V23, P312, DOI 10.1016/S0161-4754(00)90205-7; Philippaerts RM, 1998, AM J EPIDEMIOL, V147, P982, DOI 10.1093/oxfordjournals.aje.a009389; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Roland M, 2000, SPINE, V25, P3115, DOI 10.1097/00007632-200012150-00006; SHEPHARD RJ, 1988, SPORTS MED, V5, P185, DOI 10.2165/00007256-198805030-00005; Staal JB, 2003, OCCUP ENVIRON MED, V60, P618, DOI 10.1136/oem.60.9.618; Stratford PW, 1998, PHYS THER, V78, P1186, DOI 10.1093/ptj/78.11.1186; Twisk JWR, 2003, APPL LONGITUDINAL DA	22	149	160	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 20	2004	140	2					77	84		10.7326/0003-4819-140-2-200401200-00007	http://dx.doi.org/10.7326/0003-4819-140-2-200401200-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764MY	14734329				2023-01-03	WOS:000188211700001
J	Tintillier, M; Coche, E; Malaise, J; Goffin, E				Tintillier, M; Coche, E; Malaise, J; Goffin, E			Peritoneal dialysis and an inguinal hernia	LANCET			English	Editorial Material									Clin Univ St Luc, Dept Nephrol, B-1200 Brussels, Belgium; Clin Univ St Luc, Dept Radiol, B-1200 Brussels, Belgium; Clin Univ St Luc, Dept Surg, B-1200 Brussels, Belgium	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Tintillier, M (corresponding author), Clin Univ St Luc, Dept Nephrol, B-1200 Brussels, Belgium.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 6	2003	362	9399					1893	1893		10.1016/S0140-6736(03)14960-4	http://dx.doi.org/10.1016/S0140-6736(03)14960-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	750RN	14667746				2023-01-03	WOS:000187011600010
J	Albers, GW; Diener, HC; Frison, L; Grind, M; Nevinson, M; Partridge, S; Halperin, JL; Horrow, J; Olsson, SB; Petersen, P; Vahanian, A				Albers, GW; Diener, HC; Frison, L; Grind, M; Nevinson, M; Partridge, S; Halperin, JL; Horrow, J; Olsson, SB; Petersen, P; Vahanian, A		SPORTIF Executive Steering Comm; SPORTIF V Investigators	Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation - A Randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIRECT THROMBIN INHIBITOR; VENOUS THROMBOEMBOLISM; ORAL XIMELAGATRAN; KNEE REPLACEMENT; CLINICAL-TRIALS; TOTAL HIP; MELAGATRAN; MANAGEMENT; RISK; PHARMACOKINETICS	Context Inpatients with nonvalvular atrial fibrillation, warfarin prevents ischemic stroke, but dose adjustment, coagulation monitoring, and bleeding limit its use. Objective To compare the efficacy of the oral direct thrombin inhibitor ximelagatran with warfarin for prevention of stroke and systemic embolism. Design, Setting, and Participants Double-blind, randomized, multicenter trial (20002001) conducted at 409 North American sites, involving 3922 patients with nonvalvular atrial fibrillation and additional stroke risk factors. Interventions Adjusted-dose warfarin (aiming for an international normalized ratio [INR] 2.0 to 3.0) or fixed-dose oral ximelagatran, 36 mg twice daily. Main Outcome Measures The primary end point was all strokes (ischemic or hemorrhagic) and systemic embolic events. The primary analysis was based on demonstrating noninferiority within an absolute margin of 2.0% per year according to the intention-to-treat model. Results During 6405 patient-years (mean 20 months) of follow-up, 88 patients experienced primary events. The mean (SD) INR with warfarin (2.4 [0.8]) was within target during 68% of the treatment period. The primary event rate with ximelagatran was 1.6% per year and with warfarin was 1.2% per year (absolute difference, 0.45% per year; 95% confidence interval, -0.13% to 1.03% per year; P<.001 for the pre-defined noninferiority hypothesis). When all-cause mortality was included in addition to stroke and systemic embolic events, the rate difference was 0.10% per year (95% confidence interval, -0.97% to 1.2% per year; P=.86). There was no difference between treatment groups in rates of major bleeding, but total bleeding (major and minor) was lower with ximelagatran (37% vs 47% per year; 95% confidence interval for the difference, -14% to -6.0% per year; P<.001). Serum alanine aminotransferase levels rose to greater than 3 times the upper limit of normal in 6.0% of patients treated with ximelagatran, usually within 6 months and typically declined whether or not treatment continued; however, one case of documented fatal liver disease and one other suggestive case occurred. Conclusions The results establish the efficacy of fixed-dose oral ximelagatran without coagulation monitoring compared with well-controlled warfarin for prevention of thromboembolism in patients with atrial fibrillation requiring chronic anticoagulant therapy, but the potential for hepatotoxicity requires further investigation.	Mt Sinai Med Ctr, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10024 USA; Mt Sinai Med Ctr, Marie Josee & Henry R Kravis Ctr Cardiovasc Hlth, New York, NY 10024 USA; Stanford Stroke Ctr, Palo Alto, CA USA; Univ Essen Gesamthsch, Dept Neurol, Essen, Germany; AstraZeneca R&D, Dept Biostat, Molndal, Sweden; AstraZeneca Res & Dev Charnwood, Dept Clin Sci, Charnwood, England; AstraZeneca Res & Dev Charnwood, Dept Clin Project Management, Charnwood, England; AstraZeneca Res & Dev Charnwood, Dept Clin Dev, Charnwood, England; Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA; AstraZeneca LP, Dept Clin Dev, Wilmington, DE USA; Univ Lund Hosp, Dept Cardiol, S-22185 Lund, Sweden; Univ Copenhagen Hosp, Dept Neurol, DK-2100 Copenhagen, Denmark; Hosp Tenon, Dept Cardiol, Paris, France	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Stanford University; University of Duisburg Essen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Icahn School of Medicine at Mount Sinai; AstraZeneca; Lund University; Skane University Hospital; University of Copenhagen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Albers, GW (corresponding author), Mt Sinai Med Ctr, Zena & Michael A Wiener Cardiovasc Inst, 1 Gustave L Levy Pl, New York, NY 10024 USA.		Diener, Hans-Christoph/AAF-7275-2019; Halperin, Jonathan/AAJ-4721-2020	Halperin, Jonathan/0000-0002-8318-5471; Albers, Gregory/0000-0003-0263-4632				ALBERS GW, 1994, ARCH INTERN MED, V154, P1443, DOI 10.1001/archinte.154.13.1443; Albers GW, 2003, LANCET, V362, P1691; Albers GW, 2001, CHEST, V119, p194S, DOI 10.1378/chest.119.1_suppl.194S; Andersson TB, 2004, DRUG METAB REV, V36, P101; Andersson TB, 2004, DRUG METAB REV, V36, P198; ASINGER RW, 1989, ARCH NEUROL-CHICAGO, V46, P727; Blackshear JL, 1996, LANCET, V348, P633; Bredberg E, 2003, CLIN PHARMACOKINET, V42, P765, DOI 10.2165/00003088-200342080-00005; Bungard TJ, 2000, ARCH INTERN MED, V160, P41, DOI 10.1001/archinte.160.1.41; Chapman N, 2004, STROKE, V35, P116, DOI 10.1161/01.STR.0000106480.76217.6F; Collin C, 1988, Int Disabil Stud, V10, P61; Ebbutt AF, 1998, STAT MED, V17, P1691, DOI 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1691::AID-SIM971>3.3.CO;2-A; Eriksson B, 2002, LANCET, V360, P1441, DOI 10.1016/S0140-6736(02)11469-3; Eriksson BI, 2003, THROMB HAEMOSTASIS, V89, P288; Eriksson UG, 2003, EUR J CLIN PHARMACOL, V59, P35, DOI 10.1007/s00228-003-0565-7; Francis CW, 2003, NEW ENGL J MED, V349, P1703, DOI 10.1056/NEJMoa035162; Frykman V, 2001, EUR HEART J, V22, P1954, DOI 10.1053/euhj.2000.2300; Fuster V, 2001, J AM COLL CARDIOL, V38, P1231, DOI 10.1016/S0735-1097(01)01587-X; Gadisseur APA, 2003, ARCH INTERN MED, V163, P2639, DOI 10.1001/archinte.163.21.2639; Go AS, 1999, ANN INTERN MED, V131, P927, DOI 10.7326/0003-4819-131-12-199912210-00004; Gomberg-Maitland M, 2003, AM HEART J, V146, P398, DOI 10.1016/S0002-8703(03)00324-7; Halperin JL, 2003, AM HEART J, V146, P431, DOI 10.1016/S0002-8703(03)00325-9; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Johansson LC, 2003, CLIN PHARMACOKINET, V42, P381, DOI 10.2165/00003088-200342040-00006; Klement P, 2003, J THROMB HAEMOST, V1, P587, DOI 10.1046/j.1538-7836.2003.00060.x; LAN KKG, 1971, BRIT J RADIOL, V44, P793; Lebrazi J, 2003, THROMB RES, V110, P249, DOI 10.1016/S0049-3848(03)00345-1; Petersen P, 2003, J AM COLL CARDIOL, V41, P1445, DOI 10.1016/S0735-1097(03)00255-9; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; Samsa GP, 2000, ARCH INTERN MED, V160, P967, DOI 10.1001/archinte.160.7.967; Sarich TC, 2003, CLIN PHARMACOKINET, V42, P485, DOI 10.2165/00003088-200342050-00006; Schulman S, 2003, NEW ENGL J MED, V349, P1713, DOI 10.1056/NEJMoa030104; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wallentin L, 2003, LANCET, V362, P789, DOI 10.1016/S0140-6736(03)14287-0; WELLS PS, 1994, ANN INTERN MED, V121, P676, DOI 10.7326/0003-4819-121-9-199411010-00009	37	538	561	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2005	293	6					690	698						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895DX	15701910				2023-01-03	WOS:000226842200022
J	Pereira, MA; Swain, J; Goldfine, AB; Rifai, N; Ludwig, DS				Pereira, MA; Swain, J; Goldfine, AB; Rifai, N; Ludwig, DS			Effects of a low-glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							METABOLIC-RATE; INSULIN-RESISTANCE; LOW-CALORIE; NEUROENDOCRINE; PROTEIN; OBESITY; PLASMA; INDEX; HOMEOSTASIS; STARVATION	Context Weight loss elicits physiological adaptations relating to energy intake and expenditure that antagonize ongoing weight loss. Objective To test whether dietary composition affects the physiological adaptations to weight loss, as assessed by resting energy expenditure. Design, Study, and Participants A randomized parallel-design study of 39 overweight or obese young adults aged 18 to 40 years who received an energy-restricted diet, either low-glycemic load or low-fat. Participants were studied in the General Clinical Research Centers of the Brigham and Women's Hospital and the Children's Hospital, Boston, Mass, before and after 10% weight loss. The study was conducted from January 4, 2001, to May 6, 2003. Main Outcome Measures Resting energy expenditure measured in the fasting state by indirect calorimetry, body composition by dual-energy x-ray absorptiometry, cardiovascular disease risk factors, and self-reported hunger. Results Resting energy expenditure decreased less with the low-glycemic load diet than with the low-fat diet, expressed in absolute terms (mean [SE], 96 [24] vs 176 [27] kcal/d; P=.04) or as a proportion (5.9% [1.5%] vs 10.6% [1.7%]; P=.05). Participants receiving the low-glycemic load diet reported less hunger than those receiving the low-fat diet (P=.04). Insulin resistance (P=.01), serum triglycerides (P=.01), C-reactive protein (P=.03), and blood pressure (P=.07 for both systolic and diastolic) improved more with the low-glycemic load diet. Changes in body composition (fat and lean mass) in both groups were very similar (P=.85 and P=.45, respectively). Conclusions Changes in dietary composition within prevailing norms can affect physiological adaptations that defend body weight. Reduction in glycemic load may aid in the prevention or treatment of obesity, cardiovascular disease, and diabetes mellitus.	Childrens Hosp, Dept Med, Boston, MA 02115 USA; Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Gen Clin Res Ctr, Boston, MA 02115 USA; Joslin Diabet Ctr, Boston, MA 02215 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Joslin Diabetes Center, Inc.	Ludwig, DS (corresponding author), Childrens Hosp, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.	david.ludwig@childrens.harvard.edu	Biguzzi, Felipe A/E-4724-2015	Ludwig, David/0000-0003-3307-8544; Pereira, Mark/0000-0002-6704-5276	NCRR NIH HHS [M01 RR02172, M01 RR02635] Funding Source: Medline; NIDDK NIH HHS [R01 DK59240] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635, M01RR002172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059240] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agus MSD, 2000, AM J CLIN NUTR, V71, P901; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Astrup A, 1999, AM J CLIN NUTR, V69, P1117; Brand-Miller JC, 2003, J NUTR, V133, P2728, DOI 10.1093/jn/133.9.2728; Chan JL, 2003, J CLIN INVEST, V111, P1409, DOI 10.1172/JCI200317490; DURRANT ML, 1980, BRIT J NUTR, V44, P275, DOI 10.1079/BJN19800042; Ebbeling C B, 2001, Adv Pediatr, V48, P179; ELLIOT DL, 1989, AM J CLIN NUTR, V49, P93, DOI 10.1093/ajcn/49.1.93; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Fruehwald-Schultes B, 2000, METABOLISM, V49, P794, DOI 10.1053/meta.2000.6262; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Harris J. A., 1919, BIOMETRIC STUDY BASA, P279; HARRIS RBS, 1990, FASEB J, V4, P3310, DOI 10.1096/fasebj.4.15.2253845; Hirsch J, 1998, AM J CLIN NUTR, V67, p551S, DOI 10.1093/ajcn/67.3.551S; LAIRD N, 1983, AM STAT, V37, P329, DOI 10.2307/2682785; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Liu SM, 2000, AM J CLIN NUTR, V71, P1455; Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414; Ludwig DS, 2003, J NUTR, V133, P2695, DOI 10.1093/jn/133.9.2695; Ludwig DS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e26; Luscombe ND, 2003, INT J OBESITY, V27, P582, DOI 10.1038/sj.ijo.0802270; Luscombe ND, 2002, DIABETES CARE, V25, P652, DOI 10.2337/diacare.25.4.652; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Pawlak D B, 2002, Obes Rev, V3, P235, DOI 10.1046/j.1467-789X.2002.00079.x; Pawlak DB, 2004, LANCET, V364, P778, DOI 10.1016/S0140-6736(04)16937-7; Pereira M A, 1997, Med Sci Sports Exerc, V29, pS1; Raben A, 2002, Obes Rev, V3, P245, DOI 10.1046/j.1467-789X.2002.00080.x; RATTAN S, 1989, INT J OBESITY, V13, P189; Ravussin E, 1999, INT J OBESITY, V23, P37, DOI 10.1038/sj.ijo.0800793; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; Schwartz MW, 1997, NEW ENGL J MED, V336, P1802, DOI 10.1056/NEJM199706193362507; SOARES MJ, 1988, BRIT J NUTR, V60, P425, DOI 10.1079/BJN19880114; Weinsier RL, 2003, OBES RES, V11, P937, DOI 10.1038/oby.2003.129; Weinsier RL, 2000, AM J CLIN NUTR, V72, P1088; Westerterp KR, 1999, INT J OBESITY, V23, P287, DOI 10.1038/sj.ijo.0800810; YOSHIDA T, 1994, INT J OBESITY, V18, P345	39	222	232	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2004	292	20					2482	2490		10.1001/jama.292.20.2482	http://dx.doi.org/10.1001/jama.292.20.2482			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873TD	15562127	Bronze			2023-01-03	WOS:000225303000023
J	Chintu, C; Bhat, GJ; Walker, AS; Mulenga, V; Sinyinza, F; Lishimpi, K; Farrelly, L; Kaganson, N; Zumla, A; Gillespie, SH; Nunn, AJ; Gibb, DM				Chintu, C; Bhat, GJ; Walker, AS; Mulenga, V; Sinyinza, F; Lishimpi, K; Farrelly, L; Kaganson, N; Zumla, A; Gillespie, SH; Nunn, AJ; Gibb, DM		CHAP Trial Team	Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controled trial	LANCET			English	Article							PNEUMOCYSTIS-CARINII-PNEUMONIA; TRIMETHOPRIM-SULFAMETHOXAZOLE; COTE-DIVOIRE; ABIDJAN; RESISTANCE; DISEASE; BURDEN	Background No trials of co-trimoxazole (trimethoprim-sulfamethoxazole) prophylaxis for HIV-infected adults or children have been done in areas with high levels of bacterial resistance to this antibiotic. We aimed to assess the efficacy of daily co-trimoxazole in such an area. Methods We did a double-blind randomised placebo-controlled trial in children aged 1-14 years with clinical features of HIV infection in Zambia. Primary outcomes were mortality and adverse events possibly related to treatment. Analysis was by intention to treat. Findings In October, 2003, the data and safety monitoring committee recommended early stopping of the trial. 541 children had been randomly assigned; seven were subsequently identified as HIV negative and excluded. After median follow-up of 19 months, 74 (28%) children in the co-trimoxazole group and 112 (42%) in the placebo group had died (hazard ratio [HR] 0.57 [95% Cl 0.43-0.77], p=0.0002). This benefit applied in children followed up beyond 12 months (n=320, HR 0.48 [0.27-0.84], test for heterogeneity p=0.60) and across all ages (test for heterogeneity p=0.82) and baseline CD4 counts (test for heterogeneity p=0.36). 16 (6%) children in the co-trimoxazole group had grade 3 or 4 adverse events compared with 18 (7%) in the placebo group. These events included rash (one placebo), and a neutrophil count on one occasion less than 0 . 5 X 10(9)/L (16 [6%] co-trimoxazole vs seven [3%] placebo, p=0.06). Pneumocystis carinii was identified by immunofluorescence in only one (placebo) of 73 nasopharyngeal aspirates from children with pneumonia. Interpretation Our results suggest that children of all ages with clinical features of HIV infection should receive cotrimoxazole prophylaxis in resource-poor settings, irrespective of local resistance to this drug.	MRC, Clin Trials Unit, London NW1 2DA, England; Univ Teaching Hosp, Lusaka, Zambia; UCL Royal Free & Univ Coll Med Sch, London, England	Medical Research Council Clinical Trials Unit; University of Zambia; University of London; University College London; UCL Medical School	Gibb, DM (corresponding author), MRC, Clin Trials Unit, 222 Euston Rd, London NW1 2DA, England.	d.gibb@ctu.mrc.ac.uk	ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735; Gibb, Diana/0000-0002-9738-5490; Nunn, Andrew/0000-0002-9158-4595				Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; ANSARI NA, 1999, INT J TUBERC LUNG S1, V3, pS201; Arason VA, 1996, BMJ-BRIT MED J, V313, P387; Bortolotti W, 2002, AIDS, V16, P1309, DOI 10.1097/00002030-200207050-00002; Chintu C, 2002, LANCET, V360, P985, DOI 10.1016/S0140-6736(02)11082-8; FELKIN DR, 2000, J INFECT DIS, V181, P1501; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; GIBB DM, 1994, ARCH DIS CHILD, V70, P241, DOI 10.1136/adc.70.3.241; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; Graham SM, 2000, LANCET, V355, P369, DOI 10.1016/S0140-6736(98)11074-7; Graham SM, 2002, LANCET, V360, P1966, DOI 10.1016/S0140-6736(02)11921-0; Iyer JK, 2001, LANCET, V358, P1066, DOI 10.1016/S0140-6736(01)06201-8; JONES JL, 1992, MMWR-MORBID MORTAL W, V48, P1; Lishimpi K, 2002, AIDS, V16, P932, DOI 10.1097/00002030-200204120-00017; Lucas SB, 1996, BRIT MED J, V312, P335, DOI 10.1136/bmj.312.7027.335; Madhi SA, 2000, CLIN INFECT DIS, V31, P170, DOI 10.1086/313925; MOFENSON LM, 1991, NEW ENGL J MED, V325, P73, DOI 10.1056/NEJM199107113250201; Mwansa J, 2002, EMERG INFECT DIS, V8, P92, DOI 10.3201/eid0801.010018; Nathoo KJ, 2001, T ROY SOC TROP MED H, V95, P37, DOI 10.1016/S0035-9203(01)90325-6; Ndhlovua Z, 2004, J TROP PEDIATRICS, V50, P94, DOI 10.1093/tropej/50.2.94; Olliaro PL, 1995, B WORLD HEALTH ORGAN, V73, P735; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; POCOCK SJ, 1982, CLIN TRIALS PRACTICA, P213; Ruffini DD, 2002, AIDS, V16, P105, DOI 10.1097/00002030-200201040-00013; WADE AM, 1994, STAT MED, V13, P2359, DOI 10.1002/sim.4780132207; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; World Health Organization/UNAIDS, 2001, AFR HEALTH SCI, V1, P30; Zar HJ, 2000, PEDIATR INFECT DIS J, V19, P603, DOI 10.1097/00006454-200007000-00004	28	260	268	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2004	364	9448					1865	1871		10.1016/S0140-6736(04)17442-4	http://dx.doi.org/10.1016/S0140-6736(04)17442-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555666				2023-01-03	WOS:000225269300027
J	Guerin, C; Gaillard, S; Lemasson, S; Ayzac, L; Girard, R; Beuret, P; Palmier, B; Le, QV; Sirodot, M; Rosselli, S; Cadiergue, V; Sainty, JM; Barbe, P; Combourieu, E; Debatty, D; Rouffineau, J; Ezingeard, E; Millet, O; Guelon, D; Rodriguez, L; Martin, O; Renault, A; Sibille, JP; Kaidomar, M				Guerin, C; Gaillard, S; Lemasson, S; Ayzac, L; Girard, R; Beuret, P; Palmier, B; Le, QV; Sirodot, M; Rosselli, S; Cadiergue, V; Sainty, JM; Barbe, P; Combourieu, E; Debatty, D; Rouffineau, J; Ezingeard, E; Millet, O; Guelon, D; Rodriguez, L; Martin, O; Renault, A; Sibille, JP; Kaidomar, M			Effect of systematic prone positioning in hypoxemic acute respiratory failure - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISTRESS-SYNDROME; ORGAN FAILURE; GAS-EXCHANGE; LUNG INJURY; DEFINITIONS; OXYGENATION; VENTILATION; DISEASE; MODEL; ARDS	Context A recent trial showed that placing patients with acute lung injury in the prone position did not increase survival; however, whether those results hold true for patients with hypoxemic acute respiratory failure (ARF) is unclear. Objective To determine whether prone positioning improves mortality in ARF patients. Design, Setting, and Patients Prospective, unblinded, multicenter controlled trial of 791 ARF patients in 21 general intensive care units in France using concealed randomization conducted from December 14, 1998, through December 31, 2002. To be included, patients had to be at least 18 years, hemodynamically stable, receiving mechanical ventilation, and intubated and had to have a partial pressure of arterial oxygen (PaO2) to fraction of inspired oxygen (FIO2) ratio of 300 or less and no contraindications to lying prone. Interventions Patients were randomly assigned to prone position placement (n = 413), applied as early as possible for at least 8 hours per day on standard beds, or to supine position placement (n = 378). Main Outcome Measures The primary end point was 28-day mortality; secondary end points were 90-day mortality, duration of mechanical ventilation, incidence of ventilator-associated pneumonia (VAP), and oxygenation. Results The 2 groups were comparable at randomization. The 28-day mortality rate was 32.4% for the prone group and 31.5% for the supine group (relative risk [RR], 0.97; 95% confidence interval [CI], 0.79-1.19; P=.77). Ninety-day mortality for the prone group was 43.3% vs 42.2% for the supine group (RR, 0.98; 95% CI, 0.84-1.13; P=.74). The mean (SD) duration of mechanical ventilation was 13.7 (7.8) days for the prone group vs 14.1 (8.6) days for the supine group (P=.93) and the VAP incidence was 1.66 vs 2.14 episodes per 100-patients days of intubation, respectively (P=.045). The PaO2/FIO2 ratio was significantly higher in the prone group during the 28-day follow-up. However, pressure sores, selective intubation; and endotracheal tube obstruction incidences were higher in the prone group. Conclusions This trial demonstrated no beneficial outcomes and some safety concerns associated with prone positioning. For patients with hypoxemic ARF, prone position placement may lower the incidence of VAP.	Hop Croix Rousse, Serv Reanimat Med, F-69004 Lyon, France; Ctr Hosp Lyon Sud, C Clin Sud Est, F-69310 Pierre Benite, France; Ctr Hosp Lyon Sud, Serv Hyg & Epidemiol, F-69310 Pierre Benite, France; Serv Reanimat Polyvalente, Roanne, France; Hop Instruct Armees St Anne, Serv Reanimat, F-83800 Toulon, France; Serv Reanimat Polyvalente, Chalon Sur Saone, France; Serv Reanimat Polyvalente, Annecy, France; Ctr Hosp St Joseph, Serv Reanimat Med, Lyon, France; Ctr Hosp Lyon Sud, Serv Reanimat Med, Lyon, France; Hop St Marguerite, Serv Reanimat Med, Marseille, France; Serv Reanimat Polyvalente, Chambery, France; Hop Instruct Armees, Serv Reanimat, Lyon, France; Serv Reanimat Polyvalente, Macon, France; CHU La Miletrie, Serv Reanimat Med, Poitiers, France; Clin Mutualiste, Serv Reanimat, St Etienne, France; Serv Reanimat, Lons Le Saunier, France; CHU Gabriel Montpied, Serv Reanimat Chirurg, Clermont Ferrand, France; Serv Reanimat Polyvalente, Aix En Provence, France; Hop Edouard Herriot, Serv Reanimat Med, Lyon, France; CHU Brest, Serv Reanimat Med, F-29285 Brest, France; Serv Reanimat Polyvalente, Briancon, France; Serv Reanimat Polyvalente, Frejus, France	CHU Lyon; CHU Lyon; CHU Lyon; Hospital Instruction Of Armees Sainte-Anne; CHU Lyon; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Val-de-Grace Hospital; CHU Poitiers; Universite de Poitiers; CHU Clermont Ferrand; CHU Lyon; CHU Brest	Guerin, C (corresponding author), Hop Croix Rousse, Serv Reanimat Med, 103 Grande Rue Crooix Rousse, F-69004 Lyon, France.	claude.guerin@chu-lyon.fr	Millet, Oscar/F-9696-2011; guerin, claude/H-5692-2014	Millet, Oscar/0000-0001-8748-4105; guerin, claude/0000-0003-4700-6672				Albert RK, 2000, AM J RESP CRIT CARE, V161, P1660, DOI 10.1164/ajrccm.161.5.9901037; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Beuret P, 2002, INTENS CARE MED, V28, P564, DOI 10.1007/s00134-002-1266-x; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Broccard A, 2000, CRIT CARE MED, V28, P295, DOI 10.1097/00003246-200002000-00001; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; BRYAN AC, 1974, AM REV RESPIR DIS, V110, P143; Chatte G, 1997, AM J RESP CRIT CARE, V155, P473, DOI 10.1164/ajrccm.155.2.9032181; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteve J, 1994, DESCRIPTIVE EPIDEMIO; FAGON JY, 1993, INTENS CARE MED, V19, P137, DOI 10.1007/BF01720528; Gattinoni L, 2001, NEW ENGL J MED, V345, P568, DOI 10.1056/NEJMoa010043; GAUSSORGUES P, 1987, PRESSE MED, V16, P1200; Guerin C, 1999, INTENS CARE MED, V25, P1222, DOI 10.1007/s001340051050; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Leonet S, 2002, INTENS CARE MED, V28, P576, DOI 10.1007/s00134-002-1274-x; Mancebo J, 2003, INTENS CARE MED, V29, pS64; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; McCormick J, 2001, Intensive Crit Care Nurs, V17, P331, DOI 10.1054/iccn.2001.1611; Mentzelopoulos SD, 2003, ANESTH ANALG, V96, P1756, DOI 10.1213/01.ANE.0000064282.79068.1E; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Mure M, 1997, CRIT CARE MED, V25, P1539, DOI 10.1097/00003246-199709000-00022; MUTOH T, 1992, AM REV RESPIR DIS, V146, P300, DOI 10.1164/ajrccm/146.2.300; Nakos G, 2000, AM J RESP CRIT CARE, V161, P360, DOI 10.1164/ajrccm.161.2.9810037; Pelosi P, 1998, AM J RESP CRIT CARE, V157, P387, DOI 10.1164/ajrccm.157.2.97-04023; Rello J, 2003, CRIT CARE MED, V31, P2544, DOI 10.1097/01.CCM.0000089928.84326.D2; Richard JC, 2002, J APPL PHYSIOL, V93, P2181, DOI 10.1152/japplphysiol.00313.2002; Roupie E, 1999, INTENS CARE MED, V25, P920, DOI 10.1007/s001340050983; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; van Kaam AH, 2004, AM J RESP CRIT CARE, V169, P1046, DOI 10.1164/rccm.200312-1779OC	31	364	397	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2004	292	19					2379	2387		10.1001/jama.292.19.2379	http://dx.doi.org/10.1001/jama.292.19.2379			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PL	15547166	Bronze			2023-01-03	WOS:000225070100027
J	Davis, PG; Tan, A; O'Donnell, CPF; Schulze, A				Davis, PG; Tan, A; O'Donnell, CPF; Schulze, A			Resuscitation of newborn infants with 100% oxygen or air: a systematic review and meta-analysis	LANCET			English	Review							ROOM-AIR; OXIDATIVE STRESS; TERM INFANTS; 21-PERCENT; CONSENSUS	Background International consensus statements for resuscitation of newborn infants recommend provision of 100% oxygen with positive pressure if assisted ventilation is required. However, 100% oxygen exacerbates reperfusion injury in animals and reduces cerebral perfusion in newborn babies. We aimed to establish whether resuscitation with air decreased mortality or neurological disability in newborn infants compared with 100% oxygen. Methods We did a systematic review and meta-analysis of trials that compared resuscitation with air versus 100% oxygen, using the methods of the Cochrane Collaboration. We combined data for similar outcomes in the analysis where appropriate, using a fixed-effects model. Findings Five trials (two masked and three unmasked), consisting of 1302 newborn infants, fulfilled the inclusion criteria. Most babies were born at or near term in developing countries. In the three unmasked studies, infants resuscitated with room air who remained cyanotic and bradycardic were switched to 100% oxygen at 90 s. The masked studies allowed crossover to the other gas during the first minutes of life. Although no individual trial showed a difference in mortality, the pooled analysis showed a significant benefit for infants resuscitated with air (relative risk 0.71 [95% CI 0.54 to 0.94], risk difference -0.05 [-0.08 to -0.01]). The effect on long-term development could not be reliably determined because of methodological limitations in the one study that followed up infants beyond 12 months of age. Interpretation For term and near-term infants, we can reasonably conclude that air should be used initially, with oxygen as backup if initial resuscitation fails. The effect of intermediate concentrations of oxygen at resuscitation needs to be investigated. Future trials should include and stratify for premature infants.	Royal Hosp Women, Melbourne, Vic, Australia; Univ Melbourne, Melbourne, Vic, Australia; Booth Hall Childrens Hosp, Manchester, Lancs, England; Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany	University of Melbourne; Royal Manchester Children's Hospital; University of Munich	Davis, PG (corresponding author), Royal Hosp Women, 132 Grattan St, Carlton, Vic 3053, Australia.	pgd@unimelb.edu.au		O'donnell, Colm/0000-0002-8004-450X				AINLEYWALKER JC, 1979, BRIT MED J, V2, P1590, DOI 10.1136/bmj.2.6204.1590-b; [Anonymous], 2 KINGS, V4; [Anonymous], GENESIS; DEEKS JJ, ANAL PRESENTING RESU; Hammerman C, 1998, CLIN PERINATOL, V25, P757, DOI 10.1016/S0095-5108(18)30110-6; Kattwinkel J, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.4.e56; Kattwinkel J, 2003, J PEDIATR-US, V142, P221, DOI 10.1067/mpd.2003.147; Kutzsche S, 2001, PEDIATR RES, V49, P834, DOI 10.1203/00006450-200106000-00020; LUNDSTROM K, 1995, ARCH DIS CHILD, V73, P81; Milner AD, 1998, EUR J PEDIATR, V157, P524, DOI 10.1007/s004310050870; Niermeyer S, 2000, PEDIATRICS, V106; NIIJIMA S, 1988, ARCH DIS CHILD-FETAL, V63, P1126, DOI 10.1136/adc.63.10_Spec_No.1126; Ramji S, 2003, Indian Pediatr, V40, P510; RAMJI S, 1993, PEDIATR RES, V34, P809, DOI 10.1203/00006450-199312000-00023; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Saugstad OD, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e1; Saugstad OD, 2003, PEDIATRICS, V112, P296, DOI 10.1542/peds.112.2.296; Saugstad OD, 2001, PEDIATRICS, V108, P1203, DOI 10.1542/peds.108.5.1203; Saugstad OD, 1998, CLIN PERINATOL, V25, P741, DOI 10.1016/S0095-5108(18)30109-X; Silverman WA, 2004, PEDIATRICS, V113, P394, DOI 10.1542/peds.113.2.394; Soll R, 1999, LANCET, V354, P4, DOI 10.1016/S0140-6736(99)00149-X; TAN A, 2004, COCHRANE LIB; Tin W, 2001, ARCH DIS CHILD-FETAL, V84, pF106, DOI 10.1136/fn.84.2.F106; Van Marter LJ, 2000, PEDIATRICS, V105, P1194, DOI 10.1542/peds.105.6.1194; Vento M, 2003, J PEDIATR-US, V142, P240, DOI 10.1067/mpd.2003.91; Vento M, 2001, PEDIATRICS, V107, P642, DOI 10.1542/peds.107.4.642; Vento M, 2001, BIOL NEONATE, V79, P261	27	243	249	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	2004	364	9442					1329	1333		10.1016/S0140-6736(04)17189-4	http://dx.doi.org/10.1016/S0140-6736(04)17189-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860NG	15474135				2023-01-03	WOS:000224349700028
J	Tucker, J; Parry, G; Fowlie, PW; McGuire, W				Tucker, J; Parry, G; Fowlie, PW; McGuire, W			ABC of preterm birth - Organisation and delivery of perinatal services	BRITISH MEDICAL JOURNAL			English	Review									Univ Aberdeen, Dugald Baird Ctr, Dept Obstet & Gynaecol, Aberdeen AB9 1FX, Scotland; Univ Sheffield, Sch Hlth & Related Res, Med Care Res Unit, Sheffield S10 2TN, S Yorkshire, England; Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 4HN, Scotland; Perth Royal Infirm, Perth, Scotland	University of Aberdeen; University of Sheffield; University of Dundee	Tucker, J (corresponding author), Univ Aberdeen, Dugald Baird Ctr, Dept Obstet & Gynaecol, Aberdeen AB9 1FX, Scotland.		Parry, Gareth/CAF-6975-2022	McGuire, William/0000-0001-8572-3467				*CSAG, 1993, ACCESS AVAILABILITY; Parry G, 2003, LANCET, V361, P1789, DOI 10.1016/S0140-6736(03)13397-1; Tucker J, 2002, LANCET, V359, P99	3	5	7	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 25	2004	329	7468					730	732		10.1136/bmj.329.7468.730	http://dx.doi.org/10.1136/bmj.329.7468.730			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	858RV	15388617	Green Published			2023-01-03	WOS:000224210300023
J	Morrison, RS; Meier, DE				Morrison, RS; Meier, DE			Palliative care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OF-LIFE CARE; ALL-INCLUSIVE CARE; ELDERLY PACE; HEALTH-CARE; END; MANAGEMENT; PROGRAM; OUTCOMES; HOSPICE; IMPACT		Mt Sinai Sch Med, Hertzberg Palliat Care Inst, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Morrison, RS (corresponding author), Mt Sinai Sch Med, Dept Geriatr, Box 1070,1 Gustave L Levy Pl, New York, NY 10029 USA.	sean.morrison@mssm.edu			NATIONAL INSTITUTE ON AGING [K24AG022345, K07AG000903] Funding Source: NIH RePORTER; NIA NIH HHS [K24AG022345, K07AG00903] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM AC PHYS PAT, UPC COURS M; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Bernabei R, 1999, JAMA-J AM MED ASSOC, V281, P136; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Bookbinder M, 1996, J PAIN SYMPTOM MANAG, V12, P334, DOI 10.1016/S0885-3924(96)00204-7; BUCKMAN R, 2000, JAMA-J AM MED ASSOC, V283, P909; Casarett DJ, 2001, ANN INTERN MED, V135, P32, DOI 10.7326/0003-4819-135-1-200107030-00011; Christakis NA, 2003, SOC SCI MED, V57, P465, DOI 10.1016/S0277-9536(02)00370-2; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Dowsett SM, 2000, PSYCHO-ONCOL, V9, P147, DOI 10.1002/(SICI)1099-1611(200003/04)9:2<147::AID-PON443>3.0.CO;2-X; Doyle D., 2004, OXFORD TXB PALLIATIV; Ehman JW, 1999, ARCH INTERN MED, V159, P1803, DOI 10.1001/archinte.159.15.1803; Elkan R, 2001, BMJ-BRIT MED J, V323, P719, DOI 10.1136/bmj.323.7315.719; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; *EPEC PROJ, ED PALL END OF LIF C; Fallowfield L, 2002, LANCET, V359, P650, DOI 10.1016/S0140-6736(02)07810-8; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Field MJ, 1997, APPROACHING DEATH IM; Finlay IG, 2002, ANN ONCOL, V13, P257, DOI 10.1093/annonc/mdf668; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Foley KM, 1999, ARCH NEUROL-CHICAGO, V56, P413, DOI 10.1001/archneur.56.4.413; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; *HARV MED SCH CTR, PRACT ASP PALL MED I; Hughes SL, 2000, JAMA-J AM MED ASSOC, V284, P2877, DOI 10.1001/jama.284.22.2877; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Luce JM, 2001, JAMA-J AM MED ASSOC, V285, P1331, DOI 10.1001/jama.285.10.1331; Manfredi PL, 2000, J PAIN SYMPTOM MANAG, V20, P166, DOI 10.1016/S0885-3924(00)00163-9; McClain CS, 2003, LANCET, V361, P1603, DOI 10.1016/S0140-6736(03)13310-7; Meier DE, 2002, NEW ENGL J MED, V346, P1087, DOI 10.1056/NEJM200204043461413; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; Miles SH, 1996, ARCH INTERN MED, V156, P1062, DOI 10.1001/archinte.156.10.1062; Miller SC, 2003, J PAIN SYMPTOM MANAG, V26, P791, DOI 10.1016/S0885-3924(03)00284-7; MITTELMAN MS, 1995, GERONTOLOGIST, V35, P792, DOI 10.1093/geront/35.6.792; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; Morrison RS, 2003, PAIN, V103, P303, DOI 10.1016/S0304-3959(02)00458-X; Morrison RS., 2003, GERIATRIC PALLIATIVE, V1st; MORRISON RS, IN PRESS ARCH INTERN; Mukamel DB, 2002, MED CARE, V40, P1136, DOI 10.1097/00005650-200212000-00002; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; REGNARD C, 1992, Palliative Medicine, V6, P146, DOI 10.1177/026921639200600209; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Smith Thomas J, 2003, J Palliat Med, V6, P699, DOI 10.1089/109662103322515202; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Strasser F, 2002, HEMATOL ONCOL CLIN N, V16, P589, DOI 10.1016/S0889-8588(02)00011-4; Stroebe M.S., 1993, HDB BEREAVEMENT THEO; Stroebe Margaret S., 1993, P175, DOI 10.1017/CBO9780511664076.013; Sullivan AM, 2003, J GEN INTERN MED, V18, P685, DOI 10.1046/j.1525-1497.2003.21215.x; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; TULSKY JA, 2003, GERIATRIC PALLIATIVE, P314; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; West JA, 1997, AM J CARDIOL, V79, P58, DOI 10.1016/S0002-9149(96)00676-5; Wieland D, 2000, J AM GERIATR SOC, V48, P1373, DOI 10.1111/j.1532-5415.2000.tb02625.x; Wieland D, 2001, J AM GERIATR SOC, V49, P835, DOI 10.1046/j.1532-5415.2001.49166.x; 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI DOI 10.1001/JAMA.1995.03530200027032	60	357	362	4	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2004	350	25					2582	2590		10.1056/NEJMcp035232	http://dx.doi.org/10.1056/NEJMcp035232			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	829NE	15201415				2023-01-03	WOS:000222054700009
J	Kirk, P; Kirk, I; Kristjanson, L				Kirk, P; Kirk, I; Kristjanson, L			What do patients receiving palliative care for cancer and their families want to be told? A Canadian and Australian qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFORMATION NEEDS; COMMUNICATION	Objective To obtain feedback from patients receiving palliative care and their relatives from various ethnic backgrounds about their experiences of the disclosure process and their satisfaction with information sharing during the illness. Design A qualitative study with semistructured single interviews. Setting Perth, Western Australia, and Winnipeg, Manitoba, Canada. Participants 72 participants registered with palliative care: 21 patient-family dyads in Perth and 14 dyads and 2 patients in Winnipeg. Results Participants described their experiences in great detail. The analysis indicates that in information sharing the process is as important as the content. The timing, management, and delivery of information and perceived attitude of practitioners were critical to the process. This applied to information interactions at all stages of the illness. Main content areas mentioned related to prognosis and hope. Hope can be conveyed in different ways. Secondary information from various sources is accessed and synthesised with the primary information. All patients, regardless of origin, wanted information about their illness and wanted it fully shared with relatives. Almost all patients requested prognostic information, and all family members respected their wishes. Information was perceived as important for patient-family communication. Information needs of patient and family changed and diverged as illness progressed, and communication between them became less verbally explicit. Conclusions Information delivery for patients needs to be individualised with particular attention to process at all stages of illness. Patients and families use secondary sources of information to complement and verify information given by health carers.	Univ Victoria, Isl Med Program, Victoria, BC V8N 1V7, Canada; Univ British Columbia, Isl Med Program, Victoria, BC V8N 1V7, Canada; Victoria Hospice Soc, Victoria, BC V8R 1J8, Canada; Edith Cowan Univ, Sch Nursing & Publ Hlth, Perth, WA 6018, Australia	University of Victoria; University of British Columbia; University of Victoria; Edith Cowan University	Kirk, P (corresponding author), Univ Victoria, Isl Med Program, Victoria, BC V8N 1V7, Canada.	clincoor@uvic.ca						Altheide David L., 1994, HDB QUALITATIVE RES, P485; Baile W F, 2000, Oncologist, V5, P302, DOI 10.1634/theoncologist.5-4-302; Bruera E, 2000, PALLIATIVE MED, V14, P287, DOI 10.1191/026921600674582192; BUTOW PN, 1997, ANN ONCOL, V8, P821; Christakis NicholasA., 1999, DEATH FORETOLD; Code K, 1997, Aust Nurs J, V5, P20; Crawley LM, 2002, ANN INTERN MED, V136, P673, DOI 10.7326/0003-4819-136-9-200205070-00010; Davies E, 2003, SUPPORT CARE CANCER, V11, P21, DOI 10.1007/s00520-002-0392-x; Faulkner Ann, 1994, TALKING CANC PATIENT; Glaster B. G., 1967, THEORETICAL SENSITIV; Hinton J, 1999, PALLIATIVE MED, V13, P19, DOI 10.1191/026921699672169546; Kutner JS, 1999, SOC SCI MED, V48, P1341, DOI 10.1016/S0277-9536(98)00453-5; Lincoln Y.S., 1985, NATURALISTIC INQUIRY; McIllmurray MB, 2001, EUR J CANCER CARE, V10, P261, DOI 10.1046/j.1365-2354.2001.00280.x; McPherson CJ, 2001, J PUBLIC HEALTH MED, V23, P227, DOI 10.1093/pubmed/23.3.227; Mystakidou Kyriaki, 2002, BMC Palliat Care, V1, P3, DOI 10.1186/1472-684X-1-3; Ptacek JT, 1996, JAMA-J AM MED ASSOC, V276, P496; Rose KE, 1999, J CLIN NURS, V8, P81, DOI 10.1046/j.1365-2702.1999.00214.x; Schouwstra J, 1997, ANN NY ACAD SCI, V809, P422, DOI 10.1111/j.1749-6632.1997.tb48105.x; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; SURBONE A, 1992, JAMA-J AM MED ASSOC, V268, P1661; VACHON MLS, 1995, J PAIN SYMPTOM MANAG, V10, P142, DOI 10.1016/0885-3924(94)00076-W; WEISSMAN AD, 1979, COPING CANC; Wong RKS, 2002, SUPPORT CARE CANCER, V10, P408, DOI 10.1007/s00520-002-0354-3	24	262	266	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	2004	328	7452					1343	1347		10.1136/bmj.38103.423576.55	http://dx.doi.org/10.1136/bmj.38103.423576.55			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828DH	15151964	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000221952700016
J	Stephenson, AJ; Shariat, SF; Zelefsky, MJ; Kattan, MW; Butler, EB; Teh, BS; Klein, EA; Kupelian, PA; Roehrborn, CG; Pistenmaa, DA; Pacholke, HD; Liauw, SL; Katz, MS; Leibel, SA; Scardino, PT; Slawin, KM				Stephenson, AJ; Shariat, SF; Zelefsky, MJ; Kattan, MW; Butler, EB; Teh, BS; Klein, EA; Kupelian, PA; Roehrborn, CG; Pistenmaa, DA; Pacholke, HD; Liauw, SL; Katz, MS; Leibel, SA; Scardino, PT; Slawin, KM			Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITIVE SURGICAL MARGINS; ANTIGEN DOUBLING TIMES; RADIATION-THERAPY; LOCAL RECURRENCE; RETROPUBIC PROSTATECTOMY; BIOCHEMICAL FAILURE; PROGRESSION; BIOPSY; PSA; ELEVATION	Context Salvage radiotherapy may potentially cure patients with disease recurrence after radical prostatectomy, but previous evidence has suggested that it is ineffective in patients at the highest risk of metastatic disease progression. Objective To delineate patients who may benefit from salvage radiotherapy for prostate cancer recurrence by identifying variables associated with a durable response. Design, Setting, and Patients Retrospective review of a cohort of 501 patients at 5 US academic tertiary referral centers who received salvage radiotherapy between June 1987 and November 2002 for detectable and increasing prostate-specific antigen (PSA) levels after radical prostatectomy. Main Outcome Measure Disease progression after salvage radiotherapy, defined as a serum PSA value greater than or equal to0.1 ng/mL above the postradiotherapy PSA nadir confirmed by a second PSA measurement that was higher than the first by any amount, by,a continued increase in PSA level after treatment, or by the initiation of androgen deprivation therapy after treatment. Results Over a median follow-up of 45 months, 250 patients (50%) experienced disease progression after treatment, 49 (10%) developed distant metastases, 20 (4%) died from prostate cancer, and 21 (4%) died from other or unknown causes. The 4-year progression-free probability (PFP) was 45% (95% confidence interval [01, 40%-50%). By multivariable analysis, predictors of progression were Gleason score of 8 to 10 (hazard ratio [HRI, 2.6; 95% Cl, 1.7-4.1; P<.001), preradiotherapy PSA level greater than 2.0 ng/mL (HR, 2.3; 95% Cl, 1.7-3.2; P<.001), negative surgical margins (HR, 1.9; 95% Cl, 1.4-2.5; P<.001), PSA doubling time (PSADT) of 10 months or less (HR, 1.7; 95% Cl, 1.2-2.2; P=.001), and seminal vesicle invasion (HR, 1.4; 95% Cl, 1.1-1.9; P=.02). Patients with no adverse features had a 4-year PFP of 77% (95% Cl, 64%-91%). When treatment was given for early recurrence (PSA level <= 2.0 ng/mL), patients with Gleason scores of 4 to 7 and a rapid PSADT had a 4-year PFP of 64% (95% Cl, 51%-76%) and of 22% (95% Cl, 6%-38%) when the surgical margins were positive and negative, respectively. Patients with Gleason scores of 8 to 10, positive margins, and receiving early salvage radiotherapy had a 4-year PFP of 81% (95% Cl, 57%-100%) when the PSADT was longer than 10 months and of 37% (95% Cl, 16%-58%) when the PSADT was 10 months or less. Conclusions Gleason score, preradiotherapy PSA level, surgical margins, PSADT, and seminal vesicle invasion are prognostic variables for a durable response to salvage radiotherapy. Selected patients with high-grade disease and/or a rapid PSADT who were previously thought to be destined to develop progressive metastatic disease may achieve a durable response to salvage radiotherapy.	Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; Mem Sloan Kettering Canc Ctr, Dept Urol, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Radiat Oncol, Dallas, TX USA; Cleveland Clin, Dept Urol, Cleveland, OH 44106 USA; Cleveland Clin, Dept Radiat Oncol, Cleveland, OH 44106 USA; Univ Florida, Dept Radiat Oncol, Gainesville, FL USA; Methodist Hosp, Houston, TX 77030 USA	Baylor College of Medicine; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cleveland Clinic Foundation; Cleveland Clinic Foundation; State University System of Florida; University of Florida; The Methodist Hospital System; The Methodist Hospital - Houston	Slawin, KM (corresponding author), Baylor Coll Med, Scott Dept Urol, 6535 Fannin St,Suite 2100, Houston, TX 77030 USA.	kslawin@bcm.tmc.edu	Kupelian, Patrick/AAU-6311-2021; Katz, Matthew/AAA-8899-2019; Katz, Matthew/AAS-7308-2020; Kattan, Michael/AAF-9735-2021	Katz, Matthew/0000-0002-0239-9807; Kattan, Michael/0000-0002-3840-4161; Zelefsky, Michael/0000-0002-6090-6424; Liauw, Stanley/0000-0002-4701-2469	NATIONAL CANCER INSTITUTE [T32CA082088, P50CA092629] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA-82088, CA-92629] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amling CL, 2001, J UROLOGY, V165, P1146, DOI 10.1016/S0022-5347(05)66452-X; Anscher MS, 2000, INT J RADIAT ONCOL, V48, P369, DOI 10.1016/S0360-3016(00)00645-3; Cadeddu JA, 1998, J UROLOGY, V159, P173, DOI 10.1016/S0022-5347(01)64047-3; Chawla AK, 2002, UROLOGY, V59, P726, DOI 10.1016/S0090-4295(02)01540-6; Cher ML, 1998, J UROLOGY, V160, P1387, DOI 10.1016/S0022-5347(01)62545-X; Cox JD, 1999, J CLIN ONCOL, V17, P1155; D'Amico AV, 2002, J CLIN ONCOL, V20, P4567, DOI 10.1200/JCO.2002.03.061; Eastham JA, 2003, J UROLOGY, V170, P2292, DOI 10.1097/01.ju.0000091100.83725.51; Eulau SM, 1998, INT J RADIAT ONCOL, V41, P735, DOI 10.1016/S0360-3016(98)00127-8; Forman JD, 1996, UROLOGY, V47, P382, DOI 10.1016/S0090-4295(99)80457-9; Grossfeld GD, 1998, J UROLOGY, V160, P1398, DOI 10.1016/S0022-5347(01)62548-5; Han M, 2001, UROL CLIN N AM, V28, P555, DOI 10.1016/S0094-0143(05)70163-4; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; Hull GW, 2002, J UROLOGY, V167, P528, DOI 10.1016/S0022-5347(01)69079-7; Katz MS, 2003, J CLIN ONCOL, V21, P483, DOI 10.1200/JCO.2003.12.043; Koppie TM, 2001, J UROLOGY, V166, P111, DOI 10.1016/S0022-5347(05)66087-9; Leventis AK, 2001, RADIOLOGY, V219, P432, DOI 10.1148/radiology.219.2.r01ma20432; Leventis AK, 2001, J CLIN ONCOL, V19, P1030, DOI 10.1200/JCO.2001.19.4.1030; Liauw SL, 2003, UROLOGY, V61, P1204, DOI 10.1016/S0090-4295(03)00044-X; LIGHTNER DJ, 1990, J UROLOGY, V144, P921, DOI 10.1016/S0022-5347(17)39623-4; Moul JW, 2000, J UROLOGY, V163, P1632, DOI 10.1016/S0022-5347(05)67511-8; Ornstein DK, 1998, UROLOGY, V52, P1047, DOI 10.1016/S0090-4295(98)00403-8; PARTIN AW, 1994, UROLOGY, V43, P649, DOI 10.1016/0090-4295(94)90180-5; Patel A, 1997, J UROLOGY, V158, P1441, DOI 10.1016/S0022-5347(01)64238-1; Pisansky TM, 2000, J UROLOGY, V163, P845, DOI 10.1016/S0022-5347(05)67817-2; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Pruthi RS, 1997, UROLOGY, V49, P737, DOI 10.1016/S0090-4295(97)00231-8; Ravery V, 1998, PROSTATE CANCER P D, V1, P321, DOI 10.1038/sj.pcan.4500261; Roberts SG, 2001, MAYO CLIN PROC, V76, P576; Rogers R, 1998, J UROLOGY, V160, P1748, DOI 10.1016/S0022-5347(01)62398-X; Shipley WU, 1999, JAMA-J AM MED ASSOC, V281, P1598, DOI 10.1001/jama.281.17.1598; Song DY, 2002, UROLOGY, V60, P281, DOI 10.1016/S0090-4295(02)01709-0; STEPHENSON AJ, 2003, P AM SOC LIN ONCOL, V22, pA1577; Thomas CT, 2003, J CLIN ONCOL, V21, P1715, DOI 10.1200/JCO.2003.05.138; Valicenti RK, 1998, UROLOGY, V52, P1034, DOI 10.1016/S0090-4295(98)00405-1; Wieder JA, 1998, J UROLOGY, V160, P299, DOI 10.1016/S0022-5347(01)62881-7; WU JJ, 1995, INT J RADIAT ONCOL, V32, P317, DOI 10.1016/0360-3016(95)00083-B; Zelefsky MJ, 2002, INT J RADIAT ONCOL, V53, P1111, DOI 10.1016/S0360-3016(02)02857-2; Zelefsky MJ, 1998, INT J RADIAT ONCOL, V41, P491, DOI 10.1016/S0360-3016(98)00091-1; ZINCKE H, 1994, J UROLOGY, V152, P1850, DOI 10.1016/S0022-5347(17)32399-6	40	528	543	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	2004	291	11					1325	1332		10.1001/jama.291.11.1325	http://dx.doi.org/10.1001/jama.291.11.1325			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	802PF	15026399	Bronze			2023-01-03	WOS:000220174700026
J	Traub, SJ; Hoffman, RS; Nelson, LS				Traub, SJ; Hoffman, RS; Nelson, LS			Body packing - The internal concealment of illicit drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							COCAINE-PACKET INGESTION; ABDOMINAL RADIOGRAPHY; MANAGEMENT; DIAGNOSIS; INTERVENTION; OBSTRUCTION; EXPERIENCE; SMUGGLER; TOXICITY; BOWEL		Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; NYU, Sch Med, Dept Emergency Med, Bellevue Hosp Ctr, New York, NY USA; New york City Poison Control Ctr, New York, NY USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Bellevue Hospital Center; New York University; Harvard University; Harvard Medical School	Traub, SJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA.	straub@bidmc.harvard.edu		Nelson, Lewis/0000-0001-9551-3922; Hoffman, Robert/0000-0002-0091-9573				Albertson TE, 2001, ANN EMERG MED, V37, pS78, DOI 10.1067/mem.2001.114174; Aldrighetti L, 1996, PANMINERVA MED, V38, P111; Alzen G, 1987, Rofo, V146, P544, DOI 10.1055/s-2008-1048536; BECK NE, 1993, BRIT J SURG, V80, P1513, DOI 10.1002/bjs.1800801205; BEERMAN R, 1986, GASTROINTEST RADIOL, V11, P351, DOI 10.1007/BF02035108; BOGUSZ MJ, 1995, J FORENSIC SCI, V40, P811; Bulstrode N, 2002, ANN ROY COLL SURG, V84, P35; CARUANA DS, 1984, ANN INTERN MED, V100, P73, DOI 10.7326/0003-4819-100-1-73; CLAFFEY M, 2002, NEW YORK DAILY NEWS, P5; DASSEL PM, 1979, GASTROENTEROLOGY, V76, P166; DEITEL M, 1973, CAN MED ASSOC J, V109, P211; DUNNE JW, 1983, MED J AUSTRALIA, V2, P436, DOI 10.5694/j.1326-5377.1983.tb122568.x; GHERARDI RK, 1988, LANCET, V1, P1076; Gill JR, 2002, J FORENSIC SCI, V47, P843; Hahn I., 1999, Journal of Toxicology Clinical Toxicology, V37, P644; HARTOKO TJ, 1988, KLIN WOCHENSCHR, V66, P1116, DOI 10.1007/BF01727846; HIERHOLZER J, 1995, ABDOM IMAGING, V20, P333, DOI 10.1007/BF00203366; HOFFMAN RS, 1990, AM J EMERG MED, V8, P523, DOI 10.1016/0735-6757(90)90155-S; Hollander JE, 2002, GOLDFRANKS TOXICOLOG, P1004; HORROCKS AW, 1992, CLIN RADIOL, V45, P322, DOI 10.1016/S0009-9260(05)80084-4; Hutchins KD, 2000, J FORENSIC SCI, V45, P42; JOHNSON JA, 1991, AM SURGEON, V57, P723; Jones OM, 2002, ANN ROY COLL SURG, V84, P131; June R, 2000, J EMERG MED, V18, P221, DOI 10.1016/S0736-4679(99)00198-5; KARHUNEN PJ, 1991, J FORENSIC SCI, V36, P397; KERSSCHOT EAJ, 1985, FORTSCHR RONTG NEUEN, V142, P295, DOI 10.1055/s-2008-1052652; Krishnan A, 1999, J ACCID EMERG MED, V16, P381; MARC B, 1992, J TOXICOL-CLIN TOXIC, V30, P387, DOI 10.3109/15563659209021554; MARC B, 1990, J FORENSIC SCI, V35, P345; MCCARRON MM, 1983, JAMA-J AM MED ASSOC, V250, P1417; MCCLEAVE NR, 1993, MED J AUSTRALIA, V159, P750, DOI 10.5694/j.1326-5377.1993.tb141338.x; Olmedo R, 2001, AM J EMERG MED, V19, P593, DOI 10.1053/ajem.2001.21720; *PERS SEARCH REV C, 2000, REP PERS SEARCH US C; Pidoto RR, 2002, J EMERG MED, V23, P149, DOI 10.1016/S0736-4679(02)00505-X; PINSKY MF, 1978, J CAN ASSOC RADIOL, V29, P79; ROBINSON T, 1993, SURGERY, V113, P709; Shrethra, 2000, J TOXICOL-CLIN TOXIC, V2000, P176; SUAREZ CA, 1977, JAMA-J AM MED ASSOC, V238, P1391, DOI 10.1001/jama.238.13.1391; TOMASZEWSKI C, 1993, ANN EMERG MED, V22, P1804, DOI 10.1016/S0196-0644(05)80404-4; Traub SJ, 2003, AM J EMERG MED, V21, P607, DOI 10.1016/S0735-6757(03)00170-0; Traub SJ, 2003, AM J EMERG MED, V21, P511, DOI 10.1016/S0735-6757(03)00171-2; Traub SJ, 2003, ARCH PEDIAT ADOL MED, V157, P174, DOI 10.1001/archpedi.157.2.174; Utecht Michael J., 1993, Journal of Emergency Medicine, V11, P33, DOI 10.1016/0736-4679(93)90007-T; Visser L, 1998, LANCET, V352, P1352, DOI 10.1016/S0140-6736(98)08302-0; Wackerle B, 1986, Rofo, V145, P274, DOI 10.1055/s-2008-1048932; WATSON CJE, 1991, J ROY SOC MED, V84, P311, DOI 10.1177/014107689108400524; WETLI CV, 1981, J FORENSIC SCI, V26, P492; WHITE N, 1988, NATURE, V335, P19, DOI 10.1038/335019a0; Wilgoren J., 1998, NY TIMES        1206, P62; 1997, US CUSTOMS NEWS  JUN	50	190	200	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 25	2003	349	26					2519	2526		10.1056/NEJMra022719	http://dx.doi.org/10.1056/NEJMra022719			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757BT	14695412				2023-01-03	WOS:000187529500007
J	Xue, LY; Chiu, SM; Fiebig, A; Andrews, DW; Oleinick, NL				Xue, LY; Chiu, SM; Fiebig, A; Andrews, DW; Oleinick, NL			Photodamage to multiple Bcl-xL isoforms by photodynamic therapy with the phthalocyanine photosensitizer Pc 4	ONCOGENE			English	Article						Bcl-xL; Bcl-2; apoptosis; photodynamic; therapy; Pc 4	ENDOPLASMIC-RETICULUM; INDUCED APOPTOSIS; CELLS; BCL-X(L); OVEREXPRESSION; ONCOPROTEIN; RESISTANCE; INDUCTION; MEMBERS; FAMILY	The antiapoptotic oncoprotein Bcl-2 is now a recognized phototarget of photodynamic therapy (PDT) with the phthalocyanine Pc 4 and with other mitochondrion-targeting photosensitizers. Photodamage, observed on Western blots as the loss of the native 26-kDa Bcl-2 protein, is PDT dose dependent and occurs in multiple cell lines, in the cold, and immediately upon photoirradiation. In our initial study, no photochemical damage was observed to Bcl-xL, in spite of its similarity in size, sequence, location and function to Bcl-2. The original study used a commercial anti-Bcl-xS/L antibody. We have revisited this issue by examining Western blots developed using one of three epitope-specific anti-Bcl-xL antibodies from commercial sources, a polyclonal antibody generated to the entire protein, as well as the antibody used previously. All five Bcl-xL antibodies recognized bacterially expressed Bcl-xL, but not Bcl-2, whereas an anti-Bcl-2 antibody recognized Bcl-2 and not Bcl-xL. All five Bcl-xL antibodies recognized at least one protein migrating at similar to30 kDa; two of the antibodies recognized an additional band, migrating at similar to33 or similar to24 kDa. We now observe Pc 4-PDT-induced photo-damage to all Bcl-xL-related proteins, except the 33-kDa species, in several human cancer cell lines. The results indicate that, in addition to the expected quantitative differences that may reflect exposure of individual epitopes, the antibodies also detect proteins of different apparent molecular weights that may be distinct isoforms or post-translationally modified forms of Bcl-xL. No evidence for PDT-induced phosphorylation or degradation was observed. Bcl-xL localized to mitochondria was considerably more sensitive to photodamage than was Bcl-xL in the cytosol, indicating that as previously found for Bcl-2, Bcl-xL must be membrane localized to be photosensitive.	Case Western Reserve Univ, Sch Med BRB324, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, CWRU Ireland Comprehens Canc Ctr, Cleveland, OH USA; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	Case Western Reserve University; Case Western Reserve University; McMaster University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med BRB324, Dept Radiat Oncol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	nlo@po.cwru.edu		Andrews, David/0000-0002-9266-7157	NATIONAL CANCER INSTITUTE [R01CA083917, P01CA048735, P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA83917, P01 CA48735, P30 CA43703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; FANG W, 1994, J IMMUNOL, V153, P4388; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 2001, PHOTOCHEM PHOTOBIOL, V74, P318, DOI 10.1562/0031-8655(2001)074<0318:ETBITT>2.0.CO;2; Kim HRC, 1999, CANCER RES, V59, P3429; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200; Li XY, 2001, CANCER RES, V61, P1699; Liu QY, 1997, CLIN CANCER RES, V3, P2039; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; Srivastava M, 2001, J BIOL CHEM, V276, P15481, DOI 10.1074/jbc.M006920200; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; Usuda J, 2003, PHOTOCHEM PHOTOBIOL, V78, P1, DOI 10.1562/0031-8655(2003)078<0001:ABTPLO>2.0.CO;2; Usuda J, 2003, J BIOL CHEM, V278, P2021, DOI 10.1074/jbc.M205219200; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; Ye QR, 2002, J EXP MED, V196, P87, DOI 10.1084/jem.20012084	32	53	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9197	9204		10.1038/sj.onc.1207019	http://dx.doi.org/10.1038/sj.onc.1207019			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681679				2023-01-03	WOS:000187400400001
J	Finger, C				Finger, C			Health care in indigenous populations: The Xingu Indian park	LANCET			English	Article											Finger, C (corresponding author), R Pascoat Vita 405,Apt 83, BR-05445000 Sao Paulo, Brazil.								0	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S38	S39		10.1016/S0140-6736(03)15070-2	http://dx.doi.org/10.1016/S0140-6736(03)15070-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698124				2023-01-03	WOS:000187790200020
J	Hadley, EC; Lakatta, EG; Morrison-Bogorad, M; Warner, HR; Hodes, RJ				Hadley, EC; Lakatta, EG; Morrison-Bogorad, M; Warner, HR; Hodes, RJ			The future of aging therapies	CELL			English	Review							CARDIOVASCULAR-DISEASE ENTERPRISES; MILD COGNITIVE IMPAIRMENT; CONTROLS OXIDATIVE STRESS; AMES DWARF MICE; LIFE-SPAN; CAENORHABDITIS-ELEGANS; ALZHEIMERS-DISEASE; CALORIE RESTRICTION; TRANSGENIC MICE; C-ELEGANS	Advances in understanding aging processes and their consequences are leading to the development of therapies to slow or reverse adverse changes formerly considered to be "normal" aging and processes that underlie multiple age-related conditions. Estimating the effectiveness of candidate aging therapies, whose effects on human aging may require many years to determine, is a particular challenge. Strategies for identifying candidate interventions can be developed through multiple approaches, including the screening of molecular targets and pathways in vitro and in animal models, informed as well by evidence from human genetic and epidemiologic data. A number of recently established programs and networks can serve as resources for such research. For all these research approaches, from in vitro molecular studies to clinical trials, contributions of cell and molecular biology are crucial and offer the prospect of therapeutic advances that address fundamental biological processes as well as the clinically important challenges of aging.	NIA, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Hadley, EC (corresponding author), NIA, NIH, Bethesda, MD 20892 USA.	ehadley@nih.gov	Lakatta, Edward G/AAL-1447-2020	Lakatta, Edward/0000-0002-4772-0035	NATIONAL CANCER INSTITUTE [Z01BC009405, ZIABC009405] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ames BN, 2004, ANN NY ACAD SCI, V1019, P406, DOI 10.1196/annals.1297.073; Anson RM, 2003, P NATL ACAD SCI USA, V100, P6216, DOI 10.1073/pnas.1035720100; Atzmon G, 2004, J AM GERIATR SOC, V52, P274, DOI 10.1111/j.1532-5415.2004.52068.x; Barzilai N, 2003, JAMA-J AM MED ASSOC, V290, P2030, DOI 10.1001/jama.290.15.2030; Bauer JH, 2004, P NATL ACAD SCI USA, V101, P12980, DOI 10.1073/pnas.0403493101; Blalock EM, 2004, P NATL ACAD SCI USA, V101, P2173, DOI 10.1073/pnas.0308512100; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Butler RN, 2004, J GERONTOL A-BIOL, V59, P560; Carter CS, 2002, J GERONTOL A-BIOL, V57, pB177, DOI 10.1093/gerona/57.5.B177; Cawthon RM, 2003, LANCET, V361, P393, DOI 10.1016/S0140-6736(03)12384-7; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; ESQUIFINO AI, 1991, ACTA ENDOCRINOL-COP, V125, P67, DOI 10.1530/acta.0.1250067; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; Floyd RA, 2002, MECH AGEING DEV, V123, P1021, DOI 10.1016/S0047-6374(01)00385-2; Garigan D, 2002, GENETICS, V161, P1101; Garsin DA, 2003, SCIENCE, V300, P1921, DOI 10.1126/science.1080147; Gates PE, 2004, HYPERTENSION, V44, P35, DOI 10.1161/01.HYP.0000132767.74476.64; Geesaman BJ, 2003, P NATL ACAD SCI USA, V100, P14115, DOI 10.1073/pnas.1936249100; Gill MS, 2003, FREE RADICAL BIO MED, V35, P558, DOI 10.1016/S0891-5849(03)00328-9; Golden TR, 2002, AGING CELL, V1, P117, DOI 10.1046/j.1474-9728.2002.00015.x; Grundman M, 2004, ARCH NEUROL-CHICAGO, V61, P59, DOI 10.1001/archneur.61.1.59; Hadley EC, 2005, MECH AGEING DEV, V126, P231, DOI 10.1016/j.mad.2004.08.014; Hadley EC, 2001, J GERONTOL A-BIOL, V56, P5, DOI 10.1093/gerona/56.suppl_1.5; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harper JM, 2004, MECH AGEING DEV, V125, P381, DOI 10.1016/j.mad.2004.03.003; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Herndon LA, 2002, NATURE, V419, P808, DOI 10.1038/nature01135; Hitt R, 1999, LANCET, V354, P652, DOI 10.1016/S0140-6736(99)01987-X; Hodis HN, 2002, CIRCULATION, V106, P1453, DOI 10.1161/01.CIR.0000029092.99946.08; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Ikeno Y, 2003, J GERONTOL A-BIOL, V58, P291; Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; Ishii N, 2004, MECH AGEING DEV, V125, P41, DOI 10.1016/j.mad.2003.10.002; Kass DA, 2001, CIRCULATION, V104, P1464, DOI 10.1161/hc3801.097806; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Knauf F, 2002, P NATL ACAD SCI USA, V99, P14315, DOI 10.1073/pnas.222531899; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lakatta EG, 2003, CIRCULATION, V107, P139, DOI 10.1161/01.CIR.0000048892.83521.58; Lakatta EG, 2003, CIRCULATION, V107, P490, DOI 10.1161/01.CIR.0000048894.99865.02; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lee CK, 2004, FREE RADICAL BIO MED, V36, P1043, DOI 10.1016/j.freeradbiomed.2004.01.015; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Liang HY, 2003, EXP GERONTOL, V38, P1353, DOI 10.1016/j.exger.2003.10.019; Lichtenthaler SF, 2004, J CLIN INVEST, V113, P1384, DOI 10.1172/JCI200421746; Lim GP, 2001, NEUROBIOL AGING, V22, P983, DOI 10.1016/S0197-4580(01)00299-8; LITHGOW GJ, 2003, AGING KNOWLEDGE ENV, V25, DOI DOI 10.1126/SAGEKE.2003.25.PE16; Marden JH, 2003, P NATL ACAD SCI USA, V100, P3369, DOI 10.1073/pnas.0634985100; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Milgram NW, 2004, EXP GERONTOL, V39, P753, DOI 10.1016/j.exger.2004.01.007; Miller R A, 2001, Sci Aging Knowledge Environ, V2001, ppe2; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Mitsui A, 2002, ANTIOXID REDOX SIGN, V4, P693, DOI 10.1089/15230860260220201; Mufson EJ, 2002, J COMP NEUROL, V443, P136, DOI 10.1002/cne.10122; Munoz MJ, 2003, MECH AGEING DEV, V124, P43, DOI 10.1016/S0047-6374(02)00168-9; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Price JL, 2001, ARCH NEUROL-CHICAGO, V58, P1395, DOI 10.1001/archneur.58.9.1395; Roberts SB, 2001, J GERONTOL A-BIOL, V56, P66, DOI 10.1093/gerona/56.suppl_1.66; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Smith DE, 1999, P NATL ACAD SCI USA, V96, P10893, DOI 10.1073/pnas.96.19.10893; Spinetti G, 2004, ARTERIOSCL THROM VAS, V24, P1397, DOI 10.1161/01.ATV.0000134529.65173.08; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Tanzi RE, 2004, NEURON, V43, P605, DOI 10.1016/j.neuron.2004.08.024; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Thinakaran G, 2004, PHARMACOL RES, V50, P411, DOI 10.1016/j.phrs.2003.12.026; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; VAITKEVICIUS PV, 1993, CIRCULATION, V88, P1456, DOI 10.1161/01.CIR.88.4.1456; Vaitkevicius PV, 2001, P NATL ACAD SCI USA, V98, P1171, DOI 10.1073/pnas.98.3.1171; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Wang MY, 2003, HYPERTENSION, V41, P1308, DOI 10.1161/01.HYP.0000073843.56046.45; Warner HR, 2004, J GERONTOL A-BIOL, V59, P692; WARNER HR, 2003, SCI AGING KNOWLEDGE, DOI DOI 10.1126/SAGEKE.2003.6.REL; Warner Huber R., 2000, Mechanisms of Ageing and Development, V115, P199, DOI 10.1016/S0047-6374(00)00118-4; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789	93	67	69	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	2005	120	4					557	567		10.1016/j.cell.2005.01.030	http://dx.doi.org/10.1016/j.cell.2005.01.030			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	901GR	15734687	Bronze			2023-01-03	WOS:000227271500012
J	Choudhry, NK; Fletcher, RH; Soumerai, SB				Choudhry, NK; Fletcher, RH; Soumerai, SB			Systematic review: The relationship between clinical experience and quality of health care	ANNALS OF INTERNAL MEDICINE			English	Review							PHYSICIAN CHARACTERISTICS; PRACTICE BEHAVIORS; DIABETES-MELLITUS; PRACTICE PATTERNS; KNOWLEDGE-BASE; MEDICALLY ILL; OF-CARE; PATIENT; MANAGEMENT; MORTALITY	Background: Physicians with more experience are generally believed to have accumulated knowledge and skills during years in practice and therefore to deliver high-quality care. However, evidence suggests that there is an inverse relationship between the number of years that a physician has been in practice and the quality of care that the physician provides. Purpose: To systematically review studies relating medical knowledge and health care quality to years in practice and physician age. Data Sources: English-language articles in MEDLINE from 1966 to June 2004 and reference lists of retrieved articles. Study Selection: Studies that provided empirical results about knowledge or a quality-of-care outcome and included years since graduation or physician age as explanatory variables. Data Extraction: We categorized studies on the basis of the nature of the association between years in practice or age and performance. Data Synthesis: Overall, 32 of the 62 (52%) evaluations reported decreasing performance with increasing years in practice for all outcomes assessed; 13 (21%) reported decreasing performance with increasing experience for some outcomes but no association for others; 2 (3%) reported that performance initially increased with increasing experience, peaked, and then decreased (concave relationship); 13 (21%) reported no association, 1 (2%) reported increasing performance with increasing years in practice for some outcomes but no association for others; and 1 (2%) reported increasing performance with increasing years in practice for all outcomes. Results did not change substantially when the analysis was restricted to studies that used the most objective outcome measures. Limitations: Because of the lack of reliable search terms for physician experience, reports that provided relevant data may have been missed. Conclusions: Physicians who have been in practice longer may be at risk for providing lower-quality care. Therefore, this subgroup of physicians may need quality improvement interventions.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Brigham & Womens Hosp, Harvard Pilgrim Hlth Care, Boston, MA 02115 USA; Harvard Univ, PhD Program Hlth Policy, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Brigham & Women's Hospital; Harvard University	Choudhry, NK (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA.	choudhry@fas.harvard.edu	Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285				Anderson G M, 1997, J Eval Clin Pract, V3, P283, DOI 10.1046/j.1365-2753.1997.t01-1-00005.x; Anis NA, 2004, PREV MED, V38, P198, DOI 10.1016/j.ypmed.2003.09.046; AUBIN M, 1994, CAN MED ASSOC J, V150, P509; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; Beaulieu MD, 2001, QJM-INT J MED, V94, P301, DOI 10.1093/qjmed/94.6.301; BECKER MH, 1971, HEALTH SERV REP, V86, P993, DOI 10.2307/4594369; BEERS MH, 1993, J AM GERIATR SOC, V41, P802, DOI 10.1111/j.1532-5415.1993.tb06173.x; Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205; Blanc PD, 2003, AM J MED, V114, P581, DOI 10.1016/S0002-9343(03)00053-6; BLANCHARD CG, 1990, CANCER, V65, P186, DOI 10.1002/1097-0142(19900101)65:1<186::AID-CNCR2820650136>3.0.CO;2-4; BURNS LR, 1991, MED CARE, V29, P251, DOI 10.1097/00005650-199103000-00007; Carthy P, 2000, FAM PRACT, V17, P36, DOI 10.1093/fampra/17.1.36; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Cook RL, 2001, J ADOLESCENT HEALTH, V28, P204, DOI 10.1016/S1054-139X(00)00152-X; CRUFT GE, 1981, ARCH SURG-CHICAGO, V116, P1093; CZAJA R, 1994, ANN INTERN MED, V120, P602, DOI 10.7326/0003-4819-120-7-199404010-00012; DAVIDSON W, 1995, CAN MED ASSOC J, V152, P1227; Dhalla IA, 2002, J AM GERIATR SOC, V50, P995, DOI 10.1046/j.1532-5415.2002.50252.x; Ely J W, 1998, Fam Med, V30, P34; Epstein SA, 2001, PSYCHOSOMATICS, V42, P482, DOI 10.1176/appi.psy.42.6.482; Epstein SA, 1996, PSYCHOSOMATICS, V37, P356, DOI 10.1016/S0033-3182(96)71549-9; EVANS CE, 1984, CAN MED ASSOC J, V130, P719; Fehrenbach SN, 2001, AM J MANAG CARE, V7, P717; FORD LG, 1987, J CLIN ONCOL, V5, P504, DOI 10.1200/JCO.1987.5.3.504; FREIMAN MP, 1985, MED CARE, V23, P939, DOI 10.1097/00005650-198508000-00001; Geller SE, 1996, HEALTH SERV RES, V30, P729; GEMSON DH, 1991, ARCH INTERN MED, V151, P1102, DOI 10.1001/archinte.151.6.1102; Golden NH, 2001, PEDIATRICS, V107, P287, DOI 10.1542/peds.107.2.287; Greer A L, 1988, Int J Technol Assess Health Care, V4, P5; GRIMSHAW JM, 2001, MED CARE S, V39, P112; HALL JA, 1994, MED CARE, V32, P1216, DOI 10.1097/00005650-199412000-00005; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Hartz AJ, 1999, MED CARE, V37, P93, DOI 10.1097/00005650-199901000-00013; Heath K, 1997, INT J STD AIDS, V8, P609, DOI 10.1258/0956462971918869; HLATKY MA, 1988, AM J CARDIOL, V61, P510, DOI 10.1016/0002-9149(88)90755-2; HULKA BS, 1976, AM J PUBLIC HEALTH, V66, P1173, DOI 10.2105/AJPH.66.12.1173; HYNES DM, 1994, MED CARE, V32, P328, DOI 10.1097/00005650-199404000-00002; Jackson JL, 2001, SOC SCI MED, V52, P609, DOI 10.1016/S0277-9536(00)00164-7; JACQUES CHM, 1991, DIABETES CARE, V14, P712, DOI 10.2337/diacare.14.8.712; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; Jha AK, 2003, NEW ENGL J MED, V348, P2218, DOI 10.1056/NEJMsa021899; Katon W, 2000, MED CARE, V38, P552, DOI 10.1097/00005650-200006000-00002; KENNY SJ, 1993, DIABETES CARE, V16, P1507, DOI 10.2337/diacare.16.11.1507; LEWIS CE, 1987, AM J PUBLIC HEALTH, V77, P795, DOI 10.2105/AJPH.77.7.795; Marrero D G, 1991, J Community Health, V16, P259, DOI 10.1007/BF01320334; MCFALL SL, 1994, MED CARE, V32, P106, DOI 10.1097/00005650-199402000-00002; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; MESKAUSKAS JA, 1975, ANN INTERN MED, V82, P577, DOI 10.7326/0003-4819-82-4-577; Montaner J S, 1996, Antivir Ther, V1, P157; Moride Y, 2002, J AM GERIATR SOC, V50, P1365, DOI 10.1046/j.1532-5415.2002.50357.x; Norcini JJ, 2000, ACAD MED, V75, P1193, DOI 10.1097/00001888-200012000-00016; NORCINI JJ, 1985, ANN INTERN MED, V102, P385, DOI 10.7326/0003-4819-102-3-385; O'Neill L, 2000, NEUROLOGY, V55, P773, DOI 10.1212/WNL.55.6.773; PAYNE BC, 1984, HEALTH SERV RES, V19, P307; RAMSEY PG, 1991, JAMA-J AM MED ASSOC, V266, P1103, DOI 10.1001/jama.266.8.1103; Rattay KT, 2004, OBES RES, V12, P161, DOI 10.1038/oby.2004.21; RAY WA, 1976, ANN INTERN MED, V84, P266, DOI 10.7326/0003-4819-84-3-266; RHEE SO, 1976, MED CARE, V14, P733, DOI 10.1097/00005650-197609000-00002; Richards C, 1998, AM J PREV MED, V15, P246, DOI 10.1016/S0749-3797(98)00075-0; Roetzheim R G, 1991, J Fla Med Assoc, V78, P426; Roy-Byrne Peter, 2002, J Am Board Fam Pract, V15, P443; SALEMSCHATZ SR, 1990, JAMA-J AM MED ASSOC, V264, P476, DOI 10.1001/jama.264.4.476; SANAZARO PJ, 1985, MED CARE, V23, P1097, DOI 10.1097/00005650-198509000-00007; Saraiya M, 2002, AM J PUBLIC HEALTH, V92, P826, DOI 10.2105/AJPH.92.5.826; Schmittdiel J, 1997, JAMA-J AM MED ASSOC, V278, P1596, DOI 10.1001/jama.278.19.1596; Schroen AT, 2000, CHEST, V118, P129, DOI 10.1378/chest.118.1.129; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; SCHWARTZ JS, 1991, ANN INTERN MED, V114, P46, DOI 10.7326/0003-4819-114-1-46; SHAPIRO JA, 1989, BRIT MED J, V298, P1563, DOI 10.1136/bmj.298.6687.1563; SHERMAN SE, 1993, J GEN INTERN MED, V8, P243, DOI 10.1007/BF02600089; Skotniski EM, 1996, CAN J PUBLIC HEALTH, V87, P172; Stolley P D, 1972, Med Care, V10, P17, DOI 10.1097/00005650-197201000-00003; Streja DA, 1999, ARCH INTERN MED, V159, P294, DOI 10.1001/archinte.159.3.294; Thompson JW, 2003, JAMA-J AM MED ASSOC, V290, P1486, DOI 10.1001/jama.290.11.1486; Tu JV, 2001, JAMA-J AM MED ASSOC, V285, P3116, DOI 10.1001/jama.285.24.3116; Willison DJ, 2000, MED CARE, V38, P1092, DOI 10.1097/00005650-200011000-00004; YOUNG MJ, 1987, HEALTH SERV RES, V22, P623; Zerr DM, 1999, PEDIATR INFECT DIS J, V18, P232, DOI 10.1097/00006454-199903000-00005	79	892	914	1	45	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2005	142	4					260	273		10.7326/0003-4819-142-4-200502150-00008	http://dx.doi.org/10.7326/0003-4819-142-4-200502150-00008			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	900UJ	15710959				2023-01-03	WOS:000227239500004
J	Underwood, M				Underwood, M		UK BEAM Trial Team	United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: effectiveness of physical treatments for back pain in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSIOTHERAPY; FRAMEWORK; BELIEFS; THERAPY; PACKAGE	Objective To estimate the effect of adding exercise classes, spinal manipulation delivered in NHS or private premises, or manipulation followed by exercise to "best care" in general practice for patients consulting with back pain. Design Pragmatic randomised trial with factorial design. Setting 181 general practices in Medical Research Council General Practice Research Framework; 63 community settings around 14 centres across the United Kingdom. Participants 1334 patients consulting their general practices about low back pain. Main outcome measures Scores on the Roland Morris disability questionnaire at three and 12 months, adjusted for centre and baseline scores. Results All groups improved over time. Exercise improved mean disability questionnaire scores at three months by 1.4 (95% confidence interval 0.6 to 2.1) more than "best care." For manipulation the additional improvement was 1.6 (0.8 to 2.3) at three months and 1.0 (0.2 to 1.8) at 12 months. For manipulation followed by exercise the additional improvement was 1.9 (1.2 to 2.6) at three months and 1.3 (0.5 to 2.1) at 12 months. No significant differences in Outcome occurred between manipulation in NHS premises and in private premises. No serious adverse events occur-red. Conclusions Relative to "best care" in general practice, manipulation followed by exercise achieved a moderate benefit at three months and a small benefit at 12 months; spinal manipulation achieved a small to moderate benefit at three months and a small benefit at 12 months; and exercise achieved a small benefit at three months but not at 12 months.	Queen Mary Univ London, Barts & London Queen Marys Sch Med & Dent, Inst Community Hlth Sci, Ctr Gen Practice & Primary Care, London E1 4NS, England	University of London; Queen Mary University London	Underwood, M (corresponding author), Queen Mary Univ London, Barts & London Queen Marys Sch Med & Dent, Inst Community Hlth Sci, Ctr Gen Practice & Primary Care, London E1 4NS, England.	m.undenvood@qmul.ac.uk	Russell, Ian T/H-1181-2012; Underwood, Martin/D-6364-2015	Underwood, Martin/0000-0002-0309-1708				Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; ASSENDELFT WJJ, 1991, J MANIP PHYSIOL THER, V14, P281; Bombardier C, 2001, J RHEUMATOL, V28, P431; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; Harvey E, 2003, MANUAL THER, V8, P46, DOI 10.1054/math.2002.0472; KLABERMOFFETT J, 1999, BRIT MED J, V319, P279; KNIPSCHILD P, 1991, J CLIN EPIDEMIOL, V44, P461, DOI 10.1016/0895-4356(91)90208-Q; Koes BW, 2001, SPINE, V26, P2504, DOI 10.1097/00007632-200111150-00022; Manca A, 2004, BMJ-BRIT MED J, V329, P1381, DOI 10.1136/bmj.38282.607859.AE; Maniadakis N, 2000, PAIN, V84, P95, DOI 10.1016/S0304-3959(99)00187-6; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; MOFFETT JK, 2000, PHYSIOTHERAPY, V85, P295; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Roland M, 2000, BACK BOOK; Russell I, 2003, BMC HEALTH SERV RES, V3; Symonds TL, 1996, OCCUP MED-OXFORD, V46, P25, DOI 10.1093/occmed/46.1.25; Underwood M, 2002, FAM PRACT, V19, P511, DOI 10.1093/fampra/19.5.511; Underwood MR, 1999, SPINE, V24, P1104, DOI 10.1097/00007632-199906010-00010; van Tulder M, 2000, SPINE, V25, P2784, DOI 10.1097/00007632-200011010-00011; vanTulder MW, 1997, SPINE, V22, P2128, DOI 10.1097/00007632-199709150-00012; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; Waddell G, 1999, LOW BACK PAIN EVIDEN; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	24	275	277	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	2004	329	7479					1377	1381		10.1136/bmj.38282.669225AE	http://dx.doi.org/10.1136/bmj.38282.669225AE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	880JB	15556955				2023-01-03	WOS:000225785000020
J	Fanos, V; Cataldi, L				Fanos, V; Cataldi, L			Antibiotics or surgery for vesicoureteric reflux in children	LANCET			English	Review							URINARY-TRACT-INFECTION; SURGICAL-TREATMENT; RANDOMIZED TRIAL; YOUNG-CHILDREN; INFANTS; HYDRONEPHROSIS; NEPHROPATHY; PREVENTION; MANAGEMENT; DIAGNOSIS	Context 1-2% of children have vesicoureteric reflux (VUR). VUR occurs in 25-40% of children with acute pyelonephritis. VUR can lead to renal scarring, hypertension, and end-stage renal disease. The best form of treatment for children with VUR is debated: no treatment, long-term antibiotic prophylaxis, surgery, or a combination of antibiotic prophylaxis and surgery. In children with recurrent urinary tract infections (UTIs) and progressive renal damage, despite antibiotic prophylaxis, surgical correction of VUR, especially high-grade VUR, is generally recommended. Starting point Danielle Wheeler and colleagues recently did a meta-analysis of ten randomised controlled trials (964 children) to evaluate whether any intervention for VUR is better than no treatment (Cochrane Database Syst Rev 2004; 3: CD001532). The main endpoints were incidence of UTIs, new or progressive renal damage, renal growth, hypertension, and glomerular filtration rate. They concluded that it is uncertain whether the identification of children with VUR is associated with clinically important benefit. The additional benefit of surgery over antibiotics is small. Where next? New strategies for management will require a tailored diagnostic and therapeutic approach, including noninvasive or less invasive diagnostic procedures, and a less aggressive therapeutic approach. Whether the common practice of cystourethrography as a first-fine investigation is warranted needs evaluation. The goal of paediatricians in the future, to prevent kidney damage, will probably be prevention of renal parenchymal injury and not necessarily the correction of ureterovesical junction anomalies. Because two main clinical pictures of VUR (diagnosed prenatally or postnatally with different age and sex distribution) can be identified, boys and girls will probably be managed differently. The factors responsible for congenital and acquired renal injury in children with VUR need to be studied.	Univ Cagliari, Neonatal Intens Care Unit, I-09124 Cagliari, Italy; Sacred Heart Univ Rome, Policlin A Gemelli, Div Neonatol, Rome, Italy	University of Cagliari; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Fanos, V (corresponding author), Univ Cagliari, Neonatal Intens Care Unit, I-09124 Cagliari, Italy.	vafanos@tiscali.it	Fanos, Vassilios/AHI-0685-2022	Fanos, Vassilios/0000-0003-2617-2890				[Anonymous], 1987, Br Med J (Clin Res Ed), V295, P237; Arant BS, 2001, J PEDIATR-US, V139, P620, DOI 10.1067/mpd.2001.119451; Bergman DA, 1999, PEDIATRICS, V103, P843; Bosio M, 1998, PEDIATR RADIOL, V28, P250, DOI 10.1007/s002470050343; Cataldi Luigi, 2002, Rays, V27, P93; Chand DH, 2003, J UROLOGY, V170, P1548, DOI 10.1097/01.ju.0000084299.55552.6c; Chertin B, 2003, J UROLOGY, V169, P1804, DOI 10.1097/01.ju.0000058428.00284.d5; Chertin B, 2002, EUR UROL, V42, P598, DOI 10.1016/S0302-2838(02)00447-5; Fanos V, 1999, DRUG SAFETY, V20, P245, DOI 10.2165/00002018-199920030-00005; Fanos V, 2000, ACTA PAEDIATR, V89, P900, DOI 10.1080/080352500750043305; Haszon I, 2002, PEDIATR NEPHROL, V17, P1027, DOI 10.1007/s00467-002-0968-1; Hellerstein S, 2000, CURR OPIN PEDIATR, V12, P125, DOI 10.1097/00008480-200004000-00007; Hoberman A, 2003, NEW ENGL J MED, V348, P195, DOI 10.1056/NEJMoa021698; Hollowell JG, 2002, J UROLOGY, V168, P2138, DOI 10.1016/S0022-5347(05)64337-6; Jantunen ME, 2002, J INFECT DIS, V185, P375, DOI 10.1086/338771; Jodal Ulf, 2004, J Pediatr, V144, P405; Kerr KG, 1999, LANCET, V353, P673, DOI 10.1016/S0140-6736(05)75468-4; Kobayashi H, 1997, EUR UROL, V31, P343; Konda R, 1997, J UROLOGY, V157, P2282, DOI 10.1016/S0022-5347(01)64763-3; Kontiokari T, 2001, BMJ-BRIT MED J, V322, P1571, DOI 10.1136/bmj.322.7302.1571; Lightner Deborah J, 2002, Curr Opin Urol, V12, P333, DOI 10.1097/00042307-200207000-00012; Marra G, 2004, J PEDIATR-US, V144, P677, DOI 10.1016/j.jpeds.2004.01.043; McKenna P H, 2000, Curr Opin Urol, V10, P599, DOI 10.1097/00042307-200011000-00011; Nakai H, 2003, J UROLOGY, V169, P309, DOI 10.1016/S0022-5347(05)64113-4; NOE HN, 1992, J UROLOGY, V148, P1869, DOI 10.1016/S0022-5347(17)37053-2; Phan V, 2003, PEDIATR NEPHROL, V18, P1224, DOI 10.1007/s00467-003-1287-x; Piepsz A, 1998, EUR J PEDIATR, V157, P753, DOI 10.1007/s004310050929; REDDY PP, 1997, P AAP PEDIAT S; ROSENBERG AR, 1992, J UROLOGY, V148, P1746, DOI 10.1016/S0022-5347(17)37019-2; Schwab CW, 2002, J UROLOGY, V168, P2594, DOI 10.1016/S0022-5347(05)64225-5; Smellie JM, 2001, LANCET, V357, P1329, DOI 10.1016/S0140-6736(00)04520-7; Smellie JM, 2001, J PEDIATR-US, V139, P656, DOI 10.1067/mpd.2001.117583; Vallee JP, 1999, UROLOGY, V53, P812, DOI 10.1016/S0090-4295(98)00587-1; Wennerstrom M, 1998, ARCH PEDIAT ADOL MED, V152, P879; Wheeler DM., 2004, COCHRANE DB SYST REV, V3, DOI [10.1002/14651858.CD001532.pub2, DOI 10.1002/14651858.CD001532.PUB2, DOI 10.1002/14651858.CD001532.pub2]; Williams G, 2001, J PEDIATR-US, V138, P868, DOI 10.1067/mpd.2001.113785; Yeung CK, 1997, BRIT J UROL, V80, P319, DOI 10.1046/j.1464-410X.1997.00309.x	37	76	81	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 6	2004	364	9446					1720	1722		10.1016/S0140-6736(04)17359-5	http://dx.doi.org/10.1016/S0140-6736(04)17359-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530633				2023-01-03	WOS:000224921600035
J	Trohman, RG; Kim, MH; Pinski, SL				Trohman, RG; Kim, MH; Pinski, SL			Cardiac pacing: the state of the art	LANCET			English	Review							HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; CHRONIC ATRIAL-FIBRILLATION; CONGESTIVE-HEART-FAILURE; TERM-FOLLOW-UP; VASOVAGAL SYNCOPE; RESYNCHRONIZATION THERAPY; DOUBLE-BLIND; ATRIOVENTRICULAR JUNCTION; VENTRICULAR-TACHYCARDIA; RANDOMIZED-TRIAL	Permanent cardiac pacing remains the only effective treatment for chronic, symptomatic bradycardia. In recent years, the role of implantable pacing devices has expanded substantially. At the beginning of the 21st century, exciting developments in technology seem to happen at an exponential rate. Major advances have extended the use of pacing beyond the arrhythmia horizon. Such developments include dual-chamber pacers, rate-response algorithms, improved functionality of implantable cardioverter defibrillators, combinations of sensors for optimum physiological response, and advances in lead placement and extraction. Cardiac pacing is poised to help millions of patients worldwide to live better electrically. We review pacing studies of sick-sinus syndrome, neurocardiogenic syncope, hypertrophic obstructive cardiomyopathy, and cardiac resynchronisation therapy, which are common or controversial indications for cardiac pacing. We also look at the benefits and complications of implantation in specific arrhythmias, suitability of different pacing modes, and the role of permanent pacing in the management of patients with heart failure.	Rush Presbyterian St Lukes Med Ctr, Arrhythmia & Pacemaker Serv, Dept Med, Cardiol Sect, Chicago, IL 60612 USA; Rush Med Coll, Chicago, IL 60612 USA	Rush University; Rush University	Trohman, RG (corresponding author), Rush Presbyterian St Lukes Med Ctr, Arrhythmia & Pacemaker Serv, Sect Electrophysiol, Room 983 Jelke, Chicago, IL 60612 USA.	rtrohman@rush.edu		Kim, Michael/0000-0002-1458-8234				Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; ABRAHAM WT, MEDTRONIC INSYNC ICD; Achilli A, 2003, J AM COLL CARDIOL, V42, P2117, DOI 10.1016/j.jacc.2003.08.024; Ammirati F, 2001, CIRCULATION, V104, P52, DOI 10.1161/hc2601.091708; Ammirati F, 1998, PACE, V21, P2178, DOI 10.1111/j.1540-8159.1998.tb01148.x; ANDERSEN HR, 1994, LANCET, V344, P1523, DOI 10.1016/S0140-6736(94)90347-6; Andersen HR, 1997, LANCET, V350, P1210, DOI 10.1016/S0140-6736(97)03425-9; Andersen HR, 1998, CIRCULATION, V98, P1315, DOI 10.1161/01.CIR.98.13.1315; Auricchio A, 2003, J AM COLL CARDIOL, V42, P2109, DOI 10.1016/j.jacc.2003.04.003; Bakker PF, 2000, J INTERV CARD ELECTR, V4, P395; Barold SS, 2001, AM J MED, V111, P224, DOI 10.1016/S0002-9343(01)00807-5; Barold SS, 2000, CHEST, V118, P1819, DOI 10.1378/chest.118.6.1819; BAROLD SS, 1992, HEART DIS TXB CARDIO; Baron-Esquivias G, 2002, EUR HEART J, V23, P483, DOI 10.1053/euhj.2001.2900; Bernstein AD, 2002, PACE, V25, P260, DOI 10.1046/j.1460-9592.2002.00260.x; Best PJM, 1999, PACE, V22, P79, DOI 10.1111/j.1540-8159.1999.tb00303.x; Bohm A, 1999, PACE, V22, P1557, DOI 10.1111/j.1540-8159.1999.tb00365.x; Bracke F, 2002, PACE, V25, P1037, DOI 10.1046/j.1460-9592.2002.01037.x; Bradley DJ, 2003, JAMA-J AM MED ASSOC, V289, P730, DOI 10.1001/jama.289.6.730; BRANDT J, 1992, J AM COLL CARDIOL, V20, P633, DOI 10.1016/0735-1097(92)90018-I; BRECKER SJD, 1992, LANCET, V340, P1308, DOI 10.1016/0140-6736(92)92492-X; BRIGNOLE M, 1992, AM J CARDIOL, V69, P1039, DOI 10.1016/0002-9149(92)90860-2; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Byrd CL, 2002, PACE, V25, P804, DOI 10.1046/j.1460-9592.2002.t01-1-00804.x; BYRD CL, 2000, CLIN CARDIAC PACING; CALKINS H, 2001, HEART DIS TXB CARDIV; Carlson MD, 2003, J AM COLL CARDIOL, V42, P627, DOI 10.1016/S0735-1097(03)00780-0; Cazeau S, 2000, HEART, V84, P579, DOI 10.1136/heart.84.6.579; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Chua JD, 2000, ANN INTERN MED, V133, P604, DOI 10.7326/0003-4819-133-8-200010170-00011; CHUGH A, 2002, AM COLL CARDIOL CURR, V11, P77; COMAN JA, 1995, AM J CARDIOL, V76, P781, DOI 10.1016/S0002-9149(99)80226-4; Connolly SJ, 2003, JAMA-J AM MED ASSOC, V289, P2224, DOI 10.1001/jama.289.17.2224; Connolly SJ, 1999, J AM COLL CARDIOL, V33, P16, DOI 10.1016/S0735-1097(98)00549-X; Connolly SJ, 2000, NEW ENGL J MED, V342, P1385, DOI 10.1056/NEJM200005113421902; COWELL R, 1993, PACE, V16, P1441, DOI 10.1111/j.1540-8159.1993.tb01742.x; DAOUD E, 2004, HEART RHYTHM, V1, P5; *DAVID TRIAL INV, 2002, JAMA-J AM MED ASSOC, V228, P1; de Voogt WG, 1999, AM J CARDIOL, V83, p187D; Ellenbogen KA, 2003, AM J CARDIOL, V92, P740, DOI 10.1016/S0002-9149(03)00844-0; Ellenbogen KA, 2000, AM J CARDIOL, V86, P59, DOI 10.1016/S0002-9149(00)00828-6; Ertas F, 2000, J ELECTROCARDIOL, V33, P253, DOI 10.1054/jelc.2000.8234; ETIENNE Y, 2000, PACING CLIN ELECTROP, V23, P596; FANANAPAZIR L, 1994, CIRCULATION, V90, P2731, DOI 10.1161/01.CIR.90.6.2731; Flevari P, 2002, J AM COLL CARDIOL, V40, P499, DOI 10.1016/S0735-1097(02)01974-5; Francis Gary S., 2001, Cardiology Clinics, V19, P541, DOI 10.1016/S0733-8651(05)70241-1; Furman S, 2002, PACE, V25, P1, DOI 10.1046/j.1460-9592.2002.00001.x; FURMAN S, 1993, PACE, V16, P953, DOI 10.1111/j.1540-8159.1993.tb04566.x; Garrigue S, 2000, PACE, V23, P1700, DOI 10.1046/j.1460-9592.2000.01700.x; Gillis AM, 1999, CIRCULATION, V99, P2553, DOI 10.1161/01.CIR.99.19.2553; Gillis AM, 2000, CIRCULATION, V102, P736, DOI 10.1161/01.CIR.102.7.736; GILLIS AM, 2000, CARDIOL CLIN, V18, P225; Gold MR, 2000, AM J CARDIOL, V85, P1106, DOI 10.1016/S0002-9149(00)00704-9; Gregoratos G, ACC AHA NASPE 2002 G; Gronefeld GC, 2002, PACE, V25, P1708, DOI 10.1046/j.1460-9592.2002.01708.x; GROSS JN, 1992, AM J CARDIOL, V70, P1507, DOI 10.1016/0002-9149(92)90313-N; Guyomar Y, 1999, PACE, V22, P1747, DOI 10.1111/j.1540-8159.1999.tb00406.x; HARDAGE ML, 1996, IMPLANTABLE CARDIVOE; HAYWOOD GA, 1990, PACE, V13, P2054, DOI 10.1111/j.1540-8159.1990.tb06941.x; HELGUERA ME, 1994, CLEV CLIN J MED, V61, P25, DOI 10.3949/ccjm.61.1.25; Higgins SL, 2000, J AM COLL CARDIOL, V36, P824, DOI 10.1016/S0735-1097(00)00795-6; Higgins SL, 2003, J AM COLL CARDIOL, V42, P1454, DOI 10.1016/S0735-1097(03)01042-8; Higgins SL, 1998, AM J CARDIOL, V81, P1360, DOI 10.1016/S0002-9149(98)00170-2; HOCHLEITNER M, 1992, AM J CARDIOL, V70, P1320, DOI 10.1016/0002-9149(92)90769-U; JANOSIK DL, 2000, CLIN CARDIAC PACING; Jeanrenaud X, 1996, J INTERV CARDIOL, V9, P327, DOI 10.1111/j.1540-8183.1996.tb00638.x; Jeanrenaud X, 1997, PACE, V20, P1673, DOI 10.1111/j.1540-8159.1997.tb03538.x; JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7; Kappenberger L, 1997, EUR HEART J, V18, P1249; Kaushik V, 2000, CRIT CARE MED, V28, pN121, DOI 10.1097/00003246-200010001-00003; Kay GN, 2000, AM HEART J, V140, P821, DOI 10.1067/mhj.2000.110571; Kenny RA, 1999, EUROPACE, V1, P69, DOI 10.1053/eupc.1998.0016; Kenny RAM, 2001, J AM COLL CARDIOL, V38, P1491, DOI 10.1016/S0735-1097(01)01537-6; Kusumoto FM, 1996, NEW ENGL J MED, V334, P89, DOI 10.1056/NEJM199601113340206; Lamas GA, 2002, NEW ENGL J MED, V346, P1854, DOI 10.1056/NEJMoa013040; Lamas GA, 1998, NEW ENGL J MED, V338, P1097, DOI 10.1056/NEJM199804163381602; LAU CP, 1989, CLIN CARDIOL, V12, P505, DOI 10.1002/clc.4960120907; LAU CP, 1999, PACE, V22, P804; Leclercq C, 2000, HEART, V84, P125, DOI 10.1136/heart.84.2.125; Lee SH, 1998, J AM COLL CARDIOL, V31, P637, DOI 10.1016/S0735-1097(97)00530-5; Leon AR, 2002, J AM COLL CARDIOL, V39, P1258, DOI 10.1016/S0735-1097(02)01779-5; Leung Sum-Kin, 2000, Cardiology Clinics, V18, P113, DOI 10.1016/S0733-8651(05)70131-4; Linde C, 2000, HEART, V84, P123, DOI 10.1136/heart.84.2.123; LUKL J, 1994, PACE, V17, P1844, DOI 10.1111/j.1540-8159.1994.tb03760.x; MALONEY JD, 1988, CLEV CLIN J MED, V55, P542, DOI 10.3949/ccjm.55.6.542; Maron BJ, 1999, CIRCULATION, V99, P2927, DOI 10.1161/01.CIR.99.22.2927; Martinelli Filho Martino, 2002, Arq. Bras. Cardiol., V78, P110, DOI 10.1590/S0066-782X2002000100010; McAlister FA, 2004, ANN INTERN MED, V141, P381, DOI 10.7326/0003-4819-141-5-200409070-00101; Morady F, 1997, J AM COLL CARDIOL, V29, P113, DOI 10.1016/S0735-1097(96)00445-7; Naegeli B, 1996, PACE, V19, P455, DOI 10.1111/j.1540-8159.1996.tb06516.x; Nichol G, 2004, ANN INTERN MED, V141, P343, DOI 10.7326/0003-4819-141-5-200409070-00102; Nishimura RA, 1996, J AM COLL CARDIOL, V27, P421, DOI 10.1016/0735-1097(95)00445-9; Nishimura RA, 1997, J AM COLL CARDIOL, V29, P435, DOI 10.1016/S0735-1097(96)00473-1; OMAHONY D, 1995, LANCET, V346, P950, DOI 10.1016/S0140-6736(95)91563-X; Pavia S, 2001, CURR OPIN CARDIOL, V16, P66, DOI 10.1097/00001573-200101000-00010; PETERS RW, 2001, CARDIOL CLIN, V18, P55; Pinski SL, 2003, JAMA-J AM MED ASSOC, V289, P754, DOI 10.1001/jama.289.6.754; Pinski SL, 2002, PACE, V25, P1612, DOI 10.1046/j.1460-9592.2002.01612.x; Pinski SL, 2000, PACE, V23, P1667, DOI 10.1046/j.1460-9592.2000.01667.x; PINSKI SL, 2002, TXB CARDIVOASCULAR M; PINSKI SL, 2001, EVIDENCIAS CARDIOLOG, P366; Qin JX, 2001, J AM COLL CARDIOL, V38, P1994; Raviele A, 2004, EUR HEART J, V25, P1741, DOI 10.1016/j.ehj.2004.06.031; Rosenheck S, 2000, EUROPACE, V2, P60, DOI 10.1053/eupc.1999.0062; Rosenheck S, 2000, PACE, V23, P1226, DOI 10.1111/j.1540-8159.2000.tb00935.x; Saksena S, 1996, J AM COLL CARDIOL, V28, P687, DOI 10.1016/0735-1097(96)00232-X; Saksena S, 1998, J CARDIOVASC ELECTR, V9, pS155; Santini M, 2001, EUROPACE, V3, P324, DOI 10.1053/eupc.2001.0188; SCHEINMAN MM, 1982, JAMA-J AM MED ASSOC, V248, P851, DOI 10.1001/jama.248.7.851; Sethi K K, 1992, Indian Heart J, V44, P145; SGARBOSSA EB, 1993, ANN INTERN MED, V119, P359, DOI 10.7326/0003-4819-119-5-199309010-00002; SGARBOSSA EB, 1994, AM J CARDIOL, V73, P693, DOI 10.1016/0002-9149(94)90936-9; SGARBOSSA EB, 1993, CIRCULATION, V88, P1045, DOI 10.1161/01.CIR.88.3.1045; Shaw FE, 2003, BRIT MED J, V326, P73, DOI 10.1136/bmj.326.7380.73; Skanes AC, 2001, J AM COLL CARDIOL, V38, P167, DOI 10.1016/S0735-1097(01)01326-2; Slade AKB, 1996, HEART, V75, P44, DOI 10.1136/hrt.75.1.44; SORAJJA P, 2000, CARDIOL CLIN, V18, P6779; SRA JS, 1993, NEW ENGL J MED, V328, P1085, DOI 10.1056/NEJM199304153281504; STEIN K, 1999, PACING CLIN ELECTROP, V22, P824; Sutton R, 2000, CIRCULATION, V102, P294; Sweeney MO, 2002, PACE, V25, P1715, DOI 10.1046/j.1460-9592.2002.01715.x; Tang ASL, 2001, CIRCULATION, V103, P3081, DOI 10.1161/01.CIR.103.25.3081; TROHMAN RG, 1992, AM J CARDIOL, V70, P1438, DOI 10.1016/0002-9149(92)90296-B; TROHMAN RG, 1991, PACE, V14, P1448, DOI 10.1111/j.1540-8159.1991.tb04063.x; *UKPACE, 2003, LAT BREAK CLIN TRIAL; UNTEREKER DF, 2000, CLIN CARDIAC PACING; *US FDA, SUMM SAF EFF GUID CO; *US FDA, SUMM SAF EFF MEDTR I; Viskin S, 1996, J AM COLL CARDIOL, V28, P1262, DOI 10.1016/S0735-1097(96)00311-7; Viskin S, 2000, J CARDIOVASC ELECTR, V11, P593, DOI 10.1111/j.1540-8167.2000.tb00015.x; Walker S, 2000, AM J CARDIOL, V86, P231, DOI 10.1016/S0002-9149(00)00865-1; Warwick R, 1973, GRAYS ANATOMY; Wasmer K, 2001, CIRCULATION, V104, P784; Wathen MS, 2001, CIRCULATION, V104, P796, DOI 10.1161/hc3101.093906; Wiggins MJ, 2001, J BIOMED MATER RES, V58, P302; Wilkoff BL, 1999, J AM COLL CARDIOL, V33, P1671, DOI 10.1016/S0735-1097(99)00074-1; WILLIAMSON BD, 1994, NEW ENGL J MED, V331, P910, DOI 10.1056/NEJM199410063311404; WISH M, 1987, AM J CARDIOL, V60, P566, DOI 10.1016/0002-9149(87)90306-7; Yildirir A, 2002, J CARDIOVASC ELECTR, V13, P290, DOI 10.1046/j.1540-8167.2002.00290.x; Young JB, 2003, JAMA-J AM MED ASSOC, V289, P2685, DOI 10.1001/jama.289.20.2685; Zagrodzky JD, 2001, AM J CARDIOL, V87, P1208, DOI 10.1016/S0002-9149(01)01498-9	141	67	73	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2004	364	9446					1701	1719		10.1016/S0140-6736(04)17358-3	http://dx.doi.org/10.1016/S0140-6736(04)17358-3			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530632				2023-01-03	WOS:000224921600034
J	Gill, TM; Allore, HG; Holford, TR; Guo, ZC				Gill, TM; Allore, HG; Holford, TR; Guo, ZC			Hospitalization, restricted activity, and the development of disability among older persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOWER-EXTREMITY FUNCTION; FUNCTIONAL DEPENDENCE; PHYSICAL PERFORMANCE; HOME CARE; SUBSEQUENT DISABILITY; COGNITIVE IMPAIRMENT; CONTROLLED-TRIAL; ELDERLY PERSONS; UNITED-STATES; NURSING-HOME	Context Preventing the development of disability in activities of daily living is an important goal in older adults, yet relatively little is known about the disabling process. Objectives To evaluate the relationship between 2 types of intervening events (hospitalization and restricted activity) and the development of disability and to determine whether this relationship is modified by the presence of physical frailty. Design, Setting, and Participants Prospective cohort study, conducted in the general community in greater New Haven, Conn, from March 1998 to March 2003, of 754 persons aged 70 years or older, who were not disabled (ie, required no personal assistance) in 4 essential activities of daily living: bathing, dressing, walking inside the house, and transferring from a chair. Participants were categorized into 2 groups according to the presence of physical frailty (defined on the basis of slow gait speed) and were followed up with monthly telephone interviews for up to 5 years to ascertain exposure to intervening events and determine the occurrence of disability. Main Outcome Measure Disability, defined as the need for personal assistance in bathing, dressing, walking inside the house, or transferring from a chair. Results During the 5-year follow-up period, disability developed among 417 (55.3%) participants, 372 (49.3%) were hospitalized and 600 (79.6%) had at least 1 episode of restricted activity. The multivariable hazard ratios for the development of disability were 61.8 (95% confidence interval [CI], 49.0-78.0) within a month of hospitalization and 5.54 (95% Cl, 4.27-7.19) within a month of restricted activity. Strong associations were observed for participants who were physically frail and those who were not physically frail. Hospital admissions for falls were most likely to lead to disability. Intervening events occurring more than a month prior to disability onset were not associated with the development of disability. The population-attributable fractions associated with new exposure to hospitalization and restricted activity, respectively, were 0.48 and 0.19; 0.40 and 0.20, respectively, for frail participants and 0.61 and 0.16, respectively, for nonfrail participants. Conclusions Illnesses and injuries leading to either hospitalization or restricted activity represent important sources of disability for older persons living in the community, regardless of the presence of physical frailty. These intervening events may be suitable targets for the prevention of disability.	Yale Univ, Sch Med, Dorothy Adler Geriatr Assessment Ctr, Dept Internal Med, New Haven, CT 06504 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA	Yale University; Yale University	Gill, TM (corresponding author), Yale Univ, Sch Med, Dorothy Adler Geriatr Assessment Ctr, Dept Internal Med, 20 York St, New Haven, CT 06504 USA.	gill@ynhh.org	Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368; Allore, Heather/0000-0001-7685-8175	NIA NIH HHS [P30AG21342, K24AG021507, R01AG17560] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG021342, K24AG021507, R01AG017560] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], TXB GERIATRIC MED GE; Binder EF, 2004, JAMA-J AM MED ASSOC, V292, P837, DOI 10.1001/jama.292.7.837; Bortz WM, 2002, J GERONTOL A-BIOL, V57, pM283, DOI 10.1093/gerona/57.5.M283; BRUCE ML, 1994, AM J PUBLIC HEALTH, V84, P1796, DOI 10.2105/AJPH.84.11.1796; Campbell AJ, 1997, AGE AGEING, V26, P315, DOI 10.1093/ageing/26.4.315; Cohen HJ, 2002, NEW ENGL J MED, V346, P905, DOI 10.1056/NEJMsa010285; COUGHLIN TA, 1992, HEALTH SERV RES, V27, P453; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Cronin-Stubbs D, 2000, ARCH INTERN MED, V160, P3074, DOI 10.1001/archinte.160.20.3074; Ebrahim S, 1999, LANCET, V353, P1990, DOI 10.1016/S0140-6736(99)00195-6; Ferrucci L, 1997, JAMA-J AM MED ASSOC, V277, P728; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; GILL TM, 1995, J GERONTOL A-BIOL, V50, pM235, DOI 10.1093/gerona/50A.5.M235; Gill TM, 2002, NEW ENGL J MED, V347, P1068, DOI 10.1056/NEJMoa020423; Gill TM, 2004, AM J MED, V117, P484, DOI 10.1016/j.amjmed.2004.05.018; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; Gill TM, 2003, ARCH INTERN MED, V163, P1317, DOI 10.1001/archinte.163.11.1317; Gill TM, 2003, J GERONTOL A-BIOL, V58, P70; Gill TM, 1996, J GERONTOL A-BIOL, V51, pM283, DOI 10.1093/gerona/51A.6.M283; Gill TM, 1997, J GEN INTERN MED, V12, P757, DOI 10.1046/j.1525-1497.1997.07161.x; Gill TM, 2002, J AM GERIATR SOC, V50, P1492, DOI 10.1046/j.1532-5415.2002.50403.x; Gill TM, 2001, ANN INTERN MED, V135, P313, DOI 10.7326/0003-4819-135-5-200109040-00007; Gill TM, 1999, J GERONTOL A-BIOL, V54, pM377, DOI 10.1093/gerona/54.7.M377; Gill TM, 2001, J AM GERIATR SOC, V49, P1039, DOI 10.1046/j.1532-5415.2001.49206.x; Gill TM, 2004, ARCH PHYS MED REHAB, V85, P1043, DOI 10.1016/j.apmr.2003.10.021; Goodwin James S, 2002, Lancet, V359, P1358, DOI 10.1016/S0140-6736(02)08318-6; GRESHAM GE, 1995, CLIN PRACTICE GUIDEL, V16, P1; Guralnik JM, 2000, J GERONTOL A-BIOL, V55, pM221, DOI 10.1093/gerona/55.4.M221; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Guralnik JM, 2002, AM J PUBLIC HEALTH, V92, P1244, DOI 10.2105/AJPH.92.8.1244; Hamerman D, 1999, ANN INTERN MED, V130, P945, DOI 10.7326/0003-4819-130-11-199906010-00022; Hanley JA, 2001, J EPIDEMIOL COMMUN H, V55, P508, DOI 10.1136/jech.55.7.508; Hardy SE, 2004, JAMA-J AM MED ASSOC, V291, P1596, DOI 10.1001/jama.291.13.1596; Hoenig H, 1997, J AM GERIATR SOC, V45, P1371, DOI 10.1111/j.1532-5415.1997.tb02939.x; Hosmer DW, 1999, APPL SURVIVAL ANAL; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; Keeley EC, 2004, JAMA-J AM MED ASSOC, V291, P736, DOI 10.1001/jama.291.6.736; KEMPER P, 1992, HEALTH SERV RES, V27, P421; Kohout F J, 1993, J Aging Health, V5, P179, DOI 10.1177/089826439300500202; Landefeld CS, 1998, J AM GERIATR SOC, V46, P1314, DOI 10.1111/j.1532-5415.1998.tb04553.x; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lauer MS, 2002, NEW ENGL J MED, V346, P1468, DOI 10.1056/NEJMcp012672; Levine C, 1999, NEW ENGL J MED, V340, P1587, DOI 10.1056/NEJM199905203402013; MacMahon B., 1996, EPIDEMIOLOGY PRINCIP, V2nd; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; Manton KG, 2001, P NATL ACAD SCI USA, V98, P6354, DOI 10.1073/pnas.111152298; MCKINLAY JB, 1995, J AGING HEALTH, V7, P497, DOI 10.1177/089826439500700403; Morley JE, 2002, J GERONTOL A-BIOL, V57, pM698, DOI 10.1093/gerona/57.11.M698; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rich MW, 2001, J GERONTOL A-BIOL, V56, pM88, DOI 10.1093/gerona/56.2.M88; ROCKWOOD K, 1994, CAN MED ASSOC J, V150, P489; Rodgers W, 1997, J GERONTOL B-PSYCHOL, V52, P21, DOI 10.1093/geronb/52B.Special_Issue.21; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; RUDBERG MA, 1993, J GERONTOL, V48, pM261, DOI 10.1093/geronj/48.6.M261; SALIVE ME, 1994, J AM GERIATR SOC, V42, P287, DOI 10.1111/j.1532-5415.1994.tb01753.x; Sands LP, 2002, J GERONTOL A-BIOL, V57, pM449, DOI 10.1093/gerona/57.7.M449; SCHOLES D, 1991, AM J PUBLIC HEALTH, V81, P485, DOI 10.2105/AJPH.81.4.485; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; SPECTOR WD, 1987, J CHRON DIS, V40, P481, DOI 10.1016/0021-9681(87)90004-X; Straus SE, 2002, JAMA-J AM MED ASSOC, V288, P1396, DOI 10.1001/jama.288.11.1396; Studenski S, 2003, J AM GERIATR SOC, V51, P314, DOI 10.1046/j.1532-5415.2003.51104.x; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; TINETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348, DOI 10.1001/jama.273.17.1348; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; Tinetti ME, 2002, JAMA-J AM MED ASSOC, V287, P2098, DOI 10.1001/jama.287.16.2098; *US CENS BUR, 2003, AM FACTF	69	426	429	1	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2004	292	17					2115	2124		10.1001/jama.292.17.2115	http://dx.doi.org/10.1001/jama.292.17.2115			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	868OC	15523072				2023-01-03	WOS:000224921900024
J	Tercier, J				Tercier, J			Resuscitation	LANCET			English	Editorial Material									Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Tercier, J (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.	jtercier@itsa.ucsf.edu							0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	2004	364	9441					1211	1211		10.1016/S0140-6736(04)17166-3	http://dx.doi.org/10.1016/S0140-6736(04)17166-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	859HO	15464171	Bronze			2023-01-03	WOS:000224254200013
J	Jacobs, T				Jacobs, T			More than meets the eyes?	NATURE BIOTECHNOLOGY			English	Article												tom@completegrowth.com						VANBRUNT J, 2004, SIGNALS MAGAZINE MAY	1	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2004	22	10					1221	1221		10.1038/nbt1004-1221	http://dx.doi.org/10.1038/nbt1004-1221			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	860EU	15470455				2023-01-03	WOS:000224326100017
J	Steinbrook, R				Steinbrook, R			Medical marijuana, physician-assisted suicide, and the controlled substance act	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Joy JE, 1999, MARIJUANA MED ASSESS; Kassirer JP, 1997, NEW ENGL J MED, V336, P366, DOI 10.1056/NEJM199701303360509; Steinbrook R, 2002, NEW ENGL J MED, V346, P460, DOI 10.1056/NEJM200202073460624	3	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2004	351	14					1380	1383		10.1056/NEJMp048222	http://dx.doi.org/10.1056/NEJMp048222			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	857XT	15459296				2023-01-03	WOS:000224153900003
J	[Anonymous]				[Anonymous]			Prescribing of lipid regulating drugs and admissions for myocardial infarction in England	BMJ-BRITISH MEDICAL JOURNAL			English	Article													Aylin, Paul/A-1073-2014	Bottle, Alex/0000-0001-9978-2011; Aylin, Paul/0000-0003-4589-1743; Majeed, Azeem/0000-0002-2357-9858					0	3	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 18	2004	329	7467					645	+		10.1136/bmj.329.7467.645	http://dx.doi.org/10.1136/bmj.329.7467.645			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	856JU	15374914	Green Published			2023-01-03	WOS:000224042300015
J	Senghas, A; Kita, S; Ozyurek, A				Senghas, A; Kita, S; Ozyurek, A			Children creating core properties of language: Evidence from an emerging sign language in Nicaragua	SCIENCE			English	Article							GESTURE	A new sign language has been created by deaf Nicaraguans over the past 25 years, providing an opportunity to observe the inception of universal hallmarks of language. We found that in their initial creation of the language, children analyzed complex events into basic elements and sequenced these elements into hierarchically structured expressions according to principles not observed in gestures accompanying speech in the surrounding language. Successive cohorts of learners extended this procedure, transforming Nicaraguan signing from its early gestural form into a linguistic system. We propose that this early segmentation and recombination reflect mechanisms with which children learn, and thereby perpetuate, language. Thus, children naturally possess learning abilities capable of giving language its fundamental structure.	Columbia Univ Barnard Coll, Dept Psychol, New York, NY 10027 USA; Univ Bristol, Dept Expt Psychol, Bristol BS8 1TN, Avon, England; Univ Nijmegen, FC Donders Ctr Cognit Neuroimaging, NL-6525 EK Nijmegen, Netherlands; Max Planck Inst Psycholinguist, NL-6525 XD Nijmegen, Netherlands; Koc Univ, Dept Psychol, TR-34450 Istanbul, Turkey	Columbia University; University of Bristol; Radboud University Nijmegen; Max Planck Society; Koc University	Senghas, A (corresponding author), Columbia Univ Barnard Coll, Dept Psychol, 3009 Broadway, New York, NY 10027 USA.	annie@alum.mit.edu	ozyurek, asli/M-5366-2013; Galantucci, Bruno/E-5770-2010; Kita, Sotaro/B-2860-2008	Kita, Sotaro/0000-0002-0088-3654	NIDCD NIH HHS [R01 DC00491, R01 DC05407, R01 DC005407] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000491, R01DC005407] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ANDERSEN RW, 1983, PIDGINISATION CREOLI, P1; BICKERTON D, 1984, BEHAV BRAIN SCI, V7, P173, DOI 10.1017/S0140525X00044149; Christiansen MH, 2003, TRENDS COGN SCI, V7, P300, DOI 10.1016/S1364-6613(03)00136-0; Coppola M., 2002, THESIS U ROCHESTER; DeGraff M., 1999, LANGUAGE CREATION LA; Goldin-Meadow S., 1982, LANG ACQUIS, P51; Hauser MD, 2002, SCIENCE, V298, P1569, DOI 10.1126/science.298.5598.1569; Hockett C. F., 1987, REFURBISHING OUR FDN; HOLM J, 1988, PIDGINS CREOLES, V1; Jackendoff R., 2002, FDN LANGUAGE BRAIN, DOI 10.1093/acprof:oso/9780198270126.001.0001; Kegl J, 1999, LEARN DEV CONCEP CH, P179; Kirby S., 1999, FUNCTION SELECTION I; Kita S, 2003, J MEM LANG, V48, P16, DOI 10.1016/S0749-596X(02)00505-3; Lenneberg E.H., 1967, BIOL FDN LANGUAGE; McNeill D., 1992, HAND MIND WHAT GESTU; MEIER RP, 1987, J MEM LANG, V26, P362, DOI 10.1016/0749-596X(87)90119-7; Morford JP, 1996, LANG COMMUN, V16, P165, DOI 10.1016/0271-5309(96)00008-0; NEWPORT EL, 1990, COGNITIVE SCI, V14, P11, DOI 10.1207/s15516709cog1401_2; PINKER S, 1990, BEHAV BRAIN SCI, V13, P707, DOI 10.1017/S0140525X00081061; POLICH L, IN PRESS BUT SIGN LA; Sankoff Gillian, 1973, KIVUNG, V6, P32; Senghas A, 2003, COGNITIVE DEV, V18, P511, DOI 10.1016/j.cogdev.2003.09.006; Senghas A, 2001, PSYCHOL SCI, V12, P323, DOI 10.1111/1467-9280.00359; Senghas A., 1995, THESIS MIT; SENGHAS RJ, 1997, THESIS U ROCHESTER; Talmy L., 1985, LANGUAGE TYPOLOGY SY, V3, P36; TOMASELLO M, 2003, LANGUAGE EVOLUTION, P94, DOI DOI 10.1093/ACPROF:OSO/9780199244843.003.0006; [No title captured]	28	300	304	1	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2004	305	5691					1779	1782		10.1126/science.1100199	http://dx.doi.org/10.1126/science.1100199			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	856IS	15375269	Green Submitted			2023-01-03	WOS:000224039500043
J	Sprague, LD; Ferrigni, FJ				Sprague, LD; Ferrigni, FJ			Lung herniation after cardiopulmonary resuscitation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									SSM St Joseph Hlth Ctr, St Charles, MO 63301 USA		Sprague, LD (corresponding author), SSM St Joseph Hlth Ctr, St Charles, MO 63301 USA.								0	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2004	351	7					695	695		10.1056/NEJMicm030736	http://dx.doi.org/10.1056/NEJMicm030736			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	845FZ	15306671				2023-01-03	WOS:000223225500012
J	Kumarasamy, N				Kumarasamy, N			Generic antiretroviral drugs - will they be the answer to HIV in the developing world?	LANCET			English	Editorial Material							RESOURCE-LIMITED SETTINGS; TOTAL LYMPHOCYTE COUNT; THERAPY; INFECTION; REGIMENS; DISEASE; HAART; INDIA		VHS, YRG Ctr AIDS Res & Educ, Madras 600113, Tamil Nadu, India		Kumarasamy, N (corresponding author), VHS, YRG Ctr AIDS Res & Educ, Madras 600113, Tamil Nadu, India.	Kumarasamy@yrgcare.org	Kumarasasmy, Nagalingeswaran/AAB-7348-2021					Badri M, 2003, AIDS, V17, P541, DOI 10.1097/00002030-200303070-00009; BALAKRISHNAN P, IN PRESS J ACQUIR IM; Chesney M, 2003, AIDS PATIENT CARE ST, V17, P169, DOI 10.1089/108729103321619773; Crommentuyn KML, 2004, CLIN INFECT DIS, V38, pE73, DOI 10.1086/382675; Henry K, 2004, JAIDS-J ACQ IMM DEF, V35, P537, DOI 10.1097/00126334-200404150-00012; HOSSEINIPOUR M, 2003, 10 C RETR OPP INF BO, P172; JOSEFOWICZ S, 2004, 11 C RETR OPP INF SA, P96; Kumarasamy N, 2003, AIDS, V17, P2267, DOI 10.1097/00002030-200310170-00019; Kumarasamy N, 2003, CLIN INFECT DIS, V36, P79, DOI 10.1086/344756; KUMARASAMY N, 2004, 15 INT AIDS C BANGK; Macalino GE, 2004, CLIN INFECT DIS, V38, pS393, DOI 10.1086/421402; Mahajan AP, 2004, JAIDS-J ACQ IMM DEF, V36, P567, DOI 10.1097/00126334-200405010-00004; Malmsten A, 2003, J MED VIROL, V71, P347, DOI 10.1002/jmv.10492; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pozniak Anton, 2002, J HIV Ther, V7, P13; Remien RH, 2003, AIDS, V17, P786, DOI 10.1097/00002030-200303280-00030; Schupbach J, 2000, INT J ANTIMICROB AG, V16, P441, DOI 10.1016/S0924-8579(00)00272-7	17	29	29	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	2004	364	9428					3	4		10.1016/S0140-6736(04)16605-1	http://dx.doi.org/10.1016/S0140-6736(04)16605-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234833				2023-01-03	WOS:000222392900004
J	Zhang, ZQ; Wang, Y; Yao, RS; Li, J; Yan, Y; La Regina, M; Lemon, WL; Grubbs, CL; Lubet, RA; You, M				Zhang, ZQ; Wang, Y; Yao, RS; Li, J; Yan, Y; La Regina, M; Lemon, WL; Grubbs, CL; Lubet, RA; You, M			Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models	ONCOGENE			English	Article						antitumor B; lung cancer; chemoprevention; A/J mice; transgenic mice; p53; Ink4a/Arf	BREAST-CANCER CELLS; FEMALE A/J MICE; BETA-SITOSTEROL; ALPHA-SUBUNITS; G13 PROTEINS; GREEN TEA; TUMORIGENESIS; CARCINOGENESIS; PHYTOSTEROLS; INHIBITION	Antitumor B (ATB), also known as Zeng Sheng Ping, is a Chinese herbal mixture composed of six plants. Previously, clinical studies have shown a significant chemopreventive efficacy of ATB against human esophageal and lung cancers. In the present study, A/J mice harboring a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf and treated with benzo[a] pyrene were used to investigate the chemopreventive effects of ATB on chemically induced lung tumorigenesis. Mice with various genotypes treated with ATB displayed a significant reduction in lung tumor multiplicity and tumor load. Treatment with ATB resulted in an approximately 40% decrease in tumor multiplicity and a 70% decrease in tumor load in both wild-type mice and in mice with a loss of the Ink4a/Arf tumor suppressor genes. Interestingly, ATB decreased tumor multiplicity and volume by 50 and 90%, respectively, in mice with a dominant-negative p53 and in mice with both a p53 mutation and deletion of Ink4a/Arf. Kras2 mutation analysis of the lung tumors revealed that tumors harbored mutations in the 12th codon of Kras2. There were no differences in either the incidence or types of mutations between tumors treated with or without ATB. Oligonucleotide array analysis revealed 284 genes that were differentially expressed in mouse lung tumors as compared to the normal lung, and it was found that 114 out of these 284 genes changed their expression toward the normal levels in tumors treated with ATB. Most of the genes modulated by ATB belong to several cellular signaling pathways, including Notch (Notch homolog 2, manic fringe homolog), growth factor (FGF intracellular-binding protein, PDGFalpha), G protein-Ras-MAPK (MAPK3, MAP3K4, rab3A, Rap1, RSG5, PKCh), ubiquitin- proteasome (CDC34, Cullin1, 26S proteasome), and apoptosis (BAD promoter, caspase 3). These results suggest that ATB is an effective chemopreventive against mouse lung tumorigenesis. Furthermore, ATB exhibited an enhanced inhibitory effect in animals harboring genetic alterations (Kras2, p53, and Ink4a/Arf), which are often seen in human lung adenocarcinomas.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Comparat Med, St Louis, MO 63110 USA; Univ Alabama, Chemoprevent Ctr, Dept Surg, Birmingham, AL 35295 USA; NCI, Chemoprevent Branch, Bethesda, MD 20892 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL); University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu						Awad AB, 2001, NUTR CANCER, V40, P157, DOI 10.1207/S15327914NC402_12; Awad AB, 2000, J NUTR, V130, P2127, DOI 10.1093/jn/130.9.2127; Awad AB, 2000, ANTICANCER RES, V20, P821; Awad AB, 2000, NUTR CANCER, V36, P74, DOI 10.1207/S15327914NC3601_11; Awad AB, 2000, INT J MOL MED, V5, P541; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Castonguay A, 1998, EXP LUNG RES, V24, P605, DOI 10.3109/01902149809087389; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fan X, 1993, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V15, P71; Hansen H H, 1999, Cancer Chemother Biol Response Modif, V18, P336; LIN P, 1990, Proceedings of the Chinese Academy of Medical Sciences and the Peking Union Medical College, V5, P121; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MORSE MA, 1991, CANCER RES, V51, P1846; RAICHT RF, 1980, CANCER RES, V40, P403; RAO AV, 1992, NUTR CANCER, V18, P43, DOI 10.1080/01635589209514203; SHI ST, 1994, CANCER RES, V54, P4641; von Holtz RL, 1998, NUTR CANCER, V32, P8, DOI 10.1080/01635589809514709; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wang Y, 2003, CANCER RES, V63, P4389; Wattenberg LW, 1996, CANCER RES, V56, P5132; Wattenberg LW, 1997, CARCINOGENESIS, V18, P2015, DOI 10.1093/carcin/18.10.2015; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X; Zhang ZQ, 2003, ONCOGENE, V22, P6257, DOI 10.1038/sj.onc.1206630; Zhang ZQ, 2000, CANCER RES, V60, P901; Zhang ZQ, 2002, ONCOGENE, V21, P5960, DOI 10.1038/sj.onc.1205725	29	49	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3841	3850		10.1038/sj.onc.1207496	http://dx.doi.org/10.1038/sj.onc.1207496			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021904				2023-01-03	WOS:000221242500011
J	Holroyd-Leduc, JM; Straus, SE				Holroyd-Leduc, JM; Straus, SE			Management of urinary incontinence in women - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RANDOMIZED CONTROLLED TRIAL; HEALTH-CARE-SEEKING; OVERACTIVE BLADDER; HELP-SEEKING; TOLTERODINE; OXYBUTYNIN; SYMPTOMS; EFFICACY; OLDER; TOLERABILITY	Urinary incontinence, defined as involuntary loss of urine, is a common health problem among women. The prevalence rate is between 12% and 55% for having ever experienced urinary incontinence. It is associated with poor self-rated health, impaired quality of life, social isolation, and depressive symptoms. However, physicians are usually not the ones to initiate discussion about incontinence with their patients. We present clinical cases to illustrate common scenarios in which a physician may be able to help a female patient manage her urinary incontinence by specifically addressing associated factors and offering treatments to improve or possibly even cure her symptoms. Several evidence-based effective nonpharmacological, pharmacological, and surgical treatment options are outlined.	San Francisco Vet Affairs Med Ctr, San Francisco, CA USA; Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA; Univ Toronto, Univ Hlth Network, Div Gen Internal Med, Toronto, ON, Canada	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Holroyd-Leduc, JM (corresponding author), SFVAMC 181G, 4150 Clement St,Bldg 1, San Francisco, CA 94121 USA.	Jayna.Holroyd-Leduc@med.va.gov; sstraus@mtsinai.on.ca						Abrams P, 2000, LANCET, V355, P2153; Abrams P, 2003, UROLOGY, V61, P37, DOI 10.1016/S0090-4295(02)02243-4; Appell RA, 2001, MAYO CLIN PROC, V76, P358; BEZERRA CA, 2003, COCHRANE LIB; EUSTICE S, 2003, COCHRANE LIB; FANTL J, 1996, PUBLICATION US DEP H; Hannestad YS, 2002, SCAND J PRIM HEALTH, V20, P102, DOI 10.1080/713796408; HAYSMITH EJ, 2003, COCHRANE LIB; LAPITAN MC, 2003, COCHRANE LIB; Lee JG, 2002, INT J UROL, V9, P247, DOI 10.1046/j.1442-2042.2002.00460.x; Malone-Lee J, 2001, J UROLOGY, V165, P1452, DOI 10.1016/S0022-5347(05)66326-4; Norton PA, 2002, AM J OBSTET GYNECOL, V187, P40, DOI 10.1067/mob.2002.124840; Ricci JA, 2001, CLIN THER, V23, P1245, DOI 10.1016/S0149-2918(01)80104-1; Roberts RO, 1998, J AM GERIATR SOC, V46, P467, DOI 10.1111/j.1532-5415.1998.tb02468.x; Shaw C, 2001, FAM PRACT, V18, P48, DOI 10.1093/fampra/18.1.48; Stoddart H, 2001, BRIT J GEN PRACT, V51, P548; Wyman JF, 1998, AM J OBSTET GYNECOL, V179, P999, DOI 10.1016/S0002-9378(98)70206-6; Yamanishi T, 2000, UROLOGY, V55, P353, DOI 10.1016/S0090-4295(99)00476-8; Zinner NR, 2002, J AM GERIATR SOC, V50, P799, DOI 10.1046/j.1532-5415.2002.50203.x	19	28	29	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2004	291	8					996	999		10.1001/jama.291.8.996	http://dx.doi.org/10.1001/jama.291.8.996			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777MK	14982916				2023-01-03	WOS:000189182000028
J	Taylor, JA; Weber, W; Standish, L; Quinn, H; Goesling, J; McGann, M; Calabrese, C				Taylor, JA; Weber, W; Standish, L; Quinn, H; Goesling, J; McGann, M; Calabrese, C			Efficacy and safety of echinacea in treating upper respiratory tract infections in children - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALTERNATIVE MEDICINE USE; ZINC GLUCONATE LOZENGES; COMMON COLD; DOUBLE-BLIND; YOUNG-CHILDREN; COMPLEMENTARY; DURATION; SYMPTOMS	Context Echinacea is a widely used herbal remedy for treatment of upper respiratory tract infections (URls). However, there are few data on the efficacy and safety of echinacea in treating URIs in children. Objectives To determine if Echinacea purpurea is effective in reducing the duration and/or severity of URI symptoms in children and to assess its safety in this population. Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial of healthy children 2 to 11 years old recruited from a regional practice-based network and an alternative medical center in 4-month periods from 2000 through 2002. Interventions Study patients were randomized to receive either echinacea or placebo for up to 3 URIs over a 4-month period. Study medication was begun at the onset of symptoms and continued throughout the URI, for a maximum of 10 days. Main Outcome Measures Primary outcomes were duration and severity of symptoms and adverse events recorded by parents; secondary outcomes included peak severity of symptoms, number of days of peak severity, number of days of fever, and a global assessment of severity of symptoms by parents of study children. Results Data were analyzed on 707 URIs that occurred in 407 children, including 337 URIs treated with echinacea and 370 with placebo. There were 79 children who completed their study period without having a URI. The median duration of URIs was 9 days (95% confidence interval, 8-10 days); there was no difference in duration between URls treated with echinacea or placebo (P=.89). There was also no difference in the overall estimate of severity of URI symptoms between the 2 treatment groups (median, 33 in both groups; P=.69). In addition, there were no statistically significant differences between the 2 groups for peak severity of symptoms (P=.68), number of days of peak symptoms (1.60 in the echinacea group and 1.64 in the placebo group; P=37), number of days of fever (0.81 in the echinacea group vs 0.64 in the placebo group; P=.09), or parental global assessment of severity of the URI (P=.67). Overall, there was no difference in the rate of adverse events reported in the 2 treatment groups; however, rash occurred during 7.1% of the URls treated with echinacea and 2.7% of those treated with placebo (P=.008). Conclusions Echinacea purpurea, as dosed in this study, was not effective in treating URI symptoms in patients 2 to 11 years old, and its use was associated with an increased risk of rash.	Univ Washington, Inst Child Hlth, Seattle, WA 98915 USA; Childrens Hosp & Reg Med Ctr, Seattle, WA USA; Bastyr Univ, Dept Naturopath Med, Kenmore, WA USA; Mercer Isl Pediat Associates, Mercer Isl, WA USA; Natl Coll Naturopath Med, Helfgott Res Inst, Portland, OR USA	University of Washington; University of Washington Seattle; Seattle Children's Hospital	Taylor, JA (corresponding author), Univ Washington, Inst Child Hlth, Box 354920, Seattle, WA 98915 USA.	unclat@u.washington.edu		Calabrese, Carlo/0000-0003-3657-4463	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000114] Funding Source: NIH RePORTER; NCCIH NIH HHS [AT00114-01] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Aitken M, 1998, ARCH PEDIAT ADOL MED, V152, P244; Barrett B, 1999, J FAM PRACTICE, V48, P628; Barrett BP, 2002, ANN INTERN MED, V137, P939, DOI 10.7326/0003-4819-137-12-200212170-00006; Brinkeborn RM, 1999, PHYTOMEDICINE, V6, P1; CANEDY D, 1998, NY TIMES        0723, pC1; Clemens CJ, 1997, J PEDIATR-US, V130, P463, DOI 10.1016/S0022-3476(97)70211-7; DENNY FW, 1983, PEDIATRICS, V71, P871; Dingle J. H., 1964, ILLNESS HOME STUDY 2, P33; Dorn M., 1997, COMPLEMENT THER MED, V5, P40, DOI [DOI 10.1016/S0965-2299(97)80089-1, 10.1016/S0965-2299(97)80089-1]; FOX JP, 1985, AM J EPIDEMIOL, V122, P830, DOI 10.1093/oxfordjournals.aje.a114166; Henneicke-Von Zepelin HH, 1999, CURR MED RES OPIN, V15, P214, DOI 10.1185/03007999909114094; Hoheisel O., 1997, EUR J CLIN RES, V9, P261; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V272, P1025, DOI 10.1001/jama.272.13.1025; Lindenmuth GF, 2000, J ALTERN COMPLEM MED, V6, P327, DOI 10.1089/10755530050120691; Macknin ML, 1998, JAMA-J AM MED ASSOC, V279, P1962, DOI 10.1001/jama.279.24.1962; Melchart D, 1995, J Altern Complement Med, V1, P145, DOI 10.1089/acm.1995.1.145; Melchart D., 2000, COCHRANE DB SYST REV; Mossad SB, 1996, ANN INTERN MED, V125, P81, DOI 10.7326/0003-4819-125-2-199607150-00001; Mullins RJ, 2002, ANN ALLERG ASTHMA IM, V88, P42, DOI 10.1016/S1081-1206(10)63591-0; Newall CA, 1996, HERBAL MED GUIDE HLT; O'Hara M, 1998, ARCH FAM MED, V7, P523, DOI 10.1001/archfami.7.6.523; Ottolini MC, 2001, AMBUL PEDIATR, V1, P122, DOI 10.1367/1539-4409(2001)001<0122:CAAMUA>2.0.CO;2; Pitetti R, 2001, PEDIATR EMERG CARE, V17, P165, DOI 10.1097/00006565-200106000-00004; Sawni-Sikand A, 2002, AMBUL PEDIATR, V2, P99, DOI 10.1367/1539-4409(2002)002<0099:UOCATA>2.0.CO;2; Schoneberger D, 1992, FORUM IMMUNOL, V8, P2; Schulten B, 2001, ARZNEIMITTELFORSCH, V51, P563; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; SPIGELBLATT L, 1994, PEDIATRICS, V94, P811; STIMPEL M, 1984, INFECT IMMUN, V46, P845, DOI 10.1128/IAI.46.3.845-849.1984; TAYLOR JA, 1993, J PEDIATR-US, V122, P799, DOI 10.1016/S0022-3476(06)80031-4; WALD ER, 1991, PEDIATRICS, V87, P129; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084; Zink T, 1998, AM FAM PHYSICIAN, V58, P1133; 2002, MED LETT DRUGS THER, V44, P29	35	103	106	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	2003	290	21					2824	2830		10.1001/jama.290.21.2824	http://dx.doi.org/10.1001/jama.290.21.2824			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	748QP	14657066	Bronze			2023-01-03	WOS:000186872800024
J	Haggerty, JL; Reid, RJ; Freeman, GK; Starfield, BH; Adair, CE; McKendry, R				Haggerty, JL; Reid, RJ; Freeman, GK; Starfield, BH; Adair, CE; McKendry, R			Continuity of care: a multidisciplinary review	BRITISH MEDICAL JOURNAL			English	Article							MENTALLY-ILL; SERVICES		Univ Montreal, Hop Notre Dame Z8910, Dept Med Familiale, Montreal, PQ H2L 4M1, Canada; Ctr Hlth Serv & Policy Res, Vancouver, BC V6T 1W6, Canada; Univ London Imperial Coll Sci Technol & Med, Ctr Primary Care & Social Med, London W6 8RP, England; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; Univ Alberta, Dept Community Hlth Sci, Calgary, AB T2N 4N1, Canada; Univ Alberta, Dept Psychiat, Calgary, AB T2N 4N1, Canada	Universite de Montreal; Imperial College London; Johns Hopkins University; University of Alberta; University of Alberta	Haggerty, JL (corresponding author), Univ Montreal, Hop Notre Dame Z8910, Dept Med Familiale, 1560 Sherbrooke E, Montreal, PQ H2L 4M1, Canada.		Haggerty, Jeannie/GSD-7271-2022		PHS HHS [6U30CS00189-05 S1R1] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON MA, 1993, HOSP HEALTH SERV ADM, V38, P537; Bachrach L, 1993, CASE MANAGEMENT MENT, P183; BACHRACH LL, 1993, HOSP COMMUNITY PSYCH, V44, P465; BASS RD, 1972, AM J PSYCHIAT, V129, P196, DOI 10.1176/ajp.129.2.196; Benjamin A E, 1989, Med Care Rev, V46, P411, DOI 10.1177/107755878904600404; Campbell H, 1998, BMJ-BRIT MED J, V316, P133; *CAN HLTH SERV RES, 2001 OP GRANTS COMP; Freeman G, 1997, BRIT MED J, V314, P1870, DOI 10.1136/bmj.314.7098.1870; Freeman G., 2000, CONTINUITY CARE REPO; FULOP N, 1909, NATL LISTENING EXERC; Hennen B K, 1975, J Fam Pract, V2, P371; Hjortdahl P, 1990, Fam Med, V22, P361; Johnson S, 1997, SOC PSYCH PSYCH EPID, V32, P137; Keenan G, 1998, Outcomes Manag Nurs Pract, V2, P81; McWhinney I R, 1975, J Fam Pract, V2, P373; ROGERS J, 1980, AM J PUBLIC HEALTH, V70, P122, DOI 10.2105/AJPH.70.2.122; Rusch S C, 1986, Nurs Manage, V17, P38; SHORTELL SM, 1976, MED CARE, V14, P377, DOI 10.1097/00005650-197605000-00001; Sparbel KJH, 2000, J NURS SCHOLARSHIP, V32, P17, DOI 10.1111/j.1547-5069.2000.00017.x; Starfield B, 1998, PRIMARY CARE BALANCI, P143; TESSLER RC, 1986, PSYCHOSOC REHABIL, V10, P27, DOI DOI 10.1037/h0099621; Waldenstrom U, 1998, BRIT J OBSTET GYNAEC, V105, P1160, DOI 10.1111/j.1471-0528.1998.tb09969.x; WALL EM, 1981, J FAM PRACTICE, V13, P655; World Health Organization, 1996, LJUBLJ CHART REF HLT	24	1170	1213	5	146	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 22	2003	327	7425					1219	1221		10.1136/bmj.327.7425.1219	http://dx.doi.org/10.1136/bmj.327.7425.1219			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	747BB	14630762	Green Published			2023-01-03	WOS:000186784300025
J	Szegedi, A; Kohnen, R; Dienel, A; Kieser, M				Szegedi, A; Kohnen, R; Dienel, A; Kieser, M			Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PERFORATUM; IMIPRAMINE; DISORDER; PLACEBO	Objective To investigate the efficacy of hypericum extract (St John's wort) compared with paroxetine in patients with moderate to severe major depression. Design Randomised double blind, double dummy, reference controlled, multicentre non-inferiority trial. Setting 21 psychiatric primary care practices in Germany. Participants 251 adult outpatients with acute major depression with total store 22 on the 17 item Hamilton depression scale. Interventions 900 mg/day hypericum extract WS 5570 three times a day or 20 mg paroxetine once a day for six weeks. In initial non-responders doses were increased to 1800 mg/day hypcricum or 40 mg/day paroxetine after two weeks. Main outcome measures Change in score on Hamilton depression scale from baseline to day 42 (primary outcome). Secondary measures were change in scores on Montgomery-Asberg depression rating scale, clinical global impressions, and Beck depression inventory. Results The Hamilton depression total score decreased by mean 14.4 (SD 8.8) points, corresponding to 56.6% (SD 34.3%) of the baseline value, in the hypericum group and by 11.4 (SD 8.6) points (44.8% (SD 33.5%) of baseline value) in the paroxetine group (intention to treat analysis; similar results were observed in the per protocol analysis). The intention to treat analysis (lower one sided 97.5% confidence limit 1.5 points for the difference hypericum minus paroxetine) and the per protocol analysis (lower confidence limit 0.7 points) showed non-inferiority of hypericum and statistical superiority over paroxetine. The lower limits in both cases exceeded the pre-specified non-inferiority margin of - 2.5 points and the superiority margin of 0. The incidence of adverse events was 0.035 and 0.060 events per day of exposure for hypericum and paroxetine, respectively. Conclusions In the treatment of moderate to severe major depression, hypcricum extract WS 5570 is at least as effective as paroxetine and is better tolerated.	Dr Willmar Schwabe Pharmaceut, Dept Biometry, D-76209 Karlsruhe, Germany; Charite Univ Med Berlin, Dept Psychiat & Psychotherapy, D-14050 Berlin, Germany; Inst Med Res Management & Biometr GmbH, Sci Affairs, D-90478 Nurnberg, Germany; Dr Willmar Schwabe Pharmaceut, Dept Clin Trials, D-76209 Karlsruhe, Germany	Dr. Willmar Schwabe GmbH & Co. KG; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Dr. Willmar Schwabe GmbH & Co. KG	Kieser, M (corresponding author), Dr Willmar Schwabe Pharmaceut, Dept Biometry, POB 410925, D-76209 Karlsruhe, Germany.	meinhard.kieser@schwabe.de	Szegedi, Armin/M-9184-2016	Szegedi, Armin/0000-0001-6487-4071				[Anonymous], 2000, POINTS CONS SWITCH S; BAUER P, 1994, BIOMETRICS, V50, P1029, DOI 10.2307/2533441; Bourin M, 2001, CNS DRUG REV, V7, P25; Brannath W, 2002, J AM STAT ASSOC, V97, P236, DOI 10.1198/016214502753479374; *COMM PROP MED PRO, 2000, POINTS CONSIDER SWIT; Davidson JRT, 2002, JAMA-J AM MED ASSOC, V287, P1807, DOI 10.1001/jama.287.14.1807; DUNNER DL, 1992, J CLIN PSYCHIAT, V53, P21; EDERER F, 1974, AM J EPIDEMIOL, V100, P165, DOI 10.1093/oxfordjournals.aje.a112024; Golsch S, 1997, HAUTARZT, V48, P249, DOI 10.1007/s001050050578; Harrer G, 1994, J Geriatr Psychiatry Neurol, V7 Suppl 1, pS24, DOI 10.1177/089198879400700108; HARRER G, 1998, ARZNEIMITTEL-FORSCH, V49, P3; HARRER G, 1994, J GERIATR PSYCHIA S1, V7, P24; Izzo AA, 2004, INT J CLIN PHARM TH, V42, P139; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; KUPFER DJ, 1991, J CLIN PSYCHIAT, V52, P12; Lecrubier Y, 2002, AM J PSYCHIAT, V159, P1361, DOI 10.1176/appi.ajp.159.8.1361; Lindahl M, 2004, PROTEOMICS, V4, P448, DOI 10.1002/pmic.200300604; LINDE K, 2004, COCHRANE DB SYST REV; Montgomery SA., 1994, EUROPEAN NEUROPSYCHO, V4, P283, DOI [DOI 10.1016/0924-977X(94)90093-0, 10.1016/0924-977X(94)90093-0]; PAYKEL ES, 1983, BRIT J CLIN PHARMACO, V15, pS155, DOI 10.1111/j.1365-2125.1983.tb05860.x; Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534; PHILIPP M, 1999, BMJ-BRIT MED J, V3119, P1534; PRESKORN SH, 1995, J CLIN PSYCHIAT, V56, P12; Schulz V, 2001, PHYTOMEDICINE, V8, P152; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Vorbach E U, 1994, J Geriatr Psychiatry Neurol, V7 Suppl 1, pS19, DOI 10.1177/089198879400700107; Wheatley D, 1997, PHARMACOPSYCHIATRY, V30, P77, DOI 10.1055/s-2007-979523; Winkler D, 2002, CURR OPIN PSYCHIATR, V15, P63, DOI 10.1097/00001504-200201000-00011	28	136	145	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 5	2005	330	7490					503	506		10.1136/bmj.38356.655266.82	http://dx.doi.org/10.1136/bmj.38356.655266.82			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	905PM	15708844	Green Published, Bronze			2023-01-03	WOS:000227581400015
J	Ahmadi, KR; Weale, ME; Xue, ZYY; Soranzo, N; Yarnall, DP; Briley, JD; Maruyama, Y; Kobayashi, M; Wood, NW; Spurr, NK; Burns, DK; Roses, AD; Saunders, AM; Goldstein, DB				Ahmadi, KR; Weale, ME; Xue, ZYY; Soranzo, N; Yarnall, DP; Briley, JD; Maruyama, Y; Kobayashi, M; Wood, NW; Spurr, NK; Burns, DK; Roses, AD; Saunders, AM; Goldstein, DB			A single-nucleotide polymorphism tagging set for human drug metabolism and transport	NATURE GENETICS			English	Article							LINKAGE-DISEQUILIBRIUM; HAPLOTYPE BLOCKS; SNP	Interindividual variability in drug response, ranging from no therapeutic benefit to life-threatening adverse reactions, is influenced by variation in genes that control the absorption, distribution, metabolism and excretion of drugs(1). We genotyped 904 single-nucleotide polymorphisms (SNPs) from 55 such genes in two population samples (European and Japanese) and identified a set of tagging SNPs that represents the common variation in these genes, both known and unknown. Extensive empirical evaluations, including a direct assessment of association with candidate functional SNPs in a new, larger population sample, validated the performance of these tagging SNPs and confirmed their utility for linkage-disequilibrium mapping in pharmacogenetics. The analyses also suggest that rare variation is not amenable to tagging strategies.	UCL, Dept Biol, Galton Lab, London WC1E 6BT, England; GlaxoSmithKline, Genet Res, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Tsukuba Res Labs, Genet Res, Tsukuba, Ibaraki 3004247, Japan; Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England	University of London; University College London; GlaxoSmithKline; Eisai Co Ltd; GlaxoSmithKline; University of London; University College London	Goldstein, DB (corresponding author), UCL, Dept Biol, Galton Lab, Darwin Bldg,Gower St, London WC1E 6BT, England.	d.goldstein@ucl.ac.uk	Wood, Nicholas W/C-2505-2009; Goldstein, David/AAY-8125-2020; Ahmadi, Kourosh R/B-6379-2012; Weale, Michael E/F-2587-2010	Wood, Nicholas W/0000-0002-9500-3348; Weale, Michael E/0000-0003-4593-1186; Soranzo, Nicole/0000-0003-1095-3852				Capelli C, 2003, CURR BIOL, V13, P979, DOI 10.1016/S0960-9822(03)00373-7; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Chapman JM, 2003, HUM HERED, V56, P18, DOI 10.1159/000073729; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Goldstein DB, 2003, NAT REV GENET, V4, P937, DOI 10.1038/nrg1229; Goldstein DB, 2003, TRENDS GENET, V19, P615, DOI 10.1016/j.tig.2003.09.006; Kamatani N, 2004, AM J HUM GENET, V75, P190, DOI 10.1086/422853; Ke XY, 2004, HUM MOL GENET, V13, P577, DOI 10.1093/hmg/ddh060; Pritchard JK, 2001, AM J HUM GENET, V69, P1, DOI 10.1086/321275; Qin ZHS, 2002, AM J HUM GENET, V71, P1242, DOI 10.1086/344207; Salisbury BA, 2003, MUTAT RES-FUND MOL M, V526, P53, DOI 10.1016/S0027-5107(03)00014-9; Schulze TG, 2004, HUM MOL GENET, V13, P335, DOI 10.1093/hmg/ddh035; Taylor JD, 2001, BIOTECHNIQUES, V30, P661, DOI 10.2144/01303dd04; Weale ME, 2003, AM J HUM GENET, V73, P551, DOI 10.1086/378098	14	118	128	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2005	37	1					84	89		10.1038/ng1488	http://dx.doi.org/10.1038/ng1488			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	883FX	15608640				2023-01-03	WOS:000225997500025
J	Saper, RB; Kales, SN; Paquin, J; Burns, MJ; Eisenberg, DM; Davis, RB; Phillips, RS				Saper, RB; Kales, SN; Paquin, J; Burns, MJ; Eisenberg, DM; Davis, RB; Phillips, RS			Heavy metal content of Ayurvedic herbal medicine products	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD LEAD; EXPOSURE	Context Lead, mercury, and arsenic intoxication have been associated with the use of Ayurvedic herbal medicine product (HMPs). Objectives To determine the prevalence and concentration of heavy metals in Ayurvedic HMPs manufactured in South Asia and sold in Boston-area stores and to compare estimated daily metal ingestion with regulatory standards. Design and Setting Systematic search strategy to identify all stores 20 miles or less from Boston City Hall that sold Ayurvedic HMPs from South Asia by searching online Yellow Pages using the categories markets, supermarkets, and convenience stores, and business names containing the word India, Indian cities, and Indian words. An online national directory of Indian grocery stores, a South Asian community business directory, and a newspaper were also searched. We visited each store and purchased all unique Ayurvedic HMPs between April 25 and October 24, 2003. Main Outcome Measures Concentrations (mug/g) of lead, mercury, and arsenic in each HMP as measured by x-ray fluorescence spectroscopy. Estimates of daily metal ingestion for adults and children estimated using manufacturers' dosage recommendations with comparisons to US Pharmacopeia and US Environmental Protection Agency regulatory standards. Results A total of 14 (20%) of 70 HMPs (95% confidence interval, 11%-31%) contained heavy metals: lead (n=13; median concentration, 40 mug/g; range, 5-37000), mercury (n=6; median concentration, 20225 mug/g; range, 28-104000), and/or arsenic (n=6; median concentration, 430 mug/g; range, 37-8130). If taken as recommended by the manufacturers, each of these 14 could result in heavy metal intakes above published regulatory standards. Conclusions One of 5 Ayurvedic HMPs produced in South Asia and available in Boston South Asian grocery stores contains potentially harmful levels of lead, mercury, and/or arsenic. Users of Ayurvedic medicine may be at risk for heavy metal toxicity, and testing of Ayurvedic HMPs for toxic heavy metals should be mandatory.	Harvard Univ, Sch Med, Osher Inst, Div Res & Educ Complementary & Integrat Med Thera, Boston, MA USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Emergency Med, Div Toxicol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Cambridge Hosp, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; US EPA, New England Reg Lab, N Chelmsford, MA USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University; Harvard T.H. Chan School of Public Health; United States Environmental Protection Agency	Saper, RB (corresponding author), Boston Univ, Sch Med, Dept Family Med, 1 Boston Med Ctr Pl,Dowling 5 S, Boston, MA 02118 USA.	robert.saper@bmc.org	Saper, Robert B/Y-4598-2018	Saper, Robert B/0000-0002-0992-6198	NCCIH NIH HHS [K24 AT00589, T32 AT00051] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K24AT000589] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [T32AT000051] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ACHARYA VJT, 1998, RASAMRITAM; AlKhayat S, 1997, ANN TROP PAEDIATR, V17, P39; Ang HH, 2003, HUM EXP TOXICOL, V22, P445, DOI 10.1191/0960327103ht382oa; [Anonymous], 2011, NAT I STAND TECHN ST; ASLAM M, 1979, PUBLIC HEALTH, V93, P274, DOI 10.1016/S0033-3506(79)80078-5; Baer RD, 1998, SOC SCI MED, V47, P1263, DOI 10.1016/S0277-9536(98)00183-X; Barnes PM., 2004, COMPLEMENTARY ALTERN; Canfield RL, 2003, NEW ENGL J MED, V348, P1517, DOI 10.1056/NEJMoa022848; *CDCP, 1984, MMWR-MORBID MORTAL W, V33, P638; *CDCP, 1984, MMWR-MORBID MORTAL W, V33, P643; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P582; CHONGHAI T, 1975, MED J AUSTRALIA, V2, P424, DOI 10.5694/j.1326-5377.1975.tb105939.x; Chopra A, 2002, MED CLIN N AM, V86, P75, DOI 10.1016/S0025-7125(03)00073-7; Dwivedi SK, 2002, ARCH ENVIRON HEALTH, V57, P229, DOI 10.1080/00039890209602941; Ernst E, 2002, EUR J CLIN PHARMACOL, V57, P891, DOI 10.1007/s00228-001-0400-y; Gogtay NJ, 2002, DRUG SAFETY, V25, P1005, DOI 10.2165/00002018-200225140-00003; GUNN VL, 2002, H LANE HDB, P722; HONTZ J, 2004, LOS ANGELES TIM 0126, P1; Ibrahim AS, 2002, SAUDI MED J, V23, P591; KLAASSEN CD, 2001, GOODMAN GILMANS PHAR, P1851; Ko RJ, 1998, NEW ENGL J MED, V339, P847, DOI 10.1056/NEJM199809173391214; Lecours S, 1989, Can Dis Wkly Rep, V15, P177; Lekouch N, 2001, SCI TOTAL ENVIRON, V280, P39, DOI 10.1016/S0048-9697(01)00801-4; Lin JL, 2003, NEW ENGL J MED, V348, P277, DOI 10.1056/NEJMoa021672; Marcus DM, 2002, NEW ENGL J MED, V347, P2073, DOI 10.1056/NEJMsb022858; MCELVAINE MD, 1990, JAMA-J AM MED ASSOC, V264, P2212; Moore C, 2000, PEDIATRICS, V106, P600, DOI 10.1542/peds.106.3.600; Nash D, 2003, JAMA-J AM MED ASSOC, V289, P1523, DOI 10.1001/jama.289.12.1523; PrpicMajic D, 1996, J TOXICOL-CLIN TOXIC, V34, P417, DOI 10.3109/15563659609013812; Spriewald BM, 1999, OCCUP ENVIRON MED, V56, P282, DOI 10.1136/oem.56.4.282; Tait PA, 2002, MED J AUSTRALIA, V177, P193, DOI 10.5694/j.1326-5377.2002.tb04731.x; Tertian R., 1982, PRINCIPLES QUANTITAT; Traub SJ, 2002, J TOXICOL-CLIN TOXIC, V40, P781, DOI 10.1081/CLT-120015839; *US EPA, 2004, INT RISK INF SYST; *US PHARM CONV INC, 2003, 2004 USP, V27; Weide R, 2003, DEUT MED WOCHENSCHR, V128, P2418, DOI 10.1055/s-2003-43590; 2003, INDIA NEW ENGLA 0501, P27; INDIAN GROCERIES US	38	405	412	3	58	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	2004	292	23					2868	2873		10.1001/jama.292.23.2868	http://dx.doi.org/10.1001/jama.292.23.2868			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	879CR	15598918				2023-01-03	WOS:000225694500024
J	O'Rand, MG; Widgren, EE; Sivashanmugam, P; Richardson, RT; Hall, SH; French, FS; VandeVoort, CA; Ramachandra, SG; Ramesh, V; Rao, AJ				O'Rand, MG; Widgren, EE; Sivashanmugam, P; Richardson, RT; Hall, SH; French, FS; VandeVoort, CA; Ramachandra, SG; Ramesh, V; Rao, AJ			Reversible Immunocontraception in mate monkeys immunized with Eppin	SCIENCE			English	Article							PROTEASE INHIBITORS; CONTRACEPTION	Various forms of birth control have been developed for women; however, there are currently few options for men. The development of mate contraceptives that are effective, safe, and reversible is desired for family planning throughout the world. We now report contraception of mate nonhuman primates (Macaca radiata) immunized with Eppin, a testis/epididymis-specific protein. Seven out of nine mates (78%) developed high titers to Eppin, and A of these high-titer monkeys were infertile. Five out of seven (71%) high-anti-Eppin titer mates recovered fertility when immunization was stopped. This study demonstrates that effective and reversible mate immunocontraception is an attainable goal. This method of immunocontraception may be extended to humans.	Univ N Carolina, Reprod Biol Lab, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA; Indian Inst Sci, Dept Biochem, Primate Res Lab, Bangalore 560012, Karnataka, India	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Davis; Indian Institute of Science (IISC) - Bangalore	O'Rand, MG (corresponding author), Univ N Carolina, Reprod Biol Lab, Chapel Hill, NC 27599 USA.	morand@unc.edu	Addicam, Jagannadha Rao/E-2409-2012	Gudde, Ramachandra/0000-0002-0744-3627				Amory JK, 2000, TRENDS ENDOCRIN MET, V11, P61, DOI 10.1016/S1043-2760(99)00224-6; Holden C, 2002, SCIENCE, V296, P2172, DOI 10.1126/science.296.5576.2172; Kamischke A, 2004, TRENDS PHARMACOL SCI, V25, P49, DOI 10.1016/j.tips.2003.11.009; Lea IA, 1998, BIOL REPROD, V58, P794, DOI 10.1095/biolreprod58.3.794; Lea IA, 1998, BIOL REPROD, V59, P527, DOI 10.1095/biolreprod59.3.527; NASS S, 2004, NEW FRONTIERS CONTRA; O'Rand MG, 1997, J REPROD IMMUNOL, V36, P51, DOI 10.1016/S0165-0378(97)00052-1; PRIMAKOFF P, 1988, NATURE, V335, P543, DOI 10.1038/335543a0; Richardson RT, 2004, BIOL REPROD, P98; Richardson RT, 2001, GENE, V270, P93, DOI 10.1016/S0378-1119(01)00462-0; Sivashanmugam P, 2003, GENE, V312, P125, DOI 10.1016/S0378-1119(03)00608-5; TALWAR GP, 1994, P NATL ACAD SCI USA, V91, P8532, DOI 10.1073/pnas.91.18.8532; Zinkernagel RM, 2001, SCIENCE, V293, P251, DOI 10.1126/science.1063005	13	133	148	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1189	1190		10.1126/science.1099743	http://dx.doi.org/10.1126/science.1099743			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539605	Green Accepted			2023-01-03	WOS:000225193100051
J	Markowitz, AJ; Rabow, MW				Markowitz, AJ; Rabow, MW			Palliative care for patients with heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Pantilat SZ, 2004, JAMA-J AM MED ASSOC, V291, P2476, DOI 10.1001/jama.291.20.2476	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2004	292	14					1744	1744		10.1001/jama.292.14.1744	http://dx.doi.org/10.1001/jama.292.14.1744			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861JS	15479940				2023-01-03	WOS:000224413400034
J	Potter, BK				Potter, BK			The prince and the professor - With respect, professor, the Prince of Wales is not so wrong	BMJ-BRITISH MEDICAL JOURNAL			English	Letter									Asda Hulme, Manchester M15, England; Univ Nottingham, Nottingham NG7 2RD, England	University of Nottingham	Potter, BK (corresponding author), Asda Hulme, Manchester M15, England.	ldyxrkp@nottingham.ac.uk						Baum M, 2004, BRIT MED J, V329, P118, DOI 10.1136/bmj.329.7457.118	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	2004	329	7470					858	859		10.1136/bmj.329.7470.858-b	http://dx.doi.org/10.1136/bmj.329.7470.858-b			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862EK	15472281	Green Published			2023-01-03	WOS:000224472800041
J	de Kraker, J; Graf, N; van Tinteren, H; Pein, F; Sandstedt, B; Godzinski, J; Tournade, MF				de Kraker, J; Graf, N; van Tinteren, H; Pein, F; Sandstedt, B; Godzinski, J; Tournade, MF		Int Soc Paediat Oncology Nephrobla	Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial	LANCET			English	Article							PAEDIATRIC-ONCOLOGY SIOP; INTERNATIONAL-SOCIETY; PEDIATRIC-ONCOLOGY; CLINICAL-TRIAL; CANCER; EQUIVALENCE; CHILDHOOD; DURATION; SINGLE; COSTS	Background Present treatment for Wilms' tumour is very successful. Now, efforts are aimed at reducing toxicity and burden of treatment by shortening schedules without loss of effectiveness. The objective of this randomised trial was to assess whether postoperative chemotherapy for patients with stage I intermediate-risk and anaplastic Wilms' tumour could be shortened to only 4 weeks from the standard 18 weeks, while maintaining equivalent event-free survival. Methods Between June, 1993, and June, 2000, 410 patients were randomly assigned after four doses of vincristine plus one course of dactinomycin postoperatively either to stop further adjuvant chemotherapy (no further chemotherapy group, n=200), or to receive a further two courses of the same chemotherapy (standard group, n=210). Previous treatment consisted of chemotherapy before nephrectomy of four doses of vincristine and two courses of dactinomycin followed by surgical resection of the tumour. Eligible patients were at least 6 months old and had stage I tumours with either intermediate-risk histology or anaplasia. The primary endpoint of this equivalence trial was 2-year event-free survival. Both per-protocol and intention-to-treat analyses were done. Findings By 2 years, 18 recurrences were reported in the standard group, and 22 in the no further chemotherapy group. Event-free survival was 91.4% (95% CI 87.5-95.2) for the no further chemotherapy group and 88.8% (84.3-93.2) for the standard group (difference=2.6%, upper 97.5% confidence limit 8.4%). The null hypothesis, that experimental treatment is less effective than standard treatment, could be rejected (p=0.008). Conclusions Shortening duration of chemotherapy could reduce acute and late side-effects and inconvenience for patient and parents while maintaining effectiveness, and could be beneficial in terms of health costs.	Univ Amsterdam, Acad Med Ctr, Emma Kinderziekenhuis, Dept Paediat Oncol, NL-1100 DE Amsterdam, Netherlands; Univ Klin Kinder & Jugendmed, Dept Paediat Haematol Oncol, Homburg, Germany; Ctr Comprehens Canc, Amsterdam, Netherlands; Inst Gustave Roussy, Dept Paediat Oncol, Paris, France; Karolinska Inst, Astrid Lindgren Childrens Hosp, Childhood Canc Res Unit, Stockholm, Sweden; Marciniak Hosp, Dept Paediat Surg, Wroclaw, Poland	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Universitatsklinikum des Saarlandes; UNICANCER; Gustave Roussy; Karolinska Institutet	de Kraker, J (corresponding author), Univ Amsterdam, Acad Med Ctr, Emma Kinderziekenhuis, Dept Paediat Oncol, POB 22700, NL-1100 DE Amsterdam, Netherlands.	j.dekraker@amc.uva.nl	Graf, Norbert/H-1328-2011	Graf, Norbert/0000-0002-2248-323X; van Tinteren, Harm/0000-0002-4626-8702				Barr RD, 1996, INT J ONCOL, V8, P933; BLOOM BS, 1985, JAMA-J AM MED ASSOC, V253, P2393, DOI 10.1001/jama.253.16.2393; Chan ISF, 2003, STAT METHODS MED RES, V12, P37, DOI 10.1191/0962280203sm314ra; DANGIO GJ, 1989, CANCER-AM CANCER SOC, V64, P349, DOI 10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO;2-Q; Delemarre JFM, 1996, MED PEDIATR ONCOL, V26, P145, DOI 10.1002/(SICI)1096-911X(199602)26:2<145::AID-MPO15>3.0.CO;2-H; Godzinski J, 1998, EUR J PEDIATR SURG, V8, P83, DOI 10.1055/s-2008-1071127; Green DM, 1998, J CLIN ONCOL, V16, P3744, DOI 10.1200/JCO.1998.16.12.3744; Green DM, 1998, J CLIN ONCOL, V16, P237, DOI 10.1200/JCO.1998.16.1.237; LEMERLE J, 1976, CANCER, V38, P647, DOI 10.1002/1097-0142(197608)38:2<647::AID-CNCR2820380204>3.0.CO;2-C; LEMERLE J, 1983, J CLIN ONCOL, V1, P604, DOI 10.1200/JCO.1983.1.10.604; MCDONALD GB, 1993, MARROW TRANSPL REV, V3, P49; Mitchell C, 2000, BRIT J CANCER, V83, P602, DOI 10.1054/bjoc.2000.1338; RODARY C, 1989, STAT MED, V8, P593, DOI 10.1002/sim.4780080508; TOURNADE MF, 1993, J CLIN ONCOL, V11, P1014, DOI 10.1200/JCO.1993.11.6.1014; Tournade MF, 2001, J CLIN ONCOL, V19, P488, DOI 10.1200/JCO.2001.19.2.488	15	140	141	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	2004	364	9441					1229	1235		10.1016/S0140-6736(04)17139-0	http://dx.doi.org/10.1016/S0140-6736(04)17139-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	859HO	15464183				2023-01-03	WOS:000224254200029
J	Ghosh, AK; Ghosh, K				Ghosh, AK; Ghosh, K			Misinterpretation of numbers: a potential source of physician's error	LANCET			English	Editorial Material							MEDICINE; TREAT		Mayo Clin Coll Med, Div Gen Internal Med, Rochester, MN 55905 USA	Mayo Clinic	Ghosh, AK (corresponding author), Mayo Clin Coll Med, Div Gen Internal Med, W 17-B, Rochester, MN 55905 USA.	ghosh.amit@mayo.edu						Brennan TA, 2000, NEW ENGL J MED, V342, P1123, DOI 10.1056/NEJM200004133421510; Ghosh AK, 2004, J GEN INTERN MED, V19, P184; Ghosh AK, 2004, J LAB CLIN MED, V144, P60, DOI 10.1016/j.lab.2004.05.013; Ghosh AK, 2004, QJM-INT J MED, V97, P53, DOI 10.1093/qjmed/hch010; GHOSH AK, 2002, J INVEST MED, V50, P243; Hoffrage U, 2000, SCIENCE, V290, P2261, DOI 10.1126/science.290.5500.2261; Kohn LT, 2000, ERR IS HUMAN BUILDIN; Kristiansen IS, 2002, J CLIN EPIDEMIOL, V55, P888, DOI 10.1016/S0895-4356(02)00432-8; Noguchi Y, 2002, J GEN INTERN MED, V17, P848, DOI 10.1046/j.1525-1497.2002.20139.x; Wheeler DW, 2004, J ROY SOC MED, V97, P380, DOI 10.1258/jrsm.97.8.380	10	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	2004	364	9440					1108	1110		10.1016/S0140-6736(04)17119-5	http://dx.doi.org/10.1016/S0140-6736(04)17119-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	857FT	15451207				2023-01-03	WOS:000224102400008
J	Thompson, WW; Shay, DK; Weintraub, E; Brammer, I; Bridges, CB; Cox, NJ; Fukuda, K				Thompson, WW; Shay, DK; Weintraub, E; Brammer, I; Bridges, CB; Cox, NJ; Fukuda, K			Influenza-associated hospitalizations in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY SYNCYTIAL VIRUS; PANDEMIC INFLUENZA; OUTPATIENT VISITS; IMPACT; VACCINATION; EPIDEMICS; MORTALITY; CHILDREN; INFECTIONS; PNEUMONIA	Context Respiratory viral infections are responsible for a large number of hospitalizations in the United States each year. Objective To estimate annual influenza-associated hospitalizations in the United States by hospital discharge category, discharge type, and age group. Design, Setting, and Participants National Hospital Discharge Survey (NHDS) data and World Health Organization Collaborating Laboratories influenza surveillance data were used to estimate annual average numbers of hospitalizations associated with the circulation of influenza viruses from the 1979-1980 through the 2000-2001 seasons in the United States using age-specific Poisson regression models. Main Outcome Measures We estimated influenza-associated hospitalizations for primary and any listed pneumonia and influenza and respiratory and circulatory hospitalizations. Results Annual averages of 94735 (range, 18908-193561) primary and 133 900 (range, 30757-271529) any listed pneumonia and influenza hospitalizations were associated with influenza virus infections. Annual averages of 226 054 (range, 54523-430960) primary and 294128 (range, 86494-544909) any listed respiratory and circulatory hospitalizations were associated with influenza virus infections. Persons 85 years or older had the highest rates of influenza-associated primary respiratory and circulatory hospitalizations (1194.9 per 100000 persons). Children younger than 5 years (107.9 primary respiratory and circulatory hospitalizations per 100000 persons) had rates similar to persons aged 50 through 64 years. Estimated rates of influenza-associated hospitalizations were highest during seasons in which A(H3N2) viruses predominated, followed by B and A(H1N1) seasons. After adjusting for the length of each influenza season, influenza-associated primary pneumonia and influenza hospitalizations increased over time among the elderly. There were no significant increases in influenza-associated primary respiratory and circulatory hospitalizations after adjusting for the length of the influenza season. Conclusions Significant numbers of influenza-associated hospitalizations in the United States occur among the elderly, and the numbers of these hospitalizations have increased substantially over the last 2 decades due in part to the aging of the population. Children younger than 5 years had rates of influenza-associated hospitalizations similar to those among individuals aged 50 through 64 years. These findings highlight the need for improved influenza prevention efforts for both young and older US residents.	Ctr Dis Control & Prevent, Immunizat Safety Branch, Epidemiol & Surveillance Div, Natl Immunizat Program, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Thompson, WW (corresponding author), Ctr Dis Control & Prevent, Immunizat Safety Branch, Epidemiol & Surveillance Div, Natl Immunizat Program, 1600 Clifton Rd NE,MS E61, Atlanta, GA 30333 USA.	wct2@cdc.gov		Shay, David/0000-0001-9619-4820; Fukuda, Keiji/0000-0002-9598-9565				BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; BARKER WH, 1986, AM J PUBLIC HEALTH, V76, P761, DOI 10.2105/AJPH.76.7.761; Brammer T L, 2000, MMWR CDC Surveill Summ, V49, P13; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P547; Dennison C, 2000, Vital Health Stat 1, P1; *EDW BROTH, 1978, INT CLASS DIS 9 REV, V1; FRANK AL, 1983, AM J EPIDEMIOL, V118, P313, DOI 10.1093/oxfordjournals.aje.a113638; Fukuda K, 2000, INT J CLIN PRACT, P37; Gensheimer KF, 2002, VACCINE, V20, pS63, DOI 10.1016/S0264-410X(02)00135-4; Gillum B.S., 1998, VITAL HLTH STAT 13, V133, p[i, 1]; Glezen WP, 2000, NEW ENGL J MED, V342, P1752; GLEZEN WP, 1980, AM J EPIDEMIOL, V111, P13, DOI 10.1093/oxfordjournals.aje.a112865; GLEZEN WP, 1982, EPIDEMIOL REV, V4, P25, DOI 10.1093/oxfordjournals.epirev.a036250; GRAVES EJ, 1997, VITAL HLTH STAT 13, V128, P1; Hall Margaret J, 2002, Adv Data, P1; Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3; HAUPT BJ, 1992, VITAL HLTH STAT 13, V111, P1; Iwane MK, 2004, PEDIATRICS, V113, P1758, DOI 10.1542/peds.113.6.1758; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; KOZAK LJ, 2002, VITAL HLTH STAT 13, V153, P1; LAWRENCE L, 1999, ADV DATA, V308, P1; McBean AM, 2004, INT J INFECT DIS, V8, P227, DOI 10.1016/j.ijid.2004.04.013; MCBEAN AM, 1993, ARCH INTERN MED, V153, P2105, DOI 10.1001/archinte.153.18.2105; Meltzer MI, 1999, EMERG INFECT DIS, V5, P659, DOI 10.3201/eid0505.990507; Meyer KC, 2001, RESP PHYSIOL, V128, P23, DOI 10.1016/S0034-5687(01)00261-4; Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70; MULLOOLY JP, 1982, AM J PUBLIC HEALTH, V72, P1008, DOI 10.2105/AJPH.72.9.1008; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Neuzil KM, 2000, J PEDIATR-US, V137, P856, DOI 10.1067/mpd.2000.110445; Neuzil KM, 2002, J INFECT DIS, V185, P147, DOI 10.1086/338363; Nichol KL, 2003, VACCINE, V21, P1769, DOI 10.1016/S0264-410X(03)00070-7; Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028; Nichol KL, 1999, ANN INTERN MED, V130, P397, DOI 10.7326/0003-4819-130-5-199903020-00003; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; Nichols G, 1999, J ASIAN EARTH SCI, V17, P47, DOI 10.1016/S0743-9547(98)00034-8; Nordin J, 2001, J INFECT DIS, V184, P665, DOI 10.1086/323085; Simonsen L, 2000, J INFECT DIS, V181, P831, DOI 10.1086/315320; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; *US BUR CENS, 1990, INT EST POP AG SEX R; *US DEP HHS, 1999, 991232 PHS US DEP HH; Vu T, 2002, VACCINE, V20, P1831, DOI 10.1016/S0264-410X(02)00041-5	41	1682	1781	3	164	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2004	292	11					1333	1340		10.1001/jama.292.11.1333	http://dx.doi.org/10.1001/jama.292.11.1333			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853YL	15367555				2023-01-03	WOS:000223866800025
J	Henderson, C; Flood, C; Leese, M; Thornicroft, G; Sutherby, K; Szmukler, G				Henderson, C; Flood, C; Leese, M; Thornicroft, G; Sutherby, K; Szmukler, G			Effect of joint crisis plans on use of compulsory treatment in psychiatry: single blind randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							HEALTH	Objective To investigate whether a form of advance agreement for people with severe mental illness can reduce the use of inpatient services and compulsory admission or treatment. Design Single blind randomised controlled trial, with randomisation of individual patients. The investigator was blind to allocation. Setting Eight community mental health teams in southern England. Participants 160 people with an operational diagnosis of psychotic illness or non-psychotic bipolar disorder who had experienced a hospital admission within the previous two years. Intervention The joint crisis plan was formulated by the patient, care coordinator, psychiatrist, and project worker and contained contact information, details of mental and physical illnesses, treatments, indicators for relapse, and advance statements of preferences for care in the event of future relapse. Main outcome measures Admission to hospital, bed days, and use of the Mental Health Act over 15 month follow up. Results Use of the Mental Health Act was significantly reduced for the intervention group, 13% (10/80) of whom experienced compulsory admission or treatment compared with 27% (21/80) of the control group (risk ratio 0.48, 95% confidence interval 0.24 to 0.95, P = 0.028). As a consequence, the mean number of days of detention (days spent as an inpatient while under a section of the Mental Health Act) for the whole intervention group was 14 compared with 31 for the control group (difference 16, 0 to 36, P = 0.04). For those admitted under a section of the Mental Health Act, the number of days of detention was similar in the two groups (means 114 and 117, difference 3, -61 to 67, P = 0.98). The intervention group had fewer admissions (risk ratio 0.69, 0.45 to 1.04, P = 0.07). There was no evidence for differences in bed days (total number of days spent as an inpatient) (means 32 and 36, difference 4, -18 to 26, P = 0.15 for the whole sample; means 107 and 83, difference -24, -72 to 24, P = 0.39 for those admitted). Conclusions Use of joint crisis plans reduced compulsory admissions and treatment in patients with severe mental illness. The reduction in overall admission was less. This is the first structured clinical intervention that seems to reduce compulsory admission and treatment in mental health services.	Kings Coll London, Inst Psychiat, Hlth Serv Res Dept, London SE5 8AF, England; S London & Maudsley NHS Trust, Croydon CR0 1XT, England	University of London; King's College London	Henderson, C (corresponding author), Kings Coll London, Inst Psychiat, Hlth Serv Res Dept, London SE5 8AF, England.	hendersc@nypdrat.cpmc.columbia.edu	Leese, Morven N/E-4195-2010; Thornicroft, Graham/B-4027-2010; Henderson, Claire/E-4664-2010	Thornicroft, Graham/0000-0003-0662-0879; Henderson, Claire/0000-0002-6998-5659; Flood, Chris/0000-0001-5170-7792				Bracken P, 2001, BMJ-BRIT MED J, V322, P724, DOI 10.1136/bmj.322.7288.724; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; *DEP HLTH, 1999, INP FORM DET HOSP ME; *DEP HLTH, 2000, EFF CAR COORD MENT H; *DEP HLTH, 2000, NHS PLAN; Department of Health, 1999, NAT SERV FRAM MENT H; Department of Health, 1999, REP EXP COMM REV MEN; Kemp RA, 1995, SCHIZOPHR RES, V18, P21, DOI 10.1016/0920-9964(95)00018-6; MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764; *MED RES COUNC, 2000, FRAM DEV EV RCTS COM; Papageorgiou A, 2002, BRIT J PSYCHIAT, V181, P513, DOI 10.1192/bjp.181.6.513; Sutherby K, 1999, ACTA PSYCHIAT SCAND, V100, P56, DOI 10.1111/j.1600-0447.1999.tb10914.x; Sutherby K, 1998, PSYCHIAT B, V22, P4; Thomas P, 2003, BRIT J PSYCHIAT, V182, P548, DOI 10.1192/bjp.182.6.548-a; Tilley N., 1997, REALIST EVALUATION	15	176	176	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 17	2004	329	7458					136	138A		10.1136/bmj.38155.585046.63	http://dx.doi.org/10.1136/bmj.38155.585046.63			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840BP	15240438	Green Published, Green Submitted, Bronze, Green Accepted			2023-01-03	WOS:000222832300016
J	Christian, MD; Detsky, AS				Christian, MD; Detsky, AS			A twist of fate?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARTERY; MANIPULATION; CIGUATERA; STROKE		Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Hlth Network, Dept Med, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Christian, MD (corresponding author), Univ Toronto, Dept Med, Toronto, ON, Canada.		Christian, Michael/AAZ-4452-2020; Christian, Mike/AAO-6338-2020	Christian, Michael/0000-0001-9644-9950; Christian, Mike/0000-0001-9644-9950				Angibaud G, 1998, J NEUROL NEUROSUR PS, V64, P688; [Anonymous], 2002, ANN EMERG MED, V39, P108; Ernst E, 2001, STROKE, V32, P809, DOI 10.1161/01.STR.32.3.809; FRISONI GB, 1991, STROKE, V22, P1452, DOI 10.1161/01.STR.22.11.1452; Kapral MK, 2001, CAN MED ASSOC J, V165, P907; KITANAKA C, 1994, J NEUROSURG, V80, P1132; KITANAKA C, 1994, J NEUROSURG, V80, P667, DOI 10.3171/jns.1994.80.4.0667; LANGE WR, 1992, ARCH INTERN MED, V152, P2049, DOI 10.1001/archinte.152.10.2049; Norris JW, 2000, CAN MED ASSOC J, V163, P38; Pearn J, 2001, J NEUROL NEUROSUR PS, V70, P4, DOI 10.1136/jnnp.70.1.4; PHILLIPS SJ, 1989, CAN J NEUROL SCI, V16, P348, DOI 10.1017/S0317167100029218; Poli MA, 1997, TOXICON, V35, P733, DOI 10.1016/S0041-0101(96)00166-3; Rothwell DM, 2001, STROKE, V32, P1054, DOI 10.1161/01.STR.32.5.1054; Schievink WI, 2000, CURR OPIN CARDIOL, V15, P316, DOI 10.1097/00001573-200009000-00002; SHERMAN DG, 1981, STROKE, V12, P2, DOI 10.1161/01.STR.12.1.2; STURZENEGGER M, 1994, HEADACHE, V34, P187, DOI 10.1111/j.1526-4610.1994.hed3404187.x	16	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2004	351	1					69	73		10.1056/NEJMcps025162	http://dx.doi.org/10.1056/NEJMcps025162			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	833QC	15229310				2023-01-03	WOS:000222352200011
J	Deayton, JR; Sabin, CA; Johnson, MA; Emery, VC; Wilson, P; Griffiths, PD				Deayton, JR; Sabin, CA; Johnson, MA; Emery, VC; Wilson, P; Griffiths, PD			Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE-CHAIN-REACTION; CMV DNA LOAD; AIDS PATIENTS; HEMOPHILIA; RETINITIS; SURVIVAL; SEROCONVERSION; COHORT	Background Before highly active antiretroviral therapy (HAART) became available, cytomegalovirus was a major cause of opportunistic infection in HIV-infected patients and was associated with accelerated progression to AIDS and death. We have investigated whether cytomegalovirus viraemia remains a significant risk factor for progression of HIV disease and death in the era of HAART. Methods 374 patients whose CD4-cell count had ever been below 100 per muL were enrolled in a prospective study. Serial blood samples were tested for cytomegalovirus by PCR. Rates of new cytomegalovirus disease, new AIDS-defining disorders, and death were calculated over a median follow-up of 37 months after stratification according to baseline and most recent cytomegalovirus PCR status at any point during follow-up. Findings Of 2969 PCR assays, 375 (12.6%) were positive for cytomegalovirus DNA. 259 (69.3%) patients were persistently negative for cytomegalovirus by PCR; 15 were persistently positive; and 100 were intermittently positive and negative. In multivariate models, cytomegalovirus PCR-positive status as a time-updated covariate was significantly associated with increased relative rates of progression to a new AIDS-defining disorder (2.22 [95% Cl 1.27-3.88] p=0.005) and death (4.14 [1.97-8.70] p=0.0002). Interpretation Detection of cytomegalovirus in blood by PCR continues to identify patients with a poor prognosis, even in the era of HAART. Randomised controlled clinical trials of drugs active against cytomegalovirus are needed to investigate whether this virus is a marker or a determinant of HIV disease progression.	UCL, Royal Free & Univ Coll Med Sch, Dept Virol, London NW3 2PF, England; UCL, Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England; UCL, Royal Free & Univ Coll Med Sch, Dept HIV AIDS, London NW3 2PF, England	University of London; University College London; University of London; University College London; University of London; University College London	Griffiths, PD (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Virol, Royal Free Campus, London NW3 2PF, England.	pgriffiths@rfc.ucl.ac.uk	Sabin, Caroline/C-2464-2008; Emery, Vincent/G-8928-2013	Sabin, Caroline/0000-0001-5173-2760; Emery, Vincent/0000-0001-5893-9756	NIAID NIH HHS [1R01 AI41687] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041687] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECHERER PR, 1990, AM J HEMATOL, V34, P204, DOI 10.1002/ajh.2830340310; Bowen EF, 1997, AIDS, V11, P889, DOI 10.1097/00002030-199707000-00008; Bowen EF, 1996, AIDS, V10, P1515, DOI 10.1097/00002030-199611000-00009; Deayton J, 1999, AIDS, V13, P1203, DOI 10.1097/00002030-199907090-00008; Deayton JR, 2000, AIDS, V14, P1163, DOI 10.1097/00002030-200006160-00013; DETELS R, 1994, J INFECT DIS, V169, P766, DOI 10.1093/infdis/169.4.766; Dodt KK, 1997, AIDS, V11, pF21, DOI 10.1097/00002030-199703110-00001; Griffiths PD, 1998, J GEN VIROL, V79, P213, DOI 10.1099/0022-1317-79-2-213; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Kempen JH, 2003, CLIN INFECT DIS, V37, P1365, DOI 10.1086/379077; KIDD IM, 1993, TRANSPLANTATION, V56, P867, DOI 10.1097/00007890-199310000-00018; Kovacs A, 1999, NEW ENGL J MED, V341, P77, DOI 10.1056/NEJM199907083410203; MONFORTE AD, 1992, AIDS, V6, P1159, DOI 10.1097/00002030-199210000-00015; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PILLAY D, 1993, AIDS, V7, P969, DOI 10.1097/00002030-199307000-00010; RABKIN CS, 1993, J INFECT DIS, V168, P1260, DOI 10.1093/infdis/168.5.1260; Razonable RR, 2002, TRANSPLANTATION, V73, P968, DOI 10.1097/00007890-200203270-00025; Robain M, 2000, EPIDEMIOL INFECT, V125, P415, DOI 10.1017/S0950268899004549; SABIN CA, 1995, EPIDEMIOL INFECT, V114, P361, DOI 10.1017/S095026880005799X; Sabin CA, 2000, J INFECT DIS, V181, P1800, DOI 10.1086/315476; Shinkai M, 1997, J INFECT DIS, V175, P302, DOI 10.1093/infdis/175.2.302; Spector SA, 1999, J VIROL, V73, P7027, DOI 10.1128/JVI.73.8.7027-7030.1999; Spector SA, 1998, J CLIN INVEST, V101, P497, DOI 10.1172/JCI1101; Touloumi G, 1998, J ACQ IMMUN DEF SYND, V19, P89, DOI 10.1097/00042560-199809010-00014; WEBSTER A, 1989, LANCET, V2, P63; WEBSTER A, 1992, CLIN EXP IMMUNOL, V88, P6; WILKES MS, 1988, LANCET, V2, P85	27	154	166	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	2004	363	9427					2116	2121		10.1016/S0140-6736(04)16500-8	http://dx.doi.org/10.1016/S0140-6736(04)16500-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220032				2023-01-03	WOS:000222268300007
J	Fernando, B; Savelyich, BSP; Avery, AJ; Sheikh, A; Bainbridge, M; Horsfield, P; Teasdale, S				Fernando, B; Savelyich, BSP; Avery, AJ; Sheikh, A; Bainbridge, M; Horsfield, P; Teasdale, S			Prescribing safety features of general practice computer systems: evaluation using simulated test cases	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham, Div Primary Care, Nottingham NG7 2RD, England; Univ Edinburgh, GP Sect, Div Community Hlth Sci, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Nottingham, PRIMIS, Nottingham NG7 2RD, England	University of Nottingham; University of Edinburgh; University of Nottingham	Avery, AJ (corresponding author), Univ Nottingham, Div Primary Care, Nottingham NG7 2RD, England.	tony.avery@nottingham.ac.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056; Avery, Anthony/0000-0001-7591-4438				Avery Anthony J, 2003, Inform Prim Care, V11, P203; Department of Health, 2002, DEL 21 CENT IT SUPP; Magnus D, 2002, J CLIN PHARM THER, V27, P377, DOI 10.1046/j.1365-2710.2002.00434.x; Wilson T, 2002, BRIT MED J, V324, P584, DOI 10.1136/bmj.324.7337.584; YENFU C, 2001, PHARMACOEPIDEM DR S, V10, pS53	5	41	42	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	2004	328	7449					1171	1172		10.1136/bmj.328.7449.1171	http://dx.doi.org/10.1136/bmj.328.7449.1171			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	821XU	15142922	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000221497500023
J	Westerlund, H; Ferrie, J; Hagberg, J; Jeding, K; Oxenstierna, G; Theorell, T				Westerlund, H; Ferrie, J; Hagberg, J; Jeding, K; Oxenstierna, G; Theorell, T			Workplace expansion, long-term sickness absence, and hospital admission	LANCET			English	Article							FACTORY CLOSURE; HEALTH; EMPLOYEES; JOB; UNEMPLOYMENT; DISEASE; DEATH; WOMEN	Background Downsizing has in previous studies, as well as in public debate, been associated with increased sickness absence. No studies have, however, looked at the long-term relation between workplace expansion and morbidity. Methods We investigated exposure to personnel change during 1991-96 in relation to long-term (90 days or longer) medically certified sickness absence and hospital admission for specified diagnoses during 1997-99 in 24 036 participants with a complete employment record in the biennial national Swedish Work Environment Surveys from 1989 to the end of 1999. Findings Accumulated exposure to large expansion (greater than or equal to18% per year) was related to an increased risk of long-term sickness absence (odds ratio 1.07 [95% Cl 1.01-1.13], p=0.013) and hospital admission (1.09 [1.02-1.16], p=0.017). In this context, odds ratio signifies the change in odds for each additional year of exposure, varying from 0 to 6. Moderate expansion (greater than or equal to8% and <18% per year), was associated with a decreased risk of admission (0.91 [0.84-0.98], p=0.012). Moderate downsizing (>= 8% and <18% per year) was associated with an increased risk of sickness absence (1.07 (1.02-1.12], p=0.003). The strongest association between large expansion and sickness absence was in women in the public sector (1.18 [1.08-1.30], p=0.0002), corresponding to an odds ratio of 2.77 [1.62-4.74] between full exposure (all 6 years) and no exposure. Interpretation This study confirms earlier findings that downsizing is associated with health risks. It also shows that repeated exposure to rapid personnel expansion, possibly connected with centralisation of functions, statistically predicts long-term sickness absence and hospital admission. Although no conclusions about causal pathways can be drawn from our results, this exposure should be considered in future studies, policy making, and occupational health care practice.	Natl Inst Psychosocial Med, Stockholm, Sweden; UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; Univ Stockholm, Dept Stat, S-10691 Stockholm, Sweden; Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden	University of London; University College London; Stockholm University; Karolinska Institutet	Westerlund, H (corresponding author), Natl Inst Psychosocial Med, Mosseberg Res Stn, Mossebergspk 2, S-52132 Falkoping, Sweden.	hugo.westerlund@ipm.ki.se	Ferrie, Jane/AAZ-2009-2020; Westerlund, Hugo/A-3049-2012	Westerlund, Hugo/0000-0002-8806-5698; Hagberg, Jan/0000-0001-6851-265X				Aronsson G, 2000, J EPIDEMIOL COMMUN H, V54, P502, DOI 10.1136/jech.54.7.502; BEALE N, 1985, J ROY COLL GEN PRACT, V35, P510; Bjorkelund C, 2001, Lakartidningen, V98, P3314; EYER J, 1977, INT J HEALTH SERV, V7, P625, DOI 10.2190/15F1-N58K-D38Y-2X0P; EYER J, 1977, INT J HEALTH SERV, V7, P125, DOI 10.2190/9WA2-RVL3-MT9D-EL9D; Ferrie JE, 1998, SOC SCI MED, V46, P243, DOI 10.1016/S0277-9536(97)00158-5; Ferrie JE, 2001, BMJ-BRIT MED J, V322, P647, DOI 10.1136/bmj.322.7287.647; Ferrie JE, 1998, AM J PUBLIC HEALTH, V88, P1030, DOI 10.2105/AJPH.88.7.1030; Grunberg L, 2001, J Occup Health Psychol, V6, P15, DOI 10.1037/1076-8998.6.1.15; IVERSEN L, 1989, BRIT MED J, V299, P1073, DOI 10.1136/bmj.299.6707.1073; KASL SV, 1975, PSYCHOSOM MED, V37, P106, DOI 10.1097/00006842-197503000-00002; Kivimaki M, 2001, OCCUP ENVIRON MED, V58, P811, DOI 10.1136/oem.58.12.811; Kuper H, 2002, OCCUP ENVIRON MED, V59, P777, DOI 10.1136/oem.59.11.777; Landsbergis P A, 1999, J Occup Health Psychol, V4, P108, DOI 10.1037/1076-8998.4.2.108; MORRIS JK, 1991, BRIT J IND MED, V48, P1; PLATT S, 1998, CHANGING LABOUR MARK; Theorell T, 2003, OCCUP ENVIRON MED, V60, DOI 10.1136/oem.60.9.e9; Vahtera J, 1997, LANCET, V350, P1124, DOI 10.1016/S0140-6736(97)03216-9; WESTERLUND H, IN PRESS EUR J PUBLI; WESTIN S, 1989, J CLIN EPIDEMIOL, V42, P435, DOI 10.1016/0895-4356(89)90133-9; Witte H.D., 1999, EUR J WORK ORGAN PSY, V8, P155, DOI DOI 10.1080/135943299398302	21	77	79	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 10	2004	363	9416					1193	1197		10.1016/S0140-6736(04)15949-7	http://dx.doi.org/10.1016/S0140-6736(04)15949-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	811BT	15081652				2023-01-03	WOS:000220748100010
J	Stern, RS				Stern, RS			Treatment of photoaging	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; ACTINIC SKIN DAMAGE; TOXIN TYPE-A; DOUBLE-BLIND; SUNSCREEN USE; SOLAR KERATOSES; HAIRLESS MICE; BASAL-CELL; CLINICAL-TRIAL; GLYCOLIC ACID		Beth Israel Deaconess Med Ctr, Dept Dermatol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Stern, RS (corresponding author), Beth Israel Deaconess Med Ctr, Dept Dermatol, 330 Brookline Ave, Boston, MA 02215 USA.	rstern@bidmc.harvard.edu						*AM SOC AESTH PLAS, 2003, ASAPS COMM; Autier P, 1999, JNCI-J NATL CANCER I, V91, P1304, DOI 10.1093/jnci/91.15.1304; BOYD AS, 1995, J AM ACAD DERMATOL, V33, P941, DOI 10.1016/0190-9622(95)90284-8; Brooke RCC, 2001, ARCH DERMATOL, V137, P751; Carruthers JA, 2002, J AM ACAD DERMATOL, V46, P840, DOI 10.1067/mjd.2002.121356; *CTR FOOD SAF APPL, 2000, OFF COSM COL FACT SH; Darlington S, 2003, ARCH DERMATOL, V139, P451, DOI 10.1001/archderm.139.4.451; DEGRUIJL FR, 1993, CANCER RES, V53, P53; Drake LA, 1996, J AM ACAD DERMATOL, V34, P698; DRAKE LA, 1995, J AM ACAD DERMATOL, V33, P497; Drake LA, 1996, J AM ACAD DERMATOL, V35, P462; DRAKE LA, 1994, J AM ACAD DERMATOL, V31, P654; DRAKE LA, 1994, J AM ACAD DERMATOL, V31, P648; Drake Lynn A., 1995, Journal of the American Academy of Dermatology, V32, P95; Dunn LB, 1997, ARCH DERMATOL, V133, P339, DOI 10.1001/archderm.133.3.339; *FDA, 2003, T0385 FDA; FOLEY P, 1993, BRIT J DERMATOL, V128, P512, DOI 10.1111/j.1365-2133.1993.tb00227.x; *FOOD DRUG ADM, 1999, P DERM OPHTH DRUGS A; Foote JA, 2001, INT J CANCER, V95, P7, DOI 10.1002/1097-0215(20010120)95:1<7::AID-IJC1001>3.0.CO;2-X; Frost C, 2000, J INVEST DERMATOL, V115, P273, DOI 10.1046/j.1523-1747.2000.00048.x; Fulton JE, 1999, DERMATOL SURG, V25, P729, DOI 10.1046/j.1524-4725.1999.99035.x; Gebauer Kurt, 2003, Australas J Dermatol, V44, P40, DOI 10.1046/j.1440-0960.2002.00635.x; Green A, 1999, LANCET, V354, P723, DOI 10.1016/S0140-6736(98)12168-2; Green A, 1999, LANCET, V354, P723; GRIFFITHS CEM, 1993, NEW ENGL J MED, V329, P530, DOI 10.1056/NEJM199308193290803; Hecker D, 1999, J AM ACAD DERMATOL, V41, P927, DOI 10.1016/S0190-9622(99)70248-3; Hernandez-Perez E, 2001, DERMATOL SURG, V27, P637, DOI 10.1046/j.1524-4725.2001.00291.x; HOLMAN CDJ, 1984, BRIT J DERMATOL, V110, P129, DOI 10.1111/j.1365-2133.1984.tb07458.x; HOLMAN CDJ, 1984, AM J EPIDEMIOL, V120, P414, DOI 10.1093/oxfordjournals.aje.a113906; Huncharek M, 2002, AM J PUBLIC HEALTH, V92, P1173, DOI 10.2105/AJPH.92.7.1173; Kang SW, 2001, ARCH DERMATOL, V137, P1597; Kennedy C, 2003, J INVEST DERMATOL, V120, P548, DOI 10.1046/j.1523-1747.2003.12092.x; Klein AW, 2001, DERMATOL CLIN, V19, P491, DOI 10.1016/S0733-8635(05)70290-4; KLIGMAN LH, 1985, J INVEST DERMATOL, V84, P272, DOI 10.1111/1523-1747.ep12265353; KLIGMAN LH, 1982, J INVEST DERMATOL, V78, P181, DOI 10.1111/1523-1747.ep12506359; KLIGMAN LH, 1983, J INVEST DERMATOL, V81, P98, DOI 10.1111/1523-1747.ep12542169; Kurwa HA, 1999, J AM ACAD DERMATOL, V41, P414, DOI 10.1016/S0190-9622(99)70114-3; Leveque JC, 2001, CLIN GERIATR MED, V17, P673, DOI 10.1016/S0749-0690(05)70093-8; Lowe NJ, 1996, J AM ACAD DERMATOL, V35, P569, DOI 10.1016/S0190-9622(96)90682-9; MAHEUX R, 1994, AM J OBSTET GYNECOL, V170, P642, DOI 10.1016/S0002-9378(94)70242-X; Malvy DJM, 2000, J AM ACAD DERMATOL, V42, P47, DOI 10.1016/S0190-9622(00)90008-2; Matarasso SL, 2003, DERMATOL SURG, V29, P7, DOI 10.1046/j.1524-4725.2003.29017.x; Memon AA, 2000, BRIT J DERMATOL, V142, P1154, DOI 10.1046/j.1365-2133.2000.03541.x; Neale R, 2002, ARCH DERMATOL, V138, P1319, DOI 10.1001/archderm.138.10.1319; PRESTON DS, 1992, NEW ENGL J MED, V327, P1649, DOI 10.1056/NEJM199212033272307; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; STERN RS, 1986, ARCH DERMATOL, V122, P537, DOI 10.1001/archderm.122.5.537; STERN RS, 1994, J AM ACAD DERMATOL, V30, P985; Stiller MJ, 1996, ARCH DERMATOL, V132, P631, DOI 10.1001/archderm.132.6.631; Stockfleth E, 2002, ARCH DERMATOL, V138, P1498, DOI 10.1001/archderm.138.11.1498; Thibault PK, 1998, DERMATOL SURG, V24, P573, DOI 10.1111/j.1524-4725.1998.tb04209.x; THOMPSON SC, 1993, NEW ENGL J MED, V329, P1147, DOI 10.1056/NEJM199310143291602; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P527, DOI 10.1001/jama.259.4.527; Weiss JS, 1988, JAMA-J AM MED ASSOC, V260, P926; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P3274; Witheiler DD, 1997, DERMATOL SURG, V23, P191, DOI 10.1111/j.1524-4725.1997.tb00020.x; 2003, PHYS DESK REFERENCE, P1	57	44	49	1	10	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 8	2004	350	15					1526	1534		10.1056/NEJMcp023168	http://dx.doi.org/10.1056/NEJMcp023168			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	810CI	15071127				2023-01-03	WOS:000220682000008
J	Wittenstein, B; Rogers, V; Novelli, V; Clayton, PT; Kenny, MB; Peters, MJ				Wittenstein, B; Rogers, V; Novelli, V; Clayton, PT; Kenny, MB; Peters, MJ			"African medicine" and Reye's syndrome	LANCET			English	Editorial Material							ANALOGS		Great Ormond St Hosp Children NHS Trust, Paediat Intens Care Unit, London WC1N 3JH, England; Great Ormond St Hosp Children NHS Trust, Infect Dis & Microbiol Unit, London WC1N 3JH, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Peters, MJ (corresponding author), Great Ormond St Hosp Children NHS Trust, Paediat Intens Care Unit, Great Ormond St, London WC1N 3JH, England.	m.peters@ich.ucl.ac.uk	Clayton, Peter T/C-1523-2008; Peters, Mark/AAD-7518-2019	Peters, Mark/0000-0003-3653-4808; Clayton, Peter/0000-0001-7592-4302				Bonnet F, 2003, REV MED INTERNE, V24, P11, DOI 10.1016/S0248-8663(02)00702-6; BURRIS AS, 1986, SOUTHERN MED J, V79, P647, DOI 10.1097/00007611-198605000-00037; Casteels-Van Daele M, 2000, EUR J PEDIATR, V159, P641, DOI 10.1007/PL00008399; MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743	4	1	2	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	2004	363	9412					860	860		10.1016/S0140-6736(04)15733-4	http://dx.doi.org/10.1016/S0140-6736(04)15733-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031031				2023-01-03	WOS:000220231500012
J	Velkov, T; Chuang, S; Wielens, J; Sakellaris, H; Charman, WN; Porter, CJH; Scanlon, MJ				Velkov, T; Chuang, S; Wielens, J; Sakellaris, H; Charman, WN; Porter, CJH; Scanlon, MJ			The interaction of lipophilic drugs with intestinal fatty acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; ESCHERICHIA-COLI; DIFFERENT MECHANISMS; SERUM-ALBUMIN; MODEL SYSTEM; LIVER; RAT; EXPRESSION; TRANSPORT; NMR	Intestinal fatty acid-binding protein (I-FABP) is a small protein that binds long-chain dietary fatty acids in the cytosol of the columnar absorptive epithelial cells (enterocytes) of the intestine. The binding cavity of IFABP is much larger than is necessary to bind a fatty acid molecule, which suggests that the protein may be able to bind other hydrophobic and amphipathic ligands such as lipophilic drugs. Herein we describe the binding of three structurally diverse lipophilic drugs, bezafibrate, ibuprofen (both R- and S-isomers) and nitrazepam to I-FABP. The rank order of affinity for I-FABP determined for these compounds was found to be R- ibuprofen approximate to bezafibrate > S-ibuprofen >> nitrazepam. The binding affinities were not directly related to aqueous solubility or partition coefficient of the compounds; however, the freely water-soluble drug diltiazem showed no affinity for I-FABP. Drug-I-FABP interaction interfaces were defined by analysis of chemical shift perturbations in NMR spectra, which revealed that the drugs bound within the central fatty acid binding cavity. Each drug participated in a different set of interactions within the cavity; however, a number of common contacts were observed with residues also involved in fatty acid binding. These data suggest that the binding of non-fatty acid lipophilic drugs to I-FABP may increase the cytosolic solubility of these compounds and thereby facilitate drug transport from the intestinal lumen across the enterocyte to sites of distribution and metabolism.	Monash Univ, Victorian Coll Pharm, Dept Med Chem, Parkville, Vic 3052, Australia; Monash Univ, Dept Pharmaceut, Parkville, Vic 3052, Australia; Monash Univ, Dept Microbiol, Parkville, Vic 3052, Australia	Monash University; Monash University; Monash University	Scanlon, MJ (corresponding author), Monash Univ, Victorian Coll Pharm, Dept Med Chem, 381 Royal Parade, Parkville, Vic 3052, Australia.	Martin.Scanlon@vcp.monash.edu.au	Porter, Christopher JH/C-6333-2011	Porter, Christopher JH/0000-0003-3474-7551; Scanlon, Martin/0000-0002-9230-7506; Charman, William/0000-0002-7051-2023; Chuang, Sara/0000-0001-7738-5613; Wielens, Jerome/0000-0003-3406-4136; velkov, tony/0000-0002-0017-7952				Arighi CN, 2003, BIOCHEMISTRY-US, V42, P7539, DOI 10.1021/bi020680d; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BASS NM, 1986, BIOCHEM BIOPH RES CO, V137, P929, DOI 10.1016/0006-291X(86)90314-1; BURRIER RE, 1986, BIOCHIM BIOPHYS ACTA, V879, P229; EADS J, 1993, J BIOL CHEM, V268, P26375; GLATZ JFC, 1988, NEWS PHYSIOL SCI, V3, P41; GORDON JI, 1985, J BIOL CHEM, V260, P1995; Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164; Hidalgo Ismael J., 2001, Current Topics in Medicinal Chemistry, V1, P385, DOI 10.2174/1568026013395010; HILLGREN KM, 1995, MED RES REV, V15, P83, DOI 10.1002/med.2610150202; Hodsdon ME, 1996, J MOL BIOL, V264, P585, DOI 10.1006/jmbi.1996.0663; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P2278, DOI 10.1021/bi962018l; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P1450, DOI 10.1021/bi961890r; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; HUBBELL T, 1994, BIOCHEMISTRY-US, V33, P3327, DOI 10.1021/bi00177a025; Jenkins-Kruchten AE, 2003, J BIOL CHEM, V278, P47636, DOI 10.1074/jbc.M307680200; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; KANDA T, 1990, BIOCHEM BIOPH RES CO, V168, P1053, DOI 10.1016/0006-291X(90)91136-G; Kane CD, 1996, ANAL BIOCHEM, V233, P197, DOI 10.1006/abio.1996.0028; Kirk WR, 1996, BIOPHYS J, V70, P69, DOI 10.1016/S0006-3495(96)79592-9; KOCHWESER J, 1976, NEW ENGL J MED, V294, P526, DOI 10.1056/NEJM197603042941005; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kurian E, 1996, BIOCHEMISTRY-US, V35, P3865, DOI 10.1021/bi952589y; LACHAU S, 1992, J PHARM SCI, V81, P287, DOI 10.1002/jps.2600810319; Li Y, 1996, J BIOL CHEM, V271, P28038, DOI 10.1074/jbc.271.45.28038; LOWE JB, 1987, J BIOL CHEM, V262, P5931; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Motulsky H, 2003, PRACTICAL GUIDE CURV; Newcomer ME, 1998, SUB CELL BIOCHEM, V30, P53; Ory JJ, 1999, BIOPHYS J, V77, P1107, DOI 10.1016/S0006-3495(99)76961-4; Pastukhov AV, 2003, PROTEINS, V53, P607, DOI 10.1002/prot.10401; PAULUSSEN RJA, 1990, INT J BIOCHEM, V22, P393, DOI 10.1016/0020-711X(90)90142-P; Porter CJH, 2001, ADV DRUG DELIVER REV, V50, P61, DOI 10.1016/S0169-409X(01)00151-X; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SACCHETTINI JC, 1990, MOL CELL BIOCHEM, V98, P81; Shen DD, 1997, ADV DRUG DELIV REV, V27, P99; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Thompson J, 1999, BBA-MOL CELL BIOL L, V1441, P117, DOI 10.1016/S1388-1981(99)00146-8; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; Thumser AEA, 2000, J LIPID RES, V41, P647; THUMSER AEA, 1994, BIOCHEM J, V301, P801, DOI 10.1042/bj3010801; VAHOUNY GV, 1987, ADV LIPID RES, V22, P83; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; VINCENT SH, 1985, J BIOL CHEM, V260, P4521; Vorum H, 1999, DAN MED BULL, V46, P379; Weisiger RA, 2002, MOL CELL BIOCHEM, V239, P35, DOI 10.1023/A:1020550405578; Wolfrum C, 2000, BIOCHEMISTRY-US, V39, P1469, DOI 10.1021/bi991638u	50	49	52	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17769	17776		10.1074/jbc.M410193200	http://dx.doi.org/10.1074/jbc.M410193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15722357	hybrid			2023-01-03	WOS:000228807200027
J	Cooke, R				Cooke, R			Head cooling in neonatal hypoxic-ischaemic encephalopathy	LANCET			English	Editorial Material							MAGNETIC-RESONANCE-SPECTROSCOPY; ASPHYXIA; HYPOTHERMIA		Liverpool Womens Hosp, Neonatal Unit, Liverpool L8 7SS, Merseyside, England	University of Liverpool	Cooke, R (corresponding author), Liverpool Womens Hosp, Neonatal Unit, Liverpool L8 7SS, Merseyside, England.	mc19@liv.ac.uk						Bona E, 1998, PEDIATR RES, V43, P738, DOI 10.1203/00006450-199806000-00005; BOO NY, 1991, J TROP PEDIATRICS, V38, P284; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; Hanrahan JD, 1999, DEV MED CHILD NEUROL, V41, P76, DOI 10.1017/S0012162299000171; JACOBS S, 2004, COCHRANE LIB; KINOTI SN, 1993, E AFR MED J, V70, P422; Robertson NJ, 1999, PEDIATR RES, V46, P287, DOI 10.1203/00006450-199909000-00007; Roth SC, 1997, DEV MED CHILD NEUROL, V39, P718; SHANKARAN S, 1991, EARLY HUM DEV, V25, P135, DOI 10.1016/0378-3782(91)90191-5	9	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					632	634						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721456				2023-01-03	WOS:000227096800004
J	McFiggans, G				McFiggans, G			Marine aerosols and iodine emissions	NATURE			English	Editorial Material							CHEMISTRY		Univ Manchester, Sch Earth Atmospher & Environm Sci, Atmospher Sci Grp, Manchester M60 1QD, Lancs, England	University of Manchester	McFiggans, G (corresponding author), Univ Manchester, Sch Earth Atmospher & Environm Sci, Atmospher Sci Grp, POB 88, Manchester M60 1QD, Lancs, England.	g.mcfiggans@manchester.ac.uk	McFiggans, Gordon B/B-8689-2011	McFiggans, Gordon B/0000-0002-3423-7896	Natural Environment Research Council [NE/B501104/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Allan BJ, 2000, J GEOPHYS RES-ATMOS, V105, P14363, DOI 10.1029/1999JD901188; Carpenter LJ, 1999, J GEOPHYS RES-ATMOS, V104, P1679, DOI 10.1029/98JD02746; GARLAND JA, 1981, J GEOPHYS RES-OCEANS, V86, P3183, DOI 10.1029/JC086iC04p03183; McFiggans G, 2000, J GEOPHYS RES-ATMOS, V105, P14371, DOI 10.1029/1999JD901187; McFiggans G, 2004, ATMOS CHEM PHYS, V4, P701, DOI 10.5194/acp-4-701-2004; O'Dowd C, 1999, GEOPHYS RES LETT, V26, P1707, DOI 10.1029/1999GL900335; O'Dowd CD, 2001, ATMOS RES, V58, P167, DOI 10.1016/S0169-8095(01)00098-9; O'Dowd CD, 2002, NATURE, V417, P632, DOI 10.1038/nature00775; Saiz-Lopez A, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019215	9	28	27	4	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					E13	E13		10.1038/nature03372	http://dx.doi.org/10.1038/nature03372			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703706				2023-01-03	WOS:000226862000033
J	Cohen, JP; Paquette, C; Cairns, CP				Cohen, JP; Paquette, C; Cairns, CP			Switching prescription drugs to over the counter	BRITISH MEDICAL JOURNAL			English	Article									Tufts Univ, Sch Med, Tufts Ctr Study Drug Dev, Boston, MA 02111 USA	Tufts University	Cohen, JP (corresponding author), Tufts Univ, Sch Med, Tufts Ctr Study Drug Dev, 192 South St,Suite 550, Boston, MA 02111 USA.	joshua.cohen@tufts.edu						[Anonymous], 2004, LANCET, V363, P1659; *BRIST MYERS SQUIB, ADV COMM M BRIEF BOO; COHEN J, 2003, AM J THER, P1370; DiMasi J, 2001, J RES PHARMA EC, V11, P43, DOI [10.1300/J063v11n03_04, DOI 10.1300/J063V11N03_04]; *MED HEALTHC PROD, 2003, CONS DOC ARM 18 REQ; *NONPR MED AC, JOINT FDA ADV COMM R; *US FDA, FY 2004 FDA BUDG BRI; *WELLP, ISS PAP FDA PET PRES; *WORLD SELF MED IN, OTC INGR TABL	9	42	42	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 1	2005	330	7481					39	41		10.1136/bmj.330.7481.39	http://dx.doi.org/10.1136/bmj.330.7481.39			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885SH	15626806	Green Published			2023-01-03	WOS:000226176700021
J	Majumdar, SR; Almasi, EA; Stafford, RS				Majumdar, SR; Almasi, EA; Stafford, RS			Promotion and prescribing of hormone therapy after report of harm by the women's health initiative	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTINUING MEDICAL-EDUCATION; RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; NATIONAL TRENDS; UNITED-STATES; ESTROGEN; PUBLICATION; PHYSICIANS; INDUSTRY	Context Little is known about how the pharmaceutical industry responds to evidence of harm associated with its products, such as the publication in July 2002 of the Women's Health Initiative Estrogen Plus Progestin Trial (WHI E+P) report demonstrating that standard-dose Prempro produced significant harm and lacked net benefits. Objective To examine pharmaceutical industry response to the WHI E+P results by analyzing promotional expenditures for hormone therapy before and after July 2002. Design and Setting Nationally representative and prospectively collected longitudinal data (January 2001 through December 2003) on prescribing and promotion of hormone therapies were obtained from IMS Health and Consumer Media Reports. Main Outcome Measures Trends in quarterly prescriptions for hormone therapy and expenditures on 5 modes of drug promotion: samples, office-based detailing, hospital-based promotion, journal advertisements, and direct-to-consumer advertising. Results Prior to the WHI E+P report, prescribing rates and promotional spending for hormone therapy were stable. In the quarter before the WHI E+P report (April-June 2002), 22.4 million prescriptions for hormone therapy were dispensed and $71 million was spent on promotion (in annual terms, $350 per year per US physician). Within 9 months of the report's publication (quarter 1 of 2003), there was a 32% decrease in hormone therapy prescriptions, and a nadir had been reached for promotional spending (37% decrease compared with pre-WHI E+P levels). Spending decreased for all promotional activities and most hormone therapies. overall, the greatest declines were for samples (36% decrease as of quarter 1 of 2003) and direct-to-consumer advertising (100% decrease). The greatest declines in promotion occurred for standard-dose Prempro (61% decrease as of quarter 1 of 2003), the agent implicated by the WHI E+P report. More recently, promotional efforts have increased, particularly for lower-dose Prempro, a resurgence associated with modestly increased prescriptions for this newer agent. Conclusions Concordant with its widespread use, hormone therapy was among the most heavily promoted medications prior to the WHI E+P report. Following reporting of the evidence of harm from this trial, there was a substantial decline in promotional spending for hormone therapy, particularly for the agents most directly implicated in the trial. Interrelated with the impact of the trial results themselves and the ensuing media coverage, reduced promotion may have contributed to a substantial decline in hormone therapy prescriptions.	Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Program Prevent Outcomes & Practices, Stanford, CA 94305 USA; Univ Alberta, Dept Med, Edmonton, AB, Canada	Stanford University; University of Alberta	Stafford, RS (corresponding author), Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Program Prevent Outcomes & Practices, Hoover Pavil, Stanford, CA 94305 USA.	rstafford@stanford.edu	Stafford, Randall/F-3974-2017	Stafford, Randall/0000-0003-1805-1271	AHRQ HHS [R01-HS013405] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS013405] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Austin PC, 2003, JAMA-J AM MED ASSOC, V289, P3241, DOI 10.1001/jama.289.24.3241; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; GARDNER J, 1992, US NEWS WORLD RE NOV, V8, P71; Herrington DM, 2003, NEW ENGL J MED, V349, P519, DOI 10.1056/NEJMp038108; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Holmer AF, 2001, JAMA-J AM MED ASSOC, V285, P2012, DOI 10.1001/jama.285.15.2012; Katz Anne, 2003, Health Care Women Int, V24, P927, DOI 10.1080/07399330390244167; Lawton B, 2003, BRIT MED J, V327, P845, DOI 10.1136/bmj.327.7419.845; Levy R, 1994, Arch Fam Med, V3, P327, DOI 10.1001/archfami.3.4.327; Ma J, 2003, CLIN THER, V25, P1503, DOI 10.1016/S0149-2918(03)80136-4; Majumdar SR, 2003, AM J MED, V115, P467, DOI 10.1016/S0002-9343(03)00422-4; Majumdar SR, 2001, J GEN INTERN MED, V16, P351, DOI 10.1046/j.1525-1497.2001.016006351.x; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; *N AM MEN SOC, 2003, MENOPAUSE, V10, P6; Naylor CD, 2004, JAMA-J AM MED ASSOC, V291, P104, DOI 10.1001/jama.291.1.104; Petersen Melody, 2002, N Y Times Web, pC2; Relman AS, 2001, JAMA-J AM MED ASSOC, V285, P2009, DOI 10.1001/jama.285.15.2009; ROSSDEGNAN D, 1993, JAMA-J AM MED ASSOC, V270, P1937, DOI 10.1001/jama.270.16.1937; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schwartz LM, 2004, ANN INTERN MED, V140, P226, DOI 10.7326/0003-4819-140-3-200402030-00015; Smalley W, 2000, JAMA-J AM MED ASSOC, V284, P3036, DOI 10.1001/jama.284.23.3036; Stafford RS, 2004, JAMA-J AM MED ASSOC, V291, P54, DOI 10.1001/jama.291.1.54; Stafford RS, 2003, ARCH INTERN MED, V163, P1046, DOI 10.1001/archinte.163.9.1046; Wang TJ, 1999, CIRCULATION, V99, P2055, DOI 10.1161/01.CIR.99.15.2055; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; ZATE M, 2000, VENTURA COUNTY  0826; 1996, ADWEEK          1125, V46, P3	28	119	128	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2004	292	16					1983	1988		10.1001/jama.292.16.1983	http://dx.doi.org/10.1001/jama.292.16.1983			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865DO	15507584				2023-01-03	WOS:000224682900023
J	Nitzan, U; Lichtenberg, P				Nitzan, U; Lichtenberg, P			Questionnaire survey on use of placebo	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-PRACTICE; TRIALS	Objectives To gauge the frequency and circumstances of use of placebo in clinical practice and the attitudes towards its use among those who administer it. Design Retrospective questionnaire. Setting Two large hospitals and various community clinics in the Jerusalem area. Participants 31. physicians working in hospital inpatient and outpatient departments, 31 head nurses working in hospital inpatient departments, and 27 family physicians working in community clinics. Main outcome measures Self report of frequency and circumstances of; and attitudes towards, use of placebo. Results Among the 89 respondents, 53 (60%) used placebos (95% confidence interval 49% to 70%). Among users, 33 (62%) prescribed a placebo as often as once a month or more; 36 (68%) told patients they were receiving actual medication; 15 (28%) considered that placebos were a diagnostic tool; and 48/51 (94%) reported that they found placebos generally or occasionally effective. Conclusion Most practitioners questioned in this study continue to use placebos. Used wisely, placebos might have a legitimate place in therapeutics. Wider recognition of the practice and debate about its implications are imperative.	Herzog Hosp, IL-91351 Jerusalem, Israel; Hadassah Med Sch, Dept Psychiat, IL-91351 Jerusalem, Israel	Hebrew University of Jerusalem; Herzog Medical Center; Hebrew University of Jerusalem	Lichtenberg, P (corresponding author), Herzog Hosp, POB 35300, IL-91351 Jerusalem, Israel.	licht@cc.huji.ac.il						BROWN WA, 1994, NEUROPSYCHOPHARMACOL, V10, P265, DOI 10.1038/npp.1994.53; DeDeyn PP, 1996, J MED ETHICS, V22, P140, DOI 10.1136/jme.22.3.140; GOODWIN JS, 1979, ANN INTERN MED, V91, P106, DOI 10.7326/0003-4819-91-1-106; Hill Joal, 2003, Lancet, V362, P254, DOI 10.1016/S0140-6736(03)13940-2; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Hyland ME, 2003, CLIN MED, V3, P347, DOI 10.7861/clinmedicine.3-4-347; LICHTENBERG P, IN PRESS J MED ETHIC; Lione A, 2003, LANCET, V362, P999, DOI 10.1016/S0140-6736(03)14382-6; Vase L, 2002, PAIN, V99, P443, DOI 10.1016/S0304-3959(02)00205-1	9	91	91	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 23	2004	329	7472					944	946		10.1136/bmj.38236.646678.55	http://dx.doi.org/10.1136/bmj.38236.646678.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866KU	15377572	Green Published, Bronze			2023-01-03	WOS:000224773200015
J	Bates, SM; Ginsberg, JS				Bates, SM; Ginsberg, JS			Treatment of deep-vein thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOLECULAR-WEIGHT HEPARIN; RECURRENT VENOUS THROMBOEMBOLISM; ORAL ANTICOAGULANT-THERAPY; INTENSITY WARFARIN THERAPY; PULMONARY-EMBOLISM; UNFRACTIONATED HEPARIN; LONG-TERM; RANDOMIZED-TRIAL; PREVENTION; RISK	52-year-old-woman with no history of venous thromboembolism presents with a four-day history of discomfort in her left calf. Proximal deep-vein thrombosis is diagnosed by compression ultrasonography. How should her case be managed?	McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada	McMaster University	Bates, SM (corresponding author), McMaster Univ, Dept Med, HSC 3W11,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	batesm@mcmaster.ca	ginsberg, jeffrey s/ABC-1065-2020					ABRAMS J, 2002, CARDIOVASCULAR THERA, P97; Agnelli G, 2001, NEW ENGL J MED, V345, P165, DOI 10.1056/NEJM200107193450302; Baglin T, 2003, LANCET, V362, P523, DOI 10.1016/S0140-6736(03)14111-6; BAGLIN T, 2003, 19 C INT SOC THROMB; BARRITT DW, 1960, LANCET, V1, P1309; Brandjes DPM, 1997, LANCET, V349, P759, DOI 10.1016/S0140-6736(96)12215-7; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; CHRISTIANSEN S, 2003, 19 C INT SOC THROMB; Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; Douketis JD, 1998, JAMA-J AM MED ASSOC, V279, P458, DOI 10.1001/jama.279.6.458; Francis CW, 2003, BLOOD, V102, p6A; Galle C, 2001, THROMB HAEMOSTASIS, V86, P1156, DOI 10.1055/s-0037-1616044; Ginsberg JS, 2001, ARCH INTERN MED, V161, P2105, DOI 10.1001/archinte.161.17.2105; Gould MK, 1999, ANN INTERN MED, V130, P800, DOI 10.7326/0003-4819-130-10-199905180-00003; Hirsh J, 1996, CIRCULATION, V93, P2212, DOI 10.1161/01.CIR.93.12.2212; Hirsh J, 2001, CHEST, V119, p64S, DOI 10.1378/chest.119.1_suppl.64S; Hyers TM, 2001, CHEST, V119, p176S, DOI 10.1378/chest.119.1_suppl.176S; KAKKAR VV, 1969, LANCET, V2, P230; Kearon C, 1999, NEW ENGL J MED, V341, P298; Kearon C, 1998, ANN INTERN MED, V129, P425, DOI 10.7326/0003-4819-128-8-199804150-00011; Kearon C, 2003, NEW ENGL J MED, V349, P631, DOI 10.1056/NEJMoa035422; Kearon C, 2001, Semin Vasc Med, V1, P7, DOI 10.1055/s-2001-14668; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Kearon C, 2001, J THROMB THROMBOLYS, V12, P59, DOI 10.1023/A:1012790511790; Kearon C, 1998, ANN INTERN MED, V128, P663, DOI 10.7326/0003-4819-128-8-199804150-00011; KEARON C, 2001, 18 C INT SOC THROMB; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Koopman MMW, 1997, NEW ENGL J MED, V337, P1251; Kyrle PA, 2004, NEW ENGL J MED, V350, P2558, DOI 10.1056/NEJMoa032959; LAGERSTEDT CI, 1985, LANCET, V2, P515; Lee AYY, 2003, NEW ENGL J MED, V349, P146, DOI 10.1056/NEJMoa025313; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LEVINE MN, 1994, ARCH INTERN MED, V154, P49, DOI 10.1001/archinte.154.1.49; Linkins LA, 2003, ANN INTERN MED, V139, P893, DOI 10.7326/0003-4819-139-11-200312020-00007; Margaglione M, 1999, THROMB HAEMOSTASIS, V82, P1583; *MATISSE INV, 2003, 19 C INT SOC THROMB; MONREAL M, 1994, THROMB HAEMOSTASIS, V71, P7; MOSER KM, 1994, JAMA-J AM MED ASSOC, V271, P1908; MOSER KM, 1994, JAMA-J AM MED ASSOC, V271, P223, DOI 10.1001/jama.271.3.223; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; Pettila V, 2002, THROMB HAEMOSTASIS, V87, P182; Pinede L, 2001, CIRCULATION, V103, P2453; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Prins MH, 1999, THROMB HAEMOSTASIS, V82, P892; Ridker PM, 2003, NEW ENGL J MED, V348, P1425, DOI 10.1056/NEJMoa035029; Rodger M, 1998, CAN MED ASSOC J, V159, P931; Rosendaal FR, 1999, LANCET, V353, P1167, DOI 10.1016/S0140-6736(98)10266-0; Schulman S, 2003, NEW ENGL J MED, V349, P1713, DOI 10.1056/NEJMoa030104; Schulman S, 2003, NEW ENGL J MED, V349, P675, DOI 10.1056/NEJMcp025373; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; STAMATAKIS JD, 1977, BRIT MED J, V2, P223, DOI 10.1136/bmj.2.6081.223; van Der Heijden J.F., 2000, COCHRANE DB SYST REV, V4; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; Wells PS, 2001, THROMB HAEMOSTASIS, V86, P499	57	146	161	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					268	277		10.1056/NEJMcp031676	http://dx.doi.org/10.1056/NEJMcp031676			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837KA	15254285				2023-01-03	WOS:000222627200011
J	Pantilat, SZ; Steimle, AE				Pantilat, SZ; Steimle, AE			Palliative care for patients with heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED-TRIALS; MEDICARE PATIENTS; ELDERLY-PATIENTS; INCREASED RISK; SUDDEN-DEATH; ANEMIA; LIFE; PREVENTION; MANAGEMENT; MORTALITY	Heart failure accounts for more hospitalizations among Medicare beneficiaries than any other condition. Its symptoms, including shortness of breath, fatigue, and edema, can be frightening and diminish quality of life. Although treatment advances have allowed patients to live longer with a better quality of life, heart failure remains a leading cause of death in the United States. Half of heart failure patients die within 5 years of diagnosis, and for many patients, death is sudden. Given the availability of effective treatments, the prevalence of distressing symptoms, and a persistent high risk of death that may occur suddenly, physicians must simultaneously treat the underlying condition while helping patients plan for future needs and complete advance directives. Using the case of Mr R, a 74-year-old man with heart failure, we illustrate ways that physicians can address these issues to improve the care of patients with heart failure, including symptom management and discussing advance directives, prognosis, and hospice care. By combining optimal medical management with palliative care, physicians can best care for heart failure patients and their families.	Univ Calif San Francisco, Dept Med, Palliat Care Serv, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Hosp Sect, San Francisco, CA 94143 USA; Kaiser Permanente No Calif, Heart Failure Program, Santa Clara, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente	Pantilat, SZ (corresponding author), Univ Calif San Francisco, Dept Med, Palliat Care Serv, 521 Parnassus Ave,Suite C-126,Box 0903, San Francisco, CA 94143 USA.	stevep@medicine.ucsf.edu						*AM HEART ASS, 2000, HEART DIS STROK STAT; Anker SD, 1997, CIRCULATION, V96, P526; Beck A, 1997, J AM GERIATR SOC, V45, P543, DOI 10.1111/j.1532-5415.1997.tb03085.x; Berger R, 2002, CIRCULATION, V105, P2392, DOI 10.1161/01.CIR.0000016642.15031.34; Bleumink GS, 2003, DRUGS, V63, P525, DOI 10.2165/00003495-200363060-00001; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Block SD, 2001, JAMA-J AM MED ASSOC, V285, P2898, DOI 10.1001/jama.285.22.2898; *CAR MAN I KAIS PE, 2002, SUMM EV BAS GUID MAN; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Corvera-Tindel T, 2004, AM HEART J, V147, P339, DOI 10.1016/j.ahj.2003.09.007; COSTANZO MR, 1995, CIRCULATION, V92, P3593, DOI 10.1161/01.CIR.92.12.3593; CROSS KL, 2000, AAHPM B, V1, P6; Dries DL, 2000, J AM COLL CARDIOL, V35, P681, DOI 10.1016/S0735-1097(99)00608-7; ELKAYAM U, 1990, CIRCULATION, V82, P1954, DOI 10.1161/01.CIR.82.6.1954; Ezekowitz JA, 2003, ANN INTERN MED, V138, P445, DOI 10.7326/0003-4819-138-6-200303180-00007; Felker GM, 2003, AM HEART J, V145, pS18, DOI 10.1067/mhj.2003.150; Felker GM, 2003, AM J CARDIOL, V92, P625, DOI 10.1016/S0002-9149(03)00740-9; Field MJ, 1997, APPROACHING DEATH IM; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Heerdink ER, 1998, ARCH INTERN MED, V158, P1108, DOI 10.1001/archinte.158.10.1108; Heidenreich PA, 2002, AM HEART J, V144, P422, DOI 10.1067/mhj.2002.125499; Hjalmarson A, 1999, LANCET, V353, P2001; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; Hunt SA, 2002, J HEART LUNG TRANSPL, V21, P189, DOI 10.1016/S1053-2498(01)00776-8; Jiang W, 2001, ARCH INTERN MED, V161, P1849, DOI 10.1001/archinte.161.15.1849; Johnson MJ, 2002, EUR J HEART FAIL, V4, P753, DOI 10.1016/S1388-9842(02)00158-7; Kaneko Y, 2003, NEW ENGL J MED, V348, P1233, DOI 10.1056/NEJMoa022479; Kizer JR, 2001, ARCH INTERN MED, V161, P1145, DOI 10.1001/archinte.161.9.1145; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Krumholz HM, 1998, CIRCULATION, V98, P648, DOI 10.1161/01.CIR.98.7.648; Krumholz HM, 2002, J AM COLL CARDIOL, V39, P83, DOI 10.1016/S0735-1097(01)01699-0; La Rovere MT, 2003, CIRCULATION, V107, P565, DOI 10.1161/01.CIR.0000047275.25795.17; Lamont EB, 2003, JAMA-J AM MED ASSOC, V290, P98, DOI 10.1001/jama.290.1.98; Levenson JW, 2000, J AM GERIATR SOC, V48, pS101, DOI 10.1111/j.1532-5415.2000.tb03119.x; *LITTL BROWN MED D, 1994, NOM CRIT DIAGN DIS H; Liu P, 2003, CAN J CARDIOL, V19, P347; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Mancini DM, 2003, CIRCULATION, V107, P294, DOI 10.1161/01.CIR.0000044914.42696.6A; Masoudi FA, 2003, JAMA-J AM MED ASSOC, V290, P81, DOI 10.1001/jama.290.1.81; McAlister FA, 1999, AM HEART J, V138, P87, DOI 10.1016/S0002-8703(99)70251-6; McCarthy M, 1996, J ROY COLL PHYS LOND, V30, P325; MCCORMICK TR, 1995, WESTERN J MED, V163, P236; Mitka M, 2003, JAMA-J AM MED ASSOC, V290, P1835, DOI 10.1001/jama.290.14.1835; Murberg TA, 1999, INT J PSYCHIAT MED, V29, P311, DOI 10.2190/0C1C-A63U-V5XQ-1DAL; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; *NAT HOSP PALL CAR, 1996, MED GUID DET PROGN S; Oliva F, 1999, AM HEART J, V138, P247, DOI 10.1016/S0002-8703(99)70108-0; Page J, 2000, ARCH INTERN MED, V160, P777, DOI 10.1001/archinte.160.6.777; Pantilat SZ, 1999, JAMA-J AM MED ASSOC, V282, P171, DOI 10.1001/jama.282.2.171; Pantilat SZ, 1999, WESTERN J MED, V171, P253; Philbin EF, 2000, AM HEART J, V139, P491, DOI 10.1067/mhj.2000.104238; Piepoli MF, 2004, BMJ-BRIT MED J, V328, P189, DOI 10.1136/bmj.37938.645220.EE; Pozehl Bunny, 2003, Prog Cardiovasc Nurs, V18, P177; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Rabow MW, 2004, JAMA-J AM MED ASSOC, V291, P483, DOI 10.1001/jama.291.4.483; Silverberg DS, 2001, J AM COLL CARDIOL, V37, P1775, DOI 10.1016/S0735-1097(01)01248-7; Sim I, 1997, CIRCULATION, V96, P2823, DOI 10.1161/01.CIR.96.9.2823; Stevenson LW, 2003, CIRCULATION, V108, P492, DOI 10.1161/01.CIR.0000078349.43742.8A; Stevenson WG, 2001, J CARDIOVASC ELECTR, V12, P112, DOI 10.1046/j.1540-8167.2001.00112.x; Szachniewicz J, 2003, INT J CARDIOL, V90, P303, DOI 10.1016/S0167-5273(02)00574-0; Thompson PD, 2003, CIRCULATION, V107, P3109, DOI 10.1161/01.CIR.0000075572.40158.77; Torp-Pedersen C, 1999, NEW ENGL J MED, V341, P857, DOI 10.1056/NEJM199909163411201; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Williams SG, 2003, HEART, V89, P1085, DOI 10.1136/heart.89.9.1085; Young JB, 2002, JAMA-J AM MED ASSOC, V287, P1531, DOI 10.1001/jama.287.12.1531; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	69	88	90	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2004	291	20					2476	2482		10.1001/jama.291.20.2476	http://dx.doi.org/10.1001/jama.291.20.2476			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	823HB	15161899				2023-01-03	WOS:000221599700031
J	Anand, KJS; Hall, RW; Desai, N; Shephard, B; Bergqvist, LL; Young, TE; Boyle, EM; Carbajal, R; Bhutani, VK; Moore, MB; Kronsberg, SS; Barton, BA				Anand, KJS; Hall, RW; Desai, N; Shephard, B; Bergqvist, LL; Young, TE; Boyle, EM; Carbajal, R; Bhutani, VK; Moore, MB; Kronsberg, SS; Barton, BA		NEOPAIN Trial Investigators Grp	Effects of morphine analgesia in ventilated preterm neonates: primary outcomes from the NEOPAIN randomised trial	LANCET			English	Article							INTRA-VENTRICULAR HEMORRHAGE; DOUBLE-BLIND; PERIVENTRICULAR LEUKOMALACIA; NEWBORN-INFANTS; MAJOR SURGERY; PAIN; PHARMACOKINETICS; INFUSION; STRESS; DIAMORPHINE	Background Opioid analgesia is commonly used during neonatal intensive care. We undertook the Neurologic Outcomes and Pre-emptive Analgesia in Neonates (NEOPAIN) trial to investigate whether pre-emptive morphine analgesia decreases the rate of a composite primary outcome of neonatal death, severe intraventricular haemorrhage (IVH), and periventricular leucomalacia (PVL) in preterm neonates. Methods Ventilated preterm neonates (n=898) from 16 centres were randomly assigned masked placebo (n=449) or morphine (n=449) infusions. After a loading dose (100 mug/kg), morphine infusions (23-26 weeks of gestation 10 mug kg(-1) h(-1); 27-29 weeks 20 mug kg(-1) h(-1); 30-32 weeks 30 mug kg(-1) h(-1)) were continued as long as clinically justified (maximum 14 days). Open-label morphine could be given on clinical judgment (placebo group 242/443 [54.6%], morphine group 202/446 [45.3%]). Analyses were by intention to treat. Findings Baseline variables were similar in the randomised groups. The placebo and morphine groups had similar rates of the composite outcome (105/408 [26%] vs 115/419 [27%]), neonatal death (47/449 [11%] vs 58/449 [13%]), severe IVH (46/429 [11%] vs 55/411 [13%]), and PVL (34/367 [9%] vs 27/367 [7%]). For neonates who were not given open-label morphine, rates of the composite outcome (53/225 [24%] vs 27/179 [15%], p=00338) and severe IVH (19/219 [9%] vs 6/189 [3%], p=0.0209) were higher in the morphine group than the placebo group. Placebo-group neonates receiving open-label morphine had worse rates of the composite outcome than those not receiving open-label morphine (78/228 [34%] vs 27/179 [15%], p<0.0001). Morphine-group neonates receiving open-label morphine were more likely to develop severe IVH (36/190 [19%] vs 19/219 [9%], p=0.0024). Interpretation Pre-emptive morphine infusions did not reduce the frequency of severe IVH, PVL, or death in ventilated preterm neonates, but intermittent boluses of open-label morphine were associated with an increased rate of the composite outcome. The morphine doses used in this study decrease clinical signs of pain but can cause significant adverse effects in ventilated preterm neonates.	Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Anesthesiol Neurobiol & Pharmacol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA; Univ Kentucky, Med Ctr, Dept Pediat, Lexington, KY USA; Tufts Univ, Sch Med, Dept Pediat, Boston, MA 02111 USA; Astrid Lindgrens Childrens Hosp, Karolinska Inst, Neonatal Res Unit, Stockholm, Sweden; Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; Wake Med Ctr, Raleigh, NC USA; Univ Edinburgh, Simpson Mem Matern Pavil, Edinburgh, Midlothian, Scotland; Ctr Hosp Poissy St Germain, Serv Pediat & Med Neonatale, Poissy, France; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Penn Hosp, Philadelphia, PA 19107 USA; Maryland Med Res Inst, Baltimore, MD USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Kentucky; Tufts University; Karolinska Institutet; University of North Carolina; University of North Carolina Chapel Hill; University of Edinburgh; Hospital Chi of Poissy Saint Germain; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Anand, KJS (corresponding author), Arkansas Childrens Hosp, S-4417,800 Marshall St, Little Rock, AR 72202 USA.	anandsunny@uams.edu	Anand, Kanwaljeet/B-3287-2014; Boyle, Elaine/I-6298-2018	Anand, Kanwaljeet/0000-0001-6498-1483; Boyle, Elaine/0000-0002-5038-3148; Barton, Bruce/0000-0001-7878-8895	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036270, R01HD036484] Funding Source: NIH RePORTER; NICHD NIH HHS [HD36270, HD36484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anand KJS, 1998, BIOL NEONATE, V73, P1, DOI 10.1159/000013953; Anand KJS, 1999, ARCH PEDIAT ADOL MED, V153, P331; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; BARKER DP, 1995, ARCH DIS CHILD-FETAL, V73, pF22, DOI 10.1136/fn.73.1.F22; BARKER DP, 1995, ARCH DIS CHILD-FETAL, V72, pF47, DOI 10.1136/fn.72.1.F47; Barker DP, 1996, ARCH DIS CHILD-FETAL, V75, pF187, DOI 10.1136/fn.75.3.F187; BARRETT DA, 1991, BRIT J CLIN PHARMACO, V32, P31, DOI 10.1111/j.1365-2125.1991.tb05609.x; Barrett DA, 1996, BRIT J CLIN PHARMACO, V41, P531, DOI 10.1046/j.1365-2125.1996.03539.x; Bass W Thomas, 2002, J Perinatol, V22, P64; Baud O, 1999, NEW ENGL J MED, V341, P1190, DOI 10.1056/NEJM199910143411604; BHAT R, 1992, J PEDIATR-US, V120, P795, DOI 10.1016/S0022-3476(05)80251-3; BHAT R, 1990, J PEDIATR-US, V117, P477, DOI 10.1016/S0022-3476(05)81102-3; Bhutta AT, 2001, PHYSIOL BEHAV, V73, P51, DOI 10.1016/S0031-9384(01)00432-2; Bouwmeester NJ, 2001, BRIT J ANAESTH, V87, P390, DOI 10.1093/bja/87.3.390; Cunningham N, 1999, PAIN FORUM, V8, P110; De Paoli AG, 2003, ARCH DIS CHILD-FETAL, V88, P168; DYKE MP, 1995, J PAEDIATR CHILD H, V31, P176, DOI 10.1111/j.1440-1754.1995.tb00780.x; Goldstein R F, 1991, J Perinatol, V11, P365; GREENOUGH A, 2003, COCHRANE LIB, DOI UNSP CD000456; Grunau RE, 2000, CLIN J PAIN, V16, P37, DOI 10.1097/00002508-200003000-00007; HARTLEY R, 1993, ARCH DIS CHILD-FETAL, V69, P55, DOI 10.1136/adc.69.1_Spec_No.55; Howard V A, 1998, J Pediatr Nurs, V13, P164; Johnston CC, 1997, CLIN J PAIN, V13, P308, DOI 10.1097/00002508-199712000-00008; Kahn DJ, 1998, ARCH PEDIAT ADOL MED, V152, P844; Kennedy KA, 1999, J PEDIATR-US, V134, P127, DOI 10.1016/S0022-3476(99)70399-9; LAZZARA A, 1980, PEDIATRICS, V65, P30; Lemons JA, 2000, PEDIATRICS, V105, P454; Maalouf EF, 2001, PEDIATRICS, V107, P719, DOI 10.1542/peds.107.4.719; McIntosh N, 1997, EUR J PEDIATR, V156, P173, DOI 10.1007/s004310050576; Ment LR, 2002, NEUROLOGY, V58, P1726, DOI 10.1212/WNL.58.12.1726; Orsini AJ, 1996, J PEDIATR-US, V129, P140, DOI 10.1016/S0022-3476(96)70201-9; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Perlman JM, 2000, ARCH PEDIAT ADOL MED, V154, P822, DOI 10.1001/archpedi.154.8.822; POKELA ML, 1994, PEDIATRICS, V93, P379; POKELA ML, 1993, BIOL NEONATE, V64, P360; QUINN MW, 1993, LANCET, V342, P324, DOI 10.1016/0140-6736(93)91472-X; QUINN MW, 1992, EARLY HUM DEV, V30, P241, DOI 10.1016/0378-3782(92)90073-P; Richardson D K, 2001, J Perinatol, V21, P121, DOI 10.1038/sj.jp.7200501; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Sabatino G, 1997, EARLY HUM DEV, V47, P263, DOI 10.1016/S0378-3782(96)01781-1; Scott CS, 1999, J PEDIATR-US, V135, P423, DOI 10.1016/S0022-3476(99)70163-0; Simons SHP, 2003, ARCH PEDIAT ADOL MED, V157, P1058, DOI 10.1001/archpedi.157.11.1058; Simons SHP, 2003, JAMA-J AM MED ASSOC, V290, P2419, DOI 10.1001/jama.290.18.2419; Stevens B J, 1993, J Obstet Gynecol Neonatal Nurs, V22, P531, DOI 10.1111/j.1552-6909.1993.tb01838.x; Vaccarino AL, 1995, PAIN, V63, P385, DOI 10.1016/0304-3959(95)00069-0; van Dijk M, 2002, PAIN, V98, P305, DOI 10.1016/S0304-3959(02)00031-3; Volpe JJ, 1997, CLIN PERINATOL, V24, P567, DOI 10.1016/S0095-5108(18)30159-3; Volpe JJ, 2001, PEDIATR RES, V50, P553, DOI 10.1203/00006450-200111000-00003; Wu YW, 2000, JAMA-J AM MED ASSOC, V284, P1417, DOI 10.1001/jama.284.11.1417; Zahorodny W, 1998, J DEV BEHAV PEDIATR, V19, P89, DOI 10.1097/00004703-199804000-00005	50	334	348	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	2004	363	9422					1673	1682		10.1016/S0140-6736(04)16251-X	http://dx.doi.org/10.1016/S0140-6736(04)16251-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822NG	15158628				2023-01-03	WOS:000221546300007
J	Studd, RC; Stewart, PJ				Studd, RC; Stewart, PJ			Intraabdominal abscess after acupuncture	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Concord Hosp, Sydney, NSW, Australia	Concord Repatriation General Hospital	Studd, RC (corresponding author), Concord Hosp, Sydney, NSW, Australia.								0	10	11	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	2004	350	17					1763	1763		10.1056/NEJMicm010431	http://dx.doi.org/10.1056/NEJMicm010431			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	814AJ	15103003				2023-01-03	WOS:000220947300011
J	Kim, JV; Latouche, JB; Riviere, I; Sadelain, M				Kim, JV; Latouche, JB; Riviere, I; Sadelain, M			The ABCs of artificial antigen presentation	NATURE BIOTECHNOLOGY			English	Review							CD4(+) T-CELLS; TUMOR-DERIVED EXOSOMES; COLONY-STIMULATING FACTOR; PEPTIDE-BASED VACCINE; EXPRESS CD40 LIGAND; DENDRITIC CELLS; PRESENTING CELLS; IN-VIVO; METASTATIC MELANOMA; ADOPTIVE TRANSFER	Artificial antigen presentation aims to accelerate the establishment of therapeutic cellular immunity. Artificial antigen-presenting cells (AAPCs) and their cell-free substitutes are designed to stimulate the expansion and acquisition of optimal therapeutic features of T cells before therapeutic infusion, without the need for autologous antigen-presenting cells. Compelling recent advances include fibroblast AAPCs that process antigens, magnetic beads that are antigen specific, novel T-cell costimulatory combinations, the augmentation of therapeutic potency of adoptively transferred T lymphocytes by interleukin-15, and the safe use of dendritic cell-derived exosomes pulsed with tumor antigen. Whereas the safety and potency of the various systems warrant further preclinical and clinical studies, these emerging technologies are poised to have a major impact on adoptive T-cell therapy and the investigation of T cell-mediated immunity.	Mem Sloan Kettering Canc Ctr, Dept Med, Lab Gene Transfer & Gene Express, Gene Transfer & Somat Cell Engn Facil, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Sadelain, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Lab Gene Transfer & Gene Express, Gene Transfer & Somat Cell Engn Facil, 1275 York Ave, New York, NY 10021 USA.	m-sadelain@ski.mskcc.org		Latouche, Jean-Baptiste/0000-0003-4802-5429	NATIONAL CANCER INSTITUTE [T32CA009512, P01CA059350, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA-59350, CA-08748, CA-09512] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn HJ, 1997, J IMMUNOL, V159, P2125; Alpdogan O, 2003, J CLIN INVEST, V112, P1095, DOI 10.1172/JCI200317865; Andre F, 2004, J IMMUNOL, V172, P2126, DOI 10.4049/jimmunol.172.4.2126; Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Andre F, 2002, VACCINE, V20, pA28, DOI 10.1016/S0264-410X(02)00384-5; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; Bhardwaj N, 1996, J CLIN INVEST, V98, P715, DOI 10.1172/JCI118843; Brentjens RJ, 2003, NAT MED, V9, P279, DOI 10.1038/nm827; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Cai ZL, 1996, P NATL ACAD SCI USA, V93, P14736, DOI 10.1073/pnas.93.25.14736; Chaput N, 2003, ADV EXP MED BIOL, V532, P215; Chaput N, 2003, B CANCER, V90, P695; Chaput N, 2004, J IMMUNOL, V172, P2137, DOI 10.4049/jimmunol.172.4.2137; DELBRUCK A, 1968, STRUCTURAL CHEM MOL, P198; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Fehniger TA, 2002, CYTOKINE GROWTH F R, V13, P169, DOI 10.1016/S1359-6101(01)00021-1; Gajewski Thomas F, 2002, Cancer Chemother Biol Response Modif, V20, P343; Gett AV, 2003, NAT IMMUNOL, V4, P355, DOI 10.1038/ni908; Gong Michael C., 1999, Neoplasia (New York), V1, P123, DOI 10.1038/sj.neo.7900018; Hori S, 2003, ADV IMMUNOL, V81, P331, DOI 10.1016/S0065-2776(03)81008-8; Hsu DH, 2003, J IMMUNOTHER, V26, P440, DOI 10.1097/00002371-200309000-00007; Hurwitz AA, 1998, P NATL ACAD SCI USA, V95, P10067, DOI 10.1073/pnas.95.17.10067; Hurwitz AA, 2003, BIODRUGS, V17, P131, DOI 10.2165/00063030-200317020-00005; Hwang IY, 2003, P NATL ACAD SCI USA, V100, P6670, DOI 10.1073/pnas.1131852100; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; Janetzki S, 2000, J IMMUNOL METHODS, V234, P1, DOI 10.1016/S0022-1759(99)00203-3; Janeway C.A., 2001, IMMUNOBIOLOGY IMMUNE, V5th; Johnson DR, 2000, HUM IMMUNOL, V61, P389, DOI 10.1016/S0198-8859(99)00186-X; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009; Karim M, 2004, J IMMUNOL, V172, P923, DOI 10.4049/jimmunol.172.2.923; Kikuchi T, 2000, NAT MED, V6, P1154, DOI 10.1038/80498; Kikuchi T, 2000, BLOOD, V96, P91, DOI 10.1182/blood.V96.1.91.013k19_91_99; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; Krause A, 1998, J EXP MED, V188, P619, DOI 10.1084/jem.188.4.619; Laport GG, 2003, BLOOD, V102, P2004, DOI 10.1182/blood-2003-01-0095; Latouche JB, 2000, NAT BIOTECHNOL, V18, P405, DOI 10.1038/74455; Laux I, 2000, CLIN IMMUNOL, V96, P187, DOI 10.1006/clim.2000.4902; Lee SJE, 2002, TRENDS IMMUNOL, V23, P492, DOI 10.1016/S1471-4906(02)02285-8; Lee SJE, 2002, TRENDS IMMUNOL, V23, P500, DOI 10.1016/S1471-4906(02)02325-6; Levine BL, 1997, J IMMUNOL, V159, P5921; Levine BL, 1998, J HEMATOTHER, V7, P437, DOI 10.1089/scd.1.1998.7.437; Levine BL, 2002, NAT MED, V8, P47, DOI 10.1038/nm0102-47; Lohr J, 2003, NAT IMMUNOL, V4, P664, DOI 10.1038/ni939; Maus MV, 2003, CLIN IMMUNOL, V106, P16, DOI 10.1016/S1521-6616(02)00017-7; Maus MV, 2002, NAT BIOTECHNOL, V20, P143, DOI 10.1038/nbt0202-143; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; Melero I, 1998, EUR J IMMUNOL, V28, P1116, DOI 10.1002/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A; Mitchell MS, 2002, J CLIN ONCOL, V20, P1075, DOI 10.1200/JCO.20.4.1075; MOSIOR M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P185, DOI 10.1016/0005-2736(92)90178-O; Nugeyre MT, 2003, J IMMUNOL, V171, P4447, DOI 10.4049/jimmunol.171.8.4447; Oelke M, 2003, NAT MED, V9, P619, DOI 10.1038/nm869; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; Papanicolaou GA, 2003, BLOOD, V102, P2498, DOI 10.1182/blood-2003-02-0345; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; Parrish-Novak J, 2002, J LEUKOCYTE BIOL, V72, P856; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Portielje JEA, 2003, CANCER IMMUNOL IMMUN, V52, P133, DOI 10.1007/s00262-002-0356-5; Prakken B, 2000, NAT MED, V6, P1406, DOI 10.1038/82231; Puccetti P, 2002, CRIT REV IMMUNOL, V22, P373; Rapoport AP, 2004, BONE MARROW TRANSPL, V33, P53, DOI 10.1038/sj.bmt.1704317; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Reddy A, 1997, BLOOD, V90, P3640, DOI 10.1182/blood.V90.9.3640; Riddell SR, 2000, J ANTIMICROB CHEMOTH, V45, P35, DOI 10.1093/jac/45.suppl_4.35; Riddell Stanley R, 2002, Cancer Control, V9, P114; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; Rogers PR, 2001, IMMUNITY, V15, P445, DOI 10.1016/S1074-7613(01)00191-1; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; Rottman JB, 2001, NAT IMMUNOL, V2, P605, DOI 10.1038/89750; Sadelain M, 2003, NAT REV CANCER, V3, P35, DOI 10.1038/nrc971; Salama AD, 2003, AM J TRANSPLANT, V3, P390, DOI 10.1034/j.1600-6143.2003.00085.x; Savoldo B, 2000, LEUKEMIA LYMPHOMA, V39, P455, DOI 10.3109/10428190009113376; Schluns KS, 2003, NAT REV IMMUNOL, V3, P269, DOI 10.1038/nri1052; Schoenberger SP, 1998, CANCER RES, V58, P3094; Seder RA, 2003, NAT IMMUNOL, V4, P835, DOI 10.1038/ni969; Shand A, 2003, INT J COLORECTAL DIS, V18, P1, DOI 10.1007/s00384-002-0431-6; Sporici RA, 2001, CLIN IMMUNOL, V100, P263, DOI 10.1006/clim.2001.5093; Stoll S, 2002, SCIENCE, V296, P1873, DOI 10.1126/science.1071065; Strengeil M, 2002, J IMMUNOL, V169, P3600, DOI 10.4049/jimmunol.169.7.3600; Sun SQ, 1996, IMMUNITY, V4, P555, DOI 10.1016/S1074-7613(00)80482-3; Tatsumi T, 2003, CANCER RES, V63, P6378; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Thomas AK, 2002, CLIN IMMUNOL, V105, P259, DOI 10.1006/clim.2002.5277; Topp MS, 2003, J EXP MED, V198, P947, DOI 10.1084/jem.20021288; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; Villegas EN, 2002, J IMMUNOL, V169, P937, DOI 10.4049/jimmunol.169.2.937; Waldmann TA, 2001, IMMUNITY, V14, P105, DOI 10.1016/S1074-7613(01)00093-0; Waldmann T, 2002, ARTHRITIS RES THER, V4, pS161, DOI 10.1186/ar584; Wang HY, 2004, IMMUNITY, V20, P107, DOI 10.1016/S1074-7613(03)00359-5; Watford WT, 2003, CYTOKINE GROWTH F R, V14, P361, DOI 10.1016/S1359-6101(03)00043-1; Wen T, 2002, J IMMUNOL, V168, P4897, DOI 10.4049/jimmunol.168.10.4897; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Wong P, 2001, J IMMUNOL, V166, P5864, DOI 10.4049/jimmunol.166.10.5864; Wurster AL, 2002, J EXP MED, V196, P969, DOI 10.1084/jem.20020620; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	100	147	162	1	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2004	22	4					403	410		10.1038/nbt955	http://dx.doi.org/10.1038/nbt955			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	809AR	15060556				2023-01-03	WOS:000220610100028
J	Allen, TM; Cullis, PR				Allen, TM; Cullis, PR			Drug delivery systems: Entering the mainstream	SCIENCE			English	Article							PEGYLATED LIPOSOMAL DOXORUBICIN; AMPHOTERICIN-B AMBISOME; PHASE-I; POLYETHYLENE-GLYCOL; TRIAL; RELEASE; PHARMACOKINETICS; LOCALIZATION; THERAPEUTICS; PERMEABILITY	Drug delivery systems (DDS) such as lipid- or polymer-based nanoparticles can be designed to improve the pharmacological and therapeutic properties of drugs administered parenterally. Many of the early problems that hindered the clinical applications of particulate DDS have been overcome, with several DDS formulations of anticancer and antifungal drugs now approved for clinical use. Furthermore, there is considerable interest in exploiting the advantages of DDS for in vivo delivery of new drugs derived from proteomics or genomics research and for their use in ligand-targeted therapeutics.	Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Inex Pharmaceut Corp, Burnaby, BC V5J 5J8, Canada	University of Alberta; University of British Columbia	Allen, TM (corresponding author), Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada.	terry.allen@ualberta.ca						ADLERMOORE J, 1994, BONE MARROW TRANSPL, V14, pS3; Alberts DS, 1997, DRUGS, V54, P30, DOI 10.2165/00003495-199700544-00007; Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903; Batist G, 2001, J CLIN ONCOL, V19, P1444, DOI 10.1200/JCO.2001.19.5.1444; Bolotin Elijah M., 1994, Journal of Liposome Research, V4, P455, DOI 10.3109/08982109409037057; BORY C, 1991, ADV EXP MED BIOL, V309, P173; Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5; Cabanes A, 1998, INT J ONCOL, V12, P1035; Chowdhary RK, 2003, J PHARM PHARM SCI, V6, P13; Cullis PR, 1997, BBA-REV BIOMEMBRANES, V1331, P187, DOI 10.1016/S0304-4157(97)00006-3; DAVIDSON RN, 1994, Q J MED, V87, P75; Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088; Edens HA, 2002, J IMMUNOL, V169, P476, DOI 10.4049/jimmunol.169.1.476; Fang J, 2003, ADV EXP MED BIOL, V519, P29; Gabizon A, 2003, CLIN PHARMACOKINET, V42, P419, DOI 10.2165/00003088-200342050-00002; Gelmon KA, 1999, J CLIN ONCOL, V17, P697, DOI 10.1200/JCO.1999.17.2.697; Glantz MJ, 1999, J CLIN ONCOL, V17, P3110, DOI 10.1200/JCO.1999.17.10.3110; Glantz MJ, 1999, CLIN CANCER RES, V5, P3394; Glue P, 2000, HEPATOLOGY, V32, P647, DOI 10.1053/jhep.2000.16661; Guo X, 2003, ACCOUNTS CHEM RES, V36, P335, DOI 10.1021/ar9703241; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Huwyler J, 1996, P NATL ACAD SCI USA, V93, P14164, DOI 10.1073/pnas.93.24.14164; JAIN RK, 1987, CANCER METAST REV, V6, P559, DOI 10.1007/BF00047468; Kaminski MS, 2001, J CLIN ONCOL, V19, P3918, DOI 10.1200/JCO.2001.19.19.3918; Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8; LaVan DA, 2003, NAT BIOTECHNOL, V21, P1184, DOI 10.1038/nbt876; Liu MJ, 2000, J CONTROL RELEASE, V65, P121, DOI 10.1016/S0168-3659(99)00245-X; Lotem M, 2000, ARCH DERMATOL, V136, P1475, DOI 10.1001/archderm.136.12.1475; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; Mehvar Reza, 2003, Current Pharmaceutical Biotechnology, V4, P283, DOI 10.2174/1389201033489685; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Muggia F, 2001, EUR J CANCER, V37, pS15; Nabhan C, 2002, CLIN LYMPHOMA, V2, pS19, DOI 10.3816/CLM.2002.s.004; Netti PA, 1996, MICROVASC RES, V52, P27, DOI 10.1006/mvre.1996.0041; Northfelt DW, 1996, J CLIN PHARMACOL, V36, P55, DOI 10.1002/j.1552-4604.1996.tb04152.x; Ogris Manfred, 2002, Somatic Cell and Molecular Genetics, V27, P85, DOI 10.1023/A:1022988008131; Olsen E, 2001, J CLIN ONCOL, V19, P376, DOI 10.1200/JCO.2001.19.2.376; Pastorino F, 2003, CLIN CANCER RES, V9, P4595; PETERS BG, 1995, FORMULARY, V30, P388; SAMUELS BL, 1987, CANCER TREAT REP, V71, P971; Schiffelers RM, 2001, PHARMACEUT RES, V18, P780, DOI 10.1023/A:1011080211226; Semple SC, 1996, BIOCHEMISTRY-US, V35, P2521, DOI 10.1021/bi950414i; Senter PD, 2001, ADV DRUG DELIVER REV, V53, P247, DOI 10.1016/S0169-409X(01)00206-X; Seymour LW, 1998, INT J ONCOL, V12, P1217; Siena S, 2003, ONCOL REP, V10, P715; Smith DH, 2002, ANN ONCOL, V13, P1590, DOI 10.1093/annonc/mdf275; Szebeni J, 2002, J LIPOSOME RES, V12, P165, DOI 10.1081/LPR-120004790; Tardi P, 2000, CANCER RES, V60, P3389; Templeton NS, 2003, EXPERT OPIN BIOL TH, V3, P57, DOI 10.1517/eobt.3.1.57.20953; Terwogt JMM, 2002, CANCER CHEMOTH PHARM, V49, P201, DOI 10.1007/s002800100371; TOLLEMAR J, 1992, MYCOSES, V35, P215, DOI 10.1111/j.1439-0507.1992.tb00850.x; TREAT J, 2000, P AN M AM SOC CLIN, V19, pA225; UZIELY B, 1995, J CLIN ONCOL, V13, P1777, DOI 10.1200/JCO.1995.13.7.1777; Vasey PA, 1999, CLIN CANCER RES, V5, P83; Wiseman GA, 2002, BLOOD, V99, P4336, DOI 10.1182/blood.V99.12.4336	56	3417	3560	29	1979	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1818	1822		10.1126/science.1095833	http://dx.doi.org/10.1126/science.1095833			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031496				2023-01-03	WOS:000220281600044
J	Raine, TR; Harper, CC; Rocca, CH; Fischer, R; Padian, N; Klausner, JD; Darney, PD				Raine, TR; Harper, CC; Rocca, CH; Fischer, R; Padian, N; Klausner, JD; Darney, PD			Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMUNITY PHARMACIES; ADVANCE PROVISION; NATIONAL-SURVEY; USERS; PILLS; FDA	Context It is estimated that half of unintended pregnancies could be averted if emergency contraception (EC) were easily accessible and used. Objective To evaluate the effect of direct access to EC through pharmacies and advance provision on reproductive health outcomes. Design, Setting, and Participants A randomized, single-blind, controlled trial (July 2001-June 2003) of 2117 women, ages 15 to 24 years, attending 4 California clinics providing family planning services, who were not desiring pregnancy, using long-term hormonal contraception or requesting EC. Intervention Participants were assigned to 1 of the following groups: (1) pharmacy access to EC; (2) advance provision of 3 packs of levonorgestrel EC; or (3) clinic access (control). Main Outcome Measures Primary outcomes were use of EC, pregnancies, and sexually transmitted infections (STIs) assessed at 6 months; secondary outcomes were changes in contraceptive and condom use and sexual behavior. Results Women in the pharmacy access group were no more likely to use EC (24.2%) than controls (21.0%) (P=.25). Women in the advance provision group (37.4%) were almost twice as likely to use EC than controls (21.0%) (P<.001) even though the frequency of unprotected intercourse was similar (39.8% vs 41.0%, respectively, P=.46). Only half (46.7%) of study participants who had unprotected intercourse used EC over the study period. Eight percent of participants became pregnant and 12% acquired an STI; compared with controls, women in the pharmacy access and advance provision groups did not experience a significant reduction in pregnancy rate (pharmacy access group: adjusted odds ratio [OR], 0.98; 95% confidence interval [CI], 0.58-1.64; P=.93; advance provision group: OR, 1.10; 95% CI, 0.66-1.84, P=.71) or increase in STIs (pharmacy access group: adjusted OR, 1.08, 95% CI, 0.71-1.63, P=.73; advance provision group: OR, 0.94, 95% CI, 0.62-1.44, P=.79). There were no differences in patterns of contraceptive or condom use or sexual behaviors by study group. Conclusions While removing the requirement to go through pharmacists or clinics to obtain EC increases use, the public health impact may be negligible because of high rates of unprotected intercourse and relative underutilization of the method. Given that there is clear evidence that neither pharmacy access nor advance provision compromises contraceptive or sexual behavior, it seems unreasonable to restrict access to EC to clinics.	Univ Calif San Francisco, Ctr Reprod Hlth Res & Policy, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Planned Parenthood Mar Monte, San Jose, CA USA; San Francisco Dept Publ Hlth, San Francisco, CA USA	University of California System; University of California San Francisco; San Francisco Department of Public Health	Raine, TR (corresponding author), San Francisco Gen Hosp, Dept Obstet Gynecol & Reprod Sci, 1001 Potrero Ave, San Francisco, CA 94110 USA.	rainet@obgyn.ucsf.edu						Bissell P, 2003, SOC SCI MED, V57, P2367, DOI 10.1016/S0277-9536(03)00129-1; Drazen JM, 2004, NEW ENGL J MED, V350, P1561, DOI 10.1056/NEJMe048057; Ellertson C, 2001, OBSTET GYNECOL, V98, P570, DOI 10.1016/S0029-7844(01)01506-X; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; Gardner JS, 2001, FAM PLANN PERSPECT, V33, P172, DOI 10.2307/2673721; Glasier A, 1998, NEW ENGL J MED, V339, P1, DOI 10.1056/NEJM199807023390101; Glasier A, 2004, CONTRACEPTION, V69, P361, DOI 10.1016/j.contraception.2004.01.002; Gold MA, 1997, FAM PLANN PERSPECT, V29, P15, DOI 10.2307/2953348; Gold Melanie A, 2004, J Pediatr Adolesc Gynecol, V17, P87, DOI 10.1016/j.jpag.2003.11.018; Grimes D, 1998, LANCET, V352, P428; Harvey SM, 1999, FAM PLANN PERSPECT, V31, P237, DOI 10.2307/2991571; Jackson RA, 2003, OBSTET GYNECOL, V102, P8, DOI 10.1016/S0029-7844(03)00478-2; Katz MH, 2002, AM J PUBLIC HEALTH, V92, P388, DOI 10.2105/AJPH.92.3.388; Lovvorn A, 2000, CONTRACEPTION, V61, P287, DOI 10.1016/S0010-7824(00)00107-4; Mosher WD, 1998, FAM PLANN PERSPECT, V30, P43, DOI 10.2307/2991525; Paukku M, 2003, OBSTET GYNECOL, V101, P534, DOI 10.1016/S0029-7844(02)02717-5; Porco TC, 2004, AIDS, V18, P81, DOI 10.1097/00002030-200401020-00010; Raine T, 2000, OBSTET GYNECOL, V96, P1, DOI 10.1016/S0029-7844(00)00830-9; Raine T, 2002, OBSTET GYNECOL, V99, P241, DOI 10.1016/S0029-7844(01)01714-8; Roye CF, 2001, J ADOLESCENT HEALTH, V28, P165, DOI 10.1016/S1054-139X(01)00203-8; TRUSSELL J, 1992, FAM PLANN PERSPECT, V24, P269, DOI 10.2307/2135857; Vastag B, 2004, JAMA-J AM MED ASSOC, V291, P2805, DOI 10.1001/jama.291.23.2805	22	237	243	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2005	293	1					54	62		10.1001/jama.293.1.54	http://dx.doi.org/10.1001/jama.293.1.54			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QY	15632336	Bronze			2023-01-03	WOS:000226102100021
J	Brocklehurst, P; McGuire, W				Brocklehurst, P; McGuire, W			ABC of preterm birth - Evidence based care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TRIAL; CONSENT		Inst Hlth Sci, Natl Perinatal Epidemiol Unit, Oxford, England; Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 4HN, Scotland	University of Oxford; University of Dundee	Brocklehurst, P (corresponding author), Inst Hlth Sci, Natl Perinatal Epidemiol Unit, Oxford, England.		Brocklehurst, Peter/B-5804-2011	McGuire, William/0000-0001-8572-3467				Field D, 1999, ARCH DIS CHILD-FETAL, V81, pF161, DOI 10.1136/fn.81.3.F161; Horbar JD, 2004, BMJ-BRIT MED J, V329, P1004, DOI 10.1136/bmj.329.7473.1004; Leviton LC, 1999, JAMA-J AM MED ASSOC, V281, P46, DOI 10.1001/jama.281.1.46; Manning DJ, 2000, J MED ETHICS, V26, P249, DOI 10.1136/jme.26.4.249; Mason SA, 2000, LANCET, V356, P2045, DOI 10.1016/S0140-6736(00)03401-2; Tin W, 1998, ARCH DIS CHILD-FETAL, V79, pF83, DOI 10.1136/fn.79.2.F83	6	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 1	2005	330	7481					36	38		10.1136/bmj.330.7481.36	http://dx.doi.org/10.1136/bmj.330.7481.36			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885SH	15626805	Green Published			2023-01-03	WOS:000226176700020
J	Li, P; Wohland, T; Ho, B; Ding, JL				Li, P; Wohland, T; Ho, B; Ding, JL			Perturbation of lipopolysaccharide (LPS) micelles by Sushi 3 (S3) antimicrobial peptide - The importance of an intermolecular disulfide bond in S3 dimer for binding, disruption, and neutralization of LPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; FACTOR-C; HORSESHOE-CRAB; MECHANISM; ENDOTOXIN; PROTEINS; REMOVAL	S3 peptide, derived from the Sushi 3 domain of Factor C, which is the lipopolysaccharide (LPS)-sensitive serine protease of the horseshoe crab coagulation cascade, was shown previously to harbor antimicrobial activity against Gram-negative bacteria. However, the mechanism of action remains poorly understood at the molecular level. Here we demonstrate that the intermolecular disulfide bonding of S3 resulting in S3 dimers is indispensable for its interaction with LPS. The binding properties of the S3 monomer and dimer to LPS were analyzed by several approaches including enzyme-linked immunosorbent assay (ELISA)-based assay, surface plasmon resonance, and fluorescence correlation spectroscopy (FCS). It is evident that the S3 dimer exhibits stronger binding to LPS, demonstrating 50% LPS-neutralizing capability at a concentration of 1 muM. Circular dichroism spectrometry revealed that the S3 peptide undergoes conformational change in the presence of a disulfide bridge, transitioning from a random coil to beta-sheet structure. Using a fluorescence correlation spectroscopy monitoring system, we describe a novel approach for examining the mechanism of peptide interaction with LPS in the native environment. The strategy shows that intermolecular disulfide bonding of S3 into dimers plays a critical role in its propensity to disrupt LPS micelles and consequently neutralize LPS activity. S3 dimers display detergent-like properties in disrupting LPS micelles. Considering intermolecular disulfide bonds as an important parameter in the structure-activity relationship, this insight provides clues for the future design of improved LPS-binding and - neutralizing peptides.	Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Natl Univ Singapore, Dept Chem, Singapore 117543, Singapore; Natl Univ Singapore, Dept Microbiol, Singapore 117543, Singapore	National University of Singapore; National University of Singapore; National University of Singapore	Ding, JL (corresponding author), Natl Univ Singapore, Dept Biol Sci, 14,Sci Dr 4, Singapore 117543, Singapore.	dbsdjl@nus.edu.sg	Wohland, Thorsten/H-8285-2012; Ding, Jeak/H-8057-2012; WOHLAND, THORSTEN/R-6404-2019	Wohland, Thorsten/0000-0002-0148-4321; 				Aurell CA, 1998, BIOCHEM BIOPH RES CO, V253, P119, DOI 10.1006/bbrc.1998.9773; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Breithaupt H, 1999, NAT BIOTECHNOL, V17, P1165, DOI 10.1038/70705; Ding Jeak L., 1995, Molecular Marine Biology and Biotechnology, V4, P90; Ding JL, 2001, J CHROMATOGR B, V759, P237, DOI 10.1016/S0378-4347(01)00227-4; DING JL, 1993, BIOCHIM BIOPHYS ACTA, V1202, P149, DOI 10.1016/0167-4838(93)90076-4; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; Feder R, 2000, J BIOL CHEM, V275, P4230, DOI 10.1074/jbc.275.6.4230; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Frecer V, 2000, EUR J BIOCHEM, V267, P837, DOI 10.1046/j.1432-1327.2000.01069.x; Frecer V, 2000, BBA-BIOMEMBRANES, V1466, P87, DOI 10.1016/S0005-2736(00)00174-7; Gee K, 2003, J BIOL CHEM, V278, P37275, DOI 10.1074/jbc.M302309200; Gidalevitz D, 2003, P NATL ACAD SCI USA, V100, P6302, DOI 10.1073/pnas.0934731100; HO B, 1983, Microbios Letters, V24, P81; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Krichevsky O, 2002, REP PROG PHYS, V65, P251, DOI 10.1088/0034-4885/65/2/203; Lai JR, 2002, BIOCHEMISTRY-US, V41, P12835, DOI 10.1021/bi026127d; Meseth U, 1999, BIOPHYS J, V76, P1619, DOI 10.1016/S0006-3495(99)77321-2; Mueller M, 2004, J BIOL CHEM, V279, P26307, DOI 10.1074/jbc.M401231200; Neumann L, 2002, CHEMBIOCHEM, V3, P993, DOI 10.1002/1439-7633(20021004)3:10<993::AID-CBIC993>3.0.CO;2-Y; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Oren Z, 1997, J BIOL CHEM, V272, P14643, DOI 10.1074/jbc.272.23.14643; Petsch D, 2000, J BIOTECHNOL, V76, P97, DOI 10.1016/S0168-1656(99)00185-6; Situ H, 2003, BIOCHEM J, V375, P175, DOI 10.1042/BJ20030779; Tam JP, 2002, J BIOL CHEM, V277, P50450, DOI 10.1074/jbc.M208429200; Tan NS, 2000, FASEB J, V14, P859, DOI 10.1096/fasebj.14.7.859; Tan NS, 2000, FASEB J, V14, P1801, DOI 10.1096/fj.99-0866com; Thomas CJ, 2001, J BIOL CHEM, V276, P35701, DOI 10.1074/jbc.M011319200; Wang J, 2002, J BIOL CHEM, V277, P36363, DOI 10.1074/jbc.M202837200; Wohland T, 1999, BIOCHEMISTRY-US, V38, P8671, DOI 10.1021/bi990366s; Wohland T, 2001, SPRINGER SERIES CHEM, V67, P195; Wohland T, 2001, BIOPHYS J, V80, P2987, DOI 10.1016/S0006-3495(01)76264-9; Wu ZB, 2003, P NATL ACAD SCI USA, V100, P8880, DOI 10.1073/pnas.1533186100; Yau YH, 2001, ANTIMICROB AGENTS CH, V45, P2820, DOI 10.1128/AAC.45.10.2820-2825.2001; Yazawa N, 2003, BLOOD, V102, P1374, DOI 10.1182/blood-2002-11-3573; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	37	64	64	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50150	50156		10.1074/jbc.M405606200	http://dx.doi.org/10.1074/jbc.M405606200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15328339	hybrid			2023-01-03	WOS:000225229500074
J	Reidenberg, MM; Walley, T				Reidenberg, MM; Walley, T			Commentary: The pros and cons of essential medicines for rich countries	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Cornell Univ, Weill Med Coll, New York, NY 10021 USA; Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GF, Merseyside, England	Cornell University; University of Liverpool	Reidenberg, MM (corresponding author), Cornell Univ, Weill Med Coll, 1300 York Ave, New York, NY 10021 USA.	mmreid@med.cornell.edu						*AUSTR GOV, PHARM BEN SCHEM EXP; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; Drahos P, 2004, BMJ-BRIT MED J, V328, P1271, DOI 10.1136/bmj.328.7451.1271; Hogerzeil HV, 2004, BRIT MED J, V329, P1169, DOI 10.1136/bmj.329.7475.1169; Kremer JM, 2001, ANN INTERN MED, V134, P695, DOI 10.7326/0003-4819-134-8-200104170-00013	5	3	3	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2004	329	7475					1172	1172		10.1136/bmj.329.7475.1172	http://dx.doi.org/10.1136/bmj.329.7475.1172			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539677	Green Published			2023-01-03	WOS:000225169600030
J	Solomon, AW; Holland, MJ; Alexander, NDE; Massae, PA; Aguirre, A; Natividad-Sancho, A; Molina, S; Safari, S; Shao, JF; Courtright, P; Peeling, RW; West, SK; Bailey, RL; Foster, A; Mabey, DCW				Solomon, AW; Holland, MJ; Alexander, NDE; Massae, PA; Aguirre, A; Natividad-Sancho, A; Molina, S; Safari, S; Shao, JF; Courtright, P; Peeling, RW; West, SK; Bailey, RL; Foster, A; Mabey, DCW			Mass treatment with single-dose azithromycin for trachoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Meeting of the Royal-Society-of-Tropical-Medicine-and-Hygiene	DEC   12, 2002	LONDON, ENGLAND	Royal Soc Trop Med & Hyg			OCULAR CHLAMYDIAL INFECTION; CLINICAL-DIAGNOSIS; LOW-PREVALENCE; PREVENTION; BLINDNESS; NEPAL; AREAS	BACKGROUND Trachoma, caused by repeated ocular infection with Chlamydia trachomatis, is an important cause of blindness. Current recommended dosing intervals for mass azithromycin treatment for trachoma are based on a mathematical model. METHODS We collected conjunctival swabs for quantitative polymerase-chain-reaction assay of C. trachomatis before and 2, 6, 12, 18, and 24 months after mass treatment with azithromycin in a Tanzanian community in which trachoma was endemic. For ethical reasons, at 6, 12, and 18 months, we gave tetracycline eye ointment to residents who had clinically active trachoma. RESULTS: At baseline, 956 of 978 residents (97.8 percent) received either one oral dose of azithromycin or (if azithromycin was contraindicated) a course of tetracycline eye ointment. The prevalence of infection fell from 9.5 percent before mass treatment to 2.1 percent at 2 months and 0.1 percent at 24 months. The quantitative burden of ocular C. trachomatis infection in the community was 13.9 percent of the pretreatment level at 2 months and 0.8 percent at 24 months. At each time point after baseline, over 90 percent of the total community burden of C. trachomatis infection was found among subjects who had been positive the previous time they were tested. CONCLUSIONS: The prevalence and intensity of infection fell dramatically and remained low for two years after treatment. One round of very-high-coverage mass treatment with azithromycin, perhaps aided by subsequent periodic use of tetracycline eye ointment for persons with active disease, can interrupt the transmission of ocular C. trachomatis infection.	Univ London London Sch Hyg & Trop Med, Clin Res Unit, London WC1E 7HT, England; Tumaini Univ, Kilimanjaro Christian Med Coll, Moshi, Tanzania; Huruma Hosp, Mkuu, Rombo, Tanzania; MRC Labs, Fajara, Gambia; WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland; Hlth Canada, Natl Microbiol Lab, Winnipeg, MB, Canada; Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA	University of London; London School of Hygiene & Tropical Medicine; MRC Laboratory Molecular Biology; World Health Organization; Health Canada; Johns Hopkins University	Solomon, AW (corresponding author), Univ London London Sch Hyg & Trop Med, Clin Res Unit, Keppel St, London WC1E 7HT, England.	anthony.solomon@lshtm.ac.uk	Holland, Martin J/K-6502-2012	Holland, Martin J/0000-0002-5828-6318; Mabey, David/0000-0002-0031-8276; Solomon, Anthony/0000-0001-7101-6649; Foster, Allen/0000-0003-2368-4436; Andreasen, Aura/0000-0003-0664-7342	Wellcome Trust [098521, 059134] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9; Baral K, 1999, B WORLD HEALTH ORGAN, V77, P461; Bird M, 2003, J INFECT DIS, V187, P1669, DOI 10.1086/374743; Bowman RJC, 2000, INVEST OPHTH VIS SCI, V41, P4074; Dawson CR, 1997, CLIN INFECT DIS, V24, P363, DOI 10.1093/clinids/24.3.363; Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2; Everett KDE, 1999, INT J SYST BACTERIOL, V49, P415, DOI 10.1099/00207713-49-2-415; FOSTER A, 1991, LANCET, V337, P1267, DOI 10.1016/0140-6736(91)92929-V; GRAYSTON JT, 1985, REV INFECT DIS, V7, P717; Jha H, 2002, CLIN INFECT DIS, V35, P765, DOI 10.1086/342298; Kirkwood B., 1988, BR K ESSENTIALS MED; Kuper H, 2003, LANCET INFECT DIS, V3, P372, DOI 10.1016/S1473-3099(03)00659-5; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451; Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1; Mabey Denise, 2003, Expert Rev Anti Infect Ther, V1, P209, DOI 10.1586/14787210.1.2.209; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; SCHACHTER J, 1983, REV INFECT DIS, V5, pS562; SCHACHTER J, 1985, REV INFECT DIS, V7, P713; Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5; Shattock RM, 1998, SEX TRANSM INFECT, V74, P289, DOI 10.1136/sti.74.4.289; Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8; Tabbara KF, 1996, OPHTHALMOLOGY, V103, P842; TAYLOR HR, 1993, BRIT J OPHTHALMOL, V77, P66, DOI 10.1136/bjo.77.2.66; Thein J, 2002, OPHTHALMIC EPIDEMIOL, V9, P263, DOI 10.1076/opep.9.4.263.1508; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477; THYLEFORS B, 1985, REV INFECT DIS, V7, P774; Thylefors B, 1998, WORLD HEALTH FORUM, V19, P53; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1; West S K, 2001, Ophthalmic Epidemiol, V8, P137, DOI 10.1076/opep.8.2.137.4158; [No title captured]	32	190	193	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					1962	1971		10.1056/NEJMoa040979	http://dx.doi.org/10.1056/NEJMoa040979			10	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15525721	Bronze, Green Accepted			2023-01-03	WOS:000224851300008
J	Mukherjee, S				Mukherjee, S			Becoming a physician: A precarious exchange	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Dana Farber Partners Canc Care, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Mukherjee, S (corresponding author), Dana Farber Partners Canc Care, Boston, MA 02115 USA.							Halsted WS, 1904, J HOPKINS HOSP B, V15, P267; Petersen L A, 1998, Jt Comm J Qual Improv, V24, P77; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008	3	57	58	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	2004	351	18					1822	1824		10.1056/NEJMp048085	http://dx.doi.org/10.1056/NEJMp048085			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865SM	15509813				2023-01-03	WOS:000224723100003
J	Fowlie, PW; McGuire, W				Fowlie, PW; McGuire, W			ABC of preterm birth - Immediate care of the preterm infant	BRITISH MEDICAL JOURNAL			English	Review									Perth Royal Infirm, Perth, Scotland; Univ Dundee, Tayside Inst Child Hlth, Ninewells Hosp & Med Sch, Dundee DD1 4HN, Scotland	University of Dundee	Fowlie, PW (corresponding author), Perth Royal Infirm, Perth, Scotland.			McGuire, William/0000-0001-8572-3467				Gee H, 2000, PRENAT NEONAT MED, V5, P209; *JOINT WORK PART R, 1997, RES BAB BIRTH; *RES COUNC, 2002, RES BIRTH NEWB LIF S; SOLL RF, 2003, COCHRANE DATABASE SY, DOI UNSP CD000510; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601	5	6	7	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 9	2004	329	7470					845	848		10.1136/bmj.329.7470.845	http://dx.doi.org/10.1136/bmj.329.7470.845			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862EK	15472269	Green Published			2023-01-03	WOS:000224472800025
J	Niethammer, AG; Wodrich, H; Loeffler, M; Lode, HN; Emmerich, K; Abdollahi, A; Krempien, R; Debus, J; Huber, PE; Reisfeld, RA				Niethammer, AG; Wodrich, H; Loeffler, M; Lode, HN; Emmerich, K; Abdollahi, A; Krempien, R; Debus, J; Huber, PE; Reisfeld, RA			Multidrug resistance-1 (MDR-1): a new target for T cell-based immunotherapy	FASEB JOURNAL			English	Article						vaccine; T cells; cancer; immunology	ORAL DNA VACCINE; PROTECTIVE IMMUNITY; P-GLYCOPROTEIN; MYELOMA CELLS; TUMOR; CANCER; EXPRESSION; PROGRESS; THERAPY; GROWTH	Acquired multidrug resistance (MDR) remains a major challenge in the treatment of cancer with chemotherapeutic drugs. It can be mediated by the up-regulated expression of different proteins within the tumor cell membrane. Here, we used murine multidrug resistance-1 (MDR-1) as a target-antigen for the immunotherapy of cancer. We successfully demonstrated that peripheral T cell tolerance can be broken by oral administration of a DNA vaccine encoding MDR-1 and carried by attenuated Salmonella typhimurium to secondary lymphoid organs. Thus, mice, immunized orally three times at 2-wk intervals and challenged 2 wk thereafter with either MDR-1 expressing CT-26 colon carcinoma cells or MDR-1 expressing Lewis lung carcinoma cells, revealed a significant increase in life span. This was evident, when compared with animals either vaccinated with the empty control vector or challenged with the parental cell lines lacking overexpression of MDR-1. The immune response induced was antigen-specific and CD8(+) T cell-mediated. The presence of the target antigen led to up-regulation of activation markers on CD8(+) T cells and resulted in a strong cytotoxic T cell response as well as lysis of tumor target cells in vitro. We furthermore established the vaccine to be an effective treatment for established multi-drug-resistant tumor metastases, resulting in a significantly increased life span of experimental animals. Absence of CD8(+) T cells due to in vivo depletion led to abrogation of effectiveness. Taken together, our results demonstrate that T cell tolerance against the MDR-1 self-antigen can be broken. It is anticipated that the combination of such an approach with chemotherapy could lead to more effective treatments of cancer.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Heidelberg Med Sch, Dept Radiat Oncol, D-69120 Heidelberg, Germany; Charite Childrens Hosp, Dept Pediat Oncol, Berlin, Germany; Schering AG, D-13342 Berlin, Germany	Scripps Research Institute; Scripps Research Institute; Ruprecht Karls University Heidelberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Schering AG	Reisfeld, RA (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Reisfeld@scripps.edu	Wodrich, Harald/P-1777-2019	Wodrich, Harald/0000-0002-4764-1708; Lode, Holger/0000-0002-1201-208X	NATIONAL CANCER INSTITUTE [R01CA083856] Funding Source: NIH RePORTER; NCI NIH HHS [CA 83856] Funding Source: Medline; PHS HHS [T32-A107244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abdollahi A, 2004, MOL CELL, V13, P649, DOI 10.1016/S1097-2765(04)00102-9; Azuma E, 1997, EUR J HAEMATOL, V59, P14; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Darji A, 1997, CELL, V91, P765, DOI 10.1016/S0092-8674(00)80465-1; Darji A, 2000, FEMS IMMUNOL MED MIC, V27, P341; FERRY DR, 1994, BRIT MED J, V308, P148, DOI 10.1136/bmj.308.6922.148; Ferry DR, 1996, EUR J CANCER, V32A, P1070, DOI 10.1016/0959-8049(96)00091-3; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; Henness S, 2002, INT J RADIAT ONCOL, V54, P895, DOI 10.1016/S0360-3016(02)03037-7; Itoh K, 1991, In Vivo, V5, P647; Jager E, 2000, ONKOLOGIE, V23, P410, DOI 10.1159/000027202; Jager E, 2003, INT J CANCER, V106, P817, DOI 10.1002/ijc.11292; Legrand O, 2001, BLOOD, V97, P502, DOI 10.1182/blood.V97.2.502; Lode HN, 1998, P NATL ACAD SCI USA, V95, P2475, DOI 10.1073/pnas.95.5.2475; Mackensen A, 2000, INT J CANCER, V86, P385, DOI 10.1002/(SICI)1097-0215(20000501)86:3<385::AID-IJC13>3.0.CO;2-T; Marchand M, 1999, INT J CANCER, V80, P219, DOI 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.3.CO;2-J; MUUL LM, 1987, J IMMUNOL, V138, P989; Niethammer AG, 2002, NAT MED, V8, P1369, DOI 10.1038/nm794; Niethammer AG, 2001, VACCINE, V20, P421, DOI 10.1016/S0264-410X(01)00362-0; Niethammer AG, 2001, CANCER RES, V61, P6178; Reisfeld RA, 2004, INT ARCH ALLERGY IMM, V133, P295, DOI 10.1159/000077009; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; Rosenberg SA, 2001, J INTERN MED, V250, P462, DOI 10.1046/j.1365-2796.2001.00911.x; Schambach A, 2000, MOL THER, V2, P435, DOI 10.1006/mthe.2000.0191; Shtil AA, 1999, BLOOD, V93, P1831, DOI 10.1182/blood.V93.6.1831.406k38_1831_1837; Shtil AA, 2000, LEUKEMIA LYMPHOMA, V38, P59, DOI 10.3109/10428190009060319; Xiang R, 2001, CLIN CANCER RES, V7, p856S; Yamada A, 2001, CANCER RES, V61, P6459	29	18	26	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					158	+		10.1096/fj.04-2355fje	http://dx.doi.org/10.1096/fj.04-2355fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15498893				2023-01-03	WOS:000224849900011
J	Schulz, R; Belle, SH; Czaja, SJ; McGinnis, KA; Stevens, A; Zhang, S				Schulz, R; Belle, SH; Czaja, SJ; McGinnis, KA; Stevens, A; Zhang, S			Long-term care placement of dementia patients and caregiver health and well-being	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NURSING-HOME PLACEMENT; ALZHEIMERS-DISEASE; FAMILY CAREGIVERS; OLDER-PEOPLE; INSTITUTIONALIZATION; BURDEN; REACH; PREDICTORS; PROJECT; TIME	Context Placing a relative with dementia into a long-term care facility is common among caregivers. Placement transition and factors that affect caregiver health and well-being after placement of the patient are not well described. Objective To assess the impact of placing a relative with dementia in a long-term care facility on caregivers' health and well-being. Design, Setting, and Participants Prospective study from 1996 to 2000 of the placement transition in a sample of 1222 caregiver-patient dyads recruited from 6 US sites. A total of 180 patients were placed in a long-term care facility during the 18-month follow-up period. Data collected before and after placement were analyzed to identify factors associated with placement, the nature of contact between caregivers and their institutionalized relatives after placement, and the relation of both of these factors to health outcomes among dementia caregivers. Main Outcome Measures Caregiver depression (symptoms on the Center for Epidemiological Studies-Depression [CES-D] scale; range, 0-60) and anxiety (State Trait Inventory; range, 10-40) and use of prescription medications for depression and anxiety. Results Caregivers who institutionalized their relative reported depressive symptoms and anxiety to be as high as they were while in-home caregivers. Overall CES-D scores for depression did not change from before to after placement (median [IQR], 15.0 [8-24.5] and 15.0 [7.7-28]; P=.64). Overall anxiety scores on the State Trait Inventory also did not change significantly (median [IQR], 22.0 (19-27] before vs 21.1 [18-27] after; P=.21). These effects were most pronounced among caregivers who were married to the patient (P=.02 for depression), visited more frequently (P=.01 for depression and P<.001 for anxiety), and were less satisfied with the help they received from others (P=.003 for depression and P<.001 for anxiety). The use of antidepressants did not change significantly before (21.1%) to after (17.9%) placement (P=.16). The use of anxiolytics before to after placement increased from 14.6% to 19% (P=.02), and nearly half of caregivers (48.3%) were at risk for clinical depression following placement of their relative. Conclusions The transition to institutional care is particularly difficult for spouses, almost half of whom visit the patient daily and continue to provide help with physical care during their visits. Clinical interventions that better prepare the caregiver for a placement transition and treat their depression and anxiety following placement may be of great benefit to these individuals.	Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA 15260 USA; Univ Miami, Dept Psychiat & Behav Sci, Miami, FL 33152 USA; Univ Miami, Ctr Aging, Miami, FL 33152 USA; Univ Alabama Birmingham, Div Gerontol & Geriatr Med, Birmingham, AL USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Miami; University of Miami; University of Alabama System; University of Alabama Birmingham	Schulz, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Psychiat, 121 Univ Pl,6th Floor, Pittsburgh, PA 15260 USA.	schulz@pitt.edu			NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P60MD000207] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL065112] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH052247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [U01NR004261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG013305] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL65112] Funding Source: Medline; NIA NIH HHS [UO1-AG13305] Funding Source: Medline; NIMHD NIH HHS [P60 MD000207] Funding Source: Medline; NIMH NIH HHS [P30 MH52247] Funding Source: Medline; NINR NIH HHS [U01-NR04261] Funding Source: Medline	NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		BOWKER AH, 1948, J AM STAT ASSOC, V43, P572, DOI 10.2307/2280710; COLLINS C, 1994, NURS RES, V43, P221; COX DR, 1972, J R STAT SOC B, V34, P187; Dellasega C, 1991, J Community Health Nurs, V8, P197, DOI 10.1207/s15327655jchn0804_2; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gitlin LN, 2003, PSYCHOL AGING, V18, P361, DOI 10.1037/0882-7974.18.3.361; GRAFSTROM M, 1995, ALZ DIS ASSOC DIS, V9, P78, DOI 10.1097/00002093-199509020-00004; Hebert R, 2001, J GERONTOL A-BIOL, V56, pM693, DOI 10.1093/gerona/56.11.M693; Heyman A, 1997, NEUROLOGY, V48, P1304, DOI 10.1212/WNL.48.5.1304; Kaplan L, 1999, FAM PROCESS, V38, P85, DOI 10.1111/j.1545-5300.1999.00085.x; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Keefe J, 2000, FAM RELAT, V49, P235, DOI 10.1111/j.1741-3729.2000.00235.x; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Levesque L., 2000, AM OURNAL ALZHEIMERS, V15, P229; Magaziner J, 2000, GERONTOLOGIST, V40, P663, DOI 10.1093/geront/40.6.663; McDowell I, 2002, GERONTOLOGIST, V42, P643; MONTGOMERY RJV, 1994, J GERONTOL, V49, pS62, DOI 10.1093/geronj/49.2.S62; Pot AM, 2001, INT J GERIATR PSYCH, V16, P273, DOI 10.1002/gps.331.abs; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROTHENHAEUSLER HB, 1997, Z GERONTOPSYCHOL PSY, V10, P61; Schulz R, 2001, JAMA-J AM MED ASSOC, V285, P3123, DOI 10.1001/jama.285.24.3123; Schulz R, 2003, NEW ENGL J MED, V349, P1936, DOI 10.1056/NEJMsa035373; Schulz R, 1997, ANN BEHAV MED, V19, P110, DOI 10.1007/BF02883327; Schulz R, 2002, GERONTOLOGIST, V42, P589, DOI 10.1093/geront/42.5.589; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Smith GE, 2000, J AM GERIATR SOC, V48, P519, DOI 10.1111/j.1532-5415.2000.tb04998.x; Spielberger C.D., 1989, REDW CITY MIND GARD, Vsecond; Stevens A, 2004, J AGING HEALTH, V16, P375, DOI 10.1177/0898264304264206; STEVENS AB, IN PRESS AGING MENT; Tarlow BJ, 2004, RES AGING, V26, P429, DOI 10.1177/0164027504264493; TERI L, 1992, PSYCHOL AGING, V7, P622, DOI 10.1037/0882-7974.7.4.622; Tornatore JB, 2002, GERONTOLOGIST, V42, P497, DOI 10.1093/geront/42.4.497; Whitlatch CJ, 2001, GERONTOLOGIST, V41, P462, DOI 10.1093/geront/41.4.462; Wisniewski SR, 2003, PSYCHOL AGING, V18, P375, DOI 10.1037/0882-7974.18.3.375; Yaffe K, 2002, JAMA-J AM MED ASSOC, V287, P2090, DOI 10.1001/jama.287.16.2090; Yamamoto-Mitani N, 2002, J GERONTOL B-PSYCHOL, V57, pS234, DOI 10.1093/geronb/57.4.S234; ZARIT SH, 1992, GERONTOLOGIST, V32, P665, DOI 10.1093/geront/32.5.665	37	228	234	1	34	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2004	292	8					961	967		10.1001/jama.292.8.961	http://dx.doi.org/10.1001/jama.292.8.961			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	847WR	15328328				2023-01-03	WOS:000223429200021
J	Espeland, MA; Rapp, SR; Shumaker, SA; Brunner, R; Manson, JE; Sherwin, BB; Hsia, J; Margolis, KL; Hogan, PE; Wallace, R; Dailey, M; Freeman, R; Hays, J				Espeland, MA; Rapp, SR; Shumaker, SA; Brunner, R; Manson, JE; Sherwin, BB; Hsia, J; Margolis, KL; Hogan, PE; Wallace, R; Dailey, M; Freeman, R; Hays, J		Womens Hlth Initiative Memory Stud	Conjugated equine estrogens and global cognitive function in postmenopausal women - Women's Health Initiative Memory Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MENTAL-STATE-EXAMINATION; HORMONE REPLACEMENT THERAPY; PLUS PROGESTIN; DEMENTIA; IMPAIRMENT; 3MS; PREVALENCE; COHORT; RISK; MMSE	Context The Women's Health Initiative Memory Study (WHIMS) previously reported that estrogen plus progestin therapy does not protect cognition among women aged 65 years or older. The effect of estrogen-alone therapy, also evaluated in WHIMS, on cognition has not been established for this population. Objectives To determine whether conjugated equine estrogen (CEE) alters global cognitive function in older women and to compare its effect with CEE plus medroxyprogesterone acetate (CEE plus MPA). Design, Setting, and Participants A randomized, double-blind, placebo-controlled ancillary study of the Women's Health Initiative (WHI), WHIMS evaluated the effect of CEE on incidence of probable dementia among community-dwelling women aged 65 to 79 years with prior hysterectomy from 39 US academic centers that started in June 1995. Of 3200 eligible women free of probable dementia enrolled in the WHI, 2947 (92.1%) were enrolled in WHIMS. Analyses were conducted on the 2808 women (95.3%) with a baseline and at least 1 follow-up measure of global cognitive function before the trial's termination on February 29, 2004. Interventions Participants received 1 daily tablet containing either 0.625 mg of CEE (n = 1387) or matching placebo (n = 142 1). Main Outcome Measure Global cognitive function measured annually with the Modified Mini-Mental State Examination (3MSE). Results During a mean follow-up of 5.4 years, mean (SE) 3MSE scores were 0.26 (0.13) units lower than among women assigned to CEE compared with placebo (P=.04). For pooled hormone therapy (CEE combined with CEE plus MPA), the mean (SE) decrease was 0.21 (0.08; P=.006). Removing women with dementia, mild cognitive impairment, or stroke from the analyses lessened these differences. The adverse effect of hormone therapy was more pronounced among women with lower cognitive function at baseline (all P<.01). For women assigned to CEE compared with placebo, the relative risk of having a 10-unit decrease in 3MSE scores (>2 SDs) was estimated to be 1.47 (95% confidence interval, 1.04-2.07). Conclusion For women aged 65 years or older, hormone therapy had an adverse effect on cognition, which was greater among women with lower cognitive function at initiation of treatment.	Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC 27157 USA; Univ Nevada, Sch Med, Womens Hlth Ctr, Reno, NV 89557 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02115 USA; McGill Univ, Dept Psychol, Montreal, PQ, Canada; McGill Univ, Dept Obstet & Gynecol, Montreal, PQ H3A 2T5, Canada; George Washington Univ, Dept Med, Washington, DC USA; Hennepin Cty Med Ctr, Div Clin Epidemiol, Minneapolis, MN 55415 USA; Univ Iowa, Coll Med, Dept Epidemiol, Iowa City, IA USA; Montefiore Med Ctr, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY 10467 USA; Baylor Coll Med, Ctr Womens Hlth, Houston, TX 77030 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Nevada System of Higher Education (NSHE); University of Nevada Reno; Harvard University; Brigham & Women's Hospital; Harvard Medical School; McGill University; McGill University; George Washington University; Hennepin County Medical Center; University of Iowa; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine	Espeland, MA (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Med Ctr Blvd, Winston Salem, NC 27157 USA.	mespelan@wfubmc.edu		Hays-Grudo, Jennifer/0000-0002-8107-1243; Margolis, Karen/0000-0003-1862-7402				Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; BARKER A, 1995, BRIT J PSYCHIAT, V167, P642, DOI 10.1192/bjp.167.5.642; Bethea CL, 2002, FRONT NEUROENDOCRIN, V23, P41, DOI 10.1006/frne.2001.0225; Bland RC, 2001, CAN J PSYCHIAT, V46, P506, DOI 10.1177/070674370104600604; Bravo G, 1997, NEUROEPIDEMIOLOGY, V16, P141; CORIA F, 1993, J NEUROL NEUROSUR PS, V56, P973, DOI 10.1136/jnnp.56.9.973; Foy MR, 2000, CURR DIR PSYCHOL SCI, V9, P148, DOI 10.1111/1467-8721.00081; GALEN BJ, 2004, J AM GERIATR SOC, V52, P182; Gibbs RB, 1999, HORM BEHAV, V36, P222, DOI 10.1006/hbeh.1999.1541; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6; Hogervorst E, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003122; Kuller LH, 2003, NEUROEPIDEMIOLOGY, V22, P13, DOI 10.1159/000067109; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; Linzmayer L, 2001, ARZNEIMITTEL-FORSCH, V51, P238; Littell R.C., 1996, SAS SYSTEMS MIXED MO; Matthews K, 1999, J AM GERIATR SOC, V47, P518, DOI 10.1111/j.1532-5415.1999.tb02563.x; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; McDowell I, 1997, J CLIN EPIDEMIOL, V50, P377, DOI 10.1016/S0895-4356(97)00060-7; Mitchell JL, 2003, ARCH INTERN MED, V163, P2485, DOI 10.1001/archinte.163.20.2485; NADLER JD, 1995, J GERIATR PSYCH NEUR, V8, P177, DOI 10.1177/089198879500800307; Rapp PR, 2003, J NEUROSCI, V23, P5708; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Rice MM, 2000, ARCH INTERN MED, V160, P1641, DOI 10.1001/archinte.160.11.1641; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sherwin BB, 2003, ENDOCR REV, V24, P133, DOI 10.1210/er.2001-0016; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 1998, CONTROL CLIN TRIALS, V19, P604, DOI 10.1016/S0197-2456(98)00038-5; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Smith YR, 2001, J CLIN ENDOCR METAB, V86, P679, DOI 10.1210/jc.86.2.679; Stefanick ML, 2003, ANN EPIDEMIOL, V13, pS78, DOI 10.1016/S1047-2797(03)00045-0; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TENG EL, 1990, PSYCHOGERIATRICS BIO, P189; Tombaugh TN, 1996, PSYCHOL ASSESSMENT, V8, P48, DOI 10.1037/1040-3590.8.1.48; TORANALLERAND CD, 1991, PSYCHONEUROENDOCRINO, V16, P7, DOI 10.1016/0306-4530(91)90068-5; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688; Zandi PP, 2002, JAMA-J AM MED ASSOC, V288, P2123, DOI 10.1001/jama.288.17.2123; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	40	592	610	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2004	291	24					2959	2968		10.1001/jama.291.24.2959	http://dx.doi.org/10.1001/jama.291.24.2959			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831HD	15213207	Bronze			2023-01-03	WOS:000222184600025
J	Houliston, RS; Hodges, RS; Sharom, FJ; Davis, JH				Houliston, RS; Hodges, RS; Sharom, FJ; Davis, JH			Characterization of the proto-oncogenic and mutant forms of the transmembrane region of neu in micelles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; MOLECULAR-DYNAMICS SIMULATIONS; ENCODED P185 PROTEIN; HYDROGEN-EXCHANGE; POINT MUTATION; COAT PROTEIN; NEU/ERBB-2 RECEPTOR; STRUCTURAL DYNAMICS; CIRCULAR-DICHROISM; SELF-ASSOCIATION	We have investigated peptides corresponding to the complete transmembrane region of both proto-oncogenic (Val(664)) and mutant (Glu(664)) forms of the receptor Neu in detergent micelles by NMR and CD spectroscopy. Both forms of the peptide appear to adopt similar levels of helicity and dimeric interactions based on the analysis of CD spectra and nuclear Overhauser effect connectivity profiles. There are considerable differences in the chemical shifts of amide and, to a lesser extent, CHalpha resonances between the two forms of the peptides, and these differences are most pronounced in residues upstream of the mutation site and close to the N terminus of the transmembrane domain. Similarly, there are substantial differences in the amide hydrogen-deuterium exchange rates for residues close to and upstream of the mutation site; amide protons in this region of the proto-oncogenic peptide are much more resistant to exchange than those in the mutant form. In both molecules, residues downstream of the mutation site exhibit slow exchange. We therefore demonstrate that, although transmembrane Neu peptides exhibit similar levels of secondary structure when dispersed in detergent, there are detectable differences in their adopted micellar states that may provide insight into the dimer-promoting ability of the polar transforming mutation.	Univ Guelph, Dept Phys, Guelph, ON N1G 2W1, Canada; Univ Guelph, Dept Chem & Biochem, Guelph, ON N1G 2W1, Canada; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Guelph; University of Guelph; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Davis, JH (corresponding author), Univ Guelph, Dept Phys, Guelph, ON N1G 2W1, Canada.	jhd@physics.uoguelph.ca	Sharom, Frances/A-1613-2010	Sharom, Frances/0000-0002-9521-5367				Almeida FCL, 1997, J MOL BIOL, V270, P481, DOI 10.1006/jmbi.1997.1114; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; Bader R, 2002, BIOCHEMISTRY-US, V41, P8031, DOI 10.1021/bi0201419; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BRANDTRAUF PW, 1989, J PROTEIN CHEM, V8, P749, DOI 10.1007/BF01024899; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; Chen LI, 1997, J CELL BIOL, V137, P619, DOI 10.1083/jcb.137.3.619; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Damberg P, 2001, METHOD ENZYMOL, V339, P271, DOI 10.1016/S0076-6879(01)39318-7; Duneau JP, 1997, J BIOMOL STRUCT DYN, V15, P555, DOI 10.1080/07391102.1997.10508966; ENGELMAN DM, 1993, SOC GEN PHY, V48, P11; Englander SW, 2000, ANNU REV BIOPH BIOM, V29, P213, DOI 10.1146/annurev.biophys.29.1.213; ENGLANDER SW, 1983, Q REV BIOPHYS, V16, P521, DOI 10.1017/S0033583500005217; Fleishman SJ, 2002, P NATL ACAD SCI USA, V99, P15937, DOI 10.1073/pnas.252640799; Goetz M, 2001, BIOCHEMISTRY-US, V40, P6534, DOI 10.1021/bi0027938; GULLICK WJ, 1992, EMBO J, V11, P43, DOI 10.1002/j.1460-2075.1992.tb05025.x; Houliston RS, 2003, FEBS LETT, V535, P39, DOI 10.1016/S0014-5793(02)03852-8; Jones DH, 2000, BIOCHEMISTRY-US, V39, P1870, DOI 10.1021/bi992495e; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; ONEIL JDJ, 1988, BIOCHEMISTRY-US, V27, P2753, DOI 10.1021/bi00408a015; Opella SJ, 2001, METHOD ENZYMOL, V339, P285, DOI 10.1016/S0076-6879(01)39319-9; OTTING G, 1986, J MAGN RESON, V70, P500, DOI 10.1016/0022-2364(86)90144-7; Petti LM, 1998, ONCOGENE, V16, P843, DOI 10.1038/sj.onc.1201590; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Sajot N, 2000, EUR BIOPHYS J BIOPHY, V28, P648, DOI 10.1007/s002490050005; Sajot N, 2001, J BIOMOL STRUCT DYN, V19, P15, DOI 10.1080/07391102.2001.10506717; Sambrook Joseph, 1989, MOL CLONING LAB MANU; SCHAGGER H, 1994, PRACTICAL GUIDE MEMB; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; Shao HY, 1999, J MOL BIOL, V285, P755, DOI 10.1006/jmbi.1998.2348; Sharpe S, 2002, BIOCHEMISTRY-US, V41, P2341, DOI 10.1021/bi011340f; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Smith SO, 2002, BIOCHEMISTRY-US, V41, P9321, DOI 10.1021/bi012117l; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; Therien AG, 2001, NAT STRUCT BIOL, V8, P597, DOI 10.1038/89631; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; Williams KA, 1996, BIOCHEMISTRY-US, V35, P5145, DOI 10.1021/bi952897w; WILLIAMSON M P, 1990, Biopolymers, V29, P1423, DOI 10.1002/bip.360291009; Yee A, 1999, BIOCHEMISTRY-US, V38, P6489, DOI 10.1021/bi982959t; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	53	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24073	24080		10.1074/jbc.M401919200	http://dx.doi.org/10.1074/jbc.M401919200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15051716	hybrid			2023-01-03	WOS:000221702500029
J	Hurwitz, H; Fehrenbacher, L; Novotny, W; Cartwright, T; Hainsworth, J; Heim, W; Berlin, J; Baron, A; Griffing, S; Holmgren, E; Ferrara, N; Fyfe, G; Rogers, B; Ross, R; Kabbinavar, F				Hurwitz, H; Fehrenbacher, L; Novotny, W; Cartwright, T; Hainsworth, J; Heim, W; Berlin, J; Baron, A; Griffing, S; Holmgren, E; Ferrara, N; Fyfe, G; Rogers, B; Ross, R; Kabbinavar, F			Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED-TRIAL; SOLID TUMORS; ANTIBODY; THERAPY; PHASE; VEGF	Background: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. Methods: Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo. The primary end point was overall survival. Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life. Results: The median duration of survival was 20.3 months in the group given IFL plus bevacizumab, as compared with 15.6 months in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001). The median duration of progression-free survival was 10.6 months in the group given IFL plus bevacizumab, as compared with 6.2 months in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 percent and 34.8 percent (P=0.004). The median duration of the response was 10.4 months in the group given IFL plus bevacizumab, as compared with 7.1 months in the group given IFL plus placebo (hazard ratio for progression, 0.62; P=0.001). Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 percent vs. 2.3 percent) but was easily managed. Conclusions: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.	Duke Univ, Med Ctr, Dept Med Oncol & Transplantat, Durham, NC 27710 USA; Kaiser Permanente, Vallejo, CA USA; Genentech Inc, San Francisco, CA 94080 USA; Ocala Oncol, Ocala, FL USA; Sarah Cannon Canc Ctr, Nashville, TN USA; Hematol & Oncol Associates NE Penn, Scranton, PA USA; Vanderbilt Univ, Nashville, TN USA; Calif Pacific Med Ctr, San Francisco, CA USA; Univ Calif Los Angeles, Los Angeles, CA USA	Duke University; Kaiser Permanente; Roche Holding; Genentech; Sarah Cannon Research Institute; Vanderbilt University; California Pacific Medical Center; University of California System; University of California Los Angeles	Hurwitz, H (corresponding author), Duke Univ, Med Ctr, Dept Med Oncol & Transplantat, Rm 3802,Red Zone,Duke S Clin,Box 3052, Durham, NC 27710 USA.	hurwi004@mc.duke.edu			NATIONAL CANCER INSTITUTE [K23CA085582] Funding Source: NIH RePORTER; NCI NIH HHS [K23 CA085582-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENSON AB, 2003, P AN M AM SOC CLIN, V22, P243; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; HURWITZ H, 2002, P AN M AM SOC CLIN, V21, P82; HURWITZ H, 2003, 94 AACR ANN M WASH D; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Nissen NN, 1998, AM J PATHOL, V152, P1445; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; *PHARM UPJ, 2002, CPT 11 CAMPT; Presta LG, 1997, CANCER RES, V57, P4593; Rothenberg ML, 2001, J CLIN ONCOL, V19, P3801, DOI 10.1200/JCO.2001.19.18.3801; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; *SAN SYNTH, 2004, OX EL; Tebbutt NC, 2003, GUT, V52, P568, DOI 10.1136/gut.52.4.568; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491	19	8076	8484	11	755	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2004	350	23					2335	2342		10.1056/NEJMoa032691	http://dx.doi.org/10.1056/NEJMoa032691			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825JY	15175435				2023-01-03	WOS:000221754200004
J	Perondi, MBM; Reis, AG; Paiva, EF; Nadkarni, VM; Berg, RA				Perondi, MBM; Reis, AG; Paiva, EF; Nadkarni, VM; Berg, RA			A comparison of high-dose and standard-dose epinephrine in children with cardiac arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIATRIC CARDIOPULMONARY-RESUSCITATION; CRITICALLY ILL CHILDREN; MYOCARDIAL PERFUSION; BLOOD-FLOW; SWINE MODEL; CPR; PHARMACOKINETICS; PRESSURE; TRIAL; DOGS	Background: When efforts to resuscitate a child after cardiac arrest are unsuccessful despite the administration of an initial dose of epinephrine, it is unclear whether the next dose of epinephrine (i.e., the rescue dose) should be the same (standard) dose or a higher dose. Methods: We performed a prospective, randomized, double-blind trial to compare high-dose epinephrine (0.1 mg per kilogram of body weight) with standard-dose epinephrine (0.01 mg per kilogram) as rescue therapy for in-hospital cardiac arrest in children after failure of an initial, standard dose of epinephrine. The trial included 68 children, and Utstein-style reporting guidelines were used. The primary outcome measure was survival 24 hours after the arrest. Results: The rate of survival at 24 hours was lower in the group assigned to a high dose of epinephrine as rescue therapy than in the group assigned to a standard dose: 1 of the 34 patients in the high-dose group survived for 24 hours, as compared with 7 of the 34 patients in the standard-dose group (unadjusted odds ratio for death with the high dose, 8.6; 97.5 percent confidence interval, 1.0 to 397.0; P=0.05). After adjustment by multiple logistic-regression analysis for differences in the groups at the time of arrest, the high-dose group tended to have a lower 24-hour survival rate (odds ratio for death, 7.9; 97.5 percent confidence interval, 0.9 to 72.5; P=0.08). The two treatment groups did not differ significantly in terms of the rate of return of spontaneous circulation (which occurred in 20 patients in the high-dose group and 21 of those in the standard-dose group; odds ratio, 1.1; 97.5 percent confidence interval, 0.4 to 3.0). None of the patients in the high-dose group, as compared with four of those in the standard-dose group, survived to hospital discharge. Among the 30 patients whose cardiac arrest was precipitated by asphyxia, none of the 12 who were assigned to high-dose epinephrine were alive at 24 hours, as compared with 7 of the 18 who were assigned to a standard dose (P=0.02). Conclusions: We did not find any benefit of high-dose epinephrine rescue therapy for in-hospital cardiac arrest in children after failure of an initial standard dose of epinephrine. The data suggest that high-dose therapy may be worse than standard-dose therapy.	Univ Sao Paulo, Sch Med, Childrens Inst, Dept Pediat, Sao Paulo, Brazil; Univ Sao Paulo, Sch Med, Dept Med, Sao Paulo, Brazil; Univ Penn, Sch Med, Dept Anesthesiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Arizona, Coll Med, Steele Mem Childrens Res Ctr, Tucson, AZ USA; Univ Arizona, Coll Med, Dept Pediat, Tucson, AZ USA	Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Arizona; University of Arizona	Berg, RA (corresponding author), 1501 N Campbell Ave,POB 245073, Tucson, AZ 85724 USA.	rberg@peds.arizona.edu	Paiva, Edison F/H-8225-2015; Paiva, Edison F/J-7106-2014					[Anonymous], 1992, JAMA, V268, P2262; Behringer W, 1998, ANN INTERN MED, V129, P450, DOI 10.7326/0003-4819-129-6-199809150-00004; Berg RA, 1997, CIRCULATION, V96, P4364; Berg RA, 1996, CRIT CARE MED, V24, P1695, DOI 10.1097/00003246-199610000-00016; BERG RA, 1993, J PHARMACOL EXP THER, V265, P1232; BERG RA, 1994, CRIT CARE MED, V22, P282, DOI 10.1097/00003246-199402000-00020; BERG RA, 1993, CRIT CARE MED, V21, P678, DOI 10.1097/00003246-199305000-00010; BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; BROWN CG, 1986, ANN EMERG MED, V15, P1138, DOI 10.1016/S0196-0644(86)80853-8; CALLAHAM M, 1992, JAMA-J AM MED ASSOC, V268, P2667, DOI 10.1001/jama.268.19.2667; Carpenter TC, 1997, PEDIATRICS, V99, P403, DOI 10.1542/peds.99.3.403; Chameides L, 1997, PEDIAT ADV LIFE SUPP; CHASE PB, 1993, CRIT CARE MED, V21, P413, DOI 10.1097/00003246-199303000-00020; CHOUX C, 1995, RESUSCITATION, V29, P3, DOI 10.1016/0300-9572(94)00810-3; DIECKMANN RA, 1995, PEDIATRICS, V95, P901; DITCHEY RV, 1994, AM HEART J, V127, P324, DOI 10.1016/0002-8703(94)90120-1; DITCHEY RV, 1988, CIRCULATION, V78, P382, DOI 10.1161/01.CIR.78.2.382; Fish SS, 1999, EMERG MED CLIN N AM, V17, P461, DOI 10.1016/S0733-8627(05)70072-9; FISHER DG, 1993, CRIT CARE MED, V21, P111, DOI 10.1097/00003246-199301000-00021; GOETTING MG, 1991, ANN EMERG MED, V20, P22, DOI 10.1016/S0196-0644(05)81112-6; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; Gueugniaud PY, 1998, NEW ENGL J MED, V339, P1595, DOI 10.1056/NEJM199811263392204; Hornchen U, 1993, J Cardiothorac Vasc Anesth, V7, P184, DOI 10.1016/1053-0770(93)90214-6; KERN KB, 1988, RESUSCITATION, V16, P241, DOI 10.1016/0300-9572(88)90111-6; Kern KB, 1996, J AM COLL CARDIOL, V28, P232, DOI 10.1016/0735-1097(96)00130-1; KOEHLER RC, 1985, ANN EMERG MED, V14, P744, DOI 10.1016/S0196-0644(85)80050-0; LINDNER KH, 1991, ACTA ANAESTH SCAND, V35, P253, DOI 10.1111/j.1399-6576.1991.tb03283.x; LIPMAN J, 1993, ANAESTH INTENS CARE, V21, P192, DOI 10.1177/0310057X9302100210; MICHAEL JR, 1984, CIRCULATION, V69, P822, DOI 10.1161/01.CIR.69.4.822; PARADIS NA, 1991, JAMA-J AM MED ASSOC, V265, P1139, DOI 10.1001/jama.265.9.1139; Reis AG, 2002, PEDIATRICS, V109, P200, DOI 10.1542/peds.109.2.200; SANDERS AB, 1984, CRIT CARE MED, V12, P871, DOI 10.1097/00003246-198410000-00007; Sherman BW, 1997, PHARMACOTHERAPY, V17, P242; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; Suominen P, 2000, RESUSCITATION, V45, P17, DOI 10.1016/S0300-9572(00)00167-2; Torres A, 1997, PEDIATR EMERG CARE, V13, P369, DOI 10.1097/00006565-199712000-00002; Vandycke C, 2000, RESUSCITATION, V45, P161, DOI 10.1016/S0300-9572(00)00188-X; Young KD, 1999, ANN EMERG MED, V33, P195, DOI 10.1016/S0196-0644(99)70394-X; 2000, CIRCULATION S1, V102, P291	40	182	189	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 22	2004	350	17					1722	1730		10.1056/NEJMoa032440	http://dx.doi.org/10.1056/NEJMoa032440			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	814AJ	15102998				2023-01-03	WOS:000220947300006
J	Laux, WHG; Pande, P; Shoshani, I; Gao, JY; Boudou-Vivet, V; Gosselin, G; Johnson, RA				Laux, WHG; Pande, P; Shoshani, I; Gao, JY; Boudou-Vivet, V; Gosselin, G; Johnson, RA			Pro-nucleotide inhibitors of adenylyl cyclases in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-MEDIATED INHIBITION; PHOSPHATE-PROTECTING GROUPS; HUMAN-IMMUNODEFICIENCY; CYCLIC-AMP; NUCLEOSIDE 3-POLYPHOSPHATES; PHOSPHOTRIESTER DERIVATIVES; MONONUCLEOTIDE PRODRUGS; INTRACELLULAR DELIVERY; ANTIVIRAL EVALUATION; POTENT INHIBITORS	Substituted adenine derivatives with protected phosphoryl groups were synthesized and tested as inhibitors of adenylyl cyclase in isolated enzyme and intact cell systems. Protected 3'-phosphoryl derivatives of 2', 5'-dideoxyadenosine (2',5'-dd-Ado) and beta-L-2',5'-dd-Ado, protected 5'-phosphoryl derivatives of beta-L-2', 3'-dd-Ado, and protected phosphoryl derivatives of two 9-(2-phosphonomethoxy- acyl)-adenines were synthesized. Protection was afforded by two cyclosaligenyl- or three S-acyl-2-thioethyl-substituents. These pro-nucleotides were tested for their capacity to block forskolin-induced increases in [H-3] cAMP in OB1771 and F442A preadipocytes and human macrophages prelabeled with [H-3] adenine. A striking selectivity for 2', 5'- dd-Ado- 3'-phosphoryl derivatives was observed. Cyclosaligenyl-derivatives (IC50 similar to2 muM) were much less potent than S-acyl-2-thioethyl- derivatives. Best studied of these was 2', 5'-dd-Ado- 3'-O-bis(S-pivaloyl-2-thioethyl)-phosphate, which blocked [H-3] cAMP formation in preadipocytes (IC50 similar to30 nM) and suppressed opening of cAMP-dependent Cl- channels in cardiac myocytes (IC50 similar to 800 nM). None of the pro-nucleotides inhibited adenylyl cyclase per se, whether isolated from rat brain or OB1771 cells. These compounds exhibit the hallmarks of prodrugs. Data suggest they are taken up, are deprotected, and are converted to a potent inhibitory form to inhibit adenylyl cyclase, but only by intact cells. The availability and characteristics of these prodrugs should make them useful for blocking cAMP-mediated pathways in intact cell systems, in biochemical, pharmacological, and potentially therapeutic contexts.	SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Montpellier 2, Lab Chim Organ Biomol Synth, CNRS, UMR 5625, F-34095 Montpellier 5, France	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Johnson, RA (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	roger.johnson@sunysb.edu			NIDDK NIH HHS [DK38828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER P, 1994, COLLECT CZECH CHEM C, V59, P2127, DOI 10.1135/cccc19942127; Beltran T, 2001, BIOORG MED CHEM LETT, V11, P1775, DOI 10.1016/S0960-894X(01)00299-2; Benzaria S, 1996, J MED CHEM, V39, P4958, DOI 10.1021/jm960289o; Bolon PJ, 1996, BIOORG MED CHEM LETT, V6, P1657, DOI 10.1016/0960-894X(96)00293-4; CHENG WL, 1995, AM J PHYSIOL-ENDOC M, V269, pE642, DOI 10.1152/ajpendo.1995.269.4.E642; CLAUS TH, 1982, MOL CELL ENDOCRINOL, V26, P269, DOI 10.1016/0303-7207(82)90116-2; DECLERCQ E, 1997, CLIN MICROBIOL REV, V10, P1; DESAUBRY L, 1995, TETRAHEDRON LETT, V36, P995, DOI 10.1016/0040-4039(94)02424-A; DESAUBRY L, 1995, NUCLEOS NUCLEOT, V14, P1453, DOI 10.1080/15257779508010705; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Desaubry L, 1998, J BIOL CHEM, V273, P24972, DOI 10.1074/jbc.273.38.24972; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; DILLINGHAM MA, 1985, J MEMBRANE BIOL, V88, P277, DOI 10.1007/BF01871091; Doronin S, 1999, J BIOL CHEM, V274, P34745, DOI 10.1074/jbc.274.49.34745; Egron D, 2001, NUCLEOS NUCLEOT NUCL, V20, P751, DOI 10.1081/NCN-100002422; FAIN JN, 1972, J BIOL CHEM, V247, P6866; Friedman D L, 1976, Adv Cyclic Nucleotide Res, V7, P69; GAO J, 1992, J PHYSIOL-LONDON, V449, P689, DOI 10.1113/jphysiol.1992.sp019109; GARBERS DL, 1975, J BIOL CHEM, V250, P8449; GARTNER R, 1985, MOL CELL ENDOCRINOL, V42, P145, DOI 10.1016/0303-7207(85)90102-9; GREGA DS, 1987, J NEUROSCI, V7, P700; HARVEY RD, 1990, J GEN PHYSIOL, V95, P1077, DOI 10.1085/jgp.95.6.1077; HASLAM RJ, 1972, LIFE SCI 2-BIOCH GEN, V11, P1143, DOI 10.1016/0024-3205(72)90269-X; HASLAM RJ, 1978, BIOCHEM J, V176, P83, DOI 10.1042/bj1760083; HOLY A, 1987, COLLECT CZECH CHEM C, V52, P2801, DOI 10.1135/cccc19872801; HOLY A, 1995, COLLECT CZECH CHEM C, V60, P1196, DOI 10.1135/cccc19951196; HWANG TC, 1992, J GEN PHYSIOL, V99, P465, DOI 10.1085/jgp.99.4.465; Ibrahimi A, 1999, AM J PHYSIOL-CELL PH, V276, pC487, DOI 10.1152/ajpcell.1999.276.2.C487; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; Johnson RA, 1997, J BIOL CHEM, V272, P8962; JOHNSON RA, 1994, METHOD ENZYMOL, V238, P31; JONES RJ, 1995, ANTIVIR RES, V27, P1, DOI 10.1016/0166-3542(95)00011-A; LEFEBVRE I, 1995, J MED CHEM, V38, P3941, DOI 10.1021/jm00020a007; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; MCGUIGAN C, 1992, ANTIVIR RES, V17, P311, DOI 10.1016/0166-3542(92)90026-2; MCGUIGAN C, 1993, J MED CHEM, V36, P1048, DOI 10.1021/jm00060a013; Meier C, 1996, ANGEW CHEM INT EDIT, V35, P70, DOI 10.1002/anie.199600701; Meier C, 1997, BIOORG MED CHEM LETT, V7, P99, DOI 10.1016/S0960-894X(96)00597-5; Meier C, 1998, J MED CHEM, V41, P1417, DOI 10.1021/jm970664s; Meier C, 1997, BIOORG MED CHEM LETT, V7, P1577, DOI 10.1016/S0960-894X(97)00265-5; Meier C, 2002, MINI-REV MED CHEM, V2, P219, DOI 10.2174/1389557023406205; NAESENS L, 1994, REV MED VIROL, V4, P147, DOI 10.1002/rmv.1980040302; Naesens L, 1997, ANTIVIR CHEM CHEMOTH, V8, P1; NEYTS J, 1994, BIOCHEM PHARMACOL, V47, P39, DOI 10.1016/0006-2952(94)90435-9; PERIGAUD C, 1993, BIOORG MED CHEM LETT, V3, P2521, DOI 10.1016/S0960-894X(01)80709-5; PERIGAUD C, 1996, ADV ANTIV D, V2, P147; Peyrottes S, 2001, NUCLEOS NUCLEOT NUCL, V20, P315, DOI 10.1081/NCN-100002302; PIERRA C, 1997, THESIS U MONTPELLIER; REID IR, 1990, AM J PHYSIOL, V258, pE708, DOI 10.1152/ajpendo.1990.258.4.E708; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SASTRY JK, 1992, MOL PHARMACOL, V41, P441; Shoshani I, 1999, J BIOL CHEM, V274, P34742, DOI 10.1074/jbc.274.49.34742; Shoshani I, 1999, J BIOL CHEM, V274, P34735, DOI 10.1074/jbc.274.49.34735; Tesmer JJG, 2000, BIOCHEMISTRY-US, V39, P14464, DOI 10.1021/bi0015562; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Thomas CA, 1997, BLOOD, V90, P3760, DOI 10.1182/blood.V90.9.3760; Wagner CR, 2000, MED RES REV, V20, P417, DOI 10.1002/1098-1128(200011)20:6<417::AID-MED1>3.0.CO;2-Z; WEINRYB I, 1974, BIOCHIM BIOPHYS ACTA, V334, P218, DOI 10.1016/0005-2744(74)90165-X; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199	60	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13317	13332		10.1074/jbc.M309535200	http://dx.doi.org/10.1074/jbc.M309535200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14699161	hybrid			2023-01-03	WOS:000220478500008
J	Minelli, C; Abrams, KR; Sutton, AJ; Cooper, NJ				Minelli, C; Abrams, KR; Sutton, AJ; Cooper, NJ			Benefits and harms associated with hormone replacement therapy: clinical decision analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; ESTROGEN PLUS PROGESTIN; CORONARY-ARTERY DISEASE; UP HERS-II; POSTMENOPAUSAL WOMEN; ESTROGEN/PROGESTIN REPLACEMENT; BREAST-CANCER; COST-EFFECTIVENESS; ATRIAL-FIBRILLATION; RANDOMIZED TRIALS	Objective To evaluate harms and benefits associated with use of combined hormone replacement therapy (HRT) for five years in women with different baseline risks for breast cancer. Design Probabilistic clinical decision analysis. Setting Hypothetical population of white UK women aged 50 years with different baseline risks for breast cancer. Main outcome measure Gain or loss in quality adjusted life years (QALYs). Results Women free of menopausal symptoms showed a net harm from HRT use, which increased for increasing baseline risk of breast cancer. Those with a baseline risk of 1.2% would expect a loss in QALYs of 0.4 months (-0.03 QALYs, 95% credibility interval -0.05 to -0.01). The main analysis showed HRT to be on average beneficial in women with symptoms, with benefit decreasing with increasing baseline risk of breast cancer. The results were sensitive to the assumed value of quality of life with menopausal symptoms, therefore a contour plot was developed to show the probability of net harm for a range of different values and baseline risks. Conclusions HRT for primary prevention of chronic diseases in women without menopausal symptoms is unjustified. Perceived quality of life in women with symptoms should be taken into account when deciding on HRT. Thus, a decision analysis tailored to an individual woman is more appropriate in clinical practice than a population based approach.	Univ Leicester, Dept Hlth Sci, Ctr Biostat & Genet Epidemiol, Leicester LE1 6TP, Leics, England	University of Leicester	Abrams, KR (corresponding author), Univ Leicester, Dept Hlth Sci, Ctr Biostat & Genet Epidemiol, Leicester LE1 6TP, Leics, England.	keith.abrams@le.ac.uk	Abrams, Keith/AAA-2557-2020	Abrams, Keith/0000-0002-7557-1567; Sutton, Alexander/0000-0002-8934-9940				Armstrong K, 2001, OBSTET GYNECOL, V98, P996, DOI 10.1016/S0029-7844(01)01624-6; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Col NF, 1999, ARCH INTERN MED, V159, P1458, DOI 10.1001/archinte.159.13.1458; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; Daly E, 1996, MATURITAS, V23, P247, DOI 10.1016/0378-5122(95)00978-7; DALY E, 1993, BRIT MED J, V307, P836, DOI 10.1136/bmj.307.6908.836; EASTON DF, 1995, AM J HUM GENET, V56, P265; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fitzpatrick R, 1998, Health Technol Assess, V2, P1; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Gallus S, 2002, INT J CANCER, V99, P762, DOI 10.1002/ijc.10411; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Hill DA, 2000, AM J OBSTET GYNECOL, V183, P1456, DOI 10.1067/mob.2000.108081; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; Hogervorst E, 2000, NEUROSCIENCE, V101, P485, DOI 10.1016/S0306-4522(00)00410-3; HOGERVORST E, 2004, COCHRANE LIB; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; LETHABY A, 2004, COCHRANE LIB; MacLennan A, 2004, COCHRANE LIB; *MED HEALTHC PROD, REG AG US HORM REPL; *MED HEALTHC PROD, US HORM REPL THER PR; Melsop KA, 2003, AM HEART J, V145, P36, DOI 10.1067/mhj.2003.37; Miller J, 2002, ANN INTERN MED, V136, P680, DOI 10.7326/0003-4819-136-9-200205070-00011; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Neymark N, 1998, EUR J CANCER, V34, P1317, DOI 10.1016/S0959-8049(98)00074-4; *OFF NAT STAT, 2001, SOC TRENDS, V31, pCH7; Protheroe J, 2000, BRIT MED J, V320, P1380, DOI 10.1136/bmj.320.7246.1380; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rymer J, 2003, BRIT MED J, V326, P322, DOI 10.1136/bmj.326.7384.322; Simon JA, 2001, ANN INTERN MED, V135, P493, DOI 10.7326/0003-4819-135-7-200110020-00008; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Spiegelhalter DJ, 1999, BRIT MED J, V319, P508, DOI 10.1136/bmj.319.7208.508; Spiegelhalter DJ, 2004, BAYESIAN APPROACHES, DOI DOI 10.1002/0470092602; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Sturdee DW, 2000, BRIT J OBSTET GYNAEC, V107, P1392, DOI 10.1111/j.1471-0528.2000.tb11654.x; SUTTON AJ, 2004, 0401 U LEIC DEP HLTH; Tengs TO, 2000, MED CARE, V38, P583, DOI 10.1097/00005650-200006000-00004; Thomson R, 2000, LANCET, V355, P956, DOI 10.1016/S0140-6736(00)90012-6; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Uhler ML, 2000, MENOPAUSE, V7, P162, DOI 10.1097/00042192-200007030-00006; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Weinstein M C, 1983, Obstet Gynecol Surv, V38, P445, DOI 10.1097/00006254-198308000-00001; WEINSTEIN MC, 1980, NEW ENGL J MED, V303, P308, DOI 10.1056/NEJM198008073030604; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; Weinstein MC., 1996, COST EFFECTIVENESS H; White C, 2002, BRIT MED J, V325, P987, DOI 10.1136/bmj.325.7371.987; WILKES HC, 1991, BRIT MED J, V302, P1317, DOI 10.1136/bmj.302.6788.1317; Zethraeus N, 1997, BRIT J OBSTET GYNAEC, V104, P1191, DOI 10.1111/j.1471-0528.1997.tb10945.x; Zethraeus N, 1999, INT J TECHNOL ASSESS, V15, P352, DOI 10.1017/S0266462399015275	55	36	38	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	2004	328	7436					371	375		10.1136/bmj.328.7436.371	http://dx.doi.org/10.1136/bmj.328.7436.371			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	775GA	14962874	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000189031300017
J	Teno, JM; Clarridge, BR; Casey, V; Welch, LC; Wetle, T; Shield, R; Mor, V				Teno, JM; Clarridge, BR; Casey, V; Welch, LC; Wetle, T; Shield, R; Mor, V			Family perspectives on end-of-life care at the last place of care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GOOD DEATH; QUALITY; STATEMENT; HOSPICE; PATIENT	Context Over the past century, nursing homes and hospitals increasingly have become the site of death, yet no national studies have examined the adequacy or quality of end-of-life care in institutional settings compared with deaths at home. Objective To evaluate the US dying experience at home and in institutional settings. Design, Setting, and Participants Mortality follow-back survey of family members or other knowledgeable informants representing 1578 decedents, with a 2-stage probability sample used to estimate end-of-life care outcomes for 1.97 million deaths from chronic illness in the United States in 2000. Informants were asked via telephone about the patient's experience at the last place of care at which the patient spent more than 48 hours. Main Outcome Measures Patient- and family-centered end-of-life care outcomes, including whether health care workers (1) provided the desired physical comfort and emotional support to the dying person, (2) supported shared decision making, (3) treated the dying person with respect, (4) attended to the emotional needs of the family, and (5) provided coordinated care. Results For 1059 of 1578 decedents (67.1%), the last place of care was an institution. Of 519 (32.9%) patients dying at home represented by this sample, 198 (38.2%) did not receive nursing services; 65 (12.5%) had home nursing services, and 256 (49.3%) had home hospice services. About one quarter of all patients with pain or dyspnea did not receive adequate treatment, and one quarter reported concerns with physician communication. More than one third of respondents cared for by a home health agency, nursing home, or hospital reported insufficient emotional support for the patient and/or 1 or more concerns with family emotional support, compared with about one fifth of those receiving home hospice services. Nursing home residents were less likely than those cared for in a hospital or by home hospice services to always have been treated with respect at the end of life (68.2% vs 79.6% and 96.2%, respectively). Family members of patients receiving hospice services were more satisfied with overall quality of care: 70.7% rated care as "excellent" compared with less than 50% of those dying in an institutional setting or with home health services (P<.001). Conclusions Many people dying in institutions have unmet needs for symptom amelioration, physician communication, emotional support, and being treated with respect. Family members of decedents who received care at home with hospice services were more likely to report a favorable dying experience.	Brown Univ, Dept Community Hlth, Providence, RI 02912 USA; Brown Univ, Brown Med Sch, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA; Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA	Brown University; Brown University; University of Massachusetts System; University of Massachusetts Boston	Teno, JM (corresponding author), 2 Stimson Ave, Providence, RI 02912 USA.		Welch, Lisa Christine/GZK-6246-2022	Welch, Lisa/0000-0001-6269-9310				Addington-Hall J, 2001, J PAIN SYMPTOM MANAG, V22, P784, DOI 10.1016/S0885-3924(01)00330-X; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Cochran WG, 1977, SAMPLING TECHNIQUES, V3rd; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Field MJ, 1997, APPROACHING DEATH IM; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Harrington C, 2000, GERONTOLOGIST, V40, P5; Higginson IJ, 2002, J PAIN SYMPTOM MANAG, V23, P96, DOI 10.1016/S0885-3924(01)00406-7; Kish L., 1965, SURVEY SAMPLING; Lynn J, 1997, J AM GERIATR SOC, V45, P526; McPherson CJ, 2003, SOC SCI MED, V56, P95, DOI 10.1016/S0277-9536(02)00011-4; Singer PA, 2002, BMJ-BRIT MED J, V324, P1291, DOI 10.1136/bmj.324.7349.1291; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Teno JM, 1999, J PAIN SYMPTOM MANAG, V17, P109, DOI 10.1016/S0885-3924(98)00132-8; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P752, DOI 10.1016/S0885-3924(01)00331-1; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P738, DOI 10.1016/S0885-3924(01)00335-9; TENO JM, 2000, FACTS DYING POLICY R; Weitzen S, 2003, MED CARE, V41, P323, DOI 10.1097/00005650-200302000-00013; Zerzan J, 2000, JAMA-J AM MED ASSOC, V284, P2489, DOI 10.1001/jama.284.19.2489; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	21	1062	1072	5	125	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2004	291	1					88	93		10.1001/jama.291.1.88	http://dx.doi.org/10.1001/jama.291.1.88			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760LX	14709580	Bronze			2023-01-03	WOS:000187836000023
J	Shelton, JD; Peterson, EA				Shelton, JD; Peterson, EA			The imperative for family planning in ART in Africa	LANCET			English	Editorial Material							ANTIRETROVIRAL NUCLEOSIDE; MATERNAL HIV; PREGNANCY; NEVIRAPINE; INFECTION; THERAPY; MALARIA		US Agcy Int Dev, Bur Global Hlth, Washington, DC 20523 USA	United States Agency for International Development (USAID)	Shelton, JD (corresponding author), US Agcy Int Dev, Bur Global Hlth, Washington, DC 20523 USA.	jshelton@usaid.gov						Brocklehurst P, 1998, BRIT J OBSTET GYNAEC, V105, P836, DOI 10.1111/j.1471-0528.1998.tb10227.x; Cossarizza A, 2004, AIDS, V18, P137, DOI 10.1097/00002030-200401230-00002; DESCHAMPS MD, 2004, 15 INT AIDS C BANK; McIntyre J, 2003, BRIT MED BULL, V67, P127, DOI 10.1093/bmb/ldg012; Minkoff H, 2003, AM J OBSTET GYNECOL, V189, P552, DOI 10.1067/S0002-9378(03)00467-8; Mount AM, 2004, LANCET, V363, P1860, DOI 10.1016/S0140-6736(04)16354-X; Newell ML, 2003, JAIDS-J ACQ IMM DEF, V32, P380, DOI 10.1097/00126334-200304010-00006; Poirier MC, 2004, TOXICOL APPL PHARM, V199, P151, DOI 10.1016/j.taap.2003.11.034; Poirier MC, 2003, JAIDS-J ACQ IMM DEF, V33, P175, DOI 10.1097/00126334-200306010-00010; Powderly WG, 2002, J ACQ IMMUN DEF SYND, V29, pS28, DOI 10.1097/00126334-200202011-00005; SINGH S, 2004, ADD IT BEN INV SEX R; Ticconi C, 2003, JAIDS-J ACQ IMM DEF, V34, P289, DOI 10.1097/00126334-200311010-00005; Tuomala RE, 2002, NEW ENGL J MED, V346, P1863, DOI 10.1056/NEJMoa991159; *UNAIDS, 2002, REP GLOB HIV AIDS EP; van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7; Wainberg MA, 2003, JAIDS-J ACQ IMM DEF, V34, pS2, DOI 10.1097/00126334-200309011-00002; WESTOFF CF, 2001, UNMET NEED END CENTU; WHO UNICEF and UNFPA (World Health Organization United Nations Children's Fund and United Nations Population Fund), 2003, MAT MORT 2000 EST DE; World Health Organization, 2003, ENTR POINTS ANT TREA; World Health Organization, 2003, SCAL ANT THER RES LT; 2003, LANCET, V362, P179	21	19	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2004	364	9449					1916	1918		10.1016/S0140-6736(04)17489-8	http://dx.doi.org/10.1016/S0140-6736(04)17489-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15566991				2023-01-03	WOS:000225327000005
J	Pochan, DJ; Chen, ZY; Cui, HG; Hales, K; Qi, K; Wooley, KL				Pochan, DJ; Chen, ZY; Cui, HG; Hales, K; Qi, K; Wooley, KL			Toroidal triblock copolymer assemblies	SCIENCE			English	Article							DIBLOCK COPOLYMERS; BLOCK-COPOLYMERS; MULTIPLE MORPHOLOGIES; SHAPED MORPHOLOGY; DILUTE-SOLUTION; DNA COMPLEXES; F-ACTIN; MICELLES; VESICLES; SURFACTANT	A stable phase of toroidal, or ringlike, supramolecular assemblies was formed by combining dilute solution characteristics critical for both bundling of like-charged biopolymers and block copolymer micelle formation. The key to toroid versus classic cylinder micelle formation is the interaction of the negatively charged hydrophilic block of an amphiphilic triblock copolymer with a positively charged divalent organic counterion. This produces a self-attraction of cylindrical micelles that leads to toroid formation, a mechanism akin to the toroidal bundling of semiflexible charged biopolymers such as DNA. The toroids can be kinetically trapped or chemically cross-linked. insight into the mechanism of toroid formation can be gained by observation of intermediate structures kinetically trapped during film casting.	Univ Delaware, Delaware Biotechnol Inst, Newark, DE 19716 USA; Washington Univ, Ctr Mat Innovat, St Louis, MO 63130 USA; Washington Univ, Dept Chem, St Louis, MO 63130 USA	University of Delaware; Washington University (WUSTL); Washington University (WUSTL)	Pochan, DJ (corresponding author), Univ Delaware, Delaware Biotechnol Inst, Newark, DE 19716 USA.		Cui, Honggang/E-8012-2010; Wooley, Karen L/D-4399-2015; Qi, Kai/C-2558-2018; Cui, Honggang/C-6550-2008; Wooley, Karen/AAX-2259-2020	Wooley, Karen L/0000-0003-4086-384X; Qi, Kai/0000-0002-4166-7421; Wooley, Karen/0000-0003-4086-384X				Bermudez H, 2002, MACROMOLECULES, V35, P8203, DOI 10.1021/ma020669l; Bernheim-Groswasser A, 2000, J PHYS CHEM B, V104, P4005, DOI 10.1021/jp994301a; Bloomfield VA, 1997, BIOPOLYMERS, V44, P269, DOI 10.1002/(SICI)1097-0282(1997)44:3<269::AID-BIP6>3.0.CO;2-T; Bottcher C, 1998, J AM CHEM SOC, V120, P12, DOI 10.1021/ja971047w; Cornelissen JJLM, 1998, SCIENCE, V280, P1427, DOI 10.1126/science.280.5368.1427; Dalhaimer P, 2004, J POLYM SCI POL PHYS, V42, P168, DOI 10.1002/polb.10709; Discher BM, 1999, SCIENCE, V284, P1143, DOI 10.1126/science.284.5417.1143; Ewert K, 2004, CURR MED CHEM, V11, P133, DOI 10.2174/0929867043456160; Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187; In M, 1999, J PHYS CHEM B, V103, P7747, DOI 10.1021/jp9919922; Jain S, 2004, MACROMOLECULES, V37, P1511, DOI 10.1021/ma035467j; Jain S, 2003, SCIENCE, V300, P460, DOI 10.1126/science.1082193; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; Prochazka K, 1996, MACROMOLECULES, V29, P6518, DOI 10.1021/ma960630e; Raez J, 2002, J AM CHEM SOC, V124, P10381, DOI 10.1021/ja020349h; Riegel IC, 2002, LANGMUIR, V18, P3358, DOI 10.1021/la015592t; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Tang JX, 1996, J BIOL CHEM, V271, P8556, DOI 10.1074/jbc.271.15.8556; Tang JX, 2001, EUR BIOPHYS J BIOPHY, V30, P477, DOI 10.1007/s002490100178; van der Schoot P, 1999, MACROMOL THEOR SIMUL, V8, P428; Vriezema DM, 2004, MACROMOLECULES, V37, P4736, DOI 10.1021/ma035789n; Vriezema DM, 2003, ANGEW CHEM INT EDIT, V42, P772, DOI 10.1002/anie.200390204; Won YY, 1999, SCIENCE, V283, P960, DOI 10.1126/science.283.5404.960; Wong GCL, 2000, SCIENCE, V288, P2035, DOI 10.1126/science.288.5473.2035; Yu K, 1996, LANGMUIR, V12, P5980, DOI 10.1021/la960894u; ZHANG LF, 1995, SCIENCE, V268, P1728, DOI 10.1126/science.268.5218.1728; Zhang LF, 1997, PHYS REV LETT, V79, P5034, DOI 10.1103/PhysRevLett.79.5034; Zhang LF, 1996, J AM CHEM SOC, V118, P3168, DOI 10.1021/ja953709s; Zhu JT, 2004, LANGMUIR, V20, P3809, DOI 10.1021/la0361565	29	678	686	6	372	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	2004	306	5693					94	97		10.1126/science.1102866	http://dx.doi.org/10.1126/science.1102866			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	859YJ	15459386				2023-01-03	WOS:000224304000043
J	Nichol, G; Kaul, P; Huszti, E; Bridges, JFP				Nichol, G; Kaul, P; Huszti, E; Bridges, JFP			Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure	ANNALS OF INTERNAL MEDICINE			English	Article							IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; CONVENIENT APPROXIMATION; SECONDARY PREVENTION; LIFE EXPECTANCY; CLINICAL-TRIALS; CONDUCTION; UNCERTAINTY; MORBIDITY; DEALE	Background: Heart failure is a common, costly, and debilitating illness. Resynchronization of ventricular contraction in patients with heart failure improves ejection fraction. The long-term morbidity and costs associated with such cardiac resynchronization therapy remain unclear. Objective: To assess the incremental cost-effectiveness of cardiac resynchronization therapy. Design: Markov model with Monte Carlo simulation. Future costs and effects were discounted at 3%. Data Sources: Effects data were obtained from a concurrent systematic review. Health-related quality-of-life and cost data were obtained from publicly available data or from surveys. Target Population: Patients with reduced ventricular function and prolonged QRS. Time Horizon: Lifetime. Perspective: U.S. health care system. Interventions: Cardiac resynchronization therapy versus medical therapy. Outcome Measures: Quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness. Results of Base-Case Analysis: Medical therapy yielded a median of 2.64 (interquartile range, 2.47 to 2.82) discounted QALYs and a median discounted lifetime cost of $34400 (interquartile range, $31100 to $37700). Cardiac resynchronization therapy was associated with a median incremental cost of $107800 (interquartile range, $79800 to $156500) per additional QALY. Results of Sensitivity Analysis: Results were sensitive to changes in several variables, including the relative risk for death or hospitalization. Limitations: These results apply to patients who meet the inclusion criteria of the currently completed trials. Conclusions: The incremental cost per QALY for cardiac resynchronization is similar to that of other commonly used interventions but is sensitive to changes in several key variables. Resynchronization therapy should not be considered in patients with comorbid illness that shortens life expectancy.	Univ Washington, Harborview Prehosp Emergency Care Res & Training, Harborview Med Ctr, Seattle, WA 98104 USA; Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON, Canada; Univ Alberta, Edmonton, AB, Canada; Case Western Reserve Univ, Cleveland, OH 44106 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Ottawa; Ottawa Hospital Research Institute; University of Alberta; Case Western Reserve University	Nichol, G (corresponding author), Univ Washington, Harborview Prehosp Emergency Care Res & Training, Harborview Med Ctr, 325 9th Ave,Box 359747, Seattle, WA 98104 USA.	nichol@u.washington.edu	Nichol, Graham/Z-4996-2019	Kaul, Padma/0000-0003-2239-3944				Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Abraham WT, 2000, J CARD FAIL, V6, P369, DOI 10.1054/jcaf.2000.20841; Abrams KR, 2000, METHODS METAANALYSIS; *ALB EV BAS PRACT, 2003, SYST REV BIV PAC HEA; Auricchio A, 2002, J AM COLL CARDIOL, V39, P2026, DOI 10.1016/S0735-1097(02)01895-8; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; Bigger JT, 1997, NEW ENGL J MED, V337, P1569, DOI 10.1056/NEJM199711273372201; Bridges John F P, 2003, Appl Health Econ Health Policy, V2, P213; Briggs A, 1998, HEALTH ECON, V7, P723, DOI 10.1002/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.3.CO;2-F; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHRISTENSEN R, 1989, DATA DISTRIBUTIONS S; Connolly SJ, 2000, EUR HEART J, V21, P2071, DOI 10.1053/euhj.2000.2476; CRITCHFIELD GC, 1986, MED DECIS MAKING, V6, P85, DOI 10.1177/0272989X8600600205; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Eichhorn E, 2001, NEW ENGL J MED, V344, P1659; Ezekowitz JA, 2003, ANN INTERN MED, V138, P445, DOI 10.7326/0003-4819-138-6-200303180-00007; *FDA, 2002, P010012 FDA; FEENY D, 1995, PHARMACOECONOMICS, V7, P490, DOI 10.2165/00019053-199507060-00004; FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P585, DOI 10.1016/0895-4356(89)90155-8; Furlong W, 1990, WORKING PAPER SERIES, V90-9; Garrigue S, 2002, HEART, V87, P529, DOI 10.1136/heart.87.6.529; Gold MR, 1996, COST EFFECTIVENESS H, P425; Hirth RA, 2000, MED DECIS MAKING, V20, P332, DOI 10.1177/0272989X0002000310; Kaul P, 2003, J AM COLL CARDIOL, V41, p535A; Leclercq C, 2002, EUR HEART J, V23, P1780, DOI 10.1053/euhj.2002.3232; Llewellyn-Thomas H. A., 2000, ADAPTATION CHANGING, P109; LlewellynThomas HA, 1996, MED CARE, V34, pDS109; Lloyd-Williams F, 2003, J CLIN EPIDEMIOL, V56, P1157, DOI 10.1016/S0895-4356(03)00205-1; Lothgren M, 2000, HEALTH ECON, V9, P623, DOI 10.1002/1099-1050(200010)9:7<623::AID-HEC539>3.0.CO;2-V; MASON J, 1993, BRIT MED J, V306, P570, DOI 10.1136/bmj.306.6877.570; Masoudi FA, 2003, AM HEART J, V146, P250, DOI 10.1016/S0002-8703(03)00189-3; Massie BM, 1998, LANCET, V352, P29; McAlister FA, 2004, ANN INTERN MED, V141, P381, DOI 10.7326/0003-4819-141-5-200409070-00101; *N AM SOC PAC EL, CPT COD GUID; *NAT HEART LUNG BL, 2002, NHLBI FACT BOOK; Nichol G, 2003, CIRCULATION, V108, P697, DOI 10.1161/01.CIR.0000084545.65645.28; Owens DK, 1997, ANN INTERN MED, V126, P1, DOI 10.7326/0003-4819-126-1-199701010-00001; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; PORTER M, 1984, SOC SCI MED, V19, P1197, DOI 10.1016/0277-9536(84)90370-8; Rose EA, 2001, NEW ENGL J MED, V345, P1435, DOI 10.1056/NEJMoa012175; Shamim W, 1999, INT J CARDIOL, V70, P171, DOI 10.1016/S0167-5273(99)00077-7; Sox HC, 1988, MED DECISION MAKING; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; TORRANCE GW, 1995, PHARMACOECONOMICS, V7, P503, DOI 10.2165/00019053-199507060-00005; Uretsky BF, 2000, CIRCULATION, V102, P611, DOI 10.1161/01.CIR.102.6.611; *US DEP HHS, 2001, US DEC LIF TABL 1998; US Department of Labor. Bureau of Labor Statistics, CONS PRIC IND; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; VANNEUMANN J, 1994, THEORY GAMES EC BEHA; Weinstein MC., 1996, COST EFFECTIVENESS H; Wilkoff BL, 2002, JAMA-J AM MED ASSOC, V288, P3115; WINER BJ, 1971, LATIN SQUARES RELATE, P685; Xiao HB, 1996, INT J CARDIOL, V53, P163, DOI 10.1016/0167-5273(95)02502-2; Young JB, 2003, JAMA-J AM MED ASSOC, V289, P2685, DOI 10.1001/jama.289.20.2685	59	83	83	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2004	141	5					343	351		10.7326/0003-4819-141-5-200409070-00102	http://dx.doi.org/10.7326/0003-4819-141-5-200409070-00102			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CW	15353425				2023-01-03	WOS:000223733800002
J	Foster				Foster			How often are adverse events reported in English hospital statistics?	BMJ-BRITISH MEDICAL JOURNAL			English	Article								About 850 000 medical errors occur in NHS hospitals every year, resulting in 40 000 deaths. In-wl the United Kingdom, the National Patient Safety Agency (NPSA) was created to learn from patient safety incidents occurring in the NHS.(w2) In February 2004, it launched a new patient reporting system, drawing together reports of patient safety errors and systems failures provided by health professionals across England and Wales.(w3) An adverse event can be defined as "an unintended injury caused by medical management rather than a disease process, resulting in death, life threatening illness, disability at the time of discharge, admission to hospital, or prolongation of hospital stay."(w4) A medical or surgical misadventure is an adverse event that might have been avoided if the patient had received ordinary standards of care. We took at four years of hospital episode statistics to examine patterns in the recording of adverse events within this routinely collected source of data and ask whether it could be of use in monitoring this problem.	Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England	Imperial College London	Foster (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England.		Aylin, Paul/A-1073-2014	Aylin, Paul/0000-0003-4589-1743; Bottle, Alex/0000-0001-9978-2011				Australian Institute for Health and Welfare, 2001, REP ADV EV ROUT COLL; EMSLIE S, 2001, RISK MANAGEMENT NATL; Michel P, 2004, BRIT MED J, V328, P199, DOI 10.1136/bmj.328.7433.199; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; Wolff AM, 1996, MED J AUSTRALIA, V164, P458, DOI 10.5694/j.1326-5377.1996.tb122120.x	5	26	26	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 14	2004	329	7462					369	+		10.1136/bmj.329.7462.369	http://dx.doi.org/10.1136/bmj.329.7462.369			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YI	15310606	Green Published			2023-01-03	WOS:000223433600013
J	Burns, RB				Burns, RB			A 54-year-old man with obstructive sleep apnea	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Kuna ST, 2002, JAMA-J AM MED ASSOC, V288, P2032, DOI 10.1001/jama.288.16.2032	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2004	291	24					3004	3004		10.1001/jama.291.24.3004	http://dx.doi.org/10.1001/jama.291.24.3004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831HD	15213213				2023-01-03	WOS:000222184600031
J	Haas, CS; Amann, K; Braun, J				Haas, CS; Amann, K; Braun, J			Bone tumour and haemodialysis	LANCET			English	Editorial Material									Univ Erlangen Nurnberg, Dept Internal Med Nephrol, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany; KfH Dialysis Ctr, Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg	Haas, CS (corresponding author), Univ Erlangen Nurnberg, Dept Internal Med Nephrol, D-91054 Erlangen, Germany.								0	1	1	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 13	2004	363	9412					851	851		10.1016/S0140-6736(04)15731-0	http://dx.doi.org/10.1016/S0140-6736(04)15731-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031029				2023-01-03	WOS:000220231500010
J	Carratala, J; Fernandez-Sabe, N; Ortega, L; Castellsague, X; Roson, B; Dorca, J; Fernandez-Aguera, A; Verdaguer, R; Martinez, J; Manresa, F; Gudiol, F				Carratala, J; Fernandez-Sabe, N; Ortega, L; Castellsague, X; Roson, B; Dorca, J; Fernandez-Aguera, A; Verdaguer, R; Martinez, J; Manresa, F; Gudiol, F			Outpatient care compared with hospitalization for community-acquired pneumonia - A randomized trial in low-risk patients	ANNALS OF INTERNAL MEDICINE			English	Article							PRACTICE GUIDELINES; PREDICTION RULE; MANAGEMENT; LEVOFLOXACIN; SEVERITY; OUTCOMES; THERAPY; FAILURE; ADULTS	Background: The Pneumonia Severity Index (PSI) has been advocated as an objective measure of risk stratification to help determine the initial site of treatment for patients with community-acquired pneumonia. Objective: To determine whether outpatient care of PSI-defined low-risk patients with community-acquired pneumonia is as safe and effective as hospitalization. Design: Unblinded, randomized, controlled trial. Setting: 2 tertiary care hospitals. Patients: 224 immunocompetent adults in risk class II or III (PSI scores less than or equal to 90 points) who received a diagnosis of community-acquired pneumonia in the emergency department and had no extenuating circumstances. Intervention: outpatient care with oral levofloxacin therapy or hospitalization with sequential intravenous and oral levofloxacin therapy. Measurements: The primary end point was the percentage of patients with an overall successful outcome at the end of treatment, according to 7 predefined criteria. Secondary end points included patients' quality of life and satisfaction. Results: Overall successful outcome was achieved in 83.6% of outpatients and 80.7% of hospitalized patients (absolute difference, 2.9 percentage points [95% CI, -7.1 to 12.9 percentage points]). More outpatients were satisfied with their overall care (91.2% vs. 79.1%; absolute difference, 12.1 percentage points [CI, 1.8 to 22.5 percentage points]). Quality of life and the percentages of patients with adverse drug reactions (9.1% vs. 9.6%), medical complications (0.9% vs. 2.6%), subsequent hospital admissions (6.3% vs. 7.0%), and overall mortality (0.9% vs. 0%) were similar in the outpatient and hospitalization groups. Limitations: The power to detect a serious complication, such as death, was limited given the relatively small sample size. Conclusions: in selected patients who had community-acquired pneumonia, PSI risk class II and III, and were treated with levofloxacin, outpatient care in the absence of respiratory failure, unstable comorbid conditions, complicated pleural effusions, and social problems was as safe and effective as hospitalization and provided greater patient satisfaction.	Univ Barcelona, Hosp Univ Bellvitge, IDIBELL, Barcelona, Spain; Hosp Barcelona, SCIAS, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona	Carratala, J (corresponding author), Hosp Univ Bellvitge, Infect Dis Serv, Hosp Llobregat, Feixa Llarga S-N, Barcelona 08907, Spain.	jcarratala@wanadoo.es	Pique, Xavier Castellsagué/N-5795-2014; Carratalà, Jordi/B-8410-2011; Carratala, Jordi/AAC-2639-2020; Dorca, Jordi/Q-3617-2016	Pique, Xavier Castellsagué/0000-0002-0802-3595; Carratalà, Jordi/0000-0003-3209-2563; Carratala, Jordi/0000-0003-3209-2563; Sabe, Nuria/0000-0003-1697-4347; Dorca, Jordi/0000-0002-8137-878X				Alonso J, 1998, MED CLIN-BARCELONA, V111, P410; Arnold FW, 2003, CHEST, V124, P121, DOI 10.1378/chest.124.1.121; Atlas SJ, 1998, ARCH INTERN MED, V158, P1350, DOI 10.1001/archinte.158.12.1350; BARTLETT JG, 1995, NEW ENGL J MED, V333, P1618, DOI 10.1056/NEJM199512143332408; Blackwelder WC, 1998, ENCY BIOSTATISTICS; Coley CM, 1996, ARCH INTERN MED, V156, P1565, DOI 10.1001/archinte.156.14.1565; Davidson R, 2002, NEW ENGL J MED, V346, P747, DOI 10.1056/NEJMoa012122; Dean NC, 1999, CLIN CHEST MED, V20, P521, DOI 10.1016/S0272-5231(05)70233-1; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Furlanut M, 2003, J ANTIMICROB CHEMOTH, V51, P101, DOI 10.1093/jac/dkg035; Halm EA, 2002, NEW ENGL J MED, V347, P2039, DOI 10.1056/NEJMcp020499; Halm EA, 1998, JAMA-J AM MED ASSOC, V279, P1452, DOI 10.1001/jama.279.18.1452; Mandell LA, 2003, CLIN INFECT DIS, V37, P1405, DOI 10.1086/380488; Marras TK, 2000, CHEST, V118, P1339, DOI 10.1378/chest.118.5.1339; Marrie TJ, 2000, JAMA-J AM MED ASSOC, V283, P749, DOI 10.1001/jama.283.6.749; Metlay JP, 2003, ANN INTERN MED, V138, P109, DOI 10.7326/0003-4819-138-2-200301210-00012; Metlay JP, 1997, J GEN INTERN MED, V12, P423, DOI 10.1046/j.1525-1497.1997.00074.x; *NCCLS, 2001, M100S11; Niederman MS, 1998, CLIN THER, V20, P820, DOI 10.1016/S0149-2918(98)80144-6; Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010; Roson B, 2004, ARCH INTERN MED, V164, P502, DOI 10.1001/archinte.164.5.502; Roson B, 2001, CLIN INFECT DIS, V33, P158, DOI 10.1086/321808; Vergis EN, 1999, EUR J CLIN MICROBIOL, V18, P847, DOI 10.1007/s100960050418; Ware JE, 1994, SF 36 PHYSL MENTAL H	25	189	191	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	2005	142	3					165	172		10.7326/0003-4819-142-3-200502010-00006	http://dx.doi.org/10.7326/0003-4819-142-3-200502010-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900UH	15684204				2023-01-03	WOS:000227239300002
J	Jain, A; Atreja, A; Harris, M; Lehmann, M; Burns, J; Young, J				Jain, A; Atreja, A; Harris, M; Lehmann, M; Burns, J; Young, J			Responding to the rofecoxib withdrawal crisis: A new model for notifying patients at risk and their health care providers	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICIAN ORDER ENTRY; SAFETY; MEDICATION; RECALL; INFORMATION; MEDICINES; ARTHRITIS; MERCK; FDA	Background: We decided to inform our patients of the withdrawal of rofecoxib, one of the largest drug withdrawals in United States history, and instruct them to contact their providers for guidance. Objective: To identify and inform patients and providers affected by the rofecoxib withdrawal. Design: Descriptive observational study. Setting: Tertiary care center with an electronic medical record (EMR) system. Patients: Patients with an active rofecoxib prescription within the EMR. Intervention: Existing information technology and traditional communication resources were used to automate the identifying and notifying of patients and providers and to deactivate rofecoxib prescriptions in the EMR. Measurements: characteristics of patients receiving rofecoxib at our institution, details of their prescription and provider, number of EMR alerts, and medication discontinuations. Results: The 11699 patients with a rofecoxib prescription in our practice were sent notifications within 24 hours of the withdrawal. Limitations: we did not directly measure the effect of our notification on patients or providers. Conclusions: information technology enabled our institution to rapidly identify and notify individual patients and their providers about an important drug withdrawal. The methods modeled a feasible way for health care organizations with EMRs to participate in notification processes that may be applicable in a variety of situations.	Cleveland Clin Fdn, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Jain, A (corresponding author), Cleveland Clin Fdn, 9500 Euclid Ave,A91, Cleveland, OH 44195 USA.			Atreja, Ashish/0000-0002-0628-4417				Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; *CAMH, 2004, OFF HDB CAMH; Delorio NM, 2004, J EMERG MED, V26, P305, DOI 10.1016/j.jemermed.2003.09.009; DICK S, 1997, COMPUTER BASED PATIE; Folz-Murphy N, 1998, J AM MED INFORM ASSN, P260; Foster Erica, 2003, J AHIMA, V74, P34; Friedman MA, 1999, JAMA-J AM MED ASSOC, V281, P1728, DOI 10.1001/jama.281.18.1728; Greene H L, 2000, Health News, V6, P4; Harris C Martin, 2003, J Healthc Inf Manag, V17, P37; Houston TK, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.2.e7; JOHNSON LJ, 2001, MED ECON, V78, P118; Kaushal R, 2003, ARCH INTERN MED, V163, P1409, DOI 10.1001/archinte.163.12.1409; Kleinke JD, 1998, BRIT MED J, V317, P899; LIMA HA, 1995, AM J HEALTH-SYST PH, V52, P1010, DOI 10.1093/ajhp/52.9.1010; *MERCK CO INC, 2004, NEWS REL, P1; Murphy GF, 1999, ELECT HLTH RECORDS C; Poland GA, 1997, JAMA-J AM MED ASSOC, V278, P1022, DOI 10.1001/jama.278.12.1022; Rich D S, 1995, Hosp Pharm, V30, P165; Schiff GD, 2002, PHARMACOEPIDEM DR S, V11, P643, DOI 10.1002/pds.778; Singh D, 2004, BRIT MED J, V329, P816, DOI 10.1136/bmj.329.7470.816-a; SMITHELLS RW, 1963, LANCET, V1, P1095; SPOONER T, 2003, INTERNET USE REGION, P2; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; *US DEP HLTH HUM S, 2001, STAND PRIV IND ID HL; US Food and Drug Administration, 2004, FDA ISS PUBL HLTH AD; Wolfe SM, 2002, PHARMACOEPIDEM DR S, V11, P641, DOI 10.1002/pds.776; Wood AJJ, 1999, JAMA-J AM MED ASSOC, V281, P1753, DOI 10.1001/jama.281.18.1753; Zaidi STR, 2002, AM J HEALTH-SYST PH, V59, P1569, DOI 10.1093/ajhp/59.16.1569a; *ZIX CORP E PRESCR, 2004, FORB BUS WIRE; 2004, FAMILYMEDS USES NEW, P1	31	17	17	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	2005	142	3					182	186		10.7326/0003-4819-142-3-200502010-00008	http://dx.doi.org/10.7326/0003-4819-142-3-200502010-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900UH	15684206				2023-01-03	WOS:000227239300004
J	Kozer, E; Seto, W; Verjee, Z; Parshuram, C; Khattak, S; Koren, G; Jarvis, DA				Kozer, E; Seto, W; Verjee, Z; Parshuram, C; Khattak, S; Koren, G; Jarvis, DA			Prospective observational study on the incidence of medication errors during simulated resuscitation in a paediatric emergency department	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; EVENTS; CARE	Objectives To characterise the incidence and nature of medication errors during paediatric resuscitations. Design A prospective observational study of simulated emergencies. Setting Emergency department of a tertiary paediatric hospital. Participants Teams that included a clinician who commonly leads "real" resuscitations, at least two assisting physicians, and two or three paediatric nurses. Interventions The teams conducted eight mock resuscitations, including ordering medications. Exercises were videotaped and drugs ordered and administered during the resuscitation were recorded. Syringes and drugs prepared during the resuscitation were collected and analysed for concentrations and actual amounts. Main outcome measures Number and type of drug errors. Results Participants gave 125 orders for medications. In 21 (17%) of the orders the exact dose was not specified. Nine dosing errors occur-red during the ordering phase. Of these errors, five were intercepted before the drug reached the patient. Four 10-fold errors were identified. In nine (16%) out of 58 syringes analysed, measured drug concentrations showed a deviation of at least 20% from the ordered dose. A large deviation (at least 50%) from the expected dose was found in four (7%) cases. Conclusions Medication errors commonly occur during all stages of paediatric resuscitation. Many errors could be detected only by analysing syringe content, suggesting that such errors may be a major source of morbidity and mortality in resuscitated children.	Hosp Sick Children, Div Paediat Emergency Med, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Pharm, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Clin Biochem, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Kozer, E (corresponding author), Assaf Harofeh Med Ctr, Paediat Emergency Serv, IL-70300 Zerifin, Israel.	erank@asaf.health.gov.il	Parshuram, Christopher/AAI-6669-2020; Koren, Gideon/AAG-7726-2019	Parshuram, Christopher/0000-0002-7744-481X; Koren, Gideon/0000-0002-9234-0875				Dean B, 2002, LANCET, V359, P1373, DOI 10.1016/S0140-6736(02)08350-2; KOREN G, 1994, J CLIN PHARMACOL, V34, P1043, DOI 10.1002/j.1552-4604.1994.tb01978.x; Kozer E, 2002, PEDIATRICS, V110, P737, DOI 10.1542/peds.110.4.737; Kozer E, 2002, NEW ENGL J MED, V346, P1175, DOI 10.1056/NEJM200204113461518; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Lesar TS, 1997, JAMA-J AM MED ASSOC, V277, P312, DOI 10.1001/jama.277.4.312; Lesar TS, 1998, ARCH PEDIAT ADOL MED, V152, P340; Parshuram CS, 2003, CRIT CARE MED, V31, P2483, DOI 10.1097/01.CCM.0000089638.83803.B2; Schindler MB, 1996, NEW ENGL J MED, V335, P1473, DOI 10.1056/NEJM199611143352001; Shah AN, 2003, ARCH PEDIAT ADOL MED, V157, P229, DOI 10.1001/archpedi.157.3.229; Tissot E, 1999, INTENS CARE MED, V25, P353, DOI 10.1007/s001340050857	11	86	89	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 4	2004	329	7478					1321	1324		10.1136/bmj.38244.607083.55	http://dx.doi.org/10.1136/bmj.38244.607083.55			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	878PC	15454495	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000225657800020
J	Freeman, TM				Freeman, TM			Hypersensitivity to hymenoptera stings	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY SPASM; DISCONTINUING VENOM IMMUNOTHERAPY; WHOLE-BODY EXTRACTS; INSECT STINGS; RUSH IMMUNOTHERAPY; NATURAL-HISTORY; ALLERGY; ANAPHYLAXIS; SENSITIVITY; CHILDREN		Wilford Hall USAF Med Ctr, Dept Allergy & Immunol, Lackland AFB, San Antonio, TX 78023 USA	United States Department of Defense; United States Air Force	Freeman, TM (corresponding author), Wilford Hall USAF Med Ctr, Dept Allergy & Immunol, Lackland AFB, San Antonio, TX 78023 USA.	tfree95900@aol.com						BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BERNSTEIN JA, 1994, ANN ALLERGY, V73, P423; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; CHAFEE FH, 1970, ACTA ALLERGOL, V25, P292, DOI 10.1111/j.1398-9995.1970.tb01265.x; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Conraads VMA, 1998, CHEST, V113, P1417, DOI 10.1378/chest.113.5.1417; Duplantier JE, 1998, J ALLERGY CLIN IMMUN, V101, P855, DOI 10.1016/S0091-6749(98)70318-5; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; Freeman TM, 1997, ANN ALLERG ASTHMA IM, V78, P369, DOI 10.1016/S1081-1206(10)63198-5; Fujita Y, 2001, J CLIN ANESTH, V13, P221, DOI 10.1016/S0952-8180(01)00239-2; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; GODDARD J, 2003, PHYS GUIDE ARTHROPOD, P4; Goldberg A, 2001, J ALLERGY CLIN IMMUN, V107, P902, DOI 10.1067/mai.2001.114986; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1989, ALLERGY PROC, V10, P103, DOI 10.2500/108854189778960964; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P482, DOI 10.1016/0091-6749(81)90102-0; Golden DBK, 2003, J ALLERGY CLIN IMMUN, V112, P495, DOI [10.1067/mai.2003.1606, 10.1016/S0091-6749(03)01537-9]; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Golden DBK, 2003, MONOGRAPH INSECT ALL, P63; GRAFT DF, 1984, J PEDIATR-US, V104, P664, DOI 10.1016/S0022-3476(84)80940-3; Gurlanick MW, 2003, MONOGRAPH INSECT ALL, P11; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; Hoffman D., 2003, MONOGRAPH INSECT ALL, P37; HOFFMAN DR, 1984, ANN ALLERGY, V52, P276; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P818, DOI 10.1016/0091-6749(88)90084-X; HOFFMAN DR, 1991, ANN ALLERGY, V66, P29; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Kontou-Fili K, 2002, CURR OPIN ALLERGY CL, V2, P353, DOI 10.1097/00130832-200208000-00010; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P391, DOI 10.1016/0091-6749(77)90024-0; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; Machiels JP, 1996, ANN EMERG MED, V27, P674; Matucci, 2002, ALLERGY, V57, P867; MCKENNA WR, 2003, MONOGRAPH INSECT ALL, P27; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; Reisman RE, 2001, J ALLERGY CLIN IMMUN, V107, P781, DOI 10.1067/mai.2001.115042; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V84, P331, DOI 10.1016/0091-6749(89)90417-X; Rueff F, 2001, J ALLERGY CLIN IMMUN, V108, P1027, DOI 10.1067/mai.2001.119154; SCHUBERTH KC, 1983, J PEDIATR-US, V102, P361, DOI 10.1016/S0022-3476(83)80649-0; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P837, DOI 10.1016/j.jaci.2004.01.079; Simons FER., 2004, J ALLERGY CLIN IMMUN, V113, P1039; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; Tankersley MS, 2002, J ALLERGY CLIN IMMUN, V109, P556, DOI 10.1067/mai.2002.121956; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5	53	54	60	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2004	351	19					1978	1984		10.1056/NEJMcp042013	http://dx.doi.org/10.1056/NEJMcp042013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	867OG	15525723				2023-01-03	WOS:000224851300010
J	Yardley, L; Donovan-Hall, M; Smith, HE; Walsh, BM; Mullee, M; Bronstein, AM				Yardley, L; Donovan-Hall, M; Smith, HE; Walsh, BM; Mullee, M; Bronstein, AM			Effectiveness of primary care-based vestibular rehabilitation for chronic dizziness	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; COMMUNITY SAMPLE; GENERAL-PRACTICE; OLDER-ADULTS; VERTIGO; PEOPLE; THERAPY; DIZZY; FEAR	Background: Dizziness is a very common symptom and is usually managed in primary care. Vestibular rehabilitation for dizziness is a simple treatment that may be suitable for primary care delivery, but its effectiveness has not yet been determined. Objective: To evaluate the effectiveness of nurse-delivered vestibular rehabilitation in primary care for patients with chronic dizziness. Design: Single-blind randomized, controlled trial. Setting: 20 general practices in southern England. Patients: 170 adult patients with chronic dizziness who were randomly assigned to vestibular rehabilitation (n = 83) or usual medical care (n = 87). Intervention: Each patient received one 30- to 40-minute appointment with a primary care nurse. The nurse taught the patient exercises to be carried out daily at home, with the support of a treatment booklet. Measurements: Primary outcome measures were baseline, 3-month, and 6-month assessment of self-reported spontaneous and provoked symptoms of dizziness, dizziness-related quality of life, and objective measurement of postural stability with eyes open and eyes closed. Results: At 3 months, improvement on all primary outcome measures in the vestibular rehabilitation group was significantly greater than in the usual medical care group; this improvement was maintained at 6 months. Of 83 treated patients, 56 (67%) reported clinically significant improvement compared with 33 of 87 (38%) usual care patients (relative risk, 1.78 [95% CI, 1.31 to 2.42]). Limitations: Psychological elements of the therapy may have contributed to outcomes, and the treatment may be effective only for well-motivated patients. Conclusions: Vestibular rehabilitation delivered by nurses in general practice improves symptoms, postural stability, and dizziness-related handicap in patients with chronic dizziness.	Univ Southampton, Sch Psychol, Southampton SO17 1BK, Hants, England; Brighton & Sussex Med Sch, Brighton, MA USA; Univ London Imperial Coll Sci & Technol, London, England	University of Southampton; Imperial College London	Yardley, L (corresponding author), Univ Southampton, Sch Psychol, Southampton SO17 1BK, Hants, England.	L.Yardley@soton.ac.uk	Smith, Helen E/M-2449-2016	Smith, Helen E/0000-0003-1883-6124; Yardley, Lucy/0000-0002-3853-883X; Donovan-Hall, Margaret/0000-0003-3398-845X; Walsh, Bronagh/0000-0003-1008-0545	Medical Research Council [MC_U950770497] Funding Source: Medline; MRC [MC_U950770497] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Beidel DC, 2001, J ANXIETY DISORD, V15, P121, DOI 10.1016/S0887-6185(00)00046-3; Bird JC, 1998, BRIT J GEN PRACT, V48, P1828; Brandt T, 2000, J NEUROL, V247, P491, DOI 10.1007/s004150070146; BURKER EJ, 1995, PSYCHOL AGING, V10, P104, DOI 10.1037/0882-7974.10.1.104; Cohen HS, 2003, OTOLARYNG HEAD NECK, V128, P60, DOI 10.1067/mhn.2003.23; Colledge NR, 1996, BMJ-BRIT MED J, V313, P788; COOKSEY FS, 1946, P ROY SOC MED, V39, P273, DOI 10.1177/003591574603900523; Friedman SM, 2002, J AM GERIATR SOC, V50, P1329, DOI 10.1046/j.1532-5415.2002.50352.x; Hanley K, 2002, BRIT J GEN PRACT, V52, P809; Hanley K, 2001, BRIT J GEN PRACT, V51, P666; Herdman SJ, 1999, VESTIBULAR REHABILIT; Hoffman RM, 1999, AM J MED, V107, P468, DOI 10.1016/S0002-9343(99)00260-0; HORAK FB, 1992, OTOLARYNG HEAD NECK, V106, P175, DOI 10.1177/019459989210600220; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; Johansson M, 2001, OTOLARYNG HEAD NECK, V125, P151, DOI 10.1067/mhn.2001.118127; KREBSX DE, 2000, OTOLARYNGOL HEAD NEC, V128, P240; Kristinsdottir EK, 2000, SCAND J REHABIL MED, V32, P56; Kroenke K, 2000, SOUTH MED J, V93, P160; Myers LB, 1998, ADHERENCE TREATMENT; OJALA M, 1989, ACTA NEUROL SCAND, V80, P118, DOI 10.1111/j.1600-0404.1989.tb03852.x; Pocock S, 1983, CLIN TRIALS; RASCOL O, 1995, DRUGS, V50, P777, DOI 10.2165/00003495-199550050-00002; Resnick B, 2000, PATIENT EDUC COUNS, V39, P243, DOI 10.1016/S0738-3991(99)00039-7; SHEPARD NT, 1995, OTOLARYNG HEAD NECK, V112, P173, DOI 10.1016/S0194-5998(95)70317-9; SLOANE P, 1989, J AM GERIATR SOC, V37, P101, DOI 10.1111/j.1532-5415.1989.tb05867.x; Sloane PD, 2001, ANN INTERN MED, V134, P823, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00005; Steenerson RL, 1996, OTOLARYNG HEAD NECK, V114, P61, DOI 10.1016/S0194-5998(96)70284-X; Strupp M, 1998, NEUROLOGY, V51, P838, DOI 10.1212/WNL.51.3.838; Tinetti ME, 2000, ANN INTERN MED, V132, P337, DOI 10.7326/0003-4819-132-5-200003070-00002; Ware JE., 1994, SF 36 PHYS MENTAL HL; Yardley L, 1998, BRIT J GEN PRACT, V48, P1131; Yardley L, 1998, CLIN OTOLARYNGOL, V23, P442, DOI 10.1046/j.1365-2273.1998.00179.x; Yardley L, 1998, J NEUROL NEUROSUR PS, V65, P679, DOI 10.1136/jnnp.65.5.679; Yardley L, 1998, BRIT J GEN PRACT, V48, P1136; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	37	139	144	1	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	2004	141	8					598	605		10.7326/0003-4819-141-8-200410190-00007	http://dx.doi.org/10.7326/0003-4819-141-8-200410190-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	864SD	15492339	Green Published			2023-01-03	WOS:000224652300003
J	Schubert, C				Schubert, C			Cancer's weak moment	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2004	10	10					1051	1051						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	859EM	15459706				2023-01-03	WOS:000224245800027
J	Bergman, GJD; Winters, JC; Groenier, KH; Pool, JJM; Meyboom-de Jong, B; Postema, K; van der Heijden, GJMG				Bergman, GJD; Winters, JC; Groenier, KH; Pool, JJM; Meyboom-de Jong, B; Postema, K; van der Heijden, GJMG			Manipulative therapy in addition to usual medical care for patients with shoulder dysfunction and pain - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							CERVICOTHORACIC MOTION SEGMENT; GENERAL-PRACTICE; FUNCTIONAL STATUS; COMPLAINTS; DISORDERS; QUESTIONNAIRE; PHYSIOTHERAPY; MOBILITY; DESIGN	Background: Dysfunction of the cervicothoracic spine and the adjacent ribs (also called the shoulder girdle) is considered to predict occurrence and poor outcome of shoulder symptoms. it can be treated with manipulative therapy, but scientific evidence for the effectiveness of such therapy is lacking. Objective: To study the effectiveness of manipulative therapy for the shoulder girdle in addition to usual medical care for relief of shoulder pain and dysfunction. Design: Randomized, controlled trial. Setting: General practices in Groningen, the Netherlands. Patients: 150 patients with shoulder symptoms and dysfunction of the shoulder girdle. Interventions: All patients received usual medical care from their general practitioners. Only the intervention group received additional manipulative therapy, up to 6 treatment sessions in a 12-week period. Measurements: Patient-perceived recovery, severity of the main complaint, shoulder pain, shoulder disability, and general health. Data were collected during and at the end of the treatment period (at 6 and 12 weeks) and during the follow-up period (at 26 and 52 weeks). Results: During treatment (6 weeks), no significant differences were found between study groups. After completion of treatment (12 weeks), 43% of the intervention group and 21% of the control group reported full recovery. After 52 weeks, approximately the same difference in recovery rate (17 percentage points) was seen between groups. During the intervention and follow-up periods, a consistent between-group difference in severity of the main complaint, shoulder pain and disability, and general health favored additional manipulative therapy. Limitations: The sample size was small, and assessment of end points was subjective. Conclusion: manipulative therapy for the shoulder girdle in addition to usual medical care accelerates recovery of shoulder symptoms.	Univ Groningen, Dept Gen Practice, NL-9700 AD Groningen, Netherlands; Univ Groningen Hosp, Groningen, Netherlands; Maastricht Univ, Maastricht, Netherlands; Vrije Univ Amsterdam, Ctr Med, NL-1081 HV Amsterdam, Netherlands; Univ Utrecht, Ctr Med, Utrecht, Netherlands	University of Groningen; University of Groningen; Maastricht University; Vrije Universiteit Amsterdam; Utrecht University	Bergman, GJD (corresponding author), Univ Groningen, Dept Gen Practice, POB 196, NL-9700 AD Groningen, Netherlands.	g.j.d.bergman@med.rug.nl	van der Heijden, Geert/M-3733-2013	van der Heijden, Geert/0000-0003-4979-2099				Bergman GJD, 2002, J MANIP PHYSIOL THER, V25, P543, DOI 10.1067/mmt.2002.128373; Beurskens AJ, 1999, J MANIP PHYSIOL THER, V22, P144, DOI 10.1016/S0161-4754(99)70127-2; Cyriax JH, 1982, TXB ORTHOPAEDIC MED; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Goossens MEJB, 2000, J CLIN EPIDEMIOL, V53, P688, DOI 10.1016/S0895-4356(99)00177-8; Greenman P., 1996, PRINCIPLES MANUAL ME; Lewit K, 1999, MANIPULATIVE THERAPY; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Norlander S, 1997, SCAND J REHABIL MED, V29, P167; Norlander S, 1996, SCAND J REHABIL MED, V28, P183; PICAVET HS, 2000, 266807002 RIVM NAT I; Picavet HSJ, 2003, PAIN, V102, P167, DOI 10.1016/S0304-3959(02)00372-X; Sobel J S, 1996, J Manipulative Physiol Ther, V19, P469; SOBEL JS, 1995, HUISARTS WET, V38, P342; van der Heijden GJMG, 1999, BEST PRACT RES CL RH, V13, P287, DOI 10.1053/berh.1999.0021; van der Heijden GJMG, 2000, J CLIN EPIDEMIOL, V53, P29, DOI 10.1016/S0895-4356(99)00078-5; Van der Windt DAWM, 2000, BRIT J GEN PRACT, V50, P371; vanderWindt DAWM, 1996, BRIT J GEN PRACT, V46, P519; VANDERWINDT DAWM, 1995, ANN RHEUM DIS, V54, P959, DOI 10.1136/ard.54.12.959; Winters JC, 1996, SCAND J REHABIL MED, V28, P163; Winters JC, 1997, BRIT MED J, V314, P1320, DOI 10.1136/bmj.314.7090.1320; Winters JC, 1999, RHEUMATOLOGY, V38, P160, DOI 10.1093/rheumatology/38.2.160; Winters JC, 1999, BRIT MED J, V318, P1395, DOI 10.1136/bmj.318.7195.1395; WINTERS JC, 1999, HUISARTS WET, V42, P222; Wright CC, 2003, J CLIN EPIDEMIOL, V56, P833, DOI 10.1016/S0895-4356(03)00155-0	25	108	108	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	2004	141	6					432	439		10.7326/0003-4819-141-6-200409210-00008	http://dx.doi.org/10.7326/0003-4819-141-6-200409210-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	856TM	15381516				2023-01-03	WOS:000224067900003
J	Lewis, T				Lewis, T			10-minute consultation - Using the NO TEARS tool for medication review	BRITISH MEDICAL JOURNAL			English	Article									Carreg Wen Surg, Torfaen NP4 9AF, Wales		Lewis, T (corresponding author), Carreg Wen Surg, Torfaen NP4 9AF, Wales.	Tessa.Lewis@gp-w93015.wales.nhs.uk							0	30	30	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 21	2004	329	7463					434	434		10.1136/bmj.329.7463.434	http://dx.doi.org/10.1136/bmj.329.7463.434			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EA	15321901	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000223520300020
J	McDermott, MM; Liu, K; Greenland, P; Guralnik, JM; Criqui, MH; Chan, CL; Pearce, WH; Schneider, JR; Ferrucci, L; Celic, L; Taylor, LM; Vonesh, E; Martin, GJ; Clark, E				McDermott, MM; Liu, K; Greenland, P; Guralnik, JM; Criqui, MH; Chan, CL; Pearce, WH; Schneider, JR; Ferrucci, L; Celic, L; Taylor, LM; Vonesh, E; Martin, GJ; Clark, E			Functional decline in peripheral arterial disease - Associations with the ankle brachial index and leg symptoms	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC HEART-FAILURE; 6-MINUTE WALK TEST; INTERMITTENT CLAUDICATION; CARDIOVASCULAR HEALTH; PHYSICAL-DISABILITY; TREADMILL WALKING; LOWER-EXTREMITIES; LONGITUDINAL DATA; VASCULAR-DISEASE; NATURAL COURSE	Context Among individuals with lower-extremity peripheral arterial disease (PAD), specific leg symptoms and the ankle brachial index (ABI) are cross-sectionally related to the degree of functional impairment. However, relations between these clinical characteristics and objectively measured functional decline are unknown. Objective To define whether PAD, ABI, and specific leg symptoms predict functional decline at 2-year follow-up. Design, Setting, and Participants Prospective cohort study among 676 consecutively identified individuals (aged greater than or equal to55 years) with and without PAD (n=417 and n=259, respectively), with baseline functional assessments occurring between October 1, 1998, and January 31, 2000, and follow-up assessments scheduled 1 and 2 years thereafter. PAD was defined as ABI less than 0.90, and participants with PAD were categorized at baseline into 1 of 5 mutually exclusive symptom groups. Main Outcome Measures Mean annual changes in 6-minute walk performance and in usual-paced and fast-paced 4-m walking velocity, adjusted for age, sex, race, prior-year functioning, comorbid diseases, body mass index, pack-years of cigarette smoking, and patterns of missing data. Results Lower baseline ABI values were associated with greater mean (95% confidence interval) annual decline in 6-minute walk performance (-73.0 [-142 to -4.2] ft for ABI <0.50 vs -58.8 [-83.5 to -34.0] ft for ABI 0.50 to <0.90 vs -12.6 [-40.3 to 15.1] ft for ABI 0.90-1.50, P=.02). Compared with participants without PAD, PAD participants with leg pain on exertion and rest at baseline had greater mean annual decline in 6-minute walk performance (-111 [-173 to -50.0] ft vs -8.67 [-36.9 to 19.5] ft, P=.004), usual-pace 4-meter walking velocity (-0.06 [-0.09 to -0.02] m/sec vs -0.01 (-0.03 to 0.003] m/sec, P=.02), and fastest-pace 4-meter walking velocity (-0.07 [-0.11 to -0.031 m/sec vs -0.02 [-0.04 to -0.006] m/sec, P=.046). Compared with participants without PAD, asymptomatic PAD was associated with greater mean annual decline in 6-minute walk performance (-76.8 (-135 to -18.61 ft vs -8.67 (-36.9 to 19.51 ft, P=.04) and an increased odds ratio for becoming unable to walk for 6 minutes continuously (3.63; 95% confidence interval, 1.58-8.36; P=.002). Conclusions Baseline ABI and the nature of leg symptoms predict the degree of functional decline at 2-year follow-up. Previously reported lack of worsening in claudication symptoms over time in patients with PAD may be more related to declining functional performance to than lack of disease progression.	Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Surg, Div Vasc Surg, Chicago, IL 60611 USA; NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA; NIA, Lab Clin Epidemiol, Bethesda, MD 20892 USA; Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA; Evanston NW Hosp, Dept Surg, Div Vasc Surg, Evanston, IL USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Catholic Hlth Partners, Dept Surg, Div Vasc Surg, Chicago, IL USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of California System; University of California San Diego; NorthShore University Health System; Oregon Health & Science University	McDermott, MM (corresponding author), 675 N St Clair,Suite 18-200, Chicago, IL 60611 USA.	mdm608@northwestern.edu	Greenland, Philip/ABD-5528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064739, R01HL058099] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00048] Funding Source: Medline; NHLBI NIH HHS [R01-HL64739, R01-HL58099] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTMAN R, 1991, ARTHRITIS RHEUM, V34, P505, DOI 10.1002/art.1780340502; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; BENDALL MJ, 1989, AGE AGEING, V18, P327, DOI 10.1093/ageing/18.5.327; BERNSTEIN EF, 1982, SURG CLIN N AM, V62, P473; BITTNER V, 1993, JAMA-J AM MED ASSOC, V270, P1702, DOI 10.1001/jama.270.14.1702; BOYD AM, 1962, P ROY SOC MED, V55, P591, DOI 10.1177/003591576205500717; BRAUNWALD E, 2001, HEART DIS TXB CARDIV, P1467; Braunwald E., 2001, HARRISONS PRINCIPLES; Criqui M H, 1996, Vasc Med, V1, P65; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; Fitzmaurice GM, 2001, STAT MED, V20, P1009, DOI 10.1002/sim.718; FRIED LP, 1994, J CLIN EPIDEMIOL, V47, P747, DOI 10.1016/0895-4356(94)90172-4; Fried LP, 1999, J CLIN EPIDEMIOL, V52, P27, DOI 10.1016/S0895-4356(98)00124-3; Gardner AW, 1998, ANGIOLOGY, V49, P327, DOI 10.1177/000331979804900501; GREIG C, 1993, J AM GERIATR SOC, V41, P15, DOI 10.1111/j.1532-5415.1993.tb05941.x; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Guralnik JM, 1995, NIH PUBLICATION, V95-4009; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HIATT WR, 1995, CIRCULATION, V91, P1472, DOI 10.1161/01.CIR.91.5.1472; Hiatt WR, 2001, NEW ENGL J MED, V344, P1608, DOI 10.1056/NEJM200105243442108; Hirsch AT, 2001, JAMA-J AM MED ASSOC, V286, P1317, DOI 10.1001/jama.286.11.1317; IMPARATO AM, 1975, SURGERY, V78, P795; LITTLE RJA, 1995, J AM STAT ASSOC, V90, P1112, DOI 10.2307/2291350; MCALLISTER FF, 1976, AM J SURG, V132, P593, DOI 10.1016/0002-9610(76)90351-2; McDermott MM, 1998, J AM GERIATR SOC, V46, P1355, DOI 10.1111/j.1532-5415.1998.tb06001.x; McDermott MM, 2000, J VASC SURG, V32, P1164, DOI 10.1067/mva.2000.108640; McDermott MM, 2002, ANN INTERN MED, V136, P873, DOI 10.7326/0003-4819-136-12-200206180-00008; McDermott MM, 2001, JAMA-J AM MED ASSOC, V286, P1599; McDermott MM, 2001, J GEN INTERN MED, V16, P384, DOI 10.1046/j.1525-1497.2001.016006384.x; Montgomery PS, 1998, J AM GERIATR SOC, V46, P706, DOI 10.1111/j.1532-5415.1998.tb03804.x; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; OGREN M, 1995, BMJ-BRIT MED J, V310, P1294, DOI 10.1136/bmj.310.6990.1294; OLIN JW, 1998, AM J MED CONTINUING, P10; Ouriel K, 2001, LANCET, V358, P1257, DOI 10.1016/S0140-6736(01)06351-6; OURIEL K, 1982, ARCH SURG-CHICAGO, V117, P1297; Papapetropoulou V, 1998, J CLIN NEUROPHYSIOL, V15, P447, DOI 10.1097/00004691-199809000-00009; Pasini FL, 1996, ANGIOLOGY, V47, P569, DOI 10.1177/000331979604700605; Peeters P, 1996, J GERONTOL A-BIOL, V51, pM147, DOI 10.1093/gerona/51A.4.M147; REGENSTEINER JG, 1993, CIRCULATION, V87, P413, DOI 10.1161/01.CIR.87.2.413; RODRIGUEZSANCHEZ C, 1991, HISTOL HISTOPATHOL, V6, P63; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; Simonsick EM, 2000, AGING-CLIN EXP RES, V12, P274, DOI 10.1007/BF03339847; SWERTS PMJ, 1990, PHYS THER, V70, P439, DOI 10.1093/ptj/70.7.439; SWINBURN CR, 1985, THORAX, V40, P581, DOI 10.1136/thx.40.8.581; Weitz JI, 1996, CIRCULATION, V94, P3026, DOI 10.1161/01.CIR.94.11.3026; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; [No title captured]; [No title captured]	48	441	454	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	2004	292	4					453	461		10.1001/jama.292.4.453	http://dx.doi.org/10.1001/jama.292.4.453			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	841AA	15280343	Bronze			2023-01-03	WOS:000222900500022
J	Yancy, WS; Olsen, MK; Guyton, JR; Bakst, RP; Westman, EC				Yancy, WS; Olsen, MK; Guyton, JR; Bakst, RP; Westman, EC			A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							CARDIOVASCULAR RISK-FACTORS; PLACEBO-CONTROLLED TRIAL; WEIGHT-LOSS; HIGH-PROTEIN; BODY-WEIGHT; LIPOPROTEINS; PREVALENCE; SERUM; METAANALYSIS; RESTRICTION	Background: Low-carbohydrate diets remain popular despite a paucity of scientific evidence on their effectiveness. Objective: To compare the effects of a low-carbohydrate, ketogenic diet program with those of a low-fat, low-cholesterol, reduced-calorie diet. Design: Randomized, controlled trial Setting: Outpatient research clinic. Participants: 120 overweight, hyperlipidemic volunteers from the community. Intervention: Low-carbohydrate diet (initially, <20 g of carbohydrate daily) plus nutritional supplementation, exercise recommendation, and group meetings, or low-fat diet (<30% energy from fat, <300 mg of cholesterol daily, and deficit of 500 to 1000 kcal/d) plus exercise recommendation and group meetings. Measurements: Body weight, body composition, fasting serum lipid levels, and tolerability. Results: A greater proportion of the low-carbohydrate diet group than the low-fat diet group completed the study (76% vs. 57%; P = 0.02). At 24 weeks, weight loss was greater in the low-carbohydrate diet group than in the low-fat diet group (mean change, -12.9% vs. -6.7%; P < 0.001). Patients in both groups lost substantially more fat mass (change, -9.4 kg with the low-carbohydrate diet vs. -4.8 kg with the low-fat diet) than fat-free mass (change, -3.3 kg vs. -2.4 kg, respectively). Compared with recipients of the low-fat diet, recipients of the low-carbohydrate diet had greater decreases in serum triglyceride levels (change, -0.84 mmol/L vs. -0.31 mmol/L [-74.2 mg/dL vs. -27.9 mg/ dL]; P = 0.004) and greater increases in high-density lipoprotein cholesterol levels (0.14 mmol/L vs. -0.04 mmol/L [5.5 mg/dL vs. -1.6 mg/dL]; P < 0.001). Changes in low-density lipoprotein cholesterol level did not differ statistically (0.04 mmol/L [1.6 mg/dL] with the low-carbohydrate diet and -0.19 mmol/L [-7.4 mg/dL] with the low-fat diet; P = 0.2). Minor adverse effects were more frequent in the low-carbohydrate diet group. Limitations: We could not definitively distinguish effects of the low-carbohydrate diet and those of the nutritional supplements provided only to that group. In addition, participants were healthy and were followed for only 24 weeks. These factors limit the generalizability of the study results. Conclusions: Compared with a low-fat diet, a low-carbohydrate diet program had better participant retention and greater weight loss. During active weight loss, serum triglyceride levels decreased more and high-density lipoprotein cholesterol level increased more with the low-carbohydrate diet than with the low-fat diet.	Duke Univ, Med Ctr, Durham, NC 27705 USA; Ctr Hlth Serv Res Primary Care, Dept Vet Affairs Med Ctr, Durham, NC USA	Duke University	Westman, EC (corresponding author), Duke Univ, Med Ctr, Box 50,Suite 200-B Wing,2200 W Main St, Durham, NC 27705 USA.	ewestman@duke.edu	Biguzzi, Felipe A/E-4724-2015	Guyton, John/0000-0003-0224-7923				ARASE K, 1988, AM J PHYSIOL, V255, pR974, DOI 10.1152/ajpregu.1988.255.6.R974; ATKINS RC, 1998, DR ATKINS NEW DIET R; ATKINSON RL, 1985, J AM COLL NUTR, V4, P411, DOI 10.1080/07315724.1985.10720084; Bray GA, 1996, OBES RES, V4, P263, DOI 10.1002/j.1550-8528.1996.tb00544.x; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; CHAIT A, 1992, ADV INTERNAL MED, V37, P249; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; Davidson MH, 1999, JAMA-J AM MED ASSOC, V281, P235, DOI 10.1001/jama.281.3.235; DIGGLE P, 1994, APPL STAT-J ROY ST C, V43, P49; DUYFF RL, 1998, AM DIETETIC ASS COMP; Farmer A., 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.cd003205, DOI 10.1002/14651858.CD003205]; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; FLETCHER SW, 1993, ANN INTERN MED, V119, P764, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00026; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; FREE HM, 1958, CLIN CHEM, V4, P323; Golay A, 1996, AM J CLIN NUTR, V63, P174, DOI 10.1093/ajcn/63.2.174; Harper CR, 2001, ARCH INTERN MED, V161, P2185, DOI 10.1001/archinte.161.18.2185; Jeor STS, 2001, CIRCULATION, V104, P1869, DOI 10.1161/hc4001.096152; Johnston CS, 2002, J AM COLL NUTR, V21, P55, DOI 10.1080/07315724.2002.10719194; Langfort J, 1996, J PHYSIOL PHARMACOL, V47, P361; LAROSA JC, 1980, J AM DIET ASSOC, V77, P264; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; *NIH NAT HEART LUN, 2000, NIH PUBL; PHINNEY SD, 1983, METABOLISM, V32, P757, DOI 10.1016/0026-0495(83)90105-1; RABAST U, 1978, NUTR METAB, V22, P269; Reddy ST, 2002, AM J KIDNEY DIS, V40, P265, DOI 10.1053/ajkd.2002.34504; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Serdula MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/jama.282.14.1353; Sjostrom L, 1998, LANCET, V352, P167, DOI 10.1016/S0140-6736(97)11509-4; Sondike SB, 2003, J PEDIATR-US, V142, P253, DOI 10.1067/mpd.2003.4; Stubbs J, 2000, CRIT REV FOOD SCI, V40, P481, DOI 10.1080/10408690091189248; *US DEP HHS PHS NI, 1994, NIH PUBL; Westman EC, 2002, AM J MED, V113, P30, DOI 10.1016/S0002-9343(02)01129-4; Westman EC, 1999, J CLIN OUTCOMES MANA, V6, P36; Yanovski SZ, 2002, NEW ENGL J MED, V346, P591, DOI 10.1056/NEJMra012586	37	586	606	7	251	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	2004	140	10					769	777		10.7326/0003-4819-140-10-200405180-00006	http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822EX	15148063				2023-01-03	WOS:000221520900001
J	Nelson, HD				Nelson, HD			Commonly used types of postmenopausal estrogen for treatment of hot flashes - Scientific review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HORMONE REPLACEMENT THERAPY; ESTRADIOL TRANSDERMAL SYSTEM; INITIATIVE RANDOMIZED-TRIAL; VASOMOTOR SYMPTOMS; PLUS PROGESTIN; DOUBLE-BLIND; MENOPAUSAL SYMPTOMS; CONJUGATED ESTROGENS; MATRIX PATCH; WOMEN	Context Recommendations for postmenopausal hormone therapy have changed since the Women's Health Initiative indicated that estrogen was harmful for use in disease prevention; however, treatment of menopausal symptoms with low-dose estrogen remains an approved indication for use. Objective To compare the short-term efficacy and adverse effects of 2 commonly used estrogens, conjugated equine estrogen (CEE) and 17beta-estradiol, for reducing menopausal hot flashes by systematically reviewing randomized controlled trials. Data Sources MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, and Cochrane Controlled Trials Registry were searched from the database start dates to July 2003 using database-specific key words. Reference lists of published articles, experts, and pharmaceutical manufacturers were also consulted. Study Selection English-language abstracts of double-blind, randomized, placebo-controlled trials and systematic evidence reviews of oral CEE and oral and transdermal 17beta-estradiol, and treatment of menopausal hot flashes and their adverse effects. Data Extraction Study design, population characteristics, eligibility criteria, interventions, withdrawals, adverse effects, and results for each outcome. Study quality was assessed using predefined criteria based on parameters developed with the US Preventive Services Task Force and the UK National Health Services Centre. Data Synthesis A total of 32 trials including 4 head-to-head comparisons met inclusion criteria; 14 trials met criteria for meta-analysis. All estrogen agents significantly reduced the weekly number of hot flashes compared with placebo (CEE, 1 trial: mean change, -19.1; 95% confidence interval [CI], -33.0 to -5.1; oral 17beta-estradiol, 5 trials: pooled weighted mean difference, -16.8; 95% CI, -23.4 to -10.2; transdermal 17beta-estradiol, 6 trials: pooled weighted mean difference, -22.4; 95% CI, -35.9 to -10.4); differences between agents were not significant. Breast tenderness and atypical vaginal bleeding were the most frequently reported adverse effects among estrogen users. The influence of progestin or progesterone use, cyclic and continuous regimens, and differences in adverse effects could not be determined. Conclusion Conjugated equine estrogen and 17beta-estradiol have consistent and comparable effects on treatment of menopausal hot flashes and may have similar short-term adverse effects.	Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Oregon Evidence Based Practice Ctr, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Nelson, HD (corresponding author), Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Oregon Evidence Based Practice Ctr, Mail Code BICC 504,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	nelsonh@ohsu.edu						Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; ARCHER DF, 1992, ADV THER, V9, P21; Austin PC, 2003, JAMA-J AM MED ASSOC, V289, P3241, DOI 10.1001/jama.289.24.3241; BacchiModena A, 1997, MATURITAS, V27, P285, DOI 10.1016/S0378-5122(97)00039-X; Baerug U, 1998, Climacteric, V1, P219; Barnabei VM, 2002, OBSTET GYNECOL, V100, P1209, DOI 10.1016/S0029-7844(02)02369-4; BAUMGARDNER SB, 1978, OBSTET GYNECOL, V51, P445, DOI 10.1097/00006250-197804000-00013; Bech P, 1998, PSYCHOTHER PSYCHOSOM, V67, P259, DOI 10.1159/000012289; CAMPBELL S, 1976, MANAGEMENT MENOPAUSE; Carranza-Lira S, 2001, INT J GYNECOL OBSTET, V73, P169, DOI 10.1016/S0020-7292(00)00332-5; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Chung TKH, 1996, MATURITAS, V25, P115, DOI 10.1016/0378-5122(96)01050-X; CONARD J, 1995, FERTIL STERIL, V64, P957, DOI 10.1016/S0015-0282(16)57909-6; COOPE J, 1975, BRIT MED J, V4, P139, DOI 10.1136/bmj.4.5989.139; De Aloysio D, 2000, ARZNEIMITTELFORSCH, V50, pE293; de Vrijer B, 2000, MATURITAS, V34, P47, DOI 10.1016/S0378-5122(99)00085-7; DERMAN RJ, 1995, INT J FERTIL MENOP S, V40, P73; Freedman RR, 2002, FERTIL STERIL, V77, P487, DOI 10.1016/S0015-0282(01)03009-6; Good W R, 1999, Climacteric, V2, P29, DOI 10.3109/13697139909025560; GORDON SF, 1995, INT J FERTIL MENOP S, V40, P126; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Humphrey LL, 2002, ANN INTERN MED, V137, P273, DOI 10.7326/0003-4819-137-4-200208200-00012; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; KUPPERMAN H, 1959, JAMA-J AM MED ASSOC, V111, P1627; MACLENNAN A, 2002, ORAL OESTROGEN REPLA; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; MULROW CD, 1997, CONDUCT COCHRANE SYS; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; NHS Centre for Reviews and Dissemination, 2001, 4 CRD NHS CTR REV DI; Notelovitz M, 2000, AM J OBSTET GYNECOL, V182, P7, DOI 10.1016/S0002-9378(00)70483-2; Notelovitz M, 2000, OBSTET GYNECOL, V95, P726, DOI 10.1016/S0029-7844(99)00643-2; Notelovitz M, 2000, MENOPAUSE, V7, P310, DOI 10.1097/00042192-200007050-00005; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Shulman LP, 2002, MENOPAUSE, V9, P385, DOI 10.1097/00042192-200209000-00013; Shulman LP, 2002, MENOPAUSE, V9, P195, DOI 10.1097/00042192-200205000-00008; Speroff L, 1996, OBSTET GYNECOL, V88, P587, DOI 10.1016/0029-7844(96)00272-4; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; Stephenson J, 2003, JAMA-J AM MED ASSOC, V289, P537, DOI 10.1001/jama.289.5.537; STUDD JWW, 1995, MATURITAS, V22, P105, DOI 10.1016/0378-5122(95)00910-D; Utian WH, 1999, AM J OBSTET GYNECOL, V181, P71, DOI 10.1016/S0002-9378(99)70438-2; Utian WH, 2001, FERTIL STERIL, V75, P1065, DOI 10.1016/S0015-0282(01)01791-5; Vastag B, 2003, JAMA-J AM MED ASSOC, V289, P290, DOI 10.1001/jama.289.3.290-a; VIKHLYAEVA E, 1997, J AKUSHERSTVO GINECO, V5, P76; von Holst T, 2002, MATURITAS, V41, P231, DOI 10.1016/S0378-5122(01)00297-3; von Holst T, 2000, MATURITAS, V34, P143, DOI 10.1016/S0378-5122(99)00099-7; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Wells G, 2002, ENDOCR REV, V23, P529, DOI 10.1210/er.2001-5002; WIKLUND I, 1993, AM J OBSTET GYNECOL, V168, P824, DOI 10.1016/S0002-9378(12)90828-5; *WYETH PHARM, WEB SIT	51	157	166	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1610	1620		10.1001/jama.291.13.1610	http://dx.doi.org/10.1001/jama.291.13.1610			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809PQ	15069049	Bronze			2023-01-03	WOS:000220649000026
J	Wennberg, JE; Fisher, ES; Stukel, TA; Skinner, JS; Sharp, SM; Bronner, KK				Wennberg, JE; Fisher, ES; Stukel, TA; Skinner, JS; Sharp, SM; Bronner, KK			Use of hospitals, physician visits, and hospice care during last six months of life among cohorts loyal to highly respected hospitals in the United States	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTENSIVE-CARE; NEW-HAVEN; MEDICARE BENEFICIARIES; REGIONAL-VARIATIONS; SERVICES; BOSTON; DELIVERY; DEATH	Objective To evaluate the use of healthcare resources during the last six months of life among patients of US hospitals with strong reputations for high quality care in managing chronic illness. Design Retrospective cohort study based on claims data from the US Medicare programme. Participants Cohorts receiving most of their hospital care from 77 hospitals that appeared on the 2001 US News and World Report "best hospitals" list for heart and pulmonary disease, cancer, and geriatric services. Main outcome measures Use of healthcare resources in the last six months of life: number of days spent in hospital and in intensive care units; number of physician visits; percentage of patients seeing 10 or more physicians; percentage enrolled in hospice. Terminal care: percentage of deaths occurring in hospital; percentage of deaths occurring in association with a stay in an intensive care unit. Results Extensive variation in each measure existed among the 77 hospital cohorts. Days in hospital per decedent ranged from 9.4 to 27.1 (interquartile range 11.6-16.1); days in intensive care units ranged from 1.6 to 9.5 (2.6-4.5); number of physician visits ranged from 17.6 to 76.2 (25.5-39.5); percentage of patients seeing 10 or more physicians ranged from 16.9% to 58.5% (29.4-43.4%); and hospice enrolment ranged from 10.8% to 43.8% (22.0-32.0%). The percentage of deaths occurring in hospital ranged from 15.9% to 55.6% (35.4-43.1%), and the percentage of deaths associated with a stay in intensive care ranged from 8.4% to 36.8% (20.2-27.1%). Conclusion Striking variation exists in the utilisation of end of life care among US medical centres with strong national reputations for clinical care.	Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci, Hanover, NH 03755 USA; VA Outcomes Grp, White River Jct, VT 05001 USA; Inst Clin Evaluat Sci, Toronto, ON, Canada; Dartmouth Coll, Hanover, NH 03755 USA	Dartmouth College; VA Outcomes Group; University of Toronto; Dartmouth College	Wennberg, JE (corresponding author), Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci, 7251 Strasenburgh, Hanover, NH 03755 USA.	john.wennberg@Dartmouth.edu		Stukel, Therese/0000-0002-2951-1360	NIA NIH HHS [P01 AG019783-04, P01 AG019783, 1PO1AG19783-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG019783] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; FISHER ES, 1994, NEW ENGL J MED, V331, P989, DOI 10.1056/NEJM199410133311506; Fisher LS, 2000, HEALTH SERV RES, V34, P1351; IEZZONI LI, 1994, HEALTH SERV RES, V29, P435; McCullagh P., 1989, GEN LINEAR MODELS; MILLER DAF, 1993, ADOLESCENCE, V28, P621; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Schneiderman LJ, 2003, JAMA-J AM MED ASSOC, V290, P1166, DOI 10.1001/jama.290.9.1166; SINGER DE, 1983, NEW ENGL J MED, V309, P1155, DOI 10.1056/NEJM198311103091905; STRAUSS MJ, 1986, JAMA-J AM MED ASSOC, V255, P1143, DOI 10.1001/jama.255.9.1143; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; Wennberg J., 1999, QUALITY MED CARE US; Wennberg JE, 2002, BRIT MED J, V325, P961, DOI 10.1136/bmj.325.7370.961; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; WENNBERG JE, 2002, GEOGRAPHY DEBATE MED; WENNBERG JE, HLTH AFFAIRS; 2001, US NEWS WORLD REPORT, V131	22	216	219	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	2004	328	7440					607	610A		10.1136/bmj.328.7440.607	http://dx.doi.org/10.1136/bmj.328.7440.607			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	803CB	15016692	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000220208100015
J	Murch, S				Murch, S			A statement by Dr Simon Murch	LANCET			English	Editorial Material									UCL Royal Free & Univ Coll Med Sch, Ctr Paediat Gastroenterol, London NW3 2PF, England	University of London; University College London; UCL Medical School	Murch, S (corresponding author), UCL Royal Free & Univ Coll Med Sch, Ctr Paediat Gastroenterol, London NW3 2PF, England.	s.murch@rfc.ucl.ac.uk							0	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 6	2004	363	9411					821	822		10.1016/S0140-6736(04)15708-5	http://dx.doi.org/10.1016/S0140-6736(04)15708-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15022648				2023-01-03	WOS:000220092000024
J	Auerbach, AD; Kleinbart, J				Auerbach, AD; Kleinbart, J			Update in hospital medicine	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; B-NATRIURETIC PEPTIDE; CARDIAC TROPONIN-T; ELDERLY-PATIENTS; BETA-BLOCKERS; SURVIVAL; OUTCOMES; THERAPY; FAILURE; UTILITY		Emory Univ, Sch Med, Div Gen Med, Atlanta, GA 30303 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Emory University; University of California System; University of California San Francisco	Kleinbart, J (corresponding author), Emory Univ, Sch Med, Div Gen Med, 49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA.							Aronow WS, 2002, DRUG SAFETY, V25, P753, DOI 10.2165/00002018-200225110-00001; Cheng V, 2001, J AM COLL CARDIOL, V37, P386, DOI 10.1016/S0735-1097(00)01157-8; Frankel WL, 1996, AM J CLIN PATHOL, V106, P118; Krishnaswamy P, 2001, AM J MED, V111, P274, DOI 10.1016/S0002-9343(01)00841-5; Krumholz HM, 1999, ANN INTERN MED, V131, P648, DOI 10.7326/0003-4819-131-9-199911020-00003; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Maisel AS, 2001, AM HEART J, V141, P367, DOI 10.1067/mhj.2001.113215; *MED STAT SERV, 1997, MEDPAR INP HOSP FISC; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; Wang TJ, 1998, ARCH INTERN MED, V158, P1901, DOI 10.1001/archinte.158.17.1901; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; White CM, 1999, ANN PHARMACOTHER, V33, P1063, DOI 10.1345/aph.18395	16	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	2004	140	5					363	369		10.7326/0003-4819-140-5-200403020-00012	http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	778NC	14996678				2023-01-03	WOS:000189246800006
J	Le Chevalier, T; Arriagada, R; Le Pechoux, C; Grunenwald, D; Dunant, A; Pignon, JP; Tarayre, M; Abratt, R; Arriagada, R; Bergman, B; Gralla, R; Grunenwald, D; Le Chevalier, T; Orlowski, T; Papadakis, E; Pinel, MIS; Araujo, C; Della Torre, H; de Solchaga, MM; Abdi, E; Blum, R; Ball, D; Basser, R; De Boer, R; Bishop, J; Brigham, B; Davis, S; Fox, D; Richardson, G; Wyld, D; Pirker, R; Humblet, Y; Delaunois, L; Van Meerbeeck, JP; Germonpre, P; Vansteenkiste, J; Nackaerts, K; Pinel, MIS; Vauthier, G; Younes, RN; Arriagada, R; Baeza, R; Carvajal, P; Kleinman, S; Orlandi, L; Castro, C; Godoy, J; Kosatova, K; Gaafar, R; Azarian, R; Benichou, M; Boudoux, L; Boyer, G; Chirat, E; Chomy, F; Coetmeur, D; Couderc, LJ; Coudert, B; Crequit, J; David, P; Delaval, P; Dohollou, N; Foucher, P; Gonzalez, G; Jeanfaivre, T; Joveniaux, A; Kanoui, AA; Le Chevalier, T; Le Pechoux, C; Baldeyrou, P; Debrosse, D; Girard, P; Grunenwald, D; Ruffie, P; Leclerc, P; Milleron, B; Monnet, I; Monnot, H; Morere, JF; Naman, H; Dides, S; Noel, JP; Otto, J; Ozanne, F; Ozenne, G; Parent, F; Peureux, M; Picon, B; Pujol, JL; Quoix, E; Rabut, H; Riviere, A; Gervais, R; Icard, P; Rixe, O; Deplanque, G; Sevin, D; Spaeth, D; Tourani, JM; Toussaint, C; Tuchais, C; Vannetzel, JM; VArflet, F; Virally, J; Zaegel, M; Zalcman, G; Livatorwski, A; Eberhardt, W; Alexopoulos, C; Apostolopoulou, F; Bachlitzanakis, N; Bellenis, I; Christaki, P; Dosios, T; Georgoulias, V; Iliadis, K; Kardamakis, D; Konstantinou, M; Kotsovoulou, V; Pouliou, M; Michalopoulou, P; Papadakis, E; Agelidou, A; Zarogoulidis, K; Gottfried, M; Kovner, F; Agostara, B; Ascoli, M; Brigandi, A; Cigolari, S; Colucci, G; De Braud, F; Dirosa, T; Giglio, A; Maiorino, A; Masotti, A; Rusca, M; Ogawara, M; Osada, H; Park, K; Jackevicius, A; Smickoska, S; El Gueddari, BE; Aaesebo, U; Desales, R; Furman, M; Kozlowski, M; Laudansk, J; Grodzki, T; Orlowski, T; Chabowski, M; Pluzanska, A; Gaspar, L; Ciuleanu, T; Baumohl, J; Cerna, M; Bitenc, M; Abratt, R; Chasen, M; Alberola, V; Azagra, P; Garcia, PB; CArdenal, F; Curto, CP; Salinas, J; Serrate, RS; Bergman, B; Andersson, L; Hero, U; Mansson, T; Martinsson, JE; Hillerdal, G; Agrenius, V; Sederholm, C; Arvidsson, I; Ydreborg, SO; Thaning, L; Sjogren, A; Jonsson, P; Grip, H; Singer, J; Lundgren, R; Brodin, O; Andejani, D; Branden, E; Lamberg, K; Riska, H; Egli, E; Joss, R; Martinelli, G; Roth, A; Stahel, R; Stupp, R; El Kamel, A; Gralla, R; Cole, JT; Jahanzeb, M; Wiznitzer, I; Masters, GA; Radosavljevic, G; Babiker, A; Green, M; Osterlind, K; Taube, A; Wedel, H				Le Chevalier, T; Arriagada, R; Le Pechoux, C; Grunenwald, D; Dunant, A; Pignon, JP; Tarayre, M; Abratt, R; Arriagada, R; Bergman, B; Gralla, R; Grunenwald, D; Le Chevalier, T; Orlowski, T; Papadakis, E; Pinel, MIS; Araujo, C; Della Torre, H; de Solchaga, MM; Abdi, E; Blum, R; Ball, D; Basser, R; De Boer, R; Bishop, J; Brigham, B; Davis, S; Fox, D; Richardson, G; Wyld, D; Pirker, R; Humblet, Y; Delaunois, L; Van Meerbeeck, JP; Germonpre, P; Vansteenkiste, J; Nackaerts, K; Pinel, MIS; Vauthier, G; Younes, RN; Arriagada, R; Baeza, R; Carvajal, P; Kleinman, S; Orlandi, L; Castro, C; Godoy, J; Kosatova, K; Gaafar, R; Azarian, R; Benichou, M; Boudoux, L; Boyer, G; Chirat, E; Chomy, F; Coetmeur, D; Couderc, LJ; Coudert, B; Crequit, J; David, P; Delaval, P; Dohollou, N; Foucher, P; Gonzalez, G; Jeanfaivre, T; Joveniaux, A; Kanoui, AA; Le Chevalier, T; Le Pechoux, C; Baldeyrou, P; Debrosse, D; Girard, P; Grunenwald, D; Ruffie, P; Leclerc, P; Milleron, B; Monnet, I; Monnot, H; Morere, JF; Naman, H; Dides, S; Noel, JP; Otto, J; Ozanne, F; Ozenne, G; Parent, F; Peureux, M; Picon, B; Pujol, JL; Quoix, E; Rabut, H; Riviere, A; Gervais, R; Icard, P; Rixe, O; Deplanque, G; Sevin, D; Spaeth, D; Tourani, JM; Toussaint, C; Tuchais, C; Vannetzel, JM; VArflet, F; Virally, J; Zaegel, M; Zalcman, G; Livatorwski, A; Eberhardt, W; Alexopoulos, C; Apostolopoulou, F; Bachlitzanakis, N; Bellenis, I; Christaki, P; Dosios, T; Georgoulias, V; Iliadis, K; Kardamakis, D; Konstantinou, M; Kotsovoulou, V; Pouliou, M; Michalopoulou, P; Papadakis, E; Agelidou, A; Zarogoulidis, K; Gottfried, M; Kovner, F; Agostara, B; Ascoli, M; Brigandi, A; Cigolari, S; Colucci, G; De Braud, F; Dirosa, T; Giglio, A; Maiorino, A; Masotti, A; Rusca, M; Ogawara, M; Osada, H; Park, K; Jackevicius, A; Smickoska, S; El Gueddari, BE; Aaesebo, U; Desales, R; Furman, M; Kozlowski, M; Laudansk, J; Grodzki, T; Orlowski, T; Chabowski, M; Pluzanska, A; Gaspar, L; Ciuleanu, T; Baumohl, J; Cerna, M; Bitenc, M; Abratt, R; Chasen, M; Alberola, V; Azagra, P; Garcia, PB; CArdenal, F; Curto, CP; Salinas, J; Serrate, RS; Bergman, B; Andersson, L; Hero, U; Mansson, T; Martinsson, JE; Hillerdal, G; Agrenius, V; Sederholm, C; Arvidsson, I; Ydreborg, SO; Thaning, L; Sjogren, A; Jonsson, P; Grip, H; Singer, J; Lundgren, R; Brodin, O; Andejani, D; Branden, E; Lamberg, K; Riska, H; Egli, E; Joss, R; Martinelli, G; Roth, A; Stahel, R; Stupp, R; El Kamel, A; Gralla, R; Cole, JT; Jahanzeb, M; Wiznitzer, I; Masters, GA; Radosavljevic, G; Babiker, A; Green, M; Osterlind, K; Taube, A; Wedel, H		Int Adjuvant Lung Canc Trial Colla	Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STAGE-II; PREOPERATIVE CHEMOTHERAPY; TRIALS	BACKGROUND: On the basis of a previous meta-analysis, the International Adjuvant Lung Cancer Trial was designed to evaluate the effect of cisplatin-based adjuvant chemotherapy on survival after complete resection of non-small-cell lung cancer. METHODS: We randomly assigned patients either to three or four cycles of cisplatin-based chemotherapy or to observation. Before randomization, each center determined the pathological stages to include, its policy for chemotherapy (the dose of cisplatin and the drug to be combined with cisplatin), and its postoperative radiotherapy policy. The main end point was overall survival. RESULTS: A total of 1867 patients underwent randomization; 36.5 percent had pathological stage I disease, 24.2 percent stage II, and 39.3 percent stage III. The drug allocated with cisplatin was etoposide in 56.5 percent of patients, vinorelbine in 26.8 percent, vinblastine in 11.0 percent, and vindesine in 5.8 percent. Of the 932 patients assigned to chemotherapy, 73.8 percent received at least 240 mg of cisplatin per square meter of body-surface area. The median duration of follow-up was 56 months. Patients assigned to chemotherapy had a significantly higher survival rate than those assigned to observation (44.5 percent vs. 40.4 percent at five years [469 deaths vs. 504]; hazard ratio for death, 0.86; 95 percent confidence interval, 0.76 to 0.98; P<0.03). Patients assigned to chemotherapy also had a significantly higher disease-free survival rate than those assigned to observation (39.4 percent vs. 34.3 percent at five years [518 events vs. 577]; hazard ratio, 0.83; 95 percent confidence interval, 0.74 to 0.94; P<0.003). There were no significant interactions with prespecified factors. Seven patients (0.8 percent) died of chemotherapy-induced toxic effects. CONCLUSIONS: Cisplatin-based adjuvant chemotherapy improves survival among patients with completely resected non-small-cell lung cancer.	Inst Radiomed, Santiago, Chile; Sahlgrenska Hosp, Gothenburg, Sweden; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; Inst Gustave Roussy, Dept Biostat & Epidemiol, IALT Secretariat, F-94805 Villejuif, France	Sahlgrenska University Hospital; KU Leuven; University Hospital Leuven; UNICANCER; Gustave Roussy	Le Chevalier, T (corresponding author), Inst Gustave Roussy, Dept Biostat & Epidemiol, IALT Secretariat, Rue Camille Desmoulins, F-94805 Villejuif, France.		Ciuleanu, Tudor Eliade/C-3996-2011; Stupp, Roger/L-3303-2019; ZALCMAN, Gérard/L-7809-2015; Ciuleanu, Tudor-Eliade/ABH-8452-2020; van Meerbeeck, Jan/ABA-5109-2020; Cole, John/A-5803-2011; Chabowski, Mariusz/H-9847-2019; Nackaerts, Kristiaan/B-6596-2015; ZALCMAN, Gerard/M-8113-2019; ICARD, Philippe/K-6510-2015; Wyld, David K/B-8893-2015; Vansteenkiste, Johan F/B-8191-2014	ZALCMAN, Gérard/0000-0002-0343-9575; Chabowski, Mariusz/0000-0002-9232-4525; Wyld, David K/0000-0001-9523-4333; Vansteenkiste, Johan F/0000-0002-6721-2775; Arriagada, Rodrigo/0000-0002-3134-1735; PIGNON, Jean-Pierre/0000-0003-2047-1582				ALBERTI W, 1995, BRIT MED J, V311, P899; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1992, Lancet, V339, P1; Auperin A, 1999, NEW ENGL J MED, V341, P476, DOI 10.1056/NEJM199908123410703; Burdett S, 1998, LANCET, V352, P257; COX DR, 1972, J R STAT SOC B, V34, P187; Depierre A, 2001, CANCER TREAT REV, V27, P119, DOI 10.1053/ctrv.2001.0218; Depierre A, 2002, J CLIN ONCOL, V20, P247, DOI 10.1200/JCO.20.1.247; Ferlay J, 2001, GLOBOCAN 2000 CANC I; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; KATO H, 2003, P AN M AM SOC CLIN, V22, P621; Keller SM, 2000, NEW ENGL J MED, V343, P1217, DOI 10.1056/NEJM200010263431703; LABIANCA R, 1995, LANCET, V345, P939; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; Peto R, 1994, MORTALITY SMOKING DE; PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Rea D, 1998, BRIT MED J, V316, P1518, DOI 10.1136/bmj.316.7143.1518; Scagliotti GV, 2003, JNCI-J NATL CANCER I, V95, P1453, DOI 10.1093/jnci/djg059; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; Trimbos JB, 2003, JNCI-J NATL CANCER I, V95, P105; Wartelle M., 1983, Proceedings of the Second International Workshop on Statistical Database Management, P124	23	1757	1857	5	113	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 22	2004	350	4					351	360		10.1056/nejmoa031644	http://dx.doi.org/10.1056/nejmoa031644			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765EU	14736927				2023-01-03	WOS:000188254800007
J	Wong, KK; Chatterjee, S				Wong, KK; Chatterjee, S			Vaccine development for chronic myelogenous leukaemia	LANCET			English	Editorial Material							CHRONIC MYELOID-LEUKEMIA; DENDRITIC CELLS; IN-VITRO; PROTEIN		City Hope Natl Med Ctr, Beckman Res Inst, Div Virol, Duarte, CA 91024 USA; City Hope Natl Med Ctr, CML Dis Study Grp, Div Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91024 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope	Chatterjee, S (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Virol, Duarte, CA 91024 USA.	schatterjee@coh.org						Appel S, 2004, BLOOD, V103, P538, DOI 10.1182/blood-2003-03-0975; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Butt NM, 2004, BLOOD, V103, P3245, DOI 10.1182/blood-2003-11-4086; Cathcart K, 2004, BLOOD, V103, P1037, DOI 10.1182/blood-2003-03-0954; CHEN W, 1992, P NATL ACAD SCI USA, V89, P1468, DOI 10.1073/pnas.89.4.1468; Clark RE, 2001, BLOOD, V98, P2887, DOI 10.1182/blood.V98.10.2887; Cortes J, 1998, LEUKEMIA, V12, P860, DOI 10.1038/sj.leu.2401033; Dietz AB, 2004, BLOOD, V104, P1094, DOI 10.1182/blood-2003-12-4266; Dong R, 2003, BLOOD, V101, P3560, DOI 10.1182/blood-2002-06-1841; Druker BJ, 2003, SEMIN HEMATOL, V40, P1, DOI 10.1053/shem.2003.50033; Garcia-Manero G, 2003, CANCER-AM CANCER SOC, V98, P437, DOI 10.1002/cncr.11520; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Pinilla-Ibarz J, 2000, BLOOD, V95, P1781, DOI 10.1182/blood.V95.5.1781.005k46_1781_1787; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753	14	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					631	632						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721455				2023-01-03	WOS:000227096800003
J	Ruxin, J; Paluzzi, JE; Wilson, PA; Tozan, Y; Kruk, M; Teklehaimanot, A				Ruxin, J; Paluzzi, JE; Wilson, PA; Tozan, Y; Kruk, M; Teklehaimanot, A			Emerging consensus in HIV/AIDS, malaria, tuberculosis, and access to essential medicines	LANCET			English	Article									Columbia Univ, Mailman Sch Publ Hlth, Ctr Global Hlth & Econ Dev, New York, NY 10027 USA; Columbia Univ, Earth Inst, New York, NY 10027 USA; Partners Hlth, Boston, MA USA; UN Millennium Project Secretariat, New York, NY USA	Columbia University; Columbia University; Partners Healthcare System	Ruxin, J (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Ctr Global Hlth & Econ Dev, 215 W 125th St, New York, NY 10027 USA.	jnr4@columbia.edu	Kruk, Margaret E/E-3058-2010	Kruk, Margaret E/0000-0002-9549-8432				[Anonymous], 2004, HUM RES HLTH OV CRIS; Breman JG, 2004, AM J TROP MED HYG, V71, P1; Chen XY, 2004, LANCET, V364, P417; *GFATM, GFATM PROGR REP; *GLOB HIV PREV WOR, HIV PREV ER EXP TREA; Lonnroth K, 2004, B WORLD HEALTH ORGAN, V82, P580; Salomon JA, 2005, PLOS MED, V2, P50, DOI 10.1371/journal.pmed.0020016; STOP TB, 2004, PARTNERSHIP PROGR RE; *UN MILL PROJ, 2005, COMB AIDS DEV WORLD; *UN MILL PROJ, 2005, COM GRIPS MAL NEW MI; UN Millennium Project, 2005, PRESCR HLTH DEV INCR; UN Millennium Project 2005, 2005, INV STRAT REV GLOB I; *UNAIDS, 2004, 2004 REP GLOB HIV AI; WHO, WORLD MED SIT; *WHO, 2000, TECHN REP SER WHO, V892; *WHO, 2004, 3 WHO; World Health Organization, 2004, Wkly Epidemiol Rec, V79, P6	17	28	29	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					618	621						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708108				2023-01-03	WOS:000226984300037
J	Jonker, JW; Merino, G; Musters, S; van Herwaarden, AE; Bolscher, E; Wagenaar, E; Mesman, E; Dale, TC; Schinkel, AH				Jonker, JW; Merino, G; Musters, S; van Herwaarden, AE; Bolscher, E; Wagenaar, E; Mesman, E; Dale, TC; Schinkel, AH			The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk	NATURE MEDICINE			English	Article							DIETARY CARCINOGEN; FOOD MUTAGEN; TRANSPORT; CELLS; CIMETIDINE; EXPOSURE; HIV-1; RATS	Contamination of milk with drugs, pesticides and other xenotoxins can pose a major health risk to breast-fed infants and dairy consumers. Here we show that the multidrug transporter BCRP (encoded by ABCG2) is strongly induced in the mammary gland of mice, cows and humans during lactation and that it is responsible for the active secretion of clinically and toxicologically important substrates such as the dietary carcinogen PhIP, the anticancer drug topotecan and the antiulcerative cimetidine into mouse milk.	Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Expt Anim Pathol, NL-1066 CX Amsterdam, Netherlands; Univ Wales Coll Cardiff, Sch Biosci, Cardiff CF10 3US, S Glam, Wales	Netherlands Cancer Institute; Netherlands Cancer Institute; Cardiff University	Schinkel, AH (corresponding author), Netherlands Canc Inst, Div Expt Therapy, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.schinkel@nki.nl	Herwaarden, A.E./L-4369-2015; Dale, Trevor C/D-3749-2009; Merino, Gracia/H-8811-2015; Jonker, Johan W./ABE-6853-2020	Dale, Trevor C/0000-0002-4880-9963; Merino, Gracia/0000-0002-7620-3475; Jonker, Johan W./0000-0002-3919-5437				Alcorn J, 2002, ANTIMICROB AGENTS CH, V46, P1831, DOI 10.1128/AAC.46.6.1831-1836.2002; ANDERSON PO, 1991, CLIN PHARMACY, V10, P594; Boelaert JR, 2001, AIDS, V15, P2205, DOI 10.1097/00002030-200111090-00024; Chen ZS, 2003, CANCER RES, V63, P4048; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; JAGERSTAD IM, 1994, CARCINOGENESIS, V15, P2479, DOI 10.1093/carcin/15.11.2479; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Martin FL, 2000, CARCINOGENESIS, V21, P799, DOI 10.1093/carcin/21.4.799; McNamara PJ, 1996, J PHARMACOL EXP THER, V277, P1615; Paulsen JE, 1999, CARCINOGENESIS, V20, P1277, DOI 10.1093/carcin/20.7.1277; Pavek P, 2005, J PHARMACOL EXP THER, V312, P144, DOI 10.1124/jpet.104.073916; Shennan DB, 2000, PHYSIOL REV, V80, P925, DOI 10.1152/physrev.2000.80.3.925; Suzuki M, 2003, J BIOL CHEM, V278, P22644, DOI 10.1074/jbc.M212399200; van Herwaarden AE, 2003, CANCER RES, V63, P6447; Wang X, 2003, MOL PHARMACOL, V63, P65, DOI 10.1124/mol.63.1.65	15	326	336	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2005	11	2					127	129		10.1038/nm1186	http://dx.doi.org/10.1038/nm1186			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	894MZ	15685169				2023-01-03	WOS:000226797300018
J	Rose, PG; Nerenstone, S; Brady, MF; Clarke-Pearson, D; Olt, G; Rubin, SC; Moore, DH; Small, JM				Rose, PG; Nerenstone, S; Brady, MF; Clarke-Pearson, D; Olt, G; Rubin, SC; Moore, DH; Small, JM		Gynecologic Oncology Grp	Secondary surgical cytoreduction for advanced ovarian carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-III TRIAL; STAGE-III; NEOADJUVANT CHEMOTHERAPY; DEBULKING SURGERY; CANCER; CISPLATIN; PACLITAXEL; CYCLOPHOSPHAMIDE; SURVIVAL; CARBOPLATIN	Background: We evaluated the effect of adding secondary cytoreductive surgery to postoperative chemotherapy on progression-free survival and overall survival among patients who had advanced ovarian cancer and residual tumor exceeding 1 cm in diameter after primary surgery. Methods: Women were enrolled within six weeks after primary surgery. If, after three cycles of postoperative paclitaxel plus cisplatin, a patient had no evidence of progressive disease, she was randomly assigned to undergo secondary cytoreductive surgery followed by three more cycles of chemotherapy or three more cycles of chemotherapy alone. Results: We enrolled 550 women. After completing three cycles of postoperative chemotherapy, 216 eligible patients were randomly assigned to receive secondary surgical cytoreduction followed by chemotherapy and 208 to receive chemotherapy alone. Surgery was declined by or medically contraindicated in 15 patients who were assigned to secondary surgery (7 percent). As of March 2003, 296 patients had died and 82 had progressive disease. The likelihood of progression-free survival in the group assigned to secondary surgery plus chemotherapy, as compared with the chemotherapy-alone group, was 1.07 (95 percent confidence interval, 0.87 to 1.31; P=0.54), and the relative risk of death was 0.99 (95 percent confidence interval, 0.79 to 1.24; P=0.92). Conclusions: For patients with advanced ovarian carcinoma in whom primary cytoreductive surgery was considered to be maximal, the addition of secondary cytoreductive surgery to postoperative chemotherapy with paclitaxel plus cisplatin does not improve progression-free survival or overall survival.	Case Western Reserve Univ, Cleveland, OH 44106 USA; Metrohlth Med Ctr, Div Gynecol Oncol, Cleveland, OH USA; Univ Connecticut, Dept Med, Hartford, CT 06112 USA; Hartford Hosp, Hartford, CT 06115 USA; Roswell Pk Canc Inst, Gynecol Oncol Grp, Stat & Data Ctr, Buffalo, NY 14263 USA; Duke Univ, Med Ctr, Div Gynecol Oncol, Durham, NC USA; Penn State Univ, Milton S Hershey Med Ctr, Div Gynecol Oncol, Hershey, PA 17033 USA; Univ Penn, Ctr Canc, Div Gynecol Oncol, Philadelphia, PA 19104 USA; Indiana Univ, Sch Med, Div Gynecol Oncol, Indianapolis, IN USA; UniPath & Colorado Gynecol Oncol, Denver, CO USA	Case Western Reserve University; MetroHealth System; University of Connecticut; Hartford Hospital; Roswell Park Cancer Institute; Duke University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Pennsylvania; Indiana University System; Indiana University-Purdue University Indianapolis	Rose, PG (corresponding author), Gynecol Oncol Grp, Adm Off, 4 Penn Ctr,1600 JFK Blvd,Suite 1020, Philadelphia, PA 19103 USA.		Rubin, Stephen/U-8535-2019	Rubin, Stephen/0000-0003-3688-5333	NATIONAL CANCER INSTITUTE [U10CA027469, U10CA037517] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37517, CA 27469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERTELSEN K, 1990, GYNECOL ONCOL, V38, P203, DOI 10.1016/0090-8258(90)90042-J; BLESSING JA, 1984, CHEMOTHERAPY GYNECOL, P68; Boente M P, 1996, Cancer Treat Res, V82, P337; Bristow RE, 2002, J CLIN ONCOL, V20, P1248, DOI 10.1200/JCO.20.5.1248; DELGADO G, 1984, GYNECOL ONCOL, V18, P293, DOI 10.1016/0090-8258(84)90040-4; Eisenhauer EA, 1997, ANN ONCOL, V8, P963, DOI 10.1023/A:1008240421028; GRIFFITHS CT, 1975, NATL CANCER I MONOGR, P101; HACKER NF, 1983, OBSTET GYNECOL, V61, P413; HOSKINS WJ, 1994, AM J OBSTET GYNECOL, V170, P974, DOI 10.1016/S0002-9378(94)70090-7; JACOB JH, 1991, GYNECOL ONCOL, V42, P146, DOI 10.1016/0090-8258(91)90335-3; LAWTON FG, 1989, OBSTET GYNECOL, V73, P61; Markman M, 2001, J CLIN ONCOL, V19, P1001, DOI 10.1200/JCO.2001.19.4.1001; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Muggia FM, 2000, J CLIN ONCOL, V18, P106, DOI 10.1200/JCO.2000.18.1.106; Neijt J P, 1985, Prog Clin Biol Res, V201, P217; NG LW, 1990, GYNECOL ONCOL, V38, P358, DOI 10.1016/0090-8258(90)90073-T; Onnis A., 1996, European Journal of Gynaecological Oncology, V17, P393; Ozols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153; Piccart MJ, 2000, JNCI-J NATL CANCER I, V92, P699, DOI 10.1093/jnci/92.9.699; PREFONTAINE M, 1994, GYNECOL ONCOL, V55, P87, DOI 10.1006/gyno.1994.1253; RAJU KS, 1982, AM J OBSTET GYNECOL, V144, P650, DOI 10.1016/0002-9378(82)90432-X; Reynolds T, 1999, J NATL CANCER I, V91, P1182, DOI 10.1093/jnci/91.14.1182; Rubin SC, 1999, OBSTET GYNECOL, V93, P21, DOI 10.1016/S0029-7844(98)00334-2; Schwartz PE, 1999, GYNECOL ONCOL, V72, P93, DOI 10.1006/gyno.1998.5236; Surwit E, 1996, INT J GYNECOL CANCER, V6, P356, DOI 10.1046/j.1525-1438.1996.06050356.x; VANDERBURG MEL, 1995, NEW ENGL J MED, V332, P629, DOI 10.1056/NEJM199503093321002; Vergote I, 1998, GYNECOL ONCOL, V71, P431, DOI 10.1006/gyno.1998.5213; VOGEL SE, 1984, CANCER, V54, P2220; WILS J, 1986, J CLIN ONCOL, V4, P1068, DOI 10.1200/JCO.1986.4.7.1068; Winter WE, 2004, GYNECOL ONCOL, V94, P495, DOI 10.1016/j.ygyno.2004.04.008	30	277	291	2	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 9	2004	351	24					2489	2497		10.1056/NEJMoa041125	http://dx.doi.org/10.1056/NEJMoa041125			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877TE	15590951				2023-01-03	WOS:000225593100004
J	Ralat, LA; Colman, RF				Ralat, LA; Colman, RF			Glutathione S-Transferase Pi has at least three distinguishable xenobiotic substrate sites close to its glutathione-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE RESIDUES; 3-DIMENSIONAL STRUCTURE; CHEMICAL-MODIFICATION; DIRECTED MUTAGENESIS; HUMAN PLACENTA; THIOL-GROUP; P1-1; A1-1; MONOBROMOBIMANE; ISOTHIOCYANATES	Benzyl isothiocyanate (BITC), present in cruciferous vegetables, is an efficient substrate of human glutathione S-transferase P1-1 (hGST P1-1). BITC also acts as an affinity label of hGST P1-1 in the absence of glutathione, yielding an enzyme inactive toward BITC as substrate. As monitored by using BITC as substrate, the dependence of k of inactivation (K-I) of hGST P1-1 on [ BITC] is hyperbolic, with K-I = 66 +/- 7 muM. The enzyme incorporates 2 mol of BITC/mol of enzyme subunit upon complete inactivation. S-Methylglutathione and 8-anilino-1-naphthalene sulfonate (ANS) each yield partial protection against inactivation and decrease reagent incorporation, whereas S-(N-benzylthiocarbamoyl) glutathione or S-methylglutathione + ANS protects completely. Mapping of proteolytic digests of modified enzyme by using mass spectrometry reveals that Tyr(103) and Cys(47) are modified equally. S- Methylglutathione reduces modification of Cys47, indicating this residue is at/near the glutathione binding region, whereas ANS decreases modification of Tyr(103), suggesting this residue is at/near the BITC substrate site, which is also near the binding site of ANS. The Y103F and Y103S mutant enzymes were generated, expressed, and purified. Both mutants handle substrate 1-chloro-2,4-dinitrobenzene normally; however, Y103S exhibits a 30-fold increase in Km for BITC and binds ANS poorly, whereas Y103F has a normal K-m for BITC and K-d for ANS. These results indicate that an aromatic residue at position 103 is essential for the binding of BITC and ANS. This study provides evidence for the existence of a novel xenobiotic substrate site in hGST P1-1, which can be occupied by benzyl isothiocyanate and is distinct from that of monobromobimane and 1-chloro-2,4 dinitrobenzene.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	University of Delaware	Colman, RF (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.	rfcolman@chem.udel.edu			NCI NIH HHS [R01-CA66561] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066561] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACETO A, 1989, BIOCHEM PHARMACOL, V38, P3653, DOI 10.1016/0006-2952(89)90568-6; Ahn SY, 2003, B KOREAN CHEM SOC, V24, P1188; BICO P, 1994, BIOCHIM BIOPHYS ACTA, V1247, P225; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CACCURI AM, 1990, EUR J BIOCHEM, V189, P493, DOI 10.1111/j.1432-1033.1990.tb15514.x; CACCURI AM, 1992, ARCH BIOCHEM BIOPHYS, V297, P119, DOI 10.1016/0003-9861(92)90648-G; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; CHEN WL, 1992, BIOCHEM J, V286, P205, DOI 10.1042/bj2860205; COLMAN RF, 1997, PROTEIN FUNCTION, P155; DESIDERI A, 1991, J BIOL CHEM, V266, P2063; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HONG KH, 1993, PROTEIN ENG, V6, P93; HSIEH JC, 1991, BIOCHEM J, V278, P293, DOI 10.1042/bj2780293; HULBERT PB, 1983, J PHARM PHARMACOL, V35, P384, DOI 10.1111/j.2042-7158.1983.tb02962.x; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; JI XH, 1994, BIOCHEMISTRY-US, V33, P1043, DOI 10.1021/bi00171a002; Ji XH, 1997, BIOCHEMISTRY-US, V36, P9690, DOI 10.1021/bi970805s; Kase H, 1998, ACTA CYTOL, V42, P1397, DOI 10.1159/000332174; KOLM RH, 1995, BIOCHEM J, V311, P453, DOI 10.1042/bj3110453; Kolobe D, 2004, BIOCHEM J, V382, P703, DOI 10.1042/BJ20040056; KONG KH, 1992, BIOCHEM BIOPH RES CO, V184, P194, DOI 10.1016/0006-291X(92)91177-R; KONG KH, 1991, BIOCHEM BIOPH RES CO, V181, P748, DOI 10.1016/0006-291X(91)91254-A; KONG KH, 1992, BIOCHEM BIOPH RES CO, V182, P1122, DOI 10.1016/0006-291X(92)91848-K; LOBELLO M, 1990, FEBS LETT, V263, P389, DOI 10.1016/0014-5793(90)81421-J; Lyon RP, 2002, BIOCHEMISTRY-US, V41, P10920, DOI 10.1021/bi0262810; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MANOHARAN TH, 1992, J BIOL CHEM, V267, P18940; Mao LS, 2004, J MOL BIOL, V336, P787, DOI 10.1016/j.jmb.2003.12.056; MEYER DJ, 1995, BIOCHEM J, V306, P565, DOI 10.1042/bj3060565; Morrow CS, 1998, J BIOL CHEM, V273, P20114, DOI 10.1074/jbc.273.32.20114; Niitsu Y, 1998, CHEM-BIOL INTERACT, V112, P325; NISHIHIRA J, 1992, BIOCHEM BIOPH RES CO, V188, P424, DOI 10.1016/0006-291X(92)92402-J; Oakley AJ, 1999, J MOL BIOL, V291, P913, DOI 10.1006/jmbi.1999.3029; Oakley AJ, 1998, BIOCHEMISTRY-US, V37, P9912, DOI 10.1021/bi980323w; Oakley AJ, 1997, J MOL BIOL, V274, P84, DOI 10.1006/jmbi.1997.1364; Park HJ, 2001, B KOREAN CHEM SOC, V22, P77; Penefsky H S, 1979, Methods Enzymol, V56, P527; Ralat LA, 2004, FASEB J, V18, pC241; Ralat LA, 2003, PROTEIN SCI, V12, P2575, DOI 10.1110/ps.03249303; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; ZHANG YS, 1995, BIOCHEM BIOPH RES CO, V206, P748, DOI 10.1006/bbrc.1995.1106	48	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50204	50213		10.1074/jbc.M407445200	http://dx.doi.org/10.1074/jbc.M407445200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15347687	hybrid			2023-01-03	WOS:000225229500081
J	Briffa, JP				Briffa, JP			The prince and the professor - Which emperor is naked?	BRITISH MEDICAL JOURNAL			English	Letter												drjbriffa@aol.com						Baum M, 2004, BRIT MED J, V329, P118, DOI 10.1136/bmj.329.7457.118; VARMAN S, 2004, BRAVO ELECT RESPONSE	2	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 9	2004	329	7470					858	858		10.1136/bmj.329.7470.858	http://dx.doi.org/10.1136/bmj.329.7470.858			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862EK	15472283	Green Published			2023-01-03	WOS:000224472800039
J	Smith, NL; Heckbert, SR; Lemaitre, RN; Reiner, AP; Lumley, T; Weiss, NS; Larson, EB; Rosendaal, FR; Psaty, BM				Smith, NL; Heckbert, SR; Lemaitre, RN; Reiner, AP; Lumley, T; Weiss, NS; Larson, EB; Rosendaal, FR; Psaty, BM			Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; MYOCARDIAL-INFARCTION; ORAL-CONTRACEPTIVES; COAGULATION; FIBRINOLYSIS; PHARMACOKINETICS; ESTRADIOL; PROTEIN	Context Clinical trial evidence indicates that estrogen therapy with or without progestins increases venous thrombotic risk. The findings from these trials, which used oral conjugated equine estrogens, may not be generalizable to other estrogen compounds. Objective To compare risk of venous thrombosis among esterified estrogen users, conjugated equine estrogen users, and nonusers. Design, Setting, and Participants This population-based, case-control study was conducted at a large health maintenance organization in Washington State. Cases were perimenopausal and postmenopausal women aged 30 to 89 years who sustained a first venous thrombosis between January 1995 and December 2001 and controls were matched on age, hypertension status, and calendar year. Main Outcome Measure Risk of first venous thrombosis in relation to current use of esterified or conjugated equine estrogens, with or without concomitant progestin. Current use was defined as use at thrombotic event for cases and a comparable reference date for controls. Results Five hundred eighty-six incident venous thrombosis cases and 2268 controls were identified. Compared with women not currently using hormones, current users of esterified estrogen had no increase in venous thrombotic risk (odds ratio [OR], 0.92; 95% confidence interval [CI], 0.69-1.22). In contrast, women currently taking conjugated equine estrogen had an elevated risk (OR, 1.65; 95% CI, 1.24-2.19). When analyses were restricted to estrogen users, current users of conjugated equine estrogen had a higher risk than current users of esterified estrogen (OR, 1.78; 95% CI, 1.11-2.84). Among conjugated equine estrogen users, increasing daily dose was associated with increased risk (trend P value=.02). Among all estrogen users, concomitant progestin use was associated with increased risk compared with use of estrogen alone (OR, 1.60; 95% CI, 1.13-2.26). Conclusion Our finding that conjugated equine estrogen but not esterified estrogen was associated with venous thrombotic risk needs to be replicated and may have implications for the choice of hormones in perimenopausal and postmenopausal women.	Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Leiden Univ, Med Ctr, Leiden, Netherlands	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Smith, NL (corresponding author), Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA.	nlsmith@u.washington.edu	Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068986, R01HL074745, R01HL068639, R01HL043201, R01HL073410, R01HL060739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009556] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68639, HL60739, HL73410, HL68986, HL74745, HL43201] Funding Source: Medline; NIA NIH HHS [AG09556] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Andrade SE, 2000, MED CARE, V38, P970, DOI 10.1097/00005650-200009000-00010; Ansbacher R, 2001, AM J OBSTET GYNECOL, V184, P255, DOI 10.1067/mob.2001.109656; Bhavnani BR, 1998, P SOC EXP BIOL MED, V217, P6; Bitondo RD, 2002, HUM MOL GENET, V11, P723, DOI 10.1093/hmg/11.7.723; Cushman M, 2001, BRIT J HAEMATOL, V114, P162, DOI 10.1046/j.1365-2141.2001.02911.x; Friebely JS, 2001, J WOMEN HEALTH GEN-B, V10, P181, DOI 10.1089/152460901300039548; Gardner J, 1998, J WOMENS HEALTH, V7, P1027, DOI 10.1089/jwh.1998.7.1027; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; Good W R, 1999, Climacteric, V2, P29, DOI 10.3109/13697139909025560; Gottsater A, 2001, J INTERN MED, V249, P237, DOI 10.1046/j.1365-2796.2001.00797.x; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; Heckbert SR, 1997, ARCH INTERN MED, V157, P1330, DOI 10.1001/archinte.157.12.1330; JURGENS RW, 1992, AM J OBSTET GYNECOL, V167, P459, DOI 10.1016/S0002-9378(11)91429-X; Kaplan RC, 1998, AM J HYPERTENS, V11, P471, DOI 10.1016/S0895-7061(97)00494-9; Koh KK, 1999, THROMB HAEMOSTASIS, V82, P626, DOI 10.1055/s-0037-1615889; LOBO RA, 1991, J CLIN ENDOCR METAB, V73, P925, DOI 10.1210/jcem-73-5-925; Lowe GDO, 2001, THROMB HAEMOSTASIS, V86, P550; Meijers JCM, 2000, THROMB HAEMOSTASIS, V84, P9; Meyer WR, 2001, FERTIL STERIL, V75, P394, DOI 10.1016/S0015-0282(00)01712-X; Middeldorp S, 2000, THROMB HAEMOSTASIS, V84, P4; Nelson HD, 2004, JAMA-J AM MED ASSOC, V291, P1610, DOI 10.1001/jama.291.13.1610; Nozaki M, 1999, Climacteric, V2, P124, DOI 10.3109/13697139909025576; OCONNELL MB, 1995, J CLIN PHARMACOL, V35, pS18, DOI 10.1002/j.1552-4604.1995.tb04143.x; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; RAGHUNATHAN TE, 1998, IVEWARE IMPUTATION V; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Teede HJ, 2000, ARTERIOSCL THROM VAS, V20, P1404, DOI 10.1161/01.ATV.20.5.1404; van Baal WM, 1999, EUR J CLIN INVEST, V29, P913; van Tilburg NH, 2000, BLOOD, V95, P2855, DOI 10.1182/blood.V95.9.2855.009k02_2855_2859; von Holst T, 2002, MATURITAS, V43, P265, DOI 10.1016/S0378-5122(02)00203-7	32	119	121	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	2004	292	13					1581	1587		10.1001/jama.292.13.1581	http://dx.doi.org/10.1001/jama.292.13.1581			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	859HS	15467060	Bronze, Green Published			2023-01-03	WOS:000224254600025
J	Coleman, EA; Berenson, RA				Coleman, EA; Berenson, RA			Lost in transition: Challenges and opportunities for improving the quality of transitional care	ANNALS OF INTERNAL MEDICINE			English	Article							CONGESTIVE-HEART-FAILURE; OLDER PATIENTS; HOSPITAL-CARE; FOLLOW-UP; DISCHARGE; INTERVENTION; NEEDS	Transitional care has been defined as a set of actions designed to ensure the coordination and continuity of health care as patients transfer between different locations or different levels of care in the same location. Transitional care, which primarily concerns the relatively brief time interval that begins with preparing a patient to leave one setting and concludes when the patient is received in the next setting, poses challenges that distinguish it from other types of care. Many transitions are unplanned, result from unanticipated medical problems, occur in "real time" during nights and on weekends, involve clinicians who may not have an ongoing relationship with the patient, and happen so quickly that formal and informal support mechanisms cannot respond in a timely manner. This article describes the challenges involved in and potential solutions for improving the quality of transitional care.	Univ Colorado, Div Hlth Care Policy & Res, Hlth Sci Ctr, Aurora, CO 80011 USA; Urban Inst, Ctr Hlth Policy, Washington, DC 20037 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Urban Institute	Coleman, EA (corresponding author), Univ Colorado, Div Hlth Care Policy & Res, Hlth Sci Ctr, 13611 E Colfax,Suite 100, Aurora, CO 80011 USA.	Eric.Coleman@uchsc.edu						*AG HEALTHC RES QU, 2000, MED ERR SCOP PROBL; *ASTM INT MASS MED, CONT CAR REC CCR CON; Bazzoli GJ, 2003, HEALTH AFFAIR, V22, P40, DOI 10.1377/hlthaff.22.6.40; BEERS MH, 1992, HOSP FORMUL, V27, P720; BREWSTER L, EMERGENCY ROOM DIVER; Burns LR, 2002, HEALTH AFFAIR, V21, P128, DOI 10.1377/hlthaff.21.4.128; *CAL HLTH CAR FDN, RES PAT EV PERF PEP; Centers for Medicare and Medicaid Services, HEALTHC COMM PROC CO; Coleman EA, 2003, J AM GERIATR SOC, V51, P556, DOI 10.1046/j.1532-5415.2003.51186.x; Coleman EA, 2004, J AM GERIATR SOC, V52, pS1; Coleman EA, 2003, J AM GERIATR SOC, V51, P549, DOI 10.1046/j.1532-5415.2003.51185.x; COLEMAN EA, 2004, IN PRESS HLTH SERV R; COLEMAN EA, 2004, IN PRESS MED CARE; COLEMAN EA, 2002, ASP TRANS CAR C P; COLEMAN EA, 2002, DEV TESTING MEASURE; Dudas V, 2001, AM J MED, V111, P26, DOI 10.1016/S0002-9343(01)00966-4; Einstadter D, 1996, J GEN INTERN MED, V11, P684, DOI 10.1007/BF02600160; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Harrison A, 2002, HEALTH SERV RES, V37, P1031, DOI 10.1034/j.1600-0560.2002.64_2.x; *HMO CAR MAN WORKG, ON PAT MAN PLAC MAN; *I MED COMM DAT ST, 2001, KEY CAP EL HLTH REC; Institute of Medicine, 2000, ERR IS HUM BUILD SAF; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; *JOINT COMM ACCR H, 2001, STAND INT STAT 1, P69; Katz T.F., 2000, ANN LONG TERM CARE, V8, P51; KRAMER A, 2003, SUMMARY STATUS ELECT, P1; LEVINE C, 1998, CROSSINGS FAMILY CAR; *MED PAYM ADV COMM, 2003, US MARK COMP FEE FOR, P131; *MED PAYM ADV COMM, US INC IMPR QUAL CAR; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Partnership for Solutions, 2002, CHRON COND MAK CAS O; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Stewart S, 1998, ARCH INTERN MED, V158, P1067, DOI 10.1001/archinte.158.10.1067; *US DEP HHS OFF IN, 1997, US DEP HLTH HUM SERV; vom Eigen KA, 1999, MED CARE, V37, P33, DOI 10.1097/00005650-199901000-00006; Wachter RM, 2002, JAMA-J AM MED ASSOC, V287, P487, DOI 10.1001/jama.287.4.487; Weaver F M, 1998, Home Health Care Serv Q, V17, P27; Wenger NS, 2003, ANN INTERN MED, V139, P740, DOI 10.7326/0003-4819-139-9-200311040-00008	40	454	458	0	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	2004	141	7					533	535		10.7326/0003-4819-141-7-200410050-00009	http://dx.doi.org/10.7326/0003-4819-141-7-200410050-00009			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862CR	15466770				2023-01-03	WOS:000224467800005
J	Doherty, RB				Doherty, RB			Assessing the new medicare prescription drug law	ANNALS OF INTERNAL MEDICINE			English	Article								The Medicare Modernization Act (MMA) is the product of a political compromise to attract moderate Republicans and enough Democrats without losing Republican conservatives. The compromise offered more private health plans to beneficiaries while maintaining and improving traditional Medicare's benefits. This compromise did not settle the debate over the legislation, which is a major issue in the 2004 elections. Voters poorly understand the law because of its complexity. In this paper, I explain how the policy decisions made by the U.S. Congress have contributed to the law's complexity and controversy. I examine the new private health plan options that will be offered to beneficiaries, improvements made to traditional Medicare, and the impact of introducing income-based determinations into Medicare. I also discuss the impact of the drug benefit on beneficiaries in different income and assets categories and Congress's decision to prohibit the federal government from directly negotiating prices with drug manufacturers. I conclude by assessing the major claims made by critics and proponents. Both might be more circumspect in their assessments of the law's impact, since it is impossible to predict how a law of such complexity, with so many human variables, will work out in the end. The MMA is a worthwhile but imperfect effort to extend drug coverage to seniors who are most in need. It deserves neither condemnation nor indiscriminate praise but instead a commitment to help it succeed.	Amer Coll Physicians, Customer Serv, Philadelphia, PA 19106 USA	American College of Physicians	Doherty, RB (corresponding author), Amer Coll Physicians, Customer Serv, 190 N Independence Mall W, Philadelphia, PA 19106 USA.							*AARP, MED CHANG COULD AFF; Altman DE, 2004, NEW ENGL J MED, V350, P9, DOI 10.1056/NEJMp038224; BALL RM, 1997, MED PREPARING CHALLE; BUSH GW, 2003, REMARKS PRESIDENT SI; Holtz-Eakin D, 2004, COMMUNICATION   0123; *KAIS FAM FDN, 2004, MARCH APR 2004 KAIS; KENNEDY EM, 2003, DINGELL ANNOUNCE THE; 2003, ANG SEN CONTR EUPH W; 2004, PRESCR DRUG COV MED	9	25	25	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2004	141	5					391	395		10.7326/0003-4819-141-5-200409070-00100	http://dx.doi.org/10.7326/0003-4819-141-5-200409070-00100			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CW	15353431				2023-01-03	WOS:000223733800008
J	Astrup, A; Larsen, TM; Harper, A				Astrup, A; Larsen, TM; Harper, A			Atkins and other low-carbohydrate diets: hoax or an effective tool for weight loss?	LANCET			English	Review							LOW-FAT DIET; CARDIOVASCULAR RISK-FACTORS; RANDOMIZED-TRIAL; KETOGENIC DIET; OBESITY; PROTEIN; ADOLESCENTS; LIPIDS	Context The Atkins diet books have sold more than 45 million copies over 40 years, and in the obesity epidemic this diet and accompanying Atkins food products are popular. The diet claims to be effective at producing weight loss despite ad-libitum consumption of fatty meat, butter, and other high-fat dairy products, restricting only the intake of carbohydrates to under 30 g a day. Low-carbohydrate diets have been regarded as fad diets, but recent research questions this view. Starting point A systematic review of low-carbohydrate diets found that the weight loss achieved is associated with the duration of the diet and restriction of energy intake, but not with restriction of carbohydrates. Two groups have reported longer-term randomised studies that compared instruction in the low-carbohydrate diet with a low-fat calorie-reduced diet in obese patients (N Engl J Med 2003; 348: 2082-90; Ann Intern Med 2004; 140: 778-85). Both trials showed better weight loss on the low-carbohydrate diet after 6 months, but no difference after 12 months. Where next? The apparent paradox that ad-libitum intake of high-fat foods produces weight loss might be due to severe restriction of carbohydrate depleting glycogen stores, leading to excretion of bound water, the ketogenic nature of the diet being appetite suppressing, the high protein-content being highly satiating and reducing spontaneous food intake, or limited food choices leading to decreased energy intake. Long-term studies are needed to measure changes in nutritional status and body composition during the low-carbohydrate diet, and to assess fasting and postprandial cardiovascular risk factors and adverse effects. Without that information, low-carbohydrate diets cannot be recommended.	RVA Univ, Ctr Adv Food Res, Dept Human Nutr, DK-1958 Frederiksberg C, Denmark		Astrup, A (corresponding author), RVA Univ, Ctr Adv Food Res, Dept Human Nutr, DK-1958 Frederiksberg C, Denmark.	ast@kvi.dk	Biguzzi, Felipe A/E-4724-2015; Meinert Larsen, Thomas/D-4818-2015; Astrup, Arne/B-1407-2015	Meinert Larsen, Thomas/0000-0001-7621-3131; Astrup, Arne/0000-0001-8968-8996				*ATK NUTR INC, 2004, INTRO ATK HOM; ATKINS RC, 1998, DR ATKINS NEW DIET R; BANTING W, 1869, COMMUNICATION; Best TH, 2000, NEUROLOGY, V54, P2328, DOI 10.1212/WNL.54.12.2328; Bravata DM, 2003, JAMA-J AM MED ASSOC, V289, P1837, DOI 10.1001/jama.289.14.1837; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; Daniels SR, 2003, J PEDIATR-US, V142, P225, DOI 10.1067/mpd.2003.114; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Freedman MR, 2001, OBES RES, V9, p1S, DOI 10.1038/oby.2001.113; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Krauss RM, 2000, CIRCULATION, V102, P2284; Kwiterovich PO, 2003, JAMA-J AM MED ASSOC, V290, P912, DOI 10.1001/jama.290.7.912; Mikkelsen PB, 2000, AM J CLIN NUTR, V72, P1135; Porrini M, 1997, PHYSIOL BEHAV, V62, P563, DOI 10.1016/S0031-9384(97)00162-5; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; SEARS B, 1995, ZONE; Sharman MJ, 2004, J NUTR, V134, P880, DOI 10.1093/jn/134.4.880; Singh RB, 2002, LANCET, V360, P1455, DOI 10.1016/S0140-6736(02)11472-3; Skov AR, 1999, INT J OBESITY, V23, P528, DOI 10.1038/sj.ijo.0800867; Sondike SB, 2003, J PEDIATR-US, V142, P253, DOI 10.1067/mpd.2003.4; Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007; Westman EC, 2002, AM J MED, V113, P30, DOI 10.1016/S0002-9343(02)01129-4; Willi SM, 1998, PEDIATRICS, V101, P61, DOI 10.1542/peds.101.1.61; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006	24	270	275	6	145	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2004	364	9437					897	899		10.1016/S0140-6736(04)16986-9	http://dx.doi.org/10.1016/S0140-6736(04)16986-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351198				2023-01-03	WOS:000223685200037
J	Steinman, RM; Mellman, I				Steinman, RM; Mellman, I			Immunotherapy: Bewitched, bothered, and bewildered no more	SCIENCE			English	Article							REGULATORY T-CELLS; DENDRITIC CELLS; IMMUNE-RESPONSES; SHEDDING LIGHT; CANCER; THERAPY; INTERLEUKIN-2; IMMUNOLOGY; STRATEGIES; CARCINOMA	The field of immunotherapy holds clear promise not only for the development of new approaches to cancer and other diseases, but also for providing fundamental insight into the human immune response. In order for this promise to be realized, however, the scientific community must overcome an array of challenges. These challenges reflect not only the difficulties inherent in conducting investigations in human patients, but also difficulties created by the culture and practice of our own institutions, reward structure, and funding mechanisms. We suggest steps to be taken to reinvigorate basic research in human subjects as part of the mainstream of science.	Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA; Yale Univ, Sch Med, Ludwig Inst Canc Res, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ludwig Inst Canc Res, Dept Immunobiol, New Haven, CT 06520 USA	Rockefeller University; Ludwig Institute for Cancer Research; Yale University; Ludwig Institute for Cancer Research; Yale University	Steinman, RM (corresponding author), Rockefeller Univ, Cellular Physiol & Immunol Lab, 1230 York Ave, New York, NY 10021 USA.	steinma@mail.rockefeller.edu	Mellman, Ira/ABG-5896-2020; Steinman, Ralph/F-7729-2012					Banchereau J, 2001, CELL, V106, P271, DOI 10.1016/S0092-8674(01)00448-2; Beck-Engeser GB, 2001, J EXP MED, V194, P285, DOI 10.1084/jem.194.3.285; Bell J, 2003, J EXP MED, V198, P1621, DOI 10.1084/jem.20031882; Bell J, 2003, BRIT MED J, V327, P1041, DOI 10.1136/bmj.327.7422.1041; Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220; Cerundolo V, 2004, NAT IMMUNOL, V5, P7, DOI 10.1038/ni0104-7; Coulie PG, 2003, CURR OPIN IMMUNOL, V15, P131, DOI 10.1016/S0952-7915(03)00009-8; Dhodapkar MV, 2003, J EXP MED, V198, P1753, DOI 10.1084/jem.20031030; Dhodapkar MV, 2002, P NATL ACAD SCI USA, V99, P13009, DOI 10.1073/pnas.202491499; Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039; Finn OJ, 2003, J EXP MED, V198, P1623, DOI 10.1084/jem.20031787; Finn OJ, 2003, NAT REV IMMUNOL, V3, P630, DOI 10.1038/nri1150; Hall S. S., 1998, COMMOTION BLOOD; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Jager D, 2004, CANCER IMMUNOL IMMUN, V53, P144, DOI 10.1007/s00262-003-0470-z; Levitsky HI, 2000, CANCER J, V6, pS281; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; PARKINSON DR, 1990, J CLIN ONCOL, V8, P1630, DOI 10.1200/JCO.1990.8.10.1630; Perales MA, 2002, SEMIN CANCER BIOL, V12, P63, DOI 10.1006/scbi.2001.0397; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Rosenberg SA, 2004, NEW ENGL J MED, V350, P1461, DOI 10.1056/NEJMcibr045001; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; SPARANO JA, 1993, J CLIN ONCOL, V11, P1969, DOI 10.1200/JCO.1993.11.10.1969; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Takahashi T, 2003, INT REV CYTOL, V225, P1, DOI 10.1016/S0074-7696(05)25001-5; Triendl R, 2004, NAT REV IMMUNOL, V4, P72, DOI 10.1038/nri1259; van der Bruggen P, 2002, IMMUNOL REV, V188, P51, DOI 10.1034/j.1600-065X.2002.18806.x; Waldmann TA, 2003, NAT MED, V9, P269, DOI 10.1038/nm0303-269; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123; Yee C, 2002, NAT REV CANCER, V2, P409, DOI 10.1038/nrc820; Yu P, 2004, NAT IMMUNOL, V5, P141, DOI 10.1038/ni1029; Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867	37	107	119	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					197	200		10.1126/science.1099688	http://dx.doi.org/10.1126/science.1099688			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247468				2023-01-03	WOS:000222501000039
J	Stern, L; Iqbal, N; Seshadri, P; Chicano, KL; Daily, DA; McGrory, J; Williams, M; Gracely, EJ; Samaha, FF				Stern, L; Iqbal, N; Seshadri, P; Chicano, KL; Daily, DA; McGrory, J; Williams, M; Gracely, EJ; Samaha, FF			The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: One-year follow-up of a randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-FAT DIET; CHOLESTEROL; NUTRITION; PLASMA	Background: A previous paper reported the 6-month comparison of weight loss and metabolic changes in obese adults randomly assigned to either a low-carbohydrate diet or a conventional weight loss diet. Objective: To review the 1-year outcomes between these diets. Design: Randomized trial. Setting: Philadelphia Veterans Affairs Medical Center. Participants: 132 obese adults with a body mass index of 35 kg/m(2) or greater; 83% had diabetes or the metabolic syndrome. Intervention: Participants received counseling to either restrict carbohydrate intake to <30 g per day (low-carbohydrate diet) or to restrict caloric intake by 500 calories per day with <30% of calories from fat (conventional diet). Measurements: Changes in weight, lipid levels, glycemic control, and insulin sensitivity. Results: By 1 year, mean (+/-SD) weight change for persons on the low-carbohydrate diet was -5.1 +/- 8.7 kg compared with -3.1 +/- 8.4 kg for persons on the conventional diet. Differences between groups were not significant (-1.9 kg [95% CI, -4.9 to 1.0 kg]; P = 0.20). For persons on the low-carbohydrate diet, triglyceride levels decreased more (P = 0.044) and high-density lipoprotein cholesterol levels decreased less (P = 0.025). As seen in the small group of persons with diabetes (n = 54) and after adjustment for covariates, hemoglobin A(1c) levels improved more for persons on the low-carbohydrate diet. These more favorable metabolic responses to a low-carbohydrate diet remained significant after adjustment for weight loss differences. Changes in other lipids or insulin sensitivity did not differ between groups. Limitations: These findings are limited by a high dropout rate (34%) and by suboptimal dietary adherence of the enrolled persons. Conclusion: Participants on a low-carbohydrate diet had more favorable overall outcomes at 1 year than did those on a conventional diet. Weight loss was similar between groups, but effects on atherogenic dyslipidemia and glycemic control were still more favorable with a low-carbohydrate diet after adjustment for differences in weight loss.	Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; Drexel Univ, Coll Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Drexel University	Samaha, FF (corresponding author), Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, 8th Floor,MC 111C,Univ & Woodland Ave, Philadelphia, PA 19104 USA.	rick.samaha@med.va.gov	Gracely, Ed/B-7188-2014	Gracely, Ed/0000-0002-8344-3223				ATKINS RC, 1998, DR ATKINS NEW DIET R; Bonow RO, 2003, NEW ENGL J MED, V348, P2057, DOI 10.1056/NEJMp030053; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GARG A, 1992, DIABETES, V41, P1278, DOI 10.2337/diabetes.41.10.1278; Golay A, 1996, INT J OBESITY, V20, P1067; Hatahet W, 2003, J NUTR, V133, P689, DOI 10.1093/jn/133.3.689; Heshka S, 2003, JAMA-J AM MED ASSOC, V289, P1792, DOI 10.1001/jama.289.14.1792; LEWIS SB, 1977, AM J CLIN NUTR, V30, P160, DOI 10.1093/ajcn/30.2.160; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; National Heart Lung and Blood Institute, 1998, NIH PUBL, V98-4083; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Twisk JWR, 2003, APPL LONGITUDINAL DA; 2002, CONSUMER REPORTS, P26	19	567	585	1	77	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	2004	140	10					778	785		10.7326/0003-4819-140-10-200405180-00007	http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822EX	15148064				2023-01-03	WOS:000221520900002
J	Liu, J; Dehbi, M; Moeck, G; Arhin, F; Bauda, P; Bergeron, D; Callejo, M; Ferretti, V; Ha, NH; Kwan, T; McCarty, J; Srikumar, R; Williams, D; Wu, JZJ; Gros, P; Pelletier, J; DuBow, M				Liu, J; Dehbi, M; Moeck, G; Arhin, F; Bauda, P; Bergeron, D; Callejo, M; Ferretti, V; Ha, NH; Kwan, T; McCarty, J; Srikumar, R; Williams, D; Wu, JZJ; Gros, P; Pelletier, J; DuBow, M			Antimicrobial drug discovery through bacteriophage genomics	NATURE BIOTECHNOLOGY			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; COLI DNAB HELICASE; PROTEIN; GENE; THERAPY; IDENTIFICATION; REPLICATION; INITIATION; VANCOMYCIN; PRIMOSOME	Over evolutionary time bacteriophages have developed unique proteins that arrest critical cellular processes to commit bacterial host metabolism to phage reproduction. Here, we apply this concept of phage-mediated bacterial growth inhibition to antibiotic discovery. We sequenced 26 Staphylococcus aureus phages and identified 31 novel polypeptide families that inhibited growth upon expression in S. aureus. The cellular targets for some of these polypeptides were identified and several were shown to be essential components of the host DNA replication and transcription machineries. The interaction between a prototypic pair, ORF104 of phage 77 and Dnal, the putative helicase loader of S. aureus, was then used to screen for small molecule inhibitors. Several compounds were subsequently found to inhibit both bacterial growth and DNA synthesis. Our results suggest that mimicking the growth-inhibitory effect of phage polypeptides by a chemical compound, coupled with the plethora of phages on earth, will yield new antibiotics to combat infectious diseases.	PhageTech Inc, Ville Saint Laurent, PQ H4S 2A1, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Liu, J (corresponding author), PhageTech Inc, 7170 Frederick Banting,2nd Floor, Ville Saint Laurent, PQ H4S 2A1, Canada.	jliu@phagetech.com	Bauda, Pascale/AAV-4545-2021	Bauda, Pascale/0000-0001-5072-2069; Moeck, Greg/0000-0001-7827-7227				Ackermann H. W., 1987, VIRUSES PROKARYOTES, V2; Adams M., 1959, N Y; Biswas B, 2002, INFECT IMMUN, V70, P204, DOI 10.1128/IAI.70.1.204-210.2002; Bruand C, 2001, MOL MICROBIOL, V42, P245, DOI 10.1046/j.1365-2958.2001.02631.x; De Crescenzo G, 2000, BIOCHEMISTRY-US, V39, P9466, DOI 10.1021/bi992987r; Forsyth RA, 2002, MOL MICROBIOL, V43, P1387, DOI 10.1046/j.1365-2958.2002.02832.x; Jana M, 2000, PLASMID, V44, P100, DOI 10.1006/plas.2000.1473; Ji YD, 2001, SCIENCE, V293, P2266, DOI 10.1126/science.1063566; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kaito C, 2002, FEMS MICROBIOL LETT, V210, P157, DOI 10.1016/S0378-1097(02)00603-1; Kaneko J, 1998, GENE, V215, P57, DOI 10.1016/S0378-1119(98)00278-9; Khare M, 2003, EXPERT OPIN PHARMACO, V4, P165, DOI 10.1517/14656566.4.2.165; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Loeffler JM, 2001, SCIENCE, V294, P2170, DOI 10.1126/science.1066869; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; Marsin S, 2001, J BIOL CHEM, V276, P45818, DOI 10.1074/jbc.M101996200; MATHIS G, 1995, CLIN CHEM, V41, P1391; McDevitt D, 2001, TRENDS MICROBIOL, V9, P611, DOI 10.1016/S0966-842X(01)02235-1; Methot N, 1996, MOL CELL BIOL, V16, P5328; Moir DT, 1999, ANTIMICROB AGENTS CH, V43, P439, DOI 10.1128/AAC.43.3.439; *NCCLS, 2000, NCCLS SPEC COLL SUSC; Nechaev S, 1999, J MOL BIOL, V289, P815, DOI 10.1006/jmbi.1999.2782; Odegrip R, 2000, J VIROL, V74, P4057, DOI 10.1128/JVI.74.9.4057-4063.2000; ORSINI G, 1993, J BACTERIOL, V175, P85, DOI 10.1128/JB.175.1.85-93.1993; Salgado CD, 2003, CLIN INFECT DIS, V36, P131, DOI 10.1086/345436; Sambrook J., 1989, MOL CLONING LAB MANU; SCHENK S, 1992, FEMS MICROBIOL LETT, V94, P133; Schuch R, 2002, NATURE, V418, P884, DOI 10.1038/nature01026; SIMPSON RJ, 2002, PROTEINS PROTEOMICS; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Stone R, 2002, SCIENCE, V298, P728, DOI 10.1126/science.298.5594.728; Tauriainen S, 1997, APPL ENVIRON MICROB, V63, P4456, DOI 10.1128/AEM.63.11.4456-4461.1997; Tenover FC, 2001, EMERG INFECT DIS, V7, P327, DOI 10.3201/eid0702.010237; Velten M, 2003, MOL CELL, V11, P1009, DOI 10.1016/S1097-2765(03)00130-8; Walsh C., 2003, ANTIBIOTICS ACTIONS; Wang IN, 2000, ANNU REV MICROBIOL, V54, P799, DOI 10.1146/annurev.micro.54.1.799; Young R, 2000, TRENDS MICROBIOL, V8, P120, DOI 10.1016/S0966-842X(00)01705-4	39	164	175	0	40	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2004	22	2					185	191		10.1038/nbt932	http://dx.doi.org/10.1038/nbt932			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	770KT	14716317				2023-01-03	WOS:000188730500017
J	Hooton, TM; Scholes, D; Gupta, K; Stapleton, AE; Roberts, PL; Stamm, WE				Hooton, TM; Scholes, D; Gupta, K; Stapleton, AE; Roberts, PL; Stamm, WE			Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA-COLI; ACUTE BACTERIAL; HOST DEFENSES; ACID; AUGMENTIN; AMOXICLAV; CEFACLOR	Context The high prevalence of resistance to trimethoprim-sulfamethoxazole and other antimicrobials among Escherichia coli causing acute cystitis in women has led to increased use of alternative antibiotics. One such antibiotic, amoxicillin-clavulanate, has not been well studied. Objective To compare the efficacy of a 3-day regimen of amoxicillin-clavulanate to that of a 3-day regimen of ciprofloxacin in the treatment of acute cystitis in women. The primary study hypothesis was that the amoxicillin-clavulanate and ciprofloxacin treatment groups would differ in clinical cure. Design, Setting, and Patients Randomized, single-blind treatment trial of 370 women, aged 18 to 45 years, with symptoms of acute uncomplicated cystitis and a urine culture with at least 102 colony-forming units of uropathogens per milliliter from a university student health center or a health maintenance organization. Interventions Women were randomly assigned to receive amoxicillin-clavulanate (500 mg/125 mg twice daily) or ciprofloxacin (250 mg twice daily) for 3 days and were followed up for 4 months. Main Outcome Measures The main outcome measure was clinical cure. Secondary study outcomes of interest were microbiological cure and vaginal E coli colonization at the 2-week follow-up visit. Results Clinical cure was observed in 93 (58%) of 160 women treated with amoxicillin-clavulanate compared with 124 (77%) of 162 women treated with ciprofloxacin (P<.001). Amoxicillin-clavulanate was not as effective as ciprofloxacin even among women infected with strains susceptible to amoxicillin-clavulanate (65 [60%] of 109 women in the amoxicillin-clavulanate group vs 114 [77%] of 149 women in the ciprofloxacin group; P=.004). The difference in clinical cure rates occurred almost entirely within the first 2 weeks after therapy. Microbiological cure at 2 weeks was observed in 118 (76%) of 156 women treated with amoxicillin-clavulanate compared with 153 (95%) of 161 women treated with ciprofloxacin (P<.001). At this visit, 45% of women in the amoxicillin-clavulanate group compared with 10% in the ciprofloxacin group had vaginal colonization with E coli (P<.001). Conclusions A 3-day regimen of amoxicillin-clavulanate is not as effective as ciprofloxacin for the treatment of acute uncomplicated cystitis, even in women infected with susceptible strains. This difference may be due to the inferior ability of amoxicillin-clavulanate to eradicate vaginal E coli, facilitating early reinfection.	Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative	Hooton, TM (corresponding author), Harbor Med Ctr, 325 9th Ave,Box 359930, Seattle, WA 98104 USA.	hooton@u.washington.edu	Stapleton, Ann E/N-2428-2015	Stapleton, Ann E/0000-0003-0130-8659	NIDDK NIH HHS [1 PO DK53369, P01 DK053369] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053369] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY RR, 1983, NEW ZEAL MED J, V96, P970; BAILEY RR, 1995, NEW ZEAL MED J, V108, P465; BRUMFITT W, 1984, ANTIMICROB AGENTS CH, V25, P276, DOI 10.1128/AAC.25.2.276; COOPER J, 1990, INFECTION, V18, P65, DOI 10.1007/BF01641417; COUNTS GW, 1982, REV INFECT DIS, V4, P484; CROKAERT F, 1982, ANTIMICROB AGENTS CH, V22, P346, DOI 10.1128/AAC.22.2.346; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALLACHER G, 1986, J INFECTION, V12, P229, DOI 10.1016/S0163-4453(86)94164-2; GURWITH MJ, 1983, ANTIMICROB AGENTS CH, V24, P716, DOI 10.1128/AAC.24.5.716; Hooton Thomas M., 1996, P67; Hooton TM, 2004, CLIN INFECT DIS, V39, P75, DOI 10.1086/422145; Hooton TM, 2003, INFECT DIS CLIN N AM, V17, P303, DOI 10.1016/S0891-5520(03)00004-7; Huang ES, 2002, ARCH INTERN MED, V162, P41, DOI 10.1001/archinte.162.1.41; JOHNSON CE, 1993, AM J DIS CHILD, V147, P1090, DOI 10.1001/archpedi.1993.02160340076018; Kahlmeter G, 2003, J ANTIMICROB CHEMOTH, V51, P69, DOI 10.1093/jac/dkg028; Leflon-Guibout W, 2002, J ANTIMICROB CHEMOTH, V49, P367, DOI 10.1093/jac/49.2.367; MASTERTON RG, 1995, J ANTIMICROB CHEMOTH, V35, P129, DOI 10.1093/jac/35.1.129; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Mulvey MA, 2000, P NATL ACAD SCI USA, V97, P8829, DOI 10.1073/pnas.97.16.8829; Pabich WL, 2003, J INFECT DIS, V188, P1054, DOI 10.1086/378203; RAZ R, 1991, ANTIMICROB AGENTS CH, V35, P1688, DOI 10.1128/AAC.35.8.1688; RODRIGUEZ JC, 1990, ATEN PRIMARIA, V7, P127; SAMADPOUR M, 1993, J CLIN MICROBIOL, V31, P3179, DOI 10.1128/JCM.31.12.3179-3183.1993; Scheid MW, 2003, EMERG INFECT DIS, V9, P1; Schutz W, 1990, Fortschr Med, V108, P365; Steinman MA, 2003, ANN INTERN MED, V138, P525, DOI 10.7326/0003-4819-138-7-200304010-00008; Warren JW, 1999, CLIN INFECT DIS, V29, P745, DOI 10.1086/520427; WILLIAMS KJ, 1987, DRUG EXP CLIN RES, V13, P95	28	114	127	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2005	293	8					949	955		10.1001/jama.293.8.949	http://dx.doi.org/10.1001/jama.293.8.949			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899LR	15728165	Bronze			2023-01-03	WOS:000227146400016
J	Fiessinger, JN; Huisman, MV; Davidson, BL; Bounameaux, H; Francis, CW; Eriksson, H; Lundstrom, T; Berkowitz, SD; Nystrom, P; Thorsen, M; Ginsberg, JS				Fiessinger, JN; Huisman, MV; Davidson, BL; Bounameaux, H; Francis, CW; Eriksson, H; Lundstrom, T; Berkowitz, SD; Nystrom, P; Thorsen, M; Ginsberg, JS		THRIVE Treatment Study Investigato	Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRAVENOUS UNFRACTIONATED HEPARIN; VENOUS THROMBOEMBOLISM; INHIBITOR XIMELAGATRAN; SECONDARY PREVENTION; ORAL XIMELAGATRAN; KNEE REPLACEMENT; ENOXAPARIN; MELAGATRAN; ABSORPTION; THERAPY	Context Ximelagatran, an oral direct thrombin inhibitor with a rapid onset of action and predictable antithrombotic effect, has the potential to be a simple therapeutic alternative to current standard treatment of acute venous thromboembolism. Objective To compare the efficacy and safety of ximelagatran with standard enoxaparin/warfarin treatment for the prevention of recurrent venous thromboembolism. Design, Setting, and Patients Randomized, double-blind, noninferiority trial (Thrombin Inhibitor in Venous Thromboembolism [THRIVE] Treatment Study) of 2489 patients with acute deep vein thrombosis, of whom approximately one third had concomitant pulmonary embolism. The study was conducted at 279 centers in 28 countries from September 2000 through December 2002. Interventions Patients were randomized to receive 6 months of treatment with either oral ximelagatran, 36 mg twice daily, or subcutaneous enoxaparin, 1 mg/kg twice daily, for 5 to 20 days followed by warfarin adjusted to maintain an international normalized ratio of 2.0 to 3.0. Main Outcome Measures Recurrent venous thromboembolism, bleeding, and mortality. Results Venous thromboembolism recurred in 26 of the 1240 patients assigned to receive ximelagatran (estimated cumulative risk, 2.1%) and in 24 of the 1249 patients assigned to receive enoxaparin/warfarin (2.0%). The absolute difference between ximelagatran and enoxaparin/warfarin was 0.2% (95% confidence interval [Cl], -1.0% to 1.3%). This met the prespecified criterion for noninferiority. Corresponding values for major bleeding were 1.3% and 2.2% (difference, -1.0%; 95% Cl, -2.1% to 0.1%), and for mortality were 2.3% and 3.4% (difference, -1.1%; 95% Cl, -2.4% to 0.2%). Alanine aminotransferase levels increased to more than 3 times the upper limit of normal in 119 patients (9.6%) and 25 patients (2.0%) receiving ximelagatran and enoxaparin/warfarin, respectively. increased enzyme levels were mainly asymptomatic. Retrospective analysis of locally reported adverse events showed a higher rate of serious coronary events with ximelagatran (10/1240 patients) compared with enoxaparin/warfarin (1/1249 patients). Conclusions Oral ximelagatran administered in a fixed dose without coagulation monitoring, was as effective as enoxaparin/warfarin for treatment of deep vein thrombosis with or without pulmonary embolism and showed similar, low rates of bleeding. increased levels of liver enzymes in 9.6% of xi melagatran-treated patients require regular monitoring; the mechanism requires further evaluation. Prospective assessment of coronary events in future studies is warranted.	Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2300 RC Leiden, Netherlands; Hop Europeen Georges Pompidou, Dept Vasc Med, Paris, France; Swedish Med Ctr, Seattle, WA USA; Univ Washington, Sch Med, Seattle, WA USA; Univ Hosp Geneva, Dept Internal Med, Geneva, Switzerland; Univ Rochester, Dept Med, Rochester, NY USA; Sahlgrenska Univ Hosp Ostra, Gothenburg, Sweden; AstraZeneca Res & Dev Molndal, Molndal, Sweden; AstraZeneca PL, Dept Clin Dev, Wilmington, DE USA; McMaster Univ, Dept Med, Hamilton, ON, Canada	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Swedish Medical Center; University of Washington; University of Washington Seattle; University of Geneva; University of Rochester; Sahlgrenska University Hospital; AstraZeneca; AstraZeneca; McMaster University	Huisman, MV (corresponding author), Leiden Univ, Med Ctr, Dept Gen Internal Med, Room C1 R43,POB 9600, NL-2300 RC Leiden, Netherlands.	m.v.huisman@lumc.nl	ginsberg, jeffrey s/ABC-1065-2020; Kovacs, Michael/G-3315-2011; Berkowitz, Scott Darrell/AAS-9397-2021	Berkowitz, Scott Darrell/0000-0002-9428-4408				Albers GW, 2003, LANCET, V362, P1691; Ansell J, 2001, CHEST, V119, p22S, DOI 10.1378/chest.119.1_suppl.22S; Bredberg E, 2003, CLIN PHARMACOKINET, V42, P765, DOI 10.2165/00003088-200342080-00005; Buller HR, 2004, ANN INTERN MED, V140, P867, DOI 10.7326/0003-4819-140-11-200406010-00007; Charbonnier BA, 1998, THROMB HAEMOSTASIS, V79, P897; Eriksson BI, 2003, THROMB HAEMOSTASIS, V89, P288; Eriksson H, 2003, J THROMB HAEMOST, V1, P41, DOI 10.1046/j.1538-7836.2003.00034.x; Eriksson UG, 2003, DRUG METAB DISPOS, V31, P294, DOI 10.1124/dmd.31.3.294; Eriksson UG, 2003, EUR J CLIN PHARMACOL, V59, P35, DOI 10.1007/s00228-003-0565-7; Francis CW, 2003, NEW ENGL J MED, V349, P1703, DOI 10.1056/NEJMoa035162; Gustafsson D, 2001, THROMB RES, V101, P171, DOI 10.1016/S0049-3848(00)00399-6; Hirsh J, 2001, CHEST, V119, p8S, DOI 10.1378/chest.119.1_suppl.8S; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; *ICH GUID, INT C HARM TECHN REQ; Klement P, 2003, J THROMB HAEMOST, V1, P587, DOI 10.1046/j.1538-7836.2003.00060.x; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; Merli G, 2001, ANN INTERN MED, V134, P191, DOI 10.7326/0003-4819-134-3-200102060-00009; Meyer G, 2002, ARCH INTERN MED, V162, P1729, DOI 10.1001/archinte.162.15.1729; Prandoni P, 2002, BLOOD, V100, P3484, DOI 10.1182/blood-2002-01-0108; Schulman S, 2003, NEW ENGL J MED, V349, P1713, DOI 10.1056/NEJMoa030104; Siegel JP, 2000, AM HEART J, V139, pS166, DOI 10.1016/S0002-8703(00)90066-8; tenCate JW, 1997, NEW ENGL J MED, V337, P657; Wallentin L, 2003, LANCET, V362, P789, DOI 10.1016/S0140-6736(03)14287-0	24	250	263	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2005	293	6					681	689		10.1001/jama.293.6.681	http://dx.doi.org/10.1001/jama.293.6.681			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895DX	15701909				2023-01-03	WOS:000226842200021
J	Donnan, GA; Dewey, HM				Donnan, GA; Dewey, HM			Stroke and nutrition: FOOD for thought	LANCET			English	Editorial Material									Univ Melbourne, Austin Hosp, Natl Stroke Res Inst, Heidelberg West, Vic 3081, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne	Donnan, GA (corresponding author), Univ Melbourne, Austin Hosp, Natl Stroke Res Inst, Heidelberg West, Vic 3081, Australia.	gdonnan@unimelb.edu.au	DONNAN, GEOFFREY A/A-9947-2008	Donnan, Geoffrey/0000-0001-6324-3403				Davalos A, 1996, STROKE, V27, P1028, DOI 10.1161/01.STR.27.6.1028; Gariballa SE, 1998, AM J CLIN NUTR, V68, P275, DOI 10.1093/ajcn/68.2.275; Mann G, 1999, STROKE, V30, P744, DOI 10.1161/01.STR.30.4.744; *NAT STROK FDN AUS, 2003, NAT CLIN GUID AC STR; Toni D, 2004, CEREBROVASC DIS, V17, P30, DOI 10.1159/000074818	5	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB-MAR	2005	365	9461					729	730						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	901LZ	15733698				2023-01-03	WOS:000227285300003
J	Elbling, L; Weiss, RM; Teufelhofer, O; Uhl, M; Knasmueller, S; Schulte-Hermann, R; Berger, W; Mickshe, M				Elbling, L; Weiss, RM; Teufelhofer, O; Uhl, M; Knasmueller, S; Schulte-Hermann, R; Berger, W; Mickshe, M			Green tea extract and (-)-epigallocatechin-3-gallate, the major tea catechin, exert oxidant but lack antioxidant activities	FASEB JOURNAL			English	Article						oxidative stress; DNA damage; monocytic cell lines; H(2)O(2); EGCG	COLON ADENOCARCINOMA CELLS; HYDROGEN-PEROXIDE; DNA-DAMAGE; EPIGALLOCATECHIN GALLATE; POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE; CANCER CHEMOPREVENTION; GROWTH-INHIBITION; OXIDATIVE DAMAGE; REACTIVE OXYGEN; CELLULAR-DNA	Green tea is the most widely consumed beverage. It has attained high reputation as a health-promoting dietary component ascribed to the antioxidant activity of(-)-epigallocatechin-3-gallate(EGCG), its main polyphenolic constituent. Evidence is increasing that tea constituents can be cell damaging and pro-oxidant themselves. These effects were suggested to be due to spontaneous H(2)O(2) generation by polyphenols in solution. In the present study, we investigated the oxidant and antioxidant properties of green tea extracts(GTE) and of EGCG by means of the rodent macrophage-like RAW 264.7 and human promyelocytic leukemic HL60 cell lines. The results obtained show that both under cell-free conditions and in the presence of cells the oxidant activities of GTE and EGCG exceeded those of spontaneously generated H(2)O(2)(FOX assay). Increase of intracellular oxidative stress was indicated by 2',7'-dichlorofluorescin probing,and the enhanced genotoxicity was demonstrated by the alkaline comet assay and by the micronucleus assay(cytokinesis block). Time-and dose-dependent induction of cell death was monitored by trypan blue exclusion, MTT assay,and Hoechst staining. Furthermore,in our systems in vitro,EGCG neither directly scavenges H(2)O(2) nor mediates other antioxidant activities but rather increased H(2)O(2)-induced oxidative stress and DNA damage. In conclusion, our data suggest that detailed mechanistic studies on the effects of GTE and EGCG should be performed in vivo before excessive intake and/or topical application of green tea products can be recommended to healthy and/or diseased persons.	Med Univ Vienna, Inst Canc Res, Div Appl & Expt Oncol, Clin Internal Med 1, A-1090 Vienna, Austria; Med Univ Vienna, Inst Canc Res, Div Oncol Toxicol, Clin Internal Med 1, A-1090 Vienna, Austria; Med Univ Vienna, Inst Canc Res, Environm Toxicol Grp, Clin Internal Med 1, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Elbling, L (corresponding author), Med Univ Vienna, Inst Canc Res, Div Appl & Expt Oncol, Clin Internal Med 1, Borschkegasse 8A, A-1090 Vienna, Austria.	elbling.leonilla@meduniwien.ac.at	Knasmueller, Siegfried/P-4347-2014	Knasmueller, Siegfried/0000-0002-1638-4438; Berger, Walter/0000-0003-0014-1658				Anderson RF, 2001, CARCINOGENESIS, V22, P1189, DOI 10.1093/carcin/22.8.1189; August DA, 1999, CANCER EPIDEM BIOMAR, V8, P709; Azam S, 2004, TOXICOL IN VITRO, V18, P555, DOI 10.1016/j.tiv.2003.12.012; Balasubramanian S, 2002, J BIOL CHEM, V277, P1828, DOI 10.1074/jbc.M110376200; Barbier O, 2003, J BIOL CHEM, V278, P13975, DOI 10.1074/jbc.M300749200; Bertram B, 2003, MUTAT RES-GEN TOX EN, V534, P77, DOI 10.1016/S1383-5718(02)00245-0; Chai PC, 2003, BIOCHEM BIOPH RES CO, V304, P650, DOI 10.1016/S0006-291X(03)00655-7; Chen C, 2003, CARCINOGENESIS, V24, P1369, DOI 10.1093/carcin/bgg091; Chen JJ, 2004, BJU INT, V93, P1082, DOI 10.1111/j.1464-410X.2004.04785.x; Dashwood WM, 2002, BIOCHEM BIOPH RES CO, V296, P584, DOI 10.1016/S0006-291X(02)00914-2; Deguchi H, 2002, INT J ONCOL, V21, P1301; Dhawan A, 2002, MUTAT RES-GEN TOX EN, V515, P39, DOI 10.1016/S1383-5718(01)00347-3; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Forman HJ, 2004, AM J PHYSIOL-CELL PH, V287, pC246, DOI 10.1152/ajpcell.00516.2003; Frei B, 2003, J NUTR, V133, p3275S, DOI 10.1093/jn/133.10.3275S; Funatogawa K, 2004, MICROBIOL IMMUNOL, V48, P251, DOI 10.1111/j.1348-0421.2004.tb03521.x; Furukawa A, 2003, BIOCHEM PHARMACOL, V66, P1769, DOI 10.1016/S0006-2952(03)00541-0; GANOUSIS LG, 1992, MOL PHARMACOL, V42, P1118; Guo Q, 1999, BBA-GEN SUBJECTS, V1427, P13, DOI 10.1016/S0304-4165(98)00168-8; Helma C, 2000, MUTAT RES-GEN TOX EN, V466, P9, DOI 10.1016/S1383-5718(99)00232-6; Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464; Hong J, 2003, BIOCHEM BIOPH RES CO, V310, P222, DOI 10.1016/j.bbrc.2003.09.007; Hong J, 2002, CANCER RES, V62, P7241; Johnson MK, 2000, MUTAT RES-DNA REPAIR, V459, P211, DOI 10.1016/S0921-8777(99)00074-9; Kamsler A, 2004, MOL NEUROBIOL, V29, P167, DOI 10.1385/MN:29:2:167; Kannan K, 2004, FREE RADICAL BIO MED, V36, P423, DOI 10.1016/j.freeradbiomed.2003.09.012; Kitano K, 1997, BIOPHYS CHEM, V65, P157, DOI 10.1016/S0301-4622(96)02254-5; Kondo K, 1999, FREE RADICAL BIO MED, V27, P855, DOI 10.1016/S0891-5849(99)00133-1; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lambert JD, 2003, J NUTR, V133, p3262S, DOI 10.1093/jn/133.10.3262S; Lambert JD, 2003, J NUTR, V133, P4172, DOI 10.1093/jn/133.12.4172; Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025; Lee MJ, 2004, CANCER EPIDEM BIOMAR, V13, P132, DOI 10.1158/1055-9965.EPI-03-0040; Lin JK, 1999, BIOCHEM PHARMACOL, V58, P911, DOI 10.1016/S0006-2952(99)00112-4; Long LH, 2000, BIOCHEM BIOPH RES CO, V273, P50, DOI 10.1006/bbrc.2000.2895; Lu H, 2003, DRUG METAB DISPOS, V31, P572, DOI 10.1124/dmd.31.5.572; Mandel S, 2004, J NEUROCHEM, V88, P1555, DOI 10.1046/j.1471-4159.2003.02291.x; Mannisto P T, 1992, Prog Drug Res, V39, P291; Meng XF, 2002, CHEM RES TOXICOL, V15, P1042, DOI 10.1021/tx010184a; Moyers SB, 2004, NUTR REV, V62, P204, DOI [10.1301/nr.2004.may.204-211, 10.1111/j.1753-4887.2004.tb00041.x]; Murakami A, 2003, MUTAT RES-FUND MOL M, V523, P151, DOI 10.1016/S0027-5107(02)00331-7; Nakagawa H, 2004, CARCINOGENESIS, V25, P1567, DOI 10.1093/carcin/bgh168; NAKAYAMA T, 1994, CANCER RES, V54, pS1991; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; ROTHE G, 1994, METHOD ENZYMOL, V233, P539; Roy M, 2003, MUTAT RES-FUND MOL M, V523, P33, DOI 10.1016/S0027-5107(02)00319-6; Saeki K, 2002, BIOCHEM J, V368, P705, DOI 10.1042/BJ20020101; Sakagami H, 2001, ANTICANCER RES, V21, P2633; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Stanner SA, 2004, PUBLIC HEALTH NUTR, V7, P407, DOI 10.1079/PHN2003543; Stone JR, 2004, ARCH BIOCHEM BIOPHYS, V422, P119, DOI 10.1016/j.abb.2003.12.029; Sugisawa A, 2004, MUTAT RES-GEN TOX EN, V559, P97, DOI 10.1016/j.mrgentox.2004.01.002; Teufelhofer O, 2003, TOXICOL SCI, V76, P376, DOI 10.1093/toxsci/kfg234; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J; Tobi SE, 2002, INT J CANCER, V102, P439, DOI 10.1002/ijc.10730; Wei HC, 1999, FREE RADICAL BIO MED, V26, P1427, DOI 10.1016/S0891-5849(99)00005-2; Whiteside MA, 2004, NUTR REV, V62, P142, DOI 10.1111/j.1753-4887.2004.tb00036.x; Yamamoto T, 2003, J PHARMACOL EXP THER, V307, P230, DOI 10.1124/jpet.103.054676; Yamamoto T, 2004, J PHARMACOL EXP THER, V308, P317, DOI 10.1124/jpet.103.058891; Yang CS, 1999, CANCER EPIDEM BIOMAR, V8, P83; Yang CS, 1998, CANCER EPIDEM BIOMAR, V7, P351; Yang CS, 2002, ANNU REV PHARMACOL, V42, P25, DOI 10.1146/annurev.pharmtox.42.082101.154309; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yang GY, 2000, CARCINOGENESIS, V21, P2035, DOI 10.1093/carcin/21.11.2035; Yen GC, 2004, FREE RADICAL RES, V38, P193, DOI 10.1080/10715760310001638001; Zhu NQ, 2000, J AGR FOOD CHEM, V48, P979, DOI 10.1021/jf991188c	68	226	240	2	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					807	+		10.1096/fj.04-2915fje	http://dx.doi.org/10.1096/fj.04-2915fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15738004				2023-01-03	WOS:000227591900002
J	Vanhorebeek, I; De Vos, R; Mesotten, D; Wouters, PJ; De Wolf-Peeters, C; Van den Berghe, G				Vanhorebeek, I; De Vos, R; Mesotten, D; Wouters, PJ; De Wolf-Peeters, C; Van den Berghe, G			Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients	LANCET			English	Article							OXIDATIVE STRESS; CRITICAL ILLNESS; ORGAN DYSFUNCTION; MODEL; THERAPY; PHOSPHORYLATION; SEVERITY; MUSCLE; LIPIDS; DAMAGE	Background Maintenance of normoglycaemia by use of insulin reduces morbidity and mortality of patients in surgical intensive care. Studies on mitochondrial function in critical illness or diabetes suggest that effects of intensive insulin therapy on mitochondrial integrity contribute to the clinical benefits. Methods Enzyme activities of the respiratory-chain complexes and oxidative-stress-sensitive glyceraldehyde-3. phosphate dehydrogenase (GAPDH) were measured by spectrophotometry in 36 snap-frozen samples of liver and skeletal muscle obtained after death from patients who had been randomly assigned intensive (normoglycaemia) or conventional (hyperglycaemia) insulin therapy and who were similar in terms of admission diagnoses and causes of death. Mitochondrial ultrastructure was examined by electron microscopy in a random subgroup (n=20). Findings In the liver, hypertrophic mitochondria with an increased number of abnormal and irregular cristae and reduced matrix electron density were observed in seven of nine conventionally treated patients. Only one of 11 patients given intensive insulin treatment had these morphological abnormalities (p=0.005). The effect on ultrastructure was associated with higher activities of respiratory-chain complex I (median 1.53 [IQR 1.14-3.01] vs 0.81 [0.54-1.43] U/g liver; p=0.008) and complex IV (1.69 [1.40-1.97] vs 1.16 [0.97-1.40] U/g; p=0.008) in the intensive group than in the conventional group. There was no detectable difference in GAPDH activity. In skeletal muscle, mitochondrial ultrastructure and function were not affected by intensive insulin therapy. Interpretation Strict glycaemic control with intensive insulin therapy prevented or reversed ultrastructural and functional abnormalities of hepatocyte mitochondria. The lack of effect on skeletal-muscle mitochondria suggests a direct effect of glucose toxicity and glucose control, rather than of insulin, as the likely explanation. Relevance to practice Maintenance or restoration of mitochondrial function and cellular energetics is another therapeutic target, in addition to optimisation of cardiac output, systemic oxygen delivery, and regional blood flow, that might improve outcome for critically ill patients. Our findings could help to explain the mechanism underlying the reduction in mortality found when normoglycaemia was maintained with insulin, and further support use of intensive insulin therapy in this setting.	Catholic Univ Louvain, Dept Intens Care Med, B-3000 Louvain, Belgium; Catholic Univ Louvain, Dept Morphol & Mol Pathol, B-3000 Louvain, Belgium	Universite Catholique Louvain; Universite Catholique Louvain	Van den Berghe, G (corresponding author), Catholic Univ Louvain, Dept Intens Care Med, B-3000 Louvain, Belgium.	greta.vandenberghe@med.kuleuven.ac.be	Mesotten, Dieter/ABE-4176-2020; Van den Berghe, Greet/J-6788-2018	Mesotten, Dieter/0000-0002-3258-4720; Van den Berghe, Greet/0000-0002-5320-1362; Vanhorebeek, Ilse/0000-0002-5261-5192				Baumgart E, 2001, AM J PATHOL, V159, P1477, DOI 10.1016/S0002-9440(10)62534-5; BERGMEYER HU, 1985, METHOD ENZYMAT AN, P211; Bissler JJ, 2002, LAB INVEST, V82, P335, DOI 10.1038/labinvest.3780427; Bonnefont-Rousselot D, 2002, CURR OPIN CLIN NUTR, V5, P561, DOI 10.1097/00075197-200209000-00016; Brealey D, 2004, AM J PHYSIOL-REG I, V286, pR491, DOI 10.1152/ajpregu.00432.2003; Brealey D, 2002, LANCET, V360, P219, DOI 10.1016/S0140-6736(02)09459-X; BREALEY DA, 2003, 16 ANN C AMST NETH O, pS134; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bulger EM, 2001, ARCH SURG-CHICAGO, V136, P1201, DOI 10.1001/archsurg.136.10.1201; Crouser ED, 2002, CRIT CARE MED, V30, P2722, DOI 10.1097/00003246-200212000-00017; Crouser ED, 2002, CRIT CARE MED, V30, P276, DOI 10.1097/00003246-200202000-00002; Fink MP, 2002, INTENS CARE MED, V28, P369, DOI 10.1007/s00134-001-1205-2; Fink MP, 2001, CRIT CARE CLIN, V17, P219, DOI 10.1016/S0749-0704(05)70161-5; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; HALL JC, 1960, J BIOL CHEM, V235, P1536; HALL JC, 1960, J BIOL CHEM, V235, P6; Hansen TK, 2003, J CLIN ENDOCR METAB, V88, P1082, DOI 10.1210/jc.2002-021478; HUNT JV, 1988, BIOCHEM J, V256, P205, DOI 10.1042/bj2560205; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Mesotten D, 2004, J CLIN ENDOCR METAB, V89, P219, DOI 10.1210/jc.2003-030760; Miranda DR, 1996, CRIT CARE MED, V24, P64, DOI 10.1097/00003246-199601000-00012; Munnich A., 2001, METABOLIC MOL BASES, P2261; Oldham KM, 1998, J AM DIET ASSOC, V98, P1001, DOI 10.1016/S0002-8223(98)00230-2; Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311; RINEHART RW, 1982, ARCH BIOCHEM BIOPHYS, V213, P341, DOI 10.1016/0003-9861(82)90559-8; Singer M, 1999, BIOCHEM SOC SYMP, V66, P149, DOI 10.1042/bss0660149; Tirone TA, 2001, WORLD J SURG, V25, P461, DOI 10.1007/s002680020338; Tomita M, 1996, JPN CIRC J, V60, P673, DOI 10.1253/jcj.60.673; Van den Berghe G, 2003, CRIT CARE MED, V31, P359, DOI 10.1097/01.CCM.0000045568.12881.10; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; VESTER JW, 1957, J BIOL CHEM, V227, P669; Wakabayashi T, 2002, J CELL MOL MED, V6, P497, DOI 10.1111/j.1582-4934.2002.tb00452.x; Weekers F, 2002, ENDOCRINOLOGY, V143, P764, DOI 10.1210/en.143.3.764; West IC, 2000, DIABETIC MED, V17, P171, DOI 10.1046/j.1464-5491.2000.00259.x; Wolfe RR, 2000, WORLD J SURG, V24, P639, DOI 10.1007/s002689910105	35	312	336	1	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					53	59		10.1016/S0140-6736(04)17665-4	http://dx.doi.org/10.1016/S0140-6736(04)17665-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639679				2023-01-03	WOS:000226213100028
J	Tinetti, ME; Bogardus, ST; Agostini, JV				Tinetti, ME; Bogardus, ST; Agostini, JV			Potential pitfalls of disease-specific guidelines for patients with multiple conditions	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							AMERICAN-HEART-ASSOCIATION; ADVERSE DRUG EVENTS; RANDOMIZED-TRIALS; STATEMENT; THERAPY; DOCTORS; QUALITY; ADULT		Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT USA; Vet Affairs Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Tinetti, ME (corresponding author), Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.				NATIONAL INSTITUTE ON AGING [P60AG010469] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alter DA, 2004, AM J MED, V116, P540, DOI 10.1016/j.amjmed.2003.10.039; Amer Diabet Assoc, 2002, DIABETES CARE, V25, P213; BERENSON RA, 2003, CONFRONTING BARRIERS; Berry DC, 1997, PSYCHOL HEALTH, V12, P467, DOI 10.1080/08870449708406723; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Elwyn G, 2003, BMJ-BRIT MED J, V327, P864, DOI 10.1136/bmj.327.7419.864; Epstein RM, 2004, JAMA-J AM MED ASSOC, V291, P2359, DOI 10.1001/jama.291.19.2359; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Gross CP, 2002, ANN INTERN MED, V137, P10, DOI 10.7326/0003-4819-137-1-200207020-00007; Gueyffier F, 1999, LANCET, V353, P793, DOI 10.1016/S0140-6736(98)08127-6; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; Haynes RB, 1996, LANCET, V348, P383; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V285, P437, DOI 10.1001/jama.285.4.437; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Lewis DK, 2003, BMJ-BRIT MED J, V327, P841, DOI 10.1136/bmj.327.7419.841; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2; *NAT COMM QUAL ASS, 2003, STAT HLTH CAR QUAL 2; National Osteoporosis Foundation, 1999, PHYS GUID PREV TREAT; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; Smith SC, 2001, CIRCULATION, V104, P1577, DOI 10.1161/hc3801.097475; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Townsend A, 2003, BRIT MED J, V327, P837, DOI 10.1136/bmj.327.7419.837; Tsevat J, 1998, JAMA-J AM MED ASSOC, V279, P371, DOI 10.1001/jama.279.5.371; Vandenbroucke JP, 2004, LANCET, V363, P1728, DOI 10.1016/S0140-6736(04)16261-2	31	615	618	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2004	351	27					2870	2874		10.1056/NEJMsb042458	http://dx.doi.org/10.1056/NEJMsb042458			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	883IH	15625341				2023-01-03	WOS:000226004300017
J	Spielberger, R; Stiff, P; Bensinger, W; Gentile, T; Weisdorf, D; Kewalramani, T; Shea, T; Yanovich, S; Hansen, K; Noga, S; McCarty, J; LeMaistre, CF; Sung, EC; Blazar, BR; Elhardt, D; Chen, MG; Emmanouilides, C				Spielberger, R; Stiff, P; Bensinger, W; Gentile, T; Weisdorf, D; Kewalramani, T; Shea, T; Yanovich, S; Hansen, K; Noga, S; McCarty, J; LeMaistre, CF; Sung, EC; Blazar, BR; Elhardt, D; Chen, MG; Emmanouilides, C			Palifermin for oral mucositis after intensive therapy for hematologic cancers	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; KERATINOCYTE GROWTH-FACTOR; TOTAL-BODY IRRADIATION; NON-HODGKINS-LYMPHOMA; HIGH-DOSE ETOPOSIDE; PREPARATORY REGIMEN; DOUBLE-BLIND; CHEMOTHERAPY; PROPHYLAXIS	BACKGROUND: Oral mucositis is a complication of intensive chemotherapy and radiotherapy with no effective treatment. We tested the ability of palifermin (recombinant human keratinocyte growth factor) to decrease oral mucosal injury induced by cytotoxic therapy. METHODS: This double-blind study compared the effect of palifermin with that of a placebo on the development of oral mucositis in 212 patients with hematologic cancers; 106 patients received palifermin (60 microg per kilogram of body weight per day) and 106 received a placebo intravenously for three consecutive days immediately before the initiation of conditioning therapy (fractionated total-body irradiation plus high-dose chemotherapy) and after autologous hematopoietic stem-cell transplantation. Oral mucositis was evaluated daily for 28 days after transplantation. RESULTS: The incidence of oral mucositis of World Health Organization (WHO) grade 3 or 4 was 63 percent in the palifermin group and 98 percent in the placebo group (P<0.001). Among patients with this degree of mucositis, the median duration of mucositis was 6 days (range, 1 to 22) in the palifermin group and 9 days (range, 1 to 27) in the placebo group. Among all patients, regardless of the occurrence of mucositis, the median duration of oral mucositis of WHO grade 3 or 4 was 3 days (range, 0 to 22) in the palifermin group and 9 days (range, 0 to 27) in the placebo group (P<0.001). As compared with placebo, palifermin was associated with significant reductions in the incidence of grade 4 oral mucositis (20 percent vs. 62 percent, P<0.001), patient-reported soreness of the mouth and throat (area-under-the-curve score, 29.0 [range, 0 to 98] vs. 46.8 [range, 0 to 110]; P<0.001), the use of opioid analgesics (median, 212 mg of morphine equivalents [range, 0 to 9418] vs. 535 mg of morphine equivalents [range, 0 to 9418], P<0.001), and the incidence of use of total parenteral nutrition (31 percent vs. 55 percent, P<0.001). Adverse events, mainly rash, pruritus, erythema, mouth and tongue disorders, and taste alteration, were mild to moderate in severity and were transient. CONCLUSIONS: Palifermin reduced the duration and severity of oral mucositis after intensive chemotherapy and radiotherapy for hematologic cancers.	City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA; Loyola Univ, Med Ctr, Maywood, IL 60153 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; SUNY Upstate Med Univ, Syracuse, NY USA; Univ Minnesota, Minneapolis, MN USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Univ N Carolina, Chapel Hill, NC USA; Georgetown Univ, Ctr Canc, Washington, DC USA; NW Marrow Transplant Ctr, Portland, OR USA; Sinai Hosp Baltimore, Baltimore, MD USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Texas Transplant Inst, San Antonio, TX USA; Univ Calif Los Angeles, Dept Hematol Oncol, Los Angeles, CA USA; Amgen Corp, Thousand Oaks, CA 91320 USA	City of Hope; Loyola University Chicago; Fred Hutchinson Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Minnesota System; University of Minnesota Twin Cities; Memorial Sloan Kettering Cancer Center; University of North Carolina; University of North Carolina Chapel Hill; Georgetown University; Sinai Hospital of Baltimore; Virginia Commonwealth University; University of California System; University of California Los Angeles; Amgen	Spielberger, R (corresponding author), City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA.	rspielberger@coh.org	Stiff, Patrick/S-2676-2019	Sung, Eric C./0000-0002-0725-1801				Antin JH, 2002, BONE MARROW TRANSPL, V29, P373, DOI 10.1038/sj.bmt.1703394; ARMSTRONG TS, 1994, CANCER NURS, V17, P403; Bellm LA, 2000, SUPPORT CARE CANCER, V8, P33; BLUME KG, 1987, BLOOD, V69, P1015; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Dazzi C, 2003, ANN ONCOL, V14, P559, DOI 10.1093/annonc/mdg177; Donnelly JP, 2003, ANN ONCOL, V14, P505, DOI 10.1093/annonc/mdg179; Farrell CL, 1999, INT J RADIAT BIOL, V75, P609; Farrell CL, 1998, CANCER RES, V58, P933; Filicko J, 2003, BONE MARROW TRANSPL, V31, P1, DOI 10.1038/sj.bmt.1703776; Foncuberta MC, 2001, J IMMUNOTHER, V24, P384, DOI 10.1097/00002371-200107000-00014; HORNING SJ, 1994, J CLIN ONCOL, V12, P2552, DOI 10.1200/JCO.1994.12.12.2552; Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI; KOLBINSON DA, 1988, ORAL SURG ORAL MED O, V66, P130, DOI 10.1016/0030-4220(88)90080-1; LACHENBRUCH P A, 1976, Biometrische Zeitschrift, V18, P351; LANDIS JR, 1978, INT STAT REV, V46, P237, DOI 10.2307/1402373; McGuire D B, 1993, Oncol Nurs Forum, V20, P1493; Meropol NJ, 2003, J CLIN ONCOL, V21, P1452, DOI 10.1200/JCO.2003.10.079; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Moroni E, 2002, J HEMATOTH STEM CELL, V11, P19, DOI 10.1089/152581602753448513; National Cancer Institute, 1999, NAT CANC I COMM TOX; Rapoport AP, 1999, J CLIN ONCOL, V17, P2446, DOI 10.1200/JCO.1999.17.8.2446; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SEZER O, 2000, P AN M AM SOC CLIN, V19, pA56; SNYDER DS, 1993, BLOOD, V82, P2920; Sonis ST, 2001, J CLIN ONCOL, V19, P2201, DOI 10.1200/JCO.2001.19.8.2201; Sonis ST, 1998, ORAL ONCOL, V34, P39, DOI 10.1016/S1368-8375(97)00053-5; Spielberger R.T., 2001, P AN M AM SOC CLIN, V20, p7a; Stiff P, 2001, BONE MARROW TRANSPL, V27, pS3, DOI 10.1038/sj.bmt.1702863; Stiff PJ, 1998, J CLIN ONCOL, V16, P48, DOI 10.1200/JCO.1998.16.1.48; *WCCNR, 1998, CAN ONCOL NURS J, V8, P160; WOO SB, 1993, CANCER, V72, P1612, DOI 10.1002/1097-0142(19930901)72:5<1612::AID-CNCR2820720520>3.0.CO;2-Q; ZERBE MB, 1992, CANCER NURS, V15, P196	33	584	617	1	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	2004	351	25					2590	2598		10.1056/NEJMoa040125	http://dx.doi.org/10.1056/NEJMoa040125			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	879OC	15602019	Green Published			2023-01-03	WOS:000225726100006
J	Frost, H; Lamb, SE; Doll, HA; Carver, PT; Stewart-Brown, S				Frost, H; Lamb, SE; Doll, HA; Carver, PT; Stewart-Brown, S			Randomised controlled trial of physiotherapy compared with advice for low back pain	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE; INFORMATION; MANAGEMENT; QUESTIONNAIRE; DISABILITY; EXERCISE; THERAPY; BOOKLET; UK	Objective To measure the effectiveness of routine physiotherapy compared with an assessment session and advice from a physiotherapist for patients with low back pain. Design Pragmatic, multicentre, randomised controlled trial. Setting Seven NHS physiotherapy departments. Participants 286 patients with low back pain of more than six weeks' duration. Intervention Routine physiotherapy or advice on remaining active from a physiotherapist. Main outcome measures Primary outcome was scores on the Oswestry disability index at 12 months. Secondary outcomes were scores on the Oswestry disability index (2 and 6 months), scores on the Roland and Morris disability questionnaire and SF-36 (2, 6 and 12 months), and patient perceived benefit from treatment (2, 6, and 12 months). Results 200 of 286 patients (70%) provided follow up information at 12 months. Patients in the therapy group reported enhanced perceptions of benefit, but there was no evidence of a long term effect of physiotherapy in either disease specific or generic outcome measures (mean difference in change in Oswestry disability index scores at 12 months -1.0%, 95% confidence interval -3.7% to 1.6%). The most common treatments were low velocity spinal joint mobilisation techniques (72%, 104 of 144 patients) and lumbar spine mobility and abdominal strengthening exercises (94%, 136 patients). Conclusion Routine physiotherapy seemed to be no more effective than one session of assessment and advice from a physiotherapist.	Univ Warwick, Warwick Med Sch, Div Hlth Community, Coventry CV4 7AL, W Midlands, England; Univ Oxford, Dept Publ Hlth, Hlth Serv Res Unit, Oxford OX3 7LF, England; Nuffield Orthopaed Ctr NHS Trust, Oxford OX3 7LD, England	University of Warwick; University of Oxford; Nuffield Orthopaedic Centre	Frost, H (corresponding author), Univ Warwick, Warwick Med Sch, Div Hlth Community, Coventry CV4 7AL, W Midlands, England.	h.frost.l@warwick.ac.uk		Frost, Helen/0000-0001-9241-8970; Lamb, Sarah/0000-0003-4349-7195				Bekkering G., 2003, PHYSIOTHERAPY, V89, P82, DOI DOI 10.1016/S0031-9406(05)60579-2; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Burton AK, 1999, SPINE, V24, P2484, DOI 10.1097/00007632-199912010-00010; Clinical Standards Advisory Group, 1994, EP REV EP COST BACK; Clinical Standards Advisory Group on Back Pain, 1994, BACK PAIN; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; Foster NE, 1999, SPINE, V24, P1332, DOI 10.1097/00007632-199907010-00011; KIRKWOOD B, 1990, ESSENTIALS MED STAT; Knight M, 2001, J PUBLIC HEALTH MED, V23, P179, DOI 10.1093/pubmed/23.3.179; Koes BW, 2001, SPINE, V26, P2504, DOI 10.1097/00007632-200111150-00022; Little P, 2001, SPINE, V26, P2065, DOI 10.1097/00007632-200110010-00003; Maniadakis N, 2000, PAIN, V84, P95, DOI 10.1016/S0304-3959(99)00187-6; MCKENZIE RA, 1981, LUMBAR SPINE MECH DI; MOFFETT JK, 1999, BRIT MED J, V319, P270; MOFFETT JK, 1995, 129 NHS U YORK CTR H; Ong CK, 2004, HEALTH SOC CARE COMM, V12, P265, DOI 10.1111/j.1365-2524.2004.00497.x; Petersen T, 2002, SPINE, V27, P1702, DOI 10.1097/00007632-200208150-00004; Pocock SJ., 2013, CLIN TRIALS PRACTICA; PRESCOTT RJ, 1999, HEALTH TECHNOL ASSES, V3, P71; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROLAND M, 1993, SPINE, V8, P11; van Tulder M, 2000, SPINE, V25, P2784, DOI 10.1097/00007632-200011010-00011; 1997, BACK BOOK	23	132	136	1	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 25	2004	329	7468					708	711		10.1136/bmj.38216.868808.7C	http://dx.doi.org/10.1136/bmj.38216.868808.7C			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	858RV	15377573	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000224210300015
J	Binder, EF; Brown, M; Sinacore, DR; Steger-May, K; Yarasheski, KE; Schechtman, KB				Binder, EF; Brown, M; Sinacore, DR; Steger-May, K; Yarasheski, KE; Schechtman, KB			Effects of extended outpatient rehabilitation after hip fracture - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GERIATRIC-PATIENTS; PHYSICAL FUNCTION; OLDER-ADULTS; RECOVERY; BALANCE; STRENGTH; EXERCISE; MASS; VALIDITY; FRAILTY	Context Hip fractures are common in the elderly, and despite standard rehabilitation, many patients fail to regain their prefracture ambulatory or functional status. Objective To determine whether extended outpatient rehabilitation that includes progressive resistance training improves physical function and reduces disability compared with low-intensity home exercise among physically frail elderly patients with hi p fracture. Design, Setting, and Patients Randomized controlled trial conducted between August 1998 and May 2003 among 90 community-dwelling women and men aged 65 years or older who had had surgical repair of a proximal femur fracture no more than 16 weeks prior and had completed standard physical therapy. Intervention Participants were randomly assigned to 6 months of either supervised physical therapy and exercise training (n=46) or home exercise (control condition; n=44). Main Outcome Measures Primary outcome measures were total scores on a modified Physical Performance Test (PPT), the Functional Status Questionnaire physical function subscale (FSQ), and activities of daily living scales. Secondary outcome measures were standardized measures of skeletal muscle strength, gait, balance, quality of life, and body composition. Participants were evaluated at baseline, 3 months, and 6 months. Results. Changes over time in the PPT and FSQ scores favored the physical therapy group (P=.003 and P=.01, respectively). Mean change (SD) in PPT score for physical therapy was +6.5 (5.5) points (95% confidence interval [CI], 4.6-8.3), and for the control condition was +2.5 (3.7) points (95% Cl, 1.4-3.6 points). Mean change (SD) in FSQ score for physical therapy was +5.2 (5.4) points (95% Cl, 3.5-6.9) and for the control condition was +2.9 (3.8) points (95% Cl, 1.7-4.0). Physical therapy also had significantly greater improvements than the control condition in measures of muscle strength, walking speed, balance, and perceived health but not bone mineral density or fat-free mass. Conclusion In community-dwelling frail elderly patients with hip fracture, 6 months of extended outpatient rehabilitation that includes progressive resistance training can improve physical function and quality of life and reduce disability compared with low-intensity home exercise.	Washington Univ, Sch Med, Dept Internal Med, Div Geriatr & Nutr Sci, St Louis, MO 63108 USA; Washington Univ, Sch Med, Program Phys Therapy, St Louis, MO 63108 USA; Washington Univ, Sch Med, Div Biostat, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Binder, EF (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Geriatr & Nutr Sci, 4488 Forest Pk Blvd,Suite 201, St Louis, MO 63108 USA.	ebinder@im.wustl.edu	PT, David R. Sinacore/AAS-3377-2020; Yarasheski, Kevin/AAC-7450-2021; Yarasheski, Kevin E/A-3025-2008	PT, David R. Sinacore/0000-0002-7242-3585; Yarasheski, Kevin/0000-0001-5436-2451; 	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG013629] Funding Source: NIH RePORTER; NCRR NIH HHS [5-M01 RR00036] Funding Source: Medline; NIA NIH HHS [P60 AG013629] Funding Source: Medline; NIDDK NIH HHS [P30 DK56341] Funding Source: Medline; PHS HHS [R01 G15795] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALOIA JF, 1992, OSTEOPOROSIS INT, V2, P88, DOI 10.1007/BF01623842; BERG KO, 1992, ARCH PHYS MED REHAB, V73, P1073; Binder EF, 2002, J AM GERIATR SOC, V50, P1921, DOI 10.1046/j.1532-5415.2002.50601.x; BINDER EF, 2000, CLIN EXERC PHYSL, V2, P84; BOHANNON RW, 1984, PHYS THER, V64, P1067, DOI 10.1093/ptj/64.7.1067; BONAR SK, 1990, J AM GERIATR SOC, V38, P1139, DOI 10.1111/j.1532-5415.1990.tb01378.x; Brown M, 2000, J GERONTOL A-BIOL, V55, pM350, DOI 10.1093/gerona/55.6.M350; Buchner DM, 1997, J GERONTOL A-BIOL, V52, pM218, DOI 10.1093/gerona/52A.4.M218; Cameron ID, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000106; Colon-Emeric CS, 2000, AM J MED, V109, P324, DOI 10.1016/S0002-9343(00)00504-0; *CTR MED MED SERV, CARR MAN 3, pCH2; CUMMINGS SR, 1988, J AM GERIATR SOC, V36, P801, DOI 10.1111/j.1532-5415.1988.tb04263.x; Dirschl DR, 1997, BONE, V21, P79, DOI 10.1016/S8756-3282(97)00082-3; Duboeuf F, 1991, Osteoporos Int, V1, P242; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FILLENBAUM GG, 1981, J GERONTOL, V36, P428, DOI 10.1093/geronj/36.4.428; Fox KM, 2000, OSTEOPOROSIS INT, V11, P31, DOI 10.1007/s001980050003; GLOTH FM, 1995, J AM GERIATR SOC, V43, P822, DOI 10.1111/j.1532-5415.1995.tb07059.x; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hauer K, 2002, AGE AGEING, V31, P49, DOI 10.1093/ageing/31.1.49; Hoenig H, 1996, ARCH PHYS MED REHAB, V77, P58, DOI 10.1016/S0003-9993(96)90221-X; JETTE AM, 1987, PHYS THER, V67, P1854, DOI 10.1093/ptj/67.12.1854; JETTE AM, 1987, ARCH PHYS MED REHAB, V68, P735; JOHANSON NA, 1992, J BONE JOINT SURG AM, V74A, P587, DOI 10.2106/00004623-199274040-00015; JOHNELL O, 1985, ACTA ORTHOP SCAND, V56, P302, DOI 10.3109/17453678508993019; JUDGE JO, 1994, J AM GERIATR SOC, V42, P937, DOI 10.1111/j.1532-5415.1994.tb06584.x; Karlsson M, 1996, BONE, V18, P19, DOI 10.1016/8756-3282(95)00422-X; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; King AC, 1998, AM J PREV MED, V15, P316, DOI 10.1016/S0749-3797(98)00085-3; KOVAL KJ, 1995, CLIN ORTHOP RELAT R, P150; Koval KJ, 1996, J ORTHOP TRAUMA, V10, P531, DOI 10.1097/00005131-199611000-00004; Magaziner J, 2000, J GERONTOL A-BIOL, V55, pM498, DOI 10.1093/gerona/55.9.M498; MAROTTOLI RA, 1992, J AM GERIATR SOC, V40, P861, DOI 10.1111/j.1532-5415.1992.tb01980.x; *MI MED SERV, MED B FIN LOC MED RE; MOSSEY JM, 1989, AM J PUBLIC HEALTH, V79, P279, DOI 10.2105/AJPH.79.3.279; REUBEN DB, 1992, J GERONTOL, V47, pM106, DOI 10.1093/geronj/47.4.M106; REUBEN DB, 1990, J AM GERIATR SOC, V38, P1105, DOI 10.1111/j.1532-5415.1990.tb01373.x; Schafer J.L., 1997, ANAL INCOMPLETE MULT; SCHRODER HM, 1993, CLIN ORTHOP RELAT R, P166; Sherrington C, 2003, AUST J PHYSIOTHER, V49, P15, DOI 10.1016/S0004-9514(14)60184-7; Tinetti ME, 1999, ARCH PHYS MED REHAB, V80, P916, DOI 10.1016/S0003-9993(99)90083-7; Visser M, 2000, J GERONTOL A-BIOL, V55, pM434, DOI 10.1093/gerona/55.8.M434; Ware JE., 1993, HLTH SURVEY MANUAL I; WEISMAN Y, 1986, J AM GERIATR SOC, V34, P515, DOI 10.1111/j.1532-5415.1986.tb04243.x; Wolinsky FD, 1997, AM J PUBLIC HEALTH, V87, P398, DOI 10.2105/AJPH.87.3.398; WOLINSKY FD, 1994, AM J PUBLIC HEALTH, V84, P1316, DOI 10.2105/AJPH.84.8.1316; ZUCKERMAN JD, 1992, CLIN ORTHOP RELAT R, P213	48	254	264	1	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2004	292	7					837	846		10.1001/jama.292.7.837	http://dx.doi.org/10.1001/jama.292.7.837			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847FO	15315998	Bronze			2023-01-03	WOS:000223378300024
J	Orringer, JS; Kang, SW; Hamilton, T; Schumacher, W; Cho, SY; Hammerberg, C; Fisher, GJ; Karimipour, DJ; Johnson, TM; Voorhees, JJ				Orringer, JS; Kang, SW; Hamilton, T; Schumacher, W; Cho, SY; Hammerberg, C; Fisher, GJ; Karimipour, DJ; Johnson, TM; Voorhees, JJ			Treatment of acne vulgaris with a pulsed dye laser - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPY; NM; SYSTEM; LIGHT	Context The high prevalence of acne vulgaris and its significant morbidity underscore the need for convenient, low-risk, and efficacious therapy. Treatment with various lasers has been reported to improve acne. Objective To evaluate the clinical efficacy of pulsed dye laser therapy in the treatment of acne. Design, Setting, and Patients Randomized, single-blind, controlled, split-face clinical trial of a volunteer sample of 40 patients aged 13 years or older with facial acne conducted at an academic referral center from August 2002 to September 2003. Intervention One or 2 nonpurpuric pulsed dye laser treatments to half of the face (fluence of 3 J/cm(2)), serial blinded clinical assessments (lesion counts), and grading of acne severity using standardized bilateral serial photographs. Main Outcome Measures Comparison of the changes in lesion counts from baseline to 12 weeks between treated and untreated sides of the face and changes in photographic evidence of acne severity as graded by a panel of dermatologists blinded to treatment assignment. Results After 12 weeks, using intent-to-treat analysis with last observation carried forward, there were no significant differences between laser-treated and untreated skin for changes in mean papule counts (-4.2 vs -2.2; P=.08), mean pustule counts (0 vs -1.0; P=.12), or mean comedone counts (2.9 vs 1.6; P=.63). Grading of serial photographs confirmed the clinical assessments, showing no significant mean (SE) differences in Leeds scores (range, 1-12) for treated skin (3.98 [0.32] at baseline and 3.94 [0.27] at week 12) compared with untreated skin (3.83 [0.32] at baseline and 3.79 [0.28] at week 12) (P>.99). Conclusions In this study, the nonpurpuric pulsed dye laser therapy did not result in significant improvement of facial acne. More research is needed before this laser therapy may be recommended as an acne treatment.	Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Orringer, JS (corresponding author), Univ Michigan, Sch Med, Dept Dermatol, 1910 Taubman Ctr, Ann Arbor, MI 48109 USA.	jorringe@umich.edu	Cho, Soyun/B-7359-2013; Voorhees, John/AAM-9966-2020; Cho, Soyun/J-5666-2012	Voorhees, John/0000-0003-1856-785X; Cho, Soyun/0000-0003-2468-485X	NIAMS NIH HHS [1 K24 AR02159-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K24AR002159] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bjerring P, 2000, J Cutan Laser Ther, V2, P9, DOI 10.1080/14628830050516542; CUNLIFFE WJ, 1986, BRIT J DERMATOL, V115, P386, DOI 10.1111/j.1365-2133.1986.tb05757.x; EADEN E, 1993, BRIT MED J, V306, P555; ELGAMMAL C, 1995, NONINVASIVE METHODS, P517; Ellis CN, 2001, J AM ACAD DERMATOL, V45, pS150, DOI 10.1067/mjd.2001.113717; Gough A, 1996, BRIT MED J, V312, P169; Hirsch RJ, 2003, CUTIS, V71, P353; Hongcharu W, 2000, J INVEST DERMATOL, V115, P183, DOI 10.1046/j.1523-1747.2000.00046.x; Jacob CI, 2001, J AM ACAD DERMATOL, V45, P109, DOI 10.1067/mjd.2001.113451; LAYTON A, 1998, J CUTAN MED SURG S3, V2, P14; Leyden JJ, 2001, J EUR ACAD DERMATOL, V15, P51, DOI 10.1046/j.0926-9959.2001.00013.x; LEYDEN JJ, 1986, J AM ACAD DERMATOL, V15, P907, DOI 10.1016/S0190-9622(86)70250-8; Lloyd JR, 2002, LASER SURG MED, V31, P115, DOI 10.1002/lsm.10080; O'Brien SC, 1998, J DERMATOL TREAT, V9, P215, DOI 10.3109/09546639809160698; Paithankar DY, 2002, LASER SURG MED, V31, P106, DOI 10.1002/lsm.10086; Papageorgiou P, 2000, BRIT J DERMATOL, V142, P973, DOI 10.1046/j.1365-2133.2000.03481.x; Patel N, 2002, DERMATOL SURG, V28, P942, DOI 10.1046/j.1524-4725.2002.02062.x; Seaton ED, 2003, LANCET, V362, P1347, DOI 10.1016/S0140-6736(03)14629-6; STILLMAN S, 2000, J EUR ACAD DERMAT S1, V14, P47; Till AE, 2000, BRIT J DERMATOL, V142, P885, DOI 10.1046/j.1365-2133.2000.03467.x; Webster GF, 2002, BMJ-BRIT MED J, V325, P475, DOI 10.1136/bmj.325.7362.475	21	104	104	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2004	291	23					2834	2839		10.1001/jama.291.23.2834	http://dx.doi.org/10.1001/jama.291.23.2834			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828GT	15199033	Bronze			2023-01-03	WOS:000221962500028
J	Luby, SP; Agboatwalla, M; Painter, J; Altaf, A; Billhimer, WL; Hoekstra, RM				Luby, SP; Agboatwalla, M; Painter, J; Altaf, A; Billhimer, WL; Hoekstra, RM			Effect of intensive handwashing promotion on childhood diarrhea in high-risk communities in Pakistan - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERSISTENT DIARRHEA; MORTALITY; BANGLADESH; CHILDREN; SOAP; DEATHS; IMPACT; HANDS	Context Washing hands with soap prevents diarrhea, but children at the highest risk of death from diarrhea are younger than 1 year, too young to wash their own hands. Previous studies lacked sufficient power to assess the impact of household handwashing on diarrhea in infants. Objective To evaluate the effect of promoting household handwashing with, soap among children at the highest risk of death from diarrhea. Design, Setting, and Participants A cluster randomized controlled trial of 36 low-income neighborhoods in urban squatter settlements in Karachi, Pakistan. Field workers visited participating households at least weekly from April 15, 2002, to April 5, 2003. Eligible households located in the study area had at least 2 children younger than 15 years, at least 1 of whom was younger than 5 years. Interventions Weekly visits in 25 neighborhoods to promote handwashing with soap after defecation and before preparing food, eating, and feeding a child. Within intervention neighborhoods, 300 households (1523 children) received a regular supply of antibacterial soap and 300 households (1640 children) received plain soap. Eleven neighborhoods (306 households and 1528 children) comprised the control group. Main Outcome Measure Incidence density of diarrhea among children, defined as the number of diarrheal episodes per 100 person-weeks of observation. Results Children younger than 15 years living in households that received handwashing promotion and plain soap had a 53% lower incidence of diarrhea (95% confidence interval [CI], -65% to -41%) compared with children living in control neighborhoods. Infants living in households that received handwashing promotion and plain soap had 39% fewer days with diarrhea (95% CI, -61% to -16%) vs infants living in control neighborhoods. Severely malnourished children (weight forage z score, <-3.0) younger than 5 years living in households that received handwashing promotion and plain soap had 42% fewer days with diarrhea (95% CI, -69% to -16%) vs severely malnourished children in the control group. Similar reductions in diarrhea were observed among children living in households receiving antibacterial soap. Conclusion In a setting in which diarrhea is a leading cause of child death, improvement in handwashing in the household reduced the incidence of diarrhea among children at high risk of death from diarrhea.	CDCP, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Aga Khan Univ, Karachi, Pakistan; Procter & Gamble Co, Cincinnati, OH USA	Centers for Disease Control & Prevention - USA; Aga Khan University; Procter & Gamble	Luby, SP (corresponding author), CDCP, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, 1600 Clifton Rd,Mailstop A-38, Atlanta, GA 30333 USA.	sluby@cdc.gov		Hoekstra, Robert Michael/0000-0002-0340-8015; Luby, Stephen/0000-0001-5385-899X				Baqui AH, 2001, ACTA PAEDIATR, V90, P682, DOI 10.1080/080352501750258775; BHANDARI N, 1992, ACTA PAEDIATR, V81, P3, DOI 10.1111/j.1651-2227.1992.tb12363.x; BLUM D, 1983, INT J EPIDEMIOL, V12, P357, DOI 10.1093/ije/12.3.357; Curtis V, 2003, LANCET INFECT DIS, V3, P275, DOI 10.1016/S1473-3099(03)00606-6; DONNER K, 2000, RANDOMIZATION TRIALS; Fikree FF, 2002, B WORLD HEALTH ORGAN, V80, P271; HEINZE JE, 1988, EPIDEMIOL INFECT, V101, P135, DOI 10.1017/S0950268800029290; KALTENTHALER E, 1991, J TROP MED HYG, V94, P358; LIMA AAM, 1992, ACTA PAEDIATR, V81, P39, DOI 10.1111/j.1651-2227.1992.tb12370.x; LOWBURY EJL, 1964, BMJ-BRIT MED J, V2, P230, DOI 10.1136/bmj.2.5403.230; Luby S, 2001, Int J Infect Dis, V5, P144, DOI 10.1016/S1201-9712(01)90089-X; Marsh D, 1995, HEALTH POLICY PLANN, V10, P395, DOI 10.1093/heapol/10.4.395; Morris SS, 1996, AM J EPIDEMIOL, V144, P582, DOI 10.1093/oxfordjournals.aje.a008968; *PLANN DEV CORP PA, 1990, KAR DEV PLAN 2000, P20; SACHDEV HPS, 1991, J PEDIATR GASTR NUTR, V12, P76, DOI 10.1097/00005176-199101000-00016; Serfling R.J., 1980, APPROXIMATION THEORE; Shahid NS, 1996, J DIARRHOEAL DIS RES, V14, P85; SHAMEBO D, 1991, J TROP PEDIATRICS, V37, P254, DOI 10.1093/tropej/37.5.254; STANTON BF, 1987, AM J EPIDEMIOL, V125, P292, DOI 10.1093/oxfordjournals.aje.a114529; Teka T, 1996, ACTA PAEDIATR, V85, P1070, DOI 10.1111/j.1651-2227.1996.tb14219.x; Walsh SE, 2003, J APPL MICROBIOL, V94, P240, DOI 10.1046/j.1365-2672.2003.01825.x; WHO, 2002, REDUCING RISKS PROMO; Yassin KM, 2000, SOC SCI MED, V51, P185, DOI 10.1016/S0277-9536(99)00459-1; Yoon PW, 1997, AM J CLIN NUTR, V65, P1070, DOI 10.1093/ajcn/65.4.1070	24	172	172	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2004	291	21					2547	2554		10.1001/jama.291.21.2547	http://dx.doi.org/10.1001/jama.291.21.2547			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825EM	15173145	Bronze			2023-01-03	WOS:000221738800017
J	Higashi, T; Shekelle, PG; Solomon, DH; Knight, EL; Roth, C; Chang, JT; Kamberg, CJ; MaClean, CH; Young, RT; Adams, J; Reuben, DB; Avorn, J; Wenger, NS				Higashi, T; Shekelle, PG; Solomon, DH; Knight, EL; Roth, C; Chang, JT; Kamberg, CJ; MaClean, CH; Young, RT; Adams, J; Reuben, DB; Avorn, J; Wenger, NS			The quality of pharmacologic care for vulnerable older patients	ANNALS OF INTERNAL MEDICINE			English	Article							INAPPROPRIATE MEDICATION USE; ACUTE MYOCARDIAL-INFARCTION; ADVERSE DRUG-REACTIONS; EXPLICIT CRITERIA; ELDERLY-PATIENTS; CLINICAL-TRIALS; BEERS CRITERIA; HEART-FAILURE; HEALTH-CARE; COMMUNITY	Background: Although pharmacotherapy is critical to the medical care of older patients, medications can have considerable toxicity in this age group. To date, research has focused on inappropriate prescribing and policy efforts have aimed at access, but no comprehensive measurement of the quality of pharmacologic management using explicit criteria has been performed. Objective: To evaluate the broad range of pharmacologic care processes for vulnerable older patients. Design: Observational cohort study. Setting: 2 managed care organizations enrolling older persons. Patients: community-dwelling high-risk patients 65 years of age or older continuously enrolled in the managed care organizations from 1 July 1998 to 31 July 1999. Measurements: Patients' receipt of care as specified in 43 quality indicators covering 4 domains of pharmacologic care: 1) prescribing indicated medications; 2) avoiding inappropriate medications; 3) education, continuity, and documentation; and 4) medication monitoring. Results: Of 475 vulnerable older patients, 372 (78%) consented to participate and had medical records that could be abstracted.The percentage of appropriate pharmacologic management ranged from 10% for documentation of risks of nonsteroidal anti-inflammatory drugs to 100% for avoiding short-acting calcium-channel blockers in patients with heart failure and avoiding beta-blockers in patients with asthma. Pass rates for quality indicators in the "avoiding inappropriate medications" domain (97% [95% Cl, 96% to 98%]) were significantly higher than pass rates for "prescribing indicated medications" (50% [Cl, 45% to 55%]); "education, continuity, and documentation" (81% [Cl, 79% to 84%]); and "medication monitoring" (64% [Cl, 60% to 68%]). Limitations: Fewer than 10 patients were eligible for many of the quality indicators measured, and the generalizabiIity of these findings in 2 managed care organizations to the general geriatric population is uncertain. Conclusions: Failures to prescribe indicated medications, monitor medications appropriately, document necessary information, educate patients, and maintain continuity are more common prescribing problems than use of inappropriate drugs in older patients.	Univ Calif Los Angeles, Div Gen Internal Med, Los Angeles, CA 90095 USA; Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90095 USA; RAND Hlth, Washington, DC USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; RAND Corporation; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Higashi, T (corresponding author), Univ Calif Los Angeles, Div Gen Internal Med, 911 Broxton Plaza, Los Angeles, CA 90095 USA.		Chang, John T./L-7840-2019		BHP HRSA HHS [PE-19001] Funding Source: Medline	BHP HRSA HHS		*AG HEALTHC RES QU, 1996, HLTH CAR US AM 1996; [Anonymous], 2001, ANN INTERN MED, V135, P653, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00004; [Anonymous], 2000, MED EXP PAN SURV 200; Aparasu RR, 2000, ANN PHARMACOTHER, V34, P338, DOI 10.1345/aph.19006; Aparasu RR, 1997, ANN PHARMACOTHER, V31, P823, DOI 10.1177/106002809703100702; Aparasu RR, 1999, AM J HEALTH-SYST PH, V56, P433, DOI 10.1093/ajhp/56.5.433; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; CHRISCHILLES EA, 1992, ANN INTERN MED, V117, P634, DOI 10.7326/0003-4819-117-8-634; *CTR MED MED SERV, 2002, MED CURR BEN SURV; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; FINK A, 1987, JAMA-J AM MED ASSOC, V258, P1905, DOI 10.1001/jama.258.14.1905; Fitzgerald LS, 1997, ANN PHARMACOTHER, V31, P543, DOI 10.1177/106002809703100503; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; Hanlon JT, 2000, PHARMACOTHERAPY, V20, P575, DOI 10.1592/phco.20.6.575.35163; HANLON JT, 1992, J CLIN EPIDEMIOL, V45, P1045, DOI 10.1016/0895-4356(92)90144-C; Hanlon JT, 1997, J AM GERIATR SOC, V45, P945, DOI 10.1111/j.1532-5415.1997.tb02964.x; Havranek EP, 1998, ARCH INTERN MED, V158, P2024, DOI 10.1001/archinte.158.18.2024; Heiat A, 2002, ARCH INTERN MED, V162, P1682, DOI 10.1001/archinte.162.15.1682; Hunt D, 2001, ANN INTERN MED, V134, P931, DOI 10.7326/0003-4819-134-10-200105150-00007; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KANE RL, 1994, ESSENTIALS CLIN GERI; Kuperman G J, 2001, Jt Comm J Qual Improv, V27, P509; LASCHOBER MA, 2002, HLTH AFF MILWOOD; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Luck J, 2000, AM J MED, V108, P642, DOI 10.1016/S0002-9343(00)00363-6; MILLER DK, 1995, J AM GERIATR SOC, V43, P60, DOI 10.1111/j.1532-5415.1995.tb06244.x; Monane M, 1998, JAMA-J AM MED ASSOC, V280, P1249, DOI 10.1001/jama.280.14.1249; Primatesta P, 2000, BMJ-BRIT MED J, V321, P1322, DOI 10.1136/bmj.321.7272.1322; RAO JNK, 1981, J AM STAT ASSOC, V76, P221, DOI 10.2307/2287815; RATNER J, 1995, PUBLICATION US GAO; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; Rochon PA, 1999, JAMA-J AM MED ASSOC, V282, P113, DOI 10.1001/jama.282.2.113; Saliba D, 2001, J AM GERIATR SOC, V49, P1691, DOI 10.1046/j.1532-5415.2001.49281.x; SCHNEIDER JK, 1992, AM J HOSP PHARM, V49, P90, DOI 10.1093/ajhp/49.1.90; Sloss EM, 2000, J AM GERIATR SOC, V48, P363, DOI 10.1111/j.1532-5415.2000.tb04691.x; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; TAMBLYN RM, 1994, CAN MED ASSOC J, V150, P1801; Teich JM, 2000, ARCH INTERN MED, V160, P2741, DOI 10.1001/archinte.160.18.2741; Tseng CW, 2003, JAMA-J AM MED ASSOC, V290, P222, DOI 10.1001/jama.290.2.222; Wenger NS, 2003, ANN INTERN MED, V139, P740, DOI 10.7326/0003-4819-139-9-200311040-00008; Wenger NS, 2001, ANN INTERN MED, V135, P642, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00002; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292; Zhan Chunliu, 2001, JAMA (Journal of the American Medical Association), V286, P2823	45	151	155	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	2004	140	9					714	720		10.7326/0003-4819-140-9-200405040-00011	http://dx.doi.org/10.7326/0003-4819-140-9-200405040-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816XR	15126255				2023-01-03	WOS:000221143100005
J	Ding, M; Lu, YJ; Bowman, L; Huang, CS; Leonard, S; Wang, LY; Vallyathan, V; Castranova, V; Shi, XL				Ding, M; Lu, YJ; Bowman, L; Huang, CS; Leonard, S; Wang, LY; Vallyathan, V; Castranova, V; Shi, XL			Inhibition of AP-1 and neoplastic transformation by fresh apple peel extract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR PROTEIN-1 ACTIVATION; SIGNAL-TRANSDUCTION PATHWAYS; CANCER CHEMOPREVENTION; ANTIOXIDANT ACTIVITY; CRYSTALLINE SILICA; RESPONSE ELEMENT; TUMOR PROMOTION; PHORBOL ESTER; RETINOIC ACID; JB6 CELLS	Consumption of fruits and vegetables has been associated with a low incidence of cancers and other chronic diseases. Previous studies suggested that fresh apples inhibit tumor cell proliferation. Here we report that oral administration of apple peel extracts decreased the number of nonmalignant and malignant skin tumors per mouse induced by 12-O-tetradecanolyphorbol-13-acetate (TPA) in 7,12-dimethylbenz(a) anthracene-initiated mouse skin. ESR analysis indicated that apple extract strongly scavenged hydroxyl (OH) and superoxide (O-2(radical anion)) radicals. Mechanistic studies showed that pretreatment with apple peel extract inhibited AP-1 transactivation induced by ultraviolet B irradiation or TPA in JB6 cells and AP-1-luciferase reporter transgenic mice. This inhibitory effect appears to be mediated by the inhibition of ERKs and JNK activity. The results provide the first evidence that an extract from fresh apple peel extract may inhibit tumor promoter-induced carcinogenesis and associated cell signaling, and suggest that the chemopreventive effects of fresh apple may be through its antioxidant properties by blocking reactive oxygen species-mediated AP-1-MAPK activation.	NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA; NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); New York University	Ding, M (corresponding author), NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA.	mid5@cdc.gov	Shi, Xianglin/B-8588-2012	Huang, Chuanshu/0000-0003-4133-5096				Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; [Anonymous], 1996, CA Cancer J Clin, V46, P325; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BUSCHER M, 1988, ONCOGENE, V3, P301; Cao GH, 1998, AM J CLIN NUTR, V68, P1081, DOI 10.1093/ajcn/68.5.1081; Carlton PS, 2000, CANCER LETT, V159, P113, DOI 10.1016/S0304-3835(00)00464-X; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Ding M, 1999, J BIOL CHEM, V274, P30611, DOI 10.1074/jbc.274.43.30611; Ding M, 2001, J BIOL CHEM, V276, P9108, DOI 10.1074/jbc.M007666200; Eberhardt MV, 2000, NATURE, V405, P903, DOI 10.1038/35016148; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; JANZEN EG, 1968, J AM CHEM SOC, V90, P5909, DOI 10.1021/ja01023a051; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; Kresty LA, 2001, CANCER RES, V61, P6112; Krishnan K, 1998, PRIMARY CARE, V25, P361, DOI 10.1016/S0095-4543(05)70069-5; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; La Vecchia C, 1998, EUR J CANCER PREV, V7, P3, DOI 10.1097/00008469-199802001-00002; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1997, CANCER RES, V57, P3569; Lu YP, 2002, P NATL ACAD SCI USA, V99, P12455, DOI 10.1073/pnas.182429899; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORSE MA, 1993, CARCINOGENESIS, V14, P1737, DOI 10.1093/carcin/14.9.1737; Mukhtar H, 1999, TOXICOL APPL PHARM, V158, P207, DOI 10.1006/taap.1999.8721; NAITO M, 1988, CARCINOGENESIS, V9, P639, DOI 10.1093/carcin/9.4.639; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Rock CL, 1998, HEMATOL ONCOL CLIN N, V12, P975, DOI 10.1016/S0889-8588(05)70037-X; SHI XL, 1988, BIOCHEM BIOPH RES CO, V156, P137, DOI 10.1016/S0006-291X(88)80815-5; SHI XL, 1990, ARCH BIOCHEM BIOPHYS, V277, P342, DOI 10.1016/0003-9861(90)90589-Q; Wattenberg LW, 1997, P SOC EXP BIOL MED, V216, P133; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wolfe K, 2003, J AGR FOOD CHEM, V51, P609, DOI 10.1021/jf020782a; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	38	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10670	10676		10.1074/jbc.M311465200	http://dx.doi.org/10.1074/jbc.M311465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14665633	hybrid			2023-01-03	WOS:000220050400121
J	Murray, E; Fitzmaurice, D; McCahon, D; Fuller, C; Sandhur, H				Murray, E; Fitzmaurice, D; McCahon, D; Fuller, C; Sandhur, H			Training for patients in a randomised controlled trial of self management of warfarin treatment	BRITISH MEDICAL JOURNAL			English	Article							ORAL ANTICOAGULATION		Univ Birmingham, Sch Med, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Murray, E (corresponding author), Univ Birmingham, Sch Med, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.	e.t.murray@bham.ac.uk						Fitzmaurice DA, 2002, J CLIN PATHOL, V55, P845, DOI 10.1136/jcp.55.11.845; Fitzmaurice DA, 2001, BRIT MED J, V323, P985, DOI 10.1136/bmj.323.7319.985; Morsdorf S, 1999, SEMIN THROMB HEMOST, V25, P109, DOI 10.1055/s-2007-996433; Sawicki PT, 1999, JAMA-J AM MED ASSOC, V281, P145, DOI 10.1001/jama.281.2.145	4	29	29	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 21	2004	328	7437					437	438		10.1136/bmj.328.7437.437	http://dx.doi.org/10.1136/bmj.328.7437.437			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777DV	14976099	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000189161000018
J	Kaul, P; Newby, LK; Fu, YL; Mark, DB; Califf, RM; Topol, EJ; Aylward, P; Granger, CB; Van de Werf, F; Armstrong, PW				Kaul, P; Newby, LK; Fu, YL; Mark, DB; Califf, RM; Topol, EJ; Aylward, P; Granger, CB; Van de Werf, F; Armstrong, PW		VIGOUR Grp	International differences in evolution of early discharge after acute myocardial infarction	LANCET			English	Article							RISK STRATIFICATION; COST-EFFECTIVENESS; THROMBOLYSIS; ANGIOPLASTY; SAFETY; TRIAGE	Background Early discharge of low-risk patients with acute myocardial infarction is feasible and can be achieved at no additional risk of adverse events. We aimed to identify the extent to which countries have taken advantage of the opportunity for early discharge. Methods The study population consisted of 54 174 patients enrolled in GUSTO-I, GUSTO-III, and ASSENT-2 studies (enrolment period 1990-98) in the USA, Canada, Australia, New Zealand, Belgium, France, Germany, Spain, and Poland. We identified patients with uncomplicated acute myocardial infarction who were eligible for early discharge on the basis of previously established criteria, and assessed the extent to which these patients were discharged early-defined as discharged alive within 4 days of admission. The economic consequences (defined as potentially unnecessary hospital days consumed per 100 patients enrolled) were also investigated. Findings Patients in all European countries had significantly longer stays than did those from. non-European countries. Over the study period, the number of eligible patients discharged on or before day 4 increased in the USA, Canada, Australia, and New Zealand. Despite this increase, no more than 40% of patients who were eligible for early discharge were actually discharged early. The rate of early discharge of eligible patients was consistently low (<2%) in Belgium, France, Germany, Spain, and Poland. In ASSENT-2, which is the most recent trial in this study, the number of potentially unnecessary hospital days (per 100 patients enrolled) ranged from 65 in New Zealand to 839 in Germany. Interpretation Despite more than a decade of research, there is still a lot of variation between countries in international length-of-stay patterns in acute myocardial infarction. The potential for more efficient discharge of low-risk patients exists in all countries investigated, but was especially evident in the European countries included in the study (Belgium, France, Germany, Spain, and Poland).	Univ Alberta, Edmonton, AB T6G 2B7, Canada; Duke Clin Res Inst, Durham, NC USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Flinders Med Ctr, Adelaide, SA, Australia; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium	University of Alberta; Duke University; Cleveland Clinic Foundation; Flinders Medical Centre; KU Leuven; University Hospital Leuven	Kaul, P (corresponding author), Univ Alberta, 7221 Aberhart Ctr I, Edmonton, AB T6G 2B7, Canada.	pkaul@ualberta.ca	Granger, Christopher B/D-3458-2014	Granger, Christopher B/0000-0002-0045-3291; Armstrong, Paul/0000-0002-0460-3445; Aylward, Philip/0000-0002-5358-8552; Mark, Daniel/0000-0001-6340-8087; Van de Werf, Frans/0000-0001-9479-7767; Kaul, Padma/0000-0003-2239-3944; Topol, Eric/0000-0002-1478-4729				DIXON A, 2002, HLTH CARE SYSTEMS 8; Every NR, 1996, J AM COLL CARDIOL, V28, P287, DOI 10.1016/0735-1097(96)00168-4; Fu YL, 2001, CIRCULATION, V104, P2653, DOI 10.1161/hc4701.099731; Grines CL, 1998, J AM COLL CARDIOL, V31, P967, DOI 10.1016/S0735-1097(98)00031-X; HARPUR JE, 1971, LANCET, V2, P1331; Jha P, 1996, J AM COLL CARDIOL, V27, P1335, DOI 10.1016/0735-1097(96)00018-6; MARK DB, 1991, CIRCULATION, V83, P1186, DOI 10.1161/01.CIR.83.4.1186; Morrow DA, 2001, LANCET, V358, P1571, DOI 10.1016/S0140-6736(01)06649-1; Newby LK, 1996, J AM COLL CARDIOL, V27, P625; Newby LK, 2000, NEW ENGL J MED, V342, P749, DOI 10.1056/NEJM200003163421101; Ohman EM, 1999, AM J CARDIOL, V84, P1281, DOI 10.1016/S0002-9149(99)00558-5; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; SANZ G, 1993, J AM COLL CARDIOL, V22, P1795, DOI 10.1016/0735-1097(93)90759-T; Snijders T. A., 2012, MULTILEVEL ANAL INTR; Stubbs P, 1996, CIRCULATION, V94, P1291, DOI 10.1161/01.CIR.94.6.1291; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8	21	51	51	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	2004	363	9408					511	517		10.1016/S0140-6736(04)15536-0	http://dx.doi.org/10.1016/S0140-6736(04)15536-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774TA	14975612				2023-01-03	WOS:000188999900007
J	Yock, T; Schaefer, PW; Hoch, BL; Friedmann, AM; Tarbell, NJ; Rosenberg, AE; Harris, NL				Yock, T; Schaefer, PW; Hoch, BL; Friedmann, AM; Tarbell, NJ; Rosenberg, AE; Harris, NL			A nine-month-old boy with an orbital rhabdomyosarcoma - Rhabdomyosarcoma of the orbit.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INTERGROUP RHABDOMYOSARCOMA; RADIATION-THERAPY; PROTON-BEAMS; GENE FUSIONS; STUDY-II; TUMORS; CHEMOTHERAPY; RADIOTHERAPY; ONCOLOGY; CHILDREN		Massachusetts Gen Hosp, Div Pediat Hematol Oncol, Serv Pediat, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Harvard University	Yock, T (corresponding author), Massachusetts Gen Hosp, Div Pediat Hematol Oncol, Serv Pediat, Boston, MA 02114 USA.		Schaefer, Pamela/AAA-1323-2019					CASSADY JR, 1968, RADIOLOGY, V91, P116, DOI 10.1148/91.1.116; CRIST W, 1995, J CLIN ONCOL, V13, P610, DOI 10.1200/JCO.1995.13.3.610; Crist WM, 2001, J CLIN ONCOL, V19, P3091, DOI 10.1200/JCO.2001.19.12.3091; HEYN R, 1986, CANCER-AM CANCER SOC, V57, P1738, DOI 10.1002/1097-0142(19860501)57:9<1738::AID-CNCR2820570905>3.0.CO;2-3; HEYN R, 1993, J CLIN ONCOL, V11, P262, DOI 10.1200/JCO.1993.11.2.262; Hill DA, 2002, AM J SURG PATHOL, V26, P965, DOI 10.1097/00000478-200208000-00001; Hug EB, 2002, INT J RADIAT ONCOL, V52, P1017, DOI 10.1016/S0360-3016(01)02725-0; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; Loeffler JS, 1997, SEMIN ONCOL, V24, P686; MAURER HM, 1993, CANCER-AM CANCER SOC, V71, P1904, DOI 10.1002/1097-0142(19930301)71:5<1904::AID-CNCR2820710530>3.0.CO;2-X; MAURER HM, 1988, CANCER-AM CANCER SOC, V61, P209, DOI 10.1002/1097-0142(19880115)61:2<209::AID-CNCR2820610202>3.0.CO;2-L; Miralbell R, 2002, INT J RADIAT ONCOL, V54, P824, DOI 10.1016/S0360-3016(02)02982-6; Noel G, 2003, MED PEDIATR ONCOL, V40, P309, DOI 10.1002/mpo.10283; Notis CM, 1995, OPHTHALMIC GENET, V16, P159, DOI 10.3109/13816819509057857; Oberlin O, 2001, J CLIN ONCOL, V19, P197, DOI 10.1200/JCO.2001.19.1.197; RAJU MR, 1995, INT J RADIAT BIOL, V67, P237, DOI 10.1080/09553009514550301; ROUSSEAU P, 1994, J CLIN ONCOL, V12, P516, DOI 10.1200/JCO.1994.12.3.516; Sagerman R H, 1968, Trans Am Acad Ophthalmol Otolaryngol, V72, P849; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; SPIRO IJ, 2001, CANC PRINCIPLES PRAC, V2, P3229; STOBBE GD, 1950, CANCER, V3, P826, DOI 10.1002/1097-0142(1950)3:5<826::AID-CNCR2820030508>3.0.CO;2-X; SUIT H, 1982, INT J RADIAT ONCOL, V8, P2199, DOI 10.1016/0360-3016(82)90570-3; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; Weiss SW, 2001, SOFT TISSUE TUMORS, P785; WHARAM M, 1987, OPHTHALMOLOGY, V94, P251; Wharam MD, 1997, INT J RADIAT ONCOL, V38, P797, DOI 10.1016/S0360-3016(97)00120-X; WILBUR JR, 1974, CANCER CHEMOTH REP 1, V58, P281; [No title captured]	28	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2004	350	5					494	502		10.1056/NEJMcpc030036	http://dx.doi.org/10.1056/NEJMcpc030036			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767QJ	14749459				2023-01-03	WOS:000188463900014
J	Liu, YM; Coresh, J; Eustace, JA; Longenecker, JC; Jaar, B; Fink, NE; Tracy, RP; Powe, NR; Klag, MJ				Liu, YM; Coresh, J; Eustace, JA; Longenecker, JC; Jaar, B; Fink, NE; Tracy, RP; Powe, NR; Klag, MJ			Association between cholesterol level and mortality in - Role of inflammation dialysis patients and malnutrition	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; SERUM TOTAL CHOLESTEROL; ACUTE-PHASE RESPONSE; CARDIOVASCULAR-DISEASE; HEART; RISK; INTERLEUKIN-6; CORONARY; DEATH; MEN	Context Total cholesterol level is inversely associated with mortality in dialysis patients, a group at high risk of cardiovascular disease (CVD). This paradox may be explained by systemic inflammation and/or malnutrition, which are associated with lower cholesterol levels and higher mortality. Objective To determine the relationship between cholesterol level and outcome in patients undergoing dialysis, accounting for inflammation and malnutrition. Design, Setting, and Participants Prospective study of 823 patients enrolled from October 1995 to June 1998 who recently initiated dialysis, from 79 clinics, classified by absence or presence of inflammation and/or malnutrition (defined as serum albumin levels <3.6 mg/dL, C-reactive protein >= 10 mg/L, or interleukin 6 >= 3.09 pg/mL). Main Outcome Measures All-cause and cardiovascular disease mortality. Results During a median follow-up of 2.4 years, 324 deaths (159 CVD deaths), 153 renal transplantations, and 10 losses to follow-up occurred. Average serum cholesterol level was lower in the presence of inflammation/malnutrition than in its absence. In a Cox model adjusted for age, race, and sex, a 40-mg/dL (1.0-mmol/L) increment in baseline total serum cholesterol level was associated with a decreased risk of all-cause mortality overall (relative hazard [RH], 0.92; 95% confidence interval [CI], 0.87-0.98) and in the presence of inflammation/malnutrition (RH, 0.89; CI, 0.84-0.95). In contrast, serum cholesterol level was associated with an increased risk in the absence of inflammation/malnutrition (RH, 1.32; 95% CI, 1.07-1.63). For CVD mortality, an inverse trend was not statistically significant in the presence of inflammation/malnutrition, and a positive association was evident in the absence of inflammation/malnutrition (RH, 1.41; 95% CI, 1.04-1.89). Further adjustment for traditional CVD risk factors, dialysis modality, comorbidity, and inflammatory markers attenuated the inverse association but strengthened the positive association. Conclusions The inverse association of total cholesterol level with mortality in dialysis patients is likely due to the cholesterol-lowering effect of systemic inflammation and malnutrition, not to a protective effect of high cholesterol concentrations. These findings support treatment of hypercholesterolemia in this population.	Johns Hopkins Univ, Baltimore, MD 21205 USA; Kuwait Univ, Kuwait, Kuwait; Univ Vermont, Burlington, VT USA	Johns Hopkins University; Kuwait University; University of Vermont	Coresh, J (corresponding author), Johns Hopkins Univ, 2024 E Monument St,Suite 2-600, Baltimore, MD 21205 USA.	coresh@jhu.edu	Jaar, Bernard/B-1917-2009	Longenecker, Joseph/0000-0001-9471-5661; Jaar, Bernard/0000-0003-1210-7115	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058329, R01HL046696, R01HL062985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK002856, K23DK002922, R01DK059616, K24DK002643, T32DK007732] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00052] Funding Source: Medline; NHLBI NIH HHS [HL 58329, KO8-HL-03896, R01-HL-62985, HL 46696] Funding Source: Medline; NIDDK NIH HHS [K23DK02922, K24-DK-02643, K24-DK-02856, R01-DK-59616, T32 DK07732] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; Attman PO, 1996, NEPHROL DIAL TRANSPL, V11, P63; Baigent C, 2000, NEPHROL DIAL TRANSPL, V15, P1118, DOI 10.1093/ndt/15.8.1118; Behar S, 1997, EUR HEART J, V18, P52, DOI 10.1093/oxfordjournals.eurheartj.a015117; Bologa RM, 1998, AM J KIDNEY DIS, V32, P107, DOI 10.1053/ajkd.1998.v32.pm9669431; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Coresh J, 1998, J Am Soc Nephrol, V9, pS24; Cullen P, 1997, CIRCULATION, V96, P2128; deFilippi C, 2003, JAMA-J AM MED ASSOC, V290, P353, DOI 10.1001/jama.290.3.353; Dyker AG, 1997, BMJ-BRIT MED J, V314, P1584, DOI 10.1136/bmj.314.7094.1584; GREENBERG AS, 1992, CANCER RES, V52, P4113; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HARRIS T, 1992, J CLIN EPIDEMIOL, V45, P595, DOI 10.1016/0895-4356(92)90131-6; Horwich TB, 2002, J CARD FAIL, V8, P216, DOI 10.1054/jcaf.2002.126519a; IRIBARREN C, 1995, JAMA-J AM MED ASSOC, V273, P1926, DOI 10.1001/jama.273.24.1926; Iseki K, 2002, KIDNEY INT, V61, P1887, DOI 10.1046/j.1523-1755.2002.00324.x; Kaysen GA, 2000, KIDNEY INT, V58, P346, DOI 10.1046/j.1523-1755.2000.00172.x; Kaysen GA, 2002, BLOOD PURIFICAT, V20, P70, DOI 10.1159/000046988; Kaysen GA, 2001, J AM SOC NEPHROL, V12, P1549, DOI 10.1681/ASN.V1271549; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Longenecker JC, 2002, J AM SOC NEPHROL, V13, P1918, DOI 10.1097/01.ASN.0000019641.41496.1E; Lowrie E G, 1998, Am J Kidney Dis, V32, pS105, DOI 10.1016/S0272-6386(98)70172-6; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; National Kidney Foundation, 2003, AM J KIDNEY DIS S, V41, pS22; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; *NHANES III, CDCP WEB SIT; Nieto FJ, 1996, AM J EPIDEMIOL, V143, P1059; NISHIZAWA Y, 2000, KIDNEY INT S84, V63, P117; Pecoits R, 2002, NEPHROL DIAL TRANSPL, V17, P28, DOI 10.1093/ndt/17.suppl_11.28; Rocco MV, 2002, AM J KIDNEY DIS, V39, P146, DOI 10.1053/ajkd.2002.29905; SALMOND CE, 1985, BMJ-BRIT MED J, V290, P422, DOI 10.1136/bmj.290.6466.422; SAMMALKORPI KT, 1990, ANN MED, V22, P397, DOI 10.3109/07853899009147277; Schatz IJ, 2001, LANCET, V358, P351, DOI 10.1016/S0140-6736(01)05553-2; Seliger SL, 2002, KIDNEY INT, V61, P297, DOI 10.1046/j.1523-1755.2002.00109.x; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Stenvinkel P, 2002, KIDNEY INT, V61, pS103, DOI 10.1046/j.1523-1755.61.s80.19.x; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121; *US REN DAT SYST, 1999, AM J KIDNEY DIS S, V34, pS87; US Renal Data System, 1999, USRDS 1999 ANN DAT R; Visser M, 2002, J GERONTOL A-BIOL, V57, pM326, DOI 10.1093/gerona/57.5.M326	41	532	556	4	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	2004	291	4					451	459		10.1001/jama.291.4.451	http://dx.doi.org/10.1001/jama.291.4.451			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	767EF	14747502				2023-01-03	WOS:000188426700030
J	Stuart, JA; Karahalil, B; Hogue, BA; Souza-Pinto, NC; Bohr, VA				Stuart, JA; Karahalil, B; Hogue, BA; Souza-Pinto, NC; Bohr, VA			Mitochondrial and nuclear DNA base excision repair are affected differently by caloric restriction	FASEB JOURNAL			English	Article						OGG1; UDG; AP endonuclease; dietary restriction; aging; mitochondria	RAT-LIVER MITOCHONDRIA; OXIDATIVE DAMAGE; DIETARY RESTRICTION; POLYMERASE-GAMMA; LIFE-SPAN; AGE; STRESS; BRAIN; MUSCLE; MODEL	Aging is strongly correlated with the accumulation of oxidative damage in DNA, particularly in mitochondria. Oxidative damage to both mitochondrial and nuclear DNA is repaired by the base excision repair (BER) pathway. The "mitochondrial theory of aging" suggests that aging results from declining mitochondrial function, due to high loads of damage and mutation in mitochondrial DNA (mtDNA). Restriction of caloric intake is the only intervention so far proven to slow the aging rate. However, the molecular mechanisms underlying such effects are still unclear. We used caloric-restricted (CR) mice to investigate whether lifespan extension is associated with changes in mitochondrial BER activities. Mice were divided into two groups, receiving 100% (PF) or 60% (CR) of normal caloric intake, a regime that extends mean lifespan by similar to40% in CR mice. Mitochondria isolated from CR mice had slightly higher uracil (UDG) and oxoguanine DNA glycosylase (OGGI) activities but marginally lower abasic endonuclease and polymerase gamma gap-filling activities, although these differences were tissue-specific. Uracil-initiated BER synthesis incorporation activities were significantly lower in brain and kidney from CR mice but marginally enhanced in liver. However, nuclear repair synthesis activities were increased by CR, indicating differential regulation of BER in the two compartments. The results indicate that a general up-regulation of mitochondrial BER does not occur in CR.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bohr, VA (corresponding author), 5600 Nathan Shock Dr,Box 1, Baltimore, MD 21224 USA.	vbohr@nih.gov	Souza-Pinto, Nadja C./C-3462-2013; Souza-Pinto, Nadja/T-3050-2019; Bohr, Vilhelm/AAP-5931-2020; Karahalil, Bensu/AFU-8097-2022	Souza-Pinto, Nadja C./0000-0003-4206-964X; Souza-Pinto, Nadja/0000-0003-4206-964X; 	NATIONAL INSTITUTE ON AGING [ZIAAG000733, Z01AG000733] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBRING M, 1977, P NATL ACAD SCI USA, V74, P1348, DOI 10.1073/pnas.74.4.1348; Barja G, 2000, FASEB J, V14, P312, DOI 10.1096/fasebj.14.2.312; Cabelof DC, 2003, DNA REPAIR, V2, P295, DOI 10.1016/S1568-7864(02)00219-7; Chen DX, 2003, J CEREBR BLOOD F MET, V23, P88, DOI 10.1097/01.WCB.0000039286.37737.19; CHUNG MH, 1992, FREE RADICAL BIO MED, V12, P523, DOI 10.1016/0891-5849(92)90105-P; Cortopassi GA, 1996, MECH AGEING DEV, V91, P211, DOI 10.1016/S0047-6374(96)01788-5; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; de Souza-Pinto NC, 2001, FREE RADICAL BIO MED, V30, P916, DOI 10.1016/S0891-5849(01)00483-X; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Frossi B, 2002, J CELL PHYSIOL, V193, P180, DOI 10.1002/jcp.10159; Golden TR, 2001, MECH AGEING DEV, V122, P1577, DOI 10.1016/S0047-6374(01)00288-3; Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje; HARMAN D, 1994, AGE, V17, P119, DOI 10.1007/BF02435819; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HART RW, 1974, P NATL ACAD SCI USA, V71, P2169, DOI 10.1073/pnas.71.6.2169; Hudson EK, 1998, FREE RADICAL RES, V29, P573, DOI 10.1080/10715769800300611; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Kang CM, 1998, FREE RADICAL BIO MED, V24, P148, DOI 10.1016/S0891-5849(97)00204-9; Karahalil B, 2002, FASEB J, V16, P1895, DOI 10.1096/fj.02-0463com; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; Lee CM, 1997, FREE RADICAL BIO MED, V22, P1259, DOI 10.1016/S0891-5849(96)00546-1; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; Lopez-Torres M, 2002, FREE RADICAL BIO MED, V32, P882, DOI 10.1016/S0891-5849(02)00773-6; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; Melov S, 1999, MUTAT RES-DNA REPAIR, V434, P233, DOI 10.1016/S0921-8777(99)00031-2; Melov S, 1997, NUCLEIC ACIDS RES, V25, P974, DOI 10.1093/nar/25.5.974; Nyaga Simon G, 2002, Methods Mol Biol, V197, P227, DOI 10.1385/1-59259-284-8:227; Ogihara M, 2002, EXP MOL PATHOL, V73, P234, DOI 10.1006/exmp.2002.2442; PINZ KG, 1995, J BIOL CHEM, V270, P9202, DOI 10.1074/jbc.270.16.9202; Sokhansanj BA, 2002, NUCLEIC ACIDS RES, V30, P1817, DOI 10.1093/nar/30.8.1817; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; WERAARCHAKUL N, 1989, EXP CELL RES, V181, P197, DOI 10.1016/0014-4827(89)90193-6	34	79	85	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					595	+		10.1096/fj.03-0890fje	http://dx.doi.org/10.1096/fj.03-0890fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734635	Green Submitted			2023-01-03	WOS:000188829300012
